# ESC Guidelines 2021

<!-- 2021_CVD_Prevention.md -->

# ESC Guidelines: CVD Prevention (2021)

**Source**: `2021_CVD_Prevention.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 111

---

## Table of Contents

- [S5](#s5) *(p. 7)*
- [S6](#s6) *(p. 8)*
- [S7](#s7) *(p. 9)*
- [S8](#s8) *(p. 10)*
- [S9](#s9) *(p. 10)*
- [S10](#s10) *(p. 10)*
- [S11](#s11) *(p. 10)*
- [S12](#s12) *(p. 10)*
- [S13](#s13) *(p. 10)*
- [S14](#s14) *(p. 10)*
- [tblfn1](#tblfn1) *(p. 14)*
- [tblfn3a](#tblfn3a) *(p. 15)*
- [S15](#s15) *(p. 16)*
- [S16](#s16) *(p. 16)*
- [S17](#s17) *(p. 16)*
- [tblfn3](#tblfn3) *(p. 16)*
- [tblfn4](#tblfn4) *(p. 16)*
- [tblfn5](#tblfn5) *(p. 16)*
- [S18](#s18) *(p. 17)*
- [S19](#s19) *(p. 17)*
- [S20](#s20) *(p. 17)*
- [S21](#s21) *(p. 17)*
- [S22](#s22) *(p. 17)*
- [tblfn6](#tblfn6) *(p. 18)*
- [S23](#s23) *(p. 19)*
- [S24](#s24) *(p. 24)*
- [tblfn8](#tblfn8) *(p. 25)*
- [tblfn9](#tblfn9) *(p. 25)*
- [tblfn10](#tblfn10) *(p. 25)*
- [S25](#s25) *(p. 27)*
- [S26](#s26) *(p. 27)*
- [S27](#s27) *(p. 28)*
- [S28](#s28) *(p. 28)*
- [S29](#s29) *(p. 30)*
- [tblfn11](#tblfn11) *(p. 30)*
- [tblfn12](#tblfn12) *(p. 30)*
- [tblfn13](#tblfn13) *(p. 30)*
- [S30](#s30) *(p. 31)*
- [S31](#s31) *(p. 31)*
- [tblfn14](#tblfn14) *(p. 31)*
- [tblfn15](#tblfn15) *(p. 31)*
- [tblfn16](#tblfn16) *(p. 31)*
- [tblfn17](#tblfn17) *(p. 31)*
- [tblfn18](#tblfn18) *(p. 31)*
- [tblfn19](#tblfn19) *(p. 31)*
- [S32](#s32) *(p. 32)*
- [S33](#s33) *(p. 32)*
- [S34](#s34) *(p. 32)*
- [S35](#s35) *(p. 33)*
- [S36](#s36) *(p. 33)*
- [S37](#s37) *(p. 33)*
- [S38](#s38) *(p. 33)*
- [S39](#s39) *(p. 33)*
- [S40](#s40) *(p. 33)*
- [S41](#s41) *(p. 33)*
- [S43](#s43) *(p. 33)*
- [S44](#s44) *(p. 34)*
- [S45](#s45) *(p. 34)*
- [S46](#s46) *(p. 34)*
- [S47](#s47) *(p. 34)*
- [S48](#s48) *(p. 34)*
- [tblfn20](#tblfn20) *(p. 34)*
- [tblfn21](#tblfn21) *(p. 34)*
- [tblfn22](#tblfn22) *(p. 34)*
- [S49](#s49) *(p. 35)*
- [S50](#s50) *(p. 35)*
- [tblfn23](#tblfn23) *(p. 35)*
- [tblfn24](#tblfn24) *(p. 35)*
- [tblfn25](#tblfn25) *(p. 35)*
- [S51](#s51) *(p. 36)*
- [S52](#s52) *(p. 36)*
- [S53](#s53) *(p. 36)*
- [S54](#s54) *(p. 36)*
- [S55](#s55) *(p. 36)*
- [S57](#s57) *(p. 38)*
- [S58](#s58) *(p. 38)*
- [S59](#s59) *(p. 38)*
- [S60](#s60) *(p. 39)*
- [S61](#s61) *(p. 39)*
- [S62](#s62) *(p. 39)*
- [S64](#s64) *(p. 39)*
- [S65](#s65) *(p. 40)*
- [S66](#s66) *(p. 40)*
- [S67](#s67) *(p. 40)*
- [S68](#s68) *(p. 40)*
- [S69](#s69) *(p. 40)*
- [S70](#s70) *(p. 40)*
- [S71](#s71) *(p. 40)*
- [tblfn26](#tblfn26) *(p. 41)*
- [tblfn27](#tblfn27) *(p. 41)*
- [tblfn28](#tblfn28) *(p. 41)*
- [S72](#s72) *(p. 42)*
- [S73](#s73) *(p. 42)*
- [S74](#s74) *(p. 42)*
- [S75](#s75) *(p. 42)*
- [S76](#s76) *(p. 42)*
- [S78](#s78) *(p. 42)*
- [tblfn29](#tblfn29) *(p. 42)*
- [tblfn30](#tblfn30) *(p. 42)*
- [tblfn31](#tblfn31) *(p. 42)*
- [S79](#s79) *(p. 43)*
- [S80](#s80) *(p. 43)*
- [S81](#s81) *(p. 43)*
- [S82](#s82) *(p. 43)*
- [S83](#s83) *(p. 43)*
- [tblfn32](#tblfn32) *(p. 43)*
- [tblfn33](#tblfn33) *(p. 43)*
- [S84](#s84) *(p. 44)*
- [S85](#s85) *(p. 44)*
- [S86](#s86) *(p. 44)*
- [S87](#s87) *(p. 44)*
- [S88](#s88) *(p. 44)*
- [tblfn34](#tblfn34) *(p. 44)*
- [tblfn35](#tblfn35) *(p. 44)*
- [tblfn36](#tblfn36) *(p. 44)*
- [tblfn78](#tblfn78) *(p. 44)*
- [S89](#s89) *(p. 45)*
- [S90](#s90) *(p. 45)*
- [S91](#s91) *(p. 45)*
- [S92](#s92) *(p. 45)*
- [S93](#s93) *(p. 46)*
- [S94](#s94) *(p. 46)*
- [S95](#s95) *(p. 46)*
- [S96](#s96) *(p. 46)*
- [S97](#s97) *(p. 46)*
- [S98](#s98) *(p. 46)*
- [S99](#s99) *(p. 46)*
- [tblfn79](#tblfn79) *(p. 46)*
- [tblfn80](#tblfn80) *(p. 46)*
- [tblfn81](#tblfn81) *(p. 46)*
- [S101](#s101) *(p. 47)*
- [S102](#s102) *(p. 47)*
- [tblfn82](#tblfn82) *(p. 47)*
- [tblfn83](#tblfn83) *(p. 47)*
- [tblfn84](#tblfn84) *(p. 47)*
- [tblfn85](#tblfn85) *(p. 47)*
- [tblfn128](#tblfn128) *(p. 47)*
- [tblfn129](#tblfn129) *(p. 47)*
- [tblfn130](#tblfn130) *(p. 47)*
- [S103](#s103) *(p. 49)*
- [S104](#s104) *(p. 49)*
- [S105](#s105) *(p. 49)*
- [S106](#s106) *(p. 49)*
- [S107](#s107) *(p. 49)*
- [tblfn39](#tblfn39) *(p. 49)*
- [tblfn38](#tblfn38) *(p. 49)*
- [S108](#s108) *(p. 50)*
- [S109](#s109) *(p. 50)*
- [S110](#s110) *(p. 50)*
- [S111](#s111) *(p. 50)*
- [S112](#s112) *(p. 50)*
- [S113](#s113) *(p. 50)*
- [S114](#s114) *(p. 50)*
- [tblfn40](#tblfn40) *(p. 50)*
- [tblfn41](#tblfn41) *(p. 50)*
- [tblfn42](#tblfn42) *(p. 50)*
- [tblfn43](#tblfn43) *(p. 50)*
- [S115](#s115) *(p. 52)*
- [S116](#s116) *(p. 52)*
- [S117](#s117) *(p. 52)*
- [S118](#s118) *(p. 52)*
- [S119](#s119) *(p. 53)*
- [S120](#s120) *(p. 53)*
- [S121](#s121) *(p. 53)*
- [S122](#s122) *(p. 53)*
- [S123](#s123) *(p. 53)*
- [tblfn44](#tblfn44) *(p. 53)*
- [tblfn45](#tblfn45) *(p. 53)*
- [tblfn46](#tblfn46) *(p. 53)*
- [tblfn47](#tblfn47) *(p. 53)*
- [S124](#s124) *(p. 54)*
- [S125](#s125) *(p. 54)*
- [S126](#s126) *(p. 54)*
- [S127](#s127) *(p. 54)*
- [tblfn51](#tblfn51) *(p. 54)*
- [tblfn52](#tblfn52) *(p. 54)*
- [tblfn53](#tblfn53) *(p. 54)*
- [tblfn48](#tblfn48) *(p. 54)*
- [tblfn49](#tblfn49) *(p. 54)*
- [tblfn50](#tblfn50) *(p. 54)*
- [S128](#s128) *(p. 55)*
- [S129](#s129) *(p. 55)*
- [S130](#s130) *(p. 55)*
- [tblfn54](#tblfn54) *(p. 55)*
- [tblfn55](#tblfn55) *(p. 55)*
- [tblfn56](#tblfn56) *(p. 55)*
- [tblfn57](#tblfn57) *(p. 55)*
- [tblfn58](#tblfn58) *(p. 55)*
- [tblfn59](#tblfn59) *(p. 55)*
- [tblfn60](#tblfn60) *(p. 55)*
- [tblfn61](#tblfn61) *(p. 55)*
- [tblfn62](#tblfn62) *(p. 55)*
- [tblfn63](#tblfn63) *(p. 56)*
- [tblfn64](#tblfn64) *(p. 56)*
- [tblfn65](#tblfn65) *(p. 56)*
- [tblfn66](#tblfn66) *(p. 56)*
- [tblfn67](#tblfn67) *(p. 56)*
- [tblfn68](#tblfn68) *(p. 56)*
- [tblfn69](#tblfn69) *(p. 57)*
- [tblfn70](#tblfn70) *(p. 57)*
- [tblfn71](#tblfn71) *(p. 57)*
- [tblfn72](#tblfn72) *(p. 57)*
- [tblfn73](#tblfn73) *(p. 57)*
- [tblfn74](#tblfn74) *(p. 57)*
- [S139](#s139) *(p. 58)*
- [tblfn75](#tblfn75) *(p. 58)*
- [S142](#s142) *(p. 59)*
- [tblfn76](#tblfn76) *(p. 59)*
- [tblfn77](#tblfn77) *(p. 59)*
- [tblfn86](#tblfn86) *(p. 61)*
- [S148](#s148) *(p. 62)*
- [S149](#s149) *(p. 62)*
- [S150](#s150) *(p. 63)*
- [S151](#s151) *(p. 63)*
- [S152](#s152) *(p. 63)*
- [tblfn87](#tblfn87) *(p. 63)*
- [tblfn88](#tblfn88) *(p. 63)*
- [tblfn89](#tblfn89) *(p. 63)*
- [tblfn90](#tblfn90) *(p. 63)*
- [S153](#s153) *(p. 64)*
- [S154](#s154) *(p. 64)*
- [S155](#s155) *(p. 64)*
- [S156](#s156) *(p. 65)*
- [S157](#s157) *(p. 65)*
- [S158](#s158) *(p. 65)*
- [S159](#s159) *(p. 65)*
- [tblfn94](#tblfn94) *(p. 65)*
- [tblfn95](#tblfn95) *(p. 65)*
- [tblfn96](#tblfn96) *(p. 65)*
- [tblfn91](#tblfn91) *(p. 65)*
- [tblfn92](#tblfn92) *(p. 65)*
- [tblfn93](#tblfn93) *(p. 65)*
- [S160](#s160) *(p. 66)*
- [S161](#s161) *(p. 66)*
- [tblfn97](#tblfn97) *(p. 66)*
- [tblfn98](#tblfn98) *(p. 66)*
- [tblfn99](#tblfn99) *(p. 66)*
- [tblfn100](#tblfn100) *(p. 66)*
- [tblfn101](#tblfn101) *(p. 66)*
- [tblfn102](#tblfn102) *(p. 66)*
- [tblfn103](#tblfn103) *(p. 66)*
- [S162](#s162) *(p. 67)*
- [S163](#s163) *(p. 67)*
- [S164](#s164) *(p. 67)*
- [S165](#s165) *(p. 67)*
- [S166](#s166) *(p. 67)*
- [S167](#s167) *(p. 67)*
- [S168](#s168) *(p. 67)*
- [S170](#s170) *(p. 68)*
- [S171](#s171) *(p. 68)*
- [S173](#s173) *(p. 69)*
- [tblfn104](#tblfn104) *(p. 69)*
- [tblfn105](#tblfn105) *(p. 69)*
- [tblfn106](#tblfn106) *(p. 69)*
- [S174](#s174) *(p. 70)*
- [tblfn107](#tblfn107) *(p. 70)*
- [tblfn108](#tblfn108) *(p. 70)*
- [tblfn109](#tblfn109) *(p. 70)*
- [tblfn110](#tblfn110) *(p. 70)*
- [tblfn510](#tblfn510) *(p. 70)*
- [S175](#s175) *(p. 71)*
- [tblfn111](#tblfn111) *(p. 71)*
- [tblfn112](#tblfn112) *(p. 71)*
- [tblfn113](#tblfn113) *(p. 71)*
- [tblfn114](#tblfn114) *(p. 71)*
- [tblfn115](#tblfn115) *(p. 71)*
- [tblfn116](#tblfn116) *(p. 71)*
- [tblfn117](#tblfn117) *(p. 71)*
- [tblfn118](#tblfn118) *(p. 71)*
- [tblfn119](#tblfn119) *(p. 71)*
- [S176](#s176) *(p. 72)*
- [S177](#s177) *(p. 72)*
- [tblfn120](#tblfn120) *(p. 72)*
- [tblfn121](#tblfn121) *(p. 72)*
- [tblfn122](#tblfn122) *(p. 72)*
- [tblfn123](#tblfn123) *(p. 72)*
- [S178](#s178) *(p. 73)*
- [S179](#s179) *(p. 73)*
- [tblfn124](#tblfn124) *(p. 73)*
- [tblfn125](#tblfn125) *(p. 73)*
- [tblfn126](#tblfn126) *(p. 73)*
- [S180](#s180) *(p. 76)*
- [S181](#s181) *(p. 79)*
- [S182](#s182) *(p. 84)*
- [S183](#s183) *(p. 84)*
- [tblfn127](#tblfn127) *(p. 84)*
- [S184](#s184) *(p. 85)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of
Cardiology and 12 medical societies
With the special contribution of the European Association of
Preventive Cardiology (EAPC)
Authors/Task Force Members: Frank L.J. Visseren* (Chairperson) (Netherlands),
Franc¸ois Mach* (Chairperson) (Switzerland), Yvo M. Smulders† (Task Force
Coordinator) (Netherlands), David Carballo† (Task Force Coordinator)
(Switzerland), Konstantinos C. Koskinas (Switzerland), Maria B€ack (Sweden),
Athanase Benetos8 (France), Alessandro Biffi7,10 (Italy), Jose´-Manuel Boavida9
(Portugal), Davide Capodanno (Italy), Bernard Cosyns (Belgium), Carolyn Crawford
(Northern Ireland), Constantinos H. Davos (Greece), Ileana Desormais (France),
Emanuele Di Angelantonio (United Kingdom), Oscar H. Franco (Switzerland), Sigrun
Halvorsen (Norway), F. D. Richard Hobbs13 (United Kingdom), Monika Hollander
(Netherlands), Ewa A. Jankowska (Poland), Matthias Michal11 (Germany), Simona
Sacco6 (Italy), Naveed Sattar (United Kingdom), Lale Tokgozoglu2 (Turkey),
Serena Tonstad (Norway), Konstantinos P. Tsioufis5 (Greece), Ineke van Dis3
(Netherlands), Isabelle C. van Gelder (Netherlands), Christoph Wanner4 (Germany),
Bryan Williams (United Kingdom), ESC Scientific Document Group
* Corresponding authors: The two chairpersons contributed equally to the document. Frank Visseren, Department of Vascular Medicine, University Medical Center Utrecht,
Heidelberglaan 100, 3584 CX Utrecht, Netherlands. Tel: þ31 (0)88 7557324, E-mail: F.L.J.Visseren@umcutrecht.nl. Franc¸ois Mach, Cardiology Department, Geneva University Hospital,
Perret-Gentil 4, 1211 Geneva, Switzerland. Tel: þ41 (0)22 372 71 92, E-mail: francois.mach@hcuge.ch. † The two task force coordinators contributed equally to the document.
Author/Task Force Member afﬁliations: listed in Author information.
ESC Clinical Practice Guidelines Committee (CPG): listed in the Appendix.
Patient Forum
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to
Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
Disclaimer: The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientiﬁc and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other ofﬁcial recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC
Guidelines exempt health professionals from taking into full and careful consideration the relevant ofﬁcial updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientiﬁcally accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
This article has been co-published with permission in the European Heart Journal and the European Journal of Preventive Cardiology. V
C The European Society of Cardiology 2021. All rights reserved. The articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Either citation can be used when citing this article.
For ermissions, please email: journals.permissions@oup.com.
ESC GUIDELINES
doi:10.1093/eurheartj/ehab484
ESC subspecialty communities having participated in the development of this document. Associations: Association of Cardiovascular Nursing & Allied
Professions (ACNAP), European Association of Cardiovascular Imaging (EACVI), European Association of Preventive Cardiology (EAPC), European Heart Rhythm Association
(EHRA), Heart Failure Association (HFA). Councils: Council for Cardiology Practice, Council on Hypertension. Working Groups: Aorta and Peripheral Vascular Diseases,
Atherosclerosis and Vascular Biology, Cardiovascular Pharmacotherapy.


<!-- PAGE 2 -->

### Page 2

.............................................
Document Reviewers: Guy De Backer (CPG Review Coordinator) (Belgium), Vera Regitz-Zagrosek (CPG
Review Coordinator) (Germany), Anne Hege Aamodt6 (Norway), Magdy Abdelhamid (Egypt),
Victor Aboyans (France), Christian Albus11 (Germany), Riccardo Asteggiano (Italy), Magnus B€ack
(Sweden), Michael A. Borger (Germany), Carlos Brotons13 (Spain), Jelena Celutkien _e (Lithuania), Renata
Cifkova (Czech Republic), Maja Cikes (Croatia), Francesco Cosentino (Italy), Nikolaos Dagres (Germany),
Tine De Backer (Belgium), Dirk De Bacquer (Belgium), Victoria Delgado (Netherlands),
Hester Den Ruijter (Netherlands), Paul Dendale (Belgium), Heinz Drexel (Austria), Volkmar Falk
(Germany), Laurent Fauchier (France), Brian A. Ference (United Kingdom), Jean Ferrie`res (France), Marc
Ferrini (France), Miles Fisher1 (United Kingdom), Danilo Fliser4 (Germany), Zlatko Fras (Slovenia), Dan
Gaita3 (Romania), Simona Giampaoli (Italy), Stephan Gielen (Germany), Ian Graham (Ireland), Catriona
Jennings (Ireland), Torben Jorgensen (Denmark), Alexandra Kautzky-Willer12 (Austria), Maryam Kavousi
(Netherlands), Wolfgang Koenig (Germany), Aleksandra Konradi (Russia), Dipak Kotecha (United
Kingdom), Ulf Landmesser (Germany), Madalena Lettino (Italy), Basil S. Lewis (Israel), Ales Linhart (Czech
Republic), Maja-Lisa Løchen (Norway), Konstantinos Makrilakis9 (Greece), Giuseppe Mancia5 (Italy),
Pedro Marques-Vidal (Switzerland), John William McEvoy (Ireland), Paul McGreavy (United Kingdom),
Bela Merkely (Hungary), Lis Neubeck (United Kingdom), Jens Cosedis Nielsen (Denmark), Joep Perk
(Sweden), Steffen E. Petersen (United Kingdom), Anna Sonia Petronio (Italy), Massimo Piepoli (Italy),
Nana Goar Pogosova (Russia), Eva Irene Bossano Prescott (Denmark), Kausik K. Ray2 (United Kingdom),
Zeljko Reiner (Croatia), Dimitrios J. Richter (Greece), Lars Ryde´n (Sweden), Evgeny Shlyakhto (Russia),
Marta Sitges (Spain), Miguel Sousa-Uva (Portugal), Isabella Sudano (Switzerland), Monica Tiberi7,10 (Italy),
Rhian M. Touyz (United Kingdom), Andrea Ungar8 (Italy), W.M. Monique Verschuren (Netherlands),
Olov Wiklund (Sweden), David Wood (United Kingdom/Ireland), Jose Luis Zamorano (Spain)
All experts involved in the development of these guidelines have submitted declarations of interest.
These have been compiled in a report and published in a supplementary document simultaneously to the guidelines. The report is also available on the ESC website www.escardio.org/guidelines
Collaborating and endorsing societies: 1European Association for the Study of Diabetes (EASD);
2European Atherosclerosis Society (EAS); 3European Heart Network (EHN); 4European Renal Association
- European Dialysis and Transplant Association (ERA-EDTA); 5European Society of Hypertension (ESH);
6European Stroke Organization (ESO); 7European Federation of Sports Medicine Association (EFSMA);
8European Geriatric Medicine Society (EuGMS); 9International Diabetes Federation Europe (IDF Europe);
10International Federation of Sport Medicine (FIMS); 11International Society of Behavioural Medicine
(ISBM); 12International Society of Gender Medicine (IGM); 13World Organization of National Colleges,
Academies and Academic Associations of General Practitioners/Family Physicians (WONCA)  Europe
...................................................................................................................................................................................................
Keywords
Guidelines • prevention • personalized • population • risk estimation • lifetime risk • lifetime beneﬁt •
risk management • shared decision-making • stepwise approach • nutrition • smoking • healthy lifestyle •
psychosocial factors • blood pressure • lipids • diabetes • smoking • air pollution • climate change
Table of Contents
1. Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3233
2. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3234
2.1. Definition and rationale . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3235
2.2. Development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3236
2.3. Cost-effectiveness . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3236
2.4. What is new? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3236
3. Risk factors and clinical conditions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3236
3.1. Target population for assessing cardiovascular disease risk . . 3236
3.2. Risk factors and risk classification . . . . . . . . . . . . . . . . . . . . . . . . . . 3236
3.2.1. Risk factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3236
3.2.1.1 Cholesterol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3242
3.2.1.2 Blood pressure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3242
3.2.1.3 Cigarette smoking . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3242
3.2.1.4 Diabetes mellitus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3243
3.2.1.5 Adiposity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3243
3.2.2. Sex and gender and their impact on health . . . . . . . . . . . . . 3243
3.2.3. Atherosclerotic cardiovascular disease risk classification . 3243
3.2.3.1 A stepwise approach to risk factor treatment and treatment intensification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3243
3.2.3.2 Risk estimation in apparently healthy people . . . . . . . . . . . 3245
3.2.3.3 Translating cardiovascular disease risk to treatment thresholds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3250
3.2.3.4 Risk estimation and risk factor treatment in apparently healthy people 5069 years of age . . . . . . . . . . . . . . . 3253
3.2.3.5 Risk estimation and risk factor treatment estimation in apparently healthy people 70 years of age . . . . . 3253


<!-- PAGE 3 -->

### Page 3

.............................................................................................................................................................................
3.2.3.6 Risk estimation and risk factor treatment in apparently healthy people <50 years of age . . . . . . . . . . . . . . . . . 3254
3.2.3.7 Risk estimation and risk factor treatment in patients with established atherosclerotic cardiovascular disease . . . . . . . . . 3254
3.2.3.8 Risk estimation and risk factor treatment in persons with type 2 diabetes mellitus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3256
3.2.3.9 Risk estimation and risk factor treatment in persons with type 1 diabetes mellitus . . . . . . . . . . . . . . . . . . . . . . . . 3257
3.2.4. Communication of cardiovascular disease risk . . . . . . . . . . 3257
3.3. Potential risk modifiers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3258
3.3.1. Psychosocial factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3258
3.3.2. Ethnicity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3258
3.3.3. Imaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
3.3.3.1 Coronary artery calcium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3259
3.3.3.2 Contrast computed tomography coronary angiography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3259
3.3.3.3 Carotid ultrasound . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3259
3.3.3.4 Arterial stiffness . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3259
3.3.3.5 Ankle brachial index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3259
3.3.3.6 Echocardiography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3259
3.3.4. Frailty . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3259
3.3.5. Family history . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3259
3.3.6. Genetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3260
3.3.7. Socioeconomic determinants . . . . . . . . . . . . . . . . . . . . . . . . . 3260
3.3.8. Environmental exposure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3260
3.3.9. Biomarkers in blood or urine . . . . . . . . . . . . . . . . . . . . . . . . . . 3260
3.3.10. Body composition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3260
3.3.10.1 Which index of obesity is the best predictor of cardiovascular risk? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3261
3.3.10.2 Risk reclassification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3261
3.3.10.3 Assess risk factors and cardiovascular disease risk in persons with obesity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3262
3.4. Clinical conditions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3262
3.4.1. Chronic kidney disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3262
3.4.2. Atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3262
3.4.3. Heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3262
3.4.4. Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3263
3.4.4.1 Diagnosis and screening . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3264
3.4.4.2 Prevention of cardiotoxicity and cardiovascular risk factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3264
3.4.5. Chronic obstructive pulmonary disease . . . . . . . . . . . . . . . . 3264
3.4.6. Inflammatory conditions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3265
3.4.7. Infections (human immunodeficiency virus, influenza,
periodontitis) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3265
3.4.8. Migraine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3265
3.4.9. Sleep disorders and obstructive sleep apnoea . . . . . . . . . . 3265
3.4.10. Mental disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3265
3.4.11. Non-alcoholic fatty liver disease . . . . . . . . . . . . . . . . . . . . . . 3266
3.4.12. Sex-specific conditions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3266
3.4.12.1 Obstetric conditions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3266
3.4.12.2 Non-obstetric conditions . . . . . . . . . . . . . . . . . . . . . . . . . . . 3266
3.4.12.3 Erectile dysfunction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3266
4. Risk factors and interventions at the individual level . . . . . . . . . . . . . 3266
4.1. Treatment recommendations: classes, grades, and freedom of choice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3266
4.2. Optimizing cardiovascular risk management . . . . . . . . . . . . . . . . 3268
4.2.1. Goals of clinician-patient communication . . . . . . . . . . . . . . 3268
4.2.2. How to improve motivation? . . . . . . . . . . . . . . . . . . . . . . . . . . 3268
4.2.3. Optimizing drug adherence . . . . . . . . . . . . . . . . . . . . . . . . . . . 3268
4.2.4. Treatment goals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3268
4.3. Optimizing lifestyle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3268
4.3.1. Physical activity and exercise . . . . . . . . . . . . . . . . . . . . . . . . . . 3268
4.3.1.1 Physical activity prescription . . . . . . . . . . . . . . . . . . . . . . . . . . 3269
4.3.1.2 Aerobic physical activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3269
4.3.1.3 Resistance exercise . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3269
4.3.1.4 Sedentary behaviour . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3269
4.3.2. Nutrition and alcohol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4269
4.3.2.1 Fatty acids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3270
4.3.2.2 Minerals and vitamins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3270
4.3.2.3 Fibre . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3270
4.3.2.4 Specific foods and food groups . . . . . . . . . . . . . . . . . . . . . . . 3270
4.3.2.4.1. Fruits, vegetables, and pulses . . . . . . . . . . . . . . . . . . 3270
4.3.2.4.2. Nuts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3271
4.3.2.4.3. Meat . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3271
4.3.2.4.4. Fish and fish oil supplements . . . . . . . . . . . . . . . . . . 3271
4.3.2.4.5. Alcoholic beverages . . . . . . . . . . . . . . . . . . . . . . . . . . 3271
4.3.2.4.6. Soft drinks and sugar . . . . . . . . . . . . . . . . . . . . . . . . . . 3272
4.3.2.4.7. Coffee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3272
4.3.2.4.8. Functional foods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3272
4.3.2.4.9. Dietary patterns . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3272
4.3.3. Bodyweight and composition . . . . . . . . . . . . . . . . . . . . . . . . . . 3272
4.3.3.1 Treatment goals and modalities . . . . . . . . . . . . . . . . . . . . . . 3272
4.3.3.2 Diets for weight loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3272
4.4. Mental healthcare and psychosocial interventions . . . . . . . . . . 3273
4.5. Smoking intervention . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3273
4.5.1. Smoking cessation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3273
4.5.2. Evidence-based drug interventions . . . . . . . . . . . . . . . . . . . . 3275
4.5.2.1 Electronic cigarettes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3275
4.6. Lipids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3275
4.6.1. Measurement of lipids and lipoproteins . . . . . . . . . . . . . . . . 3275
4.6.1.1 Fasting vs. non-fasting measurements . . . . . . . . . . . . . . . . . 3275
4.6.1.2 Low-density lipoprotein cholesterol measurement . . . . . . . . 50
4.6.1.3 Non-high-density lipoprotein cholesterol . . . . . . . . . . . . . . . 3276
4.6.1.4 Apolipoprotein B . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3276
4.6.2. Defining lipid goals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3276
4.6.2.1 Low-density lipoprotein cholesterol goals . . . . . . . . . . . . . . 3276
4.6.2.2 Triglyceride-rich lipoproteins and their remnants . . . . . . . . 3276
4.6.2.3 High-density lipoprotein cholesterol . . . . . . . . . . . . . . . . . . . 3276
4.6.3. Strategies to control dyslipidaemias . . . . . . . . . . . . . . . . . . . . 3278
4.6.3.1 Strategies to control low-density lipoprotein cholesterol . . 3278
4.6.3.1.1. Diet and lifestyle modifications . . . . . . . . . . . . . . . . 3278
4.6.3.1.2. Drugs for treatment of dyslipidaemias . . . . . . . . . 3278
4.6.3.1.3. Statins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3279
4.6.3.1.3.1. Adverse effects, interactions, and adherence to statin therapy . . . . . . . . . . . . . . . . . . . . . . . . . 3279
4.6.3.1.4. Cholesterol absorption inhibitors (ezetimibe) . 3279
4.6.3.1.5. Proprotein convertase subtilisin/kexin type 9
inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3279
4.6.3.2 Strategies to control plasma triglycerides . . . . . . . . . . . . . . 3279
4.6.3.2.1. Fibrates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3279
4.6.4. Important groups . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3280
4.6.4.1 Women . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3280
4.6.4.2 Older patients (70 years) . . . . . . . . . . . . . . . . . . . . . . . . . . 3280
4.6.4.3 Diabetes mellitus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3280
ESC Guidelines
3229


<!-- PAGE 4 -->

### Page 4

.............................................................................................................................................................................
4.6.4.4 Chronic kidney disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3281
4.6.4.5 Familial hypercholesterolaemia . . . . . . . . . . . . . . . . . . . . . . 3281
4.7. Blood pressure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3281
4.7.1. Definition and classification of hypertension . . . . . . . . . . . . 3283
4.7.2. Blood pressure measurement . . . . . . . . . . . . . . . . . . . . . . . . . 3283
4.7.2.1 Office blood pressure measurement . . . . . . . . . . . . . . . . . . 3283
4.7.2.2 Unattended automated office blood pressure measurement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3283
4.7.2.3 Ambulatory blood pressure monitoring . . . . . . . . . . . . . . . . 3283
4.7.2.4 Home blood pressure monitoring . . . . . . . . . . . . . . . . . . . . . 3283
4.7.3. Screening and diagnosis of hypertension . . . . . . . . . . . . . . . 3283
4.7.3.1 White-coat and masked hypertension . . . . . . . . . . . . . . . . . 3284
4.7.4. Clinical evaluation and risk stratification in hypertensive patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3284
4.7.5. Treatment of hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3285
4.7.5.1 Lifestyle interventions to lower blood pressure and/or reduce cardiovascular risk . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3285
4.7.5.2 Initiation of drug treatment . . . . . . . . . . . . . . . . . . . . . . . . . . 3285
4.7.5.3 Blood pressure treatment targets . . . . . . . . . . . . . . . . . . . . . 3285
4.7.5.3.1. Blood pressure targets according to ambulatory and home blood pressure monitoring . . . . . . . . . . . . . . . . . . 3287
4.7.5.4 Drug treatment of hypertension . . . . . . . . . . . . . . . . . . . . . . 3288
4.7.6. Resistant hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3288
4.7.7. Management of hypertension in women . . . . . . . . . . . . . . . 3288
4.7.8. Duration of treatment and follow-up . . . . . . . . . . . . . . . . . . 3288
4.8. Diabetes mellitus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3288
4.8.1. Key risk factor concepts and newer paradigms . . . . . . . . . 3289
4.8.1.1 Lifestyle intervention . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3289
4.8.1.2 Glycaemic control . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3289
4.8.1.3 Newer diabetes mellitus drug classes: cardiovascular disease benefits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3290
4.8.2. Type 1 diabetes mellitus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3290
4.9. Antithrombotic therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3290
4.9.1. Antithrombotic therapy in individuals without atherosclerotic disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3291
4.9.2. Antithrombotic therapy in individuals with established atherosclerotic disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3291
4.9.3. Proton pump inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3291
4.10. Anti-inflammatory therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3291
4.11. Cardiac rehabilitation and prevention programmes . . . . . . . . 3292
5. Policy interventions at the population level . . . . . . . . . . . . . . . . . . . . . 3292
5.1. Population-level approaches to the prevention of cardiovascular disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3293
5.2. Specific risk factor interventions at the population level . . . . . 3293
5.2.1. Physical activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3293
5.2.2. Diet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3293
5.2.3. Smoking and tobacco use . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3293
5.2.4. Alcohol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3293
5.3. Environment, air pollution, and climate change . . . . . . . . . . . . . 3293
5.3.1. Climate change . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3294
5.4. Implications for public health policy and advocacy at the governmental and non-governmental level . . . . . . . . . . . . . . . . . . . . . 3294
6. Risk management of disease-specific cardiovascular disease . . . . . 3294
6.1. Coronary artery disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3294
6.2. Heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3295
6.3. Cerebrovascular diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3296
6.4. Lower extremity artery disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3297
6.5. Chronic kidney disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3298
6.6. Atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3298
6.7. Multimorbidity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3299
7. Key messages . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3299
8. Gaps in evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3302
9. ‘What to do’ and ‘what not to do’ messages from the guidelines . 3205
10. Quality indicators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3310
11. Supplementary data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3310
12. Author information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3310
13. Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3311
14. References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3312
Recommendations
Recommendations for CVD risk assessment . . . . . . . . . . . . . . . . . . . . . . 3242
Recommendations for CVD risk estimation . . . . . . . . . . . . . . . . . . . . . . 3256
Recommendation for CVD risk communication . . . . . . . . . . . . . . . . . . 3257
Recommendations for CVD risk modifiers . . . . . . . . . . . . . . . . . . . . . . . . 3257
Recommendations for cardiovascular disease risk related to air pollution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3260
Recommendations for cardiovascular disease assessment in specific clinical conditions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3261
Recommendations for physical activity . . . . . . . . . . . . . . . . . . . . . . . . . . . 3268
Recommendations for nutrition and alcohol . . . . . . . . . . . . . . . . . . . . . . 3269
Recommendations for body weight . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3272
Recommendations for mental healthcare and psychosocial interventions at the individual level . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3273
Recommendations for smoking intervention strategies . . . . . . . . . . . . 3273
Recommendation on low-density lipoprotein cholesterol goals . . . . 3276
Recommendations for pharmacological low-density lipoprotein cholesterol lowering for those <70 years of age (for recommendations for persons aged >_70 years, see respective recommendations tables) . . . . . . . . . . . . 3278
Recommendations for drug treatments of patients with hypertriglyceridaemia.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3284
Recommendations for the treatment of dyslipidaemias in older people (>_70 years) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3284
Recommendations for the treatment of dyslipidaemias in diabetes mellitus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3284
Recommendations for lipid management in patients with moderatetosevere chronic kidney disease (Kidney Disease Outcomes
Quality Initiative stages 35) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3281
Summary of recommendations for the clinical management of hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3282
Recommendations for the treatment of patients with diabetes mellitus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3288
Recommendations for antithrombotic therapy . . . . . . . . . . . . . . . . . . . . 3290
Recommendation for anti-inflammatory therapy . . . . . . . . . . . . . . . . . . 3291
Recommendations for cardiac rehabilitation . . . . . . . . . . . . . . . . . . . . . . 3292
Recommendations for policy interventions at the population level . . 3292
Recommendations for patients with coronary artery disease . . . . . . 3294
Recommendations regarding pharmacological and nonpharmacological interventions for patients with symptomatic
(New York Heart Association class II-IV) heart failure with reduced ejection fraction (left ventricular ejection fraction <40%) with proven benefits on clinical outcomes, including cardiovascular morbidity and mortality . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3295
Recommendations for patients with cerebrovascular disease . . . . . . 3297


<!-- PAGE 5 -->

### Page 5

.............................................................................................................................................................................
Recommendations for patients with lower extremity artery disease:
best medical therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3297
Recommendations in patients with chronic kidney disease: best medical therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3310
Recommendations for lifestyle interventions and management of risk factors and concomitant diseases in patients with atrial fibrillation . . 3310
Tables
Table 1 Classes of recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3234
Table 2 Levels of evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3234
Table 3 New recommendations and new and revised concepts . . . . 3237
Table 4 Patient categories and associated cardiovascular disease risk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3244
Table 5 Cardiovascular disease risk categories based on
Systemic Coronary Risk Estimation 2 and Systemic Coronary
Risk Estimation 2-Older Persons in apparently healthy people according to age . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3251
Table 6 Treatment goals for different patient categories . . . . . . . . . . . 3267
Table 7 Classification of physical activity intensity and examples of absolute and relative intensity levels
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3269
Table 8 Healthy diet characteristics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3270
Table 9 ‘Very brief advice’ for smoking cessation . . . . . . . . . . . . . . . . . . 3275
Table 10 Corresponding non-high-density lipoprotein cholesterol and apolipoprotein B levels for commonly used low-density lipoprotein cholesterol goals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3275
Table 11 Dutch Lipid ClinicNetwork diagnostic criteria for familial hypercholesterolaemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3281
Table 12 Categories for conventionally measured seated office blood pressurea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3283
Table 13 Definitions of hypertension according to office,
ambulatory, and home blood pressure . . . . . . . . . . . . . . . . . . . . . . . . . . . 3283
Table 14 Considerations in blood pressure measurement . . . . . . . . . 3283
Table 15 Indications for home blood pressure monitoring or ambulatory blood pressuremonitoring . . . . . . . . . . . . . . . . . . . . . . . . . . . 3284
Table 16 Routine tests for patients with hypertension . . . . . . . . . . . . . 3285
Table 17 Patient characteristics that should raise the suspicion of secondary hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3285
Table 18 Recommended office blood pressure target ranges. The first step in all groups is a reduction to systolic blood pressure
<140 mmHg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3287
Figures
Figure 1 Central Illustration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3235
Figure 2 Examples of a stepwise approach to risk stratification and treatment options . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3245
Figure 3 Systematic Coronary Risk Estimation 2 and Systematic
Coronary Risk Estimation 2-Older Persons risk charts for fatal and non-fatal (myocardial infarction, stroke) cardiovascular disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3246
Figure 4 Risk regions based on World Health Organization cardiovascular mortality rates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3250
Figure 5 Schematic representation of increasing 10-year cardiovascular disease risk thresholds across age groups . . . . . . . . . . 3251
Figure 6 Flow chart of cardiovascular disease risk and risk factor treatment in apparently healthy persons . . . . . . . . . . . . . . . . . . . . . . . . . . 3252
Figure 7 Flow chart of cardiovascular risk and risk factor treatment in patients with established atherosclerotic cardiovascular disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3253
Figure 8 Flow chart of cardiovascular risk and risk factor treatment in patients with type 2 diabetes mellitus . . . . . . . . . . . . . . . . . . . . . . . . . . . 3255
Figure 9 The role of risk factors and comorbidities in atrial fibrillation
3263
Figure 10 Estimated percentage change in risk of coronary heart disease associated with isocaloric substitutions of saturated fat for other types of fat or carbohydrates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3271
Figure 11 Lifetime atherosclerotic cardiovascular disease benefit from smoking cessation for apparently healthy persons, based on the following risk factors: age, sex, systolic blood pressure, and non-high-density lipoprotein-cholesterol . . . . . . . . . . . . . . . . . . . . . . . . . 3274
Figure 12 Average years-free-of-cardiovascular disease gained per
1 mmol/L (40 mg/dL) low-density lipoprotein cholesterol reduction in apparently healthy persons . . . . . . . . . . . . . . . . . . . . . . . . . . 3277
Figure 13 Expected low-density lipoprotein cholesterol reductions for combination therapies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3278
Figure 14 Screening and diagnosis of hypertension . . . . . . . . . . . . . . . . 3284
Figure 15 Lifetime benefit from lowering systolic blood pressure by 10 mmHg for apparently healthy persons, based on the following risk factors: age, sex, current smoking, systolic blood pressure, non-highdensity lipoprotein cholesterol . . . . . . . . . . . . . . . . . 3286
Figure 16 Core drug treatment strategy for hypertension . . . . . . . . . . 3287
Abbreviations and acronyms
%HRmax
Percentage of maximum heart rate
ABC
Atrial ﬁbrillation Better Care
ABI
Ankle brachial index
ABPM
Ambulatory blood pressure monitoring
ACCORD
Action to Control Cardiovascular Risk in
Diabetes
ACE
Angiotensin-converting enzyme
ACR
Albumin-to-creatinine ratio
ACS
Acute coronary syndromes
ADA
American Diabetes Association
ADVANCE
Action in Diabetes and Vascular Disease:
preterAx and diamicroN-MR Controlled
Evaluation
AF
Atrial ﬁbrillation
AMI
Acute myocardial infarction
ARB
Angiotensin receptor blocker
ARNI
Angiotensin receptor neprilysin inhibitor
ASCEND
A Study of Cardiovascular Events in Diabetes
ASCVD
Atherosclerotic cardiovascular disease b.i.d.
Bis in die (twice a day)
BMI
Body mass index
BP
Blood pressure b.p.m.
Beats per minute
CAC
Coronary artery calcium
CAD
Coronary artery disease
CANTOS
Canakinumab Antiinﬂammatory Thrombosis
Outcome Study
CCB
Calcium channel blocker
CCS
Chronic coronary syndromes
ESC Guidelines
3231


<!-- PAGE 6 -->

### Page 6

............................................................................................................................................................................
CCTA
Contrast computed tomography angiography
CHD
Coronary heart disease
CI
Conﬁdence interval
CKD
Chronic kidney disease
CKD-EPI
Chronic Kidney Disease Epidemiology
COLCOT
Colchicine Cardiovascular Outcomes Trial
COMPASS
Cardiovascular Outcomes for People Using
Anticoagulation Strategies
COPD
Chronic obstructive pulmonary disease
CR
Cardiac rehabilitation
CTA
Computed tomography angiography
CV
Cardiovascular
CVD
Cardiovascular disease
DAPA-CKD
Dapagliﬂozin and Prevention of Adverse
Outcomes in Chronic Kidney Disease
DAPT
Dual antiplatelet therapy
DASH
Dietary Approaches to Stop Hypertension
DBP
Diastolic blood pressure
DCCT
Diabetes Control and Complications Trial
DIAL
Diabetes lifetime-perspective prediction
DM
Diabetes mellitus e-cigarettes
Electronic cigarettes
EAPC
European Association of Preventive Cardiology
EAS
European Atherosclerosis Society
EASD
European Association for the Study of Diabetes
EBCR
Exercise-based cardiac rehabilitation
ECG
Electrocardiographic/electrocardiogram
ED
Erectile dysfunction eGFR
Estimated glomerular ﬁltration rate
EORP
EURObservational Research Programme
EPIC
European Prospective Investigation into Cancer and Nutrition
ESC
European Society of Cardiology
ESH
European Society of Hypertension
ESVS
European Society for Vascular Surgery
EU
European Union
EUROASPIRE
European Action on Secondary and Primary
Prevention by Intervention to Reduce Events
EuroHeart
European Uniﬁed Registries On Heart Care
Evaluation and Randomized Trials
EXPERT
EXercise Prescription in Everyday practice &
Rehabilitation Training
FEV1
Forced expiratory volume in 1 second
FH
Familial hypercholesterolaemia
FITT
Frequency, intensity, time duration, and type of exercise
GFR
Glomerular ﬁltration rate
GLP-1RA
Glucagon-like peptide-1 receptor agonist
HbA1c
Glycated haemoglobin
HBPM
Home blood pressure monitoring
HDL-C
High-density lipoprotein cholesterol
HF
Heart failure
HFpEF
Heart failure with preserved ejection fraction
HFrEF
Heart failure with reduced ejection fraction
HIV
Human immunodeﬁciency virus
HMOD
Hypertension-mediated organ damage
HR
Hazard ratio
IL
Interleukin
IMPROVE-IT
Improved Reduction of Outcomes: Vytorin
Efﬁcacy International Trial
IMT
Intima-media thickness
INVEST
INternational VErapamil-SR/Trandolapril STudy
LDL
Low-density lipoprotein
LDL-C
Low-density lipoprotein cholesterol
LDLR
Low-density lipoprotein receptor
LEAD
Lower extremity artery disease
LIFE-CVD
LIFEtime-perspective CardioVascular Disease
LoDoCo
Low-dose colchicine
LV
Left ventricular/ventricle
LVEF
Left ventricular ejection fraction
MACE
Major adverse cardiovascular events
MET
Metabolic equivalent of task mHealth
Mobile device-based healthcare
MRA
Mineralocorticoid receptor antagonist
MUFA
Monounsaturated fatty acid
N/A
Not applicable
NAFLD
Non-alcoholic fatty liver disease
NRT
Nicotine-replacement therapy
NYHA
New York Heart Association o.d.
Omni die (once a day)
OARS
Open-ended questions, Afﬁrmation, Reﬂecting listening, and Summarizing
OR
Odds ratio
OSA
Obstructive sleep apnoea
PA
Physical activity
PAD
Peripheral artery disease
PAP
Positive airway pressure
PCI
Percutaneous coronary intervention
PCSK9
Proprotein convertase subtilisin/kexin type 9
PM
Particulate matter
PM2.5
Particulate matter <2.5 mm
PUFA
Polyunsaturated fatty acid
QI
Quality indicator
RAAS
Renin-angiotensin-aldosterone system
RAS
Renin-angiotensin system
RCT
Randomized controlled trial
REDUCE-IT
Reduction of Cardiovascular Events with
Icosapent EthylIntervention Trial
REWIND
Researching Cardiovascular Events With a
Weekly Incretin in Diabetes
RPE
Rating of perceived exertion
RR
Relative risk
SAVOR-TIMI 53
Saxagliptin Assessment of Vascular Outcomes
Recorded in Patients with Diabetes Mellitus
Thrombolysis in Myocardial Infarction
SBP
Systolic blood pressure
SCORE
Systemic Coronary Risk Estimation
SCORE2
Systemic Coronary Risk Estimation 2
SCORE2-OP
Systematic Coronary Risk Estimation 2-Older
Persons
SCOT-HEART
Scottish Computed Tomography of the Heart
SGLT2
Sodium-glucose cotransporter 2


<!-- PAGE 7 -->

### Page 7

.......................................................................................................................................................................
SHARP
Study of Heart and Renal Protection
SMART
Secondary Manifestations of Arterial Disease
SMART
Speciﬁc, Measurable, Achievable, Realistic,
Timely
SMART-REACH
Secondary Manifestations of Arterial
Disease-Reduction of Atherothrombosis for
Continued Health
SNRI
Serotonin-noradrenaline reuptake inhibitor
SPRINT
Systolic Blood Pressure Intervention Trial
SSRI
Selective serotonin reuptake inhibitor
STAREE
STAtin Therapy for Reducing Events in the
Elderly
STRENGTH
Long-Term Outcomes Study to Assess Statin
Residual Risk with Epanova in High
Cardiovascular Risk Patients with
Hypertriglyceridemia
SUPRIM
Secondary Prevention in Uppsala Primary
Health Care project
SWITCHD
Stockholm Women’s Intervention Trial for
Coronary Heart Disease
TIA
Transient ischaemic attack
TNF
Tumour necrosis factor
TOD
Target organ damage
UK
United Kingdom
UKPDS
UK Prospective Diabetes Study
VADT
Veterans Affairs Diabetes Trial
VITAL
Vitamin D and Omega-3 Trial
VO2
Oxygen consumption
WHO
World Health Organization
1. Preamble
Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.
A great number of guidelines have been issued in recent years by the European Society of Cardiology (ESC), as well as by other societies and organizations. Because of their impact on clinical practice,
quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC website (https://www.escardio.org/Guidelines).
The ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated.
In addition to the publication of Clinical Practice Guidelines, the
ESC carries out the EURObservational Research Programme of international registries of cardiovascular diseases and interventions which are essential to assess diagnostic/therapeutic processes, use of resources and adherence to guidelines. These registries aim at providing a better understanding of medical practice in Europe and around the world, based on high-quality data collected during routine clinical practice.
Furthermore, the ESC has developed and embedded in this document a set of quality indicators (QIs), which are tools to evaluate the level of implementation of the guidelines and may be used by the
ESC, hospitals, healthcare providers and professionals to measure clinical practice as well as used in educational programmes, alongside the key messages from the guidelines, to improve quality of care and clinical outcomes.
The Members of this Task Force were selected by the ESC,
including representation from its relevant ESC sub-specialty groups, in order to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a comprehensive review of the published evidence for management of a given condition according to ESC
Clinical Practice Guidelines Committee (CPG) policy. A critical evaluation of diagnostic and therapeutic procedures was performed, including assessment of the riskbenefit ratio. The level of evidence and the strength of the recommendation of particular management options were weighed and graded according to predefined scales, as outlined below.
The experts of the writing and reviewing panels provided declaration of interest forms for all relationships that might be perceived as real or potential sources of conflicts of interest. Their declarations of interest were reviewed according to the ESC declaration of interest rules and can be found on the ESC website
(http://www.escardio.org/guidelines)and have been compiled in a report and published in a supplementary document simultaneously to the guidelines.
This process ensures transparency and prevents potential biases in the development and review processes. Any changes in declarations of interest that arise during the writing period were notified to the ESC and updated. The Task Force received its entire financial support from the ESC without any involvement from the healthcare industry.
The ESC CPG supervises and coordinates the preparation of new guidelines. The Committee is also responsible for the endorsement process of these guidelines. The ESC Guidelines undergo extensive review by the CPG and external experts. After appropriate revisions the guidelines are signed-off by all the experts involved in the Task
Force. The finalized document is signed-off by the CPG for publication in the European Heart Journal. The guidelines were developed after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating.
The task of developing ESC Guidelines also includes the creation of educational tools and implementation programmes for the recommendations including condensed pocket guideline versions, summary slides, summary cards for non-specialists and an electronic version for digital applications (smartphones, etc.). These versions are abridged and thus, for more detailed information, the user should always access to the full text version of the guidelines, which is freely available via the ESC website and hosted on the EHJ website. The
National Cardiac Societies of the ESC are encouraged to endorse,
adopt, translate and implement all ESC Guidelines. Implementation
ESC Guidelines
3233


<!-- PAGE 8 -->

### Page 8

.................................
programmes are needed because it has been shown that the outcome of disease may be favourably influenced by the thorough application of clinical recommendations.
Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies. However, the ESC Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient or the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription.
2. Introduction
Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are declining in many countries in Europe, but it is still a major cause of morbidity and mortality. Over the past few decades, major ASCVD risk factors have been identified. The most
Table 2
Levels of evidence
Level of 
evidence A
Data derived from multiple randomized clinical trials 
or meta-analyses. 
Level of 
evidence B
Data derived from a single randomized clinical trial or large non-randomized studies. 
Level of 
evidence C
Consensus of opinion of the experts and/or small studies, 
retrospective studies, registries.
©ESC 2021
Table 1
Classes of recommendations
©ESC 2021
Classes of recommendations
Class I 
Evidence and/or general agreement 
that a given treatment or procedure is 
Is recommended or is indicated
Wording to use
Class III 
Evidence or general agreement that the 
given treatment or procedure is not 
useful/effective, and in some cases 
may be harmful.
Is not recommended
   Class IIb established by evidence/opinion.
May be considered
   Class IIa
Weight of evidence/opinion is in 
Should be considered
Class II


<!-- PAGE 9 -->

### Page 9

.............................................
important way to prevent ASCVD is to promote a healthy lifestyle throughout life, especially not smoking. Effective and safe risk factor treatments have been developed, and most drugs are now generic and available at low costs. Nevertheless, the prevalence of unhealthy lifestyle is still high, and ASCVD risk factors are often poorly treated,
even in patients considered to be at high (residual) CVD risk.1
Prevention of CV events by reducing CVD risk is the topic of these guidelines.
2.1. Definition and rationale
The present guidelines have been developed to support healthcare professionals in their efforts to reduce the burden of ASCVD in both individual patients, as well as at a population level. The previous
European Guidelines on CVD prevention in clinical practice were published in
2016.2
Recent developments in prediction of cardiovascular disease (CVD) risk and treatment benefit, as well as novel treatments and treatment goals, necessitated new, up-to-date guidelines. The current guidelines on CVD prevention in clinical practice concentrate principally but not exclusively on the risk factors,
risk classification, and prevention of ASCVD.
The current guidelines provide recommendations on ASCVD prevention to support shared decision-making by the patient and their healthcare professional based on individual patient characteristics.
Special considerations have been given to differences in age, sex and gender, life expectancy, risk factor profiles, ethnic, and geographic differences. Estimating CVD risk not only in apparently healthy subjects,
but also in older persons and in patients with established ASCVD or diabetes mellitus (DM), provides information for tailored intervention on an individual level. Treatment goals can be individualized in a stepwise approach. ‘Residual’ CVD risk is defined as the risk
Prevention goals for all
Reduction of CVD burden
About CVD (lifetime) risk and treatment benefits tailored to individual needs and preferences considering age, comorbidities, frailty, polypharmacy
Informed discussion
Diabetes mellitus, CKD, Familial
Hypercholesterolaemia
Specific risk conditions
Residual CVD risk
Patients with established ASCVD
10-year CVD risk
Apparently healthy people
CVD risk estimation
Individual-level interventions and treatment goals
Lifestyle (physical activity, body weight, nutrition)
Psychosocial factors
Risk factor treatment (smoking,
lipids, blood pressure, diabetes)
Anti-thrombotic therapy
Disease-specific interventions
Cost-effectiveness considerations
Risk modifiers
Comorbidity e.g. cancer, COPD, inflammatory disease,
mental disorders, sex-specific conditions
Psychosocial stress
Ethnicity
Imaging (e.g. coronary calcium scoring)
Population-level interventions
Public health policy and advocacy
Specific risk factor interventions at the population level (physical activity, diet, alcohol, smoking)
Environment, air pollution,
climate change
Personalized treatment decisions
Figure 1 Central Illustration. ASCVD = atherosclerotic cardiovascular disease; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; CVD = cardiovascular disease
ESC Guidelines
3235


<!-- PAGE 10 -->

### Page 10

.............................................................................................................................................................................
estimated after initial lifestyle changes and risk factor treatment, and is mostly used in patients with established ASCVD. For younger apparently healthy subjects, lifetime CVD risk estimates are available to support treatment decisions, replacing 10-year risk algorithms that consistently estimate low 10-year risk even in the presence of high risk factor levels. In an ageing population, treatment decisions require a specific CVD risk score that takes competing non-CVD risk into account, as well as specific low-density lipoprotein cholesterol (LDLC) and blood pressure (BP) treatment considerations. Estimating lifetime benefit in individual patients of smoking cessation, LDL-C
lowering, and BP lowering provides opportunities to communicate benefit of treatment in an easy-to-understand way. Personalized treatment decisions using CVD risk estimations and a stepwise approach to treatment is more complex than a more general onesize-fits-all prevention strategy, but reflects the diversity in patients and patient characteristics in clinical practice.
Regarding LDL-C, BP, and glycaemic control in patients with DM,
goals and targets remain as recommended in recent European
Society of Cardiology (ESC) Guidelines.35 These prevention guidelines propose a new, stepwise approach to treatment intensification as a tool to help physicians and patients pursue these targets in a way that fits patient profile and preferences. Of note, however, new evidence and/or new consensus may have resulted in some differences with these recent domain-specific ESC Guidelines. New evidence on antithrombotic treatment regimens for ASCVD prevention is also presented. Sex-specific aspects are included.
ASCVD prevention needs an integrated, interdisciplinary approach including input from several disciplines and areas of expertise. We must work together in a patient- and family-centred way to address each of the core components of prevention and rehabilitation, including lifestyle modification, psychosocial factors, risk factor treatment,
and social determinants (Central Illustration).
2.2. Development
The Task Force chairs and members were appointed by the ESC
Clinical Practice Guidelines Committee (CPG). Each member of the Task Force was assigned specific writing tasks, which were reviewed by other (sub)section writers, the section coordinators,
and the chairs. The text was developed over 11 months, during which the Task Force members met collectively on three occasions and corresponded intensively between meetings. The review panel consisted of experts selected by all the scientific societies that were involved in the development of these guidelines, not only the ESC.
2.3. Cost-effectiveness
The Task Force acknowledge the fact that healthcare budgets are, in many circumstances, limited and thus that certain recommendations and goals may not always be attainable. However, the current guidelines do not provide cost-effectiveness analyses. Large national and regional differences in budgets and costs associated with both interventions and diseases/events preclude valid universal costeffectiveness analyses. However, some recommendations clearly have financial implications, either in terms of costs for individual patients and/or in terms of budget impact. Some of these recommendations pertain to diagnosis (e.g. large-scale use of expensive imaging tests such as computed tomography), others to interventions (e.g.
expensive drugs, such as novel lipid-lowering or anti-diabetic drugs).
For such recommendations, it is inappropriate to ‘unconditionally’
implement them without first considering cost-effectiveness in a national or regional context or, ideally, to perform formal costeffectiveness analyses with country-specific input parameters and cost-effectiveness thresholds.
2.4. What is new?
New recommendations, and new and revised concepts, are presented in Table 3.
3. Risk factors and clinical conditions
3.1. Target population for assessing cardiovascular disease risk
CVD risk assessment or screening can be done opportunistically or systematically. Opportunistic screening, which means screening without a predefined strategy, is done when a person presents for some other reason. Systematic screening can be done in the general population as part of a formal screening programme, with call and recall of patients, or in targeted subpopulations such as subjects with type 2
DM, or family history of premature CVD. Systematic screening results in improvements in risk factors, but has no effect on CVD outcomes.69 Opportunistic screening for ASCVD risk factors, such as
BP or lipids, is effective at increasing detection rates and is recommended, although a beneficial effect on clinical outcome is uncertain.10
Structured national programmes aiming to identify undocumented
ASCVD risk factors in adults over 40 years of age without DM or
ASCVD and treat them have shown better risk factor control, but there are conflicting results as to clinical outcomes.11,12 A high-risk strategy of inviting the population predicted to be at the highest risk according to an integrated risk score would be equally effective at preventing new cases of CVD and have potential cost savings.13 One large trial of mobile ultrasound screening for aortic aneurysm, peripheral artery disease (PAD), and hypertension in males aged 6574
years showed a 7% mortality reduction at 5 years.14
A common criticism of screening in general is the potential that false positive and false negative results may cause harm. However,
evidence on CVD screening shows that those who participate do not report mental distress.1518
Systematic CVD risk assessment assessment in the general population (adult men >40 and women >50 years of age) with no known
CV risk factors appears not cost-effective in reducing subsequent vascular events and premature death, at least in short-term follow-up,
but does increase detection of CV risk factors. Risk assessment is not a one-time event; it should be repeated, for example, every 5 years,
although there are no empirical data to guide intervals.
3.2. Risk factors and risk classification
3.2.1. Risk factors
The main causal and modifiable ASCVD risk factors are blood apolipoprotein-B-containing lipoproteins [of which low-density lipoprotein (LDL) is most abundant], high BP, cigarette smoking, and DM.


<!-- PAGE 11 -->

### Page 11

Table 3
What is new
New or revised
Recommendations in 2013 version
Class
Recommendations in 2021 version
Class
Risk factors and clinical conditions  section 3
New
In apparently healthy people <70 years of age without established
ASCVD, DM, CKD, genetic/rarer lipid or BP disorders, estimation of 10-year fatal and nonfatal CVD risk with SCORE2 is recommended.
I
New
In apparently healthy people >_70 years of age without established
ASCVD, DM, CKD, genetic/rarer lipid or BP disorder, estimation of 10-year fatal and nonfatal CVD risk with SCORE2-OP is recommended.
I
New
Patients with established ASCVD and/or DM and/or moderateto-severe renal disease and/or genetic/rarer lipid or BP disorders are to be considered at high or very high CVD risk.
I
New
A stepwise treatment-intensiﬁcation approach aiming at intensive risk factor treatment is recommended for apparently healthy people at high or very high ASCVD risk, as well as patients with established ASCVD and/or DM, with consideration of CVD risk,
treatment beneﬁt of risk factors, risk modiﬁers, comorbidities,
and patient preferences.
I
New
Treatment of ASCVD risk factors is recommended in apparently healthy people without DM, CKD, genetic/rarer lipid or BP disorders who are at very high CVD risk (SCORE2 >_7.5% for age under 50; SCORE2 >_10% for age 5069; SCORE2-OP >_15% for age >_70).
I
New
An informed discussion about CVD risk and treatment beneﬁts tailored to the needs of a patient is recommended.
I
New
It is recommended that mental disorders with either signiﬁcant functional impairment or decreased use of healthcare systems be considered as inﬂuencing
I
New
Treatment of ASCVD risk factors should be considered in apparently healthy people without DM, CKD, genetic/rarer lipid, or BP
disorders who are at high CVD risk (SCORE2 2.5 to <7.5% for age under 50; SCORE2 5 to <10% for age 5069; SCORE2-OP
7.5 to <15% for age >_70 years), taking ASCVD risk modiﬁers, lifetime risk and treatment beneﬁt, and patient preferences into account.
IIa
New
In apparently healthy people, after estimation of 10-year fatal and non-fatal CVD risk, lifetime risk and treatment beneﬁt, risk modiﬁers, frailty, polypharmacy, and patient preferences should be considered.
IIa
New
Presence of migraine with aura should be considered in CVD risk assessment.
IIa
New
Assessment of CVD risk should be considered in men with ED.
IIa
New
In women with a history of premature or stillbirth, periodic screening for hypertension and DM may be considered.
IIb
New
Assessment of total CVD risk may be considered in adults with chronic inﬂammatory conditions.
IIb
New
Avoidance of combined hormonal contraceptives may be considered in women with migraine with aura.
IIb
Risk factors and interventions at the individual level  section 4
New
It is recommended to reduce sedentary time to engage in at least light activity throughout the day to reduce all-cause and CV mortality and morbidity.
I
Continued
ESC Guidelines
3237


<!-- PAGE 12 -->

### Page 12

Table 3
Continued
New or revised
Recommendations in 2013 version
Class
Recommendations in 2021 version
Class
New
It is recommended to adopt a Mediterranean or similar diet to lower risk of CVD.
I
New
It is recommended to restrict alcohol consumption to a maximum of 100 g per week.
I
New
It is recommended to eat ﬁsh, preferably fatty, at least once a week and restrict (processed) meat.
I
New
Patients with mental disorders need intensiﬁed attention and support to improve adherence to lifestyle changes and drug treatment.
I
New
Smoking cessation is recommended regardless of weight gain, as weight gain does not lessen the ASCVD beneﬁts of cessation.
I
New
In patients with established ASCVD, lipid-lowering treatment with an ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) and a >_50%
reduction of LDL-C vs. baseline is recommended.
I
New
For secondary prevention patients not achieving their goals on a maximum tolerated dose of a statin and ezetimibe, combination therapy including a PCSK9 inhibitor is recommended.
I
New
In patients with type 2 DM at very high risk (e.g. with established
ASCVD and/or severe TOD), intensive lipid-lowering therapy,
ultimately aiming at >_50% LDL-C reduction and an LDL-C of <1.4
mmol/L (<55 mg/dL) is recommended.
I
New
In patients with type 2 DM >40 years of age at high risk, lipid-lowering treatment with an ultimate LDL-C goal of >_50% LDL-C
reduction and an LDL-C of <1.8 mmol/L (70 mg/dL) is recommended.
I
New
It is recommended that the ﬁrst objective of treatment is to lower
BP to <140/90 mmHg in all patients, and that subsequent BP targets are tailored to age and speciﬁc comorbidities.
I
New
In treated patients aged 1869 years, it is recommended that SBP
should ultimately be lowered to a target range of 120130
mmHg in most patients.
I
New
In treated patients aged >_70 years, it is recommended that SBP
should generally be targeted to <140 and down to 130 mmHg if tolerated.
I
New
In all treated patients, DBP is recommended to be lowered to
<80 mmHg.
I
New
In persons with type 2 DM and ASCVD, the use of a GLP-1RA or
SGLT2 inhibitor with proven outcome beneﬁts is recommended to reduce CV and/or cardiorenal outcomes.
I
New
In patients with type 2 DM and CKD, the use of an SGLT2 inhibitor is recommended to improve CVD and/or cardiorenal outcomes.
I
New
In patients with type 2 DM and HFrEF, use of an SGLT2 inhibitor with proven outcome beneﬁts is recommended to lessen HF hospitalizations and CV death.
I
New
Participation in a medically supervised, structured, comprehensive, multidisciplinary EBCR and prevention programme for patients after ASCVD events and/or revascularization, and for patients with HF (mainly HFrEF), is recommended to improve patient outcomes.
I
Continued


<!-- PAGE 13 -->

### Page 13

Table 3
Continued
New or revised
Recommendations in 2013 version
Class
Recommendations in 2021 version
Class
New
Lifestyle interventions, such as group or individual education,
behaviour-change techniques, telephone counselling, and use of consumer-based wearable activity trackers, should be considered to increase PA participation.
IIa
New
Bariatric surgery for obese high-risk individuals should be considered when lifestyle change does not result in maintained weight loss.
IIa
New
ASCVD patients with stress should be considered for referral to psychotherapeutic stress management to improve CVD outcomes and reduce stress symptoms.
IIa
New
Patients with CHD and moderate-to-severe major depression should be considered for antidepressive treatment with an SSRI.
IIa
New
An ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) and LDL-C
reduction of >_50% from baseline should be considered in apparently healthy persons <70 years at very high risk.
IIa
New
An ultimate LDL-C goal of <1.8 mmol/L (70 mg/dL) and LDL-C
reduction of >_50% from baseline should be considered in apparently healthy persons <70 years at high risk.
IIa
New
For those motivated to try, considerable weight loss with use of low-calorie diets followed by food reintroduction and weightmaintenance phases early after diagnosis can lead to DM remission and should be considered.
IIa
New
In patients with type 2 DM and TOD, the use of an SGLT2 inhibitor or GLP-1RA with proven outcome beneﬁts may be considered to reduce future CVD and total mortality.
IIb
New
For primary prevention patients at very high risk, but without FH,
if the LDL-C goal is not achieved on a maximum tolerated dose of a statin and ezetimibe, combination therapy including a PCSK9
inhibitor may be considered.
IIb
New
In high-risk (or above) patients with triglycerides >1.5 mmol/L
(135 mg/dL) despite statin treatment and lifestyle measures, n-3
PUFAs (icosapent ethyl 2 X 2 g/day) may be considered in combination with a statin.
IIb
New
Initiation of statin treatment for primary prevention in older people aged >_70 may be considered, if at high risk or above.
IIb
New
Statin therapy may be considered in persons aged <_40 years with type 1 or type 2 DM with evidence of TOD and/or an LDL-C
level >2.6 mmol/L (100 mg/dL), as long as pregnancy is not being planned.
IIb
New
In patients with DM at high or very high CVD risk, low-dose aspirin may be considered for primary prevention in the absence of clear contraindications.
IIb
New
Home-based CR, telehealth, and mHealth interventions may be considered to increase patient participation and long-term adherence to healthy behaviours.
IIb
New
In patients with HF and major depression, SSRIs, SNRIs, and tricyclic antidepressants are not recommended.
III
New
In patients with dialysis-dependent CKD who are free of ASCVD,
commencing statin therapy is not recommended.
III
Continued
ESC Guidelines
3239


<!-- PAGE 14 -->

### Page 14

Table 3
Continued
New or revised
Recommendations in 2013 version
Class
Recommendations in 2021 version
Class
Policy interventions at the population level  section 5
New
Putting in place measures to reduce air pollution, including reducing PM emission and gaseous pollutants, reducing the use of fossil fuels, and limiting carbon dioxide emissions, are recommended to reduce CVD mortality and morbidity.
I
Risk management of disease-speciﬁc cardiovascular disease  section 6
New
It is recommended that patients with HF are enrolled in a comprehensive CR programme to reduce the risk of HF hospitalization and death.
I
New
It is recommended to screen patients with HF for both CV and non-CV comorbidities which, if present, should be treated, provided safe and effective interventions exist, not only to alleviate symptoms but also to improve prognosis.
I
New
In patients with a cerebrovascular event, improvement of lifestyle factors in addition to appropriate pharmacological management is recommended.
I
New
Identiﬁcation and management of risk factors and concomitant diseases are recommended to be an integral part of treatment in patients with AF.
I
New
Adding a second antithrombotic drug (a P2Y12 inhibitor or lowdose rivaroxaban) to aspirin for long-term secondary prevention should be considered in patients with a high risk of ischaemic events and without high bleeding risk.
IIa
New
In patients with DM and chronic symptomatic LEAD without high bleeding risk, a combination of low-dose rivaroxaban (2.5 mg b.i.d.) and aspirin (100 mg o.d.) may be considered.
IIb
Adding a second antithrombotic drug to aspirin for long-term secondary prevention may be considered in patients with a moderate risk of ischaemic events and without a high bleeding risk.
IIb
Risk factors and clinical conditions  section 3
Revised
ABI may be considered as a risk modiﬁer in
CVD risk assessment.
IIb
The routine collection of other potential modiﬁers, such as genetic risk scores, circulating or urinary biomarkers, or vascular tests or imaging methods (other than CAC scoring or carotid ultrasound for plaque determination), is not recommended.
III
Risk factors and interventions at the individual level  section 4
Revised
Drug treatment should be considered in patients with grade 1 or 2 hypertension who are at high CVD risk.
IIa
For grade 1 hypertension, treatment initiation based on absolute
CVD risk, estimated lifetime beneﬁt, and the presence of HMOD
is recommended.
I
Revised
In patients with type 2 DM and CVD, use of an SGLT2 inhibitor should be considered early in the course of the disease to reduce CVD and total mortality.
IIa
In persons with type 2 DM and ASCVD, the use of a GLP-1RA or
SGLT2 inhibitor with proven outcome beneﬁts is recommended to reduce CV and/or cardiorenal outcomes.
I
ABI = ankle brachial index; AF = atrial ﬁbrillation; ASCVD = atherosclerotic cardiovascular disease; b.i.d. = bis in die (twice a day); BP = blood pressure; CAC = coronary artery calcium; CHD = coronary heart disease; CKD = chronic kidney disease; CR = cardiac rehabilitation; CV = cardiovascular; CVD = cardiovascular disease; DM = diabetes mellitus; EBCR = exercise-based cardiac rehabilitation; ED = erectile dysfunction; FH = familial hypercholesterolaemia; GLP-1RA = glucagon-like peptide-1 receptor agonist; HF =
heart failure; HFrEF = heart failure with reduced ejection fraction; HMOD = hypertension-mediated organ damage; LDL-C = low-density lipoprotein cholesterol; LEAD =
lower extremity artery disease; mHealth = mobile device-based healthcare; o.d. = omni die (once a day); PA = physical activity; PCSK9 = proprotein convertase subtilisin/kexin type 9; PM = particulate matter; PUFA = polyunsaturated fatty acid; SBP = systolic blood pressure; SCORE2 = Systematic Coronary Risk Estimation 2; SCORE2-OP =
Systematic Coronary Risk Estimation 2-Older Persons; SGLT2 = sodium-glucose cotransporter 2; SNRI = serotonin-noradrenaline reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor; TOD = target organ damage.
ESC 2021


<!-- PAGE 15 -->

### Page 15

New sections
Section 3
3.2.2 Sex and gender and their impact on health
3.2.3 Atherosclerotic cardiovascular disease risk classiﬁcation
3.2.3.1 A stepwise approach to risk factor treatment and treatment intensiﬁcation
3.2.3.2 Risk estimation in apparently healthy people
3.2.3.3 Translating atherosclerotic cardiovascular disease risk to treatment thresholds
3.2.3.4 Risk estimation and risk factor treatment in apparently healthy people 5069 years of age
3.2.3.5 Risk estimation and risk factor treatment estimation in apparently healthy people >_70 years of age
3.2.3.6 Risk estimation and risk factor treatment in apparently healthy people <50 years of age
3.2.3.7 Risk estimation and risk factor treatment in patients with established atherosclerotic cardiovascular disease
3.2.4 Communication of cardiovascular disease risk
3.3.1 Psychosocial factors
3.3.4 Frailty
3.3.8 Environmental exposure
3.4 Clinical conditions
3.4.2 Atrial ﬁbrillation
3.4.3 Heart failure
3.4.5 Chronic obstructive pulmonary disease
3.4.6 Inﬂammatory conditions
3.4.7 Infections (human immunodeﬁciency virus, inﬂuenza, periodontitis)
3.4.8 Migraine
3.4.9 Sleep disorders and obstructive sleep apnoea
3.4.10 Mental disorders
3.4.11 Non-alcoholic fatty liver disease
3.4.12 Sex-speciﬁc conditions
Section 4
• 4.10 Anti-inﬂammatory treatment
New /revised concepts
Section 3
• SCORE2 and SCORE2-OP risk charts for fatal and non-fatal (myocardial infarction, stroke) ASCVD
• Estimating 10-year total CVD risk in apparently healthy people 5069 years of age
• Estimating lifetime risk in apparently healthy people <50 years of age
• Estimating 10-year total CVD risk in apparently healthy people >_70 years of age
• Cut-offs of 10-year CVD risk, based on SCORE2/SCORE2-OP, to deﬁne lowmoderate risk, high risk, and very high risk for apparently healthy people in different age groups (<50, 5069,
and >_70 years)
• Estimating 10-year CVD risk in patients with established CVD and/or DM
• Lifetime beneﬁt of stopping smoking, reducing LDL-C, or lowering SBP (sections 3 and 4)
• A stepwise approach to attaining ultimate treatment goals (sections 3 and 4)
• Communication of CVD risk and beneﬁt of treatment to patients in an understandable way
• Stepwise approach to risk factor treatment and treatment intensiﬁcation
Section 4
• Explicitly addressing cost-effectiveness (on a loco-regional or national level) before implementing some recommendations
• Non-fasting lipid measurement (section 4.6.1.1)
• A stepwise approach to attaining treatment goals (sections 3 and 4)
• Anti-inﬂammatory treatment for very-high-risk patients
Section 5
• Taking into consideration population level interventions to mitigate the effects of pollution on CVD health
Section 6
• Risk management of disease-speciﬁc CVD. This section addresses CVD prevention when certain underlying diseases are present and aims to provide guidance on how to prevent the worsening of existing, or the development of further, comorbidities that could increase the overall risk of CVD
• Subsections include: 6.1 Coronary artery disease; 6.2 Heart failure; 6.3 Cerebrovascular disease; 6.4 Lower extremity artery disease; 6.5 Chronic kidney disease; 6.6 Atrial ﬁbrillation; 6.7 Multimorbidity
ASCVD = atherosclerotic cardiovascular disease; CVD = cardiovascular disease; DM =diabetes mellitus; LDL-C = low-density lipoprotein cholesterol; SBP = systolic bloodpressure; SCORE2 = Systematic Coronary Risk Estimation 2; SCORE2-OP = Systematic Coronary Risk Estimation 2-Older Persons.
ESC 2021
ESC Guidelines
3241


<!-- PAGE 16 -->

### Page 16

.........................................................................................................................................................................
Another important risk factor is adiposity, which increases CVD risk via both major conventional risk factors and other mechanisms. In addition to these, there are many other relevant risk factors, modifiers, and clinical conditions, which are addressed under risk modifiers and clinical conditions (sections 3.3 and 3.4).
3.2.1.1 Cholesterol
The causal role of LDL-C, and other apo-B-containing lipoproteins,
in the development of ASCVD is demonstrated beyond any doubt by genetic, observational, and interventional studies.20 The key attributes of LDL-C as a risk factor for ASCVD are:
• Prolonged lower LDL-C is associated with lower risk of ASCVD
throughout the range studied, and the results of randomized controlled trials (RCTs) indicate that lowering LDL-C safely reduces CVD risk even at low LDL-C levels [e.g. LDL-C <1.4
mmol/L (55 mg/dL)].20
• The relative reduction in CVD risk is proportional to the absolute size of the change in LDL-C, irrespective of the drug(s) used to achieve such change.21
• The absolute benefit of lowering LDL-C depends on the absolute risk of ASCVD and the absolute reduction in LDL-C, so even a small absolute reduction in LDL-C may be beneficial in a high- or very-high-risk patient.22
• Non-high-density lipoprotein cholesterol (HDL-C) encompasses all atherogenic (apo-B-containing) lipoproteins, and is calculated as: total cholesterol  HDL-C = non-HDL-C. The relationship between non-HDL-C and CV risk is at least as strong as the relationship with LDL-C. Non-HDL-C levels contain, in essence, the same information as a measurement of apoB plasma concentration.23,24 Non-HDL-C is used as an input in the Systemic Coronary Risk Estimation 2 (SCORE2) and
SCORE2-Older Persons (SCORE2-OP) risk algorithms.
HDL-C is inversely associated with CVD risk. Very high HDL-C levels may signal an increased CVD risk. There is, however, no evidence from Mendelian randomization studies, or randomized trials of cholesteryl ester transfer protein inhibitors, that raising plasma HDL-C
reduces CVD risk.2528 HDL-C is nonetheless a useful biomarker to refine risk estimation using the SCORE2 algorithms. The SCORE2
algorithm cannot be used for patients with a genetic lipid disorder,
such as familial hypercholesterolaemia (FH). Specific LDL-C thresholds and targets are recommended irrespective of estimated CV risk for patients with FH or other rare/genetic lipid disorders.
3.2.1.2 Blood pressure
Longitudinal studies, genetic epidemiological studies, and RCTs have shown that raised BP is a major cause of both ASCVD and nonatherosclerotic CVD [particularly heart failure (HF)], accounting for
9.4 million deaths and 7% of global disability adjusted life-years.29
Elevated BP is a risk factor for the development of coronary artery disease (CAD), HF, cerebrovascular disease, lower extremity arterial disease (LEAD), chronic kidney disease (CKD), and atrial fibrillation
(AF). The risk of death from either CAD or stroke increases linearly from BP levels as low as 90 mmHg systolic and 75 mmHg diastolic upwards.30,31 The absolute benefit of reducing systolic BP (SBP)
depends on absolute risk and the absolute reduction in SBP, except that lower limits of SBP are imposed by tolerability and safety considerations. Management is determined by the category of hypertension
(optimal, normal, high-normal, stages 1 to 3, and isolated systolic hypertension), defined according to seated office BP, ambulatory BP
monitoring (ABPM), or home BP average values (see section
4.7). Evidence suggests that lifetime BP evolution differs in women compared to men, potentially resulting in an increased CVD risk at lower BP thresholds.3234 The SCORE2 algorithm cannot be used for patients with secondary causes and rarer forms of hypertension,
such as primary hyperaldosteronism.
3.2.1.3 Cigarette smoking
Cigarette smoking is responsible for 50% of all avoidable deaths in smokers, with half of these due to ASCVD. A lifetime smoker has a
50% probability of dying due to smoking, and on average will lose 10
years of life.35 The CVD risk in smokers <50 years of age is five-fold higher than in non-smokers.36 Prolonged smoking is more hazardous for women than for men.37 Worldwide, after high SBP, smoking is the leading risk factor for disability adjusted life-years.38 Second-hand smoke is associated with an increase in CVD risk.39 Some smokeless tobacco is also associated with increased risk of CVD.40
Recommendations for CVD risk assessment
Recommendations
Classa
Levelb
Systematic global CVD risk assessment is recommended in individuals with any major vascular risk factor (i.e. family history of premature CVD,
FH, CVD risk factors such as smoking, arterial hypertension, DM, raised lipid level, obesity, or comorbidities increasing CVD risk).
I
C
Systematic or opportunistic CV risk assessment in the general population in men >40 years of age and in women >50 years of age or postmenopausal with no known ASCVD risk factors may be considered.9
IIb
C
In those individuals who have undergone CVD
risk assessment in the context of opportunistic screening, a repetition of screening after 5 years
(or sooner if risk was close to treatment thresholds) may be considered.
IIb
C
Opportunistic screening of BP in adults at risk for the development of hypertension, such as those who are overweight or with a known family history of hypertension, should be considered.19
IIa
B
Systematic CVD risk assessment in men <40
years of age and women <50 years of age with no known CV risk factors is not recommended.9
III
C
ASCVD = atherosclerotic cardiovascular disease; BP = blood pressure; CV = cardiovascular; CVD = cardiovascular disease; DM = diabetes mellitus; FH = familial hypercholesterolaemia.
aClass of recommendation.
bLevel of evidence.
ESC 2021


<!-- PAGE 17 -->

### Page 17

.............................................................................................................................................................................
3.2.1.4 Diabetes mellitus
Type 1 DM, type 2 DM, and prediabetes are independent risk factors for ASCVD, increasing risk of ASCVD by about two-fold, depending on the population and therapeutic control.41 Women with type 2
DM appear to have a particularly higher risk for stroke.42 Patients with type 2 DM are likely to have multiple ASCVD risk factors
(including dyslipidaemia and hypertension), each of which mediates an increase in risk of both ASCVD and non-ASCVD.
3.2.1.5 Adiposity
Over recent decades, body mass index (BMI)—measured as weight
(in kg) divided by squared height (in m2)—has increased substantially worldwide in children, adolescents, and adults.43 Mendelian randomization analyses suggest a linear relation between BMI and mortality in non-smokers and a J-shaped relation in ever-smokers.44 All-cause mortality is lowest at a BMI of 2025 kg/m2 in apparently healthy people, with a J-shaped or U-shaped relation.45,46 In HF patients,
there is evidence for an obesity paradox, with lower mortality risk in patients with higher BMI. A meta-analysis concluded that both BMI
and waist circumference are similarly, strongly, and continuously associated with ASCVD and type 2 DM.47
3.2.2. Sex and gender and their impact on health
The current prevention guidelines recognize the importance of integrating sex, gender, and gender identity considerations into the risk assessment and clinical management of individuals and populations.
These guidelines also acknowledge the complexity of the interrelationship between these concepts and CV, as well as psychological, health. There is, at present, no official ESC position on the specific terminology to be used.
According to the
World
Health
Organization (WHO), sex ‘refers to the different biological and physiological characteristics of females, males, and intersex persons, such as chromosomes, hormones and reproductive organs’.48
This is to be distinguished from gender, which ‘refers to the characteristics of women, men, girls and boys that are socially constructed. This includes norms, behaviours and roles associated with being a woman, man, girl or boy, as well as relationships with each other. As a social construct, gender varies from society to society and can change over time’.48 The Global Health 50/50 definition further states that gender refers ‘to the socially constructed norms that impose and determine roles, relationships, and positional power for all people across their lifetime’.49
Where evidence exists on the risk modifying effect of sex or where sex-specific clinical conditions and clinical management strategies exist, this has been included in these guidelines.50 The influence of gender on an individual’s experience and access to healthcare is paramount.50 The specific health concerns related to gender are thus also acknowledged in these prevention Guidelines.
Epigenetic effects of social constructs appear to condition the translation of biological sex into disease pathophysiology.
Furthermore, social constructs can also be determinants of health access, healthcare utilization, disease perception, decision-making,
and perhaps therapeutic response,50 including in the field of CVD and
ASCVD prevention. Research is ongoing, but gaps in evidence remain and this has also been recognized in the guidelines.
Examples of specific topics regarding physiological, pathological,
and clinical differences related to sex and gender that have been studied include left ventricular (LV) ejection fraction (LVEF), adverse drug reactions, trends in ASCVD risk factors and awareness, sex disparities in the management of and outcomes after acute coronary syndromes (ACS).5158 Furthermore, CVD health after menopause transition, pregnancy disorders, and gynaecologic conditions have recently been reviewed.59
3.2.3. Cardiovascular disease risk classification
The current guidelines on CVD prevention in clinical practice concentrate principally, but not exclusively, on risk and prevention of
ASCVD. This includes risk factors, risk prediction, risk modifiers, as well as clinical conditions that often increase the likelihood of
ASCVD.
Identifying patients who will benefit most from ASCVD risk factor treatment is central to ASCVD prevention efforts. In general, the higher the absolute CVD risk, the higher the absolute benefit of risk factor treatment, and thus the lower the number needed to treat to prevent one CVD event during a period of time.60,61 With this in mind, the estimation of CVD risk remains the cornerstone of these guidelines and thus appears at the forefront of the proposed management schemes, which are summarized in flowcharts.
Age is the major driver of CVD risk. Women below 50 years and men below 40 years of age are almost invariably at low 10-year CVD
risk, but may have unfavourable modifiable risk factors that sharply increase their longer-term CVD risk. Conversely, men over 65 years and women over 75 years of age are almost always at high 10-year
CVD risk. Only between the ages of 55 and 75 years in women and
40 and 65 years in men does the 10-year CVD risk vary around commonly used thresholds for intervention. The age categories <50,
5069, and >_70 years should be used with common sense and flexibility. Different age ranges may be considered for men and women and may differ according to geographic region. Uncertainty around risk estimations should also be considered.
CVD risk can also be assessed in patients with type 2 DM and in patients with established ASCVD. The populations or patient groups in whom CVD risk needs to be considered are summarized and presented in Table 4. Lifetime CVD risk estimation is available for various groups of patients, and enables estimation of lifetime benefit from preventive interventions such as smoking cessation (see section 4.5.1),
lipid-lowering (see section 4.6.2.1), and BP treatment (see section
4.7.5.2). Lifetime risk and benefit estimation may be used for communication in the shared decision-making process, together with consideration of comorbidities, frailty, patient preferences for initiating
(STEP 1) and intensifying (STEP 2) risk factor treatment (Figure 2).
3.2.3.1 A stepwise approach to risk factor treatment and treatment intensification
As explained before, targets and goals for LDL-C, BP, and glycaemic control in DM remain as recommended in recent ESC Guidelines.35
These guidelines propose a stepwise approach to treatment intensification as a tool to help physicians and patients pursue these targets in a way that fits patient profiles and preferences. This principle (outlined in Figure 2, using the example of a stepwise approach) is not conceptually novel, but rather reflects routine clinical practice, in which treatment strategies are initiated and then intensified, both as part of a shared decision-making process involving healthcare professionals and patients.
ESC Guidelines
3243


<!-- PAGE 18 -->

### Page 18

Table 4
Patient categories and associated cardiovascular disease risk.
Patient category
Subgroups
Risk 
categories
Apparently healthy persons
Persons without established 
ASCVD, diabetes mellitus, CKD, 
Familial Hypercholesterolemia
<50 years
Low- to high-risk
10-year CVD risk estimation (SCORE2). Lifetime risk 
 
(e.g. with the LIFE-CVD lifetime model) to facilitate the 
50-69 years
Low- to very high-risk
10-year CVD risk estimation (SCORE2). Lifetime 
 
(e.g. with the LIFE-CVD lifetime model) to facilitate the 
≥70 years
Low- to very high-risk
10-year CVD risk estimation (SCORE2-OP). Lifetime 
 
(e.g. with the LIFE-CVD lifetime model) to facilitate the 
Patients with CKD
CKD without diabetes or ASCVD
Moderate CKD (eGFR 30−44 mL/min/1.73 m2 
and ACR <30 or 
eGFR 45−59 mL/min/1.73 m2 and  
ACR 30−300 or  
eGFR ≥60 mL/min/1.73 m2 and ACR >300) 
High-risk
N/A
Severe CKD (eGFR<30 mL/min/1.73 m2 or eGFR 30−44 mL/min/1.73 m2 and ACR >30)
Very 
high-risk
N/A
Familial Hypercholesterolemia
Associated with markedly elevated 
cholesterol levels
N/A
High-risk
N/A
Patients with type 2 diabetes mellitus
Patients with type 1 DM above 
according to these criteria
Patients with well controlled short-standing 
DM (e.g. <10 years), no evidence of TOD 
and no additional ASCVD risk factors
Moderaterisk
N/A
Patients with DM without ASCVD and/or 
risk criteria. 
High-risk
Residual 10-year CVD risk estimation after general 
prevention goals (e.g. with the ADVANCE risk score or 
estimation of risk factor treatment (e.g. DIAL model).
Patients with DM with established ASCVD 
and/or severe TOD:87, 93-95
 • eGFR <45 mL/min/1.73 m2 irrespective  
  of albuminuria
 • eGFR 45-59 mL/min/1.73 m2 and  
  microalbuminuria (ACR 30 -300 mg/g)
 • Proteinuria (ACR >300 mg/g)
 • Presence of microvascular disease  
  
 
  microalbuminuria plus retinopathy  
  plus neuropathy)
Very high-risk
Residual 10-year CVD risk estimation after general 
prevention goals (e.g. with the SMART risk score for 
established CVD or with the ADVANCE risk score or 
with the DIAL model). Consider lifetime CVD risk and 
model).
Patients with established ASCVD
Documented ASCVD, clinical or 
unequivocal on imaging. Documented 
clinical ASCVD includes previous 
AMI, ACS, coronary revascularization 
and other arterial revascularization 
procedures, stroke and TIA, aortic 
aneurysm and PAD. Unequivocally 
documented ASCVD on imaging 
includes plaque on coronary 
angiography or carotid ultrasound 
or on CTA. It does NOT include 
some increase in continuous imaging 
parameters such as intima–media 
thickness of the carotid artery. 
N/A
Very high-risk
Residual CVD risk estimation after general prevention 
goals (e.g. 10-year risk with the SMART risk score for 
patients with established CVD or 1- or 2-year risk 
with EUROASPIRE risk score for patients with CHD).  
risk factor treatment (e.g. SMART-REACH model; or 
DIAL model if diabetes).
ACR = albumin-to-creatinine ratio: (to convert mg/g to mg/mmol: divide by 10); ACS = acute coronary syndromes; ADVANCE = Action in Diabetes and Vascular disease:
preterAx and diamicroN-MR Controlled Evaluation; AMI = acute myocardial infarction; ASCVD = atherosclerotic cardiovascular disease; CKD = chronic kidney disease; CTA
= computed tomography angiography; CV = cardiovascular; CVD = cardiovascular disease; DIAL = Diabetes lifetime-perspective prediction; DM = diabetes mellitus; FH =
familial hypercholesterolaemia; eGFR = estimated glomerular ﬁltration rate; IMT = intima-media thickness; LIFE-CVD = LIFEtime-perspective CardioVascular Disease; N/A =
not applicable; PAD = peripheral artery disease; REACH = Reduction of Atherothrombosis for Continued Health; SBP = systolic blood pressure; SCORE = Systematic
Coronary Risk Estimation; SMART = Secondary Manifestations of Arterial Disease; TIA = transient ischaemic attack.
ESC 2021


<!-- PAGE 19 -->

### Page 19

.......................................................
A stepwise approach starts with prevention goals for all, regardless of CVD risk. This is followed by CVD risk stratification and discussion of potential benefits of treatment with the patient. If treatment is initiated, its effect must be evaluated, and subsequent treatment intensification to reach ultimate risk factor goals must be considered in all patients, taking into account additional benefit, comorbidities, and frailty, all of which converge with patient preferences in a shared decision-making process.
In the field of DM, studies have shown benefit of a stepwise approach to treatment intensification and do not support the contention of ‘therapeutic nihilism’ occurring in either physicians or patients.
In fact, it appears that attainment of treatment goals is similar, sideeffects are fewer, and patient satisfaction is significantly higher with such an approach.66,67 We do, however, emphasize that stopping assessment of treatment goals and/or treatment routinely after the first step is inappropriate. The evidence-based ultimate targets of treatment intensification are optimal from the perspective of CVD
risk reduction and are to be considered in all patients.
3.2.3.2 Risk estimation in apparently healthy people
Apparently healthy people are those without established ASCVD,
type 2 DM, or severe comorbidities. In the 2016 ESC prevention guidelines,2 the Systemic Coronary Risk Estimation (SCORE) algorithm was used to estimate 10-year risk of CVD death. However,
CVD morbidity (non-fatal myocardial infarction, non-fatal stroke)
combined with CVD mortality better reflects the total burden of
ASCVD. The updated SCORE algorithm—SCORE2—used in these guidelines (see Figure 3), estimates an individual’s 10-year risk of fatal and non-fatal CVD events (myocardial infarction, stroke) in apparently healthy people aged 4069 years with risk factors that are untreated or have been stable for several years.68
Several specific considerations apply to CVD risk estimation in older people. First, the gradient of the relationship between classical risk factors, such as lipids and BP, with CVD risk attenuates with age.69 Second, CVD-free survival dissociates from overall survival progressively with increasing age, because risk for non-CVD mortality increases (‘competing risk’).70 For these reasons, traditional risk
Categories of individuals considered for prevention
STEP 1
10-year CVD risk
Lifetime CVD risk and treatment benefit
Comorbidities
Patient preferences
Intensified prevention and treatment goals based on:
Apparently healthy persons
(See Figure 6)
STEP 2
Patients with established ASCVD
(See Figure 7)
Patients with type 2 diabetes mellitus
(See Figure 8)
Patients with specific risk factors such as CKD
and FH (See Table 4)
Prevention goals for all
Prevention goals for all
Prevention goals for all
Specific risk factor prevention and treatment goals based on risk categories
Estimate 10-year
CVD risk
Consider risk modifiers,
lifetime CVD risk,
treatment benefit and patient preferences
Prevention goals
Ultimate prevention goals
Prevention goals based on whether patients are without or with established ASCVD
and/or severe TOD
10-year CVD risk
Lifetime CVD risk and treatment benefit
Comorbidities
Patient preferences
Intensified prevention and treatment goals based on:
Ultimate prevention goals
10-year CVD risk
Lifetime CVD risk and treatment benefit
Comorbidities
Patient preferences
Intensified prevention and treatment goals based on:
Ultimate prevention goals
Figure 2 Examples of a stepwise approach to risk stratification and treatment options. ASCVD = atherosclerotic cardiovascular disease; CKD = chronic kidney disease; DM = diabetes mellitus; FH = familial hypercholesterolaemia; TOD = target organ damage.
ESC Guidelines
3245


<!-- PAGE 20 -->

### Page 20

1
1
1
1
1
1
1
1
8
8
9
9
7
5
5
5
5
5
6
6
6
7
7
7
7
3
3
4
4
4
4
4
5
5
5
5
6
6
6
7
3
4
4
4
2
2
3
3
3
3
3
3
3
4
4
4
4
5
5
5
2
2
2
2
2
2
2
3
2
3
3
3
2
2
2
3
3
3
3
3
1
1
1
1
1
2
2
2
2
2
2
3
1
2
2
2
2
2
2
2
2
2
3
3
12 12 13 13
11
7
7
7
8
8
9
9
9
10 10 11 11
5
6
6
6
6
7
7
8
8
8
9
9
10 10
11
6
7
7
8
4
4
5
5
5
6
6
6
6
7
7
8
8
8
9
10
3
3
4
4
4
4
5
5
5
5
6
7
4
4
5
5
5
5
6
6
2
3
3
3
3
3
4
4
4
4
5
6
3
3
4
4
1
2
2
2
2
2
3
3
11 12 12 13
10
6
7
7
8
8
8
9
10
9
10 11 11
5
5
6
6
6
6
7
8
7
8
8
9
8
9
11
5
6
7
8
4
4
4
5
4
5
5
6
5
6
7
8
7
7
8
9
3
3
3
4
3
4
4
5
4
5
6
6
3
4
4
5
4
5
5
6
2
2
3
3
2
3
3
4
3
4
5
5
2
3
3
4
3
3
4
5
3
4
5
5
15 16 17 19
15
9
10 11 11
11 12 13 13
13 14 15 16
7
8
9
10
9
10 10 11
10 11 13 14
13 14
17
9
10 11 13
6
6
7
8
7
8
9
10
9
10 11 12
10 12 13 15
4
5
6
7
6
7
8
9
7
8
10 11
6
6
7
8
7
8
9
10
3
4
5
6
5
5
6
8
6
7
8
10
4
5
6
7
28 29 30 31
20 21 22 23
23 24 25 26
24 25 26 27
26 27 28 29
15 15 16 17
16 17 18 19
18 19 20 21
11 11 12 13
13 13 14 15
15 15 16 17
10
10 11
12
9
10 10 11
6
6
6
7
7
7
8
8
9
9
10
12
31 32 33 34
25 26 28 29
25 26 27 28
27 28 29 30
29 30 31 32
18 19 20 21
20 21 22 23
23 24 25 26
15 16 17 18
18 19 20 21
21 22 23 24
16
17 18
20
13 14 15 15
9
10 10 11
11 12 13 14
14 15 16
19
29 35 42 49
23 27 32 37
25 30 36 43
26 32 38 45
28 33 40 47
17 20 24 28
19 22 26 31
21 25 29 34
14 15 18 20
16 18 21 23
19 21 24 27
16
15 16
19
12 13 15 17
8
8
9
10
10 11 12 13
12 13 14
18
29 35 42 49
26 31 36 41
25 30 36 43
26 32 38 45
27 33 40 47
19 23 27 31
22 25 30 34
24 28 33 38
18 20 23 26
21 23 26 30
24 27 31 34
23
22 24
28
15 17 19 22
12 13 14 15
14 16 17 19
18 19 21
26
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
85-89
80-84
75-79
70-74
65-69
60-64
55-59
50-54
45-49
40-44
Systolic blood pressure (mmHg)
3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
Non-smoking
Smoking
Age
(y)
<50 years
<2.5%
2.5 to <7.5%
≥7.5%
50-69 years
<5%
5 to <10%
≥10%
≥70 years
<7.5%
7.5 to <15%
≥15%
SCORE2 & SCORE2-OP
10-year risk of (fatal and non-fatal) CV
events in populations at low CVD risk
Non-smoking
Smoking
Non-HDL cholesterol
Women
Men
SCORE2-OP
SCORE2
mmol/L
150 200 250
150 200 250
150 200 250
150 200 250
mg/dL
Figure 3 Systematic Coronary Risk Estimation 2 and Systematic Coronary Risk Estimation 2-Older Persons risk charts for fatal and non-fatal (myocardial infarction, stroke) cardiovascular disease.68,72 ASCVD = atherosclerotic cardiovascular disease; CV = cardiovascular; CVD = cardiovascular disease; SBP =
systolic blood pressure; HDL-C = high-density lipoprotein cholesterol; SCORE2 = Systematic Coronary Risk Estimation 2; SCORE2-OP = Systematic
Coronary Risk Estimation 2-Older Persons; TFYR = The Former Yugoslav Republic; UK = United Kingdom. For apparently healthy people aged 4069
years, the SCORE2 algorithm68 is used to estimate 10-year risk of fatal and non-fatal (myocardial infarction, stroke) CVD. For apparently healthy people
>_70 years of age, the SCORE2-OP is used.72. Low-risk countries: Belgium, Denmark, France, Israel, Luxembourg, Norway, Spain, Switzerland, the
Netherlands, and the UK. Moderate-risk countries: Austria, Cyprus, Finland, Germany, Greece, Iceland, Ireland, Italy, Malta, Portugal, San Marino,
Slovenia, and Sweden. High-risk countries: Albania, Bosnia and Herzegovina, Croatia, Czech Republic, Estonia, Hungary, Kazakhstan, Poland, Slovakia,
and Turkey. Very-high-risk countries: Algeria, Armenia, Azerbaijan, Belarus, Bulgaria, Egypt, Georgia, Kyrgyzstan, Latvia, Lebanon, Libya, Lithuania,
Montenegro, Morocco, Republic of Moldova, Romania, Russian Federation, Serbia, Syria, TFYR (Macedonia), Tunisia, Ukraine, and Uzbekistan.


<!-- PAGE 21 -->

### Page 21

1
1
1
1
1
1
1
2
10 10 11 12
8
5
6
6
6
7
7
7
8
8
9
9
9
4
4
4
5
5
5
5
6
6
6
7
7
7
8
9
4
4
5
5
3
3
3
3
3
3
4
4
4
4
5
5
5
6
6
7
2
2
2
2
2
2
3
3
3
3
3
4
2
2
3
3
3
3
4
4
1
1
1
2
1
2
2
2
2
2
3
3
2
2
2
2
2
2
2
3
3
3
3
4
15 16 17 18
14
9
9
9
10
10 11 12 12
13 13 14 15
6
7
7
8
8
9
9
10
10 11 11 12
12 13
15
8
8
9
10
5
5
6
6
6
7
7
8
8
8
9
10
10 11 11 12
3
4
4
5
5
5
6
6
6
7
8
9
5
5
6
6
6
6
7
8
3
3
3
4
3
4
5
5
5
5
6
7
3
4
4
5
2
2
2
3
2
3
3
4
14 15 17 18
13
8
9
10 10
10 11 12 13
12 13 14 15
6
7
7
8
7
8
9
10
9
10 11 12
11 12
15
7
8
9
10
4
5
6
6
5
6
7
8
7
8
9
10
9
10 11 12
3
4
4
5
4
5
5
6
5
6
7
8
4
5
5
6
5
6
7
8
2
3
3
4
3
4
4
5
4
5
6
7
3
4
4
5
3
4
5
6
4
5
6
7
20 22 23 25
20
12 13 14 15
14 15 17 18
17 18 20 21
9
10 11 12
11 13 14 15
14 15 17 18
17 18
22
11 13 15 17
7
8
9
10
9
10 11 13
11 13 14 16
14 16 17 20
5
6
7
8
7
8
10 12
9
11 13 15
7
8
9
11
9
10 12 14
4
5
6
8
6
7
8
10
8
9
11 13
5
7
8
9
37 39 40 42
27 28 30 31
30 32 33 34
32 34 35 37
35 36 38 39
19 20 21 22
21 22 24 25
24 25 27 28
14 15 15 16
16 17 18 19
19 20 21 23
13
13 14
16
12 12 13 14
7
7
8
8
9
9
10 11
11 11 12
15
41 43 44 46
34 35 37 39
34 35 37 38
36 38 39 41
39 40 42 43
24 25 27 28
27 28 30 31
30 32 33 35
20 21 22 24
24 25 26 28
27 29 30 32
22
22 23
26
17 18 19 20
12 13 13 14
15 16 17 18
18 19 20
25
37 45 53 62
30 35 41 47
32 39 47 55
34 41 49 57
36 43 51 59
22 26 31 36
25 29 34 40
27 32 37 43
17 20 23 26
21 23 27 30
24 27 31 35
20
19 21
25
15 17 19 22
10 11 12 13
12 13 15 16
15 17 18
23
37 45 53 61
34 40 46 53
32 39 46 55
34 41 48 57
35 43 51 59
25 30 35 40
28 33 38 44
31 36 42 48
23 26 29 33
27 30 34 38
31 35 39 44
30
28 31
36
19 22 25 29
15 16 18 20
19 20 22 24
23 25 28
34
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
85-89
80-84
75-79
70-74
65-69
60-64
55-59
50-54
45-49
40-44
Systolic blood pressure (mmHg)
Non-smoking
Smoking
Age
(y)
<50 years
<2.5%
2.5 to <7.5%
≥7.5%
50-69 years
<5%
5 to <10%
≥10%
≥70 years
<7.5%
7.5 to <15%
≥15%
SCORE2 & SCORE2-OP
10-year risk of (fatal and non-fatal) CV
events in populations at moderate CVD risk
Non-smoking
Smoking
Non-HDL cholesterol
Women
Men
SCORE2-OP
SCORE2
mmol/L
150 200 250
150 200 250
150 200 250
150 200 250
mg/dL
3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
Figure 3 Continued.
ESC Guidelines
3247


<!-- PAGE 22 -->

### Page 22

1
1
1
1
1
1
2
2
15 16 17 18
12
8
8
8
9
10 10 11 11
12 13 14 14
5
5
6
6
6
7
7
8
8
9
9
10
11 11
13
5
5
6
7
3
3
4
4
4
4
5
5
5
6
7
7
7
8
9
10
2
2
2
3
2
3
3
4
3
4
4
5
3
3
3
4
3
4
4
5
1
1
1
2
1
2
2
2
2
2
3
4
2
2
2
2
2
2
3
3
3
3
4
5
26 27 29 30
23
13 14 14 15
16 17 18 19
21 22 23 24
9
10 11 11
12 13 14 15
15 16 18 19
20 21
25
11 13 14 16
6
7
8
8
8
9
10 11
11 12 14 15
15 16 18 20
4
5
6
6
6
7
8
9
8
10 11 13
6
7
8
9
8
9
10 12
3
4
4
5
4
5
6
7
6
7
9
10
4
5
6
6
1
2
2
3
2
2
3
4
17 18 20 22
16
9
10 11 12
11 12 13 15
14 15 16 18
6
7
8
9
8
9
10 11
10 11 13 14
13 13
18
7
8
10 11
4
5
6
7
6
6
7
9
7
8
10 11
9
11 12 14
3
3
4
5
4
5
6
7
5
6
8
9
4
5
5
6
5
6
7
9
2
2
3
4
3
3
4
5
4
5
6
7
3
3
4
5
3
4
5
6
4
5
6
7
25 28 30 32
25
14 15 17 18
17 19 20 22
21 23 25 27
10 12 13 15
13 15 16 18
16 18 20 23
20 23
28
13 15 18 21
8
9
10 12
10 11 13 15
13 15 17 19
16 19 21 24
6
7
8
9
8
9
11 14
10 13 15 18
7
9
10 12
10 12 14 16
4
5
7
8
6
7
9
11
8
10 13 16
6
7
8
10
53 55 57 58
40 42 44 45
44 46 48 50
47 49 51 52
50 52 54 55
29 31 32 34
32 34 36 37
36 38 39 41
22 23 24 25
25 27 28 29
29 31 32 34
20
21 22
25
18 19 20 22
11 12 13 14
14 15 16 17
17 18 19
24
58 59 61 63
49 51 53 55
49 51 52 54
52 53 55 57
55 56 58 60
36 38 40 41
40 42 44 46
44 46 48 50
31 32 34 36
35 37 39 41
41 43 45 47
33
33 35
39
26 28 29 31
19 20 21 22
23 24 26 27
28 29 31
37
42 49 57 65
34 40 45 51
36 43 51 58
38 45 53 61
40 47 55 63
26 30 35 40
29 33 38 44
31 36 42 47
21 24 27 30
24 27 31 34
28 32 35 39
24
23 25
29
18 20 23 26
12 14 15 16
15 17 18 20
19 20 22
27
41 49 56 65
38 44 50 56
36 43 50 58
38 45 52 60
40 47 54 62
29 34 39 44
32 37 42 48
35 40 46 52
27 30 34 37
31 34 38 43
35 39 44 48
34
33 35
41
23 26 29 33
18 20 22 23
22 24 26 28
27 29 32
38
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
85-89
80-84
75-79
70-74
65-69
60-64
55-59
50-54
45-49
40-44
Systolic blood pressure (mmHg)
Non-smoking
Smoking
Age
(y)
<50 years
<2.5%
2.5 to <7.5%
≥7.5%
50-69 years
<5%
5 to <10%
≥10%
≥70 years
<7.5%
7.5 to <15%
≥15%
SCORE2 & SCORE2-OP
10-year risk of (fatal and non-fatal) CV
events in populations at high CVD risk
Non-smoking
Smoking
Non-HDL cholesterol
Women
Men
SCORE2-OP
SCORE2
mmol/L
150 200 250
150 200 250
150 200 250
150 200 250
mg/dL
3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
Figure 3 Continued.


<!-- PAGE 23 -->

### Page 23

2
2
2
3
3
3
4
4
27 28 30 31
22
15 16 16 17
18 19 20 21
22 23 24 26
10 11 11 12
12 13 14 15
16 17 18 19
20 21
24
10 11 12 14
7
7
8
9
8
9
10 11
11 12 13 14
14 15 17 18
4
5
5
6
5
6
7
8
7
8
9
10
6
6
7
8
8
9
9
11
3
3
3
4
4
4
5
6
5
6
7
8
4
4
5
6
5
6
6
7
7
8
9
10
41 42 44 46
37
23 24 26 27
28 30 31 33
34 36 37 39
17 18 20 21
22 23 25 26
27 29 30 32
33 35
39
21 23 25 28
13 14 15 16
16 18 19 21
21 23 24 26
26 28 31 33
9
10 11 13
12 14 15 17
16 18 21 23
12 13 15 17
16 18 19 22
7
8
9
10
9
11 12 14
13 15 17 19
9
10 12 13
3
4
4
5
4
5
6
7
26 28 30 32
25
15 17 18 19
18 20 21 23
22 24 26 27
11 12 14 15
14 15 17 18
17 19 20 22
20 23
27
12 14 16 19
8
9
10 12
10 11 13 15
13 14 16 18
16 18 20 23
6
7
8
9
7
8
10 12
9
11 13 16
7
9
10 12
10 11 13 15
4
5
6
7
5
6
8
10
7
9
11 13
5
6
8
9
6
7
9
11
8
9
11 13
36 39 42 44
36
22 24 26 28
26 28 30 33
31 33 36 38
17 19 21 23
21 23 25 28
25 28 31 33
31 33
40
21 24 28 31
13 15 17 19
17 19 21 24
21 23 26 29
25 28 32 35
10 12 14 16
13 16 18 22
17 20 24 28
13 15 17 20
17 19 22 25
8
10 12 14
11 13 16 19
14 17 20 24
10 12 14 17
62 63 64 65
53 54 55 57
56 57 58 60
58 59 60 61
60 61 62 63
44 45 47 48
47 48 49 51
50 51 52 54
37 39 40 41
41 42 43 45
44 46 47 48
36
37 38
41
34 35 36 37
26 27 28 29
29 30 31 32
33 34 35
39
65 66 67 68
59 60 62 63
59 60 61 63
61 62 63 65
63 64 65 66
50 51 53 54
53 54 56 57
56 57 59 60
46 47 48 49
49 51 52 53
53 55 56 58
47
48 49
52
42 43 44 46
34 36 37 38
39 40 41 43
43 44 46
51
49 54 59 64
44 48 52 56
46 50 55 60
47 52 56 61
48 53 58 63
38 41 45 48
40 43 47 51
42 46 49 53
34 36 39 41
37 39 42 44
40 42 45 48
36
35 37
40
31 33 36 38
25 26 28 29
28 30 31 33
32 33 35
39
49 54 59 64
47 51 55 59
46 50 55 60
47 52 56 61
48 53 58 63
40 44 48 51
43 46 50 54
45 49 52 56
39 41 44 47
42 44 47 50
45 48 51 54
44
43 45
49
36 38 41 43
31 33 34 36
35 36 38 40
39 41 42
47
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
85-89
80-84
75-79
70-74
65-69
60-64
55-59
50-54
45-49
40-44
Systolic blood pressure (mmHg)
Non-smoking
Smoking
Age
(y)
<50 years
<2.5%
2.5 to <7.5%
≥7.5%
50-69 years
<5%
5 to <10%
≥10%
≥70 years
<7.5%
7.5 to <15%
≥15%
SCORE2 & SCORE2-OP
10-year risk of (fatal and non-fatal) CV
events in populations at very high CVD risk
Non-smoking
Smoking
Non-HDL cholesterol
Women
Men
SCORE2-OP
SCORE2
mmol/L
150 200 250
150 200 250
150 200 250
150 200 250
mg/dL
3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
Figure 3 Continued.
ESC Guidelines
3249


<!-- PAGE 24 -->

### Page 24

..................................................................
models that do not take into account the competing risk of nonCVD mortality, tend to overestimate the actual 10-year risk of CVD,
and hence overestimate the potential benefit of treatment.71 The
SCORE2-OP algorithm estimates 5-year and 10-year fatal and nonfatal CVD events (myocardial infarction, stroke) adjusted for competing risks in apparently healthy people aged >_70 years.72
SCORE2 and SCORE2-OP are calibrated to four clusters of countries (low, moderate, high, and very high CVD risk) that are grouped based on national CVD mortality rates published by the WHO
(Supplementary Table 3 and Figure 4).73 Low-risk countries:
Belgium, Denmark, France, Israel, Luxembourg, Norway, Spain,
Switzerland,
the Netherlands, and the United Kingdom (UK).
Moderate-risk countries: Austria, Cyprus, Finland, Germany,
Greece, Iceland, Ireland, Italy, Malta, Portugal, San Marino, Slovenia,
and
Sweden.
High-risk countries:
Albania,
Bosnia and
Herzegovina, Croatia, Czech Republic, Estonia, Hungary, Kazakhstan,
Poland, Slovakia, and Turkey. Very high-risk countries: Algeria,
Armenia, Azerbaijan, Belarus, Bulgaria, Egypt, Georgia, Kyrgyzstan,
Latvia, Lebanon, Libya, Lithuania, Montenegro, Morocco, Republic of
Moldova, Romania, Russian Federation, Serbia, Syria, The Former
Yugoslav Republic (Macedonia), Tunisia, Ukraine, and Uzbekistan. A
multiplier approach has been used for converting CVD mortality rates to fatal and non-fatal CVD events.74 The SCORE2 algorithm can be accessed in the ESC CVD Risk app (freely available from app stores) and in risk charts for the four clusters of countries (Figure 4).
The SCORE2 charts do not apply to persons with documented CVD
or other high-risk conditions such as DM, FH, or other genetic or rare lipid or BP disorders, CKD, and in pregnant women.
To estimate a person’s 10-year risk of total CVD events, one must first identify the correct cluster of countries and the accompanying risk table for their sex, smoking status, and (nearest) age. Within that table, one then finds the cell nearest to the person’s BP and nonHDL-C. Risk estimates then need to be adjusted upwards as the person approaches the next age category.
3.2.3.3 Translating cardiovascular disease risk to treatment thresholds
While no risk threshold is universally applicable, the intensity of treatment should increase with increasing CVD risk. In individual cases,
however, no lower threshold of total CVD risk precludes treatment of risk factors. Conversely, no high threshold for total CVD risk implies ‘mandatory’ treatment. Across the entire range of CVD risk,
the decision to initiate interventions remains a matter of individual consideration and shared decision-making (see also section 4.1). In general, risk factor treatment recommendations are based on
High risk
Moderate risk
Very high risk
Low risk
Figure 4 Risk regions based on World Health Organization cardiovascular mortality rates.68,72,73


<!-- PAGE 25 -->

### Page 25

..........................................................................
categories of CVD risk (‘low-to-moderate’, ‘high’, and ‘very high’).
The cut-off risk levels for these categories are numerically different for various age groups to avoid undertreatment in the young and to avoid overtreatment in older persons. As age is a major driver of
CVD risk, but lifelong risk factor treatment benefit is higher in younger people, the risk thresholds for considering treatment are lower for younger people (Table 5).
Risk categories do not ‘automatically’ translate into recommendations for starting drug treatment. In all age groups, consideration of risk modifiers, lifetime CVD risk, treatment benefit, comorbidities,
frailty, and patient preferences may further guide treatment decisions.
Also, note that many patients can move themselves towards a lower risk category without taking drugs just by stopping smoking.
Finally, note that persons >_70 years old may be at very high risk whilst being at target SBP, and primary prevention with lipid-lowering drugs in older persons is a Class IIb (‘may consider’) recommendation; see section 4.6.
In the 5069-year age range, a 10-year CVD mortality risk threshold of 5% estimated with the previously used SCORE algorithm corresponds, on average, to a 10-year fatal and non-fatal CVD risk threshold of 10% estimated with SCORE2, as approximately the same number of people are above the risk threshold and would qualify for treatment.68
Table 5
Cardiovascular disease risk categories based on
SCORE2 and SCORE2-OP in apparently healthy people according to age
<50 years
5069
years
70 yearsa
Low-to-moderate CVD
risk: risk factor treatment generally not recommended
<2.5%
<5%
<7.5%
High CVD risk: risk factor treatment should be considered
2.5 to <7.5% 5 to <10%
7.5 to <15%
Very high CVD risk: risk factor treatment generally recommendeda
>_7.5%
>_10%
>_15%
CVD = cardiovascular disease.
aIn apparently healthy people >_70 years old, the treatment recommendation for lipid-lowering drugs is Class IIb (‘may be considered’).
The division of the population into three distinct age groups (<50, 5069, and
>_70 years) results in a discontinuous increase in risk thresholds for low-to-moderate, high, and very high risk. In reality, age is obviously continuous, and a sensible application of the thresholds in clinical practice would require some ﬂexibility in handling these risk thresholds as patients move towards the next age group, or recently passed the age cut-off. Figure 5 illustrates how a continuous increase in age relates to increasing risk thresholds, and may be used as a guide for daily practice.
ESC 2021
30
25
22.5
20
17.5
15
12.5
10
7.5
5
2.5
40
50
60
70
80
90
Age groups (years)
50-69
<50
≥70
10-year CVD risk (%)
CVD risk thresholds (%)
Very high CVD risk
High CVD risk
Low-to-moderate CVD risk
Figure 5 Schematic representation of increasing 10-year cardiovascular disease risk thresholds across age groups. CVD = atherosclerotic cardiovascular disease.
ESC Guidelines
3251


<!-- PAGE 26 -->

### Page 26

Estimate 10-year CVD risk
(SCORE2)
Apparently healthy personsa
AND
Stop smoking, lifestyle recommendations and SBP <160 mmHg (Class I)
STEP 1
Consider risk modiﬁers,
lifetime CVD risk and treatment beneﬁtb,
patient preferences
Estimate 10-year CVD risk
(SCORE2)
Estimate 10-year CVD risk
(SCORE2-OP)
Age 50 – 69 years sr a
e y 0
7 
≥
 e g
A
sr a
e y 0
5 
<
 e g
A
b
No additional prevention goals
SBP <140
to 130 mmHg if tolerated
(Class I)
SBP <140
to 130 mmHg if tolerated
(Class I)
LDL-C
<2.6 mmol/L
(<100 mg/dL)
(Class IIb)
<2.5%
≥7.5%
%
5
1
≥
%
5.7
<
%
5.7
<
 o t 5.2
7.5 to <15%
Consider risk modiﬁers,
lifetime treatment beneﬁtb, comorbidities,
frailty, polypharmacy,
patient preferences
No additional prevention goals
AND
No additional prevention goals
LDL-C
<2.6 mmol/L
(<100 mg/dL)
(Class IIa)
For speciﬁc risk factor management in patients ≥70 years,
please see Section 4
STEP 2
10-year CVD risk (SCORE2)
Lifetime CVD risk and treatment beneﬁtb
Comorbidities, frailty
Patient preferences
Intensiﬁed treatment based on:
SBP
<130 mmHg if tolerated
(Class I)
LDL-C (Class IIa)
High risk
<1.8 mmol/L
(<70 mg/dL)
Very high risk
<1.4 mmol/L
(<55 mg/dL)
AND
STEP 2
Consider risk modiﬁers,
lifetime CVD risk patient preferences
No additional prevention goals
<5%
≥10%
5 to <10%
and treatment beneﬁtb,
Figure 6 Flow chart of cardiovascular disease risk and risk factor treatment in apparently healthy persons. ASCVD = atherosclerotic cardiovascular disease; CKD = chronic kidney disease; CVD = cardiovascular disease; DM = diabetes mellitus; ESC = European Society of Cardiology; FH = familial hypercholesterolaemia; LDL-C = low-density lipoprotein cholesterol; LIFE-CVD = LIFEtime-perspective CardioVascular Disease; SBP = systolic blood pressure; SCORE2 = Systematic Coronary Risk Estimation 2; SCORE2-OP = Systematic Coronary Risk Estimation 2-Older Persons. Solid lines represent default options for the majority of people. Dotted lines represent alternative choices for some, depending on the patient-specific characteristics and conditions indicated in the boxes. Ultimate treatment goals for SBP (<130 mmHg) and LDL-C (according to level of risk) according to the respective ESC
Guidelines are to be pursued as indicated. The stepwise approach has to be applied as a whole: after STEP 1, considering proceeding to the intensified goals of STEP 2 is mandatory. Risk scores are available in the ESC CVD Risk Calculator app for mobile devices (https://www.escardio.org/Education/ESCPrevention-of-CVD-Programme/Risk-assessment/esc-cvd-risk-calculation-app) and at websites such as https://www.u-prevent.com. aDoes not include patients with CVD, DM, CKD, or FH. bThe LIFE-CVD model for estimating lifetime CVD risk and treatment benefit is calibrated for low- and moderaterisk regions (see Box 1).


<!-- PAGE 27 -->

### Page 27

.................................
As the 10-year CVD risk thresholds guide treatment decisions and have an impact on healthcare costs and resources, countries or regions may decide on using higher or lower treatment thresholds.
3.2.3.4 Risk estimation and risk factor treatment in apparently healthy people 5069 years of age
Stopping smoking, lifestyle recommendations, and SBP <160 mmHg are recommended for all (Figure 6). A 10-year CVD risk (fatal and nonfatal ASCVD events) >_10% is generally considered ‘very high risk’, and treatment of CVD risk factors is recommended. A 10-year CVD risk of
5 to <10% is considered ‘high risk’, and treatment of risk factors should be considered, taking CVD risk modifiers, lifetime risk and treatment benefit (in low- and moderate-risk regions, Box 1), and patient preferences into account. A 10-year CVD risk <5% is considered ‘low-to-moderate risk’, and would generally not qualify for risk factor treatment unless one or several risk modifiers (see section 3.3) increase risk, or the estimated lifetime risk and treatment benefit is considered substantial.
3.2.3.5 Risk estimation and risk factor treatment estimation in apparently healthy people 70 years of age
Stop smoking, lifestyle recommendations and a SBP <160 mmHg are recommended for all (Figure 6). Age is the dominant driver of CVD
STEP 2
Patients with established ASCVDa
Stop smoking and lifestyle recommendations
(Class I)
LDL-C
≥50% reduction and
<1.8 mmol/L (<70 mg/dL)
(Class I)
SBP <140 
to 130 mmHg if tolerated
(Class I)
Antithrombotic
Therapy
(Class I)
AND
Residual 10-year CVD riskc
Lifetime CVD risk and treatment benefitd
Comorbidities, frailty
Patient preferences
Intensified treatment based on:
STEP 1b
SBP
<130 mmHg if tolerated
(Class I)
LDL-C
<1.4 mmol/L
(<55 mg/dL)
(Class I)
DAPT, DPI,
novel upcoming interventions
(e.g. colchicine, EPA)
(Class IIb)
AND
AND
Figure 7 Flow chart of cardiovascular risk and risk factor treatment in patients with established atherosclerotic cardiovascular disease. Ultimate treatment goals for SBP (<130 mmHg) and LDL-C (according to level of risk) according to the respective ESC Guidelines3,4 are to be pursued as indicated. The stepwise approach has to be applied as a whole: after STEP 1, considering proceeding to the intensified goals of STEP 2 is mandatory. ACS = acute coronary syndromes; ASCVD = atherosclerotic cardiovascular disease; CR = cardiac rehabilitation; CVD = cardiovascular disease; DAPT = dual antiplatelet therapy; DM = diabetes mellitus; ESC = European Society of Cardiology; EUROASPIRE = European Action on Secondary and Primary Prevention by
Intervention to Reduce Events; LDL-C = low-density lipoprotein cholesterol; SBP = systolic blood pressure; SMART = Secondary Manifestations of
Arterial Disease. Risk scores are available in the ESC CVD Risk Calculator app for mobile devices (https://www.escardio.org/Education/ESC-Preventionof-CVD-Programme/Risk-assessment/esc-cvd-risk-calculation-app) and at websites such as https://www.u-prevent.com. aFor patients with DM see DM
flow chart (Figure 8). bFor patients with recent ACS, these prevention goals are part of participation in CR (Class I/A). cFor patients aged >_70 years, a high
10-year risk may be associated with a lower absolute lifetime benefit from treatment due to limited life expectancy. dLifetime treatment benefit is expressed as extra CVD-free life gained from a certain intervention or treatment intensification.
ESC Guidelines
3253


<!-- PAGE 28 -->

### Page 28

..................................................................................................
risk, and estimated 10-year CVD risk of almost all individuals >_70
years exceeds conventional risk thresholds. Also, lifetime benefit of treatment in terms of time gained free of CVD is lower in older people. Therefore, the CVD risk thresholds for risk factor treatment are higher in apparently healthy people >_70 years. A 10-year CVD risk
>15% is generally considered ‘very high risk’, and treatment of
ASCVD risk factors is recommended (note: the recommendation for lipid-lowering treatment in apparently healthy people >_70 years is class IIb; ‘may be considered’; see section 4.6). A 10-year CVD risk of
7.5 to <15% is considered ‘high risk’, and treatment of risk factors should be considered taking CVD risk modifiers, frailty, lifetime treatment benefit (in low and moderate risk regions, Box 1), comorbidities, polypharmacy, and patient preferences into account. Given the subjective nature of many of these factors, it is not possible to define strict criteria for these considerations. A 10-year CVD risk <7.5% is considered ‘low-to-moderate risk’, and would generally not qualify for risk factor treatment unless one or several risk modifiers (section
3.3) increase risk or the estimated lifetime risk and treatment benefit is considered substantial.7579
3.2.3.6 Risk estimation and risk factor treatment in apparently healthy people <50 years of age
Stopping smoking, lifestyle recommendations, and SBP <160 mmHg are recommended for all (Figure 6). The 10-year CVD risk in relatively young, apparently healthy people is on average low, even in the presence of high risk factor levels, but the lifetime CVD risk is in these circumstances very high. In apparently healthy people <50 years of age, a
10-year CVD risk >_7.5% is generally considered ‘very high risk’ as this risk relates to a high lifetime risk, and treatment of ASCVD risk factors is recommended. A 10-year CVD risk of 2.5 to <7.5% is considered
‘high risk’, and treatment of risk factors should be considered, taking
CVD risk modifiers, lifetime risk and treatment benefit (in low- and moderate-risk regions), and patient preferences into account. A 10year CVD risk <2.5% is considered ‘low-to-moderate risk’, and would generally not qualify for risk factor treatment unless one or several risk modifiers (see section 3.3) increase risk or the estimated lifetime risk and treatment benefit is considered substantial (see Box 1) (Figure 6).7578
In risk communication with younger people, the lifetime benefit perspective may be useful, as well as discussing the potential of avoiding a devastating CVD event in the short-to-intermediate term,
despite the fact that 10-year CVD risk may be very low.
CVD risk predictions, as well as predictions of lifetime benefit of risk factor treatment, are likely to be imprecise at very young age
(<40 years). At that age, lipid-lowering and BP-lowering drug treatment are not usually considered, except for patients with FH or specific BP disorders. A healthy lifestyle that is maintained throughout life is more relevant for the very young. Mendelian randomization studies illustrate very nicely that relatively small differences in LDL-C
or SBP maintained throughout life have large implications on CVD
risk over a lifespan.80
3.2.3.7 Risk estimation and risk factor treatment in patients with established atherosclerotic cardiovascular disease
Patients with clinically established ASCVD are, on average, at very high risk of recurrent CVD events if risk factors are not treated.
Therefore, smoking cessation, adoption of a healthy lifestyle, and risk factor treatment is recommended in all patients (STEP 1). Further intensification of risk factor treatment by aiming at lower treatment goals (STEP 2) is beneficial in most patients and must be considered,
taking 10-year CVD risk, comorbidities, lifetime risk and treatment benefit (Box 1), frailty, and patient preferences into account in a shared decision-making process (Figure 7).
After initial risk factor treatment and the achievement of risk factor treatment goals, the individual residual risk for recurrent
Box 1. Lifetime CVD risk and treatment benefit estimation
Prevention of CVD by treating risk factors is usually done with a lifetime perspective. Lifetime CVD risk can be approximated by clinical experience with clinical criteria such as age, (change in) risk factor levels, risk modifiers, etc. or estimated in apparently healthy people, patients with established ASCVD, and persons with type 2 DM with specific lifetime CVD risk scores.7577 Lifetime benefit from risk factor management can be estimated by combining lifetime risk models with HRs derived from RCTs, meta-analyses of RCTs, or Mendelian randomization studies, which may provide estimates of the effects of longer-term treatment of risk factors. Online calculators (such as the ESC CVD Risk app) can be used to estimate the average lifetime benefit of smoking cessation (see also Figure 11), lipid lowering (see also Figure 12), and BP
lowering (see also Figure 15) on an individual patient level expressed as extra CVD-free life-years.78 Average lifetime benefit is easy to interpret and may improve the communication of potential therapy benefits to patients in a shared decision-making process. This may in turn increase patient engagement, self-efficacy, and motivation to adhere to lifestyle changes and drug treatment.
The lifetime risk is an estimate of the age at which there is a 50% probability that a person will either have experienced a CVD event or have died. Lifetime benefit is the numerical difference between the predicted age at which there is a 50% probability that a person will either have experienced a CVD event or have died with and without a proposed treatment. Currently there are no formal treatment thresholds for average lifetime benefit. In addition, the estimated individual lifetime benefit should be viewed in the light of the estimated duration of treatment.
Duration of lifelong treatment will generally be longer in young persons compared to older people. Both treatment effect and treatment duration determine the individual ‘return on investment’ of risk factor treatment. In a shared decision-making process between healthcare provider and patient, the minimum desired benefit of a certain treatment needs to be established, a process in which patient preference, expected treatment harms, and costs can be taken into account.
BP = blood pressure; CVD = cardiovascular disease; DM = diabetes mellitus; ESC = European Society of Cardiology; HR = hazard ratio;
RCT = randomized controlled trial.


<!-- PAGE 29 -->

### Page 29

Highb
Moderateb
Established ASCVD or severe TODa
Patients with type 2 diabetes mellitus
AND
Stop smoking and lifestyle recommendations (Class I)
HbA1c: <53 mmol/mol (<7.0%) (Class I)
STEP 1
Risk
Residual 10-year CVD risk
Lifetime CVD risk and treatment benefitd
Comorbidities, frailty
Patient preferences
Intensified treatment based on:
SBP
<130 mmHg if tolerated
(Class I)
SGLT2-i or GLP-1RA
if not already on itc
(Class I)
LDL-C
<1.4 mmol/L
(<55 mg/dL)
(Class I)
DAPT, DPI,
novel upcoming interventions
(e.g. colchicine,
EPA)
(Class IIb)
10-year CVD risk
Lifetime CVD risk and treatment benefitd
Comorbidities, frailty
Patient preferences
Intensified treatment based on:
SBP
<130 mmHg if tolerated
(Class I)
SGLT2-i or GLP-1RA
if not already on it
(Class IIb)
LDL-C
<1.8 mmol/L
(<70 mg/dL)
(Class I)
SBP <140 to
130 mmHg if tolerated
(Class I)
LDL-C 
≥50% reduction and
<1.8 mmol/L 
(<70 mg/dL)
(Class I)
Antithrombotic therapy
(Class I)
SGLT2-i or GLP-1RA...c
… for TOD: Class IIb
… for CVD: Class I
SBP <140 to
130 mmHg if tolerated
(Class I)
LDL-C 
<2.6 mmol/
(<100 mg/dL)
(Class I)
Additional prevention goals generally not recommended
(Class III)
STEP 2
Without
With
Figure 8 Flow chart of cardiovascular risk and risk factor treatment in patients with type 2 diabetes mellitus. Ultimate treatment goals for SBP (<130
mmHg) and LDL-C (according to level of risk) according to the respective ESC Guidelines3,4 are to be pursued as indicated. The stepwise approach has to be applied as a whole: after STEP 1, considering proceeding to the intensified goals of STEP 2 is mandatory. Risk scores are available in the ESC CVD Risk
Calculator app for mobile devices (https://www.escardio.org/Education/ESC-Prevention-of-CVD-Programme/Risk-assessment/esc-cvd-risk-calculationapp) and at websites such as https://www.u-prevent.com. ACR = albumin-to-creatinine ratio; ASCVD = atherosclerotic cardiovascular disease; CKD =
chronic kidney disease; CVD = cardiovascular disease; DAPT = dual antiplatelet therapy; DM = diabetes mellitus; eGFR = estimated glomerular filtration rate; ESC = European Society of Cardiology; GLP-1RA = glucagon-like peptide-1 receptor agonist; HbA1c = glycated haemoglobin; HF = heart failure;
LDL-C = low-density lipoprotein cholesterol; SBP = systolic blood pressure; SGLT2 = sodium-glucose cotransporter 2; TOD = target organ damage (retinopathy, nephropathy, neuropathy). aSevere TOD is defined as at least one of: eGFR <45 mL/min/1.73 m2 irrespective of the presence or absence of albuminuria; eGFR 4659 mL/min/1.73 m2 and microalbuminuria (ACR 30300 mg/g or 330 mg/mmol); proteinuria (ACR >300 mg/g or >30 mg/mmol);
presence of microvascular disease in at least three different sites (e.g. microalbuminuria plus retinopathy plus neuropathy). bSee Table 4 for CVD risk groups.
cPatients with prevalent HF or CKD are recommended for SGLT2 inhibitor, and patients post stroke are recommended for GLP-1RA treatment. dLifetime treatment benefit is expressed as extra CVD-free life gained from a certain intervention or treatment intensification. See Box 1.
ESC Guidelines
3255


<!-- PAGE 30 -->

### Page 30

CVD varies widely and should be considered.81 It is evident that patients with a recent ACS or progressive vascular disease, and patients with DM and vascular disease, are all at exceptionally high risk for recurrent CVD events. For other patients with established
ASCVD, the residual risk may be less evident and could be estimated based on clinical criteria such as age, (change in) risk factor levels, and risk modifiers, or by calculation of residual CVD risk with a calculator.
The risk of recurrent CVD is influenced mainly by classical risk factors, vascular disease site, and kidney function. Risk stratification tools for secondary prevention include the
SMART
(Secondary
Manifestations of Arterial Disease) risk score (available in the ESC
CVD Risk app) for estimating 10-year residual CVD risk in patients with stable ASCVD, defined as CAD, PAD, or cerebrovascular disease,81 and the European Action on Secondary and Primary
Prevention by Intervention to Reduce Events (EUROASPIRE) risk model, which estimates 2-year risk of recurrent CVD in patients with stable CAD.82
Occasionally, recurrent CVD risk is very high despite maximum
(tolerated) conventional treatments. In such cases, novel but less well-established preventive treatments such as dual antithrombotic pathway inhibition,83 icosapent ethyl,84 or anti-inflammatory therapy with colchicine (see section 4.10)85,86 may be considered.
3.2.3.8 Risk estimation and risk factor treatment in persons with type 2
diabetes mellitus
Most adults with type 2 DM are at high or very high risk for future
CVD, particularly from middle age onwards. On average, type 2 DM
doubles CVD risk and reduces life expectancy by 4 - 6 years, with absolute risks highest in those with any target organ damage (TOD).
Type 2 DM also increases the risk for cardiorenal outcomes, in particular HF and CKD. Relative risks (RRs) for CVD in type 2 DM are higher at younger ages of onset and are modestly higher in women compared with men.87 Smoking cessation and adoption of a healthy lifestyle are recommended for all people with type 2 DM, and risk factor treatment should be considered in all people with DM, at least those above the age of 40 years (see sections 4.6 and 4.7). Still, there is a wide range in individual risk for CVD events, especially after initial risk factor management.88
Persons with DM with severe TOD (for definition: see Table 4)
can be considered to be at very high CVD risk, similar to people with established CVD (see Table 4). Most others with DM are considered to be at high ASCVD risk.64 However, an exception can be made for patients with well-controlled short-standing DM (e.g. <10 years), no evidence of TOD, and no additional ASCVD risk factors, who may be considered as being at moderate CVD risk.
In addition to the semi-quantitative division into three risk categories described above, DM-specific risk models may refine risk estimates and illustrate the impact of treatments. These models generally include duration of DM, glycated haemoglobin (HbA1c)
level, and presence of TOD. Examples are the ADVANCE (Action in
Diabetes and Vascular disease: preterAx and diamicroN-MR
Controlled Evaluation) risk score, which predicts 10-year CVD risk,
and the UKPDS (UK Prospective Diabetes Study) risk engine, which predicts fatal and non-fatal CVD risk and is available for use in the
UK. However, we recommend cautious use of these calculators,
since both are based on older cohort data89,90 (Figure 8).
Recommendations for CVD risk estimation
Recommendations
Classa
Levelb
In apparently healthy people <70 years without established ASCVD, DM, CKD, genetic/rarer lipid or BP disorders, estimation of 10-year fatal and non-fatal CVD risk with SCORE2 is recommended.68
I
B
In apparently healthy people >_70 years without established ASCVD, DM, CKD, genetic/rarer lipid or BP disorders, estimation of 10-year fatal and non-fatal CVD risk with SCORE2-OP is recommended.72
I
B
In apparently healthy people, after estimation of
10-year fatal and non-fatal CVD risk, lifetime risk and treatment beneﬁt, risk modiﬁers, frailty,
polypharmacy, and patient preferences should be considered.
IIa
C
Patients with established ASCVD and/or DM
and/or moderate-to-severe renal disease and/or genetic/rarer lipid or BP disorders are to be considered at high or very high CVD
risk.75,77,81,8890
I
A
A stepwise treatment-intensiﬁcation approach aiming at intensive risk factor treatment is recommended for apparently healthy people at high or very high CVD risk, as well as patients with established ASCVD and/or DM, with consideration of CVD risk, treatment beneﬁt of risk factors, risk modiﬁers, comorbidities, and patient preferences.66,67
I
B
Treatment of ASCVD risk factors is recommended in apparently healthy people without DM, CKD, genetic/rarer lipid, or BP
disorders who are at very high CVD risk
(SCORE2 >_7.5% for age under 50; SCORE2
>_10% for age 5069; SCORE2-OP >_15% for age >_70 years).68,72
I
C
Treatment of ASCVD risk factors should be considered in apparently healthy people without DM, CKD, genetic/rarer lipid, or BP
disorders who are at high CVD risk (SCORE2
2.5 to <7.5% for age under 50; SCORE2 5 to
<10% for age 5069; SCORE2-OP 7.5 to
<15% for age >_70 years), taking CVD risk modiﬁers, lifetime risk and treatment beneﬁt, and patient preferences into account.
IIa
C
ASCVD = atherosclerotic cardiovascular disease; BP = blood pressure; CKD =
chronic kidney disease (see deﬁnition in Table 4); DM = diabetes mellitus;
SCORE2 = Systemic Coronary Risk Estimation 2; SCORE2-OP = Systemic
Coronary Risk Estimation 2-Older Persons.
aClass of recommendation.
bLevel of evidence.
ESC 2021
............................................................................................................................................................................


<!-- PAGE 31 -->

### Page 31

............................................................
Intensification of risk factor treatment in STEP 2 must be considered in all patients, taking into account 10-year CVD risk, comorbidities, lifetime risk and treatment benefit (Box 1), frailty, and patient preferences in a shared decision-making process.75
3.2.3.9 Risk estimation and risk factor treatment in persons with type 1
diabetes mellitus
People with type 1 DM are at increased CVD risk, and earlier manifestation of type 1 DM relates to more life-years lost in women than men,
mostly due to CVD.91 RRs of CVD are, on average, higher in type 1 vs.
type 2 DM, due to an average of three to four extra decades of hyperglycaemia, and usual risk factors contribute strongly to CVD outcomes in type 1 DM.92 CVD risks have declined over time, commensurate with improvements in life expectancy.93 Lifetime CVD risks in type 1
DM are higher with poorer glycaemic control, lower social class, and younger age of onset. The absolute risk of CVD events or CVD mortality is highest among those with any evidence of microvascular disease, particularly renal complications, and is strongly influenced by age.
CVD risk stratification in persons with type 1 DM may be based on the same risk classification as for type 2 DM, summarized in Table 4,
although the level of evidence for type 1 DM is weaker.
3.2.4. Communication of cardiovascular disease risk
Reducing CVD risk at the individual level begins with appropriate assessment of individual risk and effective communication of risk and anticipated risk reduction by risk factor treatment. Patient-doctor interactions are complex and communicating risk is challenging.94,95
There is no single ‘correct’ approach; rather, it will depend on the individual’s preferences and understanding, which may differ with education status and numeracy. Risk perception is also strongly affected by emotional factors such as fear, optimism, etc. (‘patients don’t think risk, they feel risk’).96
It is important to explore whether patients understand their risk,
the anticipated risk reduction, and the pros and cons of intervention,
and to identify what is important to them. For example, one patient may focus on living free of medications, whereas another may be less able to change their lifestyle. In terms of outcomes, reducing mortality risk is crucial to some, whereas disease risk is more important to others. Short-term risk may motivate some patients, whereas lifetime benefit (see Box 1) will have more impact in others. In general, visual aids (graphs etc.) improve risk understanding, absolute risk (reduction) is better understood than RR (reduction), and the use of ‘numbers needed to treat’ is less well understood.
In apparently healthy people, the standard approach is to report absolute 10-year risk of a CVD event with SCORE2 or SCORE2-OP,
which can be found at the ESC CVD Risk Calculator app (https://
www.escardio.org/Education/ESC-Prevention-of-CVD-Programme/
Risk-assessment/esc-cvd-risk-calculation-app)
or at http://
www.heartscore.org or https://www.u-prevent.com. In specific situations, one may opt for expressing risk in terms other than absolute
10-year risk. Examples of such situations include risks in young or very old people. In young people, lifetime risk might be more informative, as 10-year CVD risk is usually low even in the presence of risk factors. In older persons, specific risk estimation is required, taking competing non-CVD mortality into account.78 Direct translation of RRs to treatment decisions is not recommended, as absolute risk remains the key criterion for starting treatment.
An alternative way of expressing individual risk is to calculate a person’s ‘risk age’.96 The risk age of a person with several ASCVD risk factors is the age of a person of the same sex with the same level of risk but with low levels of risk factors. Risk age is an intuitive and easily understood way of illustrating the likely reduction in life expectancy that a young person with a low absolute but high RR of CVD will be exposed to if preventive measures are not adopted. Risk age is also automatically calculated as part of HeartScore (http://www.heartscore.org/).9799
CVD risk may also be expressed with a lifetime rather than a 10year horizon, for example, the LIFE-CVD (LIFEtime-perspective
CardioVascular Disease) calculator (ESC CVD Risk Calculation app or https://www.u-prevent.com) (also see Box 1).78 Lifetime CVD
risk-prediction models identify high-risk individuals both in the short and long term. Such models account for predicted risk in the context of competing risks from other diseases over the remaining expected lifespan of an individual. A similar approach also employing lifetime perspective is to calculate lifetime benefit of preventive
Recommendation for CVD risk communication
Recommendation
Classa
Levelb
An informed discussion about CVD risk and treatment beneﬁts tailored to the needs of a patient is recommended.96
I
C
CVD = cardiovascular disease.
aClass of recommendation.
bLevel of evidence.
Recommendations for CVD risk modiﬁers
Recommendations
Classa
Levelb
Stress symptoms and psychosocial stressors modify CVD risk. Assessment of these stressors should be considered.100102
IIa
B
CAC scoring may be considered to improve risk classiﬁcation around treatment decision thresholds. Plaque detection by carotid ultrasound is an alternative when CAC scoring is unavailable or not feasible.103,104
IIb
B
Multiplication of calculated risk by RR for speciﬁc ethnic subgroups should be considered.105
IIa
B
The routine collection of other potential modiﬁers, such as genetic risk scores, circulating or urinary biomarkers, or vascular tests or imaging methods (other than CAC scoring or carotid ultrasound for plaque determination), is not recommended.
III
B
CVD = cardiovascular disease; CAC = coronary artery calcium; RR = relative risk.
aClass of recommendation.
bLevel of evidence.
ESC 2021
ESC 2021
............................................................................................................................................................................
ESC Guidelines
3257


<!-- PAGE 32 -->

### Page 32

.........................................................................................................................................
interventions.78 Lifetime benefit of preventive interventions can be expressed as gain in CVD-free life (years), which is easier to communicate to a patient and may support the shared decision-making process.
3.3. Potential risk modifiers
Apart from the conventional CVD risk factors included in the risk charts, additional risk factors or types of individual information can also modify calculated risk. Assessment of a potential modifier may be considered if:
• It improves measures of risk prediction, such as discrimination or reclassification (e.g. by calculation of net reclassification index)
• Public health impact is clear (e.g. number needed to screen or net benefit)
• It is feasible in daily practice
• Information is not just available on how risk increases with an unfavourable result, but also on how risk decreases if the modifier shows a favourable result
• The literature on this potential modifier is not distorted by publication bias.
Very few potential modifiers meet all of these criteria. Metaanalyses in this field are, for example, susceptible to substantial publication bias.106 Also, the exact way of integrating additional information on top of regular risk calculator input parameters is mostly unknown. Finally, RCTs to determine whether the added risk information eventually leads to improved health outcomes are generally lacking.
Assessment of potential risk modifiers seems particularly relevant if the individual’s risk is close to a decision threshold. In low-risk or very-high-risk situations, additional information is less likely to alter management decisions. The number of individuals in this ‘grey zone’ is large. Therefore, feasibility becomes a limitation as modifiers become more complex or expensive, such as some imaging techniques.
Care should be taken not to use risk modifiers solely to increase risk estimates when the modifier profile is unfavourable, but also vice versa. Although an unfavourable risk modifier may increase an individual’s estimated risk, a more favourable profile than would be expected based on other patient characteristics must have the opposite effect. Finally, it is important to acknowledge that the degree to which calculated absolute risk is affected by modifiers is generally much smaller than the (independent) RRs reported for these modifiers in the literature.107
Taking the above into account, we summarize the literature on several popular risk modifiers in this section.
3.3.1. Psychosocial factors
Psychosocial stress is associated, in a dose-response pattern, with the development and progression of ASCVD, independently of conventional risk factors and sex. Psychosocial stress includes stress symptoms
(i.e. symptoms of mental disorders), as well as stressors such as loneliness and critical life events. The RRs of psychosocial stress are commonly between 1.2 and 2.0108,109 (Supplementary Table 4). Conversely,
indicators of mental health, such as optimism and a strong sense of purpose, are associated with lower risk.109 Psychosocial stress has direct biological effects, but is also highly correlated with socioeconomic and behavioural risk factors (e.g. smoking, poor adherence).100,109113
Although the associations of psychosocial stress with CV health are robust, only ‘vital exhaustion’ has been proven to improve risk reclassification.101 Owing to the importance of stress symptoms among
ASCVD patients, several guidelines and scientific statements recommend screening of ASCVD patients for psychological stress113115
(Box 2 and Supplementary Table 5). A recent prospective cohort study with a median follow-up of 8.4 years reported favourable effects of screening for depression on major ASCVD events.102
3.3.2. Ethnicity
Europe includes many citizens whose ethnic background originates in countries such as India, China, North Africa, and Pakistan. Given the considerable variability in ASCVD risk factors between immigrant groups, no single CVD risk score performs adequately in all groups.
Rather, the use of a multiplying factor would be helpful to take account of CVD risk imposed by ethnicity independent of other risk factors in the risk score. The most contemporary relevant data come from the QRISK3 findings in the UK,105 although this focuses on a wider range of CVD outcomes and not simply on CVD mortality.
Immigrants from South Asia (notably India and Pakistan) present higher CVD rates independent of other risk factors, whereas adjusted CVD risks appear lower in most other ethnic groups. The reasons for such differences remain inadequately studied, as do the risks associated with other ethnic backgrounds. Based on such data,
the following correction factors, based on data from the UK, could be applied when assessing CVD risk using risk calculators.105 Ideally,
country and risk-calculator-specific RRs should be used, as the impact of ethnicity may vary between regions and risk calculators.
• Southern Asian: multiply the risk by 1.3 for Indians and
Bangladeshis, and 1.7 for Pakistanis.
• Other Asian: multiply the risk by 1.1.
• Black Caribbean: multiply the risk by 0.85.
• Black African and Chinese: multiply the risk by 0.7.
Box 2. Core topics for psychosocial assessment
Simultaneous diagnostic assessment
At least one in five patients carries a diagnosis of a mental disorder, usually presenting with bodily symptoms (e.g. chest tightness, shortness of breath). Therefore, physicians should be equally attentive to somatic as to emotional causes of symptoms.
Screening
Screening instruments assessing depression, anxiety, and insomnia are recommended (e.g. Patient
Health Questionnaire,116 see Supplementary Table 5).117,118
Stressors
There are simple questions to get into a conversation about significant stressors112: Are you bothered by stress at work, financial problems, difficulties in the family, loneliness, or any stressful events?
Need for mental health support
Are you interested in a referral to a psychotherapist or mental health service?


<!-- PAGE 33 -->

### Page 33

.............................................................................................................................................................................
3.3.3. Imaging
3.3.3.1 Coronary artery calcium
Coronary artery calcium (CAC) scoring can reclassify CVD risk upwards and downwards in addition to conventional risk factors,
and may thus be considered in men and women with calculated risks around decision thresholds.103,104 Availability and costeffectiveness of large-scale CAC scanning must, however, be considered in a locoregional context (see section 2.3 on costeffectiveness). If CAC is detected, its extent should be compared with what would be expected for a patient of the same sex and age. Higher-than-expected CAC increases the person’s calculated risk, whereas absent or lower-than-expected CAC is associated with lower than calculated risk. CAC scoring does not provide direct information on total plaque burden or stenosis severity,
and can be low or even zero in middle-aged patients with soft non-calcified plaque. Clinicians are advised to consult existing protocols for details of how to assess and interpret CAC scores.
3.3.3.2 Contrast computed tomography coronary angiography
Contrast computed tomography angiography (CCTA) allows identification of coronary stenoses and predicts cardiac events.119
In the
SCOT-HEART
(Scottish
Computed
Tomography of the Heart) study, 5-year rates of coronary death or myocardial infarction were reduced when CCTA was used in patients with stable chest pain.120 The relative reduction in myocardial infarction was similar in patients with non-cardiac chest pain. Whether CCTA improves risk classification or adds prognostic value over CAC scoring is unknown.
3.3.3.3 Carotid ultrasound
Systematic use of intima-media thickness (IMT) to improve risk assessment is not recommended due to the lack of methodological standardization, and the absence of added value of IMT in predicting future CVD events, even in the intermediate-risk group.121
Plaque is defined as the presence of a focal wall thickening that is
>_50% greater than the surrounding vessel wall, or as a focal region with an IMT measurement >_1.5 mm that protrudes into the lumen.122 Although the evidence is less extensive than it is for CAC,
carotid artery plaque assessment using ultrasonography probably also reclassifies CVD risk,104,122 and may be considered as a risk modifier in patients at intermediate risk when a CAC score is not feasible.
3.3.3.4 Arterial stiffness
Arterial stiffness is commonly measured using either aortic pulse wave velocity or arterial augmentation index. Studies suggest that arterial stiffness predicts future CVD risk and improves risk classification.123 However, measurement difficulties and substantial publication bias106 argue against widespread use.
3.3.3.5 Ankle brachial index
Estimates are that 1227% of middle-aged individuals have an ankle brachial index (ABI) <0.9, around 5089% of whom do not have typical claudication.124 An individual patient data metaanalysis concluded that the reclassification potential of ABI was limited, perhaps with the exception of women at intermediate risk.125
3.3.3.6 Echocardiography
In view of the lack of convincing evidence that it improves CVD risk reclassification, echocardiography is not recommended to improve
CV risk prediction.
3.3.4.Frailty
Frailty is a multidimensional state, independent of age and multimorbidity, that makes the individual more vulnerable to the effect of stressors. It constitutes a functional risk factor for unfavourable outcomes, including both high CV and non-CV morbidity and mortality.126,127
Frailty is not the same as ageing and the two should not be confused. The incidence of frailty increases with age, but people of the same chronological age can differ significantly in terms of health status and vitality. ‘Biological age’ is much more important in the context of clinical status (including frailty features) and hard clinical outcomes
(including CVD events).126,127 Similarly, although the presence of comorbidities can exacerbate frailty within an individual, frailty is not the same as multimorbidity (see section 6.7).
Frailty screening is indicated in every elderly patient, but should also be performed in every individual regardless of his/her age, when being at risk of accelerated ageing.126,127 Most of the tools relate to frail features, including slowness, weakness, low physical activity (PA), exhaustion, and shrinking (e.g. Fried scale, Short Physical Performance
Battery, Rockwood Clinical Frailty Scale, handgrip strength, gait speed).126129 Frailty assessment is important at each stage of an
ASCVD trajectory. During an acute CVD event, however, frailty assessment is more difficult, and either relies on history taking or should be postponed to when patients return to a stable condition.
Frailty is a potential modifier of global CVD risk. The impact of frailty on CVD risk has been demonstrated across the spectrum of ASCVD,
including people with ASCVD risk factors, patients with subclinical
ASCVD, stable ASCVD, acute cerebral and coronary syndromes, and
HF,126130 with frailty itself rather than classical CVD risk factors predicting both all-cause and CVD mortality in the very old.130,131
Importantly, the ability of frailty measures to improve CVD risk prediction has not been formally assessed. Hence, we do not recommend that frailty measures are integrated into formal CVD risk assessment.
Importantly, frailty may influence treatment. Non-pharmacological interventions (e.g. balanced nutrition, micronutrient supplementation, exercise training, social activation) aiming to prevent, attenuate,
or reverse frailty are of utmost importance.126,127,132 In terms of pharmacotherapy and device implantations, frailty assessment is not a method to determine the eligibility for any particular treatment, but rather serves to build an individualized care plan with predefined priorities. Frail individuals often have comorbidities, polypharmacy, and may be more susceptible to drug side-effects and serious complications during invasive and surgical procedures.126,127
3.3.5. Family history
Family history of premature CVD is a simple indicator of CVD risk,
reflecting the genetic and environment interplay.133 In the few studies that simultaneously assessed the effects of family history and genetics,
family history remained significantly associated with CVD after adjusting for genetic scores.134,135 However, family history only marginally improves the prediction of CVD risk beyond conventional ASCVD
risk factors.136141 Possible explanations are the varying definitions
ESC Guidelines
3259


<!-- PAGE 34 -->

### Page 34

.....................................
of family history applied and that conventional ASCVD risk factors largely explain the impact of family history.
A family history of premature CVD is simple, inexpensive information that can trigger comprehensive risk assessment in individuals with a family history of premature CVD.136
3.3.6. Genetics
The aetiology of ASCVD has a genetic component, but this information is not currently used in preventive approaches.142 Advances on polygenic risk scores for risk stratification could increase the use of genetics in prevention.143145 For ASCVD, there is, however, a lack of consensus regarding which genes and corresponding single nucleotide polymorphisms should be included, and whether to use risk factor-specific or outcome-specific polygenic risk scores.146
Polygenic risk scoring has shown some potential to improve ASCVD
risk prediction for primary prevention,147149 but the incremental prediction accuracy is relatively modest and needs further evaluation in both men and women.150,151 Additional evidence is also needed to evaluate the clinical utility of polygenic risk scores in other clinical settings, such as in patients with pre-existing ASCVD.152
3.3.7. Socioeconomic determinants
Low socioeconomic status and work stress are independently associated with ASCVD development and prognosis in both sexes.153,154
The strongest association has been found between low income and
CVD mortality, with a RR of 1.76 [95% confidence interval (CI)
1.452.14].155 Work stress is determined by job strain (i.e. the combination of high demands and low control at work) and effort-reward imbalance. There is preliminary evidence that the detrimental impact of work stress on ASCVD health is independent of conventional risk factors and their treatment.156
3.3.8. Environmental exposure
Environmental exposures with CVD risk modifying potential include air and soil pollution as well as above-threshold noise levels.
Evaluating individual cumulative exposure to pollutants and noise remains challenging, but when available, might impact on individual risk assessment.
Components of outdoor air pollution include airborne particulate matter [PM; ranging in size from coarse particles 2.510 mm in diameter, to fine (<2.5 mm; PM2.5), and ultrafine (<0.1 mm)] and gaseous pollutants (e.g. ozone, nitrogen dioxide, volatile organic compounds,
carbon monoxide, sulphur dioxide), produced primarily by combustion of fossil fuels. Soil and water pollutions are also CVD risk modifiers; increased exposure to lead, arsenic, and cadmium is associated with multiple CVD outcomes including hypertension, coronary heart disease (CHD), stroke, and CVD mortality.157 Ambient PM pollution recently ranked as a leading modifiable mortality risk factor and also responsible for attributable disability adjusted life-years at the global level.158 A recent model estimated that loss of life expectancy due to ambient air pollution is similar to, if not exceeding, that due to tobacco smoking, and accounts for a global excess mortality estimated at 8.8 million/year.159
The short-term attributable effects on mortality are linked primarily to exposure to PM, nitrogen dioxide, and ozone, with an average
1.0% increase of all-cause mortality for an increment of 10 lg/m3 in exposure to PM2.5; the long-term effects are associated mainly with
PM2.5. The evidence linking exposure to PM and CVD events is based on large-scale epidemiological studies and experimental studies.
Associations with ASCVD mortality vary, but the majority of cohort studies link long-term air pollution with an increased risk of fatal or non-fatal CAD, and with subclinical atherosclerosis. Evidence suggests that reduction of PM2.5 is associated with improvements in inflammation, thrombosis, and oxidative stress, and a decrease in death from ischaemic heart disease.38,160,161 As sufficiently precise individual exposure estimates are hard to obtain, formal risk reclassification is difficult to quantify at present.
3.3.9. Biomarkers in blood or urine
Many biomarkers have been suggested to improve risk stratification.
Some may be causal [e.g. lipoprotein(a), reflecting a pathogenic lipid fraction], whereas others may reflect underlying mechanisms (e.g. Creactive protein reflecting inflammation) or indicate early cardiac damage (e.g. natriuretic peptides or high-sensitivity cardiac troponin).
In the 2016 Guidelines,2 we recommended against the routine use of biomarkers because most do not improve risk prediction, and publication bias seriously distorts the evidence.106,162 New studies confirm that C-reactive protein has limited additional value.103 There is renewed interest in lipoprotein(a), but it too provides limited additional value in terms of reclassification potential.163,164 Cardiac biomarkers are promising,165,166 but further work is needed.
3.3.10. Body composition
Worldwide, BMI has increased substantially in recent decades, in children, adolescents, and adults.43 In observational studies, all-cause mortality is minimal at a BMI of 20 - 25 kg/m2, with a J- or U-shaped relation in current smokers.45,46 Mendelian randomization analyses suggest a linear relation between BMI and mortality in never-smokers and a J-shaped relation in ever-smokers.44 A meta-analysis concluded that both BMI and waist circumference are similarly strongly and continuously associated with ASCVD in the elderly and the young and in men and women.47
Among those with established ASCVD, the evidence is contradictory. Systematic reviews of patients with ACS or HF have suggested an ‘obesity paradox’ whereby obesity appears protective.167,168 169
However, this evidence should be interpreted with caution as reverse causality and other biases may be operating.45
Recommendations for cardiovascular disease risk related to air pollution
Recommendations
Classa
Levelb
Patients at (very) high risk for CVD may be encouraged to try to avoid long-term exposure to regions with high air pollution.
IIb
C
In regions where people have long-term exposure to high levels of air pollution, (opportunistic) CVD
risk screening programmes may be considered.
IIb
C
CVD = cardiovascular disease.
aClass of recommendation.
bLevel of evidence.
........................................................................................................................................
ESC 2021


<!-- PAGE 35 -->

### Page 35

###### 3.3.10.1 Which index of obesity is the best predictor of cardiovascular risk?

BMI can be measured easily and is used extensively to define categories of body weight (see Supplementary Table 6). Body fat stored in visceral and other ectopic depots carries a higher risk than subcutaneous fat. Several measures of global and abdominal fat are available,
of which waist circumference is the simplest to measure. The WHO
thresholds for waist circumference are widely accepted in Europe.
Two action levels are recommended:
• Waist circumference >_94 cm in men and >_80 cm in women: no further weight gain
• Waist circumference >_102 cm in men and >_88 cm in women:
weight reduction advised.
Different cut-offs for anthropometric measurements may be required in different ethnicities.
The phenotype of ‘metabolically healthy obesity’, defined by the presence of obesity in the absence of metabolic risk factors, has gained interest. Long-term results support the notion that metabolically healthy obesity is a transient phase moving towards glucometabolic abnormalities rather than a specific ‘state’.170
3.3.10.2 Risk reclassification
The associations between BMI, waist circumference, and waist-to-hip ratio and CVD are maintained after adjustment for conventional risk factors. However, these measures did not improve CVD risk prediction as assessed by reclassification.47
Recommendations for cardiovascular disease assessment in speciﬁc clinical conditions
Clinical condition
Recommendations
Classa
Levelb
CKD
In all CKD patients, with or without DM, appropriate screening for
ASCVD and kidney disease progression, including monitoring changes in albuminuria is recommended.172
I
C
Cancer
It is recommended to monitor cardiac dysfunction using imaging techniques and circulating biomarkers before, periodically during, and after cancer treatment.173
I
B
Cardioprotection in high-risk patients (those receiving high cumulative doses or combined radiotherapy) receiving anthracycline chemotherapy may be considered for prevention of LV
dysfunction.174,175
IIb
B
Screening for ASCVD risk factors and optimization of the CVD risk proﬁle is recommended in patients on treatment for cancer.
I
C
Continued
COPD
It is recommended that all COPD
patients be investigated for
ASCVD and ASCVD risk factors.
I
C
Inﬂammatory conditions
Assessment of total CVD risk may be considered in adults with chronic inﬂammatory conditions.176
IIb
B
Multiplication of calculated total
CVD risk by a factor of 1.5 should be considered in adults with rheumatoid arthritis.177,178
IIa
B
Migraine
Presence of migraine with aura should be considered in CVD risk assessment.179181
IIa
B
Avoidance of combined hormonal contraceptives may be considered in women with migraine with aura.182,183
IIb
B
Sleep disorders and OSA
In patients with ASCVD, obesity,
and hypertension, regular screening for non-restorative sleep is indicated (e.g. by the question:
‘how often have you been bothered by trouble falling or staying asleep, or sleeping too much?’).
I
C
If there are signiﬁcant sleep problems, which are not responding within 4 weeks to sleep hygiene,
referral to a specialist is recommended.
I
C
Mental disorders
It is recommended that mental disorders with either signiﬁcant functional impairment or decreased use of healthcare systems be considered as inﬂuencing total CVD risk.
I
C
Sex-speciﬁc conditions
In women with a history of preeclampsia and/or pregnancyinduced hypertension, periodic screening for hypertension and
DM should be considered.184187
IIa
B
In women with a history of polycystic ovary syndrome or gestational DM, periodic screening for
DM should be considered.188191
IIa
B
In women with a history of premature or stillbirth, periodic screening for hypertension and
DM may be considered.192,193
IIb
B
Assessment of CVD risk should be considered in men with ED.
IIa
C
ASCVD = atherosclerotic cardiovascular disease; CKD = chronic kidney disease;
COPD = chronic obstructive pulmonary disease; CV = cardiovascular; CVD =
cardiovascular disease; DM = diabetes mellitus; ED = erectile dysfunction; LV =
left ventricular; OSA = obstructive sleep apnoea.
aClass of recommendation.
bLevel of evidence.
ESC 2021
............................................................................................................................................................................
ESC Guidelines
3261


<!-- PAGE 36 -->

### Page 36

.............................................................................................................................................................................
3.3.10.3 Assess risk factors and cardiovascular disease risk in persons with obesity
Comprehensive CVD risk assessment should be considered in individuals with unfavourable body composition. The main risk-related sequalae of adiposity include hypertension, dyslipidaemia, insulin resistance,
systemic inflammation, a prothrombotic state, albuminuria, as well as a decline in estimated glomerular filtration rate (eGFR)171 and the development of type 2 DM, CVD events, as well as HF and AF.
3.4. Clinical conditions
Individual calculated risks of CVD, as evaluated by conventional risk factors in risk scores, are subject to refinement by potential risk modifiers as highlighted in section 3.3. Beyond these potential modifiers, specific clinical conditions can influence CVD risk. These clinical conditions often increase the likelihood of CVD, or are associated with poorer clinical prognosis. The current section reviews some of these conditions, which are not often included in traditional risk scores but may be integrated in some national risk scores. Here we discuss how these conditions increase this risk.
Many clinical conditions share common CVD and ASCVD risk factors and therefore treating these allows a synergistic reduction in the overall burden of disease.
3.4.1. Chronic kidney disease
Worldwide, the total number of individuals with chronic kidney disease (CKD) who are not treated with kidney replacement therapy was approximately 850 million in 2017.194 This number accounts to a prevalence of 10 - 12% among men and women. CKD is the third fastest growing cause of death globally.195
CKD is defined as abnormalities of kidney structure or function,
present for >3 months, with health implications. Criteria and markers of kidney damage, especially kidney disease due to DM, are albuminuria [albumin-to-creatinine ratio (ACR) >30 mg/g in spot urine specimens] and glomerular filtration rate (GFR) <60 mL/min/1.73 m2.
GFR can be estimated (eGFR) from calibrated serum creatinine and estimating equations using the CKD-EPI (Chronic Kidney Disease
Epidemiology) Collaboration formula. Kidney disease severity is differentiated into stages (categories) according to the level of GFR and albuminuria; a patient with an eGFR <60 mL/min/1.73 m2 is classified as having CKD stage 3a, which represents an advanced kidney function impairment.172
Among persons with CKD, CVD is the leading cause of morbidity and death.196 Even after adjustment for known CAD risk factors, including DM and hypertension, mortality risk progressively increases with worsening CKD.197 As GFR declines below approximately 60- 75 mL/
min/1.73 m2, the probability of developing CAD increases linearly,198
with up to triple the CVD mortality risk when reaching an eGFR of 15
mL/min/1.73 m2. Kidney disease is associated with a very high CVD risk.
Among persons with CKD, there is a high prevalence of traditional
CAD risk factors, such as DM and hypertension. The use of CAC score to risk stratify patients with CKD might be a promising tool.199203
Furthermore, persons with CKD are also exposed to other nontraditional ASCVD risk factors such as uraemia-related ones, including inflammation, oxidative stress, and promotors of vascular calcification.
CKD and kidney failure not only increase the risk of CAD, they also modify its clinical presentation and cardinal symptoms.204
3.4.2. Atrial fibrillation
Atrial fibrillation (AF) appears to be associated with an increased risk of death and of CVD and kidney disease.205 Furthermore, AF appears to be a stronger risk factor for CVD in women than in men.206
The prevalence of AF ranges between 2% and 4%, and a 2.3-fold rise is expected, owing in part to ageing of the population and intensified searching for undiagnosed AF, as well as lower CV death.207 The age-adjusted incidence, prevalence, and lifetime risk of AF are lower in women vs. men and in non-white vs. white cohorts.208,209 The lifetime AF risk estimate is now 1 in 3 individuals of European ancestry at an index age of 55 years.210 ASCVD risk factor burden and comorbidities, including lifestyle factors, and age significantly affect the lifetime risk for AF development.211213 The observed effect of clinical
ASCVD risk factor burden and multiple comorbidities on the lifetime risk of AF (significantly increasing from 23.4% among individuals with an optimal clinical risk factor profile to 33.4% and 38.4% in those with borderline and elevated clinical risk factors, respectively214) suggests that early intervention and control of modifiable ASCVD risk factors could reduce incident AF. The continuum of unhealthy lifestyle, risk factor(s), and CVDs can contribute to atrial remodelling/cardiomyopathy and development of AF that commonly results from a combined effect of multiple interacting factors (Figure 9).215 Risk factor and CVD management reduces AF burden. Targeted therapy of underlying conditions may significantly improve maintenance of sinus rhythm in patients with persistent AF and HF.216 However, studies addressing isolated management of specific conditions alone (e.g.
hypertension) yielded inconsistent findings.217
The overall annual risk of ischaemic stroke in patients with AF is
5%,
but varies considerably according to comorbidities.215
Cardioembolic strokes associated with AF are usually more severe,
and often recurrent.218 Furthermore, AF appears to be a stronger predictor of stroke in women than in men.215 AF is also associated with impaired cognitive function, ranging from mild cognitive impairment to dementia.219 AF is independently associated with a two-fold increased risk of all-cause mortality in women and a 1.5-fold increased risk in men.220 In one population, the most common causes of death were HF (14.5%), malignancy (23.1%), and infection/sepsis
(17.3%), while stroke-related mortality was only 6.5%.221 These data indicate that, in addition to anticoagulation and HF treatment, comorbid conditions need to be actively treated to reduce AF-related mortality and morbidity.
Regarding PA, both sedentary lifestyles and very high levels of PA
are associated with development of AF (U-shaped association),
through different mechanisms. Furthermore, when AF develops in athletes it is not associated with the same increased risk of stroke.
3.4.3. Heart failure
Heart failure (HF) of ischaemic origin constitutes a severe clinical manifestation of ASCVD. Conversely, HF itself (predominantly of ischaemic aetiology) increases the risk of CVD events (myocardial infarction, arrhythmias, ischaemic stroke, CV death).
Asymptomatic LV dysfunction (systolic or/and diastolic dysfunction) as well as overt symptomatic HF [across the spectrum of LVEF,
i.e. HF with reduced ejection fraction (HFrEF), HF with mid-range ejection fraction,222 and HF with preserved ejection fraction
(HFpEF)] increases the risk of urgent CV hospitalizations (including hospitalizations due to HF worsening) and CV and all-cause deaths.


<!-- PAGE 37 -->

### Page 37

.............................................
These unfavourable effects on clinical outcomes have been demonstrated in asymptomatic subjects without overt CVD, in patients with acute and previous myocardial infarction, in patients with acute and previous stroke, and in patients with other clinical manifestations of
CVD.223
The diagnosis of ischaemic HF positions individuals at very high CV
risk, and justifies recommendations as for secondary prevention therapeutic strategies. Additionally, for patients with symptomatic HFrEF,
several drugs are recommended to reduce the risk of CV morbidity and mortality (see section 6.2).
3.4.4. Cancer
In patients with cancer, there is an overlap between cancer and
ASCVD risk factors, with shared biological mechanisms and genetic predispositions. Prevention and treatment of these is therefore beneficial in reducing both CVD as well as cancer risk. Moreover, the rates of the extent of CVD risk depend on both the CVD toxicity of treatments and patient-related factors. Owing to recent improvements in clinical outcomes for many patients with cancer, CVD mortality may ultimately exceed those from most forms of cancer recurrence.224,225
The rapidly expanding variety of novel anticancer drugs/adjuvant therapies has demonstrated a wide range of both early and late CVD
side-effects, including cardiomyopathy, LV dysfunction, HF, hypertension, CAD, arrhythmias, and other injuries. Therefore, effective strategies for the prediction and prevention of CVD toxicities are critically important. The latency and severity of radiotherapy cardiotoxicity, as well as accelerated atherosclerosis and cerebral vascular disease, is related to multiple factors, including the dose (total per fraction),
the volume of the heart irradiated,
concomitant
Risk factors for AF
Hypertension
Obesity
Diabetes mellitus
Physical activity
OSA
Alcohol
Dyslipidemia
Smoking
Lifestyle modification
AF risk factors modification
Treatment of underlying CV conditions
Reduction of mortality and morbidity
Primary prevention of AF
Reduction of mortality and morbidity
Symptomatic improvement
Secondary prevention of AF
Modifiable
Ageing
Genetics
Heart failure
CAD
Valvular heart disease
COPD
Lifestyle modification
AF risk factors modification
Treatment of underlying CV conditions
Stroke prevention
Rate control
AAD therapy
Cardioversion
Catheter ablation
Surgery
Non- or partly modifiable
LA remodeling
Electrical
Biochemical
Inflammation
Reversible
Fibrosis
Scarring
Dilatation
Non-reversible
AF outcomes
Mortality
Stroke/systemic thromboembolism
Symptoms and quality of life
Heart failure
Dementia
Myocardial infarction
Hospitalizations and healthcare costs
AF development and progression
Paroxysmal
Persistent
Permanent
Figure 9 The role of risk factors and comorbidities in atrial fibrillation.215 AF = atrial fibrillation; CAD = coronary artery disease; COPD = chronic obstructive pulmonary disease; CV = cardiovascular; DM = diabetes mellitus; HF = heart failure; OSA = obstructive sleep apnoea.
ESC Guidelines
3263


<!-- PAGE 38 -->

### Page 38

.............................................................................................................................................................................
administration of other cardiotoxic drugs, and patient factors (which include, amongst other factors, younger age, traditional risk factors,
and history of heart disease).226,227 Furthermore, radio- and chemotherapy may exert direct vascular effects and increase atherosclerosis-related CVD outcomes.227,228
3.4.4.1 Diagnosis and screening
Signs or symptoms of cardiac dysfunction should be monitored before and periodically during and after cancer treatment for early detection of abnormalities in patients receiving potentially cardiotoxic chemotherapy. Detection of subclinical abnormalities using imaging and measurement of circulating biomarkers (such as cardiac troponins and natriuretic peptides) is currently recommended.173,229
Measures of myocardial strain, particularly systolic global longitudinal strain, may precede a significant decline in LVEF.230233
3.4.4.2 Prevention of cardiotoxicity and cardiovascular risk factors
RCTs of preventive therapy with renin-angiotensin-aldosterone system (RAAS) inhibitors and/or beta-blockers after trastuzumab or anthracyclines have reported contradictory results.230,234,235 The main benefits are less marked LV remodelling or a reduced decline in
LVEF observed with cardiac magnetic resonance, but translation into better outcomes remains speculative.
Exercise should be strongly advised. In particular, aerobic exercise is considered a promising non-pharmacological strategy to prevent and/
or treat chemotherapy toxicity.236 A study showed a significantly higher risk of CVD in survivors of childhood cancer than in non-cancer adult controls, and particularly in survivors of adult-onset cancer with underlying ASCVD risk factors.237 Therefore, aggressive management of ASCVD risk factors in this population is recommended.
3.4.5. Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is a complex, progressive respiratory disorder and currently the fourth leading cause of death worldwide. It is characterized by chronic airflow limitation with respiratory symptoms and is associated with an increased inflammatory response and abnormalities of the airways caused by significant exposure to noxious particles or gases (mainly smoking).
Although COPD is recognized and thoroughly investigated as a CVD
comorbidity, its role as an ASCVD risk factor is not well established.
Nevertheless, COPD patients have a two- to three- fold increased risk of CVD compared with age-matched controls when adjusted for tobacco smoking. Patients with mild-to-moderate COPD are 810
times more likely to die from ASCVD than respiratory failure, having higher rates of hospitalization and death due to CVD, stroke, and
HF.238,239 CVD also runs undiagnosed; less than one-third of COPD
patients with electrocardiographic (ECG) evidence of myocardial infarction are diagnosed with CVD.240 CVD mortality increases by
28%, and the frequency of non-fatal coronary events by 20%, for every 10% decrease in the forced expiratory volume in 1 second
(FEV1).241 Acute COPD exacerbations, mainly due to infections, are frequent and are responsible for a four-fold increase of CVD
events.242 The risk of both myocardial infarction and ischaemic stroke is increased during the 3 months after an acute exacerbation.243
The high prevalence of CVD in COPD patients may be explained by the fact that both diseases share common risk factors, such as smoking, ageing, hypertension, and dyslipidaemia.244 Metabolic syndrome and reduced PA is present in 34% of COPD patients, with its most prevalent components being hypertension (56%), abdominal obesity (39%), and hyperglycaemia (44%).245 CVD may be caused by hypoxia during exercise due to lung hyperinflation, high resting heart rates, impaired vasodilatory capacity, and peripheral, cardiac, and neurohumoral sympathetic stress. Atherosclerosis and coronary artery calcification may be the result of oxidative stress, and reductions in antiaging molecules causing both lung and vascular ageing.246
Systemic inflammation is prominent in COPD, with circulating biomarkers in high concentrations and associated with increased mortality.247 Troponin is elevated during an acute exacerbation of COPD,
and 10% of hospitalized patients meet the definition of acute myocardial infarction (AMI).248 B-natriuretic peptide level, if elevated,
increases the mortality risk.249
Systemic inflammation and oxidative stress caused by COPD promote vascular remodelling, stiffness, and atherosclerosis, and induce a ‘procoagulant’ state that affects all vasculature types.250 Cognitive impairment and dementia due to cerebral microvascular damage is correlated with COPD severity; patients have a 20% increased risk for both ischaemic and haemorrhagic stroke, which may be up to seven-fold higher following an acute exacerbation.251 PAD is present in about 9% of COPD patients,252 who have an almost doubled risk of developing PAD,253 as well as an increased prevalence of carotid plaques related to the disease severity.254 Finally, COPD is positively associated with abdominal aortic aneurysm, regardless of smoking status.255
Cardiac arrhythmias are common and may be due to the haemodynamic effects (pulmonary hypertension, diastolic dysfunction, atrial structural, and electrical remodelling) caused by the disease in combination with autonomic imbalance and abnormal ventricular repolarization.256 AF is frequent, directly associated with FEV1, usually triggered by acute exacerbations of COPD, and an independent predictor of in-hospital COPD mortality.257,258 COPD is also a risk factor for ventricular tachycardia independent of LVEF,259 and for sudden cardiac death independent of CVD risk profile.260
Unrecognized ventricular dysfunction is common in COPD,261
although HF is 3.8 times more common in COPD patients than in controls.262 Patients with frequent acute exacerbations have a high frequency of diastolic dysfunction; HFpEF risk is higher because of a high prevalence of hypertension and DM.263
Considering these facts, it seems of upmost importance to screen
COPD patients for ASCVD and ASCVD risk factors, bearing in mind that COPD affects the accuracy of CVD diagnostic tests. Achieving adequate exercise is difficult, vasodilators for myocardial perfusion scanning may be contraindicated because of the risk of bronchospasm, and stress or transthoracic echocardiography is often disturbed by poor ultrasound windows. Computed tomography coronary angiography or magnetic resonance imaging may be alternatives, but remain expensive, time consuming, and not always available.
The use of COPD medications (i.e. long-acting muscarinic antagonists and long-acting beta agonists) is not associated with overall CV
adverse events in patients with stable COPD. Olodaterol may reduce the risk of overall CV adverse events and formoterol may decrease the risk of cardiac ischaemia. Long-acting beta agonists may reduce the incidence of hypertension, but may also increase the risk of HF,
so should be used with caution in HF patients.264


<!-- PAGE 39 -->

### Page 39

.............................................................................................................................................................................
3.4.6. Inflammatory conditions
Inflammatory conditions increase CVD risk both acutely and over time. The best evidence for chronic inflammation increasing CVD
risk is available for rheumatoid arthritis, which increases CVD risk by approximately 50% beyond established risk factors.176 Hence, a low threshold for assessment of total CVD risk is appropriate in adults with rheumatoid arthritis, and one should consider increasing the risk estimate based on the level of disease activity.176 There is also evidence for an approximately 20% increased CVD risk in patients with active inflammatory bowel disease.265
In other chronic inflammatory conditions, such as psoriasis177 and ankylosing spondylitis,178 CVD risk may also be increased. However,
the strength of the evidence is less strong, as is the independence of such increased risks from the classical ASCVD risk factors.
Nonetheless, it seems prudent to at least consider CVD risk assessment in patients with any chronic inflammatory condition, and to take into account the presence of such conditions when there is doubt regarding initiation of preventive interventions. The cumulative disease burden and recent degree of inflammation are important determinants of the risk-enhancing effect.
Apart from optimal anti-inflammatory treatment, CVD risk in inflammatory conditions should be treated with similar interventions as in the general high-risk population, as there is evidence that traditional methods to lessen risk (e.g. lipid-lowering treatment) are just as beneficial in preventing ASCVD.
3.4.7. Infections (human immunodeficiency virus,
influenza, periodontitis)
Infection with human immunodeficiency virus (HIV) is associated with a 19% increased risk of LEAD and CAD beyond that explained by traditional atherosclerotic risk factors.266,267 However, for those with sustained CD4 cell counts <200 cells/mm3, the risk of incident
LEAD events is nearly two-fold higher, whereas for those with sustained CD4 cell counts >_500 cells/mm3, there is no excess risk of incident LEAD events compared with uninfected people.268
CVD and influenza have long been associated, due to an overlap in the peak incidence of each disease during winter months.
Epidemiological studies have noted an increase in CV deaths during influenza epidemics, indicating that CV complications of influenza infection, including acute ischaemic heart disease and, less often,
stroke, are important contributors to morbidity and mortality during influenza infection.
The risk of AMI or stroke is more than four times higher after a respiratory tract infection, with the highest risk in the first 3 days after diagnosis.269 Preventing influenza, particularly by means of vaccination, could prevent influenza-triggered AMI.270
Studies have linked periodontal disease to both atherosclerosis and
CVD,271273 and serological studies have linked elevated antibody titres of periodontal bacteria to atherosclerotic disease.274 Nevertheless, if active treatment or prevention of periodontitis improves, clinical prognosis requires further studies despite preliminary evidence.275277
3.4.8. Migraine
Migraine is a highly prevalent condition affecting around 15% of the general population.278 There are two main types of migraine—
migraine without aura, which is the most common subtype, and migraine with aura, which accounts for about one-third of all migraines; in many patients the two forms coexist.
Available data indicate that migraine overall is associated with a two-fold increased risk of ischaemic stroke and a 1.5-fold increase in the risk of cardiac ischaemic disease.179181,279,280 The associations are more evident for migraine with aura.179,180,280 Given the young mean age of the population affected by migraine, the absolute increase in risk is small at the individual level, but high at the population level because of the high migraine prevalence.281
Several lines of evidence also indicate that the vascular risk of subjects with migraine may be magnified by cigarette smoking182 and by the use of combined hormonal contraceptives.183,281283 Contraception using combined hormonal contraceptives should therefore be avoided in women with migraine.282,283 However, further information is needed as good-quality studies assessing risk of stroke associated with lowdose oestrogen use in women with migraine are lacking.
3.4.9.Sleep disorders and obstructive sleep apnoea
Sleep disturbances or abnormal sleep durations are associated with increased CVD risk.284286 Regarding sleep duration, 7 h seems to be optimal for CV health.287
In the general population, the prevalence of general sleep disturbances is around 32.1%: 8.2% for insomnia, 6.1% for parasomnia,
5.9% for hypersomnolence, 12.5% for restless legs disorder and limb movements during sleep, and 7.1% for sleep-related breathing disorder [e.g. obstructive sleep apnoea (OSA)].288 All sleep disturbances are strongly associated with mental disorders and share hyperarousal as an underlying mechanism.289,290
The most important sleep-related breathing disorder is OSA,
which is characterized by repetitive episodes of apnoea, each exceeding 10 seconds. Despite the strong associations of OSA with CVD,
including hypertension, stroke, HF, CAD, and AF, treatment of OSA
by positive airway pressure (PAP) has failed to improve hard CV outcomes in patients with established CVD.291293 Therefore, interventions that include behaviour change (reduction of obesity, alcohol abstinence), sleep hygiene, and stress reduction in addition to PAP are needed.290,294 Regarding hypertension and OSA, there are modest effects of PAP on BP levels, but only in patients with ABPM-confirmed resistant hypertension who use PAP for more than 5.8 h/night.295
3.4.10. Mental disorders
The 12-month prevalence of mental disorders or mental health disorders in the general European population is between 27% and 38%
depending on sources and definitions.296 All mental disorders (e.g.
anxiety disorders, somatoform disorders, substance disorders, personality disorders, mood disorders, and psychotic disorders) are associated with the development of CVD and reduced life expectancy in both sexes.297300 The risk increases with the severity of the mental disturbance and vigilance for (often non-specific) symptoms is crucial.301 The onset of CVD is associated with an approximately
23-fold increased risk of mental disorders compared to a healthy population.115,302 In this context, screening should be performed at every consultation (or 24 times/year). The 12-month prevalence of mental disorders in CVD patients is around 40%, leading to significantly worse prognosis.100,108,303,304 The onset of CVD increases the risk of committing suicide.305 In this context, awareness of anxiety and depression symptoms should be increased.
ESC Guidelines
3265


<!-- PAGE 40 -->

### Page 40

.............................................................................................................................................................................
The precise mechanism by which mental disorders increase CVD
remains uncertain. The detrimental effects are potentially caused by unhealthy lifestyle, increased exposure to socioeconomic stressors,
and cardiometabolic side-effects of some medications,113 but also by direct effects of the amygdala-based fear-defence system and other direct pathophysiological pathways.303 Abuse of psychostimulants
(e.g. cocaine) is a powerful trigger of myocardial ischaemia.306
Further, the capacity of these patients to adaptively use the healthcare systems is impaired due to their mental condition (e.g. not being able to trust other people and seek help, impaired capacity to be adherent).100 Barriers on the part of healthcare providers are stigmatizing attitudes, insufficient mental health literacy, and lack of confidence in mental healthcare.307309 Although patients with mental disorders have an increased CVD risk, they receive a lower rate of recognition and treatment of traditional ASCVD risk factors.310
Preliminary evidence suggests that taking mental disorders into account improves classical CVD risk models.311,312
Certain categories of patients with learning difficulties and associated disorders (such as Down’s syndrome) are at increased risk of
CVD disease, but perhaps not specifically ASCVD. However, health inequalities and the prevalence of CV risk factors may be greater in these populations, although epidemiology research is scarce.
3.4.11. Non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) has been associated with an increased risk of myocardial infarction and stroke. NAFLD represents accumulation of ectopic fat; persons with NAFLD are often overweight or obese, and not uncommonly have abnormal BP, glucose, and lipid levels. A recent study investigating whether NAFLD
increases CV risk beyond traditional risk factors313 shows that after adjusting for established risk factors, the associations did not persist.
Nevertheless, patients with NAFLD should have their CVD risk calculated, be screened for DM, and be recommended a healthy lifestyle with a reduction of alcohol intake.
3.4.12. Sex-specific conditions
3.4.12.1 Obstetric conditions
Pre-eclampsia (defined as pregnancy-related hypertension accompanied by proteinuria) occurs in 12% of all pregnancies and is associated with an increase in CVD risk by a factor of 1.52.7 compared with all women,185,186,314 while the RR of developing hypertension is 3187 and
DM is 2.184,185 It has not been established whether the increased CVD
risk after preeclampsia occurs independently of CV risk factors. The rationale for screening these women for the occurrence of hypertension and DM is, however, quite strong. At present, no separate risk model for women with a history of hypertensive disorders of pregnancy seems necessary, despite their higher baseline risk.315
Pregnancy-related hypertension affects 1015% of all pregnancies.
The associated risk of later CVD is lower than for preeclampsia but is still elevated (RR 1.72.5).193,314,316,317 Also, the risk for sustained or future hypertension is elevated (RRs vary, from 2.0 to 7.2 or even higher).187,318 Again, however, there was incomplete adjustment for conventional risk factors. The risk of developing DM is also elevated in these women (RR 1.62.0).314,319 Both preterm (RR 1.6) and stillbirth (RR 1.5) have been associated with a moderate increase in risk of CVD.316
Finally, gestational DM confers a sharply elevated risk of future
DM, with up to 50% of affected women developing DM within 5
years after pregnancy, and an up to two-fold increased risk of CVD in the future.188,320 Screening by fasting glucose or HbA1c may be preferable to oral glucose tolerance testing.191,321
3.4.12.2 Non-obstetric conditions
Polycystic ovary syndrome affects 5% of all women in their fertile years.322,323 It has been associated with an increased risk of CVD.314
The risk of developing hypertension is probably increased, but data are conflicting.324 Polycystic ovary syndrome is associated with a higher risk of developing DM (RR 24),189,190 suggesting that periodic screening for DM is appropriate.
Premature menopause occurs in roughly 1% of women <_40 years of age. Up to 10% of women experience an early menopause, defined as that occurring by 45 years of age.314,325 Early menopause is associated with an increased risk of CVD (RR 1.5).326328 A linear inverse relationship between earlier menopause and CHD risk has been found, whereby each 1-year decrease in age at menopause portended a 2% increased risk of CHD.329
3.4.12.3 Erectile dysfunction
Erectile dysfunction (ED), defined as the consistent inability to reach and maintain an erection satisfactory for sexual activity, has a multifactorial cause. It affects almost 40% and more than 50% of men over
40 years and 60 years of age, respectively.330,331 Men with ED have an increased risk of all-cause mortality [odds ratio (OR) 1.26, 95% CI
1.011.57] and CVD mortality (OR 1.43, 95% CI 1.002.05). ED
and CVD share common risk factors (hypercholesterolaemia, hypertension, insulin resistance and DM, smoking, obesity, metabolic syndrome, sedentary lifestyle,
and depression) and a common pathophysiological basis of aetiology and progression.332,333
Medication used to prevent CVD, such as aldosterone receptor antagonists, some beta-blockers, and thiazide diuretics, can cause
ED.330,332335 ED is associated with subclinical vascular disease,336 and precedes CAD, stroke, and PAD by a period that usually ranges from 2
to 5 years (average 3 years). Men with ED have a 4459% higher risk for total CV events, 62% for AMI, 39% for stroke, and 2433% for allcause mortality, with a higher risk in those with severe ED.337341
There is strong evidence that CVD risk assessment is needed in men presenting with ED.336,342 In men with ED and low-to-intermediate
CVD risk, detailed risk profiling by, for example, CAC score is suggested, but so far not supported by evidence.338,341 Assessment of ED
severity and physical examination should be part of the first-line CVD
risk assessment in men.333,341 Lifestyle changes are effective in improving sexual function in men: these include vigorous physical exercise,334,343
improved nutrition, weight control, and smoking cessation.343345
4. Risk factors and interventions at the individual level
4.1. Treatment recommendations:
classes, grades, and freedom of choice
Clear communication about risks and benefits is crucial before any treatment is initiated. Risk communication is discussed in section 3.2.4,


<!-- PAGE 41 -->

### Page 41

Table 6
Treatment goals for different patient categories
Patient category
Prevention goals (STEP 1)
Intensified/additional prevention goalsa (STEP 2)
Apparently healthy persons
For BP and lipids: initiation of drug treatment based on
CVD risk assessment (Table 5) or SBP >160 mmHg
<50 years
Stop smoking and lifestyle optimization
SBP <140 down to 130 mmHg if toleratedb
LDL-C <2.6 mmol/L (100 mg/dL)
SBP <130 mmHg if toleratedb
LDL-C <1.8 mmol/L (70 mg/dL) and >_50% reduction in high-risk patients
LDL-C <1.4 mmol/L (55 mg/dL) and >_50% reduction in very-high-risk patients
50 - 69 years
Stop smoking and lifestyle optimization
SBP <140 down to 130 mmHg if toleratedb
LDL-C <2.6 mmol/L (100 mg/dL)
SBP <130 mmHg if toleratedb
LDL-C <1.8 mmol/L (70 mg/dL) and >_50% reduction in high-risk patients
LDL-C <1.4 mmol/L (55 mg/dL) and >_50% reduction in very-high-risk patients
>_70 years
Stop smoking and lifestyle optimization
SBP <140 mmHg if toleratedb
LDL-C <2.6 mmol/L (100 mg/dL)
For speciﬁc risk factor management in patients >_70
years old, please see relevant sections in section 4.
Patients with CKD
Stop smoking and lifestyle optimization
SBP <140 down to 130 mmHg if toleratedb
LDL-C <2.6 mmol/L (100 mg/dL) and >_50% LDL-C
reduction
Otherwise according to ASCVD and DM history
LDL-C <1.8 mmol/L (70 mg/dL) in high-risk patients and <1.4 mmol/L (55 mg/dL) in very-high risk patients
(see Table 4)
Patients with FH
Stop smoking and lifestyle optimization
SBP <140 down to 130 mmHg if toleratedb
LDL-C <2.6 mmol/L (100 mg/dL) and >_50% LDL-C
reduction Otherwise according to ASCVD and DM
history
LDL-C <1.8 mmol/L (70 mg/dL) in high-risk patients and <1.4 mmol/L (55 mg/dL) in very-high risk patients
(see Table 4)
People with type 2 DM
Well-controlled short-standing
DM (e.g. <10 years), no evidence of TOD and no additional ASCVD
risk factors
Stop smoking and lifestyle optimization
Without established ASCVD or severe TOD (see Table 4 for deﬁnitions)
Stop smoking and lifestyle optimization
SBP <140 down to 130 mmHg if toleratedb
LDL-C <2.6 mmol/L (100 mg/dL)
HbA1c <53 mmol/mol (7.0%)
SBP <130 mmHg if toleratedb
LDL-C <1.8 mmol/L (70 mg/dL) and >_50% reduction
SGLT2 inhibitor or GLP-1RA
With established ASCVD and/or severe TOD (see Table 4 for deﬁnitions)
Stop smoking and lifestyle optimisation
SBP <140 down to 130 mmHg if toleratedb
LDL-C <1.8 mmol/L (70 mg/dL)
HbA1c <64 mmol/mol (8.0%)
SGLT2 inhibitor or GLP1-RA
CVD: antiplatelet therapy
SBP <130 mmHg if toleratedb
LDL-C <1.4 mmol/L (55 mg/dL) and >_50% reduction
SGLT2 inhibitor or GLP-1RA if not already on
May additionally consider novel upcoming treatments:
DAPT, dual pathway inhibition,a colchicine, icosapent ethyl
Patients with established
ASCVD
Stop smoking and lifestyle optimization
SBP <140 down to 130 mmHg if toleratedb
Intensive oral lipid-lowering therapy aiming at >_50%
LDL-C reduction and LDL-C <1.8 mmol/L (70 mg/dL)
Antiplatelet therapy
SBP <130 mmHg if toleratedb
LDL-C <1.4 mmol/L (55 mg/dL)
May additionally consider novel upcoming treatments:
DAPT, dual pathway inhibition, colchicine, icosapent ethyl,
etc.
ASCVD = atherosclerotic cardiovascular disease; BP = blood pressure; CKD = chronic kidney disease; CVD = cardiovascular disease; DAPT = dual antiplatelet therapy; DBP =
diastolic blood pressure; DM = diabetes mellitus; EAS = European Atherosclerosis Society; ESC = European Society of Cardiology; FH = familial hypercholesterolaemia; GLP1RA = glucagon-like peptide-1receptor agonist; HbA1c = glycated haemoglobin; LDL-C = low-density lipoprotein cholesterol; SBP = systolic blood pressure (ofﬁce); SGLT2 =
sodium-glucose cotransporter 2; TOD = target organ damage.
aDepending on 10-year (residual) risk and/or estimated lifetime beneﬁt (see Table 4 for details), comorbidities, and patient preference. Levels of evidence of intensiﬁed goals vary, see recommendation tables in sections 4.6 and 4.7. For CKD and FH, LDL-C targets are taken form the 2019 ESC/EAS Guidelines for the treatment of dyslipidaemias.3
bOfﬁce DBP treatment target range <80 mmHg.
ESC 2021
ESC Guidelines
3267


<!-- PAGE 42 -->

### Page 42

...................................................................
and benefits of individual treatment are the topic of this section. In all scenarios where recommendations for individual interventions to reduce risk are ‘strong’ (class I or IIa), it is important to realize that many patients who have received appropriate risk information often
(in up to 50% of cases, some studies suggest) consciously opt to forego the proposed intervention. This applies not only to lifestyle measures, but also to drug interventions. Apparently, what professionals feel is sufficient risk reduction for a reasonable effort or initiation of a drug with few side-effects does not always correspond to patients’ views. The reverse is also true: not only may some patients at (very) high risk forego interventions, some patients with low-tomoderate risk may be highly motivated to decrease their risk even further. Hence, treatment recommendations are never ‘imperative’
for (very) high risk patients, nor are interventions ever ‘prohibited’
for patients at low-to-moderate risk. There is evidence that a higher proportion of women, compared to men, have a low awareness of their CVD risk and the need for therapeutic interventions. This warrants efforts to improve awareness, risk assessment, and treatment in women.52,346351
4.2. Optimizing cardiovascular risk management
4.2.1. Goals of clinicianpatient communication
Clinicians should provide a personalized presentation of guidelines to improve understanding, encourage lifestyle changes, and support adherence to drug therapy. Applying this in daily practice faces different barriers.352 Patients’ ability to adopt a healthy lifestyle depends on cognitive and emotional factors, the impact of a diagnosis or symptoms, socioeconomic factors, educational level, and mental health.
Perceived susceptibility to illness and the anticipated severity of the consequences are also prominent components of patients’
motivation.353
4.2.2. How to improve motivation?
Communication strategies such as motivational interviewing are useful.354 Consultation sessions may include a family member or friend,
especially for elderly patients. Connection is paramount: focus before greeting; listen intently; agree on what matters most; connect with the person’s story; and explore emotions.355 The OARS (Open-ended questions, Affirmation, Reflective listening, and Summarizing) principle helps patients to present their perceptions, and clinicians to summarize. The SMART (Specific, Measurable, Achievable, Realistic, Timely)
principle may help with setting goals for behavioural change.353,356
Healthcare professionals must consider capability, opportunity (physical, social, or environmental) and motivation for behavioural change.357 Multidisciplinary behavioural approaches that combine the knowledge and skills of different caregivers are recommended.358
4.2.3. Optimizing drug adherence
Medication adherence ranges from 50% for primary ASCVD prevention to 66% for secondary prevention.359 Physicians should consider non-adherence in every patient and inquire non-judgmentally about it.360 Approximately 9% of cases of ASCVD in Europe can be attributed to poor medication adherence.361 Contributors to nonadherence include polypharmacy, complexity of drug/dose regimes,
poor doctor-patient relationship, lack of disease acceptance, beliefs about consequences and side-effects, intellectual/cognitive abilities,
mental disorders, physical limitations, financial aspects, and living alone.360,362364 Importantly, only substantial risk reduction motivates patients for preventive drug treatment, which obviates the need for appropriate risk communication.365,366 Depression is another important factor, and adequate treatment thereof improves adherence.367,368
Mobile phone applications may improve adherence to both medication and behavioural changes.369 Their use is easy and probably cost-effective.370
4.2.4. Treatment goals
In the subsequent sections, different domains of individual treatment are discussed. Table 6 summarizes the treatment goals and some key interventions for different categories of patients. For additional information on risk categories and the principle of a stepwise approach to treatment targets, please refer to section 3.2.3.1. For details on treatment goals, how to achieve them, strengths of recommendations and levels of supporting evidence, please go to the relevant subsections.
4.3.Optimizing lifestyle
4.3.1. Physical activity and exercise
PA reduces the risk of many adverse health outcomes and risk factors in all ages and both sexes. There is an inverse relationship between moderate-to-vigorous PA and all-cause mortality, CV morbidity and
Recommendations for physical activity
Recommendations
Classa
Levelb
It is recommended for adults of all ages to strive for at least 150 - 300 min a week of moderateintensity or 75 - 150 min a week of vigorousintensity aerobic PA, or an equivalent combination thereof, to reduce all-cause mortality, CV
mortality, and morbidity.371,372
I
A
It is recommended that adults who cannot perform 150 min of moderate-intensity PA a week should stay as active as their abilities and health condition allow.373,374
I
B
It is recommended to reduce sedentary time to engage in at least light activity throughout the day to reduce all-cause and CV mortality and morbidity.375377
I
B
Performing resistance exercise, in addition to aerobic activity, is recommended on 2 or more days per week to reduce all-cause mortality.378,379
I
B
Lifestyle interventions, such as group or individual education, behaviour-change techniques, telephone counselling, and use of consumer-based wearable activity trackers, should be considered to increase PA participation.380382
IIa
B
CV = cardiovascular; PA = physical activity.
aClass of recommendation.
bLevel of evidence.
ESC 2021
..........................................................................................................


<!-- PAGE 43 -->

### Page 43

...............................................................................................
mortality, as well as incidence of type 2 DM.371373,383387 The reduction in risk continues across the full range of PA volumes, and the slope of risk decline is steepest for the least active individuals.371374,386,387 More information on PA prescription can be found in a recent ESC Guideline.388
4.3.1.1 Physical activity prescription
PA should be individually assessed and prescribed in terms of frequency,
intensity,
time
(duration),
type,
and progression.389
Recommendations regarding pre-participation screening can be found in previous ESC Guidelines.388 Interventions shown to increase
PA level or reduce sedentary behaviour include behaviour theorybased interventions, such as goal-setting, re-evaluation of goals, selfmonitoring, and feedback.372,380,381 Using a wearable activity tracker may help increase PA.382 Most important is to encourage activity that people enjoy and/or can include in their daily routines, as such activities are more likely to be sustainable.
4.3.1.2 Aerobic physical activity
Examples of aerobic PA include walking, jogging, cycling, etc.389
Adults are recommended to perform at least 150300 min a week of moderate-intensity PA, or 75150 min of vigorous-intensity PA,
or an equivalent combination of both, spread throughout the week.371,372 Additional benefits are gained with even more PA.
Practising PA should still be encouraged in individuals unable to meet the minimum. In sedentary individuals, a gradual increase in activity level is recommended. When older adults or individuals with chronic conditions cannot achieve 150 min of moderate-intensity PA a week,
they should be as active as their abilities and conditions allow.371375,384,385 PA accumulated in bouts of even <10 min is associated with favourable outcomes, including mortality.371,390
PA can be expressed in absolute or relative terms.389 Absolute intensity is the amount of energy expended per minute of activity,
assessed by oxygen uptake per unit of time (mL/min or L/min) or by metabolic equivalent of task (MET). A compendium of the energy cost in MET values for various activities is available.391 An absolute measure does not consider individual factors such as body weight,
sex, and fitness level.389
Relative intensity is determined based on an individual’s maximum
(peak) effort, e.g. percentage of cardiorespiratory fitness (%VO2
max), percentage of maximum (peak) heart rate (%HRmax) or using rating of perceived exertion according to the Borg scale. Less fit individuals generally require a higher level of effort than fitter people to perform the same activity. A relative intensity measure is necessary to provide an individualized PA prescription.389
Classification for both absolute and relative intensity and examples are presented in Table 7.
4.3.1.3 Resistance exercise
Resistance exercise in addition to aerobic PA is associated with lower risks of total CV events and all-cause mortality.378,379,393395 The suggested prescription is one to three sets of 812 repetitions at the intensity of 6080% of the individual’s 1 repetition maximum at a frequency of at least 2 days a week in a variety of 810 different exercises involving each major muscle group. For older adults or deconditioned individuals, it is suggested to start with one set of 1015 repetitions at
4050% of 1 repetition maximum.389 In addition, older adults are recommended to perform multicomponent PA that combines aerobic,
muscle-strengthening, and balance exercises to prevent falls.372
4.3.1.4 Sedentary behaviour
Sedentary time is associated with greater risk for several major chronic diseases and mortality.371,372,375377,396399 For physically inactive adults, light-intensity PA, even as little as 15 minutes a day, is likely to produce benefits. There is mixed evidence to suggest how activity bouts that interrupt sedentary behaviour are associated with health outcomes.375,398,400
4.3.2. Nutrition and alcohol
................................................................................................................
................................................................................................
Table 7
Classiﬁcation of physical activity intensity and examples of absolute and relative intensity levels.
Absolute intensity
Relative intensity
Intensity
METa
Examples
%HRmax
RPE (Borg scale score)
Talk test
Light
1.12.9
Walking <4.7 km/h, light household work
5763
1011
Moderate
35.9
Walking at moderate or brisk pace (4.16.5 km/h),
slow cycling (15 km/h), painting/decorating, vacuuming,
gardening (mowing lawn), golf (pulling clubs in trolley),
tennis (doubles), ballroom dancing, water aerobics
6476
1213
Breathing is faster but compatible with speaking full sentences
Vigorous
>_6
Race-walking, jogging, or running, cycling >15 km/h,
heavy gardening (continuous digging or hoeing), swimming laps, tennis (singles)
7795
1417
Breathing very hard, incompatible with carrying on a conversation comfortably
%HRmax = percentage of measured or estimated maximum heart rate (220age); MET = metabolic equivalent of task; RPE = rating of perceived exertion (Borg-scale 620);
VO2 = oxygen consumption.
aMET is estimated as the energy cost of a given activity divided by resting energy expenditure: 1 MET = 3.5 mL oxygen kg1 min1 VO2.
Modiﬁed from 392
ESC 2021
Recommendations for nutrition and alcohol
Recommendations
Classa
Levelb
A healthy diet is recommended as a cornerstone of CVD prevention in all individuals.401,402
I
A
Continued
....................
ESC Guidelines
3269


<!-- PAGE 44 -->

### Page 44

....................................................................................................
Dietary habits influence CV risk, mainly through risk factors such as lipids, BP, body weight, and DM.401,402 Table 8 summarizes the characteristics of a healthy diet. Although recommendations about nutrients and foods remain important for CV health, there is a growing concern about environmental sustainability, supporting a shift from an animal- to a more plant-based food pattern.411,412
4.3.2.1 Fatty acids
Risk of CHD is reduced when dietary saturated fats are replaced appropriately (Figure 10). This is also the case when replacing meat and dairy foods.406,407 Polyunsaturated fats (-25%), monounsaturated fats (-15%), and to a lesser extent carbohydrates from whole grains
(-9%), were all associated with reduced CHD risk when isocalorically substituted for dietary saturated fat.408,409
Reducing saturated fatty acid intake to less than 10% of energy may have additional benefits.405 However, the LDL-C-lowering effect of substituting polyunsaturated fatty acids (PUFAs) for saturated fatty acids may be less in obese (5.3%) than in normal-weight persons
(9.7%).421
Trans fatty acids, formed during industrial processing of fats, have unfavourable effects on total cholesterol (increase) and HDL-C
(decrease). On average, a 2% increase in energy intake from trans fatty acids is associated with a 23% higher CHD risk.422 A regulation of the European Union (EU) Commission has set the upper limit to 2
g per 100 g of fat (April 2019) (https://ec.europa.eu/food/safety/labelling_nutrition/trans-fat-food_en).
When guidelines to lower saturated fat intake are followed, reductions in dietary cholesterol intake follow.
4.3.2.2 Minerals and vitamins
A reduction in sodium intake may reduce SBP by, on average, 5.8
mmHg in hypertensive, and 1.9 mmHg in normotensive patients.410
The DASH (Dietary Approaches to Stop Hypertension) trial showed a doseresponse relation between sodium reduction and BP
reduction.423 In a meta-analysis, salt reduction of 2.5 g/day resulted in a 20% reduction of ASCVD events (RR 0.80).410 A U- or J-shaped relation between a low salt intake and ASCVD is debated.424
Underlying illness and malnutrition may explain both low food and salt intakes as well as increased ASCVD.410,425,426 The totality of evidence warrants salt reduction to prevent CHD and stroke.
In most Western countries, salt intake is high (910 g/day),
whereas the recommended maximum intake is 5 g/day. Optimal intake might be as low as 3 g/day. Salt reduction can be achieved by dietary choices (fewer processed foods) and the reformulation of foods by lowering their salt content (see section 5.2.2).
Potassium (e.g. in fruits and vegetables) has favourable effects on
BP and risk of stroke (RR 0.76).427
As for vitamins, observational studies have found inverse associations between vitamins A and E and risk of ASCVD. However, intervention trials have failed to confirm these findings. Also, trials of supplementation with B vitamins (B6, folic acid, and B12), and vitamins C and D have not shown beneficial effects.428,429
4.3.2.3 Fibre
Each 7 g/day higher intake of total fibre is associated with a 9% lower risk of CAD (RR 0.91).430 A 10 g/day higher fibre intake was associated with a 16% lower risk of stroke (RR 0.84) and a 6% lower risk of type 2 DM (RR 0.94).431,432 A high fibre intake may reduce postprandial glucose responses after carbohydrate-rich meals and also lower triglyceride levels.433
4.3.2.4 Specific foods and food groups
4.3.2.4.1. Fruits, vegetables, and pulses. A meta-analysis reported a
4% lower risk in CV mortality for each additional serving of fruits
It is recommended to adopt a Mediterranean or similar diet to lower risk of CVD.403,404
I
A
It is recommended to replace saturated with unsaturated fats to lower the risk of
CVD.405409
I
A
It is recommended to reduce salt intake to lower
BP and risk of CVD.410
I
A
It is recommended to choose a more plantbased food pattern, rich in ﬁbre, that includes whole grains, fruits, vegetables, pulses, and nuts.411,412
I
B
It is recommended to restrict alcohol consumption to a maximum of 100 g per week.413415
I
B
It is recommended to eat ﬁsh, preferably fatty, at least once a week and restrict (processed)
meat.406,416418
I
B
It is recommended to restrict free sugar consumption, in particular sugar-sweetened beverages, to a maximum of 10% of energy intake.419,420
I
B
CVD = cardiovascular disease; BP = blood pressure.
aClass of recommendation.
bLevel of evidence.
Table 8
Healthy diet characteristics
Adopt a more plant- and less animal-based food pattern
Saturated fatty acids should account for <10% of total energy intake, through replacement by PUFAs, MUFAs, and carbohydrates from whole grains
Trans unsaturated fatty acids should be minimized as far as possible, with none from processed foods
<5 g total salt intake per day
3045 g of ﬁbre of per day, preferably from wholegrains
>_200 g of fruit per day (>_23 servings)
>_200 g of vegetables per day (>_23 servings)
Red meat should be reduced to a maximum of 350 - 500 g a week, in particular processed meat should be minimized
Fish is recommended 12 times per week, in particular fatty ﬁsh
30 g unsalted nuts per day
Consumption of alcohol should be limited to a maximum of 100 g per week
Sugar-sweetened beverages, such as soft drinks and fruit juices, must be discouraged
MUFA = monounsaturated fatty acid; PUFA = polyunsaturated fatty acid.
ESC 2021
ESC 2021
........................................................................


<!-- PAGE 45 -->

### Page 45

......................................................................................................
(equivalent to 77 g) and vegetables (equivalent to 80 g) per day, while all-cause mortality was not reduced further with intakes of more than five servings.434 A meta-analysis reported an 11% lower risk for stroke associated with three to five daily servings of fruits and vegetables and of 26% with five servings a day compared with fewer than three servings.435,436 A single portion of pulses (legumes) a day lowers LDL-C by 0.2 mmol/L and is associated with a lower risk of
CHD.437,438
4.3.2.4.2. Nuts. A meta-analysis of prospective cohort studies suggested that daily consumption of 30 g of (mixed) nuts was associated with a 30% lower risk of ASCVD.437 Both pulses and nuts contain fibre and other bioactive components.438
4.3.2.4.3. Meat. From both a health and an environmental point of view, a lower consumption of meat, especially processed meat, is recommended.411 A restriction of red meat may have little or no effect on major cardiometabolic outcomes.416 However, substituting red meat with high-quality plant foods (i.e. nuts, soy, and legumes) does improve LDL-C concentrations.406 A recent analysis showed that higher intake of processed meat and unprocessed red meat is associated with a 7% and 3%, respectively, increased risk of ASCVD.417
By reducing processed meats, salt intake will also be reduced. The
World Cancer Research Fund recommends limiting red meat consumption to 350500 g per week.439
4.3.2.4.4. Fish and fish oil supplements. Studies indicate that eating fish, particularly fish rich in n-3 PUFA, at least once a week, is associated with a 16% lower risk of CAD,418 and eating fish two to four times a week is associated with a 6% lower risk of stroke.440 The highest risk was observed in the range of no or very low intakes.
Several meta-analyses and a recent Cochrane review showed no benefits of fish oils on CV outcomes and/or mortality,441443
although a 7% lower risk of CHD events was observed. A meta-analysis of 13 RCTs included the results of VITAL (Vitamin D and
Omega-3 Trial), ASCEND (A Study of Cardiovascular Events in
Diabetes), and REDUCE-IT (Reduction of Cardiovascular Events with Icosapent EthylIntervention Trial).444 In the analysis excluding
REDUCE-IT, fish oil reduced total ASCVD (RR 0.97) and CHD death
(RR 0.92).444 Including REDUCE-IT (a study done in participants with high triglycerides, comparing very high icosapent ethyl doses vs. mineral oil placebo) strengthened the results.444 However, this is the only study that tested a high icosapent ethyl dose and questions have been raised regarding the choice of placebo. Very recently,
STRENGTH (Long-Term Outcomes Study to Assess Statin Residual
Risk with Epanova in High Cardiovascular Risk Patients with
Hypertriglyceridemia) failed to demonstrate benefit of a combined eicosapentaenoic acid and docosahexaenoic acid preparation.445
4.3.2.4.5. Alcoholic beverages. The upper safe limit of drinking alcoholic beverages is about 100 g of pure alcohol per week. How this translates into number of drinks depends on portion size, the standards of which differ per country, mostly between 8 and 14 g per drink. This limit is similar for men and women.413 Drinking above this limit lowers life expectancy.
Results from epidemiological studies have suggested that, whereas higher alcohol consumption is roughly linearly associated with a higher risk of all stroke subtypes, coronary disease, HF, and several less common CVD subtypes, it appeared approximately log-linearly associated with a lower risk of myocardial infarction.413 Moreover,
Mendelian randomization studies do not support the apparently protective effects of moderate amounts vs. no alcohol against ASCVD,
suggesting that the lowest risks for CVD outcomes are in abstainers and that any amount of alcohol uniformly increases BP and
BMI.414,415 These data challenge the concept that moderate alcohol consumption is universally associated with lower CVD risk.
Trans fat (2%)
MUFA (5%)
PUFA (5%)
Carbohydrates from refined starches/sugars (5%)
Carbohydrates from whole grains (5%)
Changes in risk (%)
-35
-30
-25
-20
-15
-10
-5
0
5
10
15
20
Figure 10 Estimated percentage change in risk of coronary heart disease associated with isocaloric substitutions of saturated fat for other types of fat or carbohydrates. Reproduced from Sacks et al.409 MUFA = monounsaturated fatty acid; PUFA = polyunsaturated fatty acid.
ESC Guidelines
3271


<!-- PAGE 46 -->

### Page 46

.......................................................................................................................................................
4.3.2.4.6. Soft drinks and sugar. Regular consumption of sugarsweetened beverages (i.e. two servings per day compared with one serving per month) was associated with a 35% higher risk of CAD in women in the Nurses’ Health Study, whereas artificially sweetened beverages were not associated with CAD. In the EPIC (European
Prospective Investigation into Cancer and Nutrition) cohort, both artificially and sugar-sweetened soft drinks were associated with all-cause mortality, while only the former was associated with circulatory diseases.419 The WHO guideline recommends a maximum intake of 10%
of energy from free sugars (mono- and disaccharides), which includes added sugars as well as sugars present in fruit juices.420
4.3.2.4.7. Coffee. Non-filtered coffee contains LDL-C-raising cafestol and kahweol, and may be associated with an up to 25% increased risk of ASCVD mortality by consumption of nine or more drinks a day.446
Non-filtered coffee includes boiled, Greek, and Turkish coffee and some espresso coffees. Moderate coffee consumption (34 cups per day) is probably not harmful, perhaps even moderately beneficial.447
4.3.2.4.8. Functional foods. Functional foods containing phytosterols
(plant sterols and stanols) are effective in lowering LDL-C levels by an average of 10% when consumed in amounts of 2 g/day.448 The effect is in addition to that obtained with a low-fat diet or use of statins. No studies with clinical endpoints have been performed yet.
Red yeast rice supplements are not recommended and may even cause side-effects.449
4.3.2.4.9. Dietary patterns. Studying the impact of a total dietary pattern shows the full preventive potential of diet. The Mediterranean diet includes high intakes of fruits, vegetables, pulses, wholegrain products, fish, and olive oil, moderate consumption of alcohol, and low consumption of (red) meat, dairy products, and saturated fatty acids. Greater adherence to a Mediterranean diet is associated with a
10% reduction in CV incidence or mortality and an 8% reduction in all-cause mortality.403 Following a Mediterranean diet enriched with nuts over a 5-year period, compared with a control diet, lowered the risk of ASCVD by 28% and by 31% with a diet enriched with extravirgin olive oil.404
Also, a shift from a more animal-based to a plant-based food pattern may reduce ASCVD.411
4.3.3. Body weight and composition
4.3.3.1 Treatment goals and modalities
Although diet, exercise, and behaviour modification are the main therapies for overweight and obesity, they are often unsuccessful in the long term. Yet, maintaining even a moderate weight loss of
5- 10% from baseline has salutary effects on risk factors including BP,
lipids, and glycaemic control,450,451 as well as on premature all-cause mortality.456 Weight loss is associated with lower morbidity but higher mortality in (biologically) older adults (the ‘obesity paradox’).
In this group, emphasis should be less on weight loss and more on maintaining muscle mass and good nutrition.
4.3.3.2 Diets for weight loss
Energy restriction is the cornerstone of management. PA is essential to maintain weight loss and prevent rebound weight gain, but is not reviewed here. Hypocaloric diets may be categorized as:
1. Diets that aim to reduce ASCVD, including plant-based457,458 and hypocaloric Mediterranean diets,458,459 with modifications to suit local food availability and preferences.
2. Changes to the fat and carbohydrate macronutrient composition of the diet, including low or very low carbohydrate diets (with
50130 g and 2049 g carbohydrates/day, respectively), moderate carbohydrate diets (>130225 g carbohydrates/day), and low-fat diets (<30% of energy from fat).
3. High-protein diets to preserve lean muscle mass and enhance satiety.
4. Diets focusing on specific food groups (e.g. increasing fruit and vegetables or avoiding refined sugars).
5. Diets that restrict energy intake for specified time periods, for example on 2 days a week or alternate days (intermittent fasting) or during certain hours of the day (time-restricted eating).
These diets give broadly similar short-term weight loss.452454 By
12 months, the effects tend to diminish.453 Benefits of the
Mediterranean diet, however, tend to persist. The quality of nutrients in a diet, for example substituting unsaturated for saturated fats (see section 4.3.2.1) and including fibre-rich carbohydrates460 determines whether a diet is healthy in the long term.
Low or very low carbohydrate diets may have advantages regarding appetite control, lowering triglycerides, and reducing medications for type 2 DM.461 Such diets may be ketogenic and need medical or at least dietetic supervision. Studies beyond 2 years are scarce.
Extreme carbohydrate intakes should be avoided in the long term and plant substitutions of fat and protein for carbohydrates are advantageous over animal ones.462
Intermittent fasting diets produce equivalent weight loss to continuous energy restriction when matched for energy intake.463
Medications approved in Europe as aids to weight loss (orlistat,
naltrexone/bupropion,
high-dose liraglutide)
may supplement lifestyle change to achieve weight loss and maintenance, although
Recommendations for body weight
Recommendations
Classa
Levelb
It is recommended that overweight and obese people aim for a reduction in weight to reduce
BP, dyslipidaemia, and risk of type 2 DM, and thus improve their CVD risk proﬁle.450,451
I
A
While a range of diets are effective for weight loss, it is recommended that a healthy diet in regard to CVD risk is maintained over time.452454
I
A
Continued
Bariatric surgery for obese high-risk individuals should be considered when lifestyle change does not result in maintained weight loss.455
IIa
B
CVD = cardiovascular disease; BP = blood pressure; DM = diabetes mellitus.
aClass of recommendation.
bLevel of evidence.
ESC 2021
.....................


<!-- PAGE 47 -->

### Page 47

...................................................................................
sometimes at the expense of side-effects.
Meta-analysis of medication-assisted weight loss found favourable effects on BP, glycaemic control, and ASCVD mortality.464
A very effective treatment option for extreme obesity or obesity with comorbidities is bariatric surgery. A meta-analysis indicated that patients undergoing bariatric surgery had over 50% lower risks of total, ASCVD, and cancer mortality compared with people of similar weight who did not have surgery.455
4.4. Mental healthcare and psychosocial interventions
Treatment of an unhealthy lifestyle will reduce CVD risk as well as improve mental health. Smoking cessation, for instance, has a positive effect on depression outcomes,474,475 as do exercise therapy113,476
and healthy dietary practices.477 Evidence-based interventions for smoking cessation, and improving PA and diet, are considered useful and applicable for persons with mental disorders.465,478480
Mental disorders are associated with an increased risk of CVD and a worse prognosis in patients with ASCVD, due to CVD events or other death causes, including suicide.100,113,305 Mental-health treatments effectively reduce stress symptoms and improve quality of life.
Several observational studies indicate that treatment or remission of depression reduces CVD risk.113,481484 Psychological interventions in patients with CHD may reduce cardiac mortality (RR 0.79) and alleviate psychological symptoms.466 Psychotherapy focusing on stress management in ASCVD patients improves CVD outcomes. In
SUPRIM (Secondary Prevention in Uppsala Primary Health Care project), patients in the intervention group had a 41% lower rate of fatal and non-fatal first recurrent ASCVD events [hazard ratio (HR
0.59)] and fewer recurrent AMIs (HR 0.55).467 In SWITCHD
(Stockholm Women’s Intervention Trial for Coronary Heart
Disease), the intervention yielded a substantial reduction in all-cause mortality (OR 0.33).468 A recent RCT reported that cardiac rehabilitation (CR) enhanced by stress management produced significant reductions in ASCVD events compared with standard CR alone (HR
0.49).469 Concerning psychopharmacotherapy of patients with CHD
and depression, selective serotonin reuptake inhibitor (SSRI) treatment lowers rates of CHD readmission (risk ratio 0.63) and all-cause mortality (risk ratio 0.56).470 A recent RCT reported that, in patients with ACS and depression, treatment with the SSRI, escitalopram,
resulted in a lower rate of the composite endpoint of all-cause mortality, myocardial infarction, or percutaneous coronary intervention
(PCI) (HR 0.69).471 Collaborative care for patients with CHD and depression has small beneficial effects on depression, but significantly reduces short-term major cardiac events.485
Concerning side-effects of psychopharmacological treatments,
many psychiatric drugs are associated with an increased risk of sudden cardiac death.486 In patients with HF, antidepressants are associated with increased risk of cardiac and all-cause mortality (HR 1.27;
for details see supplementary material for section 4.4).472 Therefore,
ASCVD patients with complex mental disorders, and particularly those needing psychiatric drug treatment, require interdisciplinary cooperation.
4.5. Smoking intervention
4.5.1. Smoking cessation
Stopping smoking is potentially the most effective of all preventive measures, with substantial reductions in (repeat) myocardial infarctions or death.487,488 Lifetime gains in CVD-free years are substantial at all ages, and benefits are obviously even more substantial if other complications from smoking would be accounted for. From age 45
years, gains of 3 - 5 years persist in men to age 65 and in women to age 75 years (Figure 11). Even in heavy smokers (>_20 cigarettes/day),
cessation lowers CVD risk within 5 years, although it remains elevated beyond 5 years. Total health benefits will be even larger because of gain in non-CVD health.
Recommendations for mental healthcare and psychosocial interventions at the individual level
Recommendations
Classa
Levelb
Patients with mental disorders need intensiﬁed attention and support to improve adherence to lifestyle changes and drug treatment.3,465
I
C
In ASCVD patients with mental disorders, evidence-based mental healthcare and interdisciplinary cooperation are recommended.100,113,466
I
B
ASCVD patients with stress should be considered for referral to psychotherapeutic stress management to improve CV outcomes and reduce stress symptoms.467469
IIa
B
Patients with CHD and moderate-to-severe major depression should be considered for antidepressive treatment with an SSRI.470,471
IIa
B
In patients with HF and major depression, SSRIs,
SNRIs, and tricyclic antidepressants are not recommended.472,473 c
III
B
ASCVD = atherosclerotic cardiovascular disease; CHD = coronary heart disease;
CV = cardiovascular; HF = heart failure; SNRI = serotonin-noradrenaline reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor.
aClass of recommendation.
bLevel of evidence.
cDetails explaining this recommendation are provided in the supplementary material section 2.1.
ESC 2021
Recommendations for smoking intervention strategies
Recommendations
Classa
Levelb
All smoking of tobacco should be stopped, as tobacco use is strongly and independently causal of ASCVD.487,488
I
A
In smokers, offering follow-up support, nicotine replacement therapy, varenicline, and bupropion individually or in combination should be considered.489494
IIa
A
Smoking cessation is recommended regardless of weight gain, as weight gain does not lessen the
ASCVD beneﬁts of cessation.495
I
B
ASCVD = atherosclerotic cardiovascular disease.
aClass of recommendation.
bLevel of evidence.
ESC 2021
.............................................................................................................
ESC Guidelines
3273


<!-- PAGE 48 -->

### Page 48

3.0
3.2
3.4
3.4
3.0
3.1
3.2
3.3
3.0
3.1
3.3
3.4
3.1
3.2
3.3
3.4
2.1
2.3
2.4
2.5
2.1
2.2
2.3
2.3
2.0
2.2
2.3
2.4
2.1
2.2
2.4
2.4
0.8
0.8
0.9
0.9
1.6
1.7
1.9
1.9
0.8
0.8
0.8
0.8
0.8
0.8
0.8
0.8
0.8
0.8
0.8
0.8
1.7
1.7
1.8
1.8
1.8
1.8
1.8
1.8
1.7
1.8
1.9
1.9
2.2
2.3
2.5
2.5
2.2
2.3
2.4
2.5
2.0
2.3
2.4
2.4
3.0
2.6
2.8
2.9
2.2
2.4
2.5
2.5
2.6
2.7
2.9
3.0
2.6
2.7
2.9
3.0
2.6
2.7
2.9
2.8
0.5
0.5
0.5
0.6
0.7
0.9
0.9
1.0
0.5
0.7
0.7
0.7
0.5
0.6
0.6
0.7
0.5
0.5
0.6
0.6
0.8
1.0
1.0
1.1
0.8
0.9
1.0
1.1
0.8
0.9
1.0
1.0
1.2
1.3
1.4
1.5
1.2
1.3
1.4
1.4
1.2
1.3
1.4
1.4
1.9
1.6
1.7
1.9
1.2
1.3
1.4
1.5
1.7
1.8
1.9
1.9
1.6
1.8
1.9
2.0
1.7
1.8
1.9
1.9
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
90+
85-89
80-84
75-79
70-74
Systolic blood pressure
(mmHg)
Age
(y)
LIFE-CVD model
CVD-free lifetime gain from smoking cessation (in years)
Non-HDL cholesterol
Women
Men mmol/L
150
200
250
mg/dL
1.0 - 1.4 years
1.5 - 2.0 years
3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
150
200
250
3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
< 0.5 years
0.5 - 0.9 years
≥2.0 years
4.2
4.4
4.6
4.7
3.9
4.0
4.2
4.3
3.8
3.6
3.6
3.8
3.9
3.3
3.5
3.6
3.7
3.4
3.6
3.7
3.8
3.4
3.6
3.9
4.1
4.3
4.5
4.6
3.6
3.6
3.8
3.9
3.6
3.7
4.0
4.0
3.7
3.9
4.1
4.2
3.7
4.0
4.1
4.3
3.8
3.9
4.0
4.1
4.2
4.4
4.6
4.7
4.3
4.5
4.8
4.9
3.9
4.0
4.3
4.3
4.0
4.2
4.4
4.5
4.5
4.7
5.0
5.1
4.1
4.2
4.4
4.5
4.4
4.5
4.8
4.9
4.1
4.3
4.4
4.5
3.3
3.4
3.6
3.7
2.9
3.1
3.2
3.3
2.9
2.7
2.7
2.9
2.9
2.4
2.6
2.7
2.7
2.5
2.7
2.8
2.8
2.6
2.7
2.9
3.3
3.5
3.7
3.8
2.7
2.7
2.9
2.9
2.8
2.9
3.0
3.1
2.9
3.0
3.2
3.3
3.0
3.1
3.3
3.4
2.8
3.0
3.1
3.2
3.3
3.5
3.7
3.9
3.5
3.7
3.9
4.2
2.9
3.1
3.3
3.4
3.1
3.2
3.5
3.6
3.7
3.9
4.2
4.4
3.1
3.2
3.3
3.5
3.4
3.7
3.9
4.1
3.1
3.3
3.4
3.6
4.1
4.3
4.5
4.5
4.3
4.5
4.6
4.8
4.4
4.6
4.9
5.0
4.5
4.8
5.1
5.2
3.2
3.3
3.4
3.6
3.3
3.5
3.7
3.9
3.5
3.7
4.0
4.2
3.7
4.0
4.3
4.5
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
65-69
60-64
55-59
50-54
45-49
160-179
140-159
120-139
100-119
40-44
Figure 11 Lifetime atherosclerotic cardiovascular disease benefit from smoking cessation for apparently healthy persons, based on the following risk factors: age, sex, systolic blood pressure, and non-high-density lipoprotein-cholesterol. The model is currently validated for low- and moderate-risk countries. CVD = cardiovascular disease; ESC = European Society of Cardiology; HDL-C = high-density lipoprotein cholesterol; HR = hazard ratio; LIFE-CVD
= LIFEtime-perspective CardioVascular Disease; SBP = systolic blood pressure. The lifetime benefit is expressed as ‘years of median life expectancy free from myocardial infarction or stroke’ gained from smoking cessation. The lifetime benefit is calculated by estimating lifetime CVD risk with the LIFE-CVD
model76 multiplied by the HR compared to sustained smoking (0.60) from a meta-analysis of studies on the CVD risk of smoking496 and multiplied by the
HR (0.73) for non-CVD competing mortality.497 For individualized estimations of lifetime benefit, this table can be used or the electronic version of LIFECVD, assessable via the ESC CVD risk app or https://u-prevent.com/.


<!-- PAGE 49 -->

### Page 49

............................................................................................................................................
Quitting must be encouraged in all smokers, and passive smoking should be avoided as much as possible. Very brief advice may be advantageous when time is limited (Table 9). A major impetus for cessation occurs at the time of diagnosis or treatment of CVD.
Prompting a person to try to quit, brief reiteration of CV and other benefits of quitting, and agreeing on a specific plan with a follow-up arrangement are evidence-based interventions.
Smokers who quit may expect an average weight gain of 5 kg, but the health benefits of tobacco cessation outweigh risks from weight gain.495 Persistent or reuptake of smoking is common in patients with
CHD, in particular in those with severe depression and environmental exposures.498 Mood-management therapies may improve outcomes in patients with current or past depression.499
4.5.2. Evidence-based drug interventions
Drug support for stopping smoking should be considered in all smokers who are ready to undertake this action. Evidence-based drug interventions include nicotine-replacement therapy (NRT), bupropion, varenicline, and cytisine (not widely available).489491 All forms of NRT
(chewing gum, transdermal nicotine patches, nasal spray, inhaler, sublingual tablets) are effective. Combination vs. single-form NRT and 4 mg vs. 2 mg gum can increase success.492 NRT shows no adverse effects in patients with ASCVD,493 but evidence of efficacy in this group is inconclusive.494 In patients with ASCVD, varenicline (RR 2.6), bupropion (RR
1.4), telephone therapy (RR 1.5), and individual counselling (RR 1.6) all increase success rates.494 The antidepressant, bupropion, aids longterm smoking cessation with similar efficacy to NRT.490
Varenicline 1 mg b.i.d. (twice a day) increases quitting rates more than two-fold compared with placebo.491 The RR for abstinence vs.
NRT was 1.25 and vs. bupropion, 1.4. Lower or variable doses are also effective and reduce side-effects. Varenicline beyond the 12week standard regimen is well tolerated. Varenicline initiated in hospital following ACS is efficacious and safe.500
The main side-effect of varenicline is nausea, but this usually subsides. A causal link between varenicline and neuropsychiatric adverse events is unlikely.501 Varenicline, bupropion, and NRT do not increase serious CV adverse event risks during or after treatment.502
Cytisine is effective for smoking cessation, but evidence to date is limited.491
4.5.2.1 Electronic cigarettes
Electronic cigarettes (e-cigarettes) simulate combustible cigarettes by heating nicotine and other chemicals into a vapour. E-cigarettes deliver nicotine without most of the tobacco chemicals, and are probably less harmful than tobacco.
Recent evidence suggests that e-cigarettes are probably more effective than NRT in terms of smoking cessation.503505 The longterm effects of e-cigarettes on CV and pulmonary health, however,
require more research.506 Dual use with cigarettes should be avoided. Furthermore, as e-cigarettes are addictive, their use should be subject to similar marketing controls as standard cigarettes, especially the flavoured varieties that appeal to children.507 Despite being lower in toxicants than regular cigarettes, ‘heat-not-burn’ cigarettes do contain tobacco and should be discouraged.
4.6. Lipids
This section covers recommendations for the diagnosis and treatment of unfavourable blood lipid levels. More detail and guidance for complex cases/tertiary care, including genetic lipid disorders, are available in the 2019 ESC/European Atherosclerosis Society (EAS)
Guidelines for the management of dyslipidaemias.3
Recent evidence has confirmed that the key initiating event in atherogenesis is the retention of LDL and other cholesterol-rich lipoproteins within the arterial wall. The causal role of LDL-C, and other apoB-containing lipoproteins, in the development of ASCVD is demonstrated beyond any doubt by genetic, observational, and interventional studies.20 Meta-analysis of clinical trials has indicated that the relative reduction in CVD risk is proportional to the absolute reduction of LDL-C, irrespective of the drug(s) used to achieve such change, with no evidence of a lower limit for LDL-C values or ‘J-curve’
effect.21 The absolute benefit of lowering LDL-C depends on the absolute risk of ASCVD and the absolute reduction in LDL-C, so even a small absolute reduction in LDL-C may translate to significant absolute risk reduction in a high- or very-high-risk patient.22 A recent
LDL-C target-driven RCT in patients after ischaemic stroke or transient ischaemic attack (TIA) demonstrated a target LDL-C level of <1.8
mmol/L (70 mg/dL) with the use of statin and, if required, ezetimibe,
was associated with a lower CVD risk than those who had a target range of 2.32.8 mmol/L (90110 mg/dL).508 Studies on the clinical safety of (very) low achieved LDL-C values have not caused particular concerns, although monitoring for longer periods is required.
4.6.1. Measurement of lipids and lipoproteins
4.6.1.1 Fasting vs. non-fasting measurements
Non-fasting sampling of lipid parameters is recommended for general risk screening, since it has the same prognostic value as fasting samples.509,510 In patients with metabolic syndrome, DM, or hypertriglyceridaemia, calculated LDL-C from non-fasting samples should be interpreted with care.
Table 10
Corresponding non-high-density lipoprotein cholesterol and apolipoprotein B levels for commonly used low-density lipoprotein cholesterol goals
LDL-C
Non-HDL-C
Apolipoprotein B
2.6 mmol/L (100 mg/dL) 3.4 mmol/L (131 mg/dL)
100 mg/dL
1.8 mmol/L (70 mg/dL)
2.6 mmol/L (100 mg/dL)
80 mg/dL
1.4 mmol/L (55 mg/dL)
2.2 mmol/L (85 mg/dL)
65 mg/dL
HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol.
ESC 2021
...................................
Table 9
‘Very brief advice’ for smoking cessation
‘Very brief advice’ on smoking is a proven 30-second clinical intervention,
developed in the UK, which identiﬁes smokers, advises them on the best method of quitting, and supports subsequent quit attempts. There are three elements to very brief advice:
• ASK - establishing and recording smoking status
• ADVISE - advising on the best ways of stopping
• ACT - offering help
UK = United Kingdom.
ESC 2021
ESC Guidelines
3275


<!-- PAGE 50 -->

### Page 50

.............................................................................................................................................................................
4.6.1.2 Low-density lipoprotein cholesterol measurement
LDL-C can be measured directly, but in most studies and many laboratories, LDL-C is calculated using the Friedewald formula:
• In mmol/L: LDL-C = total cholesterol  HDL-C  (0.45  triglycerides)
• In mg/dL: LDL-C = total cholesterol  HDL-C  (0.2  triglycerides)
The calculation is only valid when the concentration of triglycerides is <4.5 mmol/L (400 mg/dL), and not precise when LDL-C is very low [<1.3 mmol/L (50 mg/dL)]. In patients with low LDL-C levels and/or hypertriglyceridaemia (<_800 mg/dL), alternative formulae are available511,512 or LDL-C can be measured directly.
4.6.1.3 Non-high-density lipoprotein cholesterol
The non-HDL-C value is calculated by subtracting HDL-C from total cholesterol. Non-HDL-C, unlike LDL-C, does not require the triglyceride concentration to be <4.5 mmol/L (400 mg/dL). It also has an advantage in that it is accurate in a non-fasting setting, and may be more accurate in patients with DM. There is evidence for a role of non-HDL-C as a treatment target as it captures the information regarding all apolipoprotein-B-containing lipoproteins.513 We suggest it as a reasonable alternative treatment goal for all patients, particularly for those with hypertriglyceridaemia or DM. How non-HDL-C levels correspond to commonly used LDL-C goals is shown in Table 10.
4.6.1.4 Apolipoprotein B
Apolipoprotein B provides a direct estimate of the total concentration of atherogenic lipid particles, particularly in patients with elevated triglycerides. However, on average, the information conferred by apolipoprotein B is similar to that of calculated LDL-C.514
How apolipoprotein B levels correspond to commonly used LDL-C
goals is shown in Table 10.
4.6.2. Defining lipid goals
4.6.2.1 Low-density lipoprotein cholesterol goals
LDL-C goals are summarized in the recommendations below. As not all drugs are tolerated or available/affordable, treatment should focus on achieving LDL-C levels as close as possible to the given goals.
Treatment should be a shared decision-making process between physicians and the patient.
As explained earlier in these guidelines (section 3.2.3.1), we propose a stepwise approach to treatment goals, also for LDL-C (Figures 68).
This approach may seem novel but, in reality, resembles clinical practice, where treatment intensification is considered based on anticipated benefit, side-effects, and—importantly—patient preferences. The ultimate lipid goals are the same as in the 2019 ESC/EAS dyslipidaemia
Guidelines.3 Evidence from glucose-lowering treatment studies indicates that stepwise treatment does not compromise goal attainment,
and is associated with fewer side-effects and higher patient satisfaction.66,67 In specific cases (at very high risk), the physician may opt to merge both steps and proceed directly to the low LDL-C target level of STEP 2. In apparently healthy people, lifetime treatment benefit of
LDL-C reduction may play a role in shared decision-making, together with risk modifiers, comorbidities, patient preference, and frailty. Figure
12 may support decision-making, as it shows the estimated lifetime benefits in years-free-of-CVD in relation to the total CVD risk profile,
calibrated in low-to-moderate CVD risk countries.
After STEP 1, treatment intensification with STEP 2 must be considered in all patients. Given that lower is better, we encourage liberal intensification of treatment, particularly if submaximal doses of (lowcost) generic statins are used and side-effects are not apparent.
The treatment goal of LDL-C <1.4 mmol/L (55 mg/dL) in STEP 2,
in patients with established ASCVD or without ASCVD but at very high risk, is lower than the lowest LDL-C goal of 1.8 mmol/L (70 mg/
dL) in the 2016 ESC prevention Guidelines.2 This low goal was established based on data from recent Mendelian randomization studies,80
meta-analyses from the
Cholesterol
Treatment
Trialists’
Collaboration,21 RCTs such as IMPROVE-IT (Improved Reduction of
Outcomes: Vytorin Efficacy International Trial),515 and—more recently—proprotein convertase subtilisin/kexin type 9 (PCSK9)
inhibitor clinical outcome studies.516518 The class and level of evidence supporting this LDL-C target of <1.4 mmol/L (55 mg/dL) for patients with ASCVD is identical to that in the recent ESC/EAS dyslipidaemia guidelines.3 For primary prevention in very-high-risk patients, however, the class of recommendation is lower (Class I in the dyslipidaemia guidelines, Class IIa in the current guidelines),
because the Task Force was less unanimous with regards to this low
LDL-C target in the primary prevention context.
For patients with ASCVD who experience a second vascular event within 2 years (not necessarily of the same type as the first) while taking maximum tolerated statin-based therapy, an even lower LDL-C
goal of <1.0 mmol/L (40 mg/dL) may be considered. Importantly,
there are no differences in the RR reductions between men and women and between younger and older patients (at least up to age
75 years), or between those with and without DM.3
4.6.2.2 Triglyceride-rich lipoproteins and their remnants
There are no treatment goals for triglycerides, but <1.7 mmol/L (150
mg/dL) is considered to indicate lower risk, whereas higher levels indicate a need to look for other risk factors.
4.6.2.3 High-density lipoprotein cholesterol
To date, no specific goals for HDL-C levels have been determined in clinical trials, although low HDL-C is associated with (residual) risk in
ASCVD patients. PA and other lifestyle factors, rather than drug treatment, remain important means of increasing HDL-C levels.
Recommendation on low-density lipoprotein cholesterol goalsa
Recommendation
Classb
Levelc
A stepwise treatment-intensiﬁcation approach is recommended for apparently healthy people at high or very high CVD risk, as well as patients with established ASCVD and/or DM with consideration of CVD risk, treatment beneﬁt, risk modiﬁers, comorbidities, and patient preferences.
I
C
ASCVD = atherosclerotic cardiovascular disease; DM = diabetes mellitus.
aRecommendation from section 3.2.
bClass of recommendation.
cLevel of evidence.
ESC 2021


<!-- PAGE 51 -->

### Page 51

1.2 1.4 1.6 1.7
0.9 1.1 1.3 1.5
1.3 1.4 1.5 1.6
1.6
0.7 0.9 1.0 1.1
0.9 1.1 1.3 1.3
1.1 1.3 1.4 1.5
0.9 1.0 1.2 1.3
1.0 1.2 1.4 1.5
1.2 1.4 1.5 1.6
1.3 1.5
1.7
1.5 1.7 1.8 1.9
0.9 1.0 1.2 1.3
1.1 1.3 1.5 1.6
1.3 1.4 1.6 1.7
1.4 1.6 1.7 1.8
0.9 1.1 1.3 1.4
1.4 1.5 1.8 1.9
1.5 1.7 1.8 1.9
1.1 1.3 1.5 1.6
1.3 1.6 1.7 1.8
1.5 1.7 1.9 2.0
0.9 1.2 1.4 1.5
1.4 1.5 1.7 1.8
1.2 1.4 1.6 1.7
0.6 0.7 0.9 0.9
0.4 0.5 0.6 0.7
0.5 0.6 0.7 0.8
0.9
0.2 0.3 0.3 0.3
0.2 0.3 0.5 0.5
0.4 0.5 0.6 0.6
0.3 0.4 0.4 0.6
0.3 0.5 0.5 0.6
0.5 0.6 0.7 0.7
0.6 0.7
0.9
0.8 1.0 1.1 1.2
0.3 0.4 0.4 0.6
0.4 0.5 0.7 0.7
0.5 0.7 0.8 0.9
0.6 0.8 0.9 1.1
0.4 0.4 0.6 0.6
0.7 0.9 1.1 1.1
0.9 1.0 1.3 1.4
0.5 0.6 0.8 0.8
0.6 0.8 0.9 1.1
0.9 1.1 1.3 1.4
0.5 0.6 0.7 0.8
0.8 0.9 1.1 1.2
0.6 0.7 0.8 0.9
0.8 1.0 1.1 1.3
0.6 0.7 0.9 1.0
0.8 0.9 1.1 1.1
1.2
0.4 0.5 0.6 0.6
0.5 0.6 0.7 0.9
0.7 0.8 1.0 1.0
0.5 0.7 0.7 0.8
0.6 0.8 0.8 1.0
0.8 1.0 1.0 1.1
0.9 1.1
1.3
1.1 1.3 1.4 1.6
0.5 0.7 0.7 0.8
0.7 0.8 1.0 1.1
0.8 1.0 1.2 1.2
1.1 1.2 1.4 1.4
0.6 0.6 0.8 0.9
1.0 1.2 1.3 1.5
1.2 1.4 1.5 1.6
0.7 0.9 1.1 1.2
0.9 1.1 1.3 1.4
1.2 1.4 1.6 1.6
0.6 0.8 0.9 1.0
1.0 1.2 1.4 1.5
0.8 1.0 1.1 1.2
0.6 0.7 0.9 0.9
0.4 0.5 0.6 0.6
0.3 0.4 0.5 0.5
0.7
0.1 0.2 0.3 0.2
0.2 0.2 0.3 0.4
0.2 0.3 0.4 0.4
0.3 0.4 0.5 0.4
0.3 0.4 0.4 0.4
0.4 0.5 0.5 0.6
0.5 0.5
0.7
0.8 0.9 1.0 1.1
0.3 0.4 0.5 0.4
0.4 0.5 0.6 0.6
0.5 0.6 0.7 0.8
0.6 0.7 0.9 0.9
0.3 0.5 0.5 0.6
0.7 0.8 0.9 1.1
0.9 1.0 1.2 1.3
0.4 0.6 0.7 0.8
0.6 0.7 0.8 0.9
0.9 1.1 1.3 1.4
0.5 0.6 0.6 0.8
0.7 0.9 1.1 1.2
0.6 0.7 0.7 0.8
0.3 0.4 0.4 0.4
0.8 0.8 0.9 0.9
0.2 0.2 0.2 0.2
0.2 0.3 0.3 0.3
0.3 0.3 0.4 0.4
0.4 0.4 0.5 0.6
0.5 0.6 0.7 0.7
0.6 0.7 0.8 0.8
0.7 0.8 0.9 1.0
0.9 1.0 1.1 1.1
1.0 1.1 1.2 1.3
1.4
1.2 1.3
1.4
0.5 0.6 0.7 0.8
0.6 0.8 0.9 1.0
0.8 1.0 1.1 1.2
1.0 1.2 1.3
1.4
0.1 0.1 0.2 0.2
0.2 0.2 0.3 0.4
0.0 0.0 0.1 0.1
0.1 0.1 0.1 0.1
0.1 0.1 0.1 0.1
0.0 0.1 0.1 0.1
0.1 0.2 0.2 0.2
0.1 0.2 0.2 0.3
0.2 0.2 0.3 0.2
0.2 0.3 0.3 0.4
0.2 0.4 0.4 0.5
0.5
0.4 0.5
0.6
0.1 0.1 0.2 0.2
0.2 0.2 0.2 0.3
0.2 0.2 0.3 0.4
0.2 0.3 0.5
0.5
0.2 0.3 0.3 0.3
0.4 0.5 0.5 0.5
0.1 0.1 0.1 0.1
0.1 0.1 0.2 0.2
0.2 0.2 0.2 0.3
0.2 0.2 0.3 0.3
0.3 0.4 0.4 0.4
0.3 0.4 0.5 0.5
0.4 0.4 0.5 0.5
0.4 0.5 0.6 0.7
0.5 0.6 0.7 0.7
0.9
0.7 0.8
1.0
0.2 0.3 0.4 0.4
0.3 0.4 0.5 0.6
0.4 0.5 0.6 0.7
0.6 0.6 0.7
0.9
0.1 0.0 0.1 0.1
0.1 0.1 0.1 0.2
0.0 0.1 0.0 0.1
0.1 0.0 0.0 0.1
0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.1
0.0 0.0 0.1 0.1
0.1 0.1 0.1 0.1
0.0 0.1 0.1 0.1
0.1 0.1 0.2 0.2
0.1 0.2 0.2 0.2
0.3
0.2 0.2
0.3
0.0 0.0 0.0 0.1
0.1 0.1 0.2 0.1
0.1 0.2 0.2 0.2
0.2 0.2 0.3
0.3
1.0 1.2 1.4 1.5
1.2 1.4 1.6 1.7
1.4 1.5 1.7 1.8
1.6 1.7 1.9 2.0
0.5 0.6 0.7 0.8
0.6 0.8 0.9 1.0
0.8 0.9 1.1 1.2
0.9 1.1 1.3 1.4
0.6 0.8 0.9 1.0
0.8 1.0 1.1 1.3
1.0 1.2 1.4 1.5
1.3 1.4 1.6 1.7
0.5 0.6 0.7 0.8
0.6 0.8 0.9 1.0
0.8 0.9 1.1 1.3
0.9 1.2 1.4 1.5
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
90+
85-89
80-84
75-79
70-74
65-69
60-64
55-59
50-54
45-49
Systolic blood pressure (mmHg)
Non-smoking
Smoking
Age
(y)
LIFE-CVD model
CVD-free lifetime gain from 1 mmol/L
LDL-C reduction (in years)
Non-smoking
Smoking
Non-HDL cholesterol
Women
Men mmol/L
150 200 250
150 200 250
150 200 250
150 200 250
mg/dL
< 0.5 years
0.5 - 0.9 years
1.0 - 1.4 years
1.5 - 2.0 years
≥2.0 years
160-179
140-159
120-139
100-119
40-44
3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
Figure 12 Average years-free-of-cardiovascular disease gained per 1 mmol/L (40 mg/dL) low-density lipoprotein cholesterol reduction in apparently healthy persons. The model is currently validated for low- and moderate-risk countries. Lifetime benefit of 1 mmol/L LDL-C lowering for apparently healthy persons, based on the following risk factors: age, sex, current smoking, SBP, and non-HDL-C. The lifetime benefit is expressed as ‘years of median life expectancy free from myocardial infarction or stroke’ gained from 1 mmol/L LDL-C lowering. For 2 mmol/L LDL-C lowering, the average effect is almost twice as large, and so on. The lifetime benefit is calculated by estimating lifetime CVD risk with the LIFE-CVD model76 multiplied by the HR (0.78)
from a meta-analysis of the effect of lipid lowering.22 For individualized estimations of lifetime benefit, this table can be used or the electronic version of
LIFE-CVD, assessable via the ESC CVD risk app or https://u-prevent.com/. CVD = cardiovascular disease; ESC = European Society of Cardiology; HDL-C
= high-density lipoprotein cholesterol; HR = hazard ratio; LDL-C = low-density lipoprotein cholesterol; LIFE-CVD = LIFEtime-perspective
CardioVascular Disease; SBP = systolic blood pressure.
ESC Guidelines
3277


<!-- PAGE 52 -->

### Page 52

.........................
4.6.3. Strategies to control dyslipidaemias
The presence of dyslipidaemias secondary to other conditions must be excluded before beginning treatment, as treatment of underlying disease may improve hyperlipidaemia without requiring lipidlowering therapy. This is particularly true for hypothyroidism.
Secondary dyslipidaemias can also be caused by alcohol abuse, DM,
Cushing’s syndrome, diseases of the liver and kidneys, as well as by drugs (e.g. corticosteroids). In addition, lifestyle optimization is crucial in all patients with higher than optimal lipid levels.
4.6.3.1 Strategies to control low-density lipoprotein cholesterol
4.6.3.1.1. Diet and lifestyle modifications. Dietary factors influence the development of ASCVD, either directly or through their action on traditional risk factors, such as plasma lipids, BP, or glucose levels.
Consistent evidence from epidemiological studies indicates that higher consumption of fruit, non-starchy vegetables, nuts, legumes,
fish, vegetable oils, yoghurt, and wholegrains, along with a lower intake of red and processed meats, foods higher in refined carbohydrates, and salt, is associated with a lower incidence of CV events.519
Moreover, the replacement of animal fats, including dairy fat, with vegetable sources of fats and PUFAs may decrease the risk of
ASCVD.407 More detail on lifestyle recommendations can be found earlier in this section.
4.6.3.1.2. Drugs for treatment of dyslipidaemias. The currently available lipid-lowering drugs include inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (statins), fibrates, bile acid sequestrants, selective cholesterol absorption inhibitors (e.g. ezetimibe),
and—more recently—PCSK9 inhibitors. Bempedoic acid, an oral cholesterol synthesis inhibitor, has recently been approved in several countries. Usage is mainly intended in combination with ezetimibe in patients with statin intolerance. ASCVD outcome trials are not expected before the end of 2022. Additionally, inclisiran, a new small interfering ribonucleic acid, has shown to reduce LDL-C by 5055%
when applied subcutaneously twice a year. These results were obtained either on top of statin or without other lipid-lowering therapies, and with almost no side-effects. Inclisiran has been approved in several European countries. Results from the ASCVD
outcomes trial are expected for 2023.
The expected LDL-C reductions in response to therapy are shown in Figure 13, and may vary widely among individuals.
Therefore, monitoring the effect on LDL-C levels is recommended,
with assessment of LDL-C levels 4 - 6 weeks after any treatment strategy initiation or change.
Treatment
Average LDL-C reduction
Intensity of lipid-lowering treatment
Moderate-intensity statin
High-intensity statin
High-intensity statin plus ezetimibe
PCSK9 inhibitor
PCSK9 inhibitor plus high-intensity statin
PCSK9 inhibitor plus high-intensity statin plus ezetimibe
30%
50%
65%
60%
75%
85%
Figure 13 Expected low-density lipoprotein cholesterol reductions for combination therapies. LDL-C = low-density lipoprotein cholesterol; PCSK9 =
proprotein convertase subtilisin/kexin type 9. Adapted from Mach et al.3
Recommendations for pharmacological low-density lipoprotein cholesterol lowering for those <70 years of age
(for recommendations for persons aged 70 years, see respective recommendations tables).
Recommendations
Classa
Levelb
It is recommended that a high-intensity statin is prescribed up to the highest tolerated dose to reach the LDL-C goals set for the speciﬁc risk group.21,520,521
I
A
An ultimatec LDL-C goal of <1.4 mmol/L (55 mg/
dL) and LDL-C reduction of >_50% from baseline should be considered in apparently healthy persons
<70 years at very high risk.21,22,522
IIa
C
An ultimatec LDL-C goal of <1.8 mmol/L (70
mg/dL) and LDL-C reduction of >_50% from baseline should be considered in apparently healthy persons <70 years at high risk.21,22,522
IIa
C
In patients with established ASCVD, lipid-lowering treatment with an ultimatec LDL-C goal of <1.4
mmol/L (55 mg/dL) and a >_50% reduction in LDLC vs. baseline is recommended.21,508,515517,522
I
A
If the goals are not achieved with the maximum tolerated dose of a statin, combination with ezetimibe is recommended.515
I
B
For primary prevention patients at very high risk,
but without FH, if the LDL-C goal is not achieved on a maximum tolerated dose of a statin and ezetimibe, combination therapy including a PCSK9 inhibitor may be considered.
IIb
C
Continued
...........................................................................................


<!-- PAGE 53 -->

### Page 53

.............................................................................................................................................................................
4.6.3.1.3. Statins. Statins decrease LDL-C, thereby reducing ASCVD
morbidity and mortality as well as the need for coronary artery interventions. Statins also lower triglycerides, and may reduce pancreatitis risk. Therefore, they are the drug of first choice in patients at increased risk of ASCVD.3
4.6.3.1.3.1. Adverse effects, interactions, and adherence to statin therapy
The most frequent adverse effect of statin therapy is myopathy, but this is rare. A meta-analysis ruled out any contribution to an increase in non-CV mortality.522 Increased blood sugar and HbA1c levels (i.e.
increased risk of type 2 DM) can occur after treatment initiation and are dose dependent, in part linked to slight weight gain, but the benefits of statins outweigh the risks for the majority of patients.527
Adhering to lifestyle changes when prescribed a statin should lessen the risk of DM. Increased levels of liver enzymes may occur during statin therapy, and are usually reversible. Routine monitoring of liver enzyme values is not indicated.
Although 510% of patients receiving statins complain of myalgia,
in most cases it is not attributable to statins.3 The risk of myopathy
(severe muscular symptoms) can be minimized by identifying vulnerable patients and/or by avoiding statin interactions with specific drugs.
Rhabdomyolysis is extremely rare. As statins are prescribed on a long-term basis, possible interactions with other drugs deserve particular and continuous attention, as many patients will receive pharmacological therapy for concomitant conditions. In practice,
management of a patient with myalgia but without a major increase in creatine kinase is based on trial and error, and usually involves switching to a different statin or use of a very low dosage several days a week, with a gradual increase in frequency and dosage. A management algorithm may help to manage these patients.3
4.6.3.1.4. Cholesterol absorption inhibitors (ezetimibe). The combination of statin with ezetimibe brings a benefit that is in line with meta-analyses showing that LDL-C reduction has benefits independent of the approach used.3,21 The beneficial effect of ezetimibe is also supported by genetic studies.528 Together, these data support the position that ezetimibe should be considered as second-line therapy,
either on top of statins when the therapeutic goal is not achieved, or when a statin cannot be prescribed.
4.6.3.1.5. Proprotein convertase subtilisin/kexin type 9 inhibitors.
PCSK9 inhibitors (monoclonal antibodies to PCSK9) decrease LDL-C
by up to 60%, either as monotherapy or in addition to the maximum tolerated dose of statin and/or other lipid-lowering therapies, such as ezetimibe. Their efficacy appears to be largely independent of background therapy. In combination with high-intensity or maximum tolerated statins, alirocumab and evolocumab reduced LDL-C by 4673%
more than placebo, and by 30% more than ezetimibe.516,517 Among patients in whom statins cannot be prescribed, PCSK9 inhibition reduced LDL-C levels when administered in combination with ezetimibe.529 Both alirocumab and evolocumab effectively lower LDL-C
levels in patients who are at high or very high CVD risk, including those with DM, with a large reduction in future ASCVD events.516,517
PCSK9 inhibitors also lower triglycerides, raise HDL-C and apolipoprotein A-I, and lower lipoprotein(a), although the relative contributions of these lipid modifications remain unknown. PCSK9 inhibitors are costly, and their cost-effectiveness, long-term safety, and effect in primary prevention are as yet unknown. We recommend considering cost-effectiveness in a loco-regional context before implementing recommendations that involve their use. Recommendations for the use of
PCSK9 inhibitors are described in the Recommendations for pharmacological LDL-C lowering. Inclisiran is a long-acting hepatic PCSK9 synthesis inhibitor that also lowers LDL-C levels considerably.530 Its effect on clinical outcomes remains to be established.
4.6.3.2 Strategies to control plasma triglycerides
Although CVD risk is increased when fasting triglycerides are >1.7
mmol/L (150 mg/dL),531 the use of drugs to lower triglyceride levels may only be considered in high-risk patients when triglycerides are
>2.3 mmol/L (200 mg/dL) and triglycerides cannot be lowered by lifestyle measures. The available pharmacological interventions include statins, fibrates, PCSK9 inhibitors, and n-3 PUFAs (in particular icosapent ethyl in doses of 24 g/day; see section 4.3.2.4.4).
Recommendations for the treatment of hypertriglyceridaemia are shown in the Recommendations below.
4.6.3.2.1. Fibrates. Fibrates are used primarily for triglyceride lowering and, occasionally, for increasing HDL-C. Evidence supporting the use of these drugs for CVD event reduction is limited, and given the strong evidence favouring statins, routine use of these drugs in CVD
prevention is not recommended.3 To prevent pancreatitis, when
For secondary prevention patients not achieving their goals on a maximum tolerated dose of a statin and ezetimibe, combination therapy including a PCSK9 inhibitor is recommended.516,517
I
A
For very-high-risk FH patients (that is, with
ASCVD or with another major risk factor) who do not achieve their goals on a maximum tolerated dose of a statin and ezetimibe, combination therapy including a PCSK9 inhibitor is recommended.
I
C
If a statin-based regimen is not tolerated at any dosage (even after rechallenge), ezetimibe should be considered.515,523525
IIa
B
If a statin-based regimen is not tolerated at any dosage (even after rechallenge), a PCSK9 inhibitor added to ezetimibe may be considered.523,524,526
IIb
C
If the goal is not achieved, statin combination with a bile acid sequestrant may be considered.
IIb
C
Statin therapy is not recommended in premenopausal female patients who are considering pregnancy or are not using adequate contraception.
III
C
ASCVD = atherosclerotic cardiovascular disease; FH = familial hypercholesterolaemia; LDL-C = low-density lipoprotein cholesterol; PCSK9 = proprotein convertase subtilisin/kexin type 9.
aClass of recommendation.
bLevel of evidence.
cA stepwise approach to LDL-C targets is recommended; see section 3.2.3.1 and
Figures 6 and 7.
Adapted from 3
ESC 2021
ESC Guidelines
3279


<!-- PAGE 54 -->

### Page 54

.................................................................
triglycerides are >10 mmol/L (900 mg/dL), they must be reduced not only by drugs, but also by restriction of alcohol, treatment of DM,
withdrawal of oestrogen therapy, etc. In patients with severe primary hypertriglyceridaemia, referral to a specialist must be considered.
An evidence-based approach to the use of lipid-lowering nutraceuticals could improve the quality of the treatment, including therapy adherence, and achievement of the LDL-C goal in clinical practice. However, it has to be clearly stressed that there are still no outcome studies proving that nutraceuticals can prevent CVD morbidity or mortality.532
4.6.4. Important groups
4.6.4.1 Women
The proportional reductions per mmol/L reduction in LDL-C in major vascular events, major coronary events, coronary revascularization, and stroke are similar in women and men. In addition, the relative effects of non-statin drugs that lower LDL-C (ezetimibe and
PCSK9 inhibitors, on top of high-intensity statin therapy) are also similar in both women and men.3
4.6.4.2 Older patients (70 years)
Compared to the 2019 ESC/EAS dyslipidaemia guidelines,3 we provide a single cut-off for identifying ‘older persons’ as those >_70 years of age, as opposed to 75 years, for reasons of consistency with other parts of the current guidelines. As a result, class and level of evidence have been modified in some age groups, in particular the category of patients between 70 and 75 years. Although a single age cut-off is now used, it is important to stress that all such age cut-offs are relatively arbitrary, and biological age influences this threshold in clinical practice. For example, a very fit 75-year-old person may qualify for a treatment normally reserved for those <70 and, conversely, a very frail 65-year-old person should sometimes be considered ‘older’.
General recommendations for lipid-lowering treatment in older patients are summarized below.
Recent evidence has strengthened the role of LDL-C as an ASCVD
risk factor in older patients.537 Evidence from trials indicates that statins and other lipid-lowering drugs produce significant reductions in major vascular events irrespective of age.538,539 However, there is less direct evidence of statin benefit in those without evidence of ASCVD. Under the age of 70 years, statins are recommended for primary prevention depending on the level of risk. Above that age, initiation of statin treatment for primary prevention may be considered when at (very) high risk, but we explicitly recommend also taking other arguments into account, such as risk modifiers, frailty, estimated life-time benefit,
comorbidities, and patient preferences (see section 3.2.3.3 and Figure
12). In case of renal function impairment or risk for drug interactions,
the statin dose should be up-titrated carefully. In terms of LDL-C targets, there is insufficient evidence to support targets for primary prevention in older patients. Although the conventional LDL-C target of
<2.6 mmol/L (100 mg/dL) may seem reasonable, the results of ongoing primary prevention trials in older patients must be awaited [STAREE
(STAtin Therapy for Reducing Events in the Elderly) trial; clinicatrials.
gov registration: NCT02099123]. Frailty, polypharmacy, and muscle symptoms remain relevant factors to consider in older patients.
4.6.4.3 Diabetes mellitus
Lowering of LDL-C in patients with DM is consistently associated with lower CVD risk. Similar to prevention in apparently healthy individuals, we propose a stepwise approach to lipid control,
dependent on risk, estimated lifetime benefit, comorbidities, and patient preferences (Figure 8). PCSK9 inhibitors can also be used in patients with DM not reaching their LDL-C targets with statins and/
or ezetimibe.
Recommendations for the treatment of dyslipidaemias in older people (70 years).
Recommendations
Classa
Levelb
Treatment with statins is recommended for older people with ASCVD in the same way as for younger patients.538,539
I
A
Initiation of statin treatment for primary prevention in older people aged >_70 may be considered, if at high risk or above.538,539
IIb
B
It is recommended that the statin is started at a low dose if there is signiﬁcant renal impairment and/or the potential for drug interactions.
I
C
ASCVD = atherosclerotic cardiovascular disease.
aClass of recommendation.
bLevel of evidence.
Adapted from 3
............................................................................................................
Recommendations for drug treatments of patients with hypertriglyceridaemia.
Recommendations
Classa
Levelb
Statin treatment is recommended as the ﬁrst drug of choice for reducing CVD risk in high-risk individuals with hypertriglyceridaemia [triglycerides >2.3 mmol/L (200 mg/dL)].533
I
A
In patients taking statins who are at LDL-C goal with triglycerides >2.3 mmol/L (200 mg/dL), fenoﬁbrate or bezaﬁbrate may be considered.534536
IIb
B
In high-risk (or above) patients with triglycerides
>1.5 mmol/L (135 mg/dL) despite statin treatment and lifestyle measures, n-3 PUFAs (icosapent ethyl 2  2 g/day) may be considered in combination with a statin.84
IIb
B
CVD = cardiovascular disease; LDL-C = low-density lipoprotein cholesterol;
PUFA = polyunsaturated fatty acid.
aClass of recommendation.
bLevel of evidence.
Adapted from 3
Recommendations for the treatment of dyslipidaemias in diabetes mellitus.
Recommendations
Classa
Levelb
In patients with type 2 DM at very high risk (e.g.
with established ASCVD and/or severe TODc),
intensive lipid-lowering therapy, ultimatelyd aiming at >_50% LDL-C reduction and an LDL-C of
<1.4 mmol/L (55 mg/dL) is recommended.21,22,522,540,541
I
A
Continued
ESC 2021
ESC 2021


<!-- PAGE 55 -->

### Page 55

.......................................................
4.6.4.4 Chronic kidney disease
Patients with CKD are at high or very high risk of ASCVD, and have a characteristic dyslipidaemia (high triglycerides, normal LDL-C, and low HDL-C). Statin therapy or statin therapy in combination with ezetimibe (which allows larger LDL-C reductions without increasing the statin dose) has a beneficial effect on ASCVD outcomes in
CKD.543 For patients with end-stage renal disease, however, we recommend that hypolipidaemic therapy should not be initiated (see
Recommendations below). If patients with CKD already on a hypolipidaemic therapy enter end-stage renal disease, the therapy may be maintained.
4.6.4.5 Familial Hypercholesterolaemia
Patients who could have genetic dyslipidaemias, such as heterozygous
FH, can be identified by extreme lipid abnormalities and/or family history (Table 11). An LDL-C >4.9 mmol/L (190 mg/dL) in therapynaı¨ve patients requires careful evaluation for possible FH. However,
in the presence of premature ASCVD or family history, possible FH
should be considered at lower LDL-C levels. Besides genetic testing
(not always affordable), use of the Dutch Clinical Lipid Network criteria
(Table
11)
is recommended to identify possible
FH.
Homozygous FH is rare and should always be placed under the care of lipid experts.
Treatment guidelines for people with FH can be found in the 2019
ESC/EAS dyslipidaemia Guidelines.3
4.7. Blood pressure
Hypertension is one of the most important preventable causes of premature morbidity and mortality. It affects more than 150 million
In patients with type 2 DM >40 years at high risk, lipid-lowering treatment with an ultimate
LDL-C goal of >_50% LDL-C reduction and an
LDL-C of <1.8 mmol/L (70 mg/dL) is recommended.540,541
I
A
Statin therapy may be considered in persons aged <_40 years with type 1 or type 2 DM with evidence of TOD and/or an LDL-C level >2.6
mmol/L (100 mg/dL), as long as pregnancy is not being planned.
IIb
C
If the LDL-C goal is not reached, statin combination with ezetimibe should be considered.515,542
IIa
B
ASCVD = atherosclerotic cardiovascular disease; DM = diabetes mellitus; eGFR
= estimated glomerular ﬁltration rate; LDL-C = low-density lipoprotein cholesterol; TOD = target organ damage.
aClass of recommendation.
bLevel of evidence.
cSevere TOD in this speciﬁc context includes eGFR <45 mL/min/1.73 m2; eGFR
4679 mL/min/1.73 m2 plus microalbuminuria; proteinuria; presence of microvascular disease in at least three different sites (e.g. albuminuria plus retinopathy plus neuropathy). See Table 4 for details.
dA stepwise approach to LDL-C targets is recommended; see section 3.2.3.1 and
Figure 8.
Adapted from 3
Recommendations for lipid management in patients with moderate-to-severe chronic kidney disease (Kidney
Disease Outcomes Quality Initiative stages 35).
Recommendations
Classa
Levelb
The use of statins or statin/ezetimibe combination is recommended in patients with non-dialysis-dependent, stage 35 CKD.525,544,545
I
A
In patients already on statins, ezetimibe, or a statin/ezetimibe combination at the time of dialysis initiation, continuation of these drugs should be considered, particularly in patients with ASCVD.
IIa
C
In patients with dialysis-dependent CKD who are free of ASCVD, commencing statin therapy is not recommended.546,547
III
A
ASCVD = atherosclerotic cardiovascular disease; CKD = chronic kidney disease.
aClass of recommendation.
bLevel of evidence.
Adapted from 3
Table 11
Dutch Lipid Clinic Network diagnostic criteria for familial hypercholesterolaemia
Criteria (choose only one score per group, the highest applicable; diagnosis is based on the total number of points obtained)
Points
1) Family history
First-degree relative with known premature (men aged
<55 years; women <60 years) coronary or vascular disease, or ﬁrst-degree relative with known LDL-C above the 95th percentile
1
First-degree relative with tendinous xanthomata and/or arcus cornealis, or children aged <18 years with LDL-C
above the 95th percentile
2
2) Clinical history
Patient with premature (men aged <55 years; women
<60 years) CAD
2
Patient with premature (men aged <55 years; women
<60 years) cerebral or peripheral vascular disease
1
3) Physical examination
Tendinous xanthomata
6
Arcus cornealis before age 45 years
4
4) LDL-C levels (without treatment)
LDL-C >_8.5 mmol/L (326 mg/dL)
8
LDL-C 6.58.4 mmol/L (251325 mg/dL)
5
LDL-C 5.06.4 mmol/L (191250 mg/dL)
3
LDL-C 4.04.9 mmol/L (155190 mg/dL)
1
5) DNA analysis
Functional mutation in the LDLR, apolipoprotein B, or
PCSK9 genes
8
A ‘deﬁnite’ FH diagnosis requires >8 points
A ‘probable’ FH diagnosis requires 68 points
A ‘possible’ FH diagnosis requires 35 points
CAD = coronary artery disease; DNA = deoxyribonucleic acid; FH = familial hypercholesterolaemia; LDL-C = low-density lipoprotein cholesterol; LDLR = low-density lipoprotein receptor; PCSK9 = proprotein convertase subtilisin/kexin type 9.
ESC 2021
ESC 2021
ESC 2021
....................................................................................................................
ESC Guidelines
3281


<!-- PAGE 56 -->

### Page 56

.....................................
people across Europe, over 1 billion globally, with a prevalence of
3045% in adults, increasing with age to more than 60% in people aged >60 years, and accounting for 10 million deaths globally per annum.577 Despite extensive evidence for the effectiveness of BPlowering treatments at reducing CVD risk and death, the detection,
treatment, and control of BP in Europe and globally remains suboptimal.578
This section covers recommendations for the diagnosis and treatment of hypertension to be applied in routine primary and secondary care. More detail and guidance for complex cases/tertiary care are available in the 2018 ESC/European Society of Hypertension (ESH)
Guidelines for the management of arterial hypertension.4
Summary of recommendations for the clinical management of hypertension
Recommendations
Classa
Levelb
Classiﬁcation of BP
It is recommended that BP should be classiﬁed as optimal, normal, high-normal, or grades 1 - 3
hypertension, according to ofﬁce BP.
I
C
Diagnosis of hypertension
It is recommended to base the diagnosis of hypertension on:
 Repeated ofﬁce BP measurements, on more than one visit, except when hypertension is severe (e.g. grade 3 and especially in high-risk patients)
or
 Out-of-ofﬁce BP measurement with ABPM and/
or HBPM when feasible.
I
I
C
C
Assessment of HMOD
To evaluate for the presence of HMOD, measurement of serum creatinine, eGFR, electrolytes,
and ACR is recommended for all patients. A 12lead ECG is recommended for all patients, and echocardiography is recommended for those with ECG abnormalities or signs/symptoms of
LV dysfunction. Fundoscopy or retinal imaging is recommended for patients with grades 2 or 3
hypertension and all hypertensive patients with
DM.548551
I
B
Thresholds for initiation of drug treatment of hypertension
For grade 1 hypertension, treatment initiation based on absolute CVD risk, estimated lifetime beneﬁt, and the presence of HMOD is recommended.552,553
I
C
For patients with grade 2 hypertension or higher,
drug treatment is recommended.4,552
I
A
Ofﬁce BP treatment targets
It is recommended that the ﬁrst objective of treatment is to lower BP to <140/90 mmHg in all patients, and that subsequent BP targets are tailored to age and speciﬁc comorbidities.552,554
I
A
In treated patients aged 1869 years, it is recommended that SBP should ultimately be lowered to a target range of 120 - 130 mmHg in most patients.552,554556
I
A
In treated patients aged >_70 years, it is recommended that SBP should generally be targeted to
<140 and down to 130 mmHg if tolerated.552,554,557
I
A
In all treated patients, DBP is recommended to be lowered to <80 mmHg.555,558,559
I
A
Treatment of hypertension: lifestyle interventions
Lifestyle interventions are recommended for people with high-normal BP or higher.c
I
A
Continued
Treatment of hypertension: drug treatment
It is recommended to initiate antihypertensive treatment with a two-drug combination in most patients, preferably as a single-pill combination.
Exceptions are frail older patients and those with low-risk, grade 1 hypertension (particularly if SBP <150 mmHg).560565
I
B
It is recommended that the preferred combinations include a RAS blocker (i.e. an ACE inhibitor or ARB) with a CCB or diuretic, but other combinations of the ﬁve major classes can be used
(ACE inhibitor, ARB, beta-blocker, CCB, thiazide/thiazide-like diuretic).566569
I
A
It is recommended, if BP remains uncontrolled with a two-drug combination, that treatment be increased to a three-drug combination, usually a
RAS blocker with a CCB and a diuretic, preferably as a single-pill combination.563,570,571
I
A
It is recommended, if BP is not controlled by a three-drug combination, that treatment should be increased by the addition of spironolactone,
or if not tolerated, other diuretics such as amiloride or higher doses of other diuretics, an alpha-blocker or beta-blocker, or clonidine.555,572574
I
B
The combination of two RAS blockers is not recommended.575,576
III
A
Management of CVD risk in hypertensive patients
Statin therapy is recommended for many patients with hypertension.d
Section 4.6
Antiplatelet therapy is indicated for secondary prevention in patients with hypertension.e
Section 4.9
ABPM = ambulatory blood pressure monitoring; ACE = angiotensin-converting enzyme; ACR = albumin-to-creatinine ratio; ARB = angiotensin receptor blocker;
ASCVD = atherosclerotic cardiovascular disease; BP = blood pressure; CCB =
calcium channel blocker; DBP = diastolic blood pressure; DM = diabetes mellitus;
ECG = electrocardiogram; eGFR = estimated glomerular ﬁltration rate; HBPM =
home blood pressure monitoring; HMOD = hypertension-mediated organ damage; LV = left ventricular; RAS = reninangiotensin system; SBP = systolic blood pressure.
aClass of recommendation.
bLevel of evidence.
cSee section 4.3 for details.
dSee section 4.6 for details.
eSee section 4.9 for details.
ESC 2021
............................................................................................................................................................................


<!-- PAGE 57 -->

### Page 57

......................................................................
4.7.1. Definition and classification of hypertension
BP is classified according to seated office BP (Table 12), with approximately corresponding values according to ABPM or home BP average values in Table 13.
4.7.2. Blood pressure measurement
4.7.2.1 Office blood pressure measurement
Office BP should be measured in standardized conditions using validated auscultatory or (semi)automatic devices, as described in
Table 14.
4.7.2.2 Unattended automated office blood pressure measurement
Repeated automated office BP readings may improve the reproducibility of BP measurement. If the patient is seated alone and unobserved, unattended automated office BP measurement may reduce or eliminate the ‘white-coat’ effect, and unattended automated office
BP measurements are usually lower than conventional office BP
measurements, and more similar to ambulatory daytime BP or home
BP values. There is limited information on the prognostic value of unattended automated office BP measurements.4
4.7.2.3 Ambulatory blood pressure monitoring
ABPM is the average of repeated automated measurements of BP
during the daytime, night-time, and over 24 h. ABPM is a better predictor of hypertension-mediated organ damage (HMOD) and clinical outcomes than office BP, and identifies ‘white-coat’ hypertension and masked hypertension (see below). Diagnostic thresholds for hypertension are lower with ABPM than office BP (Table 12).4
4.7.2.4 Home blood pressure monitoring
Home BP is the average of all BP readings performed with a validated semiautomatic monitor, for at least 3 consecutive days (ideally 6 - 7
days), with readings in the morning and evening, taken seated in a quiet room after 5 min of rest. Home BP monitoring (HBPM) thresholds for the diagnosis of hypertension are lower than those for office
BP (Table 12). Patient self-monitoring may have a beneficial effect on medication adherence and BP control.4
Clinical indications for ambulatory or home monitoring are shown in Table 15.
4.7.3 Screening and diagnosis of hypertension
Ideally, all adults should be screened for the presence of hypertension,578,579 but most countries lack the required resources and infrastructure. Formally, these guidelines recommend opportunistic screening at least in susceptible individuals, such as those who are overweight or have a family history of hypertension (see section 3.1).
ESC 2021
Table 12
Categories for conventionally measured seated ofﬁce blood pressurea
Category
SBP (mmHg)
DBP (mmHg)
Optimal
<120
and
<80
Normal
120129
and/or
8084
High-normal
130139
and/or
8589
Grade 1 hypertension
140159
and/or
9099
Grade 2 hypertension
160179
and/or
100109
Grade 3 hypertension
>_180
and/or
>_110
Isolated systolic hypertensionb
>_140
and
<90
BP = blood pressure; DBP = diastolic blood pressure; SBP = systolic blood pressure.
aBP category is deﬁned according to seated clinic BP and by the highest level of
BP, whether systolic or diastolic.
bIsolated systolic hypertension is graded 1, 2, or 3 according to SBP values in the ranges indicated.
Table 13
Deﬁnitions of hypertension according to ofﬁce,
ambulatory, and home blood pressure
Category
SBP
(mmHg)
DBP
(mmHg)
Ofﬁce BPa
>_140
and/or
>_90
Ambulatory BP
Daytime (or awake) mean
>_135
and/or
>_85
Night-time (or asleep) mean
>_120
and/or
>_70
24-h mean
>_130
and/or
>_80
Home BP mean
>_135
and/or
>_85
BP = blood pressure; DBP = diastolic blood pressure; SBP = systolic blood pressure.
aRefers to conventional ofﬁce BP rather than unattended ofﬁce BP.
Table 14
Considerations in blood pressure measurement
Patients should be seated comfortably in a quiet environment for 5 min before BP measurements.
Three BP measurements should be recorded, 12 min apart, and additional measurements if the ﬁrst two readings differ by >10 mmHg. BP is recorded as the average of the last two BP readings.
Additional measurements may have to be performed in patients with unstable BP values due to arrhythmias, such as in patents with AF, in whom manual auscultatory methods should be used as most automated devices have not been validated for BP measurement in AF.
Use a standard bladder cuff (1213 cm wide and 35 cm long) for most patients, but use larger and smaller cuffs for larger (arm circumference
>32 cm) and smaller (arm circumference <26 cm) arms, respectively.
The cuff should be positioned at the level of the heart with the back and arm supported, to avoid muscle contraction and isometric-exercisedependant increases in BP.
When using auscultatory methods, use phase I and V (sudden reduction/
disappearance) Korotkoff sounds to identify SBP and DBP, respectively.
Measure BP in both arms at the ﬁrst visit to detect possible between-arm differences. Use the arm with the higher value as the reference.
Measure BP 1 min and 3 min after standing from the seated position in all patients at the ﬁrst measurement to exclude orthostatic hypotension.
Lying and standing BP measurements should also be considered in subsequent visits in older people, in people with DM, and in other conditions in which orthostatic hypotension may frequently occur. Initial orthostatic hypotension may occur <1 min after standing and may be difﬁcult to detect with conventional measurement techniques.
Record heart rate and use pulse palpation to exclude arrhythmia.
AF = atrial ﬁbrillation; BP = blood pressure; DBP = diastolic blood pressure; DM
= diabetes mellitus; SBP = systolic blood pressure.
.......................................................................................................
ESC 2021
ESC 2021
ESC Guidelines
3283


<!-- PAGE 58 -->

### Page 58

................................................................................
When hypertension is suspected, the diagnosis of hypertension should be confirmed, either by repeated office BP measurements over a number of visits, or by 24-h ABPM or HBPM (Figure 14).
4.7.3.1 White-coat and masked hypertension
White-coat hypertension refers to BP that is elevated in the office but is normal when measured by ABPM or HBPM. It occurs in up to
3040% of patients. The risk associated with white-coat hypertension is lower than sustained hypertension but may be higher than normotension. People with white-coat hypertension should receive lifestyle advice to reduce their CV risk and be offered BP measurement at least every 2 years by ABPM or HBPM because of high rates of transition to sustained hypertension. Routine drug treatment for white-coat hypertension is not indicated.
Masked hypertension refers to patients with a normal office BP but an elevated BP on ABPM or HBPM. These patients often have
HMOD and are at a CV risk level at least equivalent to sustained hypertension. It is more common in younger people and in those with high-normal office BP. In masked hypertension, lifestyle changes are recommended, and drug treatment should be considered to control
‘out-of-office’ BP, with periodic monitoring of BP, usually with HBPM.
4.7.4. Clinical evaluation and risk stratification in hypertensive patients
The routine work-up for hypertensive patients is shown in Table 16.
Alongside clinical examination, this is designed to:
Table 15
Indications for home blood pressure monitoring or ambulatory blood pressure monitoring
Conditions in which white-coat hypertension is more common, for example:
• Grade 1 hypertension on ofﬁce BP measurement
• Marked ofﬁce BP elevation without HMOD
Conditions in which masked hypertension is more common, for example:
• High-normal ofﬁce BP
• Normal ofﬁce BP in individuals with HMOD or at high total CV risk
Postural and post-prandial hypotension in untreated and treated patients
Evaluation of resistant hypertension
Evaluation of BP control, especially in treated higher-risk patients
Exaggerated BP response to exercise
When there is considerable variability in the ofﬁce BP
Evaluating symptoms consistent with hypotension during treatment
Speciﬁc indications for ABPM rather than HBPM:
• Assessment of nocturnal BP values and dipping status (e.g. suspicion of nocturnal hypertension, such as in sleep apnoea, CKD, DM,
endocrine hypertension, or autonomic dysfunction)
ABPM = ambulatory blood pressure monitoring; BP = blood pressure; CKD =
chronic kidney disease; CV = cardiovascular; DM = diabetes mellitus; HBPM =
home blood pressure monitoring; HMOD = hypertension-mediated organ damage.
Screening and diagnosis of hypertension
Repeat visits for office
BP measurement
OR
Out-of-office
BP measurement
(ABPM or HBPM)
Repeat BP
measurement a least annually
Repeat BP
measurement a least every 5 years
Repeat BP
measurement at least every 3 years
Blood pressure measurement
Indications for ABPM
or HBPM
Out-of-office
BP measurement
(ABPM or HBPM)
High-normal
130–139 mmHg /
85–89 mmHg
Optimal
<120/80 mmHg
Normal
120–129 mmHg /
80–84 mmHg
Hypertension
≥140/90 mmHg
Consider masked hypertension
Figure 14 Screening and diagnosis of hypertension. ABPM = ambulatory blood pressure monitoring; BP = blood pressure; HBPM = home blood pressure monitoring.
ESC 2021


<!-- PAGE 59 -->

### Page 59

....................................................................................................
• Assess risk factors for ASCVD (see section 3.2), or the presence of cardiac, vascular, or renal disease
• Detect evidence of HMOD, e.g. LV hypertrophy, renal disease,
or retinopathy
• Consider potential secondary causes of hypertension, e.g. renovascular disease, hyperaldosteronism, or pheochromocytoma
(see Table 17). Also, carefully evaluate substance abuse (e.g.
cocaine), drugs that may increase BP (e.g. cyclosporine, sympaticomimetics), liquorice, etc. More detail on work-up of suspected secondary hypertension is provided elsewhere.4
Echocardiography is recommended in patients with ECG abnormalities, and should be considered when the result will influence clinical decision-making. Fundoscopy is recommended in grade 2 or 3
hypertension and in all patients with DM. The routine measurement of other biomarkers and use of vascular imaging are not recommended.548551
4.7.5. Treatment of hypertension
The treatment of hypertension involves lifestyle interventions for all patients and drug therapy for most patients.
4.7.5.1 Lifestyle interventions to lower blood pressure and/or reduce cardiovascular risk
Lifestyle interventions are indicated for all patients with high-normal
BP or hypertension because they can delay the need for drug treatment or complement the BP-lowering effect of drug treatment.
Moreover, most lifestyle interventions have health benefits beyond their effect on BP. Lifestyle is discussed extensively in section 4.3.
4.7.5.2 Initiation of drug treatment
Drug treatment decisions in CVD prevention are mostly based on absolute CVD risk, risk modifiers, comorbidities, estimated benefit of treatment, frailty, and patient preferences. The same is true for hypertension. Drug treatment of grade 1 hypertension (SBP
140 - 159 mmHg) has level A evidence for reducing CVD risk. In younger patients, however, the absolute 10-year CVD risk is often low, and lifetime benefit of treatment should be considered and communicated before instituting treatment (Figure 6 and section 3.2.3.6).
In many such cases, the absolute lifetime benefit per 10-mmHg reduction in SBP is at least moderate to high [Figure 15 (lifetime benefit calibrated in low-to-moderate CVD risk countries]. Also, the presence of HMOD mandates treatment of grade 1 hypertension. For grade 2 hypertension or higher (SBP >160 mmHg), treatment is recommended, because not only is the lifetime benefit of reducing BP
almost universally high in such patients, there is also the importance of reducing the risk of HMOD resulting in other morbidities such as renal disease, haemorrhagic cerebrovascular disease, and HF.
4.7.5.3 Blood pressure treatment targets
When drug treatment is used, the aim is to control BP to target within 3 months. Evidence now suggests that the BP targets in the previous iteration of this guideline2 were too conservative, especially for older patients. In line with the stepwise approach (section 3.2.3.1),
it is now recommended that the first step in all treated patients should achieve a treated SBP <140 mmHg and diastolic BP (DBP)
<80 mmHg.552,554 The recommended ultimate SBP treatment target range for younger patients (1869 years) is 120130 mmHg,
although some patients may safely achieve lower treated SBP levels than this and, if they are well tolerated, there is no need to backtitrate treatment.552,554556 The ultimate target SBP for patients aged
>_70 years is <140 mmHg and down to 130 mmHg if tolerated.552,554,557,580 This change in the BP target range for older people compared with the 2016 ESC prevention guidelines2 is supported by evidence that these treatment targets are safely achieved in many older patients and are associated with significant reductions in the risk of major stroke, HF, and CV death.557,580 It also takes into account that the even lower SBP in the intensively treated group in
SPRINT (Systolic Blood Pressure Intervention Trial) (mean 124
mmHg) probably reflects a conventional office SBP range of
130139 mmHg.555 It is recognized, however, that the evidence supporting more strict targets is less strong for very old people (>80
years) and those who are frail. Also, in these older and especially frail
Table 16
Routine tests for patients with hypertension
Routine tests
Haemoglobin and/or haematocrit
Fasting blood glucose and/or HbA1c
Blood lipids: total cholesterol, LDL-C, HDL-C, triglycerides
Blood potassium and sodium
Blood uric acid
Blood creatinine and eGFR
Blood liver function tests
Urine analysis: microscopic; urinary protein by dipstick or, ideally, ACR
12-lead ECG
ACR = albumin-to-creatinine ratio; ECG = electrocardiogram; eGFR = estimated glomerular ﬁltration rate; HbA1c = glycated haemoglobin; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol.
Table 17
Patient characteristics that should raise the suspicion of secondary hypertension.
Characteristics
Younger patients (<40 years) with grade 2 hypertension or onset of any grade of hypertension in childhood
Acute worsening of hypertension in patients with previously documented chronically stable normotension
Resistant hypertension (BP uncontrolled despite treatment with optimal or best-tolerated doses of three or more drugs including a diuretic, and conﬁrmed by ABPM or HBPM)
Severe (grade 3) hypertension or a hypertension emergency
Presence of extensive HMOD
Clinical or biochemical features suggestive of endocrine causes of hypertension or CKD
Clinical features suggestive of OSA
Symptoms suggestive of pheochromocytoma or family history of pheochromocytoma
ABPM = ambulatory blood pressure monitoring; BP = blood pressure; CKD =
chronic kidney disease; HBPM = home blood pressure monitoring; HMOD =
hypertension-mediated organ damage; OSA = obstructive sleep apnoea.
Adapted from 4
ESC 2021
........................................................................
ESC 2021
ESC Guidelines
3285


<!-- PAGE 60 -->

### Page 60

1.1 1.2 1.4 1.5
n/a n/a n/a n/a
1.2 1.3 1.4 1.5
1.5
n/a n/a n/a n/a
0.8 1.0 1.1 1.2
1.0 1.3 1.4 1.5
n/a n/a n/a n/a
0.9 1.1 1.2 1.3
1.0 1.3 1.4 1.5
1.2 1.3
1.5
1.3 1.5 1.6 1.7
n/a n/a n/a n/a
1.0 1.1 1.3 1.4
1.2 1.3 1.4 1.5
1.3 1.4 1.5 1.6
n/a n/a n/a n/a
1.3 1.4 1.6 1.7
1.3 1.5 1.7 1.7
1.0 1.2 1.4 1.5
1.1 1.4 1.6 1.6
1.3 1.6 1.7 1.8
n/a n/a n/a n/a
1.3 1.4 1.6 1.6
1.1 1.2 1.4 1.5
0.5 0.7 0.8 0.8
n/a n/a n/a n/a
0.4 0.5 0.7 0.7
0.8
n/a n/a n/a n/a
0.2 0.3 0.4 0.5
0.4 0.4 0.5 0.6
n/a n/a n/a n/a
0.3 0.4 0.5 0.5
0.4 0.5 0.6 0.7
0.5 0.7
0.9
0.7 0.9 1.0 1.1
n/a n/a n/a n/a
0.4 0.4 0.6 0.6
0.5 0.6 0.7 0.8
0.6 0.7 0.9 1.0
n/a n/a n/a n/a
0.6 0.8 1.0 1.0
0.8 1.0 1.1 1.2
0.4 0.5 0.7 0.7
0.6 0.7 0.8 1.0
0.8 1.0 1.2 1.3
n/a n/a n/a n/a
0.7 0.8 1.0 1.1
0.5 06 0.7 0.8
0.8 0.9 1.0 1.2
n/a n/a n/a n/a
0.7 0.8 1.0 1.0
1.1
n/a n/a n/a n/a
0.4 0.6 0.7 0.8
0.6 0.7 0.9 0.9
n/a n/a n/a n/a
0.5 0.7 0.8 0.9
0.7 0.9 0.9 1.0
0.8 1.0
1.1
1.0 1.2 1.3 1.4
n/a n/a n/a n/a
0.7 0.7 0.9 1.0
0.8 0.9 1.1 1.1
1.0 1.1 1.2 1.3
n/a n/a n/a n/a
0.9 1.1 1.2 1.3
1.0 1.3 1.4 1.5
0.7 0.8 1.0 1.0
0.8 1.0 1.2 1.2
1.1 1.3 1.5 1.5
n/a n/a n/a n/a
0.9 1.1 1.3 1.3
0.7 0.9 1.0 1.1
0.6 0.7 0.8 0.8
n/a n/a n/a n/a
0.3 0.4 0.5 0.5
0.7
n/a n/a n/a n/a
0.1 0.2 0.3 0.3
0.2 0.3 0.4 0.4
n/a n/a n/a n/a
0.2 0.4 0.4 0.4
0.3 0.5 0.5 0.5
0.5 0.5
0.6
0.7 0.9 0.9 1.0
n/a n/a n/a n/a
0.4 0.4 0.5 0.5
0.5 0.5 0.7 0.7
0.6 0.7 0.8 0.8
n/a n/a n/a n/a
0.7 0.7 0.8 1.0
0.8 0.9 1.0 1.2
0.4 0.5 0.6 0.7
0.5 0.6 0.8 0.9
0.8 1.0 1.2 1.3
n/a n/a n/a n/a
0.7 0.8 1.0 1.1
0.5 0.6 0.7 0.7
0.3 0.3 0.4 0.4
0.7 0.8 0.8 0.8
n/a n/a n/a n/a
0.2 0.3 0.3 0.3
0.3 0.3 0.3 0.3
n/a n/a n/a n/a
0.4 0.5 0.6 0.6
0.6 0.6 0.7 0.8
0.6 0.7 0.8 0.9
0.8 0.9 1.0 1.0
0.9 1.0 1.1 1.2
1.2
1.1 1.2
1.3
n/a n/a n/a n/a n/a n/a n/a n/a
0.7 0.9 1.0 1.1
0.9 1.1 1.2
1.3
0.1 0.1 0.2 0.2
0.2 0.2 0.3 0.3
n/a n/a n/a n/a
0.0 0.1 0.1 0.1
0.1 0.1 0.1 0.1
n/a n/a n/a n/a
0.1 0.2 0.2 0.2
0.1 0.2 0.2 0.3
0.2 0.1 0.3 0.2
0.2 0.3 0.3 0.4
0.2 0.3 0.4 0.4
0.5
0.3 0.5
0.5
n/a n/a n/a n/a n/a n/a n/a n/a
0.2 0.2 0.3 0.4
0.2 0.3 0.4
0.5
0.2 0.2 0.3 0.3
0.3 0.4 0.5 0.5
n/a n/a n/a n/a
0.1 0.1 0.2 0.2
0.2 0.2 0.2 0.2
n/a n/a n/a n/a
0.3 0.3 0.3 0.4
0.3 0.3 0.4 0.5
0.3 0.4 0.4 0.5
0.4 0.5 0.6 0.6
0.5 0.5 0.6 0.7
0.8
0.6 0.7
0.9
n/a n/a n/a n/a n/a n/a n/a n/a
0.4 0.5 0.6 0.6
0.5 0.6 0.7
0.8
0.1 0.0 0.0 0.1
0.1 0.1 0.1 0.2
n/a n/a n/a n/a
0.0 0.0 0.0 0.1
0.0 0.0 0.0 0.0
n/a n/a n/a n/a
0.0 0.0 0.1 0.1
0.1 0.1 0.1 0.1
0.0 0.1 0.1 0.1
0.1 0.1 0.2 0.1
0.1 0.2 0.2 0.2
0.3
0.2 0.2
0.3
n/a n/a n/a n/a n/a n/a n/a n/a
0.1 0.2 0.2 0.2
0.2 0.2 0.3
0.3
n/a n/a n/a n/a
1.1 1.3 1.4 1.5
1.3 1.4 1.6 1.7
1.4 1.6 1.7 1.8
n/a n/a n/a n/a
0.6 0.7 0.8 0.9
0.7 0.8 1.0 1.1
0.8 1.0 1.2 1.3
n/a n/a n/a n/a
0.7 0.9 1.0 1.2
0.9 1.1 1.3 1.4
1.1 1.3 1.4 1.6
n/a n/a n/a n/a
0.6 0.7 0.8 0.9
0.7 0.9 1.0 1.2
0.9 1.1 1.3 1.4
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
160-179
140-159
120-139
100-119
90+
85-89
80-84
75-79
70-74
65-69
60-64
55-59
50-54
45-49
Systolic blood pressure (mmHg)
Non-smoking
Smoking
Age
(y)
LIFE-CVD model
CVD-free lifetime gain from 10 mmHg
Systolic Blood Pressure reduction (in years)
Non-smoking
Smoking
Non-HDL cholesterol
Women
Men mmol/L
150 200 250
150 200 250
150 200 250
150 200 250
mg/dL
< 0.5 years
0.5 - 0.9 years
1.0 - 1.4 years
1.5 - 2.0 years
≥2.0 years
160-179
140-159
120-139
100-119
40-44
3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
3.0-3.9
4.0-4.9
5.0-5.9
6.0-6.9
Figure 15 Lifetime benefit from lowering systolic blood pressure by 10 mmHg for apparently healthy persons, based on the following risk factors: age,
sex, current smoking, systolic blood pressure, non-high-density lipoprotein cholesterol. The model is currently validated for low- and moderate-risk countries. The lifetime benefit is expressed as ‘years of median life expectancy free from myocardial infarction or stroke’ gained from 10 mmHg SBP lowering.
The lifetime benefit is calculated by estimating lifetime CVD risk with the LIFE-CVD model multiplied by the HR (0.80) from a meta-analysis of the effect of
BP lowering. For 20 mmHg SBP lowering, the average effect is almost twice as large, etc. For individualized estimations of lifetime benefit, this table can be used or the electronic version of LIFE-CVD, assessable via the ESC CVD risk app or https://u-prevent.com/. BP = blood pressure; CVD = cardiovascular disease; ESC = European Society of Cardiology; HDL-C = high-density lipoprotein cholesterol; HR = hazard ratio; LIFE-CVD = LIFEtime-perspective
CardioVascular Disease; N/A = not applicable; SBP = systolic blood pressure.


<!-- PAGE 61 -->

### Page 61

...........................
patients, it may be difficult to achieve the recommended target BP
range due to poor tolerability or adverse effects, and high-quality measurement and monitoring for tolerability and adverse effects is especially important in these groups.580
Compared to previous ESC/ESH Hypertension Guidelines,4 we changed the cut-off for identifying who is ’older’ from 65 to 70 years for reasons of consistency with other parts of the current guidelines.
Although a single age cut-off is provided, it is important to stress that biological age influences this threshold in clinical practice. For example, a very fit 75-year-old person may qualify for a treatment policy normally reserved for those <70 and, vice versa, a very frail
65-year-old person should sometimes be considered ‘older’.
BP targets for patient subgroups with various comorbidities are shown in Table 18.
4.7.5.3.1. Blood pressure targets according to ambulatory and home blood pressure monitoring. There are no outcome-based trials that have used ABPM or HBPM to guide treatment. Therefore,
.........................................................................................................................................................
Table 18
Recommended ofﬁce blood pressure target ranges. The ﬁrst step in all groups is a reduction to systolic blood pressure <140 mmHg. The subsequent optimal goals are listed below.
Age group
Ofﬁce SBP treatment target ranges (mmHg)
Hypertension
1 DM
1 CKD
1 CAD
1 Stroke/TIA
18 2 69 years
120130
120130
<140130
120130
120130
Lower SBP acceptable if tolerated
70 years
<140 mmHg, down to 130 mmHg if tolerated
Lower SBP acceptable if tolerated
DBP treatment target (mmHg)
<80 for all treated patients
CAD = coronary artery disease; CKD = chronic kidney disease; DBP = diastolic blood pressure; DM = diabetes mellitus; SBP = systolic blood pressure; TIA = transient ischaemic attack.
Initial therapy
Dual combination
Consider beta-blockers at any treatment step, when there is a specific indication for their use,
e.g. heart failure, angina, post-myocardial infarction, atrial fibrillation,
or younger women with, or planning, pregnancy
Consider monotherapy in low-risk grade 1 hypertension (systolic
BP <150mmHg), or in very old (≥80 years) or frailer patients
ACEi or ARB + CCB or diuretic
1 pill
Consider referral to a specialist centre for further investigation
Step 3
Triple combination
+ spironolactone or other drug
Step 2
Triple combination
ACEi or ARB + CCB + diuretic
Resistant hypertension
Add spironolactone (25-50 mg o.d.) or other diuretic, alpha-blocker or beta-blocker
1 pill
2 pills
Beta-blockers
Figure 16 Core drug treatment strategy for hypertension. This algorithm is appropriate for most patients with hypertension-mediated organ damage,
diabetes mellitus, cerebrovascular disease, and peripheral artery disease. ACE = angiotensin-converting enzyme; AF = atrial fibrillation; ARB = angiotensin receptor blocker; BP = blood pressure; CCB = calcium channel blocker; HF = heart failure; o.d. = omni die (once a day).
ESC 2021
ESC Guidelines
3287


<!-- PAGE 62 -->

### Page 62

..........................................................................................................
ABPM and HBPM BP targets are extrapolated from observational data. A treated office SBP of 130 mmHg likely corresponds to a 24-h
SBP of 125 mmHg and home SBP <130 mmHg.4
4.7.5.4 Drug treatment of hypertension
The most important driver of benefit is the magnitude of BP lowering.
Single-drug therapy will rarely achieve optimal BP control.
Initial therapy with a combination of two drugs should be considered usual care for hypertension.560563,565,581 The only exceptions would be patients with a baseline BP close to the recommended target, who might achieve that target with a single drug, or very old (>80 years) or frail patients who may better tolerate a more gentle reduction of BP. Initial combination therapy, even low-dose combination therapy, is more effective at lowering BP than monotherapy,560,561,565 and will reduce BP faster and reduce heterogeneity in response.560,565 Moreover, initial combination therapy does not increase risk of adverse effects.560563,565 Initiating therapy with two drugs will also help overcome treatment inertia where patients remain on one drug long term despite inadequate BP control.562
Single-pill strategy to treat hypertension: poor adherence to
BP-lowering medication is a major cause of poor BP control rates,
and is directly related to the number of pills.581 Single-pill combination therapy (if available) is the preferred strategy. This strategy will control BP in most patients.560565
Recommended drug therapy and treatment algorithm: five major classes of BP-lowering drug therapy have shown benefit in reducing CV events; angiotensin-converting enzyme (ACE) inhibitors,
angiotensin receptor blockers (ARBs), beta-blockers, calcium channel blockers (CCBs), and thiazide or thiazide-like diuretics.582 A recommended treatment algorithm based on best available evidence,
pragmatic considerations (e.g. combination pill availability), and pathophysiological reasoning is shown in Figure 16.4 A combination of an
ACE inhibitor or ARB with a CCB or thiazide/thiazide-like diuretic is the preferred initial therapy for most patients with hypertension.566569 For those in whom treatment requires escalation to three drugs, a combination of an ACE inhibitor or ARB with a CCB
and a thiazide/thiazide-like diuretic should be used.563,570,571 Betablockers should be used when there is a specific indication (e.g.
angina, post myocardial infarction, arrythmia, HFrEF, or as an alternative to an ACE inhibitor or ARB in women of child-bearing potential).582 Combinations of an ACE inhibitor and an ARB are not recommended because of no added benefit on outcomes and increased risk of harm.575,576
Specific modifications to the treatment algorithm are recommended for patients with CHD, CKD, HF, and AF.4
4.7.6. Resistant hypertension
Resistant hypertension is defined as BP being uncontrolled despite treatment with optimal or best-tolerated doses of three or more drugs including a diuretic, and confirmed by ABPM or HBPM. The prevalence of resistant hypertension is likely to be <10% of treated hypertensive patients. Spironolactone is the most effective drug for lowering BP in resistant hypertension when added to existing treatment; however, the risk of hyperkalaemia is increased in patients with
CKD and eGFR <45 mL/min/m2 and blood potassium levels >4.5
mmol/L.555,572 Potassium-binding drugs reduce the risk of hyperkalaemia.573 When spironolactone is not tolerated, amiloride, alphablockers, beta-blockers, or centrally acting drugs, such as clonidine,
have evidence supporting their use.555,572,574 Renal denervation and device-based therapy may be considered for specific cases, and are discussed in the 2018 ESC/ESH hypertension guidelines.4
4.7.7. Management of hypertension in women
The diagnosis and treatment of hypertension in women is similar to that in men, except for women of child-bearing potential or during pregnancy, because of potential adverse effects of some drugs on the foetus, especially in the first trimester. In addition, the effect of oral contraceptive pills on the risk of developing or worsening hypertension should be considered.4
4.7.8. Duration of treatment and follow-up
Treatment of hypertension is usually maintained indefinitely because cessation of treatment usually results in a return of BP to pretreatment levels. In some patients with successful lifestyle changes, it may be possible to gradually reduce the dose or number of drugs. After
BP is stable and controlled, visits should be scheduled at least annually, and include the control of other risk factors, renal function, and
HMOD, as well as reinforce lifestyle advice. When there is a loss of
BP control in a previously well-controlled patient, non-compliance with therapy should be considered. Self-measurement of BP using
HBPM helps engage the patient in their own management and can improve BP control. HBPM is essential to monitor BP control in patients with a significant ‘white-coat effect’ or masked hypertension.
Supervision of patient follow-up increasingly involves nurses and pharmacists and is likely to become increasingly supported by telemedicine and app-based technologies.
4.8. Diabetes mellitus
Recommendations for the treatment of patients with diabetes mellitus
Recommendations
Classa
Levelb
Screening
When screening for DM in individuals with or without ASCVD, assessment of HbA1c (which can be done non-fasting) or fasting blood glucose should be considered.583
IIa
A
Lifestyle
Lifestyle changes including smoking cessation, a low saturated fat, high-ﬁbre diet, aerobic PA, and strength training are recommended.584
I
A
Reduction in energy intake is recommended to patients, to help achieve lower body weight or prevent or slow weight gain.584
I
B
For those motivated to try, considerable weight loss with use of low-calorie diets followed by food reintroduction and weight-maintenance phases early after diagnosis can lead to DM
remission and should be considered.585,586
IIa
A
Continued
..................................................................


<!-- PAGE 63 -->

### Page 63

.............................................................................................................................................................................
4.8.1. Key risk factor concepts and newer paradigms
Except for glucose management, prevention of ASCVD follows the same principles as for people without type 2 DM. Achieving BP and
LDL-C targets is particularly important. More recently, trial evidence has shown that drugs in the sodium-glucose cotransporter 2
(SGLT2) inhibitor or glucagon-like peptide-1 receptor agonist (GLP1RA) classes lower ASCVD, HF, and renal risks independently of baseline HbA1c and whether patients are on metformin. Such benefits are most evident in those with existing ASCVD, HF, or CKD, but appear to extend to groups at elevated risk. This has led to newer treatment algorithms.
4.8.1.1 Lifestyle intervention
Lifestyle management is a first priority for ASCVD prevention and management of DM. Most persons with DM are obese, so weight control is crucial. Several dietary patterns can be adopted, where the predominance of fruits, vegetables, wholegrain cereals, and low-fat protein sources is more important than the precise proportions of total energy provided by the major macronutrients. Salt intake should be restricted. Specific recommendations include limiting saturated and trans fats and alcohol intake, monitoring carbohydrate consumption, and increasing dietary fibre. A Mediterranean-type diet, where fat sources are derived primarily from monounsaturated oils, is protective against ASCVD. More detail is provided in section 4.3.2.
A combination of aerobic and resistance exercise training is effective in preventing the progression of type 2 DM and for the control of glycaemia. Smokers should be offered cessation support (see section 4.5). Lifestyle intervention lowers future microvascular and macrovascular risks as well as mortality in the longer term.603 Intensive lifestyle changes with low-calorie diets and mean weight losses in the region of 10 kg leads to remission of type 2 DM in around 46% of cases at 1 year and 36% by 2 years.585 In those with prediabetes,
other ASCVD risk factors should be assessed both before (to incentivize improvements) and after lifestyle changes have taken place.604
4.8.1.2 Glycaemic control
The UKPDS587 established the importance of intensive glucose lowering with respect to CVD risk reduction in persons newly diagnosed with DM, with better evidence to support metformin, which correctly remains the first agent of choice for the majority of patients diagnosed with DM. Three trials were conducted to see if CV events could be reduced further with more intensive glycaemia treatment.559,588,593 However, there were unexpected increases in total and ASCVD
deaths in the ACCORD
(Action to
Control
Cardiovascular Risk in Diabetes) trial559 and a similar trend in VADT
(Veterans Affairs Diabetes Trial).593 The results prompted concerns about pursuing tight glucose control, particularly in older people with
DM and in those with existing ASCVD. Subsequent meta-analyses of relevant trials showed reductions in non-fatal AMI and CAD events,
but no effect on stroke or total mortality.605,606 The meta-analyses suggested that CVD benefits for an average HbA1c reduction of 0.9%
over 5 years were less than via treatment of cholesterol and BP.
HbA1c targets should be personalized to individual characteristics and preferences.
Four trials of dipeptidyl peptidase-4 inhibitors607610 in patients with DM and existing ASCVD or at high risk demonstrated noninferiority (i.e. safety) but not superiority with respect to CVD risk.
Glycaemia targets
A target HbA1c for the reduction of CVD risk and microvascular complications of DM of
<7.0% (53 mmol/mol) is recommended for the majority of adults with either type 1 or type 2
DM.587,588
I
A
For patients with a long duration of DM and in old or frail adults, a relaxing of the HbA1c targets (i.e. less stringent) should be considered.588
IIa
B
A target HbA1c of <_6.5% (48 mmol/mol) should be considered at diagnosis or early in the course of type 2 DM in persons who are not frail and do not have ASCVD.587,588
IIa
B
Treatment of hyperglycaemia and ASCVD/cardiorenal risks
Metformin is recommended as ﬁrst-line therapy,
following evaluation of renal function, in the majority of patients without previous ASCVD,
CKD, or HF.589
I
B
In persons with type 2 DM with ASCVD, metformin should be considered, unless contraindications are present.5,590592
IIa
B
Avoidance of hypoglycaemia and excessive weight gain should be considered.559,588,593
IIa
B
In persons with type 2 DM and ASCVD, the use of a GLP-1RA or SGLT2 inhibitor with proven outcome beneﬁts is recommended to reduce
CV and/or cardiorenal outcomes.590592
I
A
In patients with type 2 DM and TOD,c the use of an SGLT2 inhibitor or GLP-1RA with proven outcome beneﬁts may be considered to reduce future CV and total mortality.594597
IIb
B
In patients with type 2 DM and CKD, the use of an SGLT2 inhibitor is recommended to improve
ASCVD and/or cardiorenal outcomes.598,599
I
A
In patients with type 2 DM and HFrEF, use of an
SGLT2 inhibitor with proven outcome beneﬁts is recommended to lessen HF hospitalizations and CV death.600,601
I
A
In patients with type 2 DM but without ASCVD,
HF, or CKD, use of an SGLT2 inhibitor or GLP1RA should be considered based on estimated future risks (e.g. with the ADVANCE risk score or DIAL model) for adverse CVD or cardiorenal outcomes from risk factor proﬁles.602
IIa
B
ACR = albumin-to-creatinine ratio; ADVANCE = Action in Diabetes and
Vascular disease: preterAx and diamicroN-MR Controlled Evaluation; ASCVD =
atherosclerotic cardiovascular disease; CKD = chronic kidney disease; CV = cardiovascular; DIAL = Diabetes lifetime-perspective prediction; DM = diabetes mellitus; eGFR = estimated glomerular ﬁltration rate; GLP-1RA = glucagon-like peptide-1 receptor agonist; HbA1c = glycated haemoglobin; HF = heart failure;
HFrEF = heart failure with reduced ejection fraction; PA = physical activity;
SGLT2 = sodium-glucose cotransporter 2; TOD = target organ damage.
aClass of recommendation.
bLevel of evidence.
cSee Table 4 for details.
ESC 2021
ESC Guidelines
3289


<!-- PAGE 64 -->

### Page 64

............................................................................................................................
There was, however, an increase in the rate of hospitalization for HF
with saxagliptin in the SAVOR-TIMI 53 (Saxagliptin Assessment of
Vascular Outcomes Recorded in Patients with Diabetes Mellitus
Thrombolysis in Myocardial Infarction) trial.608
4.8.1.3 Newer diabetes mellitus drug classes: cardiovascular disease benefits
Recent trials from two classes of drugs (SGLT2 inhibitors and GLP1RAs) have shown CVD benefits that appear independent of glycaemic control and, where examined, of baseline metformin use.596,597,611 Their results have recently been systematically metaanalysed (Supplementary Figures 1  4).590,591
For SGLT2 inhibitors, three trials demonstrated the CV benefits of empagliflozin, canagliflozin, and dapagliflozin.611613 Major adverse
CV events (MACE) were reduced modestly, by 14%, with no clear effect on stroke and an unclear effect on myocardial infarction.590
However, reductions in incident HF hospitalization/CVD death by
24% and renal endpoints by 44% were seen.590 The MACE benefits were evident only in those with baseline ASCVD, but HF and renal benefits appeared to extend to those with type 2 DM with multiple risk factors. However, a more recent trial in people with type 2 DM
and ASCVD showed ertugliflozin to be non-inferior to placebo with respect to MACE outcomes.614 Whether the results represent a class effect is, therefore, not clear. Four further SGLT2 inhibitor trials demonstrated the benefit of canagliflozin598 and dapagliflozin599 in patients with CKD [with DAPA-CKD (Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease) showing similar benefits in people without DM], and dapagliflozin600 and empagliflozin601 in patients with HFrEF, with both trials showing similar benefits in those without type 2 DM.
The specific pattern of trial results (e.g. early separation of curves for HF hospitalization) suggests that the benefits of SGLT2 inhibitors may relate more to cardiorenal haemodynamic effects than to atherosclerosis.600 Other than genitourinary infections, rates of adverse events (including diabetic ketoacidosis) were generally low. One trial showed an excess of amputations and fractures,612 but none of the other trials noted imbalances. Patients should be advised on the importance of genitourinary hygiene before being prescribed these medications.
GLP-1RAs reduce MACE, CV death, and all-cause mortality by around 12%, with around a 9% reduction in myocardial infarction and a 16% reduction in stroke.591 Furthermore, HF is lowered by 9% and a composite renal outcome was lowered by 17%. The results cannot be explained by lowering of glucose levels and, in multiple SGLT2
inhibitor and GLP-1RA trials, subgroup analyses suggested that these benefits could be independent of metformin use.594597 Most trials were conducted in patients with existing ASCVD or, in the REWIND
(Researching Cardiovascular Events With a Weekly Incretin in
Diabetes) trial, with a significant proportion of patients at high risk for
CVD.615 Side-effects of this class mainly include nausea and vomiting,
which can lessen with gradual up-titration. Risks of hypoglycaemia can be reduced by lowering doses of sulphonylureas or insulin.
The largely positive results of these two classes of drugs (SGLT2
inhibitors and GLP-1RAs) have led to rapid changes in DM algorithms, but with some differences in interpretation.602 Most DM
guidelines, including those within the 2020 American Diabetes
Association (ADA)/European Association for the Study of Diabetes
(EASD) consensus report,592 recommend that metformin should be used as first-line treatment, while the ESC Guidelines5 recommended in 2019 that SGLT2 inhibitors and GLP-1RAs may be used without metformin in people with DM and CVD or at high risk of CVD, as reviewed.602 A subset of the writing groups of the ADA/EASD consensus report and the ESC Guidelines616 was convened as an expert panel. The expert panel emphasized the overall commonalities of approach and the need to ensure that people with type 2 DM, CVD,
HF, or CKD are treated appropriately with an SGLT2 inhibitor or
GLP-1RA. The panel concluded that this approach should be initiated independent of background therapy, glycaemic control, or individualized treatment goals.616 The view of the ESC is that metformin should be considered, but is not mandatory first-line treatment in patients with ASCVD or evidence of TOD. Certainly, the initiation of metformin in such patients should not forego or delay the initiation of evidence-based SGLT2 inhibitors or GLP-1RAs. A risk score plus cost-effective analyses would be useful to determine which patients free from ASCVD or evidence of TOD may be recommended for these newer drugs. In all the above, there is no evidence of any sex interaction in benefits. Finally, people with type 2 DM should be involved in decision-making after explanation of the potential benefits and side-effects of the drugs.
4.8.2. Type 1 diabetes mellitus
The DCCT (Diabetes Control and Complications Trial) established the importance of tight glucose control to lessen the risks of both microvascular and macrovascular disease in both men and women with type 1 DM.617 A 27-year follow-up of this trial showed that 6.5
years of intensive DM therapy was associated with a modestly lower all-cause mortality rate.617 A glycaemic target for HbA1c of
6.57.5% (4858 mmol/mol) appears to be a balanced approach for long-term care.
Recently, metformin was shown not to lower progression of carotid IMT in persons with type 1 DM considered to be at elevated CVD
risk.618 Its use is not recommended in type 1 DM for this indication.
SGLT2 inhibitors improve metabolic control in type 1 DM and may complement insulin therapy in selected patients.
4.9. Antithrombotic therapy
................................................
Recommendations for antithrombotic therapy
Recommendations
Classa
Levelb
Aspirin 75 - 100 mg daily is recommended for secondary prevention of CVD.619
I
A
Clopidogrel 75 mg daily is recommended as an alternative to aspirin in secondary prevention in case of aspirin intolerance.620
I
B
Clopidogrel 75 mg daily may be considered in preference to aspirin in patients with established
ASCVD.620,621
IIb
A
Concomitant use of a proton pump inhibitor is recommended in patients receiving antiplatelet therapy who are at high risk of gastrointestinal bleeding.622,623
I
A
Continued


<!-- PAGE 65 -->

### Page 65

.................................................................
4.9.1. Antithrombotic therapy in individuals without atherosclerotic disease
In 2009, a meta-analysis in patients with low CVD risk reported a
12% reduction in ASCVD with aspirin but a significant increase in major bleeding.619 CVD risk reduction and bleeding risks were similar in men and women.631 More contemporary primary prevention trials reported no or little benefit in patients without ASCVD and a consistent increase in bleeding.624,626,627 An updated meta-analysis did not show a reduction in all-cause or CV mortality with aspirin, but did show a lower risk of non-fatal myocardial infarction (RR 0.82) and ischaemic stroke (RR 0.87).628 Conversely, aspirin was associated with a higher risk of major bleeding (RR 1.50), intracranial bleeding
(RR 1.32), and major gastrointestinal bleeding (RR 1.52), with no difference in the risk of fatal bleeding (RR 1.09). Bleeding risks were particularly increased in older persons. Other recent meta-analyses found very similar results.629,630 Overall, although aspirin should not be given routinely to patients without established ASCVD, we cannot exclude that in some patients at high or very high CVD
risk, the benefits outweigh the risks.632,633 In patients with DM
and no evident ASCVD, the ASCEND study reported a 12% risk reduction and a significant increase in major bleeding, but not in fatal or intracranial bleeding.624 A meta-analysis of aspirin for primary prevention in DM found a number needed to treat of
95 to prevent one major adverse ischaemic event in 5 years.625
Hence, as in patients without DM, aspirin may be considered if
CVD risk is exceptionally high. Only one in four patients in the
ASCEND study were being treated with a proton pump inhibitor.
Wider use than this could potentially amplify the benefit of aspirin in primary prevention for patients at higher atherosclerotic risk.
In apparently healthy persons <70 years of age with (very) high
CVD risk, further studies are needed. Until then, decisions in these high-risk persons should be made on a case-by-case basis, taking both ischaemic risk and bleeding risk into consideration.
4.9.2. Antithrombotic therapy in individuals with established atherosclerotic disease
In established atherosclerotic disease, aspirin is associated with significant reductions in serious vascular events, including stroke and coronary events, and a 10% reduction in total mortality.619 These benefits outweigh the bleeding hazards.
In patients with previous myocardial infarction, stroke, or
LEAD, clopidogrel showed a slight superiority for ischaemic events with respect to aspirin, with a similar safety profile.620
Subgroup analysis suggested a greater benefit of clopidogrel in patients with LEAD. A meta-analysis showed a clinically modest risk reduction with P2Y12 inhibitor monotherapy (number needed to treat: 244), and no effect on all-cause or vascular mortality and major bleeding.621 More guidance on antithrombotic treatment in the specific settings of CAD, cerebrovascular disease, and LEAD,
including possible indications for dual pathway inhibition in patients with LEAD, is given in section 6.
4.9.3. Proton pump inhibitors
Proton pump inhibitors reduce the risk of gastrointestinal bleeding in patients treated with antiplatelet drugs and may be a useful adjunctive therapy to improve safety.634,635 Proton pump inhibitors that specifically inhibit CYP2C19 (omeprazole or esomeprazole) may reduce the pharmacodynamic response to clopidogrel. Although this interaction has not been shown to affect the risk of ischaemic events, coadministration of omeprazole or esomeprazole with clopidogrel is not recommended.622
4.10. Anti-inflammatory therapy
Acknowledging that the process of atherosclerosis has inflammatory components has led to the investigation of various antiinflammatory therapies in recent years. The first study to examine the effects of reducing inflammation without impacting lipid levels was CANTOS (Canakinumab Antiinflammatory Thrombosis
Outcome Study), in which the monoclonal antibody, canakinumab, provided proof-of-concept for anti-inflammatory therapy in high-risk patients.636 This particular drug was, however, not further developed for this indication because of the risk of fatal infections and high costs. Methotrexate was the second antiinflammatory drug studied for this purpose, but was not proven effective in reducing CVD outcomes.637
In 2019, COLCOT (Colchicine Cardiovascular Outcomes Trial)
reported a significant reduction (HR 0.77) in CVD outcomes with low-dose colchicine [0.5 mg o.d. (once a day)] in patients with a recent AMI. The more recent LoDoCo2 (second low-dose colchicine) trial reinforced these results in patients with chronic CAD (HR
0.69).85 This study observed a trend towards increased non-CV mortality, which requires further attention.
The use of colchicine in daily practice remains to be established based on further clinical study data and experiences in daily practice.
Nonetheless, the encouraging results justify consideration of lowdose colchicine in selected, high-risk patients.
Recommendation for anti-inﬂammatory therapy
Recommendation
Classa
Levelb
Low-dose colchicine (0.5 mg o.d.) may be considered in secondary prevention of CVD, particularly if other risk factors are insufﬁciently controlled or if recurrent CVD events occur under optimal therapy.85,86
IIb
A
CVD = cardiovascular; o.d. = omni die (once a day).
aClass of recommendation.
bLevel of evidence.
ESC 2021
............................................................................................................
In patients with DM at high or very high CVD
risk, low-dose aspirin may be considered for primary prevention in the absence of clear contraindications.5,624,625
IIb
A
Antiplatelet therapy is not recommended in individuals with low/moderate CV risk due to the increased risk of major bleeding.624,626630
III
A
ASCVD = atherosclerotic cardiovascular disease; CV = cardiovascular; DM = diabetes mellitus.
aClass of recommendation.
bLevel of evidence.
ESC 2021
ESC Guidelines
3291


<!-- PAGE 66 -->

### Page 66

...........................................................................................................
4.11. Cardiac rehabilitation and prevention programmes
CR is a comprehensive, multidisciplinary intervention not just including exercise training and PA counselling, but also education, risk factor modification, diet/nutritional counselling, and vocational and psychosocial support.358 Prevention and rehabilitation programmes after ASCVD events or revascularization reduce CV hospitalizations,
myocardial infarction, CV mortality and, in some programmes, allcause mortality.638,640642 They may also reduce depressive/anxiety symptoms.649 In patients with chronic HF (mainly HFrEF), exercisebased cardiac rehabilitation (EBCR) may improve all-cause mortality,
reduce hospital admissions, and improve exercise capacity and quality of life.639,650 CR is generally cost-effective.651
Clinical trials and registries are highly heterogeneous, which influences national guidelines, legislation, and reimbursement.652,653 The results of recent reviews provide clinicians with minimal requirements for successful CR after ACS or coronary artery bypass graft:
• CR is a comprehensive multidisciplinary intervention466,649,654,655
• CR is supervised and carried out by adequately trained health professionals, including cardiologists649
• CR starts as soon as possible after the initial CV event649
• EBCR includes aerobic and muscular resistance exercise, which should be individually prescribed based on pre-exercise screening and exercise testing656
• The dose of EBCR (number of weeks of exercise training 
average number of sessions/week  average duration of session in minutes) exceeds 1000638
• The number of EBCR sessions needs to exceed 36641
• During CR, all individually recognized CV risk factors need to be addressed and treated.642
Recently, the European Association of Preventive Cardiology
(EAPC) proposed minimal and optimal standards for improvement of secondary prevention through CR programmes in Europe.657
Although exercise training prescription should adopt the FITT (frequency, intensity, time duration, and type of exercise) model, interclinician variance and disagreement exists.658 To optimize exercise training, the EAPC has introduced a digital, interactive decision support tool; the EXPERT (EXercise Prescription in Everyday practice &
Rehabilitation Training) Tool (https://www.escardio.org/Education/
Practice-Tools/CVD-prevention-toolbox/expert-tool).659 No single exercise component is a significant predictor of mortality; only adherence to the full intervention improves outcome.660
Despite proven benefits, rates of referral, participation, and implementation are low.653,660,661 Uptake seems lower in women, but a variety of other intrapersonal, interpersonal, clinical, logistical, health system, and CR programme-related factors affect participation and adherence.662 CR enrolment is higher if trained nurses or allied healthcare providers intervene face-to-face, whereas adherence may be higher when remote interventions are implemented (i.e. homebased).643
Nurse-coordinated programmes can increase effectiveness.644646 Home-based CR with or without telemonitoring may increase participation and appear similarly effective as centre-based CR.647 Telehealth interventions are more effective than no intervention,648 but may also complement conventional CR. Also,
mobile device-based healthcare (mHealth) delivery through smartphones may be as effective as traditional centre-based CR, showing significant improvements in health-related quality of life.663 These novel interventions may support the patient to maintain long-term healthy behaviours after specialized CR programmes.664
5. Policy interventions at the population level
Recommendations for cardiac rehabilitation
Recommendations
Classa
Levelb
Participation in a medically supervised, structured, comprehensive, multidisciplinary EBCR
and prevention programme for patients after
ASCVD events and/or revascularization, and for patients with HF (mainly HFrEF), is recommended to improve patient outcomes.638642
I
A
Methods to increase CR and prevention referral and uptake should be considered (i.e. electronic prompts or automatic referrals, referral and liaison visits, structured follow-up by nurses or health professionals, and early programme initiation after discharge).643646
IIa
B
Home-based CR, telehealth, and mHealth interventions may be considered to increase patient participation and long-term adherence to healthy behaviours.647,648
IIb
B
ASCVD = atherosclerotic cardiovascular disease; CR = cardiac rehabilitation;
EBCR = exercise-based cardiac rehabilitation; HF = heart failure; HFrEF = heart failure with reduced ejection fraction;
mHealth
=
mobile device-based healthcare.
aClass of recommendation.
bLevel of evidence.
Recommendations for policy interventions at the population level
Recommendations
Classa
Levelb,c
Policies and population approaches to PA, diet,
smoking and tobacco use, and alcohol in governmental restrictions and mandates, media and education, labelling and information, economic incentives, schools, worksites, and community settings follow different levels of recommendations (see speciﬁc tables in the supplementary material for section 5).
Putting in place measures to reduce air pollution,
including reducing PM emission and gaseous pollutants, reducing the use of fossil fuels, and limiting carbon dioxide emissions, are recommended,
to reduce CVD mortality and morbidity.
I
C
CVD = cardiovascular disease; PA = physical activity; PM = particulate matter.
aClass of recommendation.
bLevel of evidence.
cLevel of evidence applies less well to policy interventions, and the type of empirical evidence varies widely across the separate approaches suggested.
ESC 2021
..................................................................
ESC 2021


<!-- PAGE 67 -->

### Page 67

.............................................................................................................................................................................
5.1. Population-level approaches to the prevention of cardiovascular disease
Population level approaches to CVD prevention centre around upstream measures requiring broad public-health interventions targeting lifestyle and promoting monitoring of CVD. These measures are designed to address populations and are intended to shift the population attributable risk. This is based on a prevention paradox described by Geoffrey Rose in 1981.665 The population attributable risk depends on the RR and on the prevalence of a risk factor in the general population. If the prevalence of a significant RR factor is low,
then the population attributable risk may be modest. Conversely, if a low-impact RR factor is common, the population attributable risk may be high. This prevention approach following the Geoffrey Rose paradigm665,666 states that small shifts in the risk of disease across a whole population consistently lead to greater reductions in disease burden than does a large shift in high-risk individuals only.667,668 In other words, many people exposed to a small risk may generate more disease than a few exposed to a conspicuous risk. This population-wide approach—as opposed to strategies targeting highrisk individuals—has major advantages at the population level whilst sometimes having only a modest benefit at the individual level,
because it addresses the CV health of a large number of individuals over the entire life course. It should be noted that high-risk and population-level prevention strategies are not mutually exclusive and must therefore coexist.
Prevalence of high-risk conditions and incidence rates of CVD vary across countries. Many of their underlying causes are known, and they are closely related to dietary habits, PA, smoking, alcohol,
employment, social deprivation, and the environment. The objective of population approaches to prevention of CVD is to control the underlying determinants of CV health and, in this way, reduce population incidence rates. The population approach may bring numerous benefits, such as narrowing the gap in health inequalities, preventing other conditions such as cancer, pulmonary diseases, and type 2 DM,
and saving costs from the avoided CV events and early retirement due to health problems.
Individual behaviour is enacted in an environment with hierarchical levels, which encompass individual choice, family influence, cultural and ethnic grouping, workplace, healthcare, and policy at the regional, state and global levels (e.g. EU policies and international trade agreements).
The aim of this section of the guidelines is to provide evidence-based suggestions for the most effective interventions to reduce CVD risk at the population level, improve CVD health, and promote healthy choices at the community, regional, and global level. Health challenges cannot be solved by the healthcare systems alone and require political support. To advance this cause, the WHO has been organizing Global
Conferences on Health promotion since 1990.
5.2. Specific risk factor interventions at the population level
Population-level interventions aim to alter the societal environment,
modify certain social determinants of health, and provide incentives to encourage changes in individual behaviour and exposure to risk factors. Social determinants of health include socioeconomic status (education, occupation, and income), wealth inequalities, neighbourhood and urban design, and social networks, to name but a few. Healthcare professionals play an important role in advocating evidence-based population-level interventions. By modifying the general context, one can induce healthy decisions as a default in entire populations (all age groups and particularly vulnerable ones). The task for both national and local authorities is to create social environments that provide healthier defaults, taking health literacy into account.669,670 The evidence presented here builds on recent comprehensive reviews and individual studies, noting that it is rarely feasible to use an RCT to evaluate population-level interventions (in contrast to individual-level interventions).671,672 The importance of heart disease in women has become apparent and sex differences in CVD prevention have prompted sex-specific awareness campaigns with the aim of reducing sex disparities in research and clinical care. While interpreting this section, it is important to recognize that there are often vested interests, which may influence policy decisions on health promotion.
The supplementary material for this section presents evidence for population-level strategies dealing with specific risk factor interventions for PA (section 5.2.1), diet (section 5.2.2), smoking and tobacco use (section 5.2.3), and alcohol consumption (section 5.2.4). Lifestyle changes at the population level take time, may be expensive, and need to be sustained over time. Furthermore, the benefits may be slow to manifest; however, they persist over the long term and improve health-related quality of life and well-being.
5.2.1. Physical activity
Please see the supplementary material section 3.1.
5.2.2. Diet
Please see the supplementary material section 3.2.
5.2.3. Smoking and tobacco use
Please see the supplementary material section 3.3.
5.2.4. Alcohol
Please see the supplementary material section 3.4.
5.3. Environment, air pollution, and climate change
Air pollution contributes to mortality and morbidity. It specifically increases the risk of respiratory and CV diseases, notably CAD, HF,
cardiac arrhythmias and arrest, cerebrovascular disease, and venous thromboembolism.158,673,674 Loss of life-expectancy due to ambient air pollution has been estimated at 2.9 years, accounting for an estimated global excess mortality of 8.8 million/year.159 Plausible mechanisms by which air pollution is linked to CVD include promoting atherosclerosis, inflammation, thrombosis, systemic vascular dysfunction, myocardial fibrosis, epigenetic changes, and interactions with traditional risk factors.158
Important sources of fine particles are road traffic, power plants,
and industrial and residential heating using oil, coal, and wood. Main components of outdoor air pollution include airborne PM (ranging in size from coarse particles 2.510 mm, fine particles <2.5 mm (PM2.5),
and ultrafine particles <0.1 mm in diameter) and gaseous pollutants such as ozone, nitrogen dioxide, volatile organic compounds, carbon monoxide, and sulphur dioxide, produced primarily by fossil fuel combustion.158,675 Up to one-third of Europeans living in urban areas
ESC Guidelines
3293


<!-- PAGE 68 -->

### Page 68

.......................................................................................
are exposed to levels exceeding EU air-quality standards. The EU
Commission released a policy package to be implemented by 2030,
with measures to reduce harmful emissions from traffic, energy plants, and agriculture.
Indoor air pollution and exposure to noise must also be highlighted.
Household air pollution, such as that produced from burning biomass,
accounts for over 3 million deaths worldwide.38 It has been estimated by the WHO that 30% of the European population is exposed to nightly levels of noise exceeding 55 dB.161 These levels have been associated with hypertension, arteriosclerosis, CAD, CV mortality,
and stroke. It should be noted that mitigating efforts to reduce noise exposure have not, as yet, proven to have a beneficial health effect.161
The extent to which environmental exposures in soil and water contribute to CVD has also been established.157 Interventions to reduce this pollution are required, including factory regulations and drinking water controls.157
Patient organizations and health professionals have an important role in supporting education and policy initiatives. Information on patients’ behaviour during smog peaks is needed. Economic incentives, such as reduced taxes on electric and hybrid cars, can contribute to the improvement of air quality as well as incentives encouraging the use of public transport. Urban design promoting the construction of new houses and schools in areas remote from highways and polluting industries needs to be urged.
‘Clean air’ legislation aimed at promoting decreased particle emissions,
and promotion of public transport should also be encouraged. The urgency of accepting what might appear as ‘comfort sacrifices’ for distant health benefits, and the transitory high costs of reorganizing entire sections of industry, probably remain a major dilemma to the populationbased approach. An example of such legislation is the European Green
Deal, by which the EU aims to be climate neutral by 2050.
5.3.1.Climate change
Climate change resulting from the increasing use of fossil fuels, as a major source of both air pollution and ‘greenhouse’ gases, is becoming a major public health and environmental concern. Societal measures to reduce such fuels, and transfer towards renewable sources, are becoming urgent to reduce air pollution and climate change.676 The impact of diet, notably long-term non-sustainable meat-based food production chains, as well as the impact of sedentary lifestyles on climate-altering variables, will also need to be addressed by policy makers.
5.4. Implications for public health policy and advocacy at the governmental and non-governmental level
Please see the supplementary material section 3.5.
6. Risk management of diseasespecific cardiovascular disease
This section addresses CVD prevention in specific clinical contexts.
A significant number of patients already have such comorbidities,
which put them at additional risk. The general principles of lifestyle modification and treatment of major risk factors are outlined in section 4. In this section, only disease-specific aspects are added.
6.1.Coronary artery disease
Disease-specific acute management of coronary syndromes is covered in detail in recent guidelines.677680
As for antithrombotic therapy, dual antiplatelet therapy (DAPT)
for 12 months, preferably with prasugrel or ticagrelor, is the standard antithrombotic treatment after ACS.681683 There are conflicting data as to whether prasugrel is preferable to ticagrelor.684,685 A 6month duration of DAPT after ACS is generally too short,686 but may be considered in selected patients at high bleeding risk.
In patients with chronic coronary syndromes (CCS) undergoing elective PCI, the standard duration of DAPT is 6 months, but shortening this to 1 - 3 months is an option when bleeding risk is very high.622 Clopidogrel is the P2Y12 inhibitor of choice, but prasugrel and ticagrelor may be considered after complex interventions.622
Prolonged DAPT (>12 months) following PCI for either ACS or
CCS is an option for patients who tolerate DAPT well and have features of high ischaemic risk.687,688 In patients with stable CAD, dualpathway inhibition with low-dose rivaroxaban (2.5 mg b.i.d.) and aspirin improved CV outcomes at the price of more major bleeding events than aspirin alone.83
Based on the above, and in line with the CCS Guidelines,622 adding a second antithrombotic drug (P2Y12 inhibitor or low-dose rivaroxaban) to aspirin for long-term secondary prevention should be considered for patients who are at high ischaemic risk and do not have a high risk of bleeding. It may also be considered in patients who are at moderate ischaemic risk and without a high risk of bleeding, but the benefits are lower.622 More details on antithrombotic treatment options are found in the ESC Guidelines for CCS.622
Recommendations for patients with coronary artery disease
Recommendations
Classa
Levelb
Aspirin 75 - 100 mg daily is recommended for patients with a previous myocardial infarction or revascularization.619
I
A
Aspirin 75 - 100 mg daily may be considered in patients without a history of myocardial infarction or revascularization, but with deﬁnitive evidence of CAD on imaging.622
IIb
C
In ACS, DAPT with a P2Y12 inhibitor in addition to aspirin is recommended for 12 months, unless there are contraindications such as excessive risk of bleeding.681683
I
A
In patients with CCS, clopidogrel 75 mg daily is recommended, in addition to aspirin, for 6
months following coronary stenting, irrespective of stent type, unless a shorter duration (1 - 3
months) is indicated due to risk or occurrence of life-threatening bleeding.622
I
A
Adding a second antithrombotic drug (a P2Y12
inhibitor or low-dose rivaroxaban) to aspirin for long-term secondary prevention should be considered in patients with a high risk of ischaemic events and without high bleeding risk.83,622,687689
IIa
A
Continued
........................................................................................


<!-- PAGE 69 -->

### Page 69

....................................................................................
The management of dyslipidaemia and hypertension in patients with CAD is discussed in sections 4.6 and 4.7, respectively. For ACE
inhibitors (or ARBs) and beta-blockers, see also the 2019 ESC
Guidelines for diagnosis and management of CCS.622
6.2. Heart failure
The management of HF aims to improve mortality, hospitalization rate, and quality of life.690 To achieve this, multidisciplinary management programmes and structured follow-up with patient education,
optimization of medical treatment, using telehealth facilities, lifestyle changes, psychosocial support, and improved access to care are fundamental.691694
Regarding the management of CVD risk factors, similar basic rules apply for those with and without HF. However, in HF, low cholesterol levels695,696 and low body weight are associated with increased mortality.697,698 Initiation of lipid-lowering therapy is not recommended in patients with HF without compelling indications for their use.3 Whereas unintentional weight loss is associated with a worse prognosis regardless of baseline BMI, the effects of intentional weight loss remain unclear.
Conversely, regular exercise training (particularly combined aerobic and resistance exercises) improves clinical status in all patients with HF650,699,700 and improves CVD burden and prognosis in
HFrEF.700,701
It is recommended to screen all patients with HF for both CV and non-CV comorbidities; if present, they should be treated.690 These diseases include CAD, hypertension, lipid disorders, DM, obesity,
cachexia and sarcopenia, thyroid disorders, CKD, anaemia, iron deficiency, and sleep apnoea.690
For patients with symptomatic HFrEF, neurohormonal antagonists
[ACE inhibitors,702705 ARBs,706 angiotensin receptor neprilysin inhibitors (ARNIs),707710 beta-blockers,711717 and mineralocorticoid receptor antagonists (MRAs)718,719] improve survival and reduce the risk of HF hospitalizations.690 These drugs also reduce the risk of CV events in patients with symptomatic HFrEF.702719
Importantly, these drugs should be up-titrated to the maximum tolerated doses, which may be different for men and women, particularly in patients recently discharged after HF hospitalization.690,720,721
SGLT2 inhibitors (currently dapagliflozin and empagliflozin) added on top of neurohormonal blockade reduces the risk of CV death and worsening HF in patients with symptomatic HFrEF, with or without
DM,600,601 and are recommended for all patients with symptomatic
HFrEF already treated with an ACE inhibitor (or ARNI), a betablocker, and an MRA.
Recently, an oral soluble guanylate cyclase receptor stimulator
(vericiguat), administered along with standard neurohormonal blockade in symptomatic patients with HFrEF with recent HF hospitalization, reduced the composite of death from any cause or HF
hospitalization.722
Other drugs bring additional moderate benefits for selected patients with symptomatic HFrEF. Diuretics,723,724 ivabradine,725,726
and hydralazine727,728 should be considered, and digoxin729 may be considered as complementary therapies in specific patients with symptomatic HFrEF. Some of these therapies reduce CV morbidity and mortality (e.g. ivabradine).
Additionally, for selected patients with symptomatic HFrEF, there are indications for an implantable cardioverter defibrillator to reduce the risk of sudden death and all-cause mortality, and for cardiac resynchronization therapy to reduce morbidity and mortality (for details, see 2021 HF Guidelines).690
Adding a second antithrombotic drug to aspirin for long-term secondary prevention may be considered in patients with a moderate risk of ischaemic events and without a high bleeding risk.83,622,687689
IIb
A
ACE inhibitors (or ARB) are recommended if a patient has other conditions (e.g. HF, hypertension, or DM).622
I
A
Beta-blockers are recommended in patients with
LV dysfunction or systolic HF.622
I
A
In patients with established ASCVD, oral lipidlowering treatment with an ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) and a >_50% reduction in LDL-C vs. baseline is recommended.
I
A
ACE = angiotensin-converting enzyme; ACS = acute coronary syndromes; ARB
= angiotensin receptor blocker; ASCVD = atherosclerotic cardiovascular disease;
CAD = coronary artery disease; CCS = chronic coronary syndromes; DAPT =
dual antiplatelet therapy; DM = diabetes mellitus; HF = heart failure; LDL-C =
low-density lipoprotein cholesterol; LV = left ventricular.
aClass of recommendation.
bLevel of evidence.
ESC 2021
Recommendations regarding pharmacological and nonpharmacological interventions for patients with symptomatic (New York Heart Association class II2IV) heart failure with reduced ejection fraction (left ventricular ejection fraction <40%) with proven beneﬁts on clinical outcomes, including cardiovascular morbidity and mortality.
Recommendations
Classa
Levelb
It is recommended that patients with HF are enrolled in a comprehensive CR programme to reduce the risk of HF hospitalization and death.c
691-694
I
A
EBCR is recommended in stable symptomatic patients with HFrEF to reduce the risk of HF
hospitalization.700,701
I
A
It is recommended to screen patients with HF
for both CV and non-CV comorbidities which, if present, should be treated, provided safe and effective interventions exist, not only to alleviate symptoms but also to improve prognosis.c
I
A
An ACE inhibitor is recommended, in addition to a beta-blocker and an MRA, for patients with symptomatic HFrEF to reduce the risk of HF
hospitalization and death.702705
I
A
A beta-blocker is recommended, in addition to an
ACE inhibitor (or an ARNI) and an MRA, for patients with stable, symptomatic HFrEF to reduce the risk of HF hospitalization and death.711717
I
A
Continued
.........................................................................................
ESC Guidelines
3295


<!-- PAGE 70 -->

### Page 70

....................................................................................................................
6.3. Cerebrovascular diseases
Interventions for cerebrovascular diseases depend on the type of event, i.e. ischaemic or haemorrhagic.732,733 Ischaemic events are mainly caused by atherothrombosis, cardiac embolism, or small vessel disease.734 Other mechanisms (e.g. arterial dissection, patent foramen ovale, thrombophilia, inherited diseases) are relatively rare.
Intracerebral haemorrhage is mostly caused by hypertensive angiopathy and/or cerebral amyloid angiopathy.735 Bleeding can be precipitated by surges in BP values, use of anticoagulants, or diseases impairing coagulation.733,735
In patients with ischaemic stroke or TIA, antithrombotics prevent further vascular events. Cardioembolic ischaemia, which occurs mainly in AF, requires anticoagulation (see sections 3.4.3 and
6.6).736742 In non-cardioembolic mechanism, platelet inhibitors are recommended.619,620,743753
In non-cardioembolic ischaemic stroke, aspirin is the most studied antithrombotic drug. Aspirin 75150 mg/day reduces the risk of recurrent ischaemic stroke and serious vascular events.619,743
Clopidogrel shows slight superiority to aspirin.620 In patients with ischaemic stroke or TIA and ipsilateral carotid stenosis, ticagrelor added to aspirin compared to aspirin alone reduced the risk of stroke or death at 1 month, without an increase of severe bleeding.754 Adding aspirin to clopidogrel was associated with a non-significant reduction in major vascular events and an increased long-term bleeding risk.747749
However, in patients with minor ischaemic stroke or TIA, a short course of DAPT with aspirin and clopidogrel is beneficial.750,751
Similarly, ticagrelor and aspirin vs. aspirin alone reduces stroke or death at 30 days after mild-to-moderate ischaemic stroke or TIA not treated with thrombolysis or thrombectomy. However, DAPT with ticagrelor and aspirin did not improve the incidence of disability and contributed to severe bleeding.755 DAPT with dipyridamole plus aspirin also showed superiority over aspirin alone.744 In patients with ischaemic stroke, however, dipyridamole plus aspirin vs. clopidogrel alone showed similar rates of recurrent stroke, including haemorrhagic stroke,745 but more major haemorrhagic events. In patients with noncardioembolic ischaemic stroke, oral vitamin K antagonists are not superior to aspirin and carry a higher bleeding risk.752,753 In the absence of a definite cause of ischaemia and a presumed occult cardioembolic
An MRA is recommended for patients with
HFrEF already treated with an ACE inhibitor (or an ARNI) and a beta-blocker, to reduce the risk of HF hospitalization and death.718,719
I
A
Sacubitril/valsartan is recommended as a replacement for an ACE inhibitor to reduce the risk of HF hospitalization and death in patients with HFrEF.707,730
I
B
An ARB is recommended to reduce the risk of
HF hospitalization or CV death in symptomatic patients with HFrEF who are unable to tolerate an ACE inhibitor and/or ARNI (patients should also receive a beta-blocker and an MRA).706
I
B
Dapagliﬂozin or empagliﬂozin are recommended, in addition to optimal treatment of an
ACE inhibitor (or ARNI), a beta-blocker, and an
MRA, for patients with HFrEF to reduce the risk of HF hospitalization and death.600,601,730
I
A
Vericiguat may be considered in patients with symptomatic HFrEF who have experienced HF worsening despite treatment with an ACE inhibitor (or an
ARNI), a beta-blocker, and an MRA, to reduce the risk of HF hospitalization or CV death.722
IIb
B
Diuretics are recommended in patients with
HFrEF with signs and/or symptoms of congestion to reduce the risk of HF hospitalization.723,724
I
C
Ivabradine should be considered in symptomatic patients with LVEF <_35%, in sinus rhythm, and with a resting heart rate >_70 bpm despite treatment with an evidence-based dose of a beta-blocker (or maximum tolerated dose below that), an ACE
inhibitor (or an ARNI), and an MRA, to reduce the risk of HF hospitalization or CV death.725
IIa
B
Ivabradine should be considered in symptomatic patients with LVEF <_35%, in sinus rhythm, and with a resting heart rate >_70 b.p.m. who are unable to tolerate or have contraindications for a beta-blocker to reduce the risk of HF hospitalization or CV death. Patients should also receive an ACE inhibitor (or ARNI) and an MRA.726
IIa
C
Hydralazine and isosorbide dinitrate should be considered in self-identiﬁed black patients with
LVEF <_35% or with LVEF <45% combined with a dilated LV in NYHA class IIIIV despite treatment with an ACE inhibitor (or ARNI), a betablocker, and an MRA, to reduce the risk of HF
hospitalization and death.731
IIa
B
Hydralazine and isosorbide dinitrate may be considered in patients with symptomatic HFrEF who cannot tolerate ACE inhibitors, ARBs, or ARNIs
(or if they are contraindicated), to reduce the risk of death.728
IIb
B
Continued
Digoxin may be considered in patients with symptomatic HFrEF in sinus rhythm despite treatment with an ACE inhibitor (or ARNI), a beta-blocker, and an MRA, to reduce the risk of hospitalizations (all-cause and HF).729
IIb
B
ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker;
ARNI = angiotensin receptor neprilysin inhibitor; b.p.m. = beats per minute; CR
= cardiac rehabilitation; CV = cardiovascular; EBCR = exercise-based cardiac rehabilitation; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; LV = left ventricle; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; NYHA = New York Heart Association.
aClass of recommendation.
bLevel of evidence.
cApplies to all patients with HF, regardless of LVEF.
For implantable cardioverter-deﬁbrillator and cardiac resynchronization recommendations, see 690
................................................
ESC 2021


<!-- PAGE 71 -->

### Page 71

...............................................................
source (e.g. embolic stroke of undetermined cause), neither dabigatran nor rivaroxaban are better than aspirin.756,757
Recommendations for BP and lipid management are congruent to the general recommendations outlined in sections 4.6 and 4.7.4. In patients with either ischaemic or haemorrhagic cerebrovascular disease who have a BP of 140/90 mmHg or higher, lowering BP
reduces the risk of recurrent stroke.758,759 Optimal BP targets in these patients are uncertain, as is the optimal drug regimen.760
Most evidence is available for ACE inhibitors, ARBs, and diuretics.
Comorbidities may guide the choice of antihypertensive agent. In patients with recent lacunar stroke, the target SBP is <130 mmHg.761
In patients with stroke (ischaemic or haemorrhagic) or TIA with an
LDL-C level of 100 - 190 mg/dL, atorvastatin 80 mg/day reduced the overall incidence of strokes and CV events.762 A recent trial supported an LDL-C target of <1.8 mmol/L (70 mg/dL).508
Evidence of cerebrovascular lesions (e.g. white matter hyperintensities, lacunes, non-lacunar ischaemia) in the absence of any stroke history is a relatively common finding at neuroimaging, especially in older patients. Silent cerebrovascular disease is a marker of increased risk of stroke.763,764 Arterial hypertension, DM, and cigarette smoking contribute to these lesions and should be attended to. There are no studies addressing the best treatment options for silent cerebral ischaemia.765
6.4. Lower extremity artery disease
Symptomatic or asymptomatic LEAD (ABI <_0.90) is associated with a doubling of the 10-year rate of coronary events, CV mortality, and total mortality.125 Within 5 years of LEAD diagnosis, 20% develop
AMI or stroke, and mortality is 1015%.767
All LEAD patients require lifestyle improvement and pharmacological therapy. Smoking cessation increases walking distance and lowers amputation risk.2 In patients with DM, glycaemic control improves limb outcomes.768 Statins provide modest improvements in walking distance, and lower the risk of adverse limb events.769,770 Combining a statin with ezetimibe771 or a PCSK9 inhibitor also has beneficial effects.772
Platelet inhibitors are used to prevent limb-related and general CV
events. The optimal antiplatelet strategy remains unclear.773 DAPT is currently recommended only after intervention (irrespective of the stent type) for at least 1 month.
In the COMPASS (Cardiovascular Outcomes for People Using
Anticoagulation Strategies) trial, low-dose rivaroxaban added to aspirin in CVD patients with an ABI <0.90 reduced not only ASCVD events,
but also major adverse limb events, including amputation (HR 0.54),
Recommendations for patients with cerebrovascular disease
Recommendations
Classa
Levelb
In patients with a cerebrovascular event,
improvement of lifestyle factors in addition to appropriate pharmacological management is recommended.732,733,741
I
A
In patients with ischaemic stroke or TIA, prevention with antithrombotics is recommended;
choice of antithrombotic depends on the mechanism of event. Use of an antiplatelet is recommended for patients with non-cardioembolic ischaemic stroke or TIA, and use of an anticoagulant is recommended in patients with cardioembolic ischaemic stroke or TIA.732,741
I
A
In patients with non-cardioembolic ischaemic stroke or TIA, prevention with aspirin only, or dipyridamole plus aspirin, or clopidogrel alone is recommended.620,743745
I
A
In patients with minor ischaemic strokec or TIA,
DAPT with aspirin and clopidogrel or with aspirin and ticagrelor, for 3 weeks after the acute event should be considered.750,751,755
IIa
A
In patients with stroke or TIA who have BP of
140/90 mmHg or higher, BP lowering is recommended.757,766
I
A
BP = blood pressure; DAPT = dual antiplatelet therapy; TIA = transient ischaemic attack.
aClass of recommendation.
bLevel of evidence.
cMinor ischaemic stroke deﬁned as score at National Institutes of Health Stroke
Scale <_3, or <_5 depending on the trial.
ESC 2021
Recommendations for patients with lower extremity artery disease: best medical therapy
Recommendations
Classa
Levelb
Smoking cessation is recommended in all patients with LEAD.29,781
I
B
Healthy diet and PA are recommended for all patients with LEAD.
I
C
In patients with intermittent claudication:
 Supervised exercise training is recommended782784
I
A
 Non-supervised exercise training is recommended when supervised exercise training is not feasible or available.
I
C
Antiplatelet therapy is recommended in patients with symptomatic LEAD.c
I
C
In patients with LEAD and hypertension, it is recommended to control BP at <140/90
mmHg.776,785,786
I
A
In patients with LEAD and DM, strict glycaemic control is recommended.768
I
A
ACE inhibitors or ARBs should be considered as
ﬁrst-line therapy in patients with PAD and hypertension.d 575,787
IIa
B
In patients with DM and chronic symptomatic
LEAD without high bleeding risk, a combination of low-dose rivaroxaban (2.5 mg b.i.d.) and aspirin (100 mg o.d.) may be considered.774
IIb
B
ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; b.i.d.
= bis in die (twice a day); BP = blood pressure; CCB = calcium channel blocker;
DM = diabetes mellitus; LEAD = lower extremity artery disease; o.d. = omni die
(once a day); PA = physical activity; PAD = peripheral artery disease.
aClass of recommendation.
bLevel of evidence.
cEvidence is not available for all sites. When evidence is available, recommendations speciﬁc for the vascular site are presented in corresponding sections.
dCCBs should be proposed in black individuals.
ESC 2021
..............................................................................................................
ESC Guidelines
3297


<!-- PAGE 72 -->

### Page 72

..........................................................................................................
albeit at the cost of higher major bleeding risk.774 These results, combined with similar benefits of rivaroxaban vs. aspirin monotherapy, suggest a benefit of anticoagulants in LEAD. However, further studies are needed. Optimal antithrombotic therapy is addressed in more detail in the 2017 ESC/European Society for Vascular Surgery (ESVS)
Guidelines.775 Importantly, in patients with isolated asymptomatic
LEAD (e.g. low ABI), antiplatelet treatment is not recommended.775
Recommendations for BP and lipid management are congruent to the general recommendations outlined in sections 4.6 and 4.7.
Hypertension targets are based mainly on INVEST (INternational
VErapamil-SR/Trandolapril STudy).776 An SBP below 110120 mmHg may increase CV events in patients with LEAD.776 ACE inhibitors and
ARBs reduce CV events in patients with LEAD,575,777 and are preferred (as monotherapy or as part of a combination drug regimen).778
Beta-blockers are not contraindicated in mild-to-moderate LEAD as they do not affect walking capacity or adverse limb events,779 and significantly reduce coronary events.780 Nevertheless, beta-blockers should be carefully considered in critical limb-threatening ischaemia.
6.5. Chronic kidney disease
Severe CKD is associated with a very high risk of CVD and is considered a CAD risk equivalent (see section 3.2). As GFR declines, nontraditional risk factors emerge and non-atherosclerotic CVD event risk increases.204 Trials often exclude patients with eGFR <30 mL/
min/1.73 m2. In patients on dialysis, coronary syndromes may present atypically, and angina equivalents—such as shortness of breath or fatigue—are frequent.788 Standard CVD risk management is effective in patients on dialysis, but unique haemodialysis-specific syndromes
(i.e. intradialytic hypotension and myocardial stunning) associated with mortality complicate treatment and modify outcomes.
Risk classification of patients with various degrees of CKD is summarized in Table 4. Treatment with a statin or statin/ezetimibe combination is recommended in CKD patients with sufficiently high CVD
risk, but not in those treated with kidney replacement therapy. This recommendation is built on evidence from SHARP (Study of Heart and Renal Protection), which demonstrated a reduction of major atherosclerotic events.525 Statins should be dosed according to a moderate-intensity regimen based on limited experience and risks associated with high-intensity regimens.543 Subgroup analysis of a recent study with a PCSK9 inhibitor has shown that the benefits may extend to those with earlier CKD stages (6090 as well as
3060 mL/min/1.73 m2).789
Treatment with an ACE inhibitor or an ARB is recommended in patients with DM, hypertension, and albuminuria. These medications should be titrated to the maximum tolerated dose (Kidney Disease
Improving Global Outcomes grading 1B).
Individualized HbA1c targets, ranging from 6.5% to <8.0% in patients with DM and non-dialysis-dependent CKD, are recommended in parallel. The role of SGLT2 inhibitors and GLP-1RAs in
CKD associated with DM is addressed in section 4.8. Dapagliflozin has shown promising reno- and cardioprotective effects,599 and more studies investigating SGLT2 inhibitors in CKD patients without DM
are ongoing.790
Overall, the management of CAD in CKD patients must be informed by the modification of its clinical presentation in CKD, as well as comorbidity and risks of treatment side-effects. Treatment of established risk factors is often suboptimal in patients with CKD.
6.6. Atrial fibrillation
The simple ‘Atrial fibrillation Better Care’ (ABC) holistic pathway
(‘A’ = Anticoagulation/Avoid stroke; ‘B’ = Better symptom management; ‘C’ = Cardiovascular and Comorbidity optimization)
streamlines integrated care of patients with AF.215 The ABC pathway lowers risk of all-cause death and the composite of stroke,
major bleeding, CV death, or first hospitalization,791 and lowers rates of CV events792,793 and health-related costs.794
The ‘C’ component of the ABC pathway refers to identification and management of concomitant diseases, cardiometabolic risk factors, and unhealthy lifestyle factors. Therapy of underlying conditions improves rhythm control in persistent AF and HF.216 In obese patients, weight reduction prevents AF recurrences and symptoms.795802 Given that hypertension precipitates AF, treatment of hypertension is mandatory. Alcohol excess is a risk factor for incident AF,803,804 and abstinence reduced AF recurrences in regular drinkers.798 Many studies have demonstrated beneficial effects of moderate exercise/PA.805807 The incidence of AF
appears, however, to be increased in elite athletes, mainly related to endurance sports.808811 Patients should be encouraged to practise moderate-intensity exercise and remain physically active to prevent AF incidence or recurrence, but avoid excessive endurance exercise. CR is a universally recommended programme for patients with ACS and/or revascularization, and for patients with HF.639,640,655 The benefits of EBCR are more uncertain in patients with AF, but CR remains recommended in patients with the aforementioned indications.812 Continuous PAP may improve rhythm control and attenuate AF recurrences in OSA
patients.813816 Intensive glycaemic control does not affect the rate of new-onset AF.817 Optimal glycaemic control during the 12
months before AF ablation does, however, reduce AF recurrence after ablation.818 All patients with HF and AF should receive guideline-adherent HF therapy.819
Recommendations in patients with chronic kidney disease: best medical therapya
Recommendations
Classb
Levelc
Treatment with an ACE inhibitor or an ARB is recommended in patients with DM, hypertension, and albuminuria. These medications should be titrated to the highest approved dose that is tolerated.
I
B
An SGLT2 inhibitor with proven outcome beneﬁts should be considered for the prevention of renal deterioration and mortality in patients with CKD.599
IIa
B
Combination treatment with ACE inhibitors and
ARBs is not recommended.
III
C
ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker;
CKD = chronic kidney disease; DM = diabetes mellitus; SGLT2 = sodium-glucose cotransporter 2.
aRecommendations on CKD management in patients with DM are found in section 4.8.
bClass of recommendation.
cLevel of evidence.
.................................................................
ESC 2021


<!-- PAGE 73 -->

### Page 73

.............................................................................................................................................................................
6.7. Multimorbidity
The older adult population is growing fast and survival after acute
CVD has improved,820 leading to an increasing number of older patients with CVD and multimorbidity.821,822 This development is associated with high healthcare costs,823,824 worse outcome measures, higher readmission rates,825 and mortality.826
Up to 70% of patients aged >_70 years have at least one CVD and two-thirds also develop non-CVD comorbidities. Multimorbidity is important in patients with CVD.823
The prevailing CV conditions in patients aged >60 years are hypertension, hyperlipidaemia, ischaemic heart disease, arrhythmia, DM,
and CAD.823 Other frequent comorbidities include anaemia and arthritis. Low vision, back and neck problems, osteoarthritis, COPD,
depression, and cancer are the most common non-CV comorbidities in CVD patients. Most studies have found no sex differences in the number of comorbidities. However, men have more CVD comorbidities and women have more non-CVD comorbidities (in particular more depression).822,826,827
So far, guidance for the treatment of CVD has focused mainly on single CVDs. In multimorbid patients, application of a single guideline for one CVD is often not feasible as therapeutic competition is highly prevalent (22.6%)820 and treatment for one condition can worsen a coexisting condition. The challenges for managing CVD and multimorbidity are disease-disease, disease-drug, and drug-drug interactions.820 Further, pharmacokinetics can be different in patients with comorbidities, and life expectancy has to be taken into account when starting a new medication. A value-based approach should always be discussed and proposed when possible.820 The incremental benefit of medication when added to an already complex regimen is often uncertain.828 Moreover, care for multimorbid CVD patients is often fragmented and given by multiple providers, complicating decisionmaking and adherence to recommended treatment.820
Multimorbid CVD patients have been underrepresented in most clinical trials that underlie the guidelines. Trials including patients with multimorbidity and endpoints that matter to patients, pragmatic trials, and the use of registries and big data could help elucidate how to optimize treatment and care for patients with
CVD
and multimorbidity.820
There is a plea for a paradigm shift from disease-focused to patient-centred care for multimorbid CVD patients, with a central place for patients’ overarching goals of care.828 ‘What matters to you?’ should be the central question, instead of ‘what is the matter?’.
Patient-centred care should include assessment of patients’ preferences, interpretation of the evidence and its application to the specific patient, consideration of overall prognosis, including life expectancy, functional status, and quality of life, and clinical feasibility.
Adherence to treatment, the occurrence of adverse drug events, the economic burden, and the stress experienced by caregivers should be taken into account when optimizing therapies and care plans where adherence to essential medication is emphasized and nonessential drugs are stopped.828 Furthermore, advanced care planning should be initiated early. Multidisciplinary teams and close collaboration between primary care workers and specialists is needed. Finally,
automated decision support systems for multimorbidity and CVD
could help in aligning the relevant evidence and making adequate decisions.829
7. Key messages
Risk factors and risk classification
• The major risk factors for ASCVD are cholesterol, BP, cigarette smoking, DM, and adiposity.
• Risk factors are treated in a stepwise approach to reach the ultimate treatment goals in apparently healthy people, patients with established ASCVD, and patients with DM.
• 10-year CVD risk is estimated in apparently healthy people aged
4069 years with SCORE2, and in people aged >_70 years with
SCORE2-OP.
• Age-specific 10-year CVD risk thresholds—together with consideration of risk modifiers, frailty, comorbidities, lifetime CVD
risk, treatment benefit, polypharmacy, and patient preferences—
guide treatment decisions for lipid and BP treatment.
• There are various options of communicating the (residual) CVD
risk, and this should be tailored to the individual patient.
Recommendations for lifestyle interventions and management of risk factors and concomitant diseases in patients with atrial ﬁbrillation215
Recommendations
Classa
Levelb
Identiﬁcation and management of risk factors and concomitant diseases are recommended to be an integral part of treatment.795
I
B
Modiﬁcation of unhealthy lifestyle and targeted therapy of intercurrent conditions is recommended to reduce AF burden and symptom severity.216,795802
I
B
Attention to good BP control is recommended in AF patients with hypertension to reduce AF
recurrences and risk of stroke and bleeding.800,801
I
B
In obese patients with AF, weight loss together with management of other risk factors should be considered to reduce AF incidence, AF progression, AF recurrences, and symptoms.795797
IIa
B
Advice and management to avoid alcohol excess should be considered for AF prevention and in
AF patients considered for oral anticoagulant therapy.798,803,804
IIa
B
PA should be considered to help prevent AF
incidence or recurrence, with the exception of excessive endurance exercise, which may promote AF.805812
IIa
C
Optimal management of OSA may be considered to reduce AF incidence, AF progression, AF
recurrences, and symptoms.813816
IIb
C
AF = atrial ﬁbrillation; BP = blood pressure; OSA = obstructive sleep apnoea; PA
= physical activity.
aClass of recommendation.
bLevel of evidence.
ESC 2021
ESC Guidelines
3299


<!-- PAGE 74 -->

### Page 74

.............................................................................................................................................................................
Risk modifiers
• Psychosocial stress is associated with risk of ASCVD.
• Current risk scores may under- or overestimate CVD risk in differing ethnic minority groups.
• CAC scoring is the best-established imaging modality to improve
CVD risk stratification.
• Frailty is a functional risk factor of both CV and non-CV morbidity and mortality.
• Frailty assessment is not a method to determine eligibility for any particular treatment, but rather serves to build an individualized care plan with predefined priorities.
• Family history should be enquired about routinely, and a positive family history of premature ASCVD should be followed by comprehensive CVD risk assessment.
• Current data does not support the use of genomic risk scores in
CVD risk assessment in primary prevention.
• ASCVD development and prognosis are linked to social gradients.
• Air pollution is strongly associated with ASCVD.
• Additional circulating and urine biomarkers should not be routinely measured.
• Assess CVD risk in persons with obesity.
Clinical conditions
• CKD is an independent risk factor for ASCVD, and ASCVD is the leading cause of death in CKD.
• A short-term reduction in albuminuria by approximately 30%
upon starting RAAS inhibition is associated with improved CV
and kidney outcomes.
• Similarly, SGLT2 inhibitors are associated with long-term benefits in CV and renal risks.
• AF is associated with an increased risk of death and an increased risk of CVD.
• Ischaemic HF constitutes the most advanced clinical manifestation of atherosclerosis within the myocardium.
• The diagnosis of overt HF, as well as asymptomatic presentation with LV dysfunction, increases the risk of CVD events (myocardial infarction, ischaemic stroke, CV death).
• There is an overlap between cancer and CV risk factors; CV risk in patients with cancer depends on both the CV toxicity of treatments and patient-related factors.
• Signs or symptoms of cardiac dysfunction should be monitored before, periodically during, and after treatment.
• Exercise should be strongly advised, in particular aerobic exercise, to prevent cardiotoxicity.
• COPD is a major risk factor for CVD, especially ASCVD, stroke,
and HF.
• COPD patients are prone to arrhythmias (AF and ventricular tachycardia) and sudden cardiac death.
• All COPD patients should be investigated for CVD.
• Common COPD medications are usually safe in terms of CV
adverse events.
• Chronic inflammatory conditions increase CVD risk.
• Infection with HIV is associated with an increased risk of LEAD
and CAD.
• There is an association between influenza and periodontitis infections and ASCVD.
• Migraine, particularly migraine with aura, is an independent risk factor for stroke and ischaemic cardiac disease.
• The risk of ischaemic stroke in subjects with migraine with aura is magnified by the use of combined hormonal contraceptives and cigarette smoking.
• Non-restorative sleep and a sleep duration that varies significantly up or down from the optimum of 7 h are associated with increased CV risk.
• Mental disorders are common in the general population (12month prevalence of 27%) and are associated with excess mortality.
• The onset of CVD increases the risk of mental disorders by 2.2fold, leading to a worse prognosis.
• Some mental disorders—even symptoms of anxiety and depression—are associated with the development of CVD and with a worse prognosis in those with existing CVD (CHD, arterial hypertension, AF, HF).
• Excess mortality is mainly caused by behaviour-dependent risk factors (e.g. smoking addiction) and an impaired capacity for selfcare (e.g. treatment adherence).
• NAFLD is associated with other cardiometabolic risk factors.
• Patients with NAFLD should be evaluated for other cardiometabolic risk factors.
• Sex-specific conditions:
• Preeclampsia and pregnancy-related hypertension are associated with a higher risk of CVD.
• Polycystic ovary syndrome confers a significant risk for future development of DM.
• ED is associated with future CV events and mortality in men.
• CVD risk should be assessed in men with ED.
• Asking about ED should be a standard procedure in routine
CV risk assessment in men.
Risk factors and interventions at the individual level
• Regular PA is a mainstay of ASCVD prevention.
• Aerobic PA in combination with resistance exercise and the reduction of sedentary time are recommended for all adults.
• A healthy diet lowers the risk of CVD and other chronic diseases.
• A shift from a more animal- to plant-based food pattern may reduce CVD.
• Achieving and maintaining a healthy weight through lifestyle changes has favourable effects on risk factors (BP, lipids, glucose metabolism) and lowers CVD risk.
• When changes in diet and PA—as well as other conventional,
non-invasive interventions—are unsuccessful, bariatric surgery should be considered for high-risk individuals.
• Anti-obesity medications with protective ASCVD effects may also be considered.
• Patients with mental disorders have sharply increased lifestyle risks that need recognition and treatment.
• Mental healthcare improves stress symptoms and quality of life,
reduces the risk of suicide, and may improve CV outcomes.
• The treatment of ASCVD patients with mental disorders requires interdisciplinary cooperation and communication.
• Stopping smoking rapidly reduces CVD risk and is the most cost-effective strategy for ASCVD prevention.


<!-- PAGE 75 -->

### Page 75

.............................................................................................................................................................................
• There is strong evidence for medication-assisted interventions:
NRT, bupropion, varenicline, and drugs in combination. The most effective are assistance using drug therapy and follow-up support.
• Lower is better: the effect of LDL-C on the risk of CVD appears to be determined by both the baseline level and the total duration of exposure to LDL-C.
• Lowering LDL-C with statins, ezetimibe, and—if needed and cost-effective—PCSK9 inhibitors, decreases the risk of
ASCVD proportionally to the absolute achieved reduction in
LDL-C.
• When LDL-C goals according to level of risk cannot be attained,
aim to reduce LDL-C by >_50% and then strive to reduce other risk factors as part of a shared decision-making process with the patient.
• When hypertension is suspected, the diagnosis should be confirmed by repeated office BP measurement at different visits, or
ABPM or HBPM.
• Lifestyle interventions are indicated for all patients with hypertension and can delay the need for drug treatment or complement the BP-lowering effect of drug treatment.
• BP-lowering drug treatment is recommended in many adults when office BP is >_140/90 mmHg and in all adults when BP is
>_160/100 mmHg.
• BP treatment goals are lower than in the previous ESC CVD prevention guidelines for all patient groups, including independent older patients.
• Wider use of single-pill combination therapy is recommended to reduce poor adherence to BP treatment.
• A simple drug treatment algorithm should be used to treat most patients, based on combinations of a reninangiotensin system
(RAS) blocker with a CCB or thiazide/thiazide-like diuretic, or all three. Beta-blockers may also be used where there is a guideline-directed indication.
• Many patients with hypertension will be at sufficient risk to benefit from statin therapy for primary prevention. Antiplatelet therapy is indicated for secondary prevention.
• A multifactorial approach, including lifestyle changes, is critical in persons with type 2 DM.
• Management of hyperglycaemia reduces the risk of microvascular complications and, to a lesser extent, the risk of CVD.
Glycaemic targets should be relaxed in older adults and frail individuals.
• New antihyperglycaemic drugs are particularly important for persons with type 2 DM with existing ASCVD and (heightened risk of) HF or renal disease, broadly irrespective of glycaemia levels.
Type 1 diabetes mellitus
• Intensive management of hyperglycaemia in DM reduces the risk of micro- and macrovascular complications and premature mortality; a target of 6.57.5% (4858 mmol/mol) HbA1c is recommended.
• Metformin is not recommended in type 1 DM to lower CVD
risk.
• Dapagliflozin has been recommended for use in type 1 DM,
although there is an increased risk of diabetic ketoacidosis with such therapies.
• Targeting other risk factors, in particular smoking, BP, and cholesterol levels, remains an important means to lower CVD risk in type 1 DM.
• All patients with established ASCVD require some form of antithrombotic therapy.
• Anti-inflammatory therapy is a promising strategy in CVD
prevention.
• Patients after ACS and/or coronary artery bypass graft/PCI, or with chronic HFrEF, should participate as early as possible in structured, multidisciplinary EBCR and prevention programmes.
• EBCR and prevention programmes must comply with certain quality standards and be individualized to each patient’s profile.
• Participation and long-term adherence to these programmes has to be encouraged and enhanced. Telerehabilitation and mHealth may help towards achieving this target.
Population-level approaches to cardiovascular disease prevention
Physical activity
• A significant percentage of the worldwide population, in particular the European population, shows high levels of sedentary behaviour and physical inactivity.
• The percentage of those exercising at a regular level is greater in men than in women.
• Global progress to increase PA has been slow, largely due to lack of awareness and investment.
• The optimal dose of different types of PA for CVD and general prevention is still controversial and subjected to frequent updates. Increasing moderate-to-vigorous PA and reducing sitting time, however, is beneficial and any level of PA is considered better than none.
• PA for health promotion should be implemented by physicians in the same way as drug prescription and should also be promoted by other healthcare professionals.
• Population-based interventions are effective in promoting
PA for groups based on age, sex, and race, for high-, middle-, and low-income populations,
and for different environments
(e.g. kindergarten, school, gyms, companies, and worksites in general).
• Daily PA at school should be practised for at least 3 h/week, and preferably for 60 minutes per day.
• Population-based approaches are complementary to individualcentred interventions.
• Diet
• Structural measures such as changes in agricultural supply chain and food industry, product reformulation, limitations on (digital)
marketing to children, taxes on unhealthy foods/nutrients, and consumer-friendly nutrition labelling will improve healthy food choices.
• Healthy environments in the community, on public transport, at schools, and in workplaces will stimulate a healthier lifestyle.
• The WHO Global Action Plan for the Prevention and Control of Non-Communicable Diseases 20132020 extended to 2025
recommends to develop goals in global, regional, and national agendas. Within the 10 voluntary targets to reach in 2025 is a
30% relative reduction in mean population intake of sodium/
salt.830
ESC Guidelines
3301


<!-- PAGE 76 -->

### Page 76

.............................................................................................................................................................................
Smoking and tobacco use
• Adolescence is the most vulnerable period for the uptake of smoking, with lifelong consequences.
• Previous prevention campaigns reduced tobacco use in girls much less than in boys.
• Teenagers should be informed that smoking is not helpful in weight control.
• High taxes on all tobacco products is the most effective policy measure to reduce smoking uptake by the young.
• There should be restrictions on smokeless tobacco due to strong evidence of harm.
• Also, restrictions on e-cigarettes due to evidence of harm.
• Plain packaging is effective in reducing the attractiveness of tobacco products.
• There should be restrictions on advertising, promotion, and sponsorship by the tobacco industry.
• A goal would be to make a common European decision to achieve a smoking-free Europe by 2030.
Alcohol
• Alcohol intake is associated with increased CV mortality, and alcohol use is the leading risk factor for premature death and disability among people aged 1549 years.
• The interventions for addressing the harmful use of alcohol are cost-effective, with a good return (i.e. increasing alcoholic beverage minimum unit pricing and excise taxes, restricting access to alcoholic beverages, and implementing comprehensive restrictions and bans on advertising and the promotion of alcoholic beverages).
• Healthcare providers may inquire about alcohol intake in every medical evaluation and should inform patients that alcohol is energy-dense: it provides 7 kcal/g and no nutrients.
Environment, air pollution, and climate change
• Air pollution contributes to mortality and morbidity, and specifically increases the risk of respiratory and CV diseases.
• Environmental exposure has taken on new urgency, as air pollution, in addition to its health effects, has also been ascribed as a major contributor to climate changes, notably through the burning of fossil fuels leading to increasing emissions of carbon dioxide.
Risk management of disease-specific cardiovascular disease
Coronary artery disease
• Multidimensional prevention is crucial for short- and long-term outcomes in CAD.
Heart failure
• Patients with HF benefit from multidisciplinary care management programmes.
• Several neurohormonal antagonists, as well as novel molecules,
improve clinical outcomes in symptomatic patients with HFrEF.
Cerebrovascular diseases
• Ischaemic events are mainly caused by atherothrombosis, cardioembolism, or small vessel disease, whereas intracerebral haemorrhage is mostly caused by hypertensive angiopathy or cerebral amyloid angiopathy.
• Platelet inhibitors are recommended for non-cardioembolic events and anticoagulants for cardioembolic events.
• In patients with a previous stroke or TIA and high BP, BP lowering reduces the recurrence risk.
• In patients with stroke or TIA, statins prevent CVD and cerebrovascular events.
• Lower extremity artery disease
• LEAD is associated with an increased CVD risk.
• Antiplatelet therapy (alone or in combination with low-dose oral anticoagulation) reduces the risk of adverse limb events and overall CVD risk in patients with LEAD.
• Smoking cessation and control of other CVD risk factors improve prognosis.
Chronic kidney disease
• Hypertension, dyslipidaemia, and DM are prevalent among individuals with CKD and require a high-risk treatment strategy approach.
• Risk management includes lifestyle, smoking cessation, nutrition,
sufficient RAAS blockade, target BP control, lipid management,
and—in established CVD—aspirin.
• A high value is placed on self-management education programmes and team-based integrated care in patients with DM,
CKD, and CVD.
Atrial fibrillation
• Holistic management of patients with AF improves prognosis and reduces health-related costs.
• Comprehensive risk-factor modification and targeting underlying conditions reduce AF burden and recurrence.
Multimorbidity
• The number of patients with multiple CV and non-CV comorbidities is rapidly increasing.
• Therapeutic competition should be considered in multimorbid patients, as the treatment of one condition might worsen a coexisting condition.
• A paradigm shift from disease-focused to patient-centred care for multimorbid CVD patients is recommended.
8. Gaps in evidence
CVD risk classification
• Country-specific risk algorithms for patients with established
CVD and people with DM.
• Formal comparison of effectiveness and cost-effectiveness of
CVD risk-guided treatment vs. treatment guided by risk factor level.
• Comparison of the precision of competing risk-adjusted CVD
risk models vs. standard CVD risk models.
• Incorporating potential risk markers into conventional risk models, such as socioeconomic status and ethnicity.
• Comparison of treatment benefit-guided strategy vs. risk-guided strategy in reducing risk factor levels and CVD risk.


<!-- PAGE 77 -->

### Page 77

.............................................................................................................................................................................
• Management of CVD risk in older people (>85 years) with marked fragility, for whom no data currently exist.
• Comparison of different methods for the estimation of lifetime
CVD risk and lifetime benefit of risk factor treatment.
Risk modifiers
Psychosocial factors
• More evidence that psychosocial factors improve risk prediction beyond the classical risk-factor models.
Ethnicity
• Whether recalibration of factors for ethnicity are homogeneous in various European countries.
• Risks associated with other ethnic backgrounds.
Frailty
• Consensus on a clinically orientated screening tool for frailty to be applied across the spectrum of ASCVD.
• Quantitative contribution of frailty to the global CVD riskprediction scheme.
• At which degree of frailty treatment of specific risk factors should be less aggressive.
Family history
• Disentangle the role and (genetic, socioeconomic, etc.) mechanisms of family history on CVD risk.
Genetics
• The potential of polygenic risk scores to complement existing risk scores.
Socioeconomic determinants
• More evidence from different risk regions that the inclusion of socioeconomic factors improves risk prediction beyond classical risk factor models in both men and women.
Environmental exposure
• Whether air pollution reclassifies risk in individual patients.
Biomarkers
• Added value of biomarkers in risk classification.
Clinical conditions
Chronic kidney disease
• Identification of a good biomarker, besides albuminuria, and perhaps the use of CAC score to subclassify CV risk in CKD.
• Early and precise identification of progressive CKD with novel biomarkers that are more sensitive than eGFR and albuminuria.
Atrial fibrillation
• Evaluate the effect of interventions aimed at reducing outcomes beyond stroke.
• Is AF a causal factor for increased CVD morbidity and mortality?
• Stroke risk prediction for low-risk AF patients.
• Emerging evidence suggests that stroke can occur in patients with AF even after sinus rhythm is restored.
Heart failure
• It remains unknown whether patients with HFrEF of ischaemic origin should have different target LDL-C levels than those recommended for secondary prevention in individuals without HF.
Cancer
• RCTs using preventive therapy to demonstrate a clear effect on prevention of CV events.
Chronic obstructive pulmonary disease
• Although common pathophysiological pathways between CVD
and COPD are probable, they remain to be clarified.
Inflammatory conditions
• The optimal way of integrating information on chronic inflammatory conditions into CVD risk assessment.
• The effect of modern anti-inflammatory drugs on CV risk [e.g.
anti-tumour necrosis factor (TNF), interleukin (IL)-1, IL-17, IL-23
biologics].
Infections
• Large-scale studies to assess the efficacy of influenza vaccination or periodontitis treatment in preventing CVD.
• The association of infection with HIV and total CVD risk.
Migraine
• There are no data that allow reliable identification of subgroups of migraineurs at particular high risk (e.g. active migraine, highfrequency auras, young subjects, women).
• The role of comorbid factors (e.g. patent foramen ovale, thrombophilic factors) is unclear, and at the moment there is no indication to screen or to manage for these factors.
Sleep disorders
• There is lack of evidence that the inclusion of sleep improves risk prediction.
• Trials are needed that target the complex pathways linking sleep disturbances with CVD.
Mental disorders
• The precise mechanism by which mental disorders increase
CVD remains uncertain.
• How the consideration of mental disorders improves CV risk models.
Non-alcoholic fatty liver disease
• Whether NAFLD increases CV risk beyond traditional risk factors.
Sex-specific conditions
• The degree to which increased CVD risk associated with several of the female-specific conditions occurs independently of
ESC Guidelines
3303


<!-- PAGE 78 -->

### Page 78

.............................................................................................................................................................................
conventional CVD risk factors, although data in women are still underpowered compared to men.
• Information on whether female-specific conditions improve risk classification.
• There are insufficient data to draw conclusions on a possible increased risk of hypertension or
DM
with premature menopause.
• Studies on the specificities of CVD disease in the transgender population are scarce.
Erectile dysfunction
• The benefit of routine screening for ED and the most effective tool to assess it are still unclear.
• The benefit of assessment of subclinical vascular disease in men with ED and low-to-intermediate CVD risk is unclear.
Risk factors and interventions at the individual level
Physical activity and exercise
• Knowledge of the relative importance of the various characteristics of aerobic PA and resistance exercise, or their combination,
on all-cause mortality, CV incidence, and mortality.
• Understanding how sex, age, weight, race/ethnicity, occupation,
and socioeconomic status may modify associations between PA
and health outcomes.
• Implementation of strategies to achieve long-term adherence to
PA.
• Evaluation of the effects of eHealth tools in promoting PA.
Nutrition
• Effective strategies to encourage people to change their diet and to enjoy and maintain a healthy diet.
Body weight
• Knowledge and implementation of effective lifestyle and medication-assisted strategies to achieve weight loss and maintain a long-term healthy weight.
Mental healthcare and psychosocial interventions
• The effectiveness of mental healthcare for the prevention of major CVD events.
• How to implement effective CVD prevention measures in this high-risk population of patients with mental disorders.
Smoking intervention
• A better understanding of how to incorporate effective smoking cessation into clinical practice.
Lipids
• Direct empirical evidence for the stepwise approach to treatment intensification from RCTs. The feasibility and effects of reaching LDL-C levels <1.4 mmol/L (55 mg/dL) needs further investigation, especially in primary care.
• Particularly among people at low-to-moderate CVD risk, older people, and for newer interventions, more evidence of the effects of lipid-modifying treatments on overall mortality is needed in the form of long-term post-trial follow-up in RCTs.
• The cost-effectiveness of using lifetime CVD risk and more precise CVD risk scores to target interventions needs further investigation.
• The value of triglycerides or HDL-C values as a target for therapy.
• Whether lipoprotein(a) lowering against background statin, ezetimibe and PCSK9i therapy can reduce the risk of ASCVD.
• Whether functional foods and food supplements with a lipidlowering effect can safely reduce the risk of CVD.
Blood pressure
• What is the incremental benefit, over CVD risk calculators, of measures of HMOD in reclassifying the CV risk of patients with hypertension?
• Direct empirical evidence for the stepwise approach to treatment intensification from RCTs.
• What are the benefits of BP treatment for patients with BP in the high-normal range?
• More data on the benefits of BP treatment in very old people and the influence of frailty.
• Effect of single-pill vs. multidrug treatment strategies on adherence to treatment, BP control, and clinical outcomes.
• Effectiveness of antihypertensive treatment in preventing cognitive dysfunction or dementia.
• Efficacy and cost-effectiveness of invasive procedures and devices for the treatment of hypertension.
• Sex-specific BP treatment thresholds for men and women.
Diabetes mellitus
• More work is needed to develop risk scores for both MACE and
HF in type 2 DM.
• Whether combined SGLT2 inhibitor and GLP-1RA treatments lower MACE or other outcomes beyond either drug alone requires testing.
• Longer-term safety of newer classes of drug is required.
Antithrombotic therapy
• The role of antithrombotic therapy in primary prevention in
(very) high-risk individuals remains to be established.
Cardiac rehabilitation and prevention programmes
• The effect and the optimal delivery of EBCR in women, older/
frail patients, patients with cardiac implantable electronic devices, after heart transplantation or valve replacement, and in patients with
AF,
stroke,
HFpEF,
LEAD,
or multiple comorbidities.
• Alternative and cost-effective models of CR need to ensure participation globally, including low- and middle-income countries.
• Large RCTs investigating the long-term effects of home-based telerehabilitation and mHealth are needed.
Environment, air pollution, and climate change
• Individual-level exposure studies are needed to better specify the effect of mitigating measures.
Risk management of disease-specific cardiovascular disease
Coronary artery disease


<!-- PAGE 79 -->

### Page 79

...........................................................................
• The efficacy and safety of aspirin or other antithrombotic therapy in patients without clinical manifestations of CAD—but with atherosclerotic disease identified on imaging, such as CCTA—
requires further assessment.
• The optimal long-term antithrombotic therapy in patients at high risk of ischaemic events is uncertain.
• Clinical studies comparing the efficacy and safety of P2Y12 inhibitors vs. low-dose rivaroxaban or other factor Xa inhibitors, in combination with aspirin, are warranted to determine which subgroups will derive greater clinical benefit with each strategy.
Heart failure
• For patients with HFpEF, no specific pharmacotherapy or device implantation has been shown to modify the risk of any CV
outcome.
• Lower dosage of HF treatments in women with HFrEF needs to be addressed, since women were underrepresented in many HF
trials.
Cerebrovascular disease
• The optimal selection of patient for a short course of DAPT.
• The optimal antihypertensive regimen and target BP.
• The optimal target level of LDL-C.
• Optimal treatment for patients with silent cerebrovascular disease.
Lower extremity artery disease
• The optimal type and potency of antithrombotic therapy in patients with different manifestations of symptomatic or asymptomatic LEAD are partly unclear.
Chronic kidney disease
• Few CVD trials have a focus on patients with CKD, particularly those with advanced CKD.
• Additional prospective studies focusing on diagnosis, prevention,
and treatment of CAD and CVD are needed in CKD.
Atrial fibrillation
• The effects of various CV risk factors and comorbidities in AF.
• Optimal treatment of OSA and its effect on AF progression and symptoms.
Multimorbidity
• The effect of different clusters or combinations of CV and nonCV comorbidities on CV outcomes.
• Optimal, pragmatic treatment strategies in patients with CV and non-CV comorbidities, with particular focus on treatment adherence and therapeutic competition.
9. ‘What to do’ and ‘what not to do’ messages from the guidelines
Recommendations
Classa
Levelb
Recommendations for cardiovascular disease risk assessment
Systematic global CVD risk assessment is recommended in individuals with any major vascular risk factor (i.e. family history of premature CVD, FH, CVD risk factors such as smoking, arterial hypertension, DM, raised lipid level, obesity, or comorbidities increasing CVD risk).
I
C
Systematic CVD risk assessment in men <40 years of age and women <50 years of age with no known CV risk factors is not recommended.
III
C
Recommendations for cardiovascular disease risk estimation
In apparently healthy people <70 years of age without established ASCVD, DM, CKD, genetic/rarer lipid or BP disorders, estimation of 10-year fatal and non-fatal CVD risk with SCORE2 is recommended.
I
B
In apparently healthy people >_70 years of age without established ASCVD, DM, CKD, genetic/rarer lipid or BP disorder, estimation of 10-year fatal and nonfatal CVD risk with SCORE2-OP is recommended.
I
B
Patients with established CVD and/or DM and/or moderate-to-severe renal disease and/or genetic/rarer lipid or BP disorders are to be considered at high or very high CVD risk.
I
A
A stepwise treatment-intensiﬁcation approach aiming at intensive risk factor treatment is recommended for apparently healthy people at high or very high CVD risk, as well as patients with established ASCVD and/or DM, with consideration of CVD risk,
treatment beneﬁt of risk factors, risk modiﬁers, comorbidities, and patient preferences.
I
B
Treatment of ASCVD risk factors is recommended in apparently healthy people without DM, CKD, genetic/rarer lipid or BP disorders who are at very high risk (SCORE2 >_7.5% for age under 50; SCORE2 >_10% for age 5069; SCORE2-OP >_15% for age
>_70 years).
I
C
Recommendation for cardiovascular disease risk communication
An informed discussion about CVD risk and treatment beneﬁts tailored to the needs of a patient is recommended.
I
C
Recommendations for risk modiﬁers
The routine collection of other potential modiﬁers, such as genetic risk scores, circulating or urinary biomarkers, or vascular tests or imaging methods (other than CAC scoring or carotid ultrasound for plaque determination), is not recommended.
III
B
Continued
ESC Guidelines
3305


<!-- PAGE 80 -->

### Page 80

Recommendations for cardiovascular disease risk assessment in speciﬁc clinical conditions
In all CKD patients, with or without DM, appropriate screening for ASCVD and kidney disease progression, including monitoring changes in albuminuria is recommended.
I
C
It is recommended to monitor cardiac dysfunction using imaging techniques and circulating biomarkers before, periodically during,
and after cancer treatment.
I
B
Screening for CV risk factors and optimization of the CV risk proﬁle is recommended in patients on treatment for cancer.
I
C
It is recommended that all COPD patients be investigated for ASCVD and ASCVD risk factors.
I
C
In patients with CVD, obesity, and hypertension, regular screening for non-restorative sleep is indicated (e.g. by the question:
‘how often have you been bothered by trouble falling or staying asleep, or sleeping too much?’).
I
C
If there are signiﬁcant sleep problems, which are not responding within 4 weeks to sleep hygiene, referral to a specialist is recommended.
I
C
It is recommended that mental disorders with either signiﬁcant functional impairment or decreased use of healthcare systems be considered as inﬂuencing total CVD risk.
I
C
It is recommended for adults of all ages to strive for at least 150300 min a week of moderate-intensity or 75150 min a week of vigorous-intensity aerobic PA, or an equivalent combination thereof, to reduce all-cause mortality, CV mortality, and morbidity.
I
A
It is recommended that adults who cannot perform 150 min of moderate-intensity PA a week should stay as active as their abilities and health condition allow.
I
B
It is recommended to reduce sedentary time to engage in at least light activity throughout the day to reduce all-cause and CV
mortality and morbidity.
I
B
Performing resistance exercise, in addition to aerobic activity, is recommended on 2 or more days per week to reduce all-cause mortality.
I
B
Recommendations for nutrition and alcohol
A healthy diet is recommended as a cornerstone of CVD prevention in all individuals.
I
A
It is recommended to adopt a Mediterranean or similar diet to lower risk of CVD.
I
A
It is recommended to replace saturated with unsaturated fats to lower the risk of CVD.
I
A
It is recommended to reduce salt intake to lower BP and risk of CVD.
I
A
It is recommended to choose a more plant-based food pattern, rich in ﬁbre, that includes whole grains, fruits, vegetables, pulses,
and nuts.
I
B
It is recommended to restrict alcohol consumption to a maximum of 100 g per week.
I
B
It is recommended to eat ﬁsh, preferably fatty, at least once a week and restrict (processed) meat.
I
B
It is recommended to restrict free sugar consumption, in particular sugar-sweetened beverages, to a maximum of 10% of energy intake.
I
B
Recommendations for body weight
It is recommended that overweight and obese people aim for a reduction in weight to reduce BP, dyslipidaemia, and risk of type 2
DM, and thus improve their CVD risk proﬁle.
I
A
While a range of diets are effective for weight loss, it is recommended that a healthy diet in regard to CVD risk is maintained over time.
I
A
Recommendations for mental healthcare and psychosocial interventions at the individual level
Patients with mental disorders need intensiﬁed attention and support to improve adherence to lifestyle changes and drug treatment.
I
C
In ASCVD patients with mental disorders, evidence-based mental healthcare and interdisciplinary cooperation are recommended.
I
B
In patients with HF and major depression, SSRIs, SNRIs, and tricyclic antidepressants are not recommended.
III
B
Recommendations for smoking intervention strategies
All smoking of tobacco should be stopped, as tobacco use is strongly and independently causal of ASCVD.
I
A
Smoking cessation is recommended regardless of weight gain, as weight gain does not lessen the ASCVD beneﬁts of cessation.
I
B
Recommendations on low-density lipoprotein cholesterol goals
A stepwise treatment-intensiﬁcation approach is recommended for apparently healthy people at high or very high CVD risk, as well as patients with established ASCVD and/or DM with consideration of CVD risk, treatment beneﬁt, risk modiﬁers, comorbidities, and patient preferences.
I
C
Continued


<!-- PAGE 81 -->

### Page 81

Recommendations for pharmacological low-density lipoprotein cholesterol lowering for those <70 years of age
It is recommended that a high-intensity statin is prescribed up to the highest tolerated dose to reach the LDL-C goals set for the speciﬁc risk group.
I
A
In patients with established ASCVD, lipid-lowering treatment with an ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) and a
>_50% reduction in LDL-C vs. baseline is recommended.
I
A
If the goals are not achieved with the maximum tolerated dose of a statin, combination with ezetimibe is recommended.
I
B
For secondary prevention patients not achieving their goals on a maximum tolerated dose of a statin and ezetimibe, combination therapy including a PCSK9 inhibitor is recommended.
I
A
For very-high-risk FH patients (that is, with ASCVD or with another major risk factor) who do not achieve their goals on a maximum tolerated dose of a statin and ezetimibe, combination therapy including a PCSK9 inhibitor is recommended.
I
C
Statin therapy is not recommended in premenopausal female patients who are considering pregnancy or are not using adequate contraception.
III
C
Recommendation for drug treatments of patients with hypertriglyceridaemia
Statin treatment is recommended as the ﬁrst drug of choice for reducing CVD risk in high-risk individuals with hypertriglyceridaemia [triglycerides >2.3 mmol/L (200 mg/dL)].
I
A
Recommendations for the treatment of dyslipidaemias in older people (70 years)
Treatment with statins is recommended for older people with ASCVD in the same way as for younger patients.
I
A
It is recommended that the statin is started at a low dose if there is signiﬁcant renal impairment and/or the potential for drug interactions.
I
C
Recommendation for the treatment of dyslipidaemias in diabetes mellitus
In patients with type 2 DM at very high risk (e.g. with established ASCVD and/or severe TOD) intensive lipid-lowering therapy,
ultimately aiming at >_50% LDL-C reduction and an LDL-C of <1.4 mmol/L (55 mg/dL) is recommended.
I
A
In patients with type 2 DM >40 years at high risk, lipid-lowering treatment with an ultimate LDL-C goal of >_50% LDL-C reduction and an LDL-C of <1.8 mmol/L (70 mg/dL) is recommended.
I
A
Recommendations for lipid management in patients with moderate-to-severe chronic kidney disease (Kidney Disease Outcomes
Quality Initiative stages 35)
The use of statins or statin/ezetimibe combination is recommended in patients with non-dialysis-dependent, stage 35 CKD.
I
A
In patients with dialysis-dependent CKD who are free of ASCVD, commencing statin therapy is not recommended.
III
A
Recommendations for the clinical management of hypertension
Classiﬁcation of BP
It is recommended that BP should be classiﬁed as optimal, normal, high-normal, or grades 13 hypertension, according to ofﬁce
BP.
I
C
Diagnosis of hypertension
It is recommended to base the diagnosis of hypertension on:
• Repeated ofﬁce BP measurements, on more than one visit, except when hypertension is severe (e.g. grade 3 and especially in high-risk patients) or
I
C
• Out-of-ofﬁce BP measurement with ABPM and/or HBPM when feasible.
I
C
Assessment of HMOD
To evaluate for the presence of HMOD, measurement of serum creatinine, eGFR, electrolytes, and ACR is recommended for all patients. A 12-lead ECG is recommended for all patients, and echocardiography is recommended for those with ECG abnormalities or signs/symptoms of LV dysfunction. Fundoscopy or retinal imaging is recommended for patients with grades 2 or 3 hypertension and all hypertensive patients with DM.
I
B
Thresholds for initiation of drug treatment of hypertension
For grade 1 hypertension, treatment initiation based on absolute CVD risk, estimated lifetime beneﬁt, and the presence of
HMOD is recommended.
I
C
For patients with grade 2 hypertension or higher, drug treatment is recommended.
I
A
Ofﬁce BP treatment targets
It is recommended that the ﬁrst objective of treatment is to lower BP to <140/90 mmHg in all patients, and that subsequent BP
targets are tailored to age and speciﬁc comorbidities.
I
A
Continued
ESC Guidelines
3307


<!-- PAGE 82 -->

### Page 82

In treated patients aged 1869 years, it is recommended that SBP should ultimately be lowered to a target range of 120130
mmHg in most patients.
I
A
In treated patients aged >_70 years, it is recommended that SBP should generally be targeted to <140 and down to 130 mmHg if tolerated.
I
A
In all treated patients, DBP is recommended to be lowered to <80 mmHg.
I
A
Treatment of hypertension: lifestyle interventions
Lifestyle interventions are recommended for people with high-normal BP or higher.
I
A
Treatment of hypertension: drug treatment
It is recommended to initiate antihypertensive treatment with a two-drug combination in most patients, preferably as a single-pill combination. Exceptions are frail older patients and those with low-risk, grade 1 hypertension (particularly if SBP <150 mmHg).
I
B
It is recommended that the preferred combinations include a RAS blocker (i.e. an ACE inhibitor or ARB) with a CCB or diuretic,
but other combinations of the ﬁve major classes can be used (ACE inhibitor, ARB, beta-blocker, CCB, thiazide/thiazide-like diuretic).
I
A
It is recommended, if BP remains uncontrolled with a two-drug combination, that treatment be increased to a three-drug combination, usually a RAS blocker with a CCB and a diuretic, preferably as a single-pill combination.
I
A
It is recommended, if BP is not controlled by a three-drug combination, that treatment should be increased by the addition of spironolactone, or if not tolerated, other diuretics such as amiloride or higher doses of other diuretics, an alpha-blocker or betablocker, or clonidine.
I
B
The combination of two RAS blockers is not recommended.
III
A
Recommendations for the treatment of patients with diabetes mellitus
Lifestyle
Lifestyle changes including smoking cessation, a low saturated fat, high-ﬁbre diet, aerobic PA, and strength training are recommended.
I
A
Reduction in energy intake is recommended to patients, to help achieve lower body weight or prevent or slow weight gain.
I
A
Glycaemia target
A target HbA1c for the reduction of CVD risk and microvascular complications of DM of <7.0% (53 mmol/mol) is recommended for the majority of adults with either type 1 or type 2 DM.
I
A
Treatment of hyperglycaemia and ASCVD/cardiorenal risks
Metformin is recommended as ﬁrst-line therapy, following evaluation of renal function, in the majority of patients without previous ASCVD, CKD, or HF.
I
B
In persons with type 2 DM and ASCVD, the use of a GLP-1RA or SGLT2 inhibitor with proven outcome beneﬁts is recommended to reduce CV and/or cardiorenal outcomes.
I
A
In patients with type 2 DM and CKD, the use of an SGLT2 inhibitor is recommended to improve CVD and/or cardiorenal outcomes.
I
A
In patients with type 2 DM and HFrEF, use of an SGLT2 inhibitor with proven outcome beneﬁts is recommended to lessen HF
hospitalizations and CV death.
I
A
Recommendations for antithrombotic therapy
Aspirin 75100 mg daily is recommended for secondary prevention of CVD.
I
A
Clopidogrel 75 mg daily is recommended as an alternative to aspirin in secondary prevention in case of aspirin intolerance.
I
B
Concomitant use of a proton pump inhibitor is recommended in patients receiving antiplatelet therapy who are at high risk of gastrointestinal bleeding.
I
B
Antiplatelet therapy is not recommended in individuals with low/moderate CV risk due to the increased risk of major bleeding.
III
A
Recommendations for cardiac rehabilitation
Participation in a medically supervised, structured, comprehensive, multidisciplinary EBCR and prevention programme for patients after ASCVD events and/ or revascularization, and for patients with HF (mainly HFrEF), is recommended to improve patient outcomes.
I
A
Recommendation for policy interventions at the population level
Putting in place measures to reduce air pollution, including reducing PM emission and gaseous pollutants, reducing the use of fossil fuels, and limiting carbon dioxide emissions, are recommended, to reduce CVD mortality and morbidity.
I
C
Continued


<!-- PAGE 83 -->

### Page 83

Recommendations for patients with coronary artery disease
Aspirin 75100 mg daily is recommended for patients with a previous myocardial infarction or revascularization.
I
A
In ACS, DAPT with a P2Y12 inhibitor in addition to aspirin is recommended for 12 months, unless there are contraindications such as excessive risk of bleeding.
I
A
In patients with CCS, clopidogrel 75 mg daily is recommended, in addition to aspirin, for 6 months following coronary stenting,
irrespective of stent type, unless a shorter duration (13 months) is indicated due to risk or the occurrence of life-threatening bleeding.
I
A
ACE inhibitors (or ARB) are recommended if a patient has other conditions (e.g. HF, hypertension, or DM).
I
A
Beta-blockers are recommended in patients with LV dysfunction or systolic HF.
I
A
In patients with established ASCVD, oral lipid-lowering treatment with an ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) and a
>_50% reduction in LDL-C vs. baseline is recommended.
I
A
Recommendations regarding pharmacological and nonpharmacological interventions for patients with symptomatic (New York Heart
Association class II-IV) heart failure with reduced ejection fraction (left ventricular ejection fraction <40%) with proven beneﬁts on clinical outcomes, including cardiovascular morbidity and mortality
It is recommended that patients with HF are enrolled in a comprehensive CR programme to reduce the risk of HF hospitalization and death.
I
A
EBCR is recommended in stable symptomatic patients with HFrEF to reduce the risk of HF hospitalization.
I
A
It is recommended to screen patients with HF for both CV and non-CV comorbidities, which, if present, should be treated, provided safe and effective interventions exist, not only to alleviate symptoms but also to improve prognosis.
I
A
An ACE inhibitor is recommended, in addition to a beta-blocker and an MRA, for patients with symptomatic HFrEF to reduce the risk of HF hospitalization and death.
I
A
A beta-blocker is recommended, in addition to an ACE inhibitor (or an ARNI) and an MRA, for patients with stable, symptomatic
HFrEF to reduce the risk of HF hospitalization and death.
I
A
An MRA is recommended for patients with HFrEF already treated with an ACE inhibitor (or an ARNI) and a beta-blocker, to reduce the risk of HF hospitalization and death.
I
A
Sacubitril/valsartan is recommended as a replacement for an ACE inhibitor to reduce the risk of HF hospitalization and death in patients with HFrEF.
I
B
An ARB is recommended to reduce the risk of HF hospitalization or CV death in symptomatic patients with HFrEF who are unable to tolerate an ACE inhibitor and/or ARNI (patients should also receive a beta-blocker and an MRA).
I
B
Dapagliﬂozin or empagliﬂozin are recommended, in addition to optimal treatment of an ACE inhibitor (or ARNI), a beta-blocker,
and an MRA, for patients with HFrEF to reduce the risk of HF hospitalization and death.
I
A
Diuretics are recommended in patients with HFrEF with signs and/or symptoms of congestion to reduce the risk of HF
hospitalization.
I
C
Recommendations for patients with cerebrovascular disease
In patients with a cerebrovascular event, improvement of lifestyle factors in addition to appropriate pharmacological management is recommended.
I
A
In patients with ischaemic stroke or TIA, prevention with antithrombotics is recommended; choice of antithrombotic depends on the mechanism of event. Use of an antiplatelet is recommended for patients with non-cardioembolic ischaemic stroke or TIA,
and use of an anticoagulant is recommended in patients with cardioembolic ischaemic stroke or TIA.
I
A
In patients with non-cardioembolic ischaemic stroke or TIA, prevention with aspirin only, or dipyridamole plus aspirin, or clopidogrel alone is recommended.
I
A
In patients with stroke or TIA who have BP of 140/90 mmHg or higher, BP lowering is recommended.
I
A
Recommendations for patients with lower extremity artery disease: best medical therapy
Smoking cessation is recommended in all patients with LEAD.
I
B
Healthy diet and PA are recommended for all patients with LEAD.
I
C
In patients with intermittent claudication:
• Supervised exercise training is recommended
I
A
• Non-supervised exercise training is recommended when supervised exercise training is not feasible or available.
I
C
Antiplatelet therapy is recommended in patients with symptomatic LEAD.
I
C
In patients with LEAD and hypertension, it is recommended to control BP at <140/90 mmHg.
I
A
In patients with LEAD and DM, strict glycaemic control is recommended.
I
A
Continued
ESC Guidelines
3309


<!-- PAGE 84 -->

### Page 84

.................................................................................................
10. Quality indicators
Quality indicators (QIs) are tools that may be used to evaluate care quality, including that of processes of care and clinical outcomes.730
They may also serve as a mechanism for enhancing adherence to guideline recommendations, through quality assurance endeavours and benchmarking of care providers.831 As such, the role of QIs in driving quality improvement is increasingly recognized and attracts interest from healthcare authorities, professional organizations,
payers, and the public.832
The ESC recognizes the need for measuring and reporting the quality and outcomes of CV care. One aspect of this is the development and implementation of QIs for CVD. The methodology by which the ESC QIs are developed has been published832 and, to date,
a suite of QIs for an initial tranche of CV conditions has been produced.833,834 To facilitate quality improvement initiatives, the diseasespecific ESC QIs are included in corresponding ESC Clinical Practice
Guidelines.215,680 This is further enhanced by way of their integration into the EORP (EURObservational Research Programme) and the
EuroHeart (European Unified Registries On Heart Care Evaluation and Randomized Trials) project.835
For CVD prevention, QIs are available for specific conditions, such as the management of high BP836 and secondary lipid prevention.837
However, a comprehensive set of QIs that encompasses the depth and breadth of CVD prevention is lacking. Such a set may evaluate the adoption of, and adherence to, the guideline recommendations provided in this document, and may be applied retrospectively to assess the delivery of evidence-based care. Thus, and in line with other ESC Clinical Practice Guidelines, the process of developing and defining QIs for CVD prevention has been initiated during the writing of this guideline and the results will be published in a separate document.
11 Supplementary data
Supplementary data with additional Supplementary Figures, Tables,
and text complementing the full text are available on the European
Heart Journal website and via the ESC website at https://www.escar dio.org/guidelines.
12. Author information
Author/Task Force Member Affiliations: Yvo M. Smulders,
Internal
Medicine,
Amsterdam
University
Medical
Center,
Amsterdam, Netherlands; David Carballo, Cardiology, Geneva
University Hospitals, Geneva,
Switzerland;
Konstantinos
C.
Koskinas, Cardiology, Bern University Hospital  INSELSPITAL,
Bern, Switzerland; Maria B€ack, Unit of Physiotherapy, Department of Health, Medicine and Caring Sciences, Linko¨ping University,
Linko¨ping, Sweden, and Department of Molecular and Clinical
Medicine, Institute of Medicine, Sahlgrenska Academy, University of
Gothenburg, and Sahlgrenska University Hospital, Gothenburg,
Sweden; Athanase Benetos, Geriatric Department CHRU de
Nancy and ISERM DCAC, Universite´ de Lorraine, Nancy, France;
Alessandro Biffi, Cardiology, FIMS and EFSMA, Rome, Italy; Jose´-
Manuel Boavida, APDP  Diabetes Portugal, IDF-E International
Diabetes
Federation

Europe,
Lisbon,
Portugal;
Davide
Capodanno, Cardiothoracic, Vascular and Transplants, Policlinico
“G. Rodolico-San Marco”, University of Catania, Catania, Italy;
Bernard Cosyns, Cardiology, Centrum voor Hart en vaatziekte
(CHVZ) Universitair Ziekenhuis Brussel, Brussels, Belgium; Carolyn
A. Crawford, (Northern Ireland), ESC Patient Forum, Sophia
Antipolis,
France;
Constantinos
H.
Davos,
Cardiovascular
Research Laboratory, Biomedical Research Foundation, Academy of
Recommendations in patients with chronic kidney disease: best medical therapy
Treatment with an ACE inhibitor or an ARB is recommended in patients with DM, hypertension, and albuminuria. These medications should be titrated to the highest approved dose that is tolerated.
I
B
Combination treatment with ACE inhibitors and ARBs is not recommended.
III
C
Recommendations for lifestyle interventions and management of risk factors and concomitant diseases in patients with atrial
ﬁbrillation
Identiﬁcation and management of risk factors and concomitant diseases are recommended to be considered an integral part of treatment.
I
B
Modiﬁcation of unhealthy lifestyle and targeted therapy of intercurrent conditions is recommended to reduce AF burden and symptom severity.
I
B
Attention to good BP control is recommended in AF patients with hypertension to reduce AF recurrences and risk of stroke and bleeding.
I
B
ABPM = ambulatory blood pressure monitoring; ACE = angiotensin-converting enzyme; ACR = albumin-to-creatinine ratio; ACS = acute coronary syndromes; AF = atrial ﬁbrillation; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor neprilysin inhibitor; ASCVD = atherosclerotic cardiovascular disease; BP = blood pressure; CAC =
coronary artery calcium; CCB = calcium channel blocker; CCS = chronic coronary syndromes; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease;
CR = cardiac rehabilitation; CV = cardiovascular; CVD = cardiovascular disease; DAPT = dual antiplatelet therapy; DBP = diastolic blood pressure; DM = diabetes mellitus;
EBCR = exercise-based cardiac rehabilitation; ECG = electrocardiogram; eGRF = estimated glomerular ﬁltration rate; FH = familial hypercholesterolaemia; GLP-1RA = glucagon-like peptide-1 receptor agonist; HbA1c = glycated haemoglobin; HBPM = home blood pressure monitoring; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; HMOD = hypertension-mediated organ damage; LDL-C = low-density lipoprotein cholesterol; LEAD = lower extremity artery disease; LV = left ventricular; MRA =
mineralocorticoid receptor antagonist; PA = physical activity; PCSK9 = proprotein convertase subtilisin/kexin type 9; PM = particulate matter; RAS = renin-angiotensin system;
SBP = systolic blood pressure; SCORE2 = Systematic Coronary Risk Estimation 2; SCORE2-OP = Systematic Coronary Risk Estimation 2-Older Persons; SGLT2 = sodium-glucose cotransporter 2; SNRI = serotonin-noradrenaline reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor; TIA = transient ischaemic attack; TOD = target organ damage.
ESC 2021


<!-- PAGE 85 -->

### Page 85

.............................................................................................................................................................................
Athens, Athens, Greece;
Ileana Desormais, INSERM, Univ.
Limoges, CHU Limoges, IRD, U1094 Tropical Neuroepidemiology,
GEIST,
Limoges,
France;
Emanuele
Di
Angelantonio,
Department of Public Health and Primary Care, University of
Cambridge, Cambridge, UK; Oscar H. Franco Duran, ISPM
Institute of Social and Preventive Medicine, University of Bern, Bern,
Switzerland; Sigrun Halvorsen, Department of Cardiology, Oslo
University Hospital Ullevaal, Oslo, Norway; F. D. Richard Hobbs,
NDPCHS, University of Oxford, Oxford, UK; Monika Hollander,
Julius Center for Health Sciences and Primary Care, UMC Utrecht,
Utrecht University, Utrecht, Netherlands; Ewa A. Jankowska,
Department of Heart Diseases, Wroclaw Medical University,
Wroclaw, Poland; Matthias Michal, Department of Psychosomatic
Medicine and Psychotherapy, University Medical Center Mainz,
Mainz, Germany; Simona Sacco, Department of Applied Clinical and Biotechnological Sciences, University of L’Aquila, L’Aquila, Italy;
Naveed Sattar, Institute of Cardiovascular and Medical Sciences,
University of
Glasgow,
Glasgow,
UK;
Lale
Tokgozoglu,
Cardiology,
Hacettepe
University,
Ankara,
Turkey;
Serena
Tonstad, Preventive Cardiology, Oslo University Hospital, Oslo,
Norway; Konstantinos P. Tsioufis, First Cardiology Clinic, Medical
School, National and Kapodistrian University, Hippokration Hospital,
Athens, Greece; Ineke van Dis, European Heart Network,
Brussels, Belgium; Isabelle C. van Gelder, Cardiology, University of Groningen, University Medical Center Groningen; Groningen,
Netherlands; Christoph Wanner, Department of Nephrology,
University Wu¨rzburg, Germany; Bryan Williams, Institute of
Cardiovascular Science, University College London, London, UK
13. Appendix
ESC Scientific Document Group
Includes Document Reviewers and ESC National Cardiac Societies.
Document
Reviewers:
Guy
De
Backer
(CPG
Review
Coordinator)
(Belgium),
Vera
Regitz-Zagrosek
(CPG
Review
Coordinator) (Germany), Anne Hege Aamodt (Norway), Magdy
Abdelhamid (Egypt), Victor Aboyans (France), Christian Albus
(Germany), Riccardo Asteggiano (Italy), Magnus B€ack (Sweden),
Michael A. Borger (Germany), Carlos Brotons (Spain), Jelena
Celutkien_e (Lithuania), Renata Cifkova (Czech Republic), Maja Cikes
(Croatia), Francesco Cosentino (Italy), Nikolaos Dagres (Germany),
Tine De Backer (Belgium), Dirk De Bacquer (Belgium), Victoria
Delgado (Netherlands), Hester Den Ruijter (Netherlands), Paul
Dendale (Belgium), Heinz Drexel (Austria), Volkmar Falk (Germany),
Laurent Fauchier (France), Brian A. Ference1 (United Kingdom), Jean
Ferrie`res (France), Marc Ferrini (France), Miles Fisher2 (United
Kingdom), Danilo Fliser (Germany), Zlatko Fras (Slovenia), Dan Gaita
(Romania), Simona Giampaoli (Italy), Stephan Gielen (Germany), Ian
Graham (Ireland), Catriona Jennings (Ireland), Torben Jorgensen
(Denmark), Alexandra Kautzky-Willer (Austria), Maryam Kavousi
(Netherlands), Wolfgang Koenig (Germany), Aleksandra Konradi
(Russia),
Dipak
Kotecha
(United
Kingdom),
Ulf
Landmesser
(Germany), Madalena Lettino (Italy), Basil S. Lewis (Israel), Ales
Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Konstantinos
Makrilakis (Greece), Giuseppe Mancia (Italy), Pedro Marques-Vidal
(Switzerland), John William McEvoy (Ireland), Paul McGreavy
(United Kingdom), Bela Merkely (Hungary), Lis Neubeck (United
Kingdom), Jens Cosedis Nielsen (Denmark), Joep Perk (Sweden),
Steffen E. Petersen (United Kingdom), Anna Sonia Petronio (Italy),
Massimo Piepoli (Italy), Nana Goar Pogosova (Russia), Eva Irene
Bossano Prescott (Denmark), Kausik K. Ray (United Kingdom),
Zeljko Reiner (Croatia), Dimitrios J. Richter (Greece), Lars Ryde´n
(Sweden), Evgeny Shlyakhto (Russia), Marta Sitges (Spain), Miguel
Sousa-Uva (Portugal), Isabella Sudano (Switzerland), Monica Tiberi
(Italy), Rhian M. Touyz (United Kingdom), Andrea Ungar (Italy),
W.M. Monique Verschuren (Netherlands), Olov Wiklund (Sweden),
David Wood (United Kingdom/Ireland), Jose Luis Zamorano (Spain).
ESC National Cardiac Societies actively involved in the review process of the 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice:
Algeria: Algerian Society of Cardiology, Naima Hammoudi;
Armenia: Armenian Cardiologists Association, Parounak Zelveian;
Austria: Austrian Society of Cardiology, Peter Siostrzonek;
Azerbaijan: Azerbaijan Society of Cardiology, Elman Alakbarov;
Belarus: Belorussian Scientific Society of Cardiologists, Olga
Pavlova; Belgium: Belgian Society of Cardiology, Johan De Sutter;
Bosnia and Herzegovina: Association of Cardiologists of Bosnia and Herzegovina, Mirza Dilic; Bulgaria: Bulgarian Society of
Cardiology, Nina Gotcheva; Croatia: Croatian Cardiac Society,
Bosko Skoric; Cyprus: Cyprus Society of Cardiology, Hera
Heracleous
Moustra;
Czech
Republic:
Czech
Society of
Cardiology,
Renata
Cifkova;
Denmark:
Danish
Society of
Cardiology, Ann Bovin; Egypt: Egyptian Society of Cardiology,
Bassem Zarif; Estonia: Estonian Society of Cardiology, Margus
Viigimaa; Finland: Finnish Cardiac Society, Anna-Mari Hekkala;
France: French Society of Cardiology, Serge Kownator; Georgia:
Georgian Society of Cardiology, Zurab Pagava; Germany: German
Cardiac Society, Ulf Landmesser; Greece: Hellenic Society of
Cardiology, Harry Grassos; Hungary: Hungarian Society of
Cardiology,
Eszter
Szabados;
Iceland:
Icelandic
Society of
Cardiology, Karl Andersen; Ireland: Irish Cardiac Society, John
William McEvoy; Israel: Israel Heart Society, Barak Zafrir; Italy:
Italian
Federation of
Cardiology,
Francesco
Barilla;
Kosovo
(Republic of): Kosovo Society of Cardiology, Pranvera Ibrahimi;
Kyrgyzstan: Kyrgyz Society of Cardiology, Erkin Mirrakhimov;
Latvia: Latvian Society of Cardiology, Iveta Mintale; Lebanon:
Lebanese Society of Cardiology, Samir Arnaout; Lithuania:
Lithuanian Society of Cardiology, Rimvydas Slapikas; Luxembourg:
Luxembourg Society of Cardiology, Cristiana Banu; Malta: Maltese
Cardiac Society, Mark Abela; Moldova (Republic of): Moldavian
Society of Cardiology, Victor Rudi; Montenegro: Montenegro
Society of Cardiology, Aneta Boskovic; Morocco: Moroccan Society of Cardiology, Mohamed Alami; Netherlands: Netherlands Society of Cardiology, Hareld M.C. Kemps; North Macedonia: North
Macedonian Society of Cardiology, Marijan Bosevski; Norway:
Norwegian Society of Cardiology, Erik Ekker Solberg; Poland: Polish
Cardiac Society, Tomasz Zdrojewski; Portugal: Portuguese Society of Cardiology, Carlos Rabac¸al; Romania: Romanian Society of
Cardiology, Dan Gaita; Russian Federation: Russian Society of
Cardiology, Yury
Belenkov; San Marino: San Marino Society of
ESC Guidelines
3311


<!-- PAGE 86 -->

### Page 86

.............................................................................................................................................................................
Cardiology, Luca Bertelli; Serbia: Cardiology Society of Serbia,
Vojislav Giga; Slovakia: Slovak Society of Cardiology, Daniel Pella;
Slovenia: Slovenian Society of Cardiology, Zlatko Fras; Spain:
Spanish Society of Cardiology, Regina Dalmau; Sweden: Swedish
Society of Cardiology, Anna Kiessling; Switzerland: Swiss Society of
Cardiology,
Otmar
Pfister;
Syrian
Arab
Republic:
Syrian
Cardiovascular Association, Yassin Bani Marjeh; Tunisia: Tunisian
Society of
Cardiology and
Cardio-Vascular
Surgery,
Salem
Abdessalem; Turkey: Turkish Society of Cardiology, Oner Ozdogan;
Ukraine: Ukrainian Association of Cardiology, Elena Nesukay;
United Kingdom of Great Britain and Northern Ireland:
British Cardiovascular Society, Riyaz Patel; Uzbekistan: Association of Cardiologists of Uzbekistan, Guzal Mullabayeva.
ESC Clinical Practice Guidelines Committee (CPG):
Colin Baigent (Chairperson) (United Kingdom), Magdy Abdelhamid
(Egypt),
Victor
Aboyans
(France),
Sotiris
Antoniou
(United
Kingdom), Elena Arbelo (Spain), Riccardo Asteggiano (Italy), Andreas
Baumbach (United Kingdom), Michael A. Borger (Germany), Jelena
Celutkien_e (Lithuania), Maja Cikes (Croatia), Jean-Philippe Collet
(France), Volkmar Falk (Germany), Laurent Fauchier (France), Chris
P. Gale (United Kingdom), Sigrun Halvorsen (Norway), Bernard Iung
(France), Tiny Jaarsma (Sweden), Aleksandra Konradi (Russia),
Konstantinos C. Koskinas (Switzerland), Dipak Kotecha (United
Kingdom), Ulf Landmesser (Germany), Basil S. Lewis (Israel), Ales
Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Jens Cosedis
Nielsen (Denmark), Steffen E. Petersen (United Kingdom), Eva Irene
Bossano Prescott (Denmark), Amina Rakisheva (Kazakhstan), Marta
Sitges (Spain), Rhian M. Touyz (United Kingdom)
14. References
1. Kotseva K, De Backer G, De Bacquer D, Ryden L, Hoes A, Grobbee D, Maggioni
A, Marques-Vidal P, Jennings C, Abreu A, Aguiar C, Badariene J, Bruthans J,
Cifkova R, Davletov K, Dilic M, Dolzhenko M, Gaita D, Gotcheva N, Hasan-Ali H,
Jankowski P, Lionis C, Mancas S, Milicic D, Mirrakhimov E, Oganov R, Pogosova N,
Reiner Z, Vulic D, Wood D. Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of
Cardiology EURObservational Research Programme EUROASPIRE V survey in 16
European countries. Eur J Prev Cardiol 2020:2047487320908698.
2. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT,
Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Lochen ML,
Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N,
Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binno S,
ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European
Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for
Cardiovascular
Prevention
&
Rehabilitation
(EACPR).
Eur
Heart
J
2016;37:23152381.
3. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman
MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser
U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR,
Tokgozoglu L, Wiklund O, ESC Scientific Document Group. 2019 ESC/EAS
Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111188.
4. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement
DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope
L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R,
Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V,
Desormais I, ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39:30213104.
5. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M,
Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Juni P, Lettino M,
Marx N, Mellbin LG, Ostgren CJ, Rocca B, Roffi M, Sattar N, Seferovic PM, SousaUva M, Valensi P, Wheeler DC, ESC Scientific Document Group. 2019 ESC
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020;41:255323.
6. Jorgensen T, Jacobsen RK, Toft U, Aadahl M, Glumer C, Pisinger C. Effect of screening and lifestyle counselling on incidence of ischaemic heart disease in general population: Inter99 randomised trial. BMJ 2014;348:g3617.
7. Ebrahim S, Taylor F, Ward K, Beswick A, Burke M, Davey Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane
Database Syst Rev 2011:CD001561.
8. Kennedy O, Su F, Pears R, Walmsley E, Roderick P. Evaluating the effectiveness of the NHS Health Check programme in South England: a quasi-randomised controlled trial. BMJ Open 2019;9:e029420.
9. Krogsboll LT, Jorgensen KJ, Gotzsche PC. General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database Syst Rev
2019;1:CD009009.
10. Si S, Moss JR, Sullivan TR, Newton SS, Stocks NP. Effectiveness of general practice-based health checks: a systematic review and meta-analysis. Br J Gen
Pract 2014;64:e47-53.
11. Patel R, Barnard S, Thompson K, Lagord C, Clegg E, Worrall R, Evans T, Carter
S, Flowers J, Roberts D, Nuttall M, Samani NJ, Robson J, Kearney M, Deanfield J,
Waterall J. Evaluation of the uptake and delivery of the NHS Health Check programme in England, using primary care data from 9.5 million people: a crosssectional study. BMJ Open 2020;10:e042963.
12. Mehta S, Wells S, Grey C, Riddell T, Kerr A, Marshall R, Ameratunga S, Harrison
J, Kenealy T, Bramley D, Chan WC, Thornley S, Sundborn G, Jackson R.
Initiation and maintenance of cardiovascular medications following cardiovascular risk assessment in a large primary care cohort: PREDICT CVD-16. Eur J Prev
Cardiol 2014;21:192202.
13. Chamnan P, Simmons RK, Khaw KT, Wareham NJ, Griffin SJ. Estimating the population impact of screening strategies for identifying and treating people at high risk of cardiovascular disease: modelling study. BMJ 2010;340:c1693.
14. Lindholt JS, Sogaard R. Population screening and intervention for vascular disease in
Danish men
(VIVA):
a randomised controlled trial.
Lancet
2017;390:22562265.
15. Christensen B, Engberg M, Lauritzen T. No long-term psychological reaction to information about increased risk of coronary heart disease in general practice.
Eur J Cardiovasc Prev Rehabil 2004;11:239243.
16. Nielsen AD, Videbech P, Gerke O, Petersen H, Jensen JM, Sand NP, Egstrup K,
Larsen ML, Mickley H, Diederichsen AC. Population screening for coronary artery calcification does not increase mental distress and the use of psychoactive medication. J Thorac Imaging 2012;27:202206.
17. Lokkegaard T, Andersen JS, Jacobsen RK, Badsberg JH, Jorgensen T, Pisinger C.
Psychological consequences of screening for cardiovascular risk factors in an unselected general population: results from the Inter99 randomised intervention study. Scand J Public Health 2015;43:102110.
18. Jorgensen T, Ladelund S, Borch-Johnsen K, Pisinger C, Schrader AM, Thomsen T,
Glumer C, Ibsen H, Mortensen EL. Screening for risk of cardiovascular disease is not associated with mental distress: the Inter99 study. Prev Med 2009;48:242246.
19. Piper MA, Evans CV, Burda BU, Margolis KL, O’Connor E, Smith N, Webber E,
Perdue LA, Bigler KD, Whitlock EP. Screening for High Blood Pressure in Adults: A
Systematic Evidence Review for the U.S. Preventive Services Task Force. Rockville
(MD); 2014.
20. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele
RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Boren J, Fazio S, Horton JD,
Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR,
Tokgozoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ,
Catapano AL. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur
Heart J 2017;38:24592472.
21. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L,
Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J,
Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet
2010;376:16701681.
22. Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova B, Emberson J,
Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent
C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581590.
23. Pencina KM, Thanassoulis G, Wilkins JT, Vasan RS, Navar AM, Peterson ED,
Pencina MJ, Sniderman AD. Trajectories of Non-HDL Cholesterol Across


<!-- PAGE 87 -->

### Page 87

.............................................................................................................................................................................
Midlife:
Implications for
Cardiovascular
Prevention.
J
Am
Coll
Cardiol
2019;74:7079.
24. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P,
Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ,
Collins R, Thompson SG, Danesh J. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:19932000.
25. Holmes MV, Asselbergs FW, Palmer TM, Drenos F, Lanktree MB, Nelson CP,
Dale CE, Padmanabhan S, Finan C, Swerdlow DI, Tragante V, van Iperen EP,
Sivapalaratnam S, Shah S, Elbers CC, Shah T, Engmann J, Giambartolomei C,
White J, Zabaneh D, Sofat R, McLachlan S, UCLEB consortium, Doevendans PA,
Balmforth AJ, Hall AS, North KE, Almoguera B, Hoogeveen RC, Cushman M,
Fornage M, Patel SR, Redline S, Siscovick DS, Tsai MY, Karczewski KJ, Hofker
MH, Verschuren WM, Bots ML, van der Schouw YT, Melander O, Dominiczak
AF, Morris R, Ben-Shlomo Y, Price J, Kumari M, Baumert J, Peters A, Thorand B,
Koenig W, Gaunt TR, Humphries SE, Clarke R, Watkins H, Farrall M, Wilson JG,
Rich SS, de Bakker PI, Lange LA, Davey Smith G, Reiner AP, Talmud PJ, Kivimaki
M, Lawlor DA, Dudbridge F, Samani NJ, Keating BJ, Hingorani AD, Casas JP.
Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J
2015;36:539550.
26. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen
MK, Hindy G, Holm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R,
Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K,
Pirruccello JP, Saleheen D, Chen L, Stewart A, Schillert A, Thorsteinsdottir U,
Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, Stoll M, Berger K,
Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J,
Burnett MS, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki ML,
Perola M, Havulinna A, de Faire U, Gigante B, Ingelsson E, Zeller T, Wild P, de
Bakker PI, Klungel OH, Maitland-van der Zee AH, Peters BJ, de Boer A, Grobbee
DE, Kamphuisen PW, Deneer VH, Elbers CC, Onland-Moret NC, Hofker MH,
Wijmenga C, Verschuren WM, Boer JM, van der Schouw YT, Rasheed A,
Frossard P, Demissie S, Willer C, Do R, Ordovas JM, Abecasis GR, Boehnke M,
Mohlke KL, Daly MJ, Guiducci C, Burtt NP, Surti A, Gonzalez E, Purcell S,
Gabriel S, Marrugat J, Peden J, Erdmann J, Diemert P, Willenborg C, Konig IR,
Fischer M, Hengstenberg C, Ziegler A, Buysschaert I, Lambrechts D, Van de
Werf F, Fox KA, El Mokhtari NE, Rubin D, Schrezenmeir J, Schreiber S, Schafer
A, Danesh J, Blankenberg S, Roberts R, McPherson R, Watkins H, Hall AS,
Overvad K, Rimm E, Boerwinkle E, Tybjaerg-Hansen A, Cupples LA, Reilly MP,
Melander O, Mannucci PM, Ardissino D, Siscovick D, Elosua R, Stefansson K,
O’Donnell CJ, Salomaa V, Rader DJ, Peltonen L, Schwartz SM, Altshuler D,
Kathiresan S. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012;380:572580.
27. Frikke-Schmidt R, Nordestgaard BG, Stene MC, Sethi AA, Remaley AT, Schnohr
P, Grande P, Tybjaerg-Hansen A. Association of loss-of-function mutations in the
ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 2008;299:25242532.
28. HPS3/TIMI55REVEAL Collaborative Group, Bowman L, Hopewell JC, Chen F,
Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E,
Sammons E, Landray MJ. Effects of Anacetrapib in Patients with Atherosclerotic
Vascular Disease. N Engl J Med 2017;377:12171227.
29. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M,
Anderson HR, Andrews KG, Aryee M, Atkinson C, Bacchus LJ, Bahalim AN,
Balakrishnan K, Balmes J, Barker-Collo S, Baxter A, Bell ML, Blore JD, Blyth F,
Bonner C, Borges G, Bourne R, Boussinesq M, Brauer M, Brooks P, Bruce NG,
Brunekreef B, Bryan-Hancock C, Bucello C, Buchbinder R, Bull F, Burnett RT,
Byers TE, Calabria B, Carapetis J, Carnahan E, Chafe Z, Charlson F, Chen H,
Chen JS, Cheng AT, Child JC, Cohen A, Colson KE, Cowie BC, Darby S, Darling
S, Davis A, Degenhardt L, Dentener F, Des Jarlais DC, Devries K, Dherani M,
Ding EL, Dorsey ER, Driscoll T, Edmond K, Ali SE, Engell RE, Erwin PJ, Fahimi S,
Falder G, Farzadfar F, Ferrari A, Finucane MM, Flaxman S, Fowkes FG, Freedman
G, Freeman MK, Gakidou E, Ghosh S, Giovannucci E, Gmel G, Graham K,
Grainger R, Grant B, Gunnell D, Gutierrez HR, Hall W, Hoek HW, Hogan A,
Hosgood HD, 3rd, Hoy D, Hu H, Hubbell BJ, Hutchings SJ, Ibeanusi SE, Jacklyn
GL, Jasrasaria R, Jonas JB, Kan H, Kanis JA, Kassebaum N, Kawakami N, Khang
YH, Khatibzadeh S, Khoo JP, Kok C, Laden F, Lalloo R, Lan Q, Lathlean T,
Leasher JL, Leigh J, Li Y, Lin JK, Lipshultz SE, London S, Lozano R, Lu Y, Mak J,
Malekzadeh R, Mallinger L, Marcenes W, March L, Marks R, Martin R, McGale P,
McGrath J, Mehta S, Mensah GA, Merriman TR, Micha R, Michaud C, Mishra V,
Mohd Hanafiah K, Mokdad AA, Morawska L, Mozaffarian D, Murphy T, Naghavi
M, Neal B, Nelson PK, Nolla JM, Norman R, Olives C, Omer SB, Orchard J,
Osborne R, Ostro B, Page A, Pandey KD, Parry CD, Passmore E, Patra J, Pearce
N, Pelizzari PM, Petzold M, Phillips MR, Pope D, Pope CA, 3rd, Powles J, Rao M,
Razavi H, Rehfuess EA, Rehm JT, Ritz B, Rivara FP, Roberts T, Robinson C,
Rodriguez-Portales JA, Romieu I, Room R, Rosenfeld LC, Roy A, Rushton L,
Salomon JA, Sampson U, Sanchez-Riera L, Sanman E, Sapkota A, Seedat S, Shi P,
Shield K, Shivakoti R, Singh GM, Sleet DA, Smith E, Smith KR, Stapelberg NJ,
Steenland K, Stockl H, Stovner LJ, Straif K, Straney L, Thurston GD, Tran JH, Van
Dingenen R, van Donkelaar A, Veerman JL, Vijayakumar L, Weintraub R,
Weissman MM, White RA, Whiteford H, Wiersma ST, Wilkinson JD, Williams
HC, Williams W, Wilson N, Woolf AD, Yip P, Zielinski JM, Lopez AD, Murray
CJ, Ezzati M, AlMazroa MA, Memish ZA. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in
21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease
Study 2010. Lancet 2012;380:22242260.
30. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies
Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:19031913.
31. Whelton SP, McEvoy JW, Shaw L, Psaty BM, Lima JAC, Budoff M, Nasir K, Szklo
M, Blumenthal RS, Blaha MJ. Association of Normal Systolic Blood Pressure
Level With Cardiovascular Disease in the Absence of Risk Factors. JAMA Cardiol
2020;5:10111018.
32. Wills AK, Lawlor DA, Matthews FE, Sayer AA, Bakra E, Ben-Shlomo Y, Benzeval
M, Brunner E, Cooper R, Kivimaki M, Kuh D, Muniz-Terrera G, Hardy R. Life course trajectories of systolic blood pressure using longitudinal data from eight
UK cohorts. PLoS Med 2011;8:e1000440.
33. Ji H, Niiranen TJ, Rader F, Henglin M, Kim A, Ebinger JE, Claggett B, Merz CNB,
Cheng S. Sex Differences in Blood Pressure Associations With Cardiovascular
Outcomes. Circulation 2021;143:761763.
34. Ji H, Kim A, Ebinger JE, Niiranen TJ, Claggett BL, Bairey Merz CN, Cheng S. Sex
Differences in Blood Pressure Trajectories Over the Life Course. JAMA Cardiol
2020;5:1926.
35. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50
years’ observations on male British doctors. BMJ 2004;328:1519.
36. Prescott E, Hippe M, Schnohr P, Hein HO, Vestbo J. Smoking and risk of myocardial infarction in women and men:
longitudinal population study.
BMJ
1998;316:10431047.
37. Huxley RR, Woodward M. Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Lancet 2011;378:12971305.
38. GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:19231994.
39. Lv X, Sun J, Bi Y, Xu M, Lu J, Zhao L, Xu Y. Risk of all-cause mortality and cardiovascular disease associated with secondhand smoke exposure: a systematic review and meta-analysis. Int J Cardiol 2015;199:106115.
40. Gupta R, Gupta S, Sharma S, Sinha DN, Mehrotra R. Risk of Coronary Heart
Disease Among Smokeless Tobacco Users: Results of Systematic Review and
Meta-Analysis of Global Data. Nicotine Tob Res 2019;21:2531.
41. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R,
Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M,
Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray
KK, Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet
2010;375:22152222.
42. Peters SA, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64
cohorts,
including
775,385
individuals and
12,539
strokes.
Lancet
2014;383:19731980.
43. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet 2017;390:26272642.
44. Sun YQ, Burgess S, Staley JR, Wood AM, Bell S, Kaptoge SK, Guo Q, Bolton TR,
Mason AM, Butterworth AS, Di Angelantonio E, Vie GA, Bjorngaard JH, Kinge
JM, Chen Y, Mai XM. Body mass index and all cause mortality in HUNT and UK
Biobank studies: linear and non-linear mendelian randomisation analyses. BMJ
2019;364:l1042.
45. Global BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju Sh N,
Wormser D, Gao P, Kaptoge S, Berrington de Gonzalez A, Cairns BJ, Huxley R,
Jackson Ch L, Joshy G, Lewington S, Manson JE, Murphy N, Patel AV, Samet JM,
Woodward M, Zheng W, Zhou M, Bansal N, Barricarte A, Carter B, Cerhan JR,
Smith GD, Fang X, Franco OH, Green J, Halsey J, Hildebrand JS, Jung KJ, Korda
RJ, McLerran DF, Moore SC, O’Keeffe LM, Paige E, Ramond A, Reeves GK,
Rolland B, Sacerdote C, Sattar N, Sofianopoulou E, Stevens J, Thun M, Ueshima
H, Yang L, Yun YD, Willeit P, Banks E, Beral V, Chen Z, Gapstur SM, Gunter MJ,
Hartge P, Jee SH, Lam TH, Peto R, Potter JD, Willett WC, Thompson SG,
Danesh J, Hu FB. Body-mass index and all-cause mortality: individual-participantdata meta-analysis of 239 prospective studies in four continents. Lancet
2016;388:776786.
46. Aune D, Sen A, Prasad M, Norat T, Janszky I, Tonstad S, Romundstad P, Vatten
LJ. BMI and all cause mortality: systematic review and non-linear dose-response
ESC Guidelines
3313


<!-- PAGE 88 -->

### Page 88

.............................................................................................................................................................................
meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants. BMJ 2016;353:i2156.
47. Emerging Risk Factors Collaboration, Wormser D, Kaptoge S, Di Angelantonio
E, Wood AM, Pennells L, Thompson A, Sarwar N, Kizer JR, Lawlor DA,
Nordestgaard BG, Ridker P, Salomaa V, Stevens J, Woodward M, Sattar N,
Collins R, Thompson SG, Whitlock G, Danesh J. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease:
collaborative analysis of 58 prospective studies. Lancet 2011;377:10851095.
48. World Health Organization. Gender and health. https://www.who.int/healthtopics/gender#tab=tab_1 (4 June 2021).
49. Global Health 50/50. Gender and global health. https://globalhealth5050.org/gen der-and-global-health (4 June 2021).
50. Mauvais-Jarvis F, Bairey Merz N, Barnes PJ, Brinton RD, Carrero JJ, DeMeo DL,
De Vries GJ, Epperson CN, Govindan R, Klein SL, Lonardo A, Maki PM,
McCullough LD, Regitz-Zagrosek V, Regensteiner JG, Rubin JB, Sandberg K,
Suzuki A. Sex and gender: modifiers of health, disease, and medicine. Lancet
2020;396:565582.
51. Peters SAE, Muntner P, Woodward M. Sex Differences in the Prevalence of, and
Trends in, Cardiovascular Risk Factors, Treatment, and Control in the United
States, 2001 to 2016. Circulation 2019;139:10251035.
52. Lee CMY, Mnatzaganian G, Woodward M, Chow CK, Sitas F, Robinson S,
Huxley RR. Sex disparities in the management of coronary heart disease in general practices in Australia. Heart 2019;105:18981904.
53. Cushman M, Shay CM, Howard VJ, Jimenez MC, Lewey J, McSweeney JC, Newby
LK, Poudel R, Reynolds HR, Rexrode KM, Sims M, Mosca LJ, American Heart
Association. Ten-Year Differences in Women’s Awareness Related to Coronary
Heart Disease: Results of the 2019 American Heart Association National Survey:
A
Special
Report
From the
American
Heart
Association.
Circulation
2021;143:e239e248.
54. Pelletier R, Khan NA, Cox J, Daskalopoulou SS, Eisenberg MJ, Bacon SL, Lavoie
KL, Daskupta K, Rabi D, Humphries KH, Norris CM, Thanassoulis G, Behlouli H,
Pilote
L,
GENESIS-PRAXY
Investigators.
Sex
Versus
Gender-Related
Characteristics: Which Predicts Outcome After Acute Coronary Syndrome in the Young? J Am Coll Cardiol 2016;67:127135.
55. Bots SH, Groepenhoff F, Eikendal ALM, Tannenbaum C, Rochon PA, RegitzZagrosek V, Miller VM, Day D, Asselbergs FW, den Ruijter HM. Adverse Drug
Reactions to Guideline-Recommended Heart Failure Drugs in Women: A
Systematic Review of the Literature. JACC Heart Fail 2019;7:258266.
56. Regitz-Zagrosek V, Seeland U. Sex and gender differences in clinical medicine.
Handb Exp Pharmacol 2012:322.
57. Wehner GJ, Jing L, Haggerty CM, Suever JD, Leader JB, Hartzel DN, Kirchner
HL, Manus JNA, James N, Ayar Z, Gladding P, Good CW, Cleland JGF, Fornwalt
BK. Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie? Eur Heart J 2020;41:12491257.
58. Chung AK, Das SR, Leonard D, Peshock RM, Kazi F, Abdullah SM, Canham RM,
Levine BD, Drazner MH. Women have higher left ventricular ejection fractions than men independent of differences in left ventricular volume: the Dallas Heart
Study. Circulation 2006;113:15971604.
59. Maas A, Rosano G, Cifkova R, Chieffo A, van Dijken D, Hamoda H, Kunadian V,
Laan E, Lambrinoudaki I, Maclaran K, Panay N, Stevenson JC, van Trotsenburg M,
Collins P. Cardiovascular health after menopause transition, pregnancy disorders,
and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. Eur Heart J 2021;42:967984.
60. Glasziou PP, Irwig LM. An evidence based approach to individualising treatment.
BMJ 1995;311:13561359.
61. Dorresteijn JA, Visseren FL, Ridker PM, Wassink AM, Paynter NP, Steyerberg
EW,
van der
Graaf
Y,
Cook
NR.
Estimating treatment effects for individual patients based on the results of randomised clinical trials. BMJ
2011;343:d5888.
62. Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, Lee BJ,
Perkins RM, Rossing P, Sairenchi T, Tonelli M, Vassalotti JA, Yamagishi K, Coresh
J, de Jong PE, Wen CP, Nelson RG, Chronic Kidney Disease Prognosis
Consortium. Associations of kidney disease measures with mortality and endstage renal disease in individuals with and without diabetes: a meta-analysis.
Lancet 2012;380:16621673.
63. Robbins JM, Strauss G, Aron D, Long J, Kuba J, Kaplan Y. Mortality rates and diabetic foot ulcers: is it time to communicate mortality risk to patients with diabetic foot ulceration? J Am Podiatr Med Assoc 2008;98:489493.
64. Brownrigg JR, Hughes CO, Burleigh D, Karthikesalingam A, Patterson BO, Holt
PJ, Thompson MM, de Lusignan S, Ray KK, Hinchliffe RJ. Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. Lancet Diabetes Endocrinol 2016;4:588597.
65. International Society of Nephrology. KDIGO 2020 Clinical Practice Guideline for
Diabetes Management in Chronic Kidney Disease. https://kdigo.org/wp-content/
uploads/2020/10/KDIGO-2020-Diabetes-in-CKD-GL.pdf (4 June 2021).
66. Cersosimo E, Johnson EL, Chovanes C, Skolnik N. Initiating therapy in patients newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise approach. Diabetes Obes Metab 2018;20:497507.
67. Rodbard HW, Visco VE, Andersen H, Hiort LC, Shu DH. Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial.
Lancet Diabetes Endocrinol 2014;2:3037.
68. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2
risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 2021;42:24392454.
69. Kannel WB. Coronary heart disease risk factors in the elderly. Am J Geriatr
Cardiol 2002;11:101107.
70. Wolbers M, Koller MT, Witteman JC, Steyerberg EW. Prognostic models with competing risks:
methods and application to coronary risk prediction.
Epidemiology 2009;20:555561.
71. Berry SD, Ngo L, Samelson EJ, Kiel DP. Competing risk of death: an important consideration in studies of older adults. J Am Geriatr Soc 2010;58:783787.
72. SCORE2-OP
working group and
ESC
Cardiovascular risk collaboration.
SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions.
Eur
Heart
J
2021;42:24552467.
73. World Health Organization. Disease burden and mortality estimates. www.who.
int/healthinfo/global_burden_disease/estimates/en (4 June 2021).
74. Pennells L, Kaptoge S, Wood A, Sweeting M, Zhao X, White I, Burgess S, Willeit
P, Bolton T, Moons KGM, van der Schouw YT, Selmer R, Khaw KT, Gudnason V,
Assmann G, Amouyel P, Salomaa V, Kivimaki M, Nordestgaard BG, Blaha MJ,
Kuller LH, Brenner H, Gillum RF, Meisinger C, Ford I, Knuiman MW, Rosengren
A, Lawlor DA, Volzke H, Cooper C, Marin Ibanez A, Casiglia E, Kauhanen J,
Cooper JA, Rodriguez B, Sundstrom J, Barrett-Connor E, Dankner R, Nietert PJ,
Davidson KW, Wallace RB, Blazer DG, Bjorkelund C, Donfrancesco C,
Krumholz HM, Nissinen A, Davis BR, Coady S, Whincup PH, Jorgensen T,
Ducimetiere P, Trevisan M, Engstrom G, Crespo CJ, Meade TW, Visser M,
Kromhout D, Kiechl S, Daimon M, Price JF, Gomez de la Camara A, Wouter
Jukema J, Lamarche B, Onat A, Simons LA, Kavousi M, Ben-Shlomo Y, Gallacher
J, Dekker JM, Arima H, Shara N, Tipping RW, Roussel R, Brunner EJ, Koenig W,
Sakurai M, Pavlovic J, Gansevoort RT, Nagel D, Goldbourt U, Barr ELM, Palmieri
L, Njolstad I, Sato S, Monique Verschuren WM, Varghese CV, Graham I, Onuma
O, Greenland P, Woodward M, Ezzati M, Psaty BM, Sattar N, Jackson R, Ridker
PM, Cook NR, D’Agostino RB, Thompson SG, Danesh J, Di Angelantonio E,
Emerging Risk Factors Collaboration. Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of
86 prospective studies. Eur Heart J 2019;40:621631.
75. Berkelmans GFN, Gudbjornsdottir S, Visseren FLJ, Wild SH, Franzen S,
Chalmers J, Davis BR, Poulter NR, Spijkerman AM, Woodward M, Pressel SL,
Gupta AK, van der Schouw YT, Svensson AM, van der Graaf Y, Read SH,
Eliasson B, Dorresteijn JAN. Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus. Eur
Heart J 2019;40:28992906.
76. Jaspers NEM, Blaha MJ, Matsushita K, van der Schouw YT, Wareham NJ, Khaw
KT, Geisel MH, Lehmann N, Erbel R, Jockel KH, van der Graaf Y, Verschuren
WMM, Boer JMA, Nambi V, Visseren FLJ, Dorresteijn JAN. Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering,
antithrombotic therapy, and smoking cessation in apparently healthy people. Eur
Heart J 2020;41:11901199.
77. Kaasenbrood L, Bhatt DL, Dorresteijn JAN, Wilson PWF, D’Agostino RB, Sr.,
Massaro JM, van der Graaf Y, Cramer MJM, Kappelle LJ, de Borst GJ, Steg PG,
Visseren FLJ. Estimated Life Expectancy Without Recurrent Cardiovascular
Events in Patients With Vascular Disease: The SMART-REACH Model. J Am
Heart Assoc 2018;7:e009217.
78. Rossello X, Dorresteijn JA, Janssen A, Lambrinou E, Scherrenberg M, BonnefoyCudraz E, Cobain M, Piepoli MF, Visseren FL, Dendale P. Risk prediction tools in cardiovascular disease prevention: A report from the ESC Prevention of CVD
Programme led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the
Association of Cardiovascular Nursing and Allied Professions (ACNAP). Eur J
Cardiovasc Nurs 2019;18:534544.
79. Benetos A, Petrovic M, Strandberg T. Hypertension Management in Older and
Frail Older Patients. Circ Res 2019;124:10451060.
80. Ference BA, Bhatt DL, Catapano AL, Packard CJ, Graham I, Kaptoge S, Ference
TB, Guo Q, Laufs U, Ruff CT, Cupido A, Hovingh GK, Danesh J, Holmes MV,
Smith GD, Ray KK, Nicholls SJ, Sabatine MS. Association of Genetic Variants
Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower
Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA
2019;322:13811391.


<!-- PAGE 89 -->

### Page 89

.............................................................................................................................................................................
81. Kaasenbrood L, Boekholdt SM, van der Graaf Y, Ray KK, Peters RJ, Kastelein JJ,
Amarenco P, LaRosa JC, Cramer MJ, Westerink J, Kappelle LJ, de Borst GJ,
Visseren FL. Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and
Residual
Risk in a
Secondary
Prevention
Population.
Circulation
2016;134:14191429.
82. De Bacquer D, Ueda P, Reiner Z, De Sutter J, De Smedt D, Lovic D, Gotcheva
N, Fras Z, Pogosova N, Mirrakhimov E, Lehto S, Jernberg T, Kotseva K, Ryden L,
Wood D, EUROASPIRE IV and V National Coordinators. Prediction of recurrent event in patients with coronary heart disease: the EUROASPIRE Risk Model. Eur
J Prev Cardiol 2020:[Online ahead of print].
83. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O,
Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas
LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, LopezJaramillo P, O’Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Stork
S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, TorpPedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis
BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen
E, Leong D, Yusuf S, COMPASS Investigators. Rivaroxaban with or without
Aspirin in Stable Cardiovascular Disease. N Engl J Med 2017;377:13191330.
84. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT,
Jr., Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM, REDUCE-IT
Investigators.
Cardiovascular
Risk
Reduction with
Icosapent
Ethyl for
Hypertriglyceridemia. N Engl J Med 2019;380:1122.
85. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, The
SHK, Xu XF, Ireland MA, Lenderink T, Latchem D, Hoogslag P, Jerzewski A,
Nierop P, Whelan A, Hendriks R, Swart H, Schaap J, Kuijper AFM, van Hessen
MWJ, Saklani P, Tan I, Thompson AG, Morton A, Judkins C, Bax WA, Dirksen M,
Alings M, Hankey GJ, Budgeon CA, Tijssen JGP, Cornel JH, Thompson PL,
LoDoCo2 Trial Investigators. Colchicine in Patients with Chronic Coronary
Disease. N Engl J Med 2020;383:18381847.
86. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ,
Ibrahim R, Gamra H, Kiwan GS, Berry C, Lopez-Sendon J, Ostadal P, Koenig W,
Angoulvant D, Gregoire JC, Lavoie MA, Dube MP, Rhainds D, Provencher M,
Blondeau L, Orfanos A, L’Allier PL, Guertin MC, Roubille F. Efficacy and Safety of
Low-Dose
Colchicine after
Myocardial
Infarction.
N
Engl
J
Med
2019;381:24972505.
87. Sattar N, Rawshani A, Franzen S, Rawshani A, Svensson AM, Rosengren A,
McGuire DK, Eliasson B, Gudbjornsdottir S. Age at Diagnosis of Type 2 Diabetes
Mellitus and Associations With Cardiovascular and Mortality Risks. Circulation
2019;139:22282237.
88. Kaasenbrood L, Poulter NR, Sever PS, Colhoun HM, Livingstone SJ, Boekholdt
SM, Pressel SL, Davis BR, van der Graaf Y, Visseren FL, CARDS, ALLHAT, and
ASCOT Investigators. Development and Validation of a Model to Predict
Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in
Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian
Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study. Circ
Cardiovasc Qual Outcomes 2016;9:213221.
89. Kengne AP, Patel A, Marre M, Travert F, Lievre M, Zoungas S, Chalmers J,
Colagiuri S, Grobbee DE, Hamet P, Heller S, Neal B, Woodward M, ADVANCE
Collaborative Group. Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. Eur J Cardiovasc Prev Rehabil 2011;18:393398.
90. Stevens RJ, Kothari V, Adler AI, Stratton IM, United Kingdom Prospective
Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond)
2001;101:671679.
91. Rawshani A, Sattar N, Franzen S, Rawshani A, Hattersley AT, Svensson AM,
Eliasson B, Gudbjornsdottir S. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide,
register-based cohort study. Lancet 2018;392:477486.
92. Rawshani A, Rawshani A, Sattar N, Franzen S, McGuire DK, Eliasson B, Svensson
AM, Zethelius B, Miftaraj M, Rosengren A, Gudbjornsdottir S. Relative
Prognostic Importance and Optimal Levels of Risk Factors for Mortality and
Cardiovascular
Outcomes in
Type
1
Diabetes
Mellitus.
Circulation
2019;139:19001912.
93. Livingstone SJ, Looker HC, Hothersall EJ, Wild SH, Lindsay RS, Chalmers J,
Cleland S, Leese GP, McKnight J, Morris AD, Pearson DW, Peden NR, Petrie JR,
Philip S, Sattar N, Sullivan F, Colhoun HM. Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS
Med 2012;9:e1001321.
94. Spiegelhalter D, Pearson M, Short I. Visualizing uncertainty about the future.
Science 2011;333:13931400.
95. Zipkin DA, Umscheid CA, Keating NL, Allen E, Aung K, Beyth R, Kaatz S, Mann
DM, Sussman JB, Korenstein D, Schardt C, Nagi A, Sloane R, Feldstein DA.
Evidence-based risk communication: a systematic review. Ann Intern Med
2014;161:270280.
96. Karmali KN, Persell SD, Perel P, Lloyd-Jones DM, Berendsen MA, Huffman MD.
Risk scoring for the primary prevention of cardiovascular disease. Cochrane
Database Syst Rev 2017;3:CD006887.
97. Damman OC, Vonk SI, van den Haak MJ, van Hooijdonk CMJ, Timmermans
DRM. The effects of infographics and several quantitative versus qualitative formats for cardiovascular disease risk, including heart age, on people’s risk understanding. Patient Educ Couns 2018;101:14101418.
98. Cooney MT, Vartiainen E, Laatikainen T, De Bacquer D, McGorrian C, Dudina
A, Graham I, SCORE and FINRISK investigators. Cardiovascular risk age: concepts and practicalities. Heart 2012;98:941946.
99. Cuende JI, Cuende N, Calaveras-Lagartos J. How to calculate vascular age with the SCORE project scales: a new method of cardiovascular risk evaluation. Eur
Heart J 2010;31:23512358.
100. Albus C, Waller C, Fritzsche K, Gunold H, Haass M, Hamann B, Kindermann I,
Kollner V, Leithauser B, Marx N, Meesmann M, Michal M, Ronel J, Scherer M,
Schrader V, Schwaab B, Weber CS, Herrmann-Lingen C. Significance of psychosocial factors in cardiology: update 2018 : Position paper of the German
Cardiac Society. Clin Res Cardiol 2019;108:11751196.
101. Schnohr P, Marott JL, Kristensen TS, Gyntelberg F, Gronbaek M, Lange P,
Jensen MT, Jensen GB, Prescott E. Ranking of psychosocial and traditional risk factors by importance for coronary heart disease: the Copenhagen City Heart
Study. Eur Heart J 2015;36:13851393.
102. Kim JM, Stewart R, Kang HJ, Kim SY, Kim JW, Lee HJ, Lee JY, Kim SW, Shin IS,
Kim MC, Shin HY, Hong YJ, Ahn Y, Jeong MH, Yoon JS. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychol Med 2020:111.
103. Lin JS, Evans CV, Johnson E, Redmond N, Coppola EL, Smith N. Nontraditional
Risk Factors in Cardiovascular Disease Risk Assessment: Updated Evidence
Report and Systematic Review for the US Preventive Services Task Force. JAMA
2018;320:281297.
104. Peters SA, den Ruijter HM, Bots ML, Moons KG. Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review. Heart 2012;98:177184.
105. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3
risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ 2017;357:j2099.
106. Tzoulaki I, Siontis KC, Evangelou E, Ioannidis JP. Bias in associations of emerging biomarkers with cardiovascular disease.
JAMA
Intern
Med
2013;173:664671.
107. Kooter AJ, Kostense PJ, Groenewold J, Thijs A, Sattar N, Smulders YM.
Integrating information from novel risk factors with calculated risks: the critical impact of risk factor prevalence. Circulation 2011;124:741745.
108. Kivimaki M, Steptoe A. Effects of stress on the development and progression of cardiovascular disease. Nat Rev Cardiol 2018;15:215229.
109. Rozanski A. Behavioral cardiology: current advances and future directions. J Am
Coll Cardiol 2014;64:100110.
110. Crawshaw J, Auyeung V, Norton S, Weinman J. Identifying psychosocial predictors of medication non-adherence following acute coronary syndrome: A systematic review and meta-analysis. J Psychosom Res 2016;90:1032.
111. Steinberg ML, Williams JM, Li Y. Poor Mental Health and Reduced Decline in
Smoking Prevalence. Am J Prev Med 2015;49:362369.
112. Rosengren A, Hawken S, Ounpuu S, Sliwa K, Zubaid M, Almahmeed WA,
Blackett KN, Sitthi-amorn C, Sato H, Yusuf S, INTERHEART investigators.
Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART
study): case-control study. Lancet 2004;364:953962.
113. Vaccarino V, Badimon L, Bremner JD, Cenko E, Cubedo J, Dorobantu M,
Duncker DJ, Koller A, Manfrini O, Milicic D, Padro T, Pries AR, Quyyumi AA,
Tousoulis D, Trifunovic D, Vasiljevic Z, de Wit C, Bugiardini R, ESC Scientific
Document Group Reviewers. Depression and coronary heart disease: 2018
position paper of the ESC working group on coronary pathophysiology and microcirculation. Eur Heart J 2020;41:16871696.
114. Albus C, Barkhausen J, Fleck E, Haasenritter J, Lindner O, Silber S. The Diagnosis of Chronic Coronary Heart Disease. Dtsch Arztebl Int 2017;114:712719.
115. Jha MK, Qamar A, Vaduganathan M, Charney DS, Murrough JW. Screening and
Management of Depression in Patients With Cardiovascular Disease: JACC
State-of-the-Art Review. J Am Coll Cardiol 2019;73:18271845.
116. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental
Disorders. Patient Health Questionnaire. JAMA 1999;282:17371744.
117. Celano CM, Suarez L, Mastromauro C, Januzzi JL, Huffman JC. Feasibility and utility of screening for depression and anxiety disorders in patients with cardiovascular disease. Circ Cardiovasc Qual Outcomes 2013;6:498504.
118. MacGregor KL, Funderburk JS, Pigeon W, Maisto SA. Evaluation of the PHQ-9
Item 3 as a screen for sleep disturbance in primary care. J Gen Intern Med
2012;27:339344.
ESC Guidelines
3315


<!-- PAGE 90 -->

### Page 90

.............................................................................................................................................................................
119. Hadamitzky M, Freissmuth B, Meyer T, Hein F, Kastrati A, Martinoff S, Schomig
A, Hausleiter J. Prognostic value of coronary computed tomographic angiography for prediction of cardiac events in patients with suspected coronary artery disease. JACC Cardiovasc Imaging 2009;2:404411.
120. SCOT-HEART Investigators, Newby DE, Adamson PD, Berry C, Boon NA,
Dweck MR, Flather M, Forbes J, Hunter A, Lewis S, MacLean S, Mills NL,
Norrie J, Roditi G, Shah ASV, Timmis AD, van Beek EJR, Williams MC.
Coronary CT Angiography and 5-Year Risk of Myocardial Infarction. N Engl J
Med 2018;379:924933.
121. Den Ruijter HM, Peters SA, Anderson TJ, Britton AR, Dekker JM, Eijkemans MJ,
Engstrom G, Evans GW, de Graaf J, Grobbee DE, Hedblad B, Hofman A,
Holewijn S, Ikeda A, Kavousi M, Kitagawa K, Kitamura A, Koffijberg H, Lonn EM,
Lorenz MW, Mathiesen EB, Nijpels G, Okazaki S, O’Leary DH, Polak JF, Price
JF, Robertson C, Rembold CM, Rosvall M, Rundek T, Salonen JT, Sitzer M,
Stehouwer CD, Witteman JC, Moons KG, Bots ML. Common carotid intimamedia thickness measurements in cardiovascular risk prediction: a meta-analysis.
JAMA 2012;308:796803.
122. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, Najjar SS,
Rembold CM, Post WS, American Society of Echocardiography Carotid IntimaMedia Thickness Task Force. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the
American
Society of
Echocardiography
Carotid
Intima-Media
Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc
Echocardiogr 2008;21:93111; quiz 189-190.
123. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010;55:13181327.
124. McDermott MM, Greenland P, Liu K, Guralnik JM, Celic L, Criqui MH, Chan C,
Martin GJ, Schneider J, Pearce WH, Taylor LM, Clark E. The ankle brachial index is associated with leg function and physical activity: the Walking and Leg
Circulation Study. Ann Intern Med 2002;136:873883.
125. Ankle Brachial Index Collaboration, Fowkes FG, Murray GD, Butcher I, Heald
CL, Lee RJ, Chambless LE, Folsom AR, Hirsch AT, Dramaix M, deBacker G,
Wautrecht JC, Kornitzer M, Newman AB, Cushman M, Sutton-Tyrrell K,
Fowkes FG, Lee AJ, Price JF, d’Agostino RB, Murabito JM, Norman PE, Jamrozik
K, Curb JD, Masaki KH, Rodriguez BL, Dekker JM, Bouter LM, Heine RJ, Nijpels
G, Stehouwer CD, Ferrucci L, McDermott MM, Stoffers HE, Hooi JD,
Knottnerus JA, Ogren M, Hedblad B, Witteman JC, Breteler MM, Hunink MG,
Hofman A, Criqui MH, Langer RD, Fronek A, Hiatt WR, Hamman R, Resnick
HE, Guralnik J, McDermott MM. Ankle brachial index combined with
Framingham Risk Score to predict cardiovascular events and mortality: a metaanalysis. JAMA 2008;300:197208.
126. Afilalo J, Alexander KP, Mack MJ, Maurer MS, Green P, Allen LA, Popma JJ,
Ferrucci L, Forman DE. Frailty assessment in the cardiovascular care of older adults. J Am Coll Cardiol 2014;63:747762.
127. Singh M, Stewart R, White H. Importance of frailty in patients with cardiovascular disease. Eur Heart J 2014;35:17261731.
128. Tamura Y, Ishikawa J, Fujiwara Y, Tanaka M, Kanazawa N, Chiba Y, Iizuka A,
Kaito S, Tanaka J, Sugie M, Nishimura T, Kanemaru A, Shimoji K, Hirano H,
Furuta K, Kitamura A, Seino S, Shinkai S, Harada K, Kyo S, Ito H, Araki A.
Prevalence of frailty, cognitive impairment, and sarcopenia in outpatients with cardiometabolic disease in a frailty clinic. BMC Geriatr 2018;18:264.
129. Chainani V, Shaharyar S, Dave K, Choksi V, Ravindranathan S, Hanno R, Jamal
O, Abdo A, Abi Rafeh N. Objective measures of the frailty syndrome (hand grip strength and gait speed) and cardiovascular mortality: A systematic review.
Int J Cardiol 2016;215:487493.
130. Higueras-Fresnillo S, Cabanas-Sanchez V, Lopez-Garcia E, Esteban-Cornejo I,
Banegas JR, Sadarangani KP, Rodriguez-Artalejo F, Martinez-Gomez D. Physical
Activity and Association Between Frailty and All-Cause and Cardiovascular
Mortality in Older Adults: Population-Based Prospective Cohort Study. J Am
Geriatr Soc 2018;66:20972103.
131. Vaes B, Depoortere D, Van Pottelbergh G, Mathei C, Neto J, Degryse J.
Association between traditional cardiovascular risk factors and mortality in the oldest old: untangling the role of frailty. BMC Geriatr 2017;17:234.
132. Vigorito C, Abreu A, Ambrosetti M, Belardinelli R, Corra U, Cupples M, Davos
CH, Hoefer S, Iliou MC, Schmid JP, Voeller H, Doherty P. Frailty and cardiac rehabilitation: A call to action from the EAPC Cardiac Rehabilitation Section.
Eur J Prev Cardiol 2017;24:577590.
133. Bachmann JM, Willis BL, Ayers CR, Khera A, Berry JD. Association between family history and coronary heart disease death across long-term follow-up in men: the Cooper Center Longitudinal Study. Circulation 2012;125:30923098.
134. Tikkanen E, Havulinna AS, Palotie A, Salomaa V, Ripatti S. Genetic risk prediction and a 2-stage risk screening strategy for coronary heart disease. Arterioscler
Thromb Vasc Biol 2013;33:22612266.
135. Ripatti S, Tikkanen E, Orho-Melander M, Havulinna AS, Silander K, Sharma A,
Guiducci C, Perola M, Jula A, Sinisalo J, Lokki ML, Nieminen MS, Melander O,
Salomaa V, Peltonen L, Kathiresan S. A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet
2010;376:13931400.
136. Sivapalaratnam S, Boekholdt SM, Trip MD, Sandhu MS, Luben R, Kastelein JJ,
Wareham NJ, Khaw KT. Family history of premature coronary heart disease and risk prediction in the EPIC-Norfolk prospective population study. Heart
2010;96:19851989.
137. Veronesi G, Gianfagna F, Giampaoli S, Chambless LE, Mancia G, Cesana G,
Ferrario MM. Improving long-term prediction of first cardiovascular event: the contribution of family history of coronary heart disease and social status. Prev
Med 2014;64:7580.
138. Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O’Leary D, Carr JJ,
Goff DC, Greenland P, Herrington DM. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals.
JAMA 2012;308:788795.
139. Antiochos P, Marques-Vidal P, McDaid A, Waeber G, Vollenweider P.
Association between parental history and genetic risk scores for coronary heart disease prediction:
The population-based
CoLaus study.
Atherosclerosis
2016;244:5965.
140. van Dis I, Geleijnse JM, Kromhout D, Boer J, Boshuizen H, Verschuren WM. Do obesity and parental history of myocardial infarction improve cardiovascular risk prediction? Eur J Prev Cardiol 2013;20:793799.
141. Merry AH, Boer JM, Schouten LJ, Ambergen T, Steyerberg EW, Feskens EJ,
Verschuren WM, Gorgels AP, van den Brandt PA. Risk prediction of incident coronary heart disease in The Netherlands: re-estimation and improvement of the SCORE risk function. Eur J Prev Cardiol 2012;19:840848.
142. Musunuru K, Kathiresan S. Genetics of Common, Complex Coronary Artery
Disease. Cell 2019;177:132145.
143. Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. Nat Rev Genet 2018;19:581590.
144. Lambert SA, Gil L, Jupp S, Ritchie SC, Xu Y, Buniello A, McMahon A, Abraham
G, Chapman M, Parkinson H, Danesh J, MacArthur JAL, Inouye M. The
Polygenic Score Catalog as an open database for reproducibility and systematic evaluation. Nat Genet 2021;53:420425.
145. Wand H, Lambert SA, Tamburro C, Iacocca MA, O’Sullivan JW, Sillari C, Kullo
IJ, Rowley R, Dron JS, Brockman D, Venner E, McCarthy MI, Antoniou AC,
Easton DF, Hegele RA, Khera AV, Chatterjee N, Kooperberg C, Edwards K,
Vlessis K, Kinnear K, Danesh JN, Parkinson H, Ramos EM, Roberts MC,
Ormond KE, Khoury MJ, Janssens A, Goddard KAB, Kraft P, MacArthur JAL,
Inouye M, Wojcik GL. Improving reporting standards for polygenic scores in risk prediction studies. Nature 2021;591:211219.
146. Lambert SA, Abraham G, Inouye M. Towards clinical utility of polygenic risk scores. Hum Mol Genet 2019;28:R133R142.
147. Inouye M, Abraham G, Nelson CP, Wood AM, Sweeting MJ, Dudbridge F, Lai
FY, Kaptoge S, Brozynska M, Wang T, Ye S, Webb TR, Rutter MK, Tzoulaki I,
Patel RS, Loos RJF, Keavney B, Hemingway H, Thompson J, Watkins H,
Deloukas P, Di Angelantonio E, Butterworth AS, Danesh J, Samani NJ, UK
Biobank CardioMetabolic Consortium CHD Working Group. Genomic Risk
Prediction of Coronary Artery Disease in 480,000 Adults: Implications for
Primary Prevention. J Am Coll Cardiol 2018;72:18831893.
148. Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, Natarajan P,
Lander ES, Lubitz SA, Ellinor PT, Kathiresan S. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet 2018;50:12191224.
149. Sun L, Pennells L, Kaptoge S, Nelson CP, Ritchie SC, Abraham G, Arnold M,
Bell S, Bolton T, Burgess S, Dudbridge F, Guo Q, Sofianopoulou E, Stevens D,
Thompson JR, Butterworth AS, Wood A, Danesh J, Samani NJ, Inouye M, Di
Angelantonio E. Polygenic risk scores in cardiovascular risk prediction: A cohort study and modelling analyses. PLoS Med 2021;18:e1003498.
150. Elliott J, Bodinier B, Bond TA, Chadeau-Hyam M, Evangelou E, Moons KGM,
Dehghan A, Muller DC, Elliott P, Tzoulaki I. Predictive Accuracy of a Polygenic
Risk Score-Enhanced Prediction Model vs a Clinical Risk Score for Coronary
Artery Disease. JAMA 2020;323:636645.
151. Mosley JD, Gupta DK, Tan J, Yao J, Wells QS, Shaffer CM, Kundu S, RobinsonCohen C, Psaty BM, Rich SS, Post WS, Guo X, Rotter JI, Roden DM, Gerszten
RE, Wang TJ. Predictive Accuracy of a Polygenic Risk Score Compared With a
Clinical
Risk
Score for
Incident
Coronary
Heart
Disease.
JAMA
2020;323:627635.
152. Levin MG, Rader DJ. Polygenic Risk Scores and Coronary Artery Disease:
Ready for Prime Time? Circulation 2020;141:637640.
153. Schultz WM, Kelli HM, Lisko JC, Varghese T, Shen J, Sandesara P, Quyyumi AA,
Taylor HA, Gulati M, Harold JG, Mieres JH, Ferdinand KC, Mensah GA, Sperling
LS. Socioeconomic Status and Cardiovascular Outcomes: Challenges and
Interventions. Circulation 2018;137:21662178.
154. de Mestral C, Stringhini S. Socioeconomic Status and Cardiovascular Disease:
an Update. Curr Cardiol Rep 2017;19:115.


<!-- PAGE 91 -->

### Page 91

.............................................................................................................................................................................
155. Khaing W, Vallibhakara SA, Attia J, McEvoy M, Thakkinstian A. Effects of education and income on cardiovascular outcomes: A systematic review and metaanalysis. Eur J Prev Cardiol 2017;24:10321042.
156. Kivimaki M, Pentti J, Ferrie JE, Batty GD, Nyberg ST, Jokela M, Virtanen M,
Alfredsson L, Dragano N, Fransson EI, Goldberg M, Knutsson A, Koskenvuo M,
Koskinen A, Kouvonen A, Luukkonen R, Oksanen T, Rugulies R, Siegrist J,
Singh-Manoux A, Suominen S, Theorell T, Vaananen A, Vahtera J, Westerholm
PJM, Westerlund H, Zins M, Strandberg T, Steptoe A, Deanfield J, IPD-Work consortium. Work stress and risk of death in men and women with and without cardiometabolic disease: a multicohort study. Lancet Diabetes Endocrinol
2018;6:705713.
157. Burroughs Pena MS, Rollins A. Environmental Exposures and Cardiovascular
Disease: A Challenge for Health and Development in Low- and Middle-Income
Countries. Cardiol Clin 2017;35:7186.
158. Newby DE, Mannucci PM, Tell GS, Baccarelli AA, Brook RD, Donaldson K,
Forastiere F, Franchini M, Franco OH, Graham I, Hoek G, Hoffmann B,
Hoylaerts MF, Kunzli N, Mills N, Pekkanen J, Peters A, Piepoli MF, Rajagopalan
S, Storey RF, ESC Working Group on Thrombosis, European Association for
Cardiovascular Prevention and Rehabilitation, ESC Heart Failure Association.
Expert position paper on air pollution and cardiovascular disease. Eur Heart J
2015;36:8393b.
159. Lelieveld J, Pozzer A, Poschl U, Fnais M, Haines A, Munzel T. Loss of life expectancy from air pollution compared to other risk factors: a worldwide perspective. Cardiovasc Res 2020;116:19101917.
160. Liu C, Chen R, Sera F, Vicedo-Cabrera AM, Guo Y, Tong S, Coelho M, Saldiva
PHN, Lavigne E, Matus P, Valdes Ortega N, Osorio Garcia S, Pascal M, Stafoggia
M, Scortichini M, Hashizume M, Honda Y, Hurtado-Diaz M, Cruz J, Nunes B,
Teixeira JP, Kim H, Tobias A, Iniguez C, Forsberg B, Astrom C, Ragettli MS,
Guo YL, Chen BY, Bell ML, Wright CY, Scovronick N, Garland RM, Milojevic A,
Kysely J, Urban A, Orru H, Indermitte E, Jaakkola JJK, Ryti NRI, Katsouyanni K,
Analitis A, Zanobetti A, Schwartz J, Chen J, Wu T, Cohen A, Gasparrini A, Kan
H. Ambient Particulate Air Pollution and Daily Mortality in 652 Cities. N Engl J
Med 2019;381:705715.
161. Argacha JF, Mizukami T, Bourdrel T, Bind MA. Ecology of the cardiovascular system: Part II - A focus on non-air related pollutants. Trends Cardiovasc Med
2019;29:274282.
162. Ioannidis JP, Tzoulaki I. Minimal and null predictive effects for the most popular blood biomarkers of cardiovascular disease.
Circ
Res
2012;110:658662.
163. Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, Pennells L,
Kaptoge S, Caslake M, Thompson A, Butterworth AS, Sarwar N, Wormser D,
Saleheen D, Ballantyne CM, Psaty BM, Sundstrom J, Ridker PM, Nagel D, Gillum
RF, Ford I, Ducimetiere P, Kiechl S, Koenig W, Dullaart RP, Assmann G,
D’Agostino RB, Sr., Dagenais GR, Cooper JA, Kromhout D, Onat A, Tipping
RW, Gomez-de-la-Camara A, Rosengren A, Sutherland SE, Gallacher J, Fowkes
FG, Casiglia E, Hofman A, Salomaa V, Barrett-Connor E, Clarke R, Brunner E,
Jukema JW, Simons LA, Sandhu M, Wareham NJ, Khaw KT, Kauhanen J,
Salonen JT, Howard WJ, Nordestgaard BG, Wood AM, Thompson SG,
Boekholdt SM, Sattar N, Packard C, Gudnason V, Danesh J. Lipid-related markers and cardiovascular disease prediction. JAMA 2012;307:24992506.
164. Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a)
levels and improved cardiovascular risk prediction.
J
Am
Coll
Cardiol
2013;61:11461156.
165. Natriuretic Peptides Studies Collaboration, Willeit P, Kaptoge S, Welsh P,
Butterworth AS, Chowdhury R, Spackman SA, Pennells L, Gao P, Burgess S,
Freitag DF, Sweeting M, Wood AM, Cook NR, Judd S, Trompet S, Nambi V,
Olsen MH, Everett BM, Kee F, Arnlov J, Salomaa V, Levy D, Kauhanen J,
Laukkanen JA, Kavousi M, Ninomiya T, Casas JP, Daniels LB, Lind L, Kistorp
CN, Rosenberg J, Mueller T, Rubattu S, Panagiotakos DB, Franco OH, de
Lemos JA, Luchner A, Kizer JR, Kiechl S, Salonen JT, Goya Wannamethee S, de
Boer RA, Nordestgaard BG, Andersson J, Jorgensen T, Melander O, Ballantyne
Ch M, DeFilippi C, Ridker PM, Cushman M, Rosamond WD, Thompson SG,
Gudnason V, Sattar N, Danesh J, Di Angelantonio E. Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participantdata meta-analysis. Lancet Diabetes Endocrinol 2016;4:840849.
166. Willeit P, Welsh P, Evans JDW, Tschiderer L, Boachie C, Jukema JW, Ford I,
Trompet S, Stott DJ, Kearney PM, Mooijaart SP, Kiechl S, Di Angelantonio E,
Sattar N. High-Sensitivity Cardiac Troponin Concentration and Risk of FirstEver Cardiovascular Outcomes in 154,052 Participants. J Am Coll Cardiol
2017;70:558568.
167. Lamelas PM, Maheer K, Schwalm JD. Body mass index and mortality after acute coronary syndromes: a systematic review and meta-analysis. Acta Cardiol
2017;72:655661.
168. Ma WQ, Sun XJ, Wang Y, Han XQ, Zhu Y, Liu NF. Does body mass index truly affect mortality and cardiovascular outcomes in patients after coronary revascularization with percutaneous coronary intervention or coronary artery bypass graft?
A
systematic review and network meta-analysis.
Obes
Rev
2018;19:12361247.
169. Mahajan R, Stokes M, Elliott A, Munawar DA, Khokhar KB, Thiyagarajah A,
Hendriks J, Linz D, Gallagher C, Kaye D, Lau D, Sanders P. Complex interaction of obesity, intentional weight loss and heart failure: a systematic review and meta-analysis. Heart 2020;106:5868.
170. Bell JA, Hamer M, Sabia S, Singh-Manoux A, Batty GD, Kivimaki M. The natural course of healthy obesity over 20 years. J Am Coll Cardiol 2015;65:101102.
171. Chang AR, Grams ME, Ballew SH, Bilo H, Correa A, Evans M, Gutierrez OM,
Hosseinpanah F, Iseki K, Kenealy T, Klein B, Kronenberg F, Lee BJ, Li Y, Miura K,
Navaneethan
SD,
Roderick
PJ,
Valdivielso
JM,
Visseren
FLJ,
Zhang
L,
Gansevoort RT, Hallan SI, Levey AS, Matsushita K, Shalev V, Woodward M,
CKD Prognosis Consortium (CKD-PC). Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium. BMJ 2019;364:k5301.
172. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global
Burden of Disease Study 2017. Lancet 2020;395:709733.
173. Celutkiene J, Pudil R, Lopez-Fernandez T, Grapsa J, Nihoyannopoulos P,
Bergler-Klein J, Cohen-Solal A, Farmakis D, Tocchetti CG, von Haehling S,
Barberis V, Flachskampf FA, Ceponiene I, Haegler-Laube E, Suter T, Lapinskas
T, Prasad S, de Boer RA, Wechalekar K, Anker MS, Iakobishvili Z, BucciarelliDucci C, Schulz-Menger J, Cosyns B, Gaemperli O, Belenkov Y, Hulot JS,
Galderisi M, Lancellotti P, Bax J, Marwick TH, Chioncel O, Jaarsma T, Mullens
W, Piepoli M, Thum T, Heymans S, Mueller C, Moura B, Ruschitzka F,
Zamorano JL, Rosano G, Coats AJS, Asteggiano R, Seferovic P, Edvardsen T,
Lyon AR. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association
(HFA), the European Association of Cardiovascular Imaging (EACVI) and the
Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J
Heart Fail 2020;22:15041524.
174. Bosch X, Rovira M, Sitges M, Domenech A, Ortiz-Perez JT, de Caralt TM,
Morales-Ruiz M, Perea RJ, Monzo M, Esteve J. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left
Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am
Coll Cardiol 2013;61:23552362.
175. Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J
Cancer 2013;49:29002909.
176. Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, Kvien TK,
Dougados M, Radner H, Atzeni F, Primdahl J, Sodergren A, Wallberg Jonsson S,
van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay
MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DP,
Nurmohamed MT. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017;76:1728.
177. Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y, Troxel AB, Hennessy S,
Kimmel SE, Margolis DJ, Choi H, Mehta NN, Gelfand JM. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 2015;74:326332.
178. Hung YM, Chang WP, Wei JC, Chou P, Wang PY. Midlife Ankylosing
Spondylitis Increases the Risk of Cardiovascular Diseases in Males 5 Years
Later: A National Population-Based Study. Medicine (Baltimore) 2016;95:e3596.
179. Adelborg K, Szepligeti SK, Holland-Bill L, Ehrenstein V, Horvath-Puho E,
Henderson VW, Sorensen HT. Migraine and risk of cardiovascular diseases:
Danish population based matched cohort study. BMJ 2018;360:k96.
180. Mahmoud AN, Mentias A, Elgendy AY, Qazi A, Barakat AF, Saad M, Mohsen A,
Abuzaid A, Mansoor H, Mojadidi MK, Elgendy IY. Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects. BMJ Open 2018;8:e020498.
181. Sacco S, Ornello R, Ripa P, Tiseo C, Degan D, Pistoia F, Carolei A. Migraine and risk of ischaemic heart disease: a systematic review and meta-analysis of observational studies. Eur J Neurol 2015;22:10011011.
182. Chang CL, Donaghy M, Poulter N. Migraine and stroke in young women: casecontrol study. The World Health Organisation Collaborative Study of
Cardiovascular
Disease and
Steroid
Hormone
Contraception.
BMJ
1999;318:1318.
183. Champaloux SW, Tepper NK, Monsour M, Curtis KM, Whiteman MK,
Marchbanks PA, Jamieson DJ. Use of combined hormonal contraceptives among women with migraines and risk of ischemic stroke. Am J Obstet Gynecol
2017;216:489 e481489 e487.
184. Engeland A, Bjorge T, Daltveit AK, Skurtveit S, Vangen S, Vollset SE, Furu K.
Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230,000 women in Norway. Eur J Epidemiol 2011;26:157163.
ESC Guidelines
3317


<!-- PAGE 92 -->

### Page 92

.............................................................................................................................................................................
185. Lykke JA, Langhoff-Roos J, Sibai BM, Funai EF, Triche EW, Paidas MJ.
Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension 2009;53:944951.
186. Skjaerven R, Wilcox AJ, Klungsoyr K, Irgens LM, Vikse BE, Vatten LJ, Lie RT.
Cardiovascular mortality after pre-eclampsia in one child mothers: prospective,
population based cohort study. BMJ 2012;345:e7677.
187. Wilson BJ, Watson MS, Prescott GJ, Sunderland S, Campbell DM, Hannaford P,
Smith WC. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ 2003;326:845.
188. Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes:
a systematic review and meta-analysis.
Lancet
2009;373:17731779.
189. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2
diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010;16:347363.
190. Morgan CL, Jenkins-Jones S, Currie CJ, Rees DA. Evaluation of adverse outcome in young women with polycystic ovary syndrome versus matched, reference controls: a retrospective, observational study. J Clin Endocrinol Metab
2012;97:32513260.
191. Venkataraman H, Sattar N, Saravanan P. Postnatal testing following gestational diabetes: time to replace the oral glucose tolerance test? Lancet Diabetes
Endocrinol 2015;3:754756.
192. Bonamy AK, Parikh NI, Cnattingius S, Ludvigsson JF, Ingelsson E. Birth characteristics and subsequent risks of maternal cardiovascular disease: effects of gestational age and fetal growth. Circulation 2011;124:28392846.
193. Lykke JA, Paidas MJ, Damm P, Triche EW, Kuczynski E, Langhoff-Roos J.
Preterm delivery and risk of subsequent cardiovascular morbidity and type-II
diabetes in the mother. BJOG 2010;117:274281.
194. Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Nephrol Dial Transplant 2019;34:18031805.
195. GBD 2016 Causes of Death Collaborators. Global, regional, and national agesex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:11511210.
196. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ,
Mann JF, Matsushita K, Wen CP. Chronic kidney disease and cardiovascular risk:
epidemiology, mechanisms, and prevention. Lancet 2013;382:339352.
197. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M,
Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT.
Association of estimated glomerular filtration rate and albuminuria with allcause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:20732081.
198. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL,
Coresh J, Levey AS, Sarnak MJ. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol
2003;41:4755.
199. Dzaye O, Dudum R, Reiter-Brennan C, Kianoush S, Tota-Maharaj R, CainzosAchirica M, Blaha MJ. Coronary artery calcium scoring for individualized cardiovascular risk estimation in important patient subpopulations after the 2019
AHA/ACC
primary prevention guidelines.
Prog
Cardiovasc
Dis
2019;62:423430.
200. Chen J, Budoff MJ, Reilly MP, Yang W, Rosas SE, Rahman M, Zhang X, Roy JA,
Lustigova E, Nessel L, Ford V, Raj D, Porter AC, Soliman EZ, Wright JT, Jr.,
Wolf M, He J, CRIC Investigators. Coronary Artery Calcification and Risk of
Cardiovascular Disease and Death Among Patients With Chronic Kidney
Disease. JAMA Cardiol 2017;2:635643.
201. Matsushita K, Sang Y, Ballew SH, Shlipak M, Katz R, Rosas SE, Peralta CA,
Woodward M, Kramer HJ, Jacobs DR, Sarnak MJ, Coresh J. Subclinical atherosclerosis measures for cardiovascular prediction in CKD. J Am Soc Nephrol
2015;26:439447.
202. Kramer H, Toto R, Peshock R, Cooper R, Victor R. Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study.
J Am Soc Nephrol 2005;16:507513.
203. Budoff MJ, Rader DJ, Reilly MP, Mohler ER, 3rd, Lash J, Yang W, Rosen L, Glenn
M, Teal V, Feldman HI, CRIC Study Investigators. Relationship of estimated
GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency
Cohort) Study. Am J Kidney Dis 2011;58:519526.
204. Wanner C, Amann K, Shoji T. The heart and vascular system in dialysis. Lancet
2016;388:276284.
205. Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ 2016;354:i4482.
206. Emdin CA, Wong CX, Hsiao AJ, Altman DG, Peters SA, Woodward M,
Odutayo AA. Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies. BMJ 2016;532:h7013.
207. Lane DA, Skjoth F, Lip GYH, Larsen TB, Kotecha D. Temporal Trends in
Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care. J Am
Heart Assoc 2017;6:e005155.
208. Ko D, Rahman F, Schnabel RB, Yin X, Benjamin EJ, Christophersen IE. Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis. Nat Rev Cardiol 2016;13:321332.
209. Mou L, Norby FL, Chen LY, O’Neal WT, Lewis TT, Loehr LR, Soliman EZ,
Alonso A. Lifetime Risk of Atrial Fibrillation by Race and Socioeconomic Status:
ARIC Study (Atherosclerosis Risk in Communities). Circ Arrhythm Electrophysiol
2018;11:e006350.
210. Magnussen C, Niiranen TJ, Ojeda FM, Gianfagna F, Blankenberg S, Njolstad I,
Vartiainen E, Sans S, Pasterkamp G, Hughes M, Costanzo S, Donati MB,
Jousilahti P, Linneberg A, Palosaari T, de Gaetano G, Bobak M, den Ruijter HM,
Mathiesen E, Jorgensen T, Soderberg S, Kuulasmaa K, Zeller T, Iacoviello L,
Salomaa V, Schnabel RB, BiomarCaRE Consortium. Sex Differences and
Similarities in Atrial Fibrillation Epidemiology, Risk Factors, and Mortality in
Community
Cohorts:
Results
From the
BiomarCaRE
Consortium
(Biomarker for
Cardiovascular
Risk
Assessment in
Europe).
Circulation
2017;136:15881597.
211. Wyse DG, Van Gelder IC, Ellinor PT, Go AS, Kalman JM, Narayan SM, Nattel S,
Schotten U, Rienstra M. Lone atrial fibrillation: does it exist? J Am Coll Cardiol
2014;63:17151723.
212. Allan V, Honarbakhsh S, Casas JP, Wallace J, Hunter R, Schilling R, Perel P,
Morley K, Banerjee A, Hemingway H. Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants.
Thromb Haemost 2017;117:837850.
213. Feghaly J, Zakka P, London B, MacRae CA, Refaat MM. Genetics of Atrial
Fibrillation. J Am Heart Assoc 2018;7:e009884.
214. Staerk L, Wang B, Preis SR, Larson MG, Lubitz SA, Ellinor PT, McManus DD,
Ko D, Weng LC, Lunetta KL, Frost L, Benjamin EJ, Trinquart L. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart
Study. BMJ 2018;361:k1453.
215. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C,
Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman
JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN,
Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL, ESC Scientific
Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for
Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC)
Developed with the special contribution of the European Heart Rhythm
Association (EHRA) of the ESC. Eur Heart J 2021;42:373498.
216. Rienstra M, Hobbelt AH, Alings M, Tijssen JGP, Smit MD, Brugemann J,
Geelhoed B, Tieleman RG, Hillege HL, Tukkie R, Van Veldhuisen DJ, Crijns H,
Van Gelder IC, RACE 3 Investigators. Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation:
results of the RACE 3 trial. Eur Heart J 2018;39:29872996.
217. Parkash R, Wells GA, Sapp JL, Healey JS, Tardif JC, Greiss I, Rivard L, Roux JF,
Gula L, Nault I, Novak P, Birnie D, Ha A, Wilton SB, Mangat I, Gray C, Gardner
M, Tang ASL. Effect of Aggressive Blood Pressure Control on the Recurrence of Atrial Fibrillation After Catheter Ablation: A Randomized, Open-Label
Clinical Trial (SMAC-AF [Substrate Modification With Aggressive Blood
Pressure Control]). Circulation 2017;135:17881798.
218. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D’Agostino
RB. Stroke severity in atrial fibrillation. The Framingham Study. Stroke
1996;27:17601764.
219. Kalantarian S, Stern TA, Mansour M, Ruskin JN. Cognitive impairment associated with atrial fibrillation: a meta-analysis. Ann Intern Med 2013;158:338346.
220. Andersson T, Magnuson A, Bryngelsson IL, Frobert O, Henriksson KM,
Edvardsson N, Poci D. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study. Eur Heart J 2013;34:10611067.
221. An Y, Ogawa H, Yamashita Y, Ishii M, Iguchi M, Masunaga N, Esato M, Tsuji H,
Wada H, Hasegawa K, Abe M, Lip GYH, Akao M. Causes of death in Japanese patients with atrial fibrillation: The Fushimi Atrial Fibrillation Registry. Eur Heart
J Qual Care Clin Outcomes 2019;5:3542.
222. Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N,
Anker SD, Atherton J, Bohm M, Butler J, Drazner MH, Michael Felker G,
Filippatos G, Fiuzat M, Fonarow GC, Gomez-Mesa JE, Heidenreich P, Imamura
T, Jankowska EA, Januzzi J, Khazanie P, Kinugawa K, Lam CSP, Matsue Y, Metra
M, Ohtani T, Francesco Piepoli M, Ponikowski P, Rosano GMC, Sakata Y,
Seferovic P, Starling RC, Teerlink JR, Vardeny O, Yamamoto K, Yancy C, Zhang
J, Zieroth S. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the


<!-- PAGE 93 -->

### Page 93

.............................................................................................................................................................................
European Society of Cardiology, Japanese Heart Failure Society and Writing
Committee of the Universal Definition of Heart Failure: Endorsed by the
Canadian Heart Failure Society, Heart Failure Association of India, Cardiac
Society of Australia and New Zealand, and Chinese Heart Failure Association.
Eur J Heart Fail 2021;23:352380.
223. Chew DS, Heikki H, Schmidt G, Kavanagh KM, Dommasch M, Bloch Thomsen
PE, Sinnecker D, Raatikainen P, Exner DV. Change in Left Ventricular Ejection
Fraction
Following
First Myocardial
Infarction and Outcome. JACC
Clin
Electrophysiol 2018;4:672682.
224. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin
Oncol 2005;23:85978605.
225. Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast
Cancer Res 2011;13:R64.
226. Darby S, McGale P, Peto R, Granath F, Hall P, Ekbom A. Mortality from cardiovascular disease more than 10 years after radiotherapy for breast cancer:
nationwide cohort study of 90 000 Swedish women. BMJ 2003;326:256257.
227. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Bronnum D,
Correa C, Cutter D, Gagliardi G, Gigante B, Jensen MB, Nisbet A, Peto R,
Rahimi K, Taylor C, Hall P. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013;368:987998.
228. Dahlen T, Edgren G, Lambe M, Hoglund M, Bjorkholm M, Sandin F, Sjalander A,
Richter J, Olsson-Stromberg U, Ohm L, Back M, Stenke L, Swedish CML
Group, Swedish CML Register Group. Cardiovascular Events Associated With
Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A PopulationBased Cohort Study. Ann Intern Med 2016;165:161166.
229. Pudil R, Mueller C, Celutkiene J, Henriksen PA, Lenihan D, Dent S, Barac A,
Stanway S, Moslehi J, Suter TM, Ky B, Sterba M, Cardinale D, Cohen-Solal A,
Tocchetti CG, Farmakis D, Bergler-Klein J, Anker MS, Von Haehling S, Belenkov
Y, Iakobishvili Z, Maack C, Ciardiello F, Ruschitzka F, Coats AJS, Seferovic P,
Lainscak M, Piepoli MF, Chioncel O, Bax J, Hulot JS, Skouri H, Hagler-Laube ES,
Asteggiano R, Fernandez TL, de Boer RA, Lyon AR. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J
Heart Fail 2020;22:19661983.
230. Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW,
Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland A, Storas TH, Hagve
TA, Rosjo H, Steine K, Geisler J, Omland T. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized,
placebo-controlled, double-blind clinical trial of candesartan and metoprolol.
Eur Heart J 2016;37:16711680.
231. Narayan HK, French B, Khan AM, Plappert T, Hyman D, Bajulaiye A, Domchek
S, DeMichele A, Clark A, Matro J, Bradbury A, Fox K, Carver JR, Ky B.
Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential
Strain
Predict
Cancer
Therapeutics-Related
Cardiac
Dysfunction.
JACC
Cardiovasc Imaging 2016;9:11311141.
232. Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review.
J Am Coll Cardiol 2014;63:27512768.
233. Yu AF, Ky B. Roadmap for biomarkers of cancer therapy cardiotoxicity. Heart
2016;102:425430.
234. Boekhout AH, Gietema JA, Milojkovic Kerklaan B, van Werkhoven ED, Altena
R, Honkoop A, Los M, Smit WM, Nieboer P, Smorenburg CH, Mandigers CM,
van der Wouw AJ, Kessels L, van der Velden AW, Ottevanger PB, Smilde T, de
Boer J, van Veldhuisen DJ, Kema IP, de Vries EG, Schellens JH. Angiotensin IIReceptor
Inhibition
With
Candesartan to
Prevent
Trastuzumab-Related
Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized
Clinical Trial. JAMA Oncol 2016;2:10301037.
235. Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, Pagano JJ,
Chow K, Thompson RB, Vos LJ, Ghosh S, Oudit GY, Ezekowitz JA, Paterson
DI. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology
Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. J Clin Oncol 2017;35:870877.
236. Jones LW, Habel LA, Weltzien E, Castillo A, Gupta D, Kroenke CH, Kwan ML,
Quesenberry CP, Jr., Scott J, Sternfeld B, Yu A, Kushi LH, Caan BJ. Exercise and
Risk of Cardiovascular Events in Women With Nonmetastatic Breast Cancer. J
Clin Oncol 2016;34:27432749.
237. Armenian SH, Xu L, Ky B, Sun C, Farol LT, Pal SK, Douglas PS, Bhatia S, Chao
C. Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A
Community-Based
Retrospective
Cohort
Study.
J
Clin
Oncol
2016;34:11221130.
238. Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med 2015;3:631639.
239. Vanfleteren LEGW, Spruit MA, Wouters EFM, Franssen FME. Management of chronic obstructive pulmonary disease beyond the lungs. Lancet Respir Med
2016;4:911924.
240. Brekke PH, Omland T, Smith P, Soyseth V. Underdiagnosis of myocardial infarction in COPD - Cardiac Infarction Injury Score (CIIS) in patients hospitalised for COPD exacerbation. Respir Med 2008;102:12431247.
241. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005;2:811.
242. Kunisaki KM, Dransfield MT, Anderson JA, Brook RD, Calverley PMA, Celli BR,
Crim C, Hartley BF, Martinez FJ, Newby DE, Pragman AA, Vestbo J, Yates JC,
Niewoehner DE, SUMMIT Investigators. Exacerbations of Chronic Obstructive
Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the
SUMMIT Randomized Clinical Trial. Am J Respir Crit Care Med 2018;198:5157.
243. Rothnie KJ, Connell O, Mullerova H, Smeeth L, Pearce N, Douglas I, Quint JK.
Myocardial Infarction and Ischemic Stroke after Exacerbations of Chronic
Obstructive Pulmonary Disease. Ann Am Thorac Soc 2018;15:935946.
244. Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD.
Chest 2005;128:26402646.
245. Cebron Lipovec N, Beijers RJ, van den Borst B, Doehner W, Lainscak M, Schols
AM. The Prevalence of Metabolic Syndrome In Chronic Obstructive Pulmonary
Disease: A Systematic Review. COPD 2016;13:399406.
246. Wang LY, Zhu YN, Cui JJ, Yin KQ, Liu SX, Gao YH. Subclinical atherosclerosis risk markers in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. Respir Med 2017;123:1827.
247. Agusti A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, Vestbo
J, Lomas DA, Calverley PM, Wouters E, Crim C, Yates JC, Silverman EK,
Coxson HO, Bakke P, Mayer RJ, Celli B, Evaluation of COPD Longitudinally to
Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012;7:e37483.
248. MacDonald MI, Shafuddin E, King PT, Chang CL, Bardin PG, Hancox RJ. Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease.
Lancet Respir Med 2016;4:138148.
249. Chang CL, Robinson SC, Mills GD, Sullivan GD, Karalus NC, McLachlan JD,
Hancox RJ. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax 2011;66:764768.
250. Maclay JD, McAllister DA, Johnston S, Raftis J, McGuinnes C, Deans A, Newby
DE, Mills NL, MacNee W. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax 2011;66:769774.
251. Lahousse L, Tiemeier H, Ikram MA, Brusselle GG. Chronic obstructive pulmonary disease and cerebrovascular disease: A comprehensive review. Respir Med
2015;109:13711380.
252. Houben-Wilke S, Jorres RA, Bals R, Franssen FM, Glaser S, Holle R, Karch A,
Koch A, Magnussen H, Obst A, Schulz H, Spruit MA, Wacker ME, Welte T,
Wouters EF, Vogelmeier C, Watz H. Peripheral Artery Disease and Its Clinical
Relevance in Patients with Chronic Obstructive Pulmonary Disease in the
COPD and Systemic Consequences-Comorbidities Network Study. Am J Respir
Crit Care Med 2017;195:189197.
253. Terzikhan N, Lahousse L, Verhamme KMC, Franco OH, Ikram AM, Stricker BH,
Brusselle GG. COPD is associated with an increased risk of peripheral artery disease and mortality. ERJ Open Res 2018;4:[eCollection].
254. Ambrosino P, Lupoli R, Cafaro G, Iervolino S, Carone M, Pappone N, Di Minno
MND. Subclinical carotid atherosclerosis in patients with chronic obstructive pulmonary disease: a meta-analysis of literature studies. Ann Med 2017;49:513524.
255. Xiong J, Wu Z, Chen C, Guo W. Chronic obstructive pulmonary disease effect on the prevalence and postoperative outcome of abdominal aortic aneurysms:
A meta-analysis. Sci Rep 2016;6:25003.
256. Goudis
CA,
Konstantinidis
AK,
Ntalas
IV,
Korantzopoulos
P.
Electrocardiographic abnormalities and cardiac arrhythmias in chronic obstructive pulmonary disease. Int J Cardiol 2015;199:264273.
257. Buch P, Friberg J, Scharling H, Lange P, Prescott E. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J
2003;21:10121016.
258. Goudis CA. Chronic obstructive pulmonary disease and atrial fibrillation: An unknown relationship. J Cardiol 2017;69:699705.
259. Konecny T, Somers KR, Park JY, John A, Orban M, Doshi R, Scanlon PD,
Asirvatham SJ, Rihal CS, Brady PA. Chronic obstructive pulmonary disease as a risk factor for ventricular arrhythmias independent of left ventricular function.
Heart Rhythm 2018;15:832838.
260. van den Berg ME, Stricker BH, Brusselle GG, Lahousse L. Chronic obstructive pulmonary disease and sudden cardiac death: A systematic review. Trends
Cardiovasc Med 2016;26:606613.
ESC Guidelines
3319


<!-- PAGE 94 -->

### Page 94

.............................................................................................................................................................................
261. Macchia A, Rodriguez Moncalvo JJ, Kleinert M, Comignani PD, Gimeno G,
Arakaki D, Laffaye N, Fuselli JJ, Massolin HP, Gambarte J, Romero M, Tognoni
G. Unrecognised ventricular dysfunction in COPD. Eur Respir J 2012;39:5158.
262. Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring E, Jr., She D.
Cardiovascular disease in patients with chronic obstructive pulmonary disease,
Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol
2006;16:6370.
263. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J
2008;32:962969.
264. Li C, Cheng W, Guo J, Guan W. Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials. Int J Chron Obstruct
Pulmon Dis 2019;14:799808.
265. Singh S, Singh H, Loftus EV, Jr., Pardi DS. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014;12:382393 e381: quiz e322.
266. Hsue PY, Waters DD. HIV infection and coronary heart disease: mechanisms and management. Nat Rev Cardiol 2019;16:745759.
267. Sinha A, Feinstein MJ. Coronary Artery Disease Manifestations in HIV: What,
How, and Why. Can J Cardiol 2019;35:270279.
268. Beckman JA, Duncan MS, Alcorn CW, So-Armah K, Butt AA, Goetz MB, Tindle
HA, Sico JJ, Tracy RP, Justice AC, Freiberg MS. Association of Human
Immunodeficiency Virus Infection and Risk of Peripheral Artery Disease.
Circulation 2018;138:255265.
269. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J
Med 2004;351:26112618.
270. Udell JA, Zawi R, Bhatt DL, Keshtkar-Jahromi M, Gaughran F, Phrommintikul A,
Ciszewski A, Vakili H, Hoffman EB, Farkouh ME, Cannon CP. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA 2013;310:17111720.
271. Dietrich T, Jimenez M, Krall Kaye EA, Vokonas PS, Garcia RI. Age-dependent associations between chronic periodontitis/edentulism and risk of coronary heart disease. Circulation 2008;117:16681674.
272. Carrizales-Sepulveda EF, Ordaz-Farias A, Vera-Pineda R, Flores-Ramirez R.
Periodontal Disease, Systemic Inflammation and the Risk of Cardiovascular
Disease. Heart Lung Circ 2018;27:13271334.
273. Ryden L, Buhlin K, Ekstrand E, de Faire U, Gustafsson A, Holmer J, Kjellstrom B,
Lindahl B, Norhammar A, Nygren A, Nasman P, Rathnayake N, Svenungsson E,
Klinge B. Periodontitis Increases the Risk of a First Myocardial Infarction: A
Report From the PAROKRANK Study. Circulation 2016;133:576583.
274. Qi J, Zihang Z, Zhang J, Park YM, Shrestha D, Jianling B, Merchant AT.
Periodontal Antibodies and All-Cause and Cardiovascular Disease Mortality. J
Dent Res 2020;99:5159.
275. Lee YL, Hu HY, Chou P, Chu D. Dental prophylaxis decreases the risk of acute myocardial infarction: a nationwide population-based study in Taiwan. Clin Interv
Aging 2015;10:175182.
276. Holmlund A, Lampa E, Lind L. Poor Response to Periodontal Treatment May
Predict Future Cardiovascular Disease. J Dent Res 2017;96:768773.
277. Park SY, Kim SH, Kang SH, Yoon CH, Lee HJ, Yun PY, Youn TJ, Chae IH.
Improved oral hygiene care attenuates the cardiovascular risk of oral health disease: a population-based study from Korea. Eur Heart J 2019;40:11381145.
278. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K,
Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn
SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson
C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basanez
MG, Baxter A, Bell ML, Benjamin EJ, Bennett D, Bernabe E, Bhalla K, Bhandari
B, Bikbov B, Bin Abdulhak A, Birbeck G, Black JA, Blencowe H, Blore JD, Blyth
F, Bolliger I, Bonaventure A, Boufous S, Bourne R, Boussinesq M, Braithwaite T,
Brayne C, Bridgett L, Brooker S, Brooks P, Brugha TS, Bryan-Hancock C,
Bucello C, Buchbinder R, Buckle G, Budke CM, Burch M, Burney P, Burstein R,
Calabria B, Campbell B, Canter CE, Carabin H, Carapetis J, Carmona L, Cella
C, Charlson F, Chen H, Cheng AT, Chou D, Chugh SS, Coffeng LE, Colan SD,
Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M,
Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M,
Dabhadkar KC, Dahiya M, Dahodwala N, Damsere-Derry J, Danaei G, Davis A,
De Leo D, Degenhardt L, Dellavalle R, Delossantos A, Denenberg J, Derrett S,
Des Jarlais DC, Dharmaratne SD, Dherani M, Diaz-Torne C, Dolk H, Dorsey
ER, Driscoll T, Duber H, Ebel B, Edmond K, Elbaz A, Ali SE, Erskine H, Erwin PJ,
Espindola P, Ewoigbokhan SE, Farzadfar F, Feigin V, Felson DT, Ferrari A, Ferri
CP, Fevre EM, Finucane MM, Flaxman S, Flood L, Foreman K, Forouzanfar MH,
Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabbe BJ, Gabriel SE, Gakidou
E, Ganatra HA, Garcia B, Gaspari F, Gillum RF, Gmel G, Gosselin R, Grainger R,
Groeger J, Guillemin F, Gunnell D, Gupta R, Haagsma J, Hagan H, Halasa YA,
Hall W, Haring D, Haro JM, Harrison JE, Havmoeller R, Hay RJ, Higashi H, Hill
C, Hoen B, Hoffman H, Hotez PJ, Hoy D, Huang JJ, Ibeanusi SE, Jacobsen KH,
James SL, Jarvis D, Jasrasaria R, Jayaraman S, Johns N, Jonas JB, Karthikeyan G,
Kassebaum N, Kawakami N, Keren A, Khoo JP, King CH, Knowlton LM,
Kobusingye O, Koranteng A, Krishnamurthi R, Lalloo R, Laslett LL, Lathlean T,
Leasher JL, Lee YY, Leigh J, Lim SS, Limb E, Lin JK, Lipnick M, Lipshultz SE, Liu
W, Loane M, Ohno SL, Lyons R, Ma J, Mabweijano J, MacIntyre MF, Malekzadeh
R, Mallinger L, Manivannan S, Marcenes W, March L, Margolis DJ, Marks GB,
Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott
MM, McGill N, McGrath J, Medina-Mora ME, Meltzer M, Mensah GA, Merriman
TR, Meyer AC, Miglioli V, Miller M, Miller TR, Mitchell PB, Mocumbi AO,
Moffitt TE, Mokdad AA, Monasta L, Montico M, Moradi-Lakeh M, Moran A,
Morawska L, Mori R, Murdoch ME, Mwaniki MK, Naidoo K, Nair MN, Naldi L,
Narayan KM, Nelson PK, Nelson RG, Nevitt MC, Newton CR, Nolte S,
Norman P, Norman R, O’Donnell M, O’Hanlon S, Olives C, Omer SB, Ortblad
K, Osborne R, Ozgediz D, Page A, Pahari B, Pandian JD, Rivero AP, Patten SB,
Pearce N, Padilla RP, Perez-Ruiz F, Perico N, Pesudovs K, Phillips D, Phillips
MR, Pierce K, Pion S, Polanczyk GV, Polinder S, Pope CA, 3rd, Popova S,
Porrini E, Pourmalek F, Prince M, Pullan RL, Ramaiah KD, Ranganathan D,
Razavi H, Regan M, Rehm JT, Rein DB, Remuzzi G, Richardson K, Rivara FP,
Roberts T, Robinson C, De Leon FR, Ronfani L, Room R, Rosenfeld LC,
Rushton L, Sacco RL, Saha S, Sampson U, Sanchez-Riera L, Sanman E, Schwebel
DC, Scott JG, Segui-Gomez M, Shahraz S, Shepard DS, Shin H, Shivakoti R,
Singh D, Singh GM, Singh JA, Singleton J, Sleet DA, Sliwa K, Smith E, Smith JL,
Stapelberg NJ, Steer A, Steiner T, Stolk WA, Stovner LJ, Sudfeld C, Syed S,
Tamburlini G, Tavakkoli M, Taylor HR, Taylor JA, Taylor WJ, Thomas B,
Thomson WM, Thurston GD, Tleyjeh IM, Tonelli M, Towbin JA, Truelsen T,
Tsilimbaris MK, Ubeda C, Undurraga EA, van der Werf MJ, van Os J, Vavilala
MS, Venketasubramanian N, Wang M, Wang W, Watt K, Weatherall DJ,
Weinstock MA, Weintraub R, Weisskopf MG, Weissman MM, White RA,
Whiteford H, Wiersma ST, Wilkinson JD, Williams HC, Williams SR, Witt E,
Wolfe F, Woolf AD, Wulf S, Yeh PH, Zaidi AK, Zheng ZJ, Zonies D, Lopez
AD, Murray CJ, AlMazroa MA, Memish ZA. Years lived with disability (YLDs)
for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:21632196.
279. Kurth T, Winter AC, Eliassen AH, Dushkes R, Mukamal KJ, Rimm EB, Willett
WC, Manson JE, Rexrode KM. Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ 2016;353:i2610.
280. Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease:
systematic review and meta-analysis.
BMJ
2009;339:b3914.
281. Sacco S, Kurth T. Migraine and the risk for stroke and cardiovascular disease.
Curr Cardiol Rep 2014;16:524.
282. Sacco S, Merki-Feld GS, KL AE, Bitzer J Canonico M, Kurth T, Lampl C,
Lidegaard O, Anne MacGregor E, MaassenVanDenBrink A, Mitsikostas DD,
Nappi RE, Ntaios G, Sandset PM, Martelletti p, European Headache Federation
(EHF) and the European Society of Contraception and Reproductive Health
(ESC). Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation
(EHF) and the European Society of Contraception and Reproductive Health
(ESC). J Headache Pain 2017;18:108.
283. Ornello R, Canonico M, Merki-Feld GS, Kurth T, Lidegaard O, MacGregor EA,
Lampl C, Nappi RE, Martelletti P, Sacco S. Migraine, low-dose combined hormonal contraceptives, and ischemic stroke in young women: a systematic review and suggestions for future research. Expert Rev Neurother 2020;20:313317.
284. Badran M, Yassin BA, Fox N, Laher I, Ayas N. Epidemiology of Sleep
Disturbances and
Cardiovascular
Consequences.
Can
J
Cardiol
2015;31:873879.
285. Sofi F, Cesari F, Casini A, Macchi C, Abbate R, Gensini GF. Insomnia and risk of cardiovascular disease: a meta-analysis. Eur J Prev Cardiol 2014;21:5764.
286. Ge L, Guyatt G, Tian J, Pan B, Chang Y, Chen Y, Li H, Zhang J, Li Y, Ling J, Yang
K. Insomnia and risk of mortality from all-cause, cardiovascular disease, and cancer: Systematic review and meta-analysis of prospective cohort studies. Sleep
Med Rev 2019;48:101215.
287. Yin J, Jin X, Shan Z, Li S, Huang H, Li P, Peng X, Peng Z, Yu K, Bao W, Yang W,
Chen X, Liu L. Relationship of Sleep Duration With All-Cause Mortality and
Cardiovascular Events: A Systematic Review and Dose-Response Meta-Analysis of Prospective Cohort Studies. J Am Heart Assoc 2017;6:e005947.
288. Kerkhof GA. Epidemiology of sleep and sleep disorders in The Netherlands.
Sleep Med 2017;30:229239.
289. Remi J, Pollmacher T, Spiegelhalder K, Trenkwalder C, Young P. Sleep-Related
Disorders in Neurology and Psychiatry. Dtsch Arztebl Int 2019;116:681688.
290. Kalmbach DA, Cuamatzi-Castelan AS, Tonnu CV, Tran KM, Anderson JR, Roth
T, Drake CL. Hyperarousal and sleep reactivity in insomnia: current insights.
Nat Sci Sleep 2018;10:193201.
291. Tietjens JR, Claman D, Kezirian EJ, De Marco T, Mirzayan A, Sadroonri B,
Goldberg AN, Long C, Gerstenfeld EP, Yeghiazarians, Y. Obstructive Sleep


<!-- PAGE 95 -->

### Page 95

.............................................................................................................................................................................
Apnea in Cardiovascular Disease: A Review of the Literature and Proposed
Multidisciplinary
Clinical
Management
Strategy.
J
Am
Heart
Assoc
2019;8:e010440.
292. McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, Mediano O, Chen R,
Drager LF, Liu Z, Chen G, Du B, McArdle N, Mukherjee S, Tripathi M, Billot L,
Li Q, Lorenzi-Filho G, Barbe F, Redline S, Wang J, Arima H, Neal B, White DP,
Grunstein RR, Zhong N, Anderson CS, SAVE Investigators and Coordinators.
CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea. N
Engl J Med 2016;375:919931.
293. Collen J, Lettieri C, Wickwire E, Holley A. Obstructive sleep apnea and cardiovascular disease, a story of confounders! Sleep Breath 2020;24:12991313.
294. Drager LF, McEvoy RD, Barbe F, Lorenzi-Filho G, Redline S, INCOSACT
Initiative (International Collaboration of Sleep Apnea Cardiovascular Trialists).
Sleep Apnea and Cardiovascular Disease: Lessons From Recent Trials and
Need for Team Science. Circulation 2017;136:18401850.
295. Kasiakogias A, Tsioufis C, Thomopoulos C, Tousoulis D. Effects of continuous positive airway pressure on blood pressure in hypertensive patients with obstructive sleep apnoea. J Hypertens 2014;32:22792280.
296. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, Olesen
J, Allgulander C, Alonso J, Faravelli C, Fratiglioni L, Jennum P, Lieb R, Maercker
A, van Os J, Preisig M, Salvador-Carulla L, Simon R, Steinhausen HC. The size and burden of mental disorders and other disorders of the brain in Europe
2010. Eur Neuropsychopharmacol 2011;21:655679.
297. Krupchanka D, Mlada K, Winkler P, Khazaal Y, Albanese E. Mortality in people with mental disorders in the Czech Republic: a nationwide, register-based cohort study. Lancet Public Health 2018;3:e289e295.
298. Starace F, Mungai F, Baccari F, Galeazzi GM. Excess mortality in people with mental illness: findings from a Northern Italy psychiatric case register. Soc
Psychiatry Psychiatr Epidemiol 2018;53:249257.
299. John U, Rumpf HJ, Hanke M, Meyer C. Mental disorders and total mortality after 20 years in an adult general population sample. Eur Psychiatry 2020;63:e30.
300. Lawrence D, Hancock KJ, Kisely S. The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. BMJ 2013;346:f2539.
301. Scott KM, de Jonge P, Alonso J, Viana MC, Liu Z, O’Neill S, Aguilar-Gaxiola S,
Bruffaerts R, Caldas-de-Almeida JM, Stein DJ, de Girolamo G, Florescu SE, Hu
C, Taib NI, Lepine JP, Levinson D, Matschinger H, Medina-Mora ME, Piazza M,
Posada-Villa JA, Uda H, Wojtyniak BJ, Lim CC, Kessler RC. Associations between DSM-IV mental disorders and subsequent heart disease onset: beyond depression. Int J Cardiol 2013;168:52935299.
302. Harter M, Baumeister H, Reuter K, Jacobi F, Hofler M, Bengel J, Wittchen HU.
Increased 12-month prevalence rates of mental disorders in patients with chronic somatic diseases. Psychother Psychosom 2007;76:354360.
303. Dar T, Radfar A, Abohashem S, Pitman RK, Tawakol A, Osborne MT. Psychosocial
Stress and Cardiovascular Disease. Curr Treat Options Cardiovasc Med 2019;21:23.
304. Zhang WY, Nan N, Song XT, Tian JF, Yang XY. Impact of depression on clinical outcomes following percutaneous coronary intervention: a systematic review and meta-analysis. BMJ Open 2019;9:e026445.
305. Petersen BD, Stenager E, Mogensen CB, Erlangsen A. The association between heart diseases and suicide:
a nationwide cohort study.
J
Intern
Med
2020;287:558568.
306. Duflou
J.
Psychostimulant use disorder and the heart.
Addiction
2020;115:175183.
307. Schnyder N, Panczak R, Groth N, Schultze-Lutter F. Association between mental health-related stigma and active help-seeking: systematic review and metaanalysis. Br J Psychiatry 2017;210:261268.
308. Knaak S, Mantler E, Szeto A. Mental illness-related stigma in healthcare: Barriers to access and care and evidence-based solutions. Healthc Manage Forum
2017;30:111116.
309. Henderson C, Noblett J, Parke H, Clement S, Caffrey A, Gale-Grant O, Schulze
B, Druss B, Thornicroft G. Mental health-related stigma in health care and mental health-care settings. Lancet Psychiatry 2014;1:467482.
310. Thornicroft G. Physical health disparities and mental illness: the scandal of premature mortality. Br J Psychiatry 2011;199:441442.
311. Cunningham R, Poppe K, Peterson D, Every-Palmer S, Soosay I, Jackson R.
Prediction of cardiovascular disease risk among people with severe mental illness: A cohort study. PLoS One 2019;14:e0221521.
312. Piepoli MF, Abreu A, Albus C, Ambrosetti M, Brotons C, Catapano AL, Corra
U, Cosyns B, Deaton C, Graham I, Hoes A, Lochen ML, Matrone B, Redon J,
Sattar N, Smulders Y, Tiberi M. Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive
Cardiology of the European Society of Cardiology. Eur J Prev Cardiol
2020;27:181205.
313. Alexander M, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D,
Ansell D, Pasqua A, Lapi F, Rijnbeek P, Mosseveld M, Avillach P, Egger P,
Dhalwani NN, Kendrick S, Celis-Morales C, Waterworth DM, Alazawi W,
Sattar N. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million
European adults. BMJ 2019;367:l5367.
314. Young L, Cho L. Unique cardiovascular risk factors in women. Heart
2019;105:16561660.
315. Dam V, Onland-Moret NC, Verschuren WMM, Boer JMA, Benschop L, Franx
A, Moons KGM, Boersma E, van der Schouw YT, CREW-consortium.
Cardiovascular risk model performance in women with and without hypertensive disorders of pregnancy. Heart 2019;105:330336.
316. Grandi SM, Filion KB, Yoon S, Ayele HT, Doyle CM, Hutcheon JA, Smith GN,
Gore GC, Ray JG, Nerenberg K, Platt RW. Cardiovascular Disease-Related
Morbidity and
Mortality in
Women
With a
History of
Pregnancy
Complications. Circulation 2019;139:10691079.
317. Riise HKR, Sulo G, Tell GS, Igland J, Nygard O, Iversen AC, Daltveit AK.
Association Between Gestational Hypertension and Risk of Cardiovascular
Disease
Among
617
589
Norwegian
Women.
J
Am
Heart
Assoc
2018;7:e008337.
318. Grandi SM, Reynier P, Platt RW, Basso O, Filion KB. The timing of onset of hypertensive disorders in pregnancy and the risk of incident hypertension and cardiovascular disease. Int J Cardiol 2018;270:273275.
319. Timpka S, Markovitz A, Schyman T, Mogren I, Fraser A, Franks PW, RichEdwards JW. Midlife development of type 2 diabetes and hypertension in women by history of hypertensive disorders of pregnancy. Cardiovasc Diabetol
2018;17:124.
320. Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of cardiovascular disease in women:
a systematic review and meta-analysis.
Diabetologia 2019;62:905914.
321. Claesson R, Ignell C, Shaat N, Berntorp K. HbA1c as a predictor of diabetes after gestational diabetes mellitus. Prim Care Diabetes 2017;11:4651.
322. Ding T, Hardiman PJ, Petersen I, Wang FF, Qu F, Baio G. The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis. Oncotarget 2017;8:9635196358.
323. Liu J, Wu Q, Hao Y, Jiao M, Wang X, Jiang S, Han L. Measuring the global disease burden of polycystic ovary syndrome in 194 countries: Global Burden of
Disease Study 2017. Hum Reprod 2021;36:11081119.
324. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD,
Kelsey SF, Kip KE, Cooper-Dehoff RM, Johnson BD, Vaccarino V, Reis SE,
Bittner V, Hodgson TK, Rogers W, Pepine CJ. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National
Institutes of Health–National Heart, Lung, and Blood Institute sponsored
Women’s
Ischemia
Syndrome
Evaluation.
J
Clin
Endocrinol
Metab
2008;93:12761284.
325. Muka T, Oliver-Williams C, Kunutsor S, Laven JS, Fauser BC, Chowdhury R,
Kavousi M, Franco OH. Association of Age at Onset of Menopause and Time
Since Onset of Menopause With Cardiovascular Outcomes, Intermediate
Vascular Traits, and All-Cause Mortality: A Systematic Review and Meta-analysis. JAMA Cardiol 2016;1:767776.
326. Ding DC, Tsai IJ, Wang JH, Lin SZ, Sung FC. Coronary artery disease risk in young women with polycystic ovary syndrome.
Oncotarget
2018;9:87568764.
327. Hong JS, Yi SW, Kang HC, Jee SH, Kang HG, Bayasgalan G, Ohrr H. Age at menopause and cause-specific mortality in South Korean women: Kangwha
Cohort Study. Maturitas 2007;56:411419.
328. Zhao L, Zhu Z, Lou H, Zhu G, Huang W, Zhang S, Liu F. Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis.
Oncotarget 2016;7:3371533721.
329. Wellons M, Ouyang P, Schreiner PJ, Herrington DM, Vaidya D. Early menopause predicts future coronary heart disease and stroke: the Multi-Ethnic Study of Atherosclerosis. Menopause 2012;19:10811087.
330. DeLay KJ, Haney N, Hellstrom WJ. Modifying Risk Factors in the Management of Erectile Dysfunction: A Review. World J Mens Health 2016;34:89100.
331. Kessler A, Sollie S, Challacombe B, Briggs K, Van Hemelrijck M. The global prevalence of erectile dysfunction: a review. BJU Int 2019:[Online ahead of print].
332. Ibrahim A, Ali M, Kiernan TJ, Stack AG. Erectile Dysfunction and Ischaemic
Heart Disease. Eur Cardiol 2018;13:98103.
333. Miner M, Nehra A, Jackson G, Bhasin S, Billups K, Burnett AL, Buvat J, Carson
C, Cunningham G, Ganz P, Goldstein I, Guay A, Hackett G, Kloner RA, Kostis
JB, LaFlamme KE, Montorsi P, Ramsey M, Rosen R, Sadovsky R, Seftel A,
Shabsigh R, Vlachopoulos C, Wu F. All men with vasculogenic erectile dysfunction require a cardiovascular workup. Am J Med 2014;127:174182.
334. Montorsi P, Ravagnani PM, Galli S, Salonia A, Briganti A, Werba JP, Montorsi F.
Association between erectile dysfunction and coronary artery disease: Matching the right target with the right test in the right patient.
Eur
Urol
2006;50:721731.
ESC Guidelines
3321


<!-- PAGE 96 -->

### Page 96

.............................................................................................................................................................................
335. Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK, Aznaouridis KA,
Stefanadis CI. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies.
Circ Cardiovasc Qual Outcomes 2013;6:99109.
336. Zhao B, Zhang W. Does erectile dysfunction independently predict cardiovascular events?
It’s time to act on the evidence.
Eur
J
Prev
Cardiol
2018;25:13071311.
337. Chrysant SG. Antihypertensive therapy causes erectile dysfunction. Curr Opin
Cardiol 2015;30:383390.
338. Fan Y, Hu B, Man C, Cui F. Erectile dysfunction and risk of cardiovascular and all-cause mortality in the general population: a meta-analysis of cohort studies.
World J Urol 2018;36:16811689.
339. Imprialos KP, Stavropoulos K, Doumas M, Tziomalos K, Karagiannis A, Athyros
VG. Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy.
Curr Vasc Pharmacol 2018;16:130142.
340. Osondu CU, Vo B, Oni ET, Blaha MJ, Veledar E, Feldman T, Agatston AS, Nasir
K, Aneni EC. The relationship of erectile dysfunction and subclinical cardiovascular disease: A systematic review and meta-analysis. Vasc Med 2018;23:920.
341. Raheem OA, Su JJ, Wilson JR, Hsieh TC. The Association of Erectile
Dysfunction and Cardiovascular Disease: A Systematic Critical Review. Am J
Mens Health 2017;11:552563.
342. Gowani Z, Uddin SMI, Mirbolouk M, Ayyaz D, Billups KL, Miner M, Feldman DI,
Blaha MJ. Vascular Erectile Dysfunction and Subclinical Cardiovascular Disease.
Curr Sex Health Rep 2017;9:305312.
343. Shah NP, Cainzos-Achirica M, Feldman DI, Blumenthal RS, Nasir K, Miner MM,
Billups KL, Blaha MJ. Cardiovascular Disease Prevention in Men with Vascular
Erectile Dysfunction: The View of the Preventive Cardiologist. Am J Med
2016;129:251259.
344. Gerbild H, Larsen CM, Graugaard C, Areskoug Josefsson K. Physical Activity to
Improve Erectile Function: A Systematic Review of Intervention Studies. Sex
Med 2018;6:7589.
345. Vlachopoulos C, Jackson G, Stefanadis C, Montorsi P. Erectile dysfunction in the cardiovascular patient. Eur Heart J 2013;34:20342046.
346. Rachamin Y, Grischott T, Rosemann T, Meyer MR. Inferior control of lowdensity lipoprotein cholesterol in women is the primary sex difference in modifiable cardiovascular risk: A large-scale, cross-sectional study in primary care.
Atherosclerosis 2021;324:141147.
347. Victor BM, Teal V, Ahedor L, Karalis DG. Gender differences in achieving optimal lipid goals in patients with coronary artery disease. Am J Cardiol
2014;113:16111615.
348. Virani SS, Woodard LD, Ramsey DJ, Urech TH, Akeroyd JM, Shah T, Deswal A,
Bozkurt B, Ballantyne CM, Petersen LA. Gender disparities in evidence-based statin therapy in patients with cardiovascular disease.
Am
J
Cardiol
2015;115:2126.
349. Xia S, Du X, Guo L, Du J, Arnott C, Lam CSP, Huffman MD, Arima H, Yuan Y,
Zheng Y, Wu S, Guang X, Zhou X, Lin H, Cheng X, Anderson CS, Dong J, Ma
C. Sex Differences in Primary and Secondary Prevention of Cardiovascular
Disease in China. Circulation 2020;141:530539.
350. Hyun KK, Redfern J, Patel A, Peiris D, Brieger D, Sullivan D, Harris M,
Usherwood T, MacMahon S, Lyford M, Woodward M. Gender inequalities in cardiovascular risk factor assessment and management in primary healthcare.
Heart 2017;103:492498.
351. Mosca L, Barrett-Connor E, Wenger NK. Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation
2011;124:21452154.
352. Wandell PE, de Waard AM, Holzmann MJ, Gornitzki C, Lionis C, de Wit N,
Sondergaard J, Sonderlund AL, Kral N, Seifert B, Korevaar JC, Schellevis FG,
Carlsson AC. Barriers and facilitators among health professionals in primary care to prevention of cardiometabolic diseases: A systematic review. Fam Pract
2018;35:383398.
353. Astin F, Lucock M, Jennings CS. Heart and mind: behavioural cardiology demystified for the clinician. Heart 2019;105:881888.
354. Lee WW, Choi KC, Yum RW, Yu DS, Chair SY. Effectiveness of motivational interviewing on lifestyle modification and health outcomes of clients at risk or diagnosed with cardiovascular diseases: A systematic review. Int J Nurs Stud
2016;53:331341.
355. Zulman DM, Haverfield MC, Shaw JG, Brown-Johnson CG, Schwartz R, Tierney
AA, Zionts DL, Safaeinili N, Fischer M, Thadaney Israni S, Asch SM, Verghese A.
Practices to Foster Physician Presence and Connection With Patients in the
Clinical Encounter. JAMA 2020;323:7081.
356. Miller WR, Rose GS. Toward a theory of motivational interviewing. Am Psychol
2009;64:527537.
357. Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci
2011;6:42.
358. Ambrosetti M, Abreu A, Corra U, Davos CH, Hansen D, Frederix I, Iliou MC,
Pedretti RF, Schmid JP, Vigorito C, Voller H, Wilhelm M, Piepoli MF, BjarnasonWehrens B, Berger T, Cohen-Solal A, Cornelissen V, Dendale P, Doehner W,
Gaita D, Gevaert AB, Kemps H, Kraenkel N, Laukkanen J, Mendes M, Niebauer
J, Simonenko M, Zwisler AO. Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update.
A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol
2020:2047487320913379.
359. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med 2012;125:882887
e881.
360. Brown MT, Bussell J, Dutta S, Davis K, Strong S, Mathew S. Medication
Adherence: Truth and Consequences. Am J Med Sci 2016;351:387399.
361. Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, Stricker B,
Mendis S, Hofman A, Mant J, Franco OH. Adherence to cardiovascular therapy:
a meta-analysis of prevalence and clinical consequences.
Eur
Heart
J
2013;34:29402948.
362. Arlt AD, Nestoriuc Y, Rief W. Why current drug adherence programs fail:
addressing psychological risk factors of nonadherence. Curr Opin Psychiatry
2017;30:326333.
363. Easthall C, Taylor N, Bhattacharya D. Barriers to medication adherence in patients prescribed medicines for the prevention of cardiovascular disease: a conceptual framework. Int J Pharm Pract 2019;27:223231.
364. Seabury SA, Dougherty JS, Sullivan J. Medication adherence as a measure of the quality of care provided by physicians. Am J Manag Care 2019;25:7883.
365. Schneider APH, Gaedke MA, Garcez A, Barcellos NT, Paniz VMV. Effect of characteristics of pharmacotherapy on non-adherence in chronic cardiovascular disease: A systematic review and meta-analysis of observational studies. Int J Clin
Pract 2018;72:[Epub].
366. Albarqouni L, Doust J, Glasziou P. Patient preferences for cardiovascular preventive medication: a systematic review. Heart 2017;103:15781586.
367. Hennein R, Hwang SJ, Au R, Levy D, Muntner P, Fox CS, Ma J. Barriers to medication adherence and links to cardiovascular disease risk factor control: the
Framingham Heart Study. Intern Med J 2018;48:414421.
368. Goldstein CM, Gathright EC, Garcia S. Relationship between depression and medication adherence in cardiovascular disease: the perfect challenge for the integrated care team. Patient Prefer Adherence 2017;11:547559.
369. Palmer MJ, Barnard S, Perel P, Free C. Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults.
Cochrane
Database
Syst
Rev
2018;6:CD012675.
370. Guerriero C, Cairns J, Roberts I, Rodgers A, Whittaker R, Free C. The costeffectiveness of smoking cessation support delivered by mobile phone text messaging: Txt2stop. Eur J Health Econ 2013;14:789797.
371. Kraus WE, Powell KE, Haskell WL, Janz KF, Campbell WW, Jakicic JM, Troiano
RP, Sprow K, Torres A, Piercy KL, 2018 Physical Activity Guidelines Advisory
Committee. Physical Activity, All-Cause and Cardiovascular Mortality, and
Cardiovascular Disease. Med Sci Sports Exerc 2019;51:12701281.
372. Powell KE, King AC, Buchner DM, Campbell WW, DiPietro L, Erickson KI,
Hillman CH, Jakicic JM, Janz KF, Katzmarzyk PT, Kraus WE, Macko RF, Marquez
DX, McTiernan A, Pate RR, Pescatello LS, Whitt-Glover MC. The Scientific
Foundation for the Physical Activity Guidelines for Americans, 2nd Edition. J
Phys Act Health 2018:111.
373. Sattelmair J, Pertman J, Ding EL, Kohl HW, 3rd, Haskell W, Lee IM. Dose response between physical activity and risk of coronary heart disease: a metaanalysis. Circulation 2011;124:789795.
374. Hupin D, Roche F, Gremeaux V, Chatard JC, Oriol M, Gaspoz JM, Barthelemy
JC, Edouard P. Even a low-dose of moderate-to-vigorous physical activity reduces mortality by 22% in adults aged >/=60 years: a systematic review and meta-analysis. Br J Sports Med 2015;49:12621267.
375. Ekelund U, Tarp J, Steene-Johannessen J, Hansen BH, Jefferis B, Fagerland MW,
Whincup P, Diaz KM, Hooker SP, Chernofsky A, Larson MG, Spartano N,
Vasan RS, Dohrn IM, Hagstromer M, Edwardson C, Yates T, Shiroma E,
Anderssen SA, Lee IM. Dose-response associations between accelerometry measured physical activity and sedentary time and all cause mortality: systematic review and harmonised meta-analysis. BMJ 2019;366:l4570.
376. Patterson R, McNamara E, Tainio M, de Sa TH, Smith AD, Sharp SJ, Edwards P,
Woodcock J, Brage S, Wijndaele K. Sedentary behaviour and risk of all-cause,
cardiovascular and cancer mortality, and incident type 2 diabetes: a systematic review and dose response meta-analysis. Eur J Epidemiol 2018;33:811829.
377. Biswas A, Oh PI, Faulkner GE, Bajaj RR, Silver MA, Mitchell MS, Alter DA.
Sedentary time and its association with risk for disease incidence, mortality, and hospitalization in adults: a systematic review and meta-analysis. Ann Intern Med
2015;162:123132.


<!-- PAGE 97 -->

### Page 97

.............................................................................................................................................................................
378. Liu Y, Lee DC, Li Y, Zhu W, Zhang R, Sui X, Lavie CJ, Blair SN. Associations of
Resistance Exercise with Cardiovascular Disease Morbidity and Mortality. Med
Sci Sports Exerc 2019;51:499508.
379. Saeidifard F, Medina-Inojosa JR, West CP, Olson TP, Somers VK, Bonikowske
AR, Prokop LJ, Vinciguerra M, Lopez-Jimenez F. The association of resistance training with mortality: A systematic review and meta-analysis. Eur J Prev Cardiol
2019;26:16471665.
380. Cradock KA, OL G, Finucane FM, Gainforth HL, Quinlan LR, Ginis KA.
Behaviour change techniques targeting both diet and physical activity in type 2
diabetes: A systematic review and meta-analysis. Int J Behav Nutr Phys Act
2017;14:18.
381. Howlett N, Trivedi D, Troop NA, Chater AM. Are physical activity interventions for healthy inactive adults effective in promoting behavior change and maintenance, and which behavior change techniques are effective? A systematic review and meta-analysis. Transl Behav Med 2019;9:147157.
382. Brickwood KJ, Watson G, O’Brien J, Williams AD. Consumer-Based Wearable
Activity Trackers Increase Physical Activity Participation: Systematic Review and
Meta-Analysis. JMIR Mhealth Uhealth 2019;7:e11819.
383. Kyu HH, Bachman VF, Alexander LT, Mumford JE, Afshin A, Estep K, Veerman
JL, Delwiche K, Iannarone ML, Moyer ML, Cercy K, Vos T, Murray CJ,
Forouzanfar MH. Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013. BMJ
2016;354:i3857.
384. Wahid A, Manek N, Nichols M, Kelly P, Foster C, Webster P, Kaur A,
Friedemann Smith C, Wilkins E, Rayner M, Roberts N, Scarborough P.
Quantifying the Association Between Physical Activity and Cardiovascular
Disease and Diabetes: A Systematic Review and Meta-Analysis. J Am Heart Assoc
2016;5:e002495.
385. Moore SC, Patel AV, Matthews CE, Berrington de Gonzalez A, Park Y, Katki
HA, Linet MS, Weiderpass E, Visvanathan K, Helzlsouer KJ, Thun M, Gapstur
SM, Hartge P, Lee IM. Leisure time physical activity of moderate to vigorous intensity and mortality:
a large pooled cohort analysis.
PLoS
Med
2012;9:e1001335.
386. Moore SC, Lee IM, Weiderpass E, Campbell PT, Sampson JN, Kitahara CM,
Keadle SK, Arem H, Berrington de Gonzalez A, Hartge P, Adami HO, Blair CK,
Borch KB, Boyd E, Check DP, Fournier A, Freedman ND, Gunter M, Johannson
M, Khaw KT, Linet MS, Orsini N, Park Y, Riboli E, Robien K, Schairer C, Sesso
H, Spriggs M, Van Dusen R, Wolk A, Matthews CE, Patel AV. Association of
Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million
Adults. JAMA Intern Med 2016;176:816825.
387. Arem H, Moore SC, Patel A, Hartge P, Berrington de Gonzalez A, Visvanathan
K, Campbell PT, Freedman M, Weiderpass E, Adami HO, Linet MS, Lee IM,
Matthews CE. Leisure time physical activity and mortality: a detailed pooled analysis of the dose-response relationship. JAMA Intern Med 2015;175:959967.
388. Pelliccia A, Sharma S, Gati S, Back M, Borjesson M, Caselli S, Collet JP, Corrado
D, Drezner JA, Halle M, Hansen D, Heidbuchel H, Myers J, Niebauer J,
Papadakis M, Piepoli MF, Prescott E, Roos-Hesselink JW, Graham Stuart A,
Taylor RS, Thompson PD, Tiberi M, Vanhees L, Wilhelm M, ESC Scientific
Document Group. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J 2021;42:1796.
389. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM,
Nieman DC, Swain DP, American College of Sports Medicine. American
College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci
Sports Exerc 2011;43:13341359.
390. Jakicic JM, Kraus WE, Powell KE, Campbell WW, Janz KF, Troiano RP, Sprow K,
Torres A, Piercy KL, 2018 Physical Activity Guidelines Advisory Committee.
Association between Bout Duration of Physical Activity and Health: Systematic
Review. Med Sci Sports Exerc 2019;51:12131219.
391. Ainsworth BE, Haskell WL, Herrmann SD, Meckes N, Bassett DR, Jr., TudorLocke C, Greer JL, Vezina J, Whitt-Glover MC, Leon AS. 2011 Compendium of
Physical Activities: a second update of codes and MET values. Med Sci Sports
Exerc 2011;43:15751581.
392. Howley ET. Type of activity: resistance, aerobic and leisure versus occupational physical activity. Med Sci Sports Exerc 2001;33:S364369; discussion S419-320.
393. Ortega FB, Silventoinen K, Tynelius P, Rasmussen F. Muscular strength in male adolescents and premature death: cohort study of one million participants. BMJ
2012;345:e7279.
394. Ruiz JR, Sui X, Lobelo F, Morrow JR, Jr., Jackson AW, Sjostrom M, Blair SN.
Association between muscular strength and mortality in men: prospective cohort study. BMJ 2008;337:a439.
395. Volaklis KA, Halle M, Meisinger C. Muscular strength as a strong predictor of mortality: A narrative review. Eur J Intern Med 2015;26:303310.
396. Chastin SFM, De Craemer M, De Cocker K, Powell L, Van Cauwenberg J, Dall
P, Hamer M, Stamatakis E. How does light-intensity physical activity associate with adult cardiometabolic health and mortality? Systematic review with metaanalysis of experimental and observational studies.
Br
J
Sports
Med
2019;53:370376.
397. Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT, Lancet Physical
Activity Series Working Group. Effect of physical inactivity on major noncommunicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet 2012;380:219229.
398. Katzmarzyk PT, Powell KE, Jakicic JM, Troiano RP, Piercy K, Tennant B, 2018
Physical Activity Guidelines Advisory Committee. Sedentary Behavior and
Health:
Update from the
2018
Physical
Activity
Guidelines
Advisory
Committee. Med Sci Sports Exerc 2019;51:12271241.
399. Young DR, Hivert MF, Alhassan S, Camhi SM, Ferguson JF, Katzmarzyk PT,
Lewis CE, Owen N, Perry CK, Siddique J, Yong CM, Physical Activity
Committee of the Council on Lifestyle and Cardiometabolic Health, Council on
Clinical Cardiology, Council on Epidemiology and Prevention, Council on
Functional Genomics and Translational Biology, and Stroke Council. Sedentary
Behavior and Cardiovascular Morbidity and Mortality: A Science Advisory From the American Heart Association. Circulation 2016;134:e262-279.
400. Yates T, Edwardson CL, Celis-Morales C, Biddle SJH, Bodicoat D, Davies MJ,
Esliger D, Henson J, Kazi A, Khunti K, Sattar N, Sinclair AJ, Rowlands A,
Velayudhan L, Zaccardi F, Gill JMR. Metabolic Effects of Breaking Prolonged
Sitting With Standing or Light Walking in Older South Asians and White
Europeans: A Randomized Acute Study. J Gerontol A Biol Sci Med Sci
2020;75:139146.
401. Eilat-Adar S, Sinai T, Yosefy C, Henkin Y. Nutritional recommendations for cardiovascular disease prevention. Nutrients 2013;5:36463683.
402. European Heart Network. Transforming European food and drink policies for cardiovascular health. http://www.ehnheart.org/publications-and-papers/publications/
1093:transforming-european-food-and-drinks-policies-for-cardiovascular-health.
html (21 July 2020).
403. Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr 2010;92:11891196.
404. Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, Gomez-Gracia
E, Ruiz-Gutierrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L,
Pinto X, Basora J, Munoz MA, Sorli JV, Martinez JA, Fito M, Gea A, Hernan MA,
Martinez-Gonzalez MA, PREDIMED Study Investigators. Primary Prevention of
Cardiovascular Disease with a Mediterranean Diet Supplemented with ExtraVirgin Olive Oil or Nuts. N Engl J Med 2018;378:e34.
405. Mensink RP. Effects of saturated fatty acids on serum lipids and lipoproteins: a systematic review and regression analysis https://apps.who.int/iris/bitstream/handle/
10665/246104/9789241565349-eng.pdf?sequence=1 (21 July 2020).
406. Guasch-Ferre M, Satija A, Blondin SA, Janiszewski M, Emlen E, O’Connor LE,
Campbell
WW,
Hu
FB,
Willett
WC,
Stampfer
MJ.
Meta-Analysis of
Randomized Controlled Trials of Red Meat Consumption in Comparison With
Various
Comparison
Diets on
Cardiovascular
Risk
Factors.
Circulation
2019;139:18281845.
407. Chen M, Li Y, Sun Q, Pan A, Manson JE, Rexrode KM, Willett WC, Rimm EB,
Hu FB. Dairy fat and risk of cardiovascular disease in 3 cohorts of US adults.
Am J Clin Nutr 2016;104:12091217.
408. Li Y, Hruby A, Bernstein AM, Ley SH, Wang DD, Chiuve SE, Sampson L,
Rexrode KM, Rimm EB, Willett WC, Hu FB. Saturated Fats Compared With
Unsaturated Fats and Sources of Carbohydrates in Relation to Risk of
Coronary Heart Disease: A Prospective Cohort Study. J Am Coll Cardiol
2015;66:15381548.
409. Sacks FM, Lichtenstein AH, Wu JHY, Appel LJ, Creager MA, Kris-Etherton PM,
Miller M, Rimm EB, Rudel LL, Robinson JG, Stone NJ, Van Horn LV, American
Heart Association. Dietary Fats and Cardiovascular Disease: A Presidential
Advisory From the American Heart Association. Circulation 2017;136:e1e23.
410. He FJ, Tan M, Ma Y, MacGregor GA. Salt Reduction to Prevent Hypertension and Cardiovascular Disease: JACC State-of-the-Art Review. J Am Coll Cardiol
2020;75:632647.
411. Willett W, Rockstrom J, Loken B, Springmann M, Lang T, Vermeulen S, Garnett
T, Tilman D, DeClerck F, Wood A, Jonell M, Clark M, Gordon LJ, Fanzo J,
Hawkes C, Zurayk R, Rivera JA, De Vries W, Majele Sibanda L, Afshin A,
Chaudhary A, Herrero M, Agustina R, Branca F, Lartey A, Fan S, Crona B, Fox
E, Bignet V, Troell M, Lindahl T, Singh S, Cornell SE, Srinath Reddy K, Narain S,
Nishtar
S,
Murray
CJL.
Food in the
Anthropocene:
the
EAT-Lancet
Commission on healthy diets from sustainable food systems.
Lancet
2019;393:447492.
412. World Health Organization. A healthy diet sustainably produced. https://apps.
who.int/iris/bitstream/handle/10665/278948/WHO-NMH-NHD-18.12-eng.pdf?
ua=1 (21 July 2020).
ESC Guidelines
3323


<!-- PAGE 98 -->

### Page 98

.............................................................................................................................................................................
413. Wood AM, Kaptoge S, Butterworth AS, Willeit P, Warnakula S, Bolton T, Paige
E, Paul DS, Sweeting M, Burgess S, Bell S, Astle W, Stevens D, Koulman A,
Selmer RM, Verschuren WMM, Sato S, Njolstad I, Woodward M, Salomaa V,
Nordestgaard BG, Yeap BB, Fletcher A, Melander O, Kuller LH, Balkau B,
Marmot M, Koenig W, Casiglia E, Cooper C, Arndt V, Franco OH, Wennberg
P, Gallacher J, de la Camara AG, Volzke H, Dahm CC, Dale CE, Bergmann MM,
Crespo CJ, van der Schouw YT, Kaaks R, Simons LA, Lagiou P, Schoufour JD,
Boer JMA, Key TJ, Rodriguez B, Moreno-Iribas C, Davidson KW, Taylor JO,
Sacerdote C, Wallace RB, Quiros JR, Tumino R, Blazer DG, 2nd, Linneberg A,
Daimon M, Panico S, Howard B, Skeie G, Strandberg T, Weiderpass E, Nietert
PJ, Psaty BM, Kromhout D, Salamanca-Fernandez E, Kiechl S, Krumholz HM,
Grioni S, Palli D, Huerta JM, Price J, Sundstrom J, Arriola L, Arima H, Travis RC,
Panagiotakos DB, Karakatsani A, Trichopoulou A, Kuhn T, Grobbee DE,
Barrett-Connor E, van Schoor N, Boeing H, Overvad K, Kauhanen J, Wareham
N, Langenberg C, Forouhi N, Wennberg M, Despres JP, Cushman M, Cooper
JA, Rodriguez CJ, Sakurai M, Shaw JE, Knuiman M, Voortman T, Meisinger C,
Tjonneland A, Brenner H, Palmieri L, Dallongeville J, Brunner EJ, Assmann G,
Trevisan M, Gillum RF, Ford I, Sattar N, Lazo M, Thompson SG, Ferrari P, Leon
DA, Smith GD, Peto R, Jackson R, Banks E, Di Angelantonio E, Danesh J,
Emerging Risk Factors Collaboration/EPIC-CVD/UK Biobank Alcohol Study
Group. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet 2018;391:15131523.
414. Millwood IY, Walters RG, Mei XW, Guo Y, Yang L, Bian Z, Bennett DA, Chen
Y, Dong C, Hu R, Zhou G, Yu B, Jia W, Parish S, Clarke R, Davey Smith G,
Collins R, Holmes MV, Li L, Peto R, Chen Z, China Kadoorie Biobank
Collaborative Group. Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China.
Lancet 2019;393:18311842.
415. Holmes MV, Dale CE, Zuccolo L, Silverwood RJ, Guo Y, Ye Z, Prieto-Merino
D, Dehghan A, Trompet S, Wong A, Cavadino A, Drogan D, Padmanabhan S,
Li S, Yesupriya A, Leusink M, Sundstrom J, Hubacek JA, Pikhart H, Swerdlow
DI, Panayiotou AG, Borinskaya SA, Finan C, Shah S, Kuchenbaecker KB, Shah T,
Engmann J, Folkersen L, Eriksson P, Ricceri F, Melander O, Sacerdote C,
Gamble DM, Rayaprolu S, Ross OA, McLachlan S, Vikhireva O, Sluijs I, Scott
RA, Adamkova V, Flicker L, Bockxmeer FM, Power C, Marques-Vidal P, Meade
T, Marmot MG, Ferro JM, Paulos-Pinheiro S, Humphries SE, Talmud PJ, Mateo
Leach I, Verweij N, Linneberg A, Skaaby T, Doevendans PA, Cramer MJ, van der Harst P, Klungel OH, Dowling NF, Dominiczak AF, Kumari M, Nicolaides
AN, Weikert C, Boeing H, Ebrahim S, Gaunt TR, Price JF, Lannfelt L, Peasey A,
Kubinova R, Pajak A, Malyutina S, Voevoda MI, Tamosiunas A, Maitland-van der
Zee AH, Norman PE, Hankey GJ, Bergmann MM, Hofman A, Franco OH,
Cooper J, Palmen J, Spiering W, de Jong PA, Kuh D, Hardy R, Uitterlinden AG,
Ikram MA, Ford I, Hypponen E, Almeida OP, Wareham NJ, Khaw KT, Hamsten
A, Husemoen LL, Tjonneland A, Tolstrup JS, Rimm E, Beulens JW, Verschuren
WM, Onland-Moret NC, Hofker MH, Wannamethee SG, Whincup PH, Morris
R, Vicente AM, Watkins H, Farrall M, Jukema JW, Meschia J, Cupples LA, Sharp
SJ, Fornage M, Kooperberg C, LaCroix AZ, Dai JY, Lanktree MB, Siscovick DS,
Jorgenson E, Spring B, Coresh J, Li YR, Buxbaum SG, Schreiner PJ, Ellison RC,
Tsai MY, Patel SR, Redline S, Johnson AD, Hoogeveen RC, Hakonarson H,
Rotter JI, Boerwinkle E, de Bakker PI, Kivimaki M, Asselbergs FW, Sattar N,
Lawlor DA, Whittaker J, Davey Smith G, Mukamal K, Psaty BM, Wilson JG,
Lange LA, Hamidovic A, Hingorani AD, Nordestgaard BG, Bobak M, Leon DA,
Langenberg C, Palmer TM, Reiner AP, Keating BJ, Dudbridge F, Casas JP,
InterAct Consortium. Association between alcohol and cardiovascular disease:
Mendelian randomisation analysis based on individual participant data. BMJ
2014;349:g4164.
416. Zeraatkar D, Johnston BC, Bartoszko J, Cheung K, Bala MM, Valli C, Rabassa M,
Sit D, Milio K, Sadeghirad B, Agarwal A, Zea AM, Lee Y, Han MA, Vernooij
RWM, Alonso-Coello P, Guyatt GH, El Dib R. Effect of Lower Versus Higher
Red Meat Intake on Cardiometabolic and Cancer Outcomes: A Systematic
Review of Randomized Trials. Ann Intern Med 2019;171:721731.
417. Zhong VW, Van Horn L, Greenland P, Carnethon MR, Ning H, Wilkins JT,
Lloyd-Jones DM, Allen NB. Associations of Processed Meat, Unprocessed Red
Meat, Poultry, or Fish Intake With Incident Cardiovascular Disease and AllCause Mortality. JAMA Intern Med 2020;180:503512.
418. Zheng J, Huang T, Yu Y, Hu X, Yang B, Li D. Fish consumption and CHD mortality: an updated meta-analysis of seventeen cohort studies. Public Health Nutr
2012;15:725737.
419. Mullee A, Romaguera D, Pearson-Stuttard J, Viallon V, Stepien M, Freisling H,
Fagherazzi G, Mancini FR, Boutron-Ruault MC, Kuhn T, Kaaks R, Boeing H,
Aleksandrova K, Tjonneland A, Halkjaer J, Overvad K, Weiderpass E, Skeie G,
Parr CL, Quiros JR, Agudo A, Sanchez MJ, Amiano P, Cirera L, Ardanaz E,
Khaw KT, Tong TYN, Schmidt JA, Trichopoulou A, Martimianaki G, Karakatsani
A, Palli D, Agnoli C, Tumino R, Sacerdote C, Panico S, Bueno-de-Mesquita B,
Verschuren WMM, Boer JMA, Vermeulen R, Ramne S, Sonestedt E, van
Guelpen B, Holgersson PL, Tsilidis KK, Heath AK, Muller D, Riboli E, Gunter
MJ, Murphy N. Association Between Soft Drink Consumption and Mortality in
10 European Countries. JAMA Intern Med 2019;179:14791490.
420. World Health Organization. Guideline: sugars intake for adults and children.
https://www.who.int/publications/i/item/9789241549028 (21 July 2020).
421. Sundfor TM, Svendsen M, Heggen E, Dushanov S, Klemsdal TO, Tonstad S. BMI
modifies the effect of dietary fat on atherogenic lipids: a randomized clinical trial. Am J Clin Nutr 2019;110:832841.
422. Mozaffarian D, Katan MB, Ascherio A, Stampfer MJ, Willett WC. Trans fatty acids and cardiovascular disease. N Engl J Med 2006;354:16011613.
423. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E,
Conlin PR, Miller ER, 3rd, Simons-Morton DG, Karanja N, Lin PH, DASH-Sodium
Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium
Collaborative Research Group. N Engl J Med 2001;344:310.
424. Mente A, O’Donnell M, Rangarajan S, Dagenais G, Lear S, McQueen M, Diaz R,
Avezum A, Lopez-Jaramillo P, Lanas F, Li W, Lu Y, Yi S, Rensheng L, Iqbal R,
Mony P, Yusuf R, Yusoff K, Szuba A, Oguz A, Rosengren A, Bahonar A, Yusufali
A, Schutte AE, Chifamba J, Mann JF, Anand SS, Teo K, Yusuf S, PURE,
EPIDREAM and ONTARGET/TRANSCEND Investigators. Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies. Lancet
2016;388:465475.
425. Cappuccio FP, Campbell NR. Population Dietary Salt Reduction and the Risk of
Cardiovascular Disease: A Commentary on Recent Evidence. J Clin Hypertens
(Greenwich) 2017;19:45.
426. He FJ, Ma Y, Campbell NRC, MacGregor GA, Cogswell ME, Cook NR.
Formulas to Estimate Dietary Sodium Intake From Spot Urine Alter SodiumMortality Relationship. Hypertension 2019;74:572580.
427. Aburto NJ, Hanson S, Gutierrez H, Hooper L, Elliott P, Cappuccio FP. Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses. BMJ 2013;346:f1378.
428. Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, Gibson H,
Gordon D, Copeland T, D’Agostino D, Friedenberg G, Ridge C, Bubes V,
Giovannucci EL, Willett WC, Buring JE, VITAL Research Group. Vitamin D
Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J
Med 2019;380:3344.
429. Huang T, Afzal S, Yu C, Guo Y, Bian Z, Yang L, Millwood IY, Walters RG, Chen
Y, Chen N, Gao R, Chen J, Clarke R, Chen Z, Ellervik C, Nordestgaard BG, Lv
J, Li L, China Kadoorie Biobank Collaborative Group. Vitamin D and causespecific vascular disease and mortality: a Mendelian randomisation study involving 99,012 Chinese and 106,911 European adults. BMC Med 2019;17:160.
430. Threapleton DE, Greenwood DC, Evans CE, Cleghorn CL, Nykjaer C,
Woodhead C, Cade JE, Gale CP, Burley VJ. Dietary fibre intake and risk of cardiovascular disease: systematic review and meta-analysis. BMJ 2013;347:f6879.
431. Zhang Z, Xu G, Liu D, Zhu W, Fan X, Liu X. Dietary fiber consumption and risk of stroke. Eur J Epidemiol 2013;28:119130.
432. Yao B, Fang H, Xu W, Yan Y, Xu H, Liu Y, Mo M, Zhang H, Zhao Y. Dietary fiber intake and risk of type 2 diabetes: a dose-response analysis of prospective studies. Eur J Epidemiol 2014;29:7988.
433. Giacco R, Costabile G, Della Pepa G, Anniballi G, Griffo E, Mangione A,
Cipriano P, Viscovo D, Clemente G, Landberg R, Pacini G, Rivellese AA,
Riccardi G. A whole-grain cereal-based diet lowers postprandial plasma insulin and triglyceride levels in individuals with metabolic syndrome. Nutr Metab
Cardiovasc Dis 2014;24:837844.
434. Wang X, Ouyang Y, Liu J, Zhu M, Zhao G, Bao W, Hu FB. Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer:
systematic review and dose-response meta-analysis of prospective cohort studies. BMJ 2014;349:g4490.
435. He FJ, Nowson CA, MacGregor GA. Fruit and vegetable consumption and stroke: meta-analysis of cohort studies. Lancet 2006;367:320326.
436. Dauchet L, Amouyel P, Hercberg S, Dallongeville J. Fruit and vegetable consumption and risk of coronary heart disease: a meta-analysis of cohort studies. J
Nutr 2006;136:25882593.
437. Luo C, Zhang Y, Ding Y, Shan Z, Chen S, Yu M, Hu FB, Liu L. Nut consumption and risk of type 2 diabetes, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis. Am J Clin Nutr 2014;100:256269.
438. Afshin A, Micha R, Khatibzadeh S, Mozaffarian D. Consumption of nuts and legumes and risk of incident ischemic heart disease, stroke, and diabetes: a systematic review and meta-analysis. Am J Clin Nutr 2014;100:278288.
439. World Cancer Research Fund, American Institute for Cancer Research. Diet,
Nutrition, Physical Activity and Cancer: a Global Perspective, 2018. https://www.wcrf.
org/dietandcancer/recommendations/limit-red-processed-meat (21 July 2020).
440. Chowdhury R, Kunutsor S, Vitezova A, Oliver-Williams C, Chowdhury S,
Kiefte-de-Jong JC, Khan H, Baena CP, Prabhakaran D, Hoshen MB, Feldman BS,
Pan A, Johnson L, Crowe F, Hu FB, Franco OH. Vitamin D and risk of cause


<!-- PAGE 99 -->

### Page 99

.............................................................................................................................................................................
specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. BMJ 2014;348:g1903.
441. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012;308:10241033.
442. Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, Deane
KH, AlAbdulghafoor FK, Summerbell CD, Worthington HV, Song F, Hooper L.
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2018;7:CD003177.
443. Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, Geleijnse JM,
Rauch B, Ness A, Galan P, Chew EY, Bosch J, Collins R, Lewington S, Armitage J,
Clarke R, Omega-3 Treatment Trialists’ Collaboration. Associations of Omega-3
Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of
10 Trials Involving 77917 Individuals. JAMA Cardiol 2018;3:225234.
444. Hu Y, Hu FB, Manson JE. Marine Omega-3 Supplementation and Cardiovascular
Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials
Involving 127 477 Participants. J Am Heart Assoc 2019;8:e013543.
445. Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, Davidson
MH, Kastelein JJP, Koenig W, McGuire DK, Mozaffarian D, Ridker PM, Ray KK,
Katona BG, Himmelmann A, Loss LE, Rensfeldt M, Lundstrom T, Agrawal R,
Menon V, Wolski K, Nissen SE. Effect of High-Dose Omega-3 Fatty Acids vs
Corn Oil on Major Adverse Cardiovascular Events in Patients at High
Cardiovascular
Risk:
The
STRENGTH
Randomized
Clinical
Trial.
JAMA
2020;324:22682280.
446. Tverdal A, Selmer R, Cohen JM, Thelle DS. Coffee consumption and mortality from cardiovascular diseases and total mortality: Does the brewing method matter? Eur J Prev Cardiol 2020;27:19861993.
447. Poole R, Kennedy OJ, Roderick P, Fallowfield JA, Hayes PC, Parkes J. Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes. BMJ 2017;359:j5024.
448. Ras RT, Geleijnse JM, Trautwein EA. LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges: a meta-analysis of randomised controlled studies. Br J Nutr 2014;112:214219.
449. Peng D, Fong A, Pelt AV. Original Research: The Effects of Red Yeast
Rice
Supplementation on
Cholesterol
Levels in
Adults.
Am
J
Nurs
2017;117:4654.
450. Zomer E, Gurusamy K, Leach R, Trimmer C, Lobstein T, Morris S, James WP,
Finer N. Interventions that cause weight loss and the impact on cardiovascular risk factors:
a systematic review and meta-analysis.
Obes
Rev
2016;17:10011011.
451. Wing RR, Espeland MA, Clark JM, Hazuda HP, Knowler WC, Pownall HJ, Unick
J, Wadden T, Wagenknecht L, Action for Health in Diabetes (Look AHEAD)
Study Group. Association of Weight Loss Maintenance and Weight Regain on
4-Year Changes in CVD Risk Factors: the Action for Health in Diabetes (Look
AHEAD) Clinical Trial. Diabetes Care 2016;39:13451355.
452. Howell S, Kones R. "Calories in, calories out" and macronutrient intake: the hope,
hype,
and science of calories.
Am
J
Physiol
Endocrinol
Metab
2017;313:E608E612.
453. Ge L, Sadeghirad B, Ball GDC, da Costa BR, Hitchcock CL, Svendrovski A,
Kiflen R, Quadri K, Kwon HY, Karamouzian M, Adams-Webber T, Ahmed W,
Damanhoury S, Zeraatkar D, Nikolakopoulou A, Tsuyuki RT, Tian J, Yang K,
Guyatt GH, Johnston BC. Comparison of dietary macronutrient patterns of 14
popular named dietary programmes for weight and cardiovascular risk factor reduction in adults: systematic review and network meta-analysis of randomised trials. BMJ 2020;369:m696.
454. Tobias DK, Chen M, Manson JE, Ludwig DS, Willett W, Hu FB. Effect of low-fat diet interventions versus other diet interventions on long-term weight change in adults: a systematic review and meta-analysis. Lancet Diabetes Endocrinol
2015;3:968979.
455. Cardoso L, Rodrigues D, Gomes L, Carrilho F. Short- and long-term mortality after bariatric surgery: A systematic review and meta-analysis. Diabetes Obes
Metab 2017;19:12231232.
456. Ma C, Avenell A, Bolland M, Hudson J, Stewart F, Robertson C, Sharma P,
Fraser C, MacLennan G. Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis. BMJ 2017;359:j4849.
457. Mancini JG, Filion KB, Atallah R, Eisenberg MJ. Systematic Review of the
Mediterranean Diet for Long-Term Weight Loss. Am J Med 2016;129:407415
e404.
458. Sofi F, Dinu M, Pagliai G, Cesari F, Gori AM, Sereni A, Becatti M, Fiorillo C, Marcucci
R, Casini A. Low-Calorie Vegetarian Versus Mediterranean Diets for Reducing Body
Weight and
Improving
Cardiovascular
Risk
Profile:
CARDIVEG
Study
(Cardiovascular Prevention With Vegetarian Diet). Circulation 2018;137:11031113.
459. Huang RY, Huang CC, Hu FB, Chavarro JE. Vegetarian Diets and Weight
Reduction: a Meta-Analysis of Randomized Controlled Trials. J Gen Intern Med
2016;31:109116.
460. Reynolds A, Mann J, Cummings J, Winter N, Mete E, Te Morenga L.
Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. Lancet 2019;393:434445.
461. Kirkpatrick CF, Bolick JP, Kris-Etherton PM, Sikand G, Aspry KE, Soffer DE,
Willard KE, Maki KC. Review of current evidence and clinical recommendations on the effects of low-carbohydrate and very-low-carbohydrate (including ketogenic) diets for the management of body weight and other cardiometabolic risk factors: A scientific statement from the National Lipid Association Nutrition and Lifestyle Task Force. J Clin Lipidol 2019;13:689711 e681.
462. Seidelmann SB, Claggett B, Cheng S, Henglin M, Shah A, Steffen LM, Folsom
AR, Rimm EB, Willett WC, Solomon SD. Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis. Lancet Public Health
2018;3:e419e428.
463. Rynders CA, Thomas EA, Zaman A, Pan Z, Catenacci VA, Melanson EL.
Effectiveness of Intermittent Fasting and Time-Restricted Feeding Compared to
Continuous Energy Restriction for Weight Loss. Nutrients 2019;11:2442.
464. Kane JA, Mehmood T, Munir I, Kamran H, Kariyanna PT, Zhyvotovska A,
Yusupov D, Suleman UJ, Gustafson DR, McFarlane SI. Cardiovascular Risk
Reduction Associated with Pharmacological Weight Loss: A Meta-Analysis. Int J
Clin Res Trials 2019;4:131.
465. Barber S, Thornicroft G. Reducing the Mortality Gap in People With Severe
Mental Disorders: The Role of Lifestyle Psychosocial Interventions. Front
Psychiatry 2018;9:463.
466. Richards SH, Anderson L, Jenkinson CE, Whalley B, Rees K, Davies P, Bennett
P, Liu Z, West R, Thompson DR, Taylor RS. Psychological interventions for coronary heart disease. Cochrane Database Syst Rev 2017;4:CD002902.
467. Gulliksson M, Burell G, Vessby B, Lundin L, Toss H, Svardsudd K. Randomized controlled trial of cognitive behavioral therapy vs standard treatment to prevent recurrent cardiovascular events in patients with coronary heart disease:
Secondary Prevention in Uppsala Primary Health Care project (SUPRIM). Arch
Intern Med 2011;171:134140.
468. Orth-Gomer K, Schneiderman N, Wang HX, Walldin C, Blom M, Jernberg T.
Stress reduction prolongs life in women with coronary disease: the Stockholm
Women’s Intervention Trial for Coronary Heart Disease (SWITCHD). Circ
Cardiovasc Qual Outcomes 2009;2:2532.
469. Blumenthal JA, Sherwood A, Smith PJ, Watkins L, Mabe S, Kraus WE, Ingle K,
Miller
P,
Hinderliter
A.
Enhancing
Cardiac
Rehabilitation
With
Stress
Management
Training:
A
Randomized,
Clinical
Efficacy
Trial.
Circulation
2016;133:13411350.
470. Pizzi C, Rutjes AW, Costa GM, Fontana F, Mezzetti A, Manzoli L. Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol 2011;107:972979.
471. Kim JM, Stewart R, Lee YS, Lee HJ, Kim MC, Kim JW, Kang HJ, Bae KY, Kim
SW, Shin IS, Hong YJ, Kim JH, Ahn Y, Jeong MH, Yoon JS. Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in
Patients With Acute Coronary Syndrome: A Randomized Clinical Trial. JAMA
2018;320:350358.
472. He W, Zhou Y, Ma J, Wei B, Fu Y. Effect of antidepressants on death in patients with heart failure: a systematic review and meta-analysis. Heart Fail Rev
2020;25:919926.
473. Angermann CE, Gelbrich G, Stork S, Gunold H, Edelmann F, Wachter R,
Schunkert H, Graf T, Kindermann I, Haass M, Blankenberg S, Pankuweit S,
Prettin C, Gottwik M, Bohm M, Faller H, Deckert J, Ertl G, MOOD-HF Study
Investigators and Committee Members. Effect of Escitalopram on All-Cause
Mortality and Hospitalization in Patients With Heart Failure and Depression:
The MOOD-HF Randomized Clinical Trial. JAMA 2016;315:26832693.
474. Taylor G, McNeill A, Girling A, Farley A, Lindson-Hawley N, Aveyard P.
Change in mental health after smoking cessation: systematic review and metaanalysis. BMJ 2014;348:g1151.
475. Prochaska JJ, Hall SE, Delucchi K, Hall SM. Efficacy of initiating tobacco dependence treatment in inpatient psychiatry: a randomized controlled trial. Am J Public
Health 2014;104:15571565.
476. Cooney GM, Dwan K, Greig CA, Lawlor DA, Rimer J, Waugh FR, McMurdo M,
Mead GE. Exercise for depression. Cochrane Database Syst Rev 2013:CD004366.
477. Opie RS, Itsiopoulos C, Parletta N, Sanchez-Villegas A, Akbaraly TN, Ruusunen
A, Jacka FN. Dietary recommendations for the prevention of depression. Nutr
Neurosci 2017;20:161171.
478. Palmer VJ, Lewis M, Stylianopolous V, Furler J. Primary care prevention of the cardiovascular health crisis for people with severe mental illnesses: The elephant in the room. Aust J Gen Pract 2018;47:846850.
479. Druss BG, von Esenwein SA, Compton MT, Rask KJ, Zhao L, Parker RM. A
randomized trial of medical care management for community mental health settings: the Primary Care Access, Referral, and Evaluation (PCARE) study. Am J
Psychiatry 2010;167:151159.
480. Osborn D, Burton A, Walters K, Atkins L, Barnes T, Blackburn R, Craig T,
Gilbert H, Gray B, Hardoon S, Heinkel S, Holt R, Hunter R, Johnston C, King
ESC Guidelines
3325


<!-- PAGE 100 -->

### Page 100

.............................................................................................................................................................................
M, Leibowitz J, Marston L, Michie S, Morris R, Morris S, Nazareth I, Omar R,
Petersen I, Peveler R, Pinfold V, Stevenson F, Zomer E. Primary care management of cardiovascular risk for people with severe mental illnesses: the Primrose research programme including cluster RCT. Southampton (UK); 2019.
481. Seldenrijk A, Vogelzangs N, Batelaan NM, Wieman I, van Schaik DJ, Penninx BJ.
Depression, anxiety and 6-year risk of cardiovascular disease. J Psychosom Res
2015;78:123129.
482. Gilsanz P, Kubzansky LD, Tchetgen Tchetgen EJ, Wang Q, Kawachi I, Patton
KK, Fitzpatrick AL, Kop WJ, Longstreth WT, Jr., Glymour MM. Changes in
Depressive Symptoms and Subsequent Risk of Stroke in the Cardiovascular
Health Study. Stroke 2017;48:4348.
483. Smolderen KG, Buchanan DM, Gosch K, Whooley M, Chan PS, Vaccarino V,
Parashar S, Shah AJ, Ho PM, Spertus JA. Depression Treatment and 1-Year
Mortality After Acute Myocardial Infarction: Insights From the TRIUMPH
Registry (Translational Research Investigating Underlying Disparities in Acute
Myocardial Infarction Patients’ Health Status). Circulation 2017;135:16811689.
484. Smolderen KG, Spertus JA, Gosch K, Dreyer RP, D’Onofrio G, Lichtman JH,
Geda M, Beltrame J, Safdar B, Bueno H, Krumholz HM. Depression Treatment and Health Status Outcomes in Young Patients With Acute Myocardial
Infarction: Insights From the VIRGO Study (Variation in Recovery: Role of
Gender on
Outcomes of
Young
AMI
Patients).
Circulation
2017;135:17621764.
485. Tully PJ, Baumeister H. Collaborative care for comorbid depression and coronary heart disease: a systematic review and meta-analysis of randomised controlled trials. BMJ Open 2015;5:e009128.
486. Honkola J, Hookana E, Malinen S, Kaikkonen KS, Junttila MJ, Isohanni M,
Kortelainen ML, Huikuri HV. Psychotropic medications and the risk of sudden cardiac death during an acute coronary event. Eur Heart J 2012;33:745751.
487. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA
2003;290:8697.
488. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE, Lung
Health Study Research Group. The effects of a smoking cessation intervention on
14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142:233239.
489. Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev
2018;5:CD000146.
490. HughesJR, Stead LF, Lancaster T. Antidepressants for smoking cessation.
Cochrane Database Syst Rev 2007:CD000031.
491. Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev
2016:CD006103.
492. Lindson N, Chepkin SC, Ye W, Fanshawe TR, Bullen C, Hartmann-Boyce J.
Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2019;4:CD013308.
493. Woolf KJ, Zabad MN, Post JM, McNitt S, Williams GC, Bisognano JD. Effect of nicotine replacement therapy on cardiovascular outcomes after acute coronary syndromes. Am J Cardiol 2012;110:968970.
494. Suissa K, Lariviere J, Eisenberg MJ, Eberg M, Gore GC, Grad R, Joseph L,
Reynier PM, Filion KB. Efficacy and Safety of Smoking Cessation Interventions in
Patients
With
Cardiovascular
Disease:
A
Network
Meta-Analysis of
Randomized Controlled Trials. Circ Cardiovasc Qual Outcomes 2017;10:e002458.
495. Hu Y, Zong G, Liu G, Wang M, Rosner B, Pan A, Willett WC, Manson JE, Hu
FB, Sun Q. Smoking Cessation, Weight Change, Type 2 Diabetes, and Mortality.
N Engl J Med 2018;379:623632.
496. Mons U, Muezzinler A, Gellert C, Schottker B, Abnet CC, Bobak M, de Groot L,
Freedman ND, Jansen E, Kee F, Kromhout D, Kuulasmaa K, Laatikainen T,
O’Doherty MG, Bueno-de-Mesquita B, Orfanos P, Peters A, van der Schouw YT,
Wilsgaard T, Wolk A, Trichopoulou A, Boffetta P, Brenner H, CHANCES
Consortium. Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium. BMJ 2015;350:h1551.
497. Gellert C, Schottker B, Brenner H. Smoking and all-cause mortality in older people:
systematic review and meta-analysis.
Arch
Intern
Med
2012;172:837844.
498. Prugger C, Wellmann J, Heidrich J, De Bacquer D, De Backer G, Perier MC,
Empana JP, Reiner Z, Fras Z, Jennings C, Kotseva K, Wood D, Keil U,
EUROASPIRE Study Group. Readiness for smoking cessation in coronary heart disease patients across Europe: Results from the EUROASPIRE III survey. Eur J
Prev Cardiol 2015;22:12121219.
499. Hartmann-Boyce J, Stead LF, Cahill K, Lancaster T. Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews. Addiction
2014;109:14141425.
500. Eisenberg MJ, Windle SB, Roy N, Old W, Grondin FR, Bata I, Iskander A,
Lauzon C, Srivastava N, Clarke A, Cassavar D, Dion D, Haught H, Mehta SR,
Baril JF, Lambert C, Madan M, Abramson BL, Dehghani P, EVITA Investigators.
Varenicline for Smoking Cessation in Hospitalized Patients With Acute
Coronary Syndrome. Circulation 2016;133:2130.
501. Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D,
Ascher J, Russ C, Krishen A, Evins AE. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 2016;387:25072520.
502. Benowitz NL, Pipe A, West R, Hays JT, Tonstad S, McRae T, Lawrence D, St
Aubin L, Anthenelli RM. Cardiovascular Safety of Varenicline, Bupropion, and
Nicotine Patch in Smokers: A Randomized Clinical Trial. JAMA Intern Med
2018;178:622631.
503. Hartmann-Boyce J, McRobbie H, Lindson N, Bullen C, Begh R, Theodoulou A,
Notley C, Rigotti NA, Turner T, Butler AR, Hajek P. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev 2020;10:CD010216.
504. Hajek P, Phillips-Waller A, Przulj D, Pesola F, Myers Smith K, Bisal N, Li J,
Parrott S, Sasieni P, Dawkins L, Ross L, Goniewicz M, Wu Q, McRobbie HJ. A
Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy. N
Engl J Med 2019;380:629637.
505. Li J, Hajek P, Pesola F, Wu Q, Phillips-Waller A, Przulj D, Myers Smith K, Bisal
N, Sasieni P, Dawkins L, Ross L, Goniewicz ML, McRobbie H, Parrott S. Costeffectiveness of e-cigarettes compared with nicotine replacement therapy in stop smoking services in England (TEC study): a randomized controlled trial.
Addiction 2020;115:507517.
506. Kavousi M, Pisinger C, Barthelemy JC, Smedt D, Koskinas K, Marques-Vidal P,
Panagiotakos D, Prescott EB, Tiberi M, Vassiliou VS, Lochen ML. Electronic cigarettes and health with special focus on cardiovascular effects: position paper of the European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol
2020:2047487320941993.
507. European Heart Network. Electronic cigarettes and cardiovascular disease 
an update from the European Heart Network http://www.ehnheart.org/compo nent/attachments/attachments.html?task=attachment&id=3093 (21 July 2020).
508. Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, Bejot Y, Cabrejo L, Cha
JK, Ducrocq G, Giroud M, Guidoux C, Hobeanu C, Kim YJ, Lapergue B,
Lavallee PC, Lee BC, Lee KB, Leys D, Mahagne MH, Meseguer E, Nighoghossian
N, Pico F, Samson Y, Sibon I, Steg PG, Sung SM, Touboul PJ, Touze E, Varenne
O, Vicaut E, Yelles N, Bruckert E, Treat Stroke to Target Investigators. A
Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. N Engl J
Med 2020;382:9.
509. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL,
Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L,
Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgozoglu L, TybjaergHansen A, Watts GF, European Atherosclerosis Society Consensus Panel.
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011;32:13451361.
510. Cartier LJ, Collins C, Lagace M, Douville P. Comparison of fasting and nonfasting lipid profiles in a large cohort of patients presenting at a community hospital. Clin Biochem 2018;52:6166.
511. Sampson M, Ling C, Sun Q, Harb R, Ashmaig M, Warnick R, Sethi A, Fleming
JK, Otvos JD, Meeusen JW, Delaney SR, Jaffe AS, Shamburek R, Amar M,
Remaley AT. A New Equation for Calculation of Low-Density Lipoprotein
Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia.
JAMA Cardiol 2020;5:540548.
512. Penson P, Martin SS, Henney NC, Banach M. Comparison of LDL-C calculation by friedewald and martin/hopkins methods in 12,243 adults from the United
States of America [abstract]. Eur Heart J 2020;41(Suppl 2):2932.
513. Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, Simes
RJ, Durrington P, Hitman GA, Welch KM, DeMicco DA, Zwinderman AH,
Clearfield MB, Downs JR, Tonkin AM, Colhoun HM, Gotto AM, Jr., Ridker PM,
Kastelein JJ. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012;307:13021309.
514. Welsh C, Celis-Morales CA, Brown R, Mackay DF, Lewsey J, Mark PB, Gray SR,
Ferguson LD, Anderson JJ, Lyall DM, Cleland JG, Jhund PS, Gill JMR, Pell JP,
Sattar N, Welsh P. Comparison of Conventional Lipoprotein Tests and
Apolipoproteins in the Prediction of Cardiovascular Disease. Circulation
2019;140:542552.
515. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius
H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im
K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E,
Califf RM, IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after
Acute Coronary Syndromes. N Engl J Med 2015;372:23872397.
516. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA,
Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER
Steering Committee and Investigators. Evolocumab and Clinical Outcomes in
Patients with Cardiovascular Disease. N Engl J Med 2017;376:17131722.


<!-- PAGE 101 -->

### Page 101

.............................................................................................................................................................................
517. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM,
Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey
KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci
P,
White
HD,
Zeiher
AM,
ODYSSEY
OUTCOMES
Committees and
Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary
Syndrome. N Engl J Med 2018;379:20972107.
518. Ridker PM, Rose LM, Kastelein JJP, Santos RD, Wei C, Revkin J, Yunis C, Tardif
JC, Shear CL, Studies of PCSK9 Inhibition and the Reduction of vascular Events
(SPIRE) Investigators. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE
randomized trials of bococizumab. J Clin Lipidol 2018;12:958965.
519. Mozaffarian D. Natural trans fat, dairy fat, partially hydrogenated oils, and cardiometabolic health: the Ludwigshafen Risk and Cardiovascular Health Study. Eur
Heart J 2016;37:10791081.
520. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de
Craen AJ, Knopp RH, Nakamura H, Ridker P, van Domburg R, Deckers JW.
The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials.
BMJ 2009;338:b2376.
521. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network metaanalysis involving more than
65,000
patients.
J
Am
Coll
Cardiol
2008;52:17691781.
522. Cholesterol Treatment Trialists’ (CTT) Collaboration, Fulcher J, O’Connell R,
Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A,
Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P,
Franzosi MG, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015;385:13971405.
523. Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ,
Bruckert E, Jacobson TA, Kopecky SL, Baccara-Dinet MT, Du Y, Pordy R, Gipe
DA, ODYSSEY ALTERNATIVE Investigators. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The
ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol 2015;9:758769.
524. Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss
D, Bruckert E, Ceska R, Lepor N, Ballantyne CM, Gouni-Berthold I, Elliott M,
Brennan DM, Wasserman SM, Somaratne R, Scott R, Stein EA, GAUSS-3
Investigators. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients
With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical
Trial. JAMA 2016;315:15801590.
525. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner
C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L,
Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U,
Ophascharoensuk V, Fellstrom B, Holdaas H, Tesar V, Wiecek A, Grobbee D,
de Zeeuw D, Gronhagen-Riska C, Dasgupta T, Lewis D, Herrington W,
Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J,
Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S,
Simpson D, Sleight P, Young A, Collins R, SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:21812192.
526. Schreml J, Gouni-Berthold I. Role of Anti-PCSK9 Antibodies in the Treatment of Patients with Statin Intolerance. Curr Med Chem 2018;25:15381548.
527. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal
R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S,
Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P,
Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R. Interpretation of the evidence for the efficacy and safety of statin therapy.
Lancet
2016;388:25322561.
528. Myocardial Infarction Genetics Consortium Investigators, Stitziel NO, Won
HH, Morrison AC, Peloso GM, Do R, Lange LA, Fontanillas P, Gupta N, Duga
S, Goel A, Farrall M, Saleheen D, Ferrario P, Konig I, Asselta R, Merlini PA,
Marziliano N, Notarangelo MF, Schick U, Auer P, Assimes TL, Reilly M,
Wilensky R, Rader DJ, Hovingh GK, Meitinger T, Kessler T, Kastrati A, Laugwitz
KL, Siscovick D, Rotter JI, Hazen SL, Tracy R, Cresci S, Spertus J, Jackson R,
Schwartz SM, Natarajan P, Crosby J, Muzny D, Ballantyne C, Rich SS, O’Donnell
CJ, Abecasis G, Sunaev S, Nickerson DA, Buring JE, Ridker PM, Chasman DI,
Austin E, Kullo IJ, Weeke PE, Shaffer CM, Bastarache LA, Denny JC, Roden DM,
Palmer C, Deloukas P, Lin DY, Tang ZZ, Erdmann J, Schunkert H, Danesh J,
Marrugat J, Elosua R, Ardissino D, McPherson R, Watkins H, Reiner AP, Wilson
JG, Altshuler D, Gibbs RA, Lander ES, Boerwinkle E, Gabriel S, Kathiresan S.
Inactivating mutations in NPC1L1 and protection from coronary heart disease.
N Engl J Med 2014;371:20722082.
529. Cho L, Rocco M, Colquhoun D, Sullivan D, Rosenson RS, Dent R, Xue A, Scott
R, Wasserman SM, Stroes E. Clinical Profile of Statin Intolerance in the Phase 3
GAUSS-2 Study. Cardiovasc Drugs Ther 2016;30:297304.
530. Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA,
Richardson T, Jaros M, Wijngaard PLJ, Kastelein JJP, ORION-10 and ORION-11
Investigators. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL
Cholesterol. N Engl J Med 2020;382:15071519.
531. Triglyceride Coronary Disease Genetics Consortium, Emerging Risk Factors
Collaboration, Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di
Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, Saleheen
D, Lawlor D, Reilly MP, Hingorani AD, Talmud PJ, Danesh J. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies.
Lancet 2010;375:16341639.
532. Cicero AFG, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhov M, Fras
Z, Katsiki N, Langlois M, Latkovskis G, Panagiotakos DB, Paragh G, Mikhailidis
DP, Mitchenko O, Paulweber B, Pella D, Pitsavos C, Reiner Z, Ray KK, Rizzo
M, Sahebkar A, Serban MC, Sperling LS, Toth PP, Vinereanu D, Vrablik M,
Wong ND, Banach M. Lipid-lowering nutraceuticals in clinical practice: position paper from an
International
Lipid
Expert
Panel.
Nutr
Rev
2017;75:731767.
533. Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, Hovingh GK, Kastelein JJ, Melamed S,
Barter P, Waters DD, Ray KK. Triglyceride-Rich Lipoprotein Cholesterol and
Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the
TNT Trial. Circulation 2018;138:770781.
534. Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol
Ther 2010;126:314345.
535. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR, 3rd,
Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm
RH, Ismail-Beigi F, Bigger JT, Goff DC, Jr., Cushman WC, Simons-Morton DG,
Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N
Engl J Med 2010;362:15631574.
536. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A,
Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P,
d’Emden M, Whiting M, Ehnholm C, Laakso M, FIELD study investigators.
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Lancet 2005;366:18491861.
537. Mortensen MB, Nordestgaard BG. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary prevention cohort. Lancet
2020;396:16441652.
538. Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28
randomised controlled trials. Lancet 2019;393:407415.
539. Gencer B, Marston NA, Im K, Cannon CP, Sever P, Keech A, Braunwald E,
Giugliano RP, Sabatine MS. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet 2020;396:16371643.
540. Cholesterol Treatment Trialists’ (CTT) Collaborators, Kearney PM, Blackwell L,
Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117125.
541. Emerging Risk Factors Collaboration, Di Angelantonio E, Kaptoge S, Wormser
D, Willeit P, Butterworth AS, Bansal N, O’Keeffe LM, Gao P, Wood AM,
Burgess S, Freitag DF, Pennells L, Peters SA, Hart CL, Haheim LL, Gillum RF,
Nordestgaard BG, Psaty BM, Yeap BB, Knuiman MW, Nietert PJ, Kauhanen J,
Salonen JT, Kuller LH, Simons LA, van der Schouw YT, Barrett-Connor E,
Selmer R, Crespo CJ, Rodriguez B, Verschuren WM, Salomaa V, Svardsudd K,
van der Harst P, Bjorkelund C, Wilhelmsen L, Wallace RB, Brenner H,
Amouyel P, Barr EL, Iso H, Onat A, Trevisan M, D’Agostino RB, Sr., Cooper C,
Kavousi M, Welin L, Roussel R, Hu FB, Sato S, Davidson KW, Howard BV,
Leening MJ, Leening M, Rosengren A, Dorr M, Deeg DJ, Kiechl S, Stehouwer
CD, Nissinen A, Giampaoli S, Donfrancesco C, Kromhout D, Price JF, Peters A,
Meade TW, Casiglia E, Lawlor DA, Gallacher J, Nagel D, Franco OH, Assmann
G, Dagenais GR, Jukema JW, Sundstrom J, Woodward M, Brunner EJ, Khaw KT,
Wareham NJ, Whitsel EA, Njolstad I, Hedblad B, Wassertheil-Smoller S,
Engstrom G, Rosamond WD, Selvin E, Sattar N, Thompson SG, Danesh J.
Association of
Cardiometabolic
Multimorbidity
With
Mortality.
JAMA
2015;314:5260.
542. Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalan R, Spinar J, Park
JG, White JA, Bohula EA, Braunwald E, IMPROVE-IT (Improved Reduction of
Outcomes: Vytorin Efficacy International Trial) Investigators. Benefit of Adding
Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients
With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved
Reduction of Outcomes:
Vytorin Efficacy International Trial).
Circulation
2018;137:15711582.
543. Wanner C, Tonelli M, Kidney Disease: Improving Global Outcomes Lipid
Guideline Development Work Group Members. KDIGO Clinical Practice
ESC Guidelines
3327


<!-- PAGE 102 -->

### Page 102

.............................................................................................................................................................................
Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 2014;85:13031309.
544. Cholesterol
Treatment
Trialists’
(CTT)
Collaboration,
Herrington
WG,
Emberson J, Mihaylova B, Blackwell L, Reith C, Solbu MD, Mark PB, Fellstrom B,
Jardine AG, Wanner C, Holdaas H, Fulcher J, Haynes R, Landray MJ, Keech A,
Simes J, Collins R, Baigent C. Impact of renal function on the effects of LDL
cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from
28
randomised trials.
Lancet
Diabetes
Endocrinol
2016;4:829839.
545. Barylski M, Nikfar S, Mikhailidis DP, Toth PP, Salari P, Ray KK, Pencina MJ, Rizzo
M, Rysz J, Abdollahi M, Nicholls SJ, Banach M, Lipid and Blood Pressure MetaAnalysis Collaboration Group. Statins decrease all-cause mortality only in CKD
patients not requiring dialysis therapy–a meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res 2013;72:3544.
546. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E, German
Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2
diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238248.
547. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J,
Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R,
Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S,
Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP,
Gottlow M, Johnsson E, Zannad F, AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med
2009;360:13951407.
548. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S,
Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlof B, LIFE Study
Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004;292:23432349.
549. Sehestedt T, Jeppesen J, Hansen TW, Wachtell K, Ibsen H, Torp-Pedersen C,
Hildebrandt P, Olsen MH. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J 2010;31:883891.
550. Perrone-Filardi P, Coca A, Galderisi M, Paolillo S, Alpendurada F, de Simone G,
Donal E, Kahan T, Mancia G, Redon J, Schmieder R, Williams B, Agabiti-Rosei E.
Non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: A consensus paper from the European Association of Cardiovascular Imaging (EACVI), the European Society of Cardiology
Council on Hypertension, and the European Society of Hypertension (ESH).
Eur Heart J Cardiovasc Imaging 2017;18:945960.
551. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, Patel A,
Cass A, Neal B, Poulter N, Mogensen CE, Cooper M, Marre M, Williams B,
Hamet P, Mancia G, Woodward M, Macmahon S, Chalmers J, ADVANCE
Collaborative Group. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes.
J
Am
Soc
Nephrol
2009;20:18131821.
552. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J,
Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet
2016;387:957967.
553. Sundstrom J, Arima H, Jackson R, Turnbull F, Rahimi K, Chalmers J, Woodward
M, Neal B, Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med 2015;162:184191.
554. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and metaregression analyses of randomized trials. J Hypertens 2014;32:22852295.
555. SPRINT Research Group, Wright JT, Jr., Williamson JD, Whelton PK, Snyder JK,
Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel
PL, Johnson KC, Goff DC, Jr., Fine LJ, Cutler JA, Cushman WC, Cheung AK,
Ambrosius WT. A Randomized Trial of Intensive versus Standard BloodPressure Control. N Engl J Med 2015;373:21032116.
556. Patel A, ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B,
Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P,
Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY,
Rodgers A, Williams B. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet
2007;370:829840.
557. Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC,
Chertow GM, Fine LJ, Haley WE, Hawfield AT, Ix JH, Kitzman DW, Kostis JB,
Krousel-Wood MA, Launer LJ, Oparil S, Rodriguez CJ, Roumie CL, Shorr RI,
Sink KM, Wadley VG, Whelton PK, Whittle J, Woolard NF, Wright JT, Jr.,
Pajewski NM, SPRINT Research Group. Intensive vs Standard Blood Pressure
Control and Cardiovascular Disease Outcomes in Adults Aged >/=75 Years: A
Randomized Clinical Trial. JAMA 2016;315:26732682.
558. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials. J Hypertens 2016;34:613622.
559. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC, Jr.,
Grimm RH, Jr., Cutler JA, Simons-Morton DG, Basile JN, Corson MA,
Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT,
Gerstein HC, Ismail-Beigi F. Effects of intensive blood-pressure control in type
2 diabetes mellitus. N Engl J Med 2010;362:15751585.
560. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290300.
561. Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg
KS. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012;59:11241131.
562. Rea F, Corrao G, Merlino L, Mancia G. Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension.
Eur Heart J 2018;39:36543661.
563. Salam A, Kanukula R, Atkins E, Wang X, Islam S, Kishore SP, Jaffe MG, Patel A,
Rodgers A. Efficacy and safety of dual combination therapy of blood pressurelowering drugs as initial treatment for hypertension: a systematic review and meta-analysis of randomized controlled trials. J Hypertens 2019;37:17681774.
564. Gupta P, Patel P, Strauch B, Lai FY, Akbarov A, Gulsin GS, Beech A, Maresova
V, Topham PS, Stanley A, Thurston H, Smith PR, Horne R, Widimsky J, Keavney
B, Heagerty A, Samani NJ, Williams B, Tomaszewski M. Biochemical Screening for
Nonadherence
Is
Associated
With
Blood
Pressure
Reduction and
Improvement in Adherence. Hypertension 2017;70:10421048.
565. MacDonald TM, Williams B, Webb DJ, Morant S, Caulfield M, Cruickshank JK,
Ford I, Sever P, Mackenzie IS, Padmanabhan S, McCann GP, Salsbury J, McInnes
G, Brown MJ, British Hypertension Society Programme of Prevention And
Treatment of Hypertension With Algorithm-based Therapy (PATHWAY).
Combination Therapy Is Superior to Sequential Monotherapy for the Initial
Treatment of Hypertension: A Double-Blind Randomized Controlled Trial. J
Am Heart Assoc 2017;6:e006986.
566. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R,
Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E,
Ostergren J, ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian
Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895906.
567. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J,
Gatlin M, Velazquez EJ, ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J
Med 2008;359:24172428.
568. Yusuf S, Lonn E, Pais P, Bosch J, Lopez-Jaramillo P, Zhu J, Xavier D, Avezum A,
Leiter LA, Piegas LS, Parkhomenko A, Keltai M, Keltai K, Sliwa K, Chazova I,
Peters RJ, Held C, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM,
Varigos J, Accini JL, McKelvie R, Pogue J, Jung H, Liu L, Diaz R, Dans A,
Dagenais G, HOPE-3 Investigators. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. N Engl J Med 2016;374:20322043.
569. Matsuzaki M, Ogihara T, Umemoto S, Rakugi H, Matsuoka H, Shimada K, Abe
K, Suzuki N, Eto T, Higaki J, Ito S, Kamiya A, Kikuchi K, Suzuki H, Tei C, Ohashi
Y, Saruta T, Combination Therapy of Hypertension to Prevent Cardiovascular
Events Trial Group. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens 2011;29:16491659.
570. Weir MR, Hsueh WA, Nesbitt SD, Littlejohn TJ, 3rd, Graff A, Shojaee A,
Waverczak WF, Qian C, Jones CJ, Neutel JM. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil þ/- hydrochlorothiazide. J
Clin Hypertens (Greenwich) 2011;13:404412.
571. Volpe M, Christian Rump L, Ammentorp B, Laeis P. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. Clin Drug Investig 2012;32:649664.
572. Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, Ford I,
Cruickshank JK, Caulfield MJ, Padmanabhan S, Mackenzie IS, Salsbury J, Brown
MJ, British Hypertension Society programme of Prevention And Treatment of
Hypertension With Algorithm based Therapy (PATHWAY) Study Group.
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol 2018;6:464475.
573. Agarwal R, Rossignol P, Romero A, Garza D, Mayo MR, Warren S, Ma J, White
WB, Williams B. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a


<!-- PAGE 103 -->

### Page 103

.............................................................................................................................................................................
phase
2,
randomised,
double-blind,
placebo-controlled trial.
Lancet
2019;394:15401550.
574. Krieger EM, Drager LF, Giorgi DMA, Pereira AC, Barreto-Filho JAS, Nogueira
AR, Mill JG, Lotufo PA, Amodeo C, Batista MC, Bodanese LC, Carvalho ACC,
Castro I, Chaves H, Costa EAS, Feitosa GS, Franco RJS, Fuchs FD, Guimaraes
AC, Jardim PC, Machado CA, Magalhaes ME, Mion D, Jr., Nascimento RM,
Nobre F, Nobrega AC, Ribeiro ALP, Rodrigues-Sobrinho CR, Sanjuliani AF,
Teixeira M, Krieger JE, ReHOT Investigators. Spironolactone Versus Clonidine as a
Fourth-Drug
Therapy for
Resistant
Hypertension:
The
ReHOT
Randomized Study (Resistant Hypertension Optimal Treatment). Hypertension
2018;71:681690.
575. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I,
Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events.
N
Engl
J
Med
2008;358:15471559.
576. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD,
Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P,
Pfeffer MA, ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:22042213.
577. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, Alexander L,
Estep K, Hassen Abate K, Akinyemiju TF, Ali R, Alvis-Guzman N, Azzopardi P,
Banerjee A, Barnighausen T, Basu A, Bekele T, Bennett DA, Biadgilign S, CatalaLopez F, Feigin VL, Fernandes JC, Fischer F, Gebru AA, Gona P, Gupta R,
Hankey GJ, Jonas JB, Judd SE, Khang YH, Khosravi A, Kim YJ, Kimokoti RW,
Kokubo Y, Kolte D, Lopez A, Lotufo PA, Malekzadeh R, Melaku YA, Mensah
GA, Misganaw A, Mokdad AH, Moran AE, Nawaz H, Neal B, Ngalesoni FN,
Ohkubo T, Pourmalek F, Rafay A, Rai RK, Rojas-Rueda D, Sampson UK, Santos
IS, Sawhney M, Schutte AE, Sepanlou SG, Shifa GT, Shiue I, Tedla BA, Thrift
AG, Tonelli M, Truelsen T, Tsilimparis N, Ukwaja KN, Uthman OA, Vasankari
T, Venketasubramanian N, Vlassov VV, Vos T, Westerman R, Yan LL, Yano Y,
Yonemoto N, Zaki ME, Murray CJ. Global Burden of Hypertension and Systolic
Blood
Pressure of at
Least
110
to
115
mm
Hg,
1990-2015.
JAMA
2017;317:165182.
578. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, Bahonar A,
Chifamba J, Dagenais G, Diaz R, Kazmi K, Lanas F, Wei L, Lopez-Jaramillo P,
Fanghong L, Ismail NH, Puoane T, Rosengren A, Szuba A, Temizhan A,
Wielgosz A, Yusuf R, Yusufali A, McKee M, Liu L, Mony P, Yusuf S, PURE
(Prospective Urban Rural Epidemiology) Study investigators. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013;310:959968.
579. Siu AL, US Preventive Services Task Force. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. Ann
Intern Med 2015;163:778786.
580. Huang CJ, Chiang CE, Williams B, Kario K, Sung SH, Chen CH, Wang TD,
Cheng
HM.
Effect
Modification by
Age on the
Benefit or
Harm of
Antihypertensive Treatment for Elderly Hypertensives: A Systematic Review and Meta-analysis. Am J Hypertens 2019;32:163174.
581. Verma AA, Khuu W, Tadrous M, Gomes T, Mamdani MM. Fixed-dose combination antihypertensive medications,
adherence,
and clinical outcomes:
A
population-based retrospective cohort study. PLoS Med 2018;15:e1002584.
582. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs - overview and meta-analyses. J Hypertens 2015;33:195211.
583. Sattar N, Preiss D. HbA1c in type 2 diabetes diagnostic criteria: addressing the right questions to move the field forwards.
Diabetologia
2012;55:15641567.
584. The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the
European Society of Cardiology (ESC) and developed in collaboration with the
European Association for the Study of Diabetes (EASD). ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2013;34:30353087.
585. Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters
C,
Zhyzhneuskaya
S,
Al-Mrabeh
A,
Hollingsworth
KG,
Rodrigues
AM,
Rehackova L, Adamson AJ, Sniehotta FF, Mathers JC, Ross HM, McIlvenna Y,
Welsh P, Kean S, Ford I, McConnachie A, Messow CM, Sattar N, Taylor R.
Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol 2019;7:344355.
586. Taheri S, Zaghloul H, Chagoury O, Elhadad S, Ahmed SH, El Khatib N, Amona
RA, El Nahas K, Suleiman N, Alnaama A, Al-Hamaq A, Charlson M, Wells MT,
Al-Abdulla S, Abou-Samra AB. Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label,
parallel-group,
randomised controlled trial.
Lancet
Diabetes
Endocrinol
2020;8:477489.
587. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet
1998;352:837853.
588. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B,
Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P,
Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers
A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J
Med 2008;358:25602572.
589. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854865.
590. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O,
Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding
JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019;393:3139.
591. Kristensen SL, Rorth R, Jhund PS, Docherty KF, Sattar N, Preiss D, Kober L,
Petrie MC, McMurray JJV. Cardiovascular, mortality, and kidney outcomes with
GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol
2019;7:776785.
592. Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, D’Alessio
DA, Davies MJ. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA)
and the European Association for the Study of Diabetes (EASD). Diabetologia
2020;63:221228.
593. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve
FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek
ME, Henderson WG, Huang GD, VADT Investigators. Glucose control and vascular complications in veterans with type
2
diabetes.
N
Engl
J
Med
2009;360:129139.
594. Hernandez AF, Green JB, Janmohamed S, D’Agostino RB, Sr., Granger CB,
Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM,
McMurray JJV, Del Prato S, Harmony Outcomes committees and investigators.
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018;392:15191529.
595. Ferrannini G, Gerstein H, Colhoun HM, Dagenais GR, Diaz R, Dyal L,
Lakshmanan M, Mellbin L, Probstfield J, Riddle MC, Shaw JE, Avezum A, Basile
JN, Cushman WC, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Pais
P, Pirags V, Pogosova N, Raubenheimer PJ, Sheu WH, Ryden L. Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. Eur Heart J 2020:[Online ahead of print].
596. Crowley MJ, McGuire DK, Alexopoulos AS, Jensen TJ, Rasmussen S, Saevereid
HA, Verma S, Buse JB. Effects of Liraglutide on Cardiovascular Outcomes in
Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc
Analyses of the LEADER Trial. Diabetes Care 2020;43:e108e110.
597. Neuen BL, Arnott C, Perkovic V, Figtree G, de Zeeuw D, Fulcher G, Jun M,
Jardine MJ, Zoungas S, Pollock C, Mahaffey KW, Neal B, Heerspink HJL.
Sodium-glucose co-transporter-2 inhibitors with and without metformin: A
meta-analysis of cardiovascular, kidney and mortality outcomes. Diabetes Obes
Metab 2021;23:382390.
598. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM,
Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de
Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H,
Zinman B, Meininger G, Brenner BM, Mahaffey KW, CREDENCE Trial
Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and
Nephropathy. N Engl J Med 2019;380:22952306.
599. Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou
FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjostrom CD, Toto RD,
Langkilde AM, Wheeler DC, DAPA-CKD Trial Committees and Investigators.
Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med
2020;383:14361446.
600. McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA,
Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, Bohm M, Chiang CE,
Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukat A, Ge J, Howlett
JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E,
Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL,
Docherty KF, Jhund PS, Bengtsson O, Sjostrand M, Langkilde AM, DAPA-HF
Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019;381:19952008.
601. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J,
Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C,
Cotton D, Bocchi E, Bohm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N,
Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP,
ESC Guidelines
3329


<!-- PAGE 104 -->

### Page 104

.............................................................................................................................................................................
Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M,
Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F, EMPERORReduced
Trial
Investigators.
Cardiovascular and
Renal
Outcomes with
Empagliflozin in Heart Failure. N Engl J Med 2020;383:14131424.
602. Sattar N, McMurray JJ, Cheng AY. Cardiorenal risk reduction guidance in diabetes: can we reach consensus? Lancet Diabetes Endocrinol 2020;8:357360.
603. Gong Q, Zhang P, Wang J, Ma J, An Y, Chen Y, Zhang B, Feng X, Li H, Chen X,
Cheng YJ, Gregg EW, Hu Y, Bennett PH, Li G, Da Qing Diabetes Prevention
Study Group. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes
Prevention Outcome Study. Lancet Diabetes Endocrinol 2019;7:452461.
604. Celis-Morales CA, Petermann F, Hui L, Lyall DM, Iliodromiti S, McLaren J,
Anderson J, Welsh P, Mackay DF, Pell JP, Sattar N, Gill JMR, Gray SR.
Associations Between Diabetes and Both Cardiovascular Disease and All-Cause
Mortality Are Modified by Grip Strength: Evidence From UK Biobank, a
Prospective
Population-Based
Cohort
Study.
Diabetes
Care
2017;40:17101718.
605. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D,
Erqou S, Sattar N. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009;373:17651772.
606. Control Group, Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers
JP, Duckworth WC, Evans GW, Gerstein HC, Holman RR, Moritz TE, Neal BC,
Ninomiya T, Patel AA, Paul SK, Travert F, Woodward M. Intensive glucose control and macrovascular outcomes in type
2
diabetes.
Diabetologia
2009;52:22882298.
607. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R,
Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E,
Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR, TECOS
Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2
Diabetes. N Engl J Med 2015;373:232242.
608. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P,
Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR,
Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I, SAVOR-TIMI 53 Steering
Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:13171326.
609. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez
AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F,
EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:13271335.
610. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N,
Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra
D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK,
CARMELINA
Investigators.
Effect of
Linagliptin vs
Placebo on
Major
Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and
Renal
Risk:
The
CARMELINA
Randomized
Clinical
Trial.
JAMA
2019;321:6979.
611. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M,
Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG
OUTCOME
Investigators.
Empagliflozin,
Cardiovascular
Outcomes,
and
Mortality in Type 2 Diabetes. N Engl J Med 2015;373:21172128.
612. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw
W, Law G, Desai M, Matthews DR, CANVAS Program Collaborative Group.
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J
Med 2017;377:644657.
613. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG,
Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding
JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM,
Sabatine
MS,
DECLARETIMI
58
Investigators.
Dapagliflozin and
Cardiovascular
Outcomes in
Type
2
Diabetes.
N
Engl
J
Med
2019;380:347357.
614. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U,
Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG,
Cherney
DZI,
McGuire
DK,
VERTIS
CV
Investigators.
Cardiovascular
Outcomes with
Ertugliflozin in
Type
2
Diabetes.
N
Engl
J
Med
2020;383:14251435.
615. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P,
Probstfield J, Riesmeyer JS, Riddle MC, Ryden L, Xavier D, Atisso CM, Dyal L,
Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I,
Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M,
Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova
N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T, REWIND
Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes
(REWIND):
a double-blind,
randomised placebo-controlled trial.
Lancet
2019;394:121130.
616. Marx N, Davies MJ, Grant PJ, Mathieu C, Petrie JR, Cosentino F, Buse JB.
Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. Lancet Diabetes Endocrinol 2021;9:4652.
617. Writing Group for the DCCT/EDIC Research Group, Orchard TJ, Nathan DM,
Zinman B, Cleary P, Brillon D, Backlund JY, Lachin JM. Association between 7
years of intensive treatment of type 1 diabetes and long-term mortality. JAMA
2015;313:4553.
618. Petrie JR, Chaturvedi N, Ford I, Brouwers M, Greenlaw N, Tillin T, Hramiak I,
Hughes AD, Jenkins AJ, Klein BEK, Klein R, Ooi TC, Rossing P, Stehouwer
CDA, Sattar N, Colhoun HM, REMOVAL Study Group. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol
2017;5:597609.
619. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins
R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T,
Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:18491860.
620. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events
(CAPRIE).
Lancet
1996;348:13291339.
621. Chiarito M, Sanz-Sanchez J, Cannata F, Cao D, Sturla M, Panico C, Godino C,
Regazzoli D, Reimers B, De Caterina R, Condorelli G, Ferrante G, Stefanini
GG. Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. Lancet 2020;395:14871495.
622. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C,
Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen
T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip
J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ, ESC Scientific Document
Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407477.
623. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, Kastrati
A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG,
Windecker S, Zamorano JL, Levine GN, ESC Scientific Document Group. 2017
ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur J Cardiothorac Surg 2018;53:3478.
624. ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K,
Stevens W, Buck G, Barton J, Murphy K, Aung T, Haynes R, Cox J, Murawska
A, Young A, Lay M, Chen F, Sammons E, Waters E, Adler A, Bodansky J,
Farmer A, McPherson R, Neil A, Simpson D, Peto R, Baigent C, Collins R,
Parish S, Armitage J. Effects of Aspirin for Primary Prevention in Persons with
Diabetes Mellitus. N Engl J Med 2018;379:15291539.
625. Seidu S, Kunutsor SK, Sesso HD, Gaziano JM, Buring JE, Roncaglioni MC, Khunti
K. Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials. Cardiovasc Diabetol 2019;18:70.
626. McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, Reid CM,
Lockery JE, Kirpach B, Storey E, Shah RC, Williamson JD, Margolis KL, Ernst
ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin
LJ, Johnston CI, Ryan J, Radziszewska B, Jelinek M, Malik M, Eaton CB, Brauer D,
Cloud G, Wood EM, Mahady SE, Satterfield S, Grimm R, Murray AM, ASPREE
Investigator Group. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med 2018;379:15091518.
627. Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB,
Howard G, Pearson TA, Rothwell PM, Ruilope LM, Tendera M, Tognoni G,
ARRIVE Executive Committee. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 2018;392:10361046.
628. Abdelaziz HK, Saad M, Pothineni NVK, Megaly M, Potluri R, Saleh M, Kon DLC,
Roberts DH, Bhatt DL, Aronow HD, Abbott JD, Mehta JL. Aspirin for Primary
Prevention of Cardiovascular Events. J Am Coll Cardiol 2019;73:29152929.
629. Zheng SL, Roddick AJ. Association of Aspirin Use for Primary Prevention With
Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis. JAMA 2019;321:277287.
630. Mahmoud AN, Gad MM, Elgendy AY, Elgendy IY, Bavry AA. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials.
Eur
Heart
J
2019;40:607617.
631. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL.
Aspirin for the primary prevention of cardiovascular events in women and men:
a sex-specific meta-analysis of randomized controlled trials.
JAMA
2006;295:306313.
632. Halvorsen S, Andreotti F, ten Berg JM, Cattaneo M, Coccheri S, Marchioli R,
Morais
J,
Verheugt
FW,
De
Caterina
R.
Aspirin therapy in primary


<!-- PAGE 105 -->

### Page 105

.............................................................................................................................................................................
cardiovascular disease prevention: a position paper of the European Society of
Cardiology working group on thrombosis. J Am Coll Cardiol 2014;64:319327.
633. Yusuf S, Joseph P, Dans A, Gao P, Teo K, Xavier D, Lopez-Jaramillo P, Yusoff K,
Santoso A, Gamra H, Talukder S, Christou C, Girish P, Yeates K, Xavier F,
Dagenais G, Rocha C, McCready T, Tyrwhitt J, Bosch J, Pais P, International
Polycap Study 3 Investigators. Polypill with or without Aspirin in Persons without Cardiovascular Disease. N Engl J Med 2021;384:216228.
634. Scally B, Emberson JR, Spata E, Reith C, Davies K, Halls H, Holland L, Wilson K,
Bhala N, Hawkey C, Hochberg M, Hunt R, Laine L, Lanas A, Patrono C, Baigent
C. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet
Gastroenterol Hepatol 2018;3:231241.
635. Agewall S, Cattaneo M, Collet JP, Andreotti F, Lip GY, Verheugt FW, Huber K,
Grove EL, Morais J, Husted S, Wassmann S, Rosano G, Atar D, Pathak A,
Kjeldsen K, Storey RF, ESC Working Group on Cardiovascular Pharmacology and Drug Therapy and ESC Working Group on Thrombosis. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J 2013;34:17081713, 1713a1713b.
636. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C,
Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella
D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L,
Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT,
Libby P, Glynn RJ, CANTOS Trial Group. Antiinflammatory Therapy with
Canakinumab for Atherosclerotic Disease. N Engl J Med 2017;377:11191131.
637. Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E,
Mam V, Hasan A, Rosenberg Y, Iturriaga E, Gupta M, Tsigoulis M, Verma S,
Clearfield M, Libby P, Goldhaber SZ, Seagle R, Ofori C, Saklayen M, Butman S,
Singh N, Le May M, Bertrand O, Johnston J, Paynter NP, Glynn RJ, CIRT
Investigators. Low-Dose Methotrexate for the Prevention of Atherosclerotic
Events. N Engl J Med 2019;380:752762.
638. Anderson L, Thompson DR, Oldridge N, Zwisler AD, Rees K, Martin N, Taylor
RS. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane
Database Syst Rev 2016:CD001800.
639. Long L, Mordi IR, Bridges C, Sagar VA, Davies EJ, Coats AJ, Dalal H, Rees K,
Singh SJ, Taylor RS. Exercise-based cardiac rehabilitation for adults with heart failure. Cochrane Database Syst Rev 2019;1:CD003331.
640. Salzwedel A, Jensen K, Rauch B, Doherty P, Metzendorf MI, Hackbusch M,
Voller H, Schmid JP, Davos CH. Effectiveness of comprehensive cardiac rehabilitation in coronary artery disease patients treated according to contemporary evidence based medicine: Update of the Cardiac Rehabilitation Outcome Study
(CROS-II). Eur J Prev Cardiol 2020;27:17561774.
641. Santiago de Araujo Pio C, Marzolini S, Pakosh M, Grace SL. Effect of Cardiac
Rehabilitation Dose on Mortality and Morbidity: A Systematic Review and
Meta-regression Analysis. Mayo Clin Proc 2017;92:16441659.
642. van Halewijn G, Deckers J, Tay HY, van Domburg R, Kotseva K, Wood D.
Lessons from contemporary trials of cardiovascular prevention and rehabilitation: A systematic review and meta-analysis. Int J Cardiol 2017;232:294303.
643. Santiago de Araujo Pio C, Chaves GS, Davies P, Taylor RS, Grace SL.
Interventions to promote patient utilisation of cardiac rehabilitation. Cochrane
Database Syst Rev 2019;2:CD007131.
644. Jorstad HT, von Birgelen C, Alings AM, Liem A, van Dantzig JM, Jaarsma W, Lok
DJ, Kragten HJ, de Vries K, de Milliano PA, Withagen AJ, Scholte Op Reimer
WJ, Tijssen JG, Peters RJ. Effect of a nurse-coordinated prevention programme on cardiovascular risk after an acute coronary syndrome: main results of the
RESPONSE randomised trial. Heart 2013;99:14211430.
645. Jennings C, Kotseva K, De Bacquer D, Hoes A, de Velasco J, Brusaferro S, Mead
A, Jones J, Tonstad S, Wood D, EUROACTION PLUS Study Group.
Effectiveness of a preventive cardiology programme for high CVD risk persistent smokers:
the
EUROACTION
PLUS
varenicline trial.
Eur
Heart
J
2014;35:14111420.
646. Wood DA, Kotseva K, Connolly S, Jennings C, Mead A, Jones J, Holden A, De
Bacquer D, Collier T, De Backer G, Faergeman O, EUROACTION Study
Group. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet 2008;371:19992012.
647. Anderson L, Sharp GA, Norton RJ, Dalal H, Dean SG, Jolly K, Cowie A,
Zawada A, Taylor RS. Home-based versus centre-based cardiac rehabilitation.
Cochrane Database Syst Rev 2017;6:CD007130.
648. Jin K, Khonsari S, Gallagher R, Gallagher P, Clark AM, Freedman B, Briffa T,
Bauman A, Redfern J, Neubeck L. Telehealth interventions for the secondary prevention of coronary heart disease: A systematic review and meta-analysis.
Eur J Cardiovasc Nurs 2019;18:260271.
649. Verschueren S, Eskes AM, Maaskant JM, Roest AM, Latour CHM, Op Reimer
WS. The effect of exercise therapy on depressive and anxious symptoms in patients with ischemic heart disease: A systematic review. J Psychosom Res
2018;105:8091.
650. Taylor RS, Walker S, Smart NA, Piepoli MF, Warren FC, Ciani O, Whellan D,
O’Connor C, Keteyian SJ, Coats A, Davos CH, Dalal HM, Dracup K, Evangelista
LS, Jolly K, Myers J, Nilsson BB, Passino C, Witham MD, Yeh GY,
ExTraMATCH II Collaboration. Impact of Exercise Rehabilitation on Exercise
Capacity and Quality-of-Life in Heart Failure: Individual Participant MetaAnalysis. J Am Coll Cardiol 2019;73:14301443.
651. Shields GE, Wells A, Doherty P, Heagerty A, Buck D, Davies LM. Cost-effectiveness of cardiac rehabilitation:
a systematic review.
Heart
2018;104:14031410.
652. Bjarnason-Wehrens B, McGee H, Zwisler AD, Piepoli MF, Benzer W, Schmid
JP, Dendale P, Pogosova NG, Zdrenghea D, Niebauer J, Mendes M, Cardiac
Rehabilitation Section European Association of Cardiovascular Prevention and
Rehabilitation. Cardiac rehabilitation in Europe: results from the European
Cardiac
Rehabilitation
Inventory
Survey.
Eur
J
Cardiovasc
Prev
Rehabil
2010;17:410418.
653. Benzer W, Rauch B, Schmid JP, Zwisler AD, Dendale P, Davos CH, Kouidi E,
Simon A, Abreu A, Pogosova N, Gaita D, Miletic B, Bonner G, Ouarrak T,
McGee H, EuroCaReD study group. Exercise-based cardiac rehabilitation in twelve European countries results of the European cardiac rehabilitation registry. Int J Cardiol 2017;228:5867.
654. Kabboul NN, Tomlinson G, Francis TA, Grace SL, Chaves G, Rac V, DaouKabboul T, Bielecki JM, Alter DA, Krahn M. Comparative Effectiveness of the
Core Components of Cardiac Rehabilitation on Mortality and Morbidity: A
Systematic Review and Network Meta-Analysis. J Clin Med 2018;7:514.
655. Anderson L, Brown JP, Clark AM, Dalal H, Rossau HK, Bridges C, Taylor RS.
Patient education in the management of coronary heart disease. Cochrane
Database Syst Rev 2017;6:CD008895.
656. Borjesson M, Dellborg M, Niebauer J, LaGerche A, Schmied C, Solberg EE,
Halle M, Adami E, Biffi A, Carre F, Caselli S, Papadakis M, Pressler A, Rasmusen
H, Serratosa L, Sharma S, van Buuren F, Pelliccia A. Recommendations for participation in leisure time or competitive sports in athletes-patients with coronary artery disease: a position statement from the Sports Cardiology Section of the European Association of Preventive Cardiology (EAPC). Eur Heart J
2019;40:1318.
657. Abreu A, Frederix I, Dendale P, Janssen A, Doherty P, Piepoli MF, Voller H,
Secondary Prevention and Rehabilitation Section of EAPC. Standardization and quality improvement of secondary prevention through cardiovascular rehabilitation programmes in Europe: The avenue towards EAPC accreditation programme: A position statement of the Secondary Prevention and Rehabilitation
Section of the European Association of Preventive Cardiology (EAPC). Eur J
Prev Cardiol 2020:2047487320924912.
658. Hansen D, Rovelo Ruiz G, Doherty P, Iliou MC, Vromen T, Hinton S, Frederix
I, Wilhelm M, Schmid JP, Abreu A, Ambrosetti M, Garcia-Porrero E, Coninx K,
Dendale P, EAPC EXPERT working group. Do clinicians prescribe exercise similarly in patients with different cardiovascular diseases? Findings from the EAPC
EXPERT working group survey. Eur J Prev Cardiol 2018;25:682691.
659. Hansen D, Dendale P, Coninx K, Vanhees L, Piepoli MF, Niebauer J,
Cornelissen V, Pedretti R, Geurts E, Ruiz GR, Corra U, Schmid JP, Greco E,
Davos CH, Edelmann F, Abreu A, Rauch B, Ambrosetti M, Braga SS, Barna O,
Beckers P, Bussotti M, Fagard R, Faggiano P, Garcia-Porrero E, Kouidi E,
Lamotte M, Neunhauserer D, Reibis R, Spruit MA, Stettler C, Takken T, Tonoli
C, Vigorito C, Voller H, Doherty P. The European Association of Preventive
Cardiology Exercise Prescription in Everyday Practice and Rehabilitative
Training (EXPERT) tool: A digital training and decision support system for optimized exercise prescription in cardiovascular disease. Concept, definitions and construction methodology. Eur J Prev Cardiol 2017;24:10171031.
660. Abell B, Glasziou P, Hoffmann T. The Contribution of Individual Exercise
Training Components to Clinical Outcomes in Randomised Controlled Trials of
Cardiac Rehabilitation: A Systematic Review and Meta-regression. Sports Med
Open 2017;3:19.
661. Kotseva K, De Backer G, De Bacquer D, Ryden L, Hoes A, Grobbee D, Maggioni
A, Marques-Vidal P, Jennings C, Abreu A, Aguiar C, Badariene J, Bruthans J, Castro
Conde A, Cifkova R, Crowley J, Davletov K, Deckers J, De Smedt D, De Sutter J,
Dilic M, Dolzhenko M, Dzerve V, Erglis A, Fras Z, Gaita D, Gotcheva N,
Heuschmann P, Hasan-Ali H, Jankowski P, Lalic N, Lehto S, Lovic D, Mancas S,
Mellbin L, Milicic D, Mirrakhimov E, Oganov R, Pogosova N, Reiner Z, Stoerk S,
Tokgozoglu L, Tsioufis C, Vulic D, Wood D, EUROASPIRE Investigators. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27
countries: Results from the
European Society of
Cardiology
ESC-EORP
EUROASPIRE V registry. Eur J Prev Cardiol 2019;26:824835.
662. Resurreccion DM, Moreno-Peral P, Gomez-Herranz M, Rubio-Valera M, Pastor
L, Caldas de Almeida JM, Motrico E. Factors associated with non-participation in and dropout from cardiac rehabilitation programmes: a systematic review of prospective cohort studies. Eur J Cardiovasc Nurs 2019;18:3847.
ESC Guidelines
3331


<!-- PAGE 106 -->

### Page 106

.............................................................................................................................................................................
663. Hamilton SJ, Mills B, Birch EM, Thompson SC. Smartphones in the secondary prevention of cardiovascular disease: a systematic review. BMC Cardiovasc Disord
2018;18:25.
664. Giannuzzi P, Temporelli PL, Marchioli R, Maggioni AP, Balestroni G, Ceci V,
Chieffo C, Gattone M, Griffo R, Schweiger C, Tavazzi L, Urbinati S, Valagussa F,
Vanuzzo D, GOSPEL Investigators. Global secondary prevention strategies to limit event recurrence after myocardial infarction: results of the GOSPEL study,
a multicenter,
randomized controlled trial from the
Italian
Cardiac
Rehabilitation Network. Arch Intern Med 2008;168:21942204.
665. Rose G. Sick individuals and sick populations. Int J Epidemiol 1985;14:3238.
666. Rose G. Strategy of prevention: lessons from cardiovascular disease. Br Med J
(Clin Res Ed) 1981;282:18471851.
667. Sniderman AD, Thanassoulis G, Wilkins JT, Furberg CD, Pencina M. Sick
Individuals and Sick Populations by Geoffrey Rose: Cardiovascular Prevention
Updated. J Am Heart Assoc 2018;7:e010049.
668. Doyle YG, Furey A, Flowers J. Sick individuals and sick populations: 20 years later. J Epidemiol Community Health 2006;60:396398.
669. Sorensen K, Pelikan JM, Rothlin F, Ganahl K, Slonska Z, Doyle G, Fullam J,
Kondilis B, Agrafiotis D, Uiters E, Falcon M, Mensing M, Tchamov K, van den
Broucke S, Brand H, HLS-EU Consortium. Health literacy in Europe: comparative results of the European health literacy survey (HLS-EU). Eur J Public Health
2015;25:10531058.
670. Magnani JW, Mujahid MS, Aronow HD, Cene CW, Dickson VV, Havranek E,
Morgenstern LB, Paasche-Orlow MK, Pollak A, Willey JZ, American Heart
Association
Council on
Epidemiology and
Prevention,
Council on
Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke
Nursing, Council on Peripheral Vascular Disease, Council on Quality of Care and Outcomes Research, Council S. Health Literacy and Cardiovascular
Disease: Fundamental Relevance to Primary and Secondary Prevention: A
Scientific
Statement
From the
American
Heart
Association.
Circulation
2018;138:e48e74.
671. Jorgensen T, Capewell S, Prescott E, Allender S, Sans S, Zdrojewski T, De
Bacquer D, de Sutter J, Franco OH, Logstrup S, Volpe M, Malyutina S, MarquesVidal P, Reiner Z, Tell GS, Verschuren WM, Vanuzzo D, PEP section of EACPR.
Population-level changes to promote cardiovascular health. Eur J Prev Cardiol
2013;20:409421.
672. Mozaffarian D, Afshin A, Benowitz NL, Bittner V, Daniels SR, Franch HA, Jacobs
DR, Jr., Kraus WE, Kris-Etherton PM, Krummel DA, Popkin BM, Whitsel LP,
Zakai
NA,
American
Heart
Association
Council on
Epidemiology and
Prevention, Council on Nutrition, Physical Activity and Metabolism, Council on
Clinical Cardiology, Council on Cardiovascular Disease in the Young, Council on the Kidney in Cardiovascular Disease, Council on Peripheral Vascular
Disease, the American Heart Association Advocacy Coordinating Committee.
Population approaches to improve diet, physical activity, and smoking habits: a scientific statement from the
American
Heart
Association.
Circulation
2012;126:15141563.
673. Shah AS, Langrish JP, Nair H, McAllister DA, Hunter AL, Donaldson K, Newby
DE, Mills NL. Global association of air pollution and heart failure: a systematic review and meta-analysis. Lancet 2013;382:10391048.
674. Shah AS, Lee KK, McAllister DA, Hunter A, Nair H, Whiteley W, Langrish JP,
Newby DE, Mills NL. Short term exposure to air pollution and stroke: systematic review and meta-analysis. BMJ 2015;350:h1295.
675. Al-Kindi SG, Brook RD, Biswal S, Rajagopalan S. Environmental determinants of cardiovascular disease: lessons learned from air pollution. Nat Rev Cardiol
2020;17:656672.
676. Haines A, Ebi K. The Imperative for Climate Action to Protect Health. N Engl J
Med 2019;380:263273.
677. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ,
Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K,
Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S,
ESC Scientific Document Group. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent STsegment elevation: Task Force for the Management of Acute Coronary
Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016;37:267315.
678. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H,
Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A,
Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P,
Widimsky P, ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with STsegment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European
Society of Cardiology (ESC). Eur Heart J 2018;39:119177.
679. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U,
Byrne RA, Collet JP, Falk V, Head SJ, Juni P, Kastrati A, Koller A, Kristensen SD,
Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S,
Yadav R, Zembala MO, ESC Scientific Document Group. 2018 ESC/EACTS
Guidelines on myocardial revascularization. Eur Heart J 2019;40:87165.
680. Collet JP, Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt DL, Dendale
P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Juni P,
Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M,
Rutten FH, Sibbing D, Siontis GCM, ESC Scientific Document Group. 2020 ESC
Guidelines for the management of acute coronary syndromes in patients presenting without persistent
ST-segment elevation.
Eur
Heart
J
2021;42:12891367.
681. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, Clopidogrel in
Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494502.
682. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S,
Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G,
Gibson CM, Antman EM, TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes.
N
Engl
J
Med
2007;357:20012015.
683. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow
J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG,
Storey
RF,
Harrington
RA,
PLATO
Investigators.
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med
2009;361:10451057.
684. Schupke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wohrle J,
Richardt G, Liebetrau C, Witzenbichler B, Antoniucci D, Akin I, Bott-Flugel L,
Fischer M, Landmesser U, Katus HA, Sibbing D, Seyfarth M, Janisch M,
Boncompagni D, Hilz R, Rottbauer W, Okrojek R, Mollmann H, Hochholzer
W, Migliorini A, Cassese S, Mollo P, Xhepa E, Kufner S, Strehle A, Leggewie S,
Allali A, Ndrepepa G, Schuhlen H, Angiolillo DJ, Hamm CW, Hapfelmeier A,
Tolg R, Trenk D, Schunkert H, Laugwitz KL, Kastrati A, ISAR-REACT 5 Trial
Investigators. Ticagrelor or Prasugrel in Patients with Acute Coronary
Syndromes. N Engl J Med 2019;381:15241534.
685. Navarese EP, Khan SU, Kolodziejczak M, Kubica J, Buccheri S, Cannon CP,
Gurbel PA, De Servi S, Budaj A, Bartorelli A, Trabattoni D, Ohman EM,
Wallentin L, Roe MT, James S. Comparative Efficacy and Safety of Oral P2Y12
Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816
Patients From 12 Randomized Trials. Circulation 2020;142:150160.
686. Hahn JY, Song YB, Oh JH, Cho DK, Lee JB, Doh JH, Kim SH, Jeong JO, Bae JH,
Kim BO, Cho JH, Suh IW, Kim DI, Park HK, Park JS, Choi WG, Lee WS, Kim J,
Choi KH, Park TK, Lee JM, Yang JH, Choi JH, Choi SH, Gwon HC, SMARTDATE investigators. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
Lancet 2018;391:12741284.
687. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG,
Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR, Jr., Krucoff
MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP,
Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM, DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med
2014;371:21552166.
688. Bonaca MP, Braunwald E, Sabatine MS. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. N Engl J Med 2015;373:12741275.
689. Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C,
Andersson M, Himmelmann A, Ridderstrale W, Leonsson-Zachrisson M, Liu Y,
Opolski G, Zateyshchikov D, Ge J, Nicolau JC, Corbalan R, Cornel JH,
Widimsky P, Leiter LA, THEMIS Steering Committee and Investigators.
Ticagrelor in Patients with Stable Coronary Disease and Diabetes. N Engl J Med
2019;381:13091320.
690. McDonagh T, Metra M, Adamo M, Gardner R, Baumbach A, Bo¨hm M, Burri H,
Butler J, Celutkien_e J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG,
Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EW,
Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R,
Muneretto C, Piepoli MF, Price S, Rosano GMC, Ruschitzka F, Skibelund AK,
ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; doi: 10.1093/
eurheartj/ehab368.
691. Phillips CO, Wright SM, Kern DE, Singa RM, Shepperd S, Rubin HR.
Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. JAMA 2004;291:13581367.
692. Stewart S, Vandenbroek AJ, Pearson S, Horowitz JD. Prolonged beneficial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure.
Arch
Intern
Med
1999;159:257261.
693. McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol 2004;44:810819.


<!-- PAGE 107 -->

### Page 107

..........................................................................................................................................................................
694. Feltner C, Jones CD, Cene CW, Zheng ZJ, Sueta CA, Coker-Schwimmer EJ,
Arvanitis M, Lohr KN, Middleton JC, Jonas DE. Transitional care interventions to prevent readmissions for persons with heart failure: a systematic review and meta-analysis. Ann Intern Med 2014;160:774784.
695. Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002;8:216224.
696. Greene SJ, Vaduganathan M, Lupi L, Ambrosy AP, Mentz RJ, Konstam MA,
Nodari S, Subacius HP, Fonarow GC, Bonow RO, Gheorghiade M, EVEREST
Trial Investigators. Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). Am J Cardiol 2013;111:574581.
697. Sharma A, Lavie CJ, Borer JS, Vallakati A, Goel S, Lopez-Jimenez F, ArbabZadeh A, Mukherjee D, Lazar JM. Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. Am J Cardiol 2015;115:14281434.
698. Gupta PP, Fonarow GC, Horwich TB. Obesity and the obesity paradox in heart failure. Can J Cardiol 2015;31:195202.
699. Pandey A, Parashar A, Kumbhani D, Agarwal S, Garg J, Kitzman D, Levine B,
Drazner M, Berry J. Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials. Circ Heart Fail
2015;8:3340.
700. O’Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, Leifer ES,
Kraus WE, Kitzman DW, Blumenthal JA, Rendall DS, Miller NH, Fleg JL,
Schulman KA, McKelvie RS, Zannad F, Pina IL, HF-ACTION Investigators.
Efficacy and safety of exercise training in patients with chronic heart failure: HFACTION randomized controlled trial. JAMA 2009;301:14391450.
701. Taylor RS, Sagar VA, Davies EJ, Briscoe S, Coats AJ, Dalal H, Lough F, Rees K,
Singh S. Exercise-based rehabilitation for heart failure. Cochrane Database Syst
Rev 2014:CD003331.
702. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian
Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:14291435.
703. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure.
Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:14501456.
704. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie
BM, Ryden L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation
1999;100:23122318.
705. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293302.
706. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B,
Ostergren J, Pfeffer MA, Swedberg K, CHARM Investigators and Committees.
Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772776.
707. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL,
Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and
Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N
Engl J Med 2014;371:9931004.
708. Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K,
Rocha R, Braunwald E, PIONEER-HF Investigators. Angiotensin-Neprilysin
Inhibition in
Acute
Decompensated
Heart
Failure.
N
Engl
J
Med
2019;380:539548.
709. DeVore AD, Braunwald E, Morrow DA, Duffy CI, Ambrosy AP, Chakraborty
H, McCague K, Rocha R, Velazquez EJ, PIONEER-HF Investigators. Initiation of
Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure:
Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
JAMA Cardiol 2020;5:202207.
710. Wachter R, Senni M, Belohlavek J, Straburzynska-Migaj E, Witte KK, Kobalava Z,
Fonseca C, Goncalvesova E, Cavusoglu Y, Fernandez A, Chaaban S, Bohmer E,
Pouleur AC, Mueller C, Tribouilloy C, Lonn E, ALB J, Gniot J, Mozheiko M, Lelonek
M, Noe A, Schwende H, Bao W, Butylin D, Pascual-Figal D, TRANSITION
Investigators. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised
TRANSITION study. Eur J Heart Fail 2019;21:9981007.
711. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J,
Wikstrand J, El Allaf D, Vitovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus
KL, Janosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J,
Rickenbacher P, Ball S, Gottlieb S, Deedwania P. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure:
the Metoprolol CR/XL
Randomized
Intervention Trial in congestive heart failure
(MERIT-HF).
MERIT-HF
Study
Group.
JAMA
2000;283:12951302.
712. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL,
Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL, Carvedilol
Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:16511658.
713. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM,
Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J
Med 1996;334:13491355.
714. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure:
Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure
(MERIT-HF). Lancet 1999;353:20012007.
715. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P,
Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL,
Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS)
study. Circulation 2002;106:21942199.
716. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol
Study II (CIBIS-II): a randomised trial. Lancet 1999;353:913.
717. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A,
Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J,
Tavazzi L, Spinarova L, Toman J, Bohm M, Anker SD, Thompson SG, PooleWilson PA, SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215225.
718. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes
J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N
Engl J Med 1999;341:709717.
719. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent
J, Pocock SJ, Pitt B, EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:1121.
720. McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J, Lefkowitz
MP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Rizkala AR,
Sabarwal SV, Shah AM, Shah SJ, Shi VC, van Veldhuisen DJ, Zannad F, Zile MR,
Cikes M, Goncalvesova E, Katova T, Kosztin A, Lelonek M, Sweitzer N,
Vardeny O, Claggett B, Jhund PS, Solomon SD. Effects of Sacubitril-Valsartan
Versus Valsartan in Women Compared With Men With Heart Failure and
Preserved
Ejection
Fraction:
Insights
From
PARAGON-HF.
Circulation
2020;141:338351.
721. Santema BT, Ouwerkerk W, Tromp J, Sama IE, Ravera A, Regitz-Zagrosek V,
Hillege H, Samani NJ, Zannad F, Dickstein K, Lang CC, Cleland JG, Ter Maaten
JM, Metra M, Anker SD, van der Harst P, Ng LL, van der Meer P, van
Veldhuisen DJ, Meyer S, Lam CSP, ASIAN-HF investigators, Voors AA.
Identifying optimal doses of heart failure medications in men compared with women:
a prospective,
observational,
cohort study.
Lancet
2019;394:12541263.
722. Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam
CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J,
O’Connor CM, VICTORIA Study Group. Vericiguat in Patients with Heart
Failure and Reduced Ejection Fraction. N Engl J Med 2020;382:18831893.
723. Faris RF, Flather M, Purcell H, Poole-Wilson PA, Coats AJ. Diuretics for heart failure. Cochrane Database Syst Rev 2012:CD003838.
724. Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol 2002;82:149158.
725. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A,
Lerebours G, Tavazzi L, SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet
2010;376:875885.
726. Swedberg K, Komajda M, Bohm M, Borer J, Robertson M, Tavazzi L, Ford I,
SHIFT Investigators. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f)
inhibitor ivabradine Trial) study. J Am Coll Cardiol 2012;59:19381945.
727. Cina CS, Devereaux PJ, McFalls EO, ward HB, Moritz TE, Goldman S, Krupski
WC, Littooy F, Pierpont G, Santilli S, Rapp J, Hattler B, Shunk K, Jaenicke C,
Thottapurathu L, Ellis N, Reda DJ, Henderson WG. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med. 2004; 351: 2795804. Vasc Med 2006;11:61-63.
728. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE,
Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah
PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B. Effect of
ESC Guidelines
3333


<!-- PAGE 108 -->

### Page 108

.............................................................................................................................................................................
vasodilator therapy on mortality in chronic congestive heart failure. Results of a
Veterans
Administration
Cooperative
Study.
N
Engl
J
Med
1986;314:15471552.
729. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525533.
730. Minchin M, Roland M, Richardson J, Rowark S, Guthrie B. Quality of Care in the
United
Kingdom after
Removal of
Financial
Incentives.
N Engl
J Med
2018;379:948957.
731. Taylor AL, Ziesche S, Yancy C, Carson P, D’Agostino R, Jr., Ferdinand K, Taylor
M, Adams K, Sabolinski M, Worcel M, Cohn JN, African-American Heart Failure
Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:20492057.
732. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz
MD, Fang MC, Fisher M, Furie KL, Heck DV, Johnston SC, Kasner SE, Kittner SJ,
Mitchell PH, Rich MW, Richardson D, Schwamm LH, Wilson JA, American
Heart Association Stroke Council, Council on Cardiovascular and Stroke
Nursing, Council on Clinical Cardiology, Council on Peripheral Vascular
Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the
American
Heart
Association/American
Stroke
Association.
Stroke
2014;45:21602236.
733. Steiner T, Al-Shahi Salman R, Beer R, Christensen H, Cordonnier C, Csiba L,
Forsting M, Harnof S, Klijn CJ, Krieger D, Mendelow AD, Molina C, Montaner J,
Overgaard K, Petersson J, Roine RO, Schmutzhard E, Schwerdtfeger K, Stapf C,
Tatlisumak T, Thomas BM, Toni D, Unterberg A, Wagner M, European Stroke
Organisation. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke 2014;9:840855.
734. Ornello R, Degan D, Tiseo C, Di Carmine C, Perciballi L, Pistoia F, Carolei A,
Sacco S. Distribution and Temporal Trends From 1993 to 2015 of Ischemic
Stroke
Subtypes:
A
Systematic
Review and
Meta-Analysis.
Stroke
2018;49:814819.
735. Rodrigues MA, Samarasekera N, Lerpiniere C, Humphreys C, McCarron MO,
White PM, Nicoll JAR, Sudlow CLM, Cordonnier C, Wardlaw JM, Smith C, AlShahi Salman R. The Edinburgh CT and genetic diagnostic criteria for lobar intracerebral haemorrhage associated with cerebral amyloid angiopathy: model development and diagnostic test accuracy study.
Lancet
Neurol
2018;17:232240.
736. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med
2007;146:857867.
737. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern
Med 1994;154:14491457.
738. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J,
Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R,
Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering
Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:11391151.
739. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL,
Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y,
Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM,
ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:20932104.
740. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, AlKhalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz
JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo
AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL,
Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE
Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981992.
741. Klijn CJ, Paciaroni M, Berge E, Korompoki E, Korv J, Lal A, Putaala J, Werring
DJ. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline. Eur
Stroke J 2019;4:198223.
742. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G,
Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz
SD, Fox KA, Califf RM, ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883891.
743. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:7186.
744. ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A.
Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin
(ESPRIT):
randomised controlled trial.
Lancet
2006;367:16651673.
745. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y,
Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L,
Dahlof B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K,
Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P,
Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW, PRoFESS Study
Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008;359:12381251.
746. Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held
P, Jonasson J, Minematsu K, Molina CA, Wang Y, Wong KS, SOCRATES
Steering Committee and Investigators. Ticagrelor versus Aspirin in Acute
Stroke or Transient Ischemic Attack. N Engl J Med 2016;375:3543.
747. SPS3 Investigators, Benavente OR, Hart RG, McClure LA, Szychowski JM,
Coffey CS, Pearce LA. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012;367:817825.
748. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P,
Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW,
Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg
PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol
EJ, CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
N
Engl
J
Med
2006;354:17061717.
749. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys
D, Matias-Guiu J, Rupprecht HJ, MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331337.
750. Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS,
Lindblad AS,
Palesch
YY,
Clinical
Research
Collaboration, Neurological
Emergencies Treatment Trials Network, the POINT Investigators. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med
2018;379:215225.
751. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, Wang C, Li H, Meng X,
Cui L, Jia J, Dong Q, Xu A, Zeng J, Li Y, Wang Z, Xia H, Johnston SC,
CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013;369:1119.
752. Liu M, Counsell C, Sandercock P. Anticoagulants for preventing recurrence following ischaemic stroke or transient ischaemic attack. Cochrane Database Syst
Rev 2000:CD000248.
753. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers
GW, Pettigrew LC, Adams HP, Jr., Jackson CM, Pullicino P, Warfarin-Aspirin
Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:14441451.
754. Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M,
Ladenvall P, Molina CA, Wang Y, Johnston SC, THALES Steering Committee and Investigators. Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic
Stroke or
Transient
Ischemic
Attack of
Atherosclerotic
Origin.
Stroke
2020;51:35043513.
755. Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S,
Knutsson M, Ladenvall P, Molina CA, Wang Y, THALES Investigators. Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. N Engl J Med
2020;383:207217.
756. Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S,
Kreuzer J, Cronin L, Cotton D, Grauer C, Brueckmann M, Chernyatina M,
Donnan G, Ferro JM, Grond M, Kallmunzer B, Krupinski J, Lee BC, Lemmens R,
Masjuan J, Odinak M, Saver JL, Schellinger PD, Toni D, Toyoda K, RE-SPECT
ESUS Steering Committee and Investigators. Dabigatran for Prevention of
Stroke after Embolic Stroke of Undetermined
Source. N Engl J Med
2019;380:19061917.
757. Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD,
Swaminathan B, Lavados P, Wang Y, Wang Y, Davalos A, Shamalov N, Mikulik
R, Cunha L, Lindgren A, Arauz A, Lang W, Czlonkowska A, Eckstein J, Gagliardi
RJ, Amarenco P, Ameriso SF, Tatlisumak T, Veltkamp R, Hankey GJ, Toni D,
Bereczki D, Uchiyama S, Ntaios G, Yoon BW, Brouns R, Endres M, Muir KW,
Bornstein N, Ozturk S, O’Donnell MJ, De Vries Basson MM, Pare G, Pater C,
Kirsch B, Sheridan P, Peters G, Weitz JI, Peacock WF, Shoamanesh A,
Benavente OR, Joyner C, Themeles E, Connolly SJ, NAVIGATE ESUS
Investigators. Rivaroxaban for Stroke Prevention after Embolic Stroke of
Undetermined Source. N Engl J Med 2018;378:21912201.
758. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A
preliminary result. Chin Med J (Engl) 1995;108:710717.
759. Wang WT, You LK, Chiang CE, Sung SH, Chuang SY, Cheng HM, Chen CH.
Comparative Effectiveness of Blood Pressure-lowering Drugs in Patients who have Already Suffered From Stroke: Traditional and Bayesian Network Metaanalysis of Randomized Trials. Medicine (Baltimore) 2016;95:e3302.
760. Odden MC, McClure LA, Sawaya BP, White CL, Peralta CA, Field TS, Hart RG,
Benavente OR, Pergola PE. Achieved Blood Pressure and Outcomes in the


<!-- PAGE 109 -->

### Page 109

.............................................................................................................................................................................
Secondary
Prevention of
Small
Subcortical
Strokes
Trial.
Hypertension
2016;67:6369.
761. White CL, Szychowski JM, Pergola PE, Field TS, Talbert R, Lau H, Peri K,
Benavente OR, Secondary Prevention of Small Subcortical Strokes Study
Investigators. Can blood pressure be lowered safely in older adults with lacunar stroke? The Secondary Prevention of Small Subcortical Strokes study experience. J Am Geriatr Soc 2015;63:722729.
762. Amarenco P, Bogousslavsky J, Callahan A, 3rd, Goldstein LB, Hennerici M,
Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA, Stroke
Prevention by
Aggressive
Reduction in
Cholesterol
Levels
(SPARCL)
Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N
Engl J Med 2006;355:549559.
763. Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM,
Rotterdam Scan Study. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke
2003;34:11261129.
764. Bernick C, Kuller L, Dulberg C, Longstreth WT, Jr., Manolio T, Beauchamp N,
Price T, Cardiovascular Health Study Collaborative Reseach Group. Silent MRI
infarcts and the risk of future stroke: the cardiovascular health study. Neurology
2001;57:12221229.
765. Debette S, Beiser A, DeCarli C, Au R, Himali JJ, Kelly-Hayes M, Romero JR,
Kase CS, Wolf PA, Seshadri S. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality:
the Framingham Offspring Study. Stroke 2010;41:600606.
766. Katsanos AH, Filippatou A, Manios E, Deftereos S, Parissis J, Frogoudaki A,
Vrettou
AR,
Ikonomidis
I,
Pikilidou
M,
Kargiotis
O,
Voumvourakis
K,
Alexandrov AW, Alexandrov AV, Tsivgoulis G. Blood Pressure Reduction and
Secondary Stroke Prevention: A Systematic Review and Metaregression
Analysis of Randomized Clinical Trials. Hypertension 2017;69:171179.
767. Society for Vascular Surgery Lower Extremity Guidelines Writing Group,
Conte MS, Pomposelli FB, Clair DG, Geraghty PJ, McKinsey JF, Mills JL, Moneta
GL, Murad MH, Powell RJ, Reed AB, Schanzer A, Sidawy AN, Society for
Vascular Surgery. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg 2015;61:2S41S.
768. Singh S, Armstrong EJ, Sherif W, Alvandi B, Westin GG, Singh GD, Amsterdam
EA, Laird JR. Association of elevated fasting glucose with lower patency and increased major adverse limb events among patients with diabetes undergoing infrapopliteal balloon angioplasty. Vasc Med 2014;19:307314.
769. Momsen AH, Jensen MB, Norager CB, Madsen MR, Vestersgaard-Andersen T,
Lindholt JS. Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. Eur J Vasc Endovasc Surg 2009;38:463474.
770. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Jr., Goto S, Ohman
EM, Elbez Y, Sritara P, Baumgartner I, Banerjee S, Creager MA, Bhatt DL,
REACH Registry Investigators. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH
registry. Eur Heart J 2014;35:28642872.
771. Murphy SA, Cannon CP, Blazing MA, Giugliano RP, White JA, Lokhnygina Y,
Reist C, Im K, Bohula EA, Isaza D, Lopez-Sendon J, Dellborg M, Kher U,
Tershakovec AM, Braunwald E. Reduction in Total Cardiovascular Events With
Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial.
J Am Coll Cardiol 2016;67:353361.
772. Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J,
Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen
TR, Sabatine MS. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the
FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation 2018;137:338350.
773. Schmit K, Dolor RJ, Jones WS, Vemulapalli S, Hasselblad V, Subherwal S,
Heidenfelder B, Patel MR. Comparative effectiveness review of antiplatelet agents in peripheral artery disease. J Am Heart Assoc 2014;3:e001330.
774. Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, Aboyans V,
Alings M, Kakkar AK, Keltai K, Maggioni AP, Lewis BS, Stork S, Zhu J, LopezJaramillo P, O’Donnell M, Commerford PJ, Vinereanu D, Pogosova N, Ryden L,
Fox KAA, Bhatt DL, Misselwitz F, Varigos JD, Vanassche T, Avezum AA, Chen
E, Branch K, Leong DP, Bangdiwala SI, Hart RG, Yusuf S, COMPASS
Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018;391:219229.
775. The Task Force for the Diagnosis and Treatment of Peripheral Arterial
Diseases of the European Society of Cardiology (ESC) and of the European
Society for Vascular Surgery (ESVS), Aboyans V, Ricco JB, Bartelink MEL, Bjorck
M, Brodmann M, Cohnert T, Collet JP, Czerny M, De Carlo M, Debus S,
Espinola-Klein C, Kahan T, Kownator S, Mazzolai L, Naylor AR, Roffi M, Rother
J, Sprynger M, Tendera M, Tepe G, Venermo M, Vlachopoulos C, Desormais I.
Diseases, in collaboration with the European Society for Vascular Surgery
(ESVS). Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by:
the European Stroke Organization (ESO). Eur Heart J 2018;39:763816.
776. Bavry AA, Anderson RD, Gong Y, Denardo SJ, Cooper-Dehoff RM, Handberg
EM, Pepine CJ. Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational
VErapamil-SR/Trandolapril STudy. Hypertension 2010;55:4853.
777. Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P,
Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl
J Med 2000;342:145153.
778. Shahin Y, Barnes R, Barakat H, Chetter IC. Meta-analysis of angiotensin converting enzyme inhibitors effect on walking ability and ankle brachial pressure index in patients with intermittent claudication.
Atherosclerosis
2013;231:283290.
779. Paravastu SC, Mendonca DA, Da Silva A. Beta blockers for peripheral arterial disease. Cochrane Database Syst Rev 2013:CD005508.
780. Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease. Am J Cardiol 2001;87:12841286.
781. Bullen C. Impact of tobacco smoking and smoking cessation on cardiovascular risk and disease. Expert Rev Cardiovasc Ther 2008;6:883895.
782. Mazari FA, Khan JA, Samuel N, Smith G, Carradice D, McCollum PC, Chetter
IC. Long-term outcomes of a randomized clinical trial of supervised exercise,
percutaneous transluminal angioplasty or combined treatment for patients with intermittent claudication due to femoropopliteal disease.
Br
J
Surg
2017;104:7683.
783. Fakhry F, Spronk S, van der Laan L, Wever JJ, Teijink JA, Hoffmann WH, Smits
TM, van Brussel JP, Stultiens GN, Derom A, den Hoed PT, Ho GH, van Dijk
LC, Verhofstad N, Orsini M, van Petersen A, Woltman K, Hulst I, van Sambeek
MR, Rizopoulos D, Rouwet EV, Hunink MG. Endovascular Revascularization and Supervised Exercise for Peripheral Artery Disease and Intermittent
Claudication: A Randomized Clinical Trial. JAMA 2015;314:19361944.
784. Jansen SCP, Hoorweg BBN, Hoeks SE, van den Houten MML, Scheltinga MRM,
Teijink JAW, Rouwet EV. A systematic review and meta-analysis of the effects of supervised exercise therapy on modifiable cardiovascular risk factors in intermittent claudication. J Vasc Surg 2019;69:12931308 e1292.
785. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.
BMJ
2009;338:b1665.
786. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens
T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma
T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM,
Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Task
Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of
Cardiology (ESC). J Hypertens 2013;31:12811357.
787. Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, Qilong Y, Yusuf S, HOPE
study investigators. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004;25:1724.
788. Sarnak MJ, Amann K, Bangalore S, Cavalcante JL, Charytan DM, Craig JC, Gill JS,
Hlatky MA, Jardine AG, Landmesser U, Newby LK, Herzog CA, Cheung M,
Wheeler DC, Winkelmayer WC, Marwick TH, Conference Participants.
Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art
Review. J Am Coll Cardiol 2019;74:18231838.
789. Charytan DM, Sabatine MS, Pedersen TR, Im K, Park JG, Pineda AL,
Wasserman SM, Deedwania P, Olsson AG, Sever PS, Keech AC, Giugliano RP,
FOURIER Steering Committee and Investigators. Efficacy and Safety of
Evolocumab in Chronic Kidney Disease in the FOURIER Trial. J Am Coll Cardiol
2019;73:29612970.
790. Herrington WG, Preiss D, Haynes R, von Eynatten M, Staplin N, Hauske SJ,
George JT, Green JB, Landray MJ, Baigent C, Wanner C. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.
Clin Kidney J 2018;11:749761.
791. Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GYH. Improved Outcomes by Integrated Care of Anticoagulated Patients with Atrial Fibrillation Using the
Simple
ABC
(Atrial
Fibrillation
Better
Care)
Pathway.
Am
J
Med
2018;131:13591366 e1356.
792. Yoon M, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, Kim JY, Sung JH, Pak HN,
Lee MH, Joung B, Lip GYH. Improved Population-Based Clinical Outcomes of
Patients with Atrial Fibrillation by Compliance with the Simple ABC (Atrial
ESC Guidelines
3335


<!-- PAGE 110 -->

### Page 110

.............................................................................................................................................................................
Fibrillation
Better
Care)
Pathway for
Integrated
Care
Management:
A
Nationwide Cohort Study. Thromb Haemost 2019;19:16951703.
793. Pastori D, Pignatelli P, Menichelli D, Violi F, Lip GYH. Integrated Care
Management of Patients With Atrial Fibrillation and Risk of Cardiovascular
Events: The ABC (Atrial fibrillation Better Care) Pathway in the ATHERO-AF
Study Cohort. Mayo Clin Proc 2019;94:12611267.
794. Pastori D, Farcomeni A, Pignatelli P, Violi F, Lip GY. ABC (Atrial fibrillation
Better Care) Pathway and Healthcare Costs in Atrial Fibrillation: The
ATHERO-AF Study. Am J Med 2019;132:856861.
795. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME,
Lorimer MF, Lau DH, Antic NA, Brooks AG, Abhayaratna WP, Kalman JM,
Sanders P. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA 2013;310:20502060.
796. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D,
Alasady M, Hanley L, Antic NA, McEvoy RD, Kalman JM, Abhayaratna WP,
Sanders P. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll
Cardiol 2014;64:22222231.
797. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX,
Twomey D, Elliott AD, Kalman JM, Abhayaratna WP, Lau DH, Sanders P. LongTerm Effect of Goal-Directed Weight Management in an Atrial Fibrillation
Cohort:
A
Long-Term
Follow-Up
Study
(LEGACY).
J
Am
Coll
Cardiol
2015;65:21592169.
798. Voskoboinik A, Kalman JM, De Silva A, Nicholls T, Costello B, Nanayakkara S,
Prabhu S, Stub D, Azzopardi S, Vizi D, Wong G, Nalliah C, Sugumar H, Wong
M, Kotschet E, Kaye D, Taylor AJ, Kistler PM. Alcohol Abstinence in Drinkers with Atrial Fibrillation. N Engl J Med 2020;382:2028.
799. Pathak RK, Elliott A, Middeldorp ME, Meredith M, Mehta AB, Mahajan R,
Hendriks JM, Twomey D, Kalman JM, Abhayaratna WP, Lau DH, Sanders P.
Impact of CARDIOrespiratory FITness on Arrhythmia Recurrence in Obese
Individuals With Atrial Fibrillation: The CARDIO-FIT Study. J Am Coll Cardiol
2015;66:985996.
800. Lip GYH, Coca A, Kahan T, Boriani G, Manolis AS, Olsen MH, Oto A, Potpara
TS, Steffel J, Marin F, de Oliveira Figueiredo MJ, de Simone G, Tzou WS, Chiang
CE, Williams B, Reviewers, Dan GA, Gorenek B, Fauchier L, Savelieva I, Hatala
R, van Gelder I, Brguljan-Hitij J, Erdine S, Lovic D, Kim YH, Salinas-Arce J, Field
M. Hypertension and cardiac arrhythmias: a consensus document from the
European
Heart
Rhythm
Association
(EHRA)
and
ESC
Council on
Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart
Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulacion Cardiaca y
Electrofisiologia (SOLEACE). Europace 2017;19:891911.
801. Dzeshka MS, Shantsila A, Shantsila E, Lip GYH. Atrial Fibrillation and
Hypertension. Hypertension 2017;70:854861.
802. Huxley RR, Misialek JR, Agarwal SK, Loehr LR, Soliman EZ, Chen LY, Alonso A.
Physical activity, obesity, weight change, and risk of atrial fibrillation: the
Atherosclerosis
Risk in
Communities study.
Circ
Arrhythm
Electrophysiol
2014;7:620625.
803. Conen D, Albert CM. Alcohol consumption and risk of atrial fibrillation: how much is too much? J Am Coll Cardiol 2014;64:290292.
804. Larsson SC, Drca N, Wolk A. Alcohol consumption and risk of atrial fibrillation:
a prospective study and dose-response meta-analysis. J Am Coll Cardiol
2014;64:281289.
805. Lavie CJ, Thomas RJ, Squires RW, Allison TG, Milani RV. Exercise training and cardiac rehabilitation in primary and secondary prevention of coronary heart disease. Mayo Clin Proc 2009;84:373383.
806. Mont L. Arrhythmias and sport practice. Heart 2010;96:398405.
807. Menezes AR, Lavie CJ, De Schutter A, Milani RV, O’Keefe J, DiNicolantonio JJ,
Morin DP, Abi-Samra FM. Lifestyle modification in the prevention and treatment of atrial fibrillation. Prog Cardiovasc Dis 2015;58:117125.
808. Karjalainen J, Kujala UM, Kaprio J, Sarna S, Viitasalo M. Lone atrial fibrillation in vigorously exercising middle aged men:
case-control study.
BMJ
1998;316:17841785.
809. Baldesberger S, Bauersfeld U, Candinas R, Seifert B, Zuber M, Ritter M, Jenni R,
Oechslin E, Luthi P, Scharf C, Marti B, Attenhofer Jost CH. Sinus node disease and arrhythmias in the long-term follow-up of former professional cyclists. Eur
Heart J 2008;29:7178.
810. Molina L, Mont L, Marrugat J, Berruezo A, Brugada J, Bruguera J, Rebato C,
Elosua R. Long-term endurance sport practice increases the incidence of lone atrial fibrillation in men: a follow-up study. Europace 2008;10:618623.
811. Nielsen JR, Wachtell K, Abdulla J. The Relationship Between Physical Activity and Risk of Atrial Fibrillation-A Systematic Review and Meta-Analysis. J Atr
Fibrillation 2013;5:789.
812. Khan H, Kella D, Rauramaa R, Savonen K, Lloyd MS, Laukkanen JA.
Cardiorespiratory fitness and atrial fibrillation: A population-based follow-up study. Heart Rhythm 2015;12:14241430.
813. Linz D, McEvoy RD, Cowie MR, Somers VK, Nattel S, Levy P, Kalman JM,
Sanders P. Associations of Obstructive Sleep Apnea With Atrial Fibrillation and
Continuous Positive Airway Pressure Treatment: A Review. JAMA Cardiol
2018;3:532540.
814. Holmqvist F, Guan N, Zhu Z, Kowey PR, Allen LA, Fonarow GC, Hylek EM,
Mahaffey KW, Freeman JV, Chang P, Holmes DN, Peterson ED, Piccini JP,
Gersh BJ, ORBIT-AF Investigators. Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation-Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J 2015;169:647654 e642.
815. Qureshi WT, Nasir UB, Alqalyoobi S, O’Neal WT, Mawri S, Sabbagh S, Soliman
EZ, Al-Mallah MH. Meta-Analysis of Continuous Positive Airway Pressure as a
Therapy of Atrial Fibrillation in Obstructive Sleep Apnea. Am J Cardiol
2015;116:17671773.
816. Shukla A, Aizer A, Holmes D, Fowler S, Park DS, Bernstein S, Bernstein N,
Chinitz L. Effect of Obstructive Sleep Apnea Treatment on Atrial Fibrillation
Recurrence: A Meta-Analysis. JACC Clin Electrophysiol 2015;1:4151.
817. Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J, Bigger T,
Cushman W, Goff D, Soliman EZ, Thomas A, Papademetriou V. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control
Cardiovascular Risk in Diabetes Study). Am J Cardiol 2014;114:12171222.
818. Donnellan E, Aagaard P, Kanj M, Jaber W, Elshazly M, Hoosien M, Baranowski
B, Hussein A, Saliba W, Wazni O. Association Between Pre-Ablation Glycemic
Control and Outcomes Among Patients With Diabetes Undergoing Atrial
Fibrillation Ablation. JACC Clin Electrophysiol 2019;5:897903.
819. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V,
Gonzalez-Juanatey
JR,
Harjola
VP,
Jankowska
EA,
Jessup
M,
Linde
C,
Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM,
Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force Members,
Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC).
Developed with the special contribution of the Heart Failure Association
(HFA) of the ESC. Eur J Heart Fail 2016;18:891975.
820. Forman DE, Maurer MS, Boyd C, Brindis R, Salive ME, Horne FM, Bell SP,
Fulmer T, Reuben DB, Zieman S, Rich MW. Multimorbidity in Older Adults
With Cardiovascular Disease. J Am Coll Cardiol 2018;71:21492161.
821. Tran J, Norton R, Conrad N, Rahimian F, Canoy D, Nazarzadeh M, Rahimi K.
Patterns and temporal trends of comorbidity among adult patients with incident cardiovascular disease in the UK between 2000 and 2014: A population-based cohort study. PLoS Med 2018;15:e1002513.
822. Buddeke J, Bots ML, van Dis I, Liem A, Visseren FLJ, Vaartjes I. Trends in comorbidity in patients hospitalised for cardiovascular disease. Int J Cardiol
2017;248:382388.
823. Dunlay
SM,
Chamberlain
AM.
Multimorbidity in
Older
Patients with
Cardiovascular Disease. Curr Cardiovasc Risk Rep 2016;10:3.
824. Jani BD, Nicholl BI, McQueenie R, Connelly DT, Hanlon P, Gallacher KI, Lee D,
Mair FS. Multimorbidity and co-morbidity in atrial fibrillation and effects on survival: findings from UK Biobank cohort. Europace 2018;20:f329f336.
825. Tisminetzky
M,
Goldberg
R,
Gurwitz
JH.
Magnitude and
Impact of
Multimorbidity on Clinical Outcomes in Older Adults with Cardiovascular
Disease: A Literature Review. Clin Geriatr Med 2016;32:227246.
826. Bell SP, Saraf AA. Epidemiology of Multimorbidity in Older Adults with
Cardiovascular Disease. Clin Geriatr Med 2016;32:215226.
827. Hall M, Dondo TB, Yan AT, Mamas MA, Timmis AD, Deanfield JE, Jernberg T,
Hemingway H, Fox KAA, Gale CP. Multimorbidity and survival for patients with acute myocardial infarction in England and Wales: Latent class analysis of a nationwide population-based cohort. PLoS Med 2018;15:e1002501.
828. Kim DH, Rich MW. Patient-Centred Care of Older Adults With Cardiovascular
Disease and Multiple Chronic Conditions. Can J Cardiol 2016;32:10971107.
829. Rahimi K, Lam CSP, Steinhubl S. Cardiovascular disease and multimorbidity: A
call for interdisciplinary research and personalized cardiovascular care. PLoS
Med 2018;15:e1002545.
830. World Health Organization. Global Action Plan for the Prevention and Control of
NCDs 2013-2020. https://www.who.int/publications/i/item/9789241506236 (22
June 2021).
831. Song Z, Ji Y, Safran DG, Chernew ME. Health Care Spending, Utilization, and
Quality 8 Years into Global Payment. N Engl J Med 2019;381:252263.
832. Aktaa S, Batra G, Wallentin L, Baigent C, Erlinge D, James S, Ludman P,
Maggioni AP, Price S, Weston C, Casadei B, Gale CP. European Society of
Cardiology methodology for the development of quality indicators for the quantification of cardiovascular care and outcomes. Eur Heart J Qual Care Clin
Outcomes 2020:[Online ahead of print].
833. Schiele F, Aktaa S, Rossello X, Ahrens I, Claeys MJ, Collet JP, Fox KAA, Gale
CP, Huber K, Iakobishvili Z, Keys A, Lambrinou E, Leonardi S, Lettino M,


<!-- PAGE 111 -->

### Page 111

................................
Masoudi FA, Price S, Quinn T, Swahn E, Thiele H, Timmis A, Tubaro M, Vrints
CJM, Walker D, Bueno H, ESC Scientific Document Group, Halvorsen S,
Jernberg T, Jortveit J, Blondal M, Ibanez B, Hassager C. 2020 Update of the quality indicators for acute myocardial infarction: a position paper of the
Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTE-ACS guideline group. Eur Heart J Acute
Cardiovasc Care 2021;10:224233.
834. Arbelo E, Aktaa S, Bollmann A, D’Avila A, Drossart I, Dwight J, Hills MT,
Hindricks G, Kusumoto FM, Lane DA, Lau DH, Lettino M, Lip GYH, Lobban T,
Pak HN, Potpara T, Saenz LC, Van Gelder IC, Varosy P, Gale CP, Dagres N,
Reviewers, Boveda S, Deneke T, Defaye P, Conte G, Lenarczyk R, Providencia
R, Guerra JM, Takahashi Y, Pisani C, Nava S, Sarkozy A, Glotzer TV, Martins
Oliveira M. Quality indicators for the care and outcomes of adults with atrial fibrillation. Europace 2021;23:494495.
835. Wallentin L, Gale CP, Maggioni A, Bardinet I, Casadei B. EuroHeart: European
Unified Registries On Heart Care Evaluation and Randomized Trials. Eur Heart J
2019;40:27452749.
836. Casey DE, Jr., Thomas RJ, Bhalla V, Commodore-Mensah Y, Heidenreich PA,
Kolte D, Muntner P, Smith SC, Jr., Spertus JA, Windle JR, Wozniak GD, Ziaeian
B. 2019 AHA/ACC Clinical Performance and Quality Measures for Adults With
High Blood Pressure: A Report of the American College of Cardiology/
American Heart Association Task Force on Performance Measures. J Am Coll
Cardiol 2019;74:26612706.
837. Drozda JP, Jr., Ferguson TB, Jr., Jneid H, Krumholz HM, Nallamothu BK, Olin
JW, Ting HH. 2015 ACC/AHA Focused Update of Secondary Prevention Lipid
Performance Measures: A Report of the American College of Cardiology/
American Heart Association Task Force on Performance Measures. J Am Coll
Cardiol 2016;67:558587.
ESC Guidelines
3337

<!-- 2021_Cardiac_Pacing_CRT.md -->

# ESC Guidelines: Cardiac Pacing CRT (2021)

**Source**: `2021_Cardiac_Pacing_CRT.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 94

---

## Table of Contents

- [ehab364-1](#ehab364-1) *(p. 6)*
- [ehab364-2](#ehab364-2) *(p. 8)*
- [ehab364-2.1](#ehab364-21) *(p. 8)*
- [ehab364-2.2](#ehab364-22) *(p. 8)*
- [ehab364-2.3](#ehab364-23) *(p. 8)*
- [ehab364-2.3.1](#ehab364-231) *(p. 8)*
- [tblfn1](#tblfn1) *(p. 8)*
- [ehab364-2.3.2](#ehab364-232) *(p. 9)*
- [ehab364-2.3.3](#ehab364-233) *(p. 13)*
- [ehab364-3](#ehab364-3) *(p. 13)*
- [ehab364-3.1](#ehab364-31) *(p. 13)*
- [tblfn2](#tblfn2) *(p. 13)*
- [tblfn3](#tblfn3) *(p. 13)*
- [tblfn4](#tblfn4) *(p. 13)*
- [tblfn5](#tblfn5) *(p. 13)*
- [tblfn6](#tblfn6) *(p. 13)*
- [tblfn7](#tblfn7) *(p. 13)*
- [tblfn8](#tblfn8) *(p. 13)*
- [tblfn9](#tblfn9) *(p. 13)*
- [tblfn10](#tblfn10) *(p. 13)*
- [tblfn11](#tblfn11) *(p. 13)*
- [tblfn12](#tblfn12) *(p. 13)*
- [tblfn13](#tblfn13) *(p. 13)*
- [tblfn15](#tblfn15) *(p. 13)*
- [tblfn16](#tblfn16) *(p. 13)*
- [ehab364-3.2](#ehab364-32) *(p. 14)*
- [ehab364-3.3](#ehab364-33) *(p. 14)*
- [ehab364-3.4](#ehab364-34) *(p. 15)*
- [ehab364-3.4.1](#ehab364-341) *(p. 15)*
- [ehab364-3.4.2](#ehab364-342) *(p. 15)*
- [ehab364-3.4.3](#ehab364-343) *(p. 16)*
- [ehab364-3.4.4](#ehab364-344) *(p. 16)*
- [ehab364-3.4.4.1](#ehab364-3441) *(p. 16)*
- [ehab364-3.4.4.2](#ehab364-3442) *(p. 16)*
- [ehab364-3.4.5](#ehab364-345) *(p. 16)*
- [ehab364-3.4.6](#ehab364-346) *(p. 16)*
- [ehab364-3.5](#ehab364-35) *(p. 16)*
- [ehab364-4](#ehab364-4) *(p. 16)*
- [ehab364-4.1](#ehab364-41) *(p. 16)*
- [tblfn17](#tblfn17) *(p. 17)*
- [ehab364-4.2](#ehab364-42) *(p. 18)*
- [ehab364-4.3](#ehab364-43) *(p. 18)*
- [tblfn18](#tblfn18) *(p. 18)*
- [tblfn19](#tblfn19) *(p. 18)*
- [tblfn20](#tblfn20) *(p. 18)*
- [tblfn21](#tblfn21) *(p. 18)*
- [tblfn22](#tblfn22) *(p. 18)*
- [tblfn23](#tblfn23) *(p. 18)*
- [ehab364-4.3.1](#ehab364-431) *(p. 19)*
- [ehab364-4.3.2](#ehab364-432) *(p. 19)*
- [ehab364-4.3.3](#ehab364-433) *(p. 19)*
- [tblfn24](#tblfn24) *(p. 19)*
- [tblfn25](#tblfn25) *(p. 19)*
- [tblfn26](#tblfn26) *(p. 19)*
- [tblfn27](#tblfn27) *(p. 19)*
- [tblfn28](#tblfn28) *(p. 19)*
- [tblfn29](#tblfn29) *(p. 19)*
- [tblfn30](#tblfn30) *(p. 19)*
- [tblfn31](#tblfn31) *(p. 19)*
- [ehab364-4.3.4](#ehab364-434) *(p. 20)*
- [ehab364-4.3.5](#ehab364-435) *(p. 20)*
- [tblfn32](#tblfn32) *(p. 20)*
- [tblfn33](#tblfn33) *(p. 20)*
- [tblfn34](#tblfn34) *(p. 20)*
- [tblfn35](#tblfn35) *(p. 20)*
- [tblfn36](#tblfn36) *(p. 20)*
- [tblfn37](#tblfn37) *(p. 20)*
- [ehab364-4.3.6](#ehab364-436) *(p. 21)*
- [ehab364-4.3.7](#ehab364-437) *(p. 21)*
- [ehab364-4.4](#ehab364-44) *(p. 21)*
- [tblfn38](#tblfn38) *(p. 21)*
- [tblfn39](#tblfn39) *(p. 21)*
- [tblfn40](#tblfn40) *(p. 21)*
- [tblfn41](#tblfn41) *(p. 21)*
- [tblfn42](#tblfn42) *(p. 21)*
- [tblfn43](#tblfn43) *(p. 21)*
- [tblfn44](#tblfn44) *(p. 21)*
- [tblfn45](#tblfn45) *(p. 21)*
- [tblfn46](#tblfn46) *(p. 21)*
- [tblfn47](#tblfn47) *(p. 21)*
- [tblfn48](#tblfn48) *(p. 21)*
- [ehab364-4.5](#ehab364-45) *(p. 22)*
- [ehab364-5](#ehab364-5) *(p. 23)*
- [ehab364-5.1](#ehab364-51) *(p. 23)*
- [ehab364-5.1.1](#ehab364-511) *(p. 23)*
- [ehab364-5.1.1.1](#ehab364-5111) *(p. 23)*
- [tblfn49](#tblfn49) *(p. 23)*
- [tblfn50](#tblfn50) *(p. 23)*
- [tblfn51](#tblfn51) *(p. 23)*
- [ehab364-5.1.1.2](#ehab364-5112) *(p. 24)*
- [ehab364-5.1.2](#ehab364-512) *(p. 24)*
- [ehab364-5.2](#ehab364-52) *(p. 26)*
- [ehab364-5.2.1](#ehab364-521) *(p. 26)*
- [ehab364-5.2.1.1](#ehab364-5211) *(p. 26)*
- [ehab364-5.2.1.2](#ehab364-5212) *(p. 26)*
- [ehab364-5.2.1.3](#ehab364-5213) *(p. 26)*
- [ehab364-5.2.1.4](#ehab364-5214) *(p. 26)*
- [tblfn52](#tblfn52) *(p. 26)*
- [tblfn53](#tblfn53) *(p. 26)*
- [tblfn54](#tblfn54) *(p. 26)*
- [ehab364-5.2.2](#ehab364-522) *(p. 27)*
- [ehab364-5.2.2.1](#ehab364-5221) *(p. 27)*
- [ehab364-5.2.2.2](#ehab364-5222) *(p. 27)*
- [tblfn55](#tblfn55) *(p. 27)*
- [tblfn56](#tblfn56) *(p. 27)*
- [tblfn57](#tblfn57) *(p. 27)*
- [tblfn58](#tblfn58) *(p. 27)*
- [ehab364-5.3](#ehab364-53) *(p. 28)*
- [ehab364-5.3.1](#ehab364-531) *(p. 28)*
- [ehab364-5.3.1.1](#ehab364-5311) *(p. 28)*
- [ehab364-5.3.1.2](#ehab364-5312) *(p. 28)*
- [ehab364-5.3.1.3](#ehab364-5313) *(p. 29)*
- [ehab364-5.3.1.4](#ehab364-5314) *(p. 29)*
- [ehab364-5.3.1.5](#ehab364-5315) *(p. 29)*
- [ehab364-5.3.2](#ehab364-532) *(p. 29)*
- [tblfn59](#tblfn59) *(p. 29)*
- [tblfn60](#tblfn60) *(p. 29)*
- [tblfn61](#tblfn61) *(p. 29)*
- [ehab364-5.4](#ehab364-54) *(p. 30)*
- [ehab364-5.4.1](#ehab364-541) *(p. 31)*
- [ehab364-5.4.2](#ehab364-542) *(p. 32)*
- [ehab364-5.5](#ehab364-55) *(p. 32)*
- [ehab364-5.5.1](#ehab364-551) *(p. 32)*
- [ehab364-5.5.2](#ehab364-552) *(p. 32)*
- [ehab364-6](#ehab364-6) *(p. 32)*
- [ehab364-6.1](#ehab364-61) *(p. 32)*
- [tblfn62](#tblfn62) *(p. 32)*
- [tblfn63](#tblfn63) *(p. 32)*
- [tblfn64](#tblfn64) *(p. 32)*
- [tblfn65](#tblfn65) *(p. 32)*
- [tblfn66](#tblfn66) *(p. 32)*
- [tblfn67](#tblfn67) *(p. 32)*
- [ehab364-6.2](#ehab364-62) *(p. 33)*
- [tblfn68](#tblfn68) *(p. 34)*
- [tblfn69](#tblfn69) *(p. 34)*
- [tblfn70](#tblfn70) *(p. 34)*
- [ehab364-6.3](#ehab364-63) *(p. 35)*
- [ehab364-6.3.1](#ehab364-631) *(p. 35)*
- [ehab364-6.3.2](#ehab364-632) *(p. 35)*
- [ehab364-6.3.3](#ehab364-633) *(p. 36)*
- [ehab364-6.4](#ehab364-64) *(p. 37)*
- [tblfn71](#tblfn71) *(p. 37)*
- [tblfn72](#tblfn72) *(p. 37)*
- [tblfn73](#tblfn73) *(p. 37)*
- [tblfn74](#tblfn74) *(p. 37)*
- [tblfn75](#tblfn75) *(p. 37)*
- [tblfn76](#tblfn76) *(p. 37)*
- [tblfn77](#tblfn77) *(p. 37)*
- [ehab364-6.5](#ehab364-65) *(p. 38)*
- [ehab364-6.6](#ehab364-66) *(p. 38)*
- [tblfn78](#tblfn78) *(p. 38)*
- [tblfn79](#tblfn79) *(p. 38)*
- [tblfn80](#tblfn80) *(p. 38)*
- [ehab364-6.7](#ehab364-67) *(p. 39)*
- [tblfn81](#tblfn81) *(p. 39)*
- [tblfn82](#tblfn82) *(p. 39)*
- [tblfn83](#tblfn83) *(p. 39)*
- [ehab364-7](#ehab364-7) *(p. 40)*
- [ehab364-7.1](#ehab364-71) *(p. 40)*
- [ehab364-7.2](#ehab364-72) *(p. 40)*
- [ehab364-7.2.1](#ehab364-721) *(p. 40)*
- [ehab364-7.2.2](#ehab364-722) *(p. 42)*
- [ehab364-7.2.2.1](#ehab364-7221) *(p. 42)*
- [ehab364-7.2.2.2](#ehab364-7222) *(p. 42)*
- [ehab364-7.2.2.3](#ehab364-7223) *(p. 42)*
- [tblfn84](#tblfn84) *(p. 42)*
- [ehab364-7.3](#ehab364-73) *(p. 43)*
- [ehab364-7.4](#ehab364-74) *(p. 43)*
- [tblfn85](#tblfn85) *(p. 43)*
- [tblfn86](#tblfn86) *(p. 43)*
- [tblfn87](#tblfn87) *(p. 43)*
- [ehab364-8](#ehab364-8) *(p. 44)*
- [ehab364-8.1](#ehab364-81) *(p. 44)*
- [ehab364-8.2](#ehab364-82) *(p. 44)*
- [ehab364-8.2.1](#ehab364-821) *(p. 44)*
- [tblfn88](#tblfn88) *(p. 44)*
- [tblfn89](#tblfn89) *(p. 44)*
- [tblfn90](#tblfn90) *(p. 44)*
- [tblfn91](#tblfn91) *(p. 44)*
- [tblfn92](#tblfn92) *(p. 44)*
- [ehab364-8.2.2](#ehab364-822) *(p. 45)*
- [ehab364-8.2.3](#ehab364-823) *(p. 45)*
- [ehab364-8.3](#ehab364-83) *(p. 46)*
- [tblfn93](#tblfn93) *(p. 46)*
- [tblfn94](#tblfn94) *(p. 46)*
- [tblfn95](#tblfn95) *(p. 46)*
- [tblfn96](#tblfn96) *(p. 47)*
- [tblfn97](#tblfn97) *(p. 47)*
- [ehab364-8.4](#ehab364-84) *(p. 48)*
- [ehab364-8.4.1](#ehab364-841) *(p. 48)*
- [ehab364-8.4.1.1](#ehab364-8411) *(p. 48)*
- [ehab364-8.4.2](#ehab364-842) *(p. 48)*
- [ehab364-8.4.2.1](#ehab364-8421) *(p. 48)*
- [tblfn98](#tblfn98) *(p. 48)*
- [tblfn99](#tblfn99) *(p. 48)*
- [tblfn100](#tblfn100) *(p. 48)*
- [tblfn101](#tblfn101) *(p. 48)*
- [tblfn102](#tblfn102) *(p. 48)*
- [tblfn103](#tblfn103) *(p. 48)*
- [tblfn104](#tblfn104) *(p. 48)*
- [tblfn105](#tblfn105) *(p. 48)*
- [tblfn106](#tblfn106) *(p. 48)*
- [ehab364-8.4.3](#ehab364-843) *(p. 49)*
- [ehab364-8.4.3.1](#ehab364-8431) *(p. 49)*
- [ehab364-8.4.4](#ehab364-844) *(p. 49)*
- [ehab364-8.5](#ehab364-85) *(p. 49)*
- [ehab364-8.5.1](#ehab364-851) *(p. 49)*
- [ehab364-8.5.2](#ehab364-852) *(p. 49)*
- [tblfn107](#tblfn107) *(p. 49)*
- [tblfn108](#tblfn108) *(p. 49)*
- [tblfn109](#tblfn109) *(p. 49)*
- [ehab364-8.5.3](#ehab364-853) *(p. 50)*
- [ehab364-8.5.4](#ehab364-854) *(p. 50)*
- [ehab364-8.6](#ehab364-86) *(p. 50)*
- [ehab364-8.6.1](#ehab364-861) *(p. 50)*
- [ehab364-8.6.2](#ehab364-862) *(p. 50)*
- [tblfn110](#tblfn110) *(p. 50)*
- [tblfn111](#tblfn111) *(p. 50)*
- [tblfn112](#tblfn112) *(p. 50)*
- [tblfn113](#tblfn113) *(p. 50)*
- [tblfn114](#tblfn114) *(p. 50)*
- [tblfn115](#tblfn115) *(p. 50)*
- [tblfn116](#tblfn116) *(p. 50)*
- [tblfn117](#tblfn117) *(p. 50)*
- [ehab364-8.6.3](#ehab364-863) *(p. 51)*
- [ehab364-8.6.4](#ehab364-864) *(p. 51)*
- [ehab364-8.6.5](#ehab364-865) *(p. 51)*
- [ehab364-8.6.6](#ehab364-866) *(p. 51)*
- [tblfn118](#tblfn118) *(p. 51)*
- [tblfn119](#tblfn119) *(p. 51)*
- [tblfn120](#tblfn120) *(p. 51)*
- [tblfn121](#tblfn121) *(p. 51)*
- [tblfn122](#tblfn122) *(p. 51)*
- [tblfn123](#tblfn123) *(p. 51)*
- [tblfn124](#tblfn124) *(p. 51)*
- [ehab364-8.6.6.1](#ehab364-8661) *(p. 52)*
- [ehab364-8.7](#ehab364-87) *(p. 52)*
- [ehab364-9](#ehab364-9) *(p. 52)*
- [ehab364-9.1](#ehab364-91) *(p. 52)*
- [ehab364-9.2](#ehab364-92) *(p. 52)*
- [ehab364-9.3](#ehab364-93) *(p. 52)*
- [tblfn125](#tblfn125) *(p. 52)*
- [tblfn126](#tblfn126) *(p. 52)*
- [tblfn127](#tblfn127) *(p. 52)*
- [tblfn128](#tblfn128) *(p. 52)*
- [ehab364-9.4](#ehab364-94) *(p. 53)*
- [ehab364-9.5](#ehab364-95) *(p. 53)*
- [tblfn129](#tblfn129) *(p. 53)*
- [tblfn130](#tblfn130) *(p. 53)*
- [ehab364-9.6](#ehab364-96) *(p. 54)*
- [ehab364-9.7](#ehab364-97) *(p. 54)*
- [ehab364-9.8](#ehab364-98) *(p. 54)*
- [ehab364-10](#ehab364-10) *(p. 55)*
- [ehab364-10.1](#ehab364-101) *(p. 55)*
- [tblfn131](#tblfn131) *(p. 55)*
- [tblfn132](#tblfn132) *(p. 55)*
- [tblfn133](#tblfn133) *(p. 55)*
- [ehab364-10.2](#ehab364-102) *(p. 56)*
- [ehab364-10.2.1](#ehab364-1021) *(p. 56)*
- [ehab364-10.2.2](#ehab364-1022) *(p. 56)*
- [ehab364-10.2.3](#ehab364-1023) *(p. 56)*
- [ehab364-10.2.4](#ehab364-1024) *(p. 56)*
- [tblfn134](#tblfn134) *(p. 56)*
- [ehab364-10.2.5](#ehab364-1025) *(p. 57)*
- [ehab364-11](#ehab364-11) *(p. 57)*
- [ehab364-11.1](#ehab364-111) *(p. 57)*
- [ehab364-11.2](#ehab364-112) *(p. 59)*
- [tblfn135](#tblfn135) *(p. 59)*
- [tblfn136](#tblfn136) *(p. 59)*
- [tblfn137](#tblfn137) *(p. 59)*
- [tblfn138](#tblfn138) *(p. 59)*
- [ehab364-11.3](#ehab364-113) *(p. 60)*
- [ehab364-11.4](#ehab364-114) *(p. 61)*
- [ehab364-11.5](#ehab364-115) *(p. 61)*
- [tblfn139](#tblfn139) *(p. 61)*
- [tblfn140](#tblfn140) *(p. 61)*
- [ehab364-11.6](#ehab364-116) *(p. 62)*
- [ehab364-11.7](#ehab364-117) *(p. 62)*
- [tblfn141](#tblfn141) *(p. 62)*
- [tblfn142](#tblfn142) *(p. 62)*
- [tblfn143](#tblfn143) *(p. 62)*
- [tblfn144](#tblfn144) *(p. 62)*
- [tblfn145](#tblfn145) *(p. 62)*
- [tblfn1145](#tblfn1145) *(p. 62)*
- [ehab364-12](#ehab364-12) *(p. 63)*
- [ehab364-13](#ehab364-13) *(p. 63)*
- [tblfn147](#tblfn147) *(p. 63)*
- [tblfn148](#tblfn148) *(p. 63)*
- [tblfn150](#tblfn150) *(p. 63)*
- [tblfn151](#tblfn151) *(p. 63)*
- [tblfn152](#tblfn152) *(p. 63)*
- [tblfn149](#tblfn149) *(p. 64)*
- [ehab364-14](#ehab364-14) *(p. 65)*
- [tblfn153](#tblfn153) *(p. 65)*
- [tblfn154](#tblfn154) *(p. 65)*
- [tblfn155](#tblfn155) *(p. 65)*
- [ehab364-15](#ehab364-15) *(p. 66)*
- [ehab364-16](#ehab364-16) *(p. 67)*
- [tblfn156](#tblfn156) *(p. 69)*
- [tblfn157](#tblfn157) *(p. 69)*
- [tblfn158](#tblfn158) *(p. 69)*
- [tblfn159](#tblfn159) *(p. 69)*
- [tblfn160](#tblfn160) *(p. 69)*
- [tblfn161](#tblfn161) *(p. 69)*
- [tblfn162](#tblfn162) *(p. 69)*
- [tblfn163](#tblfn163) *(p. 69)*
- [ehab364-17](#ehab364-17) *(p. 70)*
- [ehab364-18](#ehab364-18) *(p. 70)*
- [ehab364-19](#ehab364-19) *(p. 70)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy
Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC)
With the special contribution of the European Heart Rhythm
Association (EHRA)
Authors/Task Force Members: Michael Glikson * (Chairperson) (Israel),
Jens Cosedis Nielsen* (Chairperson) (Denmark), Mads Brix Kronborg (Task Force
Coordinator) (Denmark), Yoav Michowitz (Task Force Coordinator) (Israel),
Angelo Auricchio (Switzerland), Israel Moshe Barbash (Israel), Jose´ A. Barrabe´s
(Spain), Giuseppe Boriani (Italy), Frieder Braunschweig (Sweden), Michele Brignole
(Italy), Haran Burri (Switzerland), Andrew J. S. Coats (United Kingdom),
Jean-Claude Deharo (France), Victoria Delgado (Netherlands), Gerhard-Paul Diller
(Germany), Carsten W. Israel (Germany), Andre Keren (Israel), Reinoud E. Knops
(Netherlands), Dipak Kotecha (United Kingdom), Christophe Leclercq (France),
* Corresponding authors: Michael Glikson, Jesselson Integrated Heart Center, Shaare Zedek Medical Center and Hebrew University Faculty of Medicine, Jerusalem, Israel,
Tel: þ972 2 6555975, Email: mglikson@szmc.org.il.
Jens Cosedis Nielsen, Department of Clinical Medicine, Aarhus University and Department of Cardiology, Aarhus University Hospital, Aarhus N, Denmark,
Tel: þ45 78 45 20 39, Email: jenniels@rm.dk.
Author/Task Force Member afﬁliations: listed in Author information.
ESC Clinical Practice Guidelines Committee (CPG): listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association for Acute CardioVascular Care (ACVC), Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of
Cardiovascular Imaging (EACVI), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), Heart Failure
Association (HFA).
Councils: Council for Cardiology Practice, Council on Basic Cardiovascular Science, Council on Cardiovascular Genomics, Council on Hypertension, Council on Stroke.
Working Groups: Adult Congenital Heart Disease, Cardiac Cellular Electrophysiology, Cardiovascular Regenerative and Reparative Medicine, Cardiovascular Surgery, eCardiology, Myocardial and Pericardial Diseases.
Patient Forum
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to
Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
Disclaimer: The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientiﬁc and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC Guidelines and any other ofﬁcial recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgement, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC
Guidelines exempt health professionals from taking into full and careful consideration the relevant ofﬁcial updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientiﬁcally accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
This article has been co-published with permission in the European Heart Journal and EP Europace. V
C the European Society of Cardiology 2021. All rights reserved.
The articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Either citation can be used when citing this article. For permissions,
please email journals.permissions@oup.com.
ESC GUIDELINES
doi:10.1093/eurheartj/ehab364


<!-- PAGE 2 -->

### Page 2

.........................................................
Be´la Merkely (Hungary), Christoph Starck (Germany), Ingela Thyle´n (Sweden),
Jose´ Maria Tolosana (Spain), ESC Scientific Document Group
Document Reviewers: Francisco Leyva (CPG Review Coordinator) (United Kingdom), Cecilia Linde
(CPG Review Coordinator) (Sweden), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Elena Arbelo
(Spain), Riccardo Asteggiano (Italy), Gonzalo Baron-Esquivias (Spain), Johann Bauersachs (Germany),
Mauro Bifﬁ(Italy), Ulrika Birgersdotter-Green (United States of America ), Maria Grazia Bongiorni (Italy),
Michael A. Borger (Germany), Jelena Celutkien _e (Lithuania), Maja Cikes (Croatia), Jean-Claude Daubert
(France), Inga Drossart (Belgium), Kenneth Ellenbogen (United States of America), Perry M. Elliott
(United Kingdom), Larissa Fabritz (United Kingdom), Volkmar Falk (Germany), Laurent Fauchier (France),
Francisco Fernandez-Avile´s (Spain), Dan Foldager (Denmark), Fredrik Gadler (Sweden), Pastora Gallego
Garcia De Vinuesa (Spain), Bulent Gorenek (Turkey), Jose M. Guerra (Spain), Kristina Hermann Haugaa
(Norway), Jeroen Hendriks (Netherlands), Thomas Kahan (Sweden), Hugo A. Katus (Germany),
Aleksandra Konradi (Russia), Konstantinos C. Koskinas (Switzerland), Hannah Law (United Kingdom),
Basil S. Lewis (Israel), Nicholas John Linker (United Kingdom), Maja-Lisa Løchen (Norway), Joost Lumens
(Netherlands), Julia Mascherbauer (Austria), Wilfried Mullens (Belgium), Klaudia Vivien Nagy (Hungary),
Eva Prescott (Denmark), Pekka Raatikainen (Finland), Amina Rakisheva (Kazakhstan), Tobias Reichlin
(Switzerland), Renato Pietro Ricci (Italy), Evgeny Shlyakhto (Russia), Marta Sitges (Spain), Miguel Sousa-Uva
(Portugal), Richard Sutton (Monaco), Piotr Suwalski (Poland), Jesper Hastrup Svendsen (Denmark),
Rhian M. Touyz (United Kingdom), Isabelle C. Van Gelder (Netherlands), Kevin Vernooy (Netherlands),
Johannes Waltenberger (Germany), Zachary Whinnett (United Kingdom), Klaus K. Witte (United Kingdom)
All experts involved in the development of these guidelines have submitted declarations of interest.
These have been compiled in a report and published in a supplementary document simultaneously to the guidelines. The report is also available on the ESC website www.escardio.org/guidelines
For the Supplementary Data which include background information and detailed discussion of the data that have provided the basis for the guidelines see European Heart Journal online
...................................................................................................................................................................................................
Keywords
Guidelines • cardiac pacing • cardiac resynchronization therapy • pacemaker • heart failure • syncope •
atrial ﬁbrillation • conduction system pacing • pacing indications • alternate site pacing • complications •
pacing in TAVI • bradycardia • temporary pacing
Table of contents
1 Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
2.1 Evidence review . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
2.2 Relationships with industry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
2.3 What is new in these guidelines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
2.3.1 New concepts and new sections . . . . . . . . . . . . . . . . . . . . . . . . . . 8
2.3.2 New recommendations in 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
2.3.3 Changes in cardiac pacing and cardiac resynchronization therapy guideline recommendations since 2013 . . . . . . . . . . . . . . . . 11
3 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
3.1 Epidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
3.2 Natural history . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
3.3 Pathophysiology and classification of bradyarrhythmias considered for permanent cardiac pacing therapy . . . . . . . . . . . . . . . . 12
3.4 Types and modes of pacing: general description . . . . . . . . . . . . . . . 13
3.4.1 Endocardial pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
3.4.2 Epicardial pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
3.4.3 Cardiac resynchronization therapy (endo-and/or epicardial) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
3.4.4 Alternative methods (conduction system pacing,
leadless pacing) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
3.4.4.1 Conduction system pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
3.4.4.2 Leadless pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
3.4.5 Pacing modes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
3.4.6 Rate-responsive pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
3.5 Sex differences . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
4 Evaluation of the patient with suspected or documented bradycardia or conduction system disease . . . . . . . . . . . . . . . . . . . . . . . . . . 14
4.1 History and physical examination . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
4.2 Electrocardiogram . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
4.3 Non-invasive evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
4.3.1 Ambulatory electrocardiographic monitoring . . . . . . . . . . . . . 16
4.3.2 Exercise testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
4.3.3 Imaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
4.3.4 Laboratory tests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
4.3.5 Genetic testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17


<!-- PAGE 3 -->

### Page 3

.............................................................................................................................................................................
4.3.6 Sleep evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
4.3.7 Tilt testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
4.4 Implantable monitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
4.5 Electrophysiology study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
5 Cardiac pacing for bradycardia and conduction system disease . . . . . 21
5.1 Pacing for sinus node dysfunction . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
5.1.1 Indications for pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
5.1.1.1 Sinus node dysfunction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
5.1.1.2 Bradycardia—tachycardia form of sinus node dysfunction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
5.1.2 Pacing mode and algorithm selection . . . . . . . . . . . . . . . . . . . . . 22
5.2 Pacing for atrioventricular block . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
5.2.1 Indications for pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
5.2.1.1 First-degree atrioventricular block . . . . . . . . . . . . . . . . . . . . . . . 24
5.2.1.2 Second-degree type I atrioventricular block
(Mobitz type I or Wenckebach) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
5.2.1.3 Second-degree Mobitz type II, 2:1, and advanced atrioventricular block (also named high-grade atrioventricular block, where the P:QRS ratio is 3:1 or higher), third-degree atrioventricular block . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
5.2.1.4 Paroxysmal atrioventricular block . . . . . . . . . . . . . . . . . . . . . . . 24
5.2.2 Pacing mode and algorithm selection . . . . . . . . . . . . . . . . . . . . . 25
5.2.2.1 Dual-chamber vs. ventricular pacing . . . . . . . . . . . . . . . . . . . . 25
5.2.2.2 Atrioventricular block in the case of permanent atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
5.3 Pacing for conduction disorders without atrioventricular block . . . 26
5.3.1 Indications for pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
5.3.1.1 Bundle branch block and unexplained syncope . . . . . . . . . . . 26
5.3.1.2 Bundle branch block, unexplained syncope, and abnormal electrophysiological study . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
5.3.1.3 Alternating bundle branch block . . . . . . . . . . . . . . . . . . . . . . . . 27
5.3.1 Bundle branch block without symptoms . . . . . . . . . . . . . . . . . . . 27
5.3.1.4 Patients with neuromuscular diseases . . . . . . . . . . . . . . . . . . . 27
5.3.2 Pacing mode and algorithm selection . . . . . . . . . . . . . . . . . . . . . 27
5.4 Pacing for reflex syncope . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
5.4.1 Indications for pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
5.4.2 Pacing mode and algorithm selection . . . . . . . . . . . . . . . . . . . . . 30
5.5 Pacing for suspected (undocumented) bradycardia . . . . . . . . . . . . 30
5.5.1 Recurrent undiagnosed syncope . . . . . . . . . . . . . . . . . . . . . . . . . 30
5.5.2 Recurrent falls . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
6 Cardiac resynchronization therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
6.1 Epidemiology, prognosis, and pathophysiology of heart failure suitable for cardiac resynchronization therapy by biventricular pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
6.2 Indication for cardiac resynchronization therapy: patients in sinus rhythm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
6.3 Patients in atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
6.3.1 Patients with atrial fibrillation and heart failure who are candidates for cardiac resynchronization therapy . . . . . . . . . . . 33
6.3.2 Patients with uncontrolled heart rate who are candidates for atrioventricular junction ablation (irrespective of QRS duration) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
6.3.3 Emerging novel modalities for CRT: role of conduction system pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
6.4 Patients with conventional pacemaker or implantable cardioverter defibrillator who need upgrade to cardiac resynchronization therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
6.5 Pacing in patients with reduced left ventricular ejection fraction and a conventional indication for antibradycardia pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
6.6 Benefit of adding implantable cardioverter defibrillator in patients with indications for cardiac resynchronization therapy . . . . 36
6.7 Factors influencing the efficacy of cardiac resynchronization therapy: role of imaging techniques . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
7 Alternative pacing strategies and sites . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
7.1 Septal pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
7.2 His bundle pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
7.2.1 Implantation and follow-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
7.2.2 Indications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
7.2.2 Pacing for bradycardia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
7.2.2 Pace and ablate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
7.2.2 Role in cardiac resynchronization therapy . . . . . . . . . . . . . . 40
7.3 Left bundle branch area pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
7.4 Leadless pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
8 Indications for pacing in specific conditions . . . . . . . . . . . . . . . . . . . . . . . . 42
8.1 Pacing in acute myocardial infarction . . . . . . . . . . . . . . . . . . . . . . . . . 42
8.2 Pacing after cardiac surgery and heart transplantation . . . . . . . . . 42
8.2.1 Pacing after coronary artery bypass graft and valve surgery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
8.2.2 Pacing after heart transplantation . . . . . . . . . . . . . . . . . . . . . . . . 43
8.2.3 Pacing after tricuspid valve surgery . . . . . . . . . . . . . . . . . . . . . . . 43
8.3 Pacing after transcatheter aortic valve implantation . . . . . . . . . . . . 44
8.4 Cardiac pacing and cardiac resynchronization therapy in congenital heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
8.4.1 Sinus node dysfunction and bradycardia—tachycardia syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
8.4.1.1 Indications for pacemaker implantation . . . . . . . . . . . . . . . . . 46
8.4.2 Congenital atrioventricular block . . . . . . . . . . . . . . . . . . . . . . . . 46
8.4.2.1 Indications for pacemaker implantation . . . . . . . . . . . . . . . . . 46
8.4.3 Post-operative atrioventricular block . . . . . . . . . . . . . . . . . . . . . 47
8.4.3.1 Indications for pacemaker implantation . . . . . . . . . . . . . . . . . 47
8.4.4 Cardiac resynchronization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
8.5 Pacing in hypertrophic cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . 47
8.5.1 Bradyarrhythmia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
8.5.2 Pacing for the management of left ventricular outflow tract obstruction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
8.5.3 Pacemaker implantation following septal myectomy and alcohol septal ablation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
8.5.4 Cardiac resynchronization therapy in end-stage hypertrophic cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
8.6 Pacing in rare diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
8.6.1 LongQT syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
8.6.2 Neuromuscular diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
8.6.3 Dilated cardiomyopathy with lamin A/C mutation . . . . . . . . 49
8.6.4 Mitochondrial cytopathies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
8.6.5 Infiltrative and metabolic diseases . . . . . . . . . . . . . . . . . . . . . . . . 49
8.6.6 Inflammatory diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
8.6.6.1 Sarcoidosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
8.7 Cardiac pacing in pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
9 Special considerations on device implantations and perioperative management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
9.1 General considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
9.2 Antibiotic prophylaxis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
9.3 Operative environment and skin antisepsis . . . . . . . . . . . . . . . . . . . 50
ESC Guidelines
3


<!-- PAGE 4 -->

### Page 4

..........................................................................................................................................................................
9.4 Management of anticoagulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
9.5 Venous access . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
9.6 Lead considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
9.7 Lead position . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
9.8 Device pocket . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
10 Complications of cardiac pacing and cardiac resynchronization therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
10.1 General complications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
10.2 Specific complications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
10.2.1 Lead complications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
10.2.2 Haematoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
10.2.3 Infection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
10.2.4 Tricuspid valve interference . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
10.2.5 Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
11 Management considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
11.1 Magnetic resonance imaging in patients with implanted cardiac devices . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
11.2 Radiation therapy in pacemaker patients . . . . . . . . . . . . . . . . . . . . . 57
11.3 Temporary pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
11.4 Peri-operative management in patients with cardiovascular implantable electronic devices . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
11.5 Cardiovascular implantable electronic devices and sports activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
11.6 When pacing is no longer indicated . . . . . . . . . . . . . . . . . . . . . . . . . 60
11.7 Device follow-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
12 Patient-centred care and shared decision-making in cardiac pacing and cardiac resynchronization therapy . . . . . . . . . . . . . . . . . . . . . . . 61
13 Quality indicators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
14 Key messages . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
15 Gaps in evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
16 ‘What to do’ and ‘what not to do’ messages from the guidelines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
17 Supplementary data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
18 Author Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
19 Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
20 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
Tables of Recommendations
Recommendations for non-invasive evaluation . . . . . . . . . . . . . . . . . . . . . . 16
Recommendation for ambulatory electrocardiographic monitoring . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Recommendations for exercise testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Recommendations regarding imaging before implantation . . . . . . . . . . . 18
Recommendations for laboratory tests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Recommendations for genetic testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Recommendation for sleep evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Recommendation for tilt testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Recommendation for implantable loop recorders . . . . . . . . . . . . . . . . . . . 19
Recommendations for electrophysiology study . . . . . . . . . . . . . . . . . . . . . 21
Recommendations for pacing in sinus node dysfunction . . . . . . . . . . . . . 24
Recommendations for pacing for atrioventricular block . . . . . . . . . . . . . 25
Recommendations for pacing in patients with bundle branch block . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
Recommendations for pacing for reflex syncope . . . . . . . . . . . . . . . . . . . . 30
Recommendations for cardiac pacing in patients with suspected (undocumented) syncope and unexplained falls . . . . . . 30
Recommendations for cardiac resynchronization therapy in patients in sinus rhythm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
Recommendations for cardiac resynchronization therapy in patients with persistent or permanent atrial fibrillation . . . . . . . . . . . . . . 35
Recommendation for upgrade from right ventricular pacing to cardiac resynchronization therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
Recommendation for patients with heart failure and atrioventricular block . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
Recommendations for adding a defibrillator with cardiac resynchronization therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
Recommendations for using His bundle pacing . . . . . . . . . . . . . . . . . . . . . . 41
Recommendations for using leadless pacing (leadless pacemaker) . . . . 42
Recommendations for cardiac pacing after acute myocardial infarction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
Recommendations for cardiac pacing after cardiac surgery and heart transplantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
Recommendations for cardiac pacing after transcatheter aortic valve implantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
Recommendations for cardiac pacing in patients with congenital heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Recommendations for pacing in hypertrophic obstructive cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
Recommendations for cardiac pacing in rare diseases . . . . . . . . . . . . . . . 48
Recommendation for patients with LMNA gene mutations . . . . . . . . . . 49
Recommendations for pacing in Kearns—Sayre syndrome . . . . . . . . . . 49
Recommendations for pacing in cardiac sarcoidosis . . . . . . . . . . . . . . . . . 50
Recommendations regarding device implantations and peri-operative management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
Recommendations for performing magnetic resonance imaging in pacemaker patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
Recommendations regarding temporary cardiac pacing . . . . . . . . . . . . . 59
Recommendation when pacing is no longer indicated . . . . . . . . . . . . . . . 60
Recommendations for pacemaker and cardiac resynchronization therapy-pacemaker follow-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
Recommendation regarding patient-centred care in cardiac pacing and cardiac resynchronization therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
List of tables
Table 1 Classes of recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
Table 2 Levels of evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
Table 3 New concepts and sections in current guidelines . . . . . . . . . . . . . 8
Table 4 New recommendations in 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Table 5 Changes in cardiac pacing and cardiac resynchronization therapy guideline recommendations since 2013 . . . . . . . . . . . . . . . . . . . . . 11
Table 6 Drugs that may cause bradycardia or conduction disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Table 7 Intrinsic and extrinsic causes of bradycardia . . . . . . . . . . . . . . . . . 16
Table 8 Choice of ambulatory electrocardiographic monitoring depending on symptom frequency . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Table 9 Advantages and disadvantages of a ‘backup’ ventricular lead with His bundle pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
Table 10 Predictors for permanent pacing after transcatheter aortic valve implantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45


<!-- PAGE 5 -->

### Page 5

..........................................................................................................................................................................
Table 11 Management of anticoagulation in pacemaker procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
Table 12 Complications of pacemaker and cardiac resynchronization therapy implantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
Table 13 Frequency of follow-up for routine pacemaker and cardiac resynchronization therapy, either in person alone or combined with remote device management . . . . . . . . . . . . . . . . . . . . . . . . 60
Table 14 Topics and content that may be included in patient education . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
Table 15 A selection of the developed quality indicators for patients undergoing cardiovascular implantable electronic device implantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
List of figures
Figure 1 Central Illustration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Figure 2 Classification of documented and suspected bradyarrhythmias . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Figure 3 Initial evaluation of patients with symptoms suggestive of bradycardia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Figure 4 Evaluation of bradycardia and conduction disease algorithm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
Figure 5 Optimal pacing mode and algorithm selection in sinus node dysfunction and atrioventricular block . . . . . . . . . . . . . . . . . . . . . . . . 23
Figure 6 Decision algorithm for patients with unexplained syncope and bundle branch block . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
Figure 7 Decision pathway for cardiac pacing in patients with reflex syncope . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
Figure 8 Summary of indications for pacing in patients >40 years of age with reflex syncope . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Figure 9 Indication for atrioventricular junction ablation in patients with symptomatic permanent atrial fibrillation or persistent atrial fibrillation unsuitable for atrial fibrillation ablation . . . . . . . . . . . . . . . . . . . 34
Figure 10 Patient’s clinical characteristics and preference to be considered for the decision-making between cardiac resynchronization therapy pacemaker or defibrillator . . . . . . . . . . . . . . . 38
Figure 11 Three patients with different types of transitions in
QRS morphology with His bundle pacing and decrementing pacing output . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
Figure 12 Management of conduction abnormalities after transcatheter aortic valve implantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
Figure 13 Integrated management of patients with pacemaker and cardiac resynchronization therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
Figure 14 Flowchart for evaluating magnetic resonance imaging in pacemaker patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
Figure 15 Pacemaker management during radiation therapy . . . . . . . . . 58
Figure 16 Example of shared decision-making in patients considered for pacemaker/CRT implantation . . . . . . . . . . . . . . . . . . . . . . . 62
Abbreviations and acronyms
AF
Atrial ﬁbrillation
APAF
Ablate and Pace in Atrial Fibrillation
(trial)
ATP
Antitachycardia pacing
AV
Atrioventricular
AVB
Atrioventricular block
AVJ
Atrioventricular junction
AVN
Atrioventricular node
BBB
Bundle branch block
BLOCK-HF
Biventricular versus RV pacing in patients with AV block (trial)
b.p.m.
Beats per minute
BRUISE CONTROL
Bridge or Continue Coumadin for
Device Surgery Randomized Controlled
Trial
BRUISE CONTROL-2
Randomized Controlled Trial of
Continued Versus Interrupted Direct
Oral Anti-Coagulant at the Time of
Device Surgery
CABG
Coronary artery bypass graft
CARE-HF
CArdiac REsynchronization in Heart
Failure (trial)
CHD
Congenital heart disease
CI
Conﬁdence interval
CIED
Cardiovascular implantable electronic device
CMR
Cardiovascular magnetic resonance
COMPANION
COmparison of Medical therapy, PAcing aNd deﬁbrillatION (trial)
CPAP
Continuous positive airway pressure
CRT
Cardiac resynchronization therapy
CRT-D
Deﬁbrillator with cardiac resynchronization therapy
CRT-P
Cardiac resynchronization therapypacemaker
CSM
Carotid sinus massage
CSS
Carotid sinus syndrome
CT
Computed tomography
DANPACE
DANish Multicenter Randomized
Trial on Single Lead Atrial PACing vs.
Dual Chamber Pacing in Sick Sinus
Syndrome
DDD
Dual-chamber, atrioventricular pacing
ECG
Electrocardiogram/electrocardiographic
Echo-CRT
Echocardiography Guided Cardiac
Resynchronization Therapy (trial)
EF
Ejection fraction
EHRA
European Heart Rhythm Association
EMI
Electromagnetic interference
EORP
EurObservational Research Programme
EPS
Electrophysiology study
ESC
European Society of Cardiology
EuroHeart
European Uniﬁed Registries On Heart
Care Evaluation and Randomized Trials
HBP
His bundle pacing
HCM
Hypertrophic cardiomyopathy
HF
Heart failure
HFmrEF
Heart failure with mildly reduced ejection fraction
HFpEF
Heart failure with preserved ejection fraction
ESC Guidelines
5


<!-- PAGE 6 -->

### Page 6

............................................................................................................................................................................
HFrEF
Heart failure with reduced ejection fraction
HOT-CRT
His-optimized cardiac resynchronization therapy
HR
Hazard ratio
HV
Hisventricular interval (time from the beginning of the H deﬂection to the earliest onset of ventricular depolarization recorded in any lead,
electrophysiology study of the heart)
ICD
Implantable cardioverter-deﬁbrillator
ILR
Implantable loop recorder
LBBB
Left bundle branch block
LGE
Late gadolinium contrast enhanced
LQTS
Long QT syndrome
LV
Left ventricular
LVEF
Left ventricular ejection fraction
MADIT-CRT
Multicenter Automatic Deﬁbrillator
Implantation with Cardiac
Resynchronization Therapy (trial)
MI
Myocardial infarction
MIRACLE
Multicenter Insync RAndomized Clinical
Evaluation (trial)
MOST
MOde Selection Trial in Sinus-Node
Dysfunction
MRI
Magnetic resonance imaging
MUSTIC
MUltisite STimulation In
Cardiomyopathies (trial)
NOAC
Non-vitamin K antagonist oral anticoagulant
NYHA
New York Heart Association
OAC
Oral anticoagulant
OMT
Optimal medical therapy
OR
Odds ratio
PATH-CHF
PAcing THerapies in Congestive Heart
Failure (trial)
PCCD
Progressive cardiac conduction disease
PCI
Percutaneous coronary intervention
PET
Positron emission tomography
PM
Pacemaker
RA
Right atrium/atrial
RAFT
ResynchronizationDeﬁbrillation for
Ambulatory Heart Failure Trial
RBBB
Right bundle branch block
RCT
Randomized controlled trial
RESET-CRT
Re-evaluation of Optimal Resynchronisation Therapy in Patients with
Chronic Heart Failure (trial)
REVERSE
REsynchronization reVErses Remodelling in Systolic left vEntricular dysfunction
(trial)
RV
Right ventricular/right ventricle
RVA
Right ventricular apical
RVOT
Right ventricular outﬂow tract
RVS
Right ventricular septum
S. aureus
Staphylococcus aureus
SAR
Speciﬁc absorption rate
SAS
Sleep apnoea syndrome
SCD
Sudden cardiac death
SND
Sinus node dysfunction
SR
Sinus rhythm
TAVI
Transcatheter aortic valve implantation
VKA
Vitamin K antagonist
WRAP-IT
World-wide Randomized Antibiotic
Envelope Infection Prevention Trial
1 Preamble
Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision-making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver, as appropriate.
A great number of guidelines have been issued in recent years by the European Society of Cardiology (ESC), as well as by other societies and organizations. Because of their impact on clinical practice,
quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC website (https://www.escardio.org/Guidelines).
The ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated.
In addition to the publication of Clinical Practice Guidelines, the ESC
carries out the EurObservational Research Programme of international registries of cardiovascular diseases and interventions which are essential to assess diagnostic/therapeutic processes, use of resources, and adherence to guidelines. These registries aim at providing a better understanding of medical practice in Europe and around the world,
based on high-quality data collected during routine clinical practice.
Furthermore, the ESC has developed and embedded in this document a set of quality indicators (QIs), which are tools to evaluate the level of implementation of the guidelines and may be used by the
ESC, hospitals, healthcare providers, and professionals to measure clinical practice as well as in educational programmes, alongside the key messages from the guidelines, to improve quality of care and clinical outcomes.
The Members of this Task Force were selected by the ESC, including representation from its relevant ESC subspecialty groups, in order to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a comprehensive review of the published evidence for management of a given condition according to ESC Clinical Practice Guidelines
Committee (CPG) policy. A critical evaluation of diagnostic and therapeutic procedures was performed, including assessment of the riskbenefit ratio. The level of evidence and the strength of the recommendation of particular management options were weighed and graded according to pre-defined scales, as outlined below.
The experts of the writing and reviewing panels provided declaration of interest forms for all relationships that might be perceived as


<!-- PAGE 7 -->

### Page 7

....................................
real or potential sources of conflicts of interest. Their declarations of interest were reviewed according to the ESC declaration of interest rules and can be found on the ESC website (http://www.escardio.org/
guidelines) and have been compiled in a report and published in a supplementary document simultaneously with the guidelines.
This process ensures transparency and prevents potential biases in the development and review processes. Any changes in declarations of interest that arose during the writing period were notified to the
ESC and updated. The Task Force received its entire financial support from the ESC without any involvement from the healthcare industry.
The ESC CPG supervises and coordinates the preparation of new guidelines. The Committee is also responsible for the endorsement process of these Guidelines. The ESC Guidelines undergo extensive review by the CPG and external experts. After appropriate revisions, the guidelines are signed-off by all the experts involved in the Task Force. The finalized document is signed-off by the CPG for publication in the European Heart
Journal. The guidelines were developed after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating.
The task of developing ESC Guidelines also includes the creation of educational tools and implementation programmes for the recommendations including condensed pocket guideline versions, summary slides, summary cards for non-specialists, and an electronic version
Table 1
Classes of recommendations
©ESC 2021
Classes of recommendations
Class I 
Evidence and/or general agreement 
that a given treatment or procedure is 
Is recommended or is indicated
Wording to use
Class III 
Evidence or general agreement that the 
given treatment or procedure is not 
useful/effective, and in some cases 
may be harmful.
Is not recommended
   Class IIb established by evidence/opinion.
May be considered
   Class IIa
Weight of evidence/opinion is in 
Should be considered
Class II 
Table 2
Levels of evidence
Level of 
evidence A
Data derived from multiple randomized clinical trials 
or meta-analyses. 
Level of 
evidence B
Data derived from a single randomized clinical trial or large non-randomized studies. 
Level of 
evidence C
Consensus of opinion of the experts and/or small studies, 
retrospective studies, registries.
©ESC 2021
ESC Guidelines
7


<!-- PAGE 8 -->

### Page 8

.........................................................................................
for digital applications (smartphones, etc.). These versions are abridged and thus, for more detailed information, the user should always access to the full text version of the guidelines, which is freely available via the ESC website and hosted on the EHJ website. The
National Cardiac Societies of the ESC are encouraged to endorse,
adopt, translate, and implement all ESC Guidelines. Implementation programmes are needed because it has been shown that the outcome of disease may be favourably influenced by the thorough application of clinical recommendations.
Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgement, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies. However, the ESC Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient or the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription.
2 Introduction
Pacing is an important part of electrophysiology and of cardiology in general. Whereas some of the situations requiring pacing are clear and have not changed over the years, many others have evolved and have been the subject of extensive recent research, such as pacing after syncope (section 5), pacing following transcatheter aortic valve implantation (TAVI; section 8), cardiac resynchronization therapy (CRT) for heart failure (HF) and for prevention of pacing-induced cardiomyopathy (section 6), and pacing in various infiltrative and inflammatory diseases of the heart, as well as in different cardiomyopathies (section 8).
Other novel topics include new diagnostic tools for decision-making on pacing (section 4), as well as a whole new area of pacing the His bundle and the left bundle branch (section 7). In addition, attention has increased in other areas, such as how to systematically minimize procedural risk and avoid complications of cardiac pacing (section 9), how to manage patients with pacemakers in special situations, such as when magnetic resonance imaging (MRI) or irradiation are needed (section
11), how to follow patients with a pacemaker with emphasis on the use of remote monitoring, and how to include shared decision-making in caring for this patient population (section 12).
The last pacing guidelines of the European Society of Cardiology
(ESC) were published in 2013; therefore, a new set of guidelines was felt to be timely and necessary.
To address these topics, a Task Force was established to create the new guidelines. As well as receiving the input of leading experts in the field of pacing, the Task Force was enhanced by representatives from the Association for Acute CardioVascular Care, the Heart
Failure Association, the European Association of Cardiothoracic
Surgery, the European Association of Percutaneous Cardiovascular
Interventions, the ESC Working Group on Myocardial and
Pericardial Diseases, as well as the Association of Cardiovascular
Nursing & Allied Professions.
2.1 Evidence review
This document is divided into sections, each with a section coordinator and several authors. They were asked to thoroughly review the recent literature on their topics, and to come up with recommendations and grade them by classification as well as by level of evidence.
Where data seemed controversial, a methodologist (Dipak Kotecha)
was asked to evaluate the strength of the evidence and to assist in determining the class of recommendation and level of evidence. All recommendations were voted on by all authors of the document and were accepted only if supported by at least 75% of the co-authors.
The leaders (Jens Cosedis Nielsen and Michael Glikson) and the coordinators of this document (Yoav Michowitz and Mads Brix
Kronborg) were responsible for alignment of the recommendations between sections, and several members of the writing committee were responsible for overlap with other ESC Guidelines, such as the
HF guidelines and the valvular heart disease guidelines.
2.2 Relationships with industry
All work in this document was voluntary and all co-authors were required to declare and prove that they do not have conflicts of interests, as defined recently by the Scientific Guideline Committee of the
ESC and the ESC board.
2.3 What is new in these guidelines
2.3.1
New concepts and new sections
Table 3
New concepts and sections in current guidelines
Concept/section
Section
New section on types and modes of pacing, including conduction system pacing and leadless pacing
3.4
New section on sex differences in pacing
3.5
New section on evaluation of patients for pacing
4
Expanded and updated section on CRT
6
New section on alternative pacing strategies and sites
7
Expanded and updated section on pacing in speciﬁc conditions, including detailed new sections on post TAVI,
postoperative and pacing in the presence of tricuspid valve diseases, and operations
8
A new section on implantation and perioperative management, including perioperative anticoagulation
9
An expanded revised section on CIED complications
10
A new section on various management considerations,
including MRI, radiotherapy, temporary pacing, perioperative management, sport activity, and follow up
11
A new section on patient-centred care
12
CIED = cardiovascular implantable electronic device; CRT = cardiac resynchronization therapy; MRI = magnetic resonance imaging; TAVI = transcatheter aortic valve implantation.
ESC 2021
..............................................................................


<!-- PAGE 9 -->

### Page 9

2.3.2
New recommendations in 2021
Table 4
New recommendations in 2021
Recommendations
Classa
Levelb
Evaluation of the patient with suspected or documented bradycardia or conduction system disease
Monitoring
In patients with infrequent (less than once a month) unexplained syncope or other symptoms suspected to be caused by bradycardia, in whom a comprehensive evaluation did not demonstrate a cause, long-term ambulatory monitoring with an ILR is recommended.
I
A
Ambulatory electrocardiographic monitoring is recommended in the evaluation of patients with suspected bradycardia to correlate rhythm disturbances with symptoms.
I
C
Carotid massage
Once carotid stenosis is ruled outc, carotid sinus massage is recommended in patients with syncope of unknown origin compatible with a reﬂex mechanism or with symptoms related to pressure/manipulation of the carotid sinus area.
I
B
Tilt test
Tilt testing should be considered in patients with suspected recurrent reﬂex syncope.
IIa
B
Exercise test
Exercise testing is recommended in patients who experience symptoms suspicious of bradycardia during or immediately after exertion.
I
C
In patients with suspected chronotropic incompetence, exercise testing should be considered to conﬁrm the diagnosis.
IIa
B
In patients with intra-ventricular conduction disease or AVB of unknown level, exercise testing may be considered to expose infranodal block.
IIb
C
Imaging
Cardiac imaging is recommended in patients with suspected or documented symptomatic bradycardia to evaluate the presence of structural heart disease, to determine left ventricular systolic function, and to diagnose potential causes of conduction disturbances.
I
C
Multimodality imaging (CMR, CT, PET) should be considered for myocardial tissue characterization in the diagnosis of speciﬁc pathologies associated with conduction abnormalities needing pacemaker implantation, particularly in patients younger than 60 years.
IIa
C
Continued
Laboratory tests
In addition to preimplant laboratory tests,d speciﬁc laboratory tests are recommended in patients with clinical suspicion for potential causes of bradycardia (e.g. thyroid function tests,
Lyme titre, digitalis level, potassium, calcium, and pH) to diagnose and treat these conditions.
I
C
Sleep evaluation
Screening for SAS is recommended in patients with symptoms of SAS and in the presence of severe bradycardia or advanced AVB during sleep.
I
C
Electrophysiological study
In patients with syncope and bifascicular block,
EPS should be considered when syncope remains unexplained after non-invasive evaluation or when an immediate decision about pacing is needed due to severity, unless empirical pacemaker implantation is preferred (especially in elderly and frail patients).
IIa
B
In patients with syncope and sinus bradycardia,
EPS may be considered when non-invasive tests have failed to show a correlation between syncope and bradycardia.
IIb
B
Genetics
Genetic testing should be considered in patients with early onset (age <50 years) of progressive cardiac conduction disease.
IIa
C
Genetic testing should be considered in family members following the identiﬁcation of a pathogenic genetic variant that explains the clinical phenotype of cardiac conduction disease in an index case.
IIa
C
Cardiac pacing for bradycardia and conduction system disease
Pacing is indicated in symptomatic patients with the bradycardia-tachycardia form of SND to correct bradyarrhythmias and enable pharmacological treatment, unless ablation of the tachyarrhythmia is preferred.
I
B
Pacing is indicated in patients with atrial arrhythmia (mainly AF) and permanent or paroxysmal third- or high-degree AVB irrespective of symptoms.
I
C
In patients with SND and DDD PM, minimization of unnecessary ventricular pacing through programming is recommended.
I
A
Dual chamber cardiac pacing is indicated to reduce recurrent syncope in patients aged >40
years with severe, unpredictable, recurrent syncope who have:
• spontaneous documented symptomatic asystolic pause/s >3 s or asymptomatic pause/s
>6 s due to sinus arrest or AVB; or
• cardioinhibitory carotid sinus syndrome; or
• asystolic syncope during tilt testing.
I
A
Continued
............................................................................................................................................................................
ESC Guidelines
9


<!-- PAGE 10 -->

### Page 10

In patients with recurrent unexplained falls, the same assessment as for unexplained syncope should be considered.
IIa
C
AF ablation should be considered as a strategy to avoid pacemaker implantation in patients with
AF-related bradycardia or symptomatic preautomaticity pauses, after AF conversion, taking into account the clinical situation.
IIa
C
In patients with the bradycardia-tachycardia variant of SND, programming of atrial ATP may be considered.
IIb
B
Dual-chamber cardiac pacing may be considered to reduce syncope recurrences in patients with the clinical features of adenosine-sensitive syncope.
IIb
B
Cardiac resynchronization therapy
In patients who are candidates for an ICD and who have CRT indication, implantation of a
CRT-D is recommended.
I
A
In patients who are candidates for CRT, implantation of a CRT-D should be considered after individual risk assessment and using shared decision-making.
IIa
B
In patients with symptomatic AF and an uncontrolled heart rate who are candidates for AVJ
ablation (irrespective of QRS duration), CRT
rather than standard RV pacing should be considered in patients with HFmrEF.
IIa
C
In patients with symptomatic AF and an uncontrolled heart rate who are candidates for AVJ
ablation (irrespective of QRS duration), RV pacing should be considered in patients with HFpEF.
IIa
B
In patients with symptomatic AF and an uncontrolled heart rate who are candidates for AVJ
ablation (irrespective of QRS duration), CRT
may be considered in patients with HFpEF.
IIb
B
Alternate site pacing
His bundle pacing
In patients treated with HBP, device programming tailored to speciﬁc requirements of His bundle pacing is recommended.
I
C
In CRT candidates in whom coronary sinus lead implantation is unsuccessful, HBP should be considered as a treatment option along with other techniques such as surgical epicardial lead.
IIa
B
In patients treated with HBP, implantation of a right ventricular lead used as “backup” for pacing should be considered in speciﬁc situations (e.g.
pacemaker-dependency, high-grade AVB, infranodal block, high pacing threshold, planned AVJ
ablation), or for sensing in case of issues with detection (e.g. risk of ventricular undersensing or oversensing of atrial/His potentials).
IIa
C
Continued
HBP with a ventricular backup lead may be considered in patients in whom a “pace-and-ablate”
strategy for rapidly conducted supraventricular arrhythmia is indicated, particularly when intrinsic QRS is narrow.
IIb
C
HBP may be considered as an alternative to right ventricular pacing in patients with AVB and LVEF
>40%, who are anticipated to have >20% ventricular pacing.
IIb
C
Leadless pacing
Leadless pacemakers should be considered as an alternative to transvenous pacemakers when no upper extremity venous access exists or when risk of device pocket infection is particularly high, such as previous infection and patients on haemodialysis.
IIa
B
Leadless pacemakers may be considered as an alternative to standard single lead ventricular pacing, taking into consideration life expectancy and using shared decision-making.
IIb
C
Indications for pacing in speciﬁc conditions
Pacing in acute myocardial infarction
Implantation of a permanent pacemaker is indicated with the same recommendations as in a general population (section 5.2) when AVB does not resolve within a waiting period of at least 5
days after MI.
I
C
In selected patients with AVB in context of anterior wall MI and acute HF, early device implantation (CRT-D/CRT-P) may be considered.
IIb
C
Pacing in cardiac surgery
1) High-degree or complete AVB after cardiac surgery. A period of clinical observation for at least 5 days is indicated in order to assess whether the rhythm disturbance is transient and resolves. However, in the case of complete AVB
with low or no escape rhythm when resolution is unlikely, this observation period can be shortened.
I
C
SND after cardiac surgery and heart transplantation. Before permanent pacemaker implantation,
a period of observation for up to 6 weeks should be considered.
IIa
C
Chronotropic incompetence after heart transplantation. Cardiac pacing should be considered for chronotropic incompetence persisting more than 6 weeks after heart transplantation to improve quality of life.
IIa
C
Continued
............................................................................................................................................................................


<!-- PAGE 11 -->

### Page 11

Surgery for valvular endocarditis and intraoperative complete AVB. Immediate epicardial pacemaker implantation should be considered in patients with surgery for valvular endocarditis and complete AVB if one of the following predictors of persistence is present: preoperative conduction abnormality, Staphylococcus aureus infection, intracardiac abscess, tricuspid valve involvement, or previous valvular surgery.
IIa
C
Patients requiring pacing at the time of tricuspid valve surgery. Transvalvular leads should be avoided and epicardial ventricular leads used.
During tricuspid valve surgery, removal of preexisting transvalvular leads should be considered and preferred over sewing-in the lead between the annulus and a bio-prosthesis or annuloplasty ring. In the case of an isolated tricuspid annuloplasty based on an individual risk-beneﬁt analysis,
a pre-existing right ventricular lead may be left in place without jailing it between ring and annulus.
IIa
C
Patients requiring pacing after biological tricuspid valve replacement/tricuspid valve ring repair.
When ventricular pacing is indicated, transvenous implantation of a coronary sinus lead or minimally invasive placement of an epicardial ventricular lead should be considered and preferred over a transvenous transvalvular approach.
IIa
C
Patients requiring pacing after mechanical tricuspid valve replacement. Implantation of a transvalvular right ventricular lead should be avoided.
III
C
Pacing in transcatheter aortic valve implantation
Permanent pacing is recommended in patients with complete or high-degree AVB that persists for 24 - 48 h after TAVI.
I
B
Permanent pacing is recommended in patients with new onset alternating BBB after TAVI.
I
C
Earlye permanent pacing should be considered in patients with pre-existing RBBB who develop any further conduction disturbance during or after TAVI.f
IIa
B
Ambulatory ECG monitoringg or an electrophysiology studyh should be considered for patients with new LBBB with QRS >150 ms or
PR >240 ms with no further prolongation during
>48 h after TAVI.
IIa
C
Continued
Ambulatory ECG monitoringg or electrophysiology studyh may be considered for TAVI patients with pre-existing conduction abnormality who develop further prolongation of QRS or PR
>20 ms.
IIb
C
Prophylactic permanent pacemaker implantation is not indicated before TAVI in patients with
RBBB and no indication for permanent pacing.
III
C
Various syndromes
In patients with neuromuscular diseases such as myotonic dystrophy type 1 and any second- or third-degree AVB or HV >_70 ms, with or without symptoms, permanent pacing is indicated.i
I
C
In patients with LMNA gene mutations, including
Emery-Dreifuss and limb girdle muscular dystrophies who fulﬁl conventional criteria for pacemaker implantation or who have prolonged PR
with LBBB, ICD implantation with pacing capabilities should be considered if at least 1-year survival is expected.
IIa
C
In patients with Kearns-Sayre syndrome who have PR prolongation, any degree of AVB, bundle branch block, or fascicular block, permanent pacing should be considered.
IIa
C
In patients with neuromuscular disease such as myotonic dystrophy type 1 with PR >_240 ms or
QRS duration >_120 ms, permanent pacemaker implantation may be considered.i
IIb
C
In patients with Kearns-Sayre Syndrome without cardiac conduction disorder, permanent pacing may be considered prophylactically.
IIb
C
Sarcoidosis
In patients with cardiac sarcoidosis who have permanent or transient AVB, implantation of a device capable of cardiac pacing should be considered.i
IIa
C
In patients with sarcoidosis and indication for permanent pacing who have LVEF <50%, implantation of a CRT-D should be considered.
IIa
C
Special considerations on device implantations and perioperative management
Administration of preoperative antibiotic prophylaxis within 1 h of skin incision is recommended to reduce risk of CIED infection.
I
A
Chlorhexidine alcohol instead of povidoneiodine alcohol should be considered for skin antisepsis.
IIa
B
Continued
.......................................................................................................................................................
ESC Guidelines
11


<!-- PAGE 12 -->

### Page 12

For venous access, the cephalic or axillary vein should be considered as ﬁrst choice.
IIa
B
For implantation of coronary sinus leads, quadripolar leads should be considered as ﬁrst choice.
IIa
C
To conﬁrm target ventricular lead position, use of multiple ﬂuoroscopic views should be considered.
IIa
C
Rinsing the device pocket with normal saline solution before wound closure should be considered.
IIa
C
In patients undergoing a reintervention CIED
procedure, the use of an antibiotic-eluting envelope may be considered.
IIb
B
Pacing of the mid-ventricular septum may be considered in patients with a high risk of perforation (elderly, previous perforation).
IIb
C
In pacemaker implantations in patients with possible pocket issues such as increased risk of erosion due to low body mass index, Twiddler’s syndrome or aesthetic reasons, a submuscular device pocket may be considered.
IIb
C
Heparin-bridging of anticoagulated patients is not recommended.
III
A
Permanent pacemaker implantation is not recommended in patients with fever. Pacemaker implantation should be delayed until the patient has been afebrile for at least 24 h.
III
B
Management considerations
Remote monitoring
Remote device management is recommended to reduce number of in-ofﬁce follow-up in patients with pacemakers who have difﬁculties to attend in-ofﬁce visits (e.g. due to reduced mobility or other commitments or according to patient preference).
I
A
Remote monitoring is recommended in case of a device component that has been recalled or is on advisory, to enable early detection of actionable events in patients, particularly those who are at increased risk (e.g. in case of pacemakerdependency).
I
C
Continued
In-ofﬁce routine follow-up of single- and dualchamber pacemakers may be spaced by up to 24
months in patients on remote device management.
IIa
A
Temporary pacing
Temporary transvenous pacing is recommended in cases of haemodynamic-compromising bradyarrhythmia refractory to intravenous chronotropic drugs.
I
C
Transcutaneous pacing should be considered in cases of haemodynamic compromising bradyarrhythmia when temporary transvenous pacing is not possible or available.
IIa
C
Temporary transvenous pacing should be considered when immediate pacing is indicated and pacing indications are expected to be reversible,
such as in the context of myocardial ischaemia,
myocarditis, electrolyte disturbances, toxic exposure, or after cardiac surgery.
IIa
C
Temporary transvenous pacing should be considered as a bridge to permanent pacemaker implantation, when this procedure is not immediately available or possible due to concomitant infection.
IIa
C
For long-term temporary transvenous pacing, an active ﬁxation lead inserted through the skin and connected to an external pacemaker should be considered.
IIa
C
Miscellaneous
When pacing is no longer indicated, a decision on the management strategy should be based on an individual risk-beneﬁt analysis in a shared decision-making process together with the patient.
I
C
MRI may be considered in pacemaker patients with abandoned transvenous leads if no alternative imaging modality is available.
IIb
C
Continued
.....................................................................................................................................


<!-- PAGE 13 -->

### Page 13

..........................
2.3.3
Changes in cardiac pacing and cardiac resynchronization therapy guideline recommendations since 2013
3 Background
3.1 Epidemiology
The prevalence and incidence of pacemaker implantation are unknown in many countries, yet several estimations have been published based on the analysis of large observational studies and databases. There is considerable variability in reported pacemaker implant rates between European countries, ranging from <25
Patient-centred care
In patients considered for pacemaker or CRT,
the decision should be based on the best available evidence with consideration of individual risk-beneﬁts of each option, the patients preferences, and goals of care, and it is recommended to follow an integrated care approach and use the principles of patientcentred care and shared decision making in the consultation.
I
C
AF = atrial ﬁbrillation; ATP = antitachycardia pacing; AV = atrioventricular; AVB
= atrioventricular block; AVJ = atrioventricular junction; BBB = bundle branch block; BMI = body mass index; CIED = cardiovascular implantable electronic device; CMR = cardiovascular magnetic resonance; CRT = cardiac resynchronization therapy; CRT-D = deﬁbrillator with cardiac resynchronization therapy;
CRT-P = cardiac resynchronization therapy-pacemaker; CSM = carotid sinus massage; CT = computed tomography; DDD = dual-chamber, atrioventricular pacing; ECG = electrocardiogram; EPS = electrophysiology study; HBP = His bundle pacing; HF = heart failure; HFmrEF = heart failure with mildly reduced ejection fraction; HFpEF = heart failure with preserved ejection fraction; HV =
Hisventricular interval; ICD = implantable cardioverter-deﬁbrillator; ILR =
implantable loop recorder; LBBB = left bundle branch block; LV = left ventricular;
LVEF = left ventricular ejection fraction; MI = myocardial infarction; MRI = magnetic resonance imaging; OMT = optimal medical therapy; PET = positron emission tomography; PR = PR interval; QRS = Q, R, and S waves; RBBB = right bundle branch block; RV = right ventricular; SAS = sleep apnoea syndrome; SND
= sinus node dysfunction; SR = sinus rhythm; TAVI = transcatheter aortic valve implantation.
aClass of recommendation.
bLevel of evidence.
cCSM should not be undertaken in patients with previous transient ischaemic attack, stroke, or known carotid stenosis. Carotid auscultation should be performed before carotid sinus massage. If a carotid bruit is present, carotid ultrasound should be performed to exclude carotid disease dComplete blood counts, prothrombin time, partial thromboplastin time, serum creatinine, and electrolytes.
eImmediately after procedure or within 24 h.
fTransient high-degree AVB, PR prolongation, or QRS axis change.
gAmbulatory continuous ECG monitoring (implantable or external) for 730
days.
hElectrophysiology study with HV >_70 ms may be considered positive for permanent pacing.
iWhenever pacing is indicated in neuromuscular disease, an ICD should be considered according to relevant guidelines.
ESC 2021
............................
Table 5
Changes in cardiac pacing and cardiac resynchronization therapy guideline recommendations since 2013
2013
2021
Classa
Cardiac pacing for bradycardia and conduction system disease
In patients with syncope, cardiac pacing may be considered to reduce recurrent syncope when asymptomatic pause(s) >6 s due to sinus arrest are documented.
IIa
IIb
Continued
Cardiac resynchronization therapy
Patients who have received a conventional pacemaker or an ICD and who subsequently develop symptomatic HF with LVEF <_35% despite OMT
and who have a signiﬁcantb proportion of RV
pacing should be considered for upgrade to
CRT.
I
IIa
CRT rather than RV pacing is recommended for patients with HFrEF (<40%) regardless of NYHA
class who have an indication for ventricular pacing and high-degree AVB in order to reduce morbidity. This includes patients with AF.
IIa
I
CRT should be considered for symptomatic patients with HF in SR with LVEF <_35%, a QRS
duration of 130149 ms, and LBBB QRS morphology despite OMT, to improve symptoms and reduce morbidity and mortality.
I
IIa
In patients with symptomatic AF and uncontrolled heart rate who are candidates for AVJ
ablation (irrespective of QRS duration), CRT is recommended in patients with HFrEF.
IIa
I
Speciﬁc indications for pacing
In patients with congenital heart disease, pacing may be considered for persistent postoperative bifascicular block associated with transient complete AVB.
IIa
IIb
Management considerations
In patients with MRI-conditional pacemaker systemsc, MRI can be performed safely following manufacturer instructions.
IIa
I
In patients with non-MRI-conditional pacemaker systems, MRI should be considered if no alternative imaging mode is available and if no epicardial leads, abandoned or damaged leads, or lead adaptors/extenders are present.
IIb
IIa
AF = atrial ﬁbrillation; AVB = atrioventricular block; AVJ = atrioventricular junction; CRT = cardiac resynchronization therapy; HFrEF = heart failure with reduced ejection fraction; ICD = implantable cardioverter-deﬁbrillator; LBBB =
left bundle branch block; LVEF = left ventricular ejection fraction; MRI = magnetic resonance imaging; NYHA = New York Heart Association; OMT = optimal medical therapy; RV = right ventricular; SR = sinus rhythm.
aClass of recommendation.
bA limit of 20% RV pacing for considering interventions for pacing-induced HF is supported by observational data. However, there are no data to support that any percentage of RV pacing can be considered as deﬁning a true limit below which
RV pacing is safe and beyond which RV pacing is harmful.
cCombination of MRI conditional generator and lead(s) from the same manufacturer.
ESC 2021
....................................................................................................................................................
ESC Guidelines
13


<!-- PAGE 14 -->

### Page 14

....................................................................
pacemaker implantations per million people in Azerbaijan, Bosnia and
Herzegovina, and Kyrgyzstan, to >1000 implantations per million people in France, Italy, and Sweden.1 These differences may result from under- or overtreatment with pacemaker therapy in some countries, or from variations in sociodemographic characteristics and pathological conditions. There is a continuous growth in the use of pacemakers due to the increasing life expectancy and ageing of populations.28 The estimated number of patients globally undergoing pacemaker implantation has increased steadily up to an annual implant rate of 1 million devices.2 Degeneration of the cardiac conduction system and changes in intercellular conduction can be manifestations of cardiac pathology or non-cardiac disease, and are most prevalent in older patients. Therefore, most bradycardias requiring cardiac pacing are observed in the elderly,
with >80% of pacemakers being implanted in patients above the age of 65 years.
3.2 Natural history
High-degree atrioventricular block (AVB) and sinus node dysfunction
(SND) are the most common indications for permanent pacemaker therapy. Conservatively treated (i.e. non-paced) patients with highdegree
AVB
have notably poorer survival compared with pacemaker-treated patients.912 In contrast, SND follows an unpredictable course, and there is no evidence to show that pacemaker therapy results in improved prognosis.1315
Improving life expectancy is not, however, the only objective of pacemaker therapy. Quality of life is an essential metric for measuring a patient’s clinical status and outcome, and provides a holistic picture of clinical treatment effectiveness.16 Studies have been unanimous in finding improved quality of life in patients receiving pacing therapy.1722
3.3 Pathophysiology and classification of bradyarrhythmias considered for permanent cardiac pacing therapy
Definitions of various conduction disturbances are presented in
Supplementary Table 1.
Sinus bradycardia can be considered physiological in response to specific situations, such as in well-conditioned athletes, young individuals, and during sleep. Pathological bradyarrhythmias are dependent on their underlying cause and can be broadly categorized into intrinsic and extrinsic aetiologies. Advanced age and age-related degenerative changes are important intrinsic causes of modifications in electrical impulse initiation and propagation of the conduction
Preimplant evaluation
Minimizing complication risk
Pacing for bradycardia
Pacing in patients with rare diseases
Pacing in patients after cardiac surgery 
High risk reflex syncope
HBP in bradycardia or CRT
Pacing in TAVI
patients
CRT indications
Leadless pacing
New in these guidelines
Figure 1 The 2021 ESC Guidelines on cardiac pacing and CRT present new and updated recommendations for these treatments in relevant patient populations.


<!-- PAGE 15 -->

### Page 15

...........................................................................
system. In addition, genetic mutations have been linked to conduction disorders (see section 4.3.5), and atrial cardiomyopathy23 may be a specific disease that can result in supraventricular tachyarrhythmia,
SND, and atrioventricular node (AVN) disease.24
It is essential to differentiate reversible from non-reversible causes of bradycardia. Potential reversible causes of bradycardia include adverse drug effects, myocardial infarction (MI), toxic exposure, infections, surgery, and electrolyte disorders. In a study including 277 patients referred to the emergency department with bradycardia, electrolyte disorders were the underlying cause in 4%, intoxication in 6%, acute MI in 14%, and adverse drug effects in 21%.25
In the case of non-reversible pathological causes of slow heart rate, the presence and severity of symptoms play an essential role in the consideration for permanent antibradycardia pacemaker therapy. This may be challenging in patients with competing mechanisms for their symptoms. In general, candidates for pacing therapy can be broadly classified into two groups: patients with persistent bradycardia and patients with intermittent [with or without electrocardiographic (ECG) documentation] bradycardia. Persistent bradycardia usually indicates an intrinsic disease in the sinus node tissue or the atrioventricular (AV) conduction system, whereas intermittent bradycardia can be a result of a wide variety of intrinsic and extrinsic pathological processes, as illustrated in Figure 2.2631
3.4 Types and modes of pacing: general description
3.4.1
Endocardial pacing
Endocardial lead-based pacemakers consist of a pulse generator commonly placed in the pectoral region and transvenous lead(s)
implanted into the myocardium with the ability to sense cardiac activity and provide therapeutic cardiac stimulation. Since the introduction of transvenous endocardial pacemakers in the 1960s, major technological advances have improved their efficacy and safety. In general, pacemaker implantation is considered a low-risk procedure,
yet it is not exempt from device- and procedure-related complications and malfunction. Pacemaker implantation is covered in detail in a recent European Heart Rhythm Association (EHRA) consensus document.34
3.4.2
Epicardial pacing
Some clinical scenarios dictate implantation of an epicardial pacemaker system. These include patients with congenital anomalies and no venous access to the heart or with an open shunt between the right and left sides of the circulation, recurrent device infections,
occluded veins, and—most commonly today—in conjunction with open cardiac surgery. Epicardial leads are currently implanted using various (minimally invasive) thoracotomy or thoracoscopy and robotic techniques.35
Patient with bradycardia-related symptoms
Persistent bradycardia
Y
N
Sinus node disease
Documented arrhythmia
(ECG/Holter/monitor)
AV block
Sinus rhythm
Atrial fibrillation
Intrinsic
Paroxysmal AV block
Sino-atrial block and sinus arresta
Atrial fibrillation with slow ventricular condition
Extrinsic (functional)
Vagally induced sinus arrest or AV block
Adenosine hypersensitivityb
Idiopathic AV block
BBB
Reflex syncope
Carotid sinus
Tilt-induced
Unexplained syncope
(suspected)
Y
N
Figure 2 Classification of documented and suspected bradyarrhythmias. AV = atrioventricular; BBB = bundle branch block; ECG = electrocardiogram.
aIncluding the bradycardiatachycardia form of sick sinus syndrome. bDeharo et al.32 Figure adapted from Brignole et al.33
ESC Guidelines
15


<!-- PAGE 16 -->

### Page 16

.............................................................................................................................................................................
3.4.3
Cardiac resynchronization therapy (endo- and/or epicardial)
Cardiac dyssynchrony is a difference in the timing of electrical and mechanical activation of the ventricles, which can result in impaired cardiac efficiency. CRT delivers biventricular pacing to correct electromechanical dyssynchrony in order to increase cardiac output.36 In multiple trials, CRT has shown a significant morbidity and mortality benefit in specific patient groups with reduced left ventricular ejection fraction (LVEF).3740
3.4.4
Alternative methods (conduction system pacing,
leadless pacing)
3.4.4.1 Conduction system pacing
Compared with right ventricular (RV) pacing, His bundle pacing
(HBP) provides a more physiological simultaneous electrical activation of the ventricles via the HisPurkinje system. HBP can restore conduction in a subset of patients with high-degree AVB, and shorten
QRS duration in some patients with left bundle branch block (LBBB)
or right bundle branch block (RBBB).4144 More studies are ongoing and required to evaluate whether HBP has clinical benefits over CRT
or RV pacing. In addition, left bundle branch area pacing is being studied as a pacing modality for patients in whom the conduction disease is too distal for HBP (see section 7.3).
3.4.4.2 Leadless pacing
Miniaturized, intracardiac leadless pacemakers have been introduced.
These devices are inserted percutaneously through the femoral vein and implanted directly in the RV wall using customized catheterbased delivery systems. The first-generation leadless pacemakers have been proven to provide effective single-chamber pacing therapy.4550 Albeit a promising technology, potential difficulty with leadless pacemaker retrieval at the end of service is a limitation. Thus far, there are no randomized controlled data available to compare clinical outcomes between leadless pacing and single-chamber transvenous pacing.
3.4.5
Pacing modes
Technological advances in pacemaker therapy have resulted in a wide variety of pacing modalities. Pacemakers can sense the heart’s intrinsic electrical activity and restore the rate and AV sequence of cardiac activation. Abnormal cardiac automaticity and conduction may be treated by single-lead atrial sensing/pacing, single-lead ventricular sensing/pacing, single leads that pace the right ventricle (RV) and sense both the atrium and ventricle, and dual-lead systems that sense and pace the right atrium (RA) and RV. For common pacing modes,
refer to Supplementary Table 2. The choice of the optimal pacing mode in the presence of conduction disturbances is driven by the underlying morbidity, the impact of pacing therapy on morbidity, and the potential harmful effect of the chosen pacing modality. The choice of pacing modes in specific situations is discussed in section 5.
3.4.6
Rate-responsive pacing
The sinus node modulates the heart rate during different types and loads of exercise (i.e. physical exercise, emotions, postural change,
and fever) proportional to the metabolic demand. Rate-responsive pacemaker systems strive to produce an appropriate compensatory heart rate during emotional or physical activity by sensing body motion/acceleration, minute ventilation, intracardiac impedance, or other surrogates of physical and mental stress, and are indicated in cases of chronotropic incompetence.5157 Dual-sensing rate-responsive pacing (e.g. accelerometer and minute ventilation) may be used in selected patients.58 A brief overview of the most commonly used rate-responsive pacing sensors is given in Supplementary Table 3.
3.5 Sex differences
Pacing indications and complication rates differ between male and female patients. In male patients, primary pacemaker implantation is more often indicated for AVB and less so for SND and atrial fibrillation (AF) with bradycardia.59,60 In female patients, the rate of procedure-related adverse events is significantly higher, corrected for age and type of device. This higher rate is driven mostly by pneumothorax, pericardial effusion, and pocket haematomas.5961
Possible explanations for this are a smaller body size in women and anatomical differences, such as smaller vein diameters and RV
diameters.
4 Evaluation of the patient with suspected or documented bradycardia or conduction system disease
4.1 History and physical examination
A careful history and physical examination are essential for the evaluation of patients with suspected or documented bradycardia
(Figure 3). Current guidelines emphasize the importance of the history and physical examination in the initial evaluation, particularly for identifying patients with structural heart disease.62,63
A complete history should include family history, comprehensive cardiovascular risk assessment, and recent/historical diagnoses that may cause bradycardia. The history should be focused on frequency,
severity, and duration of symptoms that might suggest bradycardia or conduction system disease. The relationship of symptoms to physical activity, emotional distress, positional changes, medical treatment
(Table 6), and typical triggers (e.g. urination, defecation, cough, prolonged standing, and shaving) should be explored too, as well as pulse rate if measured during an episode.
Family history may be especially important in young patients with progressive cardiac conduction disease either isolated or in association with cardiomyopathies and/or myopathies.64,65
Physical examination should focus on manifestations of bradycardia and signs of underlying structural heart disease or systemic disorders (Table 7). Symptomatic slow peripheral pulses should be confirmed with cardiac auscultation or ECG to ensure that other rhythms are not misrepresented as bradycardia (e.g. premature ventricular contractions).
Autonomic regulation disorders are important in the differential diagnosis of syncope or near syncope, and, therefore, orthostatic changes in heart rate and blood pressure may help in the evaluation of the patients.


<!-- PAGE 17 -->

### Page 17

Initial evaluation of patients with symptoms suggestive of bradycardia (SND or AV block)
History
Physical examination
Cardiac imaging
ECG
Cardiovascular risk
Complete history focusing on symptoms
Family history
Medical treatment
Figure 3 Initial evaluation of patients with symptoms suggestive of bradycardia. AVB = atrioventricular block; ECG = electrocardiogram; SND = sinus node dysfunction.
Table 6
Drugs that may cause bradycardia or conduction disorders
Sinus node bradycardia
AVB
Beta-blockers
1
1
Antihypertensives
Non-dihydropyridine calcium channel blockers
1
1
Methyldopa
1
–
Clonidine
1
–
Antiarrhythmics
Amiodarone
1
1
Dronedarone
1
1
Sotalol
1
1
Flecainide
1
1
Propafenone
1
1
Procainamide
–
1
Disopyramide
1
1
Adenosine
1
1
Digoxin
1
1
Ivabradine
1
–
Psychoactive and neuroactive drugs
Donepezil
1
1
Lithium
1
1
Opioid analgesics
1
–
Phenothiazine
1
1
Phenytoin
1
1
Selective serotonin reuptake inhibitors
–
1
Tricyclic antidepressants
–
1
Carbamazepine
1
1
Continued
ESC 2021
Table 6
Continued
Sinus node bradycardia
AVB
Others
Muscle relaxants
1
–
Cannabis
1
–
Propofol
1
–
Ticagrelor
1
1
High-dose corticosteroids
1
–
Chloroquine
–
1
H2 antagonists
1
1
Proton pump inhibitors
1
–
Chemotherapy
Arsenic trioxide
1
1
Bortezomib
1
1
Capecitabine
1
–
Cisplatin
1
–
Cyclophosphamide
1
1
Doxorubicin
1
–
Epirubicin
1
–
5-ﬂuorouracil
1
1
Ifosfamide
1
–
Interleukin-2
1
–
Methotrexate
1
–
Mitroxantrone
1
1
Paclitaxel
1
–
Rituximab
1
1
Thalidomide
1
1
Anthracycline
–
1
Taxane
–
1
AVB = atrioventricular block.
........................................................................................................
ESC Guidelines
17


<!-- PAGE 18 -->

### Page 18

Carotid sinus massage (CSM) can be helpful in any patient >_40
years old with symptoms suggestive of carotid sinus syndrome (CSS):
syncope or near syncope elicited by tight collars, shaving, or turning the head.66,67 Methodology and response to CSM are described in section 4.1 in the Supplementary data. Diagnosis of CSS requires both the reproduction of spontaneous symptoms during CSM and clinical features of spontaneous syncope compatible with a
reflex mechanism.6870
4.2 Electrocardiogram
Together with the history and physical examination, the resting ECG
is an essential component of the initial evaluation of patients with documented or suspected bradycardia. A 12-lead ECG or a rhythm strip during the symptomatic episode provides the definitive diagnosis.
For those in whom physical examination suggests a bradycardia, a
12-lead ECG is useful to confirm the rhythm, rate, nature, and extent of conduction disturbance (Supplementary Table 1). Furthermore, an
ECG may provide information about structural heart or systemic illness (e.g. LV hypertrophy, Q waves, prolonged QT interval, and low voltage) that predict adverse outcomes in symptomatic patients.62
4.3 Non-invasive evaluation
Table 7
Intrinsic and extrinsic causes of bradycardia
Sinus bradycardia or SND
AVJ
disturbances
Intrinsic
Idiopathic (ageing, degenerative)
1
1
Infarction/ischaemia
1
1
Cardiomyopathies
1
1
Genetic disorders
1
1
Inﬁltrative diseases
Sarcoidosis
1
1
Amyloidosis
1
1
Haemochromatosis
1
1
Collagen vascular diseases
Rheumatoid arthritis
1
1
Scleroderma
1
1
Systemic lupus erythematosus
1
1
Storage diseases
1
1
Neuromuscular diseases
1
1
Infectious diseases
Endocarditis (perivalvular abscess)
–
1
Chagas disease
1
1
Myocarditis
–
1
Lyme disease
–
1
Diphtheria
–
1
Toxoplasmosis
–
1
Congenital heart diseases
1
1
Cardiac surgery
Coronary artery bypass grafting
1
1
Valve surgery (including transcatheter aortic valve replacement)
1
1
Maze operation
1
–
Heart transplant
1
1
Radiation therapy
1
1
Intended or iatrogenic AVB
–
1
Sinus tachycardia ablation
1
–
Extrinsic
Physical training (sports)
1
1
Vagal reﬂex
1
1
Drug effects
1
1
Idiopathic paroxysmal AVB
–
1
Electrolyte imbalance
Hypokalaemia
1
1
Hyperkalaemia
1
1
Hypercalcaemia
1
1
Hypermagnesaemia
1
1
Metabolic disorders
Hypothyroidism
1
1
Anorexia
1
1
Hypoxia
1
1
Acidosis
1
1
Continued
Table 7
Continued
Sinus bradycardia or SND
AVJ
disturbances
Hypothermia
1
1
Neurological disorders
Increased intracranial pressure
1
1
Central nervous system tumours
1
1
Temporal epilepsy
1
1
Obstructive sleep apnoea
1
1
AV = atrioventricular; AVB = atrioventricular block; AVJ = atrioventricular junction; SND = sinus node dysfunction.
Adapted from Mangrum et al.71 and Da Costa et al.72a
Recommendations for non-invasive evaluation
Recommendations
Classa
Levelb
Once carotid stenosis is ruled out,c CSM is recommended in patients with syncope of unknown origin compatible with a reﬂex mechanism or with symptoms related to pressure/manipulation of the carotid sinus area.6870
I
B
CSM = carotid sinus massage.
aClass of recommendation.
bLevel of evidence.
cCSM should not be undertaken in patients with previous transient ischaemic attack, stroke, or known carotid stenosis. Carotid auscultation should be performed before CSM. If a carotid bruit is present, carotid ultrasound should be performed to exclude the presence of carotid disease.
ESC 2021
ESC 2021
............................................................................................................................................................................


<!-- PAGE 19 -->

### Page 19

...................................................................................
4.3.1
Ambulatory electrocardiographic monitoring
The intermittent nature of most symptomatic bradycardia secondary to conduction system disease often requires prolonged ambulatory
ECG monitoring to correlate rhythm disturbances with symptoms.
This monitoring allows detection of interruption of AV conduction by either primary disease of the conductive system, a vagal or neurocardiogenic mechanism, or reflex AV block.72,72a
Ambulatory ECG identifies defects of sinus automaticity, which includes sinus pauses, sinus bradycardia, bradycardiatachycardia syndrome, asystole post-conversion of atrial flutter or AF, and chronotropic incompetence.
Different versions of ambulatory ECG monitoring have been reviewed recently in a
comprehensive expert consensus
(Supplementary Table 4).73 Ambulatory ECG selection depends on the frequency and nature of the symptoms (Table 8).
4.3.2
Exercise testing
Exercise testing may be useful in selected patients with suspected bradycardia during or shortly after exertion. Symptoms occurring during exercise are likely to be due to cardiac causes, whereas symptoms occurring after exercise are usually caused by a reflex mechanism.
Exercise testing can be used to diagnose symptomatic chronotropic incompetence, defined as an inability to increase the heart rate commensurate with the increased metabolic demands of physical activity.74,75 The most commonly used definition of chronotropic incompetence has been failure to reach 80% of the expected heart rate reserve. Expected heart rate reserve is defined as the difference between the age-predicted maximal heart rate (220  age) and the resting heart rate. However, some medical treatments and comorbidities cause exercise intolerance and make the diagnosis of chronotropic incompetence by exercise testing more difficult.
In patients with exercise-related symptoms, the development or progression of AVB may occasionally be the underlying cause.
Tachycardia-related exercise-induced second-degree and complete
AVB have been shown to be located distal to the AVN and predict progression to permanent AVB.7678 Usually, these patients show intraventricular conduction abnormalities on the resting ECG, but a normal resting ECG has also been described in such cases.77,79
Exercise testing may expose advanced infranodal AVB in the presence of conduction system disease of uncertain location.
In rare cases, conduction disturbances induced by exercise are caused by myocardial ischaemia or coronary vasospasm, and exercise testing may reproduce the symptoms.80,81
There are no data supporting an indication for exercise testing in patients without exercise-related symptoms. Exercise testing may be useful in selected patients to distinguish AVN from conduction disturbances in the HisPurkinje system below the AVN in the setting of conduction disturbance at an unclear level.
4.3.3
Imaging
In patients with suspected or documented symptomatic bradycardia,
the use of cardiac imaging is recommended to evaluate the presence of structural heart disease, to determine LV systolic function, and to diagnose potential reversible causes of conduction disturbances
(Table 7).
Echocardiography is the most commonly available imaging technique for evaluation of the above factors. It can also be used in the
Table 8
Choice of ambulatory electrocardiographic monitoring depending on symptom frequency
Frequency of symptom
Daily
24-h Holter ECG or in-hospital telemetric monitoring
Every 4872 h
244872 h Holter ECG
Every week
7-day Holter ECG/external loop recorder/
external patch recorder
Every month
External loop recorder/external patch recorder/handheld ECG recorder
<1 per month
ILR
ECG = electrocardiogram; ILR = implantable loop recorder.
Adapted from Brignole et al.33
ESC 2021
Recommendation for ambulatory electrocardiographic monitoring
Recommendation
Classa
Levelb
Ambulatory ECG monitoring is recommended in the evaluation of patients with suspected bradycardia to correlate rhythm disturbances with symptoms.73
I
C
ECG = electrocardiogram.
aClass of recommendation.
bLevel of evidence.
ESC 2021
Recommendations for exercise testing
Recommendations
Classa
Levelb
Exercise testing is recommended in patients who experience symptoms suspicious of bradycardia during or immediately after exertion.62,7480
I
C
In patients with suspected chronotropic incompetence, exercise testing should be considered to conﬁrm the diagnosis.74,75
IIa
B
In patients with intraventricular conduction disease or AVB of unknown level, exercise testing may be considered to expose infranodal block.76,77,79
IIb
C
AVB = atrioventricular block.
aClass of recommendation.
bLevel of evidence.
ESC 2021
..........................................................................................
ESC Guidelines
19


<!-- PAGE 20 -->

### Page 20

....................................................................................................................
context of haemodynamic instability. When coronary artery disease is suspected, coronary computed tomography (CT), angiography, or stress imaging is recommended.82 Cardiovascular magnetic resonance (CMR) and nuclear imaging techniques provide information on tissue characterization (inflammation, fibrosis/scar) and should be considered before pacemaker implantation when specific aetiologies associated with conduction abnormalities are suspected (specially in young patients). Late gadolinium contrast enhanced (LGE) and T2
CMR techniques allow the diagnosis of specific causes of conduction disturbances (i.e. sarcoidosis and myocarditis). Late gadolinium contrast enhancement CMR helps in the decision-making of individuals with arrhythmic events; the presence of large areas of LGE (scar/fibrosis) has been linked to an increased risk of ventricular arrhythmias regardless of LVEF and may indicate the need for an implantable cardioverter-defibrillator (ICD).8385 T2 CMR sequences are suited for the detection of myocardial inflammation (i.e. oedema and hyperaemia) as a potential cause of transitory conduction abnormalities that may not need permanent pacemaker implantation.86 Similarly,
positron emission tomography (PET) combined with CMR or CT
helps in the diagnosis of inflammatory activity status of infiltrative cardiomyopathies (i.e. sarcoidosis).87,88
4.3.4
Laboratory tests
Laboratory tests, including full blood counts, prothrombin time, partial thromboplastin time, renal function, and electrolyte measurements, are warranted as part of pre-procedural planning for pacemaker implantation.
Bradycardia or AVB may be secondary to other conditions
(Table 7). When suspected, laboratory data are useful for identifying and treating these conditions (e.g. thyroid function, Lyme titre to diagnose myocarditis in a young person with AVB, endocarditis,
hyperkalaemia, digitalis levels, and hypercalcaemia).8994
4.3.5
Genetic testing
Most cardiac conduction disorders are due to either ageing or structural abnormalities of the cardiac conduction system caused by underlying structural heart disease. Genes responsible for inherited cardiac diseases associated with cardiac conduction disorders have been identified.65,95,96
Genetic mutations have been linked to a range of abnormalities that may present in isolated forms of cardiac conduction disorder or in association with cardiomyopathy, congenital cardiac anomalies, or extra-cardiac disorders. Most genetically mediated cardiac conduction disorders have an autosomal dominant mode of inheritance65,95
(Supplementary Table 5).
Progressive cardiac conduction disease
(PCCD)
may be diagnosed in the presence of unexplained progressive conduction abnormalities in young (<50 years) individuals with structurally normal hearts in the absence of skeletal myopathies, especially if there is a family history of PCCD.97 Common PCCD-associated genes are
SCN5A and TRPM4 for isolated forms and LMNA for PCCD associated with HF.
The diagnosis of PCCD in an index patient is based on clinical data including history, family history, and 12-lead ECG. The potential presence of congenital heart disease (CHD) and/or cardiomyopathy must be investigated with cardiac imaging.
Early-onset PCCD, either isolated or with concomitant structural heart disease, should prompt consideration of PCCD genetic testing,
particularly in patients with a positive family history of conduction abnormalities, pacemaker implants, or sudden death.97
A consensus panel has endorsed mutation-specific genetic testing for family members and appropriate relatives after the identification of a PCCD causative mutation in an index case. Such testing can be deferred in asymptomatic children because of the age-dependent nature of cardiac conduction diseases and incomplete penetrance.65
However, every case should be individually evaluated depending of the risk of the detected mutation.
Asymptomatic family members who are positive for the family’s
PCCD-associated mutation should be regularly followed for development of cardiac conduction disease-related symptoms, deterioration of cardiac conduction, and beginning of HF.
Recommendations regarding imaging before implantation
Recommendations
Classa
Levelb
Cardiac imaging is recommended in patients with suspected or documented symptomatic bradycardia to evaluate the presence of structural heart disease, to determine LV systolic function, and to diagnose potential causes of conduction disturbances.
I
C
Multimodality imaging (CMR, CT, or PET) should be considered for myocardial tissue characterization in the diagnosis of speciﬁc pathologies associated with conduction abnormalities needing pacemaker implantation, particularly in patients younger than 60 years.8386,88
IIa
C
CMR = cardiovascular magnetic resonance; CT = computed tomography; LV =
left ventricular; PET = positron emission tomography.
aClass of recommendation.
bLevel of evidence.
Recommendations for laboratory tests
Recommendations
Classa
Levelb
In addition to pre-implantation laboratory tests,c speciﬁc laboratory tests are recommended in patients with clinical suspicion for potential underlying causes of reversible bradycardia (e.g.
thyroid function tests, Lyme titre, digitalis level,
potassium, calcium, and pH) to diagnose and treat these conditions.9094
I
C
aClass of recommendation.
bLevel of evidence.
cComplete blood counts, prothrombin time, partial thromboplastin time, serum creatinine, and electrolytes.
ESC 2021
ESC 2021
...................................................


<!-- PAGE 21 -->

### Page 21

............................................
4.3.6
Sleep evaluation
Nocturnal bradyarrhythmias are common in the general population.
In most circumstances, these are physiological, vagally mediated asymptomatic events, which do not require intervention.98100
Patients with sleep apnoea syndrome (SAS) have a higher prevalence of sleep-related bradycardia (both sinus and conduction system related) during apnoeic episodes.101,102 SAS-induced hypoxaemia is a key mechanism leading to an increased vagal tone and bradycardic rhythm disorders.101,102 Another rare mechanism of sleep-related bradycardia (usually in the form of prolonged sinus arrest) is rapid eye movement sleep-related bradycardia, unrelated to apnoea. This mechanism can also be diagnosed by polysomnography.103 Although most cases quoted in the literature have been treated with pacemakers, the evidence for this is scant, and there is no consensus on how to treat these patients.103
Treatment with continuous positive airway pressure (CPAP) alleviates obstructive sleep apnoea-related symptoms and improves cardiovascular outcomes. Appropriate treatment reduces episodes of bradycardia by 7289%,104 and patients are unlikely to develop symptomatic bradycardia at long-term follow-up.104106 Therefore,
patients with asymptomatic nocturnal bradyarrhythmias or cardiac conduction diseases should be evaluated for SAS. If the diagnosis is confirmed, treatment of sleep apnoea with CPAP and weight loss can be effective in improving bradyarrhythmias occurring during sleep,
and permanent pacing should be avoided. In patients with known or suspected SAS and symptomatic bradyarrhythmias not associated with sleep, a more complex assessment of the risks associated with bradyarrhythmias vs. the benefit of cardiac pacing is needed.
4.3.7
Tilt testing
Tilt testing should be considered to confirm a diagnosis of reflex syncope in patients in whom this diagnosis was suspected but not confirmed by initial evaluation.62,107 The endpoint of tilt testing is the reproduction of symptoms along with the characteristic circulatory pattern of the reflex syncope. The methodology and classification of responses are described in section 4.2 in the Supplementary data and in Supplementary Figure 1.
A positive cardioinhibitory response to tilt testing predicts, with high probability, asystolic spontaneous syncope; this finding is relevant for therapy when cardiac pacing is considered (see section 5.4).
Conversely, the presence of a positive vasodepressor, a mixed response, or even a negative response does not exclude asystole during spontaneous syncope.62
4.4 Implantable monitors
Patients with infrequent symptoms of bradycardia (less than once per month) need a longer duration of ECG monitoring. For these patients, the implantable loop recorder (ILR) is an ideal diagnostic tool given its capacity for prolonged monitoring (up to 3 years) and without the need for active patient participation (Table 8).
In patients with unexplained syncope after the initial evaluation and infrequent symptoms (less than once a month), several studies have demonstrated a higher efficacy of initial ILR implantation compared with a conventional strategy. Many conditions diagnosed by
ILR are bradycardia mediated.108112 For further discussion on the diagnostic roles of ILR and ambulatory ECG, and indications for their use, refer to the ESC Guidelines for the diagnosis and management of syncope.62
Recommendations for genetic testing
Recommendations
Classa
Levelb
Genetic testing should be considered in patients with early onset (age <50 years) of progressive cardiac conduction disease.c 65,97
IIa
C
Genetic testing should be considered in family members following the identiﬁcation of a pathogenic genetic variant that explains the clinical phenotype of cardiac conduction disease in an index case.65
IIa
C
aClass of recommendation.
bLevel of evidence.
cProgressive cardiac conduction disease: prolonged P wave duration, PR interval,
and QRS widening with axis deviation.96
ESC 2021
Recommendation for sleep evaluation
Recommendation
Classa
Levelb
Screening for SAS is recommended in patients with symptoms of SAS and in the presence of severe bradycardia or advanced AVB during sleep.101106
I
C
AVB = atrioventricular block; SAS = sleep apnoea syndrome.
aClass of recommendation.
bLevel of evidence.
ESC 2021
Recommendation for tilt testing
Recommendation
Classa
Levelb
Tilt testing should be considered in patients with suspected recurrent reﬂex syncope.62
IIa
B
aClass of recommendation.
bLevel of evidence.
Recommendation for implantable loop recorders
Recommendation
Classa
Levelb
In patients with infrequent (less than once a month) unexplained syncope or other symptoms suspected to be caused by bradycardia, in whom a comprehensive evaluation did not demonstrate a cause, long-term ambulat ory monitoring with an ILR is recommended.108112
I
A
ILR = implantable loop recorder.
aClass of recommendation.
bLevel of evidence.
ESC 2021
ESC 2021
................................................................................................................................
ESC Guidelines
21


<!-- PAGE 22 -->

### Page 22

..............................
4.5 Electrophysiology study
The development of non-invasive ambulatory ECG technologies has reduced the need for the electrophysiology study (EPS) as a diagnostic test. EPS is generally an adjunctive tool in the evaluation of patients with syncope in whom bradycardia is suspected but has not been documented after non-invasive evaluation (Figure 4). The goal of an
EPS in the context of bradycardia evaluation is to identify abnormal sinus node function or the anatomical location of the cardiac conduction disorders (in the AVN or in the HisPurkinje system distal to the AVN).
In patients with syncope and sinus bradycardia, the pre-test probability of bradycardia-related syncope increases when there is a sinus bradycardia (<50 b.p.m.) or sinoatrial block. Observational studies have shown a relationship between prolonged sinus node recovery time with syncope and the effect of pacing on symptoms.113,114
In patients with syncope and bifascicular block, a prolonged
Hisventricular interval (HV) >_70 ms, or HV >_100 ms after pharmacological stress (ajmaline, procainamide, flecainide, or disopyramide),
or induction of second- or third-degree AVB by atrial pacing or by
History, physical examination, 12-lead ECG and cardiac imaging
Patient with symptoms suggestive of bradycardia or conduction system disease
Early onset of progressive cardiac conduction disease or family history inherited cardiac conduction disorder
Clinical suspicion for potential causes of bradycardia
Syncope and bifascicular block
Suspected scar or infiltrative cardiomyopathy
Suspected recurrent reflex syncope
Bradycardia or cardiac conduction disorders during sleep
Exercise induced symptoms
Genetic test
Laboratory test
EPS or ET for exercisedinduced block or empirical pacemaker in elderly and frail patients
Further imaging
(CMR,CT,
PET etc.)
CSM/ tilt test
Polysomnography
/sleep study
ET
Diagnostic
N
Y
SND
(See section 5.1)
CCD without
AV block
(See section 5.3)
AV block
(See section 5.2)
Reflex syncope
(See section 5.4)
Symptoms
<1 per month
AECG
monitoring
ILR
Nondiagnostic
Clinical follow-up
(non-diagnostic)
Figure 4 Evaluation of bradycardia and conduction disease algorithm. AECG = ambulatory electrocardiographic monitoring; AV = atrioventricular;
CCD = cardiac conduction disease (or disorder); CMR = cardiovascular magnetic resonance; CSM = carotid sinus massage; CT = computed tomography;
ECG = electrocardiogram; EPS = electrophysiology study; ET = exercise test; ILR = implantable loop recorder; PET = positron emission tomography;
SND = sinus node dysfunction.


<!-- PAGE 23 -->

### Page 23

..........................................................................................................................................................................
pharmacological stress, identifies a group at higher risk of developing
AVB.115122
The efficacy of EPS for the diagnosis of syncope is highest in patients with sinus bradycardia, bifascicular block, and suspected tachycardia,62 and lowest in patients with syncope, a normal ECG, no structural heart disease, and no palpitations. Therefore, EPS is preferred over ILR in patients with syncope who have a high pre-test probability for significant conduction disease (e.g. abnormal ECG,
BBB, ischaemic heart disease, or scar-related cardiomyopathy). For patients with a low pre-test probability (no structural heart disease,
normal ECG), ILR is preferred over EPS. EPS is also preferred when there is a high likelihood that another syncopal episode will be dangerous or life-threatening and an immediate diagnosis is likely if EPS is performed.
A negative EPS does not exclude an arrhythmic syncope, and further evaluation is warranted. Approximately one-third of patients with a negative EPS in whom an ILR is implanted develop AVB at follow-up.123
5 Cardiac pacing for bradycardia and conduction system disease
5.1 Pacing for sinus node dysfunction
SND, also known as sick sinus syndrome, comprises a wide spectrum of sinoatrial dysfunctions, ranging from sinus bradycardia, sinoatrial block, and sinus arrest to bradycardiatachycardia syndrome.124,125
An additional manifestation of SND is an inadequate chronotropic response to exercise, reported as chronotropic incompetence.
5.1.1
Indications for pacing
5.1.1.1 Sinus node dysfunction
In general, pacing for asymptomatic SND has never been shown to affect prognosis, as opposed to pacing for AVB. Therefore, SND can be considered as an appropriate indication for permanent pacing only when bradycardia due to SND is symptomatic.126 Patients with
SND may manifest symptoms attributable to bradyarrhythmia and/or symptoms of accompanying atrial tachyarrhythmias in the bradycardiatachycardia form of the disease. Symptoms may be present either at rest or at the end of the tachyarrhythmic episode (conversion pause also named pre-automaticity pause), or develop during exercise, and may range from mild fatigue to light-headedness, dizzy spells, near-syncope, to syncope. Dyspnoea on exertion may be related to chronotropic incompetence. Syncope is a common manifestation of SND and has been reported in 50% of patients who receive a pacemaker for SND.127
Establishing a correlation between symptoms and bradyarrhythmia is a crucial step in decision-making. However, age, concomitant heart disease, and other comorbidities may pose difficulties in establishing a clear causeeffect relationship between SND and symptoms.
The effect of cardiac pacing on the natural history of bradyarrhythmias was evaluated in non-randomized studies undertaken at the beginning of the pacemaker era, which suggested a symptomatic improvement with cardiac pacing.128131 This was confirmed by one randomized controlled trial (RCT)14 in which 107 patients (aged 73
± 11 years) with symptomatic SND were randomized to no treatment, oral theophylline, or dual-chamber (DDD) rate-responsive pacemaker therapy. In this study, the occurrence of syncope and HF
was lower in the pacemaker group during a follow-up of 19 ± 14
months.
In patients presenting with exercise intolerance in whom chronotropic incompetence has been identified, the usefulness of cardiac pacing is uncertain, and the decision to implant a pacemaker in such patients should be made on a case by case basis.
In some cases, symptomatic bradyarrhythmias may be related to transient, potentially reversible, or treatable conditions (section 4,
Table 7). In such cases, correction of these factors is required,
whereas permanent pacing is not indicated. In clinical practice, it is crucial to distinguish physiological bradycardia (due to autonomic influences or training effects) from inappropriate bradycardia that requires permanent cardiac pacing. For example, sinus bradycardia,
even when it is 4050 b.p.m. while at rest or as slow as 30 b.p.m.
while sleeping, particularly in trained athletes, could be accepted as a physiological finding that does not require cardiac pacing.
Asymptomatic bradycardia (due to either sinus pauses or AVB episodes) is not uncommon and warrants interpretation in the clinical context of the patient: in healthy subjects, pauses >2.5 s are uncommon, but this per se does not necessarily constitute a clinical disorder;
asymptomatic bradyarrhythmias are common in athletes.132 In the absence of published trials, no recommendations for bradycardia detected in asymptomatic patients can be made. On the other hand,
in patients investigated for syncope in whom asymptomatic pause(s)
>6 s due to sinus arrest are eventually documented, pacing may be indicated. Indeed, such patients constituted a small minority of those included in an observational study and a randomized trial on pacing in reflex syncope.133,134 In patients presenting with sleep-related asymptomatic intermittent bradycardia (sinus bradycardia or AVB),
sleep apnoea and rapid eye movement sleep-related bradycardia should be considered as possible causes.
Recommendations for electrophysiology study
Recommendations
Classa
Levelb
In patients with syncope and bifascicular block,
EPS should be considered when syncope remains unexplained after non-invasive evaluation or when an immediate decision about pacing is needed due to severity, unless empirical pacemaker implantation is preferred (especially in elderly and frail patients).115121
IIa
B
In patients with syncope and sinus bradycardia,
EPS may be considered when non-invasive tests have failed to show a correlation between syncope and bradycardia.113,114
IIb
B
EPS = electrophysiology study.
aClass of recommendation.
bLevel of evidence.
ESC 2021
ESC Guidelines
23


<!-- PAGE 24 -->

### Page 24

.......................................................................................................................................................................
5.1.1.2 Bradycardiatachycardia form of sinus node dysfunction
The bradycardiatachycardia variant of SND is the most common form, and is characterized by progressive, age-related, degenerative fibrosis of the sinus node tissue and atrial myocardium.
Bradyarrhythmias can be associated with various forms of atrial tachyarrhythmias, including AF.125 In this form of SND, the bradyarrhythmias may correspond to atrial pauses due to sinoatrial blocks or may be due to overdrive suppression after an atrial tachyarrhythmia.135
Atrial tachyarrhythmias may be present at the time of diagnosis,
typically with sinus arrest and asystolic pauses at the termination of atrial tachyarrhythmias or after device implant. Control of atrial tachyarrhythmias in patients presenting with high ventricular rates may be difficult before implant, as drugs prescribed for rate control may worsen bradyarrhythmias. Ablation of the atrial tachyarrhythmia,
mainly AF, has been proposed in lieu of pacing and continuing medications for selected patients,136138 but no data are available from
RCTs to show whether catheter ablation of AF is non-inferior to cardiac pacing with respect to bradycardia-related symptoms in patients with bradycardiatachycardia syndrome.139 If drug treatment is chosen, bradyarrhythmias during drug treatment for rate or rhythm control may be managed by dose reduction or discontinuation as an alternative to cardiac pacing, but in many cases bradyarrhythmias persist.
5.1.2
Pacing mode and algorithm selection
In patients with SND, controlled studies found that DDD was superior to single-chamber ventricular pacing in reducing the incidence of
AF. These studies also showed some effect of DDD pacing on the occurrence of stroke.140,141 Dual-chamber pacing reduces the risk of pacemaker syndrome, which may occur in more than a quarter of patients with SND.21,142 Pacemaker syndrome is associated with a reduction in quality of life and usually justifies the preference for
DDD vs. ventricular rate-modulated pacing in SND, when reasonable.143 Potential exceptions are very elderly and/or frail patients with infrequent pauses who have limited functional capacity and/or a short expected survival. In these patients, the benefit of DDD(R) vs.
VVIR pacing is expected to have limited or no clinical impact, and the incremental risk of complications related to the second atrial lead required in DDD(R) implants should also be considered when choosing the pacing mode. In patients with SND treated with a DDD
pacemaker, programming of the AV interval and specific algorithms for minimizing RV pacing may further reduce the risk of AF and particularly of persistent AF.144 Dual-chamber pacing is safer and more sustainable than atrial-only pacing modes used in the past,127 even though single-lead atrial pacing was found to be superior to singlelead ventricular pacing.145,146 The results of studies that evaluated different pacing modes in bradyarrhythmias, including in some cases both SND and AVB, are shown in Supplementary Table 6.
With regard to the choice between DDD(R) and atrial pacing atrial sensing inhibited-response rate-adaptive (AAIR) pacing, an RCT
with only 177 patients suggested a reduced risk of AF with AAIR.147
However, the most recent DANish Multicenter Randomized Trial on
Single Lead Atrial PACing vs. Dual Chamber Pacing in Sick Sinus
Syndrome (DANPACE), which enrolled 1415 patients followed for a mean of 5.4 years, found no difference between DDD(R) and AAIR
pacing in all-cause mortality.127 The DANPACE trial also found a higher incidence of paroxysmal AF [hazard ratio (HR) 1.27] and a two-fold increased risk of pacemaker reoperation with AAIR, with
AVB developing in 0.61.9% of patients every year.127 These findings support the routine use of DDD(R) rather than AAIR pacing in patients with SND.
In view of these data, DDD(R) is the pacing mode of first choice in
SND (Figure 5). Unnecessary RV pacing should be systematically avoided in patients with SND, because it may cause AF and deterioration of HF, particularly if systolic function is impaired or borderline.144,148 This can be achieved by programming of the AV interval or using specific algorithms for minimizing RV pacing. Programming an excessively long AV interval to avoid RV pacing in patients with prolonged AV conduction may be disadvantageous from a haemodynamic point of view by causing diastolic mitral regurgitation, which may lead to symptoms and/or AF.144,149,150
Pacing algorithms for minimizing ventricular pacing are often used in SND.144,151 A meta-analysis of algorithms for minimizing RV pacing failed to show a significant effect compared with conventional DDD
pacing in patients with normal ventricular function with regard to endpoints such as incidence of persistent/permanent AF, all-cause hospitalization, and all-cause mortality.152 However, the rationale for reducing unnecessary RV pacing remains strong and is coupled with the benefits of extending device longevity.151,152 Some manufacturerspecific algorithms are more effective in minimizing ventricular pacing,
but may confer disadvantages in allowing decoupling between atria and ventricles.153,154 Rarely, algorithms designed to minimize ventricular pacing can cause life-threatening ventricular arrhythmias that are pause dependent or pause triggered.155158 No direct comparison of these algorithms has been performed so far, but pooled data from randomized trials do not show clear-cut superiority of any specific algorithm in improving clinical outcome.152,159
In patients with severely reduced LVEF and a SND indication for pacing, in whom a high percentage of ventricular pacing is expected,
an indication for CRT or HBP should be evaluated (see section 6 on
CRT and section 7 on HBP).
The role of pacing algorithms for preventing AF has been the subject of controversy. A series of algorithms for preventing/suppressing
AF has been tested, such as dynamic atrial overdrive pacing, atrial pacing in response to atrial premature beats, pacing in response to exercise, and post-mode-switch pacing. The clinical evaluation of these algorithms, also applied at different atrial pacing sites, is not convincing and no clinical benefit with regard to major clinical endpoints has been demonstrated.160,161
Atrial antitachycardia pacing [ATP; i.e. delivery of atrial stimuli at high frequencies to convert an atrial tachyarrhythmia to sinus rhythm
(SR)] has also been tested for reducing the atrial tachyarrhythmia burden and counteracting the tendency over time towards progression to permanent AF.162 Conventional delivery of atrial ATP in a way that mirrors the delivery of ventricular ATP (bursts/ramp at arrhythmia onset) has a relatively low success rate, and indeed the trials based on conventional atrial ATP showed no benefit on AF burden or clinical events.163 A new form of ATP delivery has been


<!-- PAGE 25 -->

### Page 25

......................
proposed, specifically aimed at reducing atrial tachyarrhythmias, and its efficacy in reducing the progression to permanent AF was validated in an RCT.162,164
In this trial,164 the primary composite outcome at 2 years (death,
cardiovascular hospitalizations, or permanent AF) was significantly reduced in patients with a device combining ATP and algorithms for minimizing RV pacing [36% relative risk reduction compared with conventional DDD(R)]. The positive effect on the primary endpoint was due to a lower rate of progression to permanent AF. A post-hoc analysis indicated that this form of atrial ATP was an independent predictor of permanent or persistent AF reduction.162,164,165 In
CHD, where re-entrant atrial arrhythmias are very common, use of
DDD(R) pacemakers with atrial ATP may be considered (see section
8 on pacing in CHD).
SND
Persistent or paroxysmal
DDD(R)a
Optimal pacing mode in sinus node dysfunction and atrio-ventricular block
Y
N
Sinus rhythm:
DDD + AVM
AF: VVI +
rate hysteresis
DDDR
+ AVM
Single chamber 
AAI(R)a
VVI(R)a
Any reason to avoid 2
leadsb
Significant comorbidity
Default option
DDD
+ AVM
DDD(R)a
+ AVM
Single chamber
AAIR
Single chamber
AAI
VVIR
VVI
VVI + rate hysteresis
DDD
VVIR
VVI(R)a
VDD
VVI
VDD
VVI +
rate hysteresis
Chronotropic incompetence?
Persistent or paroxysmal no SND
AF
AV block
SND
Paroxysmal
Persistent
Persistent
Paroxysmal
Figure 5 Optimal pacing mode and algorithm selection in sinus node dysfunction and atrioventricular block. AF = atrial fibrillation; AV = atrioventricular;
AVM = atrioventricular management [i.e. AV delay programming (avoiding values >230 ms) or specific algorithms to avoid/reduce unnecessary ventricular pacing]; CRT = cardiac resynchronization therapy; SND = sinus node dysfunction. a(R) indicates that the programming of such a pacing mode is preferred only in the case of chronotropic incompetence. bReasons to avoid two leads include young age and limited venous access. Note: in patients who are candidates for a VVI/VDD pacemaker, a leadless pacemaker may be considered (see section 7). For combined CRT indications, see section 6. Adapted from
Brignole et al.62
ESC Guidelines
25


<!-- PAGE 26 -->

### Page 26

.............................................................................................................................................................................
5.2 Pacing for atrioventricular block
5.2.1
Indications for pacing
Treatment of AVB aims at ameliorating symptoms and preventing syncope and sudden cardiac death (SCD). First-degree AVB is usually asymptomatic. Syncope and dizziness are mainly observed in highdegree and complete AVB, especially in the paroxysmal forms. HF
symptoms are more common in chronic AVB with permanent bradycardia, but can also be observed in first-degree AVB with a very prolonged PR interval. Given the commonly advanced age at onset of
AVB, manifestations of fatigue, exertional intolerance, and HF are sometimes underestimated. Deterioration of cognitive functions is often only speculative so that the possibilities of improvement after implantation of a pacemaker are unpredictable and unlikely. Death in patients with untreated AVB is due not only to HF secondary to low cardiac output, but also to SCD caused by prolonged asystole or bradycardia-triggered ventricular tachyarrhythmia. Although RCTs of pacing in AVB have not been performed, it is clear from several observational studies that pacing prevents recurrence of syncope and improves survival.1012
5.2.1.1 First-degree atrioventricular block
Usually the prognosis is good in the absence of structural heart disease, and progression to high-degree block is uncommon.175 The indication for pacing relies on an established correlation between symptoms and AVB. There is weak evidence to show that marked PR
prolongation (i.e. >_300 ms), particularly when it persists or is prolonged during exercise, can lead to symptoms similar to pacemaker syndrome and/or that these can improve with pacing.176 Symptom correlation is crucial, although it may be difficult if these are nonspecific and subtle. In the absence of a clear correlation, a pacemaker is generally not indicated.
5.2.1.2 Second-degree type I atrioventricular block (Mobitz type I or
Wenckebach)
In addition to the presence or absence of symptoms, the risk of progression to higher degrees of AVB should be considered. Supranodal block has a benign course, and the risk of progression to type II or a higher degree of AV block is low. Small, retrospective studies have suggested that, over the long term, this type of AVB carries a higher risk of death in patients aged >_45 years in the absence of pacemaker implantation.177,178 Infranodal block (rare in this form of block) carries a high risk of progression to complete heart block, syncope, and sudden death, and warrants pacing even in the absence of symptoms.179,180
5.2.1.3 Second-degree Mobitz type II, 2:1, and advanced atrioventricular block (also named high-grade atrioventricular block, where the P:QRS
ratio is 3:1 or higher), third-degree atrioventricular block
In the absence of a reversible cause, due to the risk of occurrence of severe symptoms and/or possible progression towards a more severe or complete AVB, patients should receive a pacemaker even in the absence of symptoms. In asymptomatic patients in whom a 2:1
AVB is found incidentally, the decision for implantation should be made on a case by case basis including distinction between nodal and infranodal AVB. This distinction may be based on observations such as PR or PP interval prolongation before AVB, the effect of exercise on AV conduction, and an EPS.
5.2.1.4 Paroxysmal atrioventricular block
Because of the risk of syncope and SCD and of the potential progression to permanent AVB, the indications for pacing are the same for paroxysmal as for permanent AVB. It is crucial to rule out a reversible cause and to recognize the reflex forms of AVB, which may not need pacing. Documentation of infranodal block by EPS or the documentation of initiation of the block by atrial or ventricular premature beats,
or increased heart rate (tachy-dependent AVB) or decreased heart
Recommendations for pacing in sinus node dysfunction
Recommendations
Classa
Levelb
In patients with SND and a DDD pacemaker,
minimization of unnecessary ventricular pacing through programming is recommended.144,151,159,164,166169
I
A
Pacing is indicated in SND when symptoms can clearly be attributed to bradyarrhythmias.14,128131
I
B
Pacing is indicated in symptomatic patients with the bradycardiatachycardia form of SND in order to correct bradyarrhythmias and enable pharmacological treatment, unless ablation of the tachyarrhythmia is preferred.17,20,21,136138,170,171
I
B
In patients who present chronotropic incompetence and have clear symptoms during exercise,
DDD with rate-responsive pacing should be considered.172,173
IIa
B
AF ablation should be considered as a strategy to avoid pacemaker implantation in patients with
AF-related bradycardia or symptomatic preautomaticity pauses, after AF conversion, taking into account the clinical situation.136139,174
IIa
C
In patients with the bradycardiatachycardia variant of SND, programming of atrial ATP may be considered.164,165
IIb
B
In patients with syncope, cardiac pacing may be considered to reduce recurrent syncope when asymptomatic pause(s) >6 s due to sinus arrest is documented.133,134
IIb
C
Pacing may be considered in SND when symptoms are likely to be due to bradyarrhythmias,
when the evidence is not conclusive.
IIb
C
Pacing is not recommended in patients with bradyarrhythmias related to SND that are asymptomatic or due to transient causes that can be corrected and prevented.33
III
C
ATP = antitachycardia pacing; DDD = dual-chamber, atrioventricular pacing;
SND = sinus node dysfunction.
aClass of recommendation.
bLevel of evidence.
ESC 2021


<!-- PAGE 27 -->

### Page 27

.....................................................
rate (brady-dependent AVB), support a diagnosis of intrinsic infranodal AVB.27
5.2.2
Pacing mode and algorithm selection
5.2.2.1 Dual-chamber vs. ventricular pacing
Large, randomized, parallel trials that included patients with only
AVB181 or with AVB and/or SND140 failed to show superiority of
DDD over ventricular pacing with regard to mortality, and have not consistently shown superiority in terms of quality of life or morbidity
(including stroke or transient ischaemic attack and AF).20,140,181 Dualchamber pacing is beneficial over ventricular pacing due to the avoidance of pacemaker syndrome, which occurred in up to a quarter of patients with AVB in these trials. In a meta-analysis of 20 crossover trials, DDD was associated with an improved exercise capacity compared with ventricular pacing. However, the effect was driven by non-rate-modulated ventricular pacemakers, and no benefit was observed from the comparison of DDD with VVIR pacing.182
Pacemaker syndrome is associated with reduction in quality of life and may require a reintervention for upgrading, justifying the preference for DDD when reasonable (i.e. in patients who do not present with significant frailty, very advanced age, significant comorbidities limiting their life expectancy, or a very limited mobility). Another consideration is the diagnosis of AF, which is more reliable from device data in patients with DDD pacemakers. On a case by case basis, in frail elderly patients, and/or when AVB is paroxysmal and pacing anticipated to be infrequent, VVIR pacing may be considered as it carries a lower complication rate.140
There is strong evidence to show that chronic conventional RV
pacing may be deleterious in some patients and may lead to LV dysfunction and HF,148 even when AV synchrony is maintained.183 This effect is only partly explained by the abnormal activation sequence and may involve myocardial perfusion, and humoral, cellular, and molecular changes.184,185 Compared with a matched control cohort,
patients with a pacemaker and an RV lead have an increased risk of
HF, which is also associated with older age, previous MI, kidney disease, and male sex.186 Pacing-induced cardiomyopathy occurs in
1020% of patients after 24 years of RV pacing.186188 It is associated with a >20% RV pacing burden.187190 However, there are no data to support that any percentage of RV pacing can be considered as defining a true limit below which RV pacing is safe and beyond which RV pacing is harmful. For discussion of potential indications for
CRT and/or HBP to prevent pacing-induced cardiomyopathy, please refer to sections 6 and 7.
5.2.2.2 Atrioventricular block in the case of permanent atrial fibrillation
In the presence of AF, AVB should be suspected if the ventricular rate is slow and the ventricular rhythm regular. During prolonged monitoring, long ventricular pauses may be detected.191 In patients with AF and no permanent AVB or symptoms, there is no identifiable,
minimum pause duration as an indication for pacing. In the absence of a potentially reversible cause, bradycardia or inappropriate chronotropic response (due to either intermittent or complete AVB) associated or reasonably correlated with symptoms is an indication for cardiac pacing. Any high-degree or infranodal block is also an indication for pacing, even in the absence of symptoms. In the absence of symptoms due to bradycardia and of high-degree or infranodal block,
pacing is unlikely to be beneficial and is not indicated.
In patients with AF who undergo atrioventricular junction (AVJ)
ablation to control rapid ventricular rates, there is evidence to show that AVJ ablation plus RV pacing improves symptoms and quality of life.192 In contrast, neutral results were found regarding the progression of HF, hospitalization, and mortality,193 except in one study.194
Compared with pharmacological rate control, AVJ ablation and CRT
reduced the risks of death due to HF, hospitalization due to HF, or worsening HF by 62%, and improved specific symptoms of AF by
36% in elderly patients with permanent AF and narrow QRS.195 In other studies, this beneficial effect was limited to patients with HF or reduced ejection fraction (EF).166,196 For further discussion of the role of CRT following AVJ ablation, refer to section 6. There is weak evidence to support a benefit from para-Hisian and Hisian pacing after AVJ ablation for refractory AF.197200 For further discussion,
refer to section 7.
Recommendations for pacing for atrioventricular block
Recommendations
Classa
Levelb
Pacing is indicated in patients in SR with permanent or paroxysmal third- or second-degree type 2, infranodal 2:1, or high-degree AVB, irrespective of symptoms.c 912
I
C
Pacing is indicated in patients with atrial arrhythmia (mainly AF) and permanent or paroxysmal third- or high-degree AVB irrespective of symptoms.
I
C
In patients with permanent AF in need of a pacemaker, ventricular pacing with rate response function is recommended.201204
I
C
Pacing should be considered in patients with second-degree type 1 AVB that causes symptoms or is found to be located at intra- or infra-His levels at EPS.177180
IIa
C
In patients with AVB, DDD should be preferred over single-chamber ventricular pacing to avoid pacemaker syndrome and to improve quality of life.20,140,181,182
IIa
A
Permanent pacemaker implantation should be considered for patients with persistent symptoms similar to those of pacemaker syndrome and clearly attributable to ﬁrst-degree AVB (PR
>0.3 s).205207
IIa
C
Pacing is not recommended in patients with AVB
due to transient causes that can be corrected and prevented.
III
C
AF = atrial ﬁbrillation; AVB = atrioventricular block; DDD = dual-chamber, atrioventricular pacing; EPS = electrophysiology study; SR = sinus rhythm.
aClass of recommendation.
bLevel of evidence.
cIn asymptomatic narrow QRS complex and 2:1 AVB, pacing may be avoided if supra-Hisian block is clinically suspected (concomitant Wenckebach is observed and block disappears with exercise) or demonstrated at EPS.
ESC 2021
...................................................................................................................
ESC Guidelines
27


<!-- PAGE 28 -->

### Page 28

...............................................................
In patients with AF, compared with fixed rate pacing, rateresponsive pacing is associated with better exercise performance,
improved daily activities, a decrease in symptoms of shortness of breath, chest pain, and palpitations, and improved quality of life.201203 It has also been shown to improve heart rate and blood pressure response to mental stress compared with fixed rate pacing.204 Therefore, rate-adaptive pacing is the pacing mode of first choice. Fixed-rate VVI pacing should be reserved for older sedentary patients who have very limited activity. Commonly, the minimum rate is programmed higher (e.g. 70 b.p.m.) than for patients in SR in an attempt to compensate for loss of active atrial filling.
5.3 Pacing for conduction disorders without atrioventricular block
This section focuses on patients with 1:1 AV conduction and QRS
abnormalities caused by delayed or blocked conduction of the
HisPurkinje system: BBB, fascicular block in isolation or in combination with BBB, and non-specific intraventricular delay. Bifascicular block is defined as LBBB or the combination of RBBB and with left anterior or posterior fascicular block.
Isolated fascicular block and BBB are rarely associated with symptoms; however, their presence may be a marker for underlying structural heart disease. The presence or absence of symptoms referable to intermittent bradycardia will guide the evaluation of these patients.
5.3.1
Indications for pacing
5.3.1.1 Bundle branch block and unexplained syncope
Although syncope is not associated with an increased incidence of sudden death in patients with preserved cardiac function, a high incidence of total deaths (about one-third sudden) was observed in patients with BBB and HF, previous MI, or low EF.208210 Indeed, in those with low EF, syncope is a risk factor for death.211
Unfortunately, ventricular-programmed stimulation does not seem to identify these patients correctly; therefore, an ICD or a defibrillator with CRT (CRT-D) is indicated in patients with BBB and LVEF
<35% for the prevention of SCD (Figure 6).63
5.3.1.2 Bundle branch block, unexplained syncope, and abnormal electrophysiological study
Electrophysiological assessment includes measurement of the
HV at baseline, with stress by incremental atrial pacing or by
Decision algorithm for patients with unexplained syncope and BBB
Bifascicular block
LVEF ≤ 35%
Elderly and frail patients at risk of traumatic recurrrences
ICD/CRT-D
Clinical follow-up
Adapted therapy
Pacemaker implant
EPS/CSM
ILR
N
N
No diagnosis
Y
Y
Diagnosis
No diagnosis
Diagnosis
Figure 6 Decision algorithm for patients with unexplained syncope and bundle branch block. BBB = bundle branch block; CRT-D = defibrillator with cardiac resynchronization therapy; CSM = carotid sinus massage; EPS = electrophysiology study; ICD = implantable cardioverter-defibrillator; ILR =
implantable loop recorder; LVEF = left ventricular ejection fraction.


<!-- PAGE 29 -->

### Page 29

........................................................................
pharmacological provocation (ajmaline, procainamide, or flecainide).
Scheinman et al. studied the prognostic value of the HV: the progression rate to AVB at 4 years was 4% in patients with HV <70 ms, 12%
in patients with HV between 70 and 100 ms, and 24% in patients with
HV >100 ms.121 Development of intra- or infra-His block at incremental atrial pacing or by pharmacological stress test increases the sensitivity and positive predictive value of the EPS to identify patients who will develop AVB.116118,120,122,212 A positive EPS yielded a positive predictive value as high as 80% to identify patients who develop
AVB. This finding has been indirectly confirmed by a study that showed a significant reduction in syncopal recurrences in patients with positive EPS treated with a pacemaker, compared with a control group of untreated patients with a negative EPS.119 In patients with unexplained syncope and bifascicular block, EPS is highly sensitive in identifying patients with intermittent or impending high-degree AVB.
However, a negative EPS cannot rule out intermittent/paroxysmal
AVB as the cause of syncope. Indeed, in patients with a negative EPS,
intermittent or stable AVB was documented by ILR in 50% of cases.
Therefore, elderly patients with bifascicular block and unexplained syncope might benefit from an empirical pacemaker, especially in unpredictable and recurrent syncope that exposes the patient to a high risk of traumatic recurrences. The decision to implant a pacemaker in these patients should be based on individual riskbenefit evaluation.213
5.3.1.3 Alternating bundle branch block
This rare condition refers to situations in which there is clear ECG
evidence for block in all three fascicles on successive ECGs; examples are LBBB and RBBB morphologies on successive ECGs, or RBBB
with associated left anterior fascicular block on one ECG and left posterior fascicular block on another ECG.214 There is general consensus that this phenomenon is associated with significant infranodal disease and that patients will progress rapidly toward AVB.
Therefore, a pacemaker should be implanted as soon as the alternating BBB is detected, even in the absence of symptoms.
5.3.1.4 Bundle branch block without symptoms
Permanent pacemaker implantation is not indicated for BBB without symptoms, with the exception of alternating BBB, because only a minority of these patients will develop
AVB
(12%
per year).115,121,215 The risks of pacemaker implantation and long-term transvenous lead complications are higher than the benefits of pacemaker implantation.216,217
5.3.1.5 Patients with neuromuscular diseases
In patients with neuromuscular diseases, cardiac pacing should be considered, as any degree of fascicular block can progress unpredictably, even in the absence of symptoms (see section 8.5).
5.3.2
Pacing mode and algorithm selection
In intermittent bradycardia, pacing may be required only for short periods. In this situation, the benefits of bradycardia and pause prevention must be weighed against the detrimental effects of permanent pacing,
particularly pacing-induced
HF.
Low base-rate programming to achieve backup pacing, and manual adaptation of AV
interval, programming AV hysteresis, or other specific algorithms preventing unnecessary RV pacing, play a particularly important role in this patient group.144,148
In patients in SR, the optimal pacing mode is DDD. The strong evidence of superiority of DDD vs. VVI pacing is limited to improvement in symptoms and quality of life. Conversely, there is strong evidence of non-superiority with regard to survival and morbidity.20
Therefore, in elderly or frail patients with intermittent bradycardia,
the decision regarding the pacing mode should be made on an individual basis, taking into consideration the increased complication risk and costs of DDD (Figure 5).
VDD may be a pacing mode alternative for patients with advanced
AV conduction abnormalities and spared sinus node function. In comparison with DDD, VDD system implantation is associated with fewer complications, shorter procedure and fluoroscopy times, and a high incidence of atrial undersensing.218 Potential atrial undersensing is contributing to the low use of this system as most operators are aiming for AV synchrony.
Recommendations for pacing in patients with bundle branch block
Recommendations
Classa
Levelb
In patients with unexplained syncope and bifascicular block, a pacemaker is indicated in the presence of either a baseline HV of >_70 ms, second- or third-degree intra- or infra-Hisian block during incremental atrial pacing, or an abnormal response to pharmacological challenge.119,120
I
B
Pacing is indicated in patients with alternating
BBB with or without symptoms.
I
C
Pacing may be considered in selected patients with unexplained syncope and bifascicular block without EPS (elderly, frail patients, high-risk and/
or recurrent syncope).213
IIb
B
Pacing is not recommended for asymptomatic
BBB or bifascicular block.115,121,215
III
B
BBB
=
bundle branch block;
EPS
=
electrophysiology study;
HV
=
Hisventricular interval.
aClass of recommendation.
bLevel of evidence.
ESC 2021
..........................................................................
ESC Guidelines
29


<!-- PAGE 30 -->

### Page 30

......................................................
5.4 Pacing for reflex syncope
Permanent pacemaker therapy may be effective if asystole is a dominant feature of reflex syncope. Establishing a relationship between symptoms and bradycardia should be the goal of the clinical evaluation of patients with syncope and a normal baseline ECG. The efficacy of pacing depends on the clinical setting. The fact that pacing is effective does not mean it is always necessary. In patients with reflex syncope, cardiac pacing should be the last resort and should only be considered in highly selected patients [i.e. those >40 years of age
(mostly >60 years), affected by severe forms of reflex syncope with frequent recurrences associated with a high risk of injury, often without a prodrome]. The 2018 ESC Guidelines on syncope62 give a detailed description of the diagnostic pathway and indications for pacing, and provide the evidence from trials that support such recommendations. Figure 7 summarizes the suggested decision pathway.
The algorithm shown in Figure 7 has been prospectively validated in a multicentre pragmatic study, which showed a low recurrence rate of syncope with pacing of 15% at 2 years, significantly lower than the 37% rate observed in unpaced controls.219 The 3-year recurrence rate was similar in patients with cardioinhibitory carotid sinus syndrome (16%), asystolic tilt response (23%), and spontaneous asystole documented by ILR (24%), suggesting similar indications and similar results for the three forms of reflex syncope.220
Whilst some scepticism prevails over the diagnostic accuracy of tilt testing for the diagnosis of syncope, emerging evidence supports the use of tilt testing in the assessment of reflex hypotensive susceptibility.107,221 Thus, tilt testing may be considered to identify patients with an associated usually antecedent hypotensive response that would be less likely to respond to permanent cardiac pacing. Patients with hypotensive susceptibility need measures directed to counteract hypotensive susceptibility in addition to cardiac pacing (e.g. physical counterpressure manoeuvres, discontinuation/reduction of hypotensive drugs, and administration of fludrocortisone or midodrine).
Management of cardiac pacing in patients with reflex syncope
Severe, recurrent, unpredictable syncopes, age > 40 years
Cardioinhibitory carotid 
sinus syndrome 
Perform carotid sinus massage and tilt table test
Pacing not indicated
(Class III)
N
Y
Y
Positive tilt-test
Y
Y
Asystolic tilt-test
Implantable loop recorder
Asystole
Positive tilt-test
N
N
N
Y
Implant a DDD PM
and counteract hypotensive susceptibility
(Class I)
Y
Y
Implant a DDD PM
(Class I)
N
N
Figure 7 Decision pathway for cardiac pacing in patients with reflex syncope. DDD = dual-chamber, atrioventricular pacing. Note: cardioinhibitory carotid sinus syndrome is defined when the spontaneous syncope is reproduced by the carotid sinus massage in the presence of an asystolic pause >3 s;
asystolic tilt positive test is defined when the spontaneous syncope is reproduced in the presence of an asystolic pause >3 s. A symptomatic asystolic pause(s) >3 s or asymptomatic pause(s) >6 s due to sinus arrest, atrioventricular block, or the combination of the two similarly define asystole detected by implantable loop recorder. Figure adapted from Brignole et al.62


<!-- PAGE 31 -->

### Page 31

....................................................................................
5.4.1
Indications for pacing
This Task Force found sufficient evidence in the literature to recommend pacing in highly selected patients with reflex syncope (i.e. those
>40 years of age with severe recurrent unpredictable syncopal episodes when asystole has been documented, induced by either CSM
or tilt testing, or recorded through a monitoring system)133,222228
(see Supplementary Table 7). There is sufficient evidence that DDD
pacing should be considered in order to reduce recurrence of syncope in patients with dominant cardioinhibitory CSS (asystolic pause
>3 s and spontaneous syncope during CSM) and in those in whom there is a correlation between spontaneous symptoms and ECG
who are >40 years of age and have severe recurrent unpredictable syncope.62 Permanent pacemaker therapy may be effective if asystole is a dominant feature of reflex syncope. Establishing a correlation between symptoms and bradycardia should be the goal of the clinical evaluation of patients with syncope and a normal baseline ECG. The efficacy of pacing depends on the clinical setting. A comparison of results in different settings is presented in Supplementary Table 8.
Since the publication of the 2018 ESC Guidelines on syncope,62
some trials have added relevant information regarding the subset of patients with tilt-induced asystolic vasovagal syncope. The SPAIN trial was a multicentre, randomized, controlled, crossover study, performed in 46 patients aged >40 years affected by severely recurrent
(>5 episodes during life) syncope and cardioinhibitory tilt test response (defined as bradycardia <40 b.p.m. lasting >10 s or asystole
>3 s).226 During the 24-month follow-up, syncope recurred in 4 (9%)
patients treated with a DDD pacemaker with closed loop stimulation vs. in 21 (46%) patients who had received a sham pacemaker programmed off (P = 0.0001). In a propensity score-matched comparison study,229 the 5-year actuarial syncope-free rate was 81% in the pacing group and 53% in propensity-matched patients (P = 0.005; HR
= 0.25). Finally, the BioSync CLS trial was a multicentre RCT that investigated the usefulness of the tilt-table test to select candidates for cardiac pacing.228 Patients aged >_40 years who had at least two episodes of unpredictable severe reflex syncope during the past year and a tilt-induced syncope with an asystolic pause >3 s were randomized to receive either an active (63 patients) or an inactive (64
patients) dual-chamber pacemaker with close loop stimulation. The study showed that, after a median follow-up of 11.2 months, syncope occurred in significantly fewer patients in the pacing group than in the control group [10 (16%) vs. 34 (53%), respectively; HR 0.23; P =
0.00005). This study supports inclusion of tilt testing as a useful method to select patients with reflex syncope for cardiac pacing.
Based on the results of the above studies, sufficient evidence exists to upgrade from IIb to I the indication for pacing in patients aged >40
years with asystolic tilt response >3 s. Figure 8 summarizes the recommended indication for pacing. Although there is also a rationale for pacing in patients aged <_40 years who have the same severity criteria as those >40 years, this Task Force cannot make any recommendation due to the lack of evidence from trials addressing this specific population.
There is weak evidence that DDD may be useful in reducing recurrences of syncope in patients with the clinical features of adenosinesensitive syncope.62 In a small multicentre trial performed in 80 highly
Indications for pacing in patients above age 40 with reflex syncope
Spontaneous asystolic pause(s)
Y
Y
N
N
Test-induced asystolic pause(s)
Extrinsic (functional)
vagally-mediated or adenosine-sensitive
Pacing indicated
(Class I)
CI-CSS
Pacing indicated
(Class I)
Asystolic tilt
Pacing indicated
(Class I)
Adenosine induced
AV block > 10 sec 
Pacing indicated
(Class IIb)
Undocumented syncope
Pacing not indicated
(Class III)
Figure 8 Summary of indications for pacing in patients >40 years of age with reflex syncope. CI-CSS = cardioinhibitory carotid sinus syndrome. Note:
spontaneous asystolic pause = 3 s symptomatic or 6 s asymptomatic. Adapted from Brignole et al.62
ESC Guidelines
31


<!-- PAGE 32 -->

### Page 32

.....................................................
selected elderly patients with unexplained unpredictable syncope who had induction of third-degree AVB of >_10 s to intravenous injection of a bolus of 20 mg of adenosine triphosphate, DDD significantly reduced the 2-year syncope recurrence rate from 69% in the control group to 23% in the active group.230 Finally, cardiac pacing is not indicated in the absence of a documented cardioinhibitory reflex.231,232
5.4.2
Pacing mode and algorithm selection
Even if the quality of evidence is weak, DDD pacing is widely preferred in clinical practice to single-chamber RV pacing in counteracting blood pressure fall and preventing symptom recurrences. In patients with tilt-induced vasovagal syncope, DDD was used mostly with a rate-drop response feature that provides rapid DDD if the device detects a rapid decrease in heart rate. A comparison between
DDD closed-loop stimulation and conventional DDD has been performed by means of a crossover design in two small studies. Both studies showed fewer syncope recurrences with closed-loop stimulation, both in the acute setting during repeated tilt testing233 and during 18-month clinical follow-up.227 However, until a formal parallel trial is performed, no recommendation can be given regarding the selection of the pacing mode (i.e. DDD with rate-drop response or
DDD with closed-loop stimulation) and its programming.
5.5 Pacing for suspected
(undocumented) bradycardia
In patients with recurrent unexplained syncope or falls at the end of the conventional work-up, ILR monitoring should be considered in an attempt to document a spontaneous relapse instead of embarking on empiric cardiac pacing.62
5.5.1
Recurrent undiagnosed syncope
In patients with unexplained syncope at the end of a complete workup and absence of any conduction disturbance, the lack of a rationale and the negative results of small studies234,235 give sufficient evidence of inefficacy of cardiac pacing. Thus, cardiac pacing is not recommended until a diagnosis is made (Figure 8).
5.5.2
Recurrent falls
Between 15% and 20% of unexplained falls may be syncopal in nature,
possibly bradyarrhythmic. Retrograde amnesia, which is frequent in the falling elderly, is responsible for misinterpretation of the event.62
The management of unexplained falls should be the same as that for unexplained syncope (see section 5.4.1). In a randomized doubleblind trial,236 cardiac pacing was ineffective in preventing recurrences in patients with an unexplained fall in whom carotid sinus hypersensitivity was unable to induce syncope.
6 Cardiac resynchronization therapy
6.1 Epidemiology, prognosis, and pathophysiology of heart failure suitable for cardiac resynchronization therapy by biventricular pacing
The prevalence of HF in the developed world approximates 12%
of the adult population, rising to >_10% among people aged >70
years.237 The prevalence of HF is increasing (by 23% over the past decade according to one estimate) mainly due to the ageing of the population, with the age-specific incidence actually declining.238241
There are three distinct phenotypes of HF based on the measurement of LVEF [<40%, HF with reduced EF (HFrEF); 4049%, HF
with mildly reduced EF (HFmrEF); and >_50%, HF with preserved EF
(HFpEF)].242 CRT is clinically useful mainly for patients with HFrEF
and LVEF <_35%. Patients with HFrEF constitute 50% of the entire
Recommendations for pacing for reﬂex syncope
Recommendations
Classa
Levelb
Dual-chamber cardiac pacing is indicated to reduce recurrent syncope in patients aged >40
years, with severe, unpredictable, recurrent syncope who have:
• spontaneous documented symptomatic asystolic pause(s) >3 s or asymptomatic pause(s)
>6 s due to sinus arrest or AVB; or
• cardioinhibitory carotid sinus syndrome; or
• asystolic syncope during tilt testing.62,219,220,226,228,229
I
A
Dual-chamber cardiac pacing may be considered to reduce syncope recurrences in patients with the clinical features of adenosine-sensitive syncope.230
IIb
B
Cardiac pacing is not indicated in the absence of a documented cardioinhibitory reﬂex.231,232
III
B
AVB = atrioventricular block.
aClass of recommendation.
bLevel of evidence.
ESC 2021
Recommendations for cardiac pacing in patients with suspected (undocumented) syncope and unexplained falls
Recommendations
Classa
Levelb
In patients with recurrent unexplained falls, the same assessment as for unexplained syncope should be considered.62
IIa
C
Pacing is not recommended in patients with unexplained falls in the absence of any other documented indication.236
III
B
Pacing is not recommended in patients with unexplained syncope without evidence of SND
or conduction disturbance.234,235
III
C
SND = sinus node dysfunction.
aClass of recommendation.
bLevel of evidence.
ESC 2021
...................................................................................................................


<!-- PAGE 33 -->

### Page 33

.............................................................................................................................................................................
population with HF, and HFrEF is less prevalent among individuals aged 70 years or older. The prognosis of HF varies according to the defined population. In contemporary clinical trials of HFrEF, 1-year mortality rates of 6% are seen, whereas in large registry-based surveys, 1-year mortality rates exceed 20% in patients recently hospitalized for HF, but are closer to 6% in those recruited with stable outpatient HF.243 The concept of CRT is based on the fact that in patients with HF and LV systolic dysfunction, high-grade intraventricular conduction delays are frequently observed, with a prevalence of
QRS duration >120 ms in 2550% of patients and of LBBB in
1527% of cases. Moreover, in such patients, AV dyssynchrony is also often present with prolonged PR on the surface ECG in up to
52% of cases.244246 These electrical abnormalities may result in AV,
interventricular, and intra-LV mechanical dyssynchrony.247,248
Recommendations for CRT are based on the results of the major
RCTs of CRT, most of which have been restricted to the 60% of
HFrEF patients who are in SR. CRT is recommended (in addition to guideline-directed medical therapy) in only defined subsets of the HF
patient population, the majority being symptomatic HF patients in SR
with a reduced LVEF and a QRS duration >_130 ms. Other smaller groups that may be considered for CRT include New York Heart
Association (NYHA) class III or IV HF patients in AF with a reduced
LVEF and a QRS duration >_130 ms, provided a strategy to ensure biventricular capture is in place or the patient is expected to return to SR, and occasionally as an upgrade from a conventional pacemaker or an ICD in HFrEF patients who develop worsening HF with a high rate of ventricular pacing. A recent survey in the USA, which derived a nationally representative estimate of the entire US population of hospitalized patients, found that over a 10-year period (20032012),
there were an estimated 378 247 CRT-D implantations, representing
40 000 per year, or roughly 135 per million per year.249 In Europe,
previous estimates have reported that 400 patients per million population per year might be suitable for CRT. This was based on an estimated prevalence of 35% for LVEF <_35% in a representative HF
population, of which 41% of patients were estimated to have a QRS
duration >_120 ms. The change to a higher threshold of QRS duration of 130 ms will reduce these estimates modestly.250,251 In Sweden, a recent survey of 12 807 HFrEF patients showed that 7% had received
CRT and 69% had no indication for CRT, but 24% had an indication and had not received CRT. These data highlight the underuse of
CRT.252,253 Finally, the Task Force stresses the point that the decision to implant CRT requires a shared decision-making with the patient.
6.2 Indication for cardiac resynchronization therapy: patients in sinus rhythm
CRT improves cardiac function, symptoms, and well-being, and reduces morbidity and mortality in an appropriately selected group of HF patients. CRT also improves quality-adjusted life-years among patients with moderate to severe HF. The beneficial effects of CRT
have been extensively proven in patients with NYHA class II, III, and
IV.37,39,40,254266 In contrast, there is rather limited evidence of CRT
benefit in patients with NYHA functional class I and ischaemic cardiomyopathy.40,265
In the
Multicenter
Automatic
Defibrillator
Implantation with Cardiac Resynchronization Therapy (MADITCRT) study,265 a total of 265 (7.8%) of 1820 patients were class I and had an ischaemic cardiomyopathy. At 7-year follow-up, the subgroup of patients with LBBB, NYHA functional class I, and ischaemic cardiomyopathy showed a non-significant trend towards lower risk of death from any cause [relative risk 0.66, 95% confidence interval (CI)
0.301.42; P = 0.29]. Therefore, present CRT recommendations are applicable to all patients in NYHA functional class IIIV of any aetiology.
The MUltisite STimulation In Cardiomyopathies (MUSTIC),256,257
Multicenter Insync RAndomized Clinical Evaluation (MIRACLE),
PAcing THerapies in Congestive Heart Failure (PATH-CHF) I and
II,58,254,255,259
COmparison of
Medical therapy,
PAcing aNd defibrillatION (COMPANION),260 and CArdiac REsynchronization in
Heart Failure (CARE-HF)39,261 trials compared the effect of CRT vs.
guideline-directed medical therapy in NYHA functional class III or IV; in contrast, most recent trials have compared CRT-D with ICD on top of best medical therapy in NYHA functional class II.37,40,262266 Few studies have compared CRT-pacemaker (CRT-P) with conventional pacing.190,267,268 Most studies of CRT have specified that LVEF should be
<_35%,
but
MADIT-CRT40
and the
Resynchronization
Defibrillation for Ambulatory Heart Failure Trial (RAFT)37 considered an LVEF <_30%, and the REsynchronization reVErses Remodelling in
Systolic left vEntricular dysfunction (REVERSE) trial262 specified <_40%.
Relatively few patients with an LVEF of 3540% have been randomized, but an individual participant data meta-analysis suggests no diminution of the effect of CRT in this group.33
Not all patients respond favourably to CRT. Several characteristics predict reduction in ventricular volume (reverse remodelling) and improvement in morbidity and mortality. QRS width predicts CRT
response and was the inclusion criterion in all randomized trials (for
ECG criteria for LBBB and RBBB, see Supplementary Table 1). QRS
morphology has been related to a beneficial response to CRT.
Several studies have shown that patients with LBBB morphology are more likely to respond favourably, whereas there is less certainty about patients with non-LBBB morphology. Sipahi et al.269,270 performed a meta-analysis in which they examined 33 clinical trials investigating the effect of QRS morphology on CRT, but only four
(COMPANION, CARE-HF, MADIT-CRT, and RAFT) included outcomes according to QRS morphology. When they evaluated the effect of CRT on composite adverse clinical events in 3349 patients with LBBB at baseline, they observed a 36% reduction in risk with the use of CRT (relative risk 0.64, 95% CI 0.520.77; P < 0.00001).
However, such benefit was not observed in patients with non-LBBB
conduction abnormalities (relative risk 0.97, 95% CI 0.821.15; P <
0.75). When the analysis was limited to trials without ICD (CARE-HF
and COMPANION), the benefit of CRT was still observed only in patients with LBBB (P < 0.000001). In a meta-analysis excluding
COMPANION and MADIT-CRT, LBBB was not found to be a predictor of mortality, in contrast to QRS duration.266 In a recent large meta-analysis of five RCTs (COMPANION, CARE-HF, MADIT-CRT,
RAFT, and REVERSE) including 6523 participants (1766 with nonLBBB QRS morphology), CRT was not associated with a reduction in death and/or HF hospitalization in patients with non-LBBB QRS morphology (HR 0.99, 95% CI 0.82- 1.2).271 As patients have been aggregated in the non-LBBB category in nearly all studies and post-hoc analyses on the beneficial effect of QRS morphology in CRT, it is not possible to provide a separate recommendation for CRT in patients presenting with diffuse intraventricular conduction disturbance and
ESC Guidelines
33


<!-- PAGE 34 -->

### Page 34

.............................................................
RBBB.272277 Patients with RBBB do not benefit from CRT278 unless they show a so-called masked LBBB on ECG,277 characterized by a broad, slurred, sometimes notched R wave on leads I and aVL,
together with a leftward axis deviation. Individualized positioning of the LV lead is crucial in these patients.
An important recent notion is the possible role played by a prolonged PR in HF patients with non-LBBB. A few single-centre studies and two post-hoc analyses of large RCTs (COMPANION and
MADIT-CRT) indicated a potential benefit of implanting CRT in this patient subgroup.244,279,280 In MADIT-CRT, the subgroup of nonLBBB patients who had a prolonged PR did benefit from CRT-D, with a 73% reduction in the risk of HF or death and an 81% reduction in the risk of all-cause mortality compared with ICD-only therapy.279 In non LBBB patients with normal PR, CRT-D was associated with a trend towards an increased risk of HF or death and a >2-fold higher mortality compared with ICD therapy, suggesting a bidirectional significant interaction. However, the data are too limited to give a recommendation.279
The results of the MADIT-CRT, REVERSE, and RAFT trials suggest that in patients with LBBB, there is likely to be potential benefit in all patients with LBBB regardless of QRS duration, and that no cut-off point can be identified clearly to exclude patients who will not respond according to the QRS duration.272,273,275 In contrast, any benefit of CRT in patients with non-LBBB is evident mostly in those with a QRS duration >_150 ms. Importantly, as shown in the MADITCRT long-term study and RAFT, the benefit in patients with QRS
<150 ms appeared later during follow-up.265,273
The
Echocardiography
Guided
Cardiac
Resynchronization
Therapy (Echo-CRT) trial suggested possible harm from CRT when baseline echocardiographic mechanical dyssynchrony in patients with
QRS duration <130 ms is used.264,281 Therefore, selection of CRT
patients based solely on the use of cardiac imaging data is strongly discouraged in patients with so-called ‘narrow’ QRS (i.e. <130 ms).
Individual patient data pooled from three CRT-D vs. ICD trials enrolling predominantly patients with NYHA class II HF showed that women are more likely to respond than men.282 In the US Food and
Drug Administration meta-analysis of patient-level data, Zusterzeel et al.283 found that the main difference occurred in patients with LBBB
and a QRS of 130149 ms. In this group, women had a 76% reduction in HF or death [absolute CRT-D to ICD difference, 23% (HR
0.24, 95% CI 0.110.53; P < 0.001)] and a 76% reduction in death alone [absolute difference 9% (HR 0.24, 95% CI 0.060.89; P =
0.03)], whereas there was no significant benefit in men for HF or death [absolute difference 4% (HR 0.85, 95% CI 0.601.21; P =
0.38)] or death alone [absolute difference 2% (HR 0.86, 95% CI
0.491.52; P = 0.60)]. A possible explanation for the greater benefit of CRT in women has been attributed to sex difference in LV size, as sex-specific differences in response disappear when QRS duration is normalized to LV end-diastolic volume.284 Recently, computer modelling confirmed that sex differences in the LV size account for a significant proportion of the sex difference in QRS duration, and provided a possible mechanistic explanation for the sex difference in
CRT response.285,286 Simulations accounting for the smaller LV size in female CRT patients predict 9 - 13 ms lower QRS duration thresholds for females. As with other ECG parameters (e.g. duration of QT
and corrected QT), it is conceivable that QRS duration also has to reflect sex difference.
ECG criteria of intraventricular conduction disturbance, LBBB, and non-LBBB have not been consistently defined and reported in any of the past CRT studies.287,288 Similarly, the modality of QRS measurement (automatic or manual, and ECG recording machine) was not reported in CRT studies. However, the selection of ECG criteria appears to influence hard endpoints.287290 Similarly, ECG recording modality and ECG manufacturer have been shown to possibly affect the automatically measured QRS duration.
Finally, CRT is considered in patients on optimal medical treatment
(OMT), including beta-blockers, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers, and mineralocorticoid receptor antagonists. However, a study raises the question of the timing of CRT, because the efficacy of the medical treatment can be limited in patients with LBBB, suggesting considering CRT sooner.291
Moreover, whereas everyday clinical practice supports the use of sacubitril/valsartan, ivabradine, and sodiumglucose co-transporter2 inhibitors, it must be emphasized that in the landmark trials documenting the efficacy of these drugs, very few patients had an indication for CRT. Thus, there are no strong data to support the mandatory use of these drugs before considering CRT.292295
Recommendations for cardiac resynchronization therapy in patients in sinus rhythm
Recommendations
Classa
Levelb
LBBB QRS morphology
CRT is recommended for symptomatic patients with HF in SR with LVEF <_35%, QRS duration
>_150 ms, and LBBB QRS morphology despite
OMT, in order to improve symptoms and reduce morbidity and mortality.37,39,40,254266,283,284
I
A
CRT should be considered for symptomatic patients with HF in SR with LVEF <_35%, QRS
duration 130149 ms, and LBBB QRS morphology despite OMT, in order to improve symptoms and reduce morbidity and mortality.37,39,40,254266,283,284
IIa
B
Non-LBBB QRS morphology
CRT should be considered for symptomatic patients with HF in SR with LVEF <_35%, QRS
duration >_150 ms, and non-LBBB QRS morphology despite OMT, in order to improve symptoms and reduce morbidity.37,39,40,254266,283,284
IIa
B
CRT may be considered for symptomatic patients with HF in SR with LVEF <_35%, QRS
duration 130149 ms, and non-LBBB QRS morphology despite OMT, in order to improve symptoms and reduce morbidity.273278,281
IIb
B
QRS duration
CRT is not indicated in patients with HF and
QRS duration <130 ms without an indication for
RV pacing.264,282
III
A
CRT = cardiac resynchronization therapy; HF = heart failure; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; OMT = optimal medical therapy; SR = sinus rhythm.
aClass of recommendation.
bLevel of evidence.
ESC 2021
................................................................................................................


<!-- PAGE 35 -->

### Page 35

.............................................................................................................................................................................
6.3 Patients in atrial fibrillation
This section considers indications for CRT in patients with permanent AF or persistent AF unsuitable for AF ablation or after unsuccessful AF ablation. AF ablation has been reported to improve LVEF
and reduce the HF hospitalization rate in selected patients. In particular, AF ablation is recommended for reversing LV dysfunction in AF
patients when tachycardia-induced cardiomyopathy is highly probable, regardless of symptoms.296 Therefore, CRT should be considered in those patients with persistent AF and HFrEF when AF
ablation cannot be performed or is declined by the patient. With regard to indications for rate control therapy and in particular to AVJ
ablation, refer to the ESC Guidelines for the management of AF.296
6.3.1
Patients with atrial fibrillation and heart failure who are candidates for cardiac resynchronization therapy
A major determinant of the success of CRT is the effective delivery of biventricular pacing. A particular aspect of AF patients is that AF
rhythm with fast ventricular rate and irregularity may interfere with adequate biventricular pacing delivery. AF may reduce the rate of effective biventricular capture by creating spontaneous, fusion, or pseudo-fusion beats. A high rate of biventricular pacing is not reached in two-thirds of patients with persistent or permanent AF.297
Data from large registries show that AF patients undergoing CRT
have an increased risk of mortality even after adjusting for several clinical variables.297299 In most AF patients with intact AV conduction, an adequate biventricular pacing delivery can be achieved only by means of AVJ ablation.300302 A substudy of the RAFT trial300 was unable to show benefit of CRT without AVJ ablation with regard to the combined endpoint of death or hospitalization for HF; notably,
only 47% of the patients had a biventricular capture >90%. The decision to perform AVJ ablation is still a matter of debate, but most studies have shown improvements in LV function, functional capacity,
exercise capacity, and survival (with the same magnitude as in patients with SR).301 Gasparini et al.302 compared total mortality of
443 AF patients who received AVJ ablation (n = 443) and of 895 AF
patients who received rate-slowing drugs with the mortality of 6046
patients who were in SR. The long-term survival after CRT among patients with AF and AVJ ablation was similar to that observed among patients in SR (HR 0.93); the mortality was higher for AF patients treated with rate-slowing drugs (HR 1.52). The most common ratecontrolling drugs used in AF are beta-blockers; although safe even in the context of AF and HFrEF, they do not necessarily have the same benefit as in patients with SR303 and the benefitrisk ratio is influenced by other cardiovascular comorbidities.304,305 In a systematic review and meta-analysis,306 AVJ ablation, compared with no AVJ
ablation, reduced mortality by 37% and reduced the rate of nonresponse by 59% in patients with biventricular pacing <90%, but showed no benefit in those with >_90% biventricular pacing. Similarly,
Tolosana et al. observed the same rate of responders (defined as
>_10% decrease in end-systolic volume) in AF patients who received
AVJ ablation or rate-slowing drugs and patients in SR who had adequate biventricular pacing (97, 94, and 97%, respectively).307
Importantly, AVJ ablation did not improve survival for patients in AF
treated with CRT compared with those treated with rate-slowing drugs when an adequate biventricular pacing was achieved either with ablation (97%) or with drugs (94%).308
In conclusion, despite the weak evidence due to lack of large,
randomized trials, the prevailing opinion of experts is in favour of the usefulness of CRT in patients with permanent AF and NYHA class III
and IV with the same indications as for patients in SR, provided that
AVJ ablation is added in those patients with incomplete (<90 - 95%)
biventricular capture due to AF (Figure 9). However, there are other causes for incomplete biventricular pacing such as frequent premature ventricular beats, which may need to be treated (with drugs or ablation) before considering AVJ ablation. Importantly, evaluation of the biventricular pacing percentage is mainly given by the percentage of biventricular pacing using device memory, which does not reflect exactly the rate of effective biventricular capture. Holter monitoring may help to assess the real biventricular capture percentage.309,310 A
new algorithm has been developed that can continuously assess the effective biventricular pacing.311
For patients with permanent AF, there are no data supporting the difference in the magnitude of response to CRT according to the
QRS morphology or a QRS duration cut-off of 150 ms.
It is important to remember that limited data are available for patients in NYHA class II.
6.3.2
Patients with uncontrolled heart rate who are candidates for atrioventricular junction ablation
(irrespective of QRS duration)
AVJ ablation should be considered to control heart rate in patients unresponsive or intolerant to intensive rate and rhythm control therapy, or who are ineligible for AF ablation, accepting that these patients will become pacemaker dependent.296 In particular, AVJ
ablation combined with CRT may be preferred to AF ablation in severely symptomatic patients with permanent AF and at least one hospitalization for HF.296
AVJ ablation and permanent pacing from the RV apex provides highly efficient rate control and regularization of the ventricular response in AF, and improves symptoms in selected patients.192 A
large study with a propensity score-matched control group194
showed a 53% reduction in total mortality in patients who underwent
AVJ ablation compared with those treated with pharmacological rate control therapy. A class IIa indication is provided in the 2020 ESC
Guidelines on AF.296
The downside of RV pacing, however, is that it induces LV dyssynchrony in 50% of patients,312 and that this may lead to worsening of
HF symptoms in a minority. In the majority of patients, AVJ ablation improves LVEF even with RV apical (RVA) pacing due to amelioration of tachycardia-induced LV dysfunction, which commonly exists in these patients. CRT may prevent RV pacing-induced LV dyssynchrony. The multicentre, randomized, prospective Ablate and Pace in
Atrial Fibrillation (APAF) trial313 included 186 patients in whom a
CRT or RV pacing device was implanted, followed by AVJ ablation.
During a median follow-up of 20 months, CRT significantly reduced by 63% the primary composite endpoint of death due to HF, hospitalization due to HF, or worsening of HF. The beneficial effects of CRT
were similar in patients with an EF <_35%, NYHA class >_III, and QRS
width >_120 ms, and in other patients with EF>35% or NYHA class
< III or narrow QRS. Compared with the RV pacing group, responders increased from 63% to 83% (P ¼ 0.003).314 A meta-analysis of
696
patients from five trials showed a
62%
reduction in
ESC Guidelines
35


<!-- PAGE 36 -->

### Page 36

.............................................
hospitalization for HF and a modest improvement in LVEF compared with RV pacing, but not in 6-min walked distance and quality of life assessed by means of the Minnesota Living with Heart Failure questionnaire.315 In the APAF-CRT RCT, 102 elderly patients (mean age
72 years) with permanent AF, a narrow QRS (<_110 ms), and at least one hospitalization for HF in the previous year were randomized to
AVJ ablation and CRT or to pharmacological rate control therapy.195
After a median follow-up of 16 months, the primary composite outcome of HF death, hospitalization due to HF, or worsening HF had occurred in 10 patients (20%) in the ablation (AVJ) plus CRT arm and in 20 patients (38%) in the drug control arm (HR 0.38; P = 0.013). The results were mostly driven by a reduction in hospitalization for HF.
The HR was 0.18 (P = 0.01) in patients with LVEF <_35% and 0.62 (P =
0.36) in those with LVEF >35%. Furthermore, patients undergoing AVJ
ablation and CRT had a 36% reduction in the specific symptoms and physical limitations of AF at 1-year follow-up (P = 0.004). In contrast to the main composite endpoint, the greatest symptomatic improvements were observed in patients with LVEF >35% (P = 0.0003).
In conclusion, there is evidence from randomized trials of an additional benefit of performing CRT pacing in patients with reduced EF,
who are candidates for AVJ ablation for rate control to reduce hospitalization and improve quality of life. There is evidence that CRT is superior to RV pacing in relieving symptoms, but not mortality and hospitalization in patients with mid-range reduced systolic function
(Figure 9).
6.3.3
Emerging novel modalities for CRT: role of conduction system pacing
HBP, alone or in conjunction with coronary sinus pacing, is a promising novel technique for delivering CRT, useful in AF patients
OR
Controlled heart rate
Candidate for CRT
Candidate for AVJ ablation
Management of atrio-ventricular junction ablation in patients with:
Y
N
Persistent AF unsuitable for atrial fibrillation ablation 
Permanent AF 
OR
CRT
if QRS ≥ 130 ms
(Class IIa)
BiV
> 90 – 95%a
BiV
< 90 – 95%a
No AVJ
ablation
AVJ ablation
(Class IIa)
CRT
(Class I)
CRT
(Class IIa)
CRT
(Class IIb)
LVEF
< 40%
(HFrEF)
40% ≤LVEF 
LVEF < 50%
(HFmrEF)
LVEF < 50%
HBP
(Class IIb)
AVJ ablation
Y
N
RV pacing
(Class IIa)
HBP
(Class IIb)
Figure 9 Indication for atrioventricular junction ablation in patients with symptomatic permanent atrial fibrillation or persistent atrial fibrillation unsuitable for atrial fibrillation ablation. AF = atrial fibrillation; AVJ = atrioventricular junction; BiV = biventricular; CRT = cardiac resynchronization therapy; ESC
= European Society of Cardiology; HBP = His bundle pacing; HFmrEF = heart failure with mildly reduced ejection fraction; HFrEF = heart failure with reduced ejection fraction; LVEF = left ventricular ejection fraction; QRS = Q, R, and S waves; RV = right ventricular/right ventricle. aDue to a rapid ventricular response. Note: the figure is based on the recommendations in the ESC Guidelines on AF.296


<!-- PAGE 37 -->

### Page 37

......................................................................................................................
undergoing AVJ ablation.198,199,316318 Non-conventional CRT using
HBP coronary sinus pacing (so-called ‘His-optimized CRT’) or left bundle branch area pacing, in comparison with conventional CRT,
can achieve a narrower QRS with a ‘quasi-normal’ axis morphology,
echocardiographic improvement of mechanical resynchronization indexes, and a better short-term clinical outcome.319321 In general,
the potential benefit of HBP depends on the ability to achieve a narrow QRS complex that is similar to the native QRS complex,
rather than on the LVEF. Widespread adoption of this technique relies upon further validation of its efficacy in large RCTs and improvements in lead design, delivery tools, and devices (see section 7).
6.4 Patients with conventional pacemaker or implantable cardioverter defibrillator who need upgrade to cardiac resynchronization therapy
Several studies have demonstrated the deleterious effect of chronic
RV pacing with respect to an increased risk of HF symptoms or hospitalizations, which may be reduced by programming to maximize intrinsic conduction or prevented by CRT.148,183,190,324 Previously,
the benefit of CRT upgrade had been investigated only by observational controlled trials and registries,325339 mainly comparing upgrade with de novo CRT; in early, small, observational pre- vs. post-CRT
studies;340346 and in crossover trials,347350 providing only limited clinical outcome data.
Based on a recent meta-analysis of observational studies, mostly single-centre,351 echocardiographic and functional response as well as the risk of mortality or HF events was similar in patients after de novo vs. upgrade CRT; however, in previous subgroup analyses from large, randomized, prospective trials such as RAFT,37 morbidity or mortality benefit was not confirmed.
Clinical outcomes are also influenced by the clinical characteristics of patients referred to CRT upgrade. Based on data from the
European CRT Survey II,352 a high-volume registry, and clinical characteristics from previous studies,351 patients referred for a CRT
upgrade differ from patients referred for de novo CRT implantation:
they are older (even compared with those in RCTs), mainly male patients, and have more comorbidities such as AF, ischaemic heart disease, anaemia, and renal failure.
On average, the number of upgrade procedures reaches 23% of total CRT implantations, 60% from a conventional device and 40%
from an ICD352 in ESC countries, showing significant regional differences regarding the type of implanted device, such as CRT-P or
CRT-D.352,353
Regarding procedure-related complications,
several studies described a higher burden during upgrade procedures, ranging from
6.8% to 20.9% compared with de novo implantations.339,354 This was not confirmed in a recent analysis of registry data, where upgrades had similar complication rates to de novo implantations.352 Notably,
82% of these procedures were performed in high-volume centres.
However, data on the long-term infection rates or lead revisions after
CRT upgrade are scarce.354,355
The first prospective, randomized trial, the BUDAPEST CRT
Upgrade study, is still ongoing, but may clarify these questions.356
Recommendations for cardiac resynchronization therapy in patients with persistent or permanent atrial
ﬁbrillation
Recommendations
Classa
Levelb
1) In patients with HF with permanent AF who are candidates for CRT:
1A) CRT should be considered for patients with
HF and LVEF <_35% in NYHA class III or IV
despite OMT if they are in AF and have intrinsic
QRS >_130 ms, provided a strategy to ensure biventricular capture is in place, in order to improve symptoms and reduce morbidity and mortality.302,306,307,322
IIa
C
1B) AVJ ablation should be added in the case of incomplete biventricular pacing (<9095%) due to conducted AF.297302
IIa
B
2) In patients with symptomatic AF and an uncontrolled heart rate who are candidates for AVJ ablation (irrespective of QRS
duration):
2A) CRT is recommended in patients with
HFrEF.196,197,306,308
I
B
2B) CRT rather than standard RV pacing should be considered in patients with HFmrEF.
IIa
C
2C) RV pacing should be considered in patients with HFpEF.188,196,323
IIa
B
2D) CRT may be considered in patients with
HFpEF.
IIb
C
AF = atrial ﬁbrillation; AVJ = atrioventricular junction; CRT = cardiac resynchronization therapy; EF = ejection fraction; HF = heart failure; HFrEF = heart failure with reduced ejection fraction (<40%); HFmrEF = heart failure with mildly reduced ejection fraction (40- 49%); HFpEF = heart failure with preserved ejection fraction (>_50%)
according to the 2021 ESC HF Guidelines;242 LVEF = left ventricular ejection fraction;
NYHA = New York Heart Association; RV = right ventricular.
aClass of recommendation.
bLevel of evidence.
Recommendation for upgrade from right ventricular pacing to cardiac resynchronization therapy
Recommendation
Classa
Levelb
Patients who have received a conventional pacemaker or an ICD and who subsequently develop symptomatic HF with LVEF <_35% despite OMT,
and who have a signiﬁcantc proportion of RV
pacing, should be considered for upgrade to
CRT.37,148,185,190,324352
IIa
B
CRT = cardiac resynchronization therapy; HF = heart failure; ICD = implantable cardioverter-deﬁbrillator; LVEF = left ventricular ejection fraction; OMT = optimal medical therapy; RV = right ventricular.
aClass of recommendation.
bLevel of evidence.
cA limit of 20% RV pacing for considering interventions for pacing-induced HF is supported by observational data. However, there are no data to support that any percentage of RV pacing can be considered as deﬁning a true limit below which
RV pacing is safe and beyond which RV pacing is harmful.
ESC 2021
ESC 2021
.......................................................
ESC Guidelines
37


<!-- PAGE 38 -->

### Page 38

.............................................................................................................................................................................
6.5 Pacing in patients with reduced left ventricular ejection fraction and a conventional indication for antibradycardia pacing
Three randomized trials proved the superiority of biventricular pacing over RV pacing in patients with moderate to severe systolic dysfunction who required antibradycardia pacing to improve quality of life, NYHA class, and echocardiographic response.190,357,358 In the
Biventricular versus RV pacing in patients with AV block (BLOCK
HF) trial, 691 patients with AVN disease and an indication for pacemaker with a mildly reduced EF (<50% by inclusion criteria, average
42.9% in the pacemaker group) were randomized to biventricular or
RV pacing with or without an ICD, and followed for an average of 37
months.190 The primary endpoint (a composite of >_15% increase in the LV end-systolic volume, HF events, or mortality) was significantly improved in those assigned to CRT. CRT response is high among patients with systolic dysfunction and expected frequent RV pacing.
Based on the MOde Selection Trial in Sinus-Node Dysfunction
(MOST),183 at least 40% RV pacing is associated with an increased risk of HF hospitalization or AF.
For patients with normal or preserved EF, data on benefit of CRT
are conflicting with respect to hospitalization, and no mortality benefit was shown.166,268,323,359 However, adverse remodelling caused by
RV pacing was prevented by biventricular pacing, especially during long-term follow up.323,359,360 A single-centre study showed that
>20% RV pacing was associated with deleterious LV remodelling in patients with AVB and preserved LVEF.188 Frailty should also be taken into account in deciding on CRT implantation, because of the higher costs and high complication rates of this procedure.
6.6 Benefit of adding implantable cardioverter defibrillator in patients with indications for cardiac resynchronization therapy
The mortality benefit of CRT-D over CRT-P is still unclear, mostly because no head to head RCTs have been designed to compare these two treatments. While CRT-D may further improve survival over CRT-P by reducing arrhythmic death, it does also add ICDspecific risks such as lead failure and inappropriate shocks, as well as costs.
COMPANION is the only trial to randomize patients to CRT-P or
CRT-D, but was designed to assess the effects of CRT compared with OMT.260 Crucially, it was not designed to compare CRT-D and
CRT-P. CRT-P was associated with a marginally non-significant reduction in the risk of all-cause mortality (HR 0.76, 95% CI
0.58 - 1.01; P = 0.06), whereas CRT-D was associated with a significant, 36% risk reduction (HR 0.64, 95% CI 0.480.86; P = 0.004).
Analysis of cause-specific mortality showed that SCD was significantly reduced by CRT-D (HR 0.44, 95% CI 0.23 - 0.86; P = 0.02) but not
CRT-P (HR 1.21, 95% CI 0.72.07; P = 0.50).363
Nevertheless, the CARE-HF extension study proved that CRT-P
alone reduced the risk of dying suddenly by 5.6%.261 In line with these findings, subgroup analyses from RCTs in mild HF consistently found a reduction in ventricular arrhythmias with CRT.364368 These effects were especially observed among CRT responders, suggesting that the reduction in SCD risk is related to the extent of reverse LV
remodelling with CRT.
Meta-analyses have drawn different conclusions on the matter. In the study by Al-Majed et al.,369 the survival benefit of CRT was largely driven by a reduction in HF-related mortality, but SCD was not reduced. Lam et al.370 showed that CRT-D significantly reduced mortality compared with medical therapy alone [odds ratio (OR) 0.57,
95% CI 0.400.80], but not when compared with ICD without CRT
(OR 0.82, 95% CI 0.571.18) or CRT-P (OR 0.85, 95% CI
0.601.22). However, more recently, a network meta-analysis of 13
randomized trials including >12 000 patients found that CRT-D
reduced total mortality by 19% (95% CI 133%, unadjusted) compared with CRT-P.275
Some recent large observational studies highlighted the importance of HF aetiology in the assessment of potential benefits of CRTD over CRT-P.371373 CRT-D was associated with a significant risk reduction in all-cause mortality compared with CRT-P in patients with ischaemic cardiomyopathy. However, this difference was not found in patients with non-ischaemic cardiomyopathy.
These findings are consistent with the results from the DANISH
study, which assigned 1116 patients with HF and non-ischaemic cardiomyopathy to receive either a primary prophylactic ICD or usual clinical care alone.374 In both groups, 58% of patients also had CRT.
Subgroup analysis showed that CRT-D was not superior to CRT-P in reducing the primary outcome of all-cause mortality (HR 0.91, 95%
CI 0.641.29; P = 0.59) after a median follow-up of 67.6 months.
However, in a large multicentre registry of >50 000 patients, CRT-D
was associated with a significantly lower observed mortality.375
Similar results were found in a recent propensity-matched cohort,
where CRT-D was associated with a significantly lower all-cause mortality than CRT-P in patients with ischaemic aetiology and in patients with non-ischaemic HF under 75 years old.376 Furthermore,
the CeRtiTuDe Cohort study377 showed better survival in CRT-D
vs. CRT-P mainly due to a reduction of non-SCD. In an Italian multicentre CRT registry, the only independent predictor of mortality was the lack of an ICD.378 Whereas these studies are limited by their observational design, important novel information on the issue of
CRT-D vs. CRT-P is expected to come from an ongoing randomized trial, Re-evaluation of Optimal Re-synchronisation Therapy in
Recommendation for patients with heart failure and atrioventricular block
Recommendation
Classa
Levelb
CRT rather than RV pacing is recommended for patients with HFrEF (<40%) regardless of NYHA
class who have an indication for ventricular pacing and high-degree AVB in order to reduce morbidity. This includes patients with
AF.183,190,196,268,313,323,357359,361,362
I
A
AF = atrial ﬁbrillation; AVB = atrioventricular block; CRT = cardiac resynchronization therapy; HF = heart failure; HFrEF = heart failure with reduced ejection fraction (<40%) according to the 2021 ESC HF Guidelines;242 NYHA = New
York Heart Association; RV = right ventricular.
aClass of recommendation.
bLevel of evidence.
ESC 2021


<!-- PAGE 39 -->

### Page 39

..........................................................................................................................................................................
Patients with Chronic Heart Failure (RESET-CRT; ClinicalTrials.gov
Identifier NCT03494933).
In conclusion, prospective randomized trials are lacking, and available data are insufficient to firmly prove a superiority of CRT-D over
CRT-P. However, it is important to consider that CRT trials in mild
HF almost exclusively included patients with an ICD,37,40,262 and that survival benefit of CRT without an ICD is uncertain in this particular group. Furthermore, observational data point towards significant survival benefits by CRT-D over CRT-P in patients with ischaemic cardiomyopathy, while no clear benefit has been shown in those with non-ischaemic cardiomyopathy.
Further predictive power concerning the risk of ventricular arrhythmia may be derived by contrast-enhanced CMR-guided scar characterization.379,380 When discussing the choice between CRT-D
and CRT-P, it is particularly important to consider general predictors of ICD effectiveness such as age and comorbidities associated with a mortality risk that competes with sudden arrhythmic death. Thus, the addition of ICD to CRT should be considered, especially in younger patients with a good survival prognosis, ischaemic aetiology, and a favourable comorbidity profile or presence of myocardial fibrosis
(Figure 10). Moreover, the benefit of the ICD is governed by the balance between the risk of SCD and the risk of death from other causes, as well as comorbidities. Generally, the rate of sudden arrhythmic death in primary prevention appears to be declining (1%/
year).
Owing to the complexity of the matter and the lack of clear evidence, it is particularly important that the choice between CRT-P
and CRT-D is guided by a process of shared decision-making between patients and clinicians, taking into account both medical facts and patient values.
6.7 Factors influencing the efficacy of cardiac resynchronization therapy: role of imaging techniques
The role of cardiac imaging in selecting HF patients for CRT has been evaluated mostly in observational analyses. Cardiac dyssynchrony,384386 myocardial scar,387,388 and site of latest activation of the LV in relation to the LV lead position389,390 have been associated with response to CRT. LVEF is the only parameter included in the guidelines for the selection of patients for CRT and is key to define the type of HF (<40%, HFrEF; 4049%, HFmrEF; and >_50%,
HFpEF).242 Echocardiography is the imaging technique of first choice for the assessment of LVEF. However, when intravenous contrast is not available and the acoustic window does not allow accurate assessment of LVEF, CMR or nuclear imaging should be considered.242 Strain imaging (based on echocardiography or CMR) to quantify LV systolic function has shown incremental prognostic value in
HF,
and allows assessment of
LV
mechanical dyssynchrony.384,391393 CMR with LGE techniques (which show the presence of myocardial scar tissue) provide the best resolution to differentiate ischaemic cardiomyopathy and non-ischaemic cardiomyopathy.394 The location (posterolateral) and extent (transmural vs.
non-transmural and percentage of LV mass) of LGE on CMR or with nuclear techniques has been associated with the benefit from
CRT.380,387,395,396 Severe mitral regurgitation,397 lack of significant electromechanical LV dyssynchrony,384,385,392 and RV systolic dysfunction398 have been associated with less improvement in clinical symptoms and reduced survival after CRT. Several imaging techniques have been tested to assess LV mechanical dyssynchrony, but most measures of LV dyssynchrony have not been tested in randomized trials including patients with HFrEF and wide QRS.399 The presence of septal flash and apical rocking,400 time differences based on radial strain and patterns of regional longitudinal strain,384,392,401403
non-invasive and invasive ECG mapping,385,404 and vector-cardiography405 have been proposed as novel techniques to predict response to CRT. Furthermore, LV myocardial work assessed with speckletracking echocardiography has been associated with survival in CRT
recipients.406 Coronary sinus venography is commonly performed to detect a suitable coronary vein in which to deploy an LV lead.
Randomized trials have not systematically demonstrated that the guidance of LV lead implantation based on imaging (assessing myocardial scar or site of latest activation) is superior to standard practice.389,390,407,408 Initial experience on using artificial intelligence to combine clinical, electrical, and imaging parameters to define phenotypes of patients that will benefit from CRT is promising, but more data are needed.409
Significant (moderate to severe and severe) secondary mitral regurgitation is frequent among candidates for CRT and has been shown to affect long-term survival as well as response to therapy.406,410 CRT can improve mitral regurgitation in as many as 40% of patients.406 However, in 60% of patients, significant mitral regurgitation is not corrected and, at long-term follow-up, progression of the underlying disease may lead to further deterioration of mitral valve function and poor prognosis. Transcatheter edge-to-edge mitral valve repair has been demonstrated to improve the response to CRT
in registries.411414 However, results from recent RCTs including patients with symptomatic severe secondary mitral regurgitation despite guideline-directed medical therapy (including CRT when indicated) have not consistently shown a benefit from transcatheter edge-to-edge mitral valve repair.415,416
Therefore, selection of patients for CRT based on imaging is limited to the measurement of LVEF, whereas the assessment of other factors such as extent of myocardial scar, presence of mitral
Recommendations for adding a deﬁbrillator with cardiac resynchronization therapy
Recommendations
Classa
Levelb
In patients who are candidates for an ICD and who have CRT indication, implantation of a
CRT-D is recommended.260,369,370,381
I
A
In patients who are candidates for CRT, implantation of a CRT-D should be considered after individual risk assessment and using shared decision-making.382,383
IIa
B
CRT = cardiac resynchronization therapy; CRT-D = deﬁbrillator with cardiac resynchronization therapy; ICD = implantable cardioverter-deﬁbrillator.
aClass of recommendation.
bLevel of evidence.
ESC 2021
ESC Guidelines
39


<!-- PAGE 40 -->

### Page 40

......................................................................................
regurgitation, or RV systolic function is important in identifying potential non-responders that may need additional treatment (mitral valve intervention, for example).
Alternatives to conventional coronary sinus pacing for CRT (epicardial, endocardial) are described in section 6.1 in the Supplementary data.
7 Alternative pacing strategies and sites
Alternative RV pacing sites (as opposed to RVA pacing) include pacing from the RV outflow tract (RVOT), the mid and high RV septum
(RVS), HBP, para-Hisian pacing, and left bundle branch area pacing,
which includes LV septal pacing and left bundle branch pacing.
7.1 Septal pacing
Since the 2013 ESC Guidelines,33 two randomized trials found no difference in clinical outcomes between RVS and RVA pacing in the setting of AVB417 or CRT,418 respectively. A meta-analysis reported an echocardiographic benefit of RVS pacing in patients with pre-existing reduced LVEF.419 In an observational study, RVS pacing was associated with a lower risk of perforation.420 However, true RVS pacing is not easily obtained and ascertained,421 and neither beneficial nor harmful effects of RVS pacing compared with RVA pacing have been shown on relevant clinical endpoints (Supplementary Table 9).
Current evidence does not support systematically recommending either RVS or RVA pacing for all patients.
7.2 His bundle pacing
HBP was first reported in humans in 2000,199 and is steadily gaining interest for providing a more physiological alternative to RV pacing. It may also correct intraventricular conduction delay in a subset of patients, thereby providing an alternative to biventricular pacing for treating HF. The advent of new tools has greatly facilitated implantation, which has become routine in a growing number of centres. HBP
is used in lieu of RV pacing, in lieu of biventricular pacing, and as Hisoptimized CRT (HOT-CRT),319 which exploits a synergistic effect between HBP and RV pacing, LV pacing, or biventricular pacing to improve synchrony. There is growing evidence, mainly from observational studies, that HBP may be safe and effective in these settings
(Supplementary Table 10), although large RCTs and long-term followup are still lacking.422 With more data on safety and effectiveness,
HBP is likely to play a growing role in pacing therapy in the future.
7.2.1
Implantation and follow-up
The use of guiding catheters to deliver leads has facilitated implantation, with success rates exceeding 80%.422 In an international registry,
implant success was 87% after a learning curve of 40 cases.423
Selective HBP is easily recognized by an isoelectric interval (corresponding to the HV) between the pacing spike and QRS onset,
whereas with non-selective HBP, a ‘pseudo-delta’ wave is observed due to capture of local myocardium.424 In addition, correction of BBB
may be observed (Figure 11). It is important to distinguish nonselective HBP from para-Hisian pacing (where there is no capture of conduction tissue) by evaluating transitions in QRS morphology by reducing pacing output or with pacing manoeuvres.425
Patient with indication for CRT
CRT-P
CRT-D
+
-
Myocardial Fibrosis on CMR
Age
-
+
Other factors in favor of choosing 
CRT-P rather than CRT-D:
Non-ischaemic cardiomyopathy
Short life expectancy
Major comorbidities
Poor renal function
Patient preference
Shared decision making
Shared decision making
Age
-
+
Figure 10 Patient’s clinical characteristics and preference to be considered for the decision-making between cardiac resynchronization therapy pacemaker or defibrillator. CRT-P = cardiac resynchronization therapy-pacemaker; CRT-D = defibrillator with cardiac resynchronization therapy; CMR = cardiovascular magnetic resonance.


<!-- PAGE 41 -->

### Page 41

0
1
2
3
4
5
6
7
8
NS-HBP
S-HBP
LOC
NS-HBP
S-HBP corrS-HBP corr+
Myo
LOC
LOC
A
B
C
Thresholds
His
Myocardium
Bundle branch
NS-HBP
S-HBP
V
NS-HBP
Myo
V
S-HBP corr+
S-HBP corrV
A
B
C
Output  (V/0.5ms)
Figure 11 Three patients with different types of transitions in QRS morphology with His bundle pacing and decrementing pacing output. BBB = bundle branch block; Corr± = with/without correction of bundle branch block; LBBB = left bundle branch block; LOC = loss of capture; Myo = myocardium;
NSHBP = non-selective His bundle pacing; S-HBP = selective His bundle pacing. (A) Non-selective to selective His capture. Note the presence of a
‘pseudo-delta’ wave with non-selective capture and an isoelectric interval after the pacing spike with selective capture. (B) Non-selective His capture to myocardial capture only. (C) Selective His capture with correction of BBB to selective His capture with LBBB. Note: the graph on the right of the panel shows a schematic representation of the different thresholds in the three instances.
ESC Guidelines
41


<!-- PAGE 42 -->

### Page 42

.............................................................................................................................................................................
Compared with RV pacing, HBP capture thresholds are on average higher and sensing amplitudes lower. A recent observational study raised concern with regard to increasing HBP pacing thresholds with intermediate follow-up.426 The higher capture thresholds lead to shorter battery longevity (at 5 years there were 9% generator changes with HBP compared with 1% with RVP).427 Capture thresholds of HBP at implantation should aim to be <2.0 V/1 ms (or <2.5 V/
0.4 ms) and bipolar R-wave sensing amplitude >2.0 mV. With experience, thresholds decrease as implanters gain confidence to reposition leads. Sensing issues include not only ventricular undersensing, but also oversensing of atrial or His potentials (which may be potentially lethal in a pacemaker-dependent patient).
An RV backup lead should be considered if the implanter is inexperienced, or if there are high capture thresholds or sensing issues in pacemaker-dependent patients, in those scheduled for AVN ablation
(where there is a risk of compromising HBP), or in patients with highdegree or infranodal block. Pros and cons are listed in Table 9.
Several series have shown that the rate of mid-term lead revision is relatively high at 7%,318,423,427,428 (and reported to be as high as
11%426), and is higher than RV pacing, which is 23%.427,429
Therefore, it is advisable to follow-up these patients at least once every 6 months or place them on remote monitoring (ensuring that automatic threshold measurements correspond to those measured manually, as this may not be the case and depends on device configuration).430 Device programming should take into account specific requirements for HBP, which are covered in detail elsewhere.431,432
7.2.2
Indications
7.2.2.1 Pacing for bradycardia
One study reported that in patients with AVB and normal baseline
LVEF, the incidence of RV pacing-induced cardiomyopathy was
12.3% and the risk was increased if the percentage of ventricular pacing was >_20% (HR 6.76; P = 0.002).188 However, there are no data to support that any percentage of RV pacing can be considered as defining a true limit below which RV pacing is safe and beyond which RV
pacing is harmful. Observational data indicate that patients with HBP
fare better in terms of HF hospitalizations than patients with RV pacing if the percentage of ventricular pacing is >20% (HR 0.54; P =
0.01).42 Of note, the average baseline LVEF in patients with HBP in that study was 55% and the average QRS duration was 105 ms. HBP
may therefore avoid clinical deterioration in these patients, particularly if the intrinsic QRS is narrow or if BBB is corrected by HBP.
In a series of 100 patients with AVB undergoing HBP by experienced operators, implantation was successful in 41/54 (76%) patients with infranodal AVB and higher in the case of nodal block (93%; P <
0.05).433 Over a mean follow-up of 19 ± 12 months, lead revision was necessary in 2/41 (5%) patients with infranodal block and in 3/43
(7%) with nodal block. Notably, the average LVEF in this series was
54%, and there are no data reported specifically on HBP in patients with AVB and reduced LVEF. HBP is an option in patients with a narrow QRS or if HBP corrects BBB, but otherwise biventricular pacing is indicated.
There is a need for RCTs to compare the safety and efficacy of
HBP with RV pacing. It is important to balance the potential benefits of HBP with the aforementioned issues of higher capture thresholds and shorter battery longevity, a higher rate of lead revision, and more frequent sensing issues, compared with RV pacing. It is also important to consider the operator’s experience and expertise with HBP, and whether a backup ventricular pacing lead is indicated. The patient’s safety should be first and foremost in decision-making.
7.2.2.2 Pace and ablate
Seven observational series, totalling >240 patients treated with a
‘pace-and-ablate’ strategy for rapidly conducted AF, found an improvement in LVEF and NYHA class compared with baseline with
HBP.197199,434 Long-term results with a median of 3 years of followup have been reported, with favourable outcomes.434 A singleblinded, randomized, crossover study in 16 patients compared HBP
with RVA pacing over 6 months and found better NYHA and 6-min walk distance with HBP, without differences in echocardiographic parameters.200 However, only four patients in this study had confirmed HBP (with para-Hisian pacing in the remaining patients).
These studies included patients with reduced as well as preserved
LVEF,197,198 and QRS width was on average <120 ms. HBP is of particular interest in patients with a normal baseline QRS morphology as it preserves intrinsic ventricular synchrony, However, a caveat is that
AVJ ablation may result in an increase in HBP capture thresholds or in lead dislodgments in a minority of patients.197,199,318,426 Owing to these issues and risk of HBP lead failure, a backup RV lead should be considered.
7.2.2.3 Role in cardiac resynchronization therapy
In 1977, Narula showed that pacing of the His bundle can correct
LBBB in a subset of patients, implying a proximal site of conduction disturbance with longitudinal dissociation within the His bundle.435 A
recent mapping study reported intra-Hisian block in 46% of patients with LBBB, in whom 94% were corrected by temporary HBP.436 HBP
may therefore be used in lieu of biventricular pacing for HBP-based
CRT, as some data have shown that results are comparable (see
Supplementary Table 10).437439 Nevertheless, especially in CRT candidates with LBBB, biventricular pacing has more solid evidence of efficacy and safety, and therefore remains first-line therapy. However,
HBP should be considered as a bailout solution in the case of failed
Table 9
Advantages and disadvantages of a ‘backup’
ventricular lead with His bundle pacing
Advantages
• Increased safety (in case of loss of capture of the HBP lead)
• Can be used for sensing (lower risk of ventricular undersensing, no risk of His or atrial oversensing)
• Programming of pacing output with lower safety margins
• May serve to narrow the QRS with fusion pacing in the case of selective-HBP with uncorrected RBBB
Disadvantages
• Higher cost
• More transvenous hardware
• Risk associated with the additional lead (e.g. ventricular perforation)
• More complex programming
• “Off-label” use (current regulatory approval and MRI-conditionality for HBP is only granted for His leads connected to the RV port)
HBP = His bundle pacing; MRI = magnetic resonance imaging; RBBB = right bundle branch block.
ESC 2021


<!-- PAGE 43 -->

### Page 43

..........................................................................................................................................
LV lead implantation along with other options such as surgical epicardial leads424,440 (see section 6.7). An interesting population is patients with RBBB, who are known to respond less well to biventricular pacing, in whom HBP has shown promising preliminary results in a series of 37 patients.441 HBP may sometimes incompletely correct BBB, and can be used in conjunction with RV, LV, or biventricular pacing, as in the HOT-CRT study.319 This is of particular interest in patients with permanent AF, in whom a His lead may be connected to the vacant atrial port, thus offering additional therapeutic options.
7.3 Left bundle branch area pacing
With left bundle branch area pacing, the lead is implanted slightly distal to the His bundle and is screwed deep in the LV septum, ideally to capture the left bundle branch.442 Advantages of this technique are that electrical parameters are usually excellent, it may be successful in blocks that are too distal to be treated with HBP, and it also facilitates AVJ ablation, which may be challenging with HBP. However,
although the technique is very promising, data on this modality are still scarce (Supplementary Table 11), and there is concern regarding long-term lead performance and feasibility of lead extraction.
Recommendations for using left bundle branch area pacing cannot therefore be formulated at this stage. However, conduction system pacing (which includes HBP and left bundle branch area pacing) is very likely to play a growing role in the future, and the current recommendations will probably need to be revised once more solid evidence of safety and efficacy (from randomized trials) is published. A
comparison of RV pacing, HBP, and left bundle branch area pacing is provided in Supplementary Table 12.
7.4 Leadless pacing
Leadless pacemakers have been developed to address limitations typically related to pulse generator pocket and transvenous leads of conventional pacemaker systems. Currently, two leadless pacemaker systems have been studied in clinical trials, of which one is currently available for clinical use. Both are inserted into the RV cavity by a femoral venous approach using a specially designed catheter-based delivery system.
A number of prospective registries have reported that implantation success rates are high, with adequate electrical results both at implant and at follow-up (Supplementary Table 13). ‘Real-world’
results of one leadless pacemaker system, including 1817 patients,
reported serious adverse events in 2.7% of patients.50 The prevalence of leadless device infections is low as the principal sources of infection
(i.e. the subdermal surgical pocket and pacemaker leads) are absent.
However, during the initial operator experience, there was a higher incidence of peri-operative major complications (6.5%), including perforation and tamponade, vascular complications, ventricular arrhythmias, and death.445 These data highlight the importance of adequate training and supervision in this domain when starting with leadless pacemaker implantation. In addition, implanting physicians should have the same competency and accreditation as those required for standard transvenous pacing to be able to offer the most suitable system for a given patient. Implantation of leadless pacemakers should be performed in an adequate setting (i.e. with highresolution multiplane fluoroscopy) and with cardiac surgery available on site due to the risk of tamponade, which may be more difficult to manage than with standard pacing.446,447
Leadless pacemakers that only function in the VVI(R) mode restrict indications to patients with AF or very infrequent pacing (e.g.
paroxysmal AVB). Recently, VDD pacing (by detection of atrial contraction by the accelerometer) has been introduced, which extends indications to patients with AVB with preserved sinus node function.
AV synchrony is maintained 7090% of the time, depending on the patient’s position and activity, based on data from two studies including 73 patients in SR and high-degree AV block.448 There may in future be an alternative to standard DDD pacemakers in selected patients if the potential benefits of leadless pacing outweigh the potential benefits of 100% AV synchrony, atrial pacing, and atrial arrhythmia monitoring.
Indications for leadless pacemakers include obstruction of the venous route used for standard pacemaker implantation (e.g. bilateral venous thoracic outlet syndrome or chronic obstruction of the superior vena cava), pocket issues (e.g. in the case of cachexia or dementia), or particularly increased infection risk [e.g. in the case of dialysis
Recommendations for using His bundle pacing
Recommendations
Classa
Levelb
In patients treated with HBP, device programming tailored to speciﬁc requirements of HBP is recommended.430,431
I
C
In CRT candidates in whom coronary sinus lead implantation is unsuccessful, HBP should be considered as a treatment option along with other techniques such as surgical epicardial lead.318,424,440,443
IIa
B
In patients treated with HBP, implantation of an
RV lead used as ‘backup’ for pacing should be considered in speciﬁc situations (e.g. pacemaker dependency, high-grade AVB, infranodal block,
high pacing threshold, planned AVJ ablation) or for sensing in the case of issues with detection
(e.g. risk of ventricular undersensing or oversensing of atrial/His potentials).423,426,444
IIa
C
HBP with a ventricular backup lead may be considered in patients in whom a ‘pace-and-ablate’
strategy for rapidly conducted supraventricular arrhythmia is indicated, particularly when the intrinsic QRS is narrow.197,199,200,318
IIb
C
Continued
HBP may be considered as an alternative to RV
pacing in patients with AVB and LVEF >40%,
who are anticipated to have >20% ventricular pacing.42,433
IIb
C
AVB = atrioventricular block; AVJ = atrioventricular junction; CRT = cardiac resynchronization therapy; HBP = His bundle pacing; LVEF = left ventricular ejection fraction; RV = right ventricular.
aClass of recommendation.
bLevel of evidence.
ESC 2021
.................................
ESC Guidelines
43


<!-- PAGE 44 -->

### Page 44

................................................................................
or previous cardiovascular implantable electronic device (CIED)
infection]. Observational data showed that a leadless pacemaker was a safe pacing alternative in patients with previous device infection and explant, and in patients on chronic haemodialysis. Whereas observational data indicate high efficacy and low complication rates with leadless pacemakers,50 there are currently no data from RCTs documenting the long-term safety and efficacy of leadless vs. standard transvenous pacemakers, and therefore the indication for a leadless pacemaker should be carefully considered on a case by case basis.
The absence of long-term data on leadless pacemaker performance and limited data on retrievability and end-of-life strategy449 require careful consideration before selecting leadless pacemaker therapy,
especially for younger patients (e.g. with a life expectancy >20 years).
8 Indications for pacing in specific conditions
8.1 Pacing in acute myocardial infarction
In patients with acute MI, significant bradyarrhythmia may occur due to autonomic influences or damage of the conduction system by ischaemia and/or reperfusion. The right coronary artery supplies the sinus node in 60% and the AVN and His bundle in 90%
of patients.451,452 AVB is located above the His bundle in most patients with inferior infarction, but is usually infra-Hisian and preceded by intraventricular conduction disturbances in anterior infarction.451,453457
The incidence of high-degree AVB in patients with ST-segment elevation MI has declined to 34% in the primary percutaneous coronary intervention era.458460 High-degree AVB is most frequent in inferior or inferolateral infarctions.455,458461
Patients with high-degree AVB have higher clinical risk and larger infarctions especially when AVB complicates an anterior infarction.458460,462,463 New-onset intraventricular conduction disturbance is also associated with larger infarctions.464467
Sinus bradycardia and AVB at presentation can be vagally mediated and may respond to atropine.455,468 Revascularization is recommended in patients with AVB who have not yet received reperfusion therapy.469 AVB may require temporary pacing in the presence of refractory symptoms or haemodynamic compromise,
but most often resolves spontaneously within a few days and only a minority of patients require permanent pacing.451,454,456,458,462 In patients with persistent intraventricular conduction abnormalities and transient AVB in whom permanent pacing was recommended in the past, there is no evidence that permanent cardiac pacing improves outcome.454,470 These patients frequently have HF and poor LV function, and should be evaluated for ICD, CRT-P, or CRTD rather than conventional pacing if an early device implantation is considered.471
If AVB does not resolve within 10 days, a permanent pacemaker should be implanted. In the absence of robust scientific data, the waiting period before pacemaker implantation has to be decided individually. It may last up to 10 days but can be shortened to 5 days depending on the occluded vessel, time delay, and success of revascularization. Conditions favouring consideration of earlier pacemaker implantation include unsuccessful or late revascularization, anterior
MI, bifascicular block or AV block before MI, and progression of AV
block within the first days after MI. Sick sinus syndrome after occlusion of the right coronary artery resolves in most cases. If revascularization is incomplete, pacemaker implantation can usually still be postponed and implantation only be performed if symptoms due to sinus bradycardia persist.
8.2 Pacing after cardiac surgery and heart transplantation
8.2.1
Pacing after coronary artery bypass graft and valve surgery
AVB may occur in 14% of cases after cardiac surgery and in
8% after repeat valve surgery.472476 SND may occur after right lateral atriotomy or transseptal superior approaches to the mitral valve.473,474
Recommendations for using leadless pacing (leadless pacemaker)
Recommendations
Classa
Levelb
Leadless pacemakers should be considered as an alternative to transvenous pacemakers when no upper extremity venous access exists or when risk of device pocket infection is particularly high, such as previous infection and patients on haemodialysis.45,4750,450
IIa
B
Leadless pacemakers may be considered as an alternative to standard single-lead ventricular pacing, taking into consideration life expectancy and using shared decision-making.45,4750
IIb
C
aClass of recommendation.
bLevel of evidence.
ESC 2021
Recommendations for cardiac pacing after acute myocardial infarction
Recommendations
Classa
Levelb
Implantation of a permanent pacemaker is indicated with the same recommendations as in a general population (section 5.2) when AVB does not resolve within a waiting period of at least 5
days after MI.
I
C
In selected patients with AVB in the context of anterior wall MI and acute HF, early device implantation (CRT-D/CRT-P) may be considered.471
IIb
C
Pacing is not recommended if AVB resolves after revascularization or spontaneously.454456,458
III
B
AVB = atrioventricular block; CRT-D = deﬁbrillator with cardiac resynchronization therapy; CRT-P = cardiac resynchronization therapy-pacemaker; MI = myocardial infarction.
aClass of recommendation.
bLevel of evidence.
ESC 2021
..........................................................................................


<!-- PAGE 45 -->

### Page 45

........................................................................................................................................................
Pacemaker implantation is more frequent after valvular than after coronary artery bypass graft (CABG) surgery.477 In clinical practice,
an observation period of 37 days is usually applied before implanting a permanent pacemaker473 to allow regression of transient bradycardias. The ideal timing of pacemaker implantation after cardiac surgery remains a topic of controversy, due to the fact that 6070%
of patients implanted for SND and up to 25% of those implanted for
AVB are not pacemaker dependent at follow-up.473,478 In the case of complete AVB occurring within the first 24 h after valvular surgery and persisting for 48 h, resolution within the next 12 weeks is unlikely and earlier implantation of a pacemaker may be considered.479,480 The same approach appears reasonable for complete
AVB with a low rate of escape rhythm.473 The situation in CHD surgery and in children may be different (see section 8.4).
In valvular endocarditis, predictors of AVB after surgery are preoperative conduction abnormalities, Staphylococcus aureus infection,
intracardiac abscess, tricuspid valve involvement, and previous valvular surgery.481 In patients with endocarditis and peri-operative AVB,
early pacemaker implantation is reasonable, especially when one or more predicting factors are present. In light of the infected state of the patient, intra-operative implantation of an epicardial pacemaker system during valvular surgery may be reasonable despite the absence of solid data on infection rates of epicardial vs. transvenous pacemaker systems.
8.2.2
Pacing after heart transplantation
SND is common and leads to permanent pacemaker implantation after heart transplantation in 8% of patients.473 Possible causes of
SND include surgical trauma, sinus node artery damage, or ischaemia and prolonged cardiac ischaemic times.482,483 AVB is less common,
and is probably related to inadequate preservation of the donor heart.473,483,484 Chronotropic incompetence is always present following standard orthotopic heart transplantation, as a result of loss of autonomic control. As sinus node and AVN function improve during the first few weeks after transplantation, an observation period before pacemaker implantation may allow spontaneous improvement of bradycardia.485 There is general consensus that patients in whom symptomatic bradycardia persists after the third postoperative week may require permanent pacemaker implantation.
DDD(R) mode with minimized ventricular pacing in the case of intact
AVN conduction is recommended.483
8.2.3
Pacing after tricuspid valve surgery
An underestimated aspect of the surgical management of tricuspid valve disease is to address trans-tricuspid pacemaker or ICD leads.
Such leads can interfere with the function of a repaired tricuspid valve or tricuspid valve prosthesis.
Placing an epicardial RV lead at the time of tricuspid valve surgery is the most straightforward alternative in cases with type II secondor third-degree AVB. There have been doubts about the long-term performance of epicardial leads, but recent data indicate, at least for epicardial LV leads, performance comparable with transvenous leads.486
Ventricular pacing after mechanical tricuspid valve replacement using a coronary sinus lead appears safe and feasible, but only results from small patient cohorts have been published. Procedural success of implantation was 100% in 23 patients; after 5.3 ± 2.8 years, 96% of leads were functional with stable pacing and sensing parameters.487
HBP is emerging as a more physiological method of ventricular pacing and may evolve into a possible solution in patients with AV
conduction disease after tricuspid valve surgery. One study investigating 30 patients with HBP after cardiac valve operations reported successful permanent HBP in 93% of these patients.488 This study included 10 patients with tricuspid valve annuloplasty.
After replacement by a mechanical valve, transvalvular lead placement is contraindicated, and implanting either a coronary sinus lead for ventricular pacing or epicardial leads, which may be placed minimally invasively, is recommended. To avoid damaging a repaired tricuspid valve or a tricuspid bioprosthesis, the optimal solution in patients needing ventricular pacing after such surgery should not include transvalvular lead implantation. Implanting a coronary sinus lead for ventricular pacing or minimally invasively placed epicardial leads is judged to be the preferred choice.
However, as indicated in observational reports, transvalvular lead implantation was used with acceptable results,489 and still may be considered in selected patients after tricuspid valve annuloplasty,
other types of repair, and replacement of a tricuspid valve by a bioprosthesis.
Performing tricuspid valve replacement in a patient with an existing RV lead, removal of the old RV lead and implantation of an epicardial RV lead should be preferred over sewing in the existing lead between a bioprosthesis and annulus. The reasons are that sewing in the lead may be associated with higher risk of lead failure and, in the case of future need for lead extraction, such a procedure is likely to require open heart surgery, which will be a reintervention with higher operative risk. In cases of tricuspid valve repair with a current annuloplasty ring with an open segment and without concomitant leaflet procedures, an existing RV lead may be left in place without sewing it in between the ring and the annulus. However, even in isolated annuloplasty procedures, an existing RV lead should ideally be removed to avoid future lead-related complications to the repaired tricuspid valve and an epicardial RV lead should be implanted. Particularly in patients not in need of a dual-chamber device, the use of a leadless pacemaker for ventricular pacing may serve as a feasible future alternative after tricuspid valve repair or replacement by a bioprosthesis. However, experience is very limited, and no long-term data are available in this cohort. Crossing a mechanical tricuspid valve with the delivery sheath and a leadless pacemaker is contraindicated.
ESC Guidelines
45


<!-- PAGE 46 -->

### Page 46

..................................................................................................................................................
8.3 Pacing after transcatheter aortic valve implantation
For extended literature on patients with pre-procedural RBBB and post-procedural
LBBB
see sections
8.3.1
and
8.3.2
in the
Supplementary data.
Rates of permanent pacemaker implantation after TAVI range between 3.4% and 25.9% in randomized trials and large registries.490502 Whereas the association between pacing after TAVI and outcome is controversial,503509 RV pacing may lead to deterioration in LV function.183,510,511 Thus, efforts to minimize unnecessary permanent pacing are warranted.
Predictors for permanent pacing (Table 10 and supplementary table
14), especially RBBB, which has been identified as the most consistent and powerful predictor for permanent pacemaker implantation,
should be incorporated into procedural planning including transcatheter heart valve selection, implantation height, and balloon inflations.
Patients with pre-existing advanced conduction system disease who may have an indication for permanent pacing irrespective of the
TAVI procedure need consultation with an electrophysiologist before the procedure. There is currently no evidence to support permanent pacemaker implantation as a ‘prophylactic’ measure before
TAVI in asymptomatic patients or in patients who do not meet the standard indications for pacemaker implantation.
A recommended approach for the management of conduction abnormalities after TAVI is detailed in Figure 12. Patients without new conduction disturbances post-TAVI are at very low risk of developing high-degree AVB.533535 Conversely, management of patients with persistent complete or high-degree AVB should follow standard guidelines. Permanent pacemaker implantation appears warranted in patients with intraprocedural AVB that persists for 24- 48 h after
TAVI or appears later. Data to guide the management of patients with other conduction abnormalities at baseline or post-procedure are more limited.
Given the close anatomical proximity of the aortic valve and the left bundle branch, the most frequent conduction abnormality after
TAVI is new-onset LBBB.504,536538 Only a small minority of these patients require pacemaker implantation.536,537 Thus, EPS539541 or long-term monitoring536 in lieu of pacemaker implantation may be considered542,543 (see section 8 in the Supplementary data). Several high-risk subgroups of patients with new LBBB have been identified
(see Figure 12, and section 8 in the Supplementary data). In such patients with dynamic progression of conduction abnormalities after
TAVI (new BBB with dynamic prolongation of QRS and/or PR), an extended monitoring period in hospital of up to 5 days should be considered. Conversely, patients with new-onset LBBB but QRS
Recommendations for cardiac pacing after cardiac surgery and heart transplantation
Recommendations
Classa
Levelb
1) High-degree or complete AVB after cardiac surgery
A period of clinical observation of at least 5
days is indicated to assess whether the rhythm disturbance is transient and resolves.
However, in the case of complete AVB with low or no escape rhythm when resolution is unlikely, this observation period can be shortened.473,478
I
C
2) Surgery for valvular endocarditis and intraoperative complete AVB
Immediate epicardial pacemaker implantation should be considered in patients with surgery for valvular endocarditis and complete AVB if one of the following predictors of persistence is present: pre-operative conduction abnormality,
Staphylococcus aureus infection, intracardiac abscess, tricuspid valve involvement, or previous valvular surgery.481
IIa
C
3) SND after cardiac surgery and heart transplantation
Before permanent pacemaker implantation, a period of observation of up to 6 weeks should be considered.473
IIa
C
4) Chronotropic incompetence after heart transplantation
Cardiac pacing should be considered for chronotropic incompetence persisting for >6 weeks after heart transplantation to improve quality of life.485
IIa
C
5) Patients requiring pacing at the time of tricuspid valve surgery
Transvalvular leads should be avoided and epicardial ventricular leads used. During tricuspid valve surgery, removal of pre-existing transvalvular leads should be considered and preferred over sewing in the lead between the annulus and a bioprosthesis or annuloplasty ring. In the case of an isolated tricuspid annuloplasty based on an individual riskbeneﬁt analysis, a preexisting RV lead may be left in place without jailing it between ring and annulus.
IIa
C
6) Patients requiring pacing after biological tricuspid valve replacement/tricuspid valve ring repair
When ventricular pacing is indicated, transvenous implantation of a coronary sinus lead or minimally invasive placement of an epicardial ventricular lead should be considered and preferred over a transvenous transvalvular approach.487
IIa
C
Continued
7) Patients requiring pacing after mechanical tricuspid valve replacement
Implantation of a transvalvular RV lead should be avoided.
III
C
AVB = atrioventricular block; RV = right ventricular; SND = sinus node dysfunction.
aClass of recommendation.
bLevel of evidence.
ESC 2021
...........................


<!-- PAGE 47 -->

### Page 47

Table 10
Predictors for permanent pacing after transcatheter aortic valve implantation
Characteristics
References
ECG
Right BBB
512528
PR-interval prolongation
517,521,525,527
Left anterior hemiblock
517,525
Patient
Older age (per 1-year increase)
529
Male sex
518,519,525,529
Larger body mass index (per 1-unit increase)
529
Anatomical
Severe mitral annular calciﬁcation
512,515
LV outﬂow tract calciﬁcations
522
Membranous septum length
528,530
Porcelain aorta
531
Higher mean aortic valve gradient
519
Procedural
Self-expandable valve
512,513,525,529,531
Deeper valve implantation
517,518,520,522,528,532
Larger ratio between prosthesis diameter versus annulus or LV outﬂow tract diameter
524,529,532
Balloon post-dilatation
519,521,529
TAVI in native valve vs. valve-in-valve procedure
531
AVB = atrioventricular block; BBB = bundle branch block; ECG = electrocardiogram; LV = left ventricular; TAVI = transcatheter aortic valve implantation.
For more detailed data, see Supplementary Tables 14 and 15.
Management of conduction abnormalities in patients afterTAVI
Persistenta high degree AVB
New onset alternating BBB
Pre-existing RBBB
with new post-procedure conduction disturbanceb
Persistent new
LBBB with
QRS > 150 ms or PR > 240 ms with no further prolongation during > 48h after procedurec
Pre-existing conduction abnormality with prolongation of
QRS (> 20 ms) or 
PR (> 20 ms)f
Ambulatory ECG
monitoringd
(Class IIa)
Ambulatory ECG
monitoringd
(Class IIb)
OR
OR
EPSe
(Class IIa)
EPSe
(Class IIb)
Permanent PM
(Class I)
Permanent PM
(Class IIa)
Figure 12 Management of conduction abnormalities after transcatheter aortic valve implantation. AF = atrial fibrillation; AV = atrioventricular; AVB =
atrioventricular block; BBB = bundle branch block; ECG = electrocardiogram; EPS = electrophysiology study; HV = Hisventricular interval; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; PM = pacemaker; QRS = Q, R, and S waves; RBBB = right bundle branch block; TAVI =
transcatheter aortic valve implantation. a24-48 h post-procedure. bTransient high-degree AVB, PR prolongation, or axis change. cHigh-risk parameters for high-degree AV block in patients with new-onset LBBB include: AF, prolonged PR interval, and LVEF <40%. dAmbulatory continuous ECG monitoring for
7 - 30 days. eEPS with HV >_70 ms may be considered positive for permanent pacing. fWith no further prolongation of QRS or PR during 48-h observation.
ESC 2021
ESC Guidelines
47


<!-- PAGE 48 -->

### Page 48

.............................................................................................................................................................................
<150 ms may not require further evaluation during hospitalization.
When EPS is contemplated, it should be performed >_3 days postprocedure and after the conduction abnormalities have stabilized.
The type of permanent pacemaker implanted should follow standard guidance (see sections 5, 6, and 7). Given the low rates of longterm dependency on pacing,544,545 algorithms promoting spontaneous AV conduction should be used.
8.4. Cardiac pacing and cardiac resynchronization therapy in congenital heart disease
Permanent pacing in patients with moderate or complex CHD
should be performed in centres with a multidisciplinary team and expertise in CHD-related device therapy. Generally, decision-making for pacemaker therapy in patients with CHD is based on expert consensus and individual evaluation due to lack of evidence from RCTs.
In the presence of an intracardiac shunt between the systemic and pulmonary circulation, endovascular lead placement is relatively contraindicated due to the risk of arterial embolism.551
The clinical presentation may vary considerably; even severe bradycardia in congenital AVB may remain oligosymptomatic or asymptomatic. Periodic Holter recordings may be useful for patients at specific risk of bradyarrhythmia.
8.4.1
Sinus node dysfunction and bradycardiatachycardia syndrome
There is no evidence that SND directly leads to increased mortality in CHD. However, it may be associated with a higher rate of postoperative atrial flutter, with 1:1 AV conduction in CHD, and thus lead to morbidity and potentially mortality.552,553
8.4.1.1 Indications for pacemaker implantation
In patients with symptomatic chronotropic incompetence, pacemaker implantation is justified when other causes (see section 4) have been ruled out.554,555 Increasing the heart rate through permanent pacing to prevent atrial arrhythmias may be considered.556 The underlying evidence is weak, as the benefit of atrial-based pacing observed in patients without structural heart disease could not be validated in CHD.21,557,558 The general consensus is that if permanent pacing is necessary, single-lead atrial-based pacing should be preferred to limit the number of leads, especially in young patients with adequate AV conduction.559 In patients with congenitally corrected transposition of the great arteries requiring ventricular pacing because of high-degree AVB, CRT should be considered. Current evidence to use devices with atrial antitachycardia pacing to treat intra-atrial re-entrant tachycardias in patients with CHD560,561 is too limited to make general recommendations.
8.4.2
Congenital atrioventricular block
A number of maternal or fetal factors can cause congenital heart block, particularly autoimmune diseases such as systemic lupus erythematosus and Sjo¨gren syndrome (Supplementary Table 16).
Patients presenting with congenital AVB may be asymptomatic or may present with reduced exercise capacity, syncopal attacks, congestive HF, ventricular dysfunction, and dilatation. Rarely, in SCD,
congenital AVB is diagnosed as the cause.562,563 SCD may occur through increased propensity to develop bradycardia-related ventricular arrhythmias such as torsades-de-pointes.
8.4.2.1 Indications for pacemaker implantation
There is general consensus that prophylactic pacing is indicated in asymptomatic patients with any of the following risk factors: mean daytime heart rate <50 b.p.m., pauses greater than three times the cycle length of the ventricular escape rhythm, a broad QRS
escape rhythm, prolonged QT interval, or complex ventricular ectopy.564566 Clinical symptoms, such as syncope, pre-syncope, HF,
or chronotropic incompetence, are indications for pacemaker implantation.564,567,568 If ventricular dysfunction is attributed to haemodynamic compromise caused by bradycardia, permanent pacing may be indicated.518,567 Despite a modest quality of evidence, there
Recommendations for cardiac pacing after transcatheter aortic valve implantation
Recommendations
Classa
Levelb
Permanent pacing is recommended in patients with complete or high-degree AVB that persists for 24 - 48 h after TAVI.546
I
B
Permanent pacing is recommended in patients with new-onset alternating BBB after
TAVI.533,547
I
C
Earlyc permanent pacing should be considered in patients with pre-existing RBBB who develop any further conduction disturbance during or after TAVI.d
IIa
B
Ambulatory ECG monitoringe or EPSf should be considered for patients with new LBBB with
QRS >150 ms or PR >240 ms with no further prolongation during the >48 h after
TAVI.536,537,548
IIa
C
Ambulatory ECG monitoringe or EPSf may be considered for patients with a pre-existing conduction abnormality who develop prolongation of QRS or PR >20 ms.g
IIb
C
Prophylactic permanent pacemaker implantation is not indicated before TAVI in patients with
RBBB and no indication for permanent pacing.
III
C
AF = atrial ﬁbrillation; AVB = atrioventricular block; BBB = bundle branch block;
CRT = cardiac resynchronization therapy; ECG = electrocardiogram; EPS = electrophysiology study; HV = Hisventricular interval; LBBB = left bundle branch block; RBBB = right bundle branch block; SR = sinus rhythm; TAVI = transcatheter aortic valve implantation. For the deﬁnition of alternating BBB, see section
5.3.1.
aClass of recommendation.
bLevel of evidence.
cImmediately after procedure or within 24 h.
dTransient high-degree AVB, PR prolongation, or QRS axis change.
eAmbulatory continuous ECG monitoring (implantable or external) for 730
days.536,549
fEPS should be performed >_3 days after TAVI. Conduction delay with HV >_70
ms may be considered positive for permanent pacing.540,541,550
gWith no further prolongation of QRS or PR during 48-h observation.
Note: CRT in patients requiring pacing after TAVI has the same indication as for general patients (see section 6).
ESC 2021


<!-- PAGE 49 -->

### Page 49

.......................................................................................................................
is strong consensus that patients with third- or second-degree AVB
(Mobitz type II) must receive permanent cardiac pacing therapy if symptomatic or with risk factors. In asymptomatic patients without risk factors, opinion on the benefit of cardiac pacing diverges, and permanent pacing may be considered.567,569
8.4.3
Post-operative atrioventricular block
Post-operative high-degree AVB is estimated to occur in 13% of patients undergoing surgery for CHD.518,569,570 In children, transient early post-operative AVB usually resolves within 710 days.571 In adults with CHD, there are no data to support a different waiting period before deciding for permanent pacing post-operatively than after other cardiac surgery. After recovery from complete AVB, bifascicular block occasionally persists, which is associated with an increased risk of late recurrent AVB and sudden death.572 The prognosis is poor for patients with untreated post-operative complete
AVB.573
8.4.3.1 Indications for pacemaker implantation
There is a strong recommendation for permanent pacing in patients with persistent second- or third-degree AVB. In patients with persistent bifascicular block associated with transient AVB or permanent prolonged PR interval, consensus for pacemaker implantation is modest. Post-operative HV interval determination may help to estimate the risk in patients with prolonged PR or bifascicular block.573 In patients with bifascicular block and long PR after surgery for CHD,
the risk of extensive damage to the conduction system is high,572
therefore pacemaker implantation may be indicated even without
HV measurement. Implantation of epicardial leads should be considered during surgery in patients with complex CHD and a high lifetime risk of pacemaker implantation, in order to reduce the rate of reoperation.
8.4.4
Cardiac resynchronization
Standard indications for CRT may be considered in CHD, taking into account that the anatomy, morphology of the systemic ventricle, and cause of dyssynchrony, as well as QRS morphology, may be atypical.574 Multidisciplinary teams in experienced centres should be involved in the decision-making process.
8.5 Pacing in hypertrophic cardiomyopathy
8.5.1
Bradyarrhythmia
AVB in hypertrophic cardiomyopathy (HCM) should generally be treated according to the recommendations in this guideline (see section 5.2). Certain genetically inherited subtypes of HCM are more prone to develop AVB, as is the case with transthyretin amyloidosis,
AndersonFabry and Danon diseases, PRKAG2 syndrome, and mitochondrial cytopathies.575,576 An ICD/CRT-D rather than a pacemaker should be considered in patients with symptomatic bradycardia who have LVEF <_35% or otherwise fulfil the criteria for primary prevention of SCD by current guidelines.576 (For extended literature on conduction disorders in HCM see the Supplementary data, section 8.5.)
8.5.2
Pacing for the management of left ventricular outflow tract obstruction
In patients with symptoms caused by LV outflow tract obstruction,
treatment options include drugs, surgery, septal alcohol ablation, and
AV sequential pacing with a short AV delay. Three small, randomized,
placebo-controlled studies and several long-term observational studies reported reductions in LV outflow tract gradients, and variable improvement in symptoms and quality of life with AV sequential pacing.577582 Myectomy achieved superior haemodynamic results compared with DDD pacing,583 but is a more invasive and higher risk intervention. In one trial, a subgroup analysis suggested that older patients (>65 years) are more likely to benefit from DDD AV
sequential pacing.579 A recent meta-analysis—comprising 34 studies and 1135 patients—found that pacing reduced the LV outflow gradient by 35%, with a non-significant trend towards reduction in
NYHA class.584
Shared decision-making should be employed when considering the treatment of choice for patients with obstructive HCM.
Recommendations for cardiac pacing in patients with congenital heart disease
Recommendations
Classa
Levelb
In patients with congenital complete or highdegree AVB, pacing is recommended if one of the following risk factors is present:
a. Symptoms b. Pauses >3 the cycle length of the ventricular escape rhythm c. Broad QRS escape rhythm d. Prolonged QT interval e. Complex ventricular ectopy f. Mean daytime heart rate <50 b.p.m.
I
C
In patients with congenital complete or highdegree AVB, permanent pacing may be considered even if no risk factors are present.566
IIb
C
Continued
In patients with persistent post-operative bifascicular block associated with transient complete
AVB, permanent pacing may be considered.572
IIb
C
In patients with complex CHD and asymptomatic bradycardia (awake resting heart rate <40
b.p.m. or pauses >3 s), permanent pacing may be considered on an individual basis.
IIb
C
AVB = atrioventricular block; BBB = bundle branch block; b.p.m. = beats per minute; CHD = congenital heart disease; ECG = electrocardiogram.
aClass of recommendation.
bLevel of evidence.
ESC 2021
.......................................
ESC Guidelines
49


<!-- PAGE 50 -->

### Page 50

......................................................................................................................
8.5.3
Pacemaker implantation following septal myectomy and alcohol septal ablation
In a study involving 2482 patients with obstructive HCM, 2.3% developed AVB after septal myectomy588 (only 0.6% in those with normal baseline conduction vs. 34.8% in patients with pre-existing RBBB).
Alcohol septal ablation causes AVB in 720% of patients;576 those with pre-existing conduction defects, mainly LBBB, are at highest risk.585
8.5.4
Cardiac resynchronization therapy in end-stage hypertrophic cardiomyopathy
Based on the findings of a small cohort study,589 CRT was given both a class IIa and a class IIb recommendation in previous guidelines for patients with HCM, HF, LBBB, and LVEF <50%.576,590 More recent studies did not demonstrate sustained efficacy of this therapy.591593
Until further evidence becomes available, standard criteria for CRT
are recommended in patients with HCM (section 6).
8.6 Pacing in rare diseases
8.6.1
Long QT syndrome
There are multiple inter-relationships between the different forms of long QT syndrome (LQTS) and bradycardia: LQTS can be associated with sinus bradycardia; very long ventricular myocardial refractory periods can cause 2:1 AVB; sudden rate changes can trigger torsadesde-pointes tachycardia; and treatment with beta-blockers to suppress sympathetic triggers of torsades-de-pointes may cause bradycardia.
As current ICDs provide all pacemaker functions, a standalone pacemaker is rarely indicated in LQTS today. However, in individual patients with LQTS and catecholamine-induced torsades-depointes, shock therapy may be disadvantageous or even fatal; in these cases, pacing and beta-blocker therapy alone without an
ICD may be used. Pacemaker instead of ICD implantation represents a treatment option in neonates and small infants with
LQTS,594 and an alternative in LQTS patients with symptomatic bradycardia (spontaneous or due to beta-blockers) if ventricular tachyarrhythmias are unlikely or if ICD implantation is not desired
(e.g. patient preference).
An indication for a pacemaker in LQTS exists in neonates and infants with a 2:1 AVB due to excessive corrected QT prolongation with long myocardial refractory periods.595
Temporary pacing at an increased rate (usually 90- 120 b.p.m.) is an important treatment in LQTS patients with electrical storm, because an increase in the basic heart rate shortens the window of vulnerability for reinduction of torsade de pointes ventricular tachycardia.
8.6.2
Neuromuscular diseases
Neuromuscular diseases are a group of heterogeneous inherited disorders affecting the skeletal muscle and frequently also involve the heart (for extended literature on conduction disorders in neuromuscular disease, see the supplementary literature on pacing in rare disease and Supplementary Table 17). The cardiac phenotype variably includes all types of cardiomyopathies, conduction defects with or without cardiomyopathies, and supraventricular and ventricular tachyarrhythmias.596598 Duchenne, Becker, and limb-girdle types
2C, 2F, and 2I are muscular dystrophies in which the development of dilated cardiomyopathy is common and usually the predominant feature. Arrhythmias and conduction disease can be associated with the development of cardiomyopathy.596598 Such patients are considered for pacemakers or ICDs on the basis of guidelines used for other non-ischaemic cardiomyopathies.242 Myotonic dystrophy types
1 and 2, EmeryDreifuss, and limb-girdle type 1B often present with conduction disease and associated arrhythmias, and variably with cardiomyopathy.596,597 The recommendations present guidance in the instances where the recommendations for cardiac pacing differ from those used for other patients with bradycardia.
Recommendations for pacing in hypertrophic obstructive cardiomyopathy
Recommendations
Classa
Levelb
AV sequential pacing with short AV delay may be considered in patients in SR who have other pacing or ICD indications if drug-refractory symptoms or baseline or provocable LV outﬂow tract gradients >_50 mmHg are present.576581,584
IIb
B
AV sequential pacing with short AV delay may be considered in selected adults with drug-refractory symptoms, >_50 mmHg baseline or provocable LV
outﬂow tract gradient, in SR, who are unsuitable for or unwilling to consider other invasive septal reduction therapies.576581,584
IIb
B
AV sequential pacing with short AV delay may be considered in selected patients with drugrefractory symptoms, >_50 mmHg baseline or provocable LV outﬂow tract gradients, in SR, at high risk of developing AVB during septal ablation.585,586
IIb
C
AV = atrioventricular; AVB = atrioventricular block; ICD = implantable cardioverter-deﬁbrillator; LV = left ventricular; SR = sinus rhythm.
aClass of recommendation.
bLevel of evidence.
Pacing parameters should be optimized to achieve maximum pre-excitation of the RV apex with minimal compromise of LV ﬁlling (typically achieved with a resting sensed AV interval of 100 ± 30 ms).587
ESC 2021
Recommendations for cardiac pacing in rare diseases
Recommendations
Classa
Levelb
In patients with neuromuscular diseases such as myotonic dystrophy type 1 and any second- or third-degree AVB or HV >_70 ms, with or without symptoms, permanent pacing is indicated.c 599602
I
C
In patients with neuromuscular disease such as myotonic dystrophy type 1 with PR >_240 ms or
QRS duration >_120 ms, permanent pacemaker implantation may be considered.c 600,603,604
IIb
C
AVB = atrioventricular block; CRT = cardiac resynchronization therapy; HV =
Hisventricular interval; ICD = implantable cardioverter-deﬁbrillator.
aClass of recommendation.
bLevel of evidence.
cWhenever pacing is indicated in neuromuscular disease, CRT or an ICD should be considered according to relevant guidelines.
ESC 2021
......................................................


<!-- PAGE 51 -->

### Page 51

.........
8.6.3
Dilated cardiomyopathy with lamin A/C mutation
Mutations in the LMNA gene, which encodes lamin A and C intermediate filaments of the nuclear envelope, cause a variety of inherited diseases defined as ‘laminopathies’.605607 According to the type of mutation, they can lead to isolated cardiac disorders or additional systemic or musculoskeletal disorders such as the EmeryDreifuss autosomal dominant variant or limb-girdle dystrophy. Around
510% of dilated cardiomyopathies are induced by LMNA gene mutations, manifested as cardiac conduction disease, tachyarrhythmias, or impaired myocardial contractility.596,606620 SND and conduction disease are frequently the first manifestation, in many cases with preserved LV size and function.613,614 LMNA-related cardiomyopathy is more malignant than most other cardiomyopathies, carrying a higher risk of SCD in asymptomatic mutation carriers with preserved or only mildly decreased
LV
contractility.610615
Pacemaker implantation does not reduce the risk of SCD in these patients. A meta-analysis of mode of death in LMNA mutations demonstrated that 46% of patients who died suddenly had an implanted pacemaker. Sudden death rates were similar in those with isolated cardiomyopathy and those with an additional neuromuscular phenotype.611 Complex ventricular arrhythmias are common in patients with conduction disturbances.612,613,615 In two studies, patients with
LMNA mutations and an indication for permanent pacing underwent
ICD implantation, and appropriate ICD therapies occurred in 42%
and 52% of patients within 3 and 5 years, respectively.612,613 These findings led to the clinical practice to consider ICD rather than pacemaker implantation in LMNA-related conduction disease.614,620 For additional clinical risk factors for ventricular tachyarrhythmias and sudden death found in patients with dilated cardiomyopathy due to
LMNA gene mutations, see Supplementary Table 18. CRT(D) should be considered if the patient has AVB and LVEF <50%, and a high frequency of ventricular pacing is expected (section 6 and Supplementary
Table 18). The risk score of life-threatening ventricular arrhythmia in laminopathies can be predicted by a recently developed and validated module (https://lmna-risk-vta.fr/).616
8.6.4
Mitochondrial cytopathies
Mitochondrial cytopathies are a heterogeneous group of hereditary disorders, in which cardiomyopathies, conduction defects, and ventricular arrhythmias are the most common cardiac presentations.621,622 In KearnsSayre syndrome, the most common cardiac manifestation is conduction disease, which may progress to complete AVB and cause SCD.623625
8.6.5
Infiltrative and metabolic diseases
Infiltrative cardiomyopathy is secondary to abnormal deposition and accumulation of pathological products in the myocardial interstitium,
while storage diseases lead to their intracellular accumulation. The main cause of infiltrative cardiomyopathy is amyloidosis, while storage diseases include haemochromatosis, Fabry’s disease, and glycogen storage diseases. In patients with cardiac amyloid, conduction defects,
tachyarrhythmias, and SCD are common. Based upon current knowledge, conventional indications should be used for pacing in this group of patients.
8.6.6
Inflammatory diseases
Infections (viral, bacterial including Borreliosis, protozoa, fungal, parasites), autoimmune (e.g. giant cell myocarditis, sarcoidosis, rheumatic heart disease, connective tissue disease, eosinophilic myocarditis),
toxic (alcohol, cocaine, cancer therapies, especially monoclonal antibodies), and physical reactions (radiation therapy) can cause inflammatory heart disease. Involvement of the AVN and the conduction system is more frequent than that of the sinus node. AVB may indicate involvement of the septum in the inflammatory process and is a predictor of adverse outcome. Ventricular arrhythmias may also occur because of myocardial pathology.
When inflammatory heart disease is complicated by bradycardia,
especially AVB, specific therapy should be applied if available, eventually backed-up by temporary pacing or intravenous administration of isoprenaline. Otherwise, immunosuppressive therapy or awaiting spontaneous resolution may be sufficient. If bradycardia does not resolve within a clinically reasonable period or cannot be expected to resolve (e.g. after radiation therapy), permanent pacing is indicated. Before choosing a device type, the indication for an ICD and/
or CRT rather than a single-chamber or DDD pacemaker should be
Recommendation for patients with LMNA gene mutations (for references, see Supplementary Table 18)
Recommendation
Classa
Levelb
In patients with LMNA gene mutations, including
EmeryDreifuss and limb-girdle muscular dystrophies who fulﬁl conventional criteria for pacemaker implantation or who have prolonged PR
interval with LBBB, ICD implantation with pacing capabilities should be considered if at least 1year survival is expected.616
IIa
C
ICD = implantable cardioverter-deﬁbrillator; LBBB, left bundle branch block.
aClass of recommendation.
bLevel of evidence.
Recommendations for pacing in KearnsSayre syndrome
Recommendations
Classa
Levelb
In patients with KearnsSayre syndrome who have PR prolongation, any degree of AVB, BBB,
or fascicular block, permanent pacing should be considered.c 621625
IIa
C
In patients with KearnsSayre syndrome without cardiac conduction disorder, permanent pacing may be considered prophylactically.c 621625
IIb
C
AVB = atrioventricular block; BBB = bundle branch block; CRT = cardiac resynchronization therapy; ICD = implantable cardioverter-deﬁbrillator; PR = PR
interval.
aClass of recommendation.
bLevel of evidence.
cWhenever pacing is indicated, CRT or an ICD should be considered according to the relevant guidelines.
ESC 2021
ESC 2021
..................................................................................................................................................................
ESC Guidelines
51


<!-- PAGE 52 -->

### Page 52

...........................................................................................................................................................................
considered because most causes of inflammatory disease causing bradycardia may also result in reduced myocardial contractility and ventricular fibrosis.
8.6.6.1 Sarcoidosis
Persistent or intermittent AVB can occur in sarcoidosis, which shows a propensity to involve the basal intraventricular septum. In a Finnish registry, 143 of 325 patients (44%) diagnosed with cardiac sarcoidosis had Mobitz II second- or third-degree AVB in the absence of other explanatory cardiac disease.626 A history of syncope, pre-syncope, or palpitations points towards bradycardia, but also to potential ventricular tachyarrhythmia. AVB is the most common clinical presentation in patients with clinically evident cardiac sarcoidosis.627,628 Diagnostic steps include ECG monitoring, echocardiography, cardiac MRI, and myocardial or other involved tissue biopsy. Fluorodeoxyglucosepositron emission tomography may be useful.629 The chances and time course of resolution of AVB with immunosuppressive therapy are not clear,630 but may be low.88 Long-term data are available mainly from a Canadian prospective study (32 patients),627 a Japanese retrospective study (22 patients),628 and a Finnish registry (325
patients).626 Reversibility of conduction disorder is unpredictable and, even in patients with transient AVB, permanent pacing should be considered.631 Immunosuppressive treatment may increase risk of device infection. However, there are no firm data to support device implantation before initiation of immunosuppressive medication.
Patients with cardiac sarcoidosis and AVB are at high risk of SCD during long-term follow-up, even if LVEF is >35%.626 Patients with even a mild or moderate decrease in LVEF (3549%) are at increased risk of SCD.632,633 Therefore, in patients with cardiac sarcoidosis who have an indication for cardiac pacing and LVEF <50%, a CRT-D
should be considered rather than a pacemaker634 (section 6).
8.7 Cardiac pacing in pregnancy
Vaginal delivery carries no extra risks in a mother with congenital complete heart block, unless contraindicated for obstetric reasons.635 For women who have a stable, narrow complex junctional escape rhythm, pacemaker implantation may not be necessary or can be deferred until after delivery if none of the risk factors (syncope,
pauses >3 the cycle length of the ventricular escape rhythm, wide
QRS escape rhythm, prolonged QT interval, complex ventricular ectopy, mean daytime heart rate <50 b.p.m.) is present. However,
women with complete heart block who exhibit a slow, wide QRS
complex escape rhythm should undergo pacemaker implantation during pregnancy. The risks of pacemaker implantation are generally low and can be performed safely, especially if the foetus is beyond 8
weeks gestation. A pacemaker for the alleviation of symptomatic bradycardia can be implanted at any stage of pregnancy using echo guidance or electroanatomic navigation minimizing fluoroscopy.636,637
9 Special considerations on device implantations and peri-operative management
9.1 General considerations
Patients with clinical signs of active infection and/or fever should not undergo a permanent pacemaker (including leadless pacemaker)
implantation until they have been afebrile for at least 24 h. Febrile patients who have been started on antibiotics should ideally receive a complete course of antibiotic treatment and should be afebrile for
24 h after termination of antibiotic treatment before definite pacemaker implantation is performed if acute pacing is not required. If possible, the use of temporary transvenous pacing should be avoided.
In patients in need of acute pacing, temporary transvenous pacing should be established, preferably with jugular or axillar/lateral subclavian vein access.638 In a multicentre, prospective study with 6319
patients, fever within 24 h of implantation (OR 5.83, 95% CI
2.0016.98) and temporary pacing before implantation (OR 2.46,
95% CI 1.095.13) were positively correlated with the occurrence of device infection.639 In the case of patients with chronic recurrent infection, minimally invasive implantation of an epicardial pacemaker may be considered.
9.2 Antibiotic prophylaxis
The use of pre-operative systemic antibiotic prophylaxis is recommended as the standard of care in pacemaker implantation procedures. The risk of infection is significantly reduced with a single dose of prophylactic antibiotic (cefazolin 12 g i.v. or flucloxacillin
12 g i.v.) given within 3060 min [90120 min for vancomycin
(15 mg/kg)] before the procedure.640643 The antibiotic prophylaxis should cover S. aureus species, but routine coverage of methicillinresistant S. aureus is not recommended. The use of vancomycin should be guided by patient risk for methicillin-resistant S. aureus colonization and the prevalence of the bacterium in the corresponding institution.638
In contrast, post-operative antibiotic prophylaxis does not reduce the incidence of infection.644,645
9.3 Operative environment and skin antisepsis
The pacemaker implantation procedure should be performed in an operating environment that meets the standards of sterility as required for other surgical implant procedures.638,646
Recommendations for pacing in cardiac sarcoidosis
Recommendations
Classa
Levelb
In patients with cardiac sarcoidosis who have permanent or transient AVB, implantation of a device capable of cardiac pacing should be considered.c 88,629,630
IIa
C
In patients with sarcoidosis and an indication for permanent pacing who have LVEF <50%, implantation of a CRT-D should be considered.631,634
IIa
C
AVB = atrioventricular block; CRT-D = deﬁbrillator with cardiac resynchronization therapy; ICD = implantable cardioverter-deﬁbrillator; LVEF = left ventricular ejection fraction.
aClass of recommendation.
bLevel of evidence.
cWhenever pacing is indicated in sarcoidosis, an ICD should be considered according to the relevant guidelines.
ESC 2021


<!-- PAGE 53 -->

### Page 53

...........................................................................................
Based on data from surgical and intravascular catheter procedures,
skin antisepsis should be performed using chlorhexidinealcohol instead of povidone-iodinealcohol.647,648 In a large RCT comprising
2546 patients, chlorhexidinealcohol was associated with a lower incidence of short-term intravascular catheter-related infections (HR
0.15, 95% CI 0.05 - 0.41; P = 0.0002).647
9.4 Management of anticoagulation
It is well known that the development of a pocket haematoma after the implantation of a pacemaker system significantly increases the risk for subsequent pocket infection.641,643,649 The Bridge or
Continue Coumadin for Device Surgery Randomized Controlled
Trial (BRUISE CONTROL) proved that a clinically significant pocket haematoma is an independent risk factor for subsequent device infection (HR 7.7, 95% CI 2.920.5; P < 0.0001).649 Therefore, it is of utmost importance to take all steps to avoid post-operative pocket haematoma.
Heparin bridging for pacemaker implantation in patients anticoagulated with a vitamin K antagonist leads to a significant 4.6-fold increase in post-operative pocket haematoma compared with a continued warfarin strategy.650 International normalized ratio tapering and temporary shifting of dual antiplatelet to single antiplatelet administration may significantly reduce the haematoma and infection rate by 75%
and 74%, respectively, compared with heparin bridging.651
Regarding non-vitamin K antagonist oral anticoagulants, the
Randomized Controlled Trial of Continued Versus Interrupted
Direct Oral Anti-Coagulant at the Time of Device Surgery (BRUISE
CONTROL-2) was stopped prematurely due to futility because the event rate was far lower than anticipated; however, it suggested that,
depending on the clinical scenario and concomitant antiplatelet therapy, either stopping or continuing non-vitamin K antagonist oral anticoagulants might be reasonable at the time of device implantation.652
Patients on dual antiplatelet therapy have a significantly increased risk of post-operative pocket haematoma compared with patients treated with aspirin alone or without antiplatelet therapy. In such cases, P2Y12 receptor inhibitors should be discontinued for 37
days (according to the specific drug) before the procedure where possible and based on an individualized risk assessment.638,653,654 For more details on the management of anticoagulation in the pacemaker procedure, refer to Table 11.
9.5 Venous access
Transvenous lead implantation for pacemaker implantation is commonly performed by venous access via the cephalic, subclavian, or axillary vein. In the case of clinical signs of venous occlusion of the subclavian vein or the innominate vein, pre-operative imaging (venography or chest CT scan) may be useful in planning venous access or an alternative access ahead of the procedure. In the case of impossible superior venous access, appropriate, alternative approaches may be transfemoral lead implantation, or implantation of a leadless device or epicardial leads.
When using the Seldinger technique, there is a risk of a pneumothorax, haemothorax, inadvertent arterial puncture, and injury to the brachial plexus during venous puncture of the subclavian vein and
(less so) the axillary vein. These risks are avoidable by using the cephalic vein approach, which allows venous insertion of leads under direct vision. Subclavian vein access is associated with a 7.8-fold
Table 11
Management of anticoagulation in pacemaker procedures
Dual antiplatelet therapy655,656
NOAC652
VKA650
OAC 1 antiplatelet657
Thrombotic risk after PCI
Intermediate or low
>1 month PCI
>6 months acute coronary syndrome at index PCI
High
<1 month PCI
<6 months acute coronary syndrome at index PCI
Low procedural bleeding risk First implant
Continue aspirin AND
Discontinue P2Y12 inhibitors: Ticagrelor at least
3 days before surgery
Clopidogrel at least 5 days before surgery Prasugrel at least 7 days before surgery
Elective surgery: Consider postponement Otherwise:
• Continue aspirin
• Continue P2Y12
inhibitor
Continue or interrupt as per operator preference. If interruption, then based on
CrCl and speciﬁc NOAC
Continuea
Continue OAC (VKAa or
NOAC). Discontinue antiplatelet per patient-speciﬁc risk/beneﬁt analysis
High procedural bleeding risk Device exchange, upgrade/
revision procedure
Continue aspirin AND
Discontinue P2Y12 inhibitors: Ticagrelor at least 3
days before surgery,
Clopidogrel at least 5 days before surgery, Prasugrel at least 7 days before surgery.
Bridging with GP IIb/IIIa inhibitors
CrCl = creatinine clearance; GP = glycoprotein; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulant; PCI = percutaneous coronary intervention;
VKA = vitamin K antagonist.
aTarget international normalized ratio within therapeutic range.
ESC 2021
ESC Guidelines
53


<!-- PAGE 54 -->

### Page 54

.............................................................................................................................................................................
increased risk of pneumothorax.658 Prospective data on axillary vein puncture suggest a lower risk of access-related complications compared with subclavian puncture.659 Ultrasound guidance for axillary vein puncture has been described as a helpful technique for achieving a safe and uncomplicated puncture.660
With regards to lead failure after implantation, there is evidence that the axillary vein route is associated with a lower rate of lead failures in long-term follow-up. In a retrospective study comprising 409
patients and mean follow-up of 73.6 ± 33.1 months, lead failure occurred in 1.2% of patients with contrast-guided axillary vein puncture, 2.3% of patients with cephalic vein cutdown, and 5.6% of patients with subclavian vein puncture. In multivariable regression analysis, the only predictor of lead failure was subclavian vein puncture instead of axillary vein access (HR 0.26, 95% CI 0.0710.954; P
= 0.042). When analysing the success rates of the different venous access approaches, the cephalic vein approach showed the lowest success rate (78.2% vs. axillary vein 97.6% and subclavian vein 96.8%;
P < 0.001).661
9.6 Lead considerations
In choosing between active or passive fixation pacemaker leads in the
RA or RV, one should consider the potential for perforation and pericarditis, as well as extractability. Active fixation leads have a higher tendency to create pericardial effusions as well as overt perforations.
Passive fixation leads, due to the non-isodiametric design of the lead tip, may be a factor in lower procedural success rates and higher risk for complications with lead extraction, although this point is far from being clear and is still under evaluation.662 An RCT is required to clarify this issue.
Regarding perforations, an uncontrolled, non-randomized study comprising 3815 patients with implant of an RV lead showed no significant difference with regards to myocardial perforations between active and passive fixation leads (0.5% vs. 0.3%; P = 0.3).663 Active fixation leads also allow selective site pacing in regions of the RV that are smooth walled (e.g. the mid-septum). The RA is, however, thin walled, and perforation of the RA free wall by active fixation leads has been demonstrated. Some implanting physicians prefer to implant passive leads in patients at elevated risk of perforation (e.g. elderly patients). However, based on expert opinion and on the results of a single-centre, retrospective study on ICD leads (637 patients), in young patients, the use of active fixation leads in the RA and RV is recommended in terms of future extractability.664
Lead stability and phrenic nerve stimulation are important aspects of coronary sinus lead implantation. With regards to both, quadripolar leads seem to have relevant advantages. The rate of phrenic nerve stimulation requiring lead revision is significantly lower compared with that in bipolar coronary sinus leads.665,666 Furthermore, lead stability is increased because quadripolar leads can usually be implanted in the wedged position. If implanted in an apical position due to wedging, the use of the proximal poles avoids apical stimulation. Therefore, quadripolar leads are recommended for coronary sinus lead implantation. Active fixation LV leads via a side helix have been developed, and results have proved reliable stability, easy access to the target pacing site, and stable LV pacing threshold in the long term. In comparison with passive fixation quadripolar leads, active fixation bipolar and quadripolar leads achieved similar results. The lead design with an active fixation mechanism via a side helix was developed to allow for full extractability in the long term. However,
the ease of extractability at long term has not yet been proven.667669
9.7 Lead position
Ventricular pacing has traditionally been performed from the RV
apex. Since the introduction of active fixation leads, alternative pacing sites such as the RVOT septum or the mid-septum have been evaluated in order to provide more physiological pacing. However,
despite two decades of research, the clinical benefit of RV non-apical pacing remains uncertain.670 This may be partly explained by variability in the position of the lead, which is often unintentionally placed on the anterior free wall, where it may be associated with adverse outcome.671673 The main advantage of septal pacing probably lies in the avoidance of perforation of the free wall. In a study of 2200
patients implanted with a pacemaker or ICD lead, an apical position was independently associated with cardiac perforation (OR 3.37; P =
0.024).420 A septal position may therefore be preferable in patients at increased risk of perforation, such as elderly patients especially with a body mass index <20 kg/m2, as well as women.670,674
Placing the lead on the mid-septum may be challenging (even more so in the RVOT septum, which is a smaller target area). The use of multiple fluoroscopic views and specially shaped stylets is useful for this purpose and is outlined in a recent EHRA consensus paper.34 In this context, it is important to mention that the accuracy and reproducibility of fluoroscopic assessment of RV lead positions is often inaccurate.421
Multiple fluoroscopic views are also recommended for placing
RVA leads, to ensure there is no inadvertent placement of the lead in a coronary sinus tributary or in the LV via an intracardiac shunt or arterial access.
The coronary sinus may be used for LV pacing without the need to cross the tricuspid valve. It may also be used in the case of other difficulties in deploying an RV lead (e.g. in the case of a tricuspid valve prosthesis). In selected patients, the outcome is similar to RV
pacing.675,676
The RA appendage is usually the preferred site for atrial pacing.
The lateral atrium may carry a risk of phrenic nerve capture.677,678
Alternative pacing sites to avoid AF such as Bachman’s bundle and the region of the coronary sinus ostium have not shown benefit and are not to be recommended in routine practice.679,680
9.8 Device pocket
In recent years, there has been increasing awareness of the device pocket as a source of complications. Avoidance of pocket infections has become a special focus in device therapy. The role of pocket haematomas in the development of infections has been discussed earlier.
It is evident that besides adequate management of anticoagulation, a proper surgical technique with meticulous haemostasis is of utmost importance.
Most pacemakers are implanted with the creation of a subcutaneous pocket.681 In patients with a low body mass index and therefore little subcutaneous tissue, in the case of Twiddler’s syndrome, or for aesthetic reasons, creation of a submuscular pocket may be preferable. However, this may require deeper sedation for implantation and generator replacements due to pain. To date, there are no data from
RCTs comparing the two approaches for creating device pockets.


<!-- PAGE 55 -->

### Page 55

.......................................................................................................................
Historical data from 1000 patients with ICD implants showed significantly shorter procedural times for patients with subcutaneous device pockets. No significant differences with regard to pocket haematomas were found. There were no significant differences in the cumulative percentages of patients free from complication during follow-up.682
Pocket irrigation at the end of the procedure with normal saline leads to dilution of possible contaminants and eliminates debris from the wound before closure.683,684 Addition of antibiotics to the rinsing solution does not reduce the risk of device infections.683
The World-wide Randomized Antibiotic Envelope Infection
Prevention Trial (WRAP-IT study) investigated the effect of an absorbable antibiotic-eluting envelope on the development of postoperative CIED infections. A total of 6983 patients undergoing a
CIED pocket revision, generator replacement, or system upgrade, or initial implantation of a CRT-D were randomly assigned, in a 1:1 ratio,
to receive the antibiotic envelope or not. The rate of CIED infection in patients who had the antibacterial envelope was 0.7% vs. 1.2% in the control group (HR 0.6, 95% CI 0.360.98; P = 0.04).685 No effect on infection rate was observed in the subgroup with pacemakers.685
Considering cost-effectiveness aspects, the use of an antibiotic envelope may be considered in pacemaker patients at high risk for CIED
infections. Risk factors to be considered in this context are end-stage renal disease, chronic obstructive pulmonary disease, diabetes mellitus, and device replacement, revision, or upgrade procedures.638
10 Complications of cardiac pacing and cardiac resynchronization therapy
10.1 General complications
Cardiac pacing and CRT are associated with a substantial risk of complications (Table 12), most of which occur in the perioperative phase,429,690 but a sizable risk remains during long-term follow-up.691
Complication rates after dual-chamber pacemaker implantation in the MOST trial were 4.8% at 30 days, 5.5% at 90 days, and 7.5% at 3
years.692 However, ‘real-life’ data indicate a higher risk.690,693 In a recent study of >81 000 patients receiving de novo CIED implantations, major complications occurred in 8.2% within 90 days of hospital discharge.694 Mortality in hospital (0.5%) and within 30 days (0.8%)
was low.
Complication risks generally increase with the complexity of the device and are more common in the context of a device upgrade or lead revisions compared with de novo implantation. In a Danish population-based cohort study, complications were observed in
9.9% of patients at first device implantation and in 14.8% upon upgrade or lead revision.354 Procedures limited to replacement of the generator had a lower complication risk (5.9%). In the prospective REPLACE registry, a similar proportion (4%) of complication risks in the setting of generator replacement was reported, but much higher risks were found in those with one or more additional lead insertions (up to 15.3%).695 Accordingly, major complications were particularly more common with CRT upgrade procedures, a finding that was corroborated in a large US inpatient cohort339 and a prospective Italian observational study.696 The rate of procedural complications also increases with comorbidity burden.697
Thus, careful shared decision-making is warranted when considering upgrades to more complex systems. This also applies to prophylactic replacement of recalled CIED generators and leads, a scenario in which procedural risks should be carefully weighed against the risks associated with device or lead failure.698
Overall, complication rates are closely linked to individual and centre implantation volumes.429,658,693 Complications were increased by 60% in inexperienced operators who had performed fewer than
Recommendations regarding device implantations and peri-operative management
Recommendations
Classa
Levelb
Administration of pre-operative antibiotic prophylaxis within 1 h of skin incision is recommended to reduce risk of CIED
infection.641,643.686
I
A
Chlorhexidinealcohol instead of povidoneiodinealcohol should be considered for skin antisepsis.647,648
IIa
B
For venous access, the cephalic or axillary vein should be considered as ﬁrst choice.658,659
IIa
B
To conﬁrm target ventricular lead position, use of multiple ﬂuoroscopic views should be considered.
IIa
C
For implantation of coronary sinus leads, quadripolar leads should be considered as ﬁrst choice.665,666,687
IIa
C
Rinsing the device pocket with normal saline solution before wound closure should be considered.683,684
IIa
C
In patients undergoing a reintervention CIED
procedure, the use of an antibiotic-eluting envelope may be considered.685,688
IIb
B
Pacing of the mid-ventricular septum may be considered in patients at high risk of perforation
(e.g. elderly, previous perforation, low body mass index, women).420,674
IIb
C
Continued
In pacemaker implantations in patients with possible pocket issues such as increased risk of erosion due to low body mass index, Twiddler’s syndrome, or for aesthetic reasons, a submuscular device pocket may be considered.
IIb
C
Heparin bridging of anticoagulated patients is not recommended.650,689
III
A
Permanent pacemaker implantation is not recommended in patients with fever. Pacemaker implantation should be delayed until the patient has been afebrile for at least 24 h.638,639
III
B
CIED = cardiovascular implantable electronic device.
aClass of recommendation.
bLevel of evidence.
ESC 2021
.....................................................
ESC Guidelines
55


<!-- PAGE 56 -->

### Page 56

.............................................................................................................................................................................
25 implantations.429 Data from a large national quality assurance programme for pacemakers and CRT-P showed that the annual hospital implantation volume was inversely related to complication rates,
with the greatest difference observed between the lowest (1- 50
implantations/year) and the second lowest quintile (5190 implantations/year).699 Furthermore, emergency and out-of-hours procedures are associated with increased complication rates.354 These data clearly suggest that CIED procedures should be performed by operators and centres with a sufficient procedural volume.
10.2 Specific complications
10.2.1
Lead complications
Pacemaker leads are a frequent source of complications due to dislodgement, insulation defects, lead fractures, and sensing or threshold problems. In a Danish cohort, lead-related interventions (2.4%) were the most common major complication.354 LV leads have a particular propensity for complications such as dislodgement and coronary vein dissection or perforation.700 In a nationwide registry, LV leads (4.3%)
were more commonly associated with complications compared with
RA leads (2.3%) and RV leads (2.2%).429 A CRT device (OR 3.3) and passive fixation RA lead (OR 2.2) were the most important risk predictors.
A meta-analysis of 25 CRT trials noted mechanical complications in 3.2% (including coronary sinus dissection or perforation, pericardial effusion or tamponade, pneumothorax, and haemothorax), other lead problems in 6.2%, and infections in 1.4%. Peri-implantation deaths occurred in 0.3%.369
10.2.2
Haematoma
Pocket haematoma is a frequent complication (2.19.5%), which can usually be managed conservatively. Evacuation, required in 0.32%
of cases, is associated with an 15 times increased risk of infection.639
Moreover, patients developing pocket haematoma stay in hospital longer and have a higher in-hospital mortality rate (2.0% vs. 0.7%).724
Hence, appropriate precautions are critical, and reoperation should be limited to patients with severe pain, persistent bleeding, distension of the suture line, and imminent skin necrosis. Many haematomas can be avoided by careful haemostasis and optimal management of antiplatelet and anticoagulant drugs.
10.2.3
Infection
Infection is one of the most worrying CIED complications, causing significant morbidity, mortality, and healthcare costs.725,726 Infection rates are higher with device replacement or upgrade procedures,695
as well as CRT or ICD implants compared with simple pacemaker implantation.727 Olsen et al.702 reported the lifetime risk of system infection in patients with: a pacemaker (1.19%), ICD (1.91%), CRT-P
(2.18%), and CRT-D (3.35%). Specifically, patients undergoing reoperations, those with a previous device-related infection, men, and younger patients had a significantly higher risk of infection.
Similar findings have been reported in a large cohort of patients receiving an ICD, with infection rates of 1.4% for single, 1.5% for dual,
and 2.0% for biventricular ICDs.728 In addition, early reintervention
(OR 2.70), previous valvular surgery (OR 1.53), reimplantation (OR
1.35), renal failure on dialysis (OR 1.34), chronic lung disease (OR
1.22), cerebrovascular disease (OR 1.17), and warfarin use (OR 1.16)
were associated with an increased risk of infection.702 Infections also occur more frequently with use of temporary pacing or other procedures before implantation (OR 2.5 and 5.8, respectively), early reinterventions (OR 15), and lack of antibiotic prophylaxis (OR
2.5).639,729
Further comprehensive information on how to prevent, diagnose,
and treat CIED infections has been provided in a recent EHRA consensus document.642
10.2.4
Tricuspid valve interference
CIED leads may interfere with tricuspid valve function intraoperatively by causing damage to the tricuspid valve leaflets or the subvalvular apparatus, or chronically after operation or lead extraction. This damage has been linked to haemodynamic deterioration and an adverse clinical outcome.730 In fact, moderate to severe tricuspid regurgitation is generally associated with excess mortality731,732
and occurs at a significantly higher rate in CIED patients.733 The prevalence of significant tricuspid regurgitation (defined as grade 2 or above) following CIED implantation varies between 10% and 39%.
Most studies attribute a greater harm with ICD leads and in the
Table 12
Complications of pacemaker and cardiac resynchronization therapy implantation
Incidence of complications after CIED therapy
%
Lead-related reintervention354,639,690,692,695,700,701
(including dislodgement, malposition, subclavian crush syndrome, etc.)
1.05.9
CIED-related infections, <12
months354,639,641,645,685,695,702
0.71.7
Superﬁcial infection354
1.2
Pocket infections354
0.4
Systemic infections354
0.5
CIED-related infections, >12 months702709
1.14.6
Pocket infections702
1.3
Systemic infections702,705
0.51.2
Pneumothorax354,658,690,692,700,701,707
0.52.2
Haemothorax695
0.1
Brachial plexus injury695
<0.1
Cardiac perforation354,663,690,692,695
0.30.7
Coronary sinus dissection/perforation710,288
0.72.1
Revision due to pain/discomfort354,690
0.10.4
Diaphragmatic stimulation requiring reintervention711,712,665,713
0.55
Haematoma354,639,650,652,654,690,700,714,715
2.15.3
Tricuspid regurgitation716718
515
Pacemaker syndrome146,701,719
120
Generator/lead problem354,639,690
0.11.5
Deep venous thrombosis (acute or chronic)354,720,721
0.12.6
Any complication354,639,690,692,695,707,722,723
515
Mortality (<30 days)354,694
0.81.4
CIED = cardiovascular implantable electronic device.
ESC 2021


<!-- PAGE 57 -->

### Page 57

.............................................................................................................................................................................
presence of multiple RV leads.45,46,49,445,642,685,697,709,728,730732 The issue of lead interference with bioprosthetic tricuspid valves or after annuloplasty or repair is debated. Furthermore, there is no firm evidence supporting that pacing-induced RV dyssynchrony significantly contributes to tricuspid regurgitation. A recent study randomizing 63
patients to pacing lead positions in the RV apex, RVS, or LV pacing via the coronary sinus did not affect the development of tricuspid regurgitation.734 The diagnostic work-up of CIED lead-related tricuspid regurgitation based on clinical, haemodynamic, and in particular echocardiographic (2D, 3D, and Doppler) evaluation is often challenging.735 While clear guidance for the management of tricuspid regurgitation in the presence of CIED leads is still lacking, a high level of clinical suspicion is required, not discounting the possibility that worsening HF may be a consequence of the mechanical effect on tricuspid leaflet mobility or coaptation.730 General treatment options include medical therapy aiming to relieve congestion and lead extraction with careful replacement, or use of alternative pacing strategies,
such as LV pacing via the coronary sinus or epicardial leads.
However, transvenous lead extraction itself carries a risk of damage to the tricuspid valve and, hence, worsening tricuspid regurgitation.
While leadless pacing eliminates the need for transvalvular leads, it may still negatively affect tricuspid valve function, potentially due to mechanical interference and abnormal electrical and mechanical ventricular activation.736 Indications for surgical valve repair or replacement in the context of CIED-induced tricuspid regurgitation follow current recommendations based on the presence of symptoms,
severity of tricuspid regurgitation, and RV function. When considering tricuspid valve surgery, management of the RV lead should follow the recommendations outlined in section 8.2.3.737 Methods for percutaneous tricuspid repair have recently gained major attention, but evidence in favour of such interventions in the context of lead-related tricuspid regurgitation is still limited.738
10.2.5
Other
Increased complication risks have been observed in women (mainly pneumothorax and cardiac perforation) and in those with a low body mass index.354,739 Patients older than 80 years were also found to have a lower risk of lead-related reinterventions compared with patients aged 6079 years (1.0% vs. 3.1%).354
Finally, suboptimal atrioventricular synchrony may lead to the pacemaker syndrome, giving rise to cannon waves caused by simultaneous atrial and ventricular contractions and symptoms of fatigue,
dizziness, and hypotension (see section 5). Long-term RV pacing induces a dyssynchronous ventricular activation pattern that may promote progressive LV dysfunction and clinical HF. Strategies to avoid and resolve the adverse effect of RV pacing have been discussed above (section 6).
11 Management considerations
Integrated management of pacemaker and CRT patients, delivered by an interdisciplinary team in partnership with the patient and family,
should be adopted in order to deliver comprehensive treatment across the continuum of healthcare (see section 12). The integratedcare approach is indicated in pacemaker and CRT patients to ensure a patient-centred approach and patient involvement in shared decision-making. The integrated-care approach has its origins in the chronic care model developed by Wagner et al.,740 and has the potential to improve clinical and patient outcomes in arrhythmia management741743 (see section 12). Relevant specialists to be included in the interdisciplinary team are included according to the patient’s needs and local service availability (Figure 13).
11.1 Magnetic resonance imaging in patients with implanted cardiac devices
MRI is a frequent requirement in patients with implanted pacemakers.
It may cause adverse effects such as inappropriate device function due to device reset or sensing problems, interaction with the magnetic reed switch, induction of currents resulting in myocardial capture, heating at the lead tip with changes in sensing or capture thresholds, or lead perforation. Risk factors for adverse events with
MRIs are listed in Supplementary Table 19.
Currently, most manufacturers propose devices that are MRI conditional. It is the entire CIED system (i.e. combination of generator and leads, which need to be from the same manufacturer) that determines MRI conditionality, and not the individual elements. MRI scans may be limited to 1.5 T and a whole-body specific absorption rate
(SAR) <2 W/kg (head SAR <3.2 W/kg), but some models allow 3 T
and up to 4 W/kg whole-body SAR. The manufacturer may specify an exemption period (usually 6 weeks) after implantation, but it may be reasonable to perform an MRI scan earlier if clinically warranted.
There is ample evidence that MRIs can be performed safely in nonconditional pacemakers, as long as a number of precautions are taken.744746 In 2017, the Heart Rhythm Society published an expert consensus statement on MRIs in patients with CIEDs, which was developed with and endorsed by a number of associations including the EHRA and several radiological associations.745 For detailed recommendations on appropriate workflow and programming, see
Supplementary Tables 20, 21, and 22 and Supplementary Figure 2.
When leads are connected to a generator, the latter component absorbs part of the energy and dissipates heat via the large surface area. Abandoned transvenous leads are prone to heating of the lead tip by 10C as shown by an in vitro study.747 It is, however, difficult to extrapolate results from experimental models to the in vivo setting.
No adverse events were reported from four series totalling 125
patients with abandoned transvenous leads.748751 The largest study reported 80 patients749 who underwent 97 scans (including the thoracic region), limited to an SAR <1.5 W/kg. Half of the cohort had measurement of troponin levels before and after the scan, without any significant changes. Therefore, 1.5 T MRI scans (limited to SAR
<1.5 W/kg) may be considered in selected patients, taking into account the riskbenefit ratio, particularly if the scans are extrathoracic and patients are not pacemaker dependent.
Epicardial leads connected to a generator result in a 10C increase in temperature during in vitro testing, and by as much as 77C with abandoned epicardial leads.747 Data from 23 patients with epicardial leads have been reported,749752 including 14 patients with abandoned epicardial leads,749751 without any adverse effect of MRI
scans. Given the paucity of data related to safety in patients with epicardial leads, lead adaptors/extenders, or damaged leads, recommendations cannot be made at this stage regarding MRIs in these patients.
ESC Guidelines
57


<!-- PAGE 58 -->

### Page 58

...................
Evaluation must be made on a case by case basis by balancing the advantages of MRI with the potential risks and availability of alternative imaging methods and using shared decision-making.
In general, MRIs should always be performed in the context of a rigorously applied standardized institutional workflow, following the appropriate conditions of use (including programming).744,746,753755
A flowchart summarizing the management of patients with a pacemaker undergoing MRI is shown in Figure 14.
There is evidence indicating that 1.5 T MRIs may be performed in patients with temporary epicardial wires756 as well as with transvenous pacemaker active fixation leads implanted to externalized pacemakers used for temporary pacing.751
Integrated management of patients with pacemaker and CRT
Emphasising patient-centred care and shared decision making
  Ensure optimal device selection and implantation 
Pre-implant assessment and adherence to low-risk implantation surgery
Provide physiological pacing and symptom control
Structured follow-up with tailored device programming
(remote monitoring and in-office)
Management of underlying cardiac disease
Including stroke prevention in atrial fibrillation and heart failure optimization
Patient education/
self-management 
Including personal goals and/or action plan
Healthcare professional education
Including certifications for optimal quality in relevant specialities
Lifestyle modification
Smoking cessation, alcohol, dietary and exercise interventions
Psychosocial management and support
Psychological assessment and/or treatment
Strategies to promote medical adherence
Educate patients about what to expect from the device and medical treatment using available technologies
Multidisciplinary team approach
Including different disciplines when relevant;
electrophysiologists, cardiologists, nurses, allied professionals,
psychologist, dietician and pharmacist
Clear communication between primary and secondary care
Including timely end-of-life discussions
Figure 13 Integrated management of patients with pacemaker and cardiac resynchronization therapy. CRT = cardiac resynchronization therapy.


<!-- PAGE 59 -->

### Page 59

............................................................
11.2 Radiation therapy in pacemaker patients
An increasing number of patients with CIEDs are referred for radiotherapy,757 with a reported annual rate of 4.33 treatments per 100
000 person-years. Radiotherapy uses high-energy ionizing radiation including X-rays, gamma rays, and charged particles, which might cause software and hardware errors in CIEDs, especially when photon radiation beam energy exceeds 610 MV, and the radiation dose to the device is high (>210 Gy).758,759 Hard errors are rare, and are most often due to direct irradiation to the device. This can cause irreversible hardware damage, requiring device replacement. Soft errors are more common, and are associated with secondary neutron production by irradiation.760 Such errors typically include resets of the device without causing structural damage, and can be solved without replacement.757,759
Electromagnetic interference during radiotherapy can cause oversensing, although this very rarely occurs in clinical practice.760
Device relocation before radiotherapy is very rarely recommended, and only if the current location of the device interferes
Evaluating magnetic resonance imaging in pacemaker patients
MRI following conditions of use and standardized workflow
(Class I)
MRI
Alternative imaging technique
MRI following appropriate standardized workflow
(Class IIa)
MRI only if benefits outweigh risk
(max. 1.5T,
SAR < 1.5 W/Kg)
(Class IIb)
(Class IIa)
Presence of abandoned leads
MRI-conditional system
Past exemption period after implementation
Alternative imaging mode available
N
Y
Presence of epicardial leads,
or connected fractured leads,
or lead adaptors/extenders
Y
N
N
N
Strongly reconsider
MRIa
Y
Y
N
Y
Figure 14 Flowchart for evaluating magnetic resonance imaging in pacemaker patients. MRI = magnetic resonance imaging; SAR = specific absorption rate. aConsider only if there is no imaging alternative and the result of the test is crucial for applying life-saving therapies for the patient.
Recommendations for performing magnetic resonance imaging in pacemaker patients
Recommendations
Classa
Levelb
In patients with MRI-conditional pacemaker systems,c MRIs can be performed safely following the manufacturer’s instructions.745,753755
I
A
In patients with non-MRI-conditional pacemaker systems, MRI should be considered if no alternative imaging mode is available and if no epicardial leads, abandoned or damaged leads, or lead adaptors/extenders are present.744,746
IIa
B
MRI may be considered in pacemaker patients with abandoned transvenous leads if no alternative imaging modality is available.748751
IIb
C
MRI = magnetic resonance imaging.
aClass of recommendation.
bLevel of evidence.
cCombination of
MRI-conditional generator and lead(s)
from the same manufacturer.
ESC 2021
ESC Guidelines
59


<!-- PAGE 60 -->

### Page 60

.....................................................................................
with adequate tumour treatment or in very selected high-risk cases.757,761
According to published recommendations for
CIED
patients,745,759,762 the risk of malfunction (or adverse events) is higher in the following situations for pacemaker patients:
• With photon radiation applying energy >610 MV: the risk of malfunctions (usually soft errors) is due to secondary neutron production, is not associated with the target zone, and cannot be shielded.
• With a cumulative dose reaching the device >2 Gy (moderate risk) or
>10 Gy (high-risk): the dose reaching the pacemaker can be estimated before and measured during treatment, is correlated with the target zone, and can be shielded.
• If the patient is pacemaker dependent.
Appropriate decision-making is suggested in Figure 15.
Experience with proton radiation therapy in CIED patients is limited. However, compared with photon irradiation, this radiation modality produces more secondary neutrons, which may affect the risk of device errors or failure.763 Currently, no specific guidance can be given regarding proton radiation therapy in CIED patients.
The specific recommendations of CIED manufacturers are reported in Supplementary Table 23.
11.3 Temporary pacing
Temporary pacing can provide electronic cardiac stimulation in patients with acute life-threatening bradycardia or can be placed prophylactically when the need for pacing is anticipated (e.g. after cardiac surgery).764,765 Modalities for emergency temporary pacing include transvenous, epicardial, and transcutaneous approaches. The transvenous approach often requires fluoroscopic guidance, although echo-guided placement is also feasible.766 Balloon-tipped floating catheters are easier to insert, more stable, and safer than semi-rigid catheters.767,768 Patients who undergo transvenous temporary cardiac pacing have a high risk for procedure-related complications (e.g.
cardiac perforation, bleeding, malfunction, arrhythmias, and accidental electrode displacement) and complications related to immobilization (e.g. infection, delirium, and thrombotic events).764,765,769775 In addition, previous temporary pacing is associated with an increased risk of permanent pacemaker infection.639,641 A percutaneous transvenous active fixation lead connected to an external device is safer and more comfortable for patients requiring prolonged temporary pacing.776779 There are no good data that support either a jugular or axillar/subclavian access; however, intrathoracic subclavian puncture should be avoided to reduce the risk of pneumothorax. A jugular access should be preferred if implantation of a permanent ipsilateral device is planned. In selected cases where fast and efficient pacing is needed, a femoral access may be used. Owing to instability of passive leads placed through the femoral vein and immobilization of the patient, the duration of this approach should be as short as possible until bradycardia has resolved or a more permanent solution has been established. The epicardial approach is mostly used following cardiac surgery. Removal of these leads is associated with complications such as bleeding and tamponade.780782 Transcutaneous temporary pacing is a fast and effective non-invasive method, but is not as
Pacemaker management in patients undergoing radiation therapy
Avoid direct radiation
Limit cumulative dose
Reduce beam energy to minimize direct neutron radiation
Device-specific treatment planning considerations:a
N
Comprehensive PM evaluation before radiation therapy
Neutron-producing treatment ( > 10 MV)
Weekly comprehensive
PM evaluation
Comprehensive PM evaluation after end of radiation therapy
Y
Figure 15 Pacemaker management during radiation therapy ECG = electrocardiographic; PM = pacemaker. aRelocation of the device, continuous ECG
monitoring, reprogramming, or magnet application are very rarely indicated.


<!-- PAGE 61 -->

### Page 61

............................................................................................................................................................
stable as the transvenous approach, and is limited by the need for continuous sedation.783 This modality should only be used in emergency settings or when no other option is available, and under close haemodynamic monitoring.784 Before starting temporary pacing,
chronotropic medication should be considered, taking into account side effects,
contraindications,
and interactions with other medication.
This Task Force concludes that temporary transvenous pacing should be avoided if possible; when it is required, the lead should remain in situ for as short a time as possible. The use of temporary pacing should be limited to the emergency treatment of patients with severe bradyarrhythmia causing syncope and/or haemodynamic compromise, and to cases in whom those bradyarrhythmias are anticipated. Temporary transvenous pacing is recommended when pacing indications are reversible, such as in the context of antiarrhythmic drug use, myocardial ischaemia, myocarditis, electrolyte disturbances,
toxic exposure, after cardiac surgery, or as a bridge to permanent pacemaker implantation when this procedure is not immediately available or possible due to concomitant infection. Lastly, if a patient meets the permanent pacemaker implantation criteria, this procedure should be performed promptly.
11.4 Peri-operative management in patients with cardiovascular implantable electronic devices
Advisory documents to help manage patients with CIEDs in the perioperative period have been issued by several professional societies.786789
Supplementary
Table
24
summarizes general recommendations on the management of these patients.
• Electromagnetic interference (EMI) may induce oversensing
(more likely with unipolar leads), activation of rate-responsive sensors, device resetting, or other damage. The most common source of EMI is electrocautery, although it is rare during bipolar electrocautery >5 cm from the CIED and monopolar electrocautery below the umbilicus.790 To reduce the risk of EMI,
monopolar electrocautery should be applied in short (<5 s)
pulses, with the skin patches away from the area of the device.
Other sources of EMI include radiofrequency procedures, nerve stimulators, and other electronic devices.
• The peri-operative strategy should be tailored based on the individual needs and values of patients,
procedure,
and device.786789 Most procedures will not require any intervention.791 In pacemaker-dependent patients, a magnet should be applied during delivery of diathermy pulses, or, if EMI is likely to occur or magnet stability cannot be guaranteed, the device should be reprogrammed to an asynchronous mode (VOO/
DOO). The response to magnet application may differ between device manufactures. CIEDs with a rate-responsive function using an active sensor may also require magnet application or disabling of this function to prevent inappropriate rapid pacing.
Post-operative CIED interrogation is recommended if malfunction is suspected or if the device has been exposed to strong
EMI.
11.5 Cardiovascular implantable electronic devices and sports activity
Regular exercise is strongly recommended for prevention of cardiovascular disease.792795 Restrictions to patients with a pacemaker,
where appropriate, are motivated by underlying cardiovascular disease. Therefore, it is important to address issues of exercise and sports participation with all pacemaker patients as part of a shared decision-making process. Comprehensive recommendations for physical activity in patients with cardiovascular disease have been published.792,796
There is consensus that contact sports (e.g. rugby or martial arts)
should be avoided so as not to risk damage of device components or haematoma at the implantation site. For participation in sports such as football, basketball, or baseball, special protective shields are recommended to reduce the risk of trauma to the device. Sport interests and right or left arm dominance should be considered when selecting the implantation site, and submuscular placement can be considered to reduce the risk of impact. A lateral vascular access is
Recommendations regarding temporary cardiac pacing
Recommendations
Classa
Levelb
Temporary transvenous pacing is recommended in cases of haemodynamic-compromising bradyarrhythmia refractory to intravenous chronotropic drugs.764,765
I
C
Transcutaneous pacing should be considered in cases of haemodynamic-compromising bradyarrhythmia when temporary transvenous pacing is not possible or available.783785
IIa
C
Temporary transvenous pacing should be considered when immediate pacing is indicated and pacing indications are expected to be reversible,
such as in the context of myocardial ischaemia,
myocarditis, electrolyte disturbances, toxic exposure, or after cardiac surgery.771773
IIa
C
Temporary transvenous pacing should be considered as a bridge to permanent pacemaker implantation when this procedure is not immediately available or possible due to concomitant infection.771773
IIa
C
For long-term temporary transvenous pacing, an active ﬁxation lead inserted through the skin and connected to an external pacemaker should be considered.641,776,777,779
IIa
C
aClass of recommendation.
bLevel of evidence.
ESC 2021
ESC Guidelines
61


<!-- PAGE 62 -->

### Page 62

...............................................................................................................
preferable to prevent the risk of subclavian crush of the lead associated with arm exercises above shoulder level. It is recommended to abstain from vigorous exercise and ipsilateral arm exercise for 46
weeks post-device implantation.
Of note, recommendations regarding sports activity in patients with an ICD differ from those in pacemaker patients.797,798
11.6 When pacing is no longer indicated
Different management options are available in patients with implanted pacemaker systems in whom pacing is no longer indicated:
Leave pacemaker generator and pacemaker leads in situ.
Explant pacemaker generator and abandon leads.
Explant pacemaker generator and leads.
The feasibility of option 1 depends on the end-of-life behaviour of the implanted generator, which is manufacturer dependent, and may be erratic and lead to complications in rare cases.799 Option 1 is the preferred approach to selected frail and elderly patients.
Option 2 comes with a low procedural risk but may be associated with the disadvantages of lead abandonment, including future MRI.
Especially in young patients, the potential necessary future requirement for lead extraction of abandoned leads due to infection and the associated elevated procedural risk due to longer duration of implantation procedure need to be taken into account. Several studies have shown increased complexity, lower procedural success, and higher complication rates of lead extraction procedures of abandoned leads.800803
Option 3 comes with the highest initial procedural risk, but eliminates all possibilities of future device-related complications. When performed in specialized high-volume centres with current extraction tools, lead extraction procedures can be carried out with high complete procedural success rates and low complication rates.802
This approach may be appropriate for the combination of a young patient, low risk for extraction, and an experienced extractor.
As part of a patient-centred approach, the decision in such situations has to be based on an individual riskbenefit analysis in a shared decision-making process together with the patient and his/her carers.
This includes providing sufficient information to achieve an informed decision-making. Important factors to take into consideration are patient age, patient condition, comorbidities, pacemaker system, lead implant duration, and the patient’s life expectancy.
11.7 Device follow-up
General principles of follow-up are covered here, as in-depth recommendations are beyond the scope of this document. The patient and the device should be treated as a single entity, with programming tailored to meet the patient’s needs. The goals are to (i) ensure patient safety; (ii) provide physiological pacing; (iii) improve patient quality of life; (iv) improve patient clinical management; and (v) maximize device longevity. Requirement for follow-up of the underlying cardiac disease should not be overlooked. In addition to the technical check and optimization of programming, proper counselling of the patient and his/her family are necessary to meet these goals. The frequency of follow-up depends on the type of device (CRT and HBP are associated with more clinical or technical issues and need closer surveillance) and whether they are on remote device management (Table 13).
• Remote device management includes remote follow-up with full remote device interrogation at scheduled intervals (to replace in-office visits), remote monitoring with unscheduled transmission of pre-defined alert events, and patient-initiated follow-up with unscheduled interrogations as a result of a patient experiencing a real or perceived clinical event. Most studies have focused on patients with ICDs and CRT-Ds, and have shown a significant reduction in delay between event detection/clinical decision, and fewer inappropriate shocks.804 Two randomized non-inferiority trials with single-chamber805 or DDD805,806 pacemakers (no
CRT-P) showed that in-office visits can be safely spaced to
1824 month intervals if patients are on remote monitoring with devices having automatic threshold algorithms. Spacing of scheduled in-office visits is particularly convenient for elderly patients with limited mobility, but also for young or midlle-aged patients with full-time jobs, family commitments, etc., and in specific situations (e.g. to avoid exposure during a pandemic).
• It is important to conduct remote device management with an appropriate set-up that delivers a structured approach to remote follow-up and a timely response to alerts. Third-party providers can be useful to triage alerts and assist with this task.807
Importantly,
compliance with the
General
Data
Protection Regulation should be respected, as outlined in a recent ESC regulatory affairs/EHRA document.808
Recommendation when pacing is no longer indicated
Recommendation
Classa
Levelb
When pacing is no longer indicated, the decision on management strategy should be based on an individual riskbeneﬁt analysis in a shared decision-making process together with the patient.
I
C
aClass of recommendation.
bLevel of evidence.
Table 13
Frequency of follow-up for routine pacemaker and cardiac resynchronization therapy, either in person alone or combined with remote device management
In-office only
In-office 1 remote
All devices
Within 72 h and
212 weeks after implantation
In-ofﬁce within 72 h and
212 weeks after implantation
CRT-P or
HBP
Every 6 months
Remote every 6 months and in-ofﬁce every 12 monthsa
Single/dualchamber
Every 12 months then every
3 - 6 months at signs of battery depletion
Remote every 6 months and in-ofﬁce every 18 - 24
monthsa
CRT-P = cardiac resynchronization therapy-pacemaker; HBP = His bundle pacing.
aRemote follow-up can only replace in-ofﬁce visits if automatic capture threshold algorithms perform accurately (and are previously veriﬁed in-ofﬁce).
Note: additional in-ofﬁce follow-up may be required (e.g. to verify the clinical effect of modiﬁcation of programming, or for follow-up a technical issue).
Remote monitoring (i.e. of pre-deﬁned alerts) should be implemented in all instances along with remote follow-ups.
ESC 2021
ESC 2021
.................................................................


<!-- PAGE 63 -->

### Page 63

.................................................................
12
Patient-centred care and shared decision-making in cardiac pacing and cardiac resynchronization therapy
Providing patient-centred care is a holistic process that emphasizes partnerships in health between patient and clinician, acknowledging the patient’s needs, beliefs, expectations, healthcare preferences,
goals, and values.811813 In patient-centred care, the focus is on shared decision-making, accepting that patients generally prefer to take an active role in decisions about their health.814,815 This approach has been shown to improve health outcomes and healthcare experiences.814,816 Clinicians have a duty to define and explain the healthcare problem and make recommendations about the best available evidence across all available options at the time, including no treatment, while ensuring that the patient’s values and preferences are considered (Figure 16).817820
Decision aids, such as written information and/or the use of interactive websites or web-based applications, can complement the clinicians’ counselling and thus facilitate shared decision-making.822 When decision aids are used, patients feel more knowledgeable, have more accurate risk perceptions, and take a more active part in the decision.823 In patients with poor language or literacy skills, as well as in those with cognitive impairment, communication strategies, including the help of a qualified interpreter, is recommended, as this helps the patient to make a balanced decision.824826 Choosing the appropriate educational material is an important component of promoting the learning process of patients.827830 Based on the patient’s needs and preferences, the education should be performed before implantation, at discharge, and during follow-up using a person-centred approach (Table 14). All patients should receive a brochure provided by the manufacturer as well as a device identification card before discharge.
This Task Force emphasizes the importance of patient-centred care and shared decision-making between patients and clinicians. The decision to implant a pacemaker/CRT should be based on the best available evidence with consideration of the individual riskbenefits of each option, the patient’s preferences, and goals of care. The consultation should include whether the patient is a good candidate for pacemaker/CRT treatment, and possible alternative treatment options should be discussed in a way that can be understood by everyone involved in the discussion. Using the principles of shared decision-making and informed consent/refusal,
patients with decision-making capacity have the right to refuse pacemaker therapy,
even if they are pacemaker dependent.
13 Quality indicators
Quality indicators are tools that may be used to evaluate care quality,
including that of processes of care and clinical outcomes.837 They may also serve as a mechanism for enhancing adherence to guideline recommendations through quality assurance endeavours and benchmarking of care providers.838 As such, the role of quality indicators in driving quality improvement is increasingly recognized and attracts interest from healthcare authorities, professional organizations,
payers, and the public.839
The ESC recognizes the need for measuring and reporting quality and outcomes of cardiovascular care. One aspect of this is the development and implementation of quality indicators for cardiovascular disease. The methodology by which the ESC quality indicators are
Recommendations for pacemaker and cardiac resynchronization therapy-pacemaker follow-up
Recommendations
Classa
Levelb
Remote device management is recommended to reduce the number of in-ofﬁce follow-ups in patients with pacemakers who have difﬁculties to attend in-ofﬁce visits (e.g. due to reduced mobility or other commitments, or according to patient preference).805,806,809
I
A
Remote monitoring is recommended in the case of a device component that has been recalled or is on advisory, to enable early detection of actionable events in patients, particularly those who are at increased risk (e.g. in the case of pacemaker dependency).
I
C
In-ofﬁce routine follow-up of single- and dualchamber pacemakers may be spaced by up to 24
months in patients on remote device management.805,806
IIa
A
Remote device management of pacemakers should be considered in order to provide earlier detection of clinical problems (e.g. arrhythmias)
or technical issues (e.g. lead failure or battery depletion).806,810
IIa
B
aClass of recommendation.
bLevel of evidence.
ESC 2021
Recommendation regarding patient-centred care and shared decision-making in cardiac pacing and cardiac resynchronization therapy
Recommendation
Classa
Levelb
In patients considered for pacemaker or CRT,
the decision should be based on the best available evidence with consideration of individual riskbeneﬁts of each option, the patient’s preferences, and goals of care, and it is recommended to follow an integrated care approach and use the principles of patient-centred care and shared decision-making in the consultation.831836
I
C
CRT = cardiac resynchronization therapy.
aClass of recommendation.
bLevel of evidence.
ESC 2021
............................................................................................................
ESC Guidelines
63


<!-- PAGE 64 -->

### Page 64

Seek the patient’s participation
Define and explain the healthcare problem and communicate that a choice exists. Discuss possible alternative treatment options, including that  patients with decision-making capacity have the right to refuse PM/CRT therapy, even if the patient is pacemaker dependent.
The consultation should be discussed in a way that can be understood by everyone involved in the discussion.
Encourage the patient to become involved in the consultation and invite family to participate.
Help the patient explore and compare treatment options
Provide an overview of the implantation process, and address all aspects of how the device works and the conditions it treats.
Discuss the benefits and risks with each option, including potential complications and treatment refusal.
Access the patient’s values and preferences
Supplement the counselling with different decision aids to facilitate SDM. In patients with poor language skills, cognitive impairment, or low health literacy, a variety of communication strategies should be used in order for the patient to make a deliberate decision.
Take into account the patient´s preferences and goals of care, and what matters most to the patient.
Reach a decision with the patient
Make evidence based recommendations with consideration of individual risk-benefits of each option,
while ensuring that the patient's beliefs, expectations, values, goals, and preferences are considered.
Decide together on the best available option.
Evaluate the patient’s decision
Evaluate if the decision is reasonable and understood.
Based on the patient´s needs and preferences, the education should be repeated prior discharge,
and at the follow-up appointments using a person centred approach.
Figure 16 Example of shared decision-making in patients considered for pacemaker/CRT implantation. Modified from the principles of the SHARE
Approach.821CRT = Cardiac resynchronization therapy; PM = pacemaker; SDM = Shared Decision Making.
Table 14
Topics and content that may be included in patient education
Topics
Content that may be included in patient education
Biophysiological
Disease/condition, pacemaker indication, implantation process, possible periprocedural or late complications and malfunction,
pacemaker/CRT function and technical aspects, patient notiﬁer (if applicable), battery replacement
Demonstration of pacemaker dummies
Functional
Daily activities: mobility, physical activities and sports, possible physical restrictions (arm movements), sexual activities, driving restrictions, travelling, wound care, medication use
Normal postoperative signs and symptoms and self-care; pain, stiffness in the shoulder, swelling or tenderness around the pacemaker pocket
Financial
Costs of treatment and rights in the social security system, insurance issues, sick leave
Emotional
Possible emotions and reactions to pacemaker treatment: anxiety, worries, body image
Social
Available support: telephone-based support, face-to-face group sessions, patient forums, and peer-support groups
Possible employment restrictions and electromagnetic interference
Ethical
Rights and duties of patients and healthcare providers: consent/refusal of pacemaker or CRT therapy, or withdrawal of therapy
Information about registration in the national pacemaker registry
Practical
Pacemaker identiﬁcation card contact information to the pacemaker clinic
Follow-up routines: remotely or/and hospital based
Where to get more information: reliable web-based information/sources, which organizations provide reliable health information
CRT = cardiac resynchronization therapy.
ESC 2021


<!-- PAGE 65 -->

### Page 65

..............................................................
developed has been published.839 To date, a suite of quality indicators for an initial tranche of cardiovascular conditions has been produced.839,840 To facilitate quality improvement initiatives, the diseasespecific ESC quality indicators are included in corresponding ESC
Clinical Practice Guidelines.296,841 This is further enhanced by way of their integration in the ESC registries, such as the EurObservational
Research Programme (EORP) and the European Unified Registries
On Heart Care Evaluation and Randomized Trials (EuroHeart)
project.842
A number of registries exist for patients undergoing CIED implantation,843 providing ‘real-world’ data about the quality and outcomes of CIED care.702 However, there is a lack of a widely agreed set of quality indicators that encompasses the multifaceted nature of CIED
care, and that serves as a bridge between clinical registries and guideline recommendations. Thus, and in parallel with the writing of these guidelines, a suite of quality indicators for patients undergoing
CIED implantation was developed. The full list of these quality indicators, as well as their specifications and development methodology,
has been published elsewhere,844 with a selection presented in
Table 15.
14 Key messages
• In the evaluation of candidates for permanent pacemaker implantation, a thorough and detailed pre-operative evaluation is recommended. This should always include careful history taking and physical examination, laboratory testing, documentation of the type of bradyarrhythmia requiring treatment, and cardiac imaging. In selected cases, additional tests, EPS, and/or genetic testing are indicated.
• Ambulatory ECG monitoring is useful in the evaluation of patients with suspected bradycardia or cardiac conduction disorder, to correlate rhythm disturbances with symptoms. Choice of type of monitoring should be based on frequency and nature of symptoms and patient preferences.
• In patients with
SND
including those with bradycardiatachycardia type of SND, when symptoms can clearly be attributed to bradyarrhythmia, cardiac pacing is indicated.
• In patients with SR and permanent or paroxysmal third- or second-degree type 2 or high-degree AVB, cardiac pacing is indicated irrespective of symptoms.
Table 15
A selection of the developed quality indicators for patients undergoing cardiovascular implantable electronic device implantation
Quality indicator
Domain
Centres providing CIED services should participate in at least one CIED registry
Structural quality indicatora
Numerator: Number of centres participating in at least one registry for CIED
Centres providing CIED services should monitor and report the volume of procedures performed by individual operators on an annual basis
Structural quality indicator
Numerator: Number of centres monitoring and reporting the volume of procedures performed by individual operators
Centres providing CIED services should have available resources (ambulatory ECG monitoring, echocardiogram) to stratify patients according to their risk for ventricular arrhythmias
Structural quality indicator
Numerator: Number of centres with an available ambulatory ECG and echocardiogram service
Centres providing CIED services should have a preprocedural checklist to ensure discussion with the patient regarding risks, beneﬁts, and alternative treatment options
Structural quality indicator
Numerator: Number of centres that have a checklist to ensure discussion with patient regarding risks, beneﬁts, and alternative treatment options before
CIED implantation
Centres providing CIED services should have established protocols to follow-up patients within 2 - 12 weeks following implantation
Structural quality indicator
Numerator: Number of centres that have an established protocol to follow up patients within 2 - 12 weeks following CIED implantation
Proportion of patients considered for CIED implantation who receive prophylactic antibiotics 1 h before their procedure
Patient assessment
Numerator: Number of patients who receive antibiotics 1 h before their CIED implantation procedure
Denominator: Number of patients undergoing CIED implantation procedure
Annual rate of procedural complicationsb 30 days following CIED implantation
Outcomes
Numerator: Number of patients who develop one or more procedural complicationsb within 30 days of CIED implantation
Denominator: Number of patients undergoing CIED implantation procedure
CIED = cardiovascular implantable electronic device; ECG = electrocardiogram.
aStructural quality indicators are binary measurements (yes/no), and thus only the numerator is deﬁned.
bCIED-related bleeding, pneumothorax, cardiac perforation, tamponade, pocket haematoma, lead displacement (all requiring intervention), or infection.
ESC 2021
ESC Guidelines
65


<!-- PAGE 66 -->

### Page 66

..........................................................................................................................................................................
• In patients with permanent AF and permanent or paroxysmal
AVB, single-lead ventricular pacing is indicated.
• In patients with syncope and unexplained falls, the diagnosis should be ascertained using the available diagnostic methods before pacemaker treatment is considered.
• In patients with symptomatic HF and LVEF <_35% despite OMT
who are in SR and have LBBB QRS morphology, CRT is recommended when QRS duration is >_150 ms, and should be considered when QRS duration is 130149 ms. For patients with nonLBBB QRS morphology, evidence for benefit of CRT is less convincing, especially with normal PR and QRS duration <150 ms.
CRT should not be used in patients with HF and QRS duration
<130 ms, unless there is need for ventricular pacing.
• Selection of patients for CRT based on imaging is limited to the measurement of LVEF, whereas the assessment of other factors,
such as extent of myocardial scar, presence of mitral regurgitation, or RV systolic function, is important to anticipate potential non-responders who may need additional treatments (e.g. mitral valve intervention).
• In patients with permanent AF, symptomatic HF, LVEF <_35%,
and QRS >_130 ms who remain in NYHA class III or ambulatory
IV despite OMT, CRT should be considered.
• For patients with AF and CRT, AVJ ablation should be considered when at least 9095% effective biventricular pacing cannot be achieved.
• For patients with high-degree AVB and an indication for cardiac pacing who have HFrEF (LVEF <40%), CRT rather than RV pacing is recommended.
• HBP may result in normal or near-normal ventricular activation,
and is an attractive alternative to RV pacing. To date, no data from randomized trials support that HBP is non-inferior to RV
pacing with respect to safety and efficacy. Therefore, HBP may be considered for selected patients with AVB and LVEF >40%,
who are anticipated to have >20% ventricular pacing.
• In patients offered HBP, implantation of an RV lead used as
‘backup’ for pacing should be considered individually.
• HBP may correct ventricular conduction in a subset of patients with LBBB and may therefore be used in lieu of biventricular pacing for HBP-based CRT in selected patients.
• In patients treated with HBP, device programming tailored to specific requirements of HBP must be ensured.
• Implanting a leadless pacemaker should be considered when no upper extremity venous access exists, when risk of device pocket infection is particularly increased, and in patients on haemodialysis.
• Patients undergoing TAVI are at increased risk of developing
AVB. Decisions regarding cardiac pacing after TAVI should be taken based upon pre-existing and new conduction disturbances.
Ambulatory ECG monitoring for 730 days or EPS may be considered in patients post-TAVI with new LBBB or progression of pre-existing conduction anomaly, but not yet any indication for a pacemaker.
• In patients undergoing surgery for endocarditis or tricuspid valve surgery who have or develop AVB under surgery, placement of epicardial pacing leads during surgery should be considered.
• To reduce the risk of complications, pre-operative antibiotics must be administered before
CIED
procedures,
chlorhexidinealcohol should be preferred for skin antisepsis,
and cephalic or axillary vein access should be attempted as first choice.
• Heparin bridging should be avoided in CIED procedures to minimize the risk of haematoma and pocket infection.
• In patients undergoing a CIED reintervention procedure, using an antibiotic-eluting envelope may be considered to reduce the risk of infection.
• In the majority of patients with a pacemaker or CRT, a wellindicated MRI can be performed if no epicardial leads, abandoned or damaged leads, or lead adaptors/extenders are present, and certain precautions are taken.
• Radiation therapy can be offered to patients with a pacemaker or CRT if an individualized treatment planning and risk stratification is done beforehand and the device is interrogated as recommended around the period of radiation therapy.
• Remote device management is valuable for earlier detection of clinical problems and technical issues, and may allow longer spacing between in-office follow-ups.
• The principles of patient-centred care and shared decisionmaking should be used in the consultation both pre-operatively and during follow-up for patients considered for or living with a pacemaker or CRT.
15 Gaps in evidence
Clinicians responsible for managing pacemaker and CRT candidates,
and patients, must frequently make treatment decisions without adequate evidence or consensus of expert opinion. The following is a short list of selected, common issues that deserve to be addressed in future clinical research.
• Best pre-implant evaluation programme, including when to apply advanced imaging methods to ensure optimal choice of CIED for each patient.
• Benefit of implementing genetic testing of CIED patients and their relatives when conduction tissue disease is diagnosed.
• Whether use of rate-adaptive pacing in general is beneficial in patients with SND.
• Whether catheter ablation of AF without pacemaker implantation is non-inferior to pacemaker implantation with respect to freedom from bradycardia-related symptoms in patients with symptomatic conversion pauses after AF.
• In patients with reflex syncope, studies of which pacing mode is superior are needed.
• In patients with an indication for VVI pacing, the long-term efficacy and safety of choosing leadless pacing need to be documented in RCTs.
• In patients with HF, it remains to be shown that CRT improves outcome in patients without LBBB.
• In patients with permanent/persistent AF, HF, and BBB, any beneficial effects of CRT remain to be proven in RCTs.
• There is a lack of RCTs documenting the effect of CRT in patients with HF treated with novel HF drugs including sacubitril/
valsartan, ivabradine, and sodiumglucose co-transporter-2
inhibitors.


<!-- PAGE 67 -->

### Page 67

.........................................................................................
• The beneficial effects of upgrading to CRT from a standard pacemaker or ICD in patients with HF and a high frequency of RV
pacing need to be documented.
• When implanting the LV electrode, it is unknown whether targeting the latest local activation mechanically or electrically causes an improved effect of CRT and a better patient outcome.
• It is unknown whether employing any type of pre-implant imaging to decide about LV and RV lead placement in CRT may cause better a patient outcome.
• In patients with an indication for permanent pacing and need for a high frequency of RV pacing because of AVB, it is not known which patient and treatment characteristics predict development of pacing-induced cardiomyopathy or HF.
• In patients with AVB and an indication for cardiac pacing, the long-term efficacy and safety of HBP as an alternative to RV pacing need to be proven in RCTs. In addition, the selection of patients most likely to benefit from HBP is not yet defined.
• In patients with HF and an indication for CRT, the long-term efficacy and safety of implementing HBP as an alternative to or element of CRT with biventricular pacing need to be proven in
RCTs. In addition, the selection of CRT candidates who are most likely to benefit from HBP is not yet defined.
• Further studies are needed to determine whether HBP could be used to improve response in CRT non-responders.
• The efficacy and safety of left bundle branch area pacing remain to be documented.
• Superiority of a specific location for the RV lead (i.e. septal, outflow tract, or apical) has not been documented for standard pacing indicated for bradycardia or for CRT.
• Better prediction of who will develop AVB after TAVI is needed.
• In symptomatic patients with end-stage HCM and LBBB, there is a need to better define the criteria for CRT implantation and document the clinical features associated with sustained benefit from the procedure.
• Optimal treatment including cardiac pacing for patients with congenital AVB should be investigated.
• In pacemaker candidates with cardiomyopathies with >1 year expected survival who do not fulfil standard criteria for ICD
implantation, criteria for ICD instead of pacemaker implantation should be better defined.
• The optimal pre-operative handling in CIED implantations and potential use of pre-operative skin disinfection and/or prehospitalization decolonization in S. aureus carriers remains to be determined.
• The optimal approach for the different operational procedure elements in CIED implantations, especially for choice of venous access, active or passive fixation leads in right-sided chambers,
specific pacing sites, use of haemostatic agents in the pocket,
choice of suture types, and application of pressure dressing at the end of the procedure remains to be determined.
• Patients with a need for immediate cardiac pacing occasionally present with fever and infection; typically, treatment includes temporary transvenous pacing and antibiotics, followed by implantation of a permanent pacemaker after the infection has resolved. It is unknown whether immediate implantation of a permanent pacemaker after initiation of antibiotics would be inferior.
• The role of patient education, patient-centred care, and shared decision-making should be studied in CIED populations.
16 ‘What to do’ and ‘what not to do’ messages from the Guidelines
............ ............
Recommendations
Classa
Levelb
Evaluation of the patient with suspected or documented bradycardia or conduction system disease
Monitoring
Ambulatory ECG monitoring is recommended in the evaluation of patients with suspected bradycardia to correlate rhythm disturbances with symptoms.
I
C
Carotid massage
Once carotid stenosis is ruled out,c CSM is recommended in patients with syncope of unknown origin compatible with a reﬂex mechanism or with symptoms related to pressure/manipulation of the carotid sinus area.
I
B
Exercise test
Exercise testing is recommended in patients who experience symptoms suspicious of bradycardia during or immediately after exertion.
I
C
Imaging
Cardiac imaging is recommended in patients with suspected or documented symptomatic bradycardia to evaluate the presence of structural heart disease, to determine LV systolic function, and to diagnose potential causes of conduction disturbances.
I
C
Laboratory tests
In addition to pre-implant laboratory tests,d speciﬁc laboratory tests are recommended in patients with clinical suspicion for potential causes of bradycardia (e.g. thyroid function tests, Lyme titre, digitalis level, potassium, calcium, and pH) to diagnose and treat these conditions.
I
C
Continued
ESC Guidelines
67


<!-- PAGE 68 -->

### Page 68

Sleep evaluation
Screening for SAS is recommended in patients with symptoms of SAS and in the presence of severe bradycardia or advanced
AVB during sleep.
I
C
Recommendation for implantable loop recorder
In patients with infrequent (less than once a month) unexplained syncope or other symptoms suspected to be caused by bradycardia in whom a comprehensive evaluation did not demonstrate a cause, long-term ambulatory monitoring with an ILR is recommended.
I
A
Cardiac pacing for bradycardia and conduction system disease
In patients with SND and a DDD pacemaker, minimization of unnecessary ventricular pacing through programming is recommended.
I
A
Pacing is indicated in SND when symptoms can clearly be attributed to bradyarrhythmias.
I
B
Pacing is indicated in symptomatic patients with the bradycardiatachycardia form of SND to correct bradyarrhythmias and enable pharmacological treatment, unless ablation of the tachyarrhythmia is preferred.
I
B
Pacing is not recommended in patients with bradyarrhythmias related to SND which are asymptomatic or due to transient causes that can be corrected and prevented.
III
C
Pacing is indicated in patients in SR with permanent or paroxysmal third- or second-degree type 2, infranodal 2:1, or highdegree AVB, irrespective of symptoms.e
I
C
Pacing is indicated in patients with atrial arrhythmia (mainly AF) and permanent or paroxysmal third- or high-degree AVB,
irrespective of symptoms.
I
C
In patients with permanent AF in need of a pacemaker, ventricular pacing with rate response function is recommended.
I
C
Pacing is not recommended in patients with AVB due to transient causes that can be corrected and prevented.
III
C
In patients with unexplained syncope and bifascicular block, a pacemaker is indicated in the presence of either a baseline HV
interval of >_70 ms, second- or third-degree intra- or infra-Hisian block during incremental atrial pacing, or abnormal response to pharmacological challenge.
I
B
Pacing is indicated in patients with alternating BBB with or without symptoms.
I
C
Pacing is not recommended for asymptomatic BBB or bifascicular block.
III
B
Recommendations for pacing for reﬂex syncope
Dual-chamber cardiac pacing is indicated to reduce recurrent syncope in patients aged >40 years, with severe, unpredictable,
recurrent syncope who have:
• spontaneous documented symptomatic asystolic pause(s) >3 s or asymptomatic pause(s) >6 s due to sinus arrest or AVB;
or
• cardioinhibitory carotid sinus syndrome; or
• asystolic syncope during tilt testing.
I
A
Cardiac pacing is not indicated in the absence of a documented cardioinhibitory reﬂex.
III
B
Pacing is not recommended in patients with unexplained falls in the absence of any other documented indication.
III
B
Pacing is not recommended in patients with unexplained syncope without evidence of SND or conduction disturbance.
III
C
CRT
CRT is recommended for symptomatic patients with HF in SR with LVEF <_35%, QRS duration >_150 ms, and LBBB QRS morphology despite OMT, to improve symptoms and reduce morbidity and mortality.
I
A
CRT is not indicated in patients with HF and a QRS duration <130 ms without indication for RV pacing.
III
A
In patients with symptomatic AF and an uncontrolled heart rate who are candidates for AVJ ablation (irrespective of QRS
duration), CRT is recommended in patients with HFrEF.
I
B
CRT rather than RV pacing is recommended for patients with HFrEF (<40%) regardless of NYHA class who have an indication for ventricular pacing and high-degree AVB in order to reduce morbidity. This includes patients with AF.
I
A
In patients who are candidates for an ICD, and who have CRT indication, implantation of a CRT-D is recommended.
I
A
Recommendations for using His bundle pacing
In patients treated with His bundle pacing, device programming tailored to speciﬁc requirements of His bundle pacing is recommended.
I
C
Pacing in acute myocardial infarction
Implantation of a permanent pacemaker is indicated with the same recommendations as in a general population (section 5.2)
when AVB does not resolve within a waiting period of at least 5 days after MI.
I
C
Pacing is not recommended if AVB resolves after revascularization or spontaneously.
III
B
Continued


<!-- PAGE 69 -->

### Page 69

Recommendations for cardiac pacing after cardiac surgery and heart transplantation
High-degree or complete AVB after cardiac surgery: a period of clinical observation of at least 5 days is indicated to assess whether the rhythm disturbance is transient and resolves. However, this observation period can be shortened in the case of complete AVB with low or no escape rhythm when resolution is unlikely.
I
C
Patients requiring pacing after mechanical tricuspid valve replacement: implantation of a transvalvular RV lead should be avoided.
III
C
Recommendations for cardiac pacing after TAVI
Permanent pacing is recommended in patients with complete or high-degree AVB that persists for 24 - 48 h after TAVI.
I
B
Permanent pacing is recommended in patients with new-onset alternating BBB after TAVI.
I
C
Prophylactic permanent pacemaker implantation is not indicated before TAVI in patients with RBBB and no indication for permanent pacing.
III
C
Recommendations for cardiac pacing in patients with congenital heart disease
In patients with congenital complete or high-degree AVB, pacing is recommended if one of the following risk factors is present:
i. Symptoms ii. Pauses >3 the cycle length of the ventricular escape rhythm iii. Broad QRS escape rhythm iv. Prolonged QT interval v. Complex ventricular ectopy vi. Mean daytime heart rate <50 b.p.m.
I
C
Recommendations for cardiac pacing in rare diseases
In patients with neuromuscular diseases such as myotonic dystrophy type 1 and any second- or third-degree AVB or HV >_70
ms, with or without symptoms, permanent pacing is indicated.f
I
C
Recommendations regarding device implantations and peri-operative management
Administration of pre-operative antibiotic prophylaxis within 1 h of skin incision is recommended to reduce the risk of CIED infection.
I
A
Heparin bridging of anticoagulated patients is not recommended.
III
A
Permanent pacemaker implantation is not recommended in patients with fever. Pacemaker implantation should be delayed until the patient has been afebrile for at least 24 h.
III
B
Recommendations for performing magnetic resonance imaging in pacemaker patients
In patients with MRI-conditional pacemaker systems,g MRI can be performed safely following the manufacturer’s instructions.
I
A
Recommendations regarding temporary cardiac pacing
Temporary transvenous pacing is recommended in cases of haemodynamic-compromising bradyarrhythmia refractory to intravenous chronotropic drugs.
I
C
Recommendation when pacing is no longer indicated
When pacing is no longer indicated, the decision on management strategy should be based on an individual riskbeneﬁt analysis in a shared decision-making process together with the patient.
I
C
Recommendations for pacemaker and cardiac resynchronization therapy-pacemaker follow-up
Remote device management is recommended to reduce the number of in-ofﬁce follow-up visits in patients with pacemakers who have difﬁculties in attending in-ofﬁce visits (e.g. due to reduced mobility or other commitments, or according to patient preference).
I
A
Remote monitoring is recommended in the case of a device component that has been recalled or is on advisory, to enable early detection of actionable events in patients, particularly those who are at increased risk (e.g. in case of pacemaker dependency).
I
C
Recommendation regarding patient-centred care in cardiac pacing and cardiac resynchronization therapy
In patients considered for a pacemaker or CRT, the decision should be based on the best available evidence with consideration of individual riskbeneﬁts of each option, the patient’s preferences, and goals of care, and it is recommended to follow an integrated care approach and use the principles of patient-centred care and shared decision-making in the consultation.
I
C
AF = atrial ﬁbrillation; AVB = atrioventricular block; AVJ = atrioventricular junction; BBB = bundle branch block; b.p.m. = beats per minute; CIED = cardiovascular implantable electronic device; CRT = cardiac resynchronization therapy; CRT-D = deﬁbrillator with cardiac resynchronization therapy; CSM = carotid sinus massage; DDD = dual-chamber,
atrioventricular pacing; ECG = electrocardiogram; EPS = electrophysiology study; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; HV =
Hisventricular interval; ICD = implantable cardioverter-deﬁbrillator; ILR = implantable loop recorder; LBBB = left bundle branch block; LV = left ventricular; LVEF = left ventricular ejection fraction; MI = myocardial infarction; MRI = magnetic resonance imaging; NYHA = New York Heart Association; OMT = optimal medical therapy; RBBB = right bundle branch block; RV = right ventricular; SAS = sleep apnoea syndrome; SND = sinus node dysfunction; SR = sinus rhythm; TAVI = transcatheter aortic valve implantation.
aClass of recommendation.
bLevel of evidence.
cCSM should not be undertaken in patients with previous transient ischaemic attack, stroke, or known carotid stenosis. Carotid auscultation should be performed before CSM.
If a carotid bruit is present, carotid ultrasound should be performed to exclude carotid disease.
dComplete blood counts, prothrombin time, partial thromboplastin time, serum creatinine, and electrolytes.
eIn asymptomatic narrow QRS complex and 2:1 AVB, pacing may be avoided if supra-Hisian block is clinically suspected (concomitant Wenckebach is observed and block disappears with exercise) or demonstrated at EPS.
fWhenever pacing is indicated in neuromuscular disease, CRT or an implantable cardioverter-deﬁbrillator should be considered according to relevant guidelines.
gCombination of MRI conditional generator and lead(s) from the same manufacturer.
ESC 2021
ESC Guidelines
69


<!-- PAGE 70 -->

### Page 70

.............................................................................................................................................................................
17 Supplementary data
Supplementary data with additional Supplementary Figures, Tables, and text complementing the full text are available on the European Heart
Journal website and via the ESC website at https://www.escardio.org/
guidelines.
18 Author Information
Author/Task
Force
Member
Affiliations:
Mads
Brix
Kronborg, Department of Cardiology, Aarhus University Hospital,
Aarhus N, Denmark; Yoav Michowitz, Jesselson Integrated Heart
Center, Faculty of Medicine, Hebrew University, Shaare Zedek
Medical Center, Jerusalem, Israel; Angelo Auricchio, Department of Cardiology, Istituto Cardiocentro Ticino, Lugano, Switzerland;
Israel Moshe Barbash, Leviev Heart Center, Sheba Medical
Center, Sackler Faculty of Medicine, Tel Aviv University, Ramat Gan,
Israel; Jose´ A. Barrabe´s, Department of Cardiology, Vall d’Hebron
Hospital Universitari, Universitat Autonoma de Barcelona, CIBERCV,
Barcelona,
Spain;
Giuseppe
Boriani,
Cardiology
Division,
Department of
Biomedical,
Metabolic and
Neural
Sciences,
University of Modena and Reggio Emilia, Modena, Italy; Frieder
Braunschweig, Department of Cardiology, Karolinska University
Hospital, Stockholm, Sweden; Michele Brignole, Cardiology,
IRCCS Istituto Auxologico Italiano, Milan, Italy; Haran Burri,
Cardiology, University Hospital of Geneva, Geneva, Switzerland;
Andrew J. S. Coats, Faculty of Medicine, University of Warwick,
Coventry, United Kingdom; Jean-Claude Deharo, Cardiology La
Timone, Aix Marseille Universite´, Marseille, France; Victoria
Delgado, Cardiology, Leiden University Medical Center, Leiden,
Netherlands; Gerhard-Paul Diller, Department of Cardiology III,
Adult Congenital and Valvular Heart Disease, University Hospital
Muenster, Muenster, Germany; Carsten W. Israel, Department of
Medicine-Cardiology, Diabetology and Nephrology, Bethel-Clinic,
Bielefeld, Germany; Andre Keren, Cardiology, Hadassah-Hebrew
University
Hospital,
Jerusalem,
Israel;
Reinoud
E.
Knops,
Cardiology and Electrophysiology, Amsterdam University Medical
Center, Amsterdam, Netherlands; Dipak Kotecha, Institute of
Cardiovascular Sciences, University of Birmingham, Birmingham,
United Kingdom; Christophe Leclercq, Department of Cadiology,
Rennes University Hospital, Rennes, France; Be´la Merkely, Heart and Vascular Center, Semmelweis University, Budapest, Hungary;
Christoph Starck, Department of Cardiothoracic & Vascular
Surgery, German Heart Center Berlin, Berlin, Germany; Ingela
Thyle´n, Department of Health, Medicine and Caring Sciences,
Linko¨ping University, Linko¨ping, Sweden; Jose´ Maria Tolosana,
Arrhythmia
Section,
Cardiovascular
Institute,
Hospital
Clinic,
University of Barcelona, Barcelona, Catalonia, Spain.
19 Appendix
ESC Scientific Document Group
Includes Document Reviewers and ESC National Cardiac Societies.
Document
Reviewers:
Francisco
Leyva
(CPG
Review
Coordinator) (United Kingdom), Cecilia Linde (CPG Review
Coordinator) (Sweden), Magdy Abdelhamid (Egypt), Victor Aboyans
(France), Elena Arbelo (Spain), Riccardo Asteggiano (Italy), Gonzalo
Baron-Esquivias (Spain), Johann Bauersachs (Germany), Mauro Biffi
(Italy), Ulrika Birgersdotter-Green (United States of America ), Maria
Grazia Bongiorni (Italy), Michael A. Borger (Germany), Jelena
Celutkien_e (Lithuania), Maja Cikes (Croatia), Jean-Claude Daubert
(France), Inga Drossart (Belgium), Kenneth Ellenbogen (United
States of America), Perry M. Elliott (United Kingdom), Larissa Fabritz
(United Kingdom), Volkmar Falk (Germany), Laurent Fauchier
(France),
Francisco
Fernandez-Avile´s
(Spain),
Dan
Foldager
(Denmark), Fredrik Gadler (Sweden), Pastora Gallego Garcia De
Vinuesa (Spain), Bulent Gorenek (Turkey), Jose M. Guerra (Spain),
Kristina Hermann Haugaa (Norway), Jeroen Hendriks (Netherlands),
Thomas Kahan (Sweden), Hugo A. Katus (Germany), Aleksandra
Konradi (Russia), Konstantinos C. Koskinas (Switzerland), Hannah
Law (United Kingdom), Basil S. Lewis (Israel), Nicholas John Linker
(United Kingdom), Maja-Lisa Løchen (Norway), Joost Lumens
(Netherlands),
Julia
Mascherbauer
(Austria),
Wilfried
Mullens
(Belgium), KlaudiaVivien Nagy (Hungary), Eva Prescott (Denmark),
Pekka Raatikainen (Finland), Amina Rakisheva (Kazakhstan), Tobias
Reichlin (Switzerland), Renato Pietro Ricci (Italy), Evgeny Shlyakhto
(Russia), Marta Sitges (Spain), Miguel Sousa-Uva (Portugal), Richard
Sutton (Monaco), Piotr Suwalski (Poland), Jesper Hastrup Svendsen
(Denmark), Rhian M. Touyz (United Kingdom), Isabelle C. Van
Gelder (Netherlands), Kevin Vernooy (Netherlands), Johannes
Waltenberger (Germany), Zachary Whinnett (United Kingdom),
Klaus K. Witte (United Kingdom).
ESC National Cardiac Societies actively involved in the review process of the 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: Algeria: Algerian Society of Cardiology,
Brahim Kichou; Armenia: Armenian Cardiologists Association,
Armen Khachatryan; Austria: Austrian Society of Cardiology,
Daniel
Scherr;
Belarus:
Belorussian
Scientific
Society of
Cardiologists, Alexandr Chasnoits; Belgium: Belgian Society of
Cardiology, Georges H. Mairesse; Bosnia and Herzegovina:
Association of Cardiologists of Bosnia and Herzegovina, Mugdim
Bajric; Bulgaria: Bulgarian Society of Cardiology, Vasil Velchev;
Croatia: Croatian Cardiac Society, Vedran Velagic; Cyprus:
Cyprus Society of Cardiology, Elias Papasavvas; Czech Republic:
Czech Society of Cardiology, Milos Taborsky; Denmark: Danish
Society of Cardiology, Michael Vinther; Egypt: Egyptian Society of
Cardiology, John Kamel Zarif Tawadros; Estonia: Estonian Society of Cardiology, Ju¨ri Voitk; Finland: Finnish Cardiac Society, Jarkko
Karvonen; France: French Society of Cardiology, Paul Milliez;
Georgia: Georgian Society of Cardiology, Kakhaber Etsadashvili;
Germany: German Cardiac Society, Christian Veltmann; Greece:
Hellenic Society of Cardiology, Nikolaos Fragakis; Hungary:
Hungarian Society of Cardiology, Laszlo Alajos Gelle´r; Ireland: Irish
Cardiac Society, Richard Sheahan; Israel: Israel Heart Society,
Avishag Laish-Farkash; Italy: Italian Federation of Cardiology,
Massimo Zecchin; Kazakhstan: Association of Cardiologists of
Kazakhstan, Ayan Abdrakhmanov; Kosovo (Republic of): Kosovo
Society of Cardiology, Ibadete Bytyc¸i; Kyrgyzstan: Kyrgyz Society of Cardiology, Kurbanbek Kalysov; Latvia: Latvian Society of
Cardiology,
Oskars
Kalejs;
Lebanon:
Lebanese
Society of Cardiology, Bernard Abi-Saleh; Lithuania: Lithuanian Society of


<!-- PAGE 71 -->

### Page 71

.............................................................................................................................................................................
Cardiology,
Germanas Marinskis;
Luxembourg:
Luxembourg
Society of Cardiology, Laurent Groben; Malta: Maltese Cardiac
Society, Mark Adrian Sammut; Moldova (Republic of): Moldavian
Society of Cardiology, Mihail Rizov; Montenegro: Montenegro
Society of Cardiology, Mihailo Vukmirovic; Morocco: Moroccan
Society of
Cardiology,
Rachida
Bouhouch;
Netherlands:
Netherlands
Society of
Cardiology,
Mathias
Meine;
North
Macedonia: North Macedonian Society of Cardiology, Lidija
Poposka; Norway: Norwegian Society of Cardiology, Ole Christian
Mjølstad;
Poland:
Polish
Cardiac
Society,
Maciej
Sterlinski;
Portugal: Portuguese Society of Cardiology, Natalia Antonio;
Romania: Romanian Society of Cardiology, Calin Siliste; Russian
Federation: Russian Society of Cardiology, Sergey Valentinovich
Popov; San Marino: San Marino Society of Cardiology, Roberto
Bini; Serbia: Cardiology Society of Serbia, Goran Milasinovic;
Slovakia: Slovak Society of Cardiology, Peter Margitfalvi; Slovenia:
Slovenian Society of Cardiology, Igor Zupan; Spain: Spanish Society of
Cardiology,
Oscar
Cano;
Sweden:
Swedish
Society of
Cardiology, Rasmus Borgquist; Switzerland: Swiss Society of
Cardiology, Tobias Reichlin; Syrian Arab Republic: Syrian
Cardiovascular Association, Ahmad Rasheed Al Saadi; Tunisia:
Tunisian Society of Cardiology and Cardio-Vascular Surgery,
Abdeddayem Haggui; Turkey: Turkish Society of Cardiology, Ilyas
Atar; United Kingdom of Great Britain and Northern
Ireland: British Cardiovascular Society, Anthony W. C. Chow.
ESC Clinical Practice Guidelines Committee (CPG): Colin
Baigent
(Chairperson)
(United
Kingdom),
Magdy
Abdelhamid
(Egypt),
Victor
Aboyans
(France),
Sotiris
Antoniou
(United
Kingdom), Elena Arbelo (Spain), Riccardo Asteggiano (Italy), Andreas
Baumbach (United Kingdom), Michael A. Borger (Germany), Jelena
Celutkien_e (Lithuania), Maja Cikes (Croatia), Jean-Philippe Collet
(France), Volkmar Falk (Germany), Laurent Fauchier (France), Chris
P. Gale (United Kingdom), Sigrun Halvorsen (Norway), Bernard Iung
(France), Tiny Jaarsma (Sweden), Aleksandra Konradi (Russia),
Konstantinos C. Koskinas (Switzerland), Dipak Kotecha (United
Kingdom), Ulf Landmesser (Germany), Basil S. Lewis (Israel), Ales
Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Lis Neubeck
(United Kingdom), Jens Cosedis Nielsen (Denmark); Steffen E.
Petersen (United Kingdom), Eva Prescott (Denmark), Amina
Rakisheva (Kazakhstan), Marta Sitges (Spain), Rhian M. Touyz (United
Kingdom).
19 References
1. Timmis A, Townsend N, Gale C, Grobbee R, Maniadakis N, Flather M, Wilkins E,
Wright L, Vos R, Bax J, Blum M, Pinto F, Vardas P, ESC Scientific Document
Group. European Society of Cardiology: cardiovascular disease statistics 2017. Eur
Heart J 2018;39:508579.
2. Mond HG, Proclemer A. The 11th world survey of cardiac pacing and implantable cardioverter-defibrillators: calendar year 2009—a World Society of Arrhythmia’s project. Pacing Clin Electrophysiol 2011;34:10131027.
3. Gregoratos G. Permanent pacemakers in older persons. J Am Geriatr Soc
1999;47:11251135.
4. Mond HG. The World Survey of Cardiac Pacing and Cardioverter Defibrillators:
calendar year 1997. Pacing Clin Electrophysiol 2001;24:869870.
5. Mond HG. The World Survey of Cardiac Pacing and Cardioverter Defibrillators:
calendar year 1997—Asian Pacific, Middle East, South America, and Canada.
Pacing Clin Electrophysiol 2001;24:856862.
6. Ector H, Rickards AF, Kappenberger L, Linde C, Vardas P, Oto A, Santini M,
Sutton R, Working Group on Cardiac Pacing. The World Survey of Cardiac
Pacing and Implantable Cardioverter Defibrillators: calendar year 1997—Europe.
Pacing Clin Electrophysiol 2001;24:863868.
7. Mond HG, Irwin M, Ector H, Proclemer A. The world survey of cardiac pacing and cardioverter-defibrillators: calendar year 2005 an International Cardiac Pacing and
Electrophysiology
Society
(ICPES)
project.
Pacing
Clin
Electrophysiol
2008;31:12021212.
8. Bradshaw PJ, Stobie P, Knuiman MW, Briffa TG, Hobbs MS. Trends in the incidence and prevalence of cardiac pacemaker insertions in an ageing population.
Open Heart 2014;1:e000177.
9. Johansson BW. Complete heart block. A clinical, hemodynamic and pharmacological study in patients with and without an artificial pacemaker. Acta Med Scand
Suppl 1966;451:1127.
10. Edhag O. Long-term cardiac pacing. Experience of fixed-rate pacing with an endocardial electrode in 260 patients. Acta Med Scand Suppl 1969;502:9110.
11. Edhag O, Swahn A. Prognosis of patients with complete heart block or arrhythmic syncope who were not treated with artificial pacemakers. A long-term follow-up study of 101 patients. Acta Med Scand 1976;200:457463.
12. Friedberg CK, Donoso E, Stein WG. Nonsurgical acquired heart block. Ann N Y
Acad Sci 1964;111:835847.
13. Shaw DB, Holman RR, Gowers JI. Survival in sinoatrial disorder (sick-sinus syndrome). Br Med J 1980;280:139141.
14. Alboni P, Menozzi C, Brignole M, Paparella N, Gaggioli G, Lolli G, Cappato R.
Effects of permanent pacemaker and oral theophylline in sick sinus syndrome the
THEOPACE study: a randomized controlled trial. Circulation 1997;96:260266.
15. Sutton R, Kenny RA. The natural history of sick sinus syndrome. Pacing Clin
Electrophysiol 1986;9:11101114.
16. Hofer S, Anelli-Monti M, Berger T, Hintringer F, Oldridge N, Benzer W.
Psychometric properties of an established heart disease specific health-related quality of life questionnaire for pacemaker patients. Qual Life Res 2005;14:19371942.
17. Fleischmann KE, Orav EJ, Lamas GA, Mangione CM, Schron E, Lee KL, Goldman
L. Pacemaker implantation and quality of life in the Mode Selection Trial
(MOST). Heart Rhythm 2006;3:653659.
18. Lopez-Jimenez F, Goldman L, Orav EJ, Ellenbogen K, Stambler B, Marinchak R,
Wilkoff BL, Mangione CM, Yoon C, Vitale K, Lamas GA. Health values before and after pacemaker implantation. Am Heart J 2002;144:687692.
19. Newman D, Lau C, Tang AS, Irvine J, Paquette M, Woodend K, Dorian P, Gent
M, Kerr C, Connolly SJ, CTOPP Investigators. Effect of pacing mode on healthrelated quality of life in the Canadian Trial of Physiologic Pacing. Am Heart J
2003;145:430437.
20. Lamas GA, Orav EJ, Stambler BS, Ellenbogen KA, Sgarbossa EB, Huang SK,
Marinchak RA, Estes NA 3rd, Mitchell GF, Lieberman EH, Mangione CM,
Goldman L. Quality of life and clinical outcomes in elderly patients treated with ventricular pacing as compared with dual-chamber pacing. Pacemaker Selection in the Elderly Investigators. N Engl J Med 1998;338:10971104.
21. Lamas GA, Lee KL, Sweeney MO, Silverman R, Leon A, Yee R, Marinchak RA,
Flaker G, Schron E, Orav EJ, Hellkamp AS, Greer S, McAnulty J, Ellenbogen K,
Ehlert F, Freedman RA, Estes NA 3rd, Greenspon A, Goldman L, Mode
Selection Trial in Sinus-Node Dysfunction. Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med 2002;346:18541862.
22. Tjong FVY, Beurskens NEG, de Groot JR, Waweru C, Liu S, Ritter P, Reynolds D,
Wilde AAM, Knops RE, MICRA Investigators. Health-related quality of life impact of a transcatheter pacing system. J Cardiovasc Electrophysiol 2018;29:16971704.
23. Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA, Chugh SS, Corradi
D, D’Avila A, Dobrev D, Fenelon G, Gonzalez M, Hatem SN, Helm R, Hindricks G,
Ho SY, Hoit B, Jalife J, Kim YH, Lip GY, Ma CS, Marcus GM, Murray K, Nogami A,
Sanders P, Uribe W, Van Wagoner DR, Nattel S, Document Reviewers. EHRA/
HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition,
characterization, and clinical implication. Europace 2016;18:14551490.
24. Kottkamp H. Fibrotic atrial cardiomyopathy: a specific disease/syndrome supplying substrates for atrial fibrillation, atrial tachycardia, sinus node disease, AV
node disease, and thromboembolic complications. J Cardiovasc Electrophysiol
2012;23:797799.
25. Sodeck GH, Domanovits H, Meron G, Rauscha F, Losert H, Thalmann M, Vlcek
M, Laggner AN. Compromising bradycardia: management in the emergency department. Resuscitation 2007;73:96102.
26. El-Sherif N, Jalife J. Paroxysmal atrioventricular block: are phase 3 and phase 4
block mechanisms or misnomers? Heart Rhythm 2009;6:15141521.
27. Lee S, Wellens HJ, Josephson ME. Paroxysmal atrioventricular block. Heart
Rhythm 2009;6:12291234.
28. Narula OS, Samet P, Javier RP. Significance of the sinus-node recovery time.
Circulation 1972;45:140158.
29. Alboni P, Menozzi C, Brignole M, Paparella N, Lolli G, Oddone D, Dinelli M. An abnormal neural reflex plays a role in causing syncope in sinus bradycardia. J Am
Coll Cardiol 1993;22:11301134.
ESC Guidelines
71


<!-- PAGE 72 -->

### Page 72

.............................................................................................................................................................................
30. Brignole M, Menozzi C, Gianfranchi L, Oddone D, Lolli G, Bertulla A. Neurally mediated syncope detected by carotid sinus massage and head-up tilt test in sick sinus syndrome. Am J Cardiol 1991;68:10321036.
31. Brignole M, Deharo JC, De Roy L, Menozzi C, Blommaert D, Dabiri L, Ruf J,
Guieu R. Syncope due to idiopathic paroxysmal atrioventricular block: long-term follow-up of a distinct form of atrioventricular block. J Am Coll Cardiol
2011;58:167173.
32. Deharo JC, Brignole M, Guieu R. Adenosine hypersensitivity and atrioventricular block. Herzschrittmacherther Elektrophysiol 2018;29:166170.
33. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt
OA, Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW,
Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE, ESC Committee for Practice Guidelines. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J
2013;34:22812329.
34. Burri H, Starck C, Auricchio A, Biffi M, Burri M, D’Avila ALR, Deharo JC, Glikson
M, Israel C, Lau CAR, Leclercq C, Love C, Nielsen JC, Vernooy K, Reviewers,
Dagres NRC, Boveda SRC, Butter C, Marijon E, Braunschweig F, Mairesse GH,
Gleva M, Defaye P, Zanon F, Lopez-Cabanillas N, Guerra JM, Vassilikos VP,
Martins Oliveira M. EHRA expert consensus statement and practical guide on optimal implantation technique for conventional pacemakers and implantable cardioverter-defibrillators: endorsed by the Heart Rhythm Society (HRS), the
Asia Pacific Heart Rhythm Society (APHRS), and the Latin-American Heart
Rhythm Society (LAHRS). Europace 2021;doi: 10.1093/europace/euaa367.
35. Belott P, Reynolds D. Permanent pacemaker and implantable cardioverterdefibrillator implantation in adults. In: Ellenbogen KA, Wilcoff BL, Kay NG, Lau
CP, Auricchio A, eds. Clinical Cardiac Pacing, Defibrillation and Resynchronization
Therapy. 5th ed. Elsevier; 2017. p631691.
36. Auricchio A, Stellbrink C, Block M, Sack S, Vogt J, Bakker P, Klein H, Kramer A,
Ding J, Salo R, Tockman B, Pochet T, Spinelli J. Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. The Pacing Therapies for Congestive Heart Failure Study Group.
The
Guidant
Congestive
Heart
Failure
Research
Group.
Circulation
1999;99:29933001.
37. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser
SH, Nichol G, Birnie DH, Sapp JL, Yee R, Healey JS, Rouleau JL. Cardiac-resynchronization therapy for mild-to-moderate heart failure.
N
Engl
J
Med
2010;363:23852395.
38. Saxon LA, Bristow MR, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P,
DiCarlo L, Feldman AM, Galle E, Ecklund F. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and
Defibrillation in
Heart
Failure
(COMPANION)
Trial.
Circulation
2006;114:27662772.
39. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L,
Tavazzi L. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:15391549.
40. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA 3rd,
Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba
W, MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:13291338.
41. Verma N, Knight BP. Update in cardiac pacing. Arrhythm Electrophysiol Rev
2019;8:228233.
42. Abdelrahman M, Subzposh FA, Beer D, Durr B, Naperkowski A, Sun H, Oren
JW, Dandamudi G, Vijayaraman P. Clinical outcomes of His bundle pacing compared to right ventricular pacing. J Am Coll Cardiol 2018;71:23192330.
43. Bhatt AG, Musat DL, Milstein N, Pimienta J, Flynn L, Sichrovsky T, Preminger
MW, Mittal S. The efficacy of his bundle pacing: lessons learned from implementation for the first time at an experienced electrophysiology center. JACC Clin
Electrophysiol 2018;4:13971406.
44. Ali N, Keene D, Arnold A, Shun-Shin M, Whinnett ZI, Afzal Sohaib SM. His bundle pacing: a new frontier in the treatment of heart failure. Arrhythm Electrophysiol
Rev 2018;7:103110.
45. Reynolds D, Duray GZ, Omar R, Soejima K, Neuzil P, Zhang S, Narasimhan C,
Steinwender C, Brugada J, Lloyd M, Roberts PR, Sagi V, Hummel J, Bongiorni
MG, Knops RE, Ellis CR, Gornick CC, Bernabei MA, Laager V, Stromberg K,
Williams ER, Hudnall JH, Ritter P, Micra Transcatheter Pacing Study Group. A
leadless intracardiac transcatheter pacing system.
N
Engl
J
Med
2016;374:533541.
46. Reddy VY, Exner DV, Cantillon DJ, Doshi R, Bunch TJ, Tomassoni GF, Friedman
PA, Estes NA 3rd, Ip J, Niazi I, Plunkitt K, Banker R, Porterfield J, Ip JE, Dukkipati
SR, Leadless II Study Investigators. Percutaneous implantation of an entirely intracardiac leadless pacemaker. N Engl J Med 2015;373:11251135.
47. Knops RE, Tjong FV, Neuzil P, Sperzel J, Miller MA, Petru J, Simon J, Sediva L, de
Groot JR, Dukkipati SR, Koruth JS, Wilde AA, Kautzner J, Reddy VY. Chronic performance of a leadless cardiac pacemaker: 1-year follow-up of the LEADLESS
trial. J Am Coll Cardiol 2015;65:14971504.
48. Sperzel J, Defaye P, Delnoy PP, Garcia Guerrero JJ, Knops RE, Tondo C, Deharo
JC, Wong T, Neuzil P. Primary safety results from the LEADLESS Observational
Study. Europace 2018;20:14911497.
49. Roberts PR, Clementy N, Al Samadi F, Garweg C, Martinez-Sande JL, Iacopino S,
Johansen JB, Vinolas Prat X, Kowal RC, Klug D, Mont L, Steffel J, Li S, Van Osch
D, El-Chami MF. A leadless pacemaker in the real-world setting: The Micra
Transcatheter
Pacing
System
Post-Approval
Registry.
Heart
Rhythm
2017;14:13751379.
50. El-Chami MF, Al-Samadi F, Clementy N, Garweg C, Martinez-Sande JL, Piccini JP,
Iacopino S, Lloyd M, Vinolas Prat X, Jacobsen MD, Ritter P, Johansen JB, Tondo C,
Liu F, Fagan DH, Eakley AK, Roberts PR. Updated performance of the Micra transcatheter pacemaker in the real-world setting: a comparison to the investigational study and a transvenous historical control. Heart Rhythm 2018;15:18001807.
51. Ovsyshcher I, Guetta V, Bondy C, Porath A. First derivative of right ventricular pressure, dP/dt, as a sensor for a rate adaptive VVI pacemaker: initial experience.
Pacing Clin Electrophysiol 1992;15:211218.
52. Lau CP, Butrous GS, Ward DE, Camm AJ. Comparison of exercise performance of six rate-adaptive right ventricular cardiac pacemakers. Am J Cardiol 1989;63:833838.
53. Lau CP, Antoniou A, Ward DE, Camm AJ. Initial clinical experience with a minute ventilation sensing rate modulated pacemaker: improvements in exercise capacity and symptomatology. Pacing Clin Electrophysiol 1988;11:18151822.
54. Benditt DG, Mianulli M, Fetter J, Benson DW Jr, Dunnigan A, Molina E, Gornick
CC, Almquist A. Single-chamber cardiac pacing with activity-initiated chronotropic response: evaluation by cardiopulmonary exercise testing. Circulation
1987;75:184191.
55. Landzberg JS, Franklin JO, Mahawar SK, Himelman RB, Botvinick EH, Schiller NB,
Springer MJ, Griffin JC. Benefits of physiologic atrioventricular synchronization for pacing with an exercise rate response. Am J Cardiol 1990;66:193197.
56. Iwase M, Hatano K, Saito F, Kato K, Maeda M, Miyaguchi K, Aoki T, Yokota M,
Hayashi H, Saito H, Murase M. Evaluation by exercise Doppler echocardiography of maintenance of cardiac output during ventricular pacing with or without chronotropic response. Am J Cardiol 1989;63:934938.
57. Buckingham TA, Woodruff RC, Pennington DG, Redd RM, Janosik DL, Labovitz
AJ, Graves R, Kennedy HL. Effect of ventricular function on the exercise hemodynamics of variable rate pacing. J Am Coll Cardiol 1988;11:12691277.
58. Padeletti L, Pieragnoli P, Di Biase L, Colella A, Landolina M, Moro E, Orazi S,
Vicentini A, Maglia G, Pensabene O, Raciti G, Barold SS. Is a dual-sensor pacemaker appropriate in patients with sino-atrial disease? Results from the
DUSISLOG study. Pacing Clin Electrophysiol 2006;29:3440.
59. Nowak B, Misselwitz B, Expert committee ‘Pacemaker Institute of Quality
Assurance Hessen’, Erdogan A, Funck R, Irnich W, Israel CW, Olbrich HG,
Schmidt H, Sperzel J, Zegelman M. Do gender differences exist in pacemaker implantation?—results of an obligatory external quality control program.
Europace 2010;12:210215.
60. Mohamed MO, Volgman AS, Contractor T, Sharma PS, Kwok CS, Rashid M,
Martin GP, Barker D, Patwala A, Mamas MA. Trends of sex differences in outcomes of cardiac electronic device implantations in the United States. Can J
Cardiol 2020;36:6978.
61. Moore K, Ganesan A, Labrosciano C, Heddle W, McGavigan A, Hossain S,
Horton D, Hariharaputhiran S, Ranasinghe I. Sex differences in acute complications of cardiac implantable electronic devices: implications for patient safety. J
Am Heart Assoc 2019;8:e010869.
62. Brignole M, Moya A, de Lange FJ, Deharo JC, Elliott PM, Fanciulli A, Fedorowski
A, Furlan R, Kenny RA, Martin A, Probst V, Reed MJ, Rice CP, Sutton R, Ungar
A, van Dijk JG. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J 2018;39:18831948.
63. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J,
Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH,
Hernandez-Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van Veldhuisen
DJ. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the
Management of Patients with Ventricular Arrhythmias and the Prevention of
Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur
Heart J 2015;36:27932867.
64. Kaess BM, Andersson C, Duncan MS, Larson MG, Aasbjerg K, Gislason GH,
Torp-Pedersen C, Vasan RS. Familial clustering of cardiac conduction defects and pacemaker insertion. Circ Arrhythm Electrophysiol 2019;12:e007150.
65. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, Camm AJ,
Ellinor PT, Gollob M, Hamilton R, Hershberger RE, Judge DP, Le Marec H,
McKenna WJ, Schulze-Bahr E, Semsarian C, Towbin JA, Watkins H, Wilde A,
Wolpert C, Zipes DP. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Heart Rhythm
2011;8:13081339.


<!-- PAGE 73 -->

### Page 73

.............................................................................................................................................................................
66. Kerr SR, Pearce MS, Brayne C, Davis RJ, Kenny RA. Carotid sinus hypersensitivity in asymptomatic older persons: implications for diagnosis of syncope and falls.
Arch Intern Med 2006;166:515520.
67. Puggioni E, Guiducci V, Brignole M, Menozzi C, Oddone D, Donateo P, Croci F,
Solano A, Lolli G, Tomasi C, Bottoni N. Results and complications of the carotid sinus massage performed according to the ‘method of symptoms’. Am J Cardiol
2002;89:599601.
68. Brignole M, Ungar A, Casagranda I, Gulizia M, Lunati M, Ammirati F, Del Rosso A,
Sasdelli M, Santini M, Maggi R, Vitale E, Morrione A, Francese GM, Vecchi MR, Giada
F. Prospective multicentre systematic guideline-based management of patients referred to the Syncope Units of general hospitals. Europace 2010;12:109118.
69. Solari D, Maggi R, Oddone D, Solano A, Croci F, Donateo P, Brignole M. Clinical context and outcome of carotid sinus syndrome diagnosed by means of the
‘method of symptoms’. Europace 2014;16:928934.
70. Solari D, Maggi R, Oddone D, Solano A, Croci F, Donateo P, Wieling W,
Brignole M. Assessment of the vasodepressor reflex in carotid sinus syndrome.
Circ Arrhythm Electrophysiol 2014;7:505510.
71. Mangrum JM, DiMarco JP. The evaluation and management of bradycardia. N
Engl J Med 2000;342:703709.
72. Sutton R. Reflex atrioventricular block. Front Cardiovasc Med 2020;7:48.
72a.Da Costa D, Brady WJ, Edhouse J. Bradycardias and atrioventricular conduction block. BMJ 2002;324:535538.
73. Steinberg JS, Varma N, Cygankiewicz I, Aziz P, Balsam P, Baranchuk A, Cantillon
DJ, Dilaveris P, Dubner SJ, El-Sherif N, Krol J, Kurpesa M, La Rovere MT,
Lobodzinski SS, Locati ET, Mittal S, Olshansky B, Piotrowicz E, Saxon L, Stone
PH, Tereshchenko L, Turitto G, Wimmer NJ, Verrier RL, Zareba W, Piotrowicz
R. 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. Heart Rhythm 2017;14:e55-e96.
74. Brubaker PH, Kitzman DW. Chronotropic incompetence: causes, consequences,
and management. Circulation 2011;123:10101020.
75. Savonen KP, Kiviniemi V, Laukkanen JA, Lakka TA, Rauramaa TH, Salonen JT,
Rauramaa R. Chronotropic incompetence and mortality in middle-aged men with known or suspected coronary heart disease. Eur Heart J 2008;29:18961902.
76. Byrne JM, Marais HJ, Cheek GA. Exercise-induced complete heart block in a patient with chronic bifascicular block. J Electrocardiol 1994;27:339342.
77. Wissocq L, Ennezat PV, Mouquet F. Exercise-induced high-degree atrioventricular block. Arch Cardiovasc Dis 2009;102:733735.
78. Woelfel AK, Simpson RJ Jr, Gettes LS, Foster JR. Exercise-induced distal atrioventricular block. J Am Coll Cardiol 1983;2:578581.
79. Sumiyoshi M, Nakata Y, Yasuda M, Tokano T, Ogura S, Nakazato Y, Yamaguchi
H. Clinical and electrophysiologic features of exercise-induced atrioventricular block. Am Heart J 1996;132:12771281.
80. Oliveros RA, Seaworth J, Weiland FL, Boucher CA. Intermittent left anterior hemiblock during treadmill exercise test. Correlation with coronary arteriogram.
Chest 1977;72:492494.
81. Bharati S, Dhingra RC, Lev M, Towne WD, Rhimtoola SH, Rosen KM.
Conduction system in a patient with Prinzmetal’s angina and transient atrioventricular block. Am J Cardiol 1977;39:120125.
82. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott
E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J,
Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C,
Valgimigli M, Achenbach S, Bax JJ. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2019;41:407477.
83. Halliday BP, Gulati A, Ali A, Guha K, Newsome S, Arzanauskaite M, Vassiliou VS,
Lota A, Izgi C, Tayal U, Khalique Z, Stirrat C, Auger D, Pareek N, Ismail TF,
Rosen SD, Vazir A, Alpendurada F, Gregson J, Frenneaux MP, Cowie MR,
Cleland JGF, Cook SA, Pennell DJ, Prasad SK. Association between midwall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolic dysfunction.
Circulation 2017;135:21062115.
84. Kazmirczak F, Chen KA, Adabag S, von Wald L, Roukoz H, Benditt DG, Okasha
O, Farzaneh-Far A, Markowitz J, Nijjar PS, Velangi PS, Bhargava M, Perlman D,
Duval S, Akcakaya M, Shenoy C. Assessment of the 2017 AHA/ACC/HRS
Guideline
Recommendations for
Implantable
Cardioverter-Defibrillator
Implantation in Cardiac Sarcoidosis. Circ Arrhythm Electrophysiol 2019;12:e007488.
85. Aquaro GD, Perfetti M, Camastra G, Monti L, Dellegrottaglie S, Moro C, Pepe
A, Todiere G, Lanzillo C, Scatteia A, Di Roma M, Pontone G, Perazzolo Marra
M, Barison A, Di Bella G. Cardiac MR with late gadolinium enhancement in acute myocarditis with preserved systolic function: ITAMY Study. J Am Coll Cardiol
2017;70:19771987.
86. Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U,
Kindermann I, Gutberlet M, Cooper LT, Liu P, Friedrich MG. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol 2018;72:31583176.
87. Zhou Y, Lower EE, Li HP, Costea A, Attari M, Baughman RP. Cardiac sarcoidosis:
the impact of age and implanted devices on survival. Chest 2017;151:139148.
88. Kandolin R, Lehtonen J, Kupari M. Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged adults. Circ Arrhythm
Electrophysiol 2011;4:303309.
89. Turner JJO. Hypercalcaemia—presentation and management. Clin Med (Lond)
2017;17:270273.
90. Chon SB, Kwak YH, Hwang SS, Oh WS, Bae JH. Severe hyperkalemia can be detected immediately by quantitative electrocardiography and clinical history in patients with symptomatic or extreme bradycardia: a retrospective crosssectional study. J Crit Care 2013;28:1112.e71112.e13.
91. Mandell BF. Cardiovascular involvement in systemic lupus erythematosus. Semin
Arthritis Rheum 1987;17:126141.
92. Wan D, Blakely C, Branscombe P, Suarez-Fuster L, Glover B, Baranchuk A. Lyme carditis and high-degree atrioventricular block. Am J Cardiol 2018;121:11021104.
93. Nakayama Y, Ohno M, Yonemura S, Uozumi H, Kobayakawa N, Fukushima K,
Takeuchi H, Aoyagi T. A case of transient 2:1 atrioventricular block, resolved by thyroxine supplementation for subclinical hypothyroidism.
Pacing
Clin
Electrophysiol 2006;29:106108.
94. Noble K, Isles C. Hyperkalaemia causing profound bradycardia. Heart 2006;92:1063.
95. Ishikawa T, Tsuji Y, Makita N. Inherited bradyarrhythmia: a diverse genetic background. J Arrhythm 2016;32:352358.
96. Smits JP, Veldkamp MW, Wilde AA. Mechanisms of inherited cardiac conduction disease. Europace 2005;7:122137.
97. Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, Blom N, Brugada J,
Chiang CE, Huikuri H, Kannankeril P, Krahn A, Leenhardt A, Moss A, Schwartz
PJ, Shimizu W, Tomaselli G, Tracy C. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May
2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm
2013;10:19321963.
98. Brodsky M, Wu D, Denes P, Kanakis C, Rosen KM. Arrhythmias documented by
24 hour continuous electrocardiographic monitoring in 50 male medical students without apparent heart disease. Am J Cardiol 1977;39:390395.
99. Clarke JM, Hamer J, Shelton JR, Taylor S, Venning GR. The rhythm of the normal human heart. Lancet 1976;1:508512.
100. Fleg JL, Kennedy HL. Cardiac arrhythmias in a healthy elderly population: detection by 24-hour ambulatory electrocardiography. Chest 1982;81:302307.
101. Grimm W, Hoffmann J, Menz V, Kohler U, Heitmann J, Peter JH, Maisch B.
Electrophysiologic evaluation of sinus node function and atrioventricular conduction in patients with prolonged ventricular asystole during obstructive sleep apnea. Am J Cardiol 1996;77:13101314.
102. Zwillich C, Devlin T, White D, Douglas N, Weil J, Martin R. Bradycardia during sleep apnea.
Characteristics and mechanism.
J
Clin
Invest
1982;69:12861292.
103. Guilleminault C, Pool P, Motta J, Gillis AM. Sinus arrest during REM sleep in young adults. N Engl J Med 1984;311:10061010.
104. Grimm W, Koehler U, Fus E, Hoffmann J, Menz V, Funck R, Peter JH, Maisch B.
Outcome of patients with sleep apnea-associated severe bradyarrhythmias after continuous positive airway pressure therapy.
Am
J
Cardiol
2000;86:688692.
105. Koehler U, Fus E, Grimm W, Pankow W, Schafer H, Stammnitz A, Peter JH.
Heart block in patients with obstructive sleep apnoea: pathogenetic factors and effects of treatment. Eur Respir J 1998;11:434439.
106. Simantirakis EN, Schiza SI, Marketou ME, Chrysostomakis SI, Chlouverakis GI,
Klapsinos NC, Siafakas NS, Vardas PE. Severe bradyarrhythmias in patients with sleep apnoea: the effect of continuous positive airway pressure treatment: a long-term evaluation using an insertable loop recorder.
Eur
Heart
J
2004;25:10701076.
107. Sutton R, Fedorowski A, Olshansky B, Gert van Dijk J, Abe H, Brignole M, de
Lange F, Kenny RA, Lim PB, Moya A, Rosen SD, Russo V, Stewart JM, Thijs RD,
Benditt
DG.
Tilt testing remains a
valuable asset.
Eur
Heart
J
2021;42:16541660.
108. Da Costa A, Defaye P, Romeyer-Bouchard C, Roche F, Dauphinot V, Deharo
JC, Jacon P, Lamaison D, Bathelemy JC, Isaaz K, Laurent G. Clinical impact of the implantable loop recorder in patients with isolated syncope, bundle branch block and negative workup: a randomized multicentre prospective study. Arch
Cardiovasc Dis 2013;106:146154.
109. Farwell DJ, Freemantle N, Sulke N. The clinical impact of implantable loop recorders in patients with syncope. Eur Heart J 2006;27:351356.
110. Krahn AD, Klein GJ, Yee R, Skanes AC. Randomized assessment of syncope trial: conventional diagnostic testing versus a prolonged monitoring strategy.
Circulation 2001;104:4651.
111. Podoleanu C, DaCosta A, Defaye P, Taieb J, Galley D, Bru P, Maury P, Mabo P,
Boveda S, Cellarier G, Anselme F, Kouakam C, Delarche N, Deharo JC. Early use of an implantable loop recorder in syncope evaluation: a randomized study in the context of the French healthcare system (FRESH study). Arch Cardiovasc
Dis 2014;107:546552.
ESC Guidelines
73


<!-- PAGE 74 -->

### Page 74

.............................................................................................................................................................................
112. Sulke N, Sugihara C, Hong P, Patel N, Freemantle N. The benefit of a remotely monitored implantable loop recorder as a first line investigation in unexplained syncope: the EaSyAS II trial. Europace 2016;18:912918.
113. Gann D, Tolentino A, Samet P. Electrophysiologic evaluation of elderly patients with sinus bradycardia:
a long-term follow-up study.
Ann
Intern
Med
1979;90:2429.
114. Menozzi C, Brignole M, Alboni P, Boni L, Paparella N, Gaggioli G, Lolli G. The natural course of untreated sick sinus syndrome and identification of the variables predictive of unfavorable outcome. Am J Cardiol 1998;82:12051209.
115. McAnulty JH, Rahimtoola SH, Murphy E, DeMots H, Ritzmann L, Kanarek PE,
Kauffman S. Natural history of ‘high-risk’ bundle-branch block: final report of a prospective study. N Engl J Med 1982;307:137143.
116. Gronda M, Magnani A, Occhetta E, Sauro G, D’Aulerio M, Carfora A, Rossi P.
Electrophysiological study of atrio-ventricular block and ventricular conduction defects.
Prognostic and therapeutical implications.
G
Ital
Cardiol
1984;14:768773.
117. Bergfeldt L, Edvardsson N, Rosenqvist M, Vallin H, Edhag O. Atrioventricular block progression in patients with bifascicular block assessed by repeated electrocardiography and a
bradycardia-detecting pacemaker.
Am
J
Cardiol
1994;74:11291132.
118. Kaul U, Dev V, Narula J, Malhotra AK, Talwar KK, Bhatia ML. Evaluation of patients with bundle branch block and ‘unexplained’ syncope: a study based on comprehensive electrophysiologic testing and ajmaline stress. Pacing Clin
Electrophysiol 1988;11:289297.
119. Moya A, Garcia-Civera R, Croci F, Menozzi C, Brugada J, Ammirati F, Del
Rosso A, Bellver-Navarro A, Garcia-Sacristan J, Bortnik M, Mont L, Ruiz-Granell
R, Navarro X. Diagnosis, management, and outcomes of patients with syncope and bundle branch block. Eur Heart J 2011;32:15351541.
120. Twidale N, Heddle WF, Tonkin AM. Procainamide administration during electrophysiology study—utility as a provocative test for intermittent atrioventricular block. Pacing Clin Electrophysiol 1988;11:13881397.
121. Scheinman MM, Peters RW, Suave MJ, Desai J, Abbott JA, Cogan J, Wohl B,
Williams K. Value of the HQ interval in patients with bundle branch block and the role of prophylactic permanent pacing.
Am
J
Cardiol
1982;50:13161322.
122. Roca-Luque I, Oristrell G, Francisco-Pasqual J, Rodriguez-Garcia J, SantosOrtega A, Martin-Sanchez G, Rivas-Gandara N, Perez-Rodon J, FerreiraGonzalez
I,
Garcia-Dorado
D,
Moya-Mitjans
A.
Predictors of positive electrophysiological study in patients with syncope and bundle branch block:
PR interval and type of conduction disturbance. Clin Cardiol 2018;41:1537
1542.
123. Brignole M, Menozzi C, Moya A, Garcia-Civera R, Mont L, Alvarez M, Errazquin
F, Beiras J, Bottoni N, Donateo P. Mechanism of syncope in patients with bundle branch block and negative electrophysiological test.
Circulation
2001;104:20452050.
124. Rubenstein JJ, Schulman CL, Yurchak PM, DeSanctis RW. Clinical spectrum of the sick sinus syndrome. Circulation 1972;46:513.
125. Short DS. The syndrome of alternating bradycardia and tachycardia. Br Heart J
1954;16:208214.
126. Goldberger JJ, Johnson NP, Gidea C. Significance of asymptomatic bradycardia for subsequent pacemaker implantation and mortality in patients >60 years of age. Am J Cardiol 2011;108:857861.
127. Nielsen JC, Thomsen PE, Hojberg S, Moller M, Vesterlund T, Dalsgaard D,
Mortensen LS, Nielsen T, Asklund M, Friis EV, Christensen PD, Simonsen EH,
Eriksen UH, Jensen GV, Svendsen JH, Toff WD, Healey JS, Andersen HR,
DANPACE Investigators. A comparison of single-lead atrial pacing with dualchamber pacing in sick sinus syndrome. Eur Heart J 2011;32:686696.
128. Breivik K, Ohm OJ, Segadal L. Sick sinus syndrome treated with permanent pacemaker in
109
patients.
A
follow-up study.
Acta
Med
Scand
1979;206:153159.
129. Hartel G, Talvensaari T. Treatment of sinoatrial syndrome with permanent cardiac pacing in 90 patients. Acta Med Scand 1975;198:341347.
130. Rasmussen K. Chronic sinus node disease: natural course and indications for pacing. Eur Heart J 1981;2:455459.
131. Sasaki Y, Shimotori M, Akahane K, Yonekura H, Hirano K, Endoh R, Koike S,
Kawa S, Furuta S, Homma T. Long-term follow-up of patients with sick sinus syndrome: a comparison of clinical aspects among unpaced, ventricular inhibited paced,
and physiologically paced groups.
Pacing
Clin
Electrophysiol
1988;11:15751583.
132. Senturk T, Xu H, Puppala K, Krishnan B, Sakaguchi S, Chen LY, Karim R,
Dickinson O, Benditt DG. Cardiac pauses in competitive athletes: a systematic review examining the basis of current practice recommendations. Europace
2016;18:18731879.
133. Brignole M, Menozzi C, Moya A, Andresen D, Blanc JJ, Krahn AD, Wieling W,
Beiras X, Deharo JC, Russo V, Tomaino M, Sutton R, International Study on
Syncope of Uncertain Etiology Investigators. Pacemaker therapy in patients with neurally mediated syncope and documented asystole: Third International Study on Syncope of Uncertain Etiology (ISSUE-3): a randomized trial. Circulation
2012;125:25662571.
134. Brignole M, Sutton R, Menozzi C, Garcia-Civera R, Moya A, Wieling W,
Andresen D, Benditt DG, Vardas P, International Study on Syncope of
Uncertain Etiology Group. Early application of an implantable loop recorder allows effective specific therapy in patients with recurrent suspected neurally mediated syncope. Eur Heart J 2006;27:10851092.
135. Asseman P, Berzin B, Desry D, Vilarem D, Durand P, Delmotte C, Sarkis EH,
Lekieffre J, Thery C. Persistent sinus nodal electrograms during abnormally prolonged postpacing atrial pauses in sick sinus syndrome in humans: sinoatrial block vs overdrive suppression. Circulation 1983;68:3341.
136. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, Akar JG,
Badhwar V, Brugada J, Camm J, Chen PS, Chen SA, Chung MK, Cosedis Nielsen
J, Curtis AB, Davies DW, Day JD, d’Avila A, Natasja de Groot NMS, Di Biase L,
Duytschaever M, Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst S, Fenelon G,
Gerstenfeld EP, Haines DE, Haissaguerre M, Helm RH, Hylek E, Jackman WM,
Jalife J, Kalman JM, Kautzner J, Kottkamp H, Kuck KH, Kumagai K, Lee R,
Lewalter T, Lindsay BD, Macle L, Mansour M, Marchlinski FE, Michaud GF,
Nakagawa H, Natale A, Nattel S, Okumura K, Packer D, Pokushalov E,
Reynolds MR, Sanders P, Scanavacca M, Schilling R, Tondo C, Tsao HM, Verma
A, Wilber DJ, Yamane T, Document Reviewers. 2017 HRS/EHRA/ECAS/
APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace 2018;20:e1e160.
137. Chen YW, Bai R, Lin T, Salim M, Sang CH, Long DY, Yu RH, Tang RB, Guo XY,
Yan XL, Nie JG, Du X, Dong JZ, Ma CS. Pacing or ablation: which is better for paroxysmal atrial fibrillation-related tachycardiabradycardia syndrome? Pacing
Clin Electrophysiol 2014;37:403411.
138. Inada K, Yamane T, Tokutake K, Yokoyama K, Mishima T, Hioki M, Narui R, Ito
K, Tanigawa S, Yamashita S, Tokuda M, Matsuo S, Shibayama K, Miyanaga S,
Date T, Sugimoto K, Yoshimura M. The role of successful catheter ablation in patients with paroxysmal atrial fibrillation and prolonged sinus pauses: outcome during a 5-year follow-up. Europace 2014;16:208213.
139. Jackson LR, 2nd, Rathakrishnan B, Campbell K, Thomas KL, Piccini JP, Bahnson
T, Stiber JA, Daubert JP. Sinus node dysfunction and atrial fibrillation: a reversible phenomenon? Pacing Clin Electrophysiol 2017;40:442450.
140. Connolly SJ, Kerr CR, Gent M, Roberts RS, Yusuf S, Gillis AM, Sami MH, Talajic
M, Tang AS, Klein GJ, Lau C, Newman DM. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes.
Canadian
Trial of
Physiologic
Pacing
Investigators.
N
Engl
J
Med
2000;342:13851391.
141. Healey JS, Toff WD, Lamas GA, Andersen HR, Thorpe KE, Ellenbogen KA, Lee
KL, Skene AM, Schron EB, Skehan JD, Goldman L, Roberts RS, Camm AJ, Yusuf
S, Connolly SJ. Cardiovascular outcomes with atrial-based pacing compared with ventricular pacing: meta-analysis of randomized trials, using individual patient data. Circulation 2006;114:1117.
142. Ross RA, Kenny RA. Pacemaker syndrome in older people. Age Ageing
2000;29:1315.
143. Mitsuoka T, Kenny RA, Yeung TA, Chan SL, Perrins JE, Sutton R. Benefits of dual chamber pacing in sick sinus syndrome. Br Heart J 1988;60:338347.
144. Sweeney MO, Bank AJ, Nsah E, Koullick M, Zeng QC, Hettrick D, Sheldon T,
Lamas GA, Search AV Extension and Managed Ventricular Pacing for Promoting
Atrioventricular Conduction Trial. Minimizing ventricular pacing to reduce atrial fibrillation in sinus-node disease. N Engl J Med 2007;357:10001008.
145. Andersen HR, Nielsen JC, Thomsen PE, Thuesen L, Mortensen PT, Vesterlund
T, Pedersen AK. Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome.
Lancet
1997;350:12101216.
146. Andersen HR, Thuesen L, Bagger JP, Vesterlund T, Thomsen PE. Prospective randomised trial of atrial versus ventricular pacing in sick-sinus syndrome.
Lancet 1994;344:15231528.
147. Kristensen L, Nielsen JC, Mortensen PT, Pedersen OL, Pedersen AK, Andersen
HR. Incidence of atrial fibrillation and thromboembolism in a randomised trial of atrial versus dual chamber pacing in 177 patients with sick sinus syndrome.
Heart 2004;90:661666.
148. Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, Kutalek SP,
Sharma A, Dual Chamber VVI Implantable Defibrillator Trial Investigators.
Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID)
Trial. JAMA 2002;288:31153123.
149. Cheng S, Keyes MJ, Larson MG, McCabe EL, Newton-Cheh C, Levy D,
Benjamin EJ, Vasan RS, Wang TJ. Long-term outcomes in individuals with prolonged
PR
interval or first-degree atrioventricular block.
JAMA
2009;301:25712577.
150. Nielsen JC, Thomsen PE, Hojberg S, Moller M, Riahi S, Dalsgaard D, Mortensen
LS, Nielsen T, Asklund M, Friis EV, Christensen PD, Simonsen EH, Eriksen UH,


<!-- PAGE 75 -->

### Page 75

.............................................................................................................................................................................
Jensen GV, Svendsen JH, Toff WD, Healey JS, Andersen HR, DANPACE
Investigators. Atrial fibrillation in patients with sick sinus syndrome: the association with
PQ-interval and percentage of ventricular pacing.
Europace
2012;14:682689.
151. Auricchio A, Ellenbogen KA. Reducing ventricular pacing frequency in patients with atrioventricular block: is it time to change the current pacing paradigm?
Circ Arrhythm Electrophysiol 2016;9:e004404.
152. Shurrab M, Healey JS, Haj-Yahia S, Kaoutskaia A, Boriani G, Carrizo A, Botto G,
Newman D, Padeletti L, Connolly SJ, Crystal E. Reduction in unnecessary ventricular pacing fails to affect hard clinical outcomes in patients with preserved left ventricular function: a meta-analysis. Europace 2017;19:282288.
153. Jankelson L, Bordachar P, Strik M, Ploux S, Chinitz L. Reducing right ventricular pacing burden: algorithms, benefits, and risks. Europace 2019;21:539547.
154. Pascale P, Pruvot E, Graf D. Pacemaker syndrome during managed ventricular pacing mode:
what is the mechanism?
J
Cardiovasc
Electrophysiol
2009;20:574576.
155. Mansour F, Khairy P. Electrical storm due to managed ventricular pacing. Heart
Rhythm 2012;9:842843.
156. Sekita G, Hayashi H, Nakazato Y, Daida H. Ventricular fibrillation induced by shortlongshort sequence during managed ventricular pacing. J Cardiovasc
Electrophysiol 2011;22:1181.
157. Vavasis C, Slotwiner DJ, Goldner BG, Cheung JW. Frequent recurrent polymorphic ventricular tachycardia during sleep due to managed ventricular pacing.
Pacing Clin Electrophysiol 2010;33:641644.
158. van Mechelen R, Schoonderwoerd R. Risk of managed ventricular pacing in a patient with heart block. Heart Rhythm 2006;3:13841385.
159. Stockburger M, Boveda S, Moreno J, Da Costa A, Hatala R, Brachmann J, Butter
C, Garcia Seara J, Rolando M, Defaye P. Long-term clinical effects of ventricular pacing reduction with a changeover mode to minimize ventricular pacing in a general pacemaker population. Eur Heart J 2015;36:151157.
160. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau
CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES,
Hohnloser SH, ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012;366:120129.
161. Munawar DA, Mahajan R, Agbaedeng TA, Thiyagarajah A, Twomey DJ, Khokhar
K, O’Shea C, Young GD, Roberts-Thomson KC, Munawar M, Lau DH, Sanders
P. Implication of ventricular pacing burden and atrial pacing therapies on the progression of atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Heart Rhythm 2019;16:12041214.
162. Padeletti L, Purerfellner H, Mont L, Tukkie R, Manolis AS, Ricci R, Inama G,
Serra P, Scheffer MG, Martins V, Warman EN, Vimercati M, Grammatico A,
Boriani G, MINERVA Investigators. New-generation atrial antitachycardia pacing
(Reactive ATP) is associated with reduced risk of persistent or permanent atrial fibrillation in patients with bradycardia: results from the MINERVA randomized multicenter international trial. Heart Rhythm 2015;12:17171725.
163. Pujol-Lopez M, San Antonio R, Tolosana JM, Mont L. Programming pacemakers to reduce and terminate atrial fibrillation. Curr Cardiol Rep 2019;21:127.
164. Boriani G, Tukkie R, Manolis AS, Mont L, Purerfellner H, Santini M, Inama G,
Serra P, de Sousa J, Botto GL, Mangoni L, Grammatico A, Padeletti L,
MINERVA Investigators. Atrial antitachycardia pacing and managed ventricular pacing in bradycardia patients with paroxysmal or persistent atrial tachyarrhythmias: the MINERVA randomized multicentre international trial. Eur Heart J
2014;35:23522362.
165. Crossley GH, Padeletti L, Zweibel S, Hudnall JH, Zhang Y, Boriani G. Reactive atrial-based antitachycardia pacing therapy reduces atrial tachyarrhythmias.
Pacing Clin Electrophysiol 2019;42:970979.
166. Stockburger M, Gomez-Doblas JJ, Lamas G, Alzueta J, Fernandez-Lozano I,
Cobo E, Wiegand U, Concha JF, Navarro X, Navarro-Lopez F, de Teresa E.
Preventing ventricular dysfunction in pacemaker patients without advanced heart failure:
results from a multicentre international randomized trial
(PREVENT-HF). Eur J Heart Fail 2011;13:633641.
167. Stockburger M, Defaye P, Boveda S, Stancak B, Lazarus A, Sipotz J, Nardi S,
Rolando M, Moreno J. Safety and efficiency of ventricular pacing prevention with an AAI-DDD changeover mode in patients with sinus node disease or atrioventricular block: impact on battery longevity—a sub-study of the
ANSWER trial. Europace 2016;18:739746.
168. Thibault B, Simpson C, Gagne CE, Blier L, Senaratne M, McNicoll S, Stuglin C,
Williams R, Pinter A, Khaykin Y, Nitzsche R. Impact of AV conduction disorders on
SafeR
mode performance.
Pacing
Clin
Electrophysiol
2009;32
Suppl
1:S231235.
169. Thibault B, Ducharme A, Baranchuk A, Dubuc M, Dyrda K, Guerra PG, Macle
L, Mondesert B, Rivard L, Roy D, Talajic M, Andrade J, Nitzsche R, Khairy P,
CAN-SAVE R Study Investigators. Very low ventricular pacing rates can be achieved safely in a heterogeneous pacemaker population and provide clinical benefits:
the
CANadian
Multi-Centre
Randomised
Study-Spontaneous
AtrioVEntricular Conduction pReservation (CAN-SAVE R) Trial. J Am Heart
Assoc 2015;4:e001983
170. Bellocci F, Spampinato A, Ricci R, Puglisi A, Capucci A, Dini P, Boriani G, Botto
G, Curnis A, Moracchini PV, Nicotra G, Lisi F, Nigro P. Antiarrhythmic benefits of dual chamber stimulation with rate-response in patients with paroxysmal atrial fibrillation and chronotropic incompetence: a prospective, multicentre study. Europace 1999;1:220225.
171. Santini M, Ricci R, Puglisi A, Mangiameli S, Proclemer A, Menozzi C, De Fabrizio
G, Leoni G, Lisi F, De Seta F. Long-term haemodynamic and antiarrhythmic benefits of DDIR versus DDI pacing mode in sick sinus syndrome and chronotropic incompetence. G Ital Cardiol 1997;27:892900.
172. Capucci A, Boriani G, Specchia S, Marinelli M, Santarelli A, Magnani B.
Evaluation by cardiopulmonary exercise test of DDDR versus DDD pacing.
Pacing Clin Electrophysiol 1992;15:19081913.
173. Lamas GA, Knight JD, Sweeney MO, Mianulli M, Jorapur V, Khalighi K, Cook JR,
Silverman R, Rosenthal L, Clapp-Channing N, Lee KL, Mark DB. Impact of ratemodulated pacing on quality of life and exercise capacity—evidence from the
Advanced Elements of Pacing Randomized Controlled Trial (ADEPT). Heart
Rhythm 2007;4:11251132.
174. Hocini M, Sanders P, Deisenhofer I, Jais P, Hsu LF, Scavee C, Weerasoriya R,
Raybaud F, Macle L, Shah DC, Garrigue S, Le Metayer P, Clementy J,
Haissaguerre M. Reverse remodeling of sinus node function after catheter ablation of atrial fibrillation in patients with prolonged sinus pauses. Circulation
2003;108:11721175.
175. Mymin D, Mathewson FA, Tate RB, Manfreda J. The natural history of primary first-degree atrioventricular heart block. N Engl J Med 1986;315:11831187.
176. Barold SS, Ilercil A, Leonelli F, Herweg B. First-degree atrioventricular block.
Clinical manifestations, indications for pacing, pacemaker management & consequences during cardiac resynchronization.
J
Interv
Card
Electrophysiol
2006;17:139152.
177. Shaw DB, Gowers JI, Kekwick CA, New KH, Whistance AW. Is Mobitz type I
atrioventricular block benign in adults? Heart 2004;90:169174.
178. Coumbe AG, Naksuk N, Newell MC, Somasundaram PE, Benditt DG, Adabag
S. Long-term follow-up of older patients with Mobitz type I second degree atrioventricular block. Heart 2013;99:334338.
179. Strasberg B, Amat YLF, Dhingra RC, Palileo E, Swiryn S, Bauernfeind R,
Wyndham C, Rosen KM. Natural history of chronic second-degree atrioventricular nodal block. Circulation 1981;63:10431049.
180. Dhingra RC, Denes P, Wu D, Chuquimia R, Rosen KM. The significance of second degree atrioventricular block and bundle branch block. Observations regarding site and type of block. Circulation 1974;49:638646.
181. Toff WD, Camm AJ, Skehan JD, United Kingdom Pacing Cardiovascular Events
Trial Investigators. Single-chamber versus dual-chamber pacing for high-grade atrioventricular block. N Engl J Med 2005;353:145155.
182. Castelnuovo E, Stein K, Pitt M, Garside R, Payne E. The effectiveness and costeffectiveness of dual-chamber pacemakers compared with single-chamber pacemakers for bradycardia due to atrioventricular block or sick sinus syndrome:
systematic review and economic evaluation. Health Technol Assess 2005;9:iii,
xixiii, 1246.
183. Sweeney MO, Hellkamp AS, Ellenbogen KA, Greenspon AJ, Freedman RA, Lee
KL, Lamas GA. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction.
Circulation
2003;107:29322937.
184. Nahlawi M, Waligora M, Spies SM, Bonow RO, Kadish AH, Goldberger JJ. Left ventricular function during and after right ventricular pacing. J Am Coll Cardiol
2004;44:18831888.
185. Sweeney MO, Prinzen FW. A new paradigm for physiologic ventricular pacing. J
Am Coll Cardiol 2006;47:282288.
186. Tayal B, Fruelund P, Sogaard P, Riahi S, Polcwiartek C, Atwater BD, Gislason G,
Risum N, Torp-Pedersen C, Kober L, Kragholm KH. Incidence of heart failure after pacemaker implantation: a nationwide Danish Registry-based follow-up study. Eur Heart J 2019;40:36413648.
187. Khurshid S, Epstein AE, Verdino RJ, Lin D, Goldberg LR, Marchlinski FE, Frankel
DS. Incidence and predictors of right ventricular pacing-induced cardiomyopathy. Heart Rhythm 2014;11:16191625.
188. Kiehl EL, Makki T, Kumar R, Gumber D, Kwon DH, Rickard JW, Kanj M, Wazni
OM, Saliba WI, Varma N, Wilkoff BL, Cantillon DJ. Incidence and predictors of right ventricular pacing-induced cardiomyopathy in patients with complete atrioventricular block and preserved left ventricular systolic function. Heart
Rhythm 2016;13:22722278.
189. Khurshid S, Obeng-Gyimah E, Supple GE, Schaller R, Lin D, Owens AT, Epstein
AE, Dixit S, Marchlinski FE, Frankel DS. Reversal of pacing-induced cardiomyopathy following cardiac resynchronization therapy. JACC Clin Electrophysiol
2018;4:168177.
ESC Guidelines
75


<!-- PAGE 76 -->

### Page 76

.............................................................................................................................................................................
190. Curtis AB, Worley SJ, Adamson PB, Chung ES, Niazi I, Sherfesee L, Shinn T,
Sutton MS, Biventricular versus Right Ventricular Pacing in Heart Failure
Patients with Atrioventricular Block Trial Investigators. Biventricular pacing for atrioventricular block and systolic dysfunction.
N
Engl
J
Med
2013;368:15851593.
191. Pitcher D, Papouchado M, James MA, Rees JR. Twenty four hour ambulatory electrocardiography in patients with chronic atrial fibrillation. Br Med J (Clin Res
Ed) 1986;292:594.
192. Chatterjee NA, Upadhyay GA, Ellenbogen KA, McAlister FA, Choudhry NK,
Singh JP. Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis and systematic review. Circ Arrhythm Electrophysiol 2012;5:6876.
193. Ozcan C, Jahangir A, Friedman PA, Patel PJ, Munger TM, Rea RF, Lloyd MA,
Packer DL, Hodge DO, Gersh BJ, Hammill SC, Shen WK. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation.
N
Engl
J
Med
2001;344:10431051.
194. Garcia B, Clementy N, Benhenda N, Pierre B, Babuty D, Olshansky B, Fauchier
L. Mortality after atrioventricular nodal radiofrequency catheter ablation with permanent ventricular pacing in atrial fibrillation: outcomes from a controlled nonrandomized study. Circ Arrhythm Electrophysiol 2016;9.
195. Brignole M, Pokushalov E, Pentimalli F, Palmisano P, Chieffo E, Occhetta E,
Quartieri F, Calo L, Ungar A, Mont L. A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow
QRS.
Eur
Heart
J
2018;39:39994008.
196. Doshi RN, Daoud EG, Fellows C, Turk K, Duran A, Hamdan MH, Pires LA,
PAVE Study Group. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation
(the
PAVE
study).
J
Cardiovasc
Electrophysiol
2005;16:11601165.
197. Huang W, Su L, Wu S, Xu L, Xiao F, Zhou X, Ellenbogen KA. Benefits of permanent His bundle pacing combined with atrioventricular node ablation in atrial fibrillation patients with heart failure with both preserved and reduced left ventricular ejection fraction. J Am Heart Assoc 2017;6:e005309.
198. Vijayaraman P, Subzposh FA, Naperkowski A. Atrioventricular node ablation and His bundle pacing. Europace 2017;19:iv10-iv16.
199. Deshmukh P, Casavant DA, Romanyshyn M, Anderson K. Permanent, direct
His-bundle pacing: a novel approach to cardiac pacing in patients with normal
HisPurkinje activation. Circulation 2000;101:869877.
200. Occhetta E, Bortnik M, Magnani A, Francalacci G, Piccinino C, Plebani L, Marino
P. Prevention of ventricular desynchronization by permanent para-Hisian pacing after atrioventricular node ablation in chronic atrial fibrillation: a crossover,
blinded, randomized study versus apical right ventricular pacing. J Am Coll
Cardiol 2006;47:19381945.
201. Lau CP, Rushby J, Leigh-Jones M, Tam CY, Poloniecki J, Ingram A, Sutton R,
Camm AJ. Symptomatology and quality of life in patients with rate-responsive pacemakers:
a double-blind,
randomized,
crossover study.
Clin
Cardiol
1989;12:505512.
202. Leung SK, Lau CP. Developments in sensor-driven pacing. Cardiol Clin
2000;18:113155, ix.
203. Oto MA, Muderrisoglu H, Ozin MB, Korkmaz ME, Karamehmetoglu A, Oram
A, Oram E, Ugurlu S. Quality of life in patients with rate responsive pacemakers:
a randomized,
cross-over study.
Pacing
Clin
Electrophysiol
1991;14:800806.
204. Proietti R, Manzoni G, Di Biase L, Castelnuovo G, Lombardi L, Fundaro C,
Vegliante N, Pietrabissa G, Santangeli P, Canby RA, Sagone A, Viecca M, Natale
A. Closed loop stimulation is effective in improving heart rate and blood pressure response to mental stress: report of a single-chamber pacemaker study in patients with chronotropic incompetent atrial fibrillation.
Pacing
Clin
Electrophysiol 2012;35:990998.
205. Barold SS. Indications for permanent cardiac pacing in first-degree AV block:
class I, II, or III? Pacing Clin Electrophysiol 1996;19:747751.
206. Brecker SJ, Xiao HB, Sparrow J, Gibson DG. Effects of dual-chamber pacing with short atrioventricular delay in dilated cardiomyopathy.
Lancet
1992;340:13081312.
207. Carroz P, Delay D, Girod G. Pseudo-pacemaker syndrome in a young woman with first-degree atrio-ventricular block. Europace 2010;12:594596.
208. Englund A, Bergfeldt L, Rehnqvist N, Astrom H, Rosenqvist M. Diagnostic value of programmed ventricular stimulation in patients with bifascicular block: a prospective study of patients with and without syncope. J Am Coll Cardiol
1995;26:15081515.
209. Morady F, Higgins J, Peters RW, Schwartz AB, Shen EN, Bhandari A, Scheinman
MM, Sauve MJ. Electrophysiologic testing in bundle branch block and unexplained syncope. Am J Cardiol 1984;54:587591.
210. Tabrizi F, Rosenqvist M, Bergfeldt L, Englund A. Long-term prognosis in patients with bifascicular block—the predictive value of noninvasive and invasive assessment. J Intern Med 2006;260:3138.
211. Olshansky B, Hahn EA, Hartz VL, Prater SP, Mason JW. Clinical significance of syncope in the electrophysiologic study versus electrocardiographic monitoring
(ESVEM) trial. The ESVEM Investigators. Am Heart J 1999;137:878886.
212. Roca-Luque I, Francisco-Pasqual J, Oristrell G, Rodriguez-Garcia J, SantosOrtega A, Martin-Sanchez G, Rivas-Gandara N, Perez-Rodon J, FerreiraGonzalez I, Garcia-Dorado D, Moya-Mitjans A. Flecainide versus procainamide in electrophysiological study in patients with syncope and wide QRS duration.
JACC Clin Electrophysiol 2019;5:212219.
213. Santini M, Castro A, Giada F, Ricci R, Inama G, Gaggioli G, Calo L, Orazi S,
Viscusi M, Chiodi L, Bartoletti A, Foglia-Manzillo G, Ammirati F, Loricchio ML,
Pedrinazzi C, Turreni F, Gasparini G, Accardi F, Raciti G, Raviele A. Prevention of syncope through permanent cardiac pacing in patients with bifascicular block and syncope of unexplained origin: the PRESS study. Circ Arrhythm Electrophysiol
2013;6:101107.
214. Camm AJ, Lu¨scher TF, Maurer G, Serruys PW (eds). ESC CardioMed. 3rd ed.
Oxford, UK: Oxford University Press; 2018.
215. Peters RW, Scheinman MM, Modin C, O’Young J, Somelofski CA, Mies C.
Prophylactic permanent pacemakers for patients with chronic bundle branch block. Am J Med 1979;66:978985.
216. Armaganijan LV, Toff WD, Nielsen JC, Andersen HR, Connolly SJ, Ellenbogen
KA, Healey JS. Are elderly patients at increased risk of complications following pacemaker implantation? A meta-analysis of randomized trials. Pacing Clin
Electrophysiol 2012;35:131134.
217. Gadler F, Valzania C, Linde C. Current use of implantable electrical devices in
Sweden: data from the Swedish pacemaker and implantable cardioverterdefibrillator registry. Europace 2015;17:6977.
218. Shurrab M, Elitzur Y, Healey JS, Gula L, Kaoutskaia A, Israel C, Lau C, Crystal E.
VDD vs DDD pacemakers: a meta-analysis. Can J Cardiol 2014;30:13851391.
219. Brignole M, Ammirati F, Arabia F, Quartieri F, Tomaino M, Ungar A, Lunati M,
Russo V, Del Rosso A, Gaggioli G, Syncope Unit Project Two Investigators.
Assessment of a standardized algorithm for cardiac pacing in older patients affected by severe unpredictable reflex syncopes.
Eur
Heart
J
2015;36:15291535.
220. Brignole M, Arabia F, Ammirati F, Tomaino M, Quartieri F, Rafanelli M, Del
Rosso A, Rita Vecchi M, Russo V, Gaggioli G, Syncope Unit Project investigators. Standardized algorithm for cardiac pacing in older patients affected by severe unpredictable reflex syncope: 3-year insights from the Syncope Unit
Project 2 (SUP 2) study. Europace 2016;18:14271433.
221. Sutton R, Brignole M. Twenty-eight years of research permit reinterpretation of tilt-testing: hypotensive susceptibility rather than diagnosis. Eur Heart J
2014;35:22112212.
222. Claesson JE, Kristensson BE, Edvardsson N, Wahrborg P. Less syncope and milder symptoms in patients treated with pacing for induced cardioinhibitory carotid sinus syndrome: a randomized study. Europace 2007;9:932936.
223. Brignole M, Menozzi C, Lolli G, Bottoni N, Gaggioli G. Long-term outcome of paced and nonpaced patients with severe carotid sinus syndrome. Am J Cardiol
1992;69:10391043.
224. Sutton R, Brignole M, Menozzi C, Raviele A, Alboni P, Giani P, Moya A. Dualchamber pacing in the treatment of neurally mediated tilt-positive cardioinhibitory syncope: pacemaker versus no therapy: a multicenter randomized study.
The Vasovagal Syncope International Study (VASIS) Investigators. Circulation
2000;102:294299.
225. Ammirati F, Colivicchi F, Santini M, Syncope D, Treatment Study Investigators.
Permanent cardiac pacing versus medical treatment for the prevention of recurrent vasovagal syncope: a multicenter, randomized, controlled trial. Circulation
2001;104:5257.
226. Baron-Esquivias G, Morillo CA, Moya-Mitjans A, Martinez-Alday J, Ruiz-Granell
R, Lacunza-Ruiz J, Garcia-Civera R, Gutierrez-Carretero E, Romero-Garrido R.
Dual-chamber pacing with closed loop stimulation in recurrent reflex vasovagal syncope: the SPAIN study. J Am Coll Cardiol 2017;70:17201728.
227. Russo V, Rago A, Papa AA, Golino P, Calabro R, Russo MG, Nigro G. The effect of dual-chamber closed-loop stimulation on syncope recurrence in healthy patients with tilt-induced vasovagal cardioinhibitory syncope: a prospective, randomised, single-blind, crossover study. Heart 2013;99:16091613.
228. Brignole M, Russo V, Arabia F, Oliveira M, Pedrote A, Aerts A, Rapacciuolo A,
Boveda S, Deharo JC, Maglia G, Nigro G, Giacopelli D, Gargaro A, Tomaino M,
BioSync CSL trial Investigators. Cardiac pacing in severe recurrent reflex syncope and tilt-induced asystole. Eur Heart J 2020;42:508516.
229. Russo V, Rago A, De Rosa M, Papa AA, Simova I, Petrov I, Bonev N, Gargaro
A, Golino P, Nigro G. Does cardiac pacing reduce syncopal recurrences in cardioinhibitory vasovagal syncope patients selected with head-up tilt test?
Analysis of a 5-year follow-up database. Int J Cardiol 2018;270:149153.
230. Flammang D, Church TR, De Roy L, Blanc JJ, Leroy J, Mairesse GH, Otmani A,
Graux PJ, Frank R, Purnode P, ATP Multicenter Study. Treatment of unexplained syncope: a multicenter, randomized trial of cardiac pacing guided by adenosine 5’-triphosphate testing. Circulation 2012;125:3136.


<!-- PAGE 77 -->

### Page 77

.............................................................................................................................................................................
231. Connolly SJ, Sheldon R, Thorpe KE, Roberts RS, Ellenbogen KA, Wilkoff BL,
Morillo C, Gent M, VPS II Investigators. Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope: Second
Vasovagal
Pacemaker
Study
(VPS
II):
a randomized trial.
JAMA
2003;289:22242229.
232. Raviele A, Giada F, Menozzi C, Speca G, Orazi S, Gasparini G, Sutton R,
Brignole M, Vasovagal Syncope Pacing Trial Investigators. A randomized,
double-blind, placebo-controlled study of permanent cardiac pacing for the treatment of recurrent tilt-induced vasovagal syncope. The vasovagal syncope and pacing trial (SYNPACE). Eur Heart J 2004;25:17411748.
233. Palmisano P, Dell’Era G, Russo V, Zaccaria M, Mangia R, Bortnik M, De Vecchi
F, Giubertoni A, Patti F, Magnani A, Nigro G, Rago A, Occhetta E, Accogli M.
Effects of closed-loop stimulation vs. DDD pacing on haemodynamic variations and occurrence of syncope induced by head-up tilt test in older patients with refractory cardioinhibitory vasovagal syncope: the Tilt test-Induced REsponse in
Closed-loop Stimulation multicentre, prospective, single blind, randomized study. Europace 2018;20:859866.
234. Proclemer A, Facchin D, Feruglio GA. [Syncope of unknown origin after electrophysiologic study: is the treatment with pacemaker useful?]. G Ital Cardiol
1990;20:195201.
235. Raviele A, Proclemer A, Gasparini G, Di Pede F, Delise P, Piccolo E, Feruglio
GA. Long-term follow-up of patients with unexplained syncope and negative electrophysiologic study. Eur Heart J 1989;10:127132.
236. Parry SW, Steen N, Bexton RS, Tynan M, Kenny RA. Pacing in elderly recurrent fallers with carotid sinus hypersensitivity: a randomised, double-blind, placebo controlled crossover trial. Heart 2009;95:405409.
237. Mosterd
A,
Hoes
AW.
Clinical epidemiology of heart failure.
Heart
2007;93:11371146.
238. Dunlay SM, Weston SA, Jacobsen SJ, Roger VL. Risk factors for heart failure: a population-based casecontrol study. Am J Med 2009;122:10231028.
239. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel
WB, Vasan RS. Obesity and the risk of heart failure. N Engl J Med
2002;347:305313.
240. Rawshani A, Rawshani A, Franzen S, Sattar N, Eliasson B, Svensson AM,
Zethelius B, Miftaraj M, McGuire DK, Rosengren A, Gudbjornsdottir S. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N
Engl J Med 2018;379:633644.
241. Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, Allison M,
Hemingway H, Cleland JG, McMurray JJV, Rahimi K. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals.
Lancet 2018;391:572580.
242. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bo¨hm M, Burri
H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro
MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA,
Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R,
Muneretto C, Piepoli MF, Price S, Rosano GMC, Ruschitzka F, Skibelund AK;
ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;doi:10.1093/
eurheartj/ehab368.
243. Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F,
Ferrari R, Piepoli MF, Delgado Jimenez JF, Metra M, Fonseca C, Hradec J, Amir
O, Logeart D, Dahlstrom U, Merkely B, Drozdz J, Goncalvesova E, Hassanein
M, Chioncel O, Lainscak M, Seferovic PM, Tousoulis D, Kavoliuniene A,
Fruhwald F, Fazlibegovic E, Temizhan A, Gatzov P, Erglis A, Laroche C,
Mebazaa A. European Society of Cardiology Heart Failure Long-Term Registry
(ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J
Heart Fail 2016;18:613625.
244. Olshansky B, Day JD, Sullivan RM, Yong P, Galle E, Steinberg JS. Does cardiac resynchronization therapy provide unrecognized benefit in patients with prolonged PR intervals? The impact of restoring atrioventricular synchrony: an analysis from the COMPANION Trial. Heart Rhythm 2012;9:3439.
245. Gervais R, Leclercq C, Shankar A, Jacobs S, Eiskjaer H, Johannessen A,
Freemantle N, Cleland JG, Tavazzi L, Daubert C, CARE-HF investigators.
Surface electrocardiogram to predict outcome in candidates for cardiac resynchronization therapy: a sub-analysis of the CARE-HF trial. Eur J Heart Fail
2009;11:699705.
246. Friedman DJ, Bao H, Spatz ES, Curtis JP, Daubert JP, Al-Khatib SM. Association
Between a Prolonged PR interval and outcomes of cardiac resynchronization therapy: a report from the National Cardiovascular Data Registry. Circulation
2016;134:16171628.
247. Leclercq C, Kass DA. Retiming the failing heart: principles and current clinical status of cardiac resynchronization. J Am Coll Cardiol 2002;39:194201.
248. Leclercq C, Hare JM. Ventricular resynchronization: current state of the art.
Circulation 2004;109:296299.
249. Patel N, Viles-Gonzalez J, Agnihotri K, Arora S, Patel NJ, Aneja E, Shah M,
Badheka AO, Pothineni NV. Frequency of in-hospital adverse outcomes and cost utilization associated with cardiac resynchronization therapy defibrillator implantation in the United States. J Cardiovasc Electrophysiol 2018;29:14251435.
250. Khan NK, Goode KM, Cleland JG, Rigby AS, Freemantle N, Eastaugh J, Clark
AL, de Silva R, Calvert MJ, Swedberg K, Komajda M, Mareev V, Follath F.
Prevalence of ECG abnormalities in an international survey of patients with suspected or confirmed heart failure at death or discharge. Eur J Heart Fail
2007;9:491501.
251. Cleland JG, McDonagh T, Rigby AS, Yassin A, Whittaker T, Dargie HJ. The national heart failure audit for England and Wales 20082009. Heart 2011;97:876886.
252. Lund LH, Braunschweig F, Benson L, Stahlberg M, Dahlstrom U, Linde C.
Association between demographic, organizational, clinical, and socio-economic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry. Eur J Heart Fail 2017;19:12701279.
253. Dickstein K, Normand C, Auricchio A, Bogale N, Cleland JG, Gitt AK, Stellbrink
C, Anker SD, Filippatos G, Gasparini M, Hindricks G, Blomstrom Lundqvist C,
Ponikowski P, Ruschitzka F, Botto GL, Bulava A, Duray G, Israel C, Leclercq C,
Margitfalvi P, Cano O, Plummer C, Sarigul NU, Sterlinski M, Linde C. CRT
Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients—who is doing what to whom and how? Eur J Heart
Fail 2018;20:10391051.
254. Auricchio A, Stellbrink C, Sack S, Block M, Vogt J, Bakker P, Huth C,
Schondube F, Wolfhard U, Bocker D, Krahnefeld O, Kirkels H. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol
2002;39:20262033.
255. Auricchio A, Stellbrink C, Butter C, Sack S, Vogt J, Misier AR, Bocker D, Block
M, Kirkels JH, Kramer A, Huvelle E. Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay. J Am Coll Cardiol 2003;42:21092116.
256. Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, Garrigue S,
Kappenberger L, Haywood GA, Santini M, Bailleul C, Daubert JC. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001;344:873880.
257. Linde C, Leclercq C, Rex S, Garrigue S, Lavergne T, Cazeau S, McKenna W,
Fitzgerald M, Deharo JC, Alonso C, Walker S, Braunschweig F, Bailleul C,
Daubert JC. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study.
J Am Coll Cardiol 2002;40:111118.
258. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic
DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Trupp RJ, Underwood J,
Pickering F, Truex C, McAtee P, Messenger J. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002;346:18451853.
259. Abraham WT, Young JB, Leon AR, Adler S, Bank AJ, Hall SA, Lieberman R,
Liem LB, O’Connell JB, Schroeder JS, Wheelan KR. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation 2004;110:28642868.
260. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P,
DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:21402150.
261. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L,
Tavazzi L. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF)
trial extension phase]. Eur Heart J 2006;27:19281932.
262. Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C.
Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008;52:18341843.
263. Daubert C, Gold MR, Abraham WT, Ghio S, Hassager C, Goode G, Szili-Torok
T, Linde C. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction:
insights from the
European cohort of the
REVERSE
(Resynchronization
Reverses
Remodeling in
Systolic
Left
Ventricular
Dysfunction) trial. J Am Coll Cardiol 2009;54:18371846.
264. Ruschitzka F, Abraham WT, Singh JP, Bax JJ, Borer JS, Brugada J, Dickstein K,
Ford I, Gorcsan J 3rd, Gras D, Krum H, Sogaard P, Holzmeister J. Cardiacresynchronization therapy in heart failure with a narrow QRS complex. N Engl J
Med 2013;369:13951405.
265. Goldenberg I, Kutyifa V, Moss AJ. Survival with cardiac-resynchronization therapy. N Engl J Med 2014;371:477478.
266. Cleland JG, Abraham WT, Linde C, Gold MR, Young JB, Claude Daubert J,
Sherfesee L, Wells GA, Tang AS. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J
2013;34:35473556.
ESC Guidelines
77


<!-- PAGE 78 -->

### Page 78

.............................................................................................................................................................................
267. Leclercq C, Walker S, Linde C, Clementy J, Marshall AJ, Ritter P, Djiane P,
Mabo P, Levy T, Gadler F, Bailleul C, Daubert JC. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J 2002;23:17801787.
268. Funck RC, Mueller HH, Lunati M, Piorkowski C, De Roy L, Paul V, Wittenberg
M, Wuensch D, Blanc JJ. Characteristics of a large sample of candidates for permanent ventricular pacing included in the Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization Study (BioPace).
Europace 2014;16:354362.
269. Sipahi I, Carrigan TP, Rowland DY, Stambler BS, Fang JC. Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: metaanalysis of randomized controlled trials. Arch Intern Med 2011;171:14541462.
270. Sipahi I, Chou JC, Hyden M, Rowland DY, Simon DI, Fang JC. Effect of QRS
morphology on clinical event reduction with cardiac resynchronization therapy:
meta-analysis of randomized controlled trials.
Am
Heart
J
2012;163:260267.e263.
271. Cunnington C, Kwok CS, Satchithananda DK, Patwala A, Khan MA, Zaidi A,
Ahmed FZ, Mamas MA. Cardiac resynchronisation therapy is not associated with a reduction in mortality or heart failure hospitalisation in patients with non-left bundle branch block QRS morphology: meta-analysis of randomised controlled trials. Heart 2015;101:14561462.
272. Zareba W, Klein H, Cygankiewicz I, Hall WJ, McNitt S, Brown M, Cannom D,
Daubert JP, Eldar M, Gold MR, Goldberger JJ, Goldenberg I, Lichstein E,
Pitschner H, Rashtian M, Solomon S, Viskin S, Wang P, Moss AJ. Effectiveness of cardiac resynchronization therapy by QRS morphology in the Multicenter
Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy
(MADIT-CRT). Circulation 2011;123:10611072.
273. Birnie DH, Ha A, Higginson L, Sidhu K, Green M, Philippon F, Thibault B, Wells
G, Tang A. Impact of QRS morphology and duration on outcomes after cardiac resynchronization therapy: results from the Resynchronization-Defibrillation for
Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail 2013;6:11901198.
274. Bilchick KC, Kamath S, DiMarco JP, Stukenborg GJ. Bundle-branch block morphology and other predictors of outcome after cardiac resynchronization therapy in Medicare patients. Circulation 2010;122:20222030.
275. Woods B, Hawkins N, Mealing S, Sutton A, Abraham WT, Beshai JF, Klein H,
Sculpher M, Plummer CJ, Cowie MR. Individual patient data network metaanalysis of mortality effects of implantable cardiac devices.
Heart
2015;101:18001806.
276. Gold MR, Thebault C, Linde C, Abraham WT, Gerritse B, Ghio S, St John
Sutton M, Daubert JC. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the
Resynchronization
Reverses
Remodeling in
Systolic
Left
Ventricular
Dysfunction (REVERSE) study. Circulation 2012;126:822829.
277. Fantoni C, Kawabata M, Massaro R, Regoli F, Raffa S, Arora V, Salerno-Uriarte
JA, Klein HU, Auricchio A. Right and left ventricular activation sequence in patients with heart failure and right bundle branch block: a detailed analysis using three-dimensional non-fluoroscopic electroanatomic mapping system. J
Cardiovasc Electrophysiol 2005;16:112119; discussion 120121.
278. Nery PB, Ha AC, Keren A, Birnie DH. Cardiac resynchronization therapy in patients with left ventricular systolic dysfunction and right bundle branch block:
a systematic review. Heart Rhythm 2011;8:10831087.
279. Kutyifa V, Stockburger M, Daubert JP, Holmqvist F, Olshansky B, Schuger C,
Klein H, Goldenberg I, Brenyo A, McNitt S, Merkely B, Zareba W, Moss AJ. PR
interval identifies clinical response in patients with non-left bundle branch block:
a
Multicenter
Automatic
Defibrillator
Implantation
Trial-Cardiac
Resynchronization
Therapy substudy.
Circ
Arrhythm
Electrophysiol
2014;7:645651.
280. Kewcharoen J, Kanitsoraphan C. Prolonged PR interval and outcome in cardiac resynchronization therapy. Arq Bras Cardiol 2019;113:109110.
281. Steffel J, Robertson M, Singh JP, Abraham WT, Bax JJ, Borer JS, Dickstein K,
Ford I, Gorcsan J 3rd, Gras D, Krum H, Sogaard P, Holzmeister J, Brugada J,
Ruschitzka F. The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT
trial. Eur Heart J 2015;36:19831989.
282. Arshad A, Moss AJ, Foster E, Padeletti L, Barsheshet A, Goldenberg I,
Greenberg H, Hall WJ, McNitt S, Zareba W, Solomon S, Steinberg JS. Cardiac resynchronization therapy is more effective in women than in men: the
MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with
Cardiac Resynchronization Therapy) trial. J Am Coll Cardiol 2011;57:813820.
283. Zusterzeel R, Selzman KA, Sanders WE, Canos DA, O’Callaghan KM,
Carpenter JL, Pina IL, Strauss DG. Cardiac resynchronization therapy in women:
US Food and Drug Administration meta-analysis of patient-level data. JAMA
Intern Med 2014;174:13401348.
284. Zweerink A, Friedman DJ, Klem I, van de Ven PM, Vink C, Biesbroek PS,
Hansen SM, Emerek K, Kim RJ, van Rossum AC, Atwater BD, Nijveldt R, Allaart
CP. Size Matters: Normalization of QRS duration to left ventricular dimension improves prediction of long-term cardiac resynchronization therapy outcome.
Circ Arrhythm Electrophysiol 2018;11:e006767.
285. Strauss DG, Selvester RH, Wagner GS. Defining left bundle branch block in the era of cardiac resynchronization therapy. Am J Cardiol 2011;107:927934.
286. Lee AWC, O’Regan DP, Gould J, Sidhu B, Sieniewicz B, Plank G, Warriner DR,
Lamata P, Rinaldi CA, Niederer SA. Sex-dependent QRS guidelines for cardiac resynchronization therapy using computer model predictions. Biophysical Journal
2019;117:23752381.
287. Caputo ML, van Stipdonk A, Illner A, D’Ambrosio G, Regoli F, Conte G,
Moccetti T, Klersy C, Prinzen FW, Vernooy K, Auricchio A. The definition of left bundle branch block influences the response to cardiac resynchronization therapy. Int J Cardiol 2018;269:165169.
288. van Stipdonk AMW, Vanbelle S, Ter Horst IAH, Luermans JG, Meine M, Maass
AH, Auricchio A, Prinzen FW, Vernooy K. Large variability in clinical judgement and definitions of left bundle branch block to identify candidates for cardiac resynchronisation therapy. Int J Cardiol 2019;286:6165.
289. Tomlinson DR, Bashir Y, Betts TR, Rajappan K. Accuracy of manual QRS duration assessment: its importance in patient selection for cardiac resynchronization and implantable cardioverter defibrillator therapy.
Europace
2009;11:638642.
290. Vancura V, Wichterle D, Ulc I, Smid J, Brabec M, Zarybnicka M, Rokyta R. The variability of automated
QRS
duration measurement.
Europace
2017;19:636643.
291. Sze E, Samad Z, Dunning A, Campbell KB, Loring Z, Atwater BD, Chiswell K,
Kisslo JA, Velazquez EJ, Daubert JP. Impaired recovery of left ventricular function in patients with cardiomyopathy and left bundle branch block. J Am Coll
Cardiol 2018;71:306317.
292. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A,
Lerebours G, Tavazzi L, SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet
2010;376:875885.
293. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL,
Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators
Committees. Angiotensinneprilysin inhibition versus enalapril in heart failure.
N Engl J Med 2014;371:9931004.
294. Nijst P, Martens P, Dauw J, Tang WHW, Bertrand PB, Penders J, Bruckers L,
Voros G, Willems R, Vandervoort PM, Dupont M, Mullens W. Withdrawal of neurohumoral blockade after cardiac resynchronization therapy. J Am Coll
Cardiol 2020;75:14261438.
295. Mullens W, Auricchio A, Martens P, Witte K, Cowie MR, Delgado V, Dickstein
K, Linde C, Vernooy K, Leyva F, Bauersachs J, Israel CW, Lund LH, Donal E,
Boriani G, Jaarsma T, Berruezo A, Traykov V, Yousef Z, Kalarus Z, Cosedis
Nielsen J, Steffel J, Vardas P, Coats A, Seferovic P, Edvardsen T, Heidbuchel H,
Ruschitzka F, Leclercq C. Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care: a joint position statement from the Heart Failure Association (HFA), European Heart
Rhythm Association (EHRA), and European Association of Cardiovascular
Imaging (EACVI) of the European Society of Cardiology. Eur J Heart Fail
2020;22:23492369.
296. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C,
Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman
JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN,
Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL, ESC Scientific
Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of
Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020;42:373498.
297. Ousdigian KT, Borek PP, Koehler JL, Heywood JT, Ziegler PD, Wilkoff BL. The epidemic of inadequate biventricular pacing in patients with persistent or permanent atrial fibrillation and its association with mortality. Circ Arrhythm
Electrophysiol 2014;7:370376.
298. Koplan BA, Kaplan AJ, Weiner S, Jones PW, Seth M, Christman SA. Heart failure decompensation and all-cause mortality in relation to percent biventricular pacing in patients with heart failure: is a goal of 100% biventricular pacing necessary? J Am Coll Cardiol 2009;53:355360.
299. Hayes DL, Boehmer JP, Day JD, Gilliam FR 3rd, Heidenreich PA, Seth M, Jones
PW, Saxon LA. Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival.
Heart
Rhythm
2011;8:14691475.
300. Healey JS, Hohnloser SH, Exner DV, Birnie DH, Parkash R, Connolly SJ, Krahn
AD, Simpson CS, Thibault B, Basta M, Philippon F, Dorian P, Nair GM,
Sivakumaran S, Yetisir E, Wells GA, Tang AS. Cardiac resynchronization therapy in patients with permanent atrial fibrillation:
results from the
Resynchronization for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail
2012;5:566570.
301. Ganesan AN, Brooks AG, Roberts-Thomson KC, Lau DH, Kalman JM, Sanders
P. Role of AV nodal ablation in cardiac resynchronization in patients with


<!-- PAGE 79 -->

### Page 79

.............................................................................................................................................................................
coexistent atrial fibrillation and heart failure a systematic review. J Am Coll
Cardiol 2012;59:719726.
302. Gasparini M, Leclercq C, Lunati M, Landolina M, Auricchio A, Santini M, Boriani
G, Lamp B, Proclemer A, Curnis A, Klersy C, Leyva F. Cardiac resynchronization therapy in patients with atrial fibrillation: the CERTIFY study (Cardiac
Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry).
JACC Heart Fail 2013;1:500507.
303. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, Lip GY,
Coats AJ, Andersson B, Kirchhof P, von Lueder TG, Wedel H, Rosano G,
Shibata MC, Rigby A, Flather MD, Beta-Blockers in Heart Failure Collaborative
Group. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 2014;384:22352243.
304. Ziff OJ, Samra M, Howard JP, Bromage DI, Ruschitzka F, Francis DP, Kotecha D.
Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment. BMC Med 2020;18:103.
305. Docherty KF, Shen L, Castagno D, Petrie MC, Abraham WT, Bohm M, Desai
AS, Dickstein K, Kober LV, Packer M, Rouleau JL, Solomon SD, Swedberg K,
Vazir A, Zile MR, Jhund PS, McMurray JJV. Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. Eur J Heart Fail 2020;22:528538.
306. Yin J, Hu H, Wang Y, Xue M, Li X, Cheng W, Li X, Yan S. Effects of atrioventricular nodal ablation on permanent atrial fibrillation patients with cardiac resynchronization therapy: a systematic review and meta-analysis. Clin Cardiol
2014;37:707715.
307. Tolosana JM, Arnau AM, Madrid AH, Macias A, Lozano IF, Osca J, Quesada A,
Toquero J, France´s RM, Bolao IG, Berruezo A, Sitges M, Alcala MG, Brugada J,
Mont L. Cardiac resynchronization therapy in patients with permanent atrial fibrillation. Is it mandatory to ablate the atrioventricular junction to obtain a good response? Eur J Heart Fail 2012;14:635641.
308. Tolosana JM, Trucco E, Khatib M, Doltra A, Borras R, Castel M, Berruezo A,
Arbelo E, Sitges M, Matas M, Guasch E, Brugada J, Mont L. Complete atrioventricular block does not reduce long-term mortality in patients with permanent atrial fibrillation treated with cardiac resynchronization therapy. Eur J Heart Fail
2013;15:14121418.
309. Kamath GS, Cotiga D, Koneru JN, Arshad A, Pierce W, Aziz EF, Mandava A,
Mittal S, Steinberg JS. The utility of 12-lead Holter monitoring in patients with permanent atrial fibrillation for the identification of nonresponders after cardiac resynchronization therapy. J Am Coll Cardiol 2009;53:10501055.
310. Hernandez-Madrid A, Facchin D, Klepfer RN, Ghosh S, Matia R, Moreno J,
Locatelli A. Device pacing diagnostics overestimate effective cardiac resynchronization therapy pacing results of the hOLter for Efficacy analysis of CRT (OLE
CRT) study. Heart Rhythm 2017;14:541547.
311. Plummer CJ, Frank CM, Bari Z, Al Hebaishi YS, Klepfer RN, Stadler RW, Ghosh
S, Liu S, Mittal S. A novel algorithm increases the delivery of effective cardiac resynchronization therapy during atrial fibrillation: the CRTee randomized crossover trial. Heart Rhythm 2018;15:369375.
312. Tops LF, Schalij MJ, Holman ER, van Erven L, van der Wall EE, Bax JJ. Right ventricular pacing can induce ventricular dyssynchrony in patients with atrial fibrillation after atrioventricular node ablation. J Am Coll Cardiol 2006;48:16421648.
313. Brignole M, Botto G, Mont L, Iacopino S, De Marchi G, Oddone D, Luzi M,
Tolosana JM, Navazio A, Menozzi C. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. Eur Heart J 2011;32:24202429.
314. Brignole M, Botto GL, Mont L, Oddone D, Iacopino S, De Marchi G, Campoli
M, Sebastiani V, Vincenti A, Garcia Medina D, Osca Asensi J, Mocini A, Grovale
N, De Santo T, Menozzi C. Predictors of clinical efficacy of ‘Ablate and Pace’
therapy in patients with permanent atrial fibrillation. Heart 2012;98:297302.
315. Stavrakis S, Garabelli P, Reynolds DW. Cardiac resynchronization therapy after atrioventricular junction ablation for symptomatic atrial fibrillation: a meta-analysis. Europace 2012;14:14901497.
316. Sharma PS, Vijayaraman P, Ellenbogen KA. Permanent His bundle pacing: shaping the future of physiological ventricular pacing. Nat Rev Cardiol 2020;17:2236.
317. Huang W, Su L, Wu S, Xu L, Xiao F, Zhou X, Ellenbogen KA. A Novel pacing strategy with low and stable output: pacing the left bundle branch immediately beyond the conduction block. Can J Cardiol 2017;33:1736.e11736.e73.
318. Sharma PS, Dandamudi G, Herweg B, Wilson D, Singh R, Naperkowski A,
Koneru JN, Ellenbogen KA, Vijayaraman P. Permanent His-bundle pacing as an alternative to biventricular pacing for cardiac resynchronization therapy: a multicenter experience. Heart Rhythm 2018;15:413420.
319. Vijayaraman P, Herweg B, Ellenbogen KA, Gajek J. His-optimized cardiac resynchronization therapy to maximize electrical resynchronization: a feasibility study. Circ Arrhythm Electrophysiol 2019;12:e006934.
320. Boczar K, Sławuta A, Za˛bek A, DeR bski M, Vijayaraman P, Gajek J, Lelakowski J,
Małecka B. Cardiac resynchronization therapy with His bundle pacing. Pacing
Clin Electrophysiol. 2019;42:374380.
321. Coluccia G, Vitale E, Corallo S, Aste M, Odaglia F, Donateo P, Oddone D, Brignole
M. Additional benefits of nonconventional modalities of cardiac resynchronization therapy using His bundle pacing. J Cardiovasc Electrophysiol 2020;31:647657.
322. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M,
Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J,
Popescu BA, Schotten U, Van Putte B, Vardas P. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur
Heart J 2016;37:28932962.
323. Yu CM, Chan JY, Zhang Q, Omar R, Yip GW, Hussin A, Fang F, Lam KH, Chan
HC, Fung JW. Biventricular pacing in patients with bradycardia and normal ejection fraction. N Engl J Med 2009;361:21232134.
324. Tanaka H, Hara H, Adelstein EC, Schwartzman D, Saba S, Gorcsan J 3rd.
Comparative mechanical activation mapping of RV pacing to LBBB by 2D and
3D speckle tracking and association with response to resynchronization therapy. JACC Cardiovasc Imaging 2010;3:461471.
325. Marai I, Gurevitz O, Carasso S, Nof E, Bar-Lev D, Luria D, Arbel Y, Freimark D,
Feinberg MS, Eldar M, Glikson M. Improvement of congestive heart failure by upgrading of conventional to resynchronization pacemakers. Pacing
Clin
Electrophysiol 2006;29:880884.
326. Witte KK, Pipes RR, Nanthakumar K, Parker JD. Biventricular pacemaker upgrade in previously paced heart failure patients—improvements in ventricular dyssynchrony. J Card Fail 2006;12:199204.
327. Duray GZ, Israel CW, Pajitnev D, Hohnloser SH. Upgrading to biventricular pacing/defibrillation systems in right ventricular paced congestive heart failure patients: prospective assessment of procedural parameters and response rate.
Europace 2008;10:4852.
328. Nagele H, Dodeck J, Behrens S, Azizi M, Hashagen S, Eisermann C, Castel MA.
Hemodynamics and prognosis after primary cardiac resynchronization system implantation compared to ‘upgrade’ procedures. Pacing Clin Electrophysiol
2008;31:12651271.
329. Foley PW, Muhyaldeen SA, Chalil S, Smith RE, Sanderson JE, Leyva F. Longterm effects of upgrading from right ventricular pacing to cardiac resynchronization therapy in patients with heart failure. Europace 2009;11:495501.
330. Wokhlu A, Rea RF, Asirvatham SJ, Webster T, Brooke K, Hodge DO, Wiste HJ,
Dong Y, Hayes DL, Cha YM. Upgrade and de novo cardiac resynchronization therapy: impact of paced or intrinsic QRS morphology on outcomes and survival. Heart Rhythm 2009;6:14391447.
331. Frohlich G, Steffel J, Hurlimann D, Enseleit F, Luscher TF, Ruschitzka F,
Abraham WT, Holzmeister J. Upgrading to resynchronization therapy after chronic right ventricular pacing improves left ventricular remodelling. Eur Heart
J 2010;31:14771485.
332. Paparella G, Sciarra L, Capulzini L, Francesconi A, De Asmundis C, Sarkozy A,
Cazzin R, Brugada P. Long-term effects of upgrading to biventricular pacing: differences with cardiac resynchronization therapy as primary indication. Pacing
Clin Electrophysiol 2010;33:841849.
333. Bogale N, Witte K, Priori S, Cleland J, Auricchio A, Gadler F, Gitt A, Limbourg
T, Linde C, Dickstein K. The European Cardiac Resynchronization Therapy
Survey: comparison of outcomes between de novo cardiac resynchronization therapy implantations and upgrades. Eur J Heart Fail 2011;13:974983.
334. Gage RM, Burns KV, Bank AJ. Echocardiographic and clinical response to cardiac resynchronization therapy in heart failure patients with and without previous right ventricular pacing. Eur J Heart Fail 2014;16:11991205.
335. Tayal B, Gorcsan J 3rd, Delgado-Montero A, Goda A, Ryo K, Saba S, Risum N,
Sogaard P. Comparative long-term outcomes after cardiac resynchronization therapy in right ventricular paced patients versus native wide left bundle branch block patients. Heart Rhythm 2016;13:511518.
336. Ter Horst IA, Kuijpers Y, van ‘t Sant J, Tuinenburg AE, Cramer MJ, Meine M.
‘Are CRT upgrade procedures more complex and associated with more complications than de novo CRT implantations?’ A single centre experience. Neth
Heart J 2016;24:7581.
337. Lipar L, Srivathsan K, Scott LR. Short-term outcome of cardiac resynchronization therapy—a comparison between newly implanted and chronically right ventricle-paced patients. Int J Cardiol 2016;219:195199.
338. Vamos M, Erath JW, Bari Z, Vagany D, Linzbach SP, Burmistrava T, Israel CW,
Duray GZ, Hohnloser SH. Effects of upgrade versus de novo cardiac resynchronization therapy on clinical response and long-term survival: results from a multicenter study. Circ Arrhythm Electrophysiol 2017;10:e004471.
339. Cheung JW, Ip JE, Markowitz SM, Liu CF, Thomas G, Feldman DN, Swaminathan
RV, Lerman BB, Kim LK. Trends and outcomes of cardiac resynchronization therapy upgrade procedures: a comparative analysis using a United States National
Database 20032013. Heart Rhythm 2017;14:10431050.
340. Leon AR, Greenberg JM, Kanuru N, Baker CM, Mera FV, Smith AL, Langberg JJ,
DeLurgio DB. Cardiac resynchronization in patients with congestive heart failure and chronic atrial fibrillation: effect of upgrading to biventricular pacing after chronic right ventricular pacing. J Am Coll Cardiol 2002;39:12581263.
ESC Guidelines
79


<!-- PAGE 80 -->

### Page 80

.............................................................................................................................................................................
341. Baker CM, Christopher TJ, Smith PF, Langberg JJ, Delurgio DB, Leon AR.
Addition of a left ventricular lead to conventional pacing systems in patients with congestive heart failure: feasibility, safety, and early results in 60 consecutive patients. Pacing Clin Electrophysiol 2002;25:11661171.
342. Valls-Bertault V, Fatemi M, Gilard M, Pennec PY, Etienne Y, Blanc JJ. Assessment of upgrading to biventricular pacing in patients with right ventricular pacing and congestive heart failure after atrioventricular junctional ablation for chronic atrial fibrillation. Europace 2004;6:438443.
343. Eldadah ZA, Rosen B, Hay I, Edvardsen T, Jayam V, Dickfeld T, Meininger GR,
Judge DP, Hare J, Lima JB, Calkins H, Berger RD. The benefit of upgrading chronically right ventricle-paced heart failure patients to resynchronization therapy demonstrated by strain rate imaging. Heart Rhythm 2006;3:435442.
344. Shimano M, Tsuji Y, Yoshida Y, Inden Y, Tsuboi N, Itoh T, Suzuki H, Muramatsu
T, Okada T, Harata S, Yamada T, Hirayama H, Nattel S, Murohara T. Acute and chronic effects of cardiac resynchronization in patients developing heart failure with long-term pacemaker therapy for acquired complete atrioventricular block. Europace 2007;9:869874.
345. Laurenzi F, Achilli A, Avella A, Peraldo C, Orazi S, Perego GB, Cesario A,
Valsecchi S, De Santo T, Puglisi A, Tondo C. Biventricular upgrading in patients with conventional pacing system and congestive heart failure: results and response predictors. Pacing Clin Electrophysiol 2007;30:10961104.
346. Vatankulu MA, Goktekin O, Kaya MG, Ayhan S, Kucukdurmaz Z, Sutton R,
Henein M. Effect of long-term resynchronization therapy on left ventricular remodeling in pacemaker patients upgraded to biventricular devices. Am J
Cardiol 2009;103:12801284.
347. Hoijer CJ, Meurling C, Brandt J. Upgrade to biventricular pacing in patients with conventional pacemakers and heart failure: a double-blind, randomized crossover study. Europace 2006;8:5155.
348. Delnoy PP, Ottervanger JP, Vos DH, Elvan A, Misier AR, Beukema WP,
Steendijk P, van Hemel NM. Upgrading to biventricular pacing guided by pressurevolume loop analysis during implantation. J Cardiovasc Electrophysiol
2011;22:677683.
349. van Geldorp IE, Vernooy K, Delhaas T, Prins MH, Crijns HJ, Prinzen FW,
Dijkman B. Beneficial effects of biventricular pacing in chronically right ventricular paced patients with mild cardiomyopathy. Europace 2010;12:223229.
350. Leclercq C, Cazeau S, Lellouche D, Fossati F, Anselme F, Davy JM, Sadoul N,
Klug D, Mollo L, Daubert JC. Upgrading from single chamber right ventricular to biventricular pacing in permanently paced patients with worsening heart failure: the RD-CHF Study. Pacing Clin Electrophysiol 2007;30 Suppl 1:S23S30.
351. Kosztin A, Vamos M, Aradi D, Schwertner WR, Kovacs A, Nagy KV, Zima E,
Geller L, Duray GZ, Kutyifa V, Merkely B. De novo implantation vs. upgrade cardiac resynchronization therapy: a systematic review and meta-analysis. Heart
Fail Rev 2018;23:1526.
352. Linde CM, Normand C, Bogale N, Auricchio A, Sterlinski M, Marinskis G,
Sticherling C, Bulava A, Perez OC, Maass AH, Witte KK, Rekvava R, Abdelali S,
Dickstein K. Upgrades from a previous device compared to de novo cardiac resynchronization therapy in the European Society of Cardiology CRT Survey
II. Eur J Heart Fail 2018;20:14571468.
353. Raatikainen MJP, Arnar DO, Merkely B, Nielsen JC, Hindricks G, Heidbuchel H,
Camm J. A decade of information on the use of cardiac implantable electronic devices and interventional electrophysiological procedures in the European
Society of Cardiology Countries: 2017 report from the European Heart
Rhythm Association. Europace 2017;19:ii1ii90.
354. Kirkfeldt RE, Johansen JB, Nohr EA, Jorgensen OD, Nielsen JC. Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark. Eur Heart J 2014;35:11861194.
355. Boriani G, Diemberger I. Cardiac resynchronization therapy in the real world:
need to upgrade outcome research. Eur J Heart Fail 2018;20:14691471.
356. Merkely B, Kosztin A, Roka A, Geller L, Zima E, Kovacs A, Boros AM, Klein H,
Wranicz JK, Hindricks G, Clemens M, Duray GZ, Moss AJ, Goldenberg I, Kutyifa
V. Rationale and design of the BUDAPEST-CRT Upgrade Study: a prospective,
randomized, multicentre clinical trial. Europace 2017;19:15491555.
357. Kindermann M, Hennen B, Jung J, Geisel J, Bohm M, Frohlig G. Biventricular versus conventional right ventricular stimulation for patients with standard pacing indication and left ventricular dysfunction: the Homburg Biventricular Pacing
Evaluation (HOBIPACE). J Am Coll Cardiol 2006;47:19271937.
358. Martinelli Filho M, de Siqueira SF, Costa R, Greco OT, Moreira LF, D’Avila A,
Heist EK. Conventional versus biventricular pacing in heart failure and bradyarrhythmia: the COMBAT study. J Card Fail 2010;16:293300.
359. Yu CM, Fang F, Luo XX, Zhang Q, Azlan H, Razali O. Long-term follow-up results of the pacing to avoid cardiac enlargement (PACE) trial. Eur J Heart Fail
2014;16:10161025.
360. Albertsen AE, Mortensen PT, Jensen HK, Poulsen SH, Egeblad H, Nielsen JC.
Adverse effect of right ventricular pacing prevented by biventricular pacing during long-term follow-up:
a randomized comparison.
Eur
J
Echocardiogr
2011;12:767772.
361. Chung ES, St John Sutton MG, Mealing S, Sidhu MK, Padhiar A, Tsintzos SI, Lu
X, Verhees KJP, Lautenbach AA, Curtis AB. Economic value and costeffectiveness of biventricular versus right ventricular pacing: results from the
BLOCK-HF study. J Med Econ 2019;22:10881095.
362. Orlov MV, Gardin JM, Slawsky M, Bess RL, Cohen G, Bailey W, Plumb V,
Flathmann H, de Metz K. Biventricular pacing improves cardiac function and prevents further left atrial remodeling in patients with symptomatic atrial fibrillation after atrioventricular node ablation.
Am
Heart
J
2010;159:264270.
363. Carson P, Anand I, O’Connor C, Jaski B, Steinberg J, Lwin A, Lindenfeld J, Ghali
J, Barnet JH, Feldman AM, Bristow MR. Mode of death in advanced heart failure:
the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart
Failure (COMPANION) trial. J Am Coll Cardiol 2005;46:23292334.
364. Barsheshet A, Wang PJ, Moss AJ, Solomon SD, Al-Ahmad A, McNitt S, Foster
E, Huang DT, Klein HU, Zareba W, Eldar M, Goldenberg I. Reverse remodeling and the risk of ventricular tachyarrhythmias in the MADIT-CRT (Multicenter
Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy).
J Am Coll Cardiol 2011;57:24162423.
365. Gold MR, Linde C, Abraham WT, Gardiwal A, Daubert JC. The impact of cardiac resynchronization therapy on the incidence of ventricular arrhythmias in mild heart failure. Heart Rhythm 2011;8:679684.
366. Sapp JL, Parkash R, Wells GA, Yetisir E, Gardner MJ, Healey JS, Thibault B,
Sterns LD, Birnie D, Nery PB, Sivakumaran S, Essebag V, Dorian P, Tang AS.
Cardiac resynchronization therapy reduces ventricular arrhythmias in primary but not secondary prophylactic implantable cardioverter defibrillator patients:
insight from the Resynchronization in Ambulatory Heart Failure trial. Circ
Arrhythm Electrophysiol 2017;10:e004875.
367. Kutyifa V, Moss AJ, Solomon SD, McNitt S, Aktas MK, Barsheshet A, Merkely B,
Zareba W, Goldenberg I. Reduced risk of life-threatening ventricular tachyarrhythmias with cardiac resynchronization therapy: relationship to left ventricular ejection fraction. Eur J Heart Fail 2015;17:971978.
368. Gold MR, Daubert JC, Abraham WT, Hassager C, Dinerman JL, Hudnall JH,
Cerkvenik J, Linde C. Implantable defibrillators improve survival in patients with mildly symptomatic heart failure receiving cardiac resynchronization therapy:
analysis of the long-term follow-up of remodeling in systolic left ventricular dysfunction (REVERSE). Circ Arrhythm Electrophysiol 2013;6:11631168.
369. Al-Majed NS, McAlister FA, Bakal JA, Ezekowitz JA. Meta-analysis: cardiac resynchronization therapy for patients with less symptomatic heart failure. Ann
Intern Med 2011;154:401412.
370. Lam SK, Owen A. Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials. BMJ 2007;335:925.
371. Kutyifa V, Geller L, Bogyi P, Zima E, Aktas MK, Ozcan EE, Becker D, Nagy VK,
Kosztin A, Szilagyi S, Merkely B. Effect of cardiac resynchronization therapy with implantable cardioverter defibrillator versus cardiac resynchronization therapy with pacemaker on mortality in heart failure patients: results of a highvolume, single-centre experience. Eur J Heart Fail 2014;16:13231330.
372. Barra S, Boveda S, Providencia R, Sadoul N, Duehmke R, Reitan C, Borgquist R,
Narayanan K, Hidden-Lucet F, Klug D, Defaye P, Gras D, Anselme F, Leclercq
C, Hermida JS, Deharo JC, Looi KL, Chow AW, Virdee M, Fynn S, Le Heuzey
JY, Marijon E, Agarwal S. Adding defibrillation therapy to cardiac resynchronization on the basis of the myocardial substrate.
J
Am
Coll
Cardiol
2017;69:16691678.
373. Leyva F, Zegard A, Umar F, Taylor RJ, Acquaye E, Gubran C, Chalil S, Patel K,
Panting J, Marshall H, Qiu T. Long-term clinical outcomes of cardiac resynchronization therapy with or without defibrillation: impact of the aetiology of cardiomyopathy. Europace 2018;20:18041812.
374. Kober L, Thune JJ, Nielsen JC, Haarbo J, Videbaek L, Korup E, Jensen G,
Hildebrandt P, Steffensen FH, Bruun NE, Eiskjaer H, Brandes A, Thogersen AM,
Gustafsson F, Egstrup K, Videbaek R, Hassager C, Svendsen JH, Hofsten DE,
Torp-Pedersen C, Pehrson S, DANISH Investigators. Defibrillator implantation in patients with nonischemic systolic heart failure.
N
Engl
J
Med
2016;375:12211230.
375. Leyva F, Zegard A, Okafor O, de Bono J, McNulty D, Ahmed A, Marshall H,
Ray D, Qiu T. Survival after cardiac resynchronization therapy: results from 50
084 implantations. Europace 2019;21:754762.
376. Gras M, Bisson A, Bodin A, Herbert J, Babuty D, Pierre B, Clementy N,
Fauchier L. Mortality and cardiac resynchronization therapy with or without defibrillation in primary prevention. Europace 2020;22:12241233.
377. Marijon E, Leclercq C, Narayanan K, Boveda S, Klug D, Lacaze-Gadonneix J,
Defaye P, Jacob S, Piot O, Deharo JC, Perier MC, Mulak G, Hermida JS, Milliez
P, Gras D, Cesari O, Hidden-Lucet F, Anselme F, Chevalier P, Maury P, Sadoul
N, Bordachar P, Cazeau S, Chauvin M, Empana JP, Jouven X, Daubert JC, Le
Heuzey JY. Causes-of-death analysis of patients with cardiac resynchronization therapy:
an analysis of the
CeRtiTuDe cohort study.
Eur
Heart
J
2015;36:27672776.


<!-- PAGE 81 -->

### Page 81

.............................................................................................................................................................................
378. Morani G, Gasparini M, Zanon F, Casali E, Spotti A, Reggiani A, Bertaglia E,
Solimene F, Molon G, Accogli M, Tommasi C, Paoletti Perini A, Ciardiello C,
Padeletti L. Cardiac resynchronization therapy-defibrillator improves long-term survival compared with cardiac resynchronization therapy-pacemaker in patients with a class IA indication for cardiac resynchronization therapy: data from the Contak Italian Registry. Europace 2013;15:12731279.
379. Acosta J, Fernandez-Armenta J, Borras R, Anguera I, Bisbal F, Marti-Almor J,
Tolosana JM, Penela D, Andreu D, Soto-Iglesias D, Evertz R, Matiello M, Alonso
C, Villuendas R, de Caralt TM, Perea RJ, Ortiz JT, Bosch X, Serra L, Planes X,
Greiser A, Ekinci O, Lasalvia L, Mont L, Berruezo A. Scar characterization to predict life-threatening arrhythmic events and sudden cardiac death in patients with cardiac resynchronization therapy: the GAUDI-CRT study. JACC Cardiovasc
Imaging 2018;11:561572.
380. Leyva F, Zegard A, Acquaye E, Gubran C, Taylor R, Foley PWX, Umar F, Patel
K, Panting J, Marshall H, Qiu T. Outcomes of cardiac resynchronization therapy with or without defibrillation in patients with nonischemic cardiomyopathy. J
Am Coll Cardiol 2017;70:12161227.
381. Cleland JG, Freemantle N, Erdmann E, Gras D, Kappenberger L, Tavazzi L,
Daubert JC. Long-term mortality with cardiac resynchronization therapy in the
Cardiac Resynchronization-Heart Failure (CARE-HF) trial. Eur J Heart Fail
2012;14:628634.
382. Barra S, Looi KL, Gajendragadkar PR, Khan FZ, Virdee M, Agarwal S.
Applicability of a risk score for prediction of the long-term benefit of the implantable cardioverter defibrillator in patients receiving cardiac resynchronization therapy. Europace 2016;18:11871193.
383. Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, He H, Zareba W, McNitt S,
Andrews ML, MADIT-II Investigators. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2008;51:288296.
384. Lumens J, Tayal B, Walmsley J, Delgado-Montero A, Huntjens PR, Schwartzman
D, Althouse AD, Delhaas T, Prinzen FW, Gorcsan J 3rd. Differentiating electromechanical from non-electrical substrates of mechanical discoordination to identify responders to cardiac resynchronization therapy. Circ Cardiovasc Imaging
2015;8:e003744.
385. Ploux S, Lumens J, Whinnett Z, Montaudon M, Strom M, Ramanathan C, Derval
N, Zemmoura A, Denis A, De Guillebon M, Shah A, Hocini M, Jais P, Ritter P,
Haissaguerre M, Wilkoff BL, Bordachar P. Noninvasive electrocardiographic mapping to improve patient selection for cardiac resynchronization therapy:
beyond QRS duration and left bundle branch block morphology. J Am Coll
Cardiol 2013;61:24352443.
386. Parsai C, Bijnens B, Sutherland GR, Baltabaeva A, Claus P, Marciniak M, Paul V,
Scheffer M, Donal E, Derumeaux G, Anderson L. Toward understanding response to cardiac resynchronization therapy: left ventricular dyssynchrony is only one of multiple mechanisms. Eur Heart J 2009;30:940949.
387. Adelstein EC, Tanaka H, Soman P, Miske G, Haberman SC, Saba SF, Gorcsan J
3rd. Impact of scar burden by single-photon emission computed tomography myocardial perfusion imaging on patient outcomes following cardiac resynchronization therapy. Eur Heart J 2011;32:93103.
388. Taylor RJ, Umar F, Panting JR, Stegemann B, Leyva F. Left ventricular lead position, mechanical activation, and myocardial scar in relation to left ventricular reverse remodeling and clinical outcomes after cardiac resynchronization therapy: a feature-tracking and contrast-enhanced cardiovascular magnetic resonance study. Heart Rhythm 2016;13:481489.
389. Saba S, Marek J, Schwartzman D, Jain S, Adelstein E, White P, Oyenuga OA,
Onishi T, Soman P, Gorcsan J 3rd. Echocardiography-guided left ventricular lead placement for cardiac resynchronization therapy: results of the Speckle
Tracking Assisted Resynchronization Therapy for Electrode Region trial. Circ
Heart Fail 2013;6:427434.
390. Stephansen C, Sommer A, Kronborg MB, Jensen JM, Norgaard BL, Gerdes C,
Kristensen J, Jensen HK, Fyenbo DB, Bouchelouche K, Nielsen JC. Electrically vs. imaging-guided left ventricular lead placement in cardiac resynchronization therapy: a randomized controlled trial. Europace 2019;21:13691377.
391. Delgado-Montero A, Tayal B, Goda A, Ryo K, Marek JJ, Sugahara M, Qi Z,
Althouse AD, Saba S, Schwartzman D, Gorcsan J 3rd. Additive prognostic value of echocardiographic global longitudinal and global circumferential strain to electrocardiographic criteria in patients with heart failure undergoing cardiac resynchronization therapy. Circ Cardiovasc Imaging 2016;9.
392. Gorcsan J 3rd, Anderson CP, Tayal B, Sugahara M, Walmsley J, Starling RC,
Lumens J. Systolic stretch characterizes the electromechanical substrate responsive to cardiac resynchronization therapy. JACC Cardiovasc Imaging
2019;12:17411752.
393. Khidir MJH, Abou R, Yilmaz D, Ajmone Marsan N, Delgado V, Bax JJ.
Prognostic value of global longitudinal strain in heart failure patients treated with cardiac resynchronization therapy. Heart Rhythm 2018;15:15331539.
394. Donal E, Delgado V, Bucciarelli-Ducci C, Galli E, Haugaa KH, Charron P, Voigt
JU, Cardim N, Masci PG, Galderisi M, Gaemperli O, Gimelli A, Pinto YM,
Lancellotti P, Habib G, Elliott P, Edvardsen T, Cosyns B, Popescu BA, EACVI
Scientific Documents Committee. Multimodality imaging in the diagnosis, risk stratification, and management of patients with dilated cardiomyopathies: an expert consensus document from the European Association of Cardiovascular
Imaging. Eur Heart J Cardiovasc Imaging 2019;20:10751093.
395. Bleeker GB, Kaandorp TA, Lamb HJ, Boersma E, Steendijk P, de Roos A, van der Wall EE, Schalij MJ, Bax JJ. Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy.
Circulation 2006;113:969976.
396. Ypenburg C, Roes SD, Bleeker GB, Kaandorp TA, de Roos A, Schalij MJ, van der Wall EE, Bax JJ. Effect of total scar burden on contrast-enhanced magnetic resonance imaging on response to cardiac resynchronization therapy. Am J
Cardiol 2007;99:657660.
397. van der Bijl P, Khidir M, Ajmone Marsan N, Delgado V, Leon MB, Stone GW,
Bax JJ. Effect of functional mitral regurgitation on outcome in patients receiving cardiac resynchronization therapy for heart failure.
Am
J
Cardiol
2019;123:7583.
398. Leong DP, Hoke U, Delgado V, Auger D, Witkowski T, Thijssen J, van Erven L,
Bax JJ, Schalij MJ, Marsan NA. Right ventricular function and survival following cardiac resynchronisation therapy. Heart 2013;99:722728.
399. Chung ES, Leon AR, Tavazzi L, Sun JP, Nihoyannopoulos P, Merlino J, Abraham
WT, Ghio S, Leclercq C, Bax JJ, Yu CM, Gorcsan J 3rd, St John Sutton M, De
Sutter J, Murillo J. Results of the Predictors of Response to CRT (PROSPECT)
trial. Circulation 2008;117:26082616.
400. Beela AS, Unlu S, Duchenne J, Ciarka A, Daraban AM, Kotrc M, Aarones M,
Szulik M, Winter S, Penicka M, Neskovic AN, Kukulski T, Aakhus S, Willems R,
Fehske W, Faber L, Stankovic I, Voigt JU. Assessment of mechanical dyssynchrony can improve the prognostic value of guideline-based patient selection for cardiac resynchronization therapy.
Eur
Heart
J
Cardiovasc
Imaging
2019;20:6674.
401. Delgado V, Ypenburg C, van Bommel RJ, Tops LF, Mollema SA, Marsan NA,
Bleeker GB, Schalij MJ, Bax JJ. Assessment of left ventricular dyssynchrony by speckle tracking strain imaging comparison between longitudinal, circumferential, and radial strain in cardiac resynchronization therapy. J Am Coll Cardiol
2008;51:19441952.
402. Risum N, Tayal B, Hansen TF, Bruun NE, Jensen MT, Lauridsen TK, Saba S,
Kisslo J, Gorcsan J 3rd, Sogaard P. Identification of typical left bundle branch block contraction by strain echocardiography is additive to electrocardiography in prediction of long-term outcome after cardiac resynchronization therapy. J
Am Coll Cardiol 2015;66:631641.
403. Leenders GE, Lumens J, Cramer MJ, De Boeck BW, Doevendans PA, Delhaas
T, Prinzen FW. Septal deformation patterns delineate mechanical dyssynchrony and regional differences in contractility: analysis of patient data using a computer model. Circ Heart Fail 2012;5:8796.
404. Mafi-Rad M, Van’t Sant J, Blaauw Y, Doevendans PA, Cramer MJ, Crijns HJ,
Prinzen FW, Meine M, Vernooy K. Regional left ventricular electrical activation and peak contraction are closely related in candidates for cardiac resynchronization therapy. JACC Clin Electrophysiol 2017;3:854862.
405. Maass AH, Vernooy K, Wijers SC, van ‘t Sant J, Cramer MJ, Meine M, Allaart
CP, De Lange FJ, Prinzen FW, Gerritse B, Erdtsieck E, Scheerder COS, Hill
MRS, Scholten M, Kloosterman M, Ter Horst IAH, Voors AA, Vos MA, Rienstra
M, Van Gelder IC. Refining success of cardiac resynchronization therapy using a simple score predicting the amount of reverse ventricular remodelling: results from the
Markers and
Response to
CRT
(MARC)
study.
Europace
2018;20:e1-e10.
406. van der Bijl P, Vo NM, Kostyukevich MV, Mertens B, Ajmone Marsan N,
Delgado V, Bax JJ. Prognostic implications of global, left ventricular myocardial work efficiency before cardiac resynchronization therapy. Eur Heart J Cardiovasc
Imaging 2019;20:13881394.
407. Khan FZ, Virdee MS, Palmer CR, Pugh PJ, O’Halloran D, Elsik M, Read PA,
Begley D, Fynn SP, Dutka DP. Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trial. J Am Coll Cardiol 2012;59:15091518.
408. Sommer A, Kronborg MB, Norgaard BL, Poulsen SH, Bouchelouche K,
Bottcher M, Jensen HK, Jensen JM, Kristensen J, Gerdes C, Mortensen PT,
Nielsen JC. Multimodality imaging-guided left ventricular lead placement in cardiac resynchronization therapy: a randomized controlled trial. Eur J Heart Fail
2016;18:13651374.
409. Cikes M, Sanchez-Martinez S, Claggett B, Duchateau N, Piella G, Butakoff C,
Pouleur AC, Knappe D, Biering-Sorensen T, Kutyifa V, Moss A, Stein K,
Solomon SD, Bijnens B. Machine learning-based phenogrouping in heart failure to identify responders to cardiac resynchronization therapy. Eur J Heart Fail
2019;21:7485.
410. Di Biase L, Auricchio A, Mohanty P, Bai R, Kautzner J, Pieragnoli P, Regoli F,
Sorgente A, Spinucci G, Ricciardi G, Michelucci A, Perrotta L, Faletra F,
Mlcochova H, Sedlacek K, Canby R, Sanchez JE, Horton R, Burkhardt JD,
ESC Guidelines
81


<!-- PAGE 82 -->

### Page 82

.............................................................................................................................................................................
Moccetti T, Padeletti L, Natale A. Impact of cardiac resynchronization therapy on the severity of mitral regurgitation. Europace 2011;13:829838.
411. Auricchio A, Schillinger W, Meyer S, Maisano F, Hoffmann R, Ussia GP,
Pedrazzini GB, van der Heyden J, Fratini S, Klersy C, Komtebedde J, Franzen O.
Correction of mitral regurgitation in nonresponders to cardiac resynchronization therapy by MitraClip improves symptoms and promotes reverse remodeling. J Am Coll Cardiol 2011;58:21832189.
412. D’Ancona G, Ince H, Schillinger W, Senges J, Ouarrak T, Butter C, Seifert M,
Schau T, Lubos E, Boekstegers P, von Bardeleben RS, Safak E. Percutaneous treatment of mitral regurgitation in patients with impaired ventricular function: impact of intracardiac electronic devices (from the German Transcatheter Mitral Valve
Interventions Registry). Catheter Cardiovasc Interv 2019;94:755763.
413. Giaimo VL, Zappulla P, Cirasa A, Tempio D, Sanfilippo M, Rapisarda G, Trovato
D, Grazia AD, Liotta C, Grasso C, Capodanno D, Tamburino C, Calvi V. Longterm clinical and echocardiographic outcomes of Mitraclip therapy in patients nonresponders to cardiac resynchronization.
Pacing
Clin
Electrophysiol
2018;41:6572.
414. Seifert M, Schau T, Schoepp M, Arya A, Neuss M, Butter C. MitraClip in CRT
non-responders with severe mitral regurgitation. Int J Cardiol 2014;177:7985.
415. Obadia JF, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, Lefevre
T, Piot C, Rouleau F, Carrie D, Nejjari M, Ohlmann P, Leclercq F, Saint Etienne
C, Teiger E, Leroux L, Karam N, Michel N, Gilard M, Donal E, Trochu JN,
Cormier B, Armoiry X, Boutitie F, Maucort-Boulch D, Barnel C, Samson G,
Guerin P, Vahanian A, Mewton N, MITRA-FR Investigators. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med
2018;379:22972306.
416. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, Whisenant B,
Grayburn PA, Rinaldi M, Kapadia SR, Rajagopal V, Sarembock IJ, Brieke A, Marx
SO, Cohen DJ, Weissman NJ, Mack MJ, COAPT Investigators. Transcatheter mitral-valve repair in patients with heart failure.
N
Engl
J
Med
2018;379:23072318.
417. Kaye GC, Linker NJ, Marwick TH, Pollock L, Graham L, Pouliot E, Poloniecki J,
Gammage M, Protect-Pace trial investigators. Effect of right ventricular pacing lead site on left ventricular function in patients with high-grade atrioventricular block: results of the Protect-Pace study. Eur Heart J 2015;36:
856862.
418. Leclercq C, Sadoul N, Mont L, Defaye P, Osca J, Mouton E, Isnard R, Habib G,
Zamorano
J,
Derumeaux
G,
Fernandez-Lozano
I,
SEPTAL
CRT
Study
Investigators. Comparison of right ventricular septal pacing and right ventricular apical pacing in patients receiving cardiac resynchronization therapy defibrillators: the SEPTAL CRT Study. Eur Heart J 2016;37:473483.
419. Hussain MA, Furuya-Kanamori L, Kaye G, Clark J, Doi SA. The Effect of right ventricular apical and nonapical pacing on the short- and long-term changes in left ventricular ejection fraction: a systematic review and meta-analysis of randomized-controlled trials. Pacing Clin Electrophysiol 2015;38:11211136.
420. Cano O, Andres A, Alonso P, Osca J, Sancho-Tello MJ, Olague J, Martinez-Dolz L.
Incidence and predictors of clinically relevant cardiac perforation associated with systematic implantation of active-fixation pacing and defibrillation leads: a singlecentre experience with over 3800 implanted leads. Europace 2017;19:96102.
421. Sommer A, Kronborg MB, Norgaard BL, Gerdes C, Mortensen PT, Nielsen JC.
Left and right ventricular lead positions are imprecisely determined by fluoroscopy in cardiac resynchronization therapy: a comparison with cardiac computed tomography. Europace 2014;16:13341341.
422. Zanon F, Ellenbogen KA, Dandamudi G, Sharma PS, Huang W, Lustgarten DL,
Tung R, Tada H, Koneru JN, Bergemann T, Fagan DH, Hudnall JH, Vijayaraman
P. Permanent His-bundle pacing: a systematic literature review and meta-analysis. Europace 2018;20:18191826.
423. Keene D, Arnold AD, Jastrzebski M, Burri H, Zweibel S, Crespo E,
Chandrasekaran B, Bassi S, Joghetaei N, Swift M, Moskal P, Francis DP, Foley P,
Shun-Shin MJ, Whinnett ZI. His bundle pacing, learning curve, procedure characteristics, safety, and feasibility: insights from a large international observational study. J Cardiovasc Electrophysiol 2019;30:19841993.
424. Vijayaraman P, Dandamudi G, Zanon F, Sharma PS, Tung R, Huang W, Koneru
J, Tada H, Ellenbogen KA, Lustgarten DL. Permanent His bundle pacing: recommendations from a Multicenter His Bundle Pacing Collaborative Working
Group for standardization of definitions, implant measurements, and follow-up.
Heart Rhythm 2018;15:460468.
425. Burri H, Jastrzebski M, Vijayaraman P. ECG analysis for His bundle pacing at implantation and follow-up. JACC Clin Electrophysiol 2020;6:883900.
426. Teigeler T, Kolominsky J, Vo C, Shepard RK, Kalahasty G, Kron J, Huizar JF,
Kaszala K, Tan AY, Koneru JN, Ellenbogen KA, Padala SK. Intermediate term performance and safety of His bundle pacing leads: a single center experience.
Heart Rhythm 2021;18:743749.
427. Vijayaraman P, Naperkowski A, Subzposh FA, Abdelrahman M, Sharma PS,
Oren JW, Dandamudi G, Ellenbogen KA. Permanent His-bundle pacing: longterm lead performance and clinical outcomes. Heart Rhythm 2018;15:696702.
428. Zanon F, Abdelrahman M, Marcantoni L, Naperkowski A, Subzposh FA, Pastore
G, Baracca E, Boaretto G, Raffagnato P, Tiribello A, Dandamudi G, Vijayaraman
P. Long term performance and safety of His bundle pacing: a multicenter experience. J Cardiovasc Electrophysiol 2019;30:15941601.
429. Kirkfeldt RE, Johansen JB, Nohr EA, Moller M, Arnsbo P, Nielsen JC. Risk factors for lead complications in cardiac pacing: a population-based cohort study of 28,860 Danish patients. Heart Rhythm 2011;8:16221628.
430. Starr N, Dayal N, Domenichini G, Stettler C, Burri H. Electrical parameters with His-bundle pacing: considerations for automated programming. Heart
Rhythm 2019;16:18171824.
431. Burri H, Keene D, Whinnett Z, Zanon F, Vijayaraman P. Device programming for His bundle pacing. Circ Arrhythm Electrophysiol 2019;12:e006816.
432. Lustgarten DL, Sharma PS, Vijayaraman P. Troubleshooting and programming considerations for His bundle pacing. Heart Rhythm 2019;16:654662.
433. Vijayaraman
P,
Naperkowski
A,
Ellenbogen
KA,
Dandamudi
G.
Electrophysiologic insights into site of atrioventricular block.
JACC
Clin
Electrophysiol 2015;1:571581.
434. Su L, Cai M, Wu S, Wang S, Xu T, Vijayaraman P, Huang W. Long-term performance and risk factors analysis after permanent His-bundle pacing and atrioventricular node ablation in patients with atrial fibrillation and heart failure.
Europace 2020;22:ii19ii26.
435. Narula OS. Longitudinal dissociation in the His bundle. Bundle branch block due to asynchronous conduction within the His bundle in man. Circulation
1977;56:9961006.
436. Upadhyay GA, Cherian T, Shatz DY, Beaser AD, Aziz Z, Ozcan C, Broman MT,
Nayak HM, Tung R. Intracardiac delineation of septal conduction in left bundlebranch block patterns. Circulation 2019;139:18761888.
437. Upadhyay GA, Vijayaraman P, Nayak HM, Verma N, Dandamudi G, Sharma PS,
Saleem M, Mandrola J, Genovese D, Tung R. His corrective pacing or biventricular pacing for cardiac resynchronization in heart failure. J Am Coll Cardiol
2019;74:157159.
438. Upadhyay GA, Vijayaraman P, Nayak HM, Verma N, Dandamudi G, Sharma PS,
Saleem M, Mandrola J, Genovese D, Oren JW, Subzposh FA, Aziz Z, Beaser A,
Shatz D, Besser S, Lang RM, Trohman RG, Knight BP, Tung R, His-Sync
Investigators. On-treatment comparison between corrective His bundle pacing and biventricular pacing for cardiac resynchronization: a secondary analysis of the His-SYNC Pilot Trial. Heart Rhythm 2019;16:17971807.
439. Lustgarten DL, Crespo EM, Arkhipova-Jenkins I, Lobel R, Winget J, Koehler J,
Liberman E, Sheldon T. His-bundle pacing versus biventricular pacing in cardiac resynchronization therapy patients: a crossover design comparison. Heart
Rhythm 2015;12:15481557.
440. Giraldi F, Cattadori G, Roberto M, Carbucicchio C, Pepi M, Ballerini G,
Alamanni F, Della Bella P, Pontone G, Andreini D, Tondo C, Agostoni PG.
Long-term effectiveness of cardiac resynchronization therapy in heart failure patients with unfavorable cardiac veins anatomy comparison of surgical versus hemodynamic procedure. J Am Coll Cardiol 2011;58:483490.
441. Sharma PS, Naperkowski A, Bauch TD, Chan JYS, Arnold AD, Whinnett ZI,
Ellenbogen KA, Vijayaraman P. Permanent His bundle pacing for cardiac resynchronization therapy in patients with heart failure and right bundle branch block. Circ Arrhythm Electrophysiol 2018;11:e006613.
442. Huang W, Chen X, Su L, Wu S, Xia X, Vijayaraman P. A beginner’s guide to permanent left bundle branch pacing. Heart Rhythm 2019;16:17911796.
443. Barba-Pichardo R, Manovel Sanchez A, Fernandez-Gomez JM, Morina-Vazquez
P, Venegas-Gamero J, Herrera-Carranza M. Ventricular resynchronization therapy by direct His-bundle pacing using an internal cardioverter defibrillator.
Europace 2013;15:8388.
444. Zweerink A, Bakelants E, Stettler C, Burri H. Cryoablation vs. radiofrequency ablation of the atrioventricular node in patients with His-bundle pacing.
Europace 2020;23:421430.
445. Valiton V, Graf D, Pruvot E, Carroz P, Fromer M, Bisch L, Tran VN, Cook S,
Scharf C, Burri H. Leadless pacing using the transcatheter pacing system (Micra
TPS) in the real world: initial Swiss experience from the Romandie region.
Europace 2019;21:275280.
446. Defaye P, Klug D, Anselme F, Gras D, Hermida JS, Piot O, Alonso C, Fauchier
L, Gandjbakhch E, Marijon E, Maury P, Taieb J, Boveda S, Sadoul N.
Recommendations for the implantation of leadless pacemakers from the French
Working Group on Cardiac Pacing and Electrophysiology of the French Society of Cardiology. Arch Cardiovasc Dis 2018;111:5358.
447. Leadless cardiac pacemaker therapy: design of pre- and post-market clinical studies. Recommendations from MHRA Expert Advisory Group. Version 3:
Updated
January
2021.
https://assets.publishing.service.gov.uk/government/
uploads/system/uploads/attachment_data/file/956252/Leadless-EAG-guidance.
pdf (25 May 2021)
448. Steinwender C, Khelae SK, Garweg C, Sun Chan JY, Ritter P, Johansen JB, Sagi
V, Epstein LM, Piccini JP, Pascual M, Mont L, Sheldon T, Splett V, Stromberg K,
Wood N, Chinitz L. Atrioventricular synchronous pacing using a leadless


<!-- PAGE 83 -->

### Page 83

.............................................................................................................................................................................
ventricular pacemaker:
results from the
MARVEL
2
study.
JACC
Clin
Electrophysiol 2019;6:94106.
449. Beurskens NE, Tjong FV, Knops RE. End-of-life management of leadless cardiac pacemaker therapy. Arrhythm Electrophysiol Rev 2017;6:129133.
450. El-Chami MF, Johansen JB, Zaidi A, Faerestrand S, Reynolds D, Garcia-Seara J,
Mansourati J, Pasquie JL, McElderry HT, Roberts PR, Soejima K, Stromberg K,
Piccini JP. Leadless pacemaker implant in patients with pre-existing infections:
results from the Micra postapproval registry. J Cardiovasc Electrophysiol
2019;30:569574.
451. Zimetbaum PJ, Josephson ME. Use of the electrocardiogram in acute myocardial infarction. N Engl J Med 2003;348:933940.
452. Pejkovic B, Krajnc I, Anderhuber F, Kosutic D. Anatomical aspects of the arterial blood supply to the sinoatrial and atrioventricular nodes of the human heart. J
Int Med Res 2008;36:691698.
453. Ritter WS, Atkins JM, Blomqvist CG, Mullins CB. Permanent pacing in patients with transient trifascicular block during acute myocardial infarction. Am J Cardiol
1976;38:205208.
454. Ginks WR, Sutton R, Oh W, Leatham A. Long-term prognosis after acute anterior infarction with atrioventricular block. Br Heart J 1977;39:186189.
455. Feigl D, Ashkenazy J, Kishon Y. Early and late atrioventricular block in acute inferior myocardial infarction. J Am Coll Cardiol 1984;4:3538.
456. Jim MH, Chan AO, Tse HF, Barold SS, Lau CP. Clinical and angiographic findings of complete atrioventricular block in acute inferior myocardial infarction. Ann
Acad Med Singapore 2010;39:185190.
457. Sutton R, Davies M. The conduction system in acute myocardial infarction complicated by heart block. Circulation 1968;38:987992.
458. Gang UJ, Hvelplund A, Pedersen S, Iversen A, Jøns C, Abildstrøm SZ, Haarbo J,
Jensen JS, Thomsen PE. High-degree atrioventricular block complicating STsegment elevation myocardial infarction in the era of primary percutaneous coronary intervention. Europace 2012;14:16391645.
459. Auffret V, Loirat A, Leurent G, Martins RP, Filippi E, Coudert I, Hacot JP, Gilard
M, Castellant P, Rialan A, Delaunay R, Rouault G, Druelles P, Boulanger B,
Treuil J, Avez B, Bedossa M, Boulmier D, Le Guellec M, Daubert JC, Le Breton
H. High-degree atrioventricular block complicating ST segment elevation myocardial infarction in the contemporary era. Heart 2016;102:4049.
460. Kim KH, Jeong MH, Ahn Y, Kim YJ, Cho MC, Kim W, Other Korea Acute
Myocardial Infarction Registry Investigators. Differential clinical implications of high-degree atrioventricular block complicating ST-segment elevation myocardial infarction according to the location of infarction in the era of primary percutaneous coronary intervention. Korean Circ J 2016;46:315323.
461. Kosmidou I, Redfors B, Dordi R, Dizon JM, McAndrew T, Mehran R, BenYehuda O, Mintz GS, Stone GW. Incidence, predictors, and outcomes of highgrade atrioventricular block in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the
HORIZONS-AMI Trial). Am J Cardiol 2017;119:12951301.
462. Singh SM, FitzGerald G, Yan AT, Brieger D, Fox KA, Lopez-Sendon J, Yan RT,
Eagle KA, Steg PG, Budaj A, Goodman SG. High-grade atrioventricular block in acute coronary syndromes: insights from the Global Registry of Acute
Coronary Events. Eur Heart J 2015;36:976983.
463. Meine TJ, Al-Khatib SM, Alexander JH, Granger CB, White HD, Kilaru R,
Williams K, Ohman EM, Topol E, Califf RM. Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy. Am Heart J 2005;149:670674.
464. Hindman MC, Wagner GS, JaRo M, Atkins JM, Scheinman MM, DeSanctis RW,
Hutter AH, Yeatman L, Rubenfire M, Pujura C, Rubin M, Morris JJ. The clinical significance of bundle branch block complicating acute myocardial infarction. 1.
Clinical characteristics, hospital mortality, and one-year follow-up. Circulation
1978;58:679688.
465. Melgarejo-Moreno A, Galcera-Tomas J, Garcia-Alberola A, Valde´s-Chavarri M,
Castillo-Soria FJ, Mira-Sanchez E, Gil-Sanchez J, Allegue-Gallego J. Incidence,
clinical characteristics, and prognostic significance of right bundle-branch block in acute myocardial infarction: a study in the thrombolytic era. Circulation
1997;96:11391144.
466. Vivas
D,
Pe´rez-Vizcayno
MJ,
Hernandez-Antolın
R,
Fernandez-Ortiz
A,
Ba~nuelos C, Escaned J, Jime´nez-Quevedo P, De Agustın JA, Nu~nez-Gil I,
Gonzalez-Ferrer JJ, Macaya C, Alfonso F. Prognostic implications of bundle branch block in patients undergoing primary coronary angioplasty in the stent era. Am J Cardiol 2010;105:12761283.
467. Xiong Y, Wang L, Liu W, Hankey GJ, Xu B, Wang S. The prognostic significance of right bundle branch block: a meta-analysis of prospective cohort studies. Clin
Cardiol 2015;38:604613.
468. Swart G, Brady WJ, DeBehnke DJ, MA OJ, Aufderheide TP. Acute myocardial infarction complicated by hemodynamically unstable bradyarrhythmia: prehospital and ED treatment with atropine. Am J Emerg Med 1999;17:647652.
469. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H,
Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A,
Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P,
Widimsky P, ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with STsegment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European
Society of Cardiology (ESC). Eur Heart J 2018;39:119177.
470. Watson RD, Glover DR, Page AJ, Littler WA, Davies P, de Giovanni J,
Pentecost BL. The Birmingham Trial of permanent pacing in patients with intraventricular conduction disorders after acute myocardial infarction. Am Heart J
1984;108:496501.
471. Kusumoto FM, Calkins H, Boehmer J, Buxton AE, Chung MK, Gold MR,
Hohnloser SH, Indik J, Lee R, Mehra MR, Menon V, Page RL, Shen WK,
Slotwiner DJ, Stevenson LW, Varosy PD, Welikovitch L. HRS/ACC/AHA
expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. Circulation 2014;130:94125.
472. Brodell GK, Cosgrove D, Schiavone W, Underwood DA, Loop FD. Cardiac rhythm and conduction disturbances in patients undergoing mitral valve surgery.
Cleve Clin J Med 1991;58:397399.
473. Chung
MK.
Cardiac surgery:
postoperative arrhythmias.
Crit
Care
Med
2000;28:N136N144.
474. Jaeger FJ, Trohman RG, Brener S, Loop F. Permanent pacing following repeat cardiac valve surgery. Am J Cardiol 1994;74:505507.
475. Reade MC. Temporary epicardial pacing after cardiac surgery: a practical review. Part 1: general considerations in the management of epicardial pacing.
Anaesthesia 2007;62:264271.
476. Reade MC. Temporary epicardial pacing after cardiac surgery: a practical review. Part 2: selection of epicardial pacing modes and troubleshooting.
Anaesthesia 2007;62:364373.
477. Leyva F, Qiu T, McNulty D, Evison F, Marshall H, Gasparini M. Long-term requirement for pacemaker implantation after cardiac valve replacement surgery. Heart Rhythm 2017;14:529534.
478. Merin O, Ilan M, Oren A, Fink D, Deeb M, Bitran D, Silberman S. Permanent pacemaker implantation following cardiac surgery: indications and long-term follow-up. Pacing Clin Electrophysiol 2009;32:712.
479. Glikson M, Dearani JA, Hyberger LK, Schaff HV, Hammill SC, Hayes DL.
Indications, effectiveness, and long-term dependency in permanent pacing after cardiac surgery. Am J Cardiol 1997;80:13091313.
480. Kim MH, Deeb GM, Eagle KA, Bruckman D, Pelosi F, Oral H, Sticherling C,
Baker RL, Chough SP, Wasmer K, Michaud GF, Knight BP, Strickberger SA,
Morady F. Complete atrioventricular block after valvular heart surgery and the timing of pacemaker implantation. Am J Cardiol 2001;87:649651, A610.
481. Hill TE, Kiehl EL, Shrestha NK, Gordon SM, Pettersson GB, Mohan C, Hussein
A, Hussain S, Wazni O, Wilkoff BL, Menon V, Tarakji KG. Predictors of permanent pacemaker requirement after cardiac surgery for infective endocarditis.
Eur Heart J Acute Cardiovasc Care 2021;10:329334.
482. DiBiase A, Tse TM, Schnittger I, Wexler L, Stinson EB, Valantine HA. Frequency and mechanism of bradycardia in cardiac transplant recipients and need for pacemakers. Am J Cardiol 1991;67:13851389.
483. Melton IC, Gilligan DM, Wood MA, Ellenbogen KA. Optimal cardiac pacing after heart transplantation. Pacing Clin Electrophysiol 1999;22:15101527.
484. Jacquet L, Ziady G, Stein K, Griffith B, Armitage J, Hardesty R, Kormos R.
Cardiac rhythm disturbances early after orthotopic heart transplantation: prevalence and clinical importance of the observed abnormalities. J Am Coll Cardiol
1990;16:832837.
485. Holt ND, McComb JM. Cardiac transplantation and pacemakers: when and what to implant. Card Electrophysiol Rev 2002;6:140151.
486. Burger H, Pecha S, Hakmi S, Opalka B, Schoenburg M, Ziegelhoeffer T. Fiveyear follow-up of transvenous and epicardial left ventricular leads: experience with more than 1000 leads. Interact Cardiovasc Thorac Surg 2020;30:7480.
487. Noheria A, van Zyl M, Scott LR, Srivathsan K, Madhavan M, Asirvatham SJ,
McLeod CJ. Single-site ventricular pacing via the coronary sinus in patients with tricuspid valve disease. Europace 2018;20:636642.
488. Sharma PS, Subzposh FA, Ellenbogen KA, Vijayaraman P. Permanent His-bundle pacing in patients with prosthetic cardiac valves. Heart Rhythm 2017;14:5964.
489. Martins RP, Galand V, Leclercq C, Daubert JC. Cardiac electronic implantable devices after tricuspid valve surgery. Heart Rhythm 2018;15:10811088.
490. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM,
Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard
AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN,
Wang
D,
Pocock
S.
Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery.
N
Engl
J
Med
2010;363:15971607.
491. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM,
Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babaliaros
V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ,
ESC Guidelines
83


<!-- PAGE 84 -->

### Page 84

.............................................................................................................................................................................
Anderson WN, Wang D, Pocock SJ. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011;364:21872198.
492. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani
VH, Tuzcu EM, Miller DC, Herrmann HC, Doshi D, Cohen DJ, Pichard AD,
Kapadia S, Dewey T, Babaliaros V, Szeto WY, Williams MR, Kereiakes D,
Zajarias A, Greason KL, Whisenant BK, Hodson RW, Moses JW, Trento A,
Brown DL, Fearon WF, Pibarot P, Hahn RT, Jaber WA, Anderson WN, Alu
MC,
Webb
JG.
Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016;374:16091620.
493. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, Kapadia SR,
Malaisrie SC, Cohen DJ, Pibarot P, Leipsic J, Hahn RT, Blanke P, Williams MR,
McCabe JM, Brown DL, Babaliaros V, Goldman S, Szeto WY, Genereux P,
Pershad A, Pocock SJ, Alu MC, Webb JG, Smith CR. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med
2019;380:16951705.
494. Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, Gleason
TG, Buchbinder M, Hermiller J Jr, Kleiman NS, Chetcuti S, Heiser J, Merhi W,
Zorn G, Tadros P, Robinson N, Petrossian G, Hughes GC, Harrison JK, Conte
J, Maini B, Mumtaz M, Chenoweth S, Oh JK. Transcatheter aortic-valve replacement with a
self-expanding prosthesis.
N
Engl
J
Med
2014;370:17901798.
495. Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O’Hair D, Bajwa T,
Heiser JC, Merhi W, Kleiman NS, Askew J, Sorajja P, Rovin J, Chetcuti SJ,
Adams DH, Teirstein PS, Zorn GL 3rd, Forrest JK, Tchetche D, Resar J, Walton
A, Piazza N, Ramlawi B, Robinson N, Petrossian G, Gleason TG, Oh JK,
Boulware MJ, Qiao H, Mugglin AS, Reardon MJ. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med
2019;380:17061715.
496. Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Sondergaard L, Mumtaz
M, Adams DH, Deeb GM, Maini B, Gada H, Chetcuti S, Gleason T, Heiser J,
Lange R, Merhi W, Oh JK, Olsen PS, Piazza N, Williams M, Windecker S,
Yakubov SJ, Grube E, Makkar R, Lee JS, Conte J, Vang E, Nguyen H, Chang Y,
Mugglin AS, Serruys PW, Kappetein AP. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med 2017;376:13211331.
497. Barbash IM, Finkelstein A, Barsheshet A, Segev A, Steinvil A, Assali A, Ben Gal
Y, Vaknin Assa H, Fefer P, Sagie A, Guetta V, Kornowski R. Outcomes of patients at estimated low, intermediate, and high risk undergoing transcatheter aortic valve implantation for aortic stenosis.
Am
J
Cardiol
2015;116:19161922.
498. Bekeredjian R, Szabo G, Balaban U, Bleiziffer S, Bauer T, Ensminger S, Frerker
C, Herrmann E, Beyersdorf F, Hamm C, Beckmann A, Mollmann H, Karck M,
Katus HA, Walther T. Patients at low surgical risk as defined by the Society of
Thoracic Surgeons Score undergoing isolated interventional or surgical aortic valve implantation: in-hospital data and 1-year results from the German Aortic
Valve Registry (GARY). Eur Heart J 2019;40:13231330.
499. Gilard M, Eltchaninoff H, Iung B, Donzeau-Gouge P, Chevreul K, Fajadet J,
Leprince P, Leguerrier A, Lievre M, Prat A, Teiger E, Lefevre T, Himbert D,
Tchetche D, Carrie D, Albat B, Cribier A, Rioufol G, Sudre A, Blanchard D,
Collet F, Dos Santos P, Meneveau N, Tirouvanziam A, Caussin C, Guyon P,
Boschat J, Le Breton H, Collart F, Houel R, Delpine S, Souteyrand G, Favereau
X, Ohlmann P, Doisy V, Grollier G, Gommeaux A, Claudel JP, Bourlon F,
Bertrand B, Van Belle E, Laskar M. Registry of transcatheter aortic-valve implantation in high-risk patients. N Engl J Med 2012;366:17051715.
500. Moat NE, Ludman P, de Belder MA, Bridgewater B, Cunningham AD, Young
CP, Thomas M, Kovac J, Spyt T, MacCarthy PA, Wendler O, Hildick-Smith D,
Davies SW, Trivedi U, Blackman DJ, Levy RD, Brecker SJ, Baumbach A, Daniel
T, Gray H, Mullen MJ. Long-term outcomes after transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis: the U.K. TAVI
(United Kingdom Transcatheter Aortic Valve Implantation) Registry. J Am Coll
Cardiol 2011;58:21302138.
501. Thomas M, Schymik G, Walther T, Himbert D, Lefevre T, Treede H,
Eggebrecht H, Rubino P, Michev I, Lange R, Anderson WN, Wendler O. Thirtyday results of the SAPIEN aortic Bioprosthesis European Outcome (SOURCE)
Registry: a European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation 2010;122:6269.
502. Werner N, Zahn R, Beckmann A, Bauer T, Bleiziffer S, Hamm CW,
Berkeredjian R, Berkowitsch A, Mohr FW, Landwehr S, Katus HA, Harringer
W, Ensminger S, Frerker C, Mollmann H, Walther T, Schneider S, Lange R.
Patients at intermediate surgical risk undergoing isolated interventional or surgical aortic valve implantation for severe symptomatic aortic valve stenosis.
Circulation 2018;138:26112623.
503. Fadahunsi OO, Olowoyeye A, Ukaigwe A, Li Z, Vora AN, Vemulapalli S, Elgin
E, Donato A. Incidence, predictors, and outcomes of permanent pacemaker implantation following transcatheter aortic valve replacement: analysis from the
U.S. Society of Thoracic Surgeons/American College of Cardiology TVT
Registry. JACC Cardiovasc Interv 2016;9:21892199.
504. Regueiro A, Abdul-Jawad Altisent O, Del Trigo M, Campelo-Parada F, Puri R,
Urena M, Philippon F, Rodes-Cabau J. Impact of new-onset left bundle branch block and periprocedural permanent pacemaker implantation on clinical outcomes in patients undergoing transcatheter aortic valve replacement: a systematic review and meta-analysis. Circ Cardiovasc Interv 2016;9:e003635.
505. Chamandi C, Barbanti M, Munoz-Garcia A, Latib A, Nombela-Franco L,
Gutierrez-Ibanez E, Veiga-Fernandez G, Cheema AN, Cruz-Gonzalez I, Serra V,
Tamburino C, Mangieri A, Colombo A, Jimenez-Quevedo P, Elizaga J, Laughlin
G, Lee DH, Garcia Del Blanco B, Rodriguez-Gabella T, Marsal JR, Cote M,
Philippon F, Rodes-Cabau J. Long-term outcomes in patients with new permanent pacemaker implantation following transcatheter aortic valve replacement.
JACC Cardiovasc Interv 2018;11:301310.
506. Mohananey D, Jobanputra Y, Kumar A, Krishnaswamy A, Mick S, White JM,
Kapadia SR. Clinical and echocardiographic outcomes following permanent pacemaker implantation after transcatheter aortic valve replacement: metaanalysis and meta-regression. Circ Cardiovasc Interv 2017;10:e005046.
507. Ueshima D, Nai Fovino L, Mojoli M, Napodano M, Fraccaro C, Tarantini G. The interplay between permanent pacemaker implantation and mortality in patients treated by transcatheter aortic valve implantation: a systematic review and meta-analysis. Catheter Cardiovasc Interv 2018;92:E159E167.
508. Urena M, Webb JG, Tamburino C, Munoz-Garcia AJ, Cheema A, Dager AE,
Serra V, Amat-Santos IJ, Barbanti M, Imme S, Briales JH, Benitez LM, Al Lawati
H, Cucalon AM, Garcia Del Blanco B, Lopez J, Dumont E, Delarochelliere R,
Ribeiro HB, Nombela-Franco L, Philippon F, Rodes-Cabau J. Permanent pacemaker implantation after transcatheter aortic valve implantation: impact on late clinical outcomes and left ventricular function. Circulation 2014;129:12331243.
509. Fujita B, Schmidt T, Bleiziffer S, Bauer T, Beckmann A, Bekeredjian R, Mollmann
H, Walther T, Landwehr S, Hamm C, Beyersdorf F, Katus HA, Harringer W,
Ensminger S, Frerker C, GARY Executive Board. Impact of new pacemaker implantation following surgical and transcatheter aortic valve replacement on 1year outcome. Eur J Cardiothorac Surg 2020;57:151159.
510. Zhang XH, Chen H, Siu CW, Yiu KH, Chan WS, Lee KL, Chan HW, Lee SW,
Fu GS, Lau CP, Tse HF. New-onset heart failure after permanent right ventricular apical pacing in patients with acquired high-grade atrioventricular block and normal left ventricular function. J Cardiovasc Electrophysiol 2008;19:136141.
511. Dizon JM, Nazif TM, Hess PL, Biviano A, Garan H, Douglas PS, Kapadia S,
Babaliaros V, Herrmann HC, Szeto WY, Jilaihawi H, Fearon WF, Tuzcu EM,
Pichard AD, Makkar R, Williams M, Hahn RT, Xu K, Smith CR, Leon MB, Kodali
SK. Chronic pacing and adverse outcomes after transcatheter aortic valve implantation. Heart 2015;101:16651671.
512. Abramowitz Y, Kazuno Y, Chakravarty T, Kawamori H, Maeno Y, Anderson D,
Allison Z, Mangat G, Cheng W, Gopal A, Jilaihawi H, Mack MJ, Makkar RR.
Concomitant mitral annular calcification and severe aortic stenosis: prevalence,
characteristics and outcome following transcatheter aortic valve replacement.
Eur Heart J 2017;38:11941203.
513. Al-Azzam F, Greason KL, Krittanawong C, Williamson EE, McLeod CJ, King KS,
Mathew V. The influence of native aortic valve calcium and transcatheter valve oversize on the need for pacemaker implantation after transcatheter aortic valve insertion. J Thorac Cardiovasc Surg 2017;153:10561062.e1051.
514. Bagur R, Rodes-Cabau J, Gurvitch R, Dumont E, Velianou JL, Manazzoni J,
Toggweiler S, Cheung A, Ye J, Natarajan MK, Bainey KR, DeLarochelliere R,
Doyle D, Pibarot P, Voisine P, Cote M, Philippon F, Webb JG. Need for permanent pacemaker as a complication of transcatheter aortic valve implantation and surgical aortic valve replacement in elderly patients with severe aortic stenosis and similar baseline electrocardiographic findings. JACC Cardiovasc Interv
2012;5:540551.
515. Boerlage-Van Dijk K, Kooiman KM, Yong ZY, Wiegerinck EM, Damman P,
Bouma BJ, Tijssen JG, Piek JJ, Knops RE, Baan J Jr. Predictors and permanency of cardiac conduction disorders and necessity of pacing after transcatheter aortic valve implantation. Pacing Clin Electrophysiol 2014;37:15201529.
516. Calvi V, Conti S, Pruiti GP, Capodanno D, Puzzangara E, Tempio D, Di Grazia
A, Ussia GP, Tamburino C. Incidence rate and predictors of permanent pacemaker implantation after transcatheter aortic valve implantation with selfexpanding CoreValve prosthesis. J Interv Card Electrophysiol 2012;34:189195.
517. De Carlo M, Giannini C, Bedogni F, Klugmann S, Brambilla N, De Marco F,
Zucchelli G, Testa L, Oreglia J, Petronio AS. Safety of a conservative strategy of permanent pacemaker implantation after transcatheter aortic CoreValve implantation. Am Heart J 2012;163:492499.
518. Fraccaro C, Buja G, Tarantini G, Gasparetto V, Leoni L, Razzolini R, Corrado
D, Bonato R, Basso C, Thiene G, Gerosa G, Isabella G, Iliceto S, Napodano M.
Incidence, predictors, and outcome of conduction disorders after transcatheter self-expandable aortic valve implantation. Am J Cardiol 2011;107:747754.
519. Gaede L, Kim WK, Liebetrau C, Dorr O, Sperzel J, Blumenstein J, Berkowitsch
A, Walther T, Hamm C, Elsasser A, Nef H, Mollmann H. Pacemaker implantation after
TAVI:
predictors of
AV block persistence.
Clin
Res Cardiol
2018;107:6069.


<!-- PAGE 85 -->

### Page 85

.............................................................................................................................................................................
520. Guetta V, Goldenberg G, Segev A, Dvir D, Kornowski R, Finckelstein A, Hay I,
Goldenberg I, Glikson M. Predictors and course of high-degree atrioventricular block after transcatheter aortic valve implantation using the CoreValve
Revalving System. Am J Cardiol 2011;108:16001605.
521. Mangieri A, Lanzillo G, Bertoldi L, Jabbour RJ, Regazzoli D, Ancona MB, Tanaka
A, Mitomo S, Garducci S, Montalto C, Pagnesi M, Giannini F, Giglio M,
Montorfano M, Chieffo A, Rodes-Cabau J, Monaco F, Paglino G, Della Bella P,
Colombo A, Latib A. Predictors of advanced conduction disturbances requiring a late (>_48 h) permanent pacemaker following transcatheter aortic valve replacement. JACC Cardiovasc Interv 2018;11:15191526.
522. Mauri V, Reimann A, Stern D, Scherner M, Kuhn E, Rudolph V, Rosenkranz S,
Eghbalzadeh K, Friedrichs K, Wahlers T, Baldus S, Madershahian N, Rudolph
TK. Predictors of permanent pacemaker implantation after transcatheter aortic valve replacement with the
SAPIEN
3.
JACC
Cardiovasc
Interv
2016;9:22002209.
523. Mouillet G, Lellouche N, Yamamoto M, Oguri A, Dubois-Rande JL, Van Belle E,
Gilard M, Laskar M, Teiger E. Outcomes following pacemaker implantation after transcatheter aortic valve implantation with CoreValve
V
R devices: results from the FRANCE 2 Registry. Catheter Cardiovasc Interv 2015;86:E158E166.
524. Nazif TM, Dizon JM, Hahn RT, Xu K, Babaliaros V, Douglas PS, El-Chami MF,
Herrmann HC, Mack M, Makkar RR, Miller DC, Pichard A, Tuzcu EM, Szeto
WY, Webb JG, Moses JW, Smith CR, Williams MR, Leon MB, Kodali SK.
Predictors and clinical outcomes of permanent pacemaker implantation after transcatheter aortic valve replacement: the PARTNER (Placement of AoRtic
TraNscathetER Valves) trial and registry. JACC Cardiovasc Interv 2015;8:6069.
525. Siontis GC, Juni P, Pilgrim T, Stortecky S, Bullesfeld L, Meier B, Wenaweser P,
Windecker S. Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR: a meta-analysis. J Am Coll Cardiol
2014;64:129140.
526. van der Boon RM, Houthuizen P, Urena M, Poels TT, van Mieghem NM,
Brueren GR, Altintas S, Nuis RJ, Serruys PW, van Garsse LA, van Domburg RT,
Cabau JR, de Jaegere PP, Prinzen FW. Trends in the occurrence of new conduction abnormalities after transcatheter aortic valve implantation. Catheter
Cardiovasc Interv 2015;85:E144E152.
527. Gonska B, Seeger J, Kessler M, von Keil A, Rottbauer W, Wohrle J. Predictors for permanent pacemaker implantation in patients undergoing transfemoral aortic valve implantation with the Edwards Sapien 3 valve. Clin Res Cardiol
2017;106:590597.
528. Maeno Y, Abramowitz Y, Kawamori H, Kazuno Y, Kubo S, Takahashi N, Mangat
G, Okuyama K, Kashif M, Chakravarty T, Nakamura M, Cheng W, Friedman J,
Berman D, Makkar RR, Jilaihawi H. A highly predictive risk model for pacemaker implantation after TAVR. JACC Cardiovasc Imaging 2017;10:11391147.
529. Giustino G, Van der Boon RM, Molina-Martin de Nicolas J, Dumonteil N,
Chieffo A, de Jaegere PP, Tchetche D, Marcheix B, Millischer D, Cassagneau R,
Carrie D, Van Mieghem NM, Colombo A. Impact of permanent pacemaker on mortality after transcatheter aortic valve implantation: the PRAGMATIC
(Pooled Rotterdam-Milan-Toulouse in Collaboration) Pacemaker substudy.
EuroIntervention 2016;12:11851193.
530. Hamdan A, Guetta V, Klempfner R, Konen E, Raanani E, Glikson M, Goitein O,
Segev A, Barbash I, Fefer P, Spiegelstein D, Goldenberg I, Schwammenthal E.
Inverse relationship between membranous septal length and the risk of atrioventricular block in patients undergoing transcatheter aortic valve implantation.
JACC Cardiovasc Interv 2015;8:12181228.
531. Ledwoch J, Franke J, Gerckens U, Kuck KH, Linke A, Nickenig G, Krulls-Munch
J, Vohringer M, Hambrecht R, Erbel R, Richardt G, Horack M, Zahn R, Senges J,
Sievert H. Incidence and predictors of permanent pacemaker implantation following transcatheter aortic valve implantation: analysis from the German transcatheter aortic valve interventions registry.
Catheter
Cardiovasc
Interv
2013;82:E569E577.
532. Husser O, Pellegrini C, Kessler T, Burgdorf C, Thaller H, Mayr NP, Kasel AM,
Kastrati A, Schunkert H, Hengstenberg C. Predictors of permanent pacemaker implantations and new-onset conduction abnormalities with the SAPIEN 3
balloon-expandable transcatheter heart valve.
JACC
Cardiovasc
Interv
2016;9:244254.
533. Toggweiler S, Stortecky S, Holy E, Zuk K, Cuculi F, Nietlispach F, Sabti Z, Suciu
R, Maier W, Jamshidi P, Maisano F, Windecker S, Kobza R, Wenaweser P,
Luscher TF, Binder RK. The electrocardiogram after transcatheter aortic valve replacement determines the risk for post-procedural high-degree AV block and the need for telemetry monitoring. JACC Cardiovasc Interv 2016;9:12691276.
534. Urena M, Webb JG, Cheema A, Serra V, Toggweiler S, Barbanti M, Cheung A,
Ye J, Dumont E, DeLarochelliere R, Doyle D, Al Lawati HA, Peterson M,
Chisholm R, Igual A, Ribeiro HB, Nombela-Franco L, Philippon F, Garcia Del
Blanco B, Rodes-Cabau J. Impact of new-onset persistent left bundle branch block on late clinical outcomes in patients undergoing transcatheter aortic valve implantation with a
balloon-expandable valve.
JACC
Cardiovasc
Interv
2014;7:128136.
535. Mouillet G, Lellouche N, Lim P, Meguro K, Yamamoto M, Deux JF, Monin JL,
Bergoend E, Dubois-Rande JL, Teiger E. Patients without prolonged QRS after
TAVI with CoreValve device do not experience high-degree atrio-ventricular block. Catheter Cardiovasc Interv 2013;81:882887.
536. Rodes-Cabau J, Urena M, Nombela-Franco L, Amat-Santos I, Kleiman N,
Munoz-Garcia A, Atienza F, Serra V, Deyell MW, Veiga-Fernandez G, Masson
JB, Canadas-Godoy V, Himbert D, Castrodeza J, Elizaga J, Francisco Pascual J,
Webb JG, de la Torre JM, Asmarats L, Pelletier-Beaumont E, Philippon F.
Arrhythmic burden as determined by ambulatory continuous cardiac monitoring in patients with new-onset persistent left bundle branch block following transcatheter aortic valve replacement: the MARE study. JACC Cardiovasc Interv
2018;11:14951505.
537. Urena M, Webb JG, Eltchaninoff H, Munoz-Garcia AJ, Bouleti C, Tamburino C,
Nombela-Franco L, Nietlispach F, Moris C, Ruel M, Dager AE, Serra V, Cheema
AN, Amat-Santos IJ, de Brito FS, Lemos PA, Abizaid A, Sarmento-Leite R,
Ribeiro HB, Dumont E, Barbanti M, Durand E, Alonso Briales JH, Himbert D,
Vahanian A, Imme S, Garcia E, Maisano F, del Valle R, Benitez LM, Garcia del
Blanco B, Gutierrez H, Perin MA, Siqueira D, Bernardi G, Philippon F, RodesCabau J. Late cardiac death in patients undergoing transcatheter aortic valve replacement: incidence and predictors of advanced heart failure and sudden cardiac death. J Am Coll Cardiol 2015;65:437448.
538. Auffret V, Puri R, Urena M, Chamandi C, Rodriguez-Gabella T, Philippon F,
Rodes-Cabau J. Conduction disturbances after transcatheter aortic valve replacement:
current status and future perspectives.
Circulation
2017;136:10491069.
539. Rogers T, Devraj M, Thomaides A, Steinvil A, Lipinski MJ, Buchanan KD, Alraies
MC, Koifman E, Gai J, Torguson R, Okubagzi P, Ben-Dor I, Pichard AD, Satler
LF, Waksman R. Utility of invasive electrophysiology studies in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. Am J
Cardiol 2018;121:13511357.
540. Tovia-Brodie O, Ben-Haim Y, Joffe E, Finkelstein A, Glick A, Rosso R, Belhassen
B, Michowitz Y. The value of electrophysiologic study in decision-making regarding the need for pacemaker implantation after TAVI. J Interv Card
Electrophysiol 2017;48:121130.
541. Rivard L, Schram G, Asgar A, Khairy P, Andrade JG, Bonan R, Dubuc M, Guerra
PG, Ibrahim R, Macle L, Roy D, Talajic M, Dyrda K, Shohoudi A, le Polain de
Waroux JB, Thibault B. Electrocardiographic and electrophysiological predictors of atrioventricular block after transcatheter aortic valve replacement. Heart
Rhythm 2015;12:321329.
542. Lilly SM, Deshmukh AJ, Epstein AE, Ricciardi MJ, Shreenivas S, Velagapudi P,
Wyman JF. 2020 ACC Expert consensus decision pathway on management of conduction disturbances in patients undergoing transcatheter aortic valve replacement: a report of the American College of Cardiology Solution Set
Oversight Committee. J Am Coll Cardiol 2020;76:23912411.
543. Rodes-Cabau J, Ellenbogen KA, Krahn AD, Latib A, Mack M, Mittal S, MuntaneCarol G, Nazif TM, Sondergaard L, Urena M, Windecker S, Philippon F.
Management of conduction disturbances associated with transcatheter aortic valve replacement:
JACC
Scientific
Expert
Panel.
J
Am
Coll
Cardiol
2019;74:10861106.
544. Costa G, Zappulla P, Barbanti M, Cirasa A, Todaro D, Rapisarda G, Picci A,
Platania F, Tosto A, Di Grazia A, Sgroi C, Tamburino C, Calvi V. Pacemaker dependency after transcatheter aortic valve implantation: incidence, predictors and long-term outcomes. EuroIntervention 2019;15:875883.
545. Kaplan RM, Yadlapati A, Cantey EP, Passman RS, Gajjar M, Knight BP, Sweis R,
Ricciardi MJ, Pham DT, Churyla A, Malaisrie SC, Davidson CJ, Flaherty JD.
Conduction recovery following pacemaker implantation after transcatheter aortic valve replacement. Pacing Clin Electrophysiol 2019;42:146152.
546. Junquera L, Freitas-Ferraz AB, Padron R, Silva I, Nunes Ferreira-Neto A,
Guimaraes
L,
Mohammadi
S,
Moris
C,
Philippon
F,
Rodes-Cabau
J.
Intraprocedural high-degree atrioventricular block or complete heart block in transcatheter aortic valve replacement recipients with no prior intraventricular conduction disturbances. Catheter Cardiovasc Interv 2019;95:982990.
547. Auffret V, Webb JG, Eltchaninoff H, Munoz-Garcia AJ, Himbert D, Tamburino
C, Nombela-Franco L, Nietlispach F, Moris C, Ruel M, Dager AE, Serra V,
Cheema AN, Amat-Santos IJ, de Brito FS Jr, Lemos PA, Abizaid A, SarmentoLeite R, Dumont E, Barbanti M, Durand E, Alonso Briales JH, Vahanian A,
Bouleti C, Imme S, Maisano F, Del Valle R, Benitez LM, Garcia Del Blanco B,
Puri R, Philippon F, Urena M, Rodes-Cabau J. Clinical impact of baseline right bundle branch block in patients undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv 2017;10:15641574.
548. Jorgensen TH, De Backer O, Gerds TA, Bieliauskas G, Svendsen JH,
Sondergaard L. Immediate post-procedural 12-lead electrocardiography as predictor of late conduction defects after transcatheter aortic valve replacement.
JACC Cardiovasc Interv 2018;11:15091518.
549. Ream K, Sandhu A, Valle J, Weber R, Kaizer A, Wiktor DM, Borne RT, Tumolo
AZ, Kunkel M, Zipse MM, Schuller J, Tompkins C, Rosenberg M, Nguyen DT,
ESC Guidelines
85


<!-- PAGE 86 -->

### Page 86

.............................................................................................................................................................................
Cleveland JC Jr, Fullerton D, Carroll JD, Messenger J, Sauer WH, Aleong RG,
Tzou WS. Ambulatory rhythm monitoring to detect late high-grade atrioventricular block following transcatheter aortic valve replacement. J Am Coll Cardiol
2019;73:25382547.
550. Kostopoulou A, Karyofillis P, Livanis E, Thomopoulou S, Stefopoulos C,
Doudoumis K, Theodorakis G, Voudris V. Permanent pacing after transcatheter aortic valve implantation of a CoreValve prosthesis as determined by electrocardiographic and electrophysiological predictors: a single-centre experience.
Europace 2016;18:131137.
551. Khairy P, Landzberg MJ, Gatzoulis MA, Mercier L-Ae, Fernandes SM, Coˆte´ J-M,
Lavoie J-P, Fournier A, Guerra PG, Frogoudaki A, Walsh EP, Dore A.
Transvenous pacing leads and systemic thromboemboli in patients with intracardiac shunts. Circulation 2006;113:23912397.
552. Anand N. Chronotropic incompetence in young patients with late postoperative atrial flutter: a casecontrol study. Eur Heart J 2006;27:20692073.
553. Fishberger SB, Wernovsky G, Gentles TL, Gauvreau K, Burnetta J, Mayer JE,
Walsh EP. Factors that influence the development of atrial flutter after the
Fontan operation. J Thorac Cardiovasc Surg 1997;113:8086.
554. Gillette PC, Shannon C, Garson A, Porter C-BJ, Ott D, Cooley DA, McNamara
DG. Pacemaker treatment of sick sinus syndrome in children. J Am Coll Cardiol
1983;1:13251329.
555. Kay R, Estioko M, Wiener I. Primary sick sinus syndrome as an indication for chronic pacemaker therapy in young adults: incidence, clinical features, and long-term evaluation. American Heart Journal 1982;103:338342.
556. Ragonese P, Drago F, Guccione P, Santilli A, Silvetti MS, Agostino DA.
Permanent overdrive atrial pacing in the chronic management of recurrent postoperative atrial reentrant tachycardia in patients with complex congenital heart disease. Pacing Clin Electrophysiol 1997;20:29172923.
557. Opic P, Yap SC, Van Kranenburg M, Van Dijk AP, Budts W, Vliegen HW, Van Erven
L, Can A, Sahin G, De Groot NM, Witsenburg M, Roos-Hesselink JW. Atrial-based pacing has no benefit over ventricular pacing in preventing atrial arrhythmias in adults with congenital heart disease. Europace 2013;15:17571762.
558. Skanes AC, Krahn AD, Yee R, Klein GJ, Connolly SJ, Kerr CR, Gent M, Thorpe
KE, Roberts RS, Canadian Trial of Physiologic Pacing. Progression to chronic atrial fibrillation after pacing: the Canadian Trial of Physiologic Pacing. CTOPP
Investigators. J Am Coll Cardiol 2001;38:167172.
559. Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold
MR, Goldschlager NF, Hamilton RM, Joglar JA, Kim RJ, Lee R, Marine JE,
McLeod CJ, Oken KR, Patton KK, Pellegrini CN, Selzman KA, Thompson A,
Varosy PD. 2018 ACC/AHA/HRS Guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: executive summary:
a report of the American College of Cardiology/American Heart Association
Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society.
Circulation 2019;140:e333-e381.
560. Kramer CC, Maldonado JR, Olson MD, Gingerich JC, Ochoa LA, Law IH. Safety and efficacy of atrial antitachycardia pacing in congenital heart disease. Heart
Rhythm 2018;15:543547.
561. Stephenson EA, Casavant D, Tuzi J, Alexander ME, Law I, Serwer G, Strieper M,
Walsh EP, Berul CI, ATTEST Investigators. Efficacy of atrial antitachycardia pacing using the Medtronic AT500 pacemaker in patients with congenital heart disease. Am J Cardiol 2003;92:871876.
562. Jaeggi ET, Hamilton RM, Silverman ED, Zamora SA, Hornberger LK. Outcome of children with fetal, neonatal, or childhood diagnosis of isolated congenital atrioventricular block: a single institution’s experience of 30 years. ACC Current
Journal Review 2002;11:95.
563. Villain E, Coastedoat-Chalumeau N, Marijon E, Boudjemline Y, Piette JC, Bonnet
D. Presentation and prognosis of complete atrioventricular block in childhood,
according to maternal antibody status. J Am Coll Cardiol 2006;48:16821687.
564. Dewey RC, Capeless MA, Levy AM. Use of ambulatory electrocardiographic monitoring to identify high-risk patients with congenital complete heart block.
N Engl J Med 1987;316:835839.
565. Karpawich PP, Gillette PC, Garson A Jr, Hesslein PS, Porter CB, McNamara
DG. Congenital complete atrioventricular block: clinical and electrophysiologic predictors of need for pacemaker insertion. Am J Cardiol 1981;48:10981102.
566. Michaelsson M, Jonzon A, Riesenfeld T. Isolated congenital complete atrioventricular block in adult life. A prospective study. Circulation 1995;92:442449.
567. Beaufort-Krol GC, Schasfoort-van Leeuwen MJ, Stienstra Y, Bink-Boelkens MT.
Longitudinal echocardiographic follow-up in children with congenital complete atrioventricular block. Pacing Clin Electrophysiol 2007;30:13391343.
568. Breur JM, Udink Ten Cate FE, Kapusta L, Cohen MI, Crosson JE, Boramanand
N, Lubbers LJ, Friedman AH, Brenner JI, Vetter VL, Sreeram N, Meijboom EJ.
Pacemaker therapy in isolated congenital complete atrioventricular block.
Pacing Clin Electrophysiol 2002;25:16851691.
569. Bonatti V, Agnetti A, Squarcia U. Early and late postoperative complete heart block in pediatric patients submitted to open-heart surgery for congenital heart disease. Pediatr Med Chir 1998;20:181186.
570. Gross GJ, Chiu CC, Hamilton RM, Kirsh JA, Stephenson EA. Natural history of postoperative heart block in congenital heart disease: implications for pacing intervention. Heart Rhythm 2006;3:601604.
571. Murphy D. Prognosis of complete atrioventricular dissociation in children after open-heart surgery. Lancet 1970;295:750752.
572. Krongrad E. Prognosis for patients with congenital heart disease and postoperative intraventricular conduction defects. Circulation 1978;57:867870.
573. Villain E. Indications for pacing in patients with congenital heart disease. Pacing
Clin Electrophysiol 2008;31 Suppl 1:S17-20.
574. Diller GP, Okonko D, Uebing A, Ho SY, Gatzoulis MA. Cardiac resynchronization therapy for adult congenital heart disease patients with a systemic right ventricle: analysis of feasibility and review of early experience. Europace
2006;8:267272.
575. Rapezzi C, Arbustini E, Caforio ALP, Charron P, Gimeno-Blanes J, Helio T,
Linhart A, Mogensen J, Pinto Y, Ristic A, Seggewiss H, Sinagra G, Tavazzi L,
Elliott PM. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC
Working
Group on
Myocardial and
Pericardial
Diseases.
Eur
Heart
J
2012;34:14481458.
576. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P,
Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J,
Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH,
Tillmanns C, Watkins H. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy:
the
Task
Force for the
Diagnosis and
Management of Hypertrophic Cardiomyopathy of the European Society of
Cardiology (ESC). Eur Heart J 2014;35:27332779.
577. Nishimura RA, Trusty JM, Hayes DL, Ilstrup DM, Larson DR, Hayes SN,
Allison TG, Tajik AJ. Dual-chamber pacing for hypertrophic cardiomyopathy:
a randomized,
double-blind,
crossover trial.
J
Am
Coll
Cardiol
1997;29:435441.
578. Kappenberger L, Linde C, Daubert C, McKenna W, Meisel E, Sadoul N,
Chojnowska L, Guize L, Gras D, Jeanrenaud X, Ryden L. Pacing in hypertrophic obstructive cardiomyopathy: a randomized crossover study. Eur Heart J
1997;18:12491256.
579. Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS.
Assessment of permanent dual-chamber pacing as a treatment for drugrefractory symptomatic patients with obstructive hypertrophic cardiomyopathy.
A
randomized,
double-blind,
crossover study
(M-PATHY).
Circulation
1999;99:29272933.
580. Slade AK, Sadoul N, Shapiro L, Chojnowska L, Simon JP, Saumarez RC,
Dodinot B, Camm AJ, McKenna WJ, Aliot E. DDD pacing in hypertrophic cardiomyopathy: a multicentre clinical experience. Heart 1996;75:4449.
581. Megevand A, Ingles J, Richmond DR, Semsarian C. Long-term follow-up of patients with obstructive hypertrophic cardiomyopathy treated with dualchamber pacing. Am J Cardiol 2005;95:991993.
582. Linde C, Gadler F, Kappenberger L, Ryden L. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. PIC Study Group.
Pacing In Cardiomyopathy. Am J Cardiol 1999;83:903907.
583. Ommen SR, Nishimura RA, Squires RW, Schaff HV, Danielson GK, Tajik AJ.
Comparison of dual-chamber pacing versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy: a comparison of objective hemodynamic and exercise end points.
J
Am
Coll
Cardiol
1999;34:191196.
584. Arnold AD, Howard JP, Chiew K, Kerrigan WJ, de Vere F, Johns HT, Churlilov
L, Ahmad Y, Keene D, Shun-Shin MJ, Cole GD, Kanagaratnam P, Sohaib SMA,
Varnava A, Francis DP, Whinnett ZI. Right ventricular pacing for hypertrophic obstructive cardiomyopathy: meta-analysis and meta-regression of clinical trials.
Eur Heart J Qual Care Clin Outcomes 2019;5:321333.
585. Chang SM, Nagueh SF, Spencer WH 3rd, Lakkis NM. Complete heart block:
determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. J Am Coll Cardiol
2003;42:296300.
586. Lawrenz T, Lieder F, Bartelsmeier M, Leuner C, Borchert B, Meyer zu
Vilsendorf D, Strunk-Mueller C, Reinhardt J, Feuchtl A, Stellbrink C, Kuhn H.
Predictors of complete heart block after transcoronary ablation of septal hypertrophy: results of a prospective electrophysiological investigation in 172
patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol
2007;49:23562363.
587. Topilski I, Sherez J, Keren G, Copperman I. Long-term effects of dual-chamber pacing with periodic echocardiographic evaluation of optimal atrioventricular delay in patients with hypertrophic cardiomyopathy >50 years of age. Am J
Cardiol 2006;97:17691775.
588. Cui H, Schaff HV, Nishimura RA, Geske JB, Dearani JA, Lahr BD, Ommen SR.
Conduction abnormalities and long-term mortality following septal myectomy in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol
2019;74:645655.


<!-- PAGE 87 -->

### Page 87

.............................................................................................................................................................................
589. Rogers DP, Marazia S, Chow AW, Lambiase PD, Lowe MD, Frenneaux M,
McKenna WJ, Elliott PM. Effect of biventricular pacing on symptoms and cardiac remodelling in patients with end-stage hypertrophic cardiomyopathy. Eur J
Heart Fail 2008;10:507513.
590. Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL,
Hung J, Joglar JA, Kantor P, Kimmelstiel C, Kittleson M, Link MS, Maron MS,
Martinez MW, Miyake CY, Schaff HV, Semsarian C, Sorajja P. 2020 AHA/ACC
Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: Executive Summary: a Report of the American College of
Cardiology/American
Heart
Association
Joint
Committee on
Clinical
Practice
Guidelines. Circulation 2020;142:e533-e557.
591. Cappelli F, Morini S, Pieragnoli P, Targetti M, Stefano P, Marchionni N, Olivotto I.
Cardiac resynchronization therapy for end-stage hypertrophic cardiomyopathy:
the need for disease-specific criteria. J Am Coll Cardiol 2018;71:464466.
592. Killu AM, Park JY, Sara JD, Hodge DO, Gersh BJ, Nishimura RA, Asirvatham SJ,
McLeod CJ. Cardiac resynchronization therapy in patients with end-stage hypertrophic cardiomyopathy. Europace 2018;20:8288.
593. Gu M, Jin H, Hua W, Fan XH, Niu HX, Tian T, Ding LG, Wang J, Xue C, Zhang
S. Clinical outcome of cardiac resynchronization therapy in dilated-phase hypertrophic cardiomyopathy. J Geriatr Cardiol 2017;14:238244.
594. Fruh A, Siem G, Holmstrom H, Dohlen G, Haugaa KH. The Jervell and
LangeNielsen syndrome; atrial pacing combined with b-blocker therapy, a favorable approach in young high-risk patients with long QT syndrome? Heart
Rhythm 2016;13:21862192.
595. Aziz PF, Tanel RE, Zelster IJ, Pass RH, Wieand TS, Vetter VL, Vogel RL, Shah
MJ. Congenital long QT syndrome and 2:1 atrioventricular block: an optimistic outcome in the current era. Heart Rhythm 2010;7:781785.
596. Feingold B, Mahle WT, Auerbach S, Clemens P, Domenighetti AA, Jefferies JL,
Judge DP, Lal AK, Markham LW, Parks WJ, Tsuda T, Wang PJ, Yoo SJ,
American Heart Association Pediatric Heart Failure Committee of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology,
Council on Cardiovascular Radiology Intervention, Council on Functional
Genomics Translational Biology, Stroke Council. Management of cardiac involvement associated with neuromuscular diseases: a Scientific Statement from the American Heart Association. Circulation 2017;136:e200-e231.
597. Arbustini E, Di Toro A, Giuliani L, Favalli V, Narula N, Grasso M. Cardiac phenotypes in hereditary muscle disorders: JACC State-of-the-Art Review. J Am
Coll Cardiol 2018;72:24852506.
598. Groh
WJ.
Arrhythmias in the muscular dystrophies.
Heart
Rhythm
2012;9:18901895.
599. Bhakta D, Shen C, Kron J, Epstein AE, Pascuzzi RM, Groh WJ. Pacemaker and implantable cardioverter-defibrillator use in a US myotonic dystrophy type 1
population. J Cardiovasc Electrophysiol 2011;22:13691375.
600. Wahbi K, Meune C, Porcher R, Becane HM, Lazarus A, Laforet P, Stojkovic T,
Behin A, Radvanyi-Hoffmann H, Eymard B, Duboc D. Electrophysiological study with prophylactic pacing and survival in adults with myotonic dystrophy and conduction system disease. JAMA 2012;307:12921301.
601. Lazarus A, Varin J, Babuty D, Anselme F, Coste J, Duboc D. Long-term followup of arrhythmias in patients with myotonic dystrophy treated by pacing: a multicenter diagnostic pacemaker study. J Am Coll Cardiol 2002;40:16451652.
602. Laurent V, Pellieux S, Corcia P, Magro P, Pierre B, Fauchier L, Raynaud M,
Babuty D. Mortality in myotonic dystrophy patients in the area of prophylactic pacing devices. Int J Cardiol 2011;150:5458.
603. Groh WJ, Groh MR, Saha C, Kincaid JC, Simmons Z, Ciafaloni E, Pourmand R,
Otten RF, Bhakta D, Nair GV, Marashdeh MM, Zipes DP, Pascuzzi RM.
Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med 2008;358:26882697.
604. Ha AH, Tarnopolsky MA, Bergstra TG, Nair GM, Al-Qubbany A, Healey JS.
Predictors of atrio-ventricular conduction disease, long-term outcomes in patients with myotonic dystrophy types I and II. Pacing Clin Electrophysiol
2012;35:12621269.
605. Fatkin D, MacRae C, Sasaki T, Wolff MR, Porcu M, Frenneaux M, Atherton J,
Vidaillet HJ Jr, Spudich S, De Girolami U, Seidman JG, Seidman C, Muntoni F,
Muehle G, Johnson W, McDonough B. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conductionsystem disease. N Engl J Med 1999;341:17151724.
606. Arbustini E, Pilotto A, Repetto A, Grasso M, Negri A, Diegoli M, Campana C,
Scelsi L, Baldini E, Gavazzi A, Tavazzi L. Autosomal dominant dilated cardiomyopathy with atrioventricular block: a lamin A/C defect-related disease. J Am Coll
Cardiol 2002;39:981990.
607. Taylor MR, Fain PR, Sinagra G, Robinson ML, Robertson AD, Carniel E, Di
Lenarda A, Bohlmeyer TJ, Ferguson DA, Brodsky GL, Boucek MM, Lascor J,
Moss AC, Li WL, Stetler GL, Muntoni F, Bristow MR, Mestroni L, Familial
Dilated Cardiomyopathy Registry Research Group. Natural history of dilated cardiomyopathy due to lamin
A/C
gene mutations.
J Am
Coll Cardiol
2003;41:771780.
608. Sanna T. Cardiac features of EmeryDreifuss muscular dystrophy caused by lamin A/C gene mutations. Eur Heart J 2003;24:22272236.
609. Haas J, Frese KS, Peil B, Kloos W, Keller A, Nietsch R, Feng Z, Muller S,
Kayvanpour E, Vogel B, Sedaghat-Hamedani F, Lim WK, Zhao X, Fradkin D,
Kohler D, Fischer S, Franke J, Marquart S, Barb I, Li DT, Amr A, Ehlermann P,
Mereles D, Weis T, Hassel S, Kremer A, King V, Wirsz E, Isnard R, Komajda M,
Serio A, Grasso M, Syrris P, Wicks E, Plagnol V, Lopes L, Gadgaard T, Eiskjaer
H, Jorgensen M, Garcia-Giustiniani D, Ortiz-Genga M, Crespo-Leiro MG,
Deprez RH, Christiaans I, van Rijsingen IA, Wilde AA, Waldenstrom A,
Bolognesi M, Bellazzi R, Morner S, Bermejo JL, Monserrat L, Villard E,
Mogensen J, Pinto YM, Charron P, Elliott P, Arbustini E, Katus HA, Meder B.
Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J
2015;36:11231135.
610. Gigli M, Merlo M, Graw SL, Barbati G, Rowland TJ, Slavov DB, Stolfo D,
Haywood ME, Dal Ferro M, Altinier A, Ramani F, Brun F, Cocciolo A, Puggia I,
Morea G, McKenna WJ, La Rosa FG, Taylor MRG, Sinagra G, Mestroni L.
Genetic risk of arrhythmic phenotypes in patients with dilated cardiomyopathy.
J Am Coll Cardiol 2019;74:14801490.
611. van Berlo JH, de Voogt WG, van der Kooi AJ, van Tintelen JP, Bonne G, Yaou
RB, Duboc D, Rossenbacker T, Heidbuchel H, de Visser M, Crijns HJ, Pinto YM.
Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations:
do lamin A/C mutations portend a high risk of sudden death? J Mol Med (Berl)
2005;83:7983.
612. Meune C, Van Berlo JH, Anselme F, Bonne G, Pinto YM, Duboc D. Primary prevention of sudden death in patients with lamin A/C gene mutations. N Engl J
Med 2006;354:209210.
613. Anselme F, Moubarak G, Savoure A, Godin B, Borz B, Drouin-Garraud V, Gay
A. Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders. Heart Rhythm 2013;10:14921498.
614. Hasselberg NE, Haland TF, Saberniak J, Brekke PH, Berge KE, Leren TP,
Edvardsen T, Haugaa KH. Lamin A/C cardiomyopathy: young onset, high penetrance,
and frequent need for heart transplantation.
Eur
Heart
J
2018;39:853860.
615. Becane HM, Bonne G, Varnous S, Muchir A, Ortega V, Hammouda EH,
Urtizberea JA, Lavergne T, Fardeau M, Eymard B, Weber S, Schwartz K, Duboc
D. High incidence of sudden death with conduction system and myocardial disease due to lamins A and C gene mutation. Pacing Clin Electrophysiol
2000;23:16611666.
616. Wahbi K, Ben Yaou R, Gandjbakhch E, Anselme F, Gossios T, Lakdawala NK,
Stalens C, Sacher F, Babuty D, Trochu JN, Moubarak G, Savvatis K, Porcher R,
Laforet P, Fayssoil A, Marijon E, Stojkovic T, Behin A, Leonard-Louis S, Sole G,
Labombarda F, Richard P, Metay C, Quijano-Roy S, Dabaj I, Klug D, Vantyghem
MC, Chevalier P, Ambrosi P, Salort E, Sadoul N, Waintraub X, Chikhaoui K,
Mabo P, Combes N, Maury P, Sellal JM, Tedrow UB, Kalman JM, Vohra J,
Androulakis AFA, Zeppenfeld K, Thompson T, Barnerias C, Becane HM, Bieth
E, Boccara F, Bonnet D, Bouhour F, Boule S, Brehin AC, Chapon F, Cintas P,
Cuisset JM, Davy JM, De Sandre-Giovannoli A, Demurger F, Desguerre I,
Dieterich K, Durigneux J, Echaniz-Laguna A, Eschalier R, Ferreiro A, Ferrer X,
Francannet C, Fradin M, Gaborit B, Gay A, Hagege A, Isapof A, Jeru I, Juntas
Morales R, Lagrue E, Lamblin N, Lascols O, Laugel V, Lazarus A, Leturcq F,
Levy N, Magot A, Manel V, Martins R, Mayer M, Mercier S, Meune C, Michaud
M, Minot-Myhie MC, Muchir A, Nadaj-Pakleza A, Pereon Y, Petiot P, Petit F,
Praline J, Rollin A, Sabouraud P, Sarret C, Schaeffer S, Taithe F, Tard C, Tiffreau
V, Toutain A, Vatier C, Walther-Louvier U, Eymard B, Charron P, Vigouroux C,
Bonne G, Kumar S, Elliott P, Duboc D. Development and validation of a new risk prediction score for life-threatening ventricular tachyarrhythmias in laminopathies. Circulation 2019;140:293302.
617. van Rijsingen IA, Arbustini E, Elliott PM, Mogensen J, Hermans-van Ast JF, van der Kooi AJ, van Tintelen JP, van den Berg MP, Pilotto A, Pasotti M, Jenkins S,
Rowland C, Aslam U, Wilde AA, Perrot A, Pankuweit S, Zwinderman AH,
Charron P, Pinto YM. Risk factors for malignant ventricular arrhythmias in lamin
A/C
mutation carriers a
European cohort study.
J
Am
Coll
Cardiol
2012;59:493500.
618. Kumar S, Baldinger SH, Gandjbakhch E, Maury P, Sellal JM, Androulakis AF,
Waintraub X, Charron P, Rollin A, Richard P, Stevenson WG, Macintyre CJ, Ho
CY, Thompson T, Vohra JK, Kalman JM, Zeppenfeld K, Sacher F, Tedrow UB,
Lakdawala NK. Long-term arrhythmic and nonarrhythmic outcomes of lamin A/
C mutation carriers. J Am Coll Cardiol 2016;68:22992307.
619. Pasotti M, Klersy C, Pilotto A, Marziliano N, Rapezzi C, Serio A, Mannarino S,
Gambarin F, Favalli V, Grasso M, Agozzino M, Campana C, Gavazzi A, Febo O,
Marini M, Landolina M, Mortara A, Piccolo G, Vigano M, Tavazzi L, Arbustini E.
Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am
Coll Cardiol 2008;52:12501260.
620. Hasselberg NE, Edvardsen T, Petri H, Berge KE, Leren TP, Bundgaard H,
Haugaa KH. Risk prediction of ventricular arrhythmias and myocardial function in Lamin A/C mutation positive subjects. Europace 2014;16:563571.
ESC Guidelines
87


<!-- PAGE 88 -->

### Page 88

.............................................................................................................................................................................
621. Limongelli G, Tome-Esteban M, Dejthevaporn C, Rahman S, Hanna MG, Elliott
PM. Prevalence and natural history of heart disease in adults with primary mitochondrial respiratory chain disease. Eur J Heart Fail 2010;12:114121.
622. Anan R, Nakagawa M, Miyata M, Higuchi I, Nakao S, Suehara M, Osame M,
Tanaka H. Cardiac involvement in mitochondrial diseases. A study on 17 patients with documented mitochondrial DNA defects. Circulation 1995;91:955961.
623. Khambatta S, Nguyen DL, Beckman TJ, Wittich CM. KearnsSayre syndrome: a case series of 35 adults and children. Int J Gen Med 2014;7:325332.
624. Kabunga P, Lau AK, Phan K, Puranik R, Liang C, Davis RL, Sue CM, Sy RW.
Systematic review of cardiac electrical disease in KearnsSayre syndrome and mitochondrial cytopathy. Int J Cardiol 2015;181:303310.
625. Polak PE, Zijlstra F, Roelandt JR. Indications for pacemaker implantation in the
KearnsSayre syndrome. Eur Heart J 1989;10:281282.
626. Nordenswan HK, Lehtonen J, Ekstrom K, Kandolin R, Simonen P, Mayranpaa M,
Vihinen T, Miettinen H, Kaikkonen K, Haataja P, Kerola T, Rissanen TT,
Kokkonen J, Alatalo A, Pietila-Effati P, Utriainen S, Kupari M. Outcome of cardiac sarcoidosis presenting with high-grade atrioventricular block. Circ Arrhythm
Electrophysiol 2018;11:e006145.
627. Nery PB, Beanlands RS, Nair GM, Green M, Yang J, McArdle BA, Davis D,
Ohira H, Gollob MH, Leung E, Healey JS, Birnie DH. Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults. J Cardiovasc
Electrophysiol 2014;25:875881.
628. Yoshida Y, Morimoto S, Hiramitsu S, Tsuboi N, Hirayama H, Itoh T. Incidence of cardiac sarcoidosis in Japanese patients with high-degree atrioventricular block. Am Heart J 1997;134:382386.
629. Mankad P, Mitchell B, Birnie D, Kron J. Cardiac sarcoidosis. Curr Cardiol Rep
2019;21:152.
630. Sadek MM, Yung D, Birnie DH, Beanlands RS, Nery PB. Corticosteroid therapy for cardiac sarcoidosis: a systematic review. Can J Cardiol 2013;29:10341041.
631. Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, Judson
MA, Kron J, Mehta D, Cosedis Nielsen J, Patel AR, Ohe T, Raatikainen P,
Soejima K. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis.
Heart
Rhythm
2014;11:13051323.
632. Schuller JL, Zipse M, Crawford T, Bogun F, Beshai J, Patel AR, Sweiss NJ,
Nguyen DT, Aleong RG, Varosy PD, Weinberger HD, Sauer WH. Implantable cardioverter defibrillator therapy in patients with cardiac sarcoidosis. J
Cardiovasc Electrophysiol 2012;23:925929.
633. Kron J, Sauer W, Schuller J, Bogun F, Crawford T, Sarsam S, Rosenfeld L, Mitiku
TY, Cooper JM, Mehta D, Greenspon AJ, Ortman M, Delurgio DB, Valadri R,
Narasimhan C, Swapna N, Singh JP, Danik S, Markowitz SM, Almquist AK,
Krahn AD, Wolfe LG, Feinstein S, Ellenbogen KA. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis. Europace 2013;15:347354.
634. Birnie DH, Sauer WH, Judson MA. Consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis.
Heart
2016;102:411414.
635. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomstrom-Lundqvist C,
Cifkova R, De Bonis M, Iung B, Johnson MR, Kintscher U, Kranke P, Lang IM,
Morais J, Pieper PG, Presbitero P, Price S, Rosano GMC, Seeland U, Simoncini
T, Swan L, Warnes CA, ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J
2018;39:31653241.
636. Tuzcu V, Gul EE, Erdem A, Kamali H, Saritas T, Karadeniz C, Akdeniz C.
Cardiac interventions in pregnant patients without fluoroscopy. Pediatr Cardiol
2015;36:13041307.
637. Gudal M, Kervancioglu C, Oral D, Gurel T, Erol C, Sonel A. Permanent pacemaker implantation in a pregnant woman with the guidance of ECG and twodimensional echocardiography. Pacing Clin Electrophysiol 1987;10:543545.
638. Traykov V, Bongiorni MG, Boriani G, Burri H, Costa R, Dagres N, Deharo JC,
Epstein LM, Erba PA, Snygg-Martin U, Nielsen JC, Poole JE, Saghy L, Starck C,
Strathmore N, Blomstrom-Lundqvist C. Clinical practice and implementation of guidelines for the prevention, diagnosis and management of cardiac implantable electronic device infections: results of a worldwide survey under the auspices of the European Heart Rhythm Association. Europace 2019;21:12701279.
639. Klug D, Balde M, Pavin D, Hidden-Lucet F, Clementy J, Sadoul N, Rey JL, Lande G,
Lazarus A, Victor J, Barnay C, Grandbastien B, Kacet S, People Study Group. Risk factors related to infections of implanted pacemakers and cardioverterdefibrillators: results of a large prospective study. Circulation 2007;116:13491355.
640. Enzler MJ, Berbari E, Osmon DR. Antimicrobial prophylaxis in adults. Mayo Clin
Proc 2011;86:686701.
641. Polyzos KA, Konstantelias AA, Falagas ME. Risk factors for cardiac implantable electronic device infection: a systematic review and meta-analysis. Europace
2015;17:767777.
642. Blomstrom-Lundqvist C, Traykov V, Erba PA, Burri H, Nielsen JC, Bongiorni
MG, Poole J, Boriani G, Costa R, Deharo JC, Epstein LM, Saghy L, Snygg-Martin
U, Starck C, Tascini C, Strathmore N. European Heart Rhythm Association
(EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart
Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the
Latin American Heart Rhythm Society (LAHRS), International Society for
Cardiovascular Infectious Diseases (ISCVID), and the European Society of
Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J
2020;41:20122032.
643. de Oliveira JC, Martinelli M, Nishioka SA, Varejao T, Uipe D, Pedrosa AA,
Costa R, D’Avila A, Danik SB. Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter-defibrillators: results of a large,
prospective, randomized, double-blinded, placebo-controlled trial. Circ Arrhythm
Electrophysiol 2009;2:2934.
644. Madadi S, Kafi M, Kheirkhah J, Azhari A, Kiarsi M, Mehryar A, Fazelifar A,
Alizadehdiz A, Emkanjoo Z, Haghjoo M. Postoperative antibiotic prophylaxis in the prevention of cardiac implantable electronic device infection. Pacing Clin
Electrophysiol 2019;42:161165.
645. Krahn AD, Longtin Y, Philippon F, Birnie DH, Manlucu J, Angaran P, Rinne C,
Coutu B, Low RA, Essebag V, Morillo C, Redfearn D, Toal S, Becker G,
Degrace M, Thibault B, Crystal E, Tung S, LeMaitre J, Sultan O, Bennett M,
Bashir J, Ayala-Paredes F, Gervais P, Rioux L, Hemels MEW, Bouwels LHR, van
Vlies B, Wang J, Exner DV, Dorian P, Parkash R, Alings M, Connolly SJ.
Prevention of arrhythmia device infection trial: the PADIT trial. J Am Coll Cardiol
2018;72:30983109.
646. Haines DE, Beheiry S, Akar JG, Baker JL, Beinborn D, Beshai JF, Brysiewicz N,
Chiu-Man C, Collins KK, Dare M, Fetterly K, Fisher JD, Hongo R, Irefin S, Lopez
J, Miller JM, Perry JC, Slotwiner DJ, Tomassoni GF, Weiss E. Heart Rythm
Society expert consensus statement on electrophysiology laboratory standards:
process, protocols, equipment, personnel, and safety. Heart Rhythm 2014;11:e951.
647. Mimoz O, Lucet J-C, Kerforne T, Pascal J, Souweine B, Goudet V, Mercat A,
Bouadma L, Lasocki S, Alfandari S, Friggeri A, Wallet F, Allou N, Ruckly S, Balayn
D, Lepape A, Timsit J-F. Skin antisepsis with chlorhexidinealcohol versus povidone iodinealcohol, with and without skin scrubbing, for prevention of intravascular-catheter-related infection (CLEAN): an open-label, multicentre, randomised, controlled, two-by-two factorial trial. Lancet 2015;386:20692077.
648. Darouiche RO, Wall MJ Jr, Itani KM, Otterson MF, Webb AL, Carrick MM,
Miller HJ, Awad SS, Crosby CT, Mosier MC, Alsharif A, Berger DH.
Chlorhexidinealcohol versus povidone-iodine for surgical-site antisepsis. N
Engl J Med 2010;362:1826.
649. Essebag V, Verma A, Healey JS, Krahn AD, Kalfon E, Coutu B, Ayala-Paredes F,
Tang AS, Sapp J, Sturmer M, Keren A, Wells GA, Birnie DH, BRUISE
CONTROL Investigators. Clinically significant pocket hematoma increases longterm risk of device infection: BRUISE CONTROL INFECTION Study. J Am Coll
Cardiol 2016;67:13001308.
650. Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, Simpson CS,
Ayala-Paredes F, Coutu B, Leiria TLL, Essebag V, BRUISE CONTROL
Investigators. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med 2013;368:20842093.
651. Malagu M, Trevisan F, Scalone A, Marcantoni L, Sammarco G, Bertini M.
Frequency of ‘pocket’ hematoma in patients receiving vitamin K antagonist and antiplatelet therapy at the time of pacemaker or cardioverter defibrillator implantation (from the POCKET Study). Am J Cardiol 2017;119:10361040.
652. Birnie DH, Healey JS, Wells GA, Ayala-Paredes F, Coutu B, Sumner GL, Becker
G, Verma A, Philippon F, Kalfon E, Eikelboom J, Sandhu RK, Nery PB, Lellouche
N, Connolly SJ, Sapp J, Essebag V. Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events
(BRUISE
CONTROL-2).
Eur
Heart
J
2018;39:39733979.
653. Kutinsky IB, Jarandilla R, Jewett M, Haines DE. Risk of hematoma complications after device implant in the clopidogrel era. Circ Arrhythm Electrophysiol
2010;3:312318.
654. Tompkins C, Cheng A, Dalal D, Brinker JA, Leng CT, Marine JE, Nazarian S,
Spragg DD, Sinha S, Halperin H, Tomaselli GF, Berger RD, Calkins H,
Henrikson CA. Dual antiplatelet therapy and heparin ‘bridging’ significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation.
J
Am
Coll
Cardiol
2010;55:23762382.
655. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, Kastrati
A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG,
Windecker S, Zamorano JL, Levine GN, ESC Scientific Document Group, ESC
Committee for Practice Guidelines, ESC National Cardiac Societies. 2017 ESC
focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of


<!-- PAGE 89 -->

### Page 89

.............................................................................................................................................................................
the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J
2018;39:213260.
656. Rossini R, Musumeci G, Visconti LO, Bramucci E, Castiglioni B, De Servi S,
Lettieri C, Lettino M, Piccaluga E, Savonitto S, Trabattoni D, Capodanno D,
Buffoli F, Parolari A, Dionigi G, Boni L, Biglioli F, Valdatta L, Droghetti A,
Bozzani A, Setacci C, Ravelli P, Crescini C, Staurenghi G, Scarone P, Francetti L,
D’Angelo F, Gadda F, Comel A, Salvi L, Lorini L, Antonelli M, Bovenzi F,
Cremonesi A, Angiolillo DJ, Guagliumi G, Italian Society of Invasive Cardiology,
Italian Association of Hospital Cardiologists, Italian Society for Cardiac Surgery,
Italian Society of Vascular and Endovascular Surgery, Italian Association of
Hospital Surgeons, Italian Society of Surgery, Italian Society of Anaesthesia,
Intensive Care Medicine, Lombard Society of Surgery, Italian Society of
Maxillofacial Surgery, Italian Society of Reconstructive Plastic Surgery and
Aesthetics, Italian Society of Thoracic Surgeons, Italian Society of Urology,
Italian
Society of
Orthopaedics and
Traumatology,
Italian
Society of
Periodontology, Italian Federation of Scientific Societies of Digestive System
Diseases
Lombardia,
Association of
Obstetricians
Gynaecologists
Italian
Hospital Lombardia, Society of Ophthalmology Lombardia. Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological,
surgical and anaesthesiological societies. EuroIntervention 2014;10:3846.
657. Essebag V, Healey JS, Joza J, Nery PB, Kalfon E, Leiria TLL, Verma A, AyalaParedes F, Coutu B, Sumner GL, Becker G, Philippon F, Eikelboom J, Sandhu
RK, Sapp J, Leather R, Yung D, Thibault B, Simpson CS, Ahmad K, Toal S,
Sturmer M, Kavanagh K, Crystal E, Wells GA, Krahn AD, Birnie DH. Effect of direct oral anticoagulants, warfarin, and antiplatelet agents on risk of device pocket hematoma: combined analysis of BRUISE CONTROL 1 and 2. Circ
Arrhythm Electrophysiol 2019;12:e007545.
658. Kirkfeldt RE, Johansen JB, Nohr EA, Moller M, Arnsbo P, Nielsen JC.
Pneumothorax in cardiac pacing: a population-based cohort study of 28 860
Danish patients. Europace 2012;14:11321138.
659. Liu P, Zhou Y-F, Yang P, Gao Y-S, Zhao G-R, Ren S-Y, Li X-L. Optimized axillary vein technique versus subclavian vein technique in cardiovascular implantable electronic device implantation. Chin Med J 2016;129:26472651.
660. Liccardo M, Nocerino P, Gaia S, Ciardiello C. Efficacy of ultrasound-guided axillary/subclavian venous approaches for pacemaker and defibrillator lead implantation: a randomized study. J Interv Card Electrophysiol 2018;51:153160.
661. Chan NY, Kwong NP, Cheong AP. Venous access and long-term pacemaker lead failure: comparing contrast-guided axillary vein puncture with subclavian puncture and cephalic cutdown. Europace 2017;19:11931197.
662. Deharo JC, Bongiorni MG, Rozkovec A, Bracke F, Defaye P, Fernandez-Lozano
I, Golzio PG, Hansky B, Kennergren C, Manolis AS, Mitkowski P, Platou ES,
Love C, Wilkoff B. Pathways for training and accreditation for transvenous lead extraction: a European Heart Rhythm Association position paper. Europace
2012;14:124134.
663. Migliore F, Zorzi A, Bertaglia E, Leoni L, Siciliano M, De Lazzari M, Ignatiuk B,
Veronese M, Verlato R, Tarantini G, Iliceto S, Corrado D. Incidence, management, and prevention of right ventricular perforation by pacemaker and implantable cardioverter defibrillator leads.
Pacing
Clin
Electrophysiol
2014;37:16021609.
664. Segreti L, Di Cori A, Soldati E, Zucchelli G, Viani S, Paperini L, De Lucia R,
Coluccia G, Valsecchi S, Bongiorni MG. Major predictors of fibrous adherences in transvenous implantable cardioverter-defibrillator lead extraction. Heart
Rhythm 2014;11:21962201.
665. Behar JM, Bostock J, Zhu Li AP, Chin HMS, Jubb S, Lent E, Gamble J, Foley
PWX, Betts TR, Rinaldi CA, Herring N. Cardiac resynchronization therapy delivered via a multipolar left ventricular lead is associated with reduced mortality and elimination of phrenic nerve stimulation: long-term follow-up from a multicenter registry. J Cardiovasc Electrophysiol 2015;26:540546.
666. Forleo GB, Di Biase L, Panattoni G, Mantica M, Parisi Q, Martino A, Pappalardo
A, Sergi D, Tesauro M, Papavasileiou LP, Santini L, Calo L, Tondo C, Natale A,
Romeo F. Improved implant and postoperative lead performance in CRT-D
patients implanted with a quadripolar left ventricular lead. A 6-month follow-up analysis from a multicenter prospective comparative study. J Interv Card
Electrophysiol 2015;42:5966.
667. Jackson KP, Faerestrand S, Philippon F, Yee R, Kong MH, Kloppe A, Bongiorni
MG, Lee SF, Canby RC, Pouliot E, van Ginneken MME, Crossley GH.
Performance of a novel active fixation quadripolar left ventricular lead for cardiac resynchronization therapy: Attain Stability Quad Clinical Study results. J
Cardiovasc Electrophysiol 2020;31:11471154.
668. Ziacchi M, Diemberger I, Corzani A, Martignani C, Mazzotti A, Massaro G,
Valzania C, Rapezzi C, Boriani G, Biffi M. Cardiac resynchronization therapy: a comparison among left ventricular bipolar, quadripolar and active fixation leads.
Sci Rep 2018;8:13262.
669. Ziacchi M, Giannola G, Lunati M, Infusino T, Luzzi G, Rordorf R, Pecora D,
Bongiorni MG, De Ruvo E, Biffi M. Bipolar active fixation left ventricular lead or quadripolar passive fixation lead? An Italian multicenter experience. J Cardiovasc
Med (Hagerstown) 2019;20:192200.
670. Shimony A, Eisenberg MJ, Filion KB, Amit G. Beneficial effects of right ventricular non-apical vs. apical pacing: a systematic review and meta-analysis of randomized-controlled trials. Europace 2012;14:8191.
671. Ng ACT, Allman C, Vidaic J, Tie H, Hopkins AP, Leung DY. Long-term impact of right ventricular septal versus apical pacing on left ventricular synchrony and function in patients with second- or third-degree heart block. Am J Cardiol
2009;103:10961101.
672. Hattori M, Naruse Y, Oginosawa Y, Matsue Y, Hanaki Y, Kowase S, Kurosaki K,
Mizukami A, Kohno R, Abe H, Aonuma K, Nogami A. Prognostic impact of lead tip position confirmed via computed tomography in patients with right ventricular septal pacing. Heart Rhythm 2019;16:921927.
673. Domenichini G, Sunthorn H, Fleury E, Foulkes H, Stettler C, Burri H. Pacing of the interventricular septum versus the right ventricular apex: a prospective,
randomized study. Eur J Intern Med 2012;23:621627.
674. Mahapatra S, Bybee KA, Bunch TJ, Espinosa RE, Sinak LJ, McGoon MD, Hayes
DL. Incidence and predictors of cardiac perforation after permanent pacemaker placement. Heart Rhythm 2005;2:907911.
675. Biffi M, de Zan G, Massaro G, Angeletti A, Martignani C, Boriani G, Diemberger
I, Ziacchi M. Is ventricular sensing always right, when it is left? Clin Cardiol
2018;41:12381245.
676. Burri H, Muller H, Kobza R, Sticherling C, Ammann P, Zerlik H, Stettler C,
Klersy C, Prinzen F, Auricchio A. RIght VErsus Left Apical transvenous pacing for bradycardia: results of the RIVELA randomized study. Indian Pacing
Electrophysiol J 2017;17:171175.
677. Tanabe K, Kotoda M, Nakashige D, Mitsui K, Ikemoto K, Matsukawa T. Sudden onset pacemaker-induced diaphragmatic twitching during general anesthesia. JA
Clin Rep 2019;5:36.
678. Khan AA, Nash A, Ring NJ, Marshall AJ. Right hemidiaphragmatic twitching: a complication of bipolar atrial pacing. Pacing Clin Electrophysiol 1997;20:17321733.
679. Shali S, Su Y, Ge J. Interatrial septal pacing to suppress atrial fibrillation in patients with dual chamber pacemakers: a meta-analysis of randomized, controlled trials. Int J Cardiol 2016;219:421427.
680. Zhang L, Jiang H, Wang W, Bai J, Liang Y, Su Y, Ge J. Interatrial septum versus right atrial appendage pacing for prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Herz 2018;43:438446.
681. Magnusson P, Wennstrom L, Kastberg R, Liv P. Placement Of Cardiac
PacemaKEr Trial (POCKET)—rationale and design: a randomized controlled trial. Heart Int 2017;12:e8-e11.
682. Gold MR, Peters RW, Johnson JW, Shorofsky SR. Complications associated with pectoral cardioverter-defibrillator implantation: comparison of subcutaneous and submuscular approaches. J Am Coll Cardiol 1996;28:12781282.
683. Lakshmanadoss U, Nuanez B, Kutinsky I, Khalid R, Haines DE, Wong WS.
Incidence of pocket infection postcardiac device implantation using antibiotic versus saline solution for pocket irrigation.
Pacing
Clin
Electrophysiol
2016;39:978984.
684. Mueller TC, Loos M, Haller B, Mihaljevic AL, Nitsche U, Wilhelm D, Friess H,
Kleeff J, Bader FG. Intra-operative wound irrigation to reduce surgical site infections after abdominal surgery:
a systematic review and meta-analysis.
Langenbeck’s Arch Surg 2015;400:167181.
685. Tarakji KG, Mittal S, Kennergren C, Corey R, Poole JE, Schloss E, Gallastegui J,
Pickett RA, Evonich R, Philippon F, McComb JM, Roark SF, Sorrentino D,
Sholevar D, Cronin E, Berman B, Riggio D, Biffi M, Khan H, Silver MT, Collier J,
Eldadah Z, Wright DJ, Lande JD, Lexcen DR, Cheng A, Wilkoff BL, WRAP-IT
Investigators. Antibacterial envelope to prevent cardiac implantable device infection. N Engl J Med 2019;380:18951905.
686. Da Costa A, Kirkorian G, Cucherat M, Delahaye F, Chevalier P, Cerisier A,
Isaaz K, Touboul P. Antibiotic prophylaxis for permanent pacemaker implantation: a meta-analysis. Circulation 1998;97:17961801.
687. Leyva F, Zegard A, Qiu T, Acquaye E, Ferrante G, Walton J, Marshall H.
Cardiac resynchronization therapy using quadripolar versus non-quadripolar left ventricular leads programmed to biventricular pacing with single-site left ventricular pacing: impact on survival and heart failure hospitalization. J Am
Heart Assoc 2017;6:e007026.
688. Henrikson CA, Sohail MR, Acosta H, Johnson EE, Rosenthal L, Pachulski R, Dan
D, Paladino W, Khairallah FS, Gleed K, Hanna I, Cheng A, Lexcen DR, Simons
GR. Antibacterial envelope is associated with low infection rates after implantable cardioverter-defibrillator and cardiac resynchronization therapy device replacement:
results of the
Citadel and
Centurion studies.
JACC
Clin
Electrophysiol 2017;3:11581167.
689. Ghanbari H, Phard WS, Al-Ameri H, Latchamsetty R, Jongnarngsin K, Crawford
T, Good E, Chugh A, Oral H, Bogun F, Morady F, Pelosi F Jr. Meta-analysis of safety and efficacy of uninterrupted warfarin compared to heparin-based bridging therapy during implantation of cardiac rhythm devices. Am J Cardiol
2012;110:14821488.
ESC Guidelines
89


<!-- PAGE 90 -->

### Page 90

.............................................................................................................................................................................
690. Udo EO, Zuithoff NP, van Hemel NM, de Cock CC, Hendriks T, Doevendans PA,
Moons KG. Incidence and predictors of short- and long-term complications in pacemaker therapy: the FOLLOWPACE study. Heart Rhythm 2012;9:728735.
691. Koneru JN, Jones PW, Hammill EF, Wold N, Ellenbogen KA. Risk factors and temporal trends of complications associated with transvenous implantable cardiac defibrillator leads. J Am Heart Assoc 2018;7:e007691.
692. Ellenbogen KA, Hellkamp AS, Wilkoff BL, Camunas JL, Love JC, Hadjis TA, Lee
KL, Lamas GA. Complications arising after implantation of DDD pacemakers:
the MOST experience. Am J Cardiol 2003;92:740741.
693. Parsonnet V, Bernstein AD, Lindsay B. Pacemaker-implantation complication rates:
an analysis of some contributing factors.
J
Am
Coll
Cardiol
1989;13:917921.
694. Ranasinghe I, Labrosciano C, Horton D, Ganesan A, Curtis JP, Krumholz HM,
McGavigan A, Hossain S, Air T, Hariharaputhiran S. Institutional variation in quality of cardiovascular implantable electronic device implantation: a cohort study. Ann Intern Med 2019;171:309317.
695. Poole JE, Gleva MJ, Mela T, Chung MK, Uslan DZ, Borge R, Gottipaty V, Shinn
T, Dan D, Feldman LA, Seide H, Winston SA, Gallagher JJ, Langberg JJ, Mitchell
K, Holcomb R, REPLACE Registry Investigators. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. Circulation
2010;122:15531561.
696. Biffi M, Ammendola E, Menardi E, Parisi Q, Narducci ML, De Filippo P, Manzo
M, Stabile G, Potenza DR, Zanon F, Quartieri F, Rillo M, Saporito D, Zaca V,
Berisso MZ, Bertini M, Tumietto F, Malacrida M, Diemberger I. Real-life outcome of implantable cardioverter-defibrillator and cardiac resynchronization defibrillator replacement/upgrade in a contemporary population: observations from the multicentre DECODE registry. Europace 2019;21:15271536.
697. Hosseini SM, Moazzami K, Rozen G, Vaid J, Saleh A, Heist KE, Vangel M, Ruskin
JN. Utilization and in-hospital complications of cardiac resynchronization therapy:
trends in the
United
States from
2003
to
2013.
Eur
Heart
J
2017;38:21222128.
698. Zeitler EP, Patel D, Hasselblad V, Sanders GD, Al-Khatib SM. Complications from prophylactic replacement of cardiac implantable electronic device generators in response to United States Food and Drug Administration recall: a systematic review and meta-analysis. Heart Rhythm 2015;12:15581564.
699. Nowak B, Tasche K, Barnewold L, Heller G, Schmidt B, Bordignon S, Chun KR,
Furnkranz A, Mehta RH. Association between hospital procedure volume and early complications after pacemaker implantation: results from a large, unselected, contemporary cohort of the German nationwide obligatory external quality assurance programme. Europace 2015;17:787793.
700. van Rees JB, de Bie MK, Thijssen J, Borleffs CJ, Schalij MJ, van Erven L.
Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices: a systematic review of randomized clinical trials. J Am Coll Cardiol 2011;58:9951000.
701. Wiegand UK, Bode F, Bonnemeier H, Eberhard F, Schlei M, Peters W. Longterm complication rates in ventricular, single lead VDD, and dual chamber pacing. Pacing Clin Electrophysiol 2003;26:19611969.
702. Olsen T, Jorgensen OD, Nielsen JC, Thogersen AM, Philbert BT, Johansen JB.
Incidence of device-related infection in 97 750 patients: clinical data from the complete Danish device-cohort (19822018). Eur Heart J 2019;40:18621869.
703. Greenspon AJ, Patel JD, Lau E, Ochoa JA, Frisch DR, Ho RT, Pavri BB, Kurtz
SM. 16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. J Am Coll Cardiol
2011;58:10011006.
704. Rennert-May E, Chew D, Lu S, Chu A, Kuriachan V, Somayaji R. Epidemiology of cardiac implantable electronic device infections in the United States: a population-based cohort study. Heart Rhythm 2020;17:11251131.
705. Ozcan C, Raunso J, Lamberts M, Kober L, Lindhardt TB, Bruun NE, Laursen
ML, Torp-Pedersen C, Gislason GH, Hansen ML. Infective endocarditis and risk of death after cardiac implantable electronic device implantation: a nationwide cohort study. Europace 2017;19:10071014.
706. Dai M, Cai C, Vaibhav V, Sohail MR, Hayes DL, Hodge DO, Tian Y, Asirvatham
R, Cochuyt JJ, Huang C, Friedman PA, Cha YM. Trends of cardiovascular implantable electronic device infection in 3 decades: a population-based study.
JACC Clin Electrophysiol 2019;5:10711080.
707. Palmisano P, Accogli M, Zaccaria M, Luzzi G, Nacci F, Anaclerio M, Favale S.
Rate, causes, and impact on patient outcome of implantable device complications requiring surgical revision: large population survey from two centres in
Italy. Europace 2013;15:531540.
708. Sohail MR, Henrikson CA, Braid-Forbes MJ, Forbes KF, Lerner DJ. Mortality and cost associated with cardiovascular implantable electronic device infections.
Arch Intern Med 2011;171:18211828.
709. Cantillon DJ, Dukkipati SR, Ip JH, Exner DV, Niazi IK, Banker RS, Rashtian M,
Plunkitt K, Tomassoni GF, Nabutovsky Y, Davis KJ, Reddy VY. Comparative study of acute and mid-term complications with leadless and transvenous cardiac pacemakers. Heart Rhythm 2018;15:10231030.
710. Chahine J, Baranowski B, Tarakji K, Gad MM, Saliba W, Rickard J, Cantillon DJ,
Diab M, Kanj M, Callahan T, Dresing T, Bhargava M, Chung M, Niebauer MJ,
Varma N, Tchou P, Wilkoff BL, Wazni O, Hussein AA. Cardiac venous injuries:
procedural profiles and outcomes during left ventricular lead placement for cardiac resynchronization therapy. Heart Rhythm 2020;17:12981303.
711. Seifert M, Schau T, Moeller V, Neuss M, Meyhoefer J, Butter C. Influence of pacing configurations, body mass index, and position of coronary sinus lead on frequency of phrenic nerve stimulation and pacing thresholds under cardiac resynchronization therapy. Europace 2010;12:961967.
712. Biffi M, Moschini C, Bertini M, Saporito D, Ziacchi M, Diemberger I, Valzania C,
Domenichini G, Cervi E, Martignani C, Sangiorgi D, Branzi A, Boriani G. Phrenic stimulation: a challenge for cardiac resynchronization therapy. Circ Arrhythm
Electrophysiol 2009;2:402410.
713. Rijal S, Wolfe J, Rattan R, Durrani A, Althouse AD, Marroquin OC, Jain S,
Mulukutla S, Saba S. Lead related complications in quadripolar versus bipolar left ventricular leads. Indian Pacing Electrophysiol J 2017;17:37.
714. Nichols CI, Vose JG. Incidence of bleeding-related complications during primary implantation and replacement of cardiac implantable electronic devices. J Am
Heart Assoc 2017;6:e004263.
715. Wiegand UKH, LeJeune D, Boguschewski F, Bonnemeier H, Eberhardt F, Schunkert
H, Bode F. Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: influence of patient morbidity, operation strategy, and perioperative antiplatelet/anticoagulation therapy. Chest 2004;126:11771186.
716. Van De Heyning CM, Elbarasi E, Masiero S, Brambatti M, Ghazal S, Al-Maashani
S, Capucci A, Leong D, Shivalkar B, Saenen JB, Miljoen HP, Morillo CA,
Divarakarmenon S, Amit G, Ribas S, Baiocco E, Maolo A, Romandini A, Maffei S,
Connolly SJ, Healey JS, Dokainish H. Prospective study of tricuspid regurgitation associated with permanent leads after cardiac rhythm device implantation. Can J
Cardiol 2019;35:389395.
717. Cho MS, Kim J, Lee JB, Nam GB, Choi KJ, Kim YH. Incidence and predictors of moderate to severe tricuspid regurgitation after dual-chamber pacemaker implantation. Pacing Clin Electrophysiol 2019;42:8592.
718. Lee RC, Friedman SE, Kono AT, Greenberg ML, Palac RT. Tricuspid regurgitation following implantation of endocardial leads: incidence and predictors.
Pacing Clin Electrophysiol 2015;38:12671274.
719. Link MS, Hellkamp AS, Estes NA 3rd, Orav EJ, Ellenbogen KA, Ibrahim B,
Greenspon A, Rizo-Patron C, Goldman L, Lee KL, Lamas GA, MOST Study
Investigators. High incidence of pacemaker syndrome in patients with sinus node dysfunction treated with ventricular-based pacing in the Mode Selection
Trial (MOST). J Am Coll Cardiol 2004;43:20662071.
720. van Rooden CJ, Molhoek SG, Rosendaal FR, Schalij MJ, Meinders AE, Huisman
MV. Incidence and risk factors of early venous thrombosis associated with permanent pacemaker leads. J Cardiovasc Electrophysiol 2004;15:12581262.
721. Da Costa SSdC, Scalabrini Neto A, Costa R, Caldas JG, Martinelli Filho M.
Incidence and risk factors of upper extremity deep vein lesions after permanent transvenous pacemaker implant: a 6-month follow-up prospective study. Pacing
Clin Electrophysiol 2002;25:13011306.
722. Ascoeta MS, Marijon E, Defaye P, Klug D, Beganton F, Perier M-C, Gras D,
Algalarrondo V, Deharo J-C, Leclercq C, Fauchier L, Babuty D, Bordachar P,
Sadoul N, Boveda S, Piot O, DAI-PP Investigators. Impact of early complications on outcomes in patients with implantable cardioverter-defibrillator for primary prevention. Heart Rhythm 2016;13:10451051.
723. Reynolds MR, Cohen DJ, Kugelmass AD, Brown PP, Becker ER, Culler SD,
Simon AW. The frequency and incremental cost of major complications among
Medicare beneficiaries receiving implantable cardioverter-defibrillators. J Am
Coll Cardiol 2006;47:24932497.
724. Sridhar AR, Yarlagadda V, Yeruva MR, Kanmanthareddy A, Vallakati A, Dawn B,
Lakkireddy D. Impact of haematoma after pacemaker and CRT device implantation on hospitalization costs, length of stay, and mortality: a population-based study. Europace 2015;17:15481554.
725. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F,
Dulgheru R, El Khoury G, Erba PA, Iung B, Miro JM, Mulder BJ, PlonskaGosciniak E, Price S, Roos-Hesselink J, Snygg-Martin U, Thuny F, Tornos Mas P,
Vilacosta I, Zamorano JL, ESC Scientific Document Group. 2015 ESC
Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of
Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic
Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur
Heart J 2015;36:30753128.
726. Clementy N, Carion PL, Leotoing L, Lamarsalle L, Wilquin-Bequet F, Brown B,
Verhees KJP, Fernandes J, Deharo JC. Infections and associated costs following cardiovascular implantable electronic device implantations: a nationwide cohort study. Europace 2018;20:19741980.


<!-- PAGE 91 -->

### Page 91

.............................................................................................................................................................................
727. Rattanawong P, Kewcharoen J, Mekraksakit P, Mekritthikrai R, Prasitlumkum N,
Vutthikraivit W, Putthapiban P, Dworkin J. Device infections in implantable cardioverter defibrillators versus permanent pacemakers: a systematic review and meta-analysis. J Cardiovasc Electrophysiol 2019;30:10531065.
728. Prutkin JM, Reynolds MR, Bao H, Curtis JP, Al-Khatib SM, Aggarwal S, Uslan
DZ. Rates of and factors associated with infection in 200 909 Medicare implantable cardioverter-defibrillator implants:
results from the
National
Cardiovascular Data Registry. Circulation 2014;130:10371043.
729. Uslan DZ, Sohail MR, St Sauver JL, Friedman PA, Hayes DL, Stoner SM, Wilson
WR, Steckelberg JM, Baddour LM. Permanent pacemaker and implantable cardioverter defibrillator infection: a population-based study. Arch Intern Med
2007;167:669675.
730. Chang JD, Manning WJ, Ebrille E, Zimetbaum PJ. Tricuspid valve dysfunction following pacemaker or cardioverter-defibrillator implantation. J Am Coll Cardiol
2017;69:23312341.
731. Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on longterm survival. J Am Coll Cardiol 2004;43:405409.
732. Hoke U, Auger D, Thijssen J, Wolterbeek R, van der Velde ET, Holman ER,
Schalij MJ, Bax JJ, Delgado V, Marsan NA. Significant lead-induced tricuspid regurgitation is associated with poor prognosis at long-term follow-up. Heart
2014;100:960968.
733. Mutlak D, Aronson D, Lessick J, Reisner SA, Dabbah S, Agmon Y. Functional tricuspid regurgitation in patients with pulmonary hypertension: is pulmonary artery pressure the only determinant of regurgitation severity?
Chest
2009;135:115121.
734. Schleifer JW, Pislaru SV, Lin G, Powell BD, Espinosa R, Koestler C, Thome T,
Polk L, Li Z, Asirvatham SJ, Cha YM. Effect of ventricular pacing lead position on tricuspid regurgitation: a randomized prospective trial. Heart Rhythm
2018;15:10091016.
735. Cheng Y, Gao H, Tang L, Li J, Yao L. Clinical utility of three-dimensional echocardiography in the evaluation of tricuspid regurgitation induced by implantable device leads. Echocardiography 2016;33:16891696.
736. Beurskens NEG, Tjong FVY, de Bruin-Bon RHA, Dasselaar KJ, Kuijt WJ, Wilde
AAM, Knops RE. Impact of leadless pacemaker therapy on cardiac and atrioventricular valve function through 12 months of follow-up. Circ Arrhythm
Electrophysiol 2019;12:e007124.
737. Addetia K, Harb SC, Hahn RT, Kapadia S, Lang RM. Cardiac implantable electronic device lead-induced tricuspid regurgitation. JACC Cardiovasc Imaging
2019;12:622636.
738. Taramasso M, Benfari G, van der Bijl P, Alessandrini H, Attinger-Toller A,
Biasco L, Lurz P, Braun D, Brochet E, Connelly KA, de Bruijn S, Denti P,
Deuschl F, Estevez-Loureiro R, Fam N, Frerker C, Gavazzoni M, Hausleiter J,
Ho E, Juliard JM, Kaple R, Besler C, Kodali S, Kreidel F, Kuck KH, Latib A,
Lauten A, Monivas V, Mehr M, Muntane-Carol G, Nazif T, Nickening G,
Pedrazzini G, Philippon F, Pozzoli A, Praz F, Puri R, Rodes-Cabau J, Schafer U,
Schofer J, Sievert H, Tang GHL, Thiele H, Topilsky Y, Rommel KP, Delgado V,
Vahanian A, Von Bardeleben RS, Webb JG, Weber M, Windecker S, Winkel M,
Zuber M, Leon MB, Hahn RT, Bax JJ, Enriquez-Sarano M, Maisano F.
Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation. J Am Coll Cardiol 2019;74:29983008.
739. Auricchio A, Gasparini M, Linde C, Dobreanu D, Cano O, Sterlinski M, Bogale
N, Stellbrink C, Refaat MM, Blomstrom-Lundqvist C, Lober C, Dickstein K,
Normand C. Sex-related procedural aspects and complications in CRT Survey
II: a multicenter European experience in 11,088 patients. JACC Clin Electrophysiol
2019;5:10481058.
740. Wagner EH, Austin BT, Von Korff M. Organizing care for patients with chronic illness. Milbank Q 1996;74:511544.
741. Hendriks JM, de Wit R, Crijns HJ, Vrijhoef HJ, Prins MH, Pisters R, Pison LA,
Blaauw Y, Tieleman RG. Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. Eur Heart J
2012;33:26922699.
742. Gallagher C, Elliott AD, Wong CX, Rangnekar G, Middeldorp ME, Mahajan R,
Lau DH, Sanders P, Hendriks JML. Integrated care in atrial fibrillation: a systematic review and meta-analysis. Heart 2017;103:19471953.
743. Wijtvliet E, Tieleman RG, van Gelder IC, Pluymaekers N, Rienstra M, Folkeringa
RJ, Bronzwaer P, Elvan A, Elders J, Tukkie R, Luermans J, Van Asselt A, Van
Kuijk SMJ, Tijssen JG, Crijns H, RACE Investigators. Nurse-led vs. usual-care for atrial fibrillation. Eur Heart J 2020;41:634641.
744. Russo RJ, Costa HS, Silva PD, Anderson JL, Arshad A, Biederman RW, Boyle
NG, Frabizzio JV, Birgersdotter-Green U, Higgins SL, Lampert R, Machado CE,
Martin ET, Rivard AL, Rubenstein JC, Schaerf RH, Schwartz JD, Shah DJ,
Tomassoni GF, Tominaga GT, Tonkin AE, Uretsky S, Wolff SD. Assessing the risks associated with MRI in patients with a pacemaker or defibrillator. N Engl J
Med 2017;376:755764.
745. Indik JH, Gimbel JR, Abe H, Alkmim-Teixeira R, Birgersdotter-Green U, Clarke
GD, Dickfeld TL, Froelich JW, Grant J, Hayes DL, Heidbuchel H, Idriss SF,
Kanal E, Lampert R, Machado CE, Mandrola JM, Nazarian S, Patton KK, Rozner
MA, Russo RJ, Shen WK, Shinbane JS, Teo WS, Uribe W, Verma A, Wilkoff BL,
Woodard PK. 2017 HRS expert consensus statement on magnetic resonance imaging and radiation exposure in patients with cardiovascular implantable electronic devices. Heart Rhythm 2017;14:e97e153.
746. Nazarian S, Hansford R, Rahsepar AA, Weltin V, McVeigh D, Gucuk Ipek E,
Kwan A, Berger RD, Calkins H, Lardo AC, Kraut MA, Kamel IR, Zimmerman
SL, Halperin HR. Safety of magnetic resonance imaging in patients with cardiac devices. N Engl J Med 2017;377:25552564.
747. Balmer C, Gass M, Dave H, Duru F, Luechinger R. Magnetic resonance imaging of patients with epicardial leads: in vitro evaluation of temperature changes at the lead tip. J Interv Card Electrophysiol 2019;56:321326.
748. Higgins JV, Gard JJ, Sheldon SH, Espinosa RE, Wood CP, Felmlee JP, Cha YM,
Asirvatham SJ, Dalzell C, Acker N, Watson RE Jr, Friedman PA. Safety and outcomes of magnetic resonance imaging in patients with abandoned pacemaker and defibrillator leads. Pacing Clin Electrophysiol 2014;37:12841290.
749. Padmanabhan D, Kella DK, Mehta R, Kapa S, Deshmukh A, Mulpuru S, Jaffe AS,
Felmlee JP, Jondal ML, Dalzell CM, Asirvatham SJ, Cha YM, Watson RE Jr,
Friedman PA. Safety of magnetic resonance imaging in patients with legacy pacemakers and defibrillators and abandoned leads. Heart Rhythm 2018;15:228233.
750. Horwood L, Attili A, Luba F, Ibrahim EH, Parmar H, Stojanovska J, GadothGoodman S, Fette C, Oral H, Bogun F. Magnetic resonance imaging in patients with cardiac implanted electronic devices: focus on contraindications to magnetic resonance imaging protocols. Europace 2017;19:812817.
751. Vuorinen AM, Pakarinen S, Jaakkola I, Holmstrom M, Kivisto S, Kaasalainen T.
Clinical experience of magnetic resonance imaging in patients with cardiac pacing devices: unrestricted patient population. Acta Radiol 2019;60:14141421.
752. Pulver AF, Puchalski MD, Bradley DJ, Minich LL, Su JT, Saarel EV, Whitaker P,
Etheridge SP. Safety and imaging quality of MRI in pediatric and adult congenital heart disease patients with pacemakers.
Pacing
Clin
Electrophysiol
2009;32:450456.
753. Wilkoff BL, Bello D, Taborsky M, Vymazal J, Kanal E, Heuer H, Hecking K,
Johnson WB, Young W, Ramza B, Akhtar N, Kuepper B, Hunold P, Luechinger
R, Puererfellner H, Duru F, Gotte MJ, Sutton R, Sommer T, EnRhythm MRI
SureScan Pacing System Study Investigators. Magnetic resonance imaging in patients with a pacemaker system designed for the magnetic resonance environment. Heart Rhythm 2011;8:6573.
754. Shenthar J, Milasinovic G, Al Fagih A, Gotte M, Engel G, Wolff S, Tse HF, Herr
J, Carrithers J, Cerkvenik J, Nahle CP. MRI scanning in patients with new and existing CapSureFix Novus 5076 pacemaker leads: randomized trial results.
Heart Rhythm 2015;12:759765.
755. Gimbel JR, Bello D, Schmitt M, Merkely B, Schwitter J, Hayes DL, Sommer T,
Schloss EJ, Chang Y, Willey S, Kanal E. Randomized trial of pacemaker and lead system for safe scanning at 1.5 Tesla. Heart Rhythm 2013;10:685691.
756. Homsi R, Mellert F, Luechinger R, Thomas D, Doerner J, Luetkens J, Schild HH,
Naehle CP. Safety and feasibility of magnetic resonance imaging of the brain at
1.5 Tesla in patients with temporary transmyocardial pacing leads. Thorac
Cardiovasc Surg 2019;67:8691.
757. Zaremba T, Jakobsen AR, Sogaard M, Thogersen AM, Johansen MB, Madsen LB,
Riahi S. Risk of device malfunction in cancer patients with implantable cardiac device undergoing radiotherapy: a population-based cohort study. Pacing Clin
Electrophysiol 2015;38:343356.
758. Harms W, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Krug D, Piroth
MD, Sautter-Bihl ML, Sedlmayer F, Souchon R, Wenz F, Sauer R, Breast Cancer
Expert Panel of the German Society of Radiation Oncology. DEGRO practical guidelines for radiotherapy of breast cancer VI: therapy of locoregional breast cancer recurrences. Strahlenther Onkol 2016;192:199208.
759. Zecchin M, Severgnini M, Fiorentino A, Malavasi VL, Menegotti L, Alongi F,
Catanzariti D, Jereczek-Fossa BA, Stasi M, Russi E, Boriani G. Management of patients with cardiac implantable electronic devices (CIED) undergoing radiotherapy:
a consensus document from
Associazione
Italiana
Aritmologia e
Cardiostimolazione (AIAC), Associazione Italiana Radioterapia Oncologica (AIRO),
Associazione Italiana Fisica Medica (AIFM). Int J Cardiol 2018;255:175183.
760. Grant JD, Jensen GL, Tang C, Pollard JM, Kry SF, Krishnan S, Dougherty AH,
Gomez DR, Rozner MA. Radiotherapy-induced malfunction in contemporary cardiovascular implantable electronic devices: clinical incidence and predictors.
JAMA Oncol 2015;1:624632.
761. Zaremba T, Jakobsen AR, Søgaard M, Thøgersen AM, Riahi S. Radiotherapy in patients with pacemakers and implantable cardioverter defibrillators: a literature review. Europace 2016;18:479491.
762. Hurkmans CW, Knegjens JL, Oei BS, Maas AJ, Uiterwaal GJ, van der Borden AJ,
Ploegmakers MM, van Erven L, Dutch Society of Radiotherapy Oncology.
Management of radiation oncology patients with a pacemaker or ICD: a new
ESC Guidelines
91


<!-- PAGE 92 -->

### Page 92

.............................................................................................................................................................................
comprehensive practical guideline in The Netherlands. Dutch Society of
Radiotherapy and Oncology (NVRO). Radiat Oncol 2012;7:198.
763. Gomez DR, Poenisch F, Pinnix CC, Sheu T, Chang JY, Memon N, Mohan R,
Rozner MA, Dougherty AH. Malfunctions of implantable cardiac devices in patients receiving proton beam therapy: incidence and predictors. Int J Radiat
Oncol Biol Phys 2013;87:570575.
764. Tjong FVY, de Ruijter UW, Beurskens NEG, Knops RE. A comprehensive scoping review on transvenous temporary pacing therapy.
Neth
Heart
J
2019;27:462473.
765. Hynes JK, Holmes DR Jr, Harrison CE. Five-year experience with temporary pacemaker therapy in the coronary care unit. Mayo Clin Proc 1983;58:122126.
766. Ferri LA, Farina A, Lenatti L, Ruffa F, Tiberti G, Piatti L, Savonitto S. Emergent transvenous cardiac pacing using ultrasound guidance: a prospective study versus the standard fluoroscopy-guided procedure. Eur Heart J Acute Cardiovasc
Care 2016;5:125129.
767. Lang R, David D, Klein HO, Di Segni E, Libhaber C, Sareli P, Kaplinsky E. The use of the balloon-tipped floating catheter in temporary transvenous cardiac pacing. Pacing Clin Electrophysiol 1981;4:491496.
768. Ferguson JD, Banning AP, Bashir Y. Randomised trial of temporary cardiac pacing with semirigid and balloon-flotation electrode catheters. Lancet 1997;349:1883.
769. Austin JL, Preis LK, Crampton RS, Beller GA, Martin RP. Analysis of pacemaker malfunction and complications of temporary pacing in the coronary care unit.
Am J Cardiol 1982;49:301306.
770. Hill PE. Complications of permanent transvenous cardiac pacing: a 14-year review of all transvenous pacemakers inserted at one community hospital.
Pacing Clin Electrophysiol 1987;10:564570.
771. Murphy JJ. Current practice and complications of temporary transvenous cardiac pacing. BMJ 1996;312:1134.
772. Bjornstad CC, Gjertsen E, Thorup F, Gundersen T, Tobiasson K, Otterstad JE.
Temporary cardiac pacemaker treatment in five Norwegian regional hospitals.
Scand Cardiovasc J 2012;46:137143.
773. Lopez Ayerbe J, Villuendas Sabate R, Garcia Garcia C, Rodriguez Leor O, Gomez
Perez M, Curos Abadal A, Serra Flores J, Larrousse E, Valle V. [Temporary pacemakers: current use and complications]. Rev Esp Cardiol 2004;57:10451052.
774. Ng ACC, Lau JK, Chow V, Adikari D, Brieger D, Kritharides L. Outcomes of
4838 patients requiring temporary transvenous cardiac pacing: a statewide cohort study. Int J Cardiol 2018;271:98104.
775. Metkus TS, Schulman SP, Marine JE, Eid SM. Complications and outcomes of temporary transvenous pacing: an analysis of >360,000 patients from the
National Inpatient Sample. Chest 2019;155:749757.
776. Lever N, Ferguson JD, Bashir Y, Channon KM. Prolonged temporary cardiac pacing using subcutaneous tunnelled active-fixation permanent pacing leads.
Heart 2003;89:209210.
777. Rastan AJ, Doll N, Walther T, Mohr FW. Pacemaker dependent patients with device infection—a modified approach.
Eur
J
Cardiothorac
Surg
2005;27:11161118.
778. Zei PC, Eckart RE, Epstein LM. Modified temporary cardiac pacing using transvenous active fixation leads and external re-sterilized pulse generators. J Am
Coll Cardiol 2006;47:14871489.
779. Kawata H, Pretorius V, Phan H, Mulpuru S, Gadiyaram V, Patel J, Steltzner D,
Krummen D, Feld G, Birgersdotter-Green U. Utility and safety of temporary pacing using active fixation leads and externalized re-usable permanent pacemakers after lead extraction. Europace 2013;15:12871291.
780. Timothy PR, Rodeman BJ. Temporary pacemakers in critically ill patients:
assessment and management strategies. AACN Clin Issues 2004;15:305325.
781. Abd Elaziz ME, Allama AM. Temporary epicardial pacing after valve replacement: incidence and predictors. Heart Surg Forum 2018;21:E049E053.
782. Lazarescu C, Mertes PM, Longrois D. [Temporary epicardial pacing following cardiac surgery: practical aspects]. Ann Fr Anesth Reanim 2013;32:592601.
783. Bektas F, Soyuncu S. The efficacy of transcutaneous cardiac pacing in ED. Am J
Emerg Med 2016;34:20902093.
784. Quast ABE, Beurskens NEG, Ebner A, Wasley R, Vehmeijer JT, Marcovecchio A,
Sanghera R, Knops RE, Burke MC. Feasibility of an entirely extracardiac, minimally invasive, temporary pacing system. Circ Arrhythm Electrophysiol 2019;12:e007182.
785. Sherbino J, Verbeek PR, MacDonald RD, Sawadsky BV, McDonald AC,
Morrison LJ. Prehospital transcutaneous cardiac pacing for symptomatic bradycardia or bradyasystolic cardiac arrest: a systematic review. Resuscitation
2006;70:193200.
786. American Society of Anesthesiologists. Practice advisory for the perioperative management of patients with cardiac implantable electronic devices: pacemakers and implantable cardioverter-defibrillators: an updated report by the
American Society of Anesthesiologists task force on perioperative management of patients with cardiac implantable electronic devices.
Anesthesiology
2011;114:247261.
787. Crossley GH, Poole JE, Rozner MA, Asirvatham SJ, Cheng A, Chung MK,
Ferguson TB, Gallagher JD, Gold MR, Hoyt RH, Irefin S, Kusumoto FM,
Moorman LP, Thompson A. The Heart Rhythm Society (HRS)/American
Society of Anesthesiologists (ASA) Expert Consensus Statement on the perioperative management of patients with implantable defibrillators, pacemakers and arrhythmia monitors: facilities and patient management this document was developed as a joint project with the American Society of Anesthesiologists
(ASA), and in collaboration with the American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Heart Rhythm 2011;8:11141154.
788. Healey JS, Merchant R, Simpson C, Tang T, Beardsall M, Tung S, Fraser JA, Long
L, van Vlymen JM, Manninen P, Ralley F, Venkatraghavan L, Yee R, Prasloski B,
Sanatani
S,
Philippon
F,
Canadian
Cardiovascular
Society,
Canadian
Anesthesiologists’
Society,
Canadian
Heart
Rhythm
Society.
Canadian
Cardiovascular Society/Canadian Anesthesiologists’ Society/Canadian Heart
Rhythm Society joint position statement on the perioperative management of patients with implanted pacemakers, defibrillators, and neurostimulating devices. Can J Cardiol 2012;28:141151.
789. Boriani G, Fauchier L, Aguinaga L, Beattie JM, Blomstrom Lundqvist C, Cohen
A, Dan GA, Genovesi S, Israel C, Joung B, Kalarus Z, Lampert R, Malavasi VL,
Mansourati J, Mont L, Potpara T, Thornton A, Lip GYH, ESC Scientific
Document Group. European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS),
Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of
Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS).
Europace 2019;21:78.
790. Schulman PM, Treggiari MM, Yanez ND, Henrikson CA, Jessel PM, Dewland
TA, Merkel MJ, Sera V, Harukuni I, Anderson RB, Kahl E, Bingham A, Alkayed
N, Stecker EC. Electromagnetic interference with protocolized electrosurgery dispersive electrode positioning in patients with implantable cardioverter defibrillators. Anesthesiology 2019;130:530540.
791. Gifford J, Larimer K, Thomas C, May P. ICD-ON Registry for perioperative management of CIEDs: most require no change. Pacing Clin Electrophysiol
2017;40:128134.
792. Heidbuchel H, Panhuyzen-Goedkoop N, Corrado D, Hoffmann E, Biffi A,
Delise P, Blomstrom-Lundqvist C, Vanhees L, Ivarhoff P, Dorwarth U, Pelliccia
A, Study Group on Sports Cardiology of the European Association for
Cardiovascular Prevention Rehabilitation. Recommendations for participation in leisure-time physical activity and competitive sports in patients with arrhythmias and potentially arrhythmogenic conditions Part I: supraventricular arrhythmias and pacemakers. Eur J Cardiovasc Prev Rehabil 2006;13:475484.
793. Lampert R. Managing with pacemakers and implantable cardioverter defibrillators. Circulation 2013;128:15761585.
794. Pelliccia A, Fagard R, Bjornstad HH, Anastassakis A, Arbustini E, Assanelli D,
Biffi A, Borjesson M, Carre F, Corrado D, Delise P, Dorwarth U, Hirth A,
Heidbuchel H, Hoffmann E, Mellwig KP, Panhuyzen-Goedkoop N, Pisani A,
Solberg EE, van-Buuren F, Vanhees L, Blomstrom-Lundqvist C, Deligiannis A,
Dugmore D, Glikson M, Hoff PI, Hoffmann A, Hoffmann E, Horstkotte D,
Nordrehaug JE, Oudhof J, McKenna WJ, Penco M, Priori S, Reybrouck T,
Senden J, Spataro A, Thiene G. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac
Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J
2005;26:14221445.
795. Heidbuchel H, Adami PE, Antz M, Braunschweig F, Delise P, Scherr D, Solberg
EE, Wilhelm M, Pelliccia A. Recommendations for participation in leisure-time physical activity and competitive sports in patients with arrhythmias and potentially arrhythmogenic conditions: Part 1: supraventricular arrhythmias. A position statement of the Section of Sports Cardiology and Exercise from the
European Association of Preventive Cardiology (EAPC) and the European
Heart Rhythm Association (EHRA), both associations of the European Society of Cardiology. Eur J Prev Cardiol 2020;doi: 10.1177/2047487320925635
796. Pelliccia A, Sharma S, Gati S, Back M, Borjesson M, Caselli S, Collet JP, Corrado
D, Drezner JA, Halle M, Hansen D, Heidbuchel H, Myers J, Niebauer J,
Papadakis M, Piepoli MF, Prescott E, Roos-Hesselink JW, Graham Stuart A,
Taylor RS, Thompson PD, Tiberi M, Vanhees L, Wilhelm M, ESC Scientific
Document Group. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J 2020;42:1796.
797. Lampert R, Olshansky B, Heidbuchel H, Lawless C, Saarel E, Ackerman M,
Calkins H, Estes NAM, Link MS, Maron BJ, Marcus F, Scheinman M, Wilkoff BL,
Zipes DP, Berul CI, Cheng A, Jordaens L, Law I, Loomis M, Willems R, Barth C,
Broos K, Brandt C, Dziura J, Li F, Simone L, Vandenberghe K, Cannom D.
Safety of sports for athletes with implantable cardioverter-defibrillators: longterm results of a
prospective multinational registry.
Circulation
2017;135:23102312.
798. Heidbuchel H, Arbelo E, D’Ascenzi F, Borjesson M, Boveda S, Castelletti S,
Miljoen H, Mont L, Niebauer J, Papadakis M, Pelliccia A, Saenen J, Sanz de la


<!-- PAGE 93 -->

### Page 93

.............................................................................................................................................................................
Garza M, Schwartz PJ, Sharma S, Zeppenfeld K, Corrado D. Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part 2:
ventricular arrhythmias,
channelopathies,
and implantable defibrillators.
Europace 2021;23:147148.
799. Hauser RG, Hayes DL, Kallinen LM, Cannom DS, Epstein AE, Almquist AK,
Song SL, Tyers GF, Vlay SC, Irwin M. Clinical experience with pacemaker pulse generators and transvenous leads: an 8-year prospective multicenter study.
Heart Rhythm 2007;4:154160.
800. Merchant FM, Tejada T, Patel A, El-Khalil J, Desai Y, Keeling B, Lattouf OM,
Leon AR, El-Chami MF. Procedural outcomes and long-term survival associated with lead extraction in patients with abandoned leads.
Heart
Rhythm
2018;15:855859.
801. Diemberger I, Mazzotti A, Giulia MB, Biffi M, Cristian M, Massaro G, Matteo M,
Martignani C, Letizia ZM, Ziacchi M, Reggiani B, Reggiani ML, Battistini P,
Boriani G. From lead management to implanted patient management: systematic review and meta-analysis of the last 15 years of experience in lead extraction.
Expert Rev Med Devices 2013;10:551573.
802. Bongiorni MG, Kennergren C, Butter C, Deharo JC, Kutarski A, Rinaldi CA,
Romano SL, Maggioni AP, Andarala M, Auricchio A, Kuck KH, Blomstro¨mLundqvist
C,
ELECTRa
Investigators.
The
European
Lead
Extraction
ConTRolled (ELECTRa) study: a European Heart Rhythm Association (EHRA)
registry of transvenous lead extraction outcomes.
Eur
Heart
J
2017;38:29953005.
803. Segreti L, Rinaldi CA, Claridge S, Svendsen JH, Blomstrom-Lundqvist C, Auricchio
A, Butter C, Dagres N, Deharo JC, Maggioni AP, Kutarski A, Kennergren C,
Laroche C, Kempa M, Magnani A, Casteigt B, Bongiorni MG, ELECTRa
Investigators. Procedural outcomes associated with transvenous lead extraction in patients with abandoned leads: an ESC-EHRA ELECTRa (European Lead
Extraction ConTRolled) registry sub-analysis. Europace 2019;21:645654.
804. Parthiban N, Esterman A, Mahajan R, Twomey DJ, Pathak RK, Lau DH,
Roberts-Thomson KC, Young GD, Sanders P, Ganesan AN. Remote monitoring of implantable cardioverter-defibrillators: a systematic review and meta-analysis of clinical outcomes. J Am Coll Cardiol 2015;65:25912600.
805. Garcia-Fernandez FJ, Osca Asensi J, Romero R, Fernandez Lozano I, Larrazabal
JM, Martinez Ferrer J, Ortiz R, Pombo M, Tornes FJ, Moradi Kolbolandi M.
Safety and efficiency of a common and simplified protocol for pacemaker and defibrillator surveillance based on remote monitoring only: a long-term randomized trial (RM-ALONE). Eur Heart J 2019;40:18371846.
806. Mabo P, Victor F, Bazin P, Ahres S, Babuty D, Da Costa A, Binet D, Daubert JC,
COMPAS
Trial
Investigators.
A
randomized trial of long-term remote monitoring of pacemaker recipients
(the
COMPAS
trial).
Eur
Heart
J
2012;33:11051111.
807. Vogtmann T, Stiller S, Marek A, Kespohl S, Gomer M, Ku¨hlkamp V, Zach G,
Lo¨scher S, Baumann G. Workload and usefulness of daily, centralized home monitoring for patients treated with CIEDs: results of the MoniC (Model
Project
Monitor
Centre)
prospective multicentre study.
Europace
2013;15:219226.
808. Nielsen JC, Kautzner J, Casado-Arroyo R, Burri H, Callens S, Cowie MR,
Dickstein K, Drossart I, Geneste G, Erkin Z, Hyafil F, Kraus A, Kutyifa V, Marin
E, Schulze C, Slotwiner D, Stein K, Zanero S, Heidbuchel H, Fraser AG.
Remote monitoring of cardiac implanted electronic devices: legal requirements and ethical principles—ESC Regulatory Affairs Committee/EHRA joint task force report. Europace 2020;22:17421758.
809. Perl S, Stiegler P, Rotman B, Prenner G, Lercher P, Anelli-Monti M, Sereinigg M,
Riegelnik V, Kvas E, Kos C, Heinzel FR, Tscheliessnigg KH, Pieske B. Socio-economic effects and cost saving potential of remote patient monitoring (SAVEHM trial). Int J Cardiol 2013;169:402407.
810. Ricci RP, Morichelli L, Santini M. Remote control of implanted devices through
Home Monitoring technology improves detection and clinical management of atrial fibrillation. Europace 2009;11:5461.
811. McCance T, McCormack B, Dewing J. An exploration of person-centredness in practice. Online J Issues Nurs 2011;16:1.
812. Kitson A, Marshall A, Bassett K, Zeitz K. What are the core elements of patient-centred care? A narrative review and synthesis of the literature from health policy, medicine and nursing. J Adv Nurs 2013;69:415.
813. Ekman I, Swedberg K, Taft C, Lindseth A, Norberg A, Brink E, Carlsson J,
Dahlin-Ivanoff S, Johansson IL, Kjellgren K, Liden E, Ohlen J, Olsson LE, Rosen
H, Rydmark M, Sunnerhagen KS. Person-centered care—ready for prime time.
Eur J Cardiovasc Nurs 2011;10:248251.
814. Kiesler DJ, Auerbach SM. Optimal matches of patient preferences for information, decision-making and interpersonal behavior: evidence, models and interventions. Patient Educ Couns 2006;61:319341.
815. Alston C, Paget L, Halvorson G, Novelli B, Guest J, McCabe P, Hoffman K,
Koepke C, Simon M, Sutton S, Okun S, Wicks P, Undem T, Rohrbach V, von
Kohorn I. Communicating with Patients on Health Care Evidence. Washington, DC:
Institute of Medicine of the National Academies; 2012. http://www.iom.edu/
evidence.
816. Hibbard JH, Greene J. What the evidence shows about patient activation: better health outcomes and care experiences; fewer data on costs. Health Aff
(Millwood) 2013;32:207214.
817. Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med
1997;44:681692.
818. Towle A, Godolphin W. Framework for teaching and learning informed shared decision making. BMJ 1999;319:766771.
819. Makoul G, Clayman ML. An integrative model of shared decision making in medical encounters. Patient Educ Couns 2006;60:301312.
820. Pitcher D, Soar J, Hogg K, Linker N, Chapman S, Beattie JM, Jones S, George R,
McComb J, Glancy J, Patterson G, Turner S, Hampshire S, Lockey A, Baker T,
Mitchell S. Cardiovascular implanted electronic devices in people towards the end of life, during cardiopulmonary resuscitation and after death: guidance from the Resuscitation Council (UK), British Cardiovascular Society and National
Council for Palliative Care. Heart 2016;102 Suppl 7:A1-a17.
821. The SHARE Approach. https://www.ahrq.gov/health-literacy/professional-train ing/shared-decision/index.html (25 May 2021)
822. International Patient Decision Aid Standards (IPDAS). IPDAS Collaboration
Background Document,. ipdas.ohri.ca/IPDAS_Background.pdf (25 May 2021)
823. Stacey D, Legare F, Lewis K, Barry MJ, Bennett CL, Eden KB, Holmes-Rovner
M, Llewellyn-Thomas H, Lyddiatt A, Thomson R, Trevena L. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst
Rev 2017;4:Cd001431.
824. De Oliveira GS Jr, McCarthy RJ, Wolf MS, Holl J. The impact of health literacy in the care of surgical patients: a qualitative systematic review. BMC Surg
2015;15:86.
825. Berkman ND, Sheridan SL, Donahue KE, Halpern DJ, Viera A, Crotty K,
Holland A, Brasure M, Lohr KN, Harden E, Tant E, Wallace I, Viswanathan M.
Health literacy interventions and outcomes: an updated systematic review. Evid
Rep Technol Assess (Full Report) 2011:1941.
826. Wolf A, Vella R, Fors A. The impact of person-centred care on patients’ care experiences in relation to educational level after acute coronary syndrome: secondary outcome analysis of a randomised controlled trial. Eur J Cardiovasc Nurs
2019;18:299308.
827. Marcus C. Strategies for improving the quality of verbal patient and family education: a review of the literature and creation of the EDUCATE model. Health
Psychol Behav Med 2014;2:482495.
828. Friedman AJ, Cosby R, Boyko S, Hatton-Bauer J, Turnbull G. Effective teaching strategies and methods of delivery for patient education:
a systematic review and practice guideline recommendations. J Cancer Educ
2011;26:1221.
829. Sustersic M, Gauchet A, Foote A, Bosson JL. How best to use and evaluate
Patient Information Leaflets given during a consultation: a systematic review of literature reviews. Health Expect 2017;20:531542.
830. Elwyn G, Lloyd A, Joseph-Williams N, Cording E, Thomson R, Durand MA,
Edwards A. Option grids: shared decision making made easier. Patient Educ
Couns 2013;90:207212.
831. Dwamena F, Holmes-Rovner M, Gaulden CM, Jorgenson S, Sadigh G, Sikorskii
A, Lewin S, Smith RC, Coffey J, Olomu A. Interventions for providers to promote a patient-centred approach in clinical consultations. Cochrane Database
Syst Rev 2012;12:Cd003267.
832. Olsson LE, Jakobsson Ung E, Swedberg K, Ekman I. Efficacy of person-centred care as an intervention in controlled trials—a systematic review. J Clin Nurs
2013;22:456465.
833. McMillan SS, Kendall E, Sav A, King MA, Whitty JA, Kelly F, Wheeler AJ. Patientcentered approaches to health care: a systematic review of randomized controlled trials. Med Care Res Rev 2013;70:567596.
834. Ekman I, Wolf A, Olsson LE, Taft C, Dudas K, Schaufelberger M, Swedberg K.
Effects of person-centred care in patients with chronic heart failure: the PCCHF study. Eur Heart J 2012;33:11121119.
835. Ulin K, Olsson LE, Wolf A, Ekman I. Person-centred care—an approach that improves the discharge process. Eur J Cardiovasc Nurs 2016;15:e19e26.
836. Dudas K, Olsson LE, Wolf A, Swedberg K, Taft C, Schaufelberger M, Ekman I.
Uncertainty in illness among patients with chronic heart failure is less in person-centred care than in usual care.
Eur
J
Cardiovasc
Nurs
2013;12:521528.
837. Minchin M, Roland M, Richardson J, Rowark S, Guthrie B. Quality of care in the
United
Kingdom after removal of financial incentives.
N
Engl
J
Med
2018;379:948957.
838. Song Z, Ji Y, Safran DG, Chernew ME. Health care spending, utilization, and quality 8 years into global payment. N Engl J Med 2019;381:252263.
839. Aktaa S, Batra G, Wallentin L, Baigent C, Erlinge D, James S, Ludman P,
Maggioni AP, Price S, Weston C, Casadei B, Gale CP. European Society of
ESC Guidelines
93


<!-- PAGE 94 -->

### Page 94

.....................................
Cardiology methodology for the development of quality indicators for the quantification of cardiovascular care and outcomes. Eur Heart J Qual Care Clin
Outcomes 2020;TO BE UPDATED:doi: 10.1093/ehjqcco/qcaa1069. Online ahead of print.
840. Arbelo E, Aktaa S, Bollmann A, D’Avila A, Drossart I, Dwight J, Hills MT,
Hindricks G, Kusumoto FM, Lane DA, Lau DH, Lettino M, Lip GYH, Lobban T,
Pak HN, Potpara T, Saenz LC, Van Gelder IC, Varosy P, Gale CP, Dagres N,
Reviewers, Boveda S, Deneke T, Defaye P, Conte G, Lenarczyk R, Providencia
R, Guerra JM, Takahashi Y, Pisani C, Nava S, Sarkozy A, Glotzer TV, Martins
Oliveira M. Quality indicators for the care and outcomes of adults with atrial fibrillation. Europace 2021;23:494495.
841. Collet JP, Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt DL, Dendale
P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Juni P,
Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M,
Rutten FH, Sibbing D, Siontis GCM, ESC Scientific Document Group. 2020 ESC
Guidelines for the management of acute coronary syndromes in patients presenting without persistent
ST-segment elevation.
Eur
Heart
J
2021;42:12891367.
842. Wallentin L, Gale CP, Maggioni A, Bardinet I, Casadei B. EuroHeart: European unified registries on heart care evaluation and randomized trials. Eur Heart J
2019;40:27452749.
843. Zhang
S,
Gaiser
S,
Kolominsky-Rabas
PL.
Cardiac implant registries
20062016: a systematic review and summary of global experiences. BMJ Open
2018;8:e019039.
844. Aktaa S, Abdin A, Arbelo E, Burri H, Vernooy K, Blomstro¨m-Lundqvist C,
Boriani G, Defaye P, Deharo J-C, Drossart I, Foldager D, Gold MR, Johansen JB,
Leyva F, Linde C, Michowitz Y, Kronborg MB, Slotwiner D, Steen T, Tolosana
JM, Tzeis S, Varma N, Glikson M, Nielsen J-C, Gale CP. European Society of
Cardiology Quality Indicators for the care and outcomes of cardiac pacing
Developed by the Working Group for Cardiac Pacing Quality Indicators in collaboration with the European Heart Rhythm Association of the European
Society of Cardiology. Europace 2021;doi:10.1093/europace/euab193.

<!-- 2021_Heart_Failure.md -->

# ESC Guidelines: Heart Failure (2021)

**Source**: `2021_Heart_Failure.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 128

---

## Table of Contents

- [ehab368-1](#ehab368-1) *(p. 9)*
- [ehab368-2](#ehab368-2) *(p. 11)*
- [ehab368-2.1](#ehab368-21) *(p. 11)*
- [tblfn1](#tblfn1) *(p. 11)*
- [tblfn2](#tblfn2) *(p. 12)*
- [ehab368-3](#ehab368-3) *(p. 14)*
- [ehab368-3.1](#ehab368-31) *(p. 14)*
- [ehab368-3.2](#ehab368-32) *(p. 14)*
- [tblfn3](#tblfn3) *(p. 14)*
- [ehab368-3.3](#ehab368-33) *(p. 15)*
- [tblfn4](#tblfn4) *(p. 15)*
- [tblfn5](#tblfn5) *(p. 15)*
- [tblfn6](#tblfn6) *(p. 15)*
- [tblfn7](#tblfn7) *(p. 15)*
- [ehab368-4](#ehab368-4) *(p. 16)*
- [ehab368-4.1](#ehab368-41) *(p. 16)*
- [tblfn15](#tblfn15) *(p. 18)*
- [ehab368-4.2](#ehab368-42) *(p. 19)*
- [ehab368-4.3](#ehab368-43) *(p. 19)*
- [tblfn10](#tblfn10) *(p. 19)*
- [tblfn11](#tblfn11) *(p. 19)*
- [tblfn12](#tblfn12) *(p. 19)*
- [tblfn13](#tblfn13) *(p. 19)*
- [tblfn8](#tblfn8) *(p. 19)*
- [tblfn9](#tblfn9) *(p. 19)*
- [tblfn14](#tblfn14) *(p. 20)*
- [ehab368-5](#ehab368-5) *(p. 21)*
- [ehab368-5.1](#ehab368-51) *(p. 21)*
- [ehab368-5.2](#ehab368-52) *(p. 21)*
- [ehab368-5.2.1](#ehab368-521) *(p. 21)*
- [ehab368-5.2.2](#ehab368-522) *(p. 21)*
- [tblfn16](#tblfn16) *(p. 21)*
- [tblfn17](#tblfn17) *(p. 21)*
- [tblfn18](#tblfn18) *(p. 21)*
- [ehab368-5.3](#ehab368-53) *(p. 22)*
- [tblfn26](#tblfn26) *(p. 22)*
- [tblfn27](#tblfn27) *(p. 22)*
- [tblfn28](#tblfn28) *(p. 22)*
- [ehab368-5.3.1](#ehab368-531) *(p. 23)*
- [ehab368-5.3.2](#ehab368-532) *(p. 23)*
- [ehab368-5.3.3](#ehab368-533) *(p. 23)*
- [ehab368-5.3.4](#ehab368-534) *(p. 23)*
- [tblfn19](#tblfn19) *(p. 23)*
- [tblfn20](#tblfn20) *(p. 23)*
- [tblfn21](#tblfn21) *(p. 23)*
- [tblfn22](#tblfn22) *(p. 23)*
- [tblfn23](#tblfn23) *(p. 23)*
- [tblfn24](#tblfn24) *(p. 23)*
- [tblfn25](#tblfn25) *(p. 23)*
- [ehab368-5.3.5](#ehab368-535) *(p. 24)*
- [ehab368-5.4](#ehab368-54) *(p. 24)*
- [ehab368-5.4.1](#ehab368-541) *(p. 25)*
- [ehab368-5.4.2](#ehab368-542) *(p. 25)*
- [ehab368-5.4.3](#ehab368-543) *(p. 25)*
- [ehab368-5.4.4](#ehab368-544) *(p. 25)*
- [ehab368-5.4.5](#ehab368-545) *(p. 25)*
- [tblfn29](#tblfn29) *(p. 25)*
- [tblfn30](#tblfn30) *(p. 25)*
- [tblfn31](#tblfn31) *(p. 25)*
- [tblfn32](#tblfn32) *(p. 25)*
- [ehab368-5.4.6](#ehab368-546) *(p. 27)*
- [ehab368-5.5](#ehab368-55) *(p. 27)*
- [ehab368-6](#ehab368-6) *(p. 27)*
- [ehab368-6.1](#ehab368-61) *(p. 27)*
- [tblfn61](#tblfn61) *(p. 27)*
- [tblfn62](#tblfn62) *(p. 27)*
- [tblfn63](#tblfn63) *(p. 27)*
- [ehab368-6.1.1](#ehab368-611) *(p. 28)*
- [ehab368-6.1.2](#ehab368-612) *(p. 28)*
- [ehab368-6.1.3](#ehab368-613) *(p. 28)*
- [ehab368-6.1.4](#ehab368-614) *(p. 28)*
- [ehab368-6.1.5](#ehab368-615) *(p. 28)*
- [ehab368-6.2](#ehab368-62) *(p. 29)*
- [tblfn64](#tblfn64) *(p. 29)*
- [tblfn65](#tblfn65) *(p. 29)*
- [tblfn66](#tblfn66) *(p. 29)*
- [ehab368-6.3](#ehab368-63) *(p. 30)*
- [ehab368-7](#ehab368-7) *(p. 30)*
- [ehab368-7.1](#ehab368-71) *(p. 30)*
- [ehab368-7.2](#ehab368-72) *(p. 31)*
- [ehab368-7.3](#ehab368-73) *(p. 31)*
- [ehab368-7.3.1](#ehab368-731) *(p. 31)*
- [ehab368-7.3.2](#ehab368-732) *(p. 31)*
- [ehab368-7.3.3](#ehab368-733) *(p. 31)*
- [ehab368-7.3.4](#ehab368-734) *(p. 31)*
- [ehab368-7.3.5](#ehab368-735) *(p. 31)*
- [tblfn67](#tblfn67) *(p. 31)*
- [tblfn68](#tblfn68) *(p. 31)*
- [tblfn69](#tblfn69) *(p. 31)*
- [ehab368-7.3.6](#ehab368-736) *(p. 32)*
- [ehab368-7.3.7](#ehab368-737) *(p. 32)*
- [ehab368-8](#ehab368-8) *(p. 32)*
- [ehab368-8.1](#ehab368-81) *(p. 32)*
- [ehab368-8.2](#ehab368-82) *(p. 32)*
- [ehab368-8.3](#ehab368-83) *(p. 32)*
- [ehab368-8.4](#ehab368-84) *(p. 33)*
- [tblfn33](#tblfn33) *(p. 33)*
- [tblfn34](#tblfn34) *(p. 33)*
- [tblfn35](#tblfn35) *(p. 33)*
- [tblfn36](#tblfn36) *(p. 34)*
- [tblfn37](#tblfn37) *(p. 34)*
- [tblfn38](#tblfn38) *(p. 34)*
- [tblfn39](#tblfn39) *(p. 34)*
- [tblfn40](#tblfn40) *(p. 34)*
- [tblfn41](#tblfn41) *(p. 34)*
- [tblfn42](#tblfn42) *(p. 34)*
- [ehab368-9](#ehab368-9) *(p. 35)*
- [ehab368-9.1](#ehab368-91) *(p. 35)*
- [ehab368-9.2](#ehab368-92) *(p. 35)*
- [ehab368-9.3](#ehab368-93) *(p. 35)*
- [tblfn43](#tblfn43) *(p. 35)*
- [tblfn44](#tblfn44) *(p. 35)*
- [tblfn45](#tblfn45) *(p. 35)*
- [ehab368-9.4](#ehab368-94) *(p. 38)*
- [ehab368-9.5](#ehab368-95) *(p. 38)*
- [ehab368-9.6](#ehab368-96) *(p. 38)*
- [tblfn47](#tblfn47) *(p. 38)*
- [tblfn48](#tblfn48) *(p. 38)*
- [tblfn49](#tblfn49) *(p. 38)*
- [tblfn50](#tblfn50) *(p. 38)*
- [tblfn51](#tblfn51) *(p. 38)*
- [tblfn52](#tblfn52) *(p. 38)*
- [ehab368-10](#ehab368-10) *(p. 39)*
- [ehab368-10.1](#ehab368-101) *(p. 39)*
- [tblfn53](#tblfn53) *(p. 39)*
- [tblfn54](#tblfn54) *(p. 39)*
- [tblfn55](#tblfn55) *(p. 39)*
- [tblfn56](#tblfn56) *(p. 40)*
- [ehab368-10.2](#ehab368-102) *(p. 41)*
- [ehab368-10.2.1](#ehab368-1021) *(p. 41)*
- [ehab368-10.2.2](#ehab368-1022) *(p. 41)*
- [tblfn57](#tblfn57) *(p. 41)*
- [tblfn58](#tblfn58) *(p. 44)*
- [tblfn59](#tblfn59) *(p. 44)*
- [tblfn60](#tblfn60) *(p. 44)*
- [ehab368-10.2.3](#ehab368-1023) *(p. 45)*
- [tblfn70](#tblfn70) *(p. 45)*
- [tblfn71](#tblfn71) *(p. 45)*
- [tblfn71a](#tblfn71a) *(p. 45)*
- [tblfn106](#tblfn106) *(p. 45)*
- [tblfn107](#tblfn107) *(p. 45)*
- [tblfn108](#tblfn108) *(p. 45)*
- [ehab368-10.2.4](#ehab368-1024) *(p. 46)*
- [ehab368-11](#ehab368-11) *(p. 46)*
- [ehab368-11.1](#ehab368-111) *(p. 46)*
- [tblfn72](#tblfn72) *(p. 46)*
- [tblfn73](#tblfn73) *(p. 46)*
- [ehab368-11.2](#ehab368-112) *(p. 48)*
- [ehab368-11.2.1](#ehab368-1121) *(p. 48)*
- [tblfn74](#tblfn74) *(p. 48)*
- [tblfn75](#tblfn75) *(p. 48)*
- [tblfn76](#tblfn76) *(p. 48)*
- [ehab368-11.2.2](#ehab368-1122) *(p. 49)*
- [ehab368-11.2.3](#ehab368-1123) *(p. 49)*
- [ehab368-11.2.4](#ehab368-1124) *(p. 49)*
- [tblfn77](#tblfn77) *(p. 49)*
- [tblfn78](#tblfn78) *(p. 49)*
- [tblfn78a](#tblfn78a) *(p. 49)*
- [ehab368-11.3](#ehab368-113) *(p. 51)*
- [ehab368-11.3.1](#ehab368-1131) *(p. 51)*
- [ehab368-11.3.2](#ehab368-1132) *(p. 53)*
- [ehab368-11.3.3](#ehab368-1133) *(p. 54)*
- [ehab368-11.3.4](#ehab368-1134) *(p. 56)*
- [ehab368-11.3.5](#ehab368-1135) *(p. 57)*
- [ehab368-11.3.6](#ehab368-1136) *(p. 57)*
- [ehab368-11.3.7](#ehab368-1137) *(p. 57)*
- [ehab368-11.3.8](#ehab368-1138) *(p. 58)*
- [ehab368-11.3.9](#ehab368-1139) *(p. 58)*
- [ehab368-11.3.10](#ehab368-11310) *(p. 58)*
- [tblfn79](#tblfn79) *(p. 58)*
- [tblfn80](#tblfn80) *(p. 58)*
- [tblfn81](#tblfn81) *(p. 58)*
- [tblfn82](#tblfn82) *(p. 58)*
- [tblfn83](#tblfn83) *(p. 58)*
- [tblfn84](#tblfn84) *(p. 58)*
- [ehab368-12](#ehab368-12) *(p. 59)*
- [ehab368-12.1](#ehab368-121) *(p. 59)*
- [ehab368-12.1.1](#ehab368-1211) *(p. 59)*
- [tblfn85](#tblfn85) *(p. 59)*
- [tblfn86](#tblfn86) *(p. 59)*
- [tblfn87](#tblfn87) *(p. 59)*
- [ehab368-12.1.2](#ehab368-1212) *(p. 62)*
- [ehab368-12.1.3](#ehab368-1213) *(p. 62)*
- [ehab368-12.2](#ehab368-122) *(p. 62)*
- [tblfn124](#tblfn124) *(p. 62)*
- [tblfn125](#tblfn125) *(p. 62)*
- [tblfn126](#tblfn126) *(p. 62)*
- [ehab368-12.3](#ehab368-123) *(p. 64)*
- [ehab368-12.3.1](#ehab368-1231) *(p. 64)*
- [tblfn127](#tblfn127) *(p. 64)*
- [tblfn128](#tblfn128) *(p. 64)*
- [tblfn129](#tblfn129) *(p. 64)*
- [ehab368-12.3.2](#ehab368-1232) *(p. 66)*
- [ehab368-12.3.3](#ehab368-1233) *(p. 66)*
- [tblfn130](#tblfn130) *(p. 67)*
- [tblfn131](#tblfn131) *(p. 67)*
- [tblfn132](#tblfn132) *(p. 67)*
- [tblfn133](#tblfn133) *(p. 67)*
- [tblfn134](#tblfn134) *(p. 67)*
- [ehab368-12.3.4](#ehab368-1234) *(p. 68)*
- [ehab368-12.4](#ehab368-124) *(p. 68)*
- [ehab368-12.5](#ehab368-125) *(p. 68)*
- [ehab368-13](#ehab368-13) *(p. 68)*
- [ehab368-13.1](#ehab368-131) *(p. 68)*
- [ehab368-13.2](#ehab368-132) *(p. 69)*
- [tblfn135](#tblfn135) *(p. 69)*
- [tblfn136](#tblfn136) *(p. 69)*
- [tblfn137](#tblfn137) *(p. 69)*
- [ehab368-13.3](#ehab368-133) *(p. 70)*
- [ehab368-13.4](#ehab368-134) *(p. 70)*
- [ehab368-13.5](#ehab368-135) *(p. 70)*
- [ehab368-13.6](#ehab368-136) *(p. 71)*
- [tblfn138](#tblfn138) *(p. 71)*
- [tblfn139](#tblfn139) *(p. 71)*
- [tblfn140](#tblfn140) *(p. 71)*
- [ehab368-13.7](#ehab368-137) *(p. 72)*
- [ehab368-13.8](#ehab368-138) *(p. 73)*
- [ehab368-13.9](#ehab368-139) *(p. 73)*
- [ehab368-13.10](#ehab368-1310) *(p. 74)*
- [ehab368-13.11](#ehab368-1311) *(p. 74)*
- [ehab368-13.12](#ehab368-1312) *(p. 74)*
- [ehab368-13.13](#ehab368-1313) *(p. 74)*
- [tblfn88](#tblfn88) *(p. 75)*
- [ehab368-13.14](#ehab368-1314) *(p. 77)*
- [ehab368-14](#ehab368-14) *(p. 77)*
- [ehab368-14.1](#ehab368-141) *(p. 77)*
- [ehab368-14.1.1](#ehab368-1411) *(p. 77)*
- [ehab368-14.1.2](#ehab368-1412) *(p. 77)*
- [tblfn89](#tblfn89) *(p. 77)*
- [tblfn90](#tblfn90) *(p. 77)*
- [tblfn91](#tblfn91) *(p. 77)*
- [tblfn92](#tblfn92) *(p. 77)*
- [ehab368-14.2](#ehab368-142) *(p. 79)*
- [ehab368-14.2.1](#ehab368-1421) *(p. 79)*
- [ehab368-14.2.2](#ehab368-1422) *(p. 79)*
- [tblfn93](#tblfn93) *(p. 80)*
- [tblfn94](#tblfn94) *(p. 80)*
- [tblfn95](#tblfn95) *(p. 81)*
- [tblfn96](#tblfn96) *(p. 81)*
- [tblfn97](#tblfn97) *(p. 81)*
- [tblfn98](#tblfn98) *(p. 82)*
- [tblfn99](#tblfn99) *(p. 82)*
- [ehab368-14.3](#ehab368-143) *(p. 83)*
- [tblfn100](#tblfn100) *(p. 83)*
- [ehab368-14.4](#ehab368-144) *(p. 84)*
- [ehab368-14.4.1](#ehab368-1441) *(p. 84)*
- [ehab368-14.4.2](#ehab368-1442) *(p. 84)*
- [ehab368-14.4.3](#ehab368-1443) *(p. 84)*
- [ehab368-14.5](#ehab368-145) *(p. 84)*
- [ehab368-14.5.1](#ehab368-1451) *(p. 84)*
- [ehab368-14.5.2](#ehab368-1452) *(p. 84)*
- [ehab368-14.6](#ehab368-146) *(p. 84)*
- [ehab368-14.6.1](#ehab368-1461) *(p. 84)*
- [tblfn101](#tblfn101) *(p. 84)*
- [tblfn102](#tblfn102) *(p. 85)*
- [tblfn103](#tblfn103) *(p. 86)*
- [ehab368-14.6.2](#ehab368-1462) *(p. 87)*
- [ehab368-14.7](#ehab368-147) *(p. 87)*
- [tblfn104](#tblfn104) *(p. 87)*
- [tblfn105](#tblfn105) *(p. 87)*
- [tblfn109](#tblfn109) *(p. 87)*
- [ehab368-14.8](#ehab368-148) *(p. 88)*
- [tblfn110](#tblfn110) *(p. 88)*
- [tblfn111](#tblfn111) *(p. 88)*
- [tblfn811](#tblfn811) *(p. 88)*
- [tblfn112](#tblfn112) *(p. 88)*
- [tblfn113](#tblfn113) *(p. 88)*
- [tblfn114](#tblfn114) *(p. 88)*
- [ehab368-15](#ehab368-15) *(p. 90)*
- [tblfn115](#tblfn115) *(p. 90)*
- [ehab368-16](#ehab368-16) *(p. 91)*
- [ehab368-17](#ehab368-17) *(p. 92)*
- [tblfn116](#tblfn116) *(p. 94)*
- [tblfn117](#tblfn117) *(p. 94)*
- [tblfn118](#tblfn118) *(p. 94)*
- [tblfn119](#tblfn119) *(p. 94)*
- [tblfn120](#tblfn120) *(p. 94)*
- [ehab368-18](#ehab368-18) *(p. 95)*
- [tblfn121](#tblfn121) *(p. 95)*
- [tblfn122](#tblfn122) *(p. 95)*
- [tblfn123](#tblfn123) *(p. 95)*
- [ehab368-19](#ehab368-19) *(p. 96)*
- [ehab368-20](#ehab368-20) *(p. 96)*
- [app1](#app1) *(p. 96)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)
With the special contribution of the Heart Failure Association
(HFA) of the ESC
Authors/Task Force Members: Theresa A. McDonagh* (Chairperson) (United
Kingdom), Marco Metra
* (Chairperson) (Italy), Marianna Adamo (Task Force
Coordinator) (Italy), Roy S. Gardner (Task Force Coordinator) (United Kingdom),
Andreas Baumbach (United Kingdom), Michael Bo¨hm (Germany), Haran Burri
(Switzerland), Javed Butler (United States of America), Jelena Celutkien_e
(Lithuania), Ovidiu Chioncel (Romania), John G.F. Cleland (United Kingdom),
Andrew J.S. Coats (United Kingdom), Maria G. Crespo-Leiro (Spain),
Dimitrios Farmakis (Greece), Martine Gilard (France), Stephane Heymans
* Corresponding authors: The two chairpersons contributed equally to the document.
Theresa McDonagh, Cardiology Department, King’s College Hospital, Denmark Hill, London, SE5 9RS, United Kingdom. Tel: þ44 203 299 325,
E-mail: theresa.mcdonagh@kcl.ac.uk;
Marco Metra, Institute of Cardiology, ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of
Brescia, Brescia, Italy. Tel: þ39 303 07221, E-mail: metramarco@libero.it
Author/Task Force Member afﬁliations: listed in Author information.
ESC Clinical Practice Guidelines Committee (CPG): listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association for Acute CardioVascular Care (ACVC), Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of
Cardiovascular Imaging (EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European
Heart Rhythm Association (EHRA), Heart Failure Association (HFA).
Councils: Council of Cardio-Oncology, Council on Basic Cardiovascular Science, Council on Valvular Heart Disease.
Working Groups: Adult Congenital Heart Disease, Cardiovascular Pharmacotherapy, Cardiovascular Regenerative and Reparative Medicine, Cardiovascular Surgery,
e-Cardiology, Myocardial and Pericardial Diseases, Myocardial Function.
Patient Forum
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to
Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
Disclaimer: The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientiﬁc and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other ofﬁcial recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC
Guidelines exempt health professionals from taking into full and careful consideration the relevant ofﬁcial updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientiﬁcally accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
This article has been co-published with permission in the European Heart Journal and European Journal of Heart Failure. V
C the European Society of Cardiology 2021. All rights reserved.
The articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Either citation can be used when citing this article. For permissions,
please email journals.permissions@oup.com.
ESC GUIDELINES
doi:10.1093/eurheartj/ehab368


<!-- PAGE 2 -->

### Page 2

..............................
(Netherlands), Arno W. Hoes (Netherlands), Tiny Jaarsma (Sweden),
Ewa A. Jankowska (Poland), Mitja Lainscak (Slovenia), Carolyn S.P. Lam (Singapore),
Alexander R. Lyon (United Kingdom), John J.V. McMurray (United Kingdom),
Alexandre Mebazaa (France), Richard Mindham (United Kingdom),
Claudio Muneretto (Italy), Massimo Francesco Piepoli (Italy), Susanna Price (United
Kingdom), Giuseppe M.C. Rosano (United Kingdom), Frank Ruschitzka (Switzerland),
Anne Kathrine Skibelund (Denmark), ESC Scientific Document Group
Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator) (Netherlands), P. Christian Schulze
(CPG Review Coordinator) (Germany), Magdy Abdelhamid (Egypt), Victor Aboyans (France),
Stamatis Adamopoulos (Greece), Stefan D. Anker (Germany), Elena Arbelo (Spain), Riccardo Asteggiano
(Italy), Johann Bauersachs (Germany), Antoni Bayes-Genis (Spain), Michael A. Borger (Germany),
Werner Budts (Belgium), Maja Cikes (Croatia), Kevin Damman (Netherlands), Victoria Delgado
(Netherlands), Paul Dendale (Belgium), Polychronis Dilaveris (Greece), Heinz Drexel (Austria),
Justin Ezekowitz (Canada), Volkmar Falk (Germany), Laurent Fauchier (France), Gerasimos Filippatos
(Greece), Alan Fraser (United Kingdom), Norbert Frey (Germany), Chris P. Gale (United Kingdom),
Finn Gustafsson (Denmark), Julie Harris (United Kingdom), Bernard Iung (France), Stefan Janssens
(Belgium), Mariell Jessup (United States of America), Aleksandra Konradi (Russia), Dipak Kotecha (United
Kingdom), Ekaterini Lambrinou (Cyprus), Patrizio Lancellotti (Belgium), Ulf Landmesser (Germany),
Christophe Leclercq (France), Basil S. Lewis (Israel), Francisco Leyva (United Kingdom), Ales Linhart
(Czech Republic), Maja-Lisa Løchen (Norway), Lars H. Lund (Sweden), Donna Mancini (United States of
America), Josep Masip (Spain), Davor Milicic (Croatia), Christian Mueller (Switzerland), Holger Nef
(Germany), Jens-Cosedis Nielsen (Denmark), Lis Neubeck (United Kingdom), Michel Noutsias (Germany),
Steffen E. Petersen (United Kingdom), Anna Sonia Petronio (Italy), Piotr Ponikowski (Poland),
Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Dimitrios J. Richter (Greece), Evgeny Schlyakhto
(Russia), Petar Seferovic (Serbia), Michele Senni (Italy), Marta Sitges (Spain), Miguel Sousa-Uva (Portugal),
Carlo G. Tocchetti (Italy), Rhian M. Touyz (United Kingdom), Carsten Tschoepe (Germany),
Johannes Waltenberger (Germany/Switzerland)
All experts involved in the development of these guidelines have submitted declarations of interest.
These have been compiled in a report and published in a supplementary document simultaneously to the guidelines. The report is also available on the ESC website www.escardio.org/guidelines
For the Supplementary Data which include background information and detailed discussion of the data that have provided the basis for the guidelines see European Heart Journal online
Online publish-ahead-of-print 27 August 2021
...................................................................................................................................................................................................
Keywords
Guidelines • heart failure • natriuretic peptides • ejection fraction • diagnosis • pharmacotherapy •
neuro-hormonal antagonists • cardiac resynchronization therapy • mechanical circulatory support •
transplantation • arrhythmias • comorbidities • hospitalization • multidisciplinary management •
advanced heart failure • acute heart failure
Table of contents
1 Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3607
2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3609
2.1 What is new . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3609
3 Definition, epidemiology and prognosis . . . . . . . . . . . . . . . . . . . . . . . . . 3612
3.1 Definition of heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3612
3.2 Terminology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3612
3.2.1 Heart failure with preserved, mildly reduced, and reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3612
3.2.2 Right ventricular dysfunction . . . . . . . . . . . . . . . . . . . . . . . . . . . 3613
3.2.3 Other common terminology used in heart failure . . . . . . . 3613
3.2.4 Terminology related to the symptomatic severity of heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3613
3.3 Epidemiology and natural history of heart failure . . . . . . . . . . . . 3613
3.3.1 Incidence and prevalence. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3613
3.3.2 Aetiology of heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3614
3.3.3 Natural history and prognosis . . . . . . . . . . . . . . . . . . . . . . . . . . 3614
4 Chronic heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3614
4.1 Key steps in the diagnosis of chronic heart failure . . . . . . . . . . . 3614


<!-- PAGE 3 -->

### Page 3

.............................................................................................................................................................................
4.2 Natriuretic peptides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3616
4.2.1 Use in the non-acute setting . . . . . . . . . . . . . . . . . . . . . . . . . . . 3617
4.3 Investigations to determine the underlying aetiology of chronic heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3617
5 Heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . 3619
5.1 The diagnosis of heart failure with reduced ejection fraction . 3619
5.2 Pharmacological treatments for patients with heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . 3619
5.2.1 Goals of pharmacotherapy for patients with heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . 3619
5.2.2 General principles of pharmacotherapy for heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . 3619
5.3 Drugs recommended in all patients with heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3620
5.3.1 Angiotensin-converting enzyme inhibitors . . . . . . . . . . . . . . 3621
5.3.2 Beta-blockers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3621
5.3.3 Mineralocorticoid receptor antagonists . . . . . . . . . . . . . . . . 3621
5.3.4 Angiotensin receptor-neprilysin inhibitor . . . . . . . . . . . . . . . 3621
5.3.5 Sodium-glucose co-transporter 2 inhibitors . . . . . . . . . . . . 3622
5.4 Other drugs recommended or to be considered in selected patients with heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3622
5.4.1 Diuretics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3623
5.4.2 Angiotensin II type 1 receptor blockers . . . . . . . . . . . . . . . . . 3623
5.4.3 If-channel inhibitor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3623
5.4.4 Combination of hydralazine and isosorbide dinitrate . . . . 3623
5.4.5 Digoxin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3623
5.4.6 Recently reported advances from trials in heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . 3624
5.5 Strategic phenotypic overview of the management of heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . 3624
6 Cardiac rhythm management for heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3624
6.1 Implantable cardioverter-defibrillator . . . . . . . . . . . . . . . . . . . . . . . 3625
6.1.1 Secondary prevention of sudden cardiac death . . . . . . . . . 3626
6.1.2 Primary prevention of sudden cardiac death . . . . . . . . . . . . 3626
6.1.3 Patient selection for implantable cardioverterdefibrillator therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3626
6.1.4 Implantable cardioverter-defibrillator programming . . . . . 3626
6.1.5 Subcutaneous and wearable implantable cardioverter-defibrillators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3626
6.2 Cardiac resynchronization therapy . . . . . . . . . . . . . . . . . . . . . . . . . 3627
6.3 Devices under evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3628
7 Heart failure with mildly reduced ejection fraction . . . . . . . . . . . . . . 3628
7.1 The diagnosis of heart failure with mildly reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3628
7.2 Clinical characteristics of patients with heart failure with mildly reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . 3629
7.3 Treatments for patients with heart failure with mildly reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3629
7.3.1 Angiotensin-converting enzyme inhibitors . . . . . . . . . . . . . . 3629
7.3.2 Angiotensin receptor II type 1 receptor blockers . . . . . . . 3629
7.3.3 Beta-blockers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3629
7.3.4 Mineralocorticoid receptor antagonists . . . . . . . . . . . . . . . . 3629
7.3.5 Angiotensin receptor-neprilysin inhibitor . . . . . . . . . . . . . . . 3629
7.3.6 Other drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3630
7.3.7 Devices . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3630
8 Heart failure with preserved ejection fraction . . . . . . . . . . . . . . . . . . . 3630
8.1 The background to heart failure with preserved ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3630
8.2 Clinical characteristics of patients with heart failure with preserved ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3630
8.3 The diagnosis of heart failure with preserved ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3630
8.4 Treatment of heart failure with preserved ejection fraction . . 3631
9 Multidisciplinary team management for the prevention and treatment of chronic heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3633
9.1 Prevention of heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3633
9.2 Multidisciplinary management of chronic heart failure . . . . . . . 3633
9.2.1 Models of care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3633
9.2.2 Characteristics and components of a heart failure management programme . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3633
9.3 Patient education, self-care and lifestyle advice . . . . . . . . . . . . . . 3633
9.4 Exercise rehabilitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3636
9.5 Follow-up of chronic heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . 3636
9.5.1 General follow-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3636
9.5.2 Monitoring with biomarkers . . . . . . . . . . . . . . . . . . . . . . . . . . . 3636
9.6 Telemonitoring . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3636
10 Advanced heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3637
10.1 Epidemiology, diagnosis, and prognosis . . . . . . . . . . . . . . . . . . . . 3637
10.2 Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3639
10.2.1 Pharmacological therapy and renal replacement . . . . . . . 3639
10.2.2 Mechanical circulatory support . . . . . . . . . . . . . . . . . . . . . . . 3639
10.2.3 Heart transplantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3643
10.2.4 Symptom control and end-of-life care . . . . . . . . . . . . . . . . . 3644
11 Acute heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3644
11.1 Epidemiology, diagnosis and prognosis . . . . . . . . . . . . . . . . . . . . 3644
11.2 Clinical presentations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3646
11.2.1 Acute decompensated heart failure . . . . . . . . . . . . . . . . . . . 3646
11.2.2 Acute pulmonary oedema . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3647
11.2.3 Isolated right ventricular failure . . . . . . . . . . . . . . . . . . . . . . . 3647
11.2.4 Cardiogenic shock . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3647
11.3 Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3649
11.3.1 General aspects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3649
11.3.2 Oxygen therapy and/or ventilatory support . . . . . . . . . . . 3650
11.3.3 Diuretics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3652
11.3.4 Vasodilators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3654
11.3.5 Inotropes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3655
11.3.6 Vasopressors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3655
11.3.7 Opiates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3655
11.3.8 Digoxin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3656
11.3.9 Thromboembolism prophylaxis . . . . . . . . . . . . . . . . . . . . . . 3656
11.3.10 Short-term mechanical circulatory support . . . . . . . . . . 3656
11.3.11 Pre-discharge assessment and post-discharge management planning . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3657
12 Cardiovascular comorbidities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3657
12.1 Arrhythmias and conduction disturbances . . . . . . . . . . . . . . . . . 3657
12.1.1 Atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3657
12.1.2 Ventricular arrhythmias . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3660
12.1.3 Symptomatic bradycardia, pauses and atrio-ventricular block . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3660
12.2 Chronic coronary syndromes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3660
12.2.1 Medical therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3661
12.2.2 Myocardial revascularization . . . . . . . . . . . . . . . . . . . . . . . . . . 3662
ESC Guidelines
3601


<!-- PAGE 4 -->

### Page 4

.............................................................................................................................................................................
12.3 Valvular heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3662
12.3.1 Aortic stenosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3662
12.3.2 Aortic regurgitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3664
12.3.3 Mitral regurgitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3664
12.3.4 Tricuspid regurgitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3666
12.4 Hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3666
12.5 Stroke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3666
13 Non-cardiovascular comorbidities . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3666
13.1 Diabetes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3666
13.2 Thyroid disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3667
13.3 Obesity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3668
13.4 Frailty, cachexia, sarcopenia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3668
13.5 Iron deficiency and anaemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3668
13.6 Kidney dysfunction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3669
13.7 Electrolyte disorders: hypokalaemia, hyperkalaemia,
hyponatraemia, hypochloraemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3670
13.8 Lung disease, sleep-disordered breathing . . . . . . . . . . . . . . . . . . 3671
13.9 Hyperlipidaemia and lipid-modifying therapy . . . . . . . . . . . . . . . 3671
13.10 Gout and arthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3672
13.11 Erectile dysfunction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3672
13.12 Depression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3672
13.13 Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3672
13.14 Infection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3675
14 Special conditions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3675
14.1 Pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3675
14.1.1 Pregnancy in pre-existing heart failure . . . . . . . . . . . . . . . . . 3675
14.1.2 New heart failure presenting during pregnancy . . . . . . . . 3675
14.2 Cardiomyopathies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3677
14.2.1 Epidemiology and diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . 3677
14.2.2 Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3677
14.3 Left ventricular non-compaction . . . . . . . . . . . . . . . . . . . . . . . . . . 3681
14.4 Atrial disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682
14.4.1 Definition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682
14.4.2 Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682
14.4.3 Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682
14.5 Myocarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682
14.5.1 Epidemiology and diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682
14.5.2 Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682
14.6 Amyloidosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682
14.6.1 Epidemiology and diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682
14.6.2 Therapy of amyloidosis and heart failure . . . . . . . . . . . . . . 3685
14.7 Iron overload cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3685
14.8 Adult congenital heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3686
15 Key messages . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3688
16 Gaps in evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3689
17 ‘What to do’ and ‘what not to do’ messages from the guidelines . 3690
18 Quality indicators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3693
19 Supplementary data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3694
20 Author information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3694
21 Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3694
22 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3695
List of recommendations
Recommended diagnostic tests in all patients with suspected chronic heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3617
Recommendations for specialized diagnostic tests for selected patients with chronic heart failure to detect reversible/treatable causes of heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3618
Pharmacological treatments indicated in patients with
(NYHA class IIIV) heart failure with reduced ejection fraction
(LVEF <_40%) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3620
Other pharmacological treatments indicated in selected patients with NYHA class IIIV heart failure with reduced ejection fraction (LVEF <_40%) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3622
Recommendations for an implantable cardioverter-defibrillator in patients with heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3625
Recommendations for cardiac resynchronization therapy implantation in patients with heart failure . . . . . . . . . . . . . . . . . . . . . . . . . 3627
Pharmacological treatments to be considered in patients with
(NYHA class IIIV) heart failure with mildly reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3629
Recommendations for the treatment of patients with heart failure with preserved ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3632
Recommendations for the primary prevention of heart failure in patients with risk factors for its development . . . . . . . . . . . . . . . . . . . . . 3632
Multidisciplinary interventions recommended for the management of chronic heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3633
Recommendations for exercise rehabilitation in patients with chronic heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3636
Recommendations for telemonitoring . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3637
Recommendations for the treatment of patients with advanced heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3643
Recommendations for the initial treatment of acute heart failure . . . 3655
Recommendations for the use of short-term mechanical circulatory support in patients with cardiogenic shock . . . . . . . . . . . . . . . . . . . . . . . . 3656
Recommendations for pre-discharge and early post-discharge follow-up of patients hospitalized for acute heart failure . . . . . . . . . . . 3657
Recommendations for the treatment of atrial fibrillation in patients with heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3660
Recommendations for myocardial revascularization in patients with heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . 3662
Recommendations for the management of valvular heart disease in patients with heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3665
Recommendations for the treatment of diabetes in heart failure . . . 3667
Recommendations for the management of anaemia and iron deficiency in patients with heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3669
Recommendations for the management of patients with cancer and heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3675
Recommendations for the treatment of transthyretin amyloidosis-cardiac amyloidosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3686
List of tables
Table 1 Classes of recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3608
Table 2 Levels of evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3608
Table 3 Definition of heart failure with reduced ejection fraction,
mildly reduced ejection fraction and preserved ejection fraction . . . 3613
Table 4 New York Heart Association functional classification based on severity of symptoms and physical activity . . . . . . . . . . . . . . . 3614
Table 5 Causes of heart failure, common modes of presentation and specific investigations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3616
Table 6 Symptoms and signs typical of heart failure . . . . . . . . . . . . . . . . 3617


<!-- PAGE 5 -->

### Page 5

.............................................................................................................................................................................
Table 7 Causes of elevated concentrations of natriuretic peptides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3618
Table 8 Evidence-based doses of disease-modifying drugs in key randomized trials in patients with heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3621
Table 9 Objective evidence of cardiac structural, functional and serological abnormalities consistent with the presence of left ventricular diastolic dysfunction/raised left ventricular filling pressures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3631
Table 10 Risk factors for the development of heart failure and potential corrective actions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3632
Table 11 Important characteristics and components in a heart failure management programme . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3634
Table 12 Patient education and self-care . . . . . . . . . . . . . . . . . . . . . . . . . . 3634
Table 13 Criteria for definition of advanced heart failure . . . . . . . . . . . 3638
Table 14 Interagency Registry for Mechanically Assisted
Circulatory Support profile descriptions of patients with advanced heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3638
Table 15 Terms describing various indications for mechanical circulatory support . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3642
Table 16 Patients potentially eligible for implantation of a left ventricular assist device . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3642
Table 17 Heart transplantation: indications and contraindications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3643
Table 18 Patients with heart failure in whom end-of-life care should be considered . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3644
Table 19 Key components of palliative care service in patients with advanced heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3644
Table 20 Diagnostic tests in patients with acute heart failure . . . . . . . 3646
Table 21 Clinical presentations of acute heart failure . . . . . . . . . . . . . . 3647
Table 22 Inotropes and/or vasopressors used to treat acute heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3655
Table 23 Cancer drugs causing heart failure . . . . . . . . . . . . . . . . . . . . . . . 3673
Table 24 Infections in patients with heart failure . . . . . . . . . . . . . . . . . . . 3675
Table 25 Possible causes and disease modifiers of most frequent cardiomyopathies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3678
Table 26 Initial diagnostic assessment in patients with suspected cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3678
Table 27 Dilated cardiomyopathy or hypokinetic non-dilated cardiomyopathy: specific aspects of diagnosis and treatment . . . . . . . 3679
Table 28 Hypertrophic cardiomyopathy: specific aspects of diagnosis and treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3680
Table 29 Arrhythmogenic cardiomyopathy: specific aspects of diagnosis and Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3681
Table 30 Aetiologies to be considered triggering acute myocarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3682
Table 31 Diagnostic workup in suspected acute myocarditis . . . . . . . 3683
Table 32 Endomyocardial biopsy in patients with suspected myocarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3684
Table 33 Cardiac magnetic resonance in patients with suspected myocarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3685
Table 34 Treatment and follow-up of acute myocarditis . . . . . . . . . . . 3685
Table 35 “Red flags” for most common forms of cardiac amyloidosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3686
Table 36 Treatment of adult congenital heart disease and heart failure in specialized centres . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3688
Table 37 Main European Society of Cardiology Quality Indicators for the evaluation of care and outcomes for patients with heart failure . 3693
List of figures
Figure 1 The diagnostic algorithm for heart failure . . . . . . . . . . . . . . . . . 3615
Figure 2 Therapeutic algorithm of Class I Therapy Indications for a patient with heart failure with reduced ejection fraction . . . . . . . . . . . 3620
Figure 3 Central illustration. Strategic phenotypic overview of the management of heart failure with reduced ejection fraction . . . . . . . . 3624
Figure 4 Algorithm for the treatment of patients with advanced heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3640
Figure 5 Triage of patients with advanced heart failure and appropriate timing of referral . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3641
Figure 6 Diagnostic workup of new onset acute heart failure . . . . . . . 3645
Figure 7 Management of acute decompensated heart failure . . . . . . . 3648
Figure 8 Management of pulmonary oedema . . . . . . . . . . . . . . . . . . . . . . 3649
Figure 9 Management of right ventricular failure . . . . . . . . . . . . . . . . . . . 3650
Figure 10 Management of cardiogenic shock . . . . . . . . . . . . . . . . . . . . . . 3651
Figure 11 Stages of management of patients with acute heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3652
Figure 12 Initial management of acute heart failure . . . . . . . . . . . . . . . . 3653
Figure 13 Diuretic therapy (furosemide) in acute heart failure . . . . . . 3654
Figure 14 Management of atrial fibrillation in patients with heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3658
Figure 15 Algorithm for the medical treatment of chronic coronary syndrome in patients with heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3661
Figure 16 Management of patients with severe low-flow low-gradient aortic stenosis and heart failure . . . . . . . . . . . . . . . . . . . . . 3663
Figure 17 Management of secondary mitral regurgitation in patients with heart failure with reduced ejection fraction . . . . . . . . . . . . . . . . . . 3664
Figure 18 Management of patients with cancer and heart failure . . . . 3674
Figure 19 Management of patients with heart failure before and during pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3676
Figure 20 Management of patients with heart failure and acute myocarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3684
Figure 21 Diagnosis and treatment of cardiac amyloidosis in heart failure patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3687
Abbreviations and acronyms
6MWT
6-minute walk test
99mTc-PYP
Technetium-labelled pyrophosphate
AATAC
Ablation vs. Amiodarone for Treatment of
Atrial Fibrillation in Patients With
Congestive Heart Failure and an Implanted
ICD/CRTD (trial)
AC
Arrhythmogenic cardiomyopathy
ACE
Angiotensin-converting enzyme
ACE-I
Angiotensin-converting enzyme inhibitor
ACHD
Adult congenital heart disease
ACS
Acute coronary syndrome
ADHF
Acutely decompensated heart failure
AF
Atrial ﬁbrillation
AF-CHF
Atrial ﬁbrillation  Congestive Heart
Failure (trial)
ESC Guidelines
3603


<!-- PAGE 6 -->

### Page 6

............................................................................................................................................................................
AFFIRM
Atrial Fibrillation Follow-up Investigation of
Rhythm Management (trial)
AFFIRM-AHF
A Randomized, Double-blind Placebocontrolled Trial Comparing the Effect of
Intravenous Ferric Carboxymaltose on
Hospitalizations and Mortality in Irondeﬁcient Subjects Admitted for Acute Heart
Failure (trial)
AHF
Acute heart failure
AL
Light chain immunoglobulin
AL-CA
Light chain immunoglobulin cardiac amyloidosis
AMICA
Atrial Fibrillation Management in Congestive
Heart Failure With Ablation (trial)
ANCA
Antineutrophil cytoplasmic antibody
ARB
Angiotensin-receptor blocker
ARNI
Angiotensin receptor-neprilysin inhibitor
ARVC
Arrhythmogenic right ventricular cardiomyopathy
ATTR
Transthyretin amyloidosis
AV
Atrio-ventricular b.i.d.
Bis in die (twice daily)
BAG3
Bcl2-associated athanogene 3
BiVAD
Biventricular assist device
BMI
Body mass index
BNP
B-type natriuretic peptide
BP
Blood pressure b.p.m.
Beats per minute
BTB
Bridge to bridge
BTC
Bridge to candidacy
BTD
Bridge to decision
BTR
Bridge to recovery
BTT
Bridge to transplantation
CA
Cardiac amyloidosis (or amyloid cardiomyopathy)
CABANA
Catheter ABlation vs. ANti-arrhythmic drug therapy for Atrial ﬁbrillation (trial)
CABG
Coronary artery bypass graft
CAD
Coronary artery disease
CANVAS-R
CANagliﬂozin cardioVascular Assessment
Study - Renal
CARE-HF
CArdiac REsynchronization in Heart Failure
CASTLE-AF
Catheter Ablation versus Standard conventional Treatment in patients with LEft ventricular and Atrial Fibrillation (trial)
CCB
Calcium channel blocker
CCS
Chronic coronary syndrome
CHA2DS2-VASc
Congestive heart failure or left ventricular dysfunction, Hypertension, Age >_75
(doubled), Diabetes, Stroke (doubled)-
Vascular disease, Age 6574, Sex category
(female) (score)
CHAMPIT
Acute Coronary syndrome/Hypertension emergency/Arrhythmia/acute Mechanical cause/Pulmonary embolism/Infections/
Tamponade
CHARM
Candesartan in Heart Failure - Assessment of moRtality and Morbidity (trial)
CHF
Chronic heart failure
CI
Conﬁdence interval
CKD
Chronic kidney disease
CMP
Cardiomyopathy
CMR
Cardiac magnetic resonance
CMV
Cytomegalovirus
COAPT
Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for HF
patients with functional mitral regurgitation
(trial)
COC
Cardio-Oncology Council (part of the
European Society of Cardiology)
COMMANDER-HF
A Study to Assess the Effectiveness and
Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in
Participants With Heart Failure and
Coronary Artery Disease Following an
Episode of Decompensated Heart Failure
(trial)
COMPASS
Rivaroxaban for the Prevention of Major
Cardiovascular Events in Coronary or
Peripheral Artery Disease (trial)
COPD
Chronic obstructive pulmonary disease
CORONA
COntrolled ROsuvastatin multiNAtional
(trial)
COVID-19
Coronavirus disease 2019
CR
Controlled release
CREDENCE
Canagliﬂozin and Renal Endpoints in
Diabetes with Established Nephropathy
Clinical Evaluation (trial)
CRT
Cardiac resynchronization therapy
CRT-D
Cardiac resynchronization therapy with deﬁbrillator
CRT-P
Cardiac resynchronization therapy pacemaker
CSA
Central sleep apnoea
CT
Computed tomography
CTCA
Computed tomography coronary angiography
CV
Cardiovascular
DAPA-HF
Dapagliﬂozin And Prevention of Adverseoutcomes in Heart Failure (trial)
DCM
Dilated cardiomyopathy
DECLARETIMI 58
Dapagliﬂozin Effect on CardiovascuLAR
Events (Thrombolysis in Myocardial
Infarction) (trial)
DIAMOND
Patiromer for the Management of
Hyperkalemia in Subjects Receiving RAASi
Medications for the Treatment of Heart
Failure (trial)
DIG
Digitalis Investigation Group (trial)
DNA
Deoxyribonucleic acid
DOAC
Direct-acting oral anticoagulant
DPD
3,3-diphosphono-1,2-propanodicarboxylic acid


<!-- PAGE 7 -->

### Page 7

............................................................................................................................................................................
DPP-4
Dipeptidyl peptidase-4
DSC2
Desmocollin 2
DSG2
Desmoglein 2
DSP
Desmoplakin
DT
Destination therapy
E/e0 (ratio)
E/e0 (ratio) = early ﬁlling velocity on transmitral Doppler/early relaxation velocity on tissue Doppler
EACVI
European Association of Cardiovascular
Imaging (part of the European Society of
Cardiology)
EAST-AFNET 4
Early Treatment of Atrial Fibrillation for
Stroke Prevention Trial 4 (trial)
ECG
Electrocardiogram
EchoCRT
Echocardiography Guided Cardiac
Resynchronization Therapy (trial)
ECLS
Extracorporeal life support
ECMO
Extracorporeal membrane oxygenation
EF
Ejection fraction eGFR
Estimated glomerular ﬁltration rate
EHRA
European Heart Rhythm Association
EMA
European Medicines Agency
EMB
Endomyocardial biopsy
EMPA-REG
OUTCOME
Empagliﬂozin Cardiovascular Outcome
Event Trial in Type 2 Diabetes Mellitus
Patients (trial)
EMPERORReduced
EMPagliﬂozin outcomE tRial in Patients
With chrOnic heaRt Failure With Reduced
Ejection Fraction (trial)
EROA
Effective regurgitant oriﬁce area
ESC
European Society of Cardiology
EU
European Union
EuroSCORE II
European System for Cardiac Operative
Risk Evaluation II (score)
FDA
Food and Drug Administration
FDG
Fluorodeoxyglucose
FiO2
Fraction of inspired oxygen
FLN
Filamin
FLNC
Filamin C
GGT
Gamma-glutamyl transferase
GISSI-HF
Gruppo Italiano per lo Studio della
Streptochinasi nell’Infarto Miocardico 
Heart Failure (trial)
GLP-1
Glucagon-like peptide-1
GUIDE-HF
Hemodynamic-GUIDEd Management of
Heart Failure (trial)
h
Hour/hours
H2FPEF
Heavy (BMI >30 kg/m2), Hypertensive (use of
>_2 antihypertensive medications), atrial
Fibrillation (paroxysmal or persistent),
Pulmonary hypertension (Doppler
Echocardiographic estimated Pulmonary
Artery Systolic Pressure >35 mmHg), Elderly
(age >60 years), Filling pressure (Doppler
Echocardiographic E/e0 >9) (score)
HbA1c
Glycated haemoglobin
HCM
Hypertrophic cardiomyopathy
HEART
Heart Failure Revascularisation Trial
HER2
Human epidermal growth factor receptor 2
HF
Heart failure
HFA
Heart Failure Association
HFA-PEFF
Heart Failure Association of ESC diagnostic algorithm, P  Initial Workup (Step 1:
Pretest Assessment), E - Diagnostic
Workup (Step 2: Echocardiographic and
Natriuretic Peptide score), F1  Advanced
Workup (Step 3: Functional testing in Case of Uncertainty), F2  Aetiological Workup
(Step 4: Final Aetiology)
HF-MP
Heart failure management programme
HFmrEF
Heart failure with mildly reduced ejection fraction
HFpEF
Heart failure with preserved ejection fraction
HFrEF
Heart failure with reduced ejection fraction
HHV
Human herpes virus
HIV
Human immunodeﬁciency virus
HLA-DR
Human leukocyte antigen-DR isotype
HMDP
Hydroxyl-methylene-diphosphonate
HR
Hazard ratio
HT
Heart transplantation
HTM
Home telemonitoring i.v.
Intravenous
IABP
Intra-aortic balloon pump
ICCU
Intensive coronary care unit
ICD
Implantable cardioverter-deﬁbrillator
ICU
Intensive care unit
IHD
Ischaemic heart disease
INR
International normalized ratio
INTERMACS
Interagency Registry for Mechanically
Assisted Circulatory Support
INTrEPID
Investigation of Nontransplant-Eligible
Patients Who Are Inotrope Dependent
(trial)
IOCM
Iron overload cardiomyopathy
IPD
Individual patient data
I-PRESERVE
Irbesartan in Patients with Heart Failure and
PRESERVEd Ejection Fraction (trial)
KCNH2
Potassium voltage-gated channel subfamily
H member 2
KCNQ1
Potassium voltage-gated channel subfamily
Q member 1
LA
Left atrium/atrial
LAE
Left atrial enlargement
LBBB
Left bundle branch block
LDB3
LIM domain binding 3
LFT
Liver function test
LGE
Late gadolinium enhancement
LMNA
Lamin A/C
LMWH
Low-molecular-weight heparin
LUS
Lung ultrasound
LV
Left ventricular/ventricle
LVAD
Left ventricular assist device
ESC Guidelines
3605


<!-- PAGE 8 -->

### Page 8

............................................................................................................................................................................
LVEDP
Left ventricular end-diastolic pressure
LVEF
Left ventricular ejection fraction
LVESD
Left ventricular end-systolic diameter
LVH
Left ventricular hypertrophy
LVNC
Left ventricular non-compaction
LVOT
Left ventricular outﬂow tract
LVOTO
Left ventricular outﬂow tract obstruction
MADIT-CRT
Multicenter Automatic Deﬁbrillator
Implantation Trial with Cardiac
Resynchronization Therapy (trial)
MADIT-II
Multicenter Automatic Deﬁbrillator
Implantation Trial II (trial)
MADIT-RIT
Multicenter Automatic Deﬁbrillator
Implantation Trial  Reduce Inappropriate
Therapy (trial)
MAGGIC
Meta-Analysis Global Group in Chronic
Heart Failure
MCS
Mechanical circulatory support
MEK
Mitogen-activated protein kinase
MI
Myocardial infarction
MITRA-FR
Percutaneous Repair with the MitraClip
Device for Severe Functional/Secondary
Mitral Regurgitation (trial)
MMR
Mismatch repair
MR
Mitral regurgitation
MRA
Mineralocorticoid receptor antagonist
MRI
Magnetic resonance imaging mRNA
Messenger ribonucleic acid
MR-proANP
Mid-regional pro-atrial natriuretic peptide
MT
Medical therapy
MV
Mitral valve mWHO
Modiﬁed World Health Organization
MYPC
Myosin-binding protein C
NICM
Non-ischaemic cardiomyopathy
NKX2-5
NK2 transcription factor related, locus 5
NP
Natriuretic peptide
NSAID
Non-steroidal anti-inﬂammatory drug
NSVT
Non-sustained ventricular tachycardia
NT-proBNP
N-terminal pro-B-type natriuretic peptide
NYHA
New York Heart Association o.d
Omne in die (once daily)
OMT
Optimal medical therapy
OSA
Obstructive sleep apnoea
PA
Pulmonary artery
PaO2
Partial pressure of oxygen
PARADIGM-HF
Prospective comparison of ARNI with ACEI
to Determine Impact on Global Mortality and morbidity in Heart Failure (trial)
pCO2
Partial pressure of carbon dioxide
PCI
Percutaneous coronary intervention
PCR
Polymerase chain reaction
PCWP
Pulmonary capillary wedge pressure
PEP-CHF
Perindopril in Elderly People with Chronic
Heart Failure (trial)
PET
Positron emission tomography
PKP2
Plakophilin 2
PLN
Phospholamban
PPCM
Peripartum cardiomyopathy
PREVEND
Prevention of REnal and Vascular ENd-stage
Disease (trial)
PV
Pulmonary vein
PVC
Premature ventricular contraction
PVI
Pulmonary vein isolation pVO2
Peak exercise oxygen consumption
QI
Quality indicator
QOL
Quality of life
QRS
Q, R, and S waves of an ECG
RAAS
Renin-angiotensin-aldosterone system
RACE II
Rate Control Efﬁcacy in Permanent Atrial
Fibrillation: a Comparison between Lenient versus Strict Rate Control II (trial)
RAFT
Resynchronization/Deﬁbrillation for
Ambulatory Heart Failure Trial (trial)
RASi
Renin-angiotensin system inhibitor
RATE-AF
Rate Control Therapy Evaluation in
Permanent Atrial Fibrillation (trial)
RBM20
Ribonucleic acid binding motif 20
RCT
Randomized controlled trial
REMATCH
Randomized Evaluation of Mechanical
Assistance for the Treatment of Congestive
Heart Failure (trial)
REVERSE
REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction
(trial)
REVIVED
REVascularization for Ischaemic VEntricular
Dysfunction (trial)
RNA
Ribonucleic acid
RRT
Renal replacement therapy
RV
Right ventricular/ventricle
RVAD
Right ventricular assist device
RVEDP
Right ventricular end-diastolic pressure
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
SAVR
Surgical aortic valve replacement
SBP
Systolic blood pressure
SCN5a
Sodium channel alpha subunit 5
SCORED
Effect of Sotagliﬂozin on Cardiovascular and
Renal Events in Patients with Type 2
Diabetes and Moderate Renal Impairment
Who Are at Cardiovascular Risk (trial)
SENIORS
Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalizations in
Seniors with Heart Failure (trial)
SERVE-HF
Treatment of Sleep-Disordered Breathing with Predominant Central Sleep Apnea by
Adaptive Servo Ventilation in Patients with
Heart Failure (trial)
SGLT2
Sodium-glucose co-transporter 2
S-ICD
Subcutaneous implantable cardioverterdeﬁbrillator
SMR
Secondary mitral regurgitation
SPECT
Single-photon emission computed tomography


<!-- PAGE 9 -->

### Page 9

.............................................................................................................................................................................
SpO2
Transcutaneous oxygen saturation
SR
Sinus rhythm
STEMI
ST-elevation myocardial infarction
STICH
Surgical Treatment for Ischemic Heart
Failure (trial)
STICHES
Extended follow-up of patients from the
STICH trial
STS-PROM
Society of Thoracic Surgeons Predicted Risk of Mortality
SZC
Sodium zirconium cyclosilicate
T2DM
Type 2 diabetes mellitus
TAVI
Transcatheter aortic valve implantation
TFT
Thyroid function test t.i.d.
Ter in die (three times a day)
TKI
Tyrosine kinase inhibitor
TMEM43
Transmembrane protein 43
TNNT
Troponin-T
TR
Tricuspid regurgitation
TRPM4
Transient receptor potential cation channel subfamily M member 4
TSAT
Transferrin saturation
TSH
Thyroid-stimulating hormone
TTN
Titin
TTR
Transthyretin
UK
United Kingdom
US
United States
VAD
Ventricular assist device
Val-HeFT
Valsartan Heart Failure Trial (trial)
VEGF
Vascular endothelial growth factor
VERTIS-CV
Cardiovascular Outcomes Following
Ertugliﬂozin Treatment in Type 2 Diabetes
Mellitus Participants With Vascular Disease
(trial)
VEST
Vest Prevention of Early Sudden Death Trial
(trial)
VKA
Vitamin K antagonist
VO2
Oxygen consumption
VPB
Ventricular premature beat vs.
Versus
VV interval
Interventricular delay interval
WARCEF
Warfarin and Aspirin in Reduced Cardiac
Ejection Fraction (trial)
wtTTR-CA
Wild-type transthyretin cardiac amyloidosis
XL
Extended release
1 Preamble
Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.
A great number of guidelines have been issued in recent years by the European Society of Cardiology (ESC), as well as by other societies and organizations. Because of their impact on clinical practice, quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user.
The recommendations for formulating and issuing ESC Guidelines can be found on the ESC website (https://www.escardio.org/
Guidelines). The ESC Guidelines represent the official position of the
ESC on a given topic and are regularly updated.
In addition to the publication of Clinical Practice guidelines, the ESC
carries out the EURObservational Research Programme of international registries of cardiovascular (CV) diseases and interventions which are essential to assess diagnostic/therapeutic processes, use of resources and adherence to guidelines. These registries aim at providing a better understanding of medical practice in Europe and around the world,
based on high-quality data collected during routine clinical practice.
Furthermore, the ESC has developed and embedded in this document a set of quality indicators (QIs), which are tools to evaluate the level of implementation of the guidelines and may be used by the ESC, hospitals,
healthcare providers and professionals to measure clinical practice as well as used in educational programmes, alongside the key messages from the guidelines, to improve quality of care and clinical outcomes.
The Members of this Task Force were selected by the ESC, including representation from its relevant ESC sub-specialty groups, in order to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a comprehensive review of the published evidence for management of a given condition according to ESC Clinical Practice Guidelines
(CPG) Committee policy. A critical evaluation of diagnostic and therapeutic procedures was performed, including assessment of the riskbenefit ratio. The level of evidence and the strength of the recommendation of particular management options were weighed and graded according to predefined scales, as outlined below.
The experts of the writing and reviewing panels provided declaration of interest forms for all relationships that might be perceived as real or potential sources of conflicts of interest. Their declarations of interest were reviewed according to the ESC declaration of interest rules and can be found on the ESC website (http://www.escardio.org/
guidelines) and have been compiled in a report and published in a supplementary document simultaneously to the guidelines.
This process ensures transparency and prevents potential biases in the development and review processes. Any changes in declarations of interest that arise during the writing period were notified to the ESC
and updated. The Task Force received its entire financial support from the ESC without any involvement from the healthcare industry.
The ESC CPG supervises and coordinates the preparation of new guidelines. The Committee is also responsible for the endorsement process of these Guidelines. The ESC Guidelines undergo extensive review by the CPG and external experts. After appropriate revisions the guidelines are signed-off by all the experts involved in the Task
Force. The finalized document is signed-off by the CPG for publication in the European Heart Journal. The guidelines were developed after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating.
The task of developing ESC Guidelines also includes the creation of educational tools and implementation programmes for the recommendations including condensed pocket guideline versions, summary slides,
summary cards for non-specialists and an electronic version for digital applications (smartphones, etc.). These versions are abridged and thus,
ESC Guidelines
3607


<!-- PAGE 10 -->

### Page 10

..............................
for more detailed information, the user should always access to the full text version of the guidelines, which is freely available via the ESC website and hosted on the European Heart Journal website. The National
Cardiac Societies of the ESC are encouraged to endorse, adopt, translate and implement all ESC Guidelines. Implementation programmes are needed because it has been shown that the outcome of disease may be favourably influenced by the thorough application of clinical recommendations.
Health professionals are encouraged to take the
ESC
Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies.
However, the ESC Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient or the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription.
Table 2
Levels of evidence
©ESC 2021
Level of 
evidence A
Data derived from multiple randomized clinical trials 
or meta-analyses. 
Level of 
evidence B
Data derived from a single randomized clinical trial or large non-randomized studies. 
Level of 
evidence C
Consensus of opinion of the experts and/or small studies, 
retrospective studies, registries.
Table 1
Classes of recommendations
©ESC 2021
Classes of recommendations
Class I 
Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective. 
Conflicting evidence and/or a divergence of opinion about the usefulness/ 
efficacy of the given treatment or procedure. 
Is recommended or is indicated
Wording to use
Definition
Class III 
Evidence or general agreement that the given treatment or procedure is not useful/effective, and in some cases may be harmful. 
Is not recommended
     Class IIb
Usefulness/efficacy is less well established by evidence/opinion.
May be considered
 
   Class IIa
Weight of evidence/opinion is in favour of usefulness/efficacy. 
Should be considered
Class II


<!-- PAGE 11 -->

### Page 11

2 Introduction
The aim of this ESC Guideline is to help health professionals manage people with heart failure (HF) according to the best available evidence. Fortunately, we now have a wealth of clinical trials to help us select the best management to improve the outcomes for people with HF; for many, it is now both preventable and treatable. This guideline provides practical, evidence-based recommendations.
We have revised the format of the previous 2016 ESC HF
Guidelines1 to make each phenotype of HF stand-alone in terms of its diagnosis and management. The therapy recommendations mention the treatment effect supported by the class and level of evidence and are presented in tables. For HF with reduced ejection fraction
(HFrEF), the tabular recommendations focus on mortality and morbidity outcomes. Where there are symptomatic benefits, these are highlighted in the text and/or in the web appendices. Detailed summaries of the trials underpinning the recommendations are available in the web appendices. For diagnostic indications, we have suggested investigations that all patients with HF should receive, and investigations that can be targeted to specific circumstances. As diagnostic tests have rarely been subject to randomized controlled trials
(RCTs), most of the evidence would be regarded as level C.
However, that does not mean that there has not been appropriate rigorous evaluation of diagnostic tests.
In this guideline, we have decided to focus on the diagnosis and treatment of HF, not on its prevention. Management of CV risk and many CV diseases [especially systemic hypertension, diabetes mellitus, coronary artery disease, myocardial infarction (MI), atrial fibrillation (AF), and asymptomatic left ventricular (LV) systolic dysfunction]
will reduce the risk of developing HF, which is addressed by many other ESC Guidelines and in section 9.1 of the current guideline.27
This guideline is the result of a collaboration between the Task
Force (including two patient representatives), the reviewers, and the
ESC CPG Committee. As such, it is a consensus/majority opinion of the experts consulted in its development.
2.1 What is new
In addition to the recommendations listed below, the following table lists some new concepts compared with the 2016 version.
New concepts
A change of the term ‘heart failure with mid-range ejection fraction’ to
‘heart failure with mildly reduced ejection fraction’ (HFmrEF).
A new simpliﬁed treatment algorithm for HFrEF.
The addition of a treatment algorithm for HFrEF according to phenotypes.
Modiﬁed classiﬁcation for acute HF.
Updated treatments for most non-cardiovascular comorbidities including diabetes, hyperkalaemia, iron deﬁciency, and cancer.
Updates on cardiomyopathies including the role of genetic testing and new treatments.
The addition of key quality indicators.
HF = heart failure.
New recommendations
Recommendations
Class
Recommendations for the diagnosis of HF
Right heart catheterization should be considered in patients where HF is thought to be due to constrictive pericarditis,
restrictive cardiomyopathy, congenital heart disease, and high output states.
IIa
Right heart catheterization may be considered in selected patients with HFpEF to conﬁrm the diagnosis.
IIb
Recommendations for treatment of chronic HF
HFrEF
Dapagliﬂozin or empagliﬂozin are recommended for patients with HFrEF to reduce the risk of HF hospitalization and death.
I
Vericiguat may be considered in patients in NYHA class IIIV
who have had worsening HF despite treatment with an ACE-I
(or ARNI), a beta-blocker and an MRA to reduce the risk of
CV mortality or HF hospitalization.
IIb
HFmrEF
An ACE-I may be considered for patients with HFmrEF to reduce the risk of HF hospitalization and death.
IIb
An ARB may be considered for patients with HFmrEF to reduce the risk of HF hospitalization and death.
IIb
A beta-blocker may be considered for patients with HFmrEF
to reduce the risk of HF hospitalization and death.
IIb
An MRA may be considered for patients with HFmrEF to reduce the risk of HF hospitalization and death.
IIb
Sacubitril/valsartan may be considered for patients with
HFmrEF to reduce the risk of HF hospitalization and death.
IIb
HFpEF
Screening for, and treatment of, aetiologies, and CV and nonCV comorbidities are recommended in patients with HFpEF
(see relevant sections of this document).
I
Prevention and monitoring
Self-management strategies are recommended to reduce the risk of HF hospitalization and mortality.
I
Either home-based and/or clinic-based programmes improve outcomes and are recommended to reduce the risk of HF
hospitalization and mortality.
I
Inﬂuenza and pneumococcal vaccinations should be considered in order to prevent HF hospitalizations.
IIa
A supervised, exercise-based, cardiac rehabilitation programme should be considered in patients with more severe disease, frailty, or with comorbidities.
IIa
Non-invasive HTM may be considered for patients with HF in order to reduce the risk of recurrent CV and HF hospitalizations and CV death.
IIb
Recommendations for management of patients with advanced
HF
Patients being considered for long-term MCS must have good compliance, appropriate capacity for device handling and psychosocial support.
I
Continued
ESC 2021
............................................................................................................................................................................
ESC Guidelines
3609


<!-- PAGE 12 -->

### Page 12

Heart transplantation is recommended for patients with advanced HF, refractory to medical/device therapy and who do not have absolute contraindications.
I
Continuous inotropes and/or vasopressors may be considered in patients with low cardiac output and evidence of organ hypoperfusion as bridge to MCS or heart transplantation.
IIb
Recommendations for management of patients after HF
hospitalization
It is recommended that patients hospitalized for HF be carefully evaluated to exclude persistent signs of congestion before discharge and to optimize oral treatment.
I
It is recommended that evidence-based oral medical treatment be administered before discharge.
I
An early follow-up visit is recommended at 12 weeks after discharge to assess signs of congestion, drug tolerance, and start and/or uptitrate evidence-based therapy.
I
Recommendations for management of patients with HF and atrial ﬁbrillation
Long-term treatment with an oral anticoagulant should be considered for stroke prevention in AF patients with a
CHA2DS2-VASc score of 1 in men or 2 in women.
IIa
Recommendations for management of patients with HF and
CCS
CABG should be considered as the ﬁrst-choice revascularization strategy, in patients suitable for surgery, especially if they have diabetes and for those with multivessel disease.
IIa
In LVAD candidates needing coronary revascularization,
CABG should be avoided, if possible.
IIa
Coronary revascularization may be considered to improve outcomes in patients with HFrEF, CCS, and coronary anatomy suitable for revascularization, after careful evaluation of the individual risk to beneﬁt ratio, including coronary anatomy (i.e. proximal stenosis >90% of large vessels, stenosis of left main or proximal
LAD), comorbidities, life expectancy, and patient’s perspectives.
IIb
PCI may be considered as alternative to CABG, based on
Heart Team evaluation, considering coronary anatomy,
comorbidities, and surgical risk.
IIb
Recommendations for management of patients with HF and valvular heart disease
Aortic valve intervention, TAVI or SAVR is recommended in patients with HF and severe high-gradient aortic stenosis to reduce mortality and improve symptoms.
I
It is recommended that the choice between TAVI and SAVR
be made by the Heart Team, according to individual patient preference and features including age, surgical risk, clinical,
anatomical and procedural aspects, weighing the risks and beneﬁts of each approach.
I
Percutaneous edge-to-edge mitral valve repair should be considered in carefully selected patients with secondary mitral regurgitation, not eligible for surgery and not needing coronary revascularization, who are symptomatic despite OMT and who fulﬁl criteria to achieve a reduction in HF hospitalizations.
IIa
Percutaneous edge-to-edge mitral valve repair may be considered to improve symptoms in carefully selected patients with secondary mitral regurgitation, not eligible for surgery and not needing coronary revascularization, who are highly symptomatic despite OMT and who do not fulﬁl criteria for reducing HF hospitalization.
IIb
Continued
Recommendations for management of patients with HF and diabetes
SGLT2 inhibitors (canagliﬂozin, dapagliﬂozin, empagliﬂozin,
ertugliﬂozin, sotagliﬂozin) are recommended in patients with
T2DM at risk of CV events to reduce hospitalizations for HF,
major CV events, end-stage renal dysfunction, and CV death.
I
SGLT2 inhibitors (dapagliﬂozin, empagliﬂozin, and sotagliﬂozin) are recommended in patients with T2DM and HFrEF to reduce hospitalizations for HF and CV death.
I
The DPP-4 inhibitor saxagliptin is not recommended in patients with HF.
III
Recommendations for management of patients with HF and iron deﬁciency
It is recommended that all patients with HF are periodically screened for anaemia and iron deﬁciency with a full blood count, serum ferritin concentration, and TSAT.
I
Intravenous iron supplementation with ferric carboxymaltose should be considered in symptomatic HF patients recently hospitalized for HF and with LVEF <_50% and iron deﬁciency, deﬁned as serum ferritin <100 ng/mL or serum ferritin 100299 ng/mL
with TSAT <20%, to reduce the risk of HF hospitalization.
IIa
Treatment of anaemia in HF with erythropoietin stimulating agents is not recommended in the absence of other indications for this therapy.
III
Recommendations for management of patients with HF and cancer
It is recommended that cancer patients at increased risk for cardiotoxicity, deﬁned by a history or risk factors of CV disease, previous cardiotoxicity or exposure to cardiotoxic agents, undergo
CV evaluation before scheduled anticancer therapy, preferably by a cardiologist with experience/interest in Cardio-Oncology.
I
Treatment with an ACE-I and a beta-blocker (preferably carvedilol) should be considered in cancer patients developing LV systolic dysfunction, deﬁned as a 10% or more decrease in LVEF and to a value lower than 50%, during anthracycline chemotherapy.
IIa
A baseline CV risk assessment should be considered in all cancer patients scheduled to receive a cancer treatment with the potential to cause HF.
IIa
Recommendations for treatment of patients with HF and amyloidosis
Tafamidis is recommended in patients with genetic testing proven hTTR-CA and NYHA class I or II symptoms to reduce symptoms, CV hospitalization and mortality.
I
Tafamidis is recommended in patients with wtTTR-CA and
NYHA class I or II symptoms to reduce symptoms, CV hospitalization and mortality.
I
ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin-receptor blocker; ARNI = angiotensin receptor-neprilysin inhibitor; CABG = coronary artery bypass graft; CCS = chronic coronary syndrome; CHA2DS2-VASc = congestive heart failure or left ventricular dysfunction, Hypertension, Age >_75
(doubled), Diabetes, Stroke (doubled)-Vascular disease, Age 6574, Sex category (female) (score); CMP = cardiomyopathy; CV = cardiovascular; DPP-4 =
dipeptidyl peptidase-4; HF = heart failure; HFmrEF = heart failure with mildly reduced ejection fraction; HFpEF = heart failure with preserved ejection fraction;
HFrEF = heart failure with reduced ejection fraction; HTM = home telemonitoring; hTTR = hereditary transthyretin; LAD = left anterior descending artery; LV =
left ventricular; LVAD = left ventricular assist device; LVEF = left ventricular ejection fraction; MCS = mechanical circulatory support; MRA = mineralocorticoid receptor antagonist; NYHA = New York Heart Association; OMT = optimal medical therapy; PCI = percutaneous coronary intervention; SAVR = surgical aortic valve replacement; SGLT2 = sodium-glucose co-transporter 2; T2DM =
type 2 diabetes mellitus; TAVI = transcatheter aortic valve implantation; TSAT =
transferrin saturation; wtTTR-CA = wild-type transthyretin cardiac amyloidosis.
ESC 2021
..................................................................................................................................................................................


<!-- PAGE 13 -->

### Page 13

Changes in recommendations
2021
Class
2016
Class
Recommendations for diagnosis of HF
Invasive coronary angiography may be considered in patients with HFrEF with an intermediate to high pre-test probability of CAD and the presence of ischaemia in noninvasive stress tests.
IIb
Invasive coronary angiography should be considered in patients with HF and intermediate to high pre-test probability of CAD and the presence of ischaemia in non-invasive stress tests (who are considered suitable for potential coronary revascularization) in order to establish the diagnosis of CAD and its severity.
IIa
CTCA should be considered in patients with a low to intermediate pre-test probability of CAD or those with equivocal non-invasive stress tests in order to rule out coronary artery stenosis.
IIa
Cardiac CT may be considered in patients with HF and low to intermediate pre-test probability of CAD or those with equivocal non-invasive stress tests in order to rule out coronary artery stenosis.
IIb
Recommendations for device therapy in HFrEF
An ICD should be considered to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA class IIIII) of a non-ischaemic aetiology, and an LVEF <_35% despite >_3 months of OMT,
provided they are expected to survive substantially longer than 1 year with good functional status.
IIa
Primary prevention
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with symptomatic
HF (NYHA class IIIII), and an LVEF <_35% despite >_3
months of OMT, provided they are expected to survive substantially longer than 1 year with good functional status, and they have DCM.
I
CRT should be considered for symptomatic patients with
HF in sinus rhythm with a QRS duration of 130149 ms and LBBB QRS morphology and with LVEF <_35% despite
OMT in order to improve symptoms and reduce morbidity and mortality.
IIa
CRT is recommended for symptomatic patients with HF
in sinus rhythm with a QRS duration of 130149 ms and
LBBB QRS morphology and with LVEF <_35% despite
OMT in order to improve symptoms and reduce morbidity and mortality.
I
Patients with an LVEF <_35% who have received a conventional pacemaker or an ICD and subsequently develop worsening HF despite OMT and who have a signiﬁcant proportion of RV pacing should be considered for
‘upgrade’ to CRT.
IIa
Patients with HFrEF who have received a conventional pacemaker or an ICD and subsequently develop worsening HF despite OMT and who have a high proportion of RV pacing may be considered for upgrade to CRT. This does not apply to patients with stable HF.
IIb
Recommendations for management of patients with acute HF
Combination of a loop diuretic with thiazide-type diuretic should be considered in patients with resistant oedema who do not respond to an increase in loop diuretic doses.
IIa
Combination of loop diuretic with either thiazide-type diuretic or spironolactone may be considered in patients with resistant oedema or insufﬁcient symptomatic response.
IIb
In patients with AHF and SBP >110 mmHg, i.v. vasodilators may be considered as initial therapy to improve symptoms and reduce congestion.
IIb
In patients with hypertensive AHF, i.v. vasodilators should be considered as initial therapy to improve symptoms and reduce congestion.
IIa
Routine use of opiates is not recommended, unless in selected patients with severe/intractable pain or anxiety.
III
Opiates may be considered for cautious use to relieve dyspnoea and anxiety in patients with severe dyspnoea but nausea and hypopnea may occur.
IIb
Short-term MCS should be considered in patients with cardiogenic shock as a BTR, BTD, BTB. Further indications include treatment of the cause of cardiogenic shock or long-term MCS or transplantation.
IIa
Short-term MCS may be considered in refractory cardiogenic shock depending on patient age, comorbidities, and neurological function.
IIb
Continued
ESC Guidelines
3611


<!-- PAGE 14 -->

### Page 14

.........................................................
3 Definition, epidemiology and prognosis
3.1 Definition of heart failure
Heart failure is not a single pathological diagnosis, but a clinical syndrome consisting of cardinal symptoms (e.g. breathlessness, ankle swelling, and fatigue) that may be accompanied by signs (e.g. elevated jugular venous pressure,
pulmonary crackles, and peripheral oedema). It is due to a structural and/or functional abnormality of the heart that results in elevated intracardiac pressures and/or inadequate cardiac output at rest and/or during exercise.
Identification of the aetiology of the underlying cardiac dysfunction is mandatory in the diagnosis of HF as the specific pathology can determine subsequent treatment. Most commonly, HF is due to myocardial dysfunction: either systolic, diastolic, or both. However,
pathology of the valves, pericardium, and endocardium, and abnormalities of heart rhythm and conduction can also cause or contribute to HF.
3.2 Terminology
3.2.1 Heart failure with preserved, mildly reduced, and reduced ejection fraction
Traditionally, HF has been divided into distinct phenotypes based on the measurement of left ventricular ejection fraction (LVEF)
(Table 3). The rationale behind this relates to the original treatment trials in HF that demonstrated substantially improved outcomes in patients with LVEF <_40%. However, HF spans the entire range of
LVEF (a normally distributed variable), and measurement by echocardiography is subject to substantial variability. We have decided on the following classification of HF (Table 3):
• Reduced LVEF is defined as <_40%, i.e. those with a significant reduction in LV systolic function. This is designated as HFrEF.
• Patients with a LVEF between 41% and 49% have mildly reduced
LV systolic function, i.e. HFmrEF. Retrospective analyses from
RCTs in HFrEF or HF with preserved ejection fraction (HFpEF)
that have included patients with ejection fractions in the
4050% range suggest that they may benefit from similar
Recommendations for management of patients with HF and AF
DOACs are recommended in preference to VKAs in patients with HF, except in those with moderate or severe mitral stenosis or mechanical prosthetic heart valves.
I
For patients with HF and non-valvular AF eligible for anticoagulation based on a CHA2DS2-VASc score, NOACs rather than warfarin should be considered for anticoagulation as NOACs are associated with a lower risk of stroke,
intracranial haemorrhage, and mortality, which outweigh the increased risk of gastrointestinal haemorrhage.
IIa
Beta-blockers should be considered for short- and longterm rate control in patients with HF and AF.
IIa
For patients in NYHA class IIII, a beta-blocker, usually given orally, is safe and therefore is recommended as ﬁrstline treatment to control ventricular rate, provided the patient is euvolaemic.
I
In cases of a clear association between paroxysmal or persistent AF and worsening of HF symptoms, which persist despite medical therapy, catheter ablation should be considered for the prevention or treatment of AF.
IIa
AV node catheter ablation may be considered to control heart rate and relieve symptoms in patients unresponsive or intolerant to intensive pharmacological rate and rhythm control therapy, accepting that these patients will become pacemaker-dependent.
IIb
Recommendations for management of patients with HF and CCS
Coronary revascularization should be considered to relieve persistent symptoms of angina (or an anginaequivalent) in patients with HFrEF, CCS, and coronary anatomy suitable for revascularization, despite OMT
including anti-anginal drugs.
IIa
Myocardial revascularization is recommended when angina persists despite treatment with anti-anginal drugs.
I
Recommendations for management of patients with HF and diabetes
SGLT2 inhibitors (canagliﬂozin, dapagliﬂozin, empagliﬂozin, ertugliﬂozin, sotagliﬂozin) are recommended in patients with T2DM at risk of CV events to reduce hospitalizations for HF, major CV events, end-stage renal dysfunction, and CV death.
I
Empagliﬂozin should be considered in patients with T2DM
in order to prevent or delay the onset of HF and prolong life.
IIa
AF = atrial ﬁbrillation; AHF = acute heart failure; AV = atrio-ventricular; BTB = bridge to bridge; BTD = bridge to decision; BTR = bridge to cardiac recovery; CAD = coronary artery disease; CCS = chronic coronary syndrome; CHA2DS2-VASc = congestive heart failure or left ventricular dysfunction, Hypertension, Age >_75 (doubled), Diabetes,
Stroke (doubled)-Vascular disease, Age 6574, Sex category (female) (score); CRT = cardiac resynchronization therapy; CT = computed tomography; CTCA = computed tomography coronary angiography; CV = cardiovascular; DCM = dilated cardiomyopathy; DOAC = direct oral anticoagulant; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; ICD = implantable cardioverter-deﬁbrillator; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; MCS = mechanical circulatory support; NOAC = non-vitamin K antagonist oral anticoagulant; NYHA = New York Heart Association; OMT = optimal medical therapy; QRS = Q, R, and S waves of an ECG;
RV = right ventricular/ventricle; SBP = systolic blood pressure; SGLT2 = sodium-glucose co-transporter 2; T2DM = type 2 diabetes mellitus; VKA = vitamin K antagonist.
ESC 2021


<!-- PAGE 15 -->

### Page 15

..................................................................................................................
therapies to those with LVEF <_40%.813 This supports the renaming of HFmrEF from ‘heart failure with mid-range ejection fraction’ to ‘heart failure with mildly reduced ejection fraction’.14
• Those with symptoms and signs of HF, with evidence of structural and/or functional cardiac abnormalities and/or raised natriuretic peptides (NPs), and with an LVEF >_50%, have HFpEF.
The diagnosis of HFrEF, HFmrEF, and HFpEF is covered in more detail in their respective sections (sections 5, 7, and 8, respectively).
These definitions are consistent with a recent report on the
Universal Definition of Heart Failure.15
Patients with non-CV disease, e.g. anaemia, pulmonary, renal, thyroid, or hepatic disease may have symptoms and signs very similar to those of HF, but in the absence of cardiac dysfunction, they do not fulfil the criteria for HF. However, these pathologies can coexist with
HF and exacerbate the HF syndrome.
3.2.2 Right ventricular dysfunction
Heart failure can also be a result of right ventricular (RV) dysfunction. RV mechanics and function are altered in the setting of either pressure or volume overload.16 Although the main aetiology of chronic RV failure is LV dysfunction-induced pulmonary hypertension, there are a number of other causes of RV dysfunction [e.g.
MI, arrhythmogenic right ventricular cardiomyopathy (ARVC), or valve disease].17 The diagnosis is determined by a quantitative assessment of global RV function, most commonly by echocardiography, using at least one of the following measurements: fractional area change (FAC); tricuspid annular plane systolic excursion (TAPSE); and Doppler tissue imaging-derived systolic S0
velocity of the tricuspid annulus. The diagnosis and management of RV dysfunction is covered comprehensively in a recent Heart
Failure Association (HFA) position paper.18
3.2.3 Other common terminology used in heart failure
Heart failure is usually divided into two presentations: chronic heart failure (CHF) and acute heart failure (AHF). CHF describes those who have had an established diagnosis of HF or who have a more gradual onset of symptoms. If CHF deteriorates, either suddenly or slowly, the episode may be described as ‘decompensated’ HF. This can result in a hospital admission or treatment with intravenous (i.v.)
diuretic therapy in the outpatient setting. In addition, HF can present more acutely. Both of these are considered in the section on AHF
(section 11).
Some individuals with HF may recover completely [e.g. those due to alcohol-induced cardiomyopathy
(CMP),
viral myocarditis,
Takotsubo syndrome, peripartum cardiomyopathy (PPCM), or tachycardiomyopathy]. Other patients with LV systolic dysfunction may show a substantial or even complete recovery of LV systolic function after receiving drug and device therapy.
3.2.4 Terminology related to the symptomatic severity of heart failure
The simplest terminology used to describe the severity of HF is the
New York Heart Association (NYHA) functional classification
(Table 4). However, this relies solely on symptoms and there are many other better prognostic indicators in HF.19 Importantly,
patients with mild symptoms may still have a high risk of hospitalization and death.20 Predicting outcome is particularly important in advanced HF to guide selection of cardiac transplantation and device therapies. This will be covered in detail in the section on advanced
HF (section 10).
3.3 Epidemiology and natural history of heart failure
3.3.1 Incidence and prevalence
In developed countries, the age-adjusted incidence of HF may be falling, presumably reflecting better management of CV disease, but due to ageing, the overall incidence is increasing.2124 Currently, the incidence of HF in Europe is about 3/1000 person-years (all age-groups)
or about 5/1000 person-years in adults.25,26 The prevalence of HF
appears to be 12% of adults.21,2731 As studies only usually include recognized/diagnosed HF cases, the true prevalence is likely to be higher.32 The prevalence increases with age: from around 1% for those aged <55 years to >10% in those aged 70 years or over.3336 It
Table 3
Deﬁnition of heart failure with reduced ejection fraction, mildly reduced ejection fraction and preserved ejection fraction
Type of HF
HFrEF
HFmrEF
HFpEF
CRITERIA
1
Symptoms ± Signsa
Symptoms ± Signsa
Symptoms ± Signsa
2
LVEF <_40%
LVEF 4149%b
LVEF >_50%
3


Objective evidence of cardiac structural and/or functional abnormalities consistent with the presence of LV diastolic dysfunction/raised LV ﬁlling pressures, including raised natriuretic peptidesc
HF = heart failure; HFmrEF = heart failure with mildly reduced ejection fraction; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; LV = left ventricle; LVEF = left ventricular ejection fraction.
aSigns may not be present in the early stages of HF (especially in HFpEF) and in optimally treated patients.
bFor the diagnosis of HFmrEF, the presence of other evidence of structural heart disease (e.g. increased left atrial size, LV hypertrophy or echocardiographic measures of impaired LV ﬁlling) makes the diagnosis more likely.
cFor the diagnosis of HFpEF, the greater the number of abnormalities present, the higher the likelihood of HFpEF.
ESC 2021
ESC Guidelines
3613


<!-- PAGE 16 -->

### Page 16

.................................................................................................................................................................
is generally believed that, of those with HF, about 50% have HFrEF
and 50% have HFpEF/HFmrEF, mainly based on studies in hospitalized patients.32,35,37,38 The ESC Long-Term Registry, in the outpatient setting, reports that 60% have HFrEF, 24% have HFmrEF, and 16% have
HFpEF.39 Somewhat more than 50% of HF patients are female.21,40,41
3.3.2 Aetiology of heart failure
The most common causes (as well as some key investigations)
of HF are shown in Table 5. The aetiology of HF varies according to geography.
In
Western-type and developed countries,
coronary artery disease (CAD) and hypertension are predominant factors.27
With regard to ischaemic aetiology, HFmrEF resembles HFrEF,
with a higher frequency of underlying CAD compared to those with
HFpEF.38,42,43
3.3.3 Natural history and prognosis
The prognosis of patients with HF has improved considerably since the publication of the first treatment trials a few decades ago.
However, it remains poor, and quality of life (QOL) is also markedly reduced. The improvement in prognosis has been confined to those with HFrEF.
Mortality rates are higher in observational studies than in clinical trials.44 In the Olmsted County cohort, 1-year and 5-year mortality rates after diagnosis, for all types of HF patients, were 20% and 53%,
respectively, between 2000 and 2010.45 A study combining the
Framingham Heart Study (FHS) and Cardiovascular Health Study
(CHS) cohorts reported a 67% mortality rate within 5 years following diagnosis.46 Despite receiving less evidence-based treatment, women have a better survival than men.47
Overall prognosis is better in HFmrEF compared to HFrEF.39 Of note, transition in ejection fraction over time is common, and patients who progress from HFmrEF to HFrEF have a worse prognosis than those who remain stable or transition to a higher ejection fraction category.4852
HFpEF is generally considered to confer a better survival than
HFrEF, but most observational studies show that this difference is negligible.45,46 In contrast, the large MAGGIC meta-analysis concluded that the adjusted mortality risk for patients with HFpEF was considerably lower than in patients with HFrEF.53
Studies from several countries have shown that between 1980 and
2000 survival in HF patients has improved markedly.41,5457
However, this positive trend may have levelled off since then.45
After the initial diagnosis, HF patients are hospitalized once every year on average.54 From 2000 to 2010, the mean rate of hospitalization in the Olmsted County cohort was 1.3 per person-year.
Interestingly, the majority (63%) of hospitalizations were related to non-CV causes.45 Studies from several European countries and the
United States (US) have shown that HF hospitalization rates peaked in the 1990s, and then declined.54,55*,5860 However, in a recent study of incident HF conducted between 1998 and 2017 in the
United Kingdom (UK), age-adjusted rates of first hospitalizations increased by 28% for both all-cause and HF admissions, and by 42%
for non-CV admissions.61 These increases were higher in women,
perhaps related to higher comorbidity rates. The risk of HF hospitalization is 1.5 times higher in patients with diabetes compared to controls. AF, a higher body mass index (BMI), and higher glycated haemoglobin (HbA1c), as well as a low estimated glomerular filtration rate (eGFR) are strong predictors of HF hospitalizations.29
Due to population growth, ageing, and the increasing prevalence of comorbidities, the absolute number of hospital admissions for HF
is expected to increase considerably in the future, perhaps by as much as 50% in the next 25 years.24,62
4 Chronic heart failure
4.1 Key steps in the diagnosis of chronic heart failure
The diagnosis of CHF requires the presence of symptoms and/or signs of HF and objective evidence of cardiac dysfunction (Figure 1).
Typical symptoms include breathlessness, fatigue, and ankle swelling
(Table 6). Symptoms and signs lack sufficient accuracy to be used alone to make the diagnosis of HF.6366
The diagnosis of CHF is made more likely in patients with a history of MI, arterial hypertension, CAD, diabetes mellitus, alcohol misuse,
chronic kidney disease (CKD), cardiotoxic chemotherapy, and in those with a family history of CMP or sudden death.
The following diagnostic tests are recommended for the assessment of patients with suspected chronic HF:
(1)
Electrocardiogram (ECG). A normal ECG makes the diagnosis of
HF unlikely.63 The ECG may reveal abnormalities such as AF, Q
waves, LV hypertrophy (LVH), and a widened QRS complex
(Table 7) that increase the likelihood of a diagnosis of HF and also may guide therapy.
Table 4
New York Heart Association functional classiﬁcation based on severity of symptoms and physical activity
Class I
No limitation of physical activity. Ordinary physical activity does not cause undue breathlessness, fatigue, or palpitations.
Class II
Slight limitation of physical activity. Comfortable at rest,
but ordinary physical activity results in undue breathlessness, fatigue, or palpitations.
Class III
Marked limitation of physical activity. Comfortable at rest,
but less than ordinary activity results undue breathlessness, fatigue, or palpitations.
Class IV
Unable to carry on any physical activity without discomfort. Symptoms at rest can be present. If any physical activity is undertaken, discomfort is increased.
ESC 2021


<!-- PAGE 17 -->

### Page 17

Y
Suspected heart failure
Echocardiography
NT-proBNP ≥ 125 pg/mL
or BNP ≥ 35 pg/mL
N
Y
Diagnostic algorithm for heart failure
Risk factors
Symptoms and/or signs
Abnormal ECG
or if HF strongly suspected or if NT-proBNP/BNP unavailable
Abnormal findings
Y
Heart failure confirmed
Define heart failure phenotype based on LVEF measurement
≤40%
(HFrEF)
41–49%
(HFmrEF)
≥50%
(HFpEF)
Determine aetiology and commence treatment
Heart failure unlikely
Consider other diagnoses
N
Figure 1 The diagnostic algorithm for heart failure. BNP= B-type natriuretic peptide; ECG= electrocardiogram; HFmrEF= heart failure with mildly reduced ejection fraction; HFpEF= heart failure with preserved ejection fraction; HFrEF= heart failure with reduced ejection fraction; LVEF= left ventricular ejection fraction; NT-proBNP= N-terminal pro-B type natriuretic peptide. The abnormal echocardiographic findings are described in more detail in the respective sections on HFrEF (section 5), HFmrEF (section 7), and HFpEF (section 8).
ESC Guidelines
3615


<!-- PAGE 18 -->

### Page 18

Table 5
Causes of heart failure, common modes of presentation and speciﬁc investigations
Cause
Examples of presentations
Specific investigations
CAD
Myocardial infarction
Angina or “angina-equivalent”
Arrhythmias
Invasive coronary angiography
CT coronary angiography
Imaging stress tests (echo, nuclear, CMR)
Hypertension
Heart failure with preserved systolic function
Malignant hypertension/acute pulmonary oedema
24 h ambulatory BP
Plasma metanephrines, renal artery imaging
Renin and aldosterone
Valve disease
Primary valve disease e.g., aortic stenosis
Secondary valve disease, e.g. functional regurgitation
Congenital valve disease
Echo  transoesophageal/stress
Arrhythmias
Atrial tachyarrhythmias
Ventricular arrhythmias
Ambulatory ECG recording
Electrophysiology study, if indicated
CMPs
All
Dilated
Hypertrophic
Restrictive
ARVC
Peripartum
Takotsubo syndrome
Toxins: alcohol, cocaine, iron, copper
CMR, genetic testing
Right and left heart catheterization
CMR, angiography
Trace elements, toxicology, LFTs, GGT
Congenital heart disease
Congenitally corrected/repaired transposition of great arteries
Shunt lesions
Repaired tetralogy of Fallot
Ebstein’s anomaly
CMR
Infective
Viral myocarditis
Chagas disease
HIV
Lyme disease
CMR, EMB
Serology
Drug-induced
Anthracyclines
Trastuzumab
VEGF inhibitors
Immune checkpoint inhibitors
Proteasome inhibitors
RAFþMEK inhibitors
Inﬁltrative
Amyloid
Sarcoidosis
Neoplastic
Serum electrophoresis and serum free light chains, Bence
Jones protein, bone scintigraphy, CMR, CT-PET, EMB
Serum ACE, CMR, FDG-PET, chest CT, EMB
CMR, EMB
Storage disorders
Haemochromatosis
Fabry disease
Glycogen storage diseases
Iron studies, genetics, CMR (T2* imaging), EMB
a-galactosidase A, genetics, CMR (T1 mapping)
Endomyocardial disease
Radiotherapy
Endomyocardial ﬁbrosis/eosinophilia
Carcinoid
CMR
EMB
24 h urine 5-HIAA
Pericardial disease
Calciﬁcation
Inﬁltrative
Chest CT, CMR, right and left heart catheterization
Metabolic
Endocrine disease
Nutritional disease (thiamine, vitamin B1 and selenium deﬁciencies)
Autoimmune disease
TFTs, plasma metanephrines, renin and aldosterone, cortisol
Speciﬁc plasma nutrients
ANA, ANCA, rheumatology review
Neuromuscular disease
Friedreich’s ataxia
Muscular dystrophy
Nerve conduction studies, electromyogram, genetics
CK, electromyogram, genetics
5-HIAA = 5-hydroxyindoleacetic acid; ACE = angiotensin-converting enzyme; ANA = anti-nuclear antibody; ANCA = anti-nuclear cytoplasmic antibody; ARVC = arrhythmogenic right ventricular cardiomyopathy; BP = blood pressure; CAD = coronary artery disease; CMP = cardiomyopathy; CMR = cardiac magnetic resonance; CK = creatinine kinase; CT
= computed tomography; ECG = electrocardiogram; Echo = echocardiography; EMB = endomyocardial biopsy; FDG = ﬂuorodeoxyglucose; GGT = gamma-glutamyl transferase;
HIV = human immunodeﬁciency virus; h = hour; LFT = liver function test; LGE = late gadolinium enhancement; MEK = mitogen-activated protein kinase; PET = positron emission tomography; TFT = thyroid function test; VEGF = vascular endothelial growth factor.
ESC 2021


<!-- PAGE 19 -->

### Page 19

...........................................................
(2)
Measurement of NPs are recommended, if available. A plasma concentration of B-type natriuretic peptide (BNP) <35 pg/mL,
N-terminal pro-B-type natriuretic peptide (NT-proBNP) <125 pg/
mL, or mid-regional pro-atrial natriuretic peptide (MR-proANP)
<40 pmol/L68 make a diagnosis of HF unlikely. These will be discussed in more detail in section 4.2.69,70
(3)
Basic investigations such as serum urea and electrolytes, creatinine,
full blood count, liver and thyroid function tests are recommended to differentiate HF from other conditions, to provide prognostic information, and to guide potential therapy.
(4)
Echocardiography is recommended as the key investigation for the assessment of cardiac function. As well as the determination of the
LVEF, echocardiography also provides information on other parameters such as chamber size, eccentric or concentric LVH, regional wall motion abnormalities (that may suggest underlying CAD,
Takotsubo syndrome, or myocarditis), RV function, pulmonary hypertension,
valvular function,
and markers of diastolic function.16,71
(5)
A chest X-ray is recommended to investigate other potential causes of breathlessness (e.g. pulmonary disease). It may also provide supportive evidence of
HF
(e.g.
pulmonary congestion or cardiomegaly).
4.2 Natriuretic peptides
Plasma concentrations of NPs are recommended as initial diagnostic tests in patients with symptoms suggestive of HF to rule out the diagnosis. Elevated concentrations support a diagnosis of HF, are useful for prognostication,72 and may guide further cardiac investigation.73
However, it should be noted that there are many causes of an elevated NP—both CV and non-CV—that might reduce their diagnostic accuracy (Table 7). These causes include AF, increasing age, and acute or chronic kidney disease.74 Conversely, NP concentrations may be disproportionately low in obese patients.75
4.2.1 Use in the non-acute setting
The diagnostic value of NPs, in addition to signs and symptoms and other diagnostic tests, such as an ECG, has been assessed in several studies in the primary care setting.68,7680 The aim of these studies was to either exclude or establish a diagnosis of HF. The Task Force considered studies of adequate quality that included NP cut-off points in their diagnostic algorithms, below which the probability of having HF
was extremely low. The upper limits of normal in the non-acute setting are 35 pg/mL for BNP, and 125 pg/mL for NT-proBNP. In these studies, the negative predictive values of NP concentrations below these thresholds range from 0.94 to 0.98.7678 Fewer data are available for MR-proANP in CHF than in AHF. A concentration of <40 pmol/L
can be used to rule out HF.68
4.3 Investigations to determine the underlying aetiology of chronic heart failure
Recommended tests to determine the underlying aetiology of CHF
are summarized in Table 5.
Recommended diagnostic tests in all patients with suspected chronic heart failure
Recommendations
Classa
Levelb
BNP/NT-proBNPc
I
B
12-lead ECG
I
C
Transthoracic echocardiography
I
C
Chest radiography (X-ray)
I
C
Routine blood tests for comorbidities, including full blood count, urea and electrolytes, thyroid function, fasting glucose and HbA1c, lipids, iron status (TSAT and ferritin)
I
C
BNP = B-type natriuretic peptide; ECG = electrocardiogram; HbA1c = glycated haemoglobin; NT-proBNP = N-terminal pro-B-type natriuretic peptide; TSAT =
transferrin saturation.
aClass of recommendation.
bLevel of evidence.
cReferences are listed in section 4.2 for this item.
Table 6
Symptoms and signs typical of heart failure
Symptoms
Signs
Typical
More speciﬁc
Breathlessness
Orthopnoea
Paroxysmal nocturnal dyspnoea
Reduced exercise tolerance
Fatigue, tiredness, increased time to recover after exercise
Ankle swelling
Elevated jugular venous pressure
Hepatojugular reﬂux
Third heart sound (gallop rhythm)
Laterally displaced apical impulse
Less typical
Less speciﬁc
Nocturnal cough
Wheezing
Bloated feeling
Loss of appetite
Confusion (especially in the elderly)
Depression
Palpitation
Dizziness
Syncope
Bendopneaa
Weight gain (>2 kg/week)
Weight loss (in advanced HF)
Tissue wasting (cachexia)
Cardiac murmur
Peripheral oedema (ankle,
sacral, scrotal)
Pulmonary crepitations
Pleural effusion
Tachycardia
Irregular pulse
Tachypnoea
Cheyne-Stokes respiration
Hepatomegaly
Ascites
Cold extremities
Oliguria
Narrow pulse pressure
HF = heart failure.
aThis symptom of advanced HF corresponds to shortness of breath when leaning forward.67
ESC 2021
ESC 2021
..........................................................................................................
ESC Guidelines
3617


<!-- PAGE 20 -->

### Page 20

Exercise or pharmacological stress echocardiography may be used for the assessment of inducible ischaemia in those who are considered suitable for coronary revascularization.81 In patients with
HFpEF, valve disease, or unexplained dyspnoea, stress echocardiography might help clarify the diagnosis.82
Cardiac magnetic resonance (CMR) imaging with late gadolinium enhancement (LGE), T1 mapping and extracellular volume will identify myocardial fibrosis/scar, which are typically subendocardial for patients with ischaemic heart disease (IHD) in contrast to the mid-wall scar typical of dilated cardiomyopathy (DCM). In addition, CMR allows myocardial characterization in, e.g. myocarditis, amyloidosis, sarcoidosis, Chagas disease, Fabry disease, LV
non-compaction CMP, haemochromatosis, and arrhythmogenic cardiomyopathy (AC).83,84
Computed tomography coronary angiography (CTCA) may be considered in patients with a low to intermediate pre-test probability of CAD, or those with equivocal non-invasive stress tests in order to exclude the diagnosis of CAD.5
Single-photon emission CT (SPECT) can also be used to assess myocardial ischaemia and viability, myocardial inflammation or infiltration. Scintigraphy with technetium (Tc)-labelled bisphosphonate has shown high sensitivity and specificity for imaging cardiac transthyretin amyloid.85
ESC 2021
Recommendations for specialized diagnostic tests for selected patients with chronic heart failure to detect reversible/treatable causes of heart failure
Recommendations
Classa
Levelb
CMR
CMR is recommended for the assessment of myocardial structure and function in those with poor echocardiogram acoustic windows.
I
C
CMR is recommended for the characterization of myocardial tissue in suspected inﬁltrative disease, Fabry disease, inﬂammatory disease (myocarditis), LV non-compaction, amyloid,
sarcoidosis, iron overload/haemochromatosis.
I
C
CMR with LGE should be considered in DCM to distinguish between ischaemic and non-ischaemic myocardial damage.
IIa
C
Invasive coronary angiography (in those who are considered eligible for potential coronary revascularization)
Invasive coronary angiography is recommended in patients with angina despite pharmacological therapy or symptomatic ventricular arrhythmias.5
I
B
Invasive coronary angiography may be considered in patients with HFrEF with an intermediate to high pre-test probability of CAD and the presence of ischaemia in non-invasive stress tests.89
IIb
B
Non-invasive testing
CTCA should be considered in patients with a low to intermediate pre-test probability of CAD
or those with equivocal non-invasive stress tests in order to rule out coronary artery stenosis.
IIa
C
Non-invasive stress imaging (CMR, stress echocardiography, SPECT, PET) may be considered for the assessment of myocardial ischaemia and viability in patients with CAD who are considered suitable for coronary revascularization.9093
IIb
B
Exercise testing may be considered to detect reversible myocardial ischaemia and investigate the cause of dyspnoea.9496
IIb
C
Cardiopulmonary exercise testing
Cardiopulmonary exercise testing is recommended as a part of the evaluation for heart transplantation and/or MCS.9496
I
C
Cardiopulmonary exercise testing should be considered to optimize prescription of exercise training.9496
IIa
C
Cardiopulmonary exercise testing should be considered to identify the cause of unexplained dyspnoea and/or exercise intolerance.9496
IIa
C
Right heart catheterization
Right heart catheterization is recommended in patients with severe HF being evaluated for heart transplantation or MCS.
I
C
Continued
Table 7
Causes of elevated concentrations of natriuretic peptides86-88
Cardiac
Heart failure
ACS
Pulmonary embolism
Myocarditis
Left ventricular hypertrophy
Hypertrophic or restrictive cardiomyopathy
Valvular heart disease
Congenital heart disease
Atrial and ventricular tachyarrhythmias
Heart contusion
Cardioversion, ICD shock
Surgical procedures involving the heart
Pulmonary hypertension
Non-cardiac
Advanced age
Ischaemic stroke
Subarachnoid haemorrhage
Renal dysfunction
Liver dysfunction (mainly liver cirrhosis with ascites)
Paraneoplastic syndrome
COPD
Severe infections (including pneumonia and sepsis)
Severe burns
Anaemia
Severe metabolic and hormone abnormalities
(e.g. thyrotoxicosis, diabetic ketosis)
ACS = acute coronary syndrome; COPD = chronic obstructive pulmonary disease; ICD = implantable cardioverter-deﬁbrillator.
............................................................................................................................................................................


<!-- PAGE 21 -->

### Page 21

................................................................................................................................................................
Coronary angiography is recommended in patients with HF, who have angina pectoris or an ‘angina equivalent’ despite pharmacological therapy, in order to establish the diagnosis of CAD and its severity.
Coronary angiography may also be considered in patients with
HFrEF who have an intermediate to high pre-test probability of CAD
and who are considered potentially suitable for coronary revascularization.5
5 Heart failure with reduced ejection fraction
5.1 The diagnosis of heart failure with reduced ejection fraction
The diagnosis of HFrEF requires the presence of symptoms and/or signs of HF and a reduced ejection fraction (LVEF <_40%). This is most usually obtained by echocardiography. Details about the quality standards that should be adhered to when determining the presence of reduced LV systolic function by echocardiography can be found in the European Association of Cardiovascular
Imaging (EACVI) position paper.99 If assessment of EF is not possible by echocardiography, then CMR or rarely, nuclear techniques can be employed.
An algorithm for the diagnosis of HFrEF is depicted in Figure 1. For the investigation of the underlying aetiology, please refer to Table 5.
5.2 Pharmacological treatments for patients with heart failure with reduced ejection fraction
5.2.1
Goals of pharmacotherapy for patients with heart failure with reduced ejection fraction
Pharmacotherapy is the cornerstone of treatment for HFrEF and should be implemented before considering device therapy, and alongside non-pharmacological interventions.
There are three major goals of treatment for patients with HFrEF:
(i) reduction in mortality, (ii) prevention of recurrent hospitalizations due to worsening HF, and (iii) improvement in clinical status, functional capacity, and QOL.100102
The key evidence supporting the recommendations in this section for patients with symptomatic HFrEF is given in Supplementary Table 1.
Figure 2 depicts the algorithm for the treatment strategy, including drugs and devices in patients with HFrEF, for Class I indications for the reduction of mortality (either all-cause or CV). The recommendations for each treatment are summarized below.
5.2.2
General principles of pharmacotherapy for heart failure with reduced ejection fraction
Modulation of the renin-angiotensin-aldosterone (RAAS) and sympathetic nervous systems with angiotensin-converting enzyme inhibitors (ACE-I) or an angiotensin receptor-neprilysin inhibitor (ARNI),
beta-blockers, and mineralocorticoid receptor antagonists (MRA)
has been shown to improve survival, reduce the risk of HF hospitalizations, and reduce symptoms in patients with HFrEF. These drugs serve as the foundations of pharmacotherapy for patients with
HFrEF. The triad of an ACE-I/ARNI, a beta-blocker, and an MRA is recommended as cornerstone therapies for these patients, unless the drugs are contraindicated or not tolerated.103105 They should be uptitrated to the doses used in the clinical trials (or to maximally tolerated doses if that is not possible). This guideline still recommends the use of ARNI as a replacement for ACE-I in suitable patients who remain symptomatic on ACE-I, beta-blocker, and MRA
therapies; however, an ARNI may be considered as a first-line therapy instead of an ACE-I.106,107 The recommended doses of these drugs are given in Table 8. Angiotensin-receptor blockers (ARBs) still have a role in those who are intolerant to ACE-I or ARNI.
The sodium-glucose co-transporter 2 (SGLT2) inhibitors dapagliflozin and empagliflozin added to therapy with ACE-I/ARNI/betablocker/MRA reduced the risk of CV death and worsening HF in patients with HFrEF.108,109 Unless contraindicated or not tolerated,
dapagliflozin or empagliflozin are recommended for all patients with
HFrEF already treated with an ACE-I/ARNI, a beta-blocker, and an
MRA, regardless of whether they have diabetes or not.
Other drugs may be used for selected patients with HFrEF. These are discussed in section 5.4.
Right heart catheterization should be considered in patients where HF is thought to be due to constrictive pericarditis, restrictive cardiomyopathy, congenital heart disease, and high output states.
IIa
C
Right heart catheterization should be considered in patients with probable pulmonary hypertension, assessed by echo in order to conﬁrm the diagnosis and assess its reversibility before the correction of valve/structural heart disease.
IIa
C
Right heart catheterization may be considered in selected patients with HFpEF to conﬁrm the diagnosis.
IIb
C
EMB
EMB should be considered in patients with rapidly progressive HF despite standard therapy when there is a probability of a speciﬁc diagnosis,
which can be conﬁrmed only in myocardial samples.97,98
IIa
C
CAD = coronary artery disease; CMR = cardiac magnetic resonance; CTCA =
computed tomography coronary angiography; DCM = dilated cardiomyopathy;
EMB = endomyocardial biopsy; HF = heart failure; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction;
LGE = late gadolinium enhancement; LV = left ventricular; MCS = mechanical circulatory support; PET = positron emission tomography; SPECT = single-photon emission computed tomography.
aClass of recommendation.
bLevel of evidence.
ESC 2021
ESC Guidelines
3619


<!-- PAGE 22 -->

### Page 22

Management of patients with HFrEF
LVEF ≤35% and
QRS <130 ms and where appropriate
(Class I)
SR and
LVEF ≤35% and
QRS ≥130 ms
If symptoms persist, consider therapies with Class II recommendations
LVEF >35% or device therapy not indicated or inappropriate
ACE-I/ARNIa
Beta-blocker
MRA
Dapagliflozin/Empagliflozin
Loop diuretic for fluid retention
Ischaemic
(Class I)
Non-ischaemic
(Class IIa)
ICD
QRS ≥150 ms
(Class I)
QRS 130–149 ms
(Class IIa)
CRT-Db/-P
Figure 2 Therapeutic algorithm of Class I Therapy Indications for a patient with heart failure with reduced ejection fraction. ACE-I =angiotensin-converting enzyme inhibitor; ARNI = angiotensin receptor-neprilysin inhibitor; CRT-D=cardiac resynchronization therapy with defibrillator; CRT-P= cardiac resynchronization therapy pacemaker; ICD= implantable cardioverter-defibrillator; HFrEF= heart failure with reduced ejection fraction; MRA= mineralocorticoid receptor antagonist; QRS= Q, R, and S waves of an ECG; SR = sinus rhythm. aAs a replacement for ACE-I. bWhere appropriate. Class I = green.
Class IIa= Yellow.
Pharmacological treatments indicated in patients with (NYHA class II–IV) heart failure with reduced ejection fraction
(LVEF <_40%)
Recommendations
Classa
Levelb
An ACE-I is recommended for patients with HFrEF to reduce the risk of HF
hospitalization and death.110113
I
A
A beta-blocker is recommended for patients with stable HFrEF to reduce the risk of
HF hospitalization and death.114120
I
A
An MRA is recommended for patients with HFrEF to reduce the risk of HF hospitalization and death.121,122
I
A
Dapagliﬂozin or empagliﬂozin are recommended for patients with HFrEF to reduce the risk of HF hospitalization and death.108,109
I
A
Sacubitril/valsartan is recommended as a replacement for an ACE-I in patients with HFrEF to reduce the risk of HF
hospitalization and death.105
I
B
ACE-I = angiotensin-converting enzyme inhibitor; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; NYHA = New York Heart Association.
aClass of recommendation.
bLevel of evidence.
ESC 2021
5.3 Drugs recommended in all patients with heart failure with reduced ejection fraction


<!-- PAGE 23 -->

### Page 23

.............................................................................................................................................................................
5.3.1
Angiotensin-converting enzyme inhibitors
ACE-Is were the first class of drugs shown to reduce mortality and morbidity in patients with HFrEF.110113 They have also been shown to improve symptoms.111 They are recommended in all patients unless contraindicated or not tolerated. They should be uptitrated to the maximum tolerated recommended doses.
Practical guidance on how to use ACE-Is is given in Supplementary
Table 2.
5.3.2
Beta-blockers
Beta-blockers have been shown to reduce mortality and morbidity in patients with HFrEF, in addition to treatment with an ACE-I and diuretic.114120 They also improve symptoms.123 There is consensus that ACE-I and beta-blockers can be commenced together as soon as the diagnosis of symptomatic HFrEF is established. There is no evidence favouring the initiation of a beta-blocker before an ACE-I and vice versa.124 Beta-blockers should be initiated in clinically stable,
euvolaemic, patients at a low dose and gradually uptitrated to the maximum tolerated dose. In patients admitted with AHF, betablockers should be cautiously initiated in hospital, once the patient is haemodynamically stabilized.
An individual patient data (IPD) meta-analysis of all major betablocker trials in HFrEF has shown no benefit on hospital admissions and mortality in the subgroup of patients with HFrEF with AF.125
However, since this is a retrospective subgroup analysis, and because beta-blockers did not increase risk, the guideline committee decided not to make a separate recommendation according to heart rhythm.
Practical guidance on how to use beta-blockers is given in
Supplementary Table 3.
5.3.3
Mineralocorticoid receptor antagonists
MRAs (spironolactone or eplerenone) are recommended, in addition to an ACE-I and a beta-blocker, in all patients with HFrEF to reduce mortality and the risk of HF hospitalization.121,122 They also improve symptoms.121 MRAs block receptors that bind aldosterone and, with different degrees of affinity, other steroid hormones (e.g. corticosteroid and androgen) receptors. Eplerenone is more specific for aldosterone blockade and, therefore, causes less gynaecomastia.
Caution should be exercised when MRAs are used in patients with impaired renal function and in those with serum potassium concentrations >5.0 mmol/L.
Practical guidance on how to use MRAs is given in Supplementary
Table 4.
5.3.4
Angiotensin receptor-neprilysin inhibitor
In the PARADIGM-HF trial, sacubitril/valsartan, an ARNI, was shown to be superior to enalapril in reducing hospitalizations for worsening
HF, CV mortality, and all-cause mortality in patients with ambulatory
HFrEF with LVEF <_40% (changed to <_35% during the study). Patients in the trial had elevated plasma NP concentrations, an eGFR >_30 mL/
min/1.73 m2 and were able to tolerate enalapril and then sacubitril/
valsartan during the run-in period.105 Additional benefits of sacubitril/
valsartan included an improvement in symptoms and QOL,105 a reduction in the incidence of diabetes requiring insulin treatment,126
and a reduction in the decline in eGFR,127 as well as a reduced rate of hyperkalaemia.128 Additionally, the use of sacubitril/valsartan may allow a reduction in loop diuretic requirement.129 Symptomatic hypotension was reported more commonly in patients treated with sacubitril/valsartan as compared to enalapril, but despite developing hypotension, these patients also gained clinical benefits from sacubitril/valsartan therapy.128,130
Table 8
Evidence-based doses of disease-modifying drugs in key randomized trials in patients with heart failure with reduced ejection fraction
Starting dose
Target dose
ACE-I
Captoprila
6.25 mg t.i.d.
50 mg t.i.d.
Enalapril
2.5 mg b.i.d.
1020 mg b.i.d.
Lisinoprilb
2.55 mg o.d.
2035 mg o.d.
Ramipril
2.5 mg b.i.d.
5 mg b.i.d.
Trandolaprila
0.5 mg o.d.
4 mg o.d.
ARNI
Sacubitril/valsartan
49/51 mg b.i.d.c
97/103 mg b.i.d.
Beta-blockers
Bisoprolol
1.25 mg o.d.
10 mg o.d.
Carvedilol
3.125 mg b.i.d.
25 mg b.i.d.e
Metoprolol succinate
(CR/XL)
12.525 mg o.d.
200 mg o.d.
Nebivolold
1.25 mg o.d.
10 mg o.d.
MRA
Eplerenone
25 mg o.d.
50 mg o.d.
Spironolactone
25 mg o.d.f
50 mg o.d.
SGLT2 inhibitor
Dapagliﬂozin
10 mg o.d.
10 mg o.d.
Empagliﬂozin
10 mg o.d.
10 mg o.d.
Other agents
Candesartan
4 mg o.d.
32 mg o.d.
Losartan
50 mg o.d.
150 mg o.d.
Valsartan
40 mg b.i.d.
160 mg b.i.d.
Ivabradine
5 mg b.i.d.
7.5 mg b.i.d.
Vericiguat
2.5 mg o.d.
10 mg o.d.
Digoxin
62.5 mg o.d.
250 mg o.d.
Hydralazine/
Isosorbide dinitrate
37.5 mg t.i.d./20 mg t.i.d.
75 mg t.i.d./40 mg t.i.d.
ACE-I = angiotensin-converting enzyme inhibitor; ARNI = angiotensin receptorneprilysin inhibitor; b.i.d. = bis in die (twice daily); CR = controlled release; CV =
cardiovascular; MRA = mineralocorticoid receptor antagonist; o.d. = omne in die
(once daily); SGLT2 = sodium-glucose co-transporter 2; t.i.d. = ter in die (three times a day); XL = extended release.
aIndicates an ACE-I where the dosing target is derived from post-myocardial infarction trials.
bIndicates drugs where a higher dose has been shown to reduce morbidity/mortality compared with a lower dose of the same drug, but there is no substantive randomized, placebo-controlled trial and the optimum dose is uncertain.
cSacubitril/valsartan may have an optional lower starting dose of 24/26 mg b.i.d.
for those with a history of symptomatic hypotension.
dIndicates a treatment not shown to reduce CV or all-cause mortality in patients with heart failure (or shown to be non-inferior to a treatment that does).
eA maximum dose of 50 mg twice daily can be administered to patients weighing over 85 kg.
fSpironolactone has an optional starting dose of 12.5 mg in patients where renal status or hyperkalaemia warrant caution.
ESC 2021
ESC Guidelines
3621


<!-- PAGE 24 -->

### Page 24

.............................
Therefore, it is recommended that an ACE-I or ARB is replaced by sacubitril/valsartan in ambulatory patients with HFrEF, who remain symptomatic despite optimal treatment outlined above. Two studies have examined the use of ARNI in hospitalized patients, some of whom had not been previously treated with ACE-I. Initiation in this setting appears safe and reduces subsequent CV death or HF hospitalizations by 42% compared to enalapril.106,107,131 As such, initiation of sacubitril/valsartan in ACE-I naive (i.e. de novo) patients with HFrEF
may be considered (class of recommendation IIb, level of evidence
B). Patients being commenced on sacubitril/valsartan should have an adequate blood pressure (BP), and an eGFR >_30 mL/min/1.73 m2. A
washout period of at least 36 h after ACE-I therapy is required in order to minimize the risk of angioedema.
Practical guidance on how to use ARNI is given in Supplementary
Table 5.
5.3.5
Sodium-glucose co-transporter 2 inhibitors
The DAPA-HF trial investigated the long-term effects of dapagliflozin
(SGLT2 inhibitor) compared to placebo in addition to optimal medical therapy (OMT), on morbidity and mortality in patients with ambulatory HFrEF.108 Patients participated in the trial if they were in
NYHA class IIIV, and had an LVEF <_40% despite OMT. Patients were also required to have an elevated plasma NT-proBNP and an eGFR >_30 mL/min/1.73 m2.108
Therapy with dapagliflozin resulted in a 26% reduction in the primary endpoint: a composite of worsening HF (hospitalization or an urgent visit resulting in i.v. therapy for HF) or CV death. Both of these components were significantly reduced. Moreover, dapagliflozin reduced all-cause mortality,108 alleviated HF symptoms, improved physical function and QOL in patients with symptomatic HFrEF.132
Benefits were seen early after the initiation of dapagliflozin, and the absolute risk reduction was large. Survival benefits were seen to the same extent in patients with HFrEF with and without diabetes, and across the whole spectrum of HbA1c values.108
Subsequently, the EMPEROR-Reduced trial found that empagliflozin reduced the combined primary endpoint of CV death or HF hospitalization by 25% in patients with NYHA class IIIV symptoms, and an LVEF <_40% despite OMT.109 This trial included patients with an eGFR >20 mL/min/1.73 m2 and there was also a reduction in the decline in eGFR in individuals receiving empagliflozin. It was also associated with an improvement in QOL.133 Although there was not a significant reduction in CV mortality in the EMPEROR-Reduced trial,
a recent meta-analysis of the DAPA-HF and EMPEROR-Reduced trials found no heterogeneity in CV mortality.134
Therefore, dapagliflozin or empagliflozin are recommended, in addition to OMT with an ACE-I/ARNI, a beta-blocker and an MRA,
for patients with HFrEF regardless of diabetes status. The diuretic/
natriuretic properties of SGLT2 inhibitors may offer additional benefits in reducing congestion and may allow a reduction in loop diuretic requirement.135
The combined SGLT-1 and 2 inhibitor, sotagliflozin, has also been studied in patients with diabetes who were hospitalized with HF. The drug reduced CV death and hospitalization for HF.136 It is discussed further in the AHF and comorbidity sections.
Therapy with SGLT2 inhibitors may increase the risk of recurrent genital fungal infections. A small reduction in eGFR following initiation is expected and is reversible and should not lead to premature discontinuation of the drug.
Practical guidance on how to use the SGLT2 inhibitors dapagliflozin and empagliflozin are given in Supplementary Table 6.
5.4 Other drugs recommended or to be considered in selected patients with heart failure with reduced ejection fraction
Other pharmacological treatments indicated in selected patients with NYHA class II–IV heart failure with reduced ejection fraction (LVEF 40%)
Recommendations
Classa
Levelb
Loop diuretics
Diuretics are recommended in patients with
HFrEF with signs and/or symptoms of congestion to alleviate HF symptoms, improve exercise capacity, and reduce HF hospitalizations.137
I
C
ARB
An ARBc is recommended to reduce the risk of
HF hospitalization and CV death in symptomatic patients unable to tolerate an ACE-I or ARNI
(patients should also receive a beta-blocker and an MRA).138
I
B
If-channel inhibitor
Ivabradine should be considered in symptomatic patients with LVEF <_35%, in SR and a resting heart rate >_70 b.p.m. despite treatment with an evidence-based dose of beta-blocker (or maximum tolerated dose below that), ACE-I/(or
ARNI), and an MRA, to reduce the risk of HF
hospitalization and CV death.139
IIa
B
Ivabradine should be considered in symptomatic patients with LVEF <_35%, in SR and a resting heart rate >_70 b.p.m. who are unable to tolerate or have contraindications for a beta-blocker to reduce the risk of HF hospitalization and CV
death. Patients should also receive an ACE-I (or
ARNI) and an MRA.140
IIa
C
Soluble guanylate cyclase stimulator
Vericiguat may be considered in patients in
NYHA class IIIV who have had worsening HF
despite treatment with an ACE-I (or ARNI), a beta-blocker and an MRA to reduce the risk of
CV mortality or HF hospitalization.141
IIb
B
Hydralazine and isosorbide dinitrate
Hydralazine and isosorbide dinitrate should be considered in self-identiﬁed black patients with
LVEF <_35% or with an LVEF <45% combined with a dilated left ventricle in NYHA class IIIIV
despite treatment with an ACE-I (or ARNI), a beta-blocker and an MRA to reduce the risk of
HF hospitalization and death.142
IIa
B
Continued
................................................................................................................................................


<!-- PAGE 25 -->

### Page 25

.............................................................................................................................................................................
5.4.1
Diuretics
Loop diuretics are recommended to reduce the signs and/or symptoms of congestion in patients with HFrEF. The quality of the evidence regarding diuretics is poor and their effects on morbidity and mortality have not been studied in RCTs. However, it should also be remembered that the major disease-modifying treatment trials for
HFrEF were conducted with a high background use of loop diuretic therapy. One meta-analysis has shown that in patients with HFrEF,
loop and thiazide diuretics appear to reduce the risk of death and worsening HF compared with a placebo, and compared with an active control, diuretics improve exercise capacity.137
Loop diuretics produce a more intense and shorter diuresis than thiazides, although they act synergistically (sequential nephron blockade) and the combination may be used to treat diuretic resistance.
However, adverse effects are more likely, and these combinations should only be used with care. Of note, ARNI, MRAs, and SGLT2
inhibitors may also possess diuretic properties.129,145
The aim of diuretic therapy is to achieve and maintain euvolaemia with the lowest diuretic dose. In some euvolaemic/hypovolaemic patients, the use of a diuretic drug might be reduced or discontinued.146 Patients should be trained to self-adjust their diuretic dose based on monitoring of symptoms/signs of congestion and daily weight measurements.
Practical guidance on how to use diuretics is given in
Supplementary Table 7.
5.4.2
Angiotensin II type 1 receptor blockers
The place of ARBs in the management of HFrEF has changed over the last few years. They are now recommended for patients who cannot tolerate ACE-I or ARNI because of serious side effects.
Candesartan in the CHARM-Alternative study reduced CV deaths and HF hospitalizations in patients who were not receiving an ACE-I
due to previous intolerance.138 Valsartan, in addition to usual therapy,
including ACE-I, reduced HF hospitalizations in the Val-HeFT trial.147
However, no ARB has reduced all-cause mortality in any trial.
5.4.3
If -channel inhibitor
Ivabradine slows heart rate by inhibition of the If channel in the sinus node and is therefore only effective in patients in SR. Ivabradine reduced the combined endpoint of CV mortality and HF hospitalization in patients with symptomatic HFrEF with an LVEF <_35%, with HF
hospitalization in recent 12 months, in sinus rhythm (SR) and with a heart rate >_70 b.p.m. who were on evidence-based therapy including an ACE-I (or ARB), a beta-blocker, and an MRA.139,140 Our recommendation is based on the heart rate of >_70 b.p.m. used in the SHIFT
trial. However, the European Medicines Agency (EMA) approved ivabradine for use in Europe in patients with HFrEF with LVEF <_35%
and in SR with a resting heart rate >_75 b.p.m., because in this group ivabradine conferred a survival benefit148 based on a retrospective subgroup analysis. Every effort should be made to commence and uptitrate beta-blocker therapy to guideline recommended/maximally tolerated doses prior to considering ivabradine.
Practical guidance on how to use ivabradine is given in
Supplementary Table 8.
5.4.4
Combination of hydralazine and isosorbide dinitrate
There is no clear evidence to suggest the use of this fixed-dose combination therapy in all patients with HFrEF. A small RCT conducted in self-identified black patients showed that an addition of the combination of hydralazine and isosorbide dinitrate to conventional therapy
(an ACE-I, a beta-blocker, and an MRA) reduced mortality and HF
hospitalizations in patients with HFrEF and NYHA classes IIIIV.142
These results are difficult to translate to patients of other racial or ethnic origins.
Additionally, a combination of hydralazine and isosorbide dinitrate may be considered in symptomatic patients with HFrEF who cannot tolerate any of an ACE-I, ARNI, or an ARB (or if they are contraindicated) to reduce mortality. However, this recommendation is based on the results of the relatively small Veterans Administration
Cooperative Study, which included only male patients with symptomatic HFrEF who were treated with digoxin and diuretics.143
5.4.5
Digoxin
Digoxin may be considered in patients with HFrEF in SR to reduce the risk of hospitalization,144 although its effect on those routinely treated with beta-blockers has not been tested. In the DIG trial, the overall effect on mortality with digoxin was neutral.
The effects of digoxin in patients with HFrEF and AF have not been studied in RCTs. Some studies have suggested a potentially higher risk of events in patients with AF receiving digoxin,149,150 whereas another meta-analysis concluded, on the basis of non-RCTs, that digoxin has no deleterious effect on mortality in patients with AF and
HF, most of whom had HFrEF.151 Therefore, in patients with symptomatic HF and AF, digoxin may be useful for the treatment of patients with HFrEF and AF with rapid ventricular rate, when other therapeutic options cannot be pursued.150,152155
Digoxin has a narrow therapeutic window and so levels should be checked aiming for a serum digoxin concentration <1.2 ng/mL.156,157
Caution should also be exercised when using it in females, the elderly,
frail, hypokalaemic, and malnourished subjects. In patients with reduced renal function, digitoxin could be considered. Digitoxin use in HF and SR is currently being investigated.158
Hydralazine and isosorbide dinitrate may be considered in patients with symptomatic HFrEF who cannot tolerate any of an ACE-I, an ARB, or
ARNI (or they are contraindicated) to reduce the risk of death.143
IIb
B
Digoxin
Digoxin may be considered in patients with symptomatic HFrEF in sinus rhythm despite treatment with an ACE-I (or ARNI), a betablocker and an MRA, to reduce the risk of hospitalization (both all-cause and HF
hospitalizations).144
IIb
B
ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin-receptor blocker; ARNI = angiotensin receptor-neprilysin inhibitor; b.p.m. = beats per minute; CV = cardiovascular; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; NYHA = New York Heart Association; SR =
sinus rhythm.
aClass of recommendation.
bLevel of evidence.
cThe ARBs with evidence in HFrEF are candesartan, losartan, and valsartan.
ESC 2021
ESC Guidelines
3623


<!-- PAGE 26 -->

### Page 26

Diuretics
SR with LBBB ≥ 150 ms
To reduce mortality - for all patients
To reduce HF hospitalization/mortality - for selected patients
Volume overload
ACE-I/ARNI
BB
MRA
SGLT2i
Exercise rehabilitation
To reduce HF hospitalization and improve QOL - for all patients
For selected advanced HF patients
CRT-P/D
Atrial fibrillation
Anticoagulation
MCS as BTT/BTC
Aortic stenosis
SAVR/TAVI
Mitral regurgitation
TEE MV Repair
Heart rate SR>70 bpm
Ivabradine
Black Race
Hydralazine/ISDN
ACE-I/ARNI intolerance
ARB
Atrial fibrillation
Digoxin
Coronary artery disease
CABG
Iron deficiency
Ferric carboxymaltose
ICD
Ischaemic aetiology
Heart transplantation
Long-term MCS as DT
Multi-professional disease management
Non-ischaemic aetiology
SR with LBBB 130–149 ms or non LBBB ≥ 150 ms
CRT-P/D
Management of HFrEF
ICD
PVI
Figure 3 Central illustration. Strategic phenotypic overview of the management of heart failure with reduced ejection fraction. ACE-I=angiotensin-converting enzyme inhibitor; ARB=angiotensin receptor blocker; ARNI=angiotensin receptor-neprilysin inhibitor; BB=beta-blocker; b.p.m.=beats per minute; BTC
=bridge to candidacy; BTT=bridge to transplantation; CABG=coronary artery bypass graft; CRT-D= cardiac resynchronization therapy with defibrillator;
CRT-P=cardiac resynchronization therapy pacemaker; DT=destination therapy; HF=heart failure; HFrEF=heart failure with reduced ejection fraction; ICD=
implantable cardioverter-defibrillator; ISDN=isosorbide dinitrate; LBBB=left bundle branch block; MCS=mechanical circulatory support; MRA=mineralocorticoid receptor antagonist; MV=mitral valve; PVI=pulmonary vein isolation; QOL=quality of life; SAVR=surgical aortic valve replacement; SGLT2i=sodiumglucose co-transporter 2 inhibitor; SR=sinus rhythm; TAVI=transcatheter aortic valve replacement; TEE=transcatheter edge to edge. Colour code for classes of recommendation: Green for Class of recommendation I; Yellow for Class of recommendation IIa (see Table 1 for further details on classes of recommendation). The Figure shows management options with Class I and IIa recommendations. See the specific Tables for those with Class IIb recommendations.


<!-- PAGE 27 -->

### Page 27

..........
5.4.6
Recently reported advances from trials in heart failure with reduced ejection fraction
Soluble guanylate cyclase stimulator
The VICTORIA study assessed the efficacy and safety of the oral soluble guanylate cyclase stimulator, vericiguat, in patients with a reduced EF and recently decompensated CHF. The incidence of the primary endpoint of death from CV causes or hospitalization for HF was lower among those who received vericiguat than among those who received placebo.141 There was no reduction in either all-cause or CV mortality. Thus, vericiguat may be considered, in addition to standard therapy for HFrEF, to reduce the risk of CV mortality and hospitalizations for HF.
Cardiac myosin activator
The GALACTIC-HF study assessed the efficacy and safety of the cardiac myosin activator, omecamtiv mecarbil, in HFrEF patients, enrolling patients in both the inpatient and outpatient settings. The primary endpoint of a first HF event or CV death was reduced by 8%. There was no significant reduction in CV mortality. Currently, this drug is not licensed for use in HF. However, in the future it may be able to be considered, in addition to standard therapy for HFrEF to reduce the risk of CV mortality and hospitalization for HF.159
5.5 Strategic phenotypic overview of the management of heart failure with reduced ejection fraction
In addition to the general therapies considered in section 5, other therapies are appropriate to consider in selected patients. These are covered in detail in later sections. Some of the main ones (i.e. those with Class I and IIa Mortality/Hospitalization indications) are depicted in Figure 3. The effect of some interventions on symptoms/QOL are outlined in Supplementary Table 9.
6 Cardiac rhythm management for heart failure with reduced ejection fraction
This section provides recommendations on the use of implantable cardioverter-defibrillators (ICD) and cardiac resynchronization therapy (CRT). Other implantable devices will be discussed at the end of this section.
6.1 Implantable cardioverterdefibrillator
A high proportion of deaths among patients with HF, especially in those with milder symptoms, occur suddenly and unexpectedly.
Many of these may be due to electrical disturbances, including ventricular arrhythmias, bradycardia, and asystole, although some are due to other acute vascular events. Treatments that improve or delay the progression of CV disease have been shown to reduce the annual rate of sudden death,105,160 but they do not treat arrhythmic events when they occur. ICDs are effective at correcting potentially lethal ventricular arrhythmias, and in the case of transvenous systems, also prevent bradycardia. Some antiarrhythmic drugs might reduce the rate of tachyarrhythmias and sudden death, but they do not reduce overall mortality,161 and may increase it.
Recommendations for an implantable cardioverterdeﬁbrillator in patients with heart failure
Recommendations
Classa
Levelb
Secondary prevention
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients who have recovered from a ventricular arrhythmia causing haemodynamic instability, and who are expected to survive for >1 year with good functional status, in the absence of reversible causes or unless the ventricular arrhythmia has occurred <48 h after a MI.162164
I
A
Primary prevention
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA class IIIII) of an ischaemic aetiology (unless they have had a MI in the prior 40 days—see below), and an LVEF
<_35% despite >_3 months of OMT, provided they are expected to survive substantially longer than 1 year with good functional status.161,165
I
A
An ICD should be considered to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA class
IIIII) of a non-ischaemic aetiology, and an LVEF
<_35% despite >_3 months of OMT, provided they are expected to survive substantially longer than 1 year with good functional status.161,166,167
IIa
A
Patients should be carefully evaluated by an experienced cardiologist before generator replacement, because management goals, the patient’s needs and clinical status may have changed.168172
IIa
B
A wearable ICD may be considered for patients with HF who are at risk of sudden cardiac death for a limited period or as a bridge to an implanted device.173176
IIb
B
ICD implantation is not recommended within 40
days of a MI as implantation at this time does not improve prognosis.177,178
III
A
ICD therapy is not recommended in patients in
NYHA class IV with severe symptoms refractory to pharmacological therapy unless they are candidates for CRT, a VAD, or cardiac transplantation.179183
III
C
CRT = cardiac resynchronization therapy; HF = heart failure; ICD = implantable cardioverter-deﬁbrillator; LVEF = left ventricular ejection fraction; MI = myocardial infarction; NYHA = New York Heart Association; OMT = optimal medical therapy; VAD = ventricular assist device.
aClass of recommendation.
bLevel of evidence.
ESC 2021
............................................................................................................................................................................
ESC Guidelines
3625


<!-- PAGE 28 -->

### Page 28

.............................................................................................................................................................................
6.1.1
Secondary prevention of sudden cardiac death
Compared with amiodarone treatment, ICDs reduce mortality in survivors of cardiac arrest and in patients who have experienced sustained symptomatic ventricular arrhythmias. An ICD is recommended in such patients when the intent is to increase survival; the decision to implant should take into account the patient’s view and their QOL, the LVEF (survival benefit is uncertain when LVEF >35%)
and the absence of other diseases likely to cause death within the following year.162164,184
6.1.2
Primary prevention of sudden cardiac death
In an analysis of over 40 000 patients from 12 pivotal HF trials, rates of sudden cardiac death decreased by 44% over the 20-year period
(from the mid-1990s to 2015).160 This is almost certainly due to advances in HF treatment, as many key guideline-recommended therapies, including beta-blockers, MRAs, sacubitril/valsartan, and
CRT pacemakers (CRT-P), reduce the risk of sudden death. While the afore-mentioned HF therapies have been shown to reduce mortality in patients with HFrEF, amiodarone has not.161 However, if it is to be used, it should be with caution due to its significant side-effect profile. Conversely, dronedarone185 and the class I antiarrhythmic agents disopyramide, encainide, and flecainide186 should not be used for prevention of arrhythmias due to the increase in mortality seen in clinical studies.
Although an ICD reduces the rate of sudden arrhythmic death in patients with HFrEF,187 it would be expected that, in well-managed patients, the additional benefit afforded by an ICD would be lower. In the DANISH trial, rates of sudden death were low in patients with nonischaemic cardiomyopathy (NICM); only 70 patients out of 1116 followed up over 5 years had sudden death.166 Whilst there was a modest absolute reduction in sudden death with a defibrillator-containing device, this did not significantly improve the overall risk of mortality.
However, subgroup analysis suggested there was a benefit in those <_70
years.188 In a recent meta-analysis of studies that examined the effect of
ICDs in NICM a survival benefit was still seen, although the effect was significantly weakened by the inclusion of the DANISH trial.167
On average, patients with IHD are at greater risk of sudden death than patients with NICM and therefore, although the relative benefits are similar, the absolute benefit is greater in patients with IHD.187 Two
RCTs showed no benefit in patients who had an ICD implanted within
40 days after a MI.177,178 Although sudden arrhythmic deaths were reduced, this was balanced by an increase in non-arrhythmic deaths.
Accordingly, an ICD for primary prevention is contraindicated in this time period. Furthermore, ICD implantation is recommended only if a minimum of 3 months of OMT has failed to increase the LVEF to
>35%. OMT ideally includes the use of Class I recommended drugs for
HFrEF. However, the ICD trials we cite predate the use of ARNI and
SGLT2 inhibitors. Whether implantation of ICDs reduces mortality in those with an LVEF >35% is unknown. There is an ongoing trial of ICD
therapy in such patients with the presence of scar on CMR imaging.189
6.1.3
Patient selection for implantable cardioverterdefibrillator therapy
Patients with HFrEF and a QRS duration >_130 ms can be considered for CRT with a defibrillator (CRT-D) rather than ICD. See the section on CRT for further details (section 6.2).
In patients with moderate or severe HF, a reduction in sudden death may be partially or wholly offset by an increase in death due to worsening HF.161 As such, ICD therapy is not recommended in patients in NYHA class IV, with severe symptoms refractory to pharmacological therapy, who are not candidates for a ventricular assist device (VAD) or cardiac transplantation. Such patients have a very limited life expectancy and are likely to die from pump failure.
Similarly, patients with serious comorbidities who are unlikely to survive substantially more than 1 year with good QOL are unlikely to obtain substantial benefit from an ICD.179183
Although the DANISH trial did not show a significant benefit from
ICD therapy in patients with NICM, it should be remembered that
NICM is a heterogeneous condition, and certain subgroups (e.g. laminopathies, sarcoidosis) are at higher risk of sudden death and therefore merit careful consideration of ICD implantation. Tools to help risk stratification (e.g. scar burden on magnetic resonance imaging)
can be helpful in that regard.190192
Patients should be counselled as to the purpose of an ICD and involved in the decision-making process. They should also be aware of the potential complications related to implantation, any additional implications for driving, and the risk of inappropriate shocks. Furthermore,
patients should be informed about the circumstances where the defibrillator (or defibrillator component of a CRT-D) might be deactivated
(e.g. terminal disease) or explanted (e.g. infection or recovery of LV
function).193 Subsequent timely conversations regarding defibrillator deactivation should be held with the patient and caregiver(s).
When an ICD generator reaches its end of life or requires explantation, it should not be replaced automatically. Rather, shared decision making should be undertaken.168172 Patients should be carefully evaluated by an experienced cardiologist as treatment goals may have changed since implantation (the risk of fatal arrhythmia may be lower, or the risk of non-arrhythmic death may be higher).
It is a matter of some controversy whether patients whose
LVEF has greatly improved and who have not required device therapy during the lifetime of the ICD should have another device implanted.168172
6.1.4
Implantable cardioverter-defibrillator programming
Routine defibrillation threshold testing is no longer performed following implantation of an ICD or CRT-D as it does not improve shock efficacy or reduce arrhythmic death.194 Conservative programming with long delays195 between detection and the ICD delivering therapy dramatically reduces the risk of both inappropriate and appropriate but unnecessary shocks.194,196,197 Generally, for primary prevention, defibrillators are programmed to minimize pacing (e.g.
ventricular demand pacing VVI at 40/min), and with a tachycardia treatment zone >200/min.194,198 Ultimately—and particularly for secondary prevention—programming should be adapted according to the patient’s specific needs.
6.1.5
Subcutaneous and wearable implantable cardioverter-defibrillators
Subcutaneous ICDs (S-ICDs) appear to be as effective as conventional transvenous ICDs with a similar complication rate. Although the risk of inappropriate shocks appeared to be higher initially,


<!-- PAGE 29 -->

### Page 29

improved patient selection has shown S-ICDs are non-inferior to transvenous ICDs in this regard.199202 They may be the preferred option for patients with difficult venous access or those who require
ICD explantation due to infection. Patients must be carefully selected, as S-ICDs cannot treat bradyarrhythmia (except post-shock pacing) and cannot deliver either anti-tachycardia pacing or CRT.
Substantial RCTs with these devices and more long-term data on safety and efficacy are awaited.
A wearable cardioverter-defibrillator that is able to recognize and treat ventricular arrhythmias may be considered for a limited period of time in selected patients with HF who are at high risk for sudden death but otherwise are not suitable for ICD
implantation.162,175,176,203 However, the large VEST trial failed to show that the wearable cardioverter-defibrillator reduced arrhythmic death in patients with an LVEF <_35% following a recent acute
MI.204
For more detailed recommendations on the use/indications of
ICD we refer the reader to the ESC/European Heart Rhythm
Association (EHRA) Guidelines on ventricular tachyarrhythmias and sudden cardiac death.201
6.2 Cardiac resynchronization therapy
In appropriately selected individuals, CRT reduces morbidity and mortality.211 Furthermore, CRT improves cardiac function, and enhances QOL.209,225
Whilst the CARE-HF206,208 and COMPANION210 trials compared the effect of CRT with medical therapy (MT), the majority of CRT
studies have compared CRT-D with ICD, and a few have compared
CRT-P with backup pacing. The prevention of fatal bradycardia might be an important mechanism of benefit shared by all pacing devices. In
CARE-HF, at baseline, 25% of patients had a resting heart rate of <_60
b.p.m.206,208,209 If prevention of bradycardia is important, the effect of
CRT will appear greater in trials where there is no device in the control group. However, in MADIT-II, 35% of those who died with an
ICD did so suddenly even though they were protected from both brady- and tachyarrhythmia.226
Most studies of CRT have specified that the LVEF should be <_35%,
but RAFT212 and MADIT-CRT213,214 specified an LVEF <_30%, while
REVERSE207,215,227
specified
<_40%
and
BLOCK-HF216
<_50%.
Relatively few patients with an LVEF of 3540% have been randomized, but an IPD meta-analysis suggests no diminution of the effect of
CRT in this group.211
Assessing the ‘response’ to CRT is challenging. Indeed, many who do not appear to ‘respond’ favourably in terms of their symptoms or
LV function may well have experienced the mortality benefit. Several characteristics predict improvement in morbidity and mortality. The extent of reverse remodelling is one of the most important mechanisms of action of CRT. Patients with HFrEF of an ischaemic aetiology have less improvement in LV function due to myocardial scar tissue,
which is less likely to undergo favourable remodelling.228 Conversely,
women may be more likely to respond than men, possibly due to smaller body and heart size.220,224,229 QRS width predicts CRT
response and was the inclusion criterion in all randomized trials,211
but QRS morphology has also been related to a beneficial response to CRT. Several studies have shown that patients with left bundle branch block (LBBB) morphology are more likely to respond favourably to CRT, whereas there is less certainty about patients with nonLBBB morphology.230 This latter group is also underrepresented in the large CRT trials.206,210,213 However, patients with LBBB
Recommendations for cardiac resynchronization therapy implantation in patients with heart failure
Recommendations
Classa
Levelb
CRT is recommended for symptomatic patients with HF in SR with a QRS duration >_150 ms and
LBBB QRS morphology and with LVEF <_35%
despite OMT in order to improve symptoms and reduce morbidity and mortality.205215
I
A
CRT rather than RV pacing is recommended for patients with HFrEF regardless of NYHA class or
QRS width who have an indication for ventricular pacing for high degree AV block in order to reduce morbidity. This includes patients with
AF.216219
I
A
CRT should be considered for symptomatic patients with HF in SR with a QRS duration
>_150 ms and non-LBBB QRS morphology and with LVEF <_35% despite OMT in order to improve symptoms and reduce morbidity and mortality.205215
IIa
B
CRT should be considered for symptomatic patients with HF in SR with a QRS duration of
130149 ms and LBBB QRS morphology and with LVEF <_35% despite OMT in order to improve symptoms and reduce morbidity and mortality.211,220
IIa
B
Patients with an LVEF <_35% who have received a conventional pacemaker or an ICD and subsequently develop worsening HF despite OMT and who have a signiﬁcant proportion of RV pacing should be considered for ‘upgrade’ to CRT.221
IIa
B
Continued
CRT may be considered for symptomatic patients with HF in SR with a QRS duration of
130149 ms and non-LBBB QRS morphology and with LVEF <_35% despite OMT in order to improve symptoms and reduce morbidity and mortality.208,213
IIb
B
CRT is not recommended in patients with a
QRS duration <130 ms who do not have an indication for pacing due to high degree AV
block.222224
III
A
AF = atrial ﬁbrillation; AV = atrio-ventricular; CRT = cardiac resynchronization therapy; HF = heart failure; HFrEF = heart failure with reduced ejection fraction;
ICD = implantable cardioverter-deﬁbrillator; LBBB = left bundle branch block;
LVEF = left ventricular ejection fraction; NYHA = New York Heart Association;
OMT = optimal medical therapy (class I recommended medical therapies for at least 3 months); QRS = Q, R, and S waves of an ECG; RV = right ventricular; SR =
sinus rhythm.
aClass of recommendation.
bLevel of evidence.
ESC 2021
............................................................................................................................................................................
ESC Guidelines
3627


<!-- PAGE 30 -->

### Page 30

.............................................................................................................................................................................
morphology often have wider QRS durations, and there is a current debate about whether QRS durations or QRS morphology is the main predictor of a beneficial response to CRT. Evidence from two
IPD meta-analyses indicates that after accounting for QRS duration,
there is little evidence to suggest that QRS morphology or aetiology of disease influence the effect of CRT on morbidity or mortality.211,220 In addition, none of the landmark trials selected patients for inclusion according to QRS morphology, sex, or ischaemic aetiology,
nor were they powered for subgroup analyses.
The Echo-CRT trial222,223 and an IPD meta-analysis213 suggest possible harm from CRT when QRS duration is <130 ms, thus implantation of CRT is not recommended if QRS duration is <130 ms.
If a patient is scheduled to receive an ICD and is in SR, with a
LBBB, CRT-D should be considered if the QRS is between 130
and 149 ms and is recommended if QRS is >_150 ms. However,
clinical practice varies widely among countries and if the primary reason for implanting CRT is for the relief of symptoms, then the clinician should choose CRT-P or CRT-D, whichever they consider appropriate. The only randomized trial to compare CRT-P
and CRT-D210 did not demonstrate a difference in morbidity or mortality between these technologies (although the trial was not powered to show such a difference). Furthermore, in the
DANISH study in patients with NICM where 58% of patients received CRT there was no suggestion from subgroup analysis that CRT-P was inferior to CRT-D.166,167
When LVEF is reduced, RV pacing may exacerbate cardiac dyssynchrony. This can be prevented by CRT, which might improve patient outcomes.216218,231 However, a difference in outcome was not observed between CRT and RV pacing in a subgroup analysis of
RAFT.212 On balance, CRT rather than RV pacing is recommended for patients with HFrEF regardless of NYHA class who have an indication for ventricular pacing in order to reduce morbidity, although no clear effect on mortality was observed. Patients with HFrEF who have received a conventional pacemaker or an ICD and subsequently develop worsening HF with a high proportion of RV pacing, despite
OMT, should be considered for ‘upgrading’ to CRT.
Only two small trials have compared pharmacological therapy alone vs. CRT in patients with AF, with conflicting results. Several studies have indicated that CRT is superior to RV pacing in patients undergoing atrio-ventricular
(AV)
node ablation.217,218,231
However, AF is not an indication to carry out AV node ablation in patients with CRT except in a few cases when ventricular rate remains persistently high despite attempts at pharmacological rate control. A subgroup analysis of patients with AF from the RAFT
study found no benefit from CRT-D compared with ICD, although less than half of patients had >90% biventricular capture.219 In view of the paucity of evidence for the efficacy of CRT in patients with
AF, it may be an option in selected patients—particularly those with a QRS >_150 ms—ensuring a proportion of biventricular pacing as high as possible.
Observational studies report that when biventricular capture is
<98%, the prognosis of patients with CRT declines.218,232 Whether this association reflects a loss of resynchronization (which might be remedied by device programming), poor placement of the LV lead,
or greater difficulty in pacing severely diseased myocardium is uncertain. This observation has not been confirmed in any randomized trial.
Early studies suggested that imaging tests for dyssynchrony were not of value in selecting patients for CRT.233 However, a recent study has suggested that two novel markers of dyssynchrony (apical rocking and septal flash) are associated with a response to CRT, but these have not been tested as selection criteria or as prespecified subgroups in a randomized trial.234 Patients with extensive myocardial scar will have less improvement in LV function with CRT, but this is true of any treatment for HFrEF and does not reliably predict less clinical benefit. Pacing thresholds are higher in scarred myocardium and, if possible, lead placement should avoid such regions.235,236
Although patients with extensive scarring have an intrinsically worse prognosis, there is little evidence that they obtain less prognostic benefit from CRT.211
The value of trying to optimize AV intervals or interventricular delay intervals (VV intervals) after implantation using echo- or electrocardiographic criteria or BP response is uncertain but may be considered for patients who have had a disappointing response to
CRT.237,238 Other options to consider to optimize response to CRT
are covered in a recently published practical article.239
Following CRT implantation, a review of diuretic therapy is advised as a reduction in dose or its discontinuation may be required. In addition, CRT implantation may afford an opportunity to further optimize
MT for HFrEF.240
The reader is directed to guidelines on pacing and CRT for recommendations on device implantation procedures.240a
6.3 Devices under evaluation
Cardiac contractility modulation (CCM) has been evaluated in patients with NYHA class IIIIV HF, with an LVEF >_25% to <_45%
and QRS duration <130 ms, and was associated with a small improvement in exercise tolerance and QOL.241,242
Technologies that involve modification of the activity of the autonomic nervous system, e.g. baroreflex activation therapy,243,244 have also been shown to offer a modest improvement in effort capacity and QOL. However, currently, the evidence is considered insufficient to support specific guideline recommendations for a reduction in mortality or hospitalization for these and a variety of other implantable electrical therapeutic technologies (see also Gaps in Evidence in section 16).
7 Heart failure with mildly reduced ejection fraction
7.1 The diagnosis of heart failure with mildly reduced ejection fraction
The diagnosis of HFmrEF requires the presence of symptoms and/or signs of HF, and a mildly reduced EF (4149%) The presence of elevated NPs (BNP >_35 pg/mL or NT-proBNP >_125 pg/mL) and other evidence of structural heart disease [e.g. increased left atrial (LA) size,
LVH or echocardiographic measures of LV filling] make the diagnosis more likely but are not mandatory for diagnosis if there is certainty regarding the measurement of LVEF.
An algorithm for the diagnosis of HFmrEF is depicted in Figure 1.
For the investigation of the underlying aetiology, please refer to
Table 5 (which refers to investigations regardless of LVEF).


<!-- PAGE 31 -->

### Page 31

............................................................................................................................................................................
7.2 Clinical characteristics of patients with heart failure with mildly reduced ejection fraction
There is a substantial overlap of clinical characteristics, risk factors,
patterns of cardiac remodelling, and outcomes among the LVEF categories in HF. Patients with HFmrEF have, on average, features that are more similar to HFrEF than HFpEF, in that they are more commonly men,
younger,
and are more likely to have
CAD
(5060%),38,42,43 and less likely to have AF and non-cardiac comorbidities (Supplementary Table 10). However, ambulatory patients with
HFmrEF have a lower mortality than those with HFrEF, more akin to those with HFpEF.
Patients with HFmrEF may include patients whose LVEF has improved from <_40% or declined from >_50%.50
7.3 Treatments for patients with heart failure with mildly reduced ejection fraction
As in other forms of HF, diuretics should be used to control congestion. No substantial prospective RCT has been performed exclusively in patients with HFmrEF (Supplementary Table 11). Some data can be gleaned from subgroup analysis of trials in HFpEF, none of which have met their primary endpoint. Although strong recommendations cannot be made about specific therapies at this point in time, we have included a Table of Recommendations to help guide the management of patients in this category.
7.3.1
Angiotensin-converting enzyme inhibitors
There are no specific trials of ACE-I in patients with HFmrEF.
Although, the PEP-CHF trial was conducted in patients with HFpEF
and included patients with an LVEF >40%, it did not report outcomes according to LVEF.11
However, in patients with HFmrEF, many will also have CAD,
hypertension, or post-MI LV systolic dysfunction and will, therefore,
already be treated with ACE-I.
Therefore, ACE-I use may be considered in patients with HFmrEF.
7.3.2
Angiotensin receptor II type 1 receptor blockers
There are no specific trials of ARBs in HFmrEF. The CHARMPreserved trial missed its primary endpoint of CV death or HF hospitalizations.245 However, a retrospective analysis showed that candesartan reduced the number of patients hospitalized for HF among those with HFmrEF (with similar trends for CV and all-cause mortality).8 Moreover, a recurrent-event analysis suggested a reduction in hospitalizations for HF among the entire CHARM-Preserved cohort,
including those with HFmrEF.248
As for ACE-I, many with HFmrEF will already be on an ARB for other CV indications. Therefore, treatment with ARBs may be considered in patients with HFmrEF.
7.3.3
Beta-blockers
There is no specific trial of beta-blockade in HFmrEF. An IPD metaanalysis of landmark trials of beta-blockers suggested similar reductions in CV and all-cause mortality (of 50%) for patients in SR with
HFrEF and HFmrEF.12 This IPD meta-analysis included the SENIORS
trial where nebivolol reduced the composite primary endpoint of allcause mortality or CV hospital admissions in the overall population.
No interaction between LVEF (35% of patients had an LVEF of
3550%) and the effect of nebivolol on the primary outcome was observed.119,249 Many patients with HFmrEF may have another CV
indication, such as AF or angina, for a beta-blocker. Therefore, treatment with beta-blockers may be considered in patients with HFmrEF.
7.3.4
Mineralocorticoid receptor antagonists
There is no specific trial of MRAs in HFmrEF. In a retrospective analysis of the TOPCAT trial in patients with an LVEF >_45%,9 spironolactone reduced hospitalizations for HF in those with an LVEF <55%.
There was a similar trend for CV but not all-cause mortality.
Treatment with an MRA may be considered in patients with
HFmrEF.
7.3.5
Angiotensin receptor-neprilysin inhibitor
There is no specific trial of ARNI in HFmrEF. In the PARAGON-HF
trial, which included patients with EF >_45%, although the trial missed its primary endpoint overall, a significant EF-by-treatment interaction was observed. Sacubitril/valsartan, compared with valsartan, reduced the likelihood of the primary composite outcome of CV death and total HF hospitalizations by 22% in those with an EF below or equal to the median of 57%.13 Further data are available from a combined analysis of the PARADIGM-HF and PARAGON-HF trials showing that sacubitril/valsartan, compared to other forms of RAAS blockade,
has a beneficial effect, especially on hospitalizations for HF in those with HFmrEF.247
Pharmacological treatments to be considered in patients with (NYHA class II–IV) heart failure with mildly reduced ejection fraction
Recommendations
Classa
Levelb
Diuretics are recommended in patients with congestion and HFmrEF in order to alleviate symptoms and signs.137
I
C
An ACE-I may be considered for patients with
HFmrEF to reduce the risk of HF hospitalization and death.11
IIb
C
An ARB may be considered for patients with
HFmrEF to reduce the risk of HF hospitalization and death.245
IIb
C
A beta-blocker may be considered for patients with HFmrEF to reduce the risk of HF hospitalization and death.12,119
IIb
C
An MRA may be considered for patients with
HFmrEF to reduce the risk of HF hospitalization and death.246
IIb
C
Sacubitril/valsartan may be considered for patients with HFmrEF to reduce the risk of HF
hospitalization and death.13,247
IIb
C
ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin-receptor blocker; HF = heart failure; HFmrEF = heart failure with mildly reduced ejection fraction; MRA = mineralocorticoid receptor antagonist; NYHA = New York
Heart Association.
aClass of recommendation.
bLevel of evidence.
ESC 2021
ESC Guidelines
3629


<!-- PAGE 32 -->

### Page 32

.............................................................................................................................................................................
Treatment with an ARNI may be considered in patients with
HFmrEF.
7.3.6
Other drugs
In the DIG trial,10 for those with HFmrEF in SR, there was a trend to fewer hospitalizations for HF in those assigned to digoxin, but no reduction in mortality and a trend to an excess of CV deaths.
Therefore, there are insufficient data to recommend its use.
There are also insufficient data on ivabradine in HFmrEF to draw any conclusions.
7.3.7
Devices
While post hoc analyses of landmark CRT trials suggest that CRT
may benefit patients with LVEF >35%, trials of CRT for HFmrEF were abandoned due to poor recruitment.250 There are no substantial trials of ICDs for primary prevention of ventricular arrhythmias for
HFmrEF; trials conducted more than 20 years ago suggested no benefit from ICD implantation for secondary prevention of ventricular arrhythmias for HFmrEF.
Therefore, there is insufficient evidence to advise CRT or ICD
therapy in patients with HFmrEF.
In HF patients with an LVEF >_40%, the implantation of an interatrial shunt device was found to be safe, and this device is subject to investigation in a larger study before any recommendation on their use in HFpEF or HFmrEF can be given.251
8 Heart failure with preserved ejection fraction
8.1 The background to heart failure with preserved ejection fraction
This guideline acknowledges the historical changes in nomenclature and the lack of consensus on the optimal LVEF cut-off to define the group of patients with HF without overtly reduced EF. The term ‘preserved’ was originally proposed in the Candesartan in Heart failure:
Assessment of Reduction in Mortality and morbidity (CHARM)
Programme to refer to patients with an EF (>40%) that was not clearly ‘reduced’ or completely ‘normal’.252 While the current guidelines have designated patients with an LVEF 4149% as HFmrEF, we recognize that there will be debate about what constitutes ‘mildly reduced’ EF, what these EF cut-offs should be, and whether they should be different for men and women.14,253 The EACVI defines systolic dysfunction as being <52% for males and <54% for females.16
Whether patients with higher EFs and HF should be named HF
with ‘normal’ EF has also been considered.14,254 However, given the known variability of echocardiographic measurements of LVEF, the difficulties in interpreting LVEF measured using different imaging modalities, and remaining controversies regarding the precise LVEF
cut-off to define ‘normal’ , which may vary not only with sex but also with other factors such as age and ethnicity,255 this guideline has kept the nomenclature of HFpEF using an EF cut-off of 50%. Importantly,
clinicians should be aware that LVEF is a continuous variable with a normal distribution in the general population, and the EF cut-offs used in definitions are therefore arbitrary. Moreover, while the LVEF
cut-off to define ‘normal’ will likely be higher than 50%, the presence of a very high EF (e.g. above 6570%) should also prompt a search for pathology, such as cardiac amyloidosis (CA) or hypertrophic cardiomyopathy (HCM), where a ‘supra-normal’ EF may result from shrinkage of the LV end-diastolic volume (denominator of EF).256,257
8.2 Clinical characteristics of patients with heart failure with preserved ejection fraction
HFpEF differs from HFrEF and HFmrEF in that HFpEF patients are older and more often female. AF, CKD, and non-CV comorbidities are more common in patients with HFpEF than in those with
HFrEF.258
There are numerous potential causes of HFpEF (Table 5). The pathophysiology of various HFpEF syndromes differs, and thus they require distinct therapies. Red flags for the potential presence of CA
include low normal BP in patients with a history of hypertension,
intolerance to beta-blockers or ACE-I, history of bilateral carpal tunnel syndrome, low voltage on ECG and echocardiographic features such as thickening of the septum, posterior wall, or RV wall, enlarged atria, a small pericardial effusion, or valve thickening [for more details see the section on CMP (section 14.2)]. Furthermore, it is important to exclude other conditions that might mimic the HFpEF syndrome
(e.g. lung disease, anaemia, obesity, and deconditioning). For a more comprehensive overview on HFpEF, see the ESC/HFA position statement.259
8.3 The diagnosis of heart failure with preserved ejection fraction
The diagnosis of HFpEF remains challenging. Several diagnostic criteria have been proposed by societies and in clinical trials.260 These criteria vary widely in their sensitivities and specificities for diagnosing HFpEF.
More recently, two score-based algorithms (H2FPEF and HFA-PEFF)
have been proposed to aid the diagnosis.259,261 While the generalizability of the scores has been tested in various trial and observational cohorts, their diagnostic performance has varied.262269
Both scores assign a substantial proportion of suspected HFpEF
patients as intermediate likelihood, wherein additional diagnostics are proposed. Thus, depending on which score is used, different patients will be referred for additional testing or allocated as having HFpEF.
Furthermore, physicians may not have access to all the specialized tests recommended by the specific diagnostic algorithms. This limits the broad clinical applicability of the scores and demonstrates the ongoing diagnostic uncertainty in HFpEF.267
To facilitate broad clinical application, this guideline recommends a simplified pragmatic approach that distils the common major elements in prior diagnostic criteria and emphasizes the most frequently used variables widely available to clinicians. Some of these variables, in particular, LA size (LA volume index
>32 mL/m2), mitral E velocity >90 cm/s, septal e0 velocity <9 cm/s,
E/e0 ratio >9 have been shown to be pivot points beyond which the risk of CV mortality is increased, underscoring their value.270
This recommendation is therefore consistent with the consensus document of the HFA, and does not represent a new algorithm or diagnostic score but rather a simplified approach. Physicians with access to expertise may refer to the full diagnostic approach recommended by the HFA.259


<!-- PAGE 33 -->

### Page 33

.....................................................................................................
This simplified diagnostic approach starts with assessment of pretest probability (see clinical characteristics above). The diagnosis should include the following:
(1)
Symptoms and signs of HF.
(2)
An LVEF >_50%.*
(3)
Objective evidence of cardiac structural and/or functional abnormalities consistent with the presence of LV diastolic dysfunction/
raised LV filling pressures, including raised NPs (Table 9).
*Of note, patients with a history of overtly reduced LVEF (<_40%),
who later present with LVEF >_50%, should be considered to have recovered HFrEF or ‘HF with improved LVEF’ (rather than HFpEF).
Continued treatment for HFrEF is recommended in these patients.271
It is not known whether starting HF therapy in patients with recovered LVEF is beneficial. Patients with HFpEF tend to have stable trajectory of LVEF over time.272 However, in those who develop a clinical indication for a repeat echo during follow-up, around one third have a decline in LVEF.273
In the presence of AF, the threshold for LA volume index is >40
mL/m2. Exercise stress thresholds include E/e0 ratio at peak stress >_15
or tricuspid regurgitation (TR) velocity at peak stress >3.4 m/s.275 LV
global longitudinal strain <16% has a sensitivity of 62% and a specificity of 56% for the diagnosis of HFpEF by invasive testing.261
The approach to the diagnosis should involve additional confirmatory tests in cases of diagnostic uncertainty, such as cardiopulmonary exercise testing (to confirm a reduction in exercise capacity and to help differentiate the cause of dyspnoea), exercise stress testing, and invasive haemodynamic testing.259
If resting echocardiographic and laboratory markers are equivocal,
a diastolic stress test is recommended.259,274 The confirmatory test for the diagnosis of HFpEF is invasive haemodynamic exercise testing.
An invasively measured pulmonary capillary wedge pressure
(PCWP) of >_15 mmHg (at rest) or >_25 mmHg (with exercise) or LV
end-diastolic pressure >_16 mmHg (at rest) is generally considered diagnostic.266 However, instead of an exercise PCWP cut-off, some have used an index of PCWP to cardiac output for the invasive diagnosis of HFpEF260,276. Recognizing that invasive haemodynamic exercise testing is not available in many centres worldwide, and is associated with risks, its main use is limited to the research setting. In the absence of any disease-modifying treatments, the current guidelines do not mandate gold standard testing in every patient to make the diagnosis, but emphasize that the greater the number of objective non-invasive markers of raised LV filling pressures (Table 9), the higher the probability of a diagnosis of HFpEF.
8.4 Treatment of heart failure with preserved ejection fraction
To date, no treatment has been shown to convincingly reduce mortality and morbidity in patients with HFpEF, although improvements have been seen for some specific phenotypes of patients within the overall HFpEF umbrella. However, none of the large
RCTs conducted in HFpEF have achieved their primary endpoints.
These include PEP-CHF (perindopril),277 CHARM-Preserved (candesartan),245 I-PRESERVE (irbesartan),278 TOPCAT (spironolactone),246
DIG-Preserved
(digoxin),279
and
PARAGON-HF
(sacubitril/valsartan)13 (see Supplementary Table 12 for the details about these and additional trials). Hospitalizations for HF were reduced by candesartan and spironolactone and there was a trend towards reduction with sacubitril/valsartan, although as these trials were neutral for their primary endpoints, these are hypothesisgenerating findings only. Although nebivolol significantly reduced the combined primary endpoint of all-cause mortality or CV hospital admission in the SENIORS trial, this trial included only 15% with an LVEF >50%.119,249 Trials targeting the nitric oxide-cyclic guanosine monophosphate pathway have also failed to improve exercise
Table 9
Objective evidence of cardiac structural, functional and serological abnormalities consistent with the presence of left ventricular diastolic dysfunction/raised left ventricular ﬁlling pressures259,261
Parametera
Threshold
Comments
LV mass index
Relative wall thickness
>_95 g/m2 (Female), >_115 g/m2 (Male)
>0.42
Although the presence of concentric LV remodelling or hypertrophy is supportive, the absence of LV hypertrophy does not exclude the diagnosis of HFpEF
LA volume indexa
>34 mL/m2 (SR)
In the absence of AF or valve disease, LA enlargement reﬂects chronically elevated LV ﬁlling pressure (in the presence of AF, the threshold is
>40 mL/m2)
E/e’ ratio at resta
>9
Sensitivity 78%, speciﬁcity 59% for the presence of HFpEF by invasive exercise testing, although reported accuracy has varied. A higher cut-off of 13 had lower sensitivity (46%) but higher speciﬁcity (86%).71,259,274
NT-proBNP
BNP
>125 (SR) or
>365 (AF) pg/mL
>35 (SR) or
>105 (AF) pg/mL
Up to 20% of patients with invasively proven HFpEF have NPs below diagnostic thresholds, particularly in the presence of obesity
PA systolic pressure
TR velocity at resta
>35 mmHg
>2.8 m/s
Sensitivity 54%, speciﬁcity 85% for the presence of HFpEF by invasive exercise testing259,261
AF = atrial ﬁbrillation; BNP = B-type natriuretic peptide; E/e’ratio = early ﬁlling velocity on transmitral Doppler/early relaxation velocity on tissue Doppler; HFpEF = heart failure with preserved ejection fraction; LA = left atrial; LV = left ventricular; NP = natriuretic peptide; NT-proBNP = N-terminal pro-B-type natriuretic peptide; PA = pulmonary artery;
SR = sinus rhythm; TR = tricuspid regurgitation.
Note: The greater the number of abnormalities present, the higher the likelihood of HFpEF.
aOnly commonly used indices are listed in the table; for less commonly used indices refer to the consensus document of the ESC/HFA.259
ESC 2021
ESC Guidelines
3631


<!-- PAGE 34 -->

### Page 34

capacity or QOL in HFpEF, e.g. NEAT-HFpEF,280 INDIE-HFpEF,281
VITALITY-HFpEF,282 and CAPACITY-HFpEF (praliciguat).283
Despite the lack of evidence for specific disease-modifying therapies in HFpEF, as the vast majority of HFpEF patients have underlying hypertension and/or CAD, many are already treated with ACE-I/
ARB, beta-blockers, or MRAs. In the PARAGON-HF study at baseline, more than 86% of patients were on ACE-I/ARBs, 80% were on beta-blockers, and more than 24% were on MRAs.13
The Task Force acknowledge that the treatment options for
HFpEF are being revised as this guideline is being published. We note that the Food and Drug Administration (FDA) has endorsed the use of sacubitril/valsartan and spironolactone in those with an LVEF ‘less than normal’. These statements relate to patients within both the
HFmrEF and HFpEF categories. For sacubitril/valsartan, this decision was based on the subgroup analysis from the PARAGON-HF study,
which showed a reduction in HF hospitalizations in those with an
LVEF <57%, and a meta-analysis of the PARADIGM-HF and
PARAGON-HF studies, showing a reduction in CV death and HF
hospitalization in those with an LVEF below the normal range.247
Regarding spironolactone, the subgroup of individuals in the
TOPCAT study recruited in the Americas had a significant reduction in the primary endpoint of CV death and HF hospitalization,
and a subsequent post hoc analysis by EF showed a significant reduction in outcomes for those with an LVEF <55%.9,247 There are also ongoing trials with SGLT2 inhibitors. These developments may well accelerate a redefinition of HFpEF in the future and have therapeutic implications.
In the absence of recommendations regarding disease-modifying therapies, treatment should be aimed at reducing symptoms of congestion with diuretics. Loop diuretics are preferred, although thiazide diuretics may be useful for managing hypertension. Reducing body weight in obese patients and increasing exercise may further improve symptoms and exercise capacity and should therefore be considered in appropriate patients.284,285
It is important to identify and treat the underlying risk factors, aetiology, and coexisting comorbidities in HFpEF (e.g. hypertension in section 12.4, CAD in section 12.2, amyloidosis in section 14.6, AF in section 12.1.1,
and valvular heart disease in section 12.3).
Undoubtably, treatment of some of the underlying phenotypes of the the HFpEF syndrome leads to improved outcomes.
Recommendations for the treatment of patients with heart failure with preserved ejection fraction
Recommendations
Classa
Levelb
Screening for, and treatment of, aetiologies, and cardiovascular and non-cardiovascular comorbidities is recommended in patients with HFpEF
(see relevant sections of this document).
I
C
Diuretics are recommended in congested patients with HFpEF in order to alleviate symptoms and signs.137
I
C
HFpEF = heart failure with preserved ejection fraction.
aClass of recommendation.
bLevel of evidence.
ESC 2021
ESC 2021
Table 10
Risk factors for the development of heart failure and potential corrective actions
Risk factors for heart failure
Preventive strategies
Sedentary habit
Regular physical activity
Cigarette smoking
Cigarette smoking cessation
Obesity
Physical activity and healthy diet
Excessive alcohol intake286
General population: no/light alcohol intake is beneﬁcial
Patients with alcohol-induced CMP
should abstain from alcohol
Inﬂuenza
Inﬂuenza vaccination
Microbes (e.g. Trypanosoma cruzi, Streptococci)
Early diagnosis, speciﬁc antimicrobial therapy for either prevention and/or treatment
Cardiotoxic drugs (e.g.,
anthracyclines)
Cardiac function and side effect monitoring, dose adaptation, change of chemotherapy
Chest radiation
Cardiac function and side effect monitoring, dose adaptation
Hypertension
Lifestyle changes, antihypertensive therapy
Dyslipidaemia
Healthy diet, statins
Diabetes mellitus
Physical activity and healthy diet,
SGLT2 inhibitors
CAD
Lifestyle changes, statin therapy
CAD = coronary artery disease; CMP = cardiomyopathy; SGLT2 = sodium-glucose co-transporter 2.
ESC 2021
Recommendations for the primary prevention of heart failure in patients with risk factors for its development
Recommendations
Classa
Levelb
Treatment of hypertension is recommended to prevent or delay the onset of HF, and to prevent
HF hospitalizations.287290
I
A
Treatment with statins is recommended in patients at high risk of CV disease or with CV
disease in order to prevent or delay the onset of
HF, and to prevent HF hospitalizations.291,292
I
A
SGLT2 inhibitors (canagliﬂozin, dapagliﬂozin,
empagliﬂozin, ertugliﬂozin, sotagliﬂozin) are recommended in patients with diabetes at high risk of CV disease or with CV disease in order to prevent HF hospitalizations.293297
I
A
Counselling against sedentary habit, obesity, cigarette smoking, and alcohol abuse is recommended to prevent or delay the onset of
HF.298302
I
C
CV=cardiovascular; HF= heart failure; SGLT2= sodium-glucose co-transporter 2.
aClass of recommendation.
bLevel of evidence.
............................................................................................................................................................................


<!-- PAGE 35 -->

### Page 35

.......................................................
9 Multidisciplinary team management for the prevention and treatment of chronic heart failure
9.1 Prevention of heart failure
General advice about risk factors for the development of HF (see
Supplementary Figure 1) and strategies to prevent HF early in the CV
continuum are summarized in Table 10.
It is widely recognized that, in addition to optimizing medical and device therapies for HF, attention should also be given to how HF
care is delivered. The HFA of the ESC has issued several position papers that cover non-pharmacological management, discharge planning, and standards for delivering HF care.303305 It has also underscored the need for specialist HF cardiologists and specialist HF
nurses to help provide care. Detailed curricula, to aid training of these, are available to be adapted for national implementation.306,307
This section focuses on areas where recommendations with an evidence level can be given: multidisciplinary team management, lifestyle advice, exercise training, follow-up, and monitoring.
9.2 Multidisciplinary management of chronic heart failure
9.2.1 Models of care
In order to reduce hospitalizations and mortality, earlier guidelines1
recommended the use of multidisciplinary
HF
management programmes (HF-MPs), which enable patients to have the correct investigations, an accurate diagnosis, appropriate evidence-based therapy, education, and suitable follow-up. The optimal implementation of a HF-MP requires a multidisciplinary team that is active along the whole HF trajectory; from onset, through critical events, periods of apparent stability, and its terminal stages.303 Since the 2016 guidelines, new studies have been published that underscore the need for
HF-MPs and reveal more insights into how care can be delivered.
A network meta-analysis including 53 randomized trials published in 2017, concluded that both disease-management clinics and home visits by nurses reduced all-cause mortality compared to usual care;
home visits being most effective.308 An IPD meta-analysis of 20 studies, including 5624 patients, concluded that self-management interventions in HF patients improve outcomes despite heterogeneity in the intensity, content, and the personnel who deliver the interventions.309
HF-MPs vary in their components and can apply different service models, such as clinic-based approaches (in primary, secondary, or tertiary care), home-based programmes, case management, or hybrids of these. Components used in the services vary, e.g. some
HF-MPs use telemonitoring that may be applied at a local, regional,
or national level. No service model has been shown to be consistently superior to others.310 While home visits and HF clinics do reduce all-cause admissions and mortality, educational programmes,
used alone, do not.308,309 HF-MPs should be patient-centred and take a holistic approach to the patient rather than focussing solely on HF;
management of comorbid conditions, such as arrhythmias, hypertension, diabetes, renal dysfunction, and depression, improve patient well-being and self-management, leading to better outcomes.309,311
The organization of a HF-MP should be adapted to the healthcare system, available resources (infrastructure, facilities, staff, and finances), administrative policies, and tailored to the patient’s needs.
Many patients with HF would derive benefit from the early integration of a palliative and supportive approach within the care provided by all members of the HF multidisciplinary team.312,313 Palliative and supportive care should be thought about for all patients with HF,
regardless of stage of their illness. Patients in the advanced stages and those considered for mechanical circulatory support (MCS) or heart transplantation should receive a palliative care consultation before such interventions as a matter of protocol (see section 10.2.4).
9.2.2 Characteristics and components of a heart failure management programme
Clinical trials have included complex, bundled interventions, making it difficult to determine the efficiency and effectiveness of each specific component. Table 11 presents an overview of characteristics and components that are important to consider in a HF-MP.
9.3 Patient education, self-care and lifestyle advice
Adequate patient self-care is essential in the effective management of
HF and allows patients to understand what is beneficial, and to agree to self-monitoring and management plans.319 HF patients who report more effective self-care have a better QOL, lower readmission rates,
and reduced mortality.309
Misunderstandings, misconceptions, and lack of knowledge all contribute to insufficient self-care and therefore patient education is vital.
Improving patients’ knowledge of their condition is fundamental for the development of self-care skills.304
Education to improve self-care should be tailored to the individual patient and based on, where available, scientific evidence or expert opinion. There is little evidence that specific lifestyle advice improves
Multidisciplinary interventions recommended for the management of chronic heart failure
Recommendations
Classa
Levelb
It is recommended that HF patients are enrolled in a multidisciplinary HF management programme to reduce the risk of HF hospitalization and mortality.309,314,315,316
I
A
Self-management strategies are recommended to reduce the risk of HF hospitalization and mortality.309
I
A
Either home-based and/or clinic-based programmes improve outcomes and are recommended to reduce the risk of HF hospitalization and mortality.310,317
I
A
Inﬂuenza and pneumococcal vaccinations should be considered in order to prevent HF
hospitalizations.315,316
IIa
B
HF = heart failure.
aClass of recommendation.
bLevel of evidence.
ESC 2021
......................................................................................................................
ESC Guidelines
3633


<!-- PAGE 36 -->

### Page 36

Table 11
Important characteristics and components in a heart failure management programme
Characteristics
1.
Patient/person-centred318
2.
Multidisciplinary
3.
The focus of the programme should be ﬂexible and include:
• prevention of disease progression
• symptom control
• maintaining patients in their preferred place of care for end-stage heart failure
4.
Competent and professionally educated staff
5.
Encourage patient/carer engagement in the understanding and management of their condition
Components
1.
Optimized management; lifestyle choices, pharmacological, and devices
2.
Patient education, with special emphasis on self-care and symptom management
3.
Provision of psychosocial support to patients and family caregivers
4.
Follow-up after discharge (clinic; home visits; telephone support or telemonitoring)
5.
Easy access to healthcare, especially to prevent and manage decompensation
6.
Assessment of (and appropriate intervention in response to) an unexplained change in weight, nutritional and functional status, quality of life, sleep problems, psychosocial problems or other ﬁndings (e.g., laboratory values)
7.
Access to advanced treatment options; supportive and palliative care
Table 12
Patient education and self-care
Education topic
Goal for the patient and caregiver
Professional behaviour and educational tools
Explanation about HF
To understand the cause of their HF, symptoms and treatment choice.
Provide tailored information.
The HF trajectory
To understand prognosis and the different possible phases in the HF trajectory.
To make joint treatment decisions that recognise the patient’s position on the HF trajectory.
Sensitively communicate information on prognosis at time of diagnosis, during decision making about treatment options, when there is a change in the clinical condition and whenever the patient requests.
Medical treatment
Medication
To be able to make joint decisions about medication.
To understand the indications, beneﬁts, the need for longterm adherence to certain drugs, and the dosing and side effects of medication.
To be able to recognize the common side effects of medication and know what actions to take.
Provide written and oral information on indication, beneﬁts, dosing, effects and side effects.
Discuss practical issues such as optimal time-schedule, what to do in case of a missed dose etc.
Discuss possible barriers for medication taking.
Advise on support aids such as dosette box, electronic reminders etc. when appropriate.320
Implanted devices
To be able to make joint decisions on device implantation.
To understand the indications, importance, expectations and check-up routine for implanted devices, and any exception management.
To be able to recognize the common complications
(including the risk of inappropriate deﬁbrillator shocks),
and know what actions to take.
Provide written and oral information about the importance and expectations of implanted devices, and possible ways of followup (remote monitoring).
Discuss expectations and any possible impact on driving.
Clearly identify situations where the device might be deactivated or explanted.
Involve patient and caregiver in decision making.
Self-care aspects
Activity and exercise
To undertake regular exercise and be physically active.
To be able to adapt physical activity to symptom status and personal circumstances.
Advise on exercise that recognizes physical and functional limitations, such as frailty, comorbidities.
Refer to exercise programme or other activity modes.
Discuss possible barriers, side-effects and opportunities.
Sleep and breathing
To recognize the importance of sleep and rest for (CV)
health.
To be able to recognize problems with sleeping and how to optimize sleep.
Review sleep history.
Advise and discuss the importance of good sleep and provide advice on ‘sleep health’ (including timing of diuretics).
Continued
ESC 2021


<!-- PAGE 37 -->

### Page 37

Table 12
Continued
Education topic
Goal for the patient and caregiver
Professional behaviour and educational tools
Consider and carefully discuss the beneﬁts and deleterious effects of sleep medication.
Fluids
To avoid large volumes of ﬂuid intake. A ﬂuid restriction of 1.52 L/day may be considered in patients with severe HF/hyponatraemia to relieve symptoms and congestion.
To avoid dehydration: where ﬂuids are restricted, increase intake during periods of high heat/humidity and/or nausea/vomiting.
Provide information and discuss the advantages and disadvantages of ﬂuid restriction.
Advise to adapt ﬂuid intake to weight, and in times of high heat and humidity, nausea/vomiting.
Adjust advice during periods of acute decompensation and consider altering this advice towards end-of-life.
Healthy diet
To be able to prevent malnutrition and know how to eat healthily, avoiding excessive salt intake (>5 g/day) and maintaining a healthy body weight.
Discuss current food intake, role of salt, role of micronutrients.
Discuss the need for supplementing in case of nutrient deﬁciencies but there is no clear role for routine micronutrient supplementation.321
Discuss maintaining a healthy body weight.
Alcohol
To be able to abstain from or avoid excessive alcohol intake, especially for alcohol-induced CMP.
To restrict alcohol according to CV prevention guidelines.
Tailor alcohol advice to aetiology of HF; e.g. abstinence in alcoholic CMP.
Inform and discuss alcohol intake according to CV prevention guidelines (2 units per day in men or 1 unit per day in women)a.
Immunization
To be aware of the need for immunization for inﬂuenza and pneumococcal disease.
Discuss beneﬁts and possible barriers.
Advise on local immunization practice.
Smoking and recreational drugs
To be aware of the consequences for health of smoking and use of recreational drugs.
Stop smoking (including e-cigarettes) and taking recreational drugs.
Inform, discuss and help in decision making.
Refer for specialist advice for smoking cessation and drug withdrawal and replacement therapy.
Consider referral for cognitive behavioural theory and psychological support if patient wishes to stop smoking or taking drugs.
Travel, leisure, driving
To be able to prepare travel and leisure activities according to physical capacity.
To be able to take an informed decision about driving.
Inform and discuss practical issues related to long haul travel, staying abroad, exposure to sun (amiodarone effects), high humidity or heat (dehydration), and high altitude (oxygenation).
Provide practical advice related to travel with medication/devices
(keep medicines in hand luggage, have a list with medication,
device name/card and treating centres).
Inform about local/national/international regulation related to driving.
Sexual activity
To be able to resume or adapt sexual activity according to physical capacity.
To recognize possible problems with sexual activity and their relationship with HF or its treatment.
Inform and discuss that sexual activity is safe for stable HF
patients.
Provide advice on eliminating factors predisposing to sexual problems.
Discuss and provide available pharmacological treatment for sexual problems.
Refer to specialist for sexual counselling when necessary.
Symptom monitoring and symptom selfmanagement
Monitor and recognize change in signs and symptoms.
Being able to react adequately to change in signs and symptoms.
Know how and when to contact a healthcare professional.
Provide individualized information to support self-management such as:
In the case of increasing dyspnoea or oedema or a sudden unexpected weight gain of >2 kg in 3 days, patients may increase their diuretic dose and/or alert their healthcare team.
Living with HF
Psychological issues
To be able to live a good life with HF.
To be able to seek help in case of psychological problems such as depressive symptoms, anxiety or low mood which may occur in the course of the HF trajectory.
Regularly communicate information on disease, treatment options and self-care.
Regularly discuss the need for support.
Treat or referral to specialist for psychological support when necessary.
Continued
ESC Guidelines
3635


<!-- PAGE 38 -->

### Page 38

..........................................................................................................................................
QOL or prognosis; however, providing this information has become a key component of education for self-care.
General educational approaches include:
• Providing information in a variety of formats that take into account educational grade and health literacy.
Consider approaches with active roles for patients and caregivers such as
‘ask-tell-ask’, ‘teach back’, or motivational interviewing. Reinforce messages at regular time intervals.
• Recognizing barriers to communication (language, social skills,
cognition, anxiety/depression, hearing or visual challenges).
• Recommending ‘HFmatters.org’. Offer help and guidance to use it and offer discussion of questions arising.
• Inviting patients to be accompanied by a family member or friend.
Key topics to include are recommended in Table 12.
9.4 Exercise rehabilitation
There is consistent evidence that physical conditioning by exercise training improves exercise tolerance, and health-related QOL in patients with HF. Clinical trials and meta-analyses in people with
HFrEF show that exercise rehabilitation improves exercise capacity and QOL. Several meta-analyses also show that it reduces all-cause and HF hospitalizations, although uncertainty persists about its effects on mortality.322328 The effect on hospitalization is seen in those who are highly adherent to the exercise programme.329 Highintensity interval training, in patients who are able and willing,
may improve peak oxygen consumption (VO2).330,331 Supervised exercise-based rehabilitation should be considered in those who are frail, who have more severe disease or comorbidities.95
Physical conditioning also improves exercise capacity and
QOL.332335 No data on HFmrEF are available, but benefits observed in the other groups of HF should also apply to this group.
9.5 Follow-up of chronic heart failure
9.5.1 General follow-up
This is a relatively understudied area. Patients with HF, even if symptoms are well controlled and stable, require follow-up to ensure continued optimization of therapy, to detect asymptomatic progression of
HF or its comorbidities and to discuss any new advances in care. These guidelines recommend follow-up at intervals no longer than 6 months to check symptoms, heart rate and rhythm, BP, full blood count, electrolytes, and renal function. For patients recently discharged from hospital, or in those undergoing uptitration of medication, follow-up intervals should be more frequent. Whether such stable patients need to be followed-up by cardiologists is uncertain. Some studies suggest that follow-up in primary care may be appropriate.303,339 However,
uptake of evidence-based interventions is poor in many settings340,104
and several studies suggest that care and follow-up provided by HF
specialists, and use of quality improvement registries can lead to higher rates of optimal therapy and improved outcomes.341343
An ECG should be done annually to detect QRS prolongation344
as such patients may become candidates for CRT. Furthermore, it may identify conduction disturbances and AF.
Serial echocardiography is generally not necessary, although an echocardiogram should be repeated if there has been a deterioration in clinical status. An echocardiogram is also advised 36 months after optimization of standard therapies for HFrEF to determine the need for addition of newer pharmacological agents and implanted devices.
9.5.2 Monitoring with biomarkers
Trials investigating the use of biomarkers (particularly BNP and/or
NT-proBNP) to guide pharmacotherapy for HFrEF have produced conflicting results.345352 They are undoubtedly good prognostic markers.72,353,354 Conceptually, it is not clear what a biomarkersupported strategy might offer in addition to assiduous application of guideline-recommended therapy. Current evidence, therefore, does not support the routine measurement of BNP or NT-proBNP to guide titration of therapy.
9.6 Telemonitoring
Telemonitoring enables patients to provide, remotely, digital health information to support and optimize their care. Data such as
Table 12
Continued
Education topic
Goal for the patient and caregiver
Professional behaviour and educational tools
To recognise that the carer or family members may be greatly affected and need to seek help.
Family and informal caregivers
To be able to ask for support.
Discuss the preference of caregiver/family involvement.
Involve patients and caregivers in a respectful way.
CMP = cardiomyopathy; CV = cardiovascular; HF = heart failure.
a1 unit is 10 mL of pure alcohol (e.g., 1 glass of wine, 1=2 pint of beer, 1 measure of spirit).
Recommendations for exercise rehabilitation in patients with chronic heart failure
Recommendations
Classa
Levelb
Exercise is recommended for all patients who are able in order to improve exercise capacity, QOL,
and reduce HF hospitalization.c 324328,335337
I
A
A supervised, exercise-based, cardiac rehabilitation programme should be considered in patients with more severe disease, frailty, or with comorbidities.95,324327,338
IIa
C
HF = heart failure; QOL = quality of life.
aClass of recommendation.
bLevel of evidence.
cIn those who are able to adhere to the exercise programme.
ESC 2021
ESC 2021


<!-- PAGE 39 -->

### Page 39

.................
symptoms, weight, heart rate, and BP, can be collected frequently,
stored in an electronic health record and used to guide patients
(directly or through a healthcare professional), to adjust therapy or to seek further advice. Home telemonitoring (HTM) can help maintain quality of care, facilitate rapid access to care when needed,
reduce patient travel costs, and minimize the frequency of clinic visits.355 Enforced cessation of face-to-face consultations in many countries during the recent COVID-19 pandemic have highlighted some of the potential advantages of HTM.356
Trials of HTM are diverse. Patients are usually required to make measurements and, as for many other aspects of HF management,
adherence may be incomplete. HTM may be provided as a local,
regional, or national service. Systems that focus on optimizing management rather than detecting and managing medical emergencies need only to be staffed during standard working hours.
Some systems are designed also to offer support at any time requested by the patient. The comparative effectiveness and cost effectiveness of each strategy is uncertain. Systems that focus on continuous optimization of care (a health maintenance approach)
rather than trying to anticipate and manage episodes of worsening
(a strategy that is plagued by a large number of false-positive alerts), appear more successful.357 HTM is an efficient method for providing patient education and motivation and aiding delivery of care, but it should be adapted to work in synergy with existing healthcare provision.358
A Cochrane systematic review conducted in 2017 identified 39
relevant trials of HTM, largely based on assessments of symptoms,
weight, heart rate and rhythm, and BP and found that HTM was associated with a reduction in all-cause mortality of 20% and HF hospitalization of 37%.359 Since then, several neutral trials and at least one positive trial have been published.357,360364 These are unlikely to change the positive results of the systematic review. Importantly, if social distancing and the ‘green’ agenda are important, HTM only needs to show that it is not inferior to contemporary methods of delivering care to be an appropriate means of supporting care.356
Whether wearable technologies for monitoring heart rate and rhythm or lung congestion (bio-impedance or lung radar) offer additional benefits to conventional
HTM
described above is uncertain.365367
Many implanted therapeutic devices can provide, wirelessly and remotely, information either on the device itself (generator and lead function), arrhythmias, or on patient physiology (heart rate, activity,
heart sounds, bio-impedance). There is strong evidence that monitoring can detect device malfunction earlier than by conventional monitoring and that it may be useful for detecting arrhythmias such as AF. However, there is little evidence that device monitoring reduces admissions for HF or mortality.368370,371
Devices that only provide a monitoring function are also available.
Implantable loop-recorders can be injected subcutaneously and used to monitor heart rate and rhythm, activity, and bio-impedance.
Monitoring devices can also be placed in the pulmonary artery to monitor pressure wirelessly, although the external reader required to detect the device signal is rather bulky and requires patient cooperation. A rise in diastolic pulmonary artery pressure may be one of the earliest signs of congestion. A preliminary, but fairly substantial,
trial showed a reduction in the risk of recurrent HF hospitalization.372
A much larger trial has completed recruitment (GUIDE-HF).373
Thus, non-invasive HTM may be considered for patients with HF
in order to reduce the risk of recurrent CV and HF hospitalizations and CV death; further evidence on management guided by implanted systems is awaited.374
10 Advanced heart failure
10.1 Epidemiology, diagnosis, and prognosis
Many patients with HF progress into a phase of advanced HF, characterized by persistent symptoms despite maximal therapy.375377 The prevalence of advanced HF is increasing due to the growing number of patients with HF, ageing of the population, and better treatment and survival of HF. Prognosis remains poor, with a 1-year mortality ranging from 25% to 75%.378380
The updated HFA-ESC 2018 criteria for the definition of advanced
HF are reported in Table 13.376 A severely reduced LVEF is common but not required for a diagnosis of advanced HF as it may develop in patients with HFpEF as well. In addition to the reported criteria,
extra-cardiac organ dysfunction due to HF (e.g. cardiac cachexia,
liver or kidney dysfunction) or type II pulmonary hypertension may be present, but are not required for the definition of advanced
HF.376
The Interagency Registry for Mechanically Assisted Circulatory
Support (INTERMACS) profiles, developed to classify patients with a potential indication for durable MCS devices, describes clinical parameters and characteristics consistent with a need for advanced therapies (Table 14).381 This classification has also been shown to be useful in estimating the prognosis of patients undergoing urgent heart transplantation382 or LV assist device (LVAD)
implantation,383 and for risk assessment in ambulatory advanced
HF patients.384
Prognostic stratification is important to identify the ideal time for referral to an appropriate centre (i.e. one capable of providing advanced HF therapies), to properly convey expectations to patients and families, and to plan treatment and follow-up strategies
Recommendations for telemonitoring
Recommendations
Classa
Levelb
Non-invasive HTM may be considered for patients with HF in order to reduce the risk of recurrent CV and HF hospitalizations and CV
death.374
IIb
B
Monitoring of pulmonary artery pressure using a wireless haemodynamic monitoring system may be considered in symptomatic patients with HF
in order to improve clinical outcomes.372
IIb
B
CV = cardiovascular; HF = heart failure; HTM = home telemonitoring; LVEF = left ventricular ejection fraction.
aClass of recommendation.
bLevel of evidence.
ESC 2021
............................................................................................................................................................
ESC Guidelines
3637


<!-- PAGE 40 -->

### Page 40

Table 13
Criteria for deﬁnition of advanced heart failure
All the following criteria must be present despite optimal medical treatment:
1. Severe and persistent symptoms of heart failure [NYHA class III (advanced) or IV].
2. Severe cardiac dysfunction deﬁned by at least one of the following:
• LVEF <_30%
• Isolated RV failure (e.g., ARVC)
• Non-operable severe valve abnormalities
• Non-operable severe congenital abnormalities
• Persistently high (or increasing) BNP or NT-proBNP values and severe LV diastolic dysfunction or structural abnormalities (according to the deﬁnitions of HFpEF).
3. Episodes of pulmonary or systemic congestion requiring high-dose i.v. diuretics (or diuretic combinations) or episodes of low output requiring inotropes or vasoactive drugs or malignant arrhythmias causing >1 unplanned visit or hospitalization in the last 12 months.
4. Severe impairment of exercise capacity with inability to exercise or low 6MWT distance (<300 m) or pVO2 <12 mL/kg/min or <50% predicted value,
estimated to be of cardiac origin.
6MWT = 6-minute walk test; ARVC = arrhythmogenic right ventricular cardiomyopathy; BNP = B-type natriuretic peptide; HFpEF = heart failure with preserved ejection fraction; i.v. = intravenous; LV = left ventricular; LVEF = left ventricular ejection fraction; NT-proBNP = N-terminal pro-B-type natriuretic peptide; NYHA = New York Heart
Association; pVO2 = peak oxygen consumption; RV = right ventricular. Modiﬁed from 376.
ESC 2021
Table 14
Interagency Registry for Mechanically Assisted Circulatory Support proﬁle descriptions of patients with advanced heart failure
Profile
Time frame for intervention
Proﬁle 1. Critical cardiogenic shock
Patient with life-threatening hypotension despite rapidly escalating inotropic support,
critical organ hypoperfusion, often conﬁrmed by worsening acidosis and/or lactate levels. “Crash and burn.”
Deﬁnitive intervention needed within hours.
Proﬁle 2. Progressive decline
Patient with declining function despite i.v. inotropic support, may be manifest by worsening renal function, nutritional depletion, inability to restore volume balance. “Sliding on inotropes.” Also describes declining status in patients unable to tolerate inotropic therapy.
Deﬁnitive intervention needed within few days.
Proﬁle 3. Stable on inotrope or inotrope-dependent
Patient with stable blood pressure, organ function, nutrition, and symptoms on continuous i.v. inotropic support (or a temporary circulatory support device or both) but demonstrating repeated failure to wean from support due to recurrent symptomatic hypotension or renal dysfunction. “Dependent stability.”
Deﬁnitive intervention elective over a period of weeks to few months.
Proﬁle 4. Frequent Flyer
Patient can be stabilized close to normal volume status but experiences daily symptoms of congestion at rest or during activities of daily living. Doses of diuretics generally ﬂuctuate at very high levels. More intensive management and surveillance strategies should be considered, which may in some cases reveal poor compliance that would compromise outcomes with any therapy. Some patients may shuttle between 4 and 5.
Deﬁnitive intervention elective over a period of weeks to few months.
Proﬁle 5. Housebound
Comfortable at rest and with activities of daily living but unable to engage in any other activity, living predominantly within the house. Patients are comfortable at rest without congestive symptoms, but may have underlying refractory elevated volume status, often with renal dysfunction. If underlying nutritional status and organ function are marginal,
patients may be more at risk than INTERMACS 4, and require deﬁnitive intervention.
Variable urgency, depends upon maintenance of nutrition,
organ function, and activity.
Proﬁle 6. Exertion limited
Patient without evidence of ﬂuid overload, comfortable at rest and with activities of daily living and minor activities outside the home but fatigues after the ﬁrst few minutes of any meaningful activity. Attribution to cardiac limitation requires careful measurement of peak oxygen consumption, in some cases with haemodynamic monitoring, to conﬁrm severity of cardiac impairment. “Walking wounded.”
Variable, depends upon maintenance of nutrition, organ function, and activity level.
Continued


<!-- PAGE 41 -->

### Page 41

................................................................................................................
(Figure 4).376 Patients with contraindications to MCS or heart transplantation should be considered for palliative care (see section 10.2.4).
Despite many prognostic parameters (Supplementary Table 13),
predicting outcomes remains difficult and patients are often referred to advanced HF centres too late. Identifying warning signs in patients with non-advanced symptoms may allow early referral so that MCS
and heart transplantation may be offered before the development of end-organ failure (Figure 5; Supplementary Table 14).376,386 An organizational model between centres with different levels of care complexity, based on a ‘Hub and Spoke’ network is the key to good patient management.376
10.2 Management
In patients with advanced HF, pharmacological therapy and shortterm MCS may be needed until the implantation of long-term MCS
or heart transplantation becomes available.
10.2.1
Pharmacological therapy and renal replacement
Inotropes may improve haemodynamic parameters, reducing congestion, augmenting cardiac output, and aiding peripheral perfusion.
Although not proven, this may help to prevent worsening end-organ function. Conversely, traditional inotropes may favor myocardial ischaemia and/or tachyarrhythmias and worsen the clinical course.387,388 They can be used as palliative therapy for the relief of symptoms in patients without other treatment options. Intermittent long-term use of inotropes may be considered in outpatients to improve functional class and QOL.389,390
Kidney dysfunction and loop diuretic resistance often characterize the clinical course of patients with advanced HF. Doubling of the loop diuretic dose is proposed, in the first instance, followed by concomitant administration of thiazides or metolazone (see section
11.3.3).145 In patients who fail to respond to diuretic-based strategies,
renal replacement therapies should be considered. Ultrafiltration is one of the most common approaches. It may be considered in those with diuretic resistance even if data about its effects on outcomes are unsettled.391,392
10.2.2
Mechanical circulatory support
MCS can improve survival and symptoms of patients with advanced
HF.376,393 The use of MCS should be considered for the different scenarios listed in Table 15. Indications for short- and long-term MCS
should be based on the INTERMACS profiles (Table 14, Figure 4).
Short-term mechanical circulatory support
Short-term MCS devices are indicated to reverse critical endorgan hypoperfusion and hypoxia in the setting of cardiogenic shock. They can be used for a short, limited, period of time, from a few days up to several weeks. The aim is to support the central nervous system and organ perfusion, to reverse acidosis and multi-organ failure until the patient’s outcome becomes clearer be that of cardiac recovery, transition to durable MCS or heart transplantation, or, in some cases, towards a more palliative approach. The care of patients on short-term MCS is complex and requires dedicated expertise including having specific plans for stopping support when neither cardiac nor brain injury recovers.
Short-term MCS should be used in patients with INTERMACS
profiles 1 or 2 as a bridge to decision (BTD), bridge to recovery
(BTR), bridge to bridge (BTB) for either long-term MCS or urgent heart transplantation (Figure 4).394 Further details about shortterm MCS are reported in the Supplementary text 11.4.
Long-term mechanical circulatory support
Long-term MCS is indicated in selected patients when MT is insufficient or when short-term MCS has not led to cardiac recovery or clinical improvement, to prolong life and improve QOL, or to keep the patient alive until transplantation (bridge to transplantation, BTT)
or to reverse contraindications to heart transplantation (bridge to candidacy, BTC), or as destination therapy (DT) (Table 15).
Long-term
MCS
should be considered in patients with
INTERMACS profiles 2 to 4 and also in patients with INTERMACS
Table 14
Continued
Profile
Time frame for intervention
Proﬁle 7. Advanced NYHA class III symptoms
Patient without current or recent episodes of unstable ﬂuid balance, living comfortably with meaningful activity limited to mild physical exertion.
Heart transplantation or MCS may not be currently indicated.
Modiﬁers for proﬁles
Possible proﬁles that can be modiﬁed
Temporary MCS can modify proﬁle only in hospitalized patients. They include IABP,
ECMO, TandemHeart, LVAD, Impella.
1, 2, 3
Arrhythmia can modify any proﬁle. They include recurrent ventricular tachyarrhythmias that have recently contributed substantially to clinical compromise, frequent ICD shocks or requirement for external deﬁbrillation, usually more than twice weekly.
17
Frequent episodes of HF decompensation characterize patients requiring frequent emergency visits or hospitalizations for diuretics, ultraﬁltration, or temporary i.v. vasoactive therapy. Frequent episodes may be considered as at least two emergency visits/
admissions in the past 3 months or three in the past 6 months.
3 if at home, 4, 5, 6. Rarely for proﬁle 7.
ECMO = extracorporeal membrane oxygenation; HF = heart failure; IABP = intra-aortic balloon pump; ICD = implantable cardioverter-deﬁbrillator; INTERMACS = Interagency
Registry for Mechanically Assisted Circulatory Support; i.v. = intravenous; LVAD = left ventricular assist device; MCS = mechanical circulatory support; NYHA = New York
Heart Association. Modiﬁed from 381.
ESC 2021
ESC Guidelines
3639


<!-- PAGE 42 -->

### Page 42

Management of patients with advanced heart failurea
Weaning from
MCS support
LVAD-DT
(Class IIa)
List for HT or de-listing with very close follow-up in case of meaningful improvement
(Class I)
Withdrawal of
MCS support
Advanced HF
therapies
(HT/LVAD) can be deferred.
Very close follow-up
Contraindications for HT
N
Cardiac,
neurological and end-organ recovered
Neurological and end-organ recovered but no cardiac recovery
Persistence of severe brain damage and severe irreversible end-organ damage
Potentially reversible
High riskb
Contraindication reversed
LVAD-BTC
(Class IIa)
Short-term MCS
BTD/BTR/BTB/BTT
(Class IIa)
INTERMACS
>4 “Stable ambulatory”
INTERMACS
3–4
INTERMACS
2
INTERMACS
1
Y
N
Y
Y
Y
N
N
Figure 4 Algorithm for the treatment of patients with advanced heart failure. BTB = bridge to bridge; BTC= bridge to candidacy; BTD= bridge to decision; BTR= bridge to recovery; BTT= bridge to transplantation; CA= cardiac amyloidosis; DT= destination therapy; ESC= European Society of
Cardiology; HCM=hypertrophic cardiomyopathy; HF= heart failure; HFA= Heart Failure Association; HT =heart transplantation; INTERMACS =
Interagency Registry for Mechanically Assisted Circulatory Support; LVAD= left ventricular assist device; LVAD-BTC= left ventricular assist device 
bridge to candidacy; LVAD-DT= left ventricular assist device  destination therapy; MCS= mechanical circulatory support. aThis algorithm can be applied to all patients with advanced HF defined according to the ESC/HFA criteria,376 with exception of HCM, CA, arrhythmic storm, adult congenital heart disease, refractory angina. bRecurrent hospitalization, progressive end-organ failure, refractory congestion, inability to perform cardiopulmonary exercise test or peak oxygen consumption <12 mL/min/kg or <50% of expected value.385 Colour code for classes of recommendation: Green for Class of recommendation I and Yellow for Class of recommendation IIa (see Table 1 for further details on classes of recommendation).


<!-- PAGE 43 -->

### Page 43

Any of these characteristics
Very limited life expectancy and/or poor QOL conditions that may impair follow-up and/or worsened prognosis after advanced HF therapies (HT/LT-MCS)a
N
Triage of patients with advanced heart failure and appropriate timing of referral
>1 admission or unplanned visit to HF clinic within last 12 months
Prior inotropic use
Intolerant to beta-blocker or RASi/ARNI
LVEF <20%
Worsening RV function
Worsening renal function
Worsening liver function
Ventricular arrhythmias/ICD shocks
Need for escalating diuretic doses for persistent congestion
SBP <90 mmHg and/or signs of peripheral hypoperfusion
Y
N
NYHA III–IV despite optimal medical therapy
(including ICD/CRT when indicated)
NYHA class II
Manage in local HF service
Refer to or discuss with advanced HF centre
Re-evaluation every
3–6 months
Palliative care
Y
Figure 5 Triage of patients with advanced heart failure and appropriate timing of referral.376 ARNI= angiotensin receptor-neprilysin inhibitor; CRT=
cardiac resynchronization therapy; HF= heart failure; HT= heart transplantation; ICD= implantable cardioverter-defibrillator; LT-MCS= long-term mechanical circulatory support; LVEF= left ventricular ejection fraction; NYHA= New York Heart Association; RASi= renin-angiotensin system inhibitor;
RV= right ventricular; SBP= systolic blood pressure; QOL= quality of life. aLimited life expectancy may be due by major comorbidities such as cancer,
dementia, end-stage organ dysfunction; other conditions that may impair follow-up or worsen post-treatment prognosis include frailty, irreversible cognitive dysfunction, psychiatric disorder, or psychosocial issues.
ESC Guidelines
3641


<!-- PAGE 44 -->

### Page 44

.................................................................................................................
profile 56, when they have high-risk characteristics. Patients with no irreversible end-organ failure other than cardiac, recovering from
INTERMACS level 1 while on short-term MCS, may also qualify for long-term MCS (Figure 4).376,378,383,395402 The characteristics of patients potentially eligible for implantation of an LVAD are reported in Table 16.
The details of the devices and studies on long-term MCS are summarized in Supplementary Table 15.
Current 2-year survival rates in patients receiving the latest continuous-flow LVADs are comparable to those after heart transplantation, although adverse events negatively affect QOL.
Among patients with continuous flow LVADs, actuarial survival was reported of 80% at 1 year and 70% at 2 years.403,404 Two-year survival was 84.5% and survival free of disabling stroke or need of reoperation for LVAD malfunction was 76.9% with a centrifugal-flow
LVAD in MOMENTUM 3.405 The fully magnetically levitated centrifugal-flow LVAD has significantly reduced pump thrombosis. In
MOMENTUM 3, the need for reoperation to replace a malfunctioning device was 2.3% per 24 months, with only 0.6% per 24 months risk of pump replacement because of pump thrombosis. Stroke
(namely, disabling stroke), major bleeding, and gastrointestinal haemorrhage were also lower in the centrifugal-flow pump group than in the axial-flow pump group. However, the incidence of all bleeding events, thromboembolism and driveline infection remained similar to that with older devices.402
Data on fully magnetically centrifugal-flow LVAD use in real-world studies with the 2-year outcomes from the ELEVATE registry showed an overall survival of 74.5%, with gastrointestinal bleeding in
9.7%, stroke in 10.2%, and pump thrombosis in 1.5% of patients.406
According to the IMACS Registry, a new composite endpoint including QOL and adverse events beyond survival was proposed to help in guiding decision making. In this sense ‘living well at one year’
defined as freedom from death, stroke, bleeding requiring operation,
RV assist device, pump replacement, or device-related infection within the first year, was 56.8% after isolated, centrifugal flowLVAD.383
Although now outdated,
REMATCH
was the only
RCT
comparing an LVAD as DT with OMT in patients with advanced HF,
NYHA class IV and a contraindication to transplantation. REMATCH
showed lower all-cause mortality with LVAD therapy when compared with medical treatment (primary endpoint). However, there were high mortality rates at 2 years in both arms.378 Other studies were not randomized (INTrEPID, ROADMAP)396,407,408 or compared different devices (ADVANCE, ENDURANCE, MOMENTUM
3).399,402,409 The two strategies of early LVAD implantation vs. medical treatment with LVAD implantation only after serious deterioration of the patient’s condition are currently being compared in a
Table 15
Terms describing various indications for mechanical circulatory support
Bridge to decision (BTD)/
Bridge to bridge (BTB)
Use of short-term MCS (ECMO or Impella) in patients with cardiogenic shock until haemodynamics and end-organ perfusion are stabilized, contraindications for long-term MCS are excluded (brain damage after resuscitation) and additional therapeutic options including long-term VAD therapy or heart transplant can be evaluated.
Bridge to candidacy (BTC)
Use of MCS (usually LVAD) to improve end-organ function and/or to make an ineligible patient eligible for heart transplantation.
Bridge to transplantation (BTT)
Use of MCS (LVAD, BiVAD or TAH) to keep a patient alive who is otherwise at high risk of death before transplantation until a donor organ becomes available.
Bridge to recovery (BTR)
Use of MCS (short-term or long-term) to keep a patient alive until cardiac function recovers sufﬁciently to remove
MCS.
Destination therapy (DT)
Long-term use of MCS (LVAD) as an alternative to transplantation in patients with end-stage HF ineligible for transplantation.
BiVAD = biventricular assist device; ECMO = extracorporeal membrane oxygenation; HF = heart failure; LVAD = left ventricular assist device; MCS = mechanical circulatory support; TAH = total artiﬁcial heart; VAD = ventricular assist device.
ESC 2021
Table 16
Patients potentially eligible for implantation of a left ventricular assist device
Patients with persistence of severe symptoms despite optimal medical and device therapy, without severe right ventricular dysfunction and/or severe TR, with a stable psychosocial background and absence of major contraindications*, and who have at least one of the following:
 LVEF <25% and unable to exercise for HF or, if able to perform cardiopulmonary exercise testing, with peak VO2 <12 mL/kg/min and/or
<50% predicted value.
 >_3 HF hospitalizations in previous 12 months without an obvious precipitating cause.
 Dependence on i.v. inotropic therapy or temporary MCS.
 Progressive end-organ dysfunction (worsening renal and/or hepatic function, type II pulmonary hypertension, cardiac cachexia) due to reduced perfusion and not to inadequately low ventricular ﬁlling pressure (PCWP >_20 mmHg and SBP <_90 mmHg or cardiac index
<_2 L/min/m2).
HF = heart failure; i.v. = intravenous; LVAD = left ventricular assist device; LVEF =
left ventricular ejection fraction; MCS = mechanical circulatory support; PCWP =
pulmonary capillary wedge pressure; SBP = systolic blood pressure; TR = tricuspid regurgitation; VO2 = oxygen consumption.
*Stable psychosocial background includes demonstrated understanding of the technology and patient living in the same household with a caregiver that will help the patient (i.e. living alone and poor psychosocial background is LVAD contraindication). Major contraindications include contraindication to long-term oral anticoagulation, infection, severe renal dysfunction, ventricular arrhythmias.
ESC 2021


<!-- PAGE 45 -->

### Page 45

......................................................
prospective trial,
Early-VAD
(ClinicalTrials.gov
Identifier:
NCT02387112). Also, the Swedish evaluation of LVAD (SweVAD)
study is comparing the survival of patients with advanced HF ineligible for heart transplantation prospectively randomized to LVAD as DT
vs. MT (ClinicalTrials.gov Identifier: NCT02592499).410
10.2.3
Heart transplantation
Heart transplantation remains the gold standard for the treatment of advanced HF in the absence of contraindications. Post-transplant 1year survival is around 90% with a median survival of 12.5
years.385,411,412 Transplantation significantly improves QOL and functional status, although, for unclear reasons, the percentage of patients returning to work is lower than expected.412 Apart from primary graft dysfunction, the main challenges after heart transplantation relate to either the efficacy or side effects of immunosuppression
(e.g. rejection, infection, cardiac allograft vasculopathy, late graft dysfunction, malignancy, renal failure, hypertension, diabetes mellitus).
Organ donor shortage remains the main limitation to heart transplantation. Thus, the donor heart criteria have now been extended to allow an increased upper limit of the donor age, particularly in
Europe. Moreover, careful recipient selection is needed, based on pre-transplant and post-transplant life expectancy (both are influenced by pre-operative status and comorbidities).
The main indications and contraindications for heart transplantation are listed in Table 17.376,385
Active infection is a relative contraindication to transplant but in some cases of infected LVADs it may actually be an indication. Elderly age is not an absolute contraindication. Although patients aged <65
years might be more appropriate candidates due to their overall life expectancy, most programmes accept patients up to 70 years of age,
and biological age as well as chronological age must be taken into account. Surgical complexity [previous sternotomies, mediastinal radiation, adult congenital heart disease (ACHD)] should also be considered.
The decision pathway to transplantation or LVAD is never straightforward and is unique to each patient. Eligibility for each option may change according to the particular conditions of each patient, which may also change over time. Other factors, not related to the patient, such as time on the heart transplant waiting list, the
Table 17
Heart transplantation: indications and contraindications
Indications
Advanced HF376
No other therapeutic option, except for LVAD as BTT
Contraindications
Active infectiona
Severe peripheral arterial or cerebrovascular disease
Pharmacologic irreversible pulmonary hypertension (LVAD should be considered to reverse elevated pulmonary vascular resistance with subsequent re-evaluation to establish candidacy)
Malignancy with poor prognosis (a collaboration with oncology specialists should occur to stratify each patient as regards their risk of tumour progression or recurrence which increases with the use of immunosuppression)
Irreversible liver dysfunction (cirrhosis) or irreversible renal dysfunction
(e.g. creatinine clearance <30 mL/min/1.73 m2). Combined heart-liver or heart-kidney transplant may be considered
Systemic disease with multiorgan involvement
Other serious comorbidity with poor prognosis
Pre-transplant BMI >35 kg/m2 (weight loss is recommended to achieve a
BMI <35 kg/m2)
Current alcohol or drug abuse
Psychological instability that jeopardizes proper follow-up and intensive therapeutic regime after heart transplantation
Insufﬁcient social supports to achieve compliant care in the outpatient setting
BMI = body mass index; BTT = bridge to transplantation; HF = heart failure;
LVAD = left ventricular assist device.
aActive infection is a relative contraindication to transplant although in some cases of infected LVADs it may actually be an indication.
Adapted from Crespo-Leiro et al.376
Recommendations for the treatment of patients with advanced heart failure
Recommendations
Classa
Levelb
Patients being considered for long-term MCS must have good compliance, appropriate capacity for device handling and psychosocial support.414416
I
C
Heart transplantation is recommended for patients with advanced HF, refractory to medical/device therapy and who do not have absolute contraindications.
I
C
Long-term MCS should be considered in patients with advanced HFrEF despite optimal medical and device therapy, not eligible for heart transplantation or other surgical options, and without severe right ventricular dysfunction, to reduce the risk of death and improve symptoms.378,396,397,401,402,404,417
IIa
A
Long-term MCS should be considered in patients with advanced HFrEF refractory to optimal medical and device therapy as a bridge to cardiac transplantation in order to improve symptoms,
reduce the risk of HF hospitalization and the risk of premature death.398400,402,404
IIa
B
Renal replacement therapy should be considered in patients with refractory volume overload and end-stage kidney failure.
IIa
C
Continuous inotropes and/or vasopressors may be considered in patients with low cardiac output and evidence of organ hypoperfusion as bridge to MCS or heart transplantation.389,390
IIb
C
Ultraﬁltration may be considered in refractory volume overload unresponsive to diuretic treatment.391,392
IIb
C
HF = heart failure; HFrEF = heart failure with reduced ejection fraction; MCS =
mechanical circulatory support.
aClass of recommendation.
bLevel of evidence.
ESC 2021
ESC 2021
........................................................................................................................
ESC Guidelines
3643


<!-- PAGE 46 -->

### Page 46

.......................................................................................................................................................................
centre’s surgical experience, and resources, can also influence decision making.413
10.2.4
Symptom control and end-of-life care
While the disease trajectory of each patient with HF is unique, there is a generalizable pattern of gradual decline, punctuated by episodes of acute deterioration leading either to sudden death or death due to progressive HF. Communication about the disease trajectory and anticipatory planning should start when a patient is diagnosed with advanced HF. Indications for and key components of a palliative care service are reported in Tables 18 and 19.312,418
A team-based approach to palliative and end-of-life care for patients with HF has been proposed.419 Specific models of palliative care for patients with advanced HF have been also reported. They reduce hospitalizations, without a clear effect on survival, and have some effects on QOL and symptom burden.420,421
Symptom assessment should be performed on a regular basis. In addition to clinical assessment, symptoms can be assessed using the Numeric Rating Scale, the Edmonton Symptom Assessment
Scale (ESAS) or ESAS-HF, or the Integrated Palliative care Outcome
Scale.
Treatment for symptoms needs to be considered and might include additional intervention on top of OMT:
• Breathlessness: repeat doses of opioids may be considered for the relief of dyspnoea; however, their effectiveness is not demonstrated.422,423 While using opioids, all patients should be guided about opioid side effects such as constipation and nausea, urinary retention, and mental status changes. Benzodiazepines may be considered as a second- or third-line treatment, when opioids and non-pharmacological measures have failed to control breathlessness. Increasing the inspired oxygen concentration may provide relief of dyspnoea.
• Pain: non-pharmacologic management can be helpful. In addition,
opioid, oxycodone, hydromorphone, and fentanyl are generally viewed as safe options and can be provided orally, intravenously,
and transdermally, especially in the hospital or in patient palliative care or hospice setting.424
• Anxiety and depression: adequate conventional treatment should be offered.
Proactive decisions and advanced planning with regard to palliative and end-of-life care discussions should be documented, regularly reviewed, and routinely communicated to all those involved in the patient’s care. Healthcare providers should make sure that patients’
and carer preferences are followed, wherever possible. They should also take into account that patients may choose not to, or may not be in a position to, express preferences (e.g. due to symptoms of depression or cognitive impairment).
11 Acute heart failure
11.1 Epidemiology, diagnosis and prognosis
AHF refers to rapid or gradual onset of symptoms and/or signs of
HF, severe enough for the patient to seek urgent medical attention, leading to an unplanned hospital admission or an emergency department visit. Patients with AHF require urgent evaluation with subsequent initiation or intensification of treatment, including i.v. therapies or procedures. AHF is a leading cause of hospitalizations in subjects aged >65 years and is associated with high mortality and rehospitalization rates. In-hospital mortality ranges from 4% to 10%.425428 Post-discharge 1-year mortality can be
2530% with up to more than 45% deaths or readmission rates.104,426,427,429,430
AHF may be the first manifestation of HF (new onset) or, more frequently, be due to an acute decompensation of chronic HF.
Compared to patients with acutely decompensated CHF, those with new onset HF may have a higher in-hospital mortality425 but have lower post-discharge mortality and rehospitalization rates.425,428,431,432 Specific extrinsic factors may precipitate, but not cause, AHF in patients with pre-existing cardiac dysfunction
(Supplementary Table 16). Clinical severity and in-hospital trajectory are determined by the complex interplay between precipitants,
the underlying cardiac substrate,
and the patient’s comorbidities.
Table 18
Patients with heart failure in whom end-of-life care should be considered
Progressive functional decline (physical and mental) and dependence in most activities of daily living.
Severe heart failure symptoms with poor QOL despite optimal pharmacological and non-pharmacological therapies.
Frequent admissions to hospital or other serious episodes of decompensation despite optimal treatment.
Heart transplantation and MCS ruled out.
Cardiac cachexia.
Clinically judged to be close to end of life.
MCS = mechanical circulatory support; QOL = quality of life.
Table 19
Key components of palliative care service in patients with advanced heart failure
Focus on improving or maintaining the QOL of a patient and his/her family as well as possible until he/she dies.
Frequent assessment of symptoms (including dyspnoea and pain) resulting from advanced heart failure and other comorbidities and focus on symptom relief.
Access for the patient and his/her family to psychological support and spiritual care according to need.
Advanced care planning, taking into account preferences for place of death and resuscitation (which may include deactivating devices, such as
ICD or long-term MCS that may require a multidisciplinary team decision).
ICD = implantable cardioverter-deﬁbrillator; MCS = mechanical circulatory support; QOL = quality of life.
ESC 2021
ESC 2021


<!-- PAGE 47 -->

### Page 47

.........................................
The diagnostic workup of AHF starts at the time of the first medical contact, and is continued throughout the initial patient pathway,
aiming to identify the clinical presentation and to diagnose and manage any potentially reversible causes/precipitants/coexisting life-threatening conditions in a timely manner (Figure 6). Diagnostic tests are outlined at Table 20. In addition to clinical signs and symptoms, diagnostic workup includes ECG and echocardiography, if possible. Additional investigations, i.e. chest X-ray and lung ultrasound may be used to confirm AHF diagnosis, especially when NP testing is not available. Plasma NP levels (BNP or NT-proBNP or MRproANP) should be measured if the diagnosis is uncertain and a point-of-care assay is available. Normal concentrations of NPs make the diagnosis of AHF unlikely. Cut-offs for acute HF are: BNP <100
pg/mL, NT-proBNP <300 pg/mL and MR-proANP <120 pg/
mL.74,433435 However, elevated NP values are associated with a wide range of cardiac and non-cardiac conditions (Table 6). Low concentrations can be detected in some patients with advanced decompensated end-stage HF, obesity, flash pulmonary oedema or rightsided AHF. Higher levels can be found in the patients with concomitant AF and/or reduced renal function.74
Among other laboratory tests, troponin is useful for the detection of acute coronary syndrome (ACS) although elevated levels are detected in the vast majority of patients with AHF.436438 Blood urea nitrogen or urea, serum creatinine, electrolytes (sodium, potassium,
chloride), and antigen carbohydrate 125 may help tailor treatment.439,440 Detection of abnormal liver function identifies patients
Diagnostic workup of new onset acute heart failure
Electrocardiogram
Pulse oximetry
Echocardiography
Initial laboratory investigationsa
Chest X-ray
Lung ultrasound
Other specific evaluationsb
Patient history, signs and/or symptoms suspected of acute HF
Natriuretic peptide testing
BNP <100 pg/mL
NT-proBNP <300 pg/mL
MR-proANP <120 pg/mL
BNP ≥ 100 pg/mL
NT-proBNP ≥300 pg/mLc
MR-proANP ≥120 pg/mL
Acute heart failure ruled out
Acute heart failure confirmed
Comprehensive echocardiography
Figure 6 Diagnostic workup of new onset acute heart failure. ACS = acute coronary syndrome; BNP= B-type natriuretic peptide; CT= computed tomography; HF= heart failure; MR-proANP= mid-regional pro-atrial natriuretic peptide; NT-proBNP= N-terminal pro-B-type natriuretic peptide; TSH
= thyroid-stimulating hormone. aInitial laboratory exams include troponin, serum creatinine, electrolytes, blood urea nitrogen or urea, TSH, liver function tests as well as D-dimer and procalcitonin when pulmonary embolism or infection are suspected, arterial blood gas analysis in case of respiratory distress,
and lactate in case of hypoperfusion. bSpecific evaluation includes coronary angiography, in case of suspected ACS, and CT in case of suspected pulmonary embolism. cRule-in values for the diagnosis of acute HF: >450 pg/mL if aged <55 years, >900 pg/mL if aged between 55 and 75 years and >1800 pg/mL if aged >75 years.433,434
ESC Guidelines
3645


<!-- PAGE 48 -->

### Page 48

.......................................
with a poor prognosis.441 Since both hypothyroidism and hyperthyroidism may precipitate AHF, thyroid-stimulating hormone (TSH)
should be assessed in those with newly diagnosed AHF. Arterial blood gas analysis should be performed when a precise measurement of O2 and CO2 partial pressure is needed (i.e. patients with respiratory distress). Lactate and pH levels should be measured in patients with cardiogenic shock. D-dimer should be measured when acute pulmonary embolism is suspected. Procalcitonin may be used for the diagnosis of pneumonia and antibiotic therapy may have an indication when plasma levels are >0.2 lg/L. However, no impact of a strategy based on routine procalcitonin measurements on outcomes was shown in a prospective, controlled, trial.442 Pulse oximetry should be measured routinely at the time of first presentation of patients with
AHF and continuous monitoring may be needed in the first hours or days.443,444
11.2 Clinical presentations
Four major clinical presentations can be described with possible overlaps between them (Table 21).1,425,445 Clinical presentations are mainly based on the presence of signs of congestion and/or peripheral hypoperfusion and require different treatments
(Table
21).1,425427,432,446,447
11.2.1
Acute decompensated heart failure
Acute decompensated heart failure (ADHF) is the most common form of AHF, accounting for 5070% of presentations.426,427,432 It
Table 20
Diagnostic tests in patients with acute heart failure
Exam
Time of measurement
Possible findings
Diagnostic value for
AHF
Indication
ECG
Admission, during hospitalization,a,b pre-discharge
Arrhythmias, myocardial ischaemia
Exclusion of ACS or arrhythmias
Recommended
Chest-X ray
Admission, during hospitalizationa
Congestion, lung infection
Conﬁrmatory
May be considered
LUS
Admission, during hospitalization,a pre-discharge
Congestion
Conﬁrmatory
May be considered
Echocardiography
Admission, during hospitalization,a pre-discharge
Congestion, cardiac dysfunction, mechanical causes
Major
Recommended
Natriuretic peptides
(BNP, NT-proBNP,
MR-proANP)
Admission, pre-discharge
Congestion
High negative predictive value
Recommended
Serum troponin
Admission
Myocardial injury
Exclusion of ACS
Recommended
Serum creatinine
Admission, during hospitalization,a pre-discharge
Renal dysfunction
None
Recommended for prognostic assessment
Serum electrolytes
(sodium, potassium,
chloride)
Admission, during hospitalization,a pre-discharge
Electrolyte disorders
None
Recommended for prognostic assessment and treatment
Iron status (transferrin,
ferritin)
Pre-discharge
Iron depletion
None
Recommended for prognostic assessment and treatment
TSH
Admission
Hypo- hyperthyroidism
None
Recommended when hypohyperthyroidism is suspected
D-dimer
Admission
Pulmonary embolism
Useful to exclude pulmonary embolism
Recommended when pulmonary embolism is suspected
Procalcitonin
Admission
Pneumonia
Useful for diagnosis of pneumonia
May be done when pneumonia is suspected
Lactate
Admission, during hospitalizationa
Lactic acidosis
Useful to assess perfusion status
Recommended when peripheral hypoperfusion is suspected
Pulse oximetry and arterial blood gas analysis
Admission, during hospitalizationa
Respiratory failure
Useful to assess respiratory function
Recommended when respiratory failure is suspected
ACS = acute coronary syndrome; AHF = acute heart failure; BNP = B-type natriuretic peptide; ECG = electrocardiogram; LUS = lung ultrasound; MR-proANP = mid-regional pro-atrial natriuretic peptide; NT-proBNP = N-terminal pro-B-type natriuretic peptide; TSH = thyroid-stimulating hormone.
aBased on clinical conditions.
bContinuous ECG monitoring can be considered based on clinical conditions.
ESC 2021


<!-- PAGE 49 -->

### Page 49

..................................................................................
usually occurs in patients with history of HF and previous cardiac dysfunction across the spectrum of LVEF and may include RV dysfunction. Distinct from the acute pulmonary oedema phenotype, it has a more gradual onset, and the main alteration is progressive fluid retention responsible for systemic congestion. Sometimes,
congestion is associated with hypoperfusion.426 The objectives of treatment are identification of precipitants, decongestion, and in rare instances, correction of hypoperfusion (Figure 7).
11.2.2
Acute pulmonary oedema
Acute pulmonary oedema is related to lung congestion. Clinical criteria for acute pulmonary oedema diagnosis include dyspnoea with orthopnoea, respiratory failure (hypoxaemia-hypercapnia), tachypnoea, >25 breaths/min, and increased work of breathing.448
Three therapies should be commenced, if indicated. First, oxygen,
given as continuous positive airway pressure, non-invasive positivepressure-ventilation and/or high-flow nasal cannula, should be started. Second, i.v. diuretics should be administered, and third, i.v.
vasodilators may be given if systolic BP (SBP) is high, to reduce LV
afterload (Figure 8). In a few cases of advanced HF, acute pulmonary oedema may be associated with low cardiac output and, in this case,
inotropes, vasopressors, and/or MCS are indicated to restore organ perfusion.
11.2.3
Isolated right ventricular failure
RV failure is associated with increased RV and atrial pressure and systemic congestion. RV failure may also impair LV filling, and ultimately reduce systemic cardiac output, through ventricular interdependence.449
Diuretics are often the first option of therapy for venous congestion. Noradrenaline and/or inotropes are indicated for low cardiac output and haemodynamic instability. Inotropes reducing cardiac filling pressures may be preferred (i.e. levosimendan, phosphodiesterase type III inhibitors). Since inotropic agents may aggravate arterial hypotension, they may be combined with norepinephrine if needed
(Figure 9).449
11.2.4
Cardiogenic shock
Cardiogenic shock is a syndrome due to primary cardiac dysfunction resulting in an inadequate cardiac output, comprising a lifethreatening state of tissue hypoperfusion, which can result in multiorgan failure and death.450452 Cardiac insult causing severe impairment of cardiac performance may be acute, as a result of the acute loss of myocardial tissue (acute MI, myocarditis) or may be progressive as seen in patients with chronic decompensated HF who may experience a decline in disease stability as a result of the natural progression of advanced HF and/or specific precipitants.426
Diagnosis of cardiogenic shock mandates the presence of clinical signs of hypoperfusion, such as cold sweated extremities, oliguria, mental confusion, dizziness, narrow pulse pressure. In addition, biochemical manifestations of hypoperfusion, elevated serum creatinine, metabolic acidosis and elevated serum lactate are present and reflect tissue hypoxia and alterations of cellular
Table 21
Clinical presentations of acute heart failure
Acute decompensated heart failure
Acute pulmonary oedema
Isolated right ventricular failure
Cardiogenic shock
Main mechanisms
LV dysfunction
Sodium and water renal retention
Increased afterload and/or predominant LV diastolic dysfunction
Valvular heart disease
RV dysfunction and/or pre-capillary pulmonary hypertension
Severe cardiac dysfunction
Main cause of symptoms
Fluid accumulation, increased intraventricular pressure
Fluid redistribution to the lungs and acute respiratory failure
Increased central venous pressure and often systemic hypoperfusion
Systemic hypoperfusion
Onset
Gradual (days)
Rapid (hours)
Gradual or rapid
Gradual or rapid
Main haemodynamic abnormalities
Increased LVEDP and PCWPa
Low or normal cardiac output
Normal to low SBP
Increased LVEDP and
PCWPa
Normal cardiac output
Normal to high SBP
Increased RVEDP
Low cardiac output
Low SBP
Increased LVEDP and
PCWPa
Low cardiac output
Low SBP
Main clinical presentations1,446
Wet and warm OR Dry and cold
Wet and warmb
Dry and cold OR Wet and cold
Wet and cold
Main treatment
Diuretics
Inotropic agents/vasopressors
(if peripheral hypoperfusion/hypotension)
Short-term MCS or RRT if needed
Diuretics
Vasodilatorsb
Diuretics for peripheral congestion
Inotropic agents/vasopressors (if peripheral hypoperfusion/hypotension)
Short-term MCS or RRT if needed
Inotropic agents/
vasopressors
Short-term MCS
RRT
LV = left ventricular; LVEDP = left ventricular end-diastolic pressure; MCS = mechanical circulatory support; PCWP = pulmonary capillary wedge pressure; RV = right ventricular;
RVEDP = right ventricular end-diastolic pressure; RRT = renal replacement therapy; SBP = systolic blood pressure.
aMay be normal with low cardiac output.
bWet and cold proﬁle with need of inotropes and/or vasopressors may rarely occur.
ESC 2021
ESC Guidelines
3647


<!-- PAGE 50 -->

### Page 50

.................
metabolism leading to organ dysfunction.437,453 Of note, hypoperfusion is not always accompanied by hypotension, as BP may be preserved by compensatory vasoconstriction (with/without pressor agents), albeit at the cost of impaired tissue perfusion and oxygenation.426,427,450,454
Management of cardiogenic shock should start as early as possible. Early identification and treatment of the underlying cause,
concomitant with haemodynamic stabilization and management of organ dysfunction, are key components of its management (Figure
10, Supplementary text 11.1; Supplementary Figure 2).
N
Management of patients with acute decompensated heart failure
Congestion/Fluid overload
Y
Hypoperfusion
Medical therapy optimization
(Class I)
Loop diureticsa
(Class I)
Loop diureticsa (Class I)
and consider inotropes (Class IIb)
Congestion relief
Hypoperfusion and congestion relief
N
Increase diuretic doses
(Class I) and/or combine diuretics (Class IIa)   
Consider vasopressors
(Class IIb)
(i.e. norepinephrine)
Diuretic resistance or end-stage renal failure
Persistent hypoperfusion
Organ damage
N
N
Y
Renal replacement therapy
(Class IIa)
OR
Consider palliative care
MCS
(Class IIa)
AND/OR
Renal replacement therapy
(Class IIa)
OR
Consider palliative care
N
Y
Y
Y
N
Figure 7 Management of acute decompensated heart failure. MCS= mechanical circulatory support. aAdequate diuretic doses to relieve congestion and close monitoring of diuresis is recommended (see Figure13) regardless of perfusion status.


<!-- PAGE 51 -->

### Page 51

....................................................
11.3 Management
11.3.1
General aspects
Management can be subdivided in three stages (pre-hospital, in-hospital, and pre-discharge), having different goals and requiring different approaches (Figure 11).
Pre-hospital phase
In the pre-hospital setting, AHF patients should benefit from noninvasive monitoring, including pulse oximetry, BP, heart rate respiratory rate, and a continuous ECG, instituted within minutes of patient contact and in the ambulance if possible.305 Oxygen therapy may be given based on clinical judgment unless oxygen saturation is <90% in which case it should be administered. In patients with respiratory distress, respiratory rate >25 breaths/min, oxygen saturation <90%,
non-invasive ventilation should be initiated.444,448 Although therapeutic tools may be available in the prehospital setting, whether more effective pre-hospital care would alter the clinical outcome remains to be proven in randomized clinical trials.455 Furthermore, prehospital management should not delay the rapid transfer of AHF
patients to the most appropriate medical setting.455,456
In-hospital management
Diagnostic workup and appropriate pharmacological and nonpharmacological treatment must be started promptly and in parallel
(Figure 12). AHF patients are triaged to the appropriate level of care according to the degree of haemodynamic instability and severity of the critical illness. Disposition decisions are important components of the initial phase of management (see Supplementary text 11.2 and
Supplementary Tables 1719).
The type and intensity of in-hospital monitoring depends on clinical severity, settings of care and in-hospital course (see Supplementary text 11.3). As AHF is a heterogeneous condition, management may differ according to the main clinical presentation. Management starts with the search for specific causes of AHF.1,305,430 These include
Management of patients with pulmonary oedema
SBP ≥110 mmHg
Loop diuretics (Class I)
and/or vasodilators
(Class IIb)
N
Y
N
Y
Signs of hypoperfusion
Loop diuretics (Class I)
and inotropes/vasopressors
(Class IIb)
Loop diuretics
(Class I)
Congestion relief
N
Y
Medical therapy optimization
(Class I)
Consider RRT, MCS,
other devices (Class IIa)
OR
Consider palliative care
Oxygen (Class I) or ventilatory support
(Class IIa)
Figure 8 Management of pulmonary oedema. MCS= mechanical circulatory support; RRT= renal replacement therapy; SBP =systolic blood pressure.
ESC Guidelines
3649


<!-- PAGE 52 -->

### Page 52

Management of patients with isolated right ventricular failure
Y
Specific treatments
ACS with RV involvement or acute pulmonary embolism
N
Loop diuretics
(Class I)
Consider careful fluid administration
Marked congestion
Y
RVAD
AND/OR
Renal replacement therapy
OR
Consider palliative care
N
Y
Optimize fluid status
N
Peripheral hypoperfusion/
persistent hypotension
N
Vasopressors and/or inotropesa
(Class IIb)
Relief of signs and symptoms
Y
Follow-up
Figure 9 Management of right ventricular failure. ACS= acute coronary syndrome; RV= right ventricular; RVAD= right ventricular assist device.
aInotropes alone in case of hypoperfusion without hypotension.


<!-- PAGE 53 -->

### Page 53

.....................
ACS, a hypertensive emergency, rapid arrhythmias or severe bradycardia/conduction disturbance, acute mechanical causes such as acute valve regurgitation or acute pulmonary embolism, infection, including myocarditis, and tamponade (CHAMPIT) (Figure 12). After exclusion of these conditions, which need to be treated/corrected urgently,
management of AHF differs according to the clinical presentations
(Figures 710).
Pre-discharge phase
Details on this phase are shown in section 11.3.11.
11.3.2
Oxygen therapy and/or ventilatory support
In AHF, oxygen should not be used routinely in non-hypoxaemic patients, as it causes vasoconstriction and a reduction in cardiac output.457 Oxygen therapy is recommended in patients with AHF and
MCS
(Class IIa)
AND/OR
Renal replacement therapy
(Class IIa)
OR
Consider palliative care
Management of patients with cardiogenic shock
Identify and treat other specific causesb
ACS and/or mechanical complications
N
Y
Emergency PCI or surgical treatmenta
Consider oxygen
(Class I) or ventilatory support (Class IIa)
Consider inotropes/
vasopressors
(Class IIb)
Consider short-term
MCS
(Class IIa)
AND
AND
Improvement of hypoperfusion and organ dysfunction
N
Y
Weaning from inotropes/vasopressors and/or MCS
Continue aetiological treatment if needed and medical therapy optimization
(Class I)
Figure 10 Management of cardiogenic shock. ACS = acute coronary syndrome; BTT =bridge to transplantation; MCS= mechanical circulatory support;
PCI= percutaneous coronary intervention. aPCI in ACS, pericardiocentesis in tamponade, mitral valve surgery in papillary muscle rupture. In case of interventricular septum rupture, MCS as BTT should be considered. bOther causes include acute valve regurgitation, pulmonary embolism, infection, acute myocarditis, arrhythmia (see Figure 12).
ESC Guidelines
3651


<!-- PAGE 54 -->

### Page 54

.......................................................
SpO2 <90% or PaO2 <60 mmHg to correct hypoxaemia. In chronic obstructive pulmonary disease (COPD), hyper-oxygenation may increase ventilationperfusion mismatch, suppress ventilation and lead to hypercapnia. During oxygen therapy, acid-base balance and
SpO2 should be monitored.
Non-invasive positive pressure ventilation, either continuous positive airway pressure and pressure support, improves respiratory failure, increases oxygenation and pH, and decreases the partial pressure of carbon dioxide (pCO2) and work of breathing. Although a large randomized trial had neutral results, meta-analyses suggest it may improve dyspnoea and reduce the need for intubation and mortality, compared with traditional oxygen therapy.1,458,459 Noninvasive positive pressure ventilation should be started as soon as possible in patients with respiratory distress (respiratory rate >25
breaths/min, SpO2 <90%) to improve gas exchange and reduce the rate of endotracheal intubation.448,459 The fraction of inspired oxygen
(FiO2) should be increased up to 100%, if necessary, according to oxygen saturation level.
Blood pressure should be monitored regularly during non-invasive positive pressure ventilation. The increase in intrathoracic pressure with non-invasive positive pressure ventilation decreases venous return and right and left ventricular preload. It may also decrease cardiac output and BP and should therefore be used with caution in patients with reduced preload reserve and hypotension. The increase in pulmonary vascular resistance and RV afterload may also be detrimental in RV dysfunction.448
Intubation is recommended for progressive respiratory failure in spite of oxygen administration or non-invasive ventilation
(Supplementary Table 20).448
11.3.3
Diuretics
Intravenous diuretics are the cornerstone of AHF treatment. They increase renal excretion of salt and water and are indicated for the treatment of fluid overload and congestion in the vast majority of
AHF patients.
Determine aetiology
Alleviate symptoms
Improve congestion and organ perfusion
Restore oxygenation
Limit organ damage (cardiac,
renal, hepatic, gut)
Prevent thromboembolism
Close monitoring of vital signs and grading severity of symptoms/signs
Disposition decisions: ICU/ICCU
ward
Initial treatment to support circulatory and respiratory functions (vasodilators,
vasopressors, inotropes,
diuretics, supplemental O2)
Identify aetiology and relevant co-morbidities and start targeted treatment
Titrate therapy to control symptoms and to relieve congestion, manage hypoperfusion and optimize blood pressure
Initiate and up-titrate diseasemodifying pharmacological therapy
Consider device therapy in appropriate patients
Goals
Procedures
Phases
Determine aetiology
Improve signs and symptoms
Limit organ damage
Prevent thromboembolism
Improve symptoms and quality 
of life
Achieve full congestion relief
Prevent early readmission
Improve survival
Initiate and up-titrate diseasemodifying pharmacological and device therapy
Develop a care plan with the identification of caregivers, a schedule for up-titration and monitoring of pharmacological therapy, review of device therapy
Enrolment in a disease management programme
Immediate
Pre-discharge and long-term
Intermediate
Phases
Figure 11 Stages of management of patients with acute heart failure. ICCU= intensive coronary care unit; ICU= intensive care unit.


<!-- PAGE 55 -->

### Page 55

....................................................
Loop diuretics are commonly used due to their rapid onset of action and efficacy. Data defining their optimal dosing, timing, and method of administration are limited. No difference in the primary efficacy outcome of patients’ symptoms global assessment was shown with a high-dose regimen, compared with a low-dose regimen, in the DOSE trial. However, there was a greater relief of dyspnoea, change in weight and net fluid loss (with no prognostic role for increases in serum creatinine) in the higher-dose regimen.460462
High diuretic doses may cause greater neurohormonal activation and electrolyte abnormalities and are often associated with poorer outcomes, although a cause and effect relation cannot be proven by these retrospective analyses.463466 Based on these observations, it may be appropriate, when starting i.v. diuretic treatment, to use low doses, to assess the diuretic response and increase the dose when that is insufficient.
Diuretic treatment should be started with an initial i.v. dose of furosemide, or equivalent dose of bumetanide or torasemide,
corresponding to 12 times the daily oral dose taken by the patient before admission. If the patient was not on oral diuretics, a starting dose of 2040 mg of furosemide, or a bolus of 1020 mg i.v. torasemide, can be used.145,467 Furosemide can be given as 23 daily boluses or as a continuous infusion. Daily single bolus administrations are discouraged because of the possibility of post-dosing sodium retention.145,461 With continuous infusion, a loading dose may be used to achieve steady state earlier. Diuretic response should be evaluated shortly after start of diuretic therapy and may be assessed by performing a spot urine sodium content measurement after 2 or
6 h and/or by measuring the hourly urine output. A satisfactory diuretic response can be defined as a urine sodium content
>5070 mEq/L at 2 h and/or by a urine output >100150 mL/h during the first 6 h.145,468 If there is an insufficient diuretic response, the loop diuretic i.v. dose can be doubled, with a further assessment of diuretic response.145 If the diuretic response remains inadequate, e.g.
<100 mL hourly diuresis despite doubling loop diuretic dose,
Identification of acute aetiology
Cardiogenic shock and/or respiratory failure
N
Management of patients with suspected acute heart failure
Pharmacological support
Ventilatory support
MCS
Y
acute Coronary syndrome
Hypertension emergency
Arrhythmia
Mechanical causea
Pulmonary embolism
Infections
Tamponade
C
H
A
M
P
I
T
Y
Immediate initiation of specific treatment
Further treatmentb
N
Urgent phase after first medical contact
Immediate phase
(initial 60–120 min)
Figure 12 Initial management of acute heart failure. MCS= mechanical circulatory support. aAcute mechanical cause: myocardial rupture complicating acute coronary syndrome (free wall rupture, ventricular septal defect, acute mitral regurgitation), chest trauma or cardiac intervention, acute native or prosthetic valve incompetence secondary to endocarditis, aortic dissection or thrombosis. bSee Figures 710 for specific treatments according to different clinical presentations.
ESC Guidelines
3653


<!-- PAGE 56 -->

### Page 56

............................................................
concomitant administration of other diuretics acting at different sites,
namely thiazides or metolazone or acetazolamide, may be considered. However, this combination requires careful monitoring of serum electrolytes and renal function (Figure 13).145,469,470 This strategy, based on early and frequent assessment of diuretic response,
allows starting treatment with relatively low doses of loop diuretics,
with frequent dose adjustments that may be less likely to cause dehydration and increase in serum creatinine. The loop diuretic dose should be progressively decreased when a significant negative fluid balance has been obtained. However, it should be pointed out that this algorithm is entirely based on expert opinion, to date.145,461
Transition to oral treatment should be commenced when the patient’s clinical condition is stable. It is recommended that, after achievement of congestion relief, oral loop diuretics are continued at the lowest dose possible to avoid congestion.463,471 Care must also be taken to avoid patients being discharged from hospital with persistent congestion, as this is a major predictor of increased deaths and rehospitalizations.462,472 Hence, care should be taken to achieve adequate decongestion and establish an appropriate long-term diuretic dose before discharge.427,473
11.3.4
Vasodilators
Intravenous vasodilators, namely nitrates or nitroprusside (Supplementary Table 21), dilate venous and arterial vessels leading to a reduction in venous return to the heart, less congestion, lower afterload, increased stroke volume and consequent relief of symptoms.
Nitrates act mainly on peripheral veins whereas nitroprusside is more a balanced arterial and venous dilator.474,475 Because of their mechanisms of action, i.v. vasodilators may be more effective than diuretics in those patients whose acute pulmonary oedema is caused by increased afterload and fluid redistribution to the lungs in the absence or with minimal fluid accumulation.427,476478 However,
two recent randomized trials comparing usual care with early intensive and sustained vasodilation failed to show a beneficial effect of i.v.
vasodilators vs. high-dose diuretics.479,480 No recommendation favouring a regimen based on vasodilator treatment vs. usual care can thus be given, to date.
Intravenous vasodilators may be considered to relieve AHF symptoms when SBP is >110 mmHg. They may be started at low doses and uptitrated to achieve clinical improvement and BP control.
Nitrates are generally administered with an initial bolus followed by
Management of diuretic therapy in patients with acute heart failure
On oral loop diuretic
1–2 times daily oral dose i.v.
≥20–40 mg i.v.
furosemide 
Urinary spot sodium     after 2 h 
≥50–70 mEq/L
Urine output                after 6 h      ≥100–150 mL/h
Double dose i.v. until maximum i.v. dosea
Repeat similar dose i.v. every 12 h
Check serum creatinine and electrolytes at least every 24 h 
Continue until complete decongestion
Combination diuretic therapiesb
N
Y
Y
N
≥
Urinary spot sodium     50–70 mEq/L at 2–6 h
≥
Urine output                100–150 mL/h
Y
N
Figure 13 Diuretic therapy (furosemide) in acute heart failure. i.v.= intravenous. aThe maximal daily dose for i.v. loop diuretics is generally considered furosemide 400600 mg though up to 1000 mg may be considered in patients with severely impaired kidney function. bCombination therapy is the addition to the loop diuretic of a diuretic with a different site of action, e.g. thiazides or metolazone or acetazolamide. Modified from 145.


<!-- PAGE 57 -->

### Page 57

.............................................................................
continuous infusion. However, they may also be given as repeated boluses. Nitroglycerine can be given as 12 mg boluses in severely hypertensive patients with acute pulmonary oedema.477 Care should be taken to avoid hypotension due to an excessive decrease in preload and afterload. For this reason, they should be used with extreme caution in patients with LVH and/or severe aortic stenosis.
However, favorable effects were described in patients with LV systolic dysfunction and aortic stenosis when vasodilators were given with careful monitoring of haemodynamic parameters.481
11.3.5
Inotropes
Inotropes are still needed for treatment of patients with low cardiac output and hypotension (Table 22). They should be reserved for patients with LV systolic dysfunction, low cardiac output and low SBP
(e.g. <90 mmHg) resulting in poor vital organ perfusion. However,
they must be used with caution starting at low doses and uptitrating them with close monitoring.387,388
Inotropes, especially those with adrenergic mechanisms, can cause sinus tachycardia, increase ventricular rate in patients with AF,
may induce myocardial ischaemia and arrhythmias, and increase mortality.387,388,430,478
Levosimendan or type-3-phosphodiesterase inhibitors may be preferred over dobutamine for patients on beta-blockers as they act through independent mechanisms.482,483
Excessive peripheral vasodilation and hypotension can be major limitations of type-3-phosphodiestaerase inhibitors or levosimendan,
especially when administered at high doses and/or when commenced with a bolus dose.482,484
11.3.6
Vasopressors
Vasopressors used for the treatment of AHF are reported in Table 22.
Among drugs with a prominent peripheral arterial vasoconstrictor action, norepinephrine may be preferred in patients with severe hypotension. The aim is to increase perfusion to the vital organs.
However, this is at the expense of an increase in LV afterload.
Therefore, a combination of norepinephrine and inotropic agents may be considered, especially in patients with advanced HF and cardiogenic shock.
Some studies, though with limitations, support the use of norepinephrine as first choice, compared with dopamine or epinephrine.
Dopamine was compared with norepinephrine as a first-line vasopressor therapy in patients with shock and was associated with more arrhythmic events and with a greater mortality in patients with cardiogenic shock but not in those with hypovolaemic or septic shock.
Although the trial included 1679 patients, significance was seen only in a subgroup analysis of the 280 patients with cardiogenic shock and
<10% of the patients had MI. As there were no data regarding revascularization, this limits the generalizability of the results.485 In another prospective randomized trial epinephrine was compared with norepinephrine in patients with cardiogenic shock due to acute MI.486 The trial was stopped prematurely due to a higher incidence of refractory shock with epinephrine. Epinephrine was also associated with higher heart rate and lactic acidosis. Despite limitations related to its relatively small sample size, short time of follow-up and lack of data regarding the maximum reached dose, the study suggests superior efficacy and safety with norepinephrine. These data are consistent with a meta-analysis including 2583 patients with cardiogenic shock showing a three-fold increase in the risk of death with epinephrine,
compared with norepinephrine,
in patients with cardiogenic shock.487 However, the lack of information about dose, duration of treatment, and aetiology, makes these results partially explorative.
11.3.7
Opiates
Opiates relieve dyspnoea and anxiety. They may be used as sedative agents during non-invasive positive pressure ventilation to improve patient adaptation. Dose-dependent side effects include nausea,
hypotension, bradycardia, and respiratory depression. Retrospective
Table 22
Inotropes and/or vasopressors used to treat acute heart failure
Drug
Infusion rate
Dobutamine
220 lg/kg/min (betaþ)
Dopamine
35 lg/kg/min; inotropic (betaþ)
>5 lg/kg/min: inotropic (betaþ), vasopressor (alphaþ)
Milrinone
0.3750.75 lg/kg/min
Enoximone
520 lg/kg/min
Levosimendan
0.1 lg/kg/min, which can be decreased to 0.05
or increased to 0.2 lg/kg/min
Norepinephrine 0.21.0 lg/kg/min
Epinephrine
0.050.5 lg/kg/min
ESC 2021
Recommendations for the initial treatment of acute heart failure
Recommendations
Classa
Levelb
Oxygen and ventilatory support
Oxygen is recommended in patients with SpO2
<90% or PaO2 <60 mmHg to correct hypoxaemia.
I
C
Intubation is recommended for progressive respiratory failure persisting in spite of oxygen administration or non-invasive ventilation.448
I
C
Non-invasive positive pressure ventilation should be considered in patients with respiratory distress (respiratory rate >25 breaths/min, SpO2
<90%) and started as soon as possible in order to decrease respiratory distress and reduce the rate of mechanical endotracheal intubation.448
IIa
B
Diuretics
Intravenous loop diuretics are recommended for all patients with AHF admitted with signs/symptoms of ﬂuid overload to improve symptoms.145
I
C
Combination of a loop diuretic with thiazidetype diuretic should be considered in patients with resistant oedema who do not respond to an increase in loop diuretic doses.145
IIa
B
Vasodilators
In patients with AHF and SBP >110 mmHg, i.v.
vasodilators may be considered as initial therapy to improve symptoms and reduce congestion.475477,479,480
IIb
B
Continued
................................................................................................
ESC Guidelines
3655


<!-- PAGE 58 -->

### Page 58

..........................................................................................................
analyses suggest that morphine administration is associated with a greater frequency of mechanical ventilation, prolonged hospitalization,
more intensive care unit admissions, and increased mortality.488491
Thus, routine use of opiates in AHF is not recommended although they may be considered in selected patients, particularly in case of severe/intractable pain or anxiety or in the setting of palliation.
11.3.8
Digoxin
Digoxin should be considered in patients with AF with a rapid ventricular rate (>110 b.p.m.) despite beta-blockers (see also section
12.1.1).151,492,493 It can be given in boluses of 0.250.5 mg i.v., if not used previously. However, in patients with comorbidities (i.e. CKD)
or other factors affecting digoxin metabolism (including other drugs)
and/or the elderly, the maintenance dose may be difficult to estimate theoretically and measurements of serum digoxin concentrations should be performed. Digitoxin is a potential alternative to digoxin and is currently being evaluated in a randomized placebo-controlled trial (ClinicalTrials.gov Identifier: NCT03783429).158
11.3.9
Thromboembolism prophylaxis
Thromboembolism prophylaxis with heparin (e.g. low-molecularweight heparin) or another anticoagulant is recommended, unless contraindicated or unnecessary (because of existing treatment with oral anticoagulants).494,495
11.3.10
Short-term mechanical circulatory support
In patients presenting with cardiogenic shock, short-term MCS may be necessary to augment cardiac output and support end-organ perfusion. Short-term MCS can be used as a BTR, BTD or BTB.450-452
The initial improvements in cardiac output, BP and arterial lactate may be counterbalanced by significant complications. High-quality evidence regarding outcomes remains scarce. Hence, the unselected use of MCS in patients with cardiogenic shock is not supported and they require specialist multidisciplinary expertise for implantation and management, similar to that outlined for advanced HF centres
(Supplementary text 11.4; Supplementary Table 22, see also section
10.2.2).376,496 Recent studies show that a ‘standardized team-based approach’ using predefined algorithms for early MCS implant coupled with close monitoring (invasive haemodynamics, lactate, markers of end-organ damage)
may potentially translate into improved survival.497499
The Intra-aortic Balloon Pump in Cardiogenic Shock II (IABPSHOCK-II) trial showed no difference in 30-day, as well as in longterm, mortality between intra-aortic balloon pump (IABP) and OMT
in patients with cardiogenic shock following acute MI who underwent early revascularization.500502 According to these results, IABP is not routinely recommended in cardiogenic shock post-MI. However, it may still be considered in cardiogenic shock, especially if not due to
ACS, and refractory to drug therapy, as a BTD, BTR, or BTB.
Other short-term MCS were compared with IABP in small,
randomized trials and propensity-matched analyses with inconclusive results.503507 Similarly, RCTs comparing extracorporeal membrane oxygenation (ECMO) with IABP or MT are lacking. A meta-analysis including only observational studies showed favourable outcomes in patients with cardiogenic shock or cardiac arrest treated with venoarterial (VA)-ECMO compared to controls.508 VA-ECMO may also be considered in fulminant myocarditis and other conditions causing severe cardiogenic shock.509 Depending on the severity of myocardial dysfunction and/or concomitant mitral or aortic regurgitation,
VA-ECMO may increase LV afterload with an increase in LV endInotropic agents
Inotropic agents may be considered in patients with SBP <90 mmHg and evidence of hypoperfusion who do not respond to standard treatment,
including ﬂuid challenge, to improve peripheral perfusion and maintain end-organ function.387
IIb
C
Inotropic agents are not recommended routinely, due to safety concerns, unless the patient has symptomatic hypotension and evidence of hypoperfusion.387,467,478
III
C
Vasopressors
A vasopressor, preferably norepinephrine, may be considered in patients with cardiogenic shock to increase blood pressure and vital organ perfusion.485487
IIb
B
Other drugs
Thromboembolism prophylaxis (e.g. with
LMWH) is recommended in patients not already anticoagulated and with no contraindication to anticoagulation, to reduce the risk of deep venous thrombosis and pulmonary embolism.494,495
I
A
Routine use of opiates is not recommended,
unless in selected patients with severe/intractable pain or anxiety.488,489
III
C
AHF = acute heart failure; i.v. = intravenous; LMWH = low-molecular-weight heparin; PaO2 = partial pressure of oxygen; SBP = systolic blood pressure; SpO2 =
transcutaneous oxygen saturation.
aClass of recommendation.
bLevel of evidence.
ESC 2021
Recommendations for the use of short-term mechanical circulatory support in patients with cardiogenic shock
Recommendations
Classa
Levelb
Short-term MCS should be considered in patients with cardiogenic shock as a BTR, BTD,
BTB. Further indications include treatment of the cause of cardiogenic shock or long-term
MCS or transplantation.
IIa
C
IABP may be considered in patients with cardiogenic shock as a BTR, BTD, BTB, including treatment of the cause of cardiogenic shock (i.e.
mechanical complication of acute MI) or longterm MCS or transplantation.450
IIb
C
IABP is not routinely recommended in post-MI
cardiogenic shock.500502
III
B
BTB = bridge to bridge; BTD = bridge to decision; BTR = bridge to recovery;
IABP = intra-aortic balloon pump; MCS = mechanical circulatory support; MI =
myocardial infarction.
aClass of recommendation.
bLevel of evidence.
ESC 2021
...............................................................


<!-- PAGE 59 -->

### Page 59

.............................................................................................
diastolic pressure and pulmonary congestion. In these cases, LV
unloading is mandatory and can be achieved by means of transeptal/
ventricular apex vent or adding an unloading device such as the
Impella device.510,511
11.3.11 Pre-discharge assessment and post-discharge management planning
A significant proportion of patients with AHF are discharged with minimal or no weight loss and, more importantly, persistent congestion.427,472 Persistent congestion before discharge is associated with a higher risk of readmission and mortality.426,472 Treatment, including diuretic dose, should therefore be optimized in order to keep the patient free of congestion.
In those admitted with ADHF, oral OMT should be continued,
except for possible dose reduction or withdrawal if there is haemodynamic instability (symptomatic hypotension), severely impaired renal function or hyperkalaemia. Once haemodynamic stabilization is achieved with i.v. therapy, treatment should be optimized before discharge.467 Treatment optimization has three major aims. First, to relieve congestion. Second, to treat comorbidities, such as iron deficiency, that have an impact on post-discharge outcome.512 Third, to initiate, or restart oral, OMT with beneficial effects on outcome.
Doses may be uptitrated before discharge and/or in the early postdischarge phase.
Studies have shown that such optimization of medical treatment is associated with a lower risk of 30-day readmission, although prospective randomized trials have not been performed, to date.103,467,513
Retrospective analyses show that discontinuation or dose reduction of beta-blocker therapy during an AHF hospitalization is associated with worse outcomes.514 Initiation of ARNI in recently hospitalized stable patients with HFrEF, including those who are ACE-I/ARB
naı¨ve, is safe and may be considered in this setting.106,107 Safety and better outcome have also been recently shown in a prospective randomized trial with sotagliflozin in diabetic patients hospitalized for
HF, irrespective of their LVEF.136
It is recommended to have one follow-up visit within 1 to 2 weeks after discharge.515,516 Components of this follow-up visit should include monitoring of signs and symptoms of HF, assessment of volume status, BP, heart rate, and laboratory measurements including renal function, electrolytes, and possibly NPs. Iron status and hepatic function should also be assessed when not done before discharge.
Based on clinical evaluation and laboratory exams, further optimization and/or initiation of disease-modifying treatment for HFrEF
should occur. Retrospective studies show that such an approach is associated with lower 30-day readmission rates although prospective randomized trials have not been performed, to date.513,516518
12 Cardiovascular comorbidities
12.1 Arrhythmias and conduction disturbances
12.1.1
Atrial fibrillation
AF and HF frequently coexist.519,520 They can cause or exacerbate each other through mechanisms such as structural cardiac remodelling, activation of neurohormonal systems, and rate-related LV
impairment.519523 The proportion of patients with HF who develop
AF increases with age and HF severity. When AF causes HF the clinical course seems more favourable than with other causes of HF (so called tachycardiomyopathy).524 In contrast, development of AF in patients with chronic HF is associated with worse prognosis, including stroke and increased mortality.525,526
The management of patients with concomitant HF and AF is summarized in Figure 14.7,521 It includes:
(1)
Identification and treatment of possible causes or triggers of AF
(2)
Management of HF
(3)
Prevention of embolic events
(4)
Rate control
(5)
Rhythm control
Identification of triggers and management of heart failure
Potential causes or precipitating factors such as hyperthyroidism,
electrolyte disorders, uncontrolled hypertension, mitral valve disease, and infection should be identified and corrected.
Worsening congestion due to AF should be managed with diuretics. Congestion relief may reduce sympathetic drive and ventricular rate and increase the chance of spontaneous return to SR. The presence of AF may reduce or abolish the prognostic benefits of beta-blockers and renders ivabradine ineffective.12,125 Some treatments for HF decrease the risk of developing AF, including ACE-I,
slightly, and CRT, probably.7,527
Prevention of embolic events
Unless contraindicated, an oral, long-term anticoagulant is recommended in all patients with HF and paroxysmal, persistent, or permanent AF. Direct-acting oral anticoagulants (DOACs) are preferred
Recommendations for pre-discharge and early post-discharge follow-up of patients hospitalized for acute heart failure
Recommendations
Classa
Levelb
It is recommended that patients hospitalized for
HF be carefully evaluated to exclude persistent signs of congestion before discharge and to optimize oral treatment.427,472
I
C
It is recommended that evidence-based oral medical treatment be administered before discharge.103,513
I
C
An early follow-up visit is recommended at 12
weeks after discharge to assess signs of congestion, drug tolerance and start and/or uptitrate evidence-based therapy.517,518
I
C
Ferric carboxymaltose should be considered for iron deﬁciency, deﬁned as serum ferritin <100
ng/mL or serum ferritin 100299 ng/mL with
TSAT <20%, to improve symptoms and reduce rehospitalizations.512
IIa
B
HR = heart failure; TSAT = transferrin saturation.
aClass of recommendation.
bLevel of evidence.
ESC 2021
...............................................................................
ESC Guidelines
3657


<!-- PAGE 60 -->

### Page 60

Management of atrial fibrillation in patients with HFrEF
Haemodynamic instability
Anticoagulation for preventing embolic events (Class I)
Treatment of trigger(s) (Class I)
Optimization of heart failure therapies (Class I)
OR
Beta-blockers
(Class IIa)
Digoxin/digitoxin
(Class IIa)
Amiodarone i.v.
(Class IIa)
OR
Rate control
Symptom improvement
Sinus rhythm
Amiodarone
(Class IIb)
ECV
(Class IIb)
Rhythm control
PV ablation
(Class IIa)
ECV
(Class I)
Rhythm control
OR
Amiodarone
(Class IIb)
Rhythm control
PV ablation
(Class IIa)
AVN ablation
(Class IIb)
Rate control
Sinus rhythm
Follow-up
N
N
N
Y
Y
Y
Y
N
OR
OR
Figure 14 Management of atrial fibrillation in patients with heart failure with reduced ejection fraction. AF= atrial fibrillation; AVN= atrioventricular node; ECV= electrical cardioversion; HF= heart failure; i.v.= intravenous; PV= pulmonary vein. Colour code for classes of recommendation: Green for
Class of recommendation I; Yellow for Class of recommendation IIa; Orange for Class of recommendation IIb; Red for Class of recommendation III (see
Table 1 for further details on classes of recommendation).


<!-- PAGE 61 -->

### Page 61

.............................................................................................................................................................................
for the prevention of thromboembolic events in patients with AF and without severe mitral stenosis and/or mechanical valve prosthesis, as they have similar efficacy to vitamin K antagonists (VKAs) but a lower risk of intracranial haemorrhage.528
LA appendage closure can be considered in patients with HF and
AF who have a contraindication to oral anticoagulation though data from randomized trials have not included patients with contraindications to oral anticoagulants.529,530
Rate control
Data regarding rate control are not conclusive for the patients with
AF and HF. A strategy of lenient rate control, defined by a resting heart rate <110 b.p.m., was compared to a strategy of strict rate control, defined by a heart rate <80 b.p.m. at rest and <110 b.p.m. during moderate exercise, in RACE II and in a pooled analysis of RACE and
AFFIRM.152,531 The studies showed no differences in outcome between the two strategies. However, only 10% of the patients in
RACE II and 17% of those in the pooled analysis had a history of HF
hospitalization or NYHA class IIIII, respectively.152,531 Higher heart rates are associated with worse outcomes in observational studies.532,533 Thus, a lenient rate control is an acceptable initial approach with, however, treatment targeting a lower heart rate in case of persistent symptoms or cardiac dysfunction likely related to tachycardia
(e.g. tachycardia-induced cardiomyopathy).7,534
Beta-blockers can be used for rate control in patients with HFrEF
or HFmrEF because of their established safety in these patients (see section 5.3.2).7,534,535 Digoxin or digitoxin can be considered when the ventricular rate remains high, despite beta-blockers, or when beta-blockers are contraindicated or not tolerated.151,493,536 It may therefore be considered also an alternative to beta-blockers. For patients with NYHA class IV and/or haemodynamic instability, i.v.
amiodarone can be considered to reduce ventricular rate.537 For
HFpEF, there is a paucity of evidence to demonstrate efficacy of any agent. The RATE-AF trial compared digoxin with bisoprolol in patients with persistent AF and NYHA class IIIV symptoms.
Compared with bisoprolol, digoxin had the same effect on QOL at 6
months (primary endpoint) and a better effect on EHRA and NYHA
functional class.536 Only 19% of the patients had LVEF <50% so that most of the patients can be considered as having HFmrEF or
HFpEF.536
AV node ablation can be considered in patients with poor ventricular rate control despite medical treatment not eligible for rhythm control by catheter ablation or in patients with biventricular pacing.7,538540
Rhythm control
Urgent electrical cardioversion is recommended in the setting of acute worsening HF in patients presenting with rapid ventricular rates and haemodynamic instability, after consideration of the thromboembolic risk. Cardioversion should be considered also to improve symptoms in patients who have persistent and symptomatic AF, despite optimal pharmacological management. In patients who do not receive chronic therapy with oral anticoagulant and with AF onset
>48 h, at least 3 weeks of therapeutic anticoagulation or a transoesophageal echocardiography is needed before cardioversion.7 When pharmacological cardioversion is preferred, amiodarone is the drug of choice as other antiarrhythmic drugs (i.e. propafenone, flecainide,
dronedarone)
are associated with worse outcomes in
HFrEF.186,534,541544 Amiodarone can help maintain HF patients in
SR after cardioversion.545,546
Trials including patients with HF and comparing rate control and rhythm control strategies with the latter based on antiarrhythmic drugs failed to show any benefit of one strategy over the other.547550 More recently, EAST-AFNET 4, enrolling patients with early AF, 28.6% with HF, was stopped early after a median follow-up of 5.1 years for a lower occurrence of the primary outcome of death,
stroke, or hospitalization for worsening HF or ACS in the patients assigned to early rhythm control vs. those assigned to usual care.551
However, the patients assigned to the rhythm control strategy had a closer follow-up, which may have influenced their better outcome.
Catheter ablation was performed in a minority of the patients in the rhythm control arm (19.4%).551
LA catheter ablation was compared with MT, rate or rhythm control strategy, in 363 patients with persistent or paroxysmal AF, LVEF
<35% and an implanted device (ICD or CRT-D) enrolled in the
CASTLE-AF trial.552 The primary endpoint of all-cause death or HF
hospitalizations occurred in fewer patients in the ablation group vs.
the MT group, 51 patients (28.5%) vs. 82 (44.6%) [hazard ratio (HR);
95% confidence interval (CI), 0.62; 0.430.87; P =0.007]. Also, other endpoints, all-cause or CV death or worsening HF, were reduced by catheter ablation.552 This trial suggests that catheter ablation can improve the prognosis of patients with HFrEF. However, it enrolled a highly selected population, 363 of 3013 patients, was not blinded, had crossovers between the two treatment strategies and the number of events observed was low: 24 (13.4%) vs. 46 (25.0%) all-cause deaths and 37 (20.7%) vs. 66 (35.9%) HF hospitalizations in the ablation and
MT groups, respectively.552
The CABANA trial was an investigator-initiated, open-label, multicentre, randomized trial enrolling 2204 patients with symptomatic
AF. The trial failed to show a benefit of AF ablation strategy over medical care on the primary composite endpoint of death, disabling stroke, serious bleeding, or cardiac arrest in the overall population.553
In an analysis of the 778 patients (35%) with NYHA class symptoms
>II, the primary outcome occurred in 34 patients (9.0%) in the catheter ablation group vs. 49 (12.3%) in the drug therapy group (HR; 95%
CI, 0.64; 0.410.99).554 However, also in this trial, the number of events was small and HF was defined based only on symptoms with
LVEF available in 73% of the patients and >50% and 4049% in 79%
and 11.7% of the cases, respectively.554 Both CASTLE-AF and
CABANA showed a highly significant effect of catheter ablation on patients’ symptoms.552554
Two other prospective trials enrolled patients with HFrEF and persistent AF, who were randomized to catheter ablation or MT in one trial (AMICA trial, n = 140), and to catheter ablation or amiodarone in the other one (AATAC trial, n = 203).555,556 The first trial failed to show any difference in the LVEF increase between the two groups.555 The second trial showed superiority of catheter ablation with respect of AF recurrence, the primary endpoint, with also a reduction in unplanned hospitalizations and mortality.556 In contrast with the AMICA trial,555 but in accordance with CASTLE-AF,552
AATAC also showed a benefit of catheter ablation on LVEF.556
In conclusion, there is insufficient evidence in favour of a strategy of rhythm control with antiarrhythmic drugs vs. rate control in patients with HF and AF.547551 The results of randomized trials with
ESC Guidelines
3659


<!-- PAGE 62 -->

### Page 62

.............................................................................................................................................................................
catheter ablation vs. MT showed a consistent improvement in symptoms whereas the results on mortality and hospitalization were obtained with a relatively small number of events not permitting to draw definitive conclusions.152,548550,552554,557
12.1.2
Ventricular arrhythmias
Ventricular arrhythmias may be a complication, and in some instances, a cause of HF. Frequent ventricular premature beats (VPBs) may lead to reversible systolic dysfunction. Possible factors may include dyssynchrony and abnormal calcium handling.560
Initial management of ventricular arrhythmias in HF should include correction of potential precipitants (including electrolyte abnormalities, particularly hypo/hyperkalaemia, and pro-arrhythmic drugs) as well as the optimization of HF drug therapy. Although ischaemia may be a triggering factor, revascularization has not been shown to reduce risk of ventricular arrhythmias.561
Amiodarone is effective also for suppression of ventricular arrhythmias. However, it does not reduce the incidence of sudden cardiac death or overall mortality.161 For patients with premature ventricular contraction (PVC)-induced CMP, amiodarone administration may be considered to reduce recurrent arrhythmias and improve symptoms and LV function, although its side effects should be taken into consideration. Other drugs are discussed in
Supplementary text 12.1.
Radiofrequency ablation of VPBs may improve LV function and,
possibly, outcomes in patients with tachycardiomyopathy when VPBs contribute to LV dysfunction.562 A sustained reduction in the baseline
PVC burden has been associated with a lower risk of cardiac mortality, cardiac transplantation, or hospitalization for HF during followup.563,564
12.1.3
Symptomatic bradycardia, pauses and atrioventricular block
Indications for pacemaker therapy do not differ in patients with HF
from those with other CV disease. There is ample evidence that RV
pacing may have an adverse effect on LV systolic function leading, in the long term, to HF.565 Patients with HFrEF requiring frequent ventricular pacing, e.g. with AV block or slow AF, and who have systolic dysfunction, should be implanted with CRT rather than a standard pacemaker to avoid adverse outcomes, as shown in the BLOCK-HF
(Biventricular versus Right Ventricular Pacing in Heart Failure
Patients with Atrioventricular Block) trial.216 In the quest for a more physiological alternative to RV pacing, physiological pacing is being increasingly adopted.566 In a non-randomized comparison of 304 consecutive patients with His bundle pacing and 433 consecutive patients with RV pacing, the former group had less HF hospitalization and a trend in reduced mortality.567 Although the technique is promising,
more data are needed to confirm its role.
12.2 Chronic coronary syndromes
CAD is the most common cause of HF in industrialized, middleincome, and increasingly in low-income, countries. It should be considered as possible cause of HF in all patients presenting with new onset HF.
The diagnostic workup of patients with HF and chronic coronary syndromes (CCS) is reported in the recent 2019 ESC Guidelines on
CCS.5 Patients with HF should be carefully evaluated to assess signs and/or symptoms of CCS. Clinical and family histories, physical examination,
ECG
and imaging tests are recommended.5
Documentation of ischaemia using non-invasive and invasive tests can be difficult in patients with HF because of the possible exercise intolerance and the effects of increased end-diastolic LV pressures.
Coronary angiography or CTCA can be performed to establish the
Recommendations for the treatment of atrial ﬁbrillation in patients with heart failure
Recommendations
Classa
Levelb
Anticoagulation
Long-term treatment with an oral anticoagulant is recommended in all patients with AF, HF, and
CHA2DS2-VASc score >_2 in men or >_3 in women.7
I
A
DOACs are recommended in preference to
VKAs in patients with HF, except in those with moderate or severe mitral stenosis or mechanical prosthetic heart valves.528,558
I
A
Long-term treatment with an oral anticoagulant should be considered for stroke prevention in
AF patients with a CHA2DS2-VASc score of 1 in men or 2 in women.7,559
IIa
B
Rate control
Beta-blockers should be considered for shortand long-term rate control in patients with HF
and AF.535
IIa
B
Digoxin should be considered when the ventricular rate remains high, despite beta-blockers, or when beta-blockers are contraindicated or not tolerated.536
IIa
C
Cardioversion
Urgent ECV is recommended in the setting of acute worsening of HF in patients presenting with rapid ventricular rates and haemodynamic instability.
I
C
Cardioversion may be considered in patients in whom there is an association between AF and worsening of HF symptoms despite optimal medical treatment.7,541
IIb
B
AF catheter ablation
In cases of a clear association between paroxysmal or persistent AF and worsening of HF symptoms, which persist despite MT, catheter ablation should be considered for the prevention or treatment of AF.552554,557
IIa
B
AF = atrial ﬁbrillation; CHA2DS2-VASc = congestive heart failure or left ventricular dysfunction, Hypertension, Age >_75 (doubled), Diabetes, Stroke (doubled)-
Vascular disease, Age 6574, Sex category (female) (score); DOAC = directacting oral anticoagulant; ECV = electrical cardioversion; HF = heart failure; MT =
medical therapy; VKA = vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.
ESC 2021


<!-- PAGE 63 -->

### Page 63

...............................................................
presence and extent of CAD and evaluate the potential indication for revascularization (see section 4.3).5
12.2.1 Medical therapy
Beta-blockers are the mainstay of therapy in patients with HFrEF and
CAD because of their prognostic benefit.116120,568 Ivabradine should be considered as an alternative to beta-blockers (when contraindicated) or as additional anti-anginal therapy in patients in SR whose heart rate is >_70 b.p.m.139,569 Other anti-anginal drugs (e.g. amlodipine,
felodipine, nicorandil, ranolazine, and oral or transdermal nitrates) are effective for treating symptoms, although data about their effects on outcomes are neutral or lacking.5,570574 Trimetazidine seems to have additive effects, such as improvement of LV function and exercise capacity, in patients with HFrEF and CCS already on beta-blockers.575577 Trimetazidine and other anti-anginal drugs may be considered in patients with HF and angina despite beta-blocker and/or ivabradine. Short-acting nitrates should be used with caution in patients with HF as they cause hypotension. Diltiazem and verapamil increase
HF-related events in patients with HFrEF and are contraindicated.578
An algorithm for the use of anti-anginal medications in patients with HFrEF is reported in Figure 15.
Beta-blockers, long-acting nitrates, calcium channel blockers
(CCBs),
ivabradine,
ranolazine,
trimetazidine,
nicorandil and their combinations should be considered in HFpEF for angina relief but without a foreseen benefit on HF and coronary end points.
Low-dose of rivaroxaban [2.5 mg twice daily (b.i.d.)] did not add prognostic benefit in patients with HFrEF and CCS in the
COMMANDER-HF trial, a study to assess the effectiveness and safety of rivaroxaban in reducing the risk of death, MI or stroke in participants with HF and CAD following an episode of decompensated HF.579 This trial included patients with HFrEF and a recent episode of worsening HF occurring within 21 days from the time of enrolment. These patients are at high risk of HF-related events and these were the main cause of deaths and hospitalizations in the trial. Rivaroxaban had no effect on these events. In contrast, in a non-pre-specified subgroup analysis of the COMPASS trial, low dose of rivaroxaban, on top of aspirin, was associated with a reduction in ischaemic events in patients with HF, mainly HFmrEF or
HFpEF.580 Based on these data, low-dose rivaroxaban may be considered in patients with CAD (or peripheral artery disease) and
Use of anti-anginal medications in patients with CCS and HFrEF
Beta-blockers
(Class I)
Persistence of
CCS symptoms
In absence of improvement
Trimetazidine
(Class IIb)
Nicorandil
(Class IIb)
OR
OR
OR
Felopidine
(Class IIb)
Ranolazine
(Class IIb)
Nitrates
(Class IIb)
Amlodipine
(Class IIb)
Ivabradine
(Class IIa)
HR <70 bpm, and/or atrial fibrillation
HR ≥70 bpm, and sinus rhythm
Diltiazem (Class III)
Verapamil (Class III)
Figure 15 Algorithm for the medical treatment of chronic coronary syndrome in patients with heart failure with reduced ejection fraction. CCS =
chronic coronary syndrome; HFrEF= heart failure with reduced ejection fraction; HR= heart rate. Colour code for classes of recommendation: Green for
Class of recommendation I; Yellow for Class of recommendation IIa; Orange for Class of recommendation IIb; Red for Class of recommendation III (see
Table 1 for further details on classes of recommendation).
ESC Guidelines
3661


<!-- PAGE 64 -->

### Page 64

................................................................
HF, LVEF >40% and SR, when at high risk of stroke and with a low haemorrhagic risk.
12.2.2 Myocardial revascularization
Data on the benefit of myocardial revascularization in patients with
HF are limited.
STICH compared coronary artery bypass grafting (CABG) with
MT in patients with CAD, amenable by CABG, and with reduced LV
function (EF <_35%). At a median follow-up of 56 months, there was no significant difference between the CABG group and the MT group in the rate of death from any cause, primary outcome of the trial.89
The extended follow-up report showed a significant reduction of death in the CABG group vs. the control group (58.9% vs. 66.1%; HR
0.84; 95% CI, 0.730.97; P = 0.02) over 10 years.581 CV death and the combined endpoint of all-cause death or hospitalization for
CV causes were also significantly reduced after CABG at 10 years of follow-up.581 Post hoc analyses of the STICH trial suggested that neither myocardial viability, angina, nor ischaemia were related with outcomes after revascularization.92,93,582 The Heart Failure
Revascularisation Trial (HEART) was under-powered, with only 138
of the planned 800 patients to be enrolled, and failed to show differences in outcomes between HF patients receiving CABG or MT.583
There are currently no reported RCTs comparing percutaneous coronary intervention (PCI) with MT in patients with HFrEF.
However, the REVIVED-BCIS2 trial has finished recruitment
(ClinicalTrials.gov Identifier: NCT01920048).584 There are also no randomized studies comparing PCI with CABG as such randomized trials excluded patients with HFrEF. In one prospective registry,
including 4616 patients with multivessel disease and HFrEF,
propensity-score matched comparisons showed similar survival
(mean follow-up 2.9 years) in PCI vs. CABG group with PCIs associated with a higher risk of MI, particularly in patients with incomplete revascularization, and CABG associated with a higher risk of stroke.585 A propensity-matched analysis showed a significantly lower risk of death or major CV events in diabetic patients with LV
dysfunction and multivessel disease treated with CABG compared with PCI.586 CABG was associated with better outcome than PCI
also in patients with moderate or severe LV dysfunction and left main or complex coronary disease.587,588 Two meta-analyses confirmed that CABG is associated with better outcomes, including mortality,
MI,
and repeated revascularization,
compared with
PCI
and/or MT.589,590
12.3 Valvular heart disease
12.3.1
Aortic stenosis
Aortic stenosis may cause or worsen HF by increasing LV afterload and causing LV hypertrophy and remodelling.591 When HF symptoms occur in patients with severe aortic stenosis, prognosis is extremely poor. No MT for aortic stenosis can improve outcomes.
HF medical treatment should be given to all HF patients with symptomatic severe aortic stenosis. Care must be taken using vasodilators to avoid hypotension. Importantly, possible improvement of symptoms after MT should not delay intervention.
In the presence of suspected symptomatic and severe highgradient aortic stenosis (valve area <_1 cm2, mean gradient >_40
mmHg), other causes of high flow status must be excluded and corrected (i.e. anaemia, hyperthyroidism, arteriovenous shunts)
before proceeding to aortic valve intervention.592 An aortic valve intervention is recommended in patients with HF symptoms and severe,
high-gradient aortic stenosis,
regardless of
LVEF.
Management of patients with low-flow low-gradient aortic stenosis is reported in Figure 16.592
Intervention is recommended in patients with a life expectancy >1
year, avoiding futility. Transcatheter aortic valve implantation (TAVI)
has been shown to be non-inferior to surgical aortic valve replacement (SAVR) in reducing clinical events (including mortality and disabling stroke) in patients at high and intermediate risk for surgery.593600 In low-risk patients, mean age in the RCTs comparing
TAVI and SAVR was >70 years and follow-up was restricted to
2 years. Therefore, SAVR is recommended in patients aged <75 years and at low surgical risk (STS-PROM score or EuroSCORE II <4%),
whereas TAVI is recommended in those aged >75 years or at high/
prohibitive surgical risk (STS-PROM score or EuroSCORE II >8%). In all the other cases, the choice between TAVI and SAVR should be made by the Heart Team, weighing the pros and cons of each procedure, according to age, life expectancy, individual patient preference and other features including clinical and anatomical aspects. Aortic
Recommendations for myocardial revascularization in patients with heart failure with reduced ejection fraction
Recommendations
Classa
Levelb
CABG should be considered as the ﬁrst-choice revascularization strategy, in patients suitable for surgery, especially if they have diabetes and for those with multivessel disease.581,587,588,590
IIa
B
Coronary revascularization should be considered to relieve persistent symptoms of angina (or an angina-equivalent) in patients with HFrEF, CCS,
and coronary anatomy suitable for revascularization, despite OMT including anti-anginal drugs.
IIa
C
In LVAD candidates needing coronary revascularization, CABG should be avoided, if possible.
IIa
C
Coronary revascularization may be considered to improve outcomes in patients with HFrEF,
CCS, and coronary anatomy suitable for revascularization, after careful evaluation of the individual risk to beneﬁt ratio, including coronary anatomy (i.e. proximal stenosis >90% of large vessels, stenosis of left main or proximal LAD),
comorbidities, life expectancy, and patient’s perspectives.
IIb
C
PCI may be considered as an alternative to
CABG, based on Heart Team evaluation, considering coronary anatomy, comorbidities, and surgical risk.
IIb
C
CABG = coronary artery bypass graft; CCS = chronic coronary syndrome; HFrEF
= heart failure with reduced ejection fraction; LAD = left anterior descending artery; LVAD = left ventricular assist device; OMT = optimal medical therapy; PCI
= percutaneous coronary intervention.
aClass of recommendation.
bLevel of evidence.
ESC 2021
.....................................................................................................................


<!-- PAGE 65 -->

### Page 65

.........
valve interventions should be performed only in centres having both interventional cardiology and cardiac surgery services on site and a structured collaborative Heart Team approach.
Balloon aortic valvuloplasty may be considered in highly symptomatic patients with AHF (i.e. cardiogenic shock) as bridge to TAVI or
SAVR, or in advanced HF as BTR or DT.
Management of patients with heart failure and suspected severe low-flow low-gradient ASa
Dobutamine echo
LVEF < 50%
OR
TAVI
(Class I)
SAVR
(Class I)
Y
N
Flow reservec
Clinical and echo criteriab
High calcium scored by CT
Y
Severe low-flow 
low-gradient AS
N
Medical therapy optimization
(Class I)
Heart Teamg
(Class I)
Heart Teamg
(Class I)
Follow-up
Y
f
N
e
Y
f
OR
TAVI
(Class IIa)
SAVR
(Class IIa)
N
Y
Y
Figure 16 Management of patients with severe low-flow low-gradient aortic stenosis and heart failure. AS= aortic stenosis; CT = computed tomography; EuroSCORE II= European System for Cardiac Operative Risk Evaluation II; LVEF= left ventricular ejection fraction; OMT = optimal medical therapy;
SAVR= surgical aortic valve replacement; STS-PROM = Society of Thoracic Surgeons Predicted Risk of Mortality; TAVI= transcatheter aortic valve implantation. aValve area <_1 cm2, peak velocity <4.0 m/s, mean gradient <40; stroke volume index <_35 mL/m2. bAge >70 years, typical symptoms without other explanations, left ventricular hypertrophy or reduced left ventricular longitudinal function, mean gradient 3040 mmHg, valve area <_0.8 cm2, stroke volume index <_35 mL/m2 assessed by techniques other than standard Doppler. cFlow reserve is defined as stroke volume index increase >20%. dAS is very likely if calcium score is >_3000 in men and >_1600 in women. AS is likely if calcium score is >_2000 in men and >_1200 in women. AS is unlikely if calcium score is <1600 in men and <800 in women. eIncrease in valve area to >1.0 cm2 in response to flow increase (flow reserve) during dobutamine echo.
fIncrease in mean gradient to at least 40 mmHg without significant change in valve area in response to flow increase (flow reserve) during dobutamine echo. gSAVR is recommended in patients aged <75 years and low surgical risk (STS-PROM score or EuroSCORE II <4%), whereas TAVI in those aged
>75 years or at high/prohibitive surgical risk (STS-PROM score or EuroSCORE II >8%). In all the other cases, the choice between TAVI and SAVR is recommended to be decided by the Heart Team, weighing the pros and cons of each procedure, according to age, life expectancy, individual patient preference and features including clinical and anatomical aspects. Colour code for classes of recommendation: Green for Class of recommendation I; Yellow for
Class of recommendation IIa (see Table 1 for further details on classes of recommendation).
ESC Guidelines
3663


<!-- PAGE 66 -->

### Page 66

...........................
12.3.2
Aortic regurgitation
Severe aortic regurgitation can lead to progressive LV dilation with subsequent dysfunction, HF, and poor prognosis.
MT can improve HF symptoms in patients with severe aortic regurgitation. In particular, inhibitors of the RAAS can be useful.601
Beta-blockers should be cautiously used as they prolong diastole and may worsen aortic regurgitation.
Aortic valve surgery is recommended in patients with severe aortic regurgitation and HF symptoms regardless of LVEF.592,602,603 In case of high or prohibitive surgical risk, TAVI has been used to treat also aortic regurgitation.604
12.3.3
Mitral regurgitation
Primary (organic) mitral regurgitation
Primary mitral regurgitation (MR) is caused by abnormalities of the valve apparatus and can cause HF.
Surgery, preferably repair, is recommended in patients with severe primary MR and HF symptoms. If surgery is contraindicated
Management of secondary mitral regurgitation in patients with HFrEF
PCI
(Class IIb)
CABG and mitral valve surgery
(Class IIa)
Heart Team
(Class I)
Need for coronary revascularization
OMT including CRT
if indicated
Y
N
Y
High surgical risk
Persistence of HF symptomsa and significant SMRb
N
MT optimization and implant CRT if indicated
(Class I)
Y
N
N
Y
Consider surgery if low-risk
(Class IIb)
Percutaneous EE
mitral valve repair
(Class IIa)
Consider percutaneous
EE mitral valve repair to improve symptoms or as BTT or to LVAD
(Class IIb)
Maintain ongoing therapy.
Consider palliative care and/or MCS or HT,
if possible
HeartTeam
(Class I)
Follow-up
Echocardiographic and clinical criteria for outcome improvement after percutaneous EE mitral valve repairc
N
Y
Figure 17 Management of secondary mitral regurgitation in patients with heart failure with reduced ejection fraction. BTT= bridge to transplantation;
CABG= coronary artery bypass graft; CRT = cardiac resynchronization therapy; EE= edge-to-edge; EROA= effective regurgitant orifice area; HF= heart failure; LVAD= left ventricular assist device; LVEF= left ventricular ejection fraction; LVESD=left ventricular end-systolic diameter; MCS= mechanical circulatory support; MT =medical therapy; NYHA = New York Heart Association; OMT = optimal medical therapy; PCI= percutaneous coronary intervention; SMR= secondary mitral regurgitation; TR= tricuspid regurgitation. aNYHA class IIIV. bModerate-to-severe or severe (EROA >_30 mm2). cAll of the following criteria must be fulfilled: LVEF 2050%, LVESD <70 mm, systolic pulmonary pressure <70 mmHg, absence of moderate or severe right ventricular dysfunction or severe TR, absence of haemodynamic instability.612 Colour code for classes of recommendation: Green for Class of recommendation I;
Yellow for Class of recommendation IIa; Orange for Class of recommendation IIb (see Table 1 for further details on classes of recommendation).


<!-- PAGE 67 -->

### Page 67

......................................
or considered at high risk, then percutaneous repair may be considered.592,605
Secondary (functional) mitral regurgitation
Secondary mitral regurgitation (SMR) is mostly a disease of the left ventricle. It can also be caused by mitral annulus enlargement due to LA dilation.606 Moderate or severe SMR is associated with an extremely poor prognosis in patients with HF.607,608 The assessment of MR aetiology and severity should be performed by an experienced echocardiographer applying a
multi-parametric approach, and ideally in stable patient conditions, after optimization of medical and resynchronization therapies. Being SMR a dynamic condition, echocardiographic quantification during exercise may be helpful in patients with moderate SMR at rest and symptoms during physical activity.609 Early referral of patients with HF and moderate or severe MR to a multidisciplinary Heart Team, including HF specialists, is recommended for assessment and treatment planning.
The Heart Team has to verify, first of all, that the patient is on optimal therapy, including CRT, when indicated (Figure 17).
In patients with severe SMR and HFrEF requiring revascularization,
mitral valve surgery and CABG should be considered. Isolated mitral valve surgery may be considered in symptomatic patients with severe
SMR despite optimal therapy and low surgical risk.592
Two randomized trials, MITRA-FR and COAPT, evaluated the effectiveness of percutaneous edge-to-edge mitral valve repair plus
OMT compared to OMT alone, in symptomatic patients with reduced LVEF (1540% in MITRA-FR and 2050% in COAPT) and moderate-to-severe or severe SMR [effective regurgitant orifice area
(EROA) >_ 20 mm2 in MITRA-FR and EROA >_ 30 mm2 in
COAPT].610612 MITRA-FR failed to show any benefit from the intervention on all-cause mortality or HF hospitalization at 12
months (primary endpoint; HR 1.16, 95% CI 0.731.84) and at 24
months.610,611 In contrast, COAPT showed a significant reduction in hospitalization for HF at 24 months (primary endpoint; HR 0.53, 95%
CI 0.400.70) and mortality (secondary endpoint; HR 0.62, 95% CI
0.460.82).612 Differences in patient selection, concomitant MT,
echocardiographic assessment, procedural issues and severity of
SMR in relation to the degree of LV dilatation may be responsible for the diverging results of the MITRA-FR and COAPT trials.613615
Thus, percutaneous edge-to-edge mitral valve repair should be considered for outcome improvement only in carefully selected patients who remain symptomatic (NYHA class IIIV) despite OMT, with moderate-to-severe or severe SMR (EROA >_30 mm2), favourable anatomical conditions, and fulfilling the inclusion criteria of the
COAPT study (i.e. LVEF 2050%, LV end-systolic diameter <70
mm, systolic pulmonary pressure <70 mmHg, absence of moderate or severe RV dysfunction, absence of severe TR, absence of haemodynamic instability) (Figure 17).615,616
Percutaneous edge-to-to edge mitral valve repair may also be considered to improve symptoms in patients with advanced HF,
severe SMR and severe symptoms despite OMT. In these patients,
cardiac transplantation or LVAD implantation must also be considered.376,617
Other percutaneous mitral valve repair systems, such as indirect annuloplasty, are available for treatment of SMR. This approach has a shorter learning curve and lesser technical requirements than percutaneous edge-to-to edge mitral valve repair and does not preclude different procedures once it is performed. A sham-controlled randomized trial testing a transcatheter indirect mitral annuloplasty device met its primary endpoint of mitral regurgitant volume reduction with reverse LV and LA remodelling at 12 months.618 Further studies confirmed favourable results on LA volumes and LV remodelling with trends towards improvement in mean 6MWT distance and symptoms and a reduction in HF hospitalizations in an IPD meta-analysis.619622 Transcatheter mitral valve replacement is also emerging as a possible alternative option, but randomized trials are still lacking.623
Mitral valve interventions are not recommended in patients with a life expectancy of <1 year due to extra-cardiac conditions.592
Recommendations for the management of valvular heart disease in patients with heart failure
Recommendations
Classa
Levelb
Aortic stenosis
Aortic valve intervention, TAVI or SAVR, is recommended in patients with HF and severe highgradient aortic stenosis to reduce mortality and improve symptoms.594
I
B
It is recommended that the choice between
TAVI and SAVR be made by the Heart Team,
according to individual patient preference and features including age, surgical risk, clinical, anatomical and procedural aspects, weighing the risks and beneﬁts of each approach.592
I
C
Secondary mitral regurgitation
Percutaneous edge-to-edge mitral valve repair should be considered in carefully selected patients with secondary mitral regurgitation, not eligible for surgery and not needing coronary revascularization, who are symptomaticc despite
OMT and who fulﬁl criteriad for achieving a reduction in HF hospitalizations.612
IIa
B
In patients with HF, severe secondary mitral regurgitation and CAD who need revascularization, CABG and mitral valve surgery should be considered.
IIa
C
Percutaneous edge-to-edge mitral valve repair may be considered to improve symptoms in carefully selected patients with secondary mitral regurgitation, not eligible for surgery and not needing coronary revascularization, highly symptomatic despite OMT and who do not fulﬁl criteria for reducing HF hospitalization.617
IIb
C
CABG = coronary artery bypass graft; CAD = coronary artery disease; LVEF = left ventricular ejection fraction; LVESD = left ventricular end-systolic diameter;
NYHA = New York Heart Association; OMT = optimal medical therapy; SAVR =
surgical aortic valve replacement; TAVI = transcatheter aortic valve implantation;
TR = tricuspid regurgitation.
aClass of recommendation.
bLevel of evidence.
cNYHA class IIIV.
dAll of the following criteria must be fulﬁlled: LVEF 2050%, LVESD <70 mm,
systolic pulmonary pressure <70 mmHg, absence of moderate or severe right ventricular dysfunction or severe TR, absence of haemodynamic instability.612
ESC 2021
.......................................................................................................................................
ESC Guidelines
3665


<!-- PAGE 68 -->

### Page 68

.............................................................................................................................................................................
12.3.4
Tricuspid regurgitation
Tricuspid regurgitation (TR) can be caused by or be a consequence of RV dysfunction and HF. The management of HF with TR includes
MT (i.e. diuretics, neurohormonal antagonists). Transcatheter therapy and surgery may be considered in selected cases.592 A multidisciplinary Heart Team, including HF specialists, should be considered for assessment and treatment planning.
Tricuspid valve surgery is recommended in patients with severe
TR requiring left-sided cardiac surgery. It should be also considered in patients with moderate TR and tricuspid annulus dilatation requiring left-sided cardiac surgery and in symptomatic patients with isolated severe TR.592 However, surgery in isolated TR is burdened by high in-hospital mortality (8.8%) although the advanced stage of HF
may have influenced these data.624 Transcatheter techniques have recently emerged as potential treatment options of TR. Preliminary results show improvement in TR severity and symptoms with low complication rates.625 Further prospective studies are needed to show the prognostic impact of these treatments in HF patients.
12.4 Hypertension
Arterial hypertension is a leading risk factor for the development of
HF. Almost two-thirds of HF patients have a past history of hypertension.104,626 Clinical trials evaluating antihypertensive strategies and BP
targets in patients with HF and hypertension have not been performed.
Treatment of HFrEF is similar in hypertensive and normotensive patients. Recommended medications, including neurohormonal antagonists and diuretics, lower also BP. Lifestyle modifications, such as weight loss, reduced sodium intake, and increased physical activity,
are useful adjunctive measures.4 Uncontrolled hypertension in patients with HFrEF is rare, provided the patient is receiving OMT at recommended doses for HF. If further BP lowering is required, in absence of signs of fluid overload, amlodipine and felodipine have been shown to be safe in HFrEF and may be considered.570,571 Nondihydropyridine CCBs (diltiazem and verapamil) and centrally acting agents, such as moxonidine, are contraindicated as they are associated with worse outcomes.627 Alpha-blockers have no effects on survival and are therefore not indicated.143 They can be used for the treatment of concomitant prostatic hyperplasia but should be withdrawn in cases of hypotension.
Hypertension is the most important cause of HFpEF, with a prevalence of 60% to 89%.39 Patients with HFpEF also frequently have an exaggerated hypertensive response to exercise and may present with hypertensive acute pulmonary oedema.628,629 Antihypertensive agents, including ACE-I, ARBs, beta-blockers, CCB, and diuretics reduce the incidence of HF.630,631 Reducing BP leads also to LVH
regression, the degree of which depends on the class of drug used.4
ARBs, ACE-I, and CCBs cause more effective LVH regression than beta-blockers or diuretics.632 Poorly controlled hypertension may precipitate episodes of decompensation. Causes of secondary hypertension, such as renal vascular or parenchymal disease, primary aldosteronism and obstructive sleep apnoea (OSA), should be ruled out or, if confirmed, considered for treatment. Treatment of hypertension is an important issue in patients with HFpEF, but the optimal treatment strategy is uncertain. The treatment strategy used in
HFrEF should also be considered in HFpEF.4
BP targets are uncertain in both HFrEF and HFpEF. However, evaluation of patient’s age and comorbidities (i.e. diabetes, CKD, CAD,
valvular heart disease and stroke) can be helpful to personalize the
BP target.4 Every effort should be made to reach target doses of evidence-based medications in HFrEF patients, despite slight hypotension.4,633 Conversely, in HFpEF patients with LVH and limited preload reserve, hypotension should be avoided.
12.5 Stroke
HF and stroke frequently coexist because of an overlap of shared risk factors and subsequent mechanisms.519,634 A higher risk of stroke is present also in HF patients in SR.39,426,635637 AF confers an additional risk and patients with HF and AF have a five-fold increased risk compared to the control population.519,634,638
As a temporal trend, the incidence of stroke is higher in the first
30 days after HF diagnosis or an episode of HF decompensation and decreases in the first 6 months following the acute event.637,639
Patients with stroke and HF have higher mortality, more severe neurological deficits and longer hospital stays than those without
HF.637,640 Similarly, patients with HF and stroke have a higher mortality than patients without stroke.640 In COMMANDER-HF, 47.5% of strokes were either disabling, 16.5%, or fatal, 31%.637
Patients with HF and concomitant AF, including paroxysmal AF,
have a CHA2DS2-VASc score of at least 1 and have therefore an indication to anticoagulation. The indication to antithrombotic strategies in patients with HF and SR is controversial. In the Warfarin and
Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial, warfarin reduced ischaemic stroke as compared with aspirin, but increased major haemorrhages and did not influence the primary endpoint of ischaemic stroke, intracerebral haemorrhage, or death.641 Meta-analyses confirm an increased risk of bleeding outweighing ischaemic stroke prevention in placebo-controlled trials in patients with HFrEF and SR.642 In COMMANDER-HF, rivaroxaban
2.5 mg b.i.d. did not improve the composite outcome of all-cause mortality, MI or stroke, nor did it favourably influence HF-related deaths or HF hospitalizations.579 There are no data to support a routine strategy of anticoagulation in patients with HFrEF in SR who do not have history of paroxysmal AF. However, low-dose rivaroxaban may be considered in patients with concomitant CCS or peripheral artery disease, a high risk of stroke and no major haemorrhagic risk
(see section 12.2).
Patients with visible intraventricular thrombus or at high thrombotic risk, such as those with history of peripheral embolism or some patients with PPCM or LV non-compaction (LVNC), should be considered for anticoagulation.3,643645
13 Non-cardiovascular comorbidities
13.1 Diabetes
Treatment of HF is similar in patients with and without diabetes.6,646
Conversely, antidiabetic drugs differ in their effects in patients with
HF and preference must be given to drugs that are both safe and reduce HF-related events.6,646,647


<!-- PAGE 69 -->

### Page 69

.............................................................................................
The SGLT2 inhibitors canagliflozin, dapagliflozin, empagliflozin,
ertugliflozin and sotagliflozin were studied in patients with established
CV disease in the EMPA-REG OUTCOME and VERTIS-CV trials,
with established CV disease or CV risk factors in the CANVAS and
DECLARE-TIMI 58 trials, and with CKD and CV risk in the SCORED
trial, respectively.293297 A small proportion of patients had a history of HF. Empagliflozin and canagliflozin reduced the primary composite endpoint of major CV adverse events, including CV death or nonfatal MI or non-fatal stroke, and HF hospitalizations in EMPA-REG
OUTCOME and CANVAS, respectively.293,294 Empagliflozin also reduced all-cause death or CV death alone.293 The effects on the primary endpoint were driven by the reduction in HF-related events.293,294 In DECLARE-TIMI 58, dapagliflozin did not reduce major CV events but reduced the co-primary efficacy endpoint of CV
death or HF hospitalization and HF hospitalization alone.295 In
VERTIS-CV, neither the primary major CV event endpoint nor the key secondary outcome of CV death or HF hospitalization were reduced significantly by ertugliflozin, although there was a statistically significant reduction in HF hospitalization and repeated hospitalizations.297,648 In SCORED, sotagliflozin reduced CV deaths and HF
hospitalizations.296 In a meta-analysis of these trials and one further trial in patients with CKD (CREDENCE), overall SGLT2 inhibitors reduced HF and CV hospitalization by 22%.649 SGLT2 inhibitors were well tolerated, although they may cause genital fungal skin infections and, rarely, diabetic ketoacidosis.293295 Trial results with dapagliflozin and empagliflozin in patients with HFrEF, with or without diabetes, and with the SGLT1/2 inhibitor sotagliflozin in patients with type 2 diabetes stabilized after hospitalization for acute HF or within
3 days after discharge, further support the administration of these agents (see section 5.3.5 and section 11.3.11).108,109,136
EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58, and
VERTIS-CV also showed a reduction in worsening renal function,
end-stage renal disease or death from renal causes, with SGLT2
inhibitors.
Based on these results, the SGLT inhibitors canagliflozin, dapagliflozin, empagliflozin, ertugliflozin or sotagliflozin are recommended to prevent HF and CV death and worsening kidney function in patients with type 2 diabetes and CV disease and/or CV risk factors,
or CKD. Dapagliflozin and empagliflozin are also indicated for the treatment of patients with type 2 diabetes and HFrEF (see section 5.3.5 and section 11.2.4) and sotagliflozin was shown to reduce CV deaths and HF rehospitalizations in patients recently hospitalized for HF.6,296,646,647,650
Metformin is thought to be safe in patients with HF, compared with insulin and sulfonylureas, based on observational studies.651,652
However, it is not recommended in patients with an eGFR <30 mL/
min/1.73 m2 or hepatic impairment because of the risk of lactic acidosis. It has not been studied in controlled outcome trials, to date.6,646
Regarding dipeptidyl peptidase-4 (DPP-4) inhibitors, HF hospitalizations were increased by 27% in one trial with saxagliptin in patients with diabetes.653 However, no difference over placebo for HF events was found with alogliptin, sitagliptin, and linagliptin.654656 Vidagliptin was associated with an increase in LV volumes and a numerically greater number of deaths and CV events in a small trial in patients with diabetes and HF.657 Overall, the effects on mortality or CV
events were neutral in the DPP-4 inhibitor trials and metaanalyses.658,659 These drugs are therefore not recommended to reduce CV events in diabetic patients with HF.
Glucagon-like peptide-1 (GLP-1) receptor agonists reduce the risk of MI, stroke, and CV death in patients with diabetes, although probably do not reduce incident HF.6,660 Liraglutide had no effect on
LVEF, increased heart rate, and increased serious cardiac events in a randomized placebo-controlled trial in 241 patients with HFrEF with and without diabetes.661 Neutral results on the primary endpoint were found in another trial in 300 patients with a numerical increase in deaths and HF hospitalizations, compared with placebo.662 GLP-1
receptor agonists are therefore not recommended for the prevention of HF events.
Insulin is needed in patients with type 1 diabetes and to control hyperglycaemia in some patients with type 2 diabetes, especially when beta-cell function is exhausted. It is a sodium-retaining hormone and concern has been raised that it may exacerbate fluid retention in patients with HF. However, in a RCT that included patients with type 2 diabetes, impaired glucose tolerance, or impaired fasting glucose, insulin did not increase the risk of incident HF.663 Use of insulin was associated with poorer outcomes in retrospective analyses of randomized trials and administrative databases.664,665 If insulin is needed in a patient with HF, the patient should be monitored for evidence of worsening of HF after treatment initiation.
Sulfonylureas were associated with a higher risk of HF events in some analyses.666,667 Therefore, they are not a preferred treatment in patients with HF and, if needed, patients should be monitored for evidence of worsening of HF after treatment initiation.6,646
Thiazolidinediones (glitazones) cause sodium and water retention and an increased risk of worsening HF and hospitalization.668 They are contraindicated in patients with HF.
13.2 Thyroid disorders
Assessment of thyroid function is recommended in all patients with HF
as both hypo- and hyperthyroidism may cause or precipitate HF.669
Subclinical hypothyroidism and isolated low triiodothyronine levels
Recommendations for the treatment of diabetes in heart failure
Recommendation
Classa
Levelb
SGLT2 inhibitors (canagliﬂozin, dapagliﬂozin,
empagliﬂozin, ertugliﬂozin, sotagliﬂozin) are recommended in patients with T2DM at risk of CV
events to reduce hospitalizations for HF, major
CV events, end-stage renal dysfunction, and CV
death.293297
I
A
SGLT2 inhibitors (dapagliﬂozin, empagliﬂozin,
and sotagliﬂozin) are recommended in patients with T2DM and HFrEF to reduce hospitalizations for HF and CV death.108,109,136
I
A
CV = cardiovascular; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; SGLT2 = sodium-glucose co-transporter 2; T2DM = type 2 diabetes mellitus.
aClass of recommendation.
bLevel of evidence.
ESC 2021
.............................................................................
ESC Guidelines
3667


<!-- PAGE 70 -->

### Page 70

.............................................................................................................................................................................
were associated with poorer outcomes in observational studies in patients with HF.670,671 Treatment of thyroid disorders should be guided by general endocrine guidelines. There are no randomized trials evaluating the efficacy of thyroid replacement therapy in subclinical hypothyroidism, but there is a general agreement to correct it when the TSH is >10 mIU/L, particularly in patients <70 years. Correction may also be considered at lower TSH levels (710 mIU/L).672674
13.3 Obesity
Obesity is a risk factor for hypertension and CAD and is also associated with an increased risk of HF. There is possibly a stronger association with HFpEF.258,675677 Once obese patients have HF, an obesity paradox has been described such that overweight or mildly/moderately obese patients have a better prognosis than leaner patients, particularly compared with those who are underweight.678,679 However,
other variables may influence this relationship and the obesity paradox is not observed in patients with diabetes.680,681 Second, BMI
does not take into account body composition, e.g. the relation between lean skeletal muscle mass and fat mass. Obese patients who are fit and have a preserved skeletal muscle mass have better prognosis than obese sarcopenic patients.682 Waist circumference or the waist-to-hip ratio, measuring visceral obesity, is less influenced by muscle mass and may have a stronger relationship with outcomes than BMI, especially in female patients.683,684
Body fat has a major impact on the diagnostic and prognostic value of multiple parameters. Obese patients with HF have lower NP concentrations due to increased expression of clearance receptors and augmented peptide degradation by the adipose tissue.74 Peak oxygen consumption adjusted for body weight underestimates exercise capacity in obese patients and an adjustment for lean body mass should be used for risk stratification.96
Obesity may be a major cause of HFpEF and obese HFpEF patients display several pathophysiologic mechanisms that differ from nonobese patients with HFpEF.258,675677,685 Caloric restriction and exercise training had additive beneficial effects on exercise capacity and QOL of patients with obesity and HFpEF in a randomized trial.337
13.4 Frailty, cachexia, sarcopenia
Frailty is a multidimensional dynamic state, independent of age, that makes the individual more vulnerable to the effect of stressors.686 HF
and frailty are two distinct yet commonly associated conditions. The assessment of frailty in patients with HF is crucial as it is associated with both unfavourable outcomes and reduced access to, and tolerance of, treatments. Several tools have been proposed for frailty screening and assessment in different chronic conditions, including HF.
The HFA of ESC has developed a HF-specific tool based on four major domains, clinical, psycho-cognitive, functional, and social.686
Frailty is more prevalent in patients with HF than in the general population and may occur in up to 45% of the patients, according to a recent meta-analysis.687,688 Patients with HF are up to six times more likely to be frail, and frail people have a significantly increased risk of developing HF.689,690 Frailty is associated with a higher risk of death,
hospitalizations, and functional decline as well as with a longer duration of hospital stay.691693 The treatment of frailty in HF should be multifactorial and targeted to its main components and may include physical rehabilitation with exercise training, nutritional supplementation as well as an individualized approach to treating comorbidities.686
Cachexia is defined as a ‘complex metabolic syndrome associated with underlying illness and characterized by loss of muscle with or without loss of fat mass’.694 Its major clinical feature is a >5%
oedema-free body weight loss during the previous 12 months or less.694,695 Cachexia is a generalized wasting process that may coexist with frailty and may occur in 515% of patients with HF, especially those with HFrEF and more advanced disease status. It is associated with reduced functional capacity and decreased survival.695698 As it is associated with other chronic diseases, such as cancer, alternative,
non-cardiac causes for cachexia should always be investigated.699
Sarcopenia is defined by the presence of low muscle mass together with low muscle function, strength, or performance.698 It is usually identified by an appendicular skeletal muscle mass, defined as the sum of the muscle mass of the four limbs, 2 standard deviation below the mean of a healthy reference group aged 1840years with a cut-off value of 7.26 kg/m2 for men.688,700,701 It occurs physiologically with aging. However, it is accelerated by chronic diseases, such as cancer and HF. Sarcopenia can be found in 2050% of patients with HFrEF
and is often associated with frailty and increased morbidity and mortality. It is a major determinant of outcomes outweighing the effect of body weight and BMI.684,698,701,702 So far, the most effective strategy for sarcopenia treatment is resistance exercise training, possibly combined with a protein intake of 11.5 g/kg/day.698,703 Drug treatments,
including anabolic compounds like testosterone, growth hormone,
ghrelin receptor agonists, were tested in small studies, showing favourable results mostly in terms of exercise capacity and muscle strength.697,703705 There are no data showing a favourable impact of sarcopenia treatment on outcomes. However, exercise training has favourable effects in patients with HF (see section 9.4).95,323329
13.5 Iron deficiency and anaemia
Iron deficiency and anaemia are common in patients with HF, being independently associated with reduced exercise capacity, recurrent
HF hospitalizations, and high CV and all-cause mortality.706,707
According to the World Health Organization criteria, anaemia is defined as a haemoglobin concentration <12 g/dL in women and
<13 g/dL in men. In patients with HF, iron deficiency is defined as either a serum ferritin concentration <100 ng/mL or 100299 ng/
mL with transferrin saturation (TSAT) <20%.708710 Ferritin tissue expression and concentration in the peripheral blood is increased by inflammation and several disorders such as infection, cancer, liver disease, and HF itself. Hence, higher cut-off values have been applied for the definition of iron deficiency in patients with HF.709711 Another marker reflecting depleted intracellular iron can be high serum soluble transferrin receptors, which derives from proteolysis of the membrane transferrin receptor. Its synthesis is increased in case of iron deficiency and is not affected by inflammation. High serum soluble transferrin receptors identify patients at high risk of death beyond standard prognostic variables.711,712 However, its applicability for iron supplementation therapy has not been demonstrated yet.
Iron deficiency, which can be present independently of anaemia, is present in up to 55% of chronic HF patients and in up to 80% of those with AHF.713716 It may be caused by increased loss, reduced intake or absorption (i.e. malnutrition, gut congestion) and/or impaired iron metabolism caused by the chronic inflammatory activation of HF,
although the exact cause of iron deficiency in HF remains unknown.
Iron deficiency may impair functional capacity, precipitate circulatory


<!-- PAGE 71 -->

### Page 71

..........................................................................................................................................................................
decompensation, promote skeletal muscle dysfunction, and is associated with frailty, irrespective of anaemia.716718
It is recommended that all patients with HF are regularly screened for anaemia and iron deficiency with full blood count, serum ferritin concentration, and TSAT. The detection of anaemia and/or iron deficiency should prompt appropriate investigation to define their cause.
Darbepoetin-alpha failed to reduce all-cause death or HF hospitalization and increased the risk of thromboembolic events in the only large-scale randomized trial in patients with HFrEF and mild to moderate anaemia.719 As a result, erythropoietin stimulating agents are not indicated for the treatment of anaemia in HF.
RCTs have shown that iron supplementation with i.v. ferric carboxymaltose is safe and improves symptoms, exercise capacity, and
QOL of patients with HFrEF and iron deficiency.720723 Metaanalyses of RCTs showed also a reduction in the risk of the combined endpoints of all-cause death or CV hospitalization, CV death or HF
hospitalization, CV death or recurrent CV or HF hospitalizations.724,725 The favourable effects of iron supplementation were independent from anaemia coexistence.726 In AFFIRM-AHF, patients hospitalized for HF with LVEF <50% and concomitant iron deficiency were randomized to i.v. ferric carboxymaltose or placebo, repeated at 6- and then 12-week intervals if indicated according to repeat iron studies.512 Administration of ferric carboxymaltose did not significantly reduce the primary composite outcome of total HF hospitalizations and CV death at 52 weeks (rate ratio 0.79, 95% CI
0.621.01, P = 0.059). However, it reduced the composite endpoint of first HF hospitalization or CV death (HR 0.80, 95% CI 0.660.98,
P = 0.030) and total HF hospitalizations (rate ratio 0.74, 95% CI
0.580.94, P = 0.013).512 Therefore, iron supplementation with i.v.
ferric carboxymaltose should be considered for the improvement of symptoms, exercise capacity, and QOL in patients with HF and LVEF
<45%. It should also be considered for the reduction of HF rehospitalizations in patients with LVEF <50% recently hospitalized for worsening HF. Ongoing trials are expected to provide more evidence on the effects of ferric carboxymaltose in patients with HFpEF. In addition, large outcomes trials with other iron formulations are ongoing in HFrEF, HFpEF, and AHF.727 Oral iron therapy is not effective in iron repletion and did not improve exercise capacity in patients with
HFrEF and iron deficiency.728 It is therefore not recommended for the treatment of iron deficiency in the patients with HF.
13.6 Kidney dysfunction
CKD and HF frequently coexist.471,707,729 They share common risk factors, such as diabetes or hypertension. CKD may worsen CV function causing hypertension and vascular calcification. HF may worsen renal function, through the effects of neurohormonal and inflammatory activation, increased venous pressure and hypoperfusion.
Oxidative stress and fibrosis likely play a major role as pathogenic mechanisms in HF with CKD.730,731
While CKD and worsening renal function both appear more common in HFpEF as compared to in HFmrEF and HFrEF, perhaps due to shared pathophysiological mechanisms, they appear to be less associated with worse outcomes in HFpEF than in HFmrEF and
HFrEF.732,733
CKD is a major independent determinant of increased mortality and morbidity in HF.471,734736 However, there are settings in which changes in serum creatinine are not associated with worse outcomes.
When RAAS inhibitors, ARNI or SGLT2 inhibitors are started, the initial decrease in the glomerular filtration pressure may decrease GFR
and increase serum creatinine. However, these changes are generally transient and occur despite improvement in patient outcomes and slower worsening of renal function in the long term. For instance, in
EMPEROR-Reduced, the placebo-corrected eGFR dip induced by empagliflozin at week 4 was of 2.4 mL/min/1.73 m2 for patients with
CKD and 2.7 mL/min/1.73 m2 for those without CKD, corresponding to a decrease from baseline of 5.2% and 3.8%, respectively. This was followed by a slower slope of eGFR decline and by a reduced rate of the composite kidney outcome with empagliflozin vs. placebo, with no difference between patients with or without CKD at baseline.109,737
Thus, with respect to the initiation of RAAS inhibitors, ARNI or
SGLT2 inhibitors, a transient decrease in renal function should not prompt their interruption. An increase in serum creatinine of <50%
above baseline, as long as it is <266 lmol/L (3 mg/dL), or a decrease in eGFR of <10% from baseline, as long as eGFR is >25 mL/min/1.73 m2,
can be considered as acceptable (see section 5.3 and Supplementary
Table 8). Also, with respect to diuretic therapy, small and transient rises in serum creatinine during treatment of acute HF are not associated with poorer outcomes when the patient is free of congestion.108,109,460462,471,729,737740
Randomized trials have shown that patients with HF and concomitant CKD are at higher risk of events but the beneficial effects of MT
Recommendations for the management of anaemia and iron deﬁciency in patients with heart failure
Recommendations
Classa
Levelb
It is recommended that all patients with HF be periodically screened for anaemia and iron deﬁciency with a full blood count, serum ferritin concentration, and TSAT.
I
C
Intravenous iron supplementation with ferric carboxymaltose should be considered in symptomatic patients with LVEF <45% and iron deﬁciency, deﬁned as serum ferritin <100 ng/mL or serum ferritin 100299 ng/mL with TSAT
<20%, to alleviate HF symptoms, improve exercise capacity and QOL.720,722,724
IIa
A
Intravenous iron supplementation with ferric carboxymaltose should be considered in symptomatic HF patients recently hospitalized for HF
and with LVEF <50% and iron deﬁciency, deﬁned as serum ferritin <100 ng/mL or serum ferritin
100299 ng/mL with TSAT <20%, to reduce the risk of HF hospitalization.512
IIa
B
HF = heart failure; LVEF = left ventricular ejection fraction; QOL = quality of life;
TSAT = transferrin saturation.
aClass of recommendation.
bLevel of evidence.
ESC 2021
ESC Guidelines
3669


<!-- PAGE 72 -->

### Page 72

.......................................................................................................................................................................
are similar, if not greater, than in the patients with normal renal function.206,471,741,742 Beta-blockers reduce mortality in HFrEF patients with moderate (eGFR 4559 mL/min/1.73 m2) and moderately severe (eGFR 3044 mL/min/1.73 m2) renal dysfunction, whereas limited evidence is available regarding patients with severe renal impairment (eGFR <30 mL/min/1.73 m2).743 Sacubitril/valsartan,
compared with enalapril, led to a slower decline in renal function,
despite a slight increase in the urinary albumin/creatinine ratio, and improved CV outcomes to a similar extent in patients with CKD vs.
the others in PARADIGM-HF.127 SGLT2 inhibitors lead to a slower decline in renal function, compared with placebo, both in patients with HFrEF and in those with CKD.108,109,737,738,744 The improvement in cardiac output after CRT or LVAD implantation may be associated with, at least, a transient improvement in renal function.471,745,746 The benefits of ICDs may be reduced in patients with severe renal dysfunction because of the competing risk of nonarrhythmic causes of death.747749
There is little direct evidence to support any recommendations for treatment of HF patients with severe CKD as to date, RCTs excluded patients with advanced stages of CKD, i.e. eGFR <30 mL/
min/1.73 m2 (Supplementary Table 23). Cut-off values for inclusion were lower in recent trials: 25 mL/min/1.73 m2 in DAPA-CKD,
20 mL/min/1.73 m2 in EMPEROR-Reduced and GALACTIC-HF, and
15 mL/min/1.73 m2 in VICTORIA, respectively.109,141,737,738,750
Despite differences in baseline characteristics between patients with severely impaired renal function and the others, no interaction between drug effects and renal function was noted in subgroup analysis of these trials.109,141,738,750
13.7 Electrolyte disorders:
hypokalaemia, hyperkalaemia,
hyponatraemia, hypochloraemia
Electrolyte disturbances are frequent in patients with HF and may often be iatrogenic.751 Serum potassium levels have a U-shaped relation with mortality with the lowest risk of death within a relatively narrow range of 4 to 5 mmol/L.752758
Hypokalaemia is defined as serum potassium <3.5 mmol/L and may occur in up to 50% of patients with HF.759 Hypokalaemia is often induced by loop and thiazide diuretic administration. It may cause lethal ventricular arrhythmias and increase CV mortality. Its treatment includes the use of RAAS inhibitors, potassium-sparing diuretics, and prescription of oral potassium supplements (i.e. potassium chloride tablets). When oral administration is not possible, potassium supplementation by infusion may be necessary (20 to 40 mmol of potassium in 2501000 mL of normal saline). Potassium-rich solution should be infused at slow rate through a large vein using a venous catheter.
Hyperkalaemia is defined as serum potassium >5 mmol/L and can be classified as mild (>5.0 to <5.5 mmol/L), moderate (5.5 to 6.0
mmol/L), or severe (>6.0 mmol/L).760 It is associated with an increased risk of hospitalization and death.752,753,755,756,761,762
Hyperkalaemia can be associated with the administration of RAAS
inhibitors, CKD and increased absorption.760 Among patients with
HF, the prevalence of hyperkalaemia at any given time among patients with HF appears to be less than 5%,757 but the incidence is much higher, at up to 40% in chronic HF and 73% in CKD over follow-up durations of approximately 1 year.753,756,757,763765 In PARADIGMHF, treatment with sacubitril/valsartan was associated with lower risk of severe hyperkalaemia, compared with enalapril.128 Life-threatening hyperkalaemia requires immediate treatment with a combination of calcium carbonate and/or sodium bicarbonate, insulin, with or without glucose, and beta adrenoceptor agonists [e.g. salbutamol, offlabel use in some European Union (EU) countries]. These agents favour potassium entry into the cells and do not increase potassium excretion. Thus, they only provide temporary benefit and rebound hyperkalaemia can occur after few hours. Loop diuretics can be administered to facilitate potassium loss.
Potassium binders bind to potassium in the gastrointestinal tract reducing its absorption. They can be used for acute and chronic potassium lowering. They include sodium polystyrene sulfonate, calcium polystyrene sulfonate, and the much better tolerated patiromer sorbitex calcium and sodium zirconium cyclosilicate (SZC). Sodium polystyrene sulfonate is still indicated in anuric or severely oliguric patients, but it should not be used in the medium or long term as it may cause severe gastrointestinal side effects, including bowel necrosis.760 Patiromer or SZC increase faecal potassium excretion and act mainly in the colon. Both compounds are effective in normalizing elevated potassium levels, maintaining normokalaemia over time and preventing the recurrence of hyperkalaemia and can be considered for treatment of hyperkalaemia766768 (see Supplementary Table
24).
Renal dysfunction and hyperkalaemia are the major causes of underuse of
RAAS
inhibitors,
particularly
MRA,
in clinical practice.342,753,758,769771 Administration of the potassium-lowering agents, patiromer or SZC, may allow their initiation or uptitration in a larger proportion of patients. This hypothesis was tested in doubleblind, placebo-controlled, randomized trials with patiromer or placebo administration to patients with CKD and hyperkalaemia, or discontinuation of RAAS inhibitors for hyperkalaemia, and with an indication for spironolactone for HF and/or resistant hypertension.
Patiromer was more likely to lower serum potassium and decreased episodes of hyperkalaemia than spironolactone initiation and uptitration.772775 The ongoing RCT DIAMOND (NCT03888066)
is testing the impact on clinical outcomes of a strategy based on patiromer administration, compared with placebo, in patients with
HFrEF who are hyperkalaemic while on RAAS inhibitors or with a history of hyperkalaemia with subsequent reduction or discontinuation of a RAAS inhibitor776,777 (see Supplementary text 13.1).
Hyponatraemia is defined as a serum sodium concentration lower than 136 mmol/L. It is common in HF and may be present in up to
30% of patients admitted to hospital with HF. It reflects neurohormonal activation and is a powerful independent marker of poor outcomes in patients with acute or chronic HF.778,779
Severe hyponatraemia may cause neurologic symptoms (seizures,
obtundation, delirium) due to cerebral oedema and may require immediate treatment with hypertonic saline with serum sodium increases by 12 mmol/L per hour, though less than 8 mmol/L in
24 h as a more rapid correction increases the risk of myelinolysis.
Intravenous treatment is not required when hyponatraemia is less


<!-- PAGE 73 -->

### Page 73

....................................................................................................................................................................
severe, e.g. >124 mmol/L, and in the absence of symptoms. As the pathogenesis of hyponatraemia in HF is dilutional, e.g. caused by water retention induced by increased vasopressin secretion, treatment is based on water restriction or vasopressin antagonists. Fluid restrictions to less than 8001000 mL/day may be indicated to achieve a negative water balance and treat hyponatraemia. Water restriction was associated with improved QOL in a small, randomized study but with only slight increases in serum sodium in an observational registry.780,781 Tolvaptan, an orally active selective arginine vasopressin V2 receptor antagonist, can be considered to increase serum sodium and diuresis in patients with persistent hyponatraemia and congestion. However, no effects on outcomes have been shown in RCTs782785 (see Supplementary text 13.1). The infusion of hypertonic saline combined with loop diuretics was associated with an increase in serum sodium levels and greater diuretic efficacy in small trials and observational studies.786788
Hypochloraemia (<96 mmol/L) is a powerful independent predictor of mortality in patients with acute and chronic HF.439,789792
Serum chloride may have a direct role in the control of renin secretion and the response to loop or thiazide diuretics.439,793 The carbonic anhydrase inhibitor acetazolamide increases chloride reabsorption causing a greater bicarbonate and sodium excretion in the proximal tubule of the nephron. It can increase serum chloride levels and diuresis in patients with severe HF at risk of diuretic resistance.145,794 It is currently being tested in a multicentre randomized study in decompensated HF.469
13.8 Lung disease, sleep-disordered breathing
Overall, COPD affects about 20% of patients with HF and has a major impact on symptoms and outcomes.795797 Due to the overlap in symptoms and signs, the differentiation between HF and COPD may be difficult. Pulmonary function testing with spirometry is recommended as the first diagnostic tool and should be considered in patients with suspected COPD. For adequate interpretation, it should be performed in stable and euvolaemic patients to avoid congestion related to obstructive pulmonary function patterns. If there is uncertainty about the reversibility of airflow obstruction, pneumology referral for more sophisticated tests (bronchodilatatory test,
bronchial provocation tests, diffusion capacity) is warranted.798,799
Treatment of HF is generally well tolerated in COPD.800 Betablockers can worsen pulmonary function in individual patients but are not contraindicated in either COPD or asthma, as stated in the
Global initiative for chronic Obstructive Lung Disease (GOLD) and the Global INitiative for Asthma (GINA), respectively.801,802 GINA
states that asthma should not be regarded as an absolute contraindication to the use of cardioselective beta-blockers (bisoprolol, metoprolol succinate, or nebivolol) with consideration of relative risks and benefits. In clinical practice, starting with low doses of cardioselective beta-blockers combined with close monitoring for signs of airway obstruction (wheezing, shortness of breath with lengthening of the expiration) should be encouraged. Although not tested in HF
patients, inhaled corticosteroids and beta-adrenergic agonists do not seem to increase CV events, including HF, in patients at high risk.803,804 Moreover, optimal COPD management can improve cardiac function.805
Sleep-disordered breathing occurs in more than one third of patients with HF and is even more prevalent in patients with AHF.
The most common types are: central sleep apnoea (CSA, similar to
Cheyne-Stokes respiration), OSA, and a mixed pattern of the two.
CSA and OSA have been shown to be associated with a worse prognosis in HF. OSA is associated with an increased risk of incident HF in men. CSA is the most common form of sleep-disordered breathing in HFrEF and HFmrEF is the most common cause of CSA.806,807
Patients with HF can be investigated for sleep-disordered breathing. History taking should involve partners. Questionnaires are instrumental in identifying patients at risk. Home monitoring can usually identify and distinguish the type of sleep apnoea. However, overnight polysomnography remains the definitive investigation.807 The use of adaptive servo-ventilation in patients with HFrEF and predominantly
CSA is not recommended, based on the results of SERVE-HF, which was neutral regarding the composite primary endpoint of death from any cause or lifesaving CV intervention, but showed an increase in both all-cause mortality and CV mortality with adaptive servo-ventilation.808 Transvenous phrenic nerve stimulation was tested in a prospective, multicentre, randomized trial involving 151 patients with
CSA.809 The primary efficacy endpoint was the reduction of the apnoea-hypopnoea index from baseline to 6 months and was achieved by a larger percentage of patients with the active treatment.
Other measurements of sleep quality and QOL were improved and no difference in any safety endpoint was found between active treatment and control.809 Similar results were observed in the 96 patients with HF.810
Patients with HFrEF being considered for a sleep-disordered breathing treatment with positive pressure airway mask must undergo formal sleep study to document the predominant type of sleep apnoea (central vs. obstructive). When sleep-disordered breathing is caused by OSA, nocturnal hypoxaemia can be treated with nocturnal oxygen supplementation, continuous positive airway pressure, bi-level positive airway pressure, and adaptive servoventilation. However, none of these interventions has been shown to have beneficial effects on outcomes in HF.807 When sleepdisordered breathing is caused by CSA, positive pressure airway masks are contraindicated in HFrEF patients.808 In these patients,
implantable phrenic nerve stimulation can be considered for symptomatic relief.
13.9 Hyperlipidaemia and lipid-modifying therapy
Two large RCTs, including mainly patients with HFrEF, as well as a meta-analysis of 24 RCTs, showed no benefit of statin treatment on
CV mortality or stroke in patients with HFrEF.811,812 A reduction in
HF hospitalizations as well as a small reduction in MI was observed in a meta-analysis of the CORONA and GISSI-HF trials.813815 Based on current evidence, routine administration of statins in patients with
HF without other indications for their use (e.g. CAD) is not
ESC Guidelines
3671


<!-- PAGE 74 -->

### Page 74

.......................................................................................................................................................................
recommended. Because there is no evidence of harm in patients on statin treatment after the occurrence of HF, there is no need for statin discontinuation for patients already treated.
13.10 Gout and arthritis
Hyperuricemia is a common finding in patients with CHF with a prevalence up to 50%.816,817 Hyperuricemia may be caused or aggravated by diuretic treatment and it is related to symptoms, exercise capacity,
severity of diastolic dysfunction and long-term prognosis.817,818 For every 1 mg/dL increase in serum uric acid levels the risk of all-cause mortality and of HF hospitalization increases by 4% and 28%, respectively.819 Both febuxostat and allopurinol reduce uric acid levels.
However, allopurinol was associated with a lower rate of all-cause death and CV death, compared with febuxostat, in a prospective,
multicentre, double-blind, non-inferiority trial enrolling 6190 patients with gout and CV disease, 20% with HF, with a median follow-up of
32 months.820 Allopurinol is therefore recommended as the firstchoice urate-lowering drug in HF patients with no contraindication.
There is no evidence that uric acid-lowering treatment has beneficial effects on LV function, symptoms or outcomes of patients with
HF.821823
With respect to treatment of acute gout attacks, non-steroidal anti-inflammatory drugs (NSAIDs) can worsen renal function and precipitate acute HF decompensation. Colchicine should be preferred as it is associated with less side effects.824 However, it, too,
should be used with caution in patients with severe renal dysfunction and is contraindicated in patients on dialysis. An increase in ventricular vulnerability was shown in experimental models.825
Arthritis is a common comorbidity and is a common cause of both self-taken and prescribed NSAIDs. These agents are relatively contraindicated as they may precipitate acute decompensation in patients with HF.826 Rheumatoid arthritis is associated with a two- to threefold increase in the risk of HF and this increased risk is independent of ischaemic heart disease, suggesting a direct role in HF pathophysiology.827,828 The safety of disease-modifying drugs used for the treatment of rheumatoid arthritis has not been established in HF. High doses of anti-tumour necrosis factor alpha agents were associated with worsening HF in initial trials and should be used with caution.
No adverse effects were noted with lower doses.829831
13.11 Erectile dysfunction
Erectile dysfunction is a serious problem in HF patients due to its association with CV risk factors, comorbidities (e.g. diabetes), lifestyle (e.g. inactivity), and treatment (e.g. drugs).832 In the general population, the prevalence of erectile dysfunction is estimated to be 50%
in men aged >_60, but erectile dysfunction can be present in up to
81% of cardiac patients across different cultures and ethnic groups.833
Optimal assessment should include both questions assessing the presence of erectile dysfunction and factors that can be related to erectile dysfunction. Numerous classes of CV drugs, particularly diuretics and beta-blockers, have been implicated causing erectile dysfunction. However, the relationships between many contemporary
CV drugs and erectile dysfunction is not clear.834 For the treatment of erectile dysfunction, phosphodiesterase type 5 inhibitors are generally safe and effective in patients with compensated HF.834,835 No studies have shown one agent to be more effective or safer than the others. However, phosphodiesterase type 5 inhibitors should not be used in patients receiving nitrates and nitrates should not be administered to patients within 24 h of sildenafil or vardenafil administration or within 48 h of tadalafil administration.834
13.12 Depression
Depression affects 20% of patients with HF and is severe in half of them. Its occurrence is higher in women and it is associated with worse clinical status and a poor prognosis.836838 Screening using a validated questionnaire is recommended when there is a clinical suspicion of depression. The Beck Depression Inventory and Cardiac
Depression Scale are the tools formally validated for the assessment of depression in patients with HF. Other questionnaires (e.g.
Geriatric Depression Scale, Hamilton Depression Scale, Hospital
Anxiety and Depression Scale) can also be used.837,838
There is still no consensus on the best therapy for HF patients with depression. Psychosocial intervention may improve depressive symptoms but has no effect on prognosis of depressed patients with
HF.839 Depressive symptoms may improve with selective serotonin reuptake inhibitors but trials specifically designed to assess the effect of these drugs in patients with HF and depression have failed to show any significant benefit over placebo on both symptoms and outcomes.840,841 Interestingly, patients improved also in the placebo arm showing the importance of better care in these patients. Both trials showed the safety of sertraline and escitalopram, respectively.840,841
Tricyclic antidepressants should be avoided for the treatment of depression in HF as they may cause hypotension, worsening HF, and arrhythmias.837,838
13.13 Cancer
HF occurs in patients with cancer as a result of the interaction among anticancer therapy, cancer itself, and patients’ CV background (risk factors and coexisting CV disease).842846 Several anticancer therapies may cause HF directly, thorough their cardiotoxic effects (Table
23), or, indirectly, through other mechanisms, such as myocarditis,
ischaemia, systemic or pulmonary hypertension, arrhythmias or valve disease.844,845,847852 HF, in turn, may affect cancer outcomes by depriving patients of effective anticancer therapies.699 Some epidemiological and experimental evidence suggests a further reciprocal interaction between cancer and HF with some, though not all, studies showing a higher incidence rate of cancer in patients with HF.853858
The prevention of HF in patients with cancer undergoing potential cardiotoxic therapies requires careful patient’s assessment and management before, during, and after cancer therapy, preferably in the context of an integrated
Cardio-Oncology service
(Figure 18).845,859,860 A CV baseline risk assessment for all patients scheduled to receive potentially cardiotoxic cancer therapies using the HFA-ICOS risk assessment is advisable.846 Baseline CV risk assessment forms have been developed for different potentially cardiotoxic cancer therapies. History of HF or CMP characterizes patients as being at very high risk or at high risk for all cancer therapies, except anti-androgen treatments for prostate cancer. An LVEF
<50% is an additional factor for high-risk patients and elevated levels


<!-- PAGE 75 -->

### Page 75

...................................................
of NPs or troponin at baseline are additional criteria of medium risk for most of the cancer treatments.846
During cancer treatment with potential cardiotoxic therapies, LV
systolic function can be monitored through echocardiography.
Chemotherapy should be reconsidered and treatment with an ACE-I
and a beta-blocker (preferably carvedilol) should be started in patients who develop LV systolic dysfunction, defined as 10% or more absolute reduction in LVEF to a value below 50%.844,861864
Global longitudinal strain can detect cardiac dysfunction at an earlier stage.865,866 A >_12% relative reduction in global longitudinal strain was compared with an LVEF decline in a prospective randomized trial in high-risk patients undergoing potentially cardiotoxic chemotherapy. Compared to treatment based on LVEF, treatment based on changes in global longitudinal strain led to the same decrease in LVEF
(primary endpoint) but with fewer patients who developed cardiac dysfunction at the end of the study, thus suggesting usefulness of global longitudinal strain for the early detection of cardiotoxicity.867
Promising results for the early detection of cardiac dysfunction have also been obtained through monitoring of biomarkers, such as NPs and troponin.868,869 Patients on immunotherapy with immune checkpoint inhibitors are at increased risk of myocarditis and should be monitored for related symptoms and signs and by weekly assessment of cardiac troponin during at least the first 6 weeks of therapy and managed accordingly.870
Timing of the imaging procedures and biomarkers assessment depend on the anticancer treatment and patient’s risk profile
(Figure 18).865 In general, all patients scheduled for potential cardiotoxic therapies must undergo a baseline evaluation that would define the level of risk for cardiotoxicity (low, medium, or high)
and the intensity of monitoring and follow-up during and after cancer treatment.865 Cancer survivors exposed to potentially cardiotoxic therapies should be periodically monitored in the long term as HF may develop several years after cancer therapy.865,871
Table 23
Cancer drugs causing heart failure
Cancer therapy
Indication
Anthracycline chemotherapy
(doxorubicin, epirubicin, daunorubicin, idarubicin)
Breast cancer, lymphoma, acute leukaemia, sarcoma
HER2-targeted therapies
(trastuzumab, pertuzumab, trastuzumab emtansine T-DM1, lapatinib, neratinib,
tucatinib)
HER2þ breast cancer
HER2þ gastric cancer
VEGF inhibitors
TKIs (sunitinib, pazopanib, sorafenib, axitinib, tivozanib, cabozantinib, regorafenib,
lenvatinib, vandetinib) and antibodies (bevacizumab, ramucirumab)
VEGF TKIs: renal cancer, hepatocellular cancer, thyroid cancer, colon cancer, sarcoma, GIST
Antibodies: breast cancer, ovarian cancer, gastric cancer, gastro-oesophageal cancer, colon cancer
Multi-targeted kinase inhibitors:
second and third generation BCR-ABL TKIs (ponatinib, nilotinib, dasatinib,
bosutinib)
Chronic myeloid leukaemia
Proteasome inhibitors
(carﬁlzomib, bortezomib, ixazomib)
Immunomodulatory drugs
(lenalidomide, pomalidomide)
Multiple myeloma
Combination RAF and MEK inhibitors
(dabrafenibþtrametinib, vemurafenibþcobimetinib, encorafenibþ
binimetinib)
RAF mutant melanoma
Androgen deprivation therapies
GnRH agonists (goserelin, leuprorelin)
Antiandrogrens (abiraterone)
Prostate cancer, breast cancer
Immune checkpoint inhibitors:
anti-programmed cell death 1 inhibitors
(nivolumab, pembrolizumab)
anti-cytotoxic T-lymphocyte-associated protein 4 inhibitor (ipilimumab)
anti-programmed death-ligand 1 inhibitors
(avelumab, atezolizumab, durvalumab)
Melanoma (metastatic and adjuvant)
Metastatic renal cancer, non-small cell lung cancer, small cell lung cancer,
refractory Hodgkin’s lymphoma, metastatic triple negative breast cancer,
metastatic urothelial cancer, liver cancer, MMR-deﬁcient cancer
GIST = gastrointestinal stromal tumour; GnRH = gonadotropin-releasing hormone; HER2 = human epidermal growth factor receptor 2; MEK = mitogen-activated protein kinase;
MMR = mismatch repair; TKI = tyrosine kinase inhibitor; VEGF = vascular endothelial growth factor.
ESC 2021
ESC Guidelines
3673


<!-- PAGE 76 -->

### Page 76

Management of patients receiving potential cardiotoxic treatments
Baseline risk assessment including clinical assessment, ECG, resting echocardiogram and cardiac biomarkers (NP, troponin)
Pre-existing heart failure or high-risk cardiovascular disease
Medium- and high-risk patientb
Increasedc surveillance with ECG
and cardiac biomarkers during treatment
Reassessment at
3 months and 12 months after completion of cancer therapy
Low-risk patientb
Standard surveillanced
Before cardiotoxic 
cancer treatmenta
After cardiotoxic 
cancer treatmenta
During cardiotoxic 
cancer treatmenta
Reassessment at
12 months after completion of cancer therapy
Surveillance every 5 years following therapies with established cardiotoxicity
(e.g. high-dose anthracycline chemotherapy)e
Follow-up by heart failure or cardio-oncology team for new heart failure or left ventricular systolic dysfunction
Figure 18 Management of patients with cancer and heart failure. ECG= electrocardiogram; HER2= human epidermal growth factor receptor 2; HF=
heart failure; HFA= Heart Failure Association; ICOS= International Cardio-Oncology Society; MEK= mitogen-activated protein kinase; NP=natriuretic peptide; VEGF= vascular endothelial growth factor. aAnthracycline chemotherapy, trastuzumab and HER2 targeted therapies, VEGF inhibitors,
proteasome inhibitors, combination RAFþMEK inhibitors. bLow, medium and high risk may be calculated using the HFA-ICOS baseline cardiovascular risk proformas.846 cIncreased surveillance is intended between 1 and 4 weeks. dStandard surveillance is intended every 3 months. e5 yearly surveillance at follow-up= clinical review every 5 years with history, examination, NP and troponin levels, and echocardiogram.865


<!-- PAGE 77 -->

### Page 77

..................................................................................................
13.14 Infection
Infective disorders may worsen HF symptoms and be a precipitant factor for AHF.872,873 Severe sepsis and pneumonia can cause myocardial injury and depress cardiac function leading to cardiac dysfunction and HF and this risk is greater in patients with a history of
HF.873875 More recently, the coronavirus disease 2019 (COVID19) pandemic has emerged as a major cause of morbidity and mortality as well as of HF decompensation.873,876878 Specific guidance is available.879 General recommendations related to infections are given in Table 24.
Influenza vaccination is associated with a reduced risk of all-cause death in patients with HF in observational studies and retrospective analyses.880882 Influenza and pneumococcal vaccination, as well as
COVID-19 vaccination, when available, should be considered in patients with HF.879,883
14 Special conditions
14.1 Pregnancy
14.1.1
Pregnancy in pre-existing heart failure
Women with pre-existing HF have a higher risk of pregnancy-related
CV complications including HF decompensation. Moderate- and high-risk patients according to the modified
World
Health
Organization (mWHO) class IIIIV should be referred to a specialist centre with a multidisciplinary Pregnancy Heart Team.884 An algorithm for the management of HF patients before and during pregnancy is reported in Figure 19.
Pre-pregnancy management includes the modification of existing
HF medications to avoid foetal harm. ACE-Is, ARBs, ARNI, MRAs,
ivabradine, and SGLT2 inhibitors are contraindicated and should be stopped prior to conception with close clinical and echocardiographic monitoring. Beta-blockers should be continued and switched to beta-1-selective blockers (bisoprolol, metoprolol succinate).
Hydralazine, oral nitrates and methyldopa can be started if required.
Therapeutic anticoagulation with low-molecular-weight heparin
(LMWH), in the first and last trimesters, and VKAs, with the usual target international normalized ratios (INRs) or LMWH for the second trimester, is recommended for patients with HF and AF. DOACs should be avoided.884
Assessment of patients with HF in pre-pregnancy or at presentation with a new pregnancy should include a clinical assessment
(symptoms, clinical examination, BP, SaO2), ECG and resting echocardiography. The modalities of delivery should be planned by cardiologists, obstetricians, and anaesthesiologists around 35 weeks in a multidisciplinary Pregnancy Heart Team. Bimonthly assessments for women in mWHO IIIII, and monthly assessments for women with pre-existing HF in mWHO III, must be performed. Women with advanced HF (LVEF <30%, NYHA class IIIIV) in mWHO IV who are pregnant can be referred to a specialist centre for counselling regarding any consideration of termination of pregnancy. The decision regarding modalities of delivery can be planned by cardiologists,
obstetricians, and anaesthesiologists around 35 weeks in a multidisciplinary Pregnancy Heart Team and discussed with the patient.884
14.1.2
New heart failure presenting during pregnancy
The increased demands on ventricular function due to the increased circulating volume and cardiac output of pregnancy can unmask preRecommendations for the management of patients with cancer and heart failure
Recommendation
Classa
Levelb
It is recommended that cancer patients at increased risk for cardiotoxicity, deﬁned by a history or risk factors of CV disease, previous cardiotoxicity or exposure to cardiotoxic agents, undergo CV evaluation before scheduled anticancer therapy, preferably by a cardiologist with experience/interest in CardioOncology.
I
C
Treatment with an ACE-I and a beta-blocker
(preferably carvedilol) should be considered in cancer patients developing LV systolic dysfunction, deﬁned as a 10% or more decrease in LVEF and to a value lower than 50%, during anthracycline chemotherapy.861,862
IIa
B
A baseline CV risk assessment should be considered in all cancer patients scheduled to receive a cancer treatment with the potential to cause heart failure.846,865
IIa
C
ACE-I = angiotensin-converting enzyme inhibitor; CV = cardiovascular; LV = left ventricular; LVEF = left ventricular ejection fraction.
aClass of recommendation.
bLevel of evidence.
Table 24
Infections in patients with heart failure
Patients with HF are at increased risk of infections and have poorer outcomes once infected.
Telemonitoring avoids the risks of infections caused by close contact. It is useful during pandemic conditions.
Telemonitoring may be implemented for patients’ follow-up in pandemic conditions.
During pandemics, HF patients should be screened for infection at the time of hospitalization, in case of urgent admissions, or before elective hospitalizations.
Careful assessment of ﬂuid status, in addition to clinical signs of HF, is mandatory during hospitalization in patients with concomitant sepsis.
Repeated measures of inferior vena cava diameter and collapsibility by echocardiography may be used to assess ﬂuid status.
OMT (including beta-blocker, ACE-I, ARB or ARNI, MRA and SGLT2
inhibitors), should be continued in chronic HF patients whenever BP and haemodynamic conditions permit and considering drug interaction with infection related therapies and side effect proﬁle.
ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin-receptor blocker; ARNI = angiotensin receptor-neprilysin inhibitor; BP = blood pressure;
HF = heart failure; MRA = mineralocorticoid receptor antagonist; OMT = optimal medical therapy; SGLT2 = sodium-glucose co-transporter 2.
ESC 2021
ESC 2021
..........................................................................
ESC Guidelines
3675


<!-- PAGE 78 -->

### Page 78

................
existing, but previously undiagnosed, causes of HF such as CMPs and valve diseases.885 Symptoms are more likely to occur in the second trimester when the demand for an increased cardiac output is the highest. Severe emotionally stressful episodes during pregnancy and delivery can also cause Takotsubo syndrome.884,885
PPCM presents as HF secondary to LV systolic dysfunction, usually shown by an LVEF <45%, occurring towards the end of pregnancy
(third trimester) or in the months following delivery without any other identifiable cause. The majority of PPCM cases are diagnosed in post-partum. The prevalence ranges from 1:100 in Nigeria to 1:1000
Management of patients with heart failure before and during pregnancy
Bi-monthly or 
monthly review
(mWHO II)
Counselling including risk assessment and educationa
Cardiac assessment including clinical assessment, ECG, echocardiogram
Review HF therapy and switch to non-teratogenic HF medication
Moderate and high-risk HF patients 
(mWHO II, II–III and IV)
Referral  to a specialist centre for high-risk pregnancies with multidisciplinary Pregnancy Heart Team
Reassessment at the beginning of the second trimester i.e. 20 weeks
Reassessment at 20 weeks
Low-risk HF patients
(mWHO I)
Discuss with a specialist centre for high-risk pregnancies
Reassessment at the beginning of the second trimester i.e. 20 weeks
Monthly review 
(mWHO III)
Urgent counselling for consideration of pregnancy termination
(mWHO IV)
Pre-pregnancy
At pregnancy diagnosis or planning
During pregnancy
Figure 19 Management of patients with heart failure before and during pregnancy. ECG= electrocardiogram; HF= heart failure; mWHO= modified
World Health Organization. aAdvice regarding contraception, HF medication, to contact HF specialist when planning pregnancy.


<!-- PAGE 79 -->

### Page 79

.......................................................................................................................................................................
in South Africa and 1:1500 in Germany.643 Prospective large cohort studies report a 6-month mortality ranging from 2.0% in Germany to
12.6% in a 206 PPCM patient cohort from South Africa.643
PPCM frequently presents with acute HF but may also present with ventricular arrhythmias and/or cardiac arrest. An LVEF <30%,
marked LV dilatation, LV end-diastolic diameter >6.0 cm, and RV
involvement are associated with adverse outcomes.643 Cardiac recovery may occur in the first 36 months though it may be delayed to up to 2 years. Recovery rates vary among regions, from
75% to less than 50%.886888
Assessment and management of pregnant patients presenting with
HF depends upon the clinical setting and severity of presentation.
Detailed cardiac assessment with echocardiography, NP levels, foetal ultrasound and foetal monitoring is recommended. In cases of new
HF or if there is diagnostic uncertainty non-contrast CMR may be considered.
Milder cases can be treated with oral diuretics, beta-blockers,
hydralazine and oral nitrates. Pregnant women presenting with signs of acute HF require urgent hospital admission. In case of PPCM presenting with severe HF and cardiogenic shock requiring inotropic or vasopressor support, transfer to an advanced HF centre, where
ECMO, LVAD and/or cardiac transplantation can be performed, is recommended. Urgent delivery by caesarean section (irrespective of gestation) should be considered with MCS immediately available.
Adrenergic agents (dobutamine, adrenaline) may have detrimental effects.889 When a PPCM patient is haemodynamically unstable, levosimendan or MCS may be considered. LVAD implantation as a BTT
or BTR should be considered in refractory cases of cardiogenic shock.643 Bromocriptine has been proposed for patients with acute
PPCM to reduce the production of a cleaved 16 kDa prolactin fragment, which may contribute to the pathophysiology of PPCM.
Bromocriptine was tested in a randomized trial in 63 patients comparing its long-term, 8 weeks, with its short-term, 1-week, treatment.
It was associated with recovery of LV function, with no difference between the two regimens and in line with the results of a previous international PPCM registry.890,891 Bromocriptine may be considered for treatment of PPCM. Untoward effects of treatment, including deep venous thrombosis and cessation of lactation, must be considered if it is initiated. It should therefore be accompanied by prophylactic (or therapeutic) anticoagulation.
14.2 Cardiomyopathies
14.2.1
Epidemiology and diagnosis
CMPs can be either inherited (genetic/familial) and/or acquired. They can also be accelerated by disease modifiers.892894 They are a heterogeneous group of diseases and are major causes of HF.895 DCM has an estimated prevalence of 1 in 250 to 1 in 500 of the general population, HCM ranges between 1 in 500 to 1 in 5000, and AC is estimated to be present in around 1 in 1000 to 1 in 5000 persons.895,896
Direct causes of CMPs include pathogenic gene variants (mutations), toxins, auto-immunity, storage diseases, infections, and tachyarrhythmias. Disease modifiers, conditions that may aggravate or trigger a CMP, include epigenetic factors and acquired modifiers,
such as pregnancy and most CV comorbidities. It is important to consider this key interaction between genetic and acquired causes during the diagnostic workup.897 Identification of an acquired cause of the CMP does not exclude an underlying pathogenic gene variant,
whereas the latter may require an additional acquired cause and/or disease modifier to become manifest clinically. The commonest causes and disease modifiers are shown in Table 25.
The key elements of the diagnostic workup for all patients with HF
and CMP are reported in Table 26.892,894,895,898,899 Specifics aspects of diagnosis and treatment are summarized in Tables 2729. Clinical history, laboratory tests, and imaging are the first-line investigations.
Echocardiography is central for the diagnosis and monitoring of
HCM, DCM, and AC. CMR imaging provides more detailed morphological and prognostic information and should be performed at baseline. The prevalence of gene mutations may vary according to the morphological phenotype or the underlying acquired cause. Gene mutations occur in up to 40% of DCM, 60% of
HCM, and 15% in chemotherapy-induced, alcoholic or peripartum
CMPs.895,898,900905 The prevalence of genetic mutations is over
10% also in non-familial DCM.898,906 Finding a pathogenic gene variant in a patient with CMP allows better prediction of the disease outcome and progression, may contribute to the indications for device implantation and inform genetic counselling for families.
Endomyocardial biopsy (EMB) with immunohistochemical quantification of inflammatory cells remains the gold standard investigation for the identification of cardiac inflammation. It may confirm the diagnosis of auto-immune disease in patients with DCM and suspected giant cell myocarditis, eosinophilic myocarditis, vasculitis and sarcoidosis.893,907 It may also help for the diagnosis of storage diseases,
including amyloid or Fabry disease, if imaging or genetic testing does not provide a definitive diagnosis (see also section 14.6). EMB might be considered also in HCM if genetic or acquired causes cannot be identified. The risks and benefits of EBM should be evaluated and this procedure should be reserved for specific situations where its results may affect treatment.
14.2.2
Treatment
The current pharmacological treatment of HF in DCM, HCM, or AC
patients does not differ from general HF management, except for peculiar aspects reported in Tables 2729. A pilot randomized study,
TRED-HF, investigated the possibility of withdrawing medical treatment in those patients with non-ischaemic DCM who had had partial to complete recovery of LVEF (>40%). However, relapse of DCM
within 6 months was observed in 44% of patients, and rapid LV
remodelling with early tissue and functional changes, even amongst patients who did not relapse, was found.271,908
In a phase 3, randomized, double-blind, placebo-controlled trial
(EXPLORER-HCM), treatment with mavacamten improved exercise capacity, LVOT obstruction, NYHA functional class, and health status in patients with obstructive HCM. This offers the possibility of disease-specific treatment for inherited CMPs. 909
ICD implantation should be considered for patients with DCM,
HCM, or AC (see section 6).895,910912 The strength of the indication varies according to the clinical risk factors for sudden cardiac death with higher priority being given to those patients with significant LGE
ESC Guidelines
3677


<!-- PAGE 80 -->

### Page 80

Table 25
Possible causes and disease modiﬁers of most frequent cardiomyopathies
Cause
Disease modifier
Phenotype
Genetic mutations
LMNA
x
DCM
TTN
x x
DCM, (HCM)
RBM20
x
DCM
MYH7
x
DCM, HCM
MYPC
x
DCM, HCM
TNNT
x
DCM, HCM
PLN
x
DCM, HCM, AC
DSP
x x
AC, DCM, myocarditis
SCN5a x
x
AC, (DCM)
Tropomyosin-1
x
DCM
Haemochromatosis (HFE gene, C282Y)
x
HCM, DCM
Galactosidase-A (Fabry disease)
x
HCM
Neuromuscular disorders
Duchenne muscular dystrophy, Becker muscular dystrophy,
myotonic dystrophy x
DCM
Syndromic disorders
Mitochondrial X-linked mutations x
DCM
Acquired diseases
Infection (viruses)
x x
Myocarditis, DCM
Immuno-mediated diseases (rheumathoid arthritis, systemic lupus erythematosus, dermatomyositis)
x x
Myocarditis, DCM
Toxic (alcohol, amphetamines, cocaine)
x x
DCM, myocarditis
Drugs (anthracyclines, trastuzumab, immune checkpoint inhibitors)
x x
DCM, myocarditis
Overload (haemochromoatosis)
x x
HCM, DCM
Peripartum (pregnancy)
x x
DCM
Comorbidities with possible interactions with the gene mutations and an effect on phenotype and outcome
Tachy-arrhythmias x
x
DCM
Diabetes mellitus x
x
DCM, HCM
Hypertension x
x
DCM, HCM
Hypo- and hyperthyroidism x
DCM, HCM, myocarditis
AC = arrhythmogenic cardiomyopathy; DCM = dilated cardiomyopathy; DSP = desmoplakin; HCM = hypertrophic cardiomyopathy; LMNA = lamin A/C; MYH7 (gene) = myosin heavy chain 7; MYPC = myosin-binding protein C; PLN = phospholamban; RBM20 = ribonucleic acid binding motif 20; SCN5a = sodium channel alpha unit 5; TTN = titin; TNNT
= troponin-T.
Table 26
Initial diagnostic assessment in patients with suspected cardiomyopathy
History including detailed questions on any systemic disease, toxic agents (chemotherapy, alcohol, drugs), and familial history of cardiac or neuromuscular disease, or sudden cardiac death in family members at young age (<50 years).
Laboratory exams including cardiac and muscular enzymes, liver and renal function, haemoglobin, white blood cell count (including differential white blood cell count to detect eosinophilia), natriuretic peptides, thyroid function tests, iron status, and markers of systemic auto-immune disease (hsCRP, antinuclear antibodies, soluble IL-2 receptor).
Standard 12-lead ECG and echocardiography to detect arrhythmias and assess cardiac structure and function and concomitant abnormalities.
Invasive coronary angiography or CTCA to rule out signiﬁcant CAD in patients with cardiac dysfunction.
CMR imaging with T1 and T2 sequencing and LGE to visualize structural changes, storage, inﬁltration, inﬂammation, ﬁbrosis and scarring.
Genetic counselling and genetic testing should be performed depending on age, family history, cardiac phenotype.
24 or 48-hour ambulatory ECG monitoring to detect atrial and ventricular arrhythmias.
CAD = coronary artery disease; CMR = cardiac magnetic resonance; CTCA = computed tomography coronary angiography; ECG = electrocardiogram; hsCRP = high-sensitivity
C-reactive protein; IL-2 = interleukin-2; LGE = late gadolinium enhancement.
ESC 2021
ESC 2021


<!-- PAGE 81 -->

### Page 81

Table 27
Dilated cardiomyopathy or hypokinetic non-dilated cardiomyopathy: speciﬁc aspects of diagnosis and treatment
Diagnostic criteria and deﬁnitions894,895
DCM: LV dilatation and systolic dysfunction in the absence of known abnormal loading conditions or signiﬁcant CAD.
HNDC: LV or biventricular global systolic dysfunction (LVEF <45%) without dilatation in the absence of known abnormal loading conditions or signiﬁcant
CAD.
DCM and HNDC can be considered “familial” if two or more ﬁrst- or second-degree relatives have DCM or HNDC, or a ﬁrst-degree relative has autopsy proven DCM and sudden death at <50 years of age.
Genetic counselling and testing892,894,898,916
Indication. All patients with a diagnosis of DCM or HNDC and all ﬁrst-degree adult relatives of these patients and a deﬁnite disease-causing mutation,
regardless of their phenotype, in order to identify genetically affected individuals at a preclinical phase.
First-degree adult relatives should have their evaluation repeated every 5 years or less when aged <50 years or non-diagnostic abnormalities are found.
Clinical evaluation, ECG, echocardiography and possibly CMR, must be performed in ﬁrst-degree relatives of patients.
Results can identify patients with DCM or HNDC at highest risk of arrhythmia and/or deserving other speciﬁc treatments.
Early identiﬁcation of asymptomatic relatives may lead to early treatment and prevention of progression to HF and proper genetic counseling.
Minimal set of genesa: TTN, LMNA, MHC, TNNT, troponin-C, MYPC, RBM20, PLN, sodium channel alpha unit, BAG3, actin alpha cardiac muscle,
nexilin, tropomyosin-1, vinculin.
The use of additional sequencing for the analysis of very large panel of genes may be considered when there is a clear familial history or structural phenotype, by preference combined with family segregation.
Endomyocardial biopsy97,907,917919
Indication. In suspected phenotypes requiring speciﬁc treatments (i.e. giant cell myocarditis, eosinophilic myocarditis, sarcoidosis, vasculitis, SLE, other systemic, auto-immune inﬂammatory conditions, or storage diseases).
Number of samples. A minimum of 5 but possibly at least 7 samples: 3 for pathology, 2 for infection (DNA, PCR) and 2 for RNA viruses/viral replication.918,919
Aetiology. Search for common cardiotropic viruses (parvovirus B19, HHV4, HHV6, enteroviruses, adenovirus and coxsackie) by quantitative rtPCR when a viral aetiology is suspected. Viral mRNA for active viral replication should be assessed, if possible.
Further assessment if indicated: CMV, HIV, Borrelia burgdorferi (Lyme disease), Coxiella burnetii (Q-fever), Trypanosoma cruzi (Chagas disease) and
SARS-CoV-2.
Immunohistochemistry. Quantiﬁcation of CD3-, CD4-, CD8- or CD45- staining lymphocytes and CD68 macrophages per mm2; anti-HLA-DR.
Histology. Haematoxylin and eosin staining, ﬁbrosis assessment with Masson’s Trichrome and Picrosirius Red, amyloid ﬁbrils detection with Congo Red.
Therapeutic options895,917
HF treatment for HFrEF (see sections 5 and 6)
LMNA, RBM20, PLN and FLN mutation. Higher risk of sudden cardiac death: early indication for primary prevention by ICD implantation should be considered (guided by risk factors as detailed).920
TTN mutation. Higher rate of LV reverse remodeling (in up to 70%), but a higher risk of atrial and ventricular tachyarrhythmias.
Lyme disease (Borrelia). Treatment with doxycycline.
Chagas disease (Trypanosoma cruzi). Speciﬁc treatment according to current recommendations.921,922
Auto-immune/inﬂammatory. Consider immunosuppressive therapy in giant cell myocarditis, eosinophilic myocarditis, sarcoidosis or vasculitis, and in highly selected patients with increased cardiac inﬂammation of unknown origin based upon multidisciplinary counselling (cardiology and immunology).
BAG3 = Bcl2-associated athanogene 3; CAD = coronary artery disease; CMR = cardiac magnetic resonance; CMV = cytomegalovirus; DCM = dilated cardiomyopathy; DNA =
deoxyribonucleic acid; ECG = electrocardiogram; FLN = ﬁlamin; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; HHV = human herpes virus; HIV =
human immunodeﬁciency virus; HLA-DR = human leukocyte antigen-DR isotype; HNDC = hypokinetic non-dilated cardiomyopathy; ICD = implantable cardioverter-deﬁbrillator; LMNA = lamin A/C; LV = left ventricular; LVEF = left ventricular ejection fraction; MHC = myosin heavy chain; MYPC = myosin-binding protein C; mRNA = messenger ribonucleic acid; NSVT = non-sustained ventricular tachycardia; PCR = polymerase chain reaction; PLN = phospholamban; RBM20 = ribonucleic acid binding motif 20; RNA =
ribonucleic acid; rtPCR = reverse transcriptase polymerase chain reaction; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; SLE = systemic lupus erythematosus; TNNT = troponin-T; TTN = titin.
aThis list of genes is not exhaustive, and will change over time, with increasing knowledge of the pathogenicity. Contact the genetic department to ask which core panel of genes they are using.
bRisk factors in patients with a conﬁrmed LMNA mutation: NSVT during ambulatory ECG monitoring, LVEF <45% at ﬁrst evaluation, male sex and non-missense mutations
(insertion, deletion, truncations, or mutations affecting splicing).
ESC 2021
ESC Guidelines
3679


<!-- PAGE 82 -->

### Page 82

Table 28
Hypertrophic cardiomyopathy: speciﬁc aspects of diagnosis and treatment
Deﬁnition895,896,923
Wall thickness >14 mm in one or more LV myocardial segments not sufﬁciently explained solely by abnormal loading conditions.
LVOTO >_30 mmHg at rest or exercise, asymmetric hypertrophy, or increased LGE in a patchy mid-wall pattern in the most hypertrophied segment,
further suggest the presence of HCM.
It can be considered familial when two or more ﬁrst- or second-degree relatives with HCM or a ﬁrst-degree relative with autopsy proven HCM and sudden death at <50 years of age are detected.
Differential diagnosis
It might be difﬁcult with physiological hypertrophy induced by intense athletic training, severe hypertension or aortic stenosis and with isolated septal hypertrophy. Consider a genetic HCM if the degree of LV hypertrophy is disproportionate with respect to the acquired trigger.
Consider amyloidosis as a cause when increased thickness of the interatrial septum, AV valve and/or RV free wall are detected (see section 14.6).
Genetic counselling and testing
Indication. Must be offered to all patients with a diagnosis of HCM to identify a possible underlying genetic cause and to all ﬁrst-degree adult relatives of patients with HCM and a deﬁnite disease-causing mutation, regardless of their phenotype, in order to identify genetically affected individuals at a preclinical phase.
Clinical evaluation, ECG and echocardiography, must be performed in ﬁrst-degree relatives who have the same deﬁnite disease-causing mutation as the index patient.
When no deﬁnite genetic mutation is identiﬁed in the index patient or genetic testing is not performed, clinical evaluation with ECG and echocardiography should be considered in ﬁrst-degree adult relatives and repeated every 25 years or less if non-diagnostic abnormalities are present.
Minimal set of genesa (sarcomeric gene mutation in up to 60% of cases): TTN, LMNA, MHC, TNNT, Troponin-C, MYPC, RMB20, PLN, Sodium channel alpha unit, BAG3, Actin Alpha Cardiac Muscle, Nexilin, Tropomyosin-1, Vinculin.898,924926
The use of additional sequencing for the analysis of very large panel of genes may be considered if there is a clear familial history or structural phenotype,
by preference combined with family segregation.
Speciﬁc conditions.
Muscular weakness: consider mitochondrial X-linked mutations, glycogen storage disorders, FHLI mutations, Friedreich’s ataxia.
Syndromic conditions (cognitive, visual impairment, drooping eyelid): consider mitochondrial X-linked mutations, Noonan syndrome, Danon disease.
Cafe´ au lait spots (lentigines): consider Leopard/Noonan syndrome
Endomyocardial biopsy
Indication. It may be considered when the baseline clinical assessment suggests cardiac inﬂammation or storage disease which cannot be diagnosed by other means896 (see also Section 14.6).
Therapeutic options895,896,923
With LVOTO
Avoid hypovolaemia (dehydration), arterial and venous dilators (nitrates and phosphodiesterase type 5 inhibitors), and digoxin.
Use non-vasodilating beta-blockers or use verapamil if beta-blockers non-tolerated or ineffective.
Low-dose loop or thiazide diuretics must be used with caution to improve dyspnoea associated with LVOTO, but avoiding hypovolaemia.
Invasive treatment (septal reduction therapy by alcohol ablation or myomectomy), in experienced centres, may be considered in those patients with a resting or maximum provoked LVOT >_50 mmHg and/or who remain symptomatic (NYHA class III or IV, syncope) despite OMT.
Novel drugs or devices may be considered once available.909,927
Symptomatic without LVOTO
Cautious use of low-dose loop or thiazide diuretics avoiding hypovolaemia.
Verapamil/diltiazem if LVEF >50% and beta-blockers are not tolerated or ineffective.
Indication to ICD
Based on sudden cardiac death risk models.928930
Consider ICD implantation if:
-
family history of sudden cardiac death in one or more ﬁrst degree relatives under 40 years of age or sudden cardiac death in a ﬁrst degree relative with conﬁrmed HCM at any age;
-
NSVT;
-
unexplained syncope.931
Fabry disease
Enzyme replacement therapy (alpha-galactosidase A deﬁciency).895
Amyloidosis. See section 14.6 and Figure 21.
AV= atrio-ventricular; BAG3= Bcl2-associated athanogene 3; ECG= electrocardiogram; HCM= hypertrophic cardiomyopathy; ICD= implantable cardioverter-deﬁbrillator; LGE=
late gadolinium enhancement; LMNA =lamin A/C; LV= left ventricular; LVEF= left ventricular ejection fraction; LVOT= left ventricular outﬂow tract; LVOTO= left ventricular outﬂow tract obstruction; MHC= myosin heavy chain; MYPC= myosin-binding protein C; NSVT= non-sustained ventricular tachycardia; NYHA= New York Heart Association; OMT
= optimal medical therapy; PLN= phospholamban; RMB20= ribonucleic acid binding motif 20; RV= right ventricular; TNNT =troponin-T; TTN= titin.
aThe list of genes is not exhaustive, and will change over time, with increasing knowledge of the pathogenicity. Contact the genetic department to ask which core panel of genes they are using.
ESC 2021


<!-- PAGE 83 -->

### Page 83

...................
on CMR, younger age, or with a specific familial/genetic phenotype
(Tables 2729). Risk models for the prediction of ICD benefits were applied to the patients enrolled in DANISH and may help for the indication to ICD implantation in DCM.166,913 Treatment of HCM and
AC,
including indications for
ICD,
are detailed in previous documents.895,896,899,912,914,915
14.3 Left ventricular non-compaction
LVNC is a very rare congenital CMP characterized by endomyocardial trabeculations that increase in number and prominence. In most cases, including when the condition is caused by mutations in the MYH7 or MYBPC3 gene, LVNC is inherited in an autosomal dominant pattern.644,937,938 A clear overlap exists in families with
Table 29
Arrhythmogenic cardiomyopathy: speciﬁc aspects of diagnosis and treatment912,915,932
Deﬁnition
Inherited heart muscle disease characterized by progressive ﬁbrofatty replacement of the RV myocardium which may act as a substrate for ventricular arrhythmias, unexplained syncope and/or sudden cardiac death.
LV involvement and systolic dysfunction occurs in >30% of AC patients, therefore its phenotype may overlap with DCM.
Diagnosis933
Based upon the evaluation of a combination of the genetic factors (most cases autosomal dominant desmosomal mutations), documentation of ventricular arrhythmias and imaging criteria (echocardiography and MRI) of RV dysplasia with the ﬁbrofatty replacement either or not conﬁrmed by EMB. Speciﬁc ECG
abnormalities can be present or absent.
Genetic counselling/testing898,912
Indication. Must be offered to all patients with a suspected AC and has to be offered to all ﬁrst-degree adult relatives of patients with AC and a deﬁnite disease-causing mutation, regardless of their phenotype in order to identify genetically affected individuals at a preclinical phase.
Genetic family screening can be also indicated for arrhythmic risk stratiﬁcation purposes.
Clinical evaluation, ECG, echocardiography and possibly CMR have to be performed in ﬁrst-degree relatives who have the same deﬁnite disease-causing mutation as the index patient.
When no deﬁnite genetic mutation is identiﬁed in the index patient or genetic testing is not performed, clinical evaluation with ECG and echocardiography should be considered in ﬁrst-degree adult relatives and repeated every 25 years or less if non-diagnostic abnormalities are present.
Minimal set of genes:
Desmosomal, mostly with isolated RV involvement: plakoglobin, DSP, PKP2, DSG2 and DSC2a
With frequent LV involvement/DCM: DSP, FLNC, SCN5A, TMEM43, FLN, LDB3, desmin, a-actinin, BAG3, NKX2-5, RBM20, SCN5A, KCNQ1, KCNH2,
TRPM4 or PLN variants in particular.
If mild LV hypertrophy: consider TNNT variants.
Cutaneous abnormalities, palmar and plantar hyperkeratosis: consider rare recessive mutations leading to Carvajal syndrome and Naxos disease. Plakoglobin
(JUP).
With CMR presentation of myocarditis along AC: consider DSP gene variants.934,935
Endomyocardial biopsy
It should be reserved to highly selected cases after all non-invasive studies have been assessed. Fibrofatty replacement with or without replacement type ﬁbrosis at RV septal biopsies are the characteristic ﬁndings. EMB has low sensitivity for the diagnosis of AC in cases of focal distribution.
Therapeutic options
HF treatment for HFrEF (see sections 5 and 6).
Competitive sports should be avoided, limit activities to leisure-time activities.936
In patients with ventricular arrhythmias: beta-blockers must be titrated to the maximally tolerated dose as ﬁrst-line therapy. Amiodarone can be considered in addition to beta-blockers or if beta-blockers contraindicated or not tolerated; ICD implantation is indicated if history of aborted sudden cardiac death or sustained and/or haemodynamically poorly tolerated ventricular tachycardia.910912
In patients with no ventricular arrhythmias: ICD can be considered (see section 6.1) even in patients with LMNA or FLNC gene mutations and LVEF
<45%.912
AC = arrhythmogenic cardiomyopathy; BAG3 = Bcl2-associated athanogene 3; CMR = cardiac magnetic resonance; DCM = dilated cardiomyopathy; DSC2 = desmocollin 2;
DSG2 = desmoglein 2; DSP = desmoplakin; ECG = electrocardiogram; EMB = endomyocardial biopsy; FLN = ﬁlamin; FLNC = ﬁlamin C; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; ICD = implantable cardioverter-deﬁbrillator; JUP = junction plakoglobin; KCNH2 = potassium voltage-gated channel subfamily H member 2;
KCNQ1 = potassium voltage-gated channel subfamily Q member 1; LDB3 = LIM domain binding 3; LMNA = lamin A/C; LV = left ventricular; LVEF = left ventricular ejection fraction; MRI = magnetic resonance imaging; NKX2-5 = NK2 transcription factor related, locus 5; PLN = phospholamban; PKP2 = plakophilin 2; RMB20 = ribonucleic acid binding motif 20; RV = right ventricular; SCN5A = sodium channel alpha subunit 5; TMEM43 = transmembrane protein 43; TNNT = troponin-T; TRPM4 = transient receptor potential cation channel subfamily M member 4.
ESC 2021
ESC Guidelines
3681


<!-- PAGE 84 -->

### Page 84

...............................................................................................................................................................
DCM and HCM phenotypes. Quite commonly individuals with features of LVNC are found in families where other affected relatives have typical HCM or DCM. Therefore, LVNC is not treated as a separate disease entity, but as a separate rare presentation of a genetic susceptibility to either HCM or DCM.939
14.4 Atrial disease
14.4.1
Definition
Atrial disease, also termed atrial failure or myopathy, can be defined as a complex of subclinical structural, electrophysiological, and functional changes that affect the atria with the potential to produce clinical consequences.606,940,941 It has been suggested that atrial disease links the pathophysiology of HF, especially HFpEF, with AF, as they often coexist, are closely inter-related and share common risk factors.606,685,942,943
14.4.2
Diagnosis
Atrial size and function can be evaluated by multimodality imaging including two- and three-dimensional echocardiography, myocardial deformation, computed tomography (CT) and CMR.944
Cardiac biomarkers, including high-sensitivity cardiac troponins and NPs, may assess pathophysiological aspects of atrial disease.945947 The increased levels of NPs in AF may also be an indicator of an underlying atrial disease.942,948 A comprehensive characterization of atrial disease combining clinical, imaging, biochemical and molecular features is, however, still lacking.
14.4.3
Management
Atrial disease is an emerging therapeutic target in the prevention of
AF, systemic thromboembolism, and perhaps HFpEF.949 As atrial disease appears to result from the intersection of shared risk factors and comorbidities predisposing to both AF and HF, diabetes mellitus,
hypertension, obesity, smoking, and physical inactivity may be of paramount importance for its development.7,950 Effective management of
HF and AF (see section 12.1.1), as well as treatment of mitral regurgitation (see section 12.3.3), may also be important to counteract atrial disease progression.
14.5 Myocarditis
14.5.1
Epidemiology and diagnosis
The incidence of acute myocarditis is estimated to be 1.5 million cases per year globally.951 The contribution of myocarditis as a cause of HF
varies by age and region from approximately 0.5% to 4.0%.918,952
Chronic, EMB proven, inflammation can be found in 9% to 30% of adult patients with a DCM.918,953 The most frequent potential aetiologies triggering acute myocarditis in Europe are reported in Table 30.
The clinical presentation of acute myocarditis may vary from mild symptoms to cardiogenic shock. Workup for the diagnosis of acute myocarditis in patients with HF is reported in Table 31 and Figure 20.
Specific criteria about biopsies and CMR are reported in Tables 32
and 33.
14.5.2
Treatment
Hospitalization for at least 48 h may be useful for patients with acute myocarditis and HF, especially when troponins are elevated and when cardiac dysfunction, and/or arrhythmias are present at initial presentation.
Despite the lack of evidence in the specific setting of acute myocarditis, treatment of HFrEF is recommended in the presence of systolic
LV dysfunction. Immunosuppression is only indicated in selected cases of acute myocarditis (Table 34). Once cardiac enzymes decrease, arrhythmias are absent, and cardiac systolic dysfunction is stabilized, standard HF therapy should be continued for at least
6 months (see also Figure 20).
Immunosuppression has been considered for treatment of patients with chronic cardiac inflammation at EMB and no evidence of active viral infection.918,919 This was associated with an improvement in cardiac function in small studies and with better outcomes in a retrospective observational study.953,963,964 Prospective trials with old or newer immunosuppressive/immunomodulatory drugs are needed. A
placebo-controlled trial testing the effects of immunoadsorption with i.v. immunoglobulins on LV function is ongoing and other treatment options are being tested.919
14.6 Amyloidosis
14.6.1
Epidemiology and diagnosis
CA or amyloid cardiomyopathy is still an underdiagnosed cause of
HF.895,965,966 The two most prevalent forms of CA are light chain immunoglobulin (AL) and transthyretin (ATTR) amyloidosis. ATTR
includes the wild-type (>90% of cases), and the hereditary or variant type (<10% of cases). It is estimated that 6% to 16% of all patients
Table 30
Aetiologies to be considered triggering acute myocarditis917
Infectious
Viral
Parvovirus B19, human herpes virus-6, EpsteinBarr virus, enteroviruses, (coxsackievirus,
adenovirus), CMV, HIV, SARS-CoV-2
Others
Borrelia, Coxiella burnetii (Q-fever)
Systemic disease
Auto-immune and others
Sarcoidosis, giant cell myocarditis, eosinophilic myocarditis, SLE, ANCA-positive vasculitis,
rheumatoid arthritis, any other auto-immune disease
Toxic
Medications
Immune check point inhibitors, anthracyclines,
clozapine, adrenergic drugs, 5-ﬂuorouracil
Other agents
Alcohol, amphetamines, cocaine
ANCA = antineutrophil cytoplasmic antibody; CMV = cytomegalovirus; HIV =
human immunodeﬁciency virus; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; SLE = systemic lupus erythematosus.
ESC 2021


<!-- PAGE 85 -->

### Page 85

...........................
with unexplained LVH or HFpEF at hospitalization or severe aortic stenosis undergoing aortic valve replacement, aged above 65 years,
may have wtTTR-CA.967972
Diagnosis and treatment of CA were recently reviewed.973 Age
>65 years and HF along with a LV wall thickness >12 mm at echocardiography are major criteria for the suspicion of CA.973 Criteria for a suspicion of CA and to confirm diagnosis are reported in Table 35,
Supplementary Table 25, and Figure 21.973,974 Cardiac imaging and
EMB or extra-cardiac biopsy are needed for the diagnosis of AL-CA
in patients with abnormal haematological tests
(Figure
21).
Technetium-labelled 99mTc-PYP or DPD or HMDP scintigraphy with planar and SPECT imaging has a specificity and positive predictive value for TTR-CA of up to 100%.975 In contrast, CMR has a sensitivity and specificity of 85% and 92%, respectively.966,976 The hereditary form should be excluded by genetic testing. EMB is the gold standard for the diagnosis of TTR-CA with nearly 100% sensitivity and specificity if specimens are collected from >4 multiple sites and tested for amyloid deposits by Congo red staining.966 However, a biopsy is not
Table 31
Diagnostic workup in suspected acute myocarditis
Deﬁnition of suspected acute myocarditis
Clinical presentation þ >_1 mandatory diagnostic test being positive (by preference CMR) in the absence of signiﬁcant coronary artery,
valvular or congenital heart disease, or other causes.
Sensitivity
Speciﬁcity
Clinical presentation
Acute/new onset chest pain, dyspnoea, signs of left and/or right HF, and/or unexplained arrhythmias or aborted sudden death.
Low
Low
Mandatory diagnostic tests
ECG
New and dynamic ST-T abnormalities, including pseudo-infarct ST segment elevation, atrial or ventricular arrhythmias, AV blocks, QRS
abnormalities.
High
Low
Laboratory tests
Elevated troponins with dynamic changes consistent with myocardial necrosis.
Standard tests including white blood cells count to exclude eosinophilia.919,954
Intermediate
Low
Echocardiography
New structural or function abnormalities, regional wall motion abnormalities or global ventricular dysfunction without ventricular dilatation or with, generally mild, dilatation, increased wall thickness due to myocardial oedema, pericardial effusion, intracardiac thrombi, not explained by other conditions (e.g., CAD, ACS or valvular heart disease).
High
Low
CMR
Oedema, inﬂammation and ﬁbrosis detection, quantiﬁcation and localization through T1 and T2 mapping, extracellular volume assessment and
LGE (see Table 33).955,956
High
Intermediate
Additional diagnostic tests
Coronary angiography or CTCA
Excludes signiﬁcant CAD or ACS in clinically suspected myocarditis.
High
High
Endomyocardial biopsy
For diagnosis and indication to speciﬁc treatment (see Table 32).
Intermediate
High
Cardiac PET
May be useful in patients who cannot undergo CMR or with suspected systemic autoimmune disease or cardiac sarcoidosis.919,957
Low
Low
Additional laboratory test
Skeletal muscle enzymes, liver and renal function, natriuretic peptides,
thyroid function tests, iron status, markers of systemic autoimmune disease.
Low
Low
CRP elevated in 8090% patients.919,954
Intermediate
Low
PCR testing of common cardiotropic viruses. It can detect systemic infection but does not prove cardiac infection and cannot substitute viral genome analysis on EMB samples.917
Circulating IgG antibodies to cardiotropic viruses are common in the absence of viral myocarditis. Very limited diagnostic usefulness.917,918
Speciﬁc test for SARS-CoV-2, Borrelia, HIV or CMV if clinical suspicion.
Low
Low
ACS = acute coronary syndrome; AV = atrio-ventricular; CAD = coronary artery disease; CMR = cardiac magnetic resonance; CMV = cytomegalovirus; CRP = C-reactive protein; CTCA = computed tomography coronary angiography; ECG = electrocardiogram; EMB = endomyocardial biopsy; HF = heart failure; HIV = human immunodeﬁciency virus;
IgG = immunoglobulin G; LGE = late gadolinium enhancement; PCR = polymerase chain reaction; PET = positron emission tomography; QRS = Q, R and S waves (combination of three of the graphical deﬂections); SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; ST = ST segment of the electrocardiogram; ST-T = ST segment and T
wave of the electrocardiogram.
ESC 2021
ESC Guidelines
3683


<!-- PAGE 86 -->

### Page 86

Management of patients with heart failure and suspected myocarditis
Clinical history, signs and symptoms, ECG, laboratory,
echocardiography, CMR imaging, coronary CT/CAGa
Treatment of CAD if present and indicated
Suspected auto-immunity,
infectious, toxic
HF treatment
Clinical stabilization 
EMB if any doubt about diagnosis
Maintain HF treatment
Consider immunosuppressive therapy or anti-infection
Y
N
Consider MCS
Figure 20 Management of patients with heart failure and acute myocarditis. ACS= acute coronary syndrome; CAD= coronary artery disease; CAG=
coronary artery angiogram; CMR= cardiac magnetic resonance; CT= computed tomography; ECG =electrocardiogram; EMB= endomyocardial biopsy;
HF= heart failure; MCS= mechanical circulatory support. aTo exclude CAD/ACS.
Table 32
Endomyocardial biopsy in patients with suspected myocarditis
Indication (see also section 4.3).
Progressive or persistent severe cardiac dysfunction and/or life-threatening ventricular arrhythmias and/or Mobitz type 2 second-degree or higher AV block with lack of short-term (<1-2 weeks) expected response to usual medical treatment.
The aim is to identify aetiology and to indicate speciﬁc treatment (e.g. giant cell myocarditis, eosinophilic myocarditis, cardiac sarcoidosis, systemic inﬂammatory disorders).97,98,917,918,958
Number and sites of the samples
A minimum of 5 but possibly at least 7 samples, 3 for pathology, 2 for infections (DNA, PCR) and 2 for RNA viruses/viral replication. Left and/or right ventricle. CMR or PET guided sampling may be considered.919
Aetiology
Quantitative PCR viral genome analysis for common cardiotropic viruses (parvovirus B19, HHV4, HHV6, enteroviruses, adenovirus and coxsackievirus) by rtPCR.
Viral mRNA for active viral replication may be assessed although it has low sensitivity.
On indication, search for CMV, HIV, Borrelia, Coxiella burnetii (Q-fever) and SARS-CoV-2.
Diagnosis of inﬂammation
Immunohistochemistry with staining for anti-CD3-, CD4-, CD8- or CD45 antibodies for lymphocytes and anti-CD68 antibodies for macrophages and antiHLA-DR antibodies.907,917,918,959
Therapeutic implications
Immunosuppressive therapy may be indicated based on the results of EMB as in giant cell myocarditis or eosinophilic myocarditis and, possibly, also in sarcoidosis, vasculitis or selected patients with increased cardiac inﬂammation of unknown origin based upon multidisciplinary counselling.98,917919,954
Antibiotics: Borrelia (Lyme disease).
Antiviral therapy: HIV, CMV, HHV6 pending on load and viral replication (mRNA).
CMR = cardiac magnetic resonance; CMV = cytomegalovirus; DNA = deoxyribonucleic acid; EMB = endomyocardial biopsy; HHV = human herpes virus; HIV = human immunodeﬁciency virus; HLA-DR = human leucocyte antigen-DR isotype; mRNA = messenger ribonucleic acid; PCR = polymerase chain reaction; PET = positron emission tomography;
RNA = ribonucleic acid; rtPCR = reverse transcriptase polymerase chain reaction; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.
ESC 2021


<!-- PAGE 87 -->

### Page 87

.......................................................................................
needed with a grade 23 positivity of scintigraphy with SPECT
(Figure 21).973
14.6.2
Therapy of amyloidosis and heart failure
Maintenance of euvolaemia is central to management but is challenging due to the markedly reduced ventricular capacitance.977 If
HF symptoms are present, a loop diuretic, possibly with an MRA,
may be given, but orthostatic hypotension may cause intolerance.
Beta-blockers, digitalis, ACE-I, ARBs, or ARNI may not be well tolerated because of hypotension, and their place in CA treatment is unsettled. Their withdrawal must be often considered due to hypotension and/or bradycardia.973,974 CCB should be avoided as they may cause severe hypotension and fatigue, or form complexes with amyloid.966
Amyloid infiltration of the atrial wall leads to atrial myopathy and electromechanical dissociation with high embolic risk.
Patients with CA and history of AF should receive anticoagulation.
There is no evidence to support anticoagulation for patients in SR, yet.7,978 Amiodarone is the preferred antiarrhythmic agent.973
Therapy of AL-CA is based on treatment of the underlying haematological problem with chemotherapy or autologous stem-cell transplant.
TTR stabilization and reduction of its production are the basis of TTR-CA treatment. Liver and/or cardiac transplantation can be considered only in end-stage disease of familial TTR-CA.
Tafamidis reduced all-cause mortality and CV hospitalizations in cardiac or non-cardiac biopsy-proven hereditary and wtTTR-CA,
mainly in those patients with NYHA class I and II at baseline.
Functional improvement occurred within 6 months, whereas the decrease in mortality took nearly 2 years to occur.979,980
Intravenous patisiran, a small RNA interfering molecule, or subcutaneous inotersen, antisense oligonucleotide against TTR, may be considered in those patients with combined hTTRpolyneuropathy and CA (Figure 21).981,982 Off-label use of diflunisal may be considered in wtTTR-CA in combination with a proton pump inhibitor.983
14.7 Iron overload cardiomyopathy
Iron overload results either from genetically determined increased intestinal iron absorption in the context of hereditary haemochromatosis (primary iron overload) or from multiple blood transfusions required for the management of haematological conditions such as beta-thalassaemia (secondary iron overload).984 In iron overload, the iron binding capacity of transferrin is saturated and non-transferrin-bound iron enters cardiomyocytes through Ltype calcium channels, causing oxidative myocardial damage.985
Table 33
Cardiac magnetic resonance in patients with suspected myocarditis955,956
Indication
Indicated at baseline, in all patients with clinical history þ ECG, elevated troponin or echocardiographic abnormalities, and signiﬁcant CAD
excluded or unlikely.
Advised at follow-up in patients with persistent dysfunction at echocardiography, arrhythmias or ECG abnormalities.a
Main ﬁndings
At baseline: T1-weighted (inﬂammation, injury) and T2-weighted (oedema)
sequences, extracellular volume and LGE within 2 weeks after symptom onset.956,960
At follow up: LGE to evaluate the degree of scarring, T1 and T2 to identify persistent inﬂammation.a
Diagnostic signiﬁcance
At least one T2-based criterion (global or regional increase of myocardial
T2 relaxation time or an increased signal intensity in T2-weighted images),
with at least one T1-based criterion (increased myocardial T1, extracellular volume, or LGE) in the acute phase.
Only one (i.e., T2-based or T1-based) marker may still support a diagnosis of acute myocardial inﬂammation in an appropriate clinical scenario, albeit with less speciﬁcity in the acute phase.
A negative T1/T2 scan does not exclude a still ongoing inﬂammatory process in the chronic phase.a
CAD = coronary artery disease; CMR = cardiac magnetic resonance; ECG = electrocardiogram; LGE = late gadolinium enhancement.
aIt takes at least 3 months before CMR signs of oedema (secondary to inﬂammation in the acute phase/baseline) disappear. At 6 months, T1 or T2 signs of oedema should have disappeared if inﬂammation would be completely absent.
Still, the absence of T1 or T2 oedema does not exclude chronic low-grade inﬂammation.
Table 34
Treatment and follow-up of acute myocarditis
HF therapy should be started if LV systolic dysfunction is present at presentation and should be continued for at least 6 months upon complete functional recovery (EF >50%).918,919
Immunosuppression for at least 612 months is required in acute myocarditis with clinical or EMB evidence of auto-immune disease, including giant cell myocarditis, vasculitis or sarcoidosis.98,917919,953,954,961
Immunosuppression is not advised on a routine basis in acute myocarditis without clinical or EMB-based evidence of auto-immune disease.917 Initial empirical administration of i.v. corticosteroids may be taken into consideration in cases of high suspicion of immune-mediated myocarditis especially if complicated by acute HF, malignant arrhythmias and/or high degree AV block.954,962
Intense sporting activities should be avoided as long as symptoms, cardiac enzymes elevated or ECG/imaging abnormalities are present and last for at least 6 months since complete recovery.936
Yearly follow-up for at least 4 years, with an ECG and echocardiography,
is needed as acute myocarditis may lead to DCM in up to 20% of cases.
AV = atrio-ventricular;
DCM = dilated cardiomyopathy;
ECG = electrocardiogram; EF = ejection fraction; EMB = endomyocardial biopsy; HF = heart failure; i.v.
= intravenous; LV = left ventricular.
ESC 2021
ESC 2021
........................................................................
ESC Guidelines
3685


<!-- PAGE 88 -->

### Page 88

.....................................................................................................
Additional iron-induced complications, such as liver disease and endocrine abnormalities, further contribute to cardiac deterioration.986,987 The end result is the development of iron overload cardiomyopathy (IOCM), which may have either a restrictive or a dilated phenotype, the former potentially evolving to the latter as the disease advances. Myocardial iron deposition can be accurately estimated by the CMRT2* technique; T2* values are correlated with left and right ventricular systolic function and predict the development of iron-induced
HF
or arrhythmias.984
Prevention of IOCM is successfully accomplished with iron chelators, including deferoxamine, deferiprone, and deferasirox, while established IOCM may be completely reversed by intensified and combined iron chelation therapy.985
14.8 Adult congenital heart disease
The management of ACHD has been reviewed in detail in a recent
ESC guideline.988 HF is a common problem affecting 2050% of the ACHD population, and an important cause of death.989 The pathophysiology of cardiac dysfunction in ACHD is often different from non-congenital (acquired) heart disease, in particular in those with: a systemic right ventricle (RV), a failing subpulmonary ventricle, a single ventricle,988 surgery-related injury, chronic pressure/volume overload in systemic and sub-pulmonary ventricles, and those with hypertrophy or non-compaction induced by gene mutations.
Therefore,
extrapolation of current HF treatment guidelines to ACHD patients is not always appropriate. In addition, the few available data on HF treatments in ACHD patients are often inconclusive and are derived from small patient cohorts. As a consequence, ACHD specific recommendations are mostly based on clinical experience or position statements.990
Importantly, ACHD patients with HF should be referred to expert centres. The general principles of management, while awaiting transfer to specialist centres, is summarized in Table 36.
Table 35
“Red ﬂags” for most common forms of cardiac amyloidosis
Type
Red Flag
TTR
AL
Extracardiac
Polyneuropathy
X
X
Dysautonomia
X
X
Skin bruising
X
Macroglossia
X
Deafness
X
Bilateral carpal tunnel syndrome
X
Ruptured biceps tendon
X
Lumbar spinal stenosis
X
Vitreous deposits
Xa
Family history
Xa
Renal insufﬁciency
X
Proteinuria
X
Cardiac
Clinical
Hypotension or normotensive if previously hypertensive
X
X
ECG
Pseudo-infarct ECG pattern
Low/decreased QRS voltage to degree of LV thickness
AV conduction disease
X
X
X
X
X
X
Laboratory
Disproportionally elevated NTproBNP to degree of HF
Persisting elevated troponin levels
X
X
X
X
Echocardiography
Granular sparkling of myocardium
Increased right ventricular wall thickness
Increased AV valve thickness
Pericardial effusion
Reduced longitudinal strain with apical sparing pattern
X
X
X
X
X
X
X
X
X
X
CMR
Subendocardial LGE
Elevated native T1 values
Increased extracellular volume
Abnormal gadolinium kinetics
X
X
X
X
X
X
X
X
AL = light chain immunoglobulin; AV = atrio-ventricular; CA = cardiac amyloidosis; CMR = cardiac magnetic resonance; ECG = electrocardiogram; HF = heart failure; LGE = late gadolinium enhancement; LV = left ventricular; NT-proBNP = Nterminal pro-B-type natriuretic peptide; QRS = Q, R and S waves (combination of three of the graphical deﬂections); TTR = transthyretin.
Modiﬁed from973.
aHereditary TTR-CA.
Recommendations for the treatment of transthyretin amyloidosis-cardiac amyloidosis
Recommendations
Classa
Levelb
Tafamidis is recommended in patients with genetic testing proven hTTR-CA and NYHA
class I or II symptoms to reduce symptoms, CV
hospitalization and mortality.979
I
B
Tafamidis is recommended in patients with wtTTR-CA and NYHA class I or II symptoms to reduce symptoms, CV hospitalization and mortality.979
I
B
CA = cardiac amyloidosis; CV = cardiovascular; hTTR = hereditary transthyretin;
NYHA = New York Heart Association; wtTTR = wild-type transthyretin.
aClass of recommendation.
bLevel of evidence.
ESC 2021
ESC 2021
..........................................................


<!-- PAGE 89 -->

### Page 89

Diagnosis and treatment of cardiac amyloidosis in heart failure patients
Cardiac amyloidosis suspected
HF and LV wall thickness ≥12 mm
AND age ≥65 or at least 1 red flaga 
Serum free light-chain assay
Serum and urine protein electrophoresis with immunofixation
99mTc-PYP, DPD or HMDP
scintigraphy with SPECT
Histological 
confirmation to subtype
(usually cardiac)b
Amyloidosis unlikely
Histological confirmation of diagnosis
(cardiac/
extracardiac)c
Tafamidis
(Class I)
Amyloidosis unlikely
Both abnormal
Abnormal haematology
No myocardial uptake
Normal haematology
Grade 1 uptake
Normal haematology
Grade 2–3 uptake
All normal
ATTR
Genetic counselling
Cardiac amyloidosis on CMR imaging
Positive or inconclusive
Negative
Consider patisiran or inotersen if hereditaryATTR
and polyneuropathy
Figure 21 Diagnosis and treatment of cardiac amyloidosis in heart failure patients. Based on.973 ATTR = transthyretin amyloidosis; CMR = cardiac magnetic resonance; DPD = 3,3-diphosphono1,2-propanodicarboxylic acid; HF = heart failure; HMDP = hydroxymethylene diphosphonate;
LV = left ventricular; SPECT = single-photon emission computed tomography; 99mTc-PYP = technetium-labelled 99mTc-pyrophosphate. aRed flags are listed in Table 35. bGenerally requires endomyocardial biopsy for a diagnosis of the cardiac subtype. cRequires biopsy that may be cardiac or abdominal.
ESC Guidelines
3687


<!-- PAGE 90 -->

### Page 90

...........................................................................................................................................................
15 Key messages
(1)
Patients with HF are classified based on their LVEF. Those with a
LVEF between 41% and 49% are defined as ‘mildly reduced LVEF’
(HFmrEF).
(2)
Measurement of NPs and echocardiography have key roles in the diagnosis of HF.
(3)
ACE-I or ARNI, beta-blockers, MRA, and SGLT2 inhibitors are recommended as cornerstone therapies for patients with HFrEF.
(4)
ICDs are recommended in selected patients with HFrEF of an ischaemic aetiology and should be considered in those with a nonischaemic aetiology.
(5)
CRT-P/D is recommended in those patients with HFrEF, in sinus rhythm, with a LBBB >_150 ms and should be considered in those with a LBBB >_130149 ms or non-LBBB >_150 ms.
(6)
Advanced HF strategies (heart transplantation/MCS) may be appropriate in selected patients.
(7)
ACE-I/ARNI, beta-blockers, and MRA may be considered in patients with HFmrEF.
(8)
The diagnosis of HFpEF requires objective evidence of cardiac structural, or functional abnormalities as well as elevated plasma
NP concentrations consistent with the presence of LV diastolic dysfunction and raised LV filling pressures. A diastolic stress test is recommended when these markers are equivocal.
(9)
To date, no treatment has been shown to reduce mortality and morbidity in patients with HFpEF.
(10)
It is recommended that all patients with HF be enrolled in a multidisciplinary HF-MP.
(11)
Exercise is recommended for all patients who are able, to improve exercise capacity and QOL, and reduce HF hospitalization.
(12)
Patients with advanced HF refractory to medical/device therapy and who do not have absolute contraindications should be referred for consideration of heart transplantation. MCS should also be considered as BTT or DT in selected patients.
(13)
Four major clinical presentations of acute HF may occur: ADHF,
acute pulmonary oedema, RV failure, and cardiogenic shock.
(14)
Treatment of acute HF is based on diuretics for congestion, inotropes, and short- term MCS for peripheral hypoperfusion.
(15)
Patients hospitalized for HF should be carefully evaluated to exclude persistent signs of congestion. Oral treatment should be optimized before discharge.
(16)
In addition to oral anticoagulation, a strategy of rhythm control including catheter ablation should be considered in patients whose symptoms and/or cardiac dysfunction are associated with AF.
(17)
SAVR or TAVI, as advised by the Heart Team, are recommended in patients with symptomatic severe aortic valve stenosis.
(18)
Patients with isolated significant SMR and COAPT criteria should be considered for percutaneous edge-to-edge repair, whereas those with SMR and CAD, who need revascularization, should be considered for surgery.
(19)
It is recommended that patients with type II diabetes are treated with SGLT2 inhibitors.
(20)
Patients should be periodically screened for anaemia and iron deficiency and i.v. iron supplementation with ferric carboxymaltose should be considered in symptomatic patients with LVEF <45%
and iron deficiency, and in patients recently hospitalized for HF
and with LVEF <_50% and iron deficiency.
Table 36
Treatment of adult congenital heart disease and heart failure in specialized centres
ACHD patients with chronic HF should be referred to specialized centres.
Speciﬁc guidelines for medical treatment of chronic HF in ACHD are lacking, and practitioners should follow the current guidelines for medical treatment of HF. It remains unknown whether the long-term use of neurohormonal modulators affects clinical outcomes and prognosis in
ACHD.
Sacubitril/valsartan may decrease morbidity,991993 however, no recommendation can be made at this moment based on the retrospective or anecdotical nature of these observations.
Co-morbidities in HF such as diabetes mellitus, AF, CSA, iron deﬁciency,
and cachexia should be treated according to speciﬁc recommendations reported in this document.
In a biventricular circulation, patients with an impaired systemic LV
should be treated with conventional HF therapy; this may also be considered in symptomatic patients with a failing systemic right ventricle.
Diuretics are recommended to control symptoms of ﬂuid retention.
Treatment of symptomatic patients with a failing single ventricle in a
Fontan circulation, or in the case of a persistent right-to-left shunt, should always be carefully initiated, taking the labile balance of ventricular preload and systemic afterload into account.
CRT may be a therapeutic option in ACHD patients with HF, but evidence in this speciﬁc setting is still lacking. Efﬁcacy of CRT will depend on the underlying structural and functional substrate, such as anatomy of the systemic ventricle (left, right, or functionally single), presence and degree of structural systemic AV valve regurgitation, primary myocardial disease or scarring, and type of electrical conduction delay.988
Treatment of acute HF in ACHD patients should be in an expert centre,
with proper knowledge of inotropes, the availability of extracorporeal membrane oxygenation, and advanced bridging techniques.988,994
Timely evaluation for transplantation by ACHD HF specialists in a transplant centre with ACHD expertise is recommended.
Ventricular assist devices can bridge patients to transplantation, or in a subgroup of patients, may be an option as destination therapy.
ACHD = adult congenital heart disease; AF = atrial ﬁbrillation; AV = atrioventricular; CRT = cardiac resynchronization therapy; CSA = central sleep apnoea; HF =
heart failure; LV = left ventricular.
ESC 2021


<!-- PAGE 91 -->

### Page 91

.............................................................................................................................................................................
16 Gaps in evidence
Major advances in the diagnosis and treatment of patients with HF
have occurred over recent years. Strong evidence for new treatment options have been given by recent RCTs and HF management may undergo major changes in the next years. New discoveries, however,
pose new challenges and many areas with lack of evidence still remain. The following is a short list of selected, common issues that deserve to be addressed in future clinical research.
(1)
Definition and epidemiology i. Further research into the underlying characteristics, pathophysiology, and diagnosis of HFmrEF and HFpEF
ii. Consensus about normal values/ranges of EF
iii. Better phenotyping of HFpEF
iv. More information on the incidence and prevalence of
‘recovered LV’ systolic function
(2)
Diagnosis i. Definitive studies on the role of biomarkers, focusing on their additive value in the diagnosis of HF
ii. More randomized studies on screening for HF in asymptomatic subjects that may translate into improved outcomes iii. Studies on biomarkers showing the impact on outcome of their measurements for the identification of subjects at risk of developing HF as well as to guide treatment in patients with HF
iv. Validated diagnostic protocols for the diagnosis of HFmrEF
and HFpEF
(3)
Pharmacotherapy of CHF
i. Pragmatic studies on the order of adding disease-modifying drugs for HFrEF
ii. Specific therapies for HFmrEF and HFpEF and, likely, their different phenotypes iii. More data and prospective clinical trials of HFrEF therapies in patients with eGFR <30 mL/min/1.73 m2
iv. Further evidence from prospective RCTs for the treatment of specific HF phenotypes: myocarditis, cardiotoxicity, inherited
CMPs, PPCM, amyloidosis v. Management strategies and therapies for ‘recovered LV’ systolic function vi. More evidence on the effects of fluid restriction, dietary salt restriction, and nutrition
(4)
Devices and interventions i. Indications for ICDs in specific subgroups of HFmrEF/HFpEF
and optimal selection of ICD candidates in HFrEF, including patients with ischaemic and non-ischaemic cardiomyopathy ii. More research on CRT efficacy in AF
iii. Further prospective randomized studies showing the impact on outcomes of AF ablation strategies compared to OMT in
HF patients iv. Further research on the percutaneous treatment of valve heart disease and its impact on patients’ outcomes and QOL
v. Larger RCTs on CCM and baroreceptor stimulation in HFrEF
(5)
Disease management i.
The role of remote monitoring strategies in HF in the post
COVID-19 era ii.
Studies on optimal models for follow-up of stable HF patients iii.
Studies to determine specific options for palliative care
(6)
Advanced HF
i.
Better definition of risk profiles according to INTERMACS and other classifications ii.
RCTs to establish the effects on outcomes of long-term MCS
in hospitalized patients as well as in ambulatory outpatients
(for instance INTERMACS 46 profiles)
iii.
Advances in long-term MCS, including strategies to reduce the risk of bleeding, thromboembolic events, and infection iv.
Advances in medical treatment for the many patients who cannot undergo MCS or heart transplantation including development of treatment strategies, novel inotropes or myotropes for patients with advanced HF
(7)
AHF
i.
Better definition and classification of patient phenotypes to facilitate improved treatment ii.
Evidence-based use of imaging techniques and biomarkers that have an impact on patients’ clinical course iii.
Development of better strategies for congestion relief, including monitoring of diuretic administration, and/or to improve organ perfusion iv.
Identification of treatments with an impact on post-discharge outcomes v.
New devices for short-term MCS
vi.
Definition of evidence-based treatment options and therapeutic algorithms for patients with cardiogenic shock
(8)
CV comorbidities i. RCTs showing best strategies for the treatment of ventricular arrhythmias ii. RCTs to establish the role of coronary revascularization procedures in different patient subsets iii. RCTs to establish the impact on patients’ outcomes and/or
QOL of percutaneous treatment of mitral or tricuspid valve disease in patients with HF
(9)
Non-CV comorbidities i.
RCTs addressing cachexia and/or sarcopenia and/or frailty and showing the impact of treatment on QOL and/or outcome ii.
RCTs of medical therapies or devices in patients with severe
CKD and HF
iii.
RCTs showing the effects on outcomes of medical treatment of electrolyte abnormalities iv.
RCTs showing the effects on outcomes of treatment of
CSA
v.
Prospective studies showing the impact on outcomes and/or
QOL of early diagnosis, better prevention and treatment of cardiotoxicity of cancer therapies vi.
Better treatment of infections and prevention of cardiac injury with infection
(10)
Special conditions i.
RCTs of treatment for PPCM
ii.
Better phenotyping of CMPs through genetic testing, biomarkers and imaging modalities, and tailoring of therapy iii.
RCTs of treatment of different types of myocarditis, including immunosuppressive therapies iv.
RCTs of new treatments of different forms of cardiac amyloid v.
Better definition and treatment of LA myopathy.
ESC Guidelines
3689


<!-- PAGE 92 -->

### Page 92

17 ‘What to do’ and ‘what not to do’ messages from the guidelines
Recommendations
Classa
Levelb
Recommendations for the diagnosis of chronic HF
BNP/NT-proBNP.c
I
B
12-lead ECG.
I
C
Transthoracic echocardiography.
I
C
Chest radiography (X-ray).
I
C
Routine blood tests for comorbidities (including full blood count, urea and electrolytes, thyroid function, fasting glucose and
HbA1c, lipids. Iron studies (TSAT and ferritin).
I
C
CMR is recommended for the assessment of myocardial structure and function in those with poor echocardiogram acoustic windows.
I
C
CMR is recommended for the characterization of myocardial tissue in suspected inﬁltrative disease, Fabry disease, inﬂammatory disease (myocarditis), LV non-compaction, amyloid, sarcoidosis, iron overload/haemochromatosis.
I
C
Invasive coronary angiography is recommended in patients with angina despite pharmacological therapy or symptomatic ventricular arrhythmias.
I
B
Cardiopulmonary exercise testing is recommended as a part of the evaluation for heart transplantation and/or MCS.
I
C
Right heart catheterization is recommended in patients with severe HF being evaluated for heart transplantation or MCS.
I
C
Recommendations for the treatment of HFrEF
ACE-I is recommended for patients with HFrEF to reduce the risk of HF hospitalization and death.
I
A
Beta-blocker is recommended for patients with stable HFrEF to reduce the risk of HF hospitalization and death.
I
A
MRA is recommended for patients with HFrEF to reduce the risk of HF hospitalization and death.
I
A
Dapagliﬂozin or empagliﬂozin are recommended for patients with HFrEF to reduce the risk of HF hospitalization and death.
I
A
Sacubitril/valsartan is recommended as a replacement for an ACE-I in patients with HFrEF to reduce the risk of HF hospitalization and death.
I
B
Diuretics are recommended in patients with HFrEF with signs and/or symptoms of congestion to alleviate HF symptoms,
improve exercise capacity and reduce HF hospitalizations.
I
C
An ARBc is recommended to reduce the risk of HF hospitalization and CV death in symptomatic patients unable to tolerate an ACE-I or ARNI (patients should also receive a beta-blocker and an MRA).
I
B
The addition of an ARB (or renin inhibitor) to the combination of an ACE-I and an MRA is not recommended in patients with
HF, because of the increased risk of renal dysfunction and hyperkalaemia.
III
C
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients who have recovered from a ventricular arrhythmia causing haemodynamic instability, and who are expected to survive for >1 year with good functional status, in the absence of reversible causes or unless the ventricular arrhythmia has occurred <48 h after a MI.
I
A
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA
class IIIII) of an ischaemic aetiology (unless they have had an MI in the prior 40 days—see below), and an LVEF <_35% despite
>_3 months of OMT, provided they are expected to survive substantially longer than 1 year with good functional status.
I
A
ICD implantation is not recommended within 40 days of an MI as implantation at this time does not improve prognosis.
III
A
ICD therapy is not recommended in patients in NYHA class IV with severe symptoms refractory to pharmacological therapy unless they are candidates for CRT, a VAD, or cardiac transplantation.
III
C
CRT is recommended for symptomatic patients with HF in SR with a QRS duration >_150 ms and LBBB QRS morphology and with LVEF <_35% despite OMT in order to improve symptoms and reduce morbidity and mortality.
I
A
CRT rather than RV pacing is recommended for patients with HFrEF regardless of NYHA class or QRS width who have an indication for ventricular pacing for high degree AV block in order to reduce morbidity. This includes patients with AF.
I
A
CRT is not recommended in patients with a QRS duration <130 ms who do not have an indication for pacing due to highdegree AV block.
III
A
Recommendations for the treatment of HFmrEF and HFpEF
Diuretics are recommended in patients with congestion and HFmrEF in order to alleviate symptoms and signs.
I
C
Continued


<!-- PAGE 93 -->

### Page 93

Screening for, and treatment of, aetiologies, and CV and non-CV comorbidities is recommended in patients with HFpEF (see relevant sections of this document).
I
C
Diuretics are recommended in congested patients with HFpEF in order to alleviate symptoms and signs.
I
C
Recommendations for the prevention of chronic HF
Treatment of hypertension is recommended to prevent or delay the onset of HF, and to prevent HF hospitalizations.
I
A
Treatment with statins is recommended in patients at high risk of CV disease or with CV disease in order to prevent or delay the onset of HF, and to prevent HF hospitalizations.
I
A
SGLT2 inhibitors (canagliﬂozin, dapagliﬂozin, empagliﬂozin, ertugliﬂozin, sotagliﬂozin) are recommended in patients with diabetes at high risk of CV disease or with CV disease in order to prevent HF hospitalizations.
I
A
Counselling against sedentary habit, obesity, cigarette smoking, and alcohol abuse is recommended to prevent or delay the onset of HF.
I
C
Other recommendations for the management of chronic HF
It is recommended that HF patients are enrolled in a multidisciplinary HF management programme to reduce the risk of HF
hospitalization and mortality.
I
A
Self-management strategies are recommended to reduce the risk of HF hospitalization and mortality.
I
A
Either home-based and/or clinic-based programmes improve outcomes and are recommended to reduce the risk of HF hospitalization and mortality.
I
A
Exercise is recommended for all patients who are able in order to improve exercise capacity and QOL, and reduce HF
hospitalization.d
I
A
Recommendations for treatment of patients with advanced HF
Patients being considered for long-term MCS must have good compliance, appropriate capacity for device handling and psychosocial support.
I
C
Heart transplantation is recommended for patients with advanced HF, refractory to medical/device therapy and who do not have absolute contraindications.
I
C
Recommendations for treatment of patients with acute HF
Oxygen is recommended in patients with SpO2 <90% or PaO2 <60 mmHg to correct hypoxaemia.
I
C
Intubation is recommended for progressive respiratory failure persisting in spite of oxygen administration or non-invasive ventilation.
I
C
Intravenous loop diuretics are recommended for all patients with AHF admitted with signs/symptoms of ﬂuid overload to improve symptoms.
I
C
Thromboembolism prophylaxis (e.g. with LMWH) is recommended in patients not already anticoagulated and with no contraindication to anticoagulation, to reduce the risk of deep venous thrombosis and pulmonary embolism.
I
A
Inotropic agents are not recommended routinely, due to safety concerns, unless the patient has symptomatic hypotension and evidence of hypoperfusion.
III
C
Routine use of opiates is not recommended, unless in selected patients with severe/intractable pain or anxiety.
III
C
IABP is not routinely recommended in post-MI cardiogenic shock.
III
B
Recommendations for management of patients after HF hospitalization
It is recommended that patients hospitalized for HF be carefully evaluated to exclude persistent signs of congestion before discharge and to optimize oral treatment.
I
C
It is recommended that evidence-based oral medical treatment be administered before discharge.
I
C
An early follow-up visit is recommended at 12 weeks after discharge to assess signs of congestion, drug tolerance, and start and/or uptitrate evidence-based therapy.
I
C
Recommendations for treatment of patients with HF and AF
Long-term treatment with an oral anticoagulant is recommended in all patients with AF, HF, and CHA2DS2-VASc score >2 in men or >3 in women.
I
A
DOACs are recommended in preference to VKAs in patients with HF, except in those with moderate or severe mitral stenosis or mechanical prosthetic heart valves.
I
A
Urgent ECV is recommended in the setting of acute worsening of HF in patients presenting with rapid ventricular rates and haemodynamic instability.
I
C
Treatment with the anti-arrhythmic agents ﬂecainide, encainide, disopyramide, dronedarone, and D-sotalol is not recommended due to safety concerns.
III
A
Continued
ESC Guidelines
3691


<!-- PAGE 94 -->

### Page 94

Diltiazem or verapamil are not recommended in patients with HFrEF, as they increase the risk of HF worsening and HF
hospitalization.
III
C
Recommendations for treatment of patients with HF and aortic stenosis
Aortic valve intervention, TAVI or SAVR, is recommended in patients with HF and severe high-gradient aortic stenosis to reduce mortality and improve symptoms.
I
B
It is recommended that the choice between TAVI and SAVR be made by the Heart Team, according to individual patient preference and features including age, surgical risk, clinical, anatomical and procedural aspects, weighing the risks and beneﬁts of each approach.
I
C
Recommendations for treatment of patients with HF and diabetes
SGLT2 inhibitors (canagliﬂozin, dapagliﬂozin, empagliﬂozin, ertugliﬂozin, sotagliﬂozin) are recommended in patients with
T2DM at risk of CV events to reduce hospitalizations for HF, major CV events, end-stage renal dysfunction, and CV death.
I
A
SGLT2 inhibitors (dapagliﬂozin, empagliﬂozin, and sotagliﬂozin) are recommended in patients with T2DM and HFrEF to reduce hospitalizations for HF and CV death.
I
A
Thiazolidinediones (glitazones) are not recommended in patients with HF, as they increase the risk of HF worsening and HF
hospitalization.
III
A
The DPP-4 inhibitor saxagliptin is not recommended in patients with HF.
III
B
Recommendations for treatment of patients with HF and iron deﬁciency
It is recommended that all patients with HF be periodically screened for anaemia and iron deﬁciency with a full blood count,
serum ferritin concentration, and TSAT.
I
C
Treatment of anaemia in HF with erythropoietin-stimulating agents is not recommended in the absence of other indications for this therapy.
III
B
Recommendation for treatment of patients with HF and sleep apnoea
Adaptive servo-ventilation is not recommended in patients with HFrEF and a predominant CSA because of an increased allcause and CV mortality.
III
A
Recommendation for treatment of patients with HF and arthritis
NSAIDs or COX-2 inhibitors are not recommended in patients with HF, as they increase the risk of HF worsening and HF
hospitalization.
III
B
Recommendation for treatment of patients with HF and cancer
It is recommended that cancer patients at increased risk for cardiotoxicity, deﬁned by a history or risk factors of CV disease,
previous cardiotoxicity or exposure to cardiotoxic agents, undergo CV evaluation before scheduled anticancer therapy, preferably by a cardiologist with experience/interest in Cardio-Oncology.
I
C
Recommendations for treatment of patients with HF and amyloidosis
Tafamidis is recommended in patients with genetic testing proven hTTR-CA and NYHA class I or II symptoms to reduce symptoms, CV hospitalization and mortality.
I
B
Tafamidis is recommended in patients with wtTTR-CA and NYHA class I or II symptoms to reduce symptoms, CV hospitalization and mortality.
I
B
ACE-I = angiotensin-converting enzyme inhibitor; AF = atrial ﬁbrillation; AHF = acute heart failure; ARB = angiotensin-receptor blocker; ARNI = angiotensin receptor-neprilysin inhibitor; AV = atrio-ventricular; BNP = B-type natriuretic peptide; CHA2DS2-VASc = congestive heart failure or left ventricular dysfunction, Hypertension, Age >_75 (doubled),
Diabetes, Stroke (doubled)-Vascular disease, Age 6574, Sex category (female) (score); CMP = cardiomyopathy; CMR = cardiac magnetic resonance; CRT = cardiac resynchronization therapy; CSA = central sleep apnoea; CV = cardiovascular; DOAC = direct-acting oral anticoagulant; DPP-4 = dipeptidyl peptidase-4; ECG = electrocardiogram; ECV =
electrical cardioversion; HbA1c = glycated haemoglobin; HF = heart failure; HFmrEF = heart failure with mildly reduced ejection fraction; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; hTTR = hereditary transthyretin; IABP = intra-aortic balloon pump; ICD = implantable cardioverter-deﬁbrillator; LBBB = left bundle branch block; LMWH = low-molecular-weight heparin; LV = left ventricular/ventricle; LVEF = left ventricular ejection fraction; MCS = mechanical circulatory support; MI = myocardial infarction; MRA = mineralocorticoid receptor antagonist; NSAID = non-steroidal anti-inﬂammatory drug; NT-proBNP = N-terminal pro-Btype natriuretic peptide; NYHA = New York Heart Association; OMT = optimal medical therapy; PaO2 = partial pressure of oxygen; QOL = quality of life; QRS = Q, R, and S
waves (on an ECG); RV = right ventricular; SAVR = surgical aortic valve replacement; SGLT2 = sodium-glucose co-transporter 2; SpO2 = transcutaneous oxygen saturation; SR
= sinus rhythm; T2DM = type 2 diabetes mellitus; TAVI = transcatheter aortic valve implantation; TSAT = transferrin saturation; VAD = ventricular assist device; VKA = vitamin K
antagonist; wtTTR-CA = wild-type transthyretin cardiac amyloidosis.
aClass of recommendation.
bLevel of evidence.
cReferences are listed in section 4.2 for this item.
dIn those who are able to adhere to the exercise programme.
ESC 2021


<!-- PAGE 95 -->

### Page 95

....................................
18 Quality indicators
QIs are tools that may be used to evaluate care quality, including that of processes of care and clinical outcomes.995 They may also serve as a mechanism for enhancing adherence to guideline recommendations, through quality assurance endeavours and benchmarking of care providers.996 As such, the role of QIs in driving quality improvement is increasingly recognized and attracts interest from healthcare authorities, professional organizations, payers, and the public.997
The ESC recognizes the need for measuring and reporting quality and outcomes of CV care. The methodology by which the ESC QIs are developed has been published997 and, to date, a suite of QIs for an initial tranche of CV conditions has been produced.998,999 To facilitate quality improvement initiatives, the disease-specific ESC QIs are included in corresponding ESC Clinical Practice Guidelines.7,1000 This is further enhanced by way of their integration in the ESC registries,
such as the EURObservational Research Programme (EORP) and the
European Unified Registries On Heart Care Evaluation and
Randomized Trials (EuroHeart) project.1001
For patients with HF, QIs may help healthcare providers to simultaneously operationalize discrete guideline recommendations and enable the discrimination between missed opportunities and appropriate care. Furthermore, QIs allow the capture of patients’
Table 37
Main European Society of Cardiology quality indicators for the evaluation of care and outcomes for patients with heart failure (a full list is published in a separate article)
Domain 1. Structural QIsa
Main (1): Centre should have a dedicated multidisciplinary team to manage patients with HF
Numerator: Availability of a dedicated multidisciplinary team to manage patients with HF.
Domain 2. Patient assessmentb
Main (1): Proportion of patients with HF who have a documentation of their HF clinical type (HFrEF, HFmrEF, HFpEF)
Numerator: Number of patients with HF who have a documentation of their HF clinical type (HFrEF, HFmrEF, HFpEF).
Denominator: Number of patients with HF.
Main (2): Proportion of patients with HF who have a documentation of their ECG ﬁndings
Numerator: Number of patients with HF who have a documentation of their ECG ﬁndings.
Denominator: Number of patients with HF.
Main (3): Proportion of patients with HF who have their NPs measured
Numerator: Number of patients with HF who have a documentation of their NPs levels.
Denominator: Number of patients with HF.
Domain 3. Initial treatment
Main (1). Proportion of patients with HFrEF who are prescribed the beta-blocker bisoprolol, carvedilol, sustained-release metoprolol succinate, or nebivolol in the absence of any contraindications
Numerator: Number of patients with HFrEF who are prescribed the beta-blocker bisoprolol, carvedilol, sustained-release metoprolol succinate, or nebivolol.
Denominator: Number of patients with HFrEF without any contraindications for the beta-blocker bisoprolol, carvedilol, sustained-release metoprolol succinate, and nebivolol.
Main (2). Proportion of patients with HFrEF who are prescribed ACE inhibitor, ARB or ARNI in the absence of any contraindications
Numerator: Number of patients with HFrEF who are prescribed an ACE inhibitor, ARB or ARNI.
Denominator: Number of patients with HFrEF without any contraindications for ACE inhibitors, ARBs and ARNI.
Main (3). Proportion of patients with HF who are prescribed diuretic therapy if they have evidence of ﬂuid retention
Numerator: Number of patients with HF, with evidence of ﬂuid retention who are prescribed diuretic therapy.
Denominator: Number of patients with HF who have evidence of ﬂuid retention and no contraindications for diuretic therapy.
Main (4): Proportion of patients with HFrEF who are prescribed an MRA in the absence of any contraindications
Numerator: Number of patients with HFrEF who are prescribed an MRA.
Denominator: Number of patients with HFrEF without any contraindications for MRA.
Main (5): Proportion of patients with HFrEF who are prescribed a SGLT2 inhibitor in the absence of any contraindications
Numerator: Number of patients with HFrEF who are prescribed a SGLT2 inhibitor.
Denominator: Number of patients with HFrEF without any contraindications for SGLT2 inhibitor.
ACE = angiotensin-converting enzyme; ARB = angiotensin-receptor blocker; ARNI = angiotensin receptor-neprilysin inhibitor; HF = heart failure; HFmrEF = heart failure with mildly reduced ejection fraction; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; ICD = implantable cardioverterdeﬁbrillator; IHD = ischaemic heart disease; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; NP = natriuretic peptide; NYHA = New York Heart Association; OMT = optimal medical therapy; QI = quality indicator; SGLT2 = sodium-glucose co-transporter 2.
aStructural QIs are binary measurements (Yes/No), and thus, have only numerator deﬁnitions.
bBlood tests include urea, creatinine, electrolytes, full blood count, glucose, glycated haemoglobin, thyroid-stimulating hormone, liver function test, lipids, and iron proﬁle.
ESC 2021
ESC Guidelines
3693


<!-- PAGE 96 -->

### Page 96

.............................................................................................................................................................................
experience. As such, and in parallel with the writing of these guidelines, a suite of QIs for the evaluation of care and outcomes for patients with HF was developed. These QIs, alongside their specifications and development process are published separately with a short summary shown in Table 37.
19 Supplementary data
Supplementary data with additional Supplementary Figures, Tables, and text complementing the full text are available on the European Heart
Journal website and via the ESC website at www.escardio.org/guidelines.
20 Author information
Author/Task Force Member Affiliations: Marianna Adamo,
Medical and Surgical Specialties, Radiological Sciences and Public,
ASST Spedali Civili di Brescia, Brescia, Italy; Andreas Baumbach,
Barts Heart Centre, Queen Mary University of London, London,
United Kingdom; Michael Bo¨hm, Klinik fu¨r Innere Medizin III,
Saarland University, Homburg/Saar, Saarland, Germany; Haran
Burri,
Cardiology,
University
Hospital of
Geneva,
Geneva,
Switzerland; Jelena Celutkien_e, Clinic of Cardiac and Vascular
Diseases, Vilnius University, Faculty of Medicine, Vilnius, Lithuania;
Ovidiu Chioncel, Emergency Institute for Cardiovascular Diseases
‘Prof. Dr.C.C.Iliescu’, University of Medicine Carol Davila, Bucuresti,
Romania; John G.F. Cleland, Robertson Centre for Biostatistics and Clinical Trials, Institute of Health & Wellbeing, Glasgow,
Lanarkshire, United Kingdom; Andrew J.S. Coats, University of
Warwick, Coventry, United Kingdom; Maria G. Crespo-Leiro,
Cardiology,
Complexo
Hospitalario
Universitario
A
Coru~na
(CHUAC), CIBERCV, Universidade da Coru~na (UDC), Instituto de
Investigacion Biomedica de A Coru~na (INIBIC), La Coru~na, Spain;
Dimitrios Farmakis, University of Cyprus Medical School,
Nicosia, Cyprus; Roy S. Gardner, Scottish National Advanced
Heart Failure Service, Golden Jubilee National Hospital, Clyderbank,
Glasgow, Scotland, United Kingdom; Martine Gilard, Cardiology,
Brest University, Brest, France; Stephane Heymans, Department of
Cardiology,
Maastricht
University,
CARIM
School for
Cardiovascular Diseases, Maastricht, Netherlands; Arno W. Hoes,
University Medical Center Utrecht, Utrecht, Netherlands; Tiny
Jaarsma, Department of Health, Medicine and Caring Science,
Linko¨ping University, Linko¨ping, Sweden; Ewa A. Jankowska,
Department of Heart Diseases, Wroclaw Medical University,
Wroclaw, Poland; Mitja Lainscak, Division of Cardiology, General
Hospital Murska Sobota, Murska Sobota, Slovenia; Carolyn S.P.
Lam,
National
Heart
Centre
Singapore and
Duke-National
University of
Singapore,
Singapore;
Alexander
R.
Lyon,
Department of Cardiology, Royal Brompton Hospital, London,
United Kingdom; John J.V. McMurray, British Heart Foundation
Cardiovascular Research Centre, University of Glasgow, Glasgow,
Scotland, United Kingdom; Alexandre Mebazaa, Anesthesiology and Critical Care, Universite´ de Paris - Hoˆpital Lariboisie`re, Paris,
France; Richard Mindham, United Kingdom, ESC Patient Forum,
Sophia Antipolis, France; Claudio Muneretto, Cardiothoracic
Surgery, Asst Spedali Civili University of Brescia, Brescia, Italy;
Massimo Francesco Piepoli, Cardiology, Guglielmo da Saliceto
Hospital, AUSL Piacenza, Piacenza, Italy; Susanna Price, Cardiology
& Adult Intensive Care Unit, Royal Brompton Hospital, London,
United Kingdom; Giuseppe M.C. Rosano, IRCCS San Raffaele,
Roma, Italy; Frank Ruschitzka, Department of Cardiology,
University Hospital Zurich, Zurich, Switzerland; Anne Kathrine
Skibelund, Denmark, ESC Patient Forum, Sophia Antipolis, France.
21 Appendix
ESC Scientific Document Group
Includes Document Reviewers and ESC National Cardiac Societies.
Document Reviewers: Rudolf A. de Boer (CPG Review
Coordinator) (Netherlands), P. Christian Schulze (CPG Review
Coordinator)
(Germany),
Magdy
Abdelhamid
(Egypt),
Victor
Aboyans (France), Stamatis Adamopoulos (Greece), Stefan D. Anker
(Germany), Elena Arbelo (Spain), Riccardo Asteggiano (Italy), Johann
Bauersachs (Germany), Antoni Bayes-Genis (Spain), Michael A.
Borger (Germany), Werner Budts (Belgium), Maja Cikes (Croatia),
Kevin Damman (Netherlands), Victoria Delgado (Netherlands), Paul
Dendale (Belgium), Polychronis Dilaveris (Greece), Heinz Drexel
(Austria), Justin Ezekowitz (Canada), Volkmar Falk (Germany),
Laurent Fauchier (France), Gerasimos Filippatos (Greece), Alan
Fraser (United Kingdom), Norbert Frey (Germany), Chris P. Gale
(United Kingdom), Finn Gustafsson (Denmark), Julie Harris (United
Kingdom), Bernard Iung (France), Stefan Janssens (Belgium), Mariell
Jessup (United States of America), Aleksandra Konradi (Russia),
Dipak Kotecha (United Kingdom), Ekatirini Lambrinou (Cyprus),
Patrizio
Lancellotti
(Belgium),
Ulf
Landmesser
(Germany),
Christophe Leclercq (France), Basil S. Lewis (Israel), Francisco Leyva
(United Kingdom), Ales Linhart (Czech Republic), Maja-Lisa Løchen
(Norway), Lars H. Lund (Sweden), Donna Mancini (United States of
America), Josep Masip (Spain), Davor Milicic (Croatia), Christian
Mueller (Switzerland), Holger Nef (Germany), Jens-Cosedis Nielsen
(Denmark), Lis Neubeck (United Kingdom), Michel Noutsias
(Germany), Steffen E. Petersen (United Kingdom), Anna Sonia
Petronio (Italy), Piotr Ponikowski (Poland), Eva Prescott (Denmark),
Amina Rakisheva (Kazakhstan), Dimitrios Richter (Greece), Evgeny
Schlyakhto (Russia), Petar Seferovic (Serbia), Michele Senni (Italy),
Marta Sitges (Spain), Miguel Sousa-Uva (Portugal), Carlo Gabriele
Tocchetti (Italy), Rhian Touyz (United Kingdom), Carsten Tschoepe
(Germany), Johannes Waltenberger (Germany).
ESC National Cardiac Societies actively involved in the review process of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:
Algeria: Algerian Society of Cardiology, Messaad Krim; Armenia:
Armenian Cardiologists Association, Hamlet Hayrapetyan; Austria:
Austrian Society of Cardiology, Deddo Moertl; Azerbaijan:
Azerbaijan Society of Cardiology, Isakh Mustafayev; Belarus:
Belorussian Scientific Society of Cardiologists, Alena Kurlianskaya;
Belgium: Belgian Society of Cardiology, Michel Depauw; Bosnia and Herzegovina: Association of Cardiologists of Bosnia and
Herzegovina, Zumreta Kusljugic; Bulgaria: Bulgarian Society of


<!-- PAGE 97 -->

### Page 97

.............................................................................................................................................................................
Cardiology, Plamen Gatzov; Croatia: Croatian Cardiac Society,
Davor Milicic; Cyprus: Cyprus Society of Cardiology, Petros
Agathangelou; Czech Republic: Czech Society of Cardiology,
Vojtech Melenovsky; Denmark: Danish Society of Cardiology,
Brian Bridal Løgstrup; Egypt: Egyptian Society of Cardiology, Ahmed
Magdy Mostafa; Estonia: Estonian Society of Cardiology, Tiina
Uuetoa; Finland: Finnish Cardiac Society, Johan Lassus; France:
French Society of Cardiology, Damien Logeart; Georgia: Georgian
Society of Cardiology, Zviad Kipiani; Germany: German Cardiac
Society, Johann Bauersachs; Greece: Hellenic Society of Cardiology,
Christina Chrysohoou; Hungary: Hungarian Society of Cardiology,
Robert Sepp; Iceland: Icelandic Society of Cardiology, Inga Jona
Ingimarsdottir; Ireland: Irish Cardiac Society, Jim O’Neill; Israel:
Israel Heart Society, Israel Gotsman; Italy: Italian Federation of
Cardiology,
Massimo
Iacoviello;
Kazakhstan:
Association of
Cardiologists of Kazakhstan, Amina Rakisheva; Kosovo (Republic of): Kosovo Society of Cardiology, Gani Bajraktari; Kyrgyzstan:
Kyrgyz Society of Cardiology, Olga Lunegova, Latvia: Latvian
Society of Cardiology, Ginta Kamzola; Lebanon: Lebanese Society of Cardiology, Tony Abdel Massih; Libya: Libyan Cardiac Society,
Hisham Benlamin; Lithuania: Lithuanian Society of Cardiology,
DianaZaliaduonyt_e;
Luxembourg:
Luxembourg
Society of
Cardiology, Stephanie Noppe; Malta: Maltese Cardiac Society, Alice
Moore; Moldova (Republic of): Moldavian Society of Cardiology,
Eleonora
Vataman;
Montenegro:
Montenegro
Society of
Cardiology, Aneta Boskovic; Morocco: Moroccan Society of
Cardiology, Ahmed Bennis; Netherlands: Netherlands Society of
Cardiology, Olivier C. Manintveld; North Macedonia: North
Macedonian Society of Cardiology, Elizabeta Srbinovska Kostovska;
Norway: Norwegian Society of Cardiology, Geeta Gulati; Poland:
Polish
Cardiac
Society,
Ewa
Straburzynska-Migaj;
Portugal:
Portuguese Society of Cardiology, Jose´ Silva-Cardoso; Romania:
Romanian Society of Cardiology, Roxana Cristina Rimbas¸; Russian
Federation: Russian Society of Cardiology, Yury Lopatin; San
Marino: San Marino Society of Cardiology, Marina Foscoli; Serbia:
Cardiology Society of Serbia, Sinisa Stojkovic; Slovakia: Slovak
Society of Cardiology, Eva Goncalvesova; Slovenia: Slovenian
Society of Cardiology, Zlatko Fras; Spain: Spanish Society of
Cardiology, Javier Segovia; Sweden: Swedish Society of Cardiology,
Krister Lindmark; Switzerland: Swiss Society of Cardiology, Micha
T.
Maeder;
Syrian
Arab
Republic:
Syrian
Cardiovascular
Association, Walid Bsata; Tunisia: Tunisian Society of Cardiology and Cardio-Vascular Surgery, Leila Abid; Turkey: Turkish Society of
Cardiology, Hakan Altay; Ukraine: Ukrainian Association of
Cardiology, Leonid Voronkov; United Kingdom of Great
Britain and Northern Ireland: British Cardiovascular Society,
Ceri
Davies,
Uzbekistan:
Association of
Cardiologists of
Uzbekistan, Timur Abdullaev.
ESC Clinical Practice Guidelines Committee (CPG): Colin
N. Baigent (Chairperson) (United Kingdom), Magdy Abdelhamid
(Egypt),
Victor
Aboyans
(France),
Sotiris
Antoniou
(United
Kingdom), Elena Arbelo (Spain), Riccardo Asteggiano (Italy), Andreas
Baumbach (United Kingdom), Michael A. Borger (Germany), Jelena
Celutkien_e (Lithuania), Maja Cikes (Croatia), Jean-Philippe Collet
(France), Volkmar Falk (Germany), Laurent Fauchier (France), Chris
P. Gale (United Kingdom), Sigrun Halvorsen (Norway), Bernard Iung
(France), Tiny Jaarsma (Sweden), Aleksandra Konradi (Russia),
Konstantinos C. Koskinas (Switzerland), Dipak Kotecha (United
Kingdom), Ulf Landmesser (Germany), Basil S. Lewis (Israel), Ales
Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Jens-Cosedis
Nielsen (Denmark), Steffen E. Petersen (United Kingdom), Eva
Prescott (Denmark), Lis Neubeck (United Kingdom), Amina
Rakisheva (Kazakhstan), Marta Sitges (Spain), Rhian M. Touyz (United
Kingdom).
22 References
1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V,
Gonzalez-Juanatey
JR,
Harjola
VP,
Jankowska
EA,
Jessup
M,
Linde
C,
Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM,
Ruschitzka F, Rutten FH, van der Meer P, ESC Scientific Document Group. 2016
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:
The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J
2016;37:21292200.
2. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT,
Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Lochen ML,
Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N,
Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binno S,
ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European
Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for
Cardiovascular
Prevention
&
Rehabilitation
(EACPR).
Eur
Heart
J
2016;37:23152381.
3. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio
ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ,
Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsky P, ESC
Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task
Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur
Heart J 2018;39:119177.
4. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement
DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope
L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R,
Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V,
Desormais I, ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39:30213104.
5. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C,
Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T,
Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J,
Muneretto C, Valgimigli M, Achenbach S, Bax JJ, ESC Scientific Document Group.
6. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M,
Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Juni P, Lettino M,
Marx N, Mellbin LG, Ostgren CJ, Rocca B, Roffi M, Sattar N, Seferovic PM, SousaUva M, Valensi P, Wheeler DC, ESC Scientific Document Group. 2019 ESC
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020;41:255323.
7. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C,
Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM,
La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN,
Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL, ESC Scientific Document
Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic
Surgery (EACTS). Eur Heart J 2021;42:373498.
8. Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, Swedberg K, Yusuf S,
Granger CB, Pfeffer MA, McMurray JJV, Solomon SD. Heart failure with midrange ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.
Eur
J
Heart
Fail
2018;20:12301239.
ESC Guidelines
3695


<!-- PAGE 98 -->

### Page 98

.............................................................................................................................................................................
9. Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, O’Meara E,
Shah SJ, McKinlay S, Fleg JL, Sopko G, Pitt B, Pfeffer MA, TOPCAT Investigators.
Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J
2016;37:455462.
10. Abdul-Rahim AH, Shen L, Rush CJ, Jhund PS, Lees KR, McMurray JJV, VICCTAHeart Failure Collaborators. Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction. Eur J Heart Fail
2018;20:11391145.
11. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, PEP-CHF
Investigators. The perindopril in elderly people with chronic heart failure (PEPCHF) study. Eur Heart J 2006;27:23382345.
12. Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS,
Manzano L, McMurray JJV, Ruschitzka F, van Veldhuisen DJ, von Lueder TG,
Bohm M, Andersson B, Kjekshus J, Packer M, Rigby AS, Rosano G, Wedel H,
Hjalmarson A, Wikstrand J, Kotecha D, Beta-blockers in Heart Failure
Collaborative Group. Beta-blockers for heart failure with reduced, mid-range,
and preserved ejection fraction: an individual patient-level analysis of doubleblind randomized trials. Eur Heart J 2018;39:2635.
13. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F,
Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ,
Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J,
Cleland J, Dungen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M,
Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP,
PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction.
N
Engl
J
Med
2019;381:16091620.
14. Lam CSP, Voors AA, Piotr P, McMurray JJV, Solomon SD. Time to rename the middle child of heart failure: heart failure with mildly reduced ejection fraction.
Eur Heart J 2020;41:23532355.
15. Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N,
Anker SD, Atherton J, Bohm M, Butler J, Drazner MH, Michael Felker G,
Filippatos G, Fiuzat M, Fonarow GC, Gomez-Mesa JE, Heidenreich P, Imamura T,
Jankowska EA, Januzzi J, Khazanie P, Kinugawa K, Lam CSP, Matsue Y, Metra M,
Ohtani T, Francesco Piepoli M, Ponikowski P, Rosano GMC, Sakata Y, Seferovic
P, Starling RC, Teerlink JR, Vardeny O, Yamamoto K, Yancy C, Zhang J, Zieroth
S. Universal definition and classification of heart failure: a report of the Heart
Failure Society of America, Heart Failure Association of the European Society of
Cardiology, Japanese Heart Failure Society and Writing Committee of the
Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure
Society, Heart Failure Association of India, Cardiac Society of Australia and New
Zealand,
and
Chinese
Heart
Failure
Association.
Eur
J
Heart
Fail
2021;23:352380.
16. Galderisi M, Cosyns B, Edvardsen T, Cardim N, Delgado V, Di Salvo G, Donal E,
Sade LE, Ernande L, Garbi M, Grapsa J, Hagendorff A, Kamp O, Magne J, Santoro
C, Stefanidis A, Lancellotti P, Popescu B, Habib G, EACVI Scientific Documents
Committee. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European
Association of
Cardiovascular
Imaging.
Eur
Heart
J
Cardiovasc
Imaging
2017;18:13011310.
17. Arrigo M, Huber LC, Winnik S, Mikulicic F, Guidetti F, Frank M, Flammer AJ,
Ruschitzka F. Right ventricular failure: pathophysiology, diagnosis and treatment.
Card Fail Rev 2019;5:140146.
18. Gorter TM, van Veldhuisen DJ, Bauersachs J, Borlaug BA, Celutkiene J, Coats
AJS, Crespo-Leiro MG, Guazzi M, Harjola VP, Heymans S, Hill L, Lainscak M,
Lam CSP, Lund LH, Lyon AR, Mebazaa A, Mueller C, Paulus WJ, Pieske B, Piepoli
MF, Ruschitzka F, Rutten FH, Seferovic PM, Solomon SD, Shah SJ, Triposkiadis F,
Wachter R, Tschope C, de Boer RA. Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of
Cardiology. Eur J Heart Fail 2018;20:1637.
19. Caraballo C, Desai NR, Mulder H, Alhanti B, Wilson FP, Fiuzat M, Felker GM,
Pina IL, O’Connor CM, Lindenfeld J, Januzzi JL, Cohen LS, Ahmad T. Clinical implications of the New York Heart Association classification. J Am Heart Assoc
2019;8:e014240.
20. Solomon SD, Claggett B, Packer M, Desai A, Zile MR, Swedberg K, Rouleau J,
Shi V, Lefkowitz M, McMurray JJV. Efficacy of sacubitril/valsartan relative to a prior decompensation:
the
PARADIGM-HF
trial.
JACC
Heart
Fail
2016;4:816822.
21. Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, Allison M,
Hemingway H, Cleland JG, McMurray JJV, Rahimi K. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals.
Lancet 2018;391:572580.
22. Dunlay SM, Roger VL. Understanding the epidemic of heart failure: past, present,
and future. Curr Heart Fail Rep 2014;11:404415.
23. Roth GA, Forouzanfar MH, Moran AE, Barber R, Nguyen G, Feigin VL, Naghavi
M, Mensah GA, Murray CJ. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med 2015;372:13331341.
24. Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev
2017;3:711.
25. Meyer S, Brouwers FP, Voors AA, Hillege HL, de Boer RA, Gansevoort RT, van der Harst P, Rienstra M, van Gelder IC, van Veldhuisen DJ, van Gilst WH, van der Meer P. Sex differences in new-onset heart failure. Clin Res Cardiol
2015;104:342350.
26. Brouwers FP, de Boer RA, van der Harst P, Voors AA, Gansevoort RT, Bakker
SJ, Hillege HL, van Veldhuisen DJ, van Gilst WH. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort:
11-year follow-up of
PREVEND.
Eur
Heart
J
2013;34:14241431.
27. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global,
regional, and national incidence, prevalence, and years lived with disability for
354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the
Global
Burden of
Disease
Study
2017.
Lancet
2018;392:17891858.
28. Roger VL. Epidemiology of heart failure. Circ Res 2013;113:646659.
29. Mosterd
A,
Hoes
AW.
Clinical epidemiology of heart failure.
Heart
2007;93:11371146.
30. Smeets M, Vaes B, Mamouris P, Van Den Akker M, Van Pottelbergh G, Goderis
G, Janssens S, Aertgeerts B, Henrard S. Burden of heart failure in Flemish general practices:
a registry-based study in the
Intego database.
BMJ
Open
2019;9:e022972.
31. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP,
Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV,
Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland
DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS,
Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA,
Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL,
Stokes A, Tirschwell DL, VanWagner LB, Tsao CW, American Heart Association
Council on Epidemiology and Prevention Statistics Committee and Stroke
Statistics Subcommittee. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation 2020;141:e139e596.
32. van Riet EE, Hoes AW, Limburg A, Landman MA, van der Hoeven H, Rutten FH.
Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion. Eur J Heart Fail 2014;16:772777.
33. van Riet EE, Hoes AW, Wagenaar KP, Limburg A, Landman MA, Rutten FH.
Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail
2016;18:242252.
34. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S,
Chiuve SE, Cushman M, Delling FN, Deo R, de Ferranti SD, Ferguson JF, Fornage
M, Gillespie C, Isasi CR, Jimenez MC, Jordan LC, Judd SE, Lackland D, Lichtman
JH, Lisabeth L, Liu S, Longenecker CT, Lutsey PL, Mackey JS, Matchar DB,
Matsushita K, Mussolino ME, Nasir K, O’Flaherty M, Palaniappan LP, Pandey A,
Pandey DK, Reeves MJ, Ritchey MD, Rodriguez CJ, Roth GA, Rosamond WD,
Sampson UKA, Satou GM, Shah SH, Spartano NL, Tirschwell DL, Tsao CW,
Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P,
American Heart Association Council on Epidemiology and Prevention Statistics
Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2018 update: a report from the American Heart Association. Circulation
2018;137:e67e492.
35. Ceia F, Fonseca C, Mota T, Morais H, Matias F, de Sousa A, Oliveira A, EPICA
Investigators. Prevalence of chronic heart failure in Southwestern Europe: the
EPICA study. Eur J Heart Fail 2002;4:531539.
36. Bibbins-Domingo K, Pletcher MJ, Lin F, Vittinghoff E, Gardin JM, Arynchyn A,
Lewis CE, Williams OD, Hulley SB. Racial differences in incident heart failure among young adults. N Engl J Med 2009;360:11791190.
37. Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers
JW, Witteman JC, Stricker BH. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam
Study. Eur Heart J 2004;25:16141619.
38. Koh AS, Tay WT, Teng THK, Vedin O, Benson L, Dahlstrom U, Savarese G, Lam
CSP, Lund LH. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail 2017;19:16241634.
39. Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP,
Parissis J, Laroche C, Piepoli MF, Fonseca C, Mebazaa A, Lund L, Ambrosio GA,
Coats AJ, Ferrari R, Ruschitzka F, Maggioni AP, Filippatos G. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, midrange and reduced ejection fraction: an analysis of the ESC Heart Failure LongTerm Registry. Eur J Heart Fail 2017;19:15741585.
40. Shah RU, Klein L, Lloyd-Jones DM. Heart failure in women: epidemiology, biology and treatment. Womens Health (Lond) 2009;5:517527.


<!-- PAGE 99 -->

### Page 99

.............................................................................................................................................................................
41. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP,
Jacobsen SJ. Trends in heart failure incidence and survival in a community-based population. JAMA 2004;292:344350.
42. Vedin O, Lam CSP, Koh AS, Benson L, Teng THK, Tay WT, Braun OO, Savarese
G, Dahlstrom U, Lund LH. Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study. Circ Heart Fail 2017;10:e003875.
43. Kapoor JR, Kapoor R, Ju C, Heidenreich PA, Eapen ZJ, Hernandez AF, Butler J,
Yancy CW, Fonarow GC. Precipitating clinical factors, heart failure characterization, and outcomes in patients hospitalized with heart failure with reduced, borderline, and preserved ejection fraction. JACC Heart Fail 2016;4:464472.
44. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 2002;162:16821688.
45. Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R,
Killian JM, Roger VL. A contemporary appraisal of the heart failure epidemic in
Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med 2015;175:9961004.
46. Tsao CW, Lyass A, Enserro D, Larson MG, Ho JE, Kizer JR, Gottdiener JS, Psaty
BM, Vasan RS. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC Heart Fail
2018;6:678685.
47. Motiejunaite J, Akiyama E, Cohen-Solal A, Maggioni AP, Mueller C, Choi DJ,
Kavoliuniene A, Celutkiene J, Parenica J, Lassus J, Kajimoto K, Sato N, Miro O,
Peacock WF, Matsue Y, Voors AA, Lam CSP, Ezekowitz JA, Ahmed A, Fonarow
GC, Gayat E, Regitz-Zagrosek V, Mebazaa A. The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions. Eur Heart J 2020;41:13571364.
48. Dunlay SM, Roger VL, Weston SA, Jiang R, Redfield MM. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail 2012;5:720726.
49. Clarke CL, Grunwald GK, Allen LA, Baron AE, Peterson PN, Brand DW, Magid
DJ, Masoudi FA. Natural history of left ventricular ejection fraction in patients with heart failure. Circ Cardiovasc Qual Outcomes 2013;6:680686.
50. Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Onose T, Abe R, Oikawa
T, Kasahara S, Sato M, Shiroto T, Takahashi J, Miyata S, Shimokawa H, CHART-2
Investigators. Characterization of heart failure patients with mid-range left ventricular ejection fraction–a report from the CHART-2 Study. Eur J Heart Fail
2017;19:12581269.
51. Rastogi A, Novak E, Platts AE, Mann DL. Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction. Eur J
Heart Fail 2017;19:15971605.
52. Lupon J, Gavidia-Bovadilla G, Ferrer E, de Antonio M, Perera-Lluna A, LopezAyerbe J, Domingo M, Nunez J, Zamora E, Moliner P, Diaz-Ruata P, Santesmases
J, Bayes-Genis A. Dynamic trajectories of left ventricular ejection fraction in heart failure. J Am Coll Cardiol 2018;72:591601.
53. Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Kober L, Squire IB, Swedberg K,
Dobson J, Poppe KK, Whalley GA, Doughty RN, Meta-Analysis Global Group in
Chronic Heart Failure. Predicting survival in heart failure: a risk score based on
39 372 patients from 30 studies. Eur Heart J 2013;34:14041413.
54. Barasa A, Schaufelberger M, Lappas G, Swedberg K, Dellborg M, Rosengren A.
Heart failure in young adults: 20-year trends in hospitalization, aetiology, and case fatality in Sweden. Eur Heart J 2014;35:2532.
55. Jhund PS, Macintyre K, Simpson CR, Lewsey JD, Stewart S, Redpath A, Chalmers
JW, Capewell S, McMurray JJ. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of
5.1 million people. Circulation 2009;119:515523.
56. Dunlay SM, Redfield MM, Weston SA, Therneau TM, Hall Long K, Shah ND,
Roger VL. Hospitalizations after heart failure diagnosis a community perspective.
J Am Coll Cardiol 2009;54:16951702.
57. Taylor CJ, Ordonez-Mena JM, Roalfe AK, Lay-Flurrie S, Jones NR, Marshall T,
Hobbs FDR. Trends in survival after a diagnosis of heart failure in the United
Kingdom 2000-2017: population based cohort study. BMJ 2019;364:l223.
58. Lorenzoni G, Azzolina D, Lanera C, Brianti G, Gregori D, Vanuzzo D, Baldi I.
Time trends in first hospitalization for heart failure in a community-based population. Int J Cardiol 2018;271:195199.
59. Mosterd A, Reitsma JB, Grobbee DE. Angiotensin converting enzyme inhibition and hospitalisation rates for heart failure in the Netherlands, 1980 to 1999: the end of an epidemic? Heart 2002;87:7576.
60. Chen J, Hsieh AF, Dharmarajan K, Masoudi FA, Krumholz HM. National trends in heart failure hospitalization after acute myocardial infarction for Medicare beneficiaries: 1998-2010. Circulation 2013;128:25772584.
61. Lawson CA, Zaccardi F, Squire I, Ling S, Davies MJ, Lam CSP, Mamas MA, Khunti
K, Kadam UT. 20-year trends in cause-specific heart failure outcomes by sex,
socioeconomic status, and place of diagnosis: a population-based study. Lancet
Public Health 2019;4:e406e420.
62. Al-Mohammad A, Mant J, Laramee
P, Swain S,
Chronic
Heart
Failure
Guideline
Development
Group.
Diagnosis and management of adults with chronic heart failure:
summary of updated
NICE
guidance.
BMJ
2010;341:c4130.
63. Mant J, Doust J, Roalfe A, Barton P, Cowie MR, Glasziou P, Mant D, McManus RJ,
Holder R, Deeks J, Fletcher K, Qume M, Sohanpal S, Sanders S, Hobbs FD.
Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess 2009;13:1207, iii.
64. Davie AP, Francis CM, Caruana L, Sutherland GR, McMurray JJ. Assessing diagnosis in heart failure: which features are any use? QJM 1997;90:335339.
65. Oudejans I, Mosterd A, Bloemen JA, Valk MJ, van Velzen E, Wielders JP, Zuithoff
NP, Rutten FH, Hoes AW. Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests. Eur J Heart
Fail 2011;13:518527.
66. Kelder JC, Cramer MJ, van Wijngaarden J, van Tooren R, Mosterd A, Moons KG,
Lammers JW, Cowie MR, Grobbee DE, Hoes AW. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation 2011;124:28652873.
67. Thibodeau JT, Turer AT, Gualano SK, Ayers CR, Velez-Martinez M, Mishkin JD,
Patel
PC,
Mammen
PP,
Markham
DW,
Levine
BD,
Drazner
MH.
Characterization of a novel symptom of advanced heart failure: bendopnea. JACC
Heart Fail 2014;2:2431.
68. Gohar A, Rutten FH, den Ruijter H, Kelder JC, von Haehling S, Anker SD,
Mockel M, Hoes AW. Mid-regional pro-atrial natriuretic peptide for the early detection of non-acute heart failure. Eur J Heart Fail 2019;21:12191227.
69. Hildebrandt P, Collinson PO. Amino-terminal pro-B-type natriuretic peptide testing to assist the diagnostic evaluation of heart failure in symptomatic primary care patients. Am J Cardiol 2008;101:2528.
70. Maisel A, Mueller C, Adams K, Jr., Anker SD, Aspromonte N, Cleland JG,
Cohen-Solal A, Dahlstrom U, DeMaria A, Di Somma S, Filippatos GS, Fonarow
GC, Jourdain P, Komajda M, Liu PP, McDonagh T, McDonald K, Mebazaa A,
Nieminen MS, Peacock WF, Tubaro M, Valle R, Vanderhyden M, Yancy CW,
Zannad F, Braunwald E. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008;10:824839.
71. Lancellotti P, Galderisi M, Edvardsen T, Donal E, Goliasch G, Cardim N, Magne J,
Laginha S, Hagendorff A, Haland TF, Aaberge L, Martinez C, Rapacciuolo A,
Santoro C, Ilardi F, Postolache A, Dulgheru R, Mateescu AD, Beladan CC,
Deleanu D, Marchetta S, Auffret V, Schwammenthal E, Habib G, Popescu BA.
Echo-Doppler estimation of left ventricular filling pressure: results of the multicentre
EACVI
Euro-Filling study.
Eur
Heart
J
Cardiovasc
Imaging
2017;18:961968.
72. Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003;24:17351743.
73. Roberts E, Ludman AJ, Dworzynski K, Al-Mohammad A, Cowie MR, McMurray
JJ, Mant J, NICE Guideline Development Group for Acute Heart Failure. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ 2015;350:h910.
74. Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N,
Coats AJS, Metra M, Mebazaa A, Ruschitzka F, Lainscak M, Filippatos G, Seferovic
PM, Meijers WC, Bayes-Genis A, Mueller T, Richards M, Januzzi JL Jr, Heart
Failure Association of the European Society of Cardiology. Heart Failure
Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail 2019;21:715731.
75. Madamanchi C, Alhosaini H, Sumida A, Runge MS. Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. Int J Cardiol 2014;176:611617.
76. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson
PA, Sutton GC. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:13491353.
77. Zaphiriou A, Robb S, Murray-Thomas T, Mendez G, Fox K, McDonagh T,
Hardman SM, Dargie HJ, Cowie MR. The diagnostic accuracy of plasma BNP and
NTproBNP in patients referred from primary care with suspected heart failure:
results of the UK natriuretic peptide study. Eur J Heart Fail 2005;7:537541.
78. Kelder JC, Cramer MJ, Verweij WM, Grobbee DE, Hoes AW. Clinical utility of three B-type natriuretic peptide assays for the initial diagnostic assessment of new slow-onset heart failure. J Card Fail 2011;17:729734.
79. Verdu JM, Comin-Colet J, Domingo M, Lupon J, Gomez M, Molina L,
Casacuberta JM, Munoz MA, Mena A, Bruguera-Cortada J. Rapid point-of-care
NT-proBNP optimal cut-off point for heart failure diagnosis in primary care. Rev
Esp Cardiol (Engl Ed) 2012;65:613619.
80. Taylor CJ, Roalfe AK, Iles R, Hobbs FR, investigators R, Barton P, Deeks J,
McCahon D, Cowie MR, Sutton G, Davis RC, Mant J, McDonagh T, Tait L.
Primary care REFerral for EchocaRdiogram (REFER) in heart failure: a diagnostic accuracy study. Br J Gen Pract 2017;67:e94e102.
81. Sicari R, Nihoyannopoulos P, Evangelista A, Kasprzak J, Lancellotti P, Poldermans
D, Voigt JU, Zamorano JL, European Association of Echocardiography. Stress
ESC Guidelines
3697


<!-- PAGE 100 -->

### Page 100

.............................................................................................................................................................................
Echocardiography Expert Consensus Statement–Executive Summary: European
Association of Echocardiography (EAE) (a registered branch of the ESC). Eur
Heart J 2009;30:278289.
82. Lancellotti P, Pellikka PA, Budts W, Chaudhry FA, Donal E, Dulgheru R,
Edvardsen T, Garbi M, Ha JW, Kane GC, Kreeger J, Mertens L, Pibarot P, Picano
E, Ryan T, Tsutsui JM, Varga A. The clinical use of stress echocardiography in non-ischaemic heart disease: recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur
Heart J Cardiovasc Imaging 2016;17:11911229.
83. Gonzalez JA, Kramer CM. Role of imaging techniques for diagnosis, prognosis and management of heart failure patients: cardiac magnetic resonance. Curr Heart
Fail Rep 2015;12:276283.
84. Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P,
Mascherbauer J, Nezafat R, Salerno M, Schelbert EB, Taylor AJ, Thompson R,
Ugander M, van Heeswijk RB, Friedrich MG. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2 and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance
(SCMR) endorsed by the European Association for Cardiovascular Imaging
(EACVI). J Cardiovasc Magn Reson 2017;19:75.
85. Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM, Gospodinova M,
Obici L, Rapezzi C, Garcia-Pavia P. Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail 2019;7:709716.
86. Gupta DK, Wang TJ. Natriuretic peptides and cardiometabolic health. Circ J
2015;79:16471655.
87. Zois NE, Bartels ED, Hunter I, Kousholt BS, Olsen LH, Goetze JP. Natriuretic peptides in cardiometabolic regulation and disease. Nat Rev Cardiol 2014;11:403412.
88. Nishikimi T, Kuwahara K, Nakao K. Current biochemistry, molecular biology,
and clinical relevance of natriuretic peptides. J Cardiol 2011;57:131140.
89. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G,
Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H, Ferrazzi P, Petrie
MC, O’Connor CM, Panchavinnin P, She L, Bonow RO, Rankin GR, Jones RH,
Rouleau JL, STICH Investigators. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011;364:16071616.
90. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol
2002;39:11511158.
91. Ling LF, Marwick TH, Flores DR, Jaber WA, Brunken RC, Cerqueira MD,
Hachamovitch R. Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction: inducible ischemia versus hibernating myocardium. Circ Cardiovasc Imaging 2013;6:363372.
92. Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P,
Drozdz J, Farsky PS, Feldman AM, Doenst T, Michler RE, Berman DS, Nicolau JC,
Pellikka PA, Wrobel K, Alotti N, Asch FM, Favaloro LE, She L, Velazquez EJ,
Jones RH, Panza JA, STICH Trial Investigators. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med 2011;364:16171625.
93. Panza JA, Ellis AM, Al-Khalidi HR, Holly TA, Berman DS, Oh JK, Pohost GM,
Sopko G, Chrzanowski L, Mark DB, Kukulski T, Favaloro LE, Maurer G, Farsky
PS, Tan RS, Asch FM, Velazquez EJ, Rouleau JL, Lee KL, Bonow RO. Myocardial viability and long-term outcomes in ischemic cardiomyopathy. N Engl J Med
2019;381:739748.
94. Corra U, Piepoli MF, Adamopoulos S, Agostoni P, Coats AJ, Conraads V,
Lambrinou E, Pieske B, Piotrowicz E, Schmid JP, Seferovic PM, Anker SD,
Filippatos G, Ponikowski PP. Cardiopulmonary exercise testing in systolic heart failure in 2014: the evolving prognostic role: a position paper from the
Committee on Exercise Physiology and Training of the Heart Failure Association of the ESC. Eur J Heart Fail 2014;16:929941.
95. Piepoli MF, Conraads V, Corra U, Dickstein K, Francis DP, Jaarsma T, McMurray
J, Pieske B, Piotrowicz E, Schmid JP, Anker SD, Solal AC, Filippatos GS, Hoes
AW, Gielen S, Giannuzzi P, Ponikowski PP. Exercise training in heart failure:
from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation.
Eur J Heart Fail 2011;13:347357.
96. Corra U, Agostoni PG, Anker SD, Coats AJS, Crespo Leiro MG, de Boer RA,
Hairola VP, Hill L, Lainscak M, Lund LH, Metra M, Ponikowski P, Riley J, Seferovic
PM, Piepoli MF. Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of
Cardiology. Eur J Heart Fail 2018;20:315.
97. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, Levine
GN, Narula J, Starling RC, Towbin J, Virmani R. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the
European Society of Cardiology Endorsed by the Heart Failure Society of
America and the Heart Failure Association of the European Society of
Cardiology. Eur Heart J 2007;28:30763093.
98. Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis–natural history and treatment.
Multicenter
Giant
Cell
Myocarditis
Study
Group
Investigators. N Engl J Med 1997;336:18601866.
99. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf
FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH,
Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of
Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16:233270.
100. Gheorghiade M, Shah AN, Vaduganathan M, Butler J, Bonow RO, Rosano GM,
Taylor S, Kupfer S, Misselwitz F, Sharma A, Fonarow GC. Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes: academics’, clinicians’, industry’s, regulators’, and payers’ perspectives.
Heart Fail Clin 2013;9:285290, v-vi.
101. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M,
Nodari
S,
Lam
CSP,
Sato
N,
Shah
AN,
Gheorghiade
M.
The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries.
J
Am
Coll
Cardiol
2014;63:11231133.
102. Anker SD, Schroeder S, Atar D, Bax JJ, Ceconi C, Cowie MR, Crisp A,
Dominjon F, Ford I, Ghofrani HA, Gropper S, Hindricks G, Hlatky MA,
Holcomb R, Honarpour N, Jukema JW, Kim AM, Kunz M, Lefkowitz M, Le
Floch C, Landmesser U, McDonagh TA, McMurray JJ, Merkely B, Packer M,
Prasad K, Revkin J, Rosano GM, Somaratne R, Stough WG, Voors AA,
Ruschitzka F. Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. Eur J Heart Fail 2016;18:482489.
103. Gayat E, Arrigo M, Littnerova S, Sato N, Parenica J, Ishihara S, Spinar J, Muller
C, Harjola VP, Lassus J, Miro O, Maggioni AP, AlHabib KF, Choi DJ, Park JJ,
Zhang Y, Zhang J, Januzzi JL, Jr., Kajimoto K, Cohen-Solal A, Mebazaa A,
Network G. Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study. Eur J Heart
Fail 2018;20:345354.
104. Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F,
Ferrari R, Piepoli MF, Delgado Jimenez JF, Metra M, Fonseca C, Hradec J, Amir
O, Logeart D, Dahlstrom U, Merkely B, Drozdz J, Goncalvesova E, Hassanein
M, Chioncel O, Lainscak M, Seferovic PM, Tousoulis D, Kavoliuniene A,
Fruhwald F, Fazlibegovic E, Temizhan A, Gatzov P, Erglis A, Laroche C,
Mebazaa A, Heart Failure Association of the European Society of Cardiology.
European Society of Cardiology Heart Failure Long-Term Registry (ESC-HFLT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail
2016;18:613625.
105. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL,
Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and
Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N
Engl J Med 2014;371:9931004.
106. Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K,
Rocha R, Braunwald E, PIONEER-HF Investigators. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2019;380:
539548.
107. Wachter R, Senni M, Belohlavek J, Straburzynska-Migaj E, Witte KK, Kobalava
Z, Fonseca C, Goncalvesova E, Cavusoglu Y, Fernandez A, Chaaban S, Bohmer
E, Pouleur AC, Mueller C, Tribouilloy C, Lonn E, Buraiki ALJ, Gniot J, Mozheiko
M, Lelonek M, Noe` A, Schwende H, Bao W, Butylin D, Pascual-Figal D,
TRANSITION Investigators. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised
TRANSITION
study.
Eur
J
Heart
Fail
2019;21:9981007.
108. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA,
Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, Bo¨hm M, Chiang C-E,
Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukat A, Ge J, Howlett
JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E,
Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL,
Docherty KF, Jhund PS, Bengtsson O, Sjo¨strand M, Langkilde AM, DAPA-HF
Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:19952008.
109. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J,
Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C,
Cotton D, Bocchi E, Bohm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N,
Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP,
Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M,
Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F, EMPERORReduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383:14131424.
110. The CONSENSUS Trial Study Group. Enalapril for congestive heart failure. N
Engl J Med 1987;317:13491351.


<!-- PAGE 101 -->

### Page 101

.............................................................................................................................................................................
111. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure.
Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:14501456.
112. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie
BM, Ryden L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation
1999;100:23122318.
113. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293302.
114. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure:
Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure
(MERIT-HF). Lancet 1999;353:20012007.
115. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM,
Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J
Med 1996;334:13491355.
116. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL,
Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL, Carvedilol
Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:16511658.
117. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J,
Wikstrand J, El Allaf D, Vitovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus
KL, Janosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J,
Rickenbacher P, Ball S, Gottlieb S, Deedwania P. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure
(MERIT-HF).
MERIT-HF
Study
Group.
JAMA
2000;283:12951302.
118. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P,
Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL,
Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS)
study. Circulation 2002;106:21942199.
119. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A,
Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J,
Tavazzi L, Spinarova L, Toman J, Bohm M, Anker SD, Thompson SG, PooleWilson PA, SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215225.
120. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol
Study II (CIBIS-II): a randomised trial. Lancet 1999;353:913.
121. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes
J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N
Engl J Med 1999;341:709717.
122. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent
J, Pocock SJ, Pitt B, EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:1121.
123. Fowler MB. Effects of beta blockers on symptoms and functional capacity in heart failure. Am J Cardiol 1997;80:55L58L.
124. Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H,
Ponikowski P, Skene A, van de Ven L, Verkenne P, Lechat P, CIBIS III
Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency
Bisoprolol Study (CIBIS) III. Circulation 2005;112:24262435.
125. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, Lip GY,
Coats AJ, Andersson B, Kirchhof P, von Lueder TG, Wedel H, Rosano G,
Shibata
MC,
Rigby
A,
Flather
MD,
Beta-Blockers in
Heart
Failure
Collaborative Group. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation:
an individual-patient data meta-analysis.
Lancet
2014;384:22352243.
126. Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, Rouleau
JL, Swedberg K, Lefkowitz M, Shi VC, Desai AS, McMurray JJV, Solomon SD.
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF
trial. Lancet Diabetes Endocrinol 2017;5:333340.
127. Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP, Prescott MF,
Shi VC, Rouleau JL, Swedberg K, Zile MR, Packer M, Desai AS, Solomon SD,
McMurray JJV. Renal effects and associated outcomes during angiotensinneprilysin inhibition in heart failure. JACC Heart Fail 2018;6:489498.
128. Desai AS, Vardeny O, Claggett B, McMurray JJ, Packer M, Swedberg K, Rouleau
JL, Zile MR, Lefkowitz M, Shi V, Solomon SD. Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF Trial. JAMA Cardiol 2017;2:7985.
129. Vardeny O, Claggett B, Kachadourian J, Desai AS, Packer M, Rouleau J, Zile MR,
Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the
PARADIGM-HF trial. Eur J Heart Fail 2019;21:337341.
130. Vardeny O, Claggett B, Kachadourian J, Pearson SM, Desai AS, Packer M,
Rouleau J, Zile MR, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon
SD. Incidence, predictors, and outcomes associated with hypotensive episodes among heart failure patients receiving sacubitril/valsartan or enalapril: the
PARADIGM-HF
trial
(Prospective
Comparison of
Angiotensin
Receptor
Neprilysin
Inhibitor
With
Angiotensin-Converting
Enzyme
Inhibitor to
Determine Impact on Global Mortality and Morbidity in Heart Failure). Circ
Heart Fail 2018;11:e004745.
131. Morrow DA, Velazquez EJ, DeVore AD, Desai AS, Duffy CI, Ambrosy AP,
Gurmu Y, McCague K, Rocha R, Braunwald E. Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril/valsartan or enalapril in the PIONEER-HF trial. Circulation 2019;139:22852288.
132. Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, Nicolau
JC, Merkely B, Kitakaze M, DeMets DL, Inzucchi SE, Kober L, Martinez FA,
Ponikowski P, Sabatine MS, Solomon SD, Bengtsson O, Lindholm D, Niklasson
A, Sjostrand M, Langkilde AM, McMurray JJV. Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation 2020;141:9099.
133. Butler J, Anker SD, Filippatos G, Khan MS, Ferreira JP, Pocock SJ, Giannetti N,
Januzzi JL, Pina IL, Lam CSP, Ponikowski P, Sattar N, Verma S, Brueckmann M,
Jamal W, Vedin O, Peil B, Zeller C, Zannad F, Packer M, EMPEROR-Reduced
Trial Committees and Investigators. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the
EMPEROR-Reduced trial. Eur Heart J 2021;42:12031212.
134. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann
M, Ofstad AP, Pfarr E, Jamal W, Packer M. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPERORReduced and DAPA-HF trials. Lancet 2020;396:819829.
135. Jackson AM, Dewan P, Anand IS, Belohlavek J, Bengtsson O, de Boer RA, Bohm
M, Boulton DW, Chopra VK, DeMets DL, Docherty KF, Dukat A, Greasley PJ,
Howlett JG, Inzucchi SE, Katova T, Kober L, Kosiborod MN, Langkilde AM,
Lindholm D, Ljungman CEA, Martinez FA, O’Meara E, Sabatine MS, Sjostrand
M, Solomon SD, Tereshchenko S, Verma S, Jhund PS, McMurray JJV.
Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF. Circulation 2020;142:10401054.
136. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB,
Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS,
Ponikowski P, Lopes RD, Verma S, Lapuerta P, Pitt B, SOLOIST-WHF Trial
Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 2021;384:117128.
137. Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol 2002;82:149158.
138. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B,
Ostergren J, Pfeffer MA, Swedberg K, CHARM Investigators and Committees.
Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772776.
139. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A,
Lerebours G, Tavazzi L, SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet
2010;376:875885.
140. Swedberg K, Komajda M, Bohm M, Borer J, Robertson M, Tavazzi L, Ford I,
SHIFT Investigators. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f)
inhibitor ivabradine Trial) study. J Am Coll Cardiol 2012;59:19381945.
141. Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam
CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J,
O’Connor CM, VICTORIA Study Group. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 2020;382:18831893.
142. Taylor AL, Ziesche S, Yancy C, Carson P, D’Agostino R, Jr., Ferdinand K, Taylor
M, Adams K, Sabolinski M, Worcel M, Cohn JN, African-American Heart Failure
Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:20492057.
143. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE,
Dunkman WB, Jacobs W, Francis GS, Flohr KH. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans
Administration Cooperative Study. N Engl J Med 1986;314:15471552.
ESC Guidelines
3699


<!-- PAGE 102 -->

### Page 102

.............................................................................................................................................................................
144. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525533.
145. Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens
P, Testani JM, Tang WHW, Orso F, Rossignol P, Metra M, Filippatos G,
Seferovic PM, Ruschitzka F, Coats AJ. The use of diuretics in heart failure with congestion – a position statement from the Heart Failure Association of the
European Society of Cardiology. Eur J Heart Fail 2019;21:137155.
146. Rohde LE, Rover MM, Figueiredo Neto JA, Danzmann LC, Bertoldi EG, Simoes
MV, Silvestre OM, Ribeiro ALP, Moura LZ, Beck-da-Silva L, Prado D, Sant’Anna
RT, Bridi LH, Zimerman A, Raupp da Rosa P, Biolo A. Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial. Eur
Heart J 2019;40:36053612.
147. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N
Engl J Med 2001;345:16671675.
148. Bohm M, Borer J, Ford I, Gonzalez-Juanatey JR, Komajda M, Lopez-Sendon J,
Reil JC, Swedberg K, Tavazzi L. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013;102:1122.
149. Ouyang AJ, Lv YN, Zhong HL, Wen JH, Wei XH, Peng HW, Zhou J, Liu LL.
Meta-analysis of digoxin use and risk of mortality in patients with atrial fibrillation. Am J Cardiol 2015;115:901906.
150. Vamos
M,
Erath
JW,
Hohnloser
SH.
Digoxin-associated mortality:
a systematic review and meta-analysis of the literature.
Eur
Heart
J
2015;36:18311838.
151. Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GY, Steeds RP, Townend
J, Kotecha D. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ 2015;351:h4451.
152. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM,
Hillege HL, Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, Van
Veldhuisen DJ, Van den Berg MP, RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010;362:13631373.
153. Bavishi C, Khan AR, Ather S. Digoxin in patients with atrial fibrillation and heart failure: a meta-analysis. Int J Cardiol 2015;188:99101.
154. Freeman JV, Reynolds K, Fang M, Udaltsova N, Steimle A, Pomernacki NK,
Borowsky LH, Harrison TN, Singer DE, Go AS. Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study. Circ Arrhythm Electrophysiol
2015;8:4958.
155. Washam JB, Stevens SR, Lokhnygina Y, Halperin JL, Breithardt G, Singer DE,
Mahaffey KW, Hankey GJ, Berkowitz SD, Nessel CC, Fox KA, Califf RM, Piccini
JP, Patel MR, ROCKET Steering Committee and Investigators. Digoxin use in patients with atrial fibrillation AF and adverse cardiovascular outcomes: retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa
Inhibition Compared with Vitamin a K Antagonism for Prevention of Stroke and
Embolism
Trial in
Atrial
Fibrillation
(ROCKET
AF).
Lancet
2015;385:23632370.
156. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA
2003;289:871878.
157. Adams KF, Jr., Patterson JH, Gattis WA, O’Connor CM, Lee CR, Schwartz TA,
Gheorghiade M. Relationship of serum digoxin concentration to mortality and morbidity in women in the Digitalis Investigation Group trial: a retrospective analysis. J Am Coll Cardiol 2005;46:497504.
158. Bavendiek U, Berliner D, Davila LA, Schwab J, Maier L, Philipp SA, Rieth A,
Westenfeld R, Piorkowski C, Weber K, Hanselmann A, Oldhafer M, Schallhorn
S, von der Leyen H, Schroder C, Veltmann C, Stork S, Bohm M, Koch A,
Bauersachs J, DIGIT-HF Investigators and Committees. Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study.
Eur J Heart Fail 2019;21:676684.
159. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams
KF, Anand I, Arias-Mendoza A, Biering-Sorensen T, Bohm M, Bonderman D,
Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlstrom U, Echeverria LE, Fang
JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear
DE, Li J, Lund M, Macdonald P, Mareev V, Momomura SI, O’Meara E,
Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter
TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB,
Zannad F, Sharpsten L, Legg JC, Varin C, Honarpour N, Abbasi SA, Malik FI,
Kurtz CE, GALACTIC-HF Investigators. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med 2021;384:105116.
160. Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, Dargie HJ,
Granger CB, Kjekshus J, Kuˆ¡ber L, Latini R, Maggioni AP, Packer M, Pitt B,
Solomon SD, Swedberg K, Tavazzi L, Wikstrand J, Zannad F, Zile MR,
McMurray JJV. Declining risk of sudden death in heart failure. N Engl J Med
2017;377:4151.
161. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M,
Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N,
Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH, Sudden Cardiac
Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med
2005;352:225237.
162. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, Greene
HL, Boczor S, Domanski M, Follmann D, Gent M, Roberts RS, investigators of the AVID, CASH and CIDS studies. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials.
Eur
Heart
J
2000;21:20712078.
163. Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med
1997;337:15761583.
164. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation
2000;102:748754.
165. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP,
Higgins SL, Brown MW, Andrews ML, Multicenter Automatic Defibrillator
Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med
2002;346:877883.
166. Kober L, Thune JJ, Nielsen JC, Haarbo J, Videbaek L, Korup E, Jensen G,
Hildebrandt P, Steffensen FH, Bruun NE, Eiskjaer H, Brandes A, Thogersen AM,
Gustafsson F, Egstrup K, Videbaek R, Hassager C, Svendsen JH, Hofsten DE,
Torp-Pedersen C, Pehrson S, DANISH Investigators. Defibrillator implantation in patients with nonischemic systolic heart failure.
N
Engl
J
Med
2016;375:12211230.
167. Beggs SAS, Jhund PS, Jackson CE, McMurray JJV, Gardner RS. Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis. Heart 2018;104:144150.
168. Merchant FM, Jones P, Wehrenberg S, Lloyd MS, Saxon LA. Incidence of defibrillator shocks after elective generator exchange following uneventful first battery life. J Am Heart Assoc 2014;3:e001289.
169. Yap SC, Schaer BA, Bhagwandien RE, Kuhne M, Dabiri Abkenari L, Osswald S,
Szili-Torok T, Sticherling C, Theuns DA. Evaluation of the need of elective implantable cardioverter-defibrillator generator replacement in primary prevention patients without prior appropriate
ICD
therapy.
Heart
2014;100:11881192.
170. Kini V, Soufi MK, Deo R, Epstein AE, Bala R, Riley M, Groeneveld PW, Shalaby
A, Dixit S. Appropriateness of primary prevention implantable cardioverterdefibrillators at the time of generator replacement: are indications still met? J
Am Coll Cardiol 2014;63:23882394.
171. Erkapic D, Sperzel J, Stiller S, Meltendorf U, Mermi J, Wegscheider K, Hugl B,
Investigators I. Long-term benefit of implantable cardioverter/defibrillator therapy after elective device replacement: results of the INcidence free SUrvival after ICD REplacement (INSURE) trial–a prospective multicentre study. Eur
Heart J 2013;34:130137.
172. Alsheikh-Ali AA, Homer M, Maddukuri PV, Kalsmith B, Estes NA, 3rd, Link MS.
Time-dependence of appropriate implantable defibrillator therapy in patients with ischemic cardiomyopathy. J Cardiovasc Electrophysiol 2008;19:784789.
173. Opreanu M, Wan C, Singh V, Salehi N, Ahmad J, Szymkiewicz SJ, Thakur RK.
Wearable cardioverter-defibrillator as a bridge to cardiac transplantation: a national database analysis. J Heart Lung Transplant 2015;34:13051309.
174. Zishiri ET, Williams S, Cronin EM, Blackstone EH, Ellis SG, Roselli EE, Smedira
NG, Gillinov AM, Glad JA, Tchou PJ, Szymkiewicz SJ, Chung MK. Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator. Circ
Arrhythm Electrophysiol 2013;6:117128.
175. Kutyifa V, Moss AJ, Klein H, Biton Y, McNitt S, MacKecknie B, Zareba W,
Goldenberg I. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable
Cardioverter
Defibrillator
(WEARIT-II
Registry).
Circulation
2015;132:16131619.
176. Kutyifa V, Moss AJ, Klein HU, McNitt S, Zareba W, Goldenberg I. One-year follow-up of the
Prospective
Registry of
Patients
Using the
Wearable
Defibrillator (WEARIT-II Registry). Pacing Clin Electrophysiol 2018;41:13071313.
177. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, Fain E,
Gent M, Connolly SJ, DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med
2004;351:24812488.
178. Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D,
Kornacewicz-Jach Z, Sredniawa B, Lupkovics G, Hofgartner F, Lubinski A,
Rosenqvist M, Habets A, Wegscheider K, Senges J, IRIS Investigators.


<!-- PAGE 103 -->

### Page 103

.............................................................................................................................................................................
Defibrillator implantation early after myocardial infarction. N Engl J Med
2009;361:14271436.
179. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005;353:14711480.
180. Steinberg BA, Al-Khatib SM, Edwards R, Han J, Bardy GH, Bigger JT, Buxton AE,
Moss AJ, Lee KL, Steinman R, Dorian P, Hallstrom A, Cappato R, Kadish AH,
Kudenchuk PJ, Mark DB, Inoue LY, Sanders GD. Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of
4
randomized clinical trials.
JACC
Heart
Fail
2014;2:623629.
181. Raphael CE, Finegold JA, Barron AJ, Whinnett ZI, Mayet J, Linde C, Cleland JG,
Levy WC, Francis DP. The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter defibrillator therapy:
who benefits the most? Eur Heart J 2015;36:16761688.
182. Miller RJ, Howlett JG, Exner DV, Campbell PM, Grant AD, Wilton SB. Baseline functional class and therapeutic efficacy of common heart failure interventions:
a systematic review and meta-analysis. Can J Cardiol 2015;31:792799.
183. Hess PL, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, Buxton A,
Cappato R, Dorian P, Hallstrom A, Kadish AH, Kudenchuk PJ, Lee KL, Mark
DB, Moss AJ, Steinman R, Inoue LY, Sanders G. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials. Circ Cardiovasc Qual
Outcomes 2015;8:179186.
184. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, Mitchell LB,
Green MS, Klein GJ, O’Brien B. Canadian implantable defibrillator study (CIDS):
a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000;101:12971302.
185. Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H, Amlie J,
Carlsen J, Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:26782687.
186. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH,
Arensberg D, Baker A, Friedman L, Greene HL. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia
Suppression Trial. N Engl J Med 1991;324:781788.
187. Theuns DA, Smith T, Hunink MG, Bardy GH, Jordaens L. Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis. Europace 2010;12:15641570.
188. Elming MB, Nielsen JC, Haarbo J, Videbaek L, Korup E, Signorovitch J, Olesen
LL, Hildebrandt P, Steffensen FH, Bruun NE, Eiskjaer H, Brandes A, Thogersen
AM, Gustafsson F, Egstrup K, Videbaek R, Hassager C, Svendsen JH, Hofsten
DE, Torp-Pedersen C, Pehrson S, Kober L, Thune JJ. Age and outcomes of primary prevention implantable cardioverter-defibrillators in patients with nonischemic systolic heart failure. Circulation 2017;136:17721780.
189. Selvanayagam JB, Hartshorne T, Billot L, Grover S, Hillis GS, Jung W, Krum H,
Prasad S, McGavigan AD. Cardiovascular magnetic resonance-GUIDEd management of mild to moderate left ventricular systolic dysfunction (CMR GUIDE):
Study protocol for a randomized controlled trial. Ann Noninvasive Electrocardiol
2017;22:e12420.
190. Leyva F, Zegard A, Acquaye E, Gubran C, Taylor R, Foley PWX, Umar F, Patel
K, Panting J, Marshall H, Qiu T. Outcomes of cardiac resynchronization therapy with or without defibrillation in patients with nonischemic cardiomyopathy. J
Am Coll Cardiol 2017;70:12161227.
191. Di Marco A, Anguera I, Schmitt M, Klem I, Neilan TG, White JA, Sramko M,
Masci PG, Barison A, McKenna P, Mordi I, Haugaa KH, Leyva F, Rodriguez
Capitan J, Satoh H, Nabeta T, Dallaglio PD, Campbell NG, Sabate X, Cequier
A. Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy: systematic review and meta-analysis.
JACC Heart Fail 2017;5:2838.
192. Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, Morarji K, Brown TD,
Ismail NA, Dweck MR, Di Pietro E, Roughton M, Wage R, Daryani Y, O’Hanlon R,
Sheppard MN, Alpendurada F, Lyon AR, Cook SA, Cowie MR, Assomull RG,
Pennell DJ, Prasad SK. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA 2013;309:896908.
193. Stewart GC, Weintraub JR, Pratibhu PP, Semigran MJ, Camuso JM, Brooks K,
Tsang SW, Anello MS, Nguyen VT, Lewis EF, Nohria A, Desai AS, Givertz MM,
Stevenson LW. Patient expectations from implantable defibrillators to prevent death in heart failure. J Card Fail 2010;16:106113.
194. Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, Estes NA,
3rd, Greenberg H, Hall WJ, Huang DT, Kautzner J, Klein H, McNitt S,
Olshansky B, Shoda M, Wilber D, Zareba W, MADIT-RIT Trial Investigators.
Reduction in inappropriate therapy and mortality through ICD programming. N
Engl J Med 2012;367:22752283.
195. Healey JS, Hohnloser SH, Glikson M, Neuzner J, Mabo P, Vinolas X, Kautzner J,
O’Hara G, VanErven L, Gadler F, Pogue J, Appl U, Gilkerson J, Pochet T, Stein
KM, Merkely B, Chrolavicius S, Meeks B, Foldesi C, Thibault B, Connolly SJ,
Shockless IMPLant Evaluation Investigators. Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority,
randomised controlled trial (SIMPLE). Lancet 2015;385:785791.
196. Gasparini M, Proclemer A, Klersy C, Kloppe A, Lunati M, Ferrer JB, Hersi A,
Gulaj M, Wijfels MC, Santi E, Manotta L, Arenal A. Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA 2013;309:19031911.
197. Cleland JG, Buga L. Device therapy: defibrillators–a shocking therapy for cardiomyopathy? Nat Rev Cardiol 2010;7:6970.
198. Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, Kutalek SP,
Sharma A, Dual Chamber and VVI Implantable Defibrillator Trial Investigators.
Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID)
Trial. JAMA 2002;288:31153123.
199. Boersma L, Barr C, Knops R, Theuns D, Eckardt L, Neuzil P, Scholten M, Hood
M, Kuschyk J, Jones P, Duffy E, Husby M, Stein K, Lambiase PD, Group EI.
Implant and midterm outcomes of the subcutaneous implantable cardioverterdefibrillator registry:
the
EFFORTLESS
study.
J
Am
Coll
Cardiol
2017;70:830841.
200. Burke MC, Gold MR, Knight BP, Barr CS, Theuns D, Boersma LVA, Knops RE,
Weiss R, Leon AR, Herre JM, Husby M, Stein KM, Lambiase PD. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE study and EFFORTLESS registry. J Am Coll Cardiol
2015;65:16051615.
201. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J,
Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck
KH, Hernandez-Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van
Veldhuisen DJ, ESC Scientific Document Group. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with
Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the
European Society of Cardiology (ESC). Endorsed by: Association for European
Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36:27932867.
202. Knops RE, Olde Nordkamp LRA, Delnoy PHM, Boersma LVA, Kuschyk J, ElChami MF, Bonnemeier H, Behr ER, Brouwer TF, Kaab S, Mittal S, Quast ABE,
Smeding L, van der Stuijt W, de Weger A, de Wilde KC, Bijsterveld NR,
Richter S, Brouwer MA, de Groot JR, Kooiman KM, Lambiase PD, Neuzil P,
Vernooy K, Alings M, Betts TR, Bracke F, Burke MC, de Jong J, Wright DJ,
Tijssen JGP, Wilde AAM, PRAETORIAN Investigators. Subcutaneous or transvenous defibrillator therapy. N Engl J Med 2020;383:526536.
203. Duncker D, Konig T, Hohmann S, Bauersachs J, Veltmann C. Avoiding untimely implantable cardioverter/defibrillator implantation by intensified heart failure therapy optimization supported by the wearable cardioverter/defibrillator–the
PROLONG Study. J Am Heart Assoc 2017;6:e004512.
204. Olgin JE, Pletcher MJ, Vittinghoff E, Wranicz J, Malik R, Morin DP, Zweibel S,
Buxton AE, Elayi CS, Chung EH, Rashba E, Borggrefe M, Hue TF, Maguire C, Lin
F, Simon JA, Hulley S, Lee BK, VEST Investigators. Wearable cardioverterdefibrillator after myocardial infarction. N Engl J Med 2018;379:12051215.
205. Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, Garrigue S,
Kappenberger L, Haywood GA, Santini M, Bailleul C, Daubert JC, Multisite
Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001;344:873880.
206. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L,
Tavazzi
L,
Cardiac
Resynchronization-Heart
Failure
(CARE-HF)
Study
Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:15391549.
207. Daubert C, Gold MR, Abraham WT, Ghio S, Hassager C, Goode G, Szili-Torok
T, Linde C, REVERSE Study Group. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the
REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular
Dysfunction) trial. J Am Coll Cardiol 2009;54:18371846.
208. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L,
Tavazzi L. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF)
trial extension phase]. Eur Heart J 2006;27:19281932.
209. Cleland JG, Freemantle N, Erdmann E, Gras D, Kappenberger L, Tavazzi L,
Daubert JC. Long-term mortality with cardiac resynchronization therapy in the
Cardiac Resynchronization-Heart Failure (CARE-HF) trial. Eur J Heart Fail
2012;14:628634.
210. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P,
DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM, Comparison of
Medical Therapy Pacing and Defibrillation in Heart Failure (COMPANION)
Investigators. Cardiac-resynchronization therapy with or without an implantable
ESC Guidelines
3701


<!-- PAGE 104 -->

### Page 104

.............................................................................................................................................................................
defibrillator in advanced chronic heart failure.
N
Engl
J
Med
2004;350:21402150.
211. Cleland JG, Abraham WT, Linde C, Gold MR, Young JB, Claude Daubert J,
Sherfesee L, Wells GA, Tang AS. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J
2013;34:35473556.
212. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser
SH,
Nichol
G,
Birnie
DH,
Sapp
JL,
Yee
R,
Healey
JS,
Rouleau
JL,
Resynchronization-Defibrillation for
Ambulatory
Heart
Failure
Trial
Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010;363:23852395.
213. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA,
3rd, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D,
Zareba W, MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:13291338.
214. Goldenberg I, Kutyifa V, Klein HU, Cannom DS, Brown MW, Dan A, Daubert
JP, Estes NA, 3rd, Foster E, Greenberg H, Kautzner J, Klempfner R, Kuniss M,
Merkely B, Pfeffer MA, Quesada A, Viskin S, McNitt S, Polonsky B, Ghanem A,
Solomon
SD,
Wilber
D,
Zareba
W,
Moss
AJ.
Survival with cardiacresynchronization therapy in mild heart failure.
N
Engl
J
Med
2014;370:16941701.
215. Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C,
REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) Study Group. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol
2008;52:18341843.
216. Curtis AB, Worley SJ, Adamson PB, Chung ES, Niazi I, Sherfesee L, Shinn T,
Sutton MS, Biventricular versus Right Ventricular Pacing in Heart Failure
Patients with
Atrioventricular
Block
(BLOCK
AF)
Trial
Investigators.
Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J
Med 2013;368:15851593.
217. Brignole M, Botto G, Mont L, Iacopino S, De Marchi G, Oddone D, Luzi M,
Tolosana JM, Navazio A, Menozzi C. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. Eur Heart J 2011;32:24202429.
218. Stavrakis S, Garabelli P, Reynolds DW. Cardiac resynchronization therapy after atrioventricular junction ablation for symptomatic atrial fibrillation: a meta-analysis. Europace 2012;14:14901497.
219. Leclercq C, Walker S, Linde C, Clementy J, Marshall AJ, Ritter P, Djiane P,
Mabo P, Levy T, Gadler F, Bailleul C, Daubert JC. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J 2002;23:17801787.
220. Woods B, Hawkins N, Mealing S, Sutton A, Abraham WT, Beshai JF, Klein H,
Sculpher M, Plummer CJ, Cowie MR. Individual patient data network metaanalysis of mortality effects of implantable cardiac devices.
Heart
2015;101:18001806.
221. Gage RM, Burns KV, Bank AJ. Echocardiographic and clinical response to cardiac resynchronization therapy in heart failure patients with and without previous right ventricular pacing. Eur J Heart Fail 2014;16:11991205.
222. Ruschitzka F, Abraham WT, Singh JP, Bax JJ, Borer JS, Brugada J, Dickstein K,
Ford I, Gorcsan J, 3rd, Gras D, Krum H, Sogaard P, Holzmeister J, EchoCRT
Study Group. Cardiac-resynchronization therapy in heart failure with a narrow
QRS complex. N Engl J Med 2013;369:13951405.
223. Steffel J, Robertson M, Singh JP, Abraham WT, Bax JJ, Borer JS, Dickstein K,
Ford I, Gorcsan J, 3rd, Gras D, Krum H, Sogaard P, Holzmeister J, Brugada J,
Ruschitzka F. The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT
trial. Eur Heart J 2015;36:19831989.
224. Zusterzeel R, Selzman KA, Sanders WE, Canos DA, O’Callaghan KM,
Carpenter JL, Pina IL, Strauss DG. Cardiac resynchronization therapy in women:
US Food and Drug Administration meta-analysis of patient-level data. JAMA
Intern Med 2014;174:13401348.
225. Sohaib SM, Finegold JA, Nijjer SS, Hossain R, Linde C, Levy WC, Sutton R,
Kanagaratnam P, Francis DP, Whinnett ZI. Opportunity to increase life span in narrow QRS cardiac resynchronization therapy recipients by deactivating ventricular pacing: evidence from randomized controlled trials. JACC Heart Fail
2015;3:327336.
226. Greenberg H, Case RB, Moss AJ, Brown MW, Carroll ER, Andrews ML,
MADIT-II Investigators. Analysis of mortality events in the Multicenter
Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol
2004;43:14591465.
227. Linde C, Gold MR, Abraham WT, St John Sutton M, Ghio S, Cerkvenik J,
Daubert C, REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction Study Group. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study.
Eur Heart J 2013;34:25922599.
228. Cleland JG, Mareev Y, Linde C. Reflections on EchoCRT: sound guidance on
QRS duration and morphology for CRT? Eur Heart J 2015;36:19481951.
229. Linde C, Stahlberg M, Benson L, Braunschweig F, Edner M, Dahlstrom U,
Alehagen U, Lund LH. Gender, underutilization of cardiac resynchronization therapy, and prognostic impact of QRS prolongation and left bundle branch block in heart failure. Europace 2015;17:424431.
230. Cunnington C, Kwok CS, Satchithananda DK, Patwala A, Khan MA, Zaidi A,
Ahmed FZ, Mamas MA. Cardiac resynchronisation therapy is not associated with a reduction in mortality or heart failure hospitalisation in patients with non-left bundle branch block QRS morphology: meta-analysis of randomised controlled trials. Heart 2015;101:14561462.
231. Doshi RN, Daoud EG, Fellows C, Turk K, Duran A, Hamdan MH, Pires LA,
PAVE Study Group. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation
(the
PAVE
study).
J
Cardiovasc
Electrophysiol
2005;16:11601165.
232. Koplan BA, Kaplan AJ, Weiner S, Jones PW, Seth M, Christman SA. Heart failure decompensation and all-cause mortality in relation to percent biventricular pacing in patients with heart failure: is a goal of 100% biventricular pacing necessary? J Am Coll Cardiol 2009;53:355360.
233. Hawkins NM, Petrie MC, Burgess MI, McMurray JJ. Selecting patients for cardiac resynchronization therapy: the fallacy of echocardiographic dyssynchrony. J Am
Coll Cardiol 2009;53:19441959.
234. Beela AS, Unlu S, Duchenne J, Ciarka A, Daraban AM, Kotrc M, Aarones M,
Szulik M, Winter S, Penicka M, Neskovic AN, Kukulski T, Aakhus S, Willems R,
Fehske W, Faber L, Stankovic I, Voigt JU. Assessment of mechanical dyssynchrony can improve the prognostic value of guideline-based patient selection for cardiac resynchronization therapy.
Eur
Heart
J
Cardiovasc
Imaging
2019;20:6674.
235. Khan FZ, Virdee MS, Palmer CR, Pugh PJ, O’Halloran D, Elsik M, Read PA,
Begley D, Fynn SP, Dutka DP. Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trial. J Am Coll Cardiol 2012;59:15091518.
236. Saba S, Marek J, Schwartzman D, Jain S, Adelstein E, White P, Oyenuga OA,
Onishi T, Soman P, Gorcsan J, 3rd. Echocardiography-guided left ventricular lead placement for cardiac resynchronization therapy: results of the Speckle
Tracking Assisted Resynchronization Therapy for Electrode Region trial. Circ
Heart Fail 2013;6:427434.
237. Kosmala W, Marwick TH. Meta-analysis of effects of optimization of cardiac resynchronization therapy on left ventricular function, exercise capacity, and quality of life in patients with heart failure. Am J Cardiol 2014;113:988994.
238. Whinnett ZI, Francis DP, Denis A, Willson K, Pascale P, van Geldorp I, De
Guillebon M, Ploux S, Ellenbogen K, Haissaguerre M, Ritter P, Bordachar P.
Comparison of different invasive hemodynamic methods for AV delay optimization in patients with cardiac resynchronization therapy: implications for clinical trial design and clinical practice. Int J Cardiol 2013;168:22282237.
239. Daubert C, Behar N, Martins RP, Mabo P, Leclercq C. Avoiding nonresponders to cardiac resynchronization therapy: a practical guide. Eur Heart J
2017;38:14631472.
240. Mullens W, Auricchio A, Martens P, Witte K, Cowie MR, Delgado V, Dickstein
K, Linde C, Vernooy K, Leyva F, Bauersachs J, Israel CW, Lund LH, Donal E,
Boriani G, Jaarsma T, Berruezo A, Traykov V, Yousef Z, Kalarus Z, Cosedis
Nielsen J, Steffel J, Vardas P, Coats A, Seferovic P, Edvardsen T, Heidbuchel H,
Ruschitzka F, Leclercq C. Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care: a joint position statement from the Heart Failure Association (HFA), European Heart
Rhythm Association (EHRA), and European Association of Cardiovascular
Imaging (EACVI) of the European Society of Cardiology. Eur J Heart Fail
2020;22:23492369.
240a.Glikson M, Nielsen JC, Michowitz Y, Kronborg MB, Auricchio A, Barbash IM,
Barrabe´s JA, Boriani G, Braunschweig F, Brignole M, Burri H, Coats AJS,
Deharo JC, Delgado V, Diller GP, Israel CW, Keren A, Knops RE, Kotecha D,
Leclercq C, Merkely B, Starck C, Thyle´n I, Tolosana JM; ESC Scientific
Document Group. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J 2021; doi: 10.1093/eurheartj/ehab364 [Epub ahead of print].
241. Abraham WT, Kuck KH, Goldsmith RL, Lindenfeld J, Reddy VY, Carson PE, Mann
DL, Saville B, Parise H, Chan R, Wiegn P, Hastings JL, Kaplan AJ, Edelmann F,
Luthje L, Kahwash R, Tomassoni GF, Gutterman DD, Stagg A, Burkhoff D,
Hasenfuss G. A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation. JACC Heart Fail 2018;6:874883.
242. NICE: National Institute for Health and Care Excellence. Interventional procedures guidance. Cardiac contractility modulation device implantation for heart failure. www.nice.org.uk/guidance/ipg655 (28 May 2021).


<!-- PAGE 105 -->

### Page 105

...........................................................................................................................................................................
243. Abraham WT, Zile MR, Weaver FA, Butter C, Ducharme A, Halbach M, Klug
D, Lovett EG, Muller-Ehmsen J, Schafer JE, Senni M, Swarup V, Wachter R,
Little WC. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction. JACC Heart Fail 2015;3:487496.
244. Zile MR, Lindenfeld J, Weaver FA, Zannad F, Galle E, Rogers T, Abraham WT.
Baroreflex activation therapy in patients with heart failure with reduced ejection fraction. J Am Coll Cardiol 2020;76:113.
245. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson
EL, Olofsson B, Ostergren J, CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003;362:777781.
246. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N,
Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis
EF, O’Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer
NK, Yang S, McKinlay SM, TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:13831392.
247. Solomon SD, Vaduganathan M, Claggett BL, Packer M, Zile M, Swedberg K,
Rouleau J, Pfeffer MA, Desai A, Lund LH, Kober L, Anand I, Sweitzer N, Linssen
G, Merkely B, Luis Arango J, Vinereanu D, Chen CH, Senni M, Sibulo A,
Boytsov S, Shi V, Rizkala A, Lefkowitz M, McMurray JJV. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure.
Circulation
2020;141:352361.
248. Rogers JK, Pocock SJ, McMurray JJ, Granger CB, Michelson EL, Ostergren J,
Pfeffer MA, Solomon SD, Swedberg K, Yusuf S. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to
CHARM-Preserved. Eur J Heart Fail 2014;16:3340.
249. van Veldhuisen DJ, Cohen-Solal A, Bohm M, Anker SD, Babalis D, Roughton M,
Coats AJ, Poole-Wilson PA, Flather MD, SENIORS Investigators. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol
Intervention on Outcomes and Rehospitalization in Seniors With Heart
Failure). J Am Coll Cardiol 2009;53:21502158.
250. Hai OY, Mentz RJ, Zannad F, Gasparini M, De Ferrari GM, Daubert JC,
Holzmeister J, Lam CS, Pochet T, Vincent A, Linde C. Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction. Eur J Heart Fail 2015;17:135143.
251. Shah SJ, Feldman T, Ricciardi MJ, Kahwash R, Lilly S, Litwin S, Nielsen CD, van der Harst P, Hoendermis E, Penicka M, Bartunek J, Fail PS, Kaye DM, Walton A,
Petrie MC, Walker N, Basuray A, Yakubov S, Hummel SL, Chetcuti S, FordeMcLean R, Herrmann HC, Burkhoff D, Massaro JM, Cleland JGF, Mauri L. Oneyear safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the Reduce
Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF
I) Trial: a randomized clinical trial. JAMA Cardiol 2018;3:968977.
252. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL,
Olofsson B, Ostergren J, Yusuf S, Pocock S, CHARM Investigators and
Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure:
the
CHARM-Overall programme.
Lancet
2003;362:759766.
253. Dewan P, Jackson A, Lam CSP, Pfeffer MA, Zannad F, Pitt B, Solomon SD,
McMurray JJV. Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure.
Eur
J
Heart
Fail
2020;22:898901.
254. Campbell RT, Petrie MC, McMurray JJV. Redefining heart failure phenotypes based on ejection fraction. Eur J Heart Fail 2018;20:16341635.
255. Echocardiographic
Normal
Ranges
Meta-Analysis of the
Left
Heart
Collaboration. Ethnic-specific normative reference values for echocardiographic
LA and LV size, LV mass, and systolic function: the EchoNoRMAL Study. JACC
Cardiovasc Imaging 2015;8:656665.
256. Wehner GJ, Jing L, Haggerty CM, Suever JD, Leader JB, Hartzel DN, Kirchner
HL, Manus JNA, James N, Ayar Z, Gladding P, Good CW, Cleland JGF,
Fornwalt BK. Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie? Eur Heart J 2020;41:12491257.
257. Stewart S, Playford D, Scalia GM, Currie P, Celermajer DS, Prior D, Codde J,
Strange G, NEDA Investigators. Ejection fraction and mortality: a nationwide register-based cohort study of 499 153 women and men. Eur J Heart Fail
2021;23:406416.
258. Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol 2020;17:559573.
259. Pieske B, Tschope C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann
F, Fu M, Guazzi M, Lam CSP, Lancellotti P, Melenovsky V, Morris DA, Nagel
E, Pieske-Kraigher E, Ponikowski P, Solomon SD, Vasan RS, Rutten FH, Voors
AA, Ruschitzka F, Paulus WJ, Seferovic P, Filippatos G. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association
(HFA)
of the
European
Society of
Cardiology
(ESC).
Eur
Heart
J
2019;40:32973317.
260. Ho JE, Zern EK, Wooster L, Bailey CS, Cunningham T, Eisman AS, Hardin KM,
Zampierollo GA, Jarolim P, Pappagianopoulos PP, Malhotra R, Nayor M, Lewis
GD. Differential clinical profiles, exercise responses, and outcomes associated with existing HFpEF definitions. Circulation 2019;140:353365.
261. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple,
evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 2018;138:861870.
262. Segar MW, Patel KV, Berry JD, Grodin JL, Pandey A. Generalizability and implications of the H2FPEF score in a cohort of patients with heart failure with preserved ejection fraction. Circulation 2019;139:18511853.
263. Myhre PL, Vaduganathan M, Claggett BL, Lam CSP, Desai AS, Anand IS,
Sweitzer NK, Fang JC, O’Meara E, Shah SJ, Shah AM, Lewis EF, Rouleau J, Pitt B,
Solomon SD. Application of the H2 FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial.
Eur J Heart Fail 2019;21:12881291.
264. Sepehrvand N, Alemayehu W, Dyck GJB, Dyck JRB, Anderson T, Howlett J,
Paterson I, McAlister FA, Ezekowitz JA. External validation of the H2F-PEF
model in diagnosing patients with heart failure and preserved ejection fraction.
Circulation 2019;139:23772379.
265. Sueta D, Yamamoto E, Nishihara T, Tokitsu T, Fujisue K, Oike F, Takae M,
Usuku H, Takashio S, Arima Y, Suzuki S, Nakamura T, Ito M, Kanazawa H,
Sakamoto K, Kaikita K, Tsujita K. H2FPEF score as a prognostic value in HFpEF
patients. Am J Hypertens 2019;32:10821090.
266. Barandiaran Aizpurua A, Sanders-van Wijk S, Brunner-La Rocca HP, Henkens
M, Heymans S, Beussink-Nelson L, Shah SJ, van Empel VPM. Validation of the
HFA-PEFF score for the diagnosis of heart failure with preserved ejection fraction. Eur J Heart Fail 2020;22:413421.
267. Sanders-van Wijk S, Barandiaran Aizpurua A, Brunner-La Rocca HP, Henkens
M, Weerts J, Knackstedt C, Uszko-Lencer N, Heymans S, van Empel V. The
HFA-PEFF and H2 FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction. Eur J Heart Fail
2021;23:838840.
268. Selvaraj S, Myhre PL, Vaduganathan M, Claggett BL, Matsushita K, Kitzman DW,
Borlaug BA, Shah AM, Solomon SD. Application of diagnostic algorithms for heart failure with preserved ejection fraction to the community. JACC Heart Fail
2020;8:640653.
269. Ouwerkerk W, Tromp J, Jin X, Jaufeerally F, Yeo PSD, Leong KTG, Ong HY,
Ling LH, Loh SY, Sim D, Lee S, Soon D, Chin C, Richards AM, Lam CSP. Heart failure with preserved ejection fraction diagnostic scores in an Asian population.
Eur J Heart Fail 2020;22:17371739.
270. Playford D, Strange G, Celermajer DS, Evans G, Scalia GM, Stewart S, Prior D,
NEDA Investigators. Diastolic dysfunction and mortality in 436 360 men and women: the National Echo Database Australia (NEDA). Eur Heart J Cardiovasc
Imaging 2021;22:505515.
271. Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S, Jackson R,
Rahneva T, Wage R, Smith G, Venneri L, Tayal U, Auger D, Midwinter W,
Whiffin N, Rajani R, Dungu JN, Pantazis A, Cook SA, Ware JS, Baksi AJ,
Pennell DJ, Rosen SD, Cowie MR, Cleland JGF, Prasad SK. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet
2019;393:6173.
272. Lupon J, Gavidia-Bovadilla G, Ferrer E, de Antonio M, Perera-Lluna A, LopezAyerbe J, Domingo M, Nunez J, Zamora E, Moliner P, Santiago-Vacas E,
Santesmases J, Bayes-Genis A. Heart failure with preserved ejection fraction infrequently evolves toward a reduced phenotype in long-term survivors. Circ
Heart Fail 2019;12:e005652.
273. Savarese G, Vedin O, D’Amario D, Uijl A, Dahlstrom U, Rosano G, Lam CSP,
Lund LH. Prevalence and prognostic implications of longitudinal ejection fraction change in heart failure. JACC Heart Fail 2019;7:306317.
274. Nauta JF, Hummel YM, van der Meer P, Lam CSP, Voors AA, van Melle JP.
Correlation with invasive left ventricular filling pressures and prognostic relevance of the echocardiographic diastolic parameters used in the 2016 ESC
heart failure guidelines and in the 2016 ASE/EACVI recommendations: a systematic review in patients with heart failure with preserved ejection fraction.
Eur J Heart Fail 2018;20:13031311.
275. Sharifov OF, Schiros CG, Aban I, Denney TS, Gupta H. Diagnostic accuracy of tissue Doppler index E/e’ for evaluating left ventricular filling pressure and diastolic dysfunction/heart failure with preserved ejection fraction: a systematic review and meta-analysis. J Am Heart Assoc 2016;5:e002078.
276. Eisman AS, Shah RV, Dhakal BP, Pappagianopoulos PP, Wooster L, Bailey C,
Cunningham TF, Hardin KM, Baggish AL, Ho JE, Malhotra R, Lewis GD.
Pulmonary capillary wedge pressure patterns during exercise predict exercise capacity and incident heart failure. Circ Heart Fail 2018;11:e004750.
ESC Guidelines
3703


<!-- PAGE 106 -->

### Page 106

.............................................................................................................................................................................
277. Cleland JG, Tendera M, Adamus J, Freemantle N, Gray CS, Lye M,
O’Mahony D, Polonski L, Taylor J. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP Investigators. Eur J Heart
Fail 1999;1:211217.
278. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR,
Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A, I-PRESERVE
Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:24562467.
279. Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, Love TE,
Aronow WS, Adams KF Jr, Gheorghiade M. Effects of digoxin on morbidity and mortality in diastolic heart failure: the Ancillary Digitalis Investigation Group trial. Circulation 2006;114:397403.
280. Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH,
LeWinter MM, Joseph SM, Shah SJ, Semigran MJ, Felker GM, Cole RT, Reeves
GR, Tedford RJ, Tang WH, McNulty SE, Velazquez EJ, Shah MR, Braunwald E,
NHLBI Heart Failure Clinical Research Network. Isosorbide mononitrate in heart failure with preserved ejection fraction.
N
Engl
J
Med
2015;373:23142324.
281. Borlaug BA, Anstrom KJ, Lewis GD, Shah SJ, Levine JA, Koepp GA, Givertz MM,
Felker GM, LeWinter MM, Mann DL, Margulies KB, Smith AL, Tang WHW,
Whellan DJ, Chen HH, Davila-Roman VG, McNulty S, Desvigne-Nickens P,
Hernandez AF, Braunwald E, Redfield MM, National Heart, Lung, and Blood
Institute Heart Failure Clinical Research Network. Effect of inorganic nitrite vs placebo on exercise capacity among patients with heart failure with preserved ejection fraction:
the
INDIE-HFpEF
randomized clinical trial.
JAMA
2018;320:17641773.
282. Armstrong PW, Lam CSP, Anstrom KJ, Ezekowitz J, Hernandez AF, O’Connor
CM, Pieske B, Ponikowski P, Shah SJ, Solomon SD, Voors AA, She L, Vlajnic V,
Carvalho F, Bamber L, Blaustein RO, Roessig L, Butler J, VITALITY-HFpEF
Study Group. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial. JAMA 2020;324:15121521.
283. Udelson JE, Lewis GD, Shah SJ, Zile MR, Redfield MM, Burnett J, Jr., Parker J,
Seferovic JP, Wilson P, Mittleman RS, Profy AT, Konstam MA. Effect of praliciguat on peak rate of oxygen consumption in patients with heart failure with preserved ejection fraction: the CAPACITY HFpEF randomized clinical trial.
JAMA 2020;324:15221531.
284. Omar W, Pandey A, Haykowsky MJ, Berry JD, Lavie CJ. The evolving role of cardiorespiratory fitness and exercise in prevention and management of heart failure. Curr Heart Fail Rep 2018;15:7580.
285. Kitzman DW, Upadhya B, Reeves G. Hospitalizations and prognosis in elderly patients with heart failure and preserved ejection fraction: time to treat the whole patient. JACC Heart Fail 2015;3:442444.
286. Wood AM, Kaptoge S, Butterworth AS, Willeit P, Warnakula S, Bolton T, Paige
E, Paul DS, Sweeting M, Burgess S, Bell S, Astle W, Stevens D, Koulman A,
Selmer RM, Verschuren WMM, Sato S, Njolstad I, Woodward M, Salomaa V,
Nordestgaard BG, Yeap BB, Fletcher A, Melander O, Kuller LH, Balkau B,
Marmot M, Koenig W, Casiglia E, Cooper C, Arndt V, Franco OH, Wennberg
P, Gallacher J, de la Camara AG, Volzke H, Dahm CC, Dale CE, Bergmann MM,
Crespo CJ, van der Schouw YT, Kaaks R, Simons LA, Lagiou P, Schoufour JD,
Boer JMA, Key TJ, Rodriguez B, Moreno-Iribas C, Davidson KW, Taylor JO,
Sacerdote C, Wallace RB, Quiros JR, Tumino R, Blazer DG, 2nd, Linneberg A,
Daimon M, Panico S, Howard B, Skeie G, Strandberg T, Weiderpass E, Nietert
PJ, Psaty BM, Kromhout D, Salamanca-Fernandez E, Kiechl S, Krumholz HM,
Grioni S, Palli D, Huerta JM, Price J, Sundstrom J, Arriola L, Arima H, Travis RC,
Panagiotakos DB, Karakatsani A, Trichopoulou A, Kuhn T, Grobbee DE,
Barrett-Connor E, van Schoor N, Boeing H, Overvad K, Kauhanen J, Wareham
N, Langenberg C, Forouhi N, Wennberg M, Despres JP, Cushman M, Cooper
JA, Rodriguez CJ, Sakurai M, Shaw JE, Knuiman M, Voortman T, Meisinger C,
Tjonneland A, Brenner H, Palmieri L, Dallongeville J, Brunner EJ, Assmann G,
Trevisan M, Gillum RF, Ford I, Sattar N, Lazo M, Thompson SG, Ferrari P, Leon
DA, Smith GD, Peto R, Jackson R, Banks E, Di Angelantonio E, Danesh J,
Emerging Risk Factors Collaboration/EPIC-CVD/UK Biobank Alcohol Study
Group. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet 2018;391:15131523.
287. Kostis JB, Davis BR, Cutler J, Grimm RH, Jr., Berge KG, Cohen JD, Lacy CR,
Perry HM, Jr., Blaufox MD, Wassertheil-Smoller S, Black HR, Schron E,
Berkson DM, Curb JD, Smith WM, McDonald R, Applegate WB. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension.
SHEP
Cooperative
Research
Group.
JAMA
1997;278:212216.
288. Group SR, Wright JT, Jr., Williamson JD, Whelton PK, Snyder JK, Sink KM,
Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson
KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT.
A randomized trial of intensive versus standard blood-pressure control. N Engl
J Med 2015;373:21032116.
289. Sciarretta S, Palano F, Tocci G, Baldini R, Volpe M. Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network metaanalysis of studies in patients with hypertension and high cardiovascular risk.
Arch Intern Med 2011;171:384394.
290. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D,
Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F,
Rajkumar C, Thijs L, Banya W, Bulpitt CJ, HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med
2008;358:18871898.
291. Scirica BM, Morrow DA, Cannon CP, Ray KK, Sabatine MS, Jarolim P, Shui A,
McCabe CH, Braunwald E, PROVE IT-TIMI Investigators. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 2006;47:23262331.
292. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997;3:249254.
293. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M,
Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG
OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:21172128.
294. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw
W, Law G, Desai M, Matthews DR, CANVAS Program Collaborative Group.
Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J
Med 2017;377:644657.
295. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG,
Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding
JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM,
Sabatine MS, DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347357.
296. Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB,
Riddle MC, Inzucchi SE, Kosiborod MN, Cherney DZI, Dwyer JP, Scirica BM,
Bailey CJ, Diaz R, Ray KK, Udell JA, Lopes RD, Lapuerta P, Steg PG, SCORED
Investigators. Sotagliflozin in patients with diabetes and chronic kidney disease.
N Engl J Med 2020;384:129139.
297. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U,
Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG,
Cherney DZI, McGuire DK, VERTIS CV Investigators. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 2020;383:14251435.
298. Suskin N, Sheth T, Negassa A, Yusuf S. Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. J Am
Coll Cardiol 2001;37:16771682.
299. Dorans KS, Mostofsky E, Levitan EB, Hakansson N, Wolk A, Mittleman MA.
Alcohol and incident heart failure among middle-aged and elderly men: cohort of Swedish men. Circ Heart Fail 2015;8:422427.
300. Goncalves A, Claggett B, Jhund PS, Rosamond W, Deswal A, Aguilar D, Shah
AM, Cheng S, Solomon SD. Alcohol consumption and risk of heart failure: the
Atherosclerosis Risk in Communities Study. Eur Heart J 2015;36:939945.
301. Pandey A, Garg S, Khunger M, Darden D, Ayers C, Kumbhani DJ, Mayo HG, de
Lemos JA, Berry JD. Dose-response relationship between physical activity and risk of heart failure: a meta-analysis. Circulation 2015;132:17861794.
302. Padwal R, McAlister FA, McMurray JJ, Cowie MR, Rich M, Pocock S, Swedberg K,
Maggioni A, Gamble G, Ariti C, Earle N, Whalley G, Poppe KK, Doughty RN,
Bayes-Genis A, Meta-analysis Global Group in Chronic Heart Failure (MAGGIC).
The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data. Int J Obes (Lond)
2014;38:11101114.
303. McDonagh TA, Blue L, Clark AL, Dahlstrom U, Ekman I, Lainscak M, McDonald
K, Ryder M, Stromberg A, Jaarsma T, European Society of Cardiology Heart
Failure
Association
Committee on
Patient
Care.
European
Society of
Cardiology Heart Failure Association Standards for delivering heart failure care.
Eur J Heart Fail 2011;13:235241.
304. Lainscak M, Blue L, Clark AL, Dahlstrom U, Dickstein K, Ekman I, McDonagh T,
McMurray JJ, Ryder M, Stewart S, Stromberg A, Jaarsma T. Self-care management of heart failure: practical recommendations from the Patient Care
Committee of the Heart Failure Association of the European Society of
Cardiology. Eur J Heart Fail 2011;13:115126.
305. Mebazaa A, Yilmaz MB, Levy P, Ponikowski P, Peacock WF, Laribi S, Ristic AD,
Lambrinou E, Masip J, Riley JP, McDonagh T, Mueller C, deFilippi C, Harjola VP,
Thiele H, Piepoli MF, Metra M, Maggioni A, McMurray JJ, Dickstein K, Damman
K, Seferovic PM, Ruschitzka F, Leite-Moreira AF, Bellou A, Anker SD, Filippatos
G. Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the
European Society of Cardiology, the European Society of Emergency Medicine


<!-- PAGE 107 -->

### Page 107

...........................................................................................................................................................................
and the Society of Academic Emergency Medicine–short version. Eur Heart J
2015;36:19581966.
306. McDonagh TA, Gardner RS, Lainscak M, Nielsen OW, Parissis J, Filippatos G,
Anker SD. Heart Failure Association of the European Society of Cardiology specialist heart failure curriculum. Eur J Heart Fail 2014;16:151162.
307. Riley JP, Astin F, Crespo-Leiro MG, Deaton CM, Kienhorst J, Lambrinou E,
McDonagh TA, Rushton CA, Stromberg A, Filippatos G, Anker SD. Heart
Failure Association of the European Society of Cardiology heart failure nurse curriculum. Eur J Heart Fail 2016;18:736743.
308. Van Spall HGC, Rahman T, Mytton O, Ramasundarahettige C, Ibrahim Q,
Kabali C, Coppens M, Brian Haynes R, Connolly S. Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta-analysis. Eur J Heart Fail
2017;19:14271443.
309. Jonkman NH, Westland H, Groenwold RH, Agren S, Anguita M, Blue L,
Bruggink-Andre de la Porte PW, DeWalt DA, Hebert PL, Heisler M, Jaarsma T,
Kempen GI, Leventhal ME, Lok DJ, Martensson J, Muniz J, Otsu H, PetersKlimm F, Rich MW, Riegel B, Stromberg A, Tsuyuki RT, Trappenburg JC,
Schuurmans MJ, Hoes AW. What are effective program characteristics of selfmanagement interventions in patients with heart failure? An individual patient data meta-analysis. J Card Fail 2016;22:861871.
310. Takeda A, Martin N, Taylor RS, Taylor SJ. Disease management interventions for heart failure. Cochrane Database Syst Rev 2019;1:CD002752.
311. Kalogirou F, Forsyth F, Kyriakou M, Mantle R, Deaton C. Heart failure disease management: a systematic review of effectiveness in heart failure with preserved ejection fraction. ESC Heart Fail 2020;7:194212.
312. Hill L, Prager Geller T, Baruah R, Beattie JM, Boyne J, de Stoutz N, Di Stolfo G,
Lambrinou E, Skibelund AK, Uchmanowicz I, Rutten FH, Celutkiene J, Piepoli
MF, Jankowska EA, Chioncel O, Ben Gal T, Seferovic PM, Ruschitzka F, Coats
AJS, Stromberg A, Jaarsma T. Integration of a palliative approach into heart failure care: a European Society of Cardiology Heart Failure Association position paper. Eur J Heart Fail 2020;22:23272339.
313. Kyriakou M, Middleton N, Ktisti S, Philippou K, Lambrinou E. Supportive care interventions to promote health-related quality of life in patients living with heart failure:
a systematic review and meta-analysis.
Heart
Lung
Circ
2020;29:16331647.
314. Feltner C, Jones CD, Cene CW, Zheng ZJ, Sueta CA, Coker-Schwimmer EJ,
Arvanitis M, Lohr KN, Middleton JC, Jonas DE. Transitional care interventions to prevent readmissions for persons with heart failure: a systematic review and meta-analysis. Ann Intern Med 2014;160:774784.
315. Blue L, Lang E, McMurray JJ, Davie AP, McDonagh TA, Murdoch DR, Petrie
MC, Connolly E, Norrie J, Round CE, Ford I, Morrison CE. Randomised controlled trial of specialist nurse intervention in heart failure.
BMJ
2001;323:715718.
316. Lambrinou E, Kalogirou F, Lamnisos D, Sourtzi P. Effectiveness of heart failure management programmes with nurse-led discharge planning in reducing readmissions:
a systematic review and meta-analysis.
Int
J
Nurs
Stud
2012;49:610624.
317. Stewart S, Vandenbroek AJ, Pearson S, Horowitz JD. Prolonged beneficial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure.
Arch
Intern
Med
1999;159:257261.
318. Ekman I, Wolf A, Olsson LE, Taft C, Dudas K, Schaufelberger M, Swedberg K.
Effects of person-centred care in patients with chronic heart failure: the PCCHF study. Eur Heart J 2012;33:11121119.
319. Riegel B, Bennett JA, Davis A, Carlson B, Montague J, Robin H, Glaser D.
Cognitive impairment in heart failure: issues of measurement and etiology. Am J
Crit Care 2002;11:520528.
320. Laufs U, Rettig-Ewen V, Bohm M. Strategies to improve drug adherence. Eur
Heart J 2011;32:264268.
321. Abraityte A, Aukrust P, Kou L, Anand IS, Young J, McMurray JJV, van Veldhuisen
DJ, Gullestad L, Ueland T. T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure:
results from
RED-HF.
Clin
Res
Cardiol
2019;108:133141.
322. Flynn KE, Pina IL, Whellan DJ, Lin L, Blumenthal JA, Ellis SJ, Fine LJ, Howlett JG,
Keteyian SJ, Kitzman DW, Kraus WE, Miller NH, Schulman KA, Spertus JA,
O’Connor CM, Weinfurt KP, HF-ACTION Investigators. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION
randomized controlled trial. JAMA 2009;301:14511459.
323. O’Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, Leifer ES,
Kraus WE, Kitzman DW, Blumenthal JA, Rendall DS, Miller NH, Fleg JL,
Schulman KA, McKelvie RS, Zannad F, Pina IL, HF-ACTION Investigators.
Efficacy and safety of exercise training in patients with chronic heart failure: HFACTION randomized controlled trial. JAMA 2009;301:14391450.
324. Taylor RS, Walker S, Smart NA, Piepoli MF, Warren FC, Ciani O, Whellan D,
O’Connor C, Keteyian SJ, Coats A, Davos CH, Dalal HM, Dracup K, Evangelista
LS, Jolly K, Myers J, Nilsson BB, Passino C, Witham MD, Yeh GY,
ExTraMATCH II Collaboration. Impact of exercise rehabilitation on exercise capacity and quality-of-life in heart failure: individual participant meta-analysis. J
Am Coll Cardiol 2019;73:14301443.
325. Taylor RS, Walker S, Smart NA, Piepoli MF, Warren FC, Ciani O, O’Connor C,
Whellan D, Keteyian SJ, Coats A, Davos CH, Dalal HM, Dracup K, Evangelista
L, Jolly K, Myers J, McKelvie RS, Nilsson BB, Passino C, Witham MD, Yeh GY,
Zwisler AO, ExTraMATCH II Collaboration. Impact of exercise-based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: an individual patient data meta-analysis of randomised trials. Eur
J Heart Fail 2018;20:17351743.
326. Pandey A, Parashar A, Kumbhani D, Agarwal S, Garg J, Kitzman D, Levine B,
Drazner M, Berry J. Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials. Circ Heart Fail
2015;8:3340.
327. Taylor RS, Long L, Mordi IR, Madsen MT, Davies EJ, Dalal H, Rees K, Singh SJ,
Gluud C, Zwisler AD. Exercise-based rehabilitation for heart failure: Cochrane
Systematic Review, meta-analysis, and trial sequential analysis. JACC Heart Fail
2019;7:691705.
328. Taylor RS, Walker S, Ciani O, Warren F, Smart NA, Piepoli M, Davos CH.
Exercise-based cardiac rehabilitation for chronic heart failure:
the
EXTRAMATCH II individual participant data meta-analysis. Health Technol Assess
2019;23:198.
329. Cooper LB, Mentz RJ, Sun JL, Schulte PJ, Fleg JL, Cooper LS, Pina IL, Leifer ES,
Kraus WE, Whellan DJ, Keteyian SJ, O’Connor CM. Psychosocial factors, exercise adherence, and outcomes in heart failure patients: insights from Heart
Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HFACTION). Circ Heart Fail 2015;8:10441051.
330. Gomes Neto M, Duraes AR, Conceicao LSR, Saquetto MB, Ellingsen O,
Carvalho VO. High intensity interval training versus moderate intensity continuous training on exercise capacity and quality of life in patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis. Int J
Cardiol 2018;261:134141.
331. Ellingsen O, Halle M, Conraads V, Stoylen A, Dalen H, Delagardelle C, Larsen
AI, Hole T, Mezzani A, Van Craenenbroeck EM, Videm V, Beckers P, Christle
JW, Winzer E, Mangner N, Woitek F, Hollriegel R, Pressler A, Monk-Hansen T,
Snoer M, Feiereisen P, Valborgland T, Kjekshus J, Hambrecht R, Gielen S,
Karlsen T, Prescott E, Linke A, SMARTEX Heart Failure Study Group. Highintensity interval training in patients with heart failure with reduced ejection fraction. Circulation 2017;135:839849.
332. Edelmann F, Gelbrich G, Dungen HD, Frohling S, Wachter R, Stahrenberg R,
Binder L, Topper A, Lashki DJ, Schwarz S, Herrmann-Lingen C, Loffler M,
Hasenfuss G, Halle M, Pieske B. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol 2011;58:17801791.
333. Nolte K, Herrmann-Lingen C, Wachter R, Gelbrich G, Dungen HD, Duvinage
A, Hoischen N, von Oehsen K, Schwarz S, Hasenfuss G, Halle M, Pieske B,
Edelmann F. Effects of exercise training on different quality of life dimensions in heart failure with preserved ejection fraction: the Ex-DHF-P trial. Eur J Prev
Cardiol 2015;22:582593.
334. Ismail H, McFarlane JR, Nojoumian AH, Dieberg G, Smart NA. Clinical outcomes and cardiovascular responses to different exercise training intensities in patients with heart failure: a systematic review and meta-analysis. JACC Heart
Fail 2013;1:514522.
335. Kitzman DW, Brubaker PH, Herrington DM, Morgan TM, Stewart KP, Hundley
WG, Abdelhamed A, Haykowsky MJ. Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. J Am
Coll Cardiol 2013;62:584592.
336. Ismail H, McFarlane J, Smart NA. Is exercise training beneficial for heart failure patients taking beta-adrenergic blockers? A systematic review and meta-analysis.
Congest Heart Fail 2013;19:6169.
337. Kitzman DW, Brubaker P, Morgan T, Haykowsky M, Hundley G, Kraus WE,
Eggebeen J, Nicklas BJ. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA
2016;315:3646.
338. Taylor RS, Sagar VA, Davies EJ, Briscoe S, Coats AJ, Dalal H, Lough F, Rees K,
Singh S. Exercise-based rehabilitation for heart failure. Cochrane Database Syst
Rev 2014:CD003331.
339. Schou M, Gustafsson F, Videbaek L, Tuxen C, Keller N, Handberg J, Sejr
Knudsen A, Espersen G, Markenvard J, Egstrup K, Ulriksen H, Hildebrandt PR,
ESC Guidelines
3705


<!-- PAGE 108 -->

### Page 108

..........................................................................................................................................................................
the NorthStar Investigators, all members of The Danish Heart Failure Clinics
Network. Extended heart failure clinic follow-up in low-risk patients: a randomized clinical trial (NorthStar). Eur Heart J 2013;34:432442.
340. Thorvaldsen T, Benson L, Dahlstrom U, Edner M, Lund LH. Use of evidencebased therapy and survival in heart failure in Sweden 2003-2012. Eur J Heart Fail
2016;18:503511.
341. Lund LH, Braunschweig F, Benson L, Stahlberg M, Dahlstrom U, Linde C.
Association between demographic, organizational, clinical, and socio-economic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry. Eur J Heart Fail 2017;19:12701279.
342. Savarese G, Carrero JJ, Pitt B, Anker SD, Rosano GMC, Dahlstrom U, Lund LH.
Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail 2018;20:13261334.
343. Lund LH, Carrero JJ, Farahmand B, Henriksson KM, Jonsson A, Jernberg T,
Dahlstrom U. Association between enrolment in a heart failure quality registry and subsequent mortality–a nationwide cohort study. Eur J Heart Fail
2017;19:11071116.
344. Clark AL, Goode K, Cleland JG. The prevalence and incidence of left bundle branch block in ambulant patients with chronic heart failure. Eur J Heart Fail
2008;10:696702.
345. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards
AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:11261130.
346. Berger R, Moertl D, Peter S, Ahmadi R, Huelsmann M, Yamuti S, Wagner B,
Pacher R. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3arm, prospective, randomized pilot study. J Am Coll Cardiol 2010;55:645653.
347. Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, Aupetit JF,
Aumont MC, Galinier M, Eicher JC, Cohen-Solal A, Juilliere Y. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the
STARS-BNP Multicenter Study. J Am Coll Cardiol 2007;49:17331739.
348. Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A,
Yandle TG, Hamid AK, Nicholls MG, Richards AM. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the
BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac
Readmissions and Death) trial. J Am Coll Cardiol 2009;55:5360.
349. Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, Vuillomenet
A, Jeker U, Dubach P, Beer H, Yoon SI, Suter T, Osterhues HH, Schieber MM,
Hilti P, Schindler R, Brunner-La Rocca HP, TIME-CHF Investigators. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard
Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF)
randomized trial. JAMA 2009;301:383392.
350. Felker GM, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-Miller N,
Januzzi JL, Jr., Mark DB, Pina IL, Passmore G, Whellan DJ, Yang H, Cooper LS,
Leifer ES, Desvigne-Nickens P, O’Connor CM. Effect of natriuretic peptideguided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2017;318:713720.
351. Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med
2010;170:507514.
352. Troughton RW, Frampton CM, Brunner-La Rocca HP, Pfisterer M, Eurlings LW,
Erntell H, Persson H, O’Connor CM, Moertl D, Karlstrom P, Dahlstrom U,
Gaggin HK, Januzzi JL, Berger R, Richards AM, Pinto YM, Nicholls MG. Effect of
B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J
2014;35:15591567.
353. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, Glazer RD,
Tognoni G, Cohn JN, Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan
Heart Failure Trial (Val-HeFT). Circulation 2003;107:12781283.
354. Zile MR, Claggett BL, Prescott MF, McMurray JJ, Packer M, Rouleau JL,
Swedberg K, Desai AS, Gong J, Shi VC, Solomon SD. Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure. J Am Coll Cardiol 2016;68:24252436.
355. Brahmbhatt DH, Cowie MR. Remote management of heart failure: an overview of telemonitoring technologies. Card Fail Rev 2019;5:8692.
356. Cleland JG, Clark RA, Pellicori P, Inglis SC. Caring for people with heart failure and many other medical problems through and beyond the COVID-19 pandemic: the advantages of universal access to home telemonitoring. Eur J Heart
Fail 2020;22:995998.
357. Inglis SC, Clark RA, Dierckx R, Prieto-Merino D, Cleland JG. Structured telephone support or non-invasive telemonitoring for patients with heart failure.
Heart 2017;103:255257.
358. Frederix I, Caiani EG, Dendale P, Anker S, Bax J, Bohm A, Cowie M, Crawford
J, de Groot N, Dilaveris P, Hansen T, Koehler F, Krstacic G, Lambrinou E,
Lancellotti P, Meier P, Neubeck L, Parati G, Piotrowicz E, Tubaro M, van der
Velde E. ESC e-Cardiology Working Group Position Paper: Overcoming challenges in digital health implementation in cardiovascular medicine. Eur J Prev
Cardiol 2019;26:11661177.
359. Lin MH, Yuan WL, Huang TC, Zhang HF, Mai JT, Wang JF. Clinical effectiveness of telemedicine for chronic heart failure: a systematic review and meta-analysis.
J Investig Med 2017;65:899911.
360. Adamson PB, Ginn G, Anker SD, Bourge RC, Abraham WT. Remote haemodynamic-guided care for patients with chronic heart failure: a metaanalysis of completed trials. Eur J Heart Fail 2017;19:426433.
361. Chaudhry SI, Mattera JA, Curtis JP, Spertus JA, Herrin J, Lin Z, Phillips CO,
Hodshon BV, Cooper LS, Krumholz HM. Telemonitoring in patients with heart failure. N Engl J Med 2010;363:23012309.
362. Koehler F, Winkler S, Schieber M, Sechtem U, Stangl K, Bohm M, Boll H,
Baumann G, Honold M, Koehler K, Gelbrich G, Kirwan BA, Anker SD,
Telemedical Interventional Monitoring in Heart Failure Investigators. Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study. Circulation 2011;123:18731880.
363. Koehler F, Koehler K, Deckwart O, Prescher S, Wegscheider K, Winkler S,
Vettorazzi E, Polze A, Stangl K, Hartmann O, Marx A, Neuhaus P, Scherf M,
Kirwan BA, Anker SD. Telemedical Interventional Management in Heart Failure
II (TIM-HF2), a randomised, controlled trial investigating the impact of telemedicine on unplanned cardiovascular hospitalisations and mortality in heart failure patients: study design and description of the intervention. Eur J Heart Fail
2018;20:14851493.
364. Koehler F, Koehler K, Deckwart O, Prescher S, Wegscheider K, Kirwan BA,
Winkler S, Vettorazzi E, Bruch L, Oeff M, Zugck C, Doerr G, Naegele H, Stork
S, Butter C, Sechtem U, Angermann C, Gola G, Prondzinsky R, Edelmann F,
Spethmann S, Schellong SM, Schulze PC, Bauersachs J, Wellge B, Schoebel C,
Tajsic M, Dreger H, Anker SD, Stangl K. Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled,
parallel-group, unmasked trial. Lancet 2018;392:10471057.
365. Kalter-Leibovici O, Freimark D, Freedman LS, Kaufman G, Ziv A, Murad H,
Benderly M, Silverman BG, Friedman N, Cukierman-Yaffe T, Asher E, Grupper
A, Goldman D, Amitai M, Matetzky S, Shani M, Silber H, Israel Heart Failure
Disease Management Study investigators. Disease management in the treatment of patients with chronic heart failure who have universal access to health care:
a randomized controlled trial. BMC Med 2017;15:90.
366. Jayaram NM, Khariton Y, Krumholz HM, Chaudhry SI, Mattera J, Tang F, Herrin
J, Hodshon B, Spertus JA. Impact of telemonitoring on health status. Circ
Cardiovasc Qual Outcomes 2017;10:e004148.
367. Shochat MK, Shotan A, Blondheim DS, Kazatsker M, Dahan I, Asif A, Rozenman
Y, Kleiner I, Weinstein JM, Frimerman A, Vasilenko L, Meisel SR. Non-invasive lung IMPEDANCE-guided preemptive treatment in chronic heart failure patients: a randomized controlled trial (IMPEDANCE-HF Trial). J Card Fail
2016;22:713722.
368. van Veldhuisen DJ, Braunschweig F, Conraads V, Ford I, Cowie MR, Jondeau G,
Kautzner J, Aguilera RM, Lunati M, Yu CM, Gerritse B, Borggrefe M, DOT-HF
Investigators. Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure. Circulation 2011;124:17191726.
369. Hindricks G, Taborsky M, Glikson M, Heinrich U, Schumacher B, Katz A,
Brachmann J, Lewalter T, Goette A, Block M, Kautzner J, Sack S, Husser D,
Piorkowski C, Sogaard P, IN-TIME Study Group. Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial. Lancet 2014;384:583590.
370. Morgan JM, Kitt S, Gill J, McComb JM, Ng GA, Raftery J, Roderick P, Seed A,
Williams SG, Witte KK, Wright DJ, Harris S, Cowie MR. Remote management of heart failure using implantable electronic devices.
Eur
Heart
J
2017;38:23522360.
371. Bohm M, Drexler H, Oswald H, Rybak K, Bosch R, Butter C, Klein G, Gerritse
B, Monteiro J, Israel C, Bimmel D, Kaab S, Huegl B, Brachmann J, OptiLink HF
Study Investigators. Fluid status telemedicine alerts for heart failure: a randomized controlled trial. Eur Heart J 2016;37:31543163.
372. Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson
PB,
CHAMPION
Trial
Study
Group.
Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the
CHAMPION
randomised trial.
Lancet
2016;387:453461.
373. Lindenfeld J, Abraham WT, Maisel A, Zile M, Smart F, Costanzo MR, Mehra
MR, Ducharme A, Sears SF, Desai AS, Paul S, Sood P, Johnson N, Ginn G,
Adamson PB. Hemodynamic-GUIDEd management of Heart Failure (GUIDEHF). Am Heart J 2019;214:1827.


<!-- PAGE 109 -->

### Page 109

..........................................................................................................................................................................
374. Dierckx R, Inglis SC, Clark RA, Prieto-Merino D, Cleland JG. Telemedicine in heart failure: new insights from the Cochrane meta-analyses. Eur J Heart Fail
2017;19:304306.
375. Fang JC, Ewald GA, Allen LA, Butler J, Westlake Canary CA, Colvin-Adams M,
Dickinson MG, Levy P, Stough WG, Sweitzer NK, Teerlink JR, Whellan DJ,
Albert NM, Krishnamani R, Rich MW, Walsh MN, Bonnell MR, Carson PE,
Chan MC, Dries DL, Hernandez AF, Hershberger RE, Katz SD, Moore S,
Rodgers JE, Rogers JG, Vest AR, Givertz MM, Heart Failure Society of America
Guidelines Committee. Advanced (stage D) heart failure: a statement from the
Heart
Failure
Society of
America
Guidelines
Committee.
J
Card
Fail
2015;21:519534.
376. Crespo-Leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filippatos G,
Gustafsson F, Tsui S, Barge-Caballero E, De Jonge N, Frigerio M, Hamdan R,
Hasin T, Hulsmann M, Nalbantgil S, Potena L, Bauersachs J, Gkouziouta A,
Ruhparwar A, Ristic AD, Straburzynska-Migaj E, McDonagh T, Seferovic P,
Ruschitzka F. Advanced heart failure: a position statement of the Heart Failure
Association of the
European
Society of
Cardiology.
Eur
J
Heart
Fail
2018;20:15051535.
377. Truby LK, Rogers JG. Advanced heart failure: epidemiology, diagnosis, and therapeutic approaches. JACC Heart Fail 2020;8:523536.
378. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W,
Long JW, Ascheim DD, Tierney AR, Levitan RG, Watson JT, Meier P, Ronan
NS, Shapiro PA, Lazar RM, Miller LW, Gupta L, Frazier OH, Desvigne-Nickens
P, Oz MC, Poirier VL, Randomized Evaluation of Mechanical Assistance for the
Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med
2001;345:14351443.
379. Ammar KA, Jacobsen SJ, Mahoney DW, Kors JA, Redfield MM, Burnett JC, Jr.,
Rodeheffer RJ. Prevalence and prognostic significance of heart failure stages:
application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. Circulation 2007;115:15631570.
380. Xanthakis V, Enserro DM, Larson MG, Wollert KC, Januzzi JL, Levy D, Aragam
J, Benjamin EJ, Cheng S, Wang TJ, Mitchell GF, Vasan RS. Prevalence, neurohormonal correlates, and prognosis of heart failure stages in the community. JACC
Heart Fail 2016;4:808815.
381. Stevenson LW, Pagani FD, Young JB, Jessup M, Miller L, Kormos RL, Naftel DC,
Ulisney K, Desvigne-Nickens P, Kirklin JK. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant 2009;28:535541.
382. Barge-Caballero E, Segovia-Cubero J, Almenar-Bonet L, Gonzalez-Vilchez F,
Villa-Arranz A, Delgado-Jimenez J, Lage-Galle E, Perez-Villa F, LambertRodriguez JL, Manito-Lorite N, Arizon-Del Prado JM, Brossa-Loidi V, PascualFigal D, Fuente-Galan Lde L, Sanz-Julve M, Muniz-Garcia J, Crespo-Leiro M.
Preoperative INTERMACS profiles determine postoperative outcomes in critically ill patients undergoing emergency heart transplantation: analysis of the
Spanish National Heart Transplant Registry. Circ Heart Fail 2013;6:763772.
383. Goldstein DJ, Meyns B, Xie R, Cowger J, Pettit S, Nakatani T, Netuka I, Shaw S,
Yanase M, Kirklin JK. Third annual report from the ISHLT Mechanically
Assisted Circulatory Support Registry: a comparison of centrifugal and axial continuous-flow left ventricular assist devices.
J
Heart
Lung
Transplant
2019;38:352363.
384. Kittleson MM, Shah P, Lala A, McLean RC, Pamboukian S, Horstmanshof DA,
Thibodeau J, Shah K, Teuteberg J, Gilotra NA, Taddei-Peters WC, Cascino TM,
Richards B, Khalatbari S, Jeffries N, Stevenson LW, Mann D, Aaronson KD,
Stewart GC, REVIVAL Investigators. INTERMACS profiles and outcomes of ambulatory advanced heart failure patients: a report from the REVIVAL
Registry. J Heart Lung Transplant 2020;39:1626.
385. Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA,
Danziger-Isakov L, Kirklin JK, Kirk R, Kushwaha SS, Lund LH, Potena L, Ross HJ,
Taylor DO, Verschuuren EAM, Zuckermann A, International Society for Heart
Lung Transplantation (ISHLT) Infectious Diseases, Pediatric and Heart Failure and Transplantation Councils. The 2016 International Society for Heart Lung
Transplantation listing criteria for heart transplantation: a 10-year update. J
Heart Lung Transplant 2016;35:123.
386. Baumwol J. "I need help"–a mnemonic to aid timely referral in advanced heart failure. J Heart Lung Transplant 2017;36:593594.
387. Maack C, Eschenhagen T, Hamdani N, Heinzel FR, Lyon AR, Manstein DJ,
Metzger J, Papp Z, Tocchetti CG, Yilmaz MB, Anker SD, Balligand JL,
Bauersachs J, Brutsaert D, Carrier L, Chlopicki S, Cleland JG, de Boer RA, Dietl
A, Fischmeister R, Harjola VP, Heymans S, Hilfiker-Kleiner D, Holzmeister J, de
Keulenaer G, Limongelli G, Linke WA, Lund LH, Masip J, Metra M, Mueller C,
Pieske B, Ponikowski P, Ristic A, Ruschitzka F, Seferovic PM, Skouri H,
Zimmermann WH, Mebazaa A. Treatments targeting inotropy. Eur Heart J
2019;40:36263644.
388. Ahmad T, Miller PE, McCullough M, Desai NR, Riello R, Psotka M, Bohm M,
Allen LA, Teerlink JR, Rosano GMC, Lindenfeld J. Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials. Eur J Heart Fail
2019;21:10641078.
389. Comin-Colet J, Manito N, Segovia-Cubero J, Delgado J, Garcia Pinilla JM,
Almenar L, Crespo-Leiro MG, Sionis A, Blasco T, Pascual-Figal D, GonzalezVilchez
F,
Lambert-Rodriguez
JL,
Grau
M,
Bruguera
J,
LION-HEART
Study Investigators. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the
LION-HEART
multicentre randomised trial.
Eur
J
Heart
Fail
2018;20:11281136.
390. Nizamic T, Murad MH, Allen LA, McIlvennan CK, Wordingham SE, Matlock
DD, Dunlay SM. Ambulatory inotrope infusions in advanced heart failure: a systematic review and meta-analysis. JACC Heart Fail 2018;6:757767.
391. Bart BA, Goldsmith SR, Lee KL, Givertz MM, O’Connor CM, Bull DA, Redfield
MM, Deswal A, Rouleau JL, LeWinter MM, Ofili EO, Stevenson LW, Semigran
MJ, Felker GM, Chen HH, Hernandez AF, Anstrom KJ, McNulty SE, Velazquez
EJ, Ibarra JC, Mascette AM, Braunwald E, Heart Failure Clinical Research
Network. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012;367:22962304.
392. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, Jaski
BE, Fang JC, Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA,
UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol
2007;49:675683.
393. Gustafsson F, Rogers JG. Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes. Eur J Heart Fail 2017;19:595602.
394. Barge-Caballero E, Almenar-Bonet L, Gonzalez-Vilchez F, Lambert-Rodriguez
JL, Gonzalez-Costello J, Segovia-Cubero J, Castel-Lavilla MA, Delgado-Jimenez J,
Garrido-Bravo IP, Rangel-Sousa D, Martinez-Selles M, De la Fuente-Galan L,
Rabago-AracilJuan- G, Sanz-Julve M, Hervas-Sotomayor D, Mirabet-Perez S,
Muniz J, Crespo-Leiro MG. Clinical outcomes of temporary mechanical circulatory support as a direct bridge to heart transplantation: a nationwide Spanish registry. Eur J Heart Fail 2018;20:178186.
395. Potapov EV, Antonides C, Crespo-Leiro MG, Combes A, Farber G, Hannan
MM, Kukucka M, de Jonge N, Loforte A, Lund LH, Mohacsi P, Morshuis M,
Netuka I, Ozbaran M, Pappalardo F, Scandroglio AM, Schweiger M, Tsui S,
Zimpfer D, Gustafsson F. 2019 EACTS Expert Consensus on long-term mechanical circulatory support. Eur J Cardiothorac Surg 2019;56:230270.
396. Rogers JG, Butler J, Lansman SL, Gass A, Portner PM, Pasque MK, Pierson RN,
3rd, INTrEPID Investigators. Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates:
results of the INTrEPID Trial. J Am Coll Cardiol 2007;50:741747.
397. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, Sun B,
Tatooles AJ, Delgado RM, 3rd, Long JW, Wozniak TC, Ghumman W, Farrar DJ,
Frazier OH, HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular assist device.
N
Engl
J
Med
2009;361:22412251.
398. Starling RC, Naka Y, Boyle AJ, Gonzalez-Stawinski G, John R, Jorde U, Russell
SD, Conte JV, Aaronson KD, McGee EC, Jr., Cotts WG, DeNofrio D, Pham
DT,
Farrar
DJ,
Pagani
FD.
Results of the post-U.S.
Food and
Drug
Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the
INTERMACS (Interagency Registry for Mechanically Assisted Circulatory
Support). J Am Coll Cardiol 2011;57:18901898.
399. Rogers JG, Pagani FD, Tatooles AJ, Bhat G, Slaughter MS, Birks EJ, Boyce SW,
Najjar SS, Jeevanandam V, Anderson AS, Gregoric ID, Mallidi H, Leadley K,
Aaronson KD, Frazier OH, Milano CA. Intrapericardial left ventricular assist device for advanced heart failure. N Engl J Med 2017;376:451460.
400. Truby LK, Farr MA, Garan AR, Givens R, Restaino SW, Latif F, Takayama H,
Naka Y, Takeda K, Topkara VK. Impact of bridge to transplantation with continuous-flow left ventricular assist devices on posttransplantation mortality.
Circulation 2019;140:459469.
401. Goldstein DJ, Naka Y, Horstmanshof D, Ravichandran AK, Schroder J, Ransom
J, Itoh A, Uriel N, Cleveland JC, Jr., Raval NY, Cogswell R, Suarez EE, Lowes
BD, Kim G, Bonde P, Sheikh FH, Sood P, Farrar DJ, Mehra MR. Association of clinical outcomes with left ventricular assist device use by bridge to transplant or destination therapy intent: the Multicenter Study of MagLev Technology in
Patients
Undergoing
Mechanical
Circulatory
Support
Therapy
With
HeartMate 3 (MOMENTUM 3) Randomized Clinical Trial. JAMA Cardiol
2020;5:411419.
402. Mehra MR, Uriel N, Naka Y, Cleveland JC, Jr., Yuzefpolskaya M, Salerno CT,
Walsh MN, Milano CA, Patel CB, Hutchins SW, Ransom J, Ewald GA, Itoh A,
Raval NY, Silvestry SC, Cogswell R, John R, Bhimaraj A, Bruckner BA, Lowes
BD, Um JY, Jeevanandam V, Sayer G, Mangi AA, Molina EJ, Sheikh F, Aaronson
K, Pagani FD, Cotts WG, Tatooles AJ, Babu A, Chomsky D, Katz JN, Tessmann
PB, Dean D, Krishnamoorthy A, Chuang J, Topuria I, Sood P, Goldstein DJ,
ESC Guidelines
3707


<!-- PAGE 110 -->

### Page 110

.............................................................................................................................................................................
MOMENTUM 3 Investigators. A fully magnetically levitated left ventricular assist device – final report. N Engl J Med 2019;380:16181627.
403. Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, Myers
SL, Miller MA, Baldwin JT, Young JB. Seventh INTERMACS annual report:
15,000 patients and counting. J Heart Lung Transplant 2015;34:14951504.
404. Theochari CA, Michalopoulos G, Oikonomou EK, Giannopoulos S, Doulamis
IP, Villela MA, Kokkinidis DG. Heart transplantation versus left ventricular assist devices as destination therapy or bridge to transplantation for 1-year mortality:
a systematic review and meta-analysis. Ann Cardiothorac Surg 2018;7:311.
405. Mehra MR, Goldstein DJ, Uriel N, Cleveland JC, Jr., Yuzefpolskaya M, Salerno
C,
Walsh
MN,
Milano
CA,
Patel
CB,
Ewald
GA,
Itoh
A,
Dean
D,
Krishnamoorthy A, Cotts WG, Tatooles AJ, Jorde UP, Bruckner BA, Estep JD,
Jeevanandam V, Sayer G, Horstmanshof D, Long JW, Gulati S, Skipper ER,
O’Connell JB, Heatley G, Sood P, Naka Y, MOMENTUM 3 Investigators.
Two-year outcomes with a magnetically levitated cardiac pump in heart failure.
N Engl J Med 2018;378:13861395.
406. Zimpfer D, Gustafsson F, Potapov E, Pya Y, Schmitto J, Berchtold-Herz M,
Morshuis M, Shaw SM, Saeed D, Lavee J, Heatley G, Gazzola C, Garbade J.
Two-year outcome after implantation of a full magnetically levitated left ventricular assist device: results from the ELEVATE Registry. Eur Heart J
2020;41:38013809.
407. Estep JD, Starling RC, Horstmanshof DA, Milano CA, Selzman CH, Shah KB,
Loebe M, Moazami N, Long JW, Stehlik J, Kasirajan V, Haas DC, O’Connell JB,
Boyle AJ, Farrar DJ, Rogers JG, ROADMAP Study Investigators. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: results from the ROADMAP
study. J Am Coll Cardiol 2015;66:17471761.
408. Starling RC, Estep JD, Horstmanshof DA, Milano CA, Stehlik J, Shah KB,
Bruckner BA, Lee S, Long JW, Selzman CH, Kasirajan V, Haas DC, Boyle AJ,
Chuang J, Farrar DJ, Rogers JG, ROADMAP Study Investigators. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: the ROADMAP study 2-year results. JACC Heart Fail 2017;5:518527.
409. Slaughter MS, Pagani FD, McGee EC, Birks EJ, Cotts WG, Gregoric I, Howard
Frazier O, Icenogle T, Najjar SS, Boyce SW, Acker MA, John R, Hathaway DR,
Najarian KB, Aaronson KD, HeartWare Bridge to Transplant ADVANCE Trial
Investigators. HeartWare ventricular assist system for bridge to transplant:
combined results of the bridge to transplant and continued access protocol trial. J Heart Lung Transplant 2013;32:675683.
410. Karason K, Lund LH, Dalen M, Bjorklund E, Grinnemo K, Braun O, Nilsson J,
van der Wal H, Holm J, Hubbert L, Lindmark K, Szabo B, Holmberg E,
Dellgren G, SweVAD Investigators. Randomized trial of a left ventricular assist device as destination therapy versus guideline-directed medical therapy in patients with advanced heart failure. Rationale and design of the SWEdish evaluation of left Ventricular Assist Device (SweVAD) trial. Eur J Heart Fail
2020;22:739750.
411. Khush KK, Cherikh WS, Chambers DC, Harhay MO, Hayes D, Jr., Hsich E,
Meiser B, Potena L, Robinson A, Rossano JW, Sadavarte A, Singh TP,
Zuckermann
A,
Stehlik
J,
International
Society for
Heart and
Lung
Transplantation. The International Thoracic Organ Transplant Registry of the
International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report–2019; focus theme: donor and recipient size match. J Heart Lung Transplant 2019;38:10561066.
412. Lund LH, Edwards LB, Kucheryavaya AY, Dipchand AI, Benden C, Christie JD,
Dobbels F, Kirk R, Rahmel AO, Yusen RD, Stehlik J, International Society for H,
Heart and Lung Transplantation. The Registry of the International Society for
Heart and Lung Transplantation: Thirtieth official adult heart transplant report–
2013; focus theme: age. J Heart Lung Transplant 2013;32:951964.
413. Guglin M, Zucker MJ, Borlaug BA, Breen E, Cleveland J, Johnson MR, Panjrath
GS, Patel JK, Starling RC, Bozkurt B, ACC Heart Failure and Transplant
Member Section and Leadership Council. Evaluation for heart transplantation and LVAD implantation: JACC Council perspectives. J Am Coll Cardiol
2020;75:14711487.
414. Bernhardt AM, Schloglhofer T, Lauenroth V, Mueller F, Mueller M, Schoede A,
Klopsch C, Driveline Expert STagINg and carE DESTINE study group, a
Ventricular Assist Device Driveline Infection Study Group. Prevention and early treatment of driveline infections in ventricular assist device patients – the
DESTINE staging proposal and the first standard of care protocol. J Crit Care
2020;56:106112.
415. DeFilippis EM, Breathett K, Donald EM, Nakagawa S, Takeda K, Takayama H,
Truby LK, Sayer G, Colombo PC, Yuzefpolskaya M, Uriel N, Farr MA, Topkara
VK. Psychosocial risk and its association with outcomes in continuous-flow left ventricular assist device patients. Circ Heart Fail 2020;13:e006910.
416. Jaarsma T, Hill L, Bayes-Genis A, La Rocca HB, Castiello T, Celutkiene J, MarquesSule E, Plymen CM, Piper SE, Riegel B, Rutten FH, Ben Gal T, Bauersachs J, Coats
AJS, Chioncel O, Lopatin Y, Lund LH, Lainscak M, Moura B, Mullens W, Piepoli MF,
Rosano G, Seferovic P, Stromberg A. Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European
Society of Cardiology. Eur J Heart Fail 2021;23:157174.
417. Jorde UP, Kushwaha SS, Tatooles AJ, Naka Y, Bhat G, Long JW, Horstmanshof
DA, Kormos RL, Teuteberg JJ, Slaughter MS, Birks EJ, Farrar DJ, Park SJ,
HeartMate II Clinical Investigators. Results of the destination therapy post-food and drug administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS registry (Interagency
Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol
2014;63:17511757.
418. Sahlollbey N, Lee CKS, Shirin A, Joseph P. The impact of palliative care on clinical and patient-centred outcomes in patients with advanced heart failure: a systematic review of randomized controlled trials.
Eur
J
Heart
Fail
2020;22:23402346.
419. Fendler TJ, Swetz KM, Allen LA. Team-based palliative and end-of-life care for heart failure. Heart Fail Clin 2015;11:479498.
420. Brannstrom M, Boman K. Effects of person-centred and integrated chronic heart failure and palliative home care. PREFER: a randomized controlled study.
Eur J Heart Fail 2014;16:11421151.
421. O’Donnell AE, Schaefer KG, Stevenson LW, DeVoe K, Walsh K, Mehra MR,
Desai AS. Social worker-aided palliative care intervention in high-risk patients with Heart Failure (SWAP-HF): a pilot randomized clinical trial. JAMA Cardiol
2018;3:516519.
422. Johnson MJ, McDonagh TA, Harkness A, McKay SE, Dargie HJ. Morphine for the relief of breathlessness in patients with chronic heart failure–a pilot study.
Eur J Heart Fail 2002;4:753756.
423. Oxberry SG, Bland JM, Clark AL, Cleland JG, Johnson MJ. Repeat dose opioids may be effective for breathlessness in chronic heart failure if given for long enough. J Palliat Med 2013;16:250255.
424. Blinderman CD, Billings JA. Comfort care for patients dying in the hospital. N
Engl J Med 2015;373:25492561.
425. Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP,
Hochadel M, Komajda M, Lassus J, Lopez-Sendon JL, Ponikowski P, Tavazzi L,
EuroHeart Survey Investigators, Heart Failure Association of the European
Society of Cardiology. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J
2006;27:27252736.
426. Chioncel O, Mebazaa A, Harjola VP, Coats AJ, Piepoli MF, Crespo-Leiro MG,
Laroche C, Seferovic PM, Anker SD, Ferrari R, Ruschitzka F, Lopez-Fernandez
S, Miani D, Filippatos G, Maggioni AP, ESC Heart Failure Long-Term Registry
Investigators. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. Eur J Heart Fail
2017;19:12421254.
427. Chioncel O, Mebazaa A, Maggioni AP, Harjola VP, Rosano G, Laroche C,
Piepoli MF, Crespo-Leiro MG, Lainscak M, Ponikowski P, Filippatos G,
Ruschitzka F, Seferovic P, Coats AJS, Lund LH, ESC-EORP-HFA Heart Failure
Long-Term Registry Investigators. Acute heart failure congestion and perfusion status – impact of the clinical classification on in-hospital and long-term outcomes: insights from the ESC-EORP-HFA heart failure long-term registry. Eur J
Heart Fail 2019;21:13381352.
428. Miro O, Garcia Sarasola A, Fuenzalida C, Calderon S, Jacob J, Aguirre A, Wu
DM, Rizzi MA, Malchair P, Haro A, Herrera S, Gil V, Martin-Sanchez FJ, Llorens
P, Herrero Puente P, Bueno H, Dominguez Rodriguez A, Muller CE, Mebazaa
A, Chioncel O, Alquezar-Arbe A, ICA-SEMES Research Group. Departments involved during the first episode of acute heart failure and subsequent emergency department revisits and rehospitalisations: an outlook through the
NOVICA cohort. Eur J Heart Fail 2019;21:12311244.
429. Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJ, Granger CB, Yusuf S,
Swedberg K, Young JB, Michelson EL, Pfeffer MA, Candesartan in Heart failure:
Assessment of Reduction in Mortality and morbidity (CHARM) Investigators.
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007;116:14821487.
430. Tomasoni D, Lombardi CM, Sbolli M, Cotter G, Metra M. Acute heart failure:
more questions than answers. Prog Cardiovasc Dis 2020;63:599606.
431. Butt JH, Fosbol EL, Gerds TA, Andersson C, McMurray JJV, Petrie MC,
Gustafsson F, Madelaire C, Kristensen SL, Gislason GH, Torp-Pedersen C,
Kober L, Schou M. Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort.
Eur J Heart Fail 2020;22:17771785.
432. Javaloyes P, Miro O, Gil V, Martin-Sanchez FJ, Jacob J, Herrero P, Takagi K,
Alquezar-Arbe A, Lopez Diez MP, Martin E, Bibiano C, Escoda R, Gil C,
Fuentes M, Llopis Garcia G, Alvarez Perez JM, Jerez A, Tost J, Llauger L,
Romero R, Garrido JM, Rodriguez-Adrada E, Sanchez C, Rossello X, Parissis
J, Mebazaa A, Chioncel O, Llorens P, ICA-SEMES Research Group. Clinical phenotypes of acute heart failure based on signs and symptoms of perfusion and congestion at emergency department presentation and their relationship


<!-- PAGE 111 -->

### Page 111

.............................................................................................................................................................................
with patient management and outcomes.
Eur
J
Heart
Fail
2019;21:13531365.
433. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J,
Santalo-Bel M, Pinto YM, Richards M. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study.
Eur Heart J 2006;27:330337.
434. Januzzi JL Jr, Chen-Tournoux AA, Christenson RH, Doros G, Hollander JE, Levy
PD, Nagurney JT, Nowak RM, Pang PS, Patel D, Peacock WF, Rivers EJ, Walters
EL, Gaggin HK, ICON-RELOADED Investigators. N-terminal pro-B-type natriuretic peptide in the emergency department: the ICON-RELOADED study. J Am
Coll Cardiol 2018;71:11911200.
435. Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P,
Mockel M, Hogan C, Wu AH, Richards M, Clopton P, Filippatos GS, Di Somma
S, Anand I, Ng L, Daniels LB, Neath SX, Christenson R, Potocki M, McCord J,
Terracciano G, Kremastinos D, Hartmann O, von Haehling S, Bergmann A,
Morgenthaler NG, Anker SD. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute
Heart Failure) trial. J Am Coll Cardiol 2010;55:20622076.
436. Harjola VP, Parissis J, Bauersachs J, Brunner-La Rocca HP, Bueno H, Celutkiene
J, Chioncel O, Coats AJS, Collins SP, de Boer RA, Filippatos G, Gayat E, Hill L,
Laine M, Lassus J, Lommi J, Masip J, Mebazaa A, Metra M, Miro O, Mortara A,
Mueller
C,
Mullens
W,
Peacock
WF,
Pentikainen
M,
Piepoli
MF,
Polyzogopoulou E, Rudiger A, Ruschitzka F, Seferovic P, Sionis A, Teerlink JR,
Thum T, Varpula M, Weinstein JM, Yilmaz MB. Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2020;22:12981314.
437. Harjola VP, Mullens W, Banaszewski M, Bauersachs J, Brunner-La Rocca HP,
Chioncel O, Collins SP, Doehner W, Filippatos GS, Flammer AJ, Fuhrmann V,
Lainscak M, Lassus J, Legrand M, Masip J, Mueller C, Papp Z, Parissis J, Platz E,
Rudiger A, Ruschitzka F, Schafer A, Seferovic PM, Skouri H, Yilmaz MB,
Mebazaa A. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute
Heart Failure Committee of the Heart Failure Association (HFA) of the
European Society of Cardiology (ESC). Eur J Heart Fail 2017;19:821836.
438. Harjola VP, Parissis J, Brunner-La Rocca HP, Celutkiene J, Chioncel O, Collins
SP, De Backer D, Filippatos GS, Gayat E, Hill L, Lainscak M, Lassus J, Masip J,
Mebazaa A, Miro O, Mortara A, Mueller C, Mullens W, Nieminen MS, Rudiger
A, Ruschitzka F, Seferovic PM, Sionis A, Vieillard-Baron A, Weinstein JM, de
Boer RA, Crespo-Leiro MG, Piepoli M, Riley JP. Comprehensive in-hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology
(ESC). Eur J Heart Fail 2018;20:10811099.
439. Ter Maaten JM, Damman K, Hanberg JS, Givertz MM, Metra M, O’Connor CM,
Teerlink JR, Ponikowski P, Cotter G, Davison B, Cleland JG, Bloomfield DM,
Hillege HL, van Veldhuisen DJ, Voors AA, Testani JM. Hypochloremia, diuretic resistance, and outcome in patients with acute heart failure. Circ Heart Fail 2016;9.
440. Nunez J, Llacer P, Garcia-Blas S, Bonanad C, Ventura S, Nunez JM, Sanchez R,
Facila L, de la Espriella R, Vaquer JM, Cordero A, Roque M, Chamorro C, Bodi
V, Valero E, Santas E, Moreno MDC, Minana G, Carratala A, Rodriguez E,
Mollar A, Palau P, Bosch MJ, Bertomeu-Gonzalez V, Lupon J, Navarro J, Chorro
FJ, Gorriz JL, Sanchis J, Voors AA, Bayes-Genis A. CA125-guided diuretic treatment versus usual care in patients with acute heart failure and renal dysfunction. Am J Med 2020;133:370380 e374.
441. Nikolaou M, Parissis J, Yilmaz MB, Seronde MF, Kivikko M, Laribi S, PaugamBurtz C, Cai D, Pohjanjousi P, Laterre PF, Deye N, Poder P, Cohen-Solal A,
Mebazaa A. Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. Eur Heart J 2013;34:742749.
442. Mockel M, de Boer RA, Slagman AC, von Haehling S, Schou M, Vollert JO,
Wiemer JC, Ebmeyer S, Martın-Sanchez FJ, Maisel AS, Giannitsis E. Improve
Management of acute heart failure with ProcAlCiTonin in EUrope: results of the randomized clinical trial IMPACT EU Biomarkers in Cardiology (BIC) 18.
Eur J Heart Fail 2020;22:267275.
443. Masip J, De Mendoza D, Planas K, Paez J, Sanchez B, Cancio B. Peripheral venous blood gases and pulse-oximetry in acute cardiogenic pulmonary oedema. Eur Heart J Acute Cardiovasc Care 2012;1:275280.
444. Masip J, Gaya M, Paez J, Betbese A, Vecilla F, Manresa R, Ruiz P. Pulse oximetry in the diagnosis of acute heart failure.
Rev
Esp
Cardiol
(Engl
Ed)
2012;65:879884.
445. Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, Hasin
Y, Lopez-Sendon J, Mebazaa A, Metra M, Rhodes A, Swedberg K, Priori SG,
Garcia MA, Blanc JJ, Budaj A, Cowie MR, Dean V, Deckers J, Burgos EF, Lekakis
J, Lindahl B, Mazzotta G, Morais J, Oto A, Smiseth OA, Garcia MA, Dickstein K,
Albuquerque A, Conthe P, Crespo-Leiro M, Ferrari R, Follath F, Gavazzi A,
Janssens U, Komajda M, Morais J, Moreno R, Singer M, Singh S, Tendera M,
Thygesen K, ESC Committe for Practice Guideline (CPG). Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task
Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart
J 2005;26:384416.
446. Nohria A, Tsang SW, Fang JC, Lewis EF, Jarcho JA, Mudge GH, Stevenson LW.
Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 2003;41:17971804.
447. Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG,
Dickstein K, Drazner MH, Fonarow GC, Jaarsma T, Jondeau G, Sendon JL,
Mebazaa A, Metra M, Nieminen M, Pang PS, Seferovic P, Stevenson LW, van
Veldhuisen DJ, Zannad F, Anker SD, Rhodes A, McMurray JJ, Filippatos G,
European Society of Cardiology, European Society of Intensive Care Medicine.
Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the Heart Failure Association of the
European Society of Cardiology and endorsed by the European Society of
Intensive Care Medicine. Eur J Heart Fail 2010;12:423433.
448. Masip J, Peacock WF, Price S, Cullen L, Martin-Sanchez FJ, Seferovic P, Maisel
AS, Miro O, Filippatos G, Vrints C, Christ M, Cowie M, Platz E, McMurray J,
DiSomma S, Zeymer U, Bueno H, Gale CP, Lettino M, Tavares M, Ruschitzka F,
Mebazaa A, Harjola VP, Mueller C, Acute Heart Failure Study Group of the
Acute Cardiovascular Care Association and the Committee on Acute Heart
Failure of the Heart Failure Association of the European Society of Cardiology.
Indications and practical approach to non-invasive ventilation in acute heart failure. Eur Heart J 2018;39:1725.
449. Harjola VP, Mebazaa A, Celutkiene J, Bettex D, Bueno H, Chioncel O, CrespoLeiro MG, Falk V, Filippatos G, Gibbs S, Leite-Moreira A, Lassus J, Masip J,
Mueller C, Mullens W, Naeije R, Nordegraaf AV, Parissis J, Riley JP, Ristic A,
Rosano G, Rudiger A, Ruschitzka F, Seferovic P, Sztrymf B, Vieillard-Baron A,
Yilmaz MB, Konstantinides S. Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working
Group on Pulmonary Circulation and Right Ventricular Function of the
European Society of Cardiology. Eur J Heart Fail 2016;18:226241.
450. Chioncel O, Parissis J, Mebazaa A, Thiele H, Desch S, Bauersachs J, Harjola VP,
Antohi EL, Arrigo M, Gal TB, Celutkiene J, Collins SP, DeBacker D, Iliescu VA,
Jankowska E, Jaarsma T, Keramida K, Lainscak M, Lund LH, Lyon AR, Masip J,
Metra M, Miro O, Mortara A, Mueller C, Mullens W, Nikolaou M, Piepoli M,
Price S, Rosano G, Vieillard-Baron A, Weinstein JM, Anker SD, Filippatos G,
Ruschitzka F, Coats AJS, Seferovic P. Epidemiology, pathophysiology and contemporary management of cardiogenic shock – a position statement from the
Heart Failure Association of the European Society of Cardiology. Eur J Heart
Fail 2020;22:13151341.
451. Thiele H, Ohman EM, de Waha-Thiele S, Zeymer U, Desch S. Management of cardiogenic shock complicating myocardial infarction: an update 2019. Eur Heart
J 2019;40:26712683.
452. Mebazaa A, Combes A, van Diepen S, Hollinger A, Katz JN, Landoni G, Hajjar
LA, Lassus J, Lebreton G, Montalescot G, Park JJ, Price S, Sionis A, Yannopolos
D, Harjola VP, Levy B, Thiele H. Management of cardiogenic shock complicating myocardial infarction. Intensive Care Med 2018;44:760773.
453. Zymlinski R, Biegus J, Sokolski M, Siwolowski P, Nawrocka-Millward S, Todd J,
Jankowska EA, Banasiak W, Cotter G, Cleland JG, Ponikowski P. Increased blood lactate is prevalent and identifies poor prognosis in patients with acute heart failure without overt peripheral hypoperfusion. Eur J Heart Fail 2018;20:10111018.
454. Menon V, Slater JN, White HD, Sleeper LA, Cocke T, Hochman JS. Acute myocardial infarction complicated by systemic hypoperfusion without hypotension:
report of the SHOCK trial registry. Am J Med 2000;108:374380.
455. Harjola P, Miro O, Martin-Sanchez FJ, Escalada X, Freund Y, Penaloza A, Christ
M, Cone DC, Laribi S, Kuisma M, Tarvasmaki T, Harjola VP, EMS-AHF Study
Group. Pre-hospital management protocols and perceived difficulty in diagnosing acute heart failure. ESC Heart Fail 2020;7:289296.
456. Takahashi M, Kohsaka S, Miyata H, Yoshikawa T, Takagi A, Harada K, Miyamoto
T, Sakai T, Nagao K, Sato N, Takayama M, Tokyo CCU Network Council.
Association between prehospital time interval and short-term outcome in acute heart failure patients. J Card Fail 2011;17:742747.
457. Park JH, Balmain S, Berry C, Morton JJ, McMurray JJ. Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction. Heart 2010;96:533538.
458. Gray A, Goodacre S, Newby DE, Masson M, Sampson F, Nicholl J, 3CPO
Trialists Noninvasive ventilation in acute cardiogenic pulmonary edema. N Engl J
Med 2008;359:142151.
459. Weng CL, Zhao YT, Liu QH, Fu CJ, Sun F, Ma YL, Chen YW, He QY. Metaanalysis: noninvasive ventilation in acute cardiogenic pulmonary edema. Ann
Intern Med 2010;152:590600.
460. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR,
LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF,
McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ,
ESC Guidelines
3709


<!-- PAGE 112 -->

### Page 112

.............................................................................................................................................................................
Bart BA, Mascette AM, Braunwald E, O’Connor CM, Network NHFCR.
Diuretic strategies in patients with acute decompensated heart failure. N Engl J
Med 2011;364:797805.
461. Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM. Diuretic therapy for patients with heart failure: JACC state-of-the-art review. J Am Coll Cardiol
2020;75:11781195.
462. Brisco MA, Zile MR, Hanberg JS, Wilson FP, Parikh CR, Coca SG, Tang WH,
Testani JM. Relevance of changes in serum creatinine during a heart failure trial of decongestive strategies:
insights from the
DOSE
trial.
J
Card
Fail
2016;22:753760.
463. Damman K, Kjekshus J, Wikstrand J, Cleland JG, Komajda M, Wedel H,
Waagstein F, McMurray JJ. Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction. Eur J Heart Fail
2016;18:328336.
464. Ter Maaten JM, Martens P, Damman K, Dickstein K, Ponikowski P, Lang CC, Ng
LL, Anker SD, Samani NJ, Filippatos G, Cleland JG, Zannad F, Hillege HL, van
Veldhuisen DJ, Metra M, Voors AA, Mullens W. Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction.
Clin
Res
Cardiol
2020;109:10481059.
465. Cubbon RM, Woolston A, Adams B, Gale CP, Gilthorpe MS, Baxter PD,
Kearney LC, Mercer B, Rajwani A, Batin PD, Kahn M, Sapsford RJ, Witte KK,
Kearney MT. Prospective development and validation of a model to predict heart failure hospitalisation. Heart 2014;100:923929.
466. Kapelios CJ, Laroche C, Crespo-Leiro MG, Anker SD, Coats AJS, Diaz-Molina
B, Filippatos G, Lainscak M, Maggioni AP, McDonagh T, Mebazaa A, Metra M,
Moura B, Mullens W, Piepoli MF, Rosano GMC, Ruschitzka F, Seferovic PM,
Lund LH, Heart Failure Long-Term Registry Investigators Group. Association between loop diuretic dose changes and outcomes in chronic heart failure:
observations from the ESC-EORP heart failure long-term registry. Eur J Heart
Fail 2020;22:14241437.
467. Mebazaa A, Yilmaz MB, Levy P, Ponikowski P, Peacock WF, Laribi S, Ristic AD,
Lambrinou E, Masip J, Riley JP, McDonagh T, Mueller C, deFilippi C, Harjola VP,
Thiele H, Piepoli MF, Metra M, Maggioni A, McMurray J, Dickstein K, Damman
K, Seferovic PM, Ruschitzka F, Leite-Moreira AF, Bellou A, Anker SD, Filippatos
G. Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the
European Society of Cardiology, the European Society of Emergency Medicine and the
Society of
Academic
Emergency
Medicine.
Eur
J
Heart
Fail
2015;17:544558.
468. Damman K, Ter Maaten JM, Coster JE, Krikken JA, van Deursen VM, Krijnen
HK, Hofman M, Nieuwland W, van Veldhuisen DJ, Voors AA, van der Meer P.
Clinical importance of urinary sodium excretion in acute heart failure. Eur J
Heart Fail 2020;22:14381447.
469. Mullens W, Verbrugge FH, Nijst P, Martens P, Tartaglia K, Theunissen E,
Bruckers L, Droogne W, Troisfontaines P, Damman K, Lassus J, Mebazaa A,
Filippatos G, Ruschitzka F, Dupont M. Rationale and design of the ADVOR
(Acetazolamide in Decompensated Heart Failure with Volume Overload) trial.
Eur J Heart Fail 2018;20:15911600.
470. Cox ZL, Hung R, Lenihan DJ, Testani JM. Diuretic strategies for loop diuretic resistance in acute heart failure: the 3T trial. JACC Heart Fail 2020;8:157168.
471. Damman K, Testani JM. The kidney in heart failure: an update. Eur Heart J
2015;36:14371444.
472. Ambrosy AP, Pang PS, Khan S, Konstam MA, Fonarow GC, Traver B, Maggioni
AP, Cook T, Swedberg K, Burnett JC, Jr., Grinfeld L, Udelson JE, Zannad F,
Gheorghiade M, EVEREST Trial Investigators. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J 2013;34:835843.
473. Faselis C, Arundel C, Patel S, Lam PH, Gottlieb SS, Zile MR, Deedwania P,
Filippatos G, Sheriff HM, Zeng Q, Morgan CJ, Wopperer S, Nguyen T, Allman
RM, Fonarow GC, Ahmed A. Loop diuretic prescription and 30-day outcomes in older patients with heart failure. J Am Coll Cardiol 2020;76:669679.
474. Sharon A, Shpirer I, Kaluski E, Moshkovitz Y, Milovanov O, Polak R, Blatt A,
Simovitz A, Shaham O, Faigenberg Z, Metzger M, Stav D, Yogev R, Golik A,
Krakover R, Vered Z, Cotter G. High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema. J Am Coll Cardiol 2000;36:832837.
475. Publication Committee for the VMAC Investigators (Vasodilatation in the
Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial.
JAMA 2002;287:15311540.
476. Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Simovitz A, Shaham O,
Marghitay D, Koren M, Blatt A, Moshkovitz Y, Zaidenstein R, Golik A.
Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998;351:389393.
477. Levy P, Compton S, Welch R, Delgado G, Jennett A, Penugonda N, Dunne R,
Zalenski R. Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis. Ann Emerg Med
2007;50:144152.
478. Mebazaa A, Motiejunaite J, Gayat E, Crespo-Leiro MG, Lund LH, Maggioni AP,
Chioncel O, Akiyama E, Harjola VP, Seferovic P, Laroche C, Julve MS, Roig E,
Ruschitzka F, Filippatos G, ESC Heart Failure Long-Term Registry Investigators.
Long-term safety of intravenous cardiovascular agents in acute heart failure:
results from the European Society of Cardiology heart failure long-term registry. Eur J Heart Fail 2018;20:332341.
479. Kozhuharov N, Goudev A, Flores D, Maeder MT, Walter J, Shrestha S,
Gualandro DM, de Oliveira Junior MT, Sabti Z, Muller B, Noveanu M, Socrates
T, Ziller R, Bayes-Genis A, Sionis A, Simon P, Michou E, Gujer S, Gori T,
Wenzel P, Pfister O, Conen D, Kapos I, Kobza R, Rickli H, Breidthardt T,
Munzel T, Erne P, Mueller C, Investigators G, Mueller C, Erne P, Muller B, Rickli
H, Maeder M, Tavares de Oliveira M Jr, Munzel T, Bayes-Genis A, Sionis A,
Goudev A, Dimov B, Hartwiger S, Arenja N, Glatz B, Herr N, Isenrich R,
Mosimann T, Twerenbold R, Boeddinghaus J, Nestelberger T, Puelacher C,
Freese M, Vogele J, Meissner K, Martin J, Strebel I, Wussler D, Schumacher C,
Osswald S, Vogt F, Hilti J, Barata S, Schneider D, Schwarz J, Fitze B, Hartwiger
S, Arenja N, Glatz B, Herr N, Isenrich R, Mosimann T, Twerenbold R,
Boeddinghaus J, Nestelberger T, Puelacher C, Freese M, Vogele J, Meissner K,
Martin J, Strebel I, Wussler D, Schumacher C, Osswald S, Vogt F, Hilti J, Barata
S, Schneider D, Schwarz J, Fitze B, Arenja N, Rentsch K, Bossa A, Jallad S,
Soeiro A, Georgiev D, Jansen T, Gebel G, Bossard M, Christ M. Effect of a strategy of comprehensive vasodilation vs usual care on mortality and heart failure rehospitalization among patients with acute heart failure: the GALACTIC
randomized clinical trial. JAMA 2019;322:22922302.
480. Freund Y, Cachanado M, Delannoy Q, Laribi S, Yordanov Y, Gorlicki J,
Chouihed T, Feral-Pierssens AL, Truchot J, Desmettre T, Occelli C, Bobbia X,
Khellaf M, Ganansia O, Bokobza J, Balen F, Beaune S, Bloom B, Simon T,
Mebazaa A. Effect of an emergency department care bundle on 30-day hospital discharge and survival among elderly patients with acute heart failure: the
ELISABETH randomized clinical trial. JAMA 2020;324:19481956.
481. Khot UN, Novaro GM, Popovic ZB, Mills RM, Thomas JD, Tuzcu EM,
Hammer D, Nissen SE, Francis GS. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis.
N
Engl
J
Med
2003;348:17561763.
482. Mebazaa A, Nieminen MS, Filippatos GS, Cleland JG, Salon JE, Thakkar R,
Padley RJ, Huang B, Cohen-Solal A. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail
2009;11:304311.
483. Metra M, Nodari S, D’Aloia A, Muneretto C, Robertson AD, Bristow MR, Dei
Cas L. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 2002;40:12481258.
484. Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, Padley RJ,
Thakkar R, Delgado-Herrera L, Salon J, Garratt C, Huang B, Sarapohja T,
REVIVE Heart Failure Study Group. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart
Fail 2013;1:103111.
485. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur
A, Defrance P, Gottignies P, Vincent JL, SOAP II Investigators. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med
2010;362:779789.
486. Levy B, Clere-Jehl R, Legras A, Morichau-Beauchant T, Leone M, Frederique G,
Quenot JP, Kimmoun A, Cariou A, Lassus J, Harjola VP, Meziani F, Louis G,
Rossignol P, Duarte K, Girerd N, Mebazaa A, Vignon P, Collaborators.
Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol 2018;72:173182.
487. Leopold V, Gayat E, Pirracchio R, Spinar J, Parenica J, Tarvasmaki T, Lassus J,
Harjola VP, Champion S, Zannad F, Valente S, Urban P, Chua HR, Bellomo R,
Popovic B, Ouweneel DM, Henriques JPS, Simonis G, Levy B, Kimmoun A,
Gaudard P, Basir MB, Markota A, Adler C, Reuter H, Mebazaa A, Chouihed T.
Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients. Intensive Care Med 2018;44:847856.
488. Peacock WF, Hollander JE, Diercks DB, Lopatin M, Fonarow G, Emerman CL.
Morphine and outcomes in acute decompensated heart failure: an ADHERE
analysis. Emerg Med J 2008;25:205209.
489. Gil V, Dominguez-Rodriguez A, Masip J, Peacock WF, Miro O. Morphine use in the treatment of acute cardiogenic pulmonary edema and its effects on patient outcome: a systematic review. Curr Heart Fail Rep 2019;16:8188.


<!-- PAGE 113 -->

### Page 113

.............................................................................................................................................................................
490. Miro O, Gil V, Martin-Sanchez FJ, Herrero-Puente P, Jacob J, Mebazaa A,
Harjola VP, Rios J, Hollander JE, Peacock WF, Llorens P, ICA-SEMES Research
Group. Morphine use in the ED and outcomes of patients with acute heart failure: a propensity score-matching analysis based on the EAHFE registry. Chest
2017;152:821832.
491. Caspi O, Naami R, Halfin E, Aronson D. Adverse dose-dependent effects of morphine therapy in acute heart failure. Int J Cardiol 2019;293:131136.
492. Sethi NJ, Nielsen EE, Safi S, Feinberg J, Gluud C, Jakobsen JC. Digoxin for atrial fibrillation and atrial flutter: a systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.
PLoS
One
2018;13:e0193924.
493. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 2003;42:19441951.
494. Tebbe U, Schellong SM, Haas S, Gerlach HE, Abletshauser C, Sieder C,
Bramlage P, Riess H. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure:
a subgroup analysis of the randomized, controlled CERTIFY study. Am Heart J
2011;161:322328.
495. Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 2007;146:278288.
496. Seferovic PM, Piepoli MF, Lopatin Y, Jankowska E, Polovina M, Anguita-Sanchez
M, Stork S, Lainscak M, Milicic D, Milinkovic I, Filippatos G, Coats AJS, Heart
Failure Association Board of the European Society of Cardiology. Heart Failure
Association of the European Society of Cardiology quality of care centres programme: design and accreditation document. Eur J Heart Fail 2020;22:763774.
497. Tehrani BN, Truesdell AG, Sherwood MW, Desai S, Tran HA, Epps KC, Singh
R, Psotka M, Shah P, Cooper LB, Rosner C, Raja A, Barnett SD, Saulino P,
deFilippi CR, Gurbel PA, Murphy CE, O’Connor CM. Standardized team-based care for cardiogenic shock. J Am Coll Cardiol 2019;73:16591669.
498. Basir MB, Kapur NK, Patel K, Salam MA, Schreiber T, Kaki A, Hanson I, Almany
S, Timmis S, Dixon S, Kolski B, Todd J, Senter S, Marso S, Lasorda D, Wilkins
C, Lalonde T, Attallah A, Larkin T, Dupont A, Marshall J, Patel N, Overly T,
Green M, Tehrani B, Truesdell AG, Sharma R, Akhtar Y, McRae T, 3rd, O’Neill
B, Finley J, Rahman A, Foster M, Askari R, Goldsweig A, Martin S, Bharadwaj A,
Khuddus M, Caputo C, Korpas D, Cawich I, McAllister D, Blank N, Alraies MC,
Fisher R, Khandelwal A, Alaswad K, Lemor A, Johnson T, Hacala M, O’Neill
WW, National Cardiogenic Shock Initiative Investigators. Improved outcomes associated with the use of shock protocols: updates from the National
Cardiogenic Shock Initiative. Catheter Cardiovasc Interv 2019;93:11731183.
499. Tehrani BN, Truesdell AG, Psotka MA, Rosner C, Singh R, Sinha SS, Damluji
AA, Batchelor WB. A standardized and comprehensive approach to the management of cardiogenic shock. JACC Heart Fail 2020;8:879891.
500. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J,
Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I,
Hambrecht R, Fuhrmann J, Bohm M, Ebelt H, Schneider S, Schuler G,
Werdan K, IABP-SHOCK II Trial Investigators. Intraaortic balloon support for myocardial infarction with cardiogenic shock.
N
Engl
J
Med
2012;367:12871296.
501. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, de
Waha A, Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I,
Hambrecht R, Lauer B, Bohm M, Ebelt H, Schneider S, Werdan K, Schuler G,
Intraaortic Balloon Pump in cardiogenic shock II (IABP-SHOCK II) trial investigators. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet 2013;382:16381645.
502. Thiele H, Zeymer U, Thelemann N, Neumann FJ, Hausleiter J, Abdel-Wahab M,
Meyer-Saraei R, Fuernau G, Eitel I, Hambrecht R, Bohm M, Werdan K, Felix SB,
Hennersdorf M, Schneider S, Ouarrak T, Desch S, de Waha-Thiele S, IABPSHOCK II Trial Investigators. Intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarction: long-term 6-year outcome of the randomized IABP-SHOCK II Trial. Circulation 2019;139:395403.
503. Seyfarth M, Sibbing D, Bauer I, Frohlich G, Bott-Flugel L, Byrne R, Dirschinger J,
Kastrati A, Schomig A. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J
Am Coll Cardiol 2008;52:15841588.
504. Ouweneel DM, Eriksen E, Sjauw KD, van Dongen IM, Hirsch A, Packer EJ, Vis
MM, Wykrzykowska JJ, Koch KT, Baan J, de Winter RJ, Piek JJ, Lagrand WK, de
Mol BA, Tijssen JG, Henriques JP. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol 2017;69:278287.
505. Schrage B, Ibrahim K, Loehn T, Werner N, Sinning JM, Pappalardo F, Pieri M,
Skurk C, Lauten A, Landmesser U, Westenfeld R, Horn P, Pauschinger M,
Eckner D, Twerenbold R, Nordbeck P, Salinger T, Abel P, Empen K, Busch MC,
Felix SB, Sieweke JT, Moller JE, Pareek N, Hill J, MacCarthy P, Bergmann MW,
Henriques JPS, Mobius-Winkler S, Schulze PC, Ouarrak T, Zeymer U,
Schneider S, Blankenberg S, Thiele H, Schafer A, Westermann D. Impella support for acute myocardial infarction complicated by cardiogenic shock.
Circulation 2019;139:12491258.
506. Dhruva SS, Ross JS, Mortazavi BJ, Hurley NC, Krumholz HM, Curtis JP,
Berkowitz A, Masoudi FA, Messenger JC, Parzynski CS, Ngufor C, Girotra S,
Amin AP, Shah ND, Desai NR. Association of use of an intravascular microaxial left ventricular assist device vs intra-aortic balloon pump with in-hospital mortality and major bleeding among patients with acute myocardial infarction complicated by cardiogenic shock. JAMA 2020;323:734745.
507. Kar B, Gregoric ID, Basra SS, Idelchik GM, Loyalka P. The percutaneous ventricular assist device in severe refractory cardiogenic shock. J Am Coll Cardiol
2011;57:688696.
508. Ouweneel DM, Schotborgh JV, Limpens J, Sjauw KD, Engstrom AE, Lagrand
WK,
Cherpanath
TGV,
Driessen
AHG,
de
Mol
B,
Henriques
JPS.
Extracorporeal life support during cardiac arrest and cardiogenic shock: a systematic review and meta-analysis. Intensive Care Med 2016;42:19221934.
509. Combes A, Price S, Slutsky AS, Brodie D. Temporary circulatory support for cardiogenic shock. Lancet 2020;396:199212.
510. Pappalardo F, Schulte C, Pieri M, Schrage B, Contri R, Soeffker G, Greco T,
Lembo R, Mullerleile K, Colombo A, Sydow K, De Bonis M, Wagner F,
Reichenspurner H, Blankenberg S, Zangrillo A, Westermann D. Concomitant implantation of Impella((R)) on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock. Eur J
Heart Fail 2017;19:404412.
511. Anderson MB, Goldstein J, Milano C, Morris LD, Kormos RL, Bhama J, Kapur
NK, Bansal A, Garcia J, Baker JN, Silvestry S, Holman WL, Douglas PS, O’Neill
W. Benefits of a novel percutaneous ventricular assist device for right heart failure: the prospective RECOVER RIGHT study of the Impella RP device. J Heart
Lung Transplant 2015;34:15491560.
512. Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J,
Fabien V, Filippatos G, Gohring UM, Keren A, Khintibidze I, Kragten H,
Martinez FA, Metra M, Milicic D, Nicolau JC, Ohlsson M, Parkhomenko A,
Pascual-Figal DA, Ruschitzka F, Sim D, Skouri H, van der Meer P, Lewis BS,
Comin-Colet J, von Haehling S, Cohen-Solal A, Danchin N, Doehner W, Dargie
HJ, Motro M, Butler J, Friede T, Jensen KH, Pocock S, Jankowska EA, AFFIRMAHF Investigators. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
Lancet 2020;396:18951904.
513. Bhagat AA, Greene SJ, Vaduganathan M, Fonarow GC, Butler J. Initiation, continuation, switching, and withdrawal of heart failure medical therapies during hospitalization. JACC Heart Fail 2019;7:112.
514. Prins KW, Neill JM, Tyler JO, Eckman PM, Duval S. Effects of beta-blocker withdrawal in acute decompensated heart failure: a systematic review and metaanalysis. JACC Heart Fail 2015;3:647653.
515. Metra M, Gheorghiade M, Bonow RO, Dei Cas L. Postdischarge assessment after a
heart failure hospitalization:
the next step forward.
Circulation
2010;122:17821785.
516. Greene SJ, Fonarow GC, Vaduganathan M, Khan SS, Butler J, Gheorghiade M.
The vulnerable phase after hospitalization for heart failure. Nat Rev Cardiol
2015;12:220229.
517. Lee KK, Yang J, Hernandez AF, Steimle AE, Go AS. Post-discharge Follow-up characteristics associated with 30-day readmission after heart failure hospitalization. Med Care 2016;54:365372.
518. Edmonston DL, Wu J, Matsouaka RA, Yancy C, Heidenreich P, Pina IL,
Hernandez A, Fonarow GC, DeVore AD. Association of post-discharge specialty outpatient visits with readmissions and mortality in high-risk heart failure patients. Am Heart J 2019;212:101112.
519. Ling LH, Kistler PM, Kalman JM, Schilling RJ, Hunter RJ. Comorbidity of atrial fibrillation and heart failure. Nat Rev Cardiol 2016;13:131147.
520. Carlisle MA, Fudim M, DeVore AD, Piccini JP. Heart failure and atrial fibrillation,
like fire and fury. JACC Heart Fail 2019;7:447456.
521. Gorenek B, Halvorsen S, Kudaiberdieva G, Bueno H, Van Gelder IC, Lettino M,
Marin F, Masip J, Mueller C, Okutucu S, Poess J, Potpara TS, Price S, Lip GYH.
Atrial fibrillation in acute heart failure: a position statement from the Acute
Cardiovascular Care Association and European Heart Rhythm Association of the European Society of Cardiology. Eur Heart J Acute Cardiovasc Care
2020;9:348357.
522. Slawik J, Adrian L, Hohl M, Lothschutz S, Laufs U, Bohm M. Irregular pacing of ventricular cardiomyocytes induces pro-fibrotic signalling involving paracrine effects of transforming growth factor beta and connective tissue growth factor.
Eur J Heart Fail 2019;21:482491.
523. Kotecha D, Lam CS, Van Veldhuisen DJ, Van Gelder IC, Voors AA, Rienstra M.
Heart failure with preserved ejection fraction and atrial fibrillation: vicious twins. J Am Coll Cardiol 2016;68:22172228.
ESC Guidelines
3711


<!-- PAGE 114 -->

### Page 114

.............................................................................................................................................................................
524. Smit MD, Moes ML, Maass AH, Achekar ID, Van Geel PP, Hillege HL, van
Veldhuisen DJ, Van Gelder IC. The importance of whether atrial fibrillation or heart failure develops first. Eur J Heart Fail 2012;14:10301040.
525. Swedberg K, Olsson LG, Charlesworth A, Cleland J, Hanrath P, Komajda M,
Metra M, Torp-Pedersen C, Poole-Wilson P. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J 2005;26:13031308.
526. Mogensen UM, Jhund PS, Abraham WT, Desai AS, Dickstein K, Packer M,
Rouleau JL, Solomon SD, Swedberg K, Zile MR, Køber L, McMurray JJV,
PARADIGM-HF and ATMOSPHERE Investigators and Committees. Type of atrial fibrillation and outcomes in patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 2017;70:24902500.
527. Hoppe UC, Casares JM, Eiskjaer H, Hagemann A, Cleland JG, Freemantle N,
Erdmann E. Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. Circulation 2006;114:1825.
528. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz
MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM.
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet
2014;383:955962.
529. Reddy VY, Doshi SK, Sievert H, Buchbinder M, Neuzil P, Huber K, Halperin JL,
Holmes D, PROTECT AF Investigators. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic
Protection in
Patients with
Atrial
Fibrillation)
trial.
Circulation
2013;127:720729.
530. Holmes DR, Jr., Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, Huber K,
Reddy VY. Prospective randomized evaluation of the Watchman Left Atrial
Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 2014;64:112.
531. Van Gelder IC, Wyse DG, Chandler ML, Cooper HA, Olshansky B, Hagens VE,
Crijns HJ, RACE and AFFIRM Investigators. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE
and AFFIRM studies. Europace 2006;8:935942.
532. Hess PL, Sheng S, Matsouaka R, DeVore AD, Heidenreich PA, Yancy CW,
Bhatt DL, Allen LA, Peterson PN, Ho PM, Lewis WR, Hernandez AF, Fonarow
GC, Piccini JP. Strict versus lenient versus poor rate control among patients with atrial fibrillation and heart failure (from the Get With The Guidelines –
Heart Failure Program). Am J Cardiol 2020;125:894900.
533. Sartipy U, Savarese G, Dahlstrom U, Fu M, Lund LH. Association of heart rate with mortality in sinus rhythm and atrial fibrillation in heart failure with preserved ejection fraction. Eur J Heart Fail 2019;21:471479.
534. Van Gelder IC, Rienstra M, Crijns HJ, Olshansky B. Rate control in atrial fibrillation. Lancet 2016;388:818828.
535. Kotecha D, Flather MD, Altman DG, Holmes J, Rosano G, Wikstrand J, Packer
M, Coats AJS, Manzano L, Bohm M, van Veldhuisen DJ, Andersson B, Wedel H,
von Lueder TG, Rigby AS, Hjalmarson A, Kjekshus J, Cleland JGF, Beta-Blockers in Heart Failure Collaborative Group. Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure.
J
Am
Coll
Cardiol
2017;69:28852896.
536. Kotecha D, Bunting KV, Gill SK, Mehta S, Stanbury M, Jones JC, Haynes S,
Calvert MJ, Deeks JJ, Steeds RP, Strauss VY, Rahimi K, Camm AJ, Griffith M, Lip
GYH, Townend JN, Kirchhof P, Rate Control Therapy Evaluation in Permanent
Atrial Fibrillation (RATE-AF) Team. Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF
randomized clinical trial. JAMA 2020;324:24972508.
537. Hofmann R, Steinwender C, Kammler J, Kypta A, Leisch F. Effects of a high dose intravenous bolus amiodarone in patients with atrial fibrillation and a rapid ventricular rate. Int J Cardiol 2006;110:2732.
538. Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation
2000;101:11381144.
539. Lim KT, Davis MJ, Powell A, Arnolda L, Moulden K, Bulsara M, Weerasooriya R.
Ablate and pace strategy for atrial fibrillation: long-term outcome of AIRCRAFT
trial. Europace 2007;9:498505.
540. Gasparini M, Kloppe A, Lunati M, Anselme F, Landolina M, Martinez-Ferrer JB,
Proclemer A, Morani G, Biffi M, Ricci R, Rordorf R, Mangoni L, Manotta L,
Grammatico A, Leyva F, Boriani G. Atrioventricular junction ablation in patients with atrial fibrillation treated with cardiac resynchronization therapy: positive impact on ventricular arrhythmias, implantable cardioverter-defibrillator therapies and hospitalizations. Eur J Heart Fail 2018;20:14721481.
541. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN.
Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the Veterans
Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy
(CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators.
Circulation 1998;98:25742579.
542. Antiarrhythmic Drug Evaluation Group (A.D.E.G.). A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Eur Heart J
1992;13:12511258.
543. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D,
Avezum A, Blomstrom P, Borggrefe M, Budaj A, Chen SA, Ching CK,
Commerford P, Dans A, Davy JM, Delacretaz E, Di Pasquale G, Diaz R, Dorian
P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbuchel H,
Kautzner J, Kim JS, Lanas F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimhan
C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles MK, Tanomsup S,
Toivonen L, Tomcsanyi J, Torp-Pedersen C, Tse HF, Vardas P, Vinereanu D,
Xavier D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, Yusuf S,
Chrolavicius S, Afzal R, Hohnloser SH, PALLAS Investigators. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011;365:22682276.
544. Chatterjee S, Ghosh J, Lichstein E, Aikat S, Mukherjee D. Meta-analysis of cardiovascular outcomes with dronedarone in patients with atrial fibrillation or heart failure. Am J Cardiol 2012;110:607613.
545. Shelton RJ, Clark AL, Goode K, Rigby AS, Houghton T, Kaye GC, Cleland JG. A
randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure:
(CAFE-II
Study).
Heart
2009;95:924930.
546. Capucci A, Villani GQ, Aschieri D, Rosi A, Piepoli MF. Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. Eur Heart J 2000;21:6673.
547. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA,
Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ, Rate Control versus
Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:18341840.
548. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB,
Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD, Atrial Fibrillation
Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N
Engl J Med 2002;347:18251833.
549. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, Walter S, Tebbe
U, STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation
(STAF) study. J Am Coll Cardiol 2003;41:16901696.
550. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold
JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG,
Hohnloser SH, Lambert J, Le Heuzey JY, O’Hara G, Pedersen OD, Rouleau JL,
Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL, Atrial
Fibrillation and Congestive Heart Failure Investigators Rhythm control versus rate control for atrial fibrillation and heart failure.
N
Engl
J
Med
2008;358:26672677.
551. Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, Fetsch T, van
Gelder IC, Haase D, Haegeli LM, Hamann F, Heidbuchel H, Hindricks G,
Kautzner J, Kuck KH, Mont L, Ng GA, Rekosz J, Schoen N, Schotten U, Suling
A, Taggeselle J, Themistoclakis S, Vettorazzi E, Vardas P, Wegscheider K,
Willems S, Crijns H, Breithardt G, EAST-AFNET 4 Trial Investigators. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med
2020;383:13051316.
552. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L,
Merkely B, Pokushalov E, Sanders P, Proff J, Schunkert H, Christ H, Vogt J,
Bansch D, CASTLE-AF Investigators. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378:417427.
553. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE,
Noseworthy PA, Rosenberg YD, Jeffries N, Mitchell LB, Flaker GC, Pokushalov
E, Romanov A, Bunch TJ, Noelker G, Ardashev A, Revishvili A, Wilber DJ,
Cappato R, Kuck KH, Hindricks G, Davies DW, Kowey PR, Naccarelli GV,
Reiffel JA, Piccini JP, Silverstein AP, Al-Khalidi HR, Lee KL, CABANA
Investigators. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation:
the CABANA randomized clinical trial. JAMA 2019;321:12611274.
554. Packer DL, Piccini JP, Monahan KH, Al-Khalidi HR, Silverstein AP, Noseworthy
PA, Poole JE, Bahnson TD, Lee KL, Mark DB, CABANA Investigators. Ablation versus drug therapy for atrial fibrillation in heart failure: results from the
CABANA trial. Circulation 2021;143:13771390.
555. Kuck KH, Merkely B, Zahn R, Arentz T, Seidl K, Schluter M, Tilz RR, Piorkowski
C, Geller L, Kleemann T, Hindricks G. Catheter ablation versus best medical therapy in patients with persistent atrial fibrillation and congestive heart failure:
the randomized AMICA trial. Circ Arrhythm Electrophysiol 2019;12:e007731.
556. Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D, Reddy
M, Jais P, Themistoclakis S, Dello Russo A, Casella M, Pelargonio G, Narducci


<!-- PAGE 115 -->

### Page 115

.............................................................................................................................................................................
ML, Schweikert R, Neuzil P, Sanchez J, Horton R, Beheiry S, Hongo R, Hao S,
Rossillo A, Forleo G, Tondo C, Burkhardt JD, Haissaguerre M, Natale A.
Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the
AATAC multicenter randomized trial. Circulation 2016;133:16371644.
557. Mark DB, Anstrom KJ, Sheng S, Piccini JP, Baloch KN, Monahan KH, Daniels
MR, Bahnson TD, Poole JE, Rosenberg Y, Lee KL, Packer DL, CABANA
Investigators. Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial.
JAMA 2019;321:12751285.
558. Xiong Q, Lau YC, Senoo K, Lane DA, Hong K, Lip GY. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. Eur J
Heart Fail 2015;17:11921200.
559. Nielsen PB, Larsen TB, Skjoth F, Overvad TF, Lip GY. Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: a nationwide cohort study. Sci Rep 2016;6:27410.
560. Latchamsetty R, Bogun F. Premature ventricular complex-induced cardiomyopathy. JACC Clin Electrophysiol 2019;5:537550.
561. Mondesert B, Khairy P, Schram G, Shohoudi A, Talajic M, Andrade JG, Dubuc
M, Guerra PG, Macle L, Roy D, Dyrda K, Thibault B, Barrero M, Diaz A, Kouz
S, McNicoll S, Nowakowska D, Rivard L. Impact of revascularization in patients with sustained ventricular arrhythmias, prior myocardial infarction, and preserved left ventricular ejection fraction. Heart Rhythm 2016;13:12211227.
562. Yarlagadda RK, Iwai S, Stein KM, Markowitz SM, Shah BK, Cheung JW, Tan V,
Lerman BB, Mittal S. Reversal of cardiomyopathy in patients with repetitive monomorphic ventricular ectopy originating from the right ventricular outflow tract. Circulation 2005;112:10921097.
563. Berruezo A, Penela D, Jauregui B, Soto-Iglesias D, Aguinaga L, Ordonez A,
Fernandez-Armenta J, Martinez M, Tercedor L, Bisbal F, Acosta J, Marti-Almor J,
Acena M, Anguera I, Rossi L, Linhart M, Borras R, Doltra A, Sanchez P,
Ortiz-Perez JT, Perea RJ, Prat-Gonzalez S, Teres C, Bosch X. Mortality and morbidity reduction after frequent premature ventricular complexes ablation in patients with left ventricular systolic dysfunction. Europace 2019;21:1079
1087.
564. Cronin EM, Bogun FM, Maury P, Peichl P, Chen M, Namboodiri N, Aguinaga L,
Leite LR, Al-Khatib SM, Anter E, Berruezo A, Callans DJ, Chung MK, Cuculich
P, d’Avila A, Deal BJ, Della Bella P, Deneke T, Dickfeld TM, Hadid C, Haqqani
HM, Kay GN, Latchamsetty R, Marchlinski F, Miller JM, Nogami A, Patel AR,
Pathak RK, Saenz Morales LC, Santangeli P, Sapp JL, Sarkozy A, Soejima K,
Stevenson WG, Tedrow UB, Tzou WS, Varma N, Zeppenfeld K, ESC Scientific
Document Group. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.
Europace
2019;21:11431144.
565. Cho SW, Gwag HB, Hwang JK, Chun KJ, Park KM, On YK, Kim JS, Park SJ.
Clinical features, predictors, and long-term prognosis of pacing-induced cardiomyopathy. Eur J Heart Fail 2019;21:643651.
566. Vijayaraman P, Herweg B, Ellenbogen KA, Gajek J. His-optimized cardiac resynchronization therapy to maximize electrical resynchronization: a feasibility study. Circ Arrhythm Electrophysiol 2019;12:e006934.
567. Abdelrahman M, Subzposh FA, Beer D, Durr B, Naperkowski A, Sun H, Oren
JW, Dandamudi G, Vijayaraman P. Clinical outcomes of His bundle pacing compared to right ventricular pacing. J Am Coll Cardiol 2018;71:23192330.
568. Ziff OJ, Samra M, Howard JP, Bromage DI, Ruschitzka F, Francis DP, Kotecha D.
Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment. BMC Med 2020;18:103.
569. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, BEAUTIFUL
Investigators. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized,
controlled BEAUTIFUL trial. Eur Heart J 2009;30:23372345.
570. Packer M, O’Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller
AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL. Effect of amlodipine on morbidity and mortality in severe chronic heart failure.
Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J
Med 1996;335:11071114.
571. Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, Cintron G,
Boden W, Baruch L, Rochin P, Loss L. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT)
Study Group. Circulation 1997;96:856863.
572. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial.
Lancet 2002;359:12691275.
573. Kanamasa K, Hayashi T, Kimura A, Ikeda A, Ishikawa K. Long-term, continuous treatment with both oral and transdermal nitrates increases cardiac events in healed myocardial infarction patients. Angiology 2002;53:399408.
574. Wilson SR, Scirica BM, Braunwald E, Murphy SA, Karwatowska-Prokopczuk E,
Buros JL, Chaitman BR, Morrow DA. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in
Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll
Cardiol 2009;53:15101516.
575. Gao D, Ning N, Niu X, Hao G, Meng Z. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart 2011;97:278286.
576. Vitale C, Wajngaten M, Sposato B, Gebara O, Rossini P, Fini M, Volterrani M,
Rosano GM. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease.
Eur
Heart
J
2004;25:18141821.
577. Zhang L, Lu Y, Jiang H, Zhang L, Sun A, Zou Y, Ge J. Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. J Am Coll Cardiol
2012;59:913922.
578. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction.
The
Adverse
Experience
Committee;
and the
Multicenter
Diltiazem
Postinfarction
Research
Group.
Circulation
1991;83:5260.
579. Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade M, Lam
CSP, Mehra MR, Neaton JD, Nessel CC, Spiro TE, van Veldhuisen DJ,
Greenberg B, COMMANDER HF Investigators. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med 2018;379:
13321342.
580. Branch KR, Probstfield JL, Eikelboom JW, Bosch J, Maggioni AP, Cheng RK,
Bhatt DL, Avezum A, Fox KAA, Connolly SJ, Shestakovska O, Yusuf S.
Rivaroxaban with or without aspirin in patients with heart failure and chronic coronary or peripheral artery disease. Circulation 2019;140:529537.
581. Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, Michler RE,
Bonow RO, Doenst T, Petrie MC, Oh JK, She L, Moore VL, DesvigneNickens P, Sopko G, Rouleau JL, STICHES Investigators. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med
2016;374:15111520.
582. Panza JA, Holly TA, Asch FM, She L, Pellikka PA, Velazquez EJ, Lee KL, BorgesNeto S, Farsky PS, Jones RH, Berman DS, Bonow RO. Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol 2013;61:18601870.
583. Cleland JG, Calvert M, Freemantle N, Arrow Y, Ball SG, Bonser RS,
Chattopadhyay S, Norell MS, Pennell DJ, Senior R. The Heart Failure
Revascularisation Trial (HEART). Eur J Heart Fail 2011;13:227233.
584. Perera D, Clayton T, Petrie MC, Greenwood JP, O’Kane PD, Evans R, Sculpher
M, McDonagh T, Gershlick A, de Belder M, Redwood S, Carr-White G, Marber
M, REVIVED Investigators. Percutaneous revascularization for ischemic ventricular dysfunction: rationale and design of the REVIVED-BCIS2 trial: percutaneous coronary intervention for ischemic cardiomyopathy.
JACC
Heart
Fail
2018;6:517526.
585. Bangalore S, Guo Y, Samadashvili Z, Blecker S, Hannan EL. Revascularization in patients with multivessel coronary artery disease and severe left ventricular systolic dysfunction: everolimus-eluting stents versus coronary artery bypass graft surgery. Circulation 2016;133:21322140.
586. Nagendran J, Bozso SJ, Norris CM, McAlister FA, Appoo JJ, Moon MC, Freed
DH, Nagendran J. Coronary artery bypass surgery improves outcomes in patients with diabetes and left ventricular dysfunction. J Am Coll Cardiol
2018;71:819827.
587. Park S, Ahn JM, Kim TO, Park H, Kang DY, Lee PH, Jeong YJ, Hyun J, Lee J, Kim
JH, Yang Y, Choe K, Park SJ, Park DW, IRIS-MAIN Registry Investigators.
Revascularization in patients with left main coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol 2020;76:13951406.
588. Marui A, Kimura T, Nishiwaki N, Mitsudo K, Komiya T, Hanyu M, Shiomi H,
Tanaka S, Sakata R, CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators.
Comparison of five-year outcomes of coronary artery bypass grafting versus percutaneous coronary intervention in patients with left ventricular ejection fractions </ = 50% versus >50% (from the CREDO-Kyoto PCI/CABG Registry
Cohort-2). Am J Cardiol 2014;114:988996.
589. Wolff G, Dimitroulis D, Andreotti F, Kolodziejczak M, Jung C, Scicchitano P,
Devito F, Zito A, Occhipinti M, Castiglioni B, Calveri G, Maisano F, Ciccone
MM, De Servi S, Navarese EP. Survival benefits of invasive versus conservative strategies in heart failure in patients with reduced ejection fraction and coronary artery disease: a meta-analysis. Circ Heart Fail 2017;10:e003255.
590. Gaudino M, Hameed I, Khan FM, Tam DY, Rahouma M, Yongle R, Naik A, Di
Franco A, Demetres M, Petrie MC, Jolicoeur EM, Girardi LN, Fremes SE.
ESC Guidelines
3713


<!-- PAGE 116 -->

### Page 116

.............................................................................................................................................................................
Treatment strategies in ischaemic left ventricular dysfunction: a network metaanalysis. Eur J Cardiothorac Surg 2021;59:293301.
591. Genereux P, Pibarot P, Redfors B, Mack MJ, Makkar RR, Jaber WA, Svensson
LG, Kapadia S, Tuzcu EM, Thourani VH, Babaliaros V, Herrmann HC, Szeto
WY, Cohen DJ, Lindman BR, McAndrew T, Alu MC, Douglas PS, Hahn RT,
Kodali SK, Smith CR, Miller DC, Webb JG, Leon MB. Staging classification of aortic stenosis based on the extent of cardiac damage.
Eur
Heart
J
2017;38:33513358.
592. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Johann B, Capodanno
D, Conradi L, De Bonis M, De Paulis R, Delgado V, Freemantle N, Gilard M,
Haugaa KH, Jeppsson A, Ju¨ni P, Pierard L, Prendergast PD, Rafael Sadaba J,
Tribouilloy C, Wojakowski W; ESC/EACTS Scientific Document Group. 2021
ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart
J 2021; doi:10.1093/eurheartj/ehab395.
593. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM,
Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard
AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN,
Wang D, Pocock S, PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl
J Med 2010;363:15971607.
594. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM,
Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babaliaros
V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ,
Anderson
WN,
Wang
D,
Pocock
SJ,
PARTNER
Trial
Investigators.
Transcatheter versus surgical aortic-valve replacement in high-risk patients. N
Engl J Med 2011;364:21872198.
595. Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, Gleason
TG, Buchbinder M, Hermiller J Jr, Kleiman NS, Chetcuti S, Heiser J, Merhi W,
Zorn G, Tadros P, Robinson N, Petrossian G, Hughes GC, Harrison JK, Conte
J, Maini B, Mumtaz M, Chenoweth S, Oh JK, US CoreValve Clinical
Investigators. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 2014;370:17901798.
596. Popma JJ, Adams DH, Reardon MJ, Yakubov SJ, Kleiman NS, Heimansohn D,
Hermiller J, Jr., Hughes GC, Harrison JK, Coselli J, Diez J, Kafi A, Schreiber T,
Gleason TG, Conte J, Buchbinder M, Deeb GM, Carabello B, Serruys PW,
Chenoweth
S,
Oh
JK,
CoreValve
United
States
Clinical
Investigators.
Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol
2014;63:19721981.
597. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani
VH, Tuzcu EM, Miller DC, Herrmann HC, Doshi D, Cohen DJ, Pichard AD,
Kapadia S, Dewey T, Babaliaros V, Szeto WY, Williams MR, Kereiakes D,
Zajarias A, Greason KL, Whisenant BK, Hodson RW, Moses JW, Trento A,
Brown DL, Fearon WF, Pibarot P, Hahn RT, Jaber WA, Anderson WN, Alu
MC, Webb JG, PARTNER 2 Investigators. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016;374:16091620.
598. Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Sondergaard L, Mumtaz
M, Adams DH, Deeb GM, Maini B, Gada H, Chetcuti S, Gleason T, Heiser J,
Lange R, Merhi W, Oh JK, Olsen PS, Piazza N, Williams M, Windecker S,
Yakubov SJ, Grube E, Makkar R, Lee JS, Conte J, Vang E, Nguyen H, Chang Y,
Mugglin AS, Serruys PW, Kappetein AP, SURTAVI Investigators. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J
Med 2017;376:13211331.
599. Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O’Hair D, Bajwa T,
Heiser JC, Merhi W, Kleiman NS, Askew J, Sorajja P, Rovin J, Chetcuti SJ,
Adams DH, Teirstein PS, Zorn GL, 3rd, Forrest JK, Tchetche D, Resar J,
Walton A, Piazza N, Ramlawi B, Robinson N, Petrossian G, Gleason TG, Oh JK,
Boulware MJ, Qiao H, Mugglin AS, Reardon MJ, Evolut Low Risk Trial
Investigators. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 2019;380:17061715.
600. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, Kapadia SR,
Malaisrie SC, Cohen DJ, Pibarot P, Leipsic J, Hahn RT, Blanke P, Williams MR,
McCabe JM, Brown DL, Babaliaros V, Goldman S, Szeto WY, Genereux P,
Pershad A, Pocock SJ, Alu MC, Webb JG, Smith CR, PARTNER 3 Investigators.
Transcatheter aortic-valve replacement with a balloon-expandable valve in lowrisk patients. N Engl J Med 2019;380:16951705.
601. Elder DH, Wei L, Szwejkowski BR, Libianto R, Nadir A, Pauriah M, Rekhraj S,
Lim TK, George J, Doney A, Pringle SD, Choy AM, Struthers AD, Lang CC.
The impact of renin-angiotensin-aldosterone system blockade on heart failure outcomes and mortality in patients identified to have aortic regurgitation: a large population cohort study. J Am Coll Cardiol 2011;58:20842091.
602. Chaliki HP, Mohty D, Avierinos JF, Scott CG, Schaff HV, Tajik AJ, EnriquezSarano M. Outcomes after aortic valve replacement in patients with severe aortic regurgitation and markedly reduced left ventricular function. Circulation
2002;106:26872693.
603. Tornos P, Sambola A, Permanyer-Miralda G, Evangelista A, Gomez Z, SolerSoler J. Long-term outcome of surgically treated aortic regurgitation: influence of guideline adherence toward early surgery.
J
Am
Coll
Cardiol
2006;47:10121017.
604. Yoon SH, Schmidt T, Bleiziffer S, Schofer N, Fiorina C, Munoz-Garcia AJ,
Yzeiraj E, Amat-Santos IJ, Tchetche D, Jung C, Fujita B, Mangieri A, Deutsch
MA, Ubben T, Deuschl F, Kuwata S, De Biase C, Williams T, Dhoble A, Kim
WK, Ferrari E, Barbanti M, Vollema EM, Miceli A, Giannini C, Attizzani GF,
Kong WKF, Gutierrez-Ibanes E, Jimenez Diaz VA, Wijeysundera HC, Kaneko H,
Chakravarty T, Makar M, Sievert H, Hengstenberg C, Prendergast BD, Vincent
F, Abdel-Wahab M, Nombela-Franco L, Silaschi M, Tarantini G, Butter C,
Ensminger SM, Hildick-Smith D, Petronio AS, Yin WH, De Marco F, Testa L,
Van Mieghem NM, Whisenant BK, Kuck KH, Colombo A, Kar S, Moris C,
Delgado V, Maisano F, Nietlispach F, Mack MJ, Schofer J, Schaefer U, Bax JJ,
Frerker C, Latib A, Makkar RR. Transcatheter aortic valve replacement in pure native aortic valve regurgitation. J Am Coll Cardiol 2017;70:27522763.
605. Feldman T, Foster E, Glower DD, Kar S, Rinaldi MJ, Fail PS, Smalling RW, Siegel
R, Rose GA, Engeron E, Loghin C, Trento A, Skipper ER, Fudge T, Letsou GV,
Massaro JM, Mauri L, EVEREST II Investigators. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 2011;364:13951406.
606. Tamargo M, Obokata M, Reddy YNV, Pislaru SV, Lin G, Egbe AC, Nishimura
RA, Borlaug BA. Functional mitral regurgitation and left atrial myopathy in heart failure with preserved ejection fraction. Eur J Heart Fail 2020;22:489498.
607. Dziadzko V, Clavel MA, Dziadzko M, Medina-Inojosa JR, Michelena H, Maalouf J,
Nkomo V, Thapa P, Enriquez-Sarano M. Outcome and undertreatment of mitral regurgitation: a community cohort study. Lancet 2018;391:960969.
608. Goliasch G, Bartko PE, Pavo N, Neuhold S, Wurm R, Mascherbauer J, Lang IM,
Strunk G, Hulsmann M. Refining the prognostic impact of functional mitral regurgitation in chronic heart failure. Eur Heart J 2018;39:3946.
609. Bertrand PB, Schwammenthal E, Levine RA, Vandervoort PM. Exercise dynamics in secondary mitral regurgitation: pathophysiology and therapeutic implications. Circulation 2017;135:297314.
610. Obadia JF, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, Lefevre
T, Piot C, Rouleau F, Carrie D, Nejjari M, Ohlmann P, Leclercq F, Saint Etienne
C, Teiger E, Leroux L, Karam N, Michel N, Gilard M, Donal E, Trochu JN,
Cormier B, Armoiry X, Boutitie F, Maucort-Boulch D, Barnel C, Samson G,
Guerin P, Vahanian A, Mewton N, MITRA-FR Investigators. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med
2018;379:22972306.
611. Iung B, Armoiry X, Vahanian A, Boutitie F, Mewton N, Trochu JN, Lefevre T,
Messika-Zeitoun D, Guerin P, Cormier B, Brochet E, Thibault H, Himbert D,
Thivolet S, Leurent G, Bonnet G, Donal E, Piriou N, Piot C, Habib G, Rouleau
F, Carrie D, Nejjari M, Ohlmann P, Saint Etienne C, Leroux L, Gilard M,
Samson G, Rioufol G, Maucort-Boulch D, Obadia JF, MITRA-FR Investigators.
Percutaneous repair or medical treatment for secondary mitral regurgitation:
outcomes at 2 years. Eur J Heart Fail 2019;21:16191627.
612. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, Whisenant B,
Grayburn PA, Rinaldi M, Kapadia SR, Rajagopal V, Sarembock IJ, Brieke A, Marx
SO, Cohen DJ, Weissman NJ, Mack MJ, COAPT Investigators. Transcatheter mitral-valve repair in patients with heart failure.
N
Engl
J
Med
2018;379:23072318.
613. Senni M, Adamo M, Metra M, Alfieri O, Vahanian A. Treatment of functional mitral regurgitation in chronic heart failure: can we get a ‘proof of concept’
from the MITRA-FR and COAPT trials? Eur J Heart Fail 2019;21:852861.
614. Grayburn PA, Sannino A, Packer M. Proportionate and disproportionate functional mitral regurgitation: a new conceptual framework that reconciles the results of the
MITRA-FR
and
COAPT
trials.
JACC
Cardiovasc
Imaging
2019;12:353362.
615. Coats AJS, Anker SD, Baumbach A, Alfieri O, von Bardeleben RS, Bauersachs J,
Bax JJ, Boveda S, Celutkiene J, Cleland JG, Dagres N, Deneke T, Farmakis D,
Filippatos G, Hausleiter J, Hindricks G, Jankowska EA, Lainscak M, Leclercq C,
Lund LH, McDonagh T, Mehra MR, Metra M, Mewton N, Mueller C, Mullens W,
Muneretto C, Obadia JF, Ponikowski P, Praz F, Rudolph V, Ruschitzka F, Vahanian
A, Windecker S, Zamorano JL, Edvardsen T, Heidbuchel H, Seferovic PM,
Prendergast B. The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA),
European Association of Cardiovascular Imaging (EACVI), European Heart
Rhythm
Association
(EHRA),
and
European Association of
Percutaneous
Cardiovascular
Interventions
(EAPCI)
of the
ESC.
Eur
Heart
J
2021;42:12541269.
616. Adamo M, Fiorelli F, Melica B, D’Ortona R, Lupi L, Giannini C, Silva G, Fiorina
C, Branca L, Chiari E, Chizzola G, Spontoni P, Espada Guerreiro C, Curello S,
Petronio AS, Metra M. COAPT-like profile predicts long-term outcomes in patients with secondary mitral regurgitation undergoing MitraClip implantation.
JACC Cardiovasc Interv 2021;14:1525.


<!-- PAGE 117 -->

### Page 117

...........................................................................................................................................................................
617. Godino C, Munafo A, Scotti A, Estevez-Loureiro R, Portoles Hernandez A,
Arzamendi D, Fernandez Peregrina E, Taramasso M, Fam NP, Ho EC, Asgar A,
Vitrella G, Raineri C, Adamo M, Fiorina C, Montalto C, Fraccaro C, Giannini C,
Fiorelli F, Popolo Rubbio A, Ooms JF, Compagnone M, Maffeo D, Bettari L,
Furholz M, Tamburino C, Petronio AS, Grasso C, Agricola E, Van Mieghem
NM, Tarantini G, Curello S, Praz F, Pascual I, Potena L, Colombo A, Maisano F,
Metra M, Margonato A, Crimi G, Saia F. MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the
International
MitraBridge
Registry.
J
Heart
Lung
Transplant
2020;39:13531362.
618. Witte KK, Lipiecki J, Siminiak T, Meredith IT, Malkin CJ, Goldberg SL, Stark MA,
von Bardeleben RS, Cremer PC, Jaber WA, Celermajer DS, Kaye DM, Sievert
H. The REDUCE FMR trial: a randomized sham-controlled study of percutaneous mitral annuloplasty in functional mitral regurgitation. JACC Heart Fail
2019;7:945955.
619. Geyer M, Keller K, Sotiriou E, Tamm AR, Ruf TF, Kreidel F, Beiras-Fernandez A,
Gori T, Schulz E, Munzel T, von Bardeleben RS. Association of transcatheter direct mitral annuloplasty with acute anatomic, haemodynamic, and clinical outcomes in severe mitral valve regurgitation. ESC Heart Fail 2020;7:33363344.
620. Giallauria F, Di Lorenzo A, Parlato A, Testa C, Bobbio E, Vigorito C, Coats AJS.
Individual patient data meta-analysis of the effects of the CARILLON
V
R mitral contour system. ESC Heart Fail 2020;7:33833391.
621. Lipiecki J, Fahrat H, Monzy S, Caillot N, Siminiak T, Johnson T, Vogt S, Stark
MA, Goldberg SL. Long-term prognosis of patients treated by coronary sinusbased percutaneous annuloplasty: single centre experience. ESC Heart Fail
2020;7:33293335.
622. Ruf TF, Kreidel F, Tamm AR, Geyer M, Hahad O, Zirbs JC, Schwidtal BL,
Beiras-Fernandez A, Witte KK, Munzel T, von Bardeleben RS. Transcatheter indirect mitral annuloplasty induces annular and left atrial remodelling in secondary mitral regurgitation. ESC Heart Fail 2020;7:14001408.
623. Sorajja P, Moat N, Badhwar V, Walters D, Paone G, Bethea B, Bae R, Dahle G,
Mumtaz M, Grayburn P, Kapadia S, Babaliaros V, Guerrero M, Satler L,
Thourani V, Bedogni F, Rizik D, Denti P, Dumonteil N, Modine T, Sinhal A,
Chuang ML, Popma JJ, Blanke P, Leipsic J, Muller D. Initial feasibility study of a new transcatheter mitral prosthesis: the first 100 patients. J Am Coll Cardiol
2019;73:12501260.
624. Zack CJ, Fender EA, Chandrashekar P, Reddy YNV, Bennett CE, Stulak JM,
Miller VM, Nishimura RA. National trends and outcomes in isolated tricuspid valve surgery. J Am Coll Cardiol 2017;70:29532960.
625. Taramasso M, Benfari G, van der Bijl P, Alessandrini H, Attinger-Toller A,
Biasco L, Lurz P, Braun D, Brochet E, Connelly KA, de Bruijn S, Denti P,
Deuschl F, Estevez-Loureiro R, Fam N, Frerker C, Gavazzoni M, Hausleiter J,
Ho E, Juliard JM, Kaple R, Besler C, Kodali S, Kreidel F, Kuck KH, Latib A,
Lauten A, Monivas V, Mehr M, Muntane-Carol G, Nazif T, Nickening G,
Pedrazzini G, Philippon F, Pozzoli A, Praz F, Puri R, Rodes-Cabau J, Schafer U,
Schofer J, Sievert H, Tang GHL, Thiele H, Topilsky Y, Rommel KP, Delgado V,
Vahanian A, Von Bardeleben RS, Webb JG, Weber M, Windecker S, Winkel M,
Zuber M, Leon MB, Hahn RT, Bax JJ, Enriquez-Sarano M, Maisano F.
Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation. J Am Coll Cardiol 2019;74:29983008.
626. Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S,
White IR, Caulfield MJ, Deanfield JE, Smeeth L, Williams B, Hingorani A,
Hemingway H. Blood pressure and incidence of twelve cardiovascular diseases:
lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet 2014;383:18991911.
627. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C,
Wright TJ, MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure
(MOXCON). Eur J Heart Fail 2003;5:659667.
628. Kato S, Onishi K, Yamanaka T, Takamura T, Dohi K, Yamada N, Wada H,
Nobori T, Ito M. Exaggerated hypertensive response to exercise in patients with diastolic heart failure. Hypertens Res 2008;31:679684.
629. Uijl A, Savarese G, Vaartjes I, Dahlstrom U, Brugts JJ, Linssen GCM, van Empel
V, Brunner-La Rocca HP, Asselbergs FW, Lund LH, Hoes AW, Koudstaal S.
Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction. Eur J Heart Fail 2021;23:973982.
630. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 - effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis. J Hypertens 2018;36:16371647.
631. Vaduganathan M, Pareek M, Kristensen AMD, Biering-Sorensen T, Byrne C,
Almarzooq Z, Olesen TB, Olsen MH, Bhatt DL. Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy. Eur J Heart Fail
2021;23:384392.
632. Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies.
Hypertension 2009;54:10841091.
633. Cautela J, Tartiere JM, Cohen-Solal A, Bellemain-Appaix A, Theron A, Tibi T,
Januzzi JL, Jr., Roubille F, Girerd N. Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. Eur J Heart Fail
2020;22:13571365.
634. Kang SH, Kim J, Park JJ, Oh IY, Yoon CH, Kim HJ, Kim K, Choi DJ. Risk of stroke in congestive heart failure with and without atrial fibrillation. Int J Cardiol
2017;248:182187.
635. Abdul-Rahim AH, Perez AC, Fulton RL, Jhund PS, Latini R, Tognoni G,
Wikstrand J, Kjekshus J, Lip GY, Maggioni AP, Tavazzi L, Lees KR, McMurray JJ,
Investigators of the Controlled Rosuvastatin Multinational Study in Heart
Failure
(CORONA),
GISSI-Heart
Failure
(GISSI-HF)
Committees and
Investigators. Risk of stroke in chronic heart failure patients without atrial fibrillation: analysis of the Controlled Rosuvastatin in Multinational Trial Heart
Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell’Insufficienza
Cardiaca-Heart
Failure
(GISSI-HF)
trials.
Circulation
2015;131:14861494; discussion 1494.
636. Abdul-Rahim AH, Perez AC, MacIsaac RL, Jhund PS, Claggett BL, Carson PE,
Komajda M, McKelvie RS, Zile MR, Swedberg K, Yusuf S, Pfeffer MA, Solomon
SD, Lip GYH, Lees KR, McMurray JJV, Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity-Preserved (CHARM-Preserved) and the Irbesartan in Heart Failure with Preserved Systolic Function (I-Preserve)
Steering Committees. Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARMPreserved and I-Preserve trials. Eur Heart J 2017;38:742750.
637. Mehra MR, Vaduganathan M, Fu M, Ferreira JP, Anker SD, Cleland JGF, Lam
CSP, van Veldhuisen DJ, Byra WM, Spiro TE, Deng H, Zannad F, Greenberg B.
A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. Eur Heart J 2019;40:35933602.
638. Kotecha D, Chudasama R, Lane DA, Kirchhof P, Lip GY. Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: a systematic review and meta-analysis of death and adverse outcomes. Int J Cardiol
2016;203:660666.
639. Adelborg K, Szepligeti S, Sundboll J, Horvath-Puho E, Henderson VW, Ording
A, Pedersen L, Sorensen HT. Risk of stroke in patients with heart failure: a population-based 30-year cohort study. Stroke 2017;48:11611168.
640. Witt BJ, Brown RD Jr, Jacobsen SJ, Weston SA, Ballman KV, Meverden RA,
Roger VL. Ischemic stroke after heart failure: a community-based study. Am
Heart J 2006;152:102109.
641. Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR,
Ammon SE, Graham S, Sacco RL, Mann DL, Mohr JP, Massie BM, Labovitz AJ,
Anker SD, Lok DJ, Ponikowski P, Estol CJ, Lip GY, Di Tullio MR, Sanford AR,
Mejia V, Gabriel AP, del Valle ML, Buchsbaum R, WARCEF Investigators.
Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J
Med 2012;366:18591869.
642. Hopper I, Skiba M, Krum H. Updated meta-analysis on antithrombotic therapy in patients with heart failure and sinus rhythm. Eur J Heart Fail 2013;15:6978.
643. Bauersachs J, Konig T, van der Meer P, Petrie MC, Hilfiker-Kleiner D, Mbakwem
A, Hamdan R, Jackson AM, Forsyth P, de Boer RA, Mueller C, Lyon AR, Lund
LH, Piepoli MF, Heymans S, Chioncel O, Anker SD, Ponikowski P, Seferovic
PM, Johnson MR, Mebazaa A, Sliwa K. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart
Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail 2019;21:827843.
644. Singh DP, Patel H. Left ventricular non-compaction cardiomyopathy. In:
StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021; PMID
30725710.
645. Subahi A, Hassan AAI, Abubakar H, Ibrahim W. Isolated left ventricular noncompaction (LVNC) and recurrent strokes: to anticoagulate or not to anticoagulate, that is the question. BMJ Case Rep 2017;2017:bcr2017220954.
646. Seferovic PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J,
Paulus WJ, Komajda M, Cosentino F, de Boer RA, Farmakis D, Doehner W,
Lambrinou E, Lopatin Y, Piepoli MF, Theodorakis MJ, Wiggers H, Lekakis J,
Mebazaa A, Mamas MA, Tschope C, Hoes AW, Seferovic JP, Logue J,
McDonagh T, Riley JP, Milinkovic I, Polovina M, van Veldhuisen DJ, Lainscak M,
Maggioni AP, Ruschitzka F, McMurray JJV. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the
European Society of Cardiology. Eur J Heart Fail 2018;20:853872.
647. Seferovic PM, Coats AJS, Ponikowski P, Filippatos G, Huelsmann M, Jhund PS,
Polovina MM, Komajda M, Seferovic J, Sari I, Cosentino F, Ambrosio G, Metra
M, Piepoli M, Chioncel O, Lund LH, Thum T, De Boer RA, Mullens W, Lopatin
Y, Volterrani M, Hill L, Bauersachs J, Lyon A, Petrie MC, Anker S, Rosano
ESC Guidelines
3715


<!-- PAGE 118 -->

### Page 118

.............................................................................................................................................................................
GMC. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. Eur J Heart Fail 2020;22:196213.
648. Cosentino F, Cannon CP, Cherney DZI, Masiukiewicz U, Pratley R, DagogoJack S, Frederich R, Charbonnel B, Mancuso J, Shih WJ, Terra SG, Cater NB,
Gantz I, McGuire DK, VERTIS CV Investigators. Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial. Circulation
2020;142:22052215.
649. McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack
S, Pratley R, Greenberg M, Wang S, Huyck S, Gantz I, Terra SG, Masiukiewicz
U, Cannon CP. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol
2021;6:148158.
650. Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF,
de Boer RA, Drexel H, Ben Gal T, Hill L, Jaarsma T, Jankowska EA, Anker MS,
Lainscak M, Lewis BS, McDonagh T, Metra M, Milicic D, Mullens W, Piepoli MF,
Rosano G, Ruschitzka F, Volterrani M, Voors AA, Filippatos G, Coats AJS.
Clinical practice update on heart failure 2019: pharmacotherapy, procedures,
devices and patient management. An expert consensus meeting report of the
Heart Failure Association of the European Society of Cardiology. Eur J Heart
Fail 2019;21:11691186.
651. Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L,
Vanderloo SE, McAlister FA. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail 2013;6:395402.
652. Andersson C, Olesen JB, Hansen PR, Weeke P, Norgaard ML, Jorgensen CH,
Lange T, Abildstrom SZ, Schramm TK, Vaag A, Kober L, Torp-Pedersen C,
Gislason GH. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study.
Diabetologia 2010;53:25462553.
653. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P,
Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR,
Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I, SAVOR-TIMI 53
Steering
Committee and
Investigators.
Saxagliptin and cardiovascular outcomes in patients with type
2
diabetes mellitus.
N
Engl
J
Med
2013;369:13171326.
654. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR,
Mehta CR, Kupfer S, Wilson C, Lam H, White WB, EXAMINE Investigators.
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015;385:20672076.
655. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R,
Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E,
Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR, TECOS
Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes.
N Engl J Med 2015;373:232242.
656. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N,
Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra
D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK,
CARMELINA Investigators. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 2019;321:6979.
657. McMurray JJV, Ponikowski P, Bolli GB, Lukashevich V, Kozlovski P, Kothny W,
Lewsey JD, Krum H, VIVIDD Trial Committees and Investigators. Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure:
a randomized placebo-controlled trial.
JACC
Heart
Fail
2018;6:817.
658. Sinha B, Ghosal S. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2
inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Pract
2019;150:816.
659. Savarese G, D’Amore C, Federici M, De Martino F, Dellegrottaglie S, Marciano
C, Ferrazzano F, Losco T, Lund LH, Trimarco B, Rosano GM, Perrone-Filardi P.
Effects of dipeptidyl peptidase
4
inhibitors and sodium-glucose linked cotransporter-2 inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis. Int J Cardiol 2016;220:595601.
660. Kristensen SL, Rorth R, Jhund PS, Docherty KF, Sattar N, Preiss D, Kober L,
Petrie MC, McMurray JJV. Cardiovascular, mortality, and kidney outcomes with
GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol
2019;7:776785.
661. Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hanselmann A,
Nilsson B, Moller JE, Hjort J, Rasmussen J, Boesgaard TW, Schou M, Videbaek
L, Gustafsson I, Flyvbjerg A, Wiggers H, Tarnow L. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, doubleblind, randomised, placebo-controlled trial. Eur J Heart Fail 2017;19:6977.
662. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R,
Mann DL, Whellan DJ, Kiernan MS, Felker GM, McNulty SE, Anstrom KJ, Shah
MR, Braunwald E, Cappola TP, NHLBI Heart Failure Clinical Research
Network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA
2016;316:500508.
663. Gerstein HC, Jung H, Ryden L, Diaz R, Gilbert RE, Yusuf S, ORIGIN
Investigators. Effect of basal insulin glargine on first and recurrent episodes of heart failure hospitalization: the ORIGIN trial (Outcome Reduction With Initial
Glargine Intervention). Circulation 2018;137:8890.
664. Cosmi F, Shen L, Magnoli M, Abraham WT, Anand IS, Cleland JG, Cohn JN,
Cosmi D, De Berardis G, Dickstein K, Franzosi MG, Gullestad L, Jhund PS,
Kjekshus J, Kober L, Lepore V, Lucisano G, Maggioni AP, Masson S, McMurray
JJV, Nicolucci A, Petrarolo V, Robusto F, Staszewsky L, Tavazzi L, Teli R,
Tognoni G, Wikstrand J, Latini R. Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. Eur J Heart
Fail 2018;20:888895.
665. Shen L, Rorth R, Cosmi D, Kristensen SL, Petrie MC, Cosmi F, Latini R, Kober
L, Anand IS, Carson PE, Granger CB, Komajda M, McKelvie RS, Solomon SD,
Staszewsky L, Swedberg K, Huynh T, Zile MR, Jhund PS, McMurray JJV. Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. Eur J Heart Fail 2019;21:974984.
666. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti
K, Wilkins MR, Majeed A, Elliott P. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
BMJ 2009;339:b4731.
667. Roumie CL, Min JY, D’Agostino McGowan L, Presley C, Grijalva CG, Hackstadt
AJ, Hung AM, Greevy RA, Elasy T, Griffin MR. Comparative safety of sulfonylurea and metformin monotherapy on the risk of heart failure: a cohort study. J
Am Heart Assoc 2017;6.
668. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones:
a meta-analysis of randomised clinical trials. Lancet 2007;370:11291136.
669. Vargas-Uricoechea H, Bonelo-Perdomo A. Thyroid dysfunction and heart failure: mechanisms and associations. Curr Heart Fail Rep 2017;14:4858.
670. Kannan L, Shaw PA, Morley MP, Brandimarto J, Fang JC, Sweitzer NK, Cappola
TP, Cappola AR. Thyroid dysfunction in heart failure and cardiovascular outcomes. Circ Heart Fail 2018;11:e005266.
671. Sato Y, Yoshihisa A, Kimishima Y, Kiko T, Kanno Y, Yokokawa T, Abe S, Misaka
T, Sato T, Oikawa M, Kobayashi A, Yamaki T, Kunii H, Nakazato K, Takeishi Y.
Low T3 syndrome is associated with high mortality in hospitalized patients with heart failure. J Card Fail 2019;25:195203.
672. Stott DJ, Rodondi N, Kearney PM, Ford I, Westendorp RGJ, Mooijaart SP,
Sattar N, Aubert CE, Aujesky D, Bauer DC, Baumgartner C, Blum MR, Browne
JP, Byrne S, Collet TH, Dekkers OM, den Elzen WPJ, Du Puy RS, Ellis G, Feller
M, Floriani C, Hendry K, Hurley C, Jukema JW, Kean S, Kelly M, Krebs D,
Langhorne P, McCarthy G, McCarthy V, McConnachie A, McDade M, Messow
M, O’Flynn A, O’Riordan D, Poortvliet RKE, Quinn TJ, Russell A, Sinnott C,
Smit JWA, Van Dorland HA, Walsh KA, Walsh EK, Watt T, Wilson R,
Gussekloo J, TRUST Study Group. Thyroid hormone therapy for older adults with subclinical hypothyroidism. N Engl J Med 2017;376:25342544.
673. Feller M, Snel M, Moutzouri E, Bauer DC, de Montmollin M, Aujesky D, Ford I,
Gussekloo J, Kearney PM, Mooijaart S, Quinn T, Stott D, Westendorp R,
Rodondi N, Dekkers OM. Association of thyroid hormone therapy with quality of life and thyroid-related symptoms in patients with subclinical hypothyroidism:
a systematic review and meta-analysis. JAMA 2018;320:13491359.
674. Peeters RP. Subclinical hypothyroidism. N Engl J Med 2017;376:25562565.
675. Packer M, Lam CSP, Lund LH, Maurer MS, Borlaug BA. Characterization of the inflammatory-metabolic phenotype of heart failure and a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease. Eur J Heart Fail 2020;22:15511567.
676. Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 2017;136:619.
677. Rao VN, Fudim M, Mentz RJ, Michos ED, Felker GM. Regional adiposity and heart failure with preserved ejection fraction.
Eur
J
Heart
Fail
2020;22:15401550.
678. Carbone S, Lavie CJ, Arena R. Obesity and heart failure: focus on the obesity paradox. Mayo Clin Proc 2017;92:266279.
679. Horwich TB, Fonarow GC, Clark AL. Obesity and the obesity paradox in heart failure. Prog Cardiovasc Dis 2018;61:151156.
680. Adamopoulos C, Meyer P, Desai RV, Karatzidou K, Ovalle F, White M, Aban I,
Love TE, Deedwania P, Anker SD, Ahmed A. Absence of obesity paradox in


<!-- PAGE 119 -->

### Page 119

.............................................................................................................................................................................
patients with chronic heart failure and diabetes mellitus: a propensity-matched study. Eur J Heart Fail 2011;13:200206.
681. Zamora E, Lupon J, Enjuanes C, Pascual-Figal D, de Antonio M, Domingo M,
Comin-Colet J, Vila J, Penafiel J, Farre N, Alonso N, Santesmases J, Troya M,
Bayes-Genis A. No benefit from the obesity paradox for diabetic patients with heart failure. Eur J Heart Fail 2016;18:851858.
682. Piepoli MF, Corra U, Veglia F, Bonomi A, Salvioni E, Cattadori G, Metra M,
Lombardi C, Sinagra G, Limongelli G, Raimondo R, Re F, Magri D, Belardinelli
R, Parati G, Mina C, Scardovi AB, Guazzi M, Cicoira M, Scrutinio D, Di Lenarda
A, Bussotti M, Frigerio M, Correale M, Villani GQ, Paolillo S, Passino C,
Agostoni P, MECKI Score Research Group. Exercise tolerance can explain the obesity paradox in patients with systolic heart failure: data from the MECKI
Score Research Group. Eur J Heart Fail 2016;18:545553.
683. Streng KW, Voors AA, Hillege HL, Anker SD, Cleland JG, Dickstein K,
Filippatos G, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ,
Zwinderman AH, Zannad F, Damman K, van der Meer P, Lang CC. Waist-tohip ratio and mortality in heart failure. Eur J Heart Fail 2018;20:12691277.
684. Carbone S, Elagizi A, Lavie CJ. Obesity and mortality risk in heart failure: when adipose tissue distribution matters. Eur J Heart Fail 2018;20:12781280.
685. Packer M. Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment. Eur J Heart
Fail 2020;22:214227.
686. Vitale C, Jankowska E, Hill L, Piepoli M, Doehner W, Anker SD, Lainscak M,
Jaarsma T, Ponikowski P, Rosano GMC, Seferovic P, Coats AJ. Heart Failure
Association/European Society of Cardiology position paper on frailty in patients with heart failure. Eur J Heart Fail 2019;21:12991305.
687. Denfeld QE, Winters-Stone K, Mudd JO, Gelow JM, Kurdi S, Lee CS. The prevalence of frailty in heart failure: a systematic review and meta-analysis. Int J
Cardiol 2017;236:283289.
688. Bielecka-Dabrowa A, Ebner N, Dos Santos MR, Ishida J, Hasenfuss G, von
Haehling S. Cachexia, muscle wasting, and frailty in cardiovascular disease. Eur J
Heart Fail 2020;22:23142326.
689. Khan H, Kalogeropoulos AP, Georgiopoulou VV, Newman AB, Harris TB,
Rodondi N, Bauer DC, Kritchevsky SB, Butler J. Frailty and risk for heart failure in older adults: the health, aging, and body composition study. Am Heart J
2013;166:887894.
690. Woods NF, LaCroix AZ, Gray SL, Aragaki A, Cochrane BB, Brunner RL, Masaki
K, Murray A, Newman AB, Women’s Health Initiative. Frailty: emergence and consequences in women aged 65 and older in the Women’s Health Initiative
Observational Study. J Am Geriatr Soc 2005;53:13211330.
691. Vidan MT, Blaya-Novakova V, Sanchez E, Ortiz J, Serra-Rexach JA, Bueno H.
Prevalence and prognostic impact of frailty and its components in nondependent elderly patients with heart failure.
Eur
J
Heart
Fail
2016;18:869875.
692. Dewan P, Jackson A, Jhund PS, Shen L, Ferreira JP, Petrie MC, Abraham WT,
Desai AS, Dickstein K, Kober L, Packer M, Rouleau JL, Solomon SD, Swedberg
K, Zile MR, McMurray JJV. The prevalence and importance of frailty in heart failure with reduced ejection fraction – an analysis of PARADIGM-HF and
ATMOSPHERE. Eur J Heart Fail 2020;22:21232133.
693. Sanders NA, Supiano MA, Lewis EF, Liu J, Claggett B, Pfeffer MA, Desai AS,
Sweitzer NK, Solomon SD, Fang JC. The frailty syndrome and outcomes in the
TOPCAT trial. Eur J Heart Fail 2018;20:15701577.
694. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, Jatoi A,
Kalantar-Zadeh K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M,
Najand A, Ponikowski P, Rossi Fanelli F, Schambelan M, Schols A, Schuster M,
Thomas D, Wolfe R, Anker SD. Cachexia: a new definition. Clin Nutr
2008;27:793799.
695. Loncar G, Springer J, Anker M, Doehner W, Lainscak M. Cardiac cachexia: hic et nunc. J Cachexia Sarcopenia Muscle 2016;7:246260.
696. von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther 2009;121:227252.
697. Anker MS, Holcomb R, Muscaritoli M, von Haehling S, Haverkamp W, Jatoi A,
Morley JE, Strasser F, Landmesser U, Coats AJS, Anker SD. Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review. J Cachexia Sarcopenia Muscle 2019;10:2234.
698. Bauer J, Morley JE, Schols A, Ferrucci L, Cruz-Jentoft AJ, Dent E, Baracos VE,
Crawford JA, Doehner W, Heymsfield SB, Jatoi A, Kalantar-Zadeh K, Lainscak
M, Landi F, Laviano A, Mancuso M, Muscaritoli M, Prado CM, Strasser F, von
Haehling S, Coats AJS, Anker SD. Sarcopenia: a time for action. An SCWD
position paper. J Cachexia Sarcopenia Muscle 2019;10:956961.
699. Ameri P, Canepa M, Anker MS, Belenkov Y, Bergler-Klein J, Cohen-Solal A,
Farmakis D, Lopez-Fernandez T, Lainscak M, Pudil R, Ruschitska F, Seferovic P,
Filippatos G, Coats A, Suter T, Von Haehling S, Ciardiello F, de Boer RA, Lyon
AR, Tocchetti CG, Heart Failure Association Cardio-Oncology Study Group of the European Society of Cardiology. Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. Eur J Heart Fail
2018;20:879887.
700. Fonseca G, Dos Santos MR, de Souza FR, Takayama L, Rodrigues Pereira RM,
Negrao CE, Alves MNN. Discriminating sarcopenia in overweight/obese male patients with heart failure: the influence of body mass index. ESC Heart Fail
2020;7:8491.
701. Emami A, Saitoh M, Valentova M, Sandek A, Evertz R, Ebner N, Loncar G,
Springer J, Doehner W, Lainscak M, Hasenfuss G, Anker SD, von Haehling S.
Comparison of sarcopenia and cachexia in men with chronic heart failure:
results from the Studies Investigating Co-morbidities Aggravating Heart Failure
(SICA-HF). Eur J Heart Fail 2018;20:15801587.
702. Fulster S, Tacke M, Sandek A, Ebner N, Tschope C, Doehner W, Anker SD,
von Haehling S. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICAHF). Eur Heart J 2013;34:512519.
703. Springer J, Springer JI, Anker SD. Muscle wasting and sarcopenia in heart failure and beyond: update 2017. ESC Heart Fail 2017;4:492498.
704. von Haehling S, Ebner N, Dos Santos MR, Springer J, Anker SD. Muscle wasting and cachexia in heart failure: mechanisms and therapies. Nat Rev Cardiol
2017;14:323341.
705. Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M, Mammi C,
Piepoli M, Fini M, Rosano GM. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a doubleblind,
placebo-controlled,
randomized study.
J
Am
Coll
Cardiol
2009;54:919927.
706. Anand IS, Gupta P. Anemia and iron deficiency in heart failure: current concepts and emerging therapies. Circulation 2018;138:8098.
707. Iorio A, Senni M, Barbati G, Greene SJ, Poli S, Zambon E, Di Nora C, Cioffi G,
Tarantini L, Gavazzi A, Sinagra G, Di Lenarda A. Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study. Eur J Heart Fail
2018;20:12571266.
708. Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol 2011;58:12411251.
709. McDonagh T, Damy T, Doehner W, Lam CSP, Sindone A, van der Meer P,
Cohen-Solal A, Kindermann I, Manito N, Pfister O, Pohjantahti-Maaroos H,
Taylor J, Comin-Colet J. Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. Eur J Heart Fail 2018;20:16641672.
710. Cappellini MD, Comin-Colet J, de Francisco A, Dignass A, Doehner W, Lam
CS, Macdougall IC, Rogler G, Camaschella C, Kadir R, Kassebaum NJ, Spahn
DR, Taher AT, Musallam KM, IRON CORE Group. Iron deficiency across chronic inflammatory conditions: international expert opinion on definition,
diagnosis, and management. Am J Hematol 2017;92:10681078.
711. Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia.
Lancet 2016;387:907916.
712. Sierpinski R, Josiak K, Suchocki T, Wojtas-Polc K, Mazur G, Butrym A,
Rozentryt P, van der Meer P, Comin-Colet J, von Haehling S, Kosmala W,
Przewlocka-Kosmala M, Banasiak W, Nowak J, Voors AA, Anker SD, Cleland
JGF, Ponikowski P, Jankowska EA. High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality. Eur J Heart Fail 2020 Oct 27. doi: 10.1002/ejhf.2036 [Epub ahead of print].
713. Rocha BML, Cunha GJL, Falcao Menezes LF. The burden of iron deficiency in heart failure: therapeutic approach. J Am Coll Cardiol 2018;71:782793.
714. Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, Lok
DJ, Rosentryt P, Torrens A, Polonski L, van Veldhuisen DJ, van der Meer P,
Jankowska EA. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J 2013;165:575582.e3.
715. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska
B, Borodulin-Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JJ,
Anker SD, Ponikowski P. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010;31:18721880.
716. von Haehling S, Jankowska EA, van Veldhuisen DJ, Ponikowski P, Anker SD.
Iron deficiency and cardiovascular disease. Nat Rev Cardiol 2015;12:659669.
717. Stugiewicz M, Tkaczyszyn M, Kasztura M, Banasiak W, Ponikowski P, Jankowska
EA. The influence of iron deficiency on the functioning of skeletal muscles:
experimental evidence and clinical implications.
Eur
J
Heart
Fail
2016;18:762773.
718. Jankowska EA, Malyszko J, Ardehali H, Koc-Zorawska E, Banasiak W, von
Haehling S, Macdougall IC, Weiss G, McMurray JJ, Anker SD, Gheorghiade M,
Ponikowski P. Iron status in patients with chronic heart failure. Eur Heart J
2013;34:827834.
719. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP,
McMurray JJ, O’Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van
ESC Guidelines
3717


<!-- PAGE 120 -->

### Page 120

.............................................................................................................................................................................
Veldhuisen DJ, RED-HF Committees, RED-HF Investigators. Treatment of anemia with darbepoetin alfa in systolic heart failure.
N
Engl
J
Med
2013;368:12101219.
720. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler
H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von
Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P, FAIR-HF Trial
Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:24362448.
721. Comin-Colet J, Lainscak M, Dickstein K, Filippatos GS, Johnson P, Luscher TF,
Mori C, Willenheimer R, Ponikowski P, Anker SD. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. Eur Heart J
2013;34:3038.
722. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V,
McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B,
Filippatos G, Ruschitzka F, Anker SD, CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J
2015;36:657668.
723. van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Bohm M, Doletsky
A, Voors AA, Macdougall IC, Anker SD, Roubert B, Zakin L, Cohen-Solal A,
EFFECT-HF Investigators. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency.
Circulation
2017;136:13741383.
724. Jankowska EA, Tkaczyszyn M, Suchocki T, Drozd M, von Haehling S, Doehner
W, Banasiak W, Filippatos G, Anker SD, Ponikowski P. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail 2016;18:786795.
725. Anker SD, Kirwan BA, van Veldhuisen DJ, Filippatos G, Comin-Colet J,
Ruschitzka F, Luscher TF, Arutyunov GP, Motro M, Mori C, Roubert B, Pocock
SJ, Ponikowski P. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail 2018;20:125133.
726. Filippatos G, Farmakis D, Colet JC, Dickstein K, Luscher TF, Willenheimer R,
Parissis J, Gaudesius G, Mori C, von Eisenhart Rothe B, Greenlaw N, Ford I,
Ponikowski P, Anker SD. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the
FAIR-HF trial. Eur J Heart Fail 2013;15:12671276.
727. von Haehling S, Ebner N, Evertz R, Ponikowski P, Anker SD. Iron deficiency in heart failure: an overview. JACC Heart Fail 2019;7:3646.
728. Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM, Tang
WHW, LaRue SJ, Redfield MM, Semigran MJ, Givertz MM, Van Buren P,
Whellan D, Anstrom KJ, Shah MR, Desvigne-Nickens P, Butler J, Braunwald E,
NHLBI Heart Failure Clinical Research Network. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA
2017;317:19581966.
729. Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, Tang
WHW, Skouri H, Verbrugge FH, Orso F, Hill L, Ural D, Lainscak M, Rossignol
P, Metra M, Mebazaa A, Seferovic P, Ruschitzka F, Coats A. Evaluation of kidney function throughout the heart failure trajectory – a position statement from the
Heart Failure Association of the European Society of Cardiology. Eur J Heart
Fail 2020;22:584603.
730. Ter Maaten JM, Damman K, Verhaar MC, Paulus WJ, Duncker DJ, Cheng C, van
Heerebeek L, Hillege HL, Lam CS, Navis G, Voors AA. Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. Eur J Heart Fail 2016;18:588598.
731. van der Pol A, van Gilst WH, Voors AA, van der Meer P. Treating oxidative stress in heart failure:
past,
present and future.
Eur
J
Heart
Fail
2019;21:425435.
732. Lofman I, Szummer K, Dahlstrom U, Jernberg T, Lund LH. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved,
mid-range, and reduced ejection fraction. Eur J Heart Fail 2017;19:16061614.
733. Lofman I, Szummer K, Evans M, Carrero JJ, Lund LH, Jernberg T. Incidence of,
associations with and prognostic impact of worsening renal function in heart failure with different ejection fraction categories.
Am
J
Cardiol
2019;124:15751583.
734. Schefold JC, Filippatos G, Hasenfuss G, Anker SD, von Haehling S. Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev
Nephrol 2016;12:610623.
735. Damman K, Valente MA, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege
HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 2014;35:455469.
736. Braunwald E. Diabetes, heart failure, and renal dysfunction: the vicious circles.
Prog Cardiovasc Dis 2019;62:298302.
737. Zannad F, Ferreira JP, Pocock SJ, Zeller C, Anker SD, Butler J, Filippatos G,
Hauske SJ, Brueckmann M, Pfarr E, Schnee J, Wanner C, Packer M. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-Reduced. Circulation 2021;143:310321.
738. Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou
FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjostrom CD, Toto RD,
Langkilde AM, Wheeler DC, DAPA-CKD Trial Committees and Investigators.
Dapagliflozin in patients with chronic kidney disease.
N
Engl
J
Med
2020;383:14361446.
739. Metra M, Davison B, Bettari L, Sun H, Edwards C, Lazzarini V, Piovanelli B,
Carubelli V, Bugatti S, Lombardi C, Cotter G, Dei Cas L. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail
2012;5:5462.
740. Testani JM, Kimmel SE, Dries DL, Coca SG. Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction.
Circ
Heart
Fail
2011;4:685691.
741. Damman K, Tang WH, Felker GM, Lassus J, Zannad F, Krum H, McMurray JJ.
Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data. J Am Coll
Cardiol 2014;63:853871.
742. House AA. Management of heart failure in advancing CKD: core curriculum
2018. Am J Kidney Dis 2018;72:284295.
743. Kotecha D, Gill SK, Flather MD, Holmes J, Packer M, Rosano G, Bohm M,
McMurray JJV, Wikstrand J, Anker SD, van Veldhuisen DJ, Manzano L, von
Lueder TG, Rigby AS, Andersson B, Kjekshus J, Wedel H, Ruschitzka F, Cleland
JGF, Damman K, Redon J, Coats AJS, Beta-Blockers in Heart Failure
Collaborative Group. Impact of renal impairment on beta-blocker efficacy in patients with heart failure. J Am Coll Cardiol 2019;74:28932904.
744. Jhund PS, Solomon SD, Docherty KF, Heerspink HJL, Anand IS, Bohm M,
Chopra V, de Boer RA, Desai AS, Ge J, Kitakaze M, Merkley B, O’Meara E,
Shou M, Tereshchenko S, Verma S, Vinh PN, Inzucchi SE, Kober L, Kosiborod
MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Langkilde AM,
Sjostrand M, McMurray JJV. Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of
DAPA-HF. Circulation 2021;143:298309.
745. Boerrigter G, Costello-Boerrigter LC, Abraham WT, Sutton MG, Heublein DM,
Kruger KM, Hill MR, McCullough PA, Burnett JC Jr. Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate. J Card Fail 2008;14:539546.
746. Roehm B, Vest AR, Weiner DE. Left ventricular assist devices kidney disease and dialysis. Am J Kidney Dis 2018;71:257266.
747. Goldenberg I, Moss AJ, McNitt S, Zareba W, Andrews ML, Hall WJ, Greenberg
H,
Case
RB,
Multicenter
Automatic
Defibrillator
Implantation
Trial-II
Investigators. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction. Am J Cardiol 2006;98:485490.
748. Goldenberg I, Younis A, Aktas MK, McNitt S, Zareba W, Kutyifa V. Competing risk analysis of ventricular arrhythmia events in heart failure patients with moderately compromised renal dysfunction. Europace 2020;22:13841390.
749. Coiro S, Girerd N, Sharma A, Rossignol P, Tritto I, Pitt B, Pfeffer MA,
McMurray JJV, Ambrosio G, Dickstein K, Moss A, Zannad F. Association of diabetes and kidney function according to age and systolic function with the incidence of sudden cardiac death and non-sudden cardiac death in myocardial infarction survivors with heart failure. Eur J Heart Fail 2019;21:12481258.
750. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams
KF, Anand I, Arias-Mendoza A, Biering-Sorensen T, Bohm M, Bonderman D,
Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlstrom U, Echeverria Correa
LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG,
Lanfear DE, Lund M, Macdonald P, Mareev V, Momomura SI, O’Meara E,
Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter
TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB,
Zannad F, Sharpsten L, Legg JC, Abbasi SA, Varin C, Malik FI, Kurtz CE,
GALACTIC-HF Investigators. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. Eur J Heart Fail 2020;22:21602171.
751. Urso C, Brucculeri S, Caimi G. Acid-base and electrolyte abnormalities in heart failure: pathophysiology and implications. Heart Fail Rev 2015;20:493503.
752. Butler J, Vijayakumar S, Pitt B. Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists. Eur J Heart Fail 2018;20:12471251.
753. Vardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F, Pitt B,
Solomon SD, Randomized Aldactone Evaluation Study (RALES) Investigators.
Incidence, predictors, and outcomes related to hypo- and hyperkalemia in


<!-- PAGE 121 -->

### Page 121

.............................................................................................................................................................................
patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail 2014;7:573579.
754. Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ,
Shi H, Messig M, Vincent J, Girerd N, Bakris G, Pitt B, Zannad F. Incidence,
determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy:
results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail 2014;7:5158.
755. Nunez J, Bayes-Genis A, Zannad F, Rossignol P, Nunez E, Bodi V, Minana G,
Santas E, Chorro FJ, Mollar A, Carratala A, Navarro J, Gorriz JL, Lupon J,
Husser O, Metra M, Sanchis J. Long-term potassium monitoring and dynamics in heart failure and risk of mortality. Circulation 2018;137:13201330.
756. Linde C, Qin L, Bakhai A, Furuland H, Evans M, Ayoubkhani D, Palaka E,
Bennett H, McEwan P. Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK. ESC Heart Fail
2019;6:280290.
757. Cooper LB, Benson L, Mentz RJ, Savarese G, DeVore AD, Carrero JJ,
Dahlstrom U, Anker SD, Lainscak M, Hernandez AF, Pitt B, Lund LH.
Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure
Registry. Eur J Heart Fail 2020;22:13901398.
758. Rossignol P, Lainscak M, Crespo-Leiro MG, Laroche C, Piepoli MF, Filippatos G,
Rosano GMC, Savarese G, Anker SD, Seferovic PM, Ruschitzka F, Coats AJS,
Mebazaa A, McDonagh T, Sahuquillo A, Penco M, Maggioni AP, Lund LH, Heart
Failure Long-Term Registry Investigators Group. Unravelling the interplay between hyperkalaemia,
renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESCHFA-EORP
Heart
Failure
Long-Term
Registry.
Eur
J
Heart
Fail
2020;22:13781389.
759. Ahmed A, Zannad F, Love TE, Tallaj J, Gheorghiade M, Ekundayo OJ, Pitt B. A
propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur Heart J 2007;28:13341343.
760. Rosano GMC, Tamargo J, Kjeldsen KP, Lainscak M, Agewall S, Anker SD,
Ceconi C, Coats AJS, Drexel H, Filippatos G, Kaski JC, Lund L, Niessner A,
Ponikowski P, Savarese G, Schmidt TA, Seferovic P, Wassmann S, Walther T,
Lewis BS. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular
Pharmacotherapy of the European Society of Cardiology. Eur Heart J Cardiovasc
Pharmacother 2018;4:180188.
761. Ferreira JP, Mogensen UM, Jhund PS, Desai AS, Rouleau JL, Zile MR, Rossignol
P, Zannad F, Packer M, Solomon SD, McMurray JJV. Serum potassium in the
PARADIGM-HF trial. Eur J Heart Fail 2020;22:20562064.
762. Rossignol P, Duarte K, Girerd N, Karoui M, McMurray JJV, Swedberg K, van
Veldhuisen DJ, Pocock S, Dickstein K, Zannad F, Pitt B. Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction. Eur
J Heart Fail 2020;22:14021411.
763. Desai AS, Liu J, Pfeffer MA, Claggett B, Fleg J, Lewis EF, McKinlay S, O’Meara E,
Shah SJ, Sweitzer NK, Solomon S, Pitt B. Incident hyperkalemia, hypokalemia,
and clinical outcomes during spironolactone treatment of heart failure with preserved ejection fraction:
analysis of the
TOPCAT
trial.
J
Card
Fail
2018;24:313320.
764. Desai AS. Hyperkalemia in patients with heart failure: incidence, prevalence,
and management. Curr Heart Fail Rep 2009;6:272280.
765. Savarese G, Xu H, Trevisan M, Dahlstrom U, Rossignol P, Pitt B, Lund LH,
Carrero JJ. Incidence, predictors, and outcome associations of dyskalemia in heart failure with preserved, mid-range, and reduced ejection fraction. JACC
Heart Fail 2019;7:6576.
766. Rosano GMC, Spoletini I, Agewall S. Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate. Eur Heart J Suppl
2019;21:A28A33.
767. Anker SD, Kosiborod M, Zannad F, Pina IL, McCullough PA, Filippatos G, van der Meer P, Ponikowski P, Rasmussen HS, Lavin PT, Singh B, Yang A,
Deedwania P. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, doubleblind, placebo-controlled trial. Eur J Heart Fail 2015;17:10501056.
768. Pitt B, Bakris GL, Bushinsky DA, Garza D, Mayo MR, Stasiv Y, Christ-Schmidt
H, Berman L, Weir MR. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail 2015;17:10571065.
769. Trevisan M, de Deco P, Xu H, Evans M, Lindholm B, Bellocco R, Barany P,
Jernberg T, Lund LH, Carrero JJ. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur J
Heart Fail 2018;20:12171226.
770. Ferreira JP, Rossello X, Pocock SJ, Rossignol P, Claggett BL, Rouleau JL,
Solomon SD, Pitt B, Pfeffer MA, Zannad F. Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT. Eur J Heart Fail
2020;22:16151624.
771. Volterrani M, Perrone V, Sangiorgi D, Giacomini E, Iellamo F, Degli Esposti L,
LHUs Study Group. Effects of hyperkalaemia and non-adherence to reninangiotensin-aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity-matched study. Eur J Heart Fail 2020;22:20492055.
772. Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ,
Investigators PEARL-HF. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 2011;32:820828.
773. Pitt B, Bakris GL, Weir MR, Freeman MW, Lainscak M, Mayo MR, Garza D,
Zawadzki R, Berman L, Bushinsky DA. Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers:
results from AMETHYST-DN. ESC Heart Fail 2018;5:592602.
774. Agarwal R, Rossignol P, Romero A, Garza D, Mayo MR, Warren S, Ma J, White
WB, Williams B. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase
2,
randomised,
double-blind,
placebo-controlled trial.
Lancet
2019;394:15401550.
775. Rossignol P, Williams B, Mayo MR, Warren S, Arthur S, Ackourey G, White
WB, Agarwal R. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER):
results in the pre-specified subgroup with heart failure. Eur J Heart Fail
2020;22:14621471.
776. Pitt B, Bushinsky DA, Kitzman DW, Ruschitzka F, Metra M, Filippatos G,
Rossignol P, Du Mond C, Garza D, Berman L, Lainscak M, Patiromer
Investigators. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. ESC Heart Fail 2018;5:257266.
777. Ali W, Bakris G. Evolution of patiromer use: a review. Curr Cardiol Rep
2020;22:94.
778. Farmakis D, Filippatos G, Parissis J, Kremastinos DT, Gheorghiade M.
Hyponatremia in heart failure. Heart Fail Rev 2009;14:5963.
779. Rodriguez M, Hernandez M, Cheungpasitporn
W, Kashani KB,
Riaz I,
Rangaswami J, Herzog E, Guglin M, Krittanawong C. Hyponatremia in heart failure: pathogenesis and management. Curr Cardiol Rev 2019;15:252261.
780. Albert NM, Nutter B, Forney J, Slifcak E, Tang WH. A randomized controlled pilot study of outcomes of strict allowance of fluid therapy in hyponatremic heart failure (SALT-HF). J Card Fail 2013;19:19.
781. Dunlap ME, Hauptman PJ, Amin AN, Chase SL, Chiodo JA, 3rd, Chiong JR,
Dasta JF. Current management of hyponatremia in acute heart failure: a report from the
Hyponatremia
Registry for
Patients
With
Euvolemic and
Hypervolemic Hyponatremia (HN Registry). J Am Heart Assoc 2017;6:e005261.
782. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg
K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C, Efficacy of
Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan
(EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure:
the
EVEREST
Outcome
Trial.
JAMA
2007;297:13191331.
783. Felker GM, Mentz RJ, Cole RT, Adams KF, Egnaczyk GF, Fiuzat M, Patel CB,
Echols M, Khouri MG, Tauras JM, Gupta D, Monds P, Roberts R, O’Connor
CM. Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure. J Am Coll Cardiol 2017;69:13991406.
784. Matsue Y, Ter Maaten JM, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y,
Fujii H, Kitai T, Nishioka T, Sugi K, Onishi Y, Noda M, Kagiyama N, Satoh Y,
Yoshida K, van der Meer P, Damman K, Voors AA, Goldsmith SR. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction. Clin Res Cardiol 2017;106:802812.
785. Konstam MA, Kiernan M, Chandler A, Dhingra R, Mody FV, Eisen H, Haught
WH, Wagoner L, Gupta D, Patten R, Gordon P, Korr K, Fileccia R, Pressler SJ,
Gregory D, Wedge P, Dowling D, Romeling M, Konstam JM, Massaro JM,
Udelson JE, SECRET of CHF Investigators, Coordinators, and Committee
Members. Short-term effects of tolvaptan in patients with acute heart failure and volume overload. J Am Coll Cardiol 2017;69:14091419.
786. Licata G, Di Pasquale P, Parrinello G, Cardinale A, Scandurra A, Follone G,
Argano C, Tuttolomondo A, Paterna S. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
Am Heart J 2003;145:459466.
787. Paterna S, Di Pasquale P, Parrinello G, Amato P, Cardinale A, Follone G,
Giubilato A, Licata G. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure. Eur J Heart Fail 2000;2:305313.
ESC Guidelines
3719


<!-- PAGE 122 -->

### Page 122

.............................................................................................................................................................................
788. Griffin M, Soufer A, Goljo E, Colna M, Rao VS, Jeon S, Raghavendra P,
D’Ambrosi J, Riello R, Coca SG, Mahoney D, Jacoby D, Ahmad T, Chen M,
Tang WHW, Turner J, Mullens W, Wilson FP, Testani JM. Real world use of hypertonic saline in refractory acute decompensated heart failure: a U.S. center’s experience. JACC Heart Fail 2020;8:199208.
789. Cuthbert JJ, Pellicori P, Rigby A, Pan D, Kazmi S, Shah P, Clark AL. Low serum chloride in patients with chronic heart failure: clinical associations and prognostic significance. Eur J Heart Fail 2018;20:14261435.
790. Testani JM, Hanberg JS, Arroyo JP, Brisco MA, Ter Maaten JM, Wilson FP,
Bellumkonda L, Jacoby D, Tang WH, Parikh CR. Hypochloraemia is strongly and independently associated with mortality in patients with chronic heart failure. Eur J Heart Fail 2016;18:660668.
791. Marchenko R, Sigal A, Wasser TE, Reyer J, Green J, Mercogliano C, Khan MS,
Donato AA. Hypochloraemia and 30 day readmission rate in patients with acute decompensated heart failure. ESC Heart Fail 2020;7:903907.
792. Grodin JL, Simon J, Hachamovitch R, Wu Y, Jackson G, Halkar M, Starling RC,
Testani JM, Tang WH. Prognostic role of serum chloride levels in acute decompensated heart failure. J Am Coll Cardiol 2015;66:659666.
793. Hanberg JS, Rao V, Ter Maaten JM, Laur O, Brisco MA, Perry Wilson F, Grodin
JL, Assefa M, Samuel Broughton J, Planavsky NJ, Ahmad T, Bellumkonda L, Tang
WH, Parikh CR, Testani JM. Hypochloremia and diuretic resistance in heart failure: mechanistic insights. Circ Heart Fail 2016;9.
794. Verbrugge FH, Martens P, Ameloot K, Haemels V, Penders J, Dupont M, Tang
WHW, Droogne W, Mullens W. Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance. Eur J Heart Fail
2019;21:14151422.
795. Axson EL, Ragutheeswaran K, Sundaram V, Bloom CI, Bottle A, Cowie MR,
Quint JK. Hospitalisation and mortality in patients with comorbid COPD and heart failure: a systematic review and meta-analysis. Respir Res 2020;21:54.
796. Canepa M, Straburzynska-Migaj E, Drozdz J, Fernandez-Vivancos C, Pinilla JMG,
Nyolczas N, Temporelli PL, Mebazaa A, Lainscak M, Laroche C, Maggioni AP,
Piepoli MF, Coats AJS, Ferrari R, Tavazzi L, ESC-HFA Heart Failure Long-Term
Registry Investigators. Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term
Registry. Eur J Heart Fail 2018;20:100110.
797. Uijl A, Koudstaal S, Direk K, Denaxas S, Groenwold RHH, Banerjee A, Hoes
AW, Hemingway H, Asselbergs FW. Risk factors for incident heart failure in age- and sex-specific strata: a population-based cohort using linked electronic health records. Eur J Heart Fail 2019;21:11971206.
798. Caravita S, Vachiery JL. Obstructive ventilatory disorder in heart failure–caused by the heart or the lung? Curr Heart Fail Rep 2016;13:310318.
799. Magnussen H, Canepa M, Zambito PE, Brusasco V, Meinertz T, Rosenkranz S.
What can we learn from pulmonary function testing in heart failure? Eur J Heart
Fail 2017;19:12221229.
800. Canepa M, Franssen FME, Olschewski H, Lainscak M, Bohm M, Tavazzi L,
Rosenkranz
S.
Diagnostic and therapeutic gaps in patients with heart failure and chronic obstructive pulmonary disease.
JACC
Heart
Fail
2019;7:823833.
801. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2020 report. https://goldcopd.org/wp-content/uploads/2019/12/GOLD2020-FINAL-ver1.2-03Dec19_WMV.pdf (31 May 2020).
802. Global Initiative for Asthma. Global Strategy for Asthma Management and
Prevention, 2019. www.ginasthma.org (28 May 2021).
803. Brook RD, Anderson JA, Calverley PM, Celli BR, Crim C, Denvir MA, Magder S,
Martinez FJ, Rajagopalan S, Vestbo J, Yates J, Newby DE, SUMMIT Investigators.
Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. Heart 2017;103:15361542.
804. Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, Martinez F,
Yates J, Newby DE, SUMMIT Investigators. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet
2016;387:18171826.
805. Hohlfeld JM, Vogel-Claussen J, Biller H, Berliner D, Berschneider K, Tillmann
HC, Hiltl S, Bauersachs J, Welte T. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD
(CLAIM): a double-blind, randomised, crossover, placebo-controlled, singlecentre trial. Lancet Respir Med 2018;6:368378.
806. Pearse SG, Cowie MR. Sleep-disordered breathing in heart failure. Eur J Heart
Fail 2016;18:353361.
807. Cowie MR, Gallagher AM. Sleep disordered breathing and heart failure: what does the future hold? JACC Heart Fail 2017;5:715723.
808. Cowie MR, Woehrle H, Wegscheider K, Angermann C, d’Ortho MP, Erdmann
E, Levy P, Simonds AK, Somers VK, Zannad F, Teschler H. Adaptive servoventilation for central sleep apnea in systolic heart failure. N Engl J Med
2015;373:10951105.
809. Costanzo MR, Ponikowski P, Javaheri S, Augostini R, Goldberg L, Holcomb R,
Kao A, Khayat RN, Oldenburg O, Stellbrink C, Abraham WT, remede´ System
Pivotal Trial Study Group. Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial. Lancet 2016;388:974982.
810. Costanzo MR, Ponikowski P, Coats A, Javaheri S, Augostini R, Goldberg LR,
Holcomb R, Kao A, Khayat RN, Oldenburg O, Stellbrink C, McKane S,
Abraham WT, remede´ System Pivotal Trial Study Group. Phrenic nerve stimulation to treat patients with central sleep apnoea and heart failure. Eur J Heart
Fail 2018;20:17461754.
811. Kjekshus J, Apetrei E, Barrios V, Bo¨hm M, Cleland JG, Cornel JH, Dunselman P,
Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Janosi A,
Kamensky G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ,
Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F,
Wedel H, Wikstrand J, CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:22482261.
812. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D,
Nicolosi GL, Porcu M, Tognoni G, GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, doubleblind, placebo-controlled trial. Lancet 2008;372:12311239.
813. Al-Gobari M, Le HH, Fall M, Gueyffier F, Burnand B. No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: a meta-analysis of randomized controlled trials. PLoS One
2017;12:e0171168.
814. Rogers JK, Jhund PS, Perez AC, Bohm M, Cleland JG, Gullestad L, Kjekshus J,
van Veldhuisen DJ, Wikstrand J, Wedel H, McMurray JJ, Pocock SJ. Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA trial
(Controlled Rosuvastatin Multinational Trial in Heart Failure). JACC Heart Fail
2014;2:289297.
815. Feinstein MJ, Jhund P, Kang J, Ning H, Maggioni A, Wikstrand J, Kjekshus J,
Tavazzi L, McMurray J, Lloyd-Jones DM. Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. Eur J Heart Fail 2015;17:434441.
816. Thanassoulis G, Brophy JM, Richard H, Pilote L. Gout, allopurinol use, and heart failure outcomes. Arch Intern Med 2010;170:13581364.
817. Borghi C, Palazzuoli A, Landolfo M, Cosentino E. Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure. Heart Fail Rev
2020;25:4351.
818. Doehner W, Springer J, Landmesser U, Struthers AD, Anker SD. Uric acid in chronic heart failure–current pathophysiological concepts. Eur J Heart Fail
2008;10:12691270.
819. Huang H, Huang B, Li Y, Huang Y, Li J, Yao H, Jing X, Chen J, Wang J. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail
2014;16:1524.
820. White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B,
Castillo M, Gunawardhana L, CARES Investigators. Cardiovascular safety of febuxostat or allopurinol in patients with gout.
N
Engl
J
Med
2018;378:12001210.
821. Hare JM, Mangal B, Brown J, Fisher C, Jr., Freudenberger R, Colucci WS, Mann
DL, Liu P, Givertz MM, Schwarz RP, OPT-CHF Investigators. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J
Am Coll Cardiol 2008;51:23012309.
822. Ogino K, Kato M, Furuse Y, Kinugasa Y, Ishida K, Osaki S, Kinugawa T, Igawa O,
Hisatome I, Shigemasa C, Anker SD, Doehner W. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail 2010;3:7381.
823. Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, Tang
WH, Dunlap ME, LeWinter MM, Mann DL, Felker GM, O’Connor CM,
Goldsmith SR, Ofili EO, Saltzberg MT, Margulies KB, Cappola TP, Konstam MA,
Semigran MJ, McNulty SE, Lee KL, Shah MR, Hernandez AF, NHLBI Heart
Failure Clinical Research Network. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the Xanthine Oxidase Inhibition for
Hyperuricemic
Heart
Failure
Patients
(EXACT-HF)
study.
Circulation
2015;131:17631771.
824. Verma S, Eikelboom JW, Nidorf SM, Al-Omran M, Gupta N, Teoh H, Friedrich
JO. Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 2015;15:96.
825. Frommeyer G, Krawczyk J, Dechering DG, Kochhauser S, Leitz P, Fehr M,
Eckardt L. Colchicine increases ventricular vulnerability in an experimental whole-heart model. Basic Clin Pharmacol Toxicol 2017;120:505508.
826. Arfe A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, Schink T,
Garbe E, Herings R, Straatman H, Schade R, Villa M, Lucchi S, Valkhoff V,
Romio S, Thiessard F, Schuemie M, Pariente A, Sturkenboom M, Corrao G,
Safety of Non-steroidal Anti-inflammatory Drugs Project Consortium. Non3720
ESC Guidelines


<!-- PAGE 123 -->

### Page 123

.............................................................................................................................................................................
steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ 2016;354:i4857.
827. Khalid Y, Dasu N, Shah A, Brown K, Kaell A, Levine A, Dasu K, Raminfard A.
Incidence of congestive heart failure in rheumatoid arthritis: a review of literature and meta-regression analysis. ESC Heart Fail 2020;7:37453753.
828. Mantel A, Holmqvist M, Andersson DC, Lund LH, Askling J. Association between rheumatoid arthritis and risk of ischemic and nonischemic heart failure. J Am Coll Cardiol 2017;69:12751285.
829. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, Anti-TNF Therapy
Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure:
results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH)
trial. Circulation 2003;107:31333140.
830. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J,
Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van
Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T.
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation
2004;109:15941602.
831. Kotyla PJ. Bimodal function of anti-TNF treatment: shall we be concerned about anti-TNF treatment in patients with rheumatoid arthritis and heart failure? Int J
Mol Sci 2018;19:1739.
832. Baumhakel M, Schlimmer N, Kratz M, Hackett G, Jackson G, Bohm M.
Cardiovascular risk, drugs and erectile function–a systematic analysis. Int J Clin
Pract 2011;65:289298.
833. Jaarsma T. Sexual function of patients with heart failure: facts and numbers. ESC
Heart Fail 2017;4:37.
834. Levine AB, Punihaole D, Levine TB. Characterization of the role of nitric oxide and its clinical applications. Cardiology 2012;122:5568.
835. Giannetta E, Feola T, Gianfrilli D, Pofi R, Dall’Armi V, Badagliacca R, Barbagallo
F, Lenzi A, Isidori AM. Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials. BMC Med
2014;12:185.
836. Angermann CE, Ertl G. Depression, anxiety, and cognitive impairment: comorbid mental health disorders in heart failure.
Curr
Heart
Fail
Rep
2018;15:398410.
837. Sbolli M, Fiuzat M, Cani D, O’Connor CM. Depression and heart failure: the lonely comorbidity. Eur J Heart Fail 2020;22:20072017.
838. Jha MK, Qamar A, Vaduganathan M, Charney DS, Murrough JW. Screening and management of depression in patients with cardiovascular disease: JACC stateof-the-art review. J Am Coll Cardiol 2019;73:18271845.
839. Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ,
Czajkowski SM, DeBusk R, Hosking J, Jaffe A, Kaufmann PG, Mitchell P, Norman
J, Powell LH, Raczynski JM, Schneiderman N, Enhancing Recovery in Coronary
Heart Disease Patients Investigators. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the
Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) randomized trial. JAMA 2003;289:31063116.
840. O’Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD,
Zakhary B, Stough WG, Arias RM, Rivelli SK, Krishnan R, SADHART-CHF
Investigators. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and
Heart
Disease in
Chronic
Heart
Failure)
trial.
J
Am
Coll
Cardiol
2010;56:692699.
841. Angermann CE, Gelbrich G, Stork S, Gunold H, Edelmann F, Wachter R,
Schunkert H, Graf T, Kindermann I, Haass M, Blankenberg S, Pankuweit S,
Prettin C, Gottwik M, Bohm M, Faller H, Deckert J, Ertl G, MOOD-HF Study
Investigators and Committee Members. Effect of escitalopram on all-cause mortality and hospitalization in patients with heart failure and depression: the
MOOD-HF randomized clinical trial. JAMA 2016;315:26832693.
842. de Boer RA, Meijers WC, van der Meer P, van Veldhuisen DJ. Cancer and heart disease: associations and relations. Eur J Heart Fail 2019;21:15151525.
843. Farmakis D, Mantzourani M, Filippatos G. Anthracycline-induced cardiomyopathy: secrets and lies. Eur J Heart Fail 2018;20:907909.
844. Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R,
Galderisi M, Habib G, Lenihan DJ, Lip GY, Lyon AR, Lopez Fernandez T, Mohty
D, Piepoli MF, Tamargo J, Torbicki A, Suter TM, Zamorano JL, Aboyans V,
Achenbach S, Agewall S, Badimon L, Baron-Esquivias G, Baumgartner H, Bax JJ,
Bueno H, Carerj S, Dean V, Erol C, Fitzsimons D, Gaemperli O, Kirchhof P,
Kolh P, Lancellotti P, Lip GY, Nihoyannopoulos P, Piepoli MF, Ponikowski P,
Roffi M, Torbicki A, Vaz Carneiro A, Windecker S, Authors/Task Force
Members, ESC Committee for Practice Guidelines, Document Reviewers. 2016
ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task
Force for cancer treatments and cardiovascular toxicity of the European
Society of Cardiology (ESC). Eur J Heart Fail 2017;19:942.
845. Zamorano JL, Gottfridsson C, Asteggiano R, Atar D, Badimon L, Bax JJ,
Cardinale D, Cardone A, Feijen EAM, Ferdinandy P, Lopez-Fernandez T, Gale
CP, Maduro JH, Moslehi J, Omland T, Plana Gomez JC, Scott J, Suter TM,
Minotti
G.
The cancer patient and cardiology.
Eur
J
Heart
Fail
2020;22:22902309.
846. Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A,
Tocchetti CG, Moslehi JJ, Groarke JD, Bergler-Klein J, Khoo V, Tan LL, Anker
MS, von Haehling S, Maack C, Pudil R, Barac A, Thavendiranathan P, Ky B,
Neilan TG, Belenkov Y, Rosen SD, Iakobishvili Z, Sverdlov AL, Hajjar LA,
Macedo AVS, Manisty C, Ciardiello F, Farmakis D, de Boer RA, Skouri H, Suter
TM, Cardinale D, Witteles RM, Fradley MG, Herrmann J, Cornell RF,
Wechelaker A, Mauro MJ, Milojkovic D, de Lavallade H, Ruschitzka F, Coats
AJS, Seferovic PM, Chioncel O, Thum T, Bauersachs J, Andres MS, Wright DJ,
Lopez-Fernandez T, Plummer C, Lenihan D. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology
Study Group of the Heart Failure Association of the European Society of
Cardiology in collaboration with the International Cardio-Oncology Society.
Eur J Heart Fail 2020;22:19451960.
847. Ganatra S, Carver JR, Hayek SS, Ky B, Leja MJ, Lenihan DJ, Lenneman C,
Mousavi N, Park JH, Perales MA, Ryan TD, Scherrer-Crosbie M, Steingart RM,
Yang EH, Zaha V, Barac A, Liu JE. Chimeric antigen receptor T-cell therapy for cancer and heart:
JACC
council perspectives.
J
Am
Coll
Cardiol
2019;74:31533163.
848. Lenneman CG, Sawyer DB. Cardio-oncology: an update on cardiotoxicity of cancer-related treatment. Circ Res 2016;118:10081020.
849. Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol 2018;19:e447e458.
850. Boekel NB, Duane FK, Jacobse JN, Hauptmann M, Schaapveld M, Sonke GS,
Gietema JA, Hooning MJ, Seynaeve CM, Maas A, Darby SC, Aleman BMP,
Taylor CW, van Leeuwen FE. Heart failure after treatment for breast cancer.
Eur J Heart Fail 2020;22:366374.
851. Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol 2014;63:945953.
852. Tromp J, Boerman LM, Sama IE, Maass S, Maduro JH, Hummel YM, Berger MY,
de Bock GH, Gietema JA, Berendsen AJ, van der Meer P. Long-term survivors of early breast cancer treated with chemotherapy are characterized by a proinflammatory biomarker profile compared to matched controls. Eur J Heart Fail
2020;22:12391246.
853. Hasin T, Gerber Y, Weston SA, Jiang R, Killian JM, Manemann SM, Cerhan JR,
Roger VL. Heart failure after myocardial infarction is associated with increased risk of cancer. J Am Coll Cardiol 2016;68:265271.
854. Banke A, Schou M, Videbaek L, Moller JE, Torp-Pedersen C, Gustafsson F, Dahl
JS, Kober L, Hildebrandt PR, Gislason GH. Incidence of cancer in patients with chronic heart failure:
a long-term follow-up study.
Eur
J
Heart
Fail
2016;18:260266.
855. Meijers WC, de Boer RA. Common risk factors for heart failure and cancer.
Cardiovasc Res 2019;115:844853.
856. de Boer RA, Hulot JS, Tocchetti CG, Aboumsallem JP, Ameri P, Anker SD,
Bauersachs J, Bertero E, Coats AJS, Celutkiene J, Chioncel O, Dodion P,
Eschenhagen T, Farmakis D, Bayes-Genis A, Jager D, Jankowska EA, Kitsis RN,
Konety SH, Larkin J, Lehmann L, Lenihan DJ, Maack C, Moslehi JJ, Muller OJ,
Nowak-Sliwinska P, Piepoli MF, Ponikowski P, Pudil R, Rainer PP, Ruschitzka F,
Sawyer D, Seferovic PM, Suter T, Thum T, van der Meer P, Van Laake LW, von
Haehling S, Heymans S, Lyon AR, Backs J. Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational
Research Committee of the Heart Failure Association (HFA) of the European
Society of Cardiology (ESC). Eur J Heart Fail 2020;22:22722289.
857. Selvaraj S, Bhatt DL, Claggett B, Djousse L, Shah SJ, Chen J, Imran TF, Qazi S,
Sesso HD, Gaziano JM, Schrag D. Lack of association between heart failure and incident cancer. J Am Coll Cardiol 2018;71:15011510.
858. Meijers WC, Maglione M, Bakker SJL, Oberhuber R, Kieneker LM, de Jong S,
Haubner BJ, Nagengast WB, Lyon AR, van der Vegt B, van Veldhuisen DJ,
Westenbrink BD, van der Meer P, Sillje HHW, de Boer RA. Heart failure stimulates tumor growth by circulating factors. Circulation 2018;138:678691.
859. Lancellotti P, Suter TM, Lopez-Fernandez T, Galderisi M, Lyon AR, Van der
Meer P, Cohen Solal A, Zamorano JL, Jerusalem G, Moonen M, Aboyans V, Bax
JJ, Asteggiano R. Cardio-oncology services: rationale, organization, and implementation. Eur Heart J 2019;40:17561763.
860. Farmakis D, Keramida K, Filippatos G. How to build a cardio-oncology service?
Eur J Heart Fail 2018;20:17321734.
861. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G,
Rubino
M,
Veglia
F,
Fiorentini
C,
Cipolla
CM.
Anthracycline-induced
ESC Guidelines
3721


<!-- PAGE 124 -->

### Page 124

...........................................................................................................................................................................
cardiomyopathy: clinical relevance and response to pharmacologic therapy. J
Am Coll Cardiol 2010;55:213220.
862. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli
M, Lamantia G, Colombo N, Curigliano G, Fiorentini C, Cipolla CM. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015;131:19811988.
863. Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW,
Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland A, Storas TH, Hagve
TA, Rosjo H, Steine K, Geisler J, Omland T. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized,
placebo-controlled, double-blind clinical trial of candesartan and metoprolol.
Eur Heart J 2016;37:16711680.
864. Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, Pagano JJ,
Chow K, Thompson RB, Vos LJ, Ghosh S, Oudit GY, Ezekowitz JA, Paterson
DI. Multidisciplinary approach to novel therapies in cardio-oncology research
(MANTICORE
101-Breast):
a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol 2017;35:870877.
865. Celutkiene J, Pudil R, Lopez-Fernandez T, Grapsa J, Nihoyannopoulos P,
Bergler-Klein J, Cohen-Solal A, Farmakis D, Tocchetti CG, von Haehling S,
Barberis V, Flachskampf FA, Ceponiene I, Haegler-Laube E, Suter T, Lapinskas
T, Prasad S, de Boer RA, Wechalekar K, Anker MS, Iakobishvili Z, BucciarelliDucci C, Schulz-Menger J, Cosyns B, Gaemperli O, Belenkov Y, Hulot JS,
Galderisi M, Lancellotti P, Bax J, Marwick TH, Chioncel O, Jaarsma T, Mullens
W, Piepoli M, Thum T, Heymans S, Mueller C, Moura B, Ruschitzka F,
Zamorano JL, Rosano G, Coats AJS, Asteggiano R, Seferovic P, Edvardsen T,
Lyon AR. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association
(HFA), the European Association of Cardiovascular Imaging (EACVI) and the
Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J
Heart Fail 2020;22:15041524.
866. Keramida K, Farmakis D, Bingcang J, Sulemane S, Sutherland S, Bingcang RA,
Ramachandran K, Tzavara C, Charalampopoulos G, Filippiadis D, Kouris N,
Nihoyannopoulos P. Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients. Eur J Heart Fail
2019;21:529535.
867. Thavendiranathan P, Negishi T, Somerset E, Negishi K, Penicka M, Lemieux J,
Aakhus S, Miyazaki S, Shirazi M, Galderisi M, Marwick TH, SUCCOUR
Investigators. Strain-guided management of potentially cardiotoxic cancer therapy. J Am Coll Cardiol 2021;77:392401.
868. Michel L, Mincu RI, Mahabadi AA, Settelmeier S, Al-Rashid F, Rassaf T, Totzeck
M. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. Eur J Heart Fail 2020;22:350361.
869. Pudil R, Mueller C, Celutkiene J, Henriksen PA, Lenihan D, Dent S, Barac A,
Stanway S, Moslehi J, Suter TM, Ky B, Sterba M, Cardinale D, Cohen-Solal A,
Tocchetti CG, Farmakis D, Bergler-Klein J, Anker MS, Von Haehling S, Belenkov
Y, Iakobishvili Z, Maack C, Ciardiello F, Ruschitzka F, Coats AJS, Seferovic P,
Lainscak M, Piepoli MF, Chioncel O, Bax J, Hulot JS, Skouri H, Hagler-Laube ES,
Asteggiano R, Fernandez TL, de Boer RA, Lyon AR. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J
Heart Fail 2020;22:19661983.
870. Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, Lyon AR,
Padera RF, Johnson DB, Moslehi J. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res 2019;115:854868.
871. Banke A, Fosbol EL, Moller JE, Gislason GH, Andersen M, Bernsdorf M, Jensen
MB, Schou M, Ejlertsen B. Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial. Eur
J Heart Fail 2018;20:14471453.
872. Platz E, Jhund PS, Claggett BL, Pfeffer MA, Swedberg K, Granger CB, Yusuf S,
Solomon SD, McMurray JJ. Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality. Eur J Heart Fail 2018;20:295303.
873. Tomasoni D, Italia L, Adamo M, Inciardi RM, Lombardi CM, Solomon SD, Metra
M. COVID 19 and heart failure: from infection to inflammation and angiotensin
II stimulation. Searching for evidence from a new disease. Eur J Heart Fail
2020;22:957966;23:512526.
874. Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus DC, Chirinos JA, Chang
CC, Newman A, Loehr L, Folsom AR, Elkind MS, Lyles MF, Kronmal RA, Yende
S. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA 2015;313:264274.
875. Violi F, Cangemi R, Falcone M, Taliani G, Pieralli F, Vannucchi V, Nozzoli C,
Venditti
M,
Chirinos
JA,
Corrales-Medina
VF,
SIXTUS
Study
Group.
Cardiovascular complications and short-term mortality risk in communityacquired pneumonia. Clin Infect Dis 2017;64:14861493.
876. Rey JR, Caro-Codon J, Rosillo SO, Iniesta AM, Castrejon-Castrejon S, MarcoClement I, Martin-Polo L, Merino-Argos C, Rodriguez-Sotelo L, Garcia-Veas JM,
Martinez-Marin LA, Martinez-Cossiani M, Buno A, Gonzalez-Valle L, Herrero A,
Lopez-Sendon JL, Merino JL, CARD-COVID Investigators. Heart failure in
COVID-19 patients: prevalence, incidence and prognostic implications. Eur J
Heart Fail 2020;22:22052215.
877. Cannata A, Bromage DI, Rind IA, Gregorio C, Bannister C, Albarjas M, Piper S,
Shah AM, McDonagh TA. Temporal trends in decompensated heart failure and outcomes during COVID-19: a multisite report from heart failure referral centres in London. Eur J Heart Fail 2020;22:22192224.
878. Konig S, Hohenstein S, Meier-Hellmann A, Kuhlen R, Hindricks G, Bollmann A,
Helios Hospitals G. In-hospital care in acute heart failure during the COVID-19
pandemic: insights from the German-wide Helios hospital network. Eur J Heart
Fail 2020;22:21902201.
879. Zhang Y, Coats AJS, Zheng Z, Adamo M, Ambrosio G, Anker SD, Butler J, Xu
D, Mao J, Khan MS, Bai L, Mebazaa A, Ponikowski P, Tang Q, Ruschitzka F,
Seferovic P, Tschope C, Zhang S, Gao C, Zhou S, Senni M, Zhang J, Metra M.
Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. Eur J
Heart Fail 2020;22:941956.
880. Modin D, Jorgensen ME, Gislason G, Jensen JS, Kober L, Claggett B, Hegde SM,
Solomon SD, Torp-Pedersen C, Biering-Sorensen T. Influenza vaccine in heart failure. Circulation 2019;139:575586.
881. Vardeny O, Claggett B, Udell JA, Packer M, Zile M, Rouleau J, Swedberg K,
Desai AS, Lefkowitz M, Shi V, McMurray JJV, Solomon SD, PARADIGM-HF
Investigators. Influenza vaccination in patients with chronic heart failure: the
PARADIGM-HF trial. JACC Heart Fail 2016;4:152158.
882. Gotsman I, Shuvy M, Tahiroglu I, Zwas DR, Keren A. Influenza vaccination and outcome in heart failure. Am J Cardiol 2020;128:134139.
883. Bhatt AS, Jering KS, Vaduganathan M, Claggett BL, Cunningham JW, Rosenthal
N, Signorovitch J, Thune JJ, Vardeny O, Solomon SD. Clinical outcomes in patients with heart failure hospitalized with COVID-19. JACC Heart Fail
2021;9:6573.
884. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomstro¨m-Lundqvist C,
Cıfkova R, De Bonis M, Iung B, Johnson MR, Kintscher U, Kranke P, Lang IM,
Morais J, Pieper PG, Presbitero P, Price S, Rosano GMC, Seeland U, Simoncini
T, Swan L, Warnes CA, ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J
2018;39:31653241.
885. Sliwa K, van der Meer P, Petrie MC, Frogoudaki A, Johnson MR, Hilfiker-Kleiner
D, Hamdan R, Jackson AM, Ibrahim B, Mbakwem A, Tschope C, RegitzZagrosek V, Omerovic E, Roos-Hesselink J, Gatzoulis M, Tutarel O, Price S,
Heymans S, Coats AJS, Muller C, Chioncel O, Thum T, de Boer RA, Jankowska
E, Ponikowski P, Lyon AR, Rosano G, Seferovic PM, Bauersachs J. Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the
Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. Eur J Heart Fail 2021;23:527540.
886. Sliwa K, Petrie MC, van der Meer P, Mebazaa A, Hilfiker-Kleiner D, Jackson AM,
Maggioni AP, Laroche C, Regitz-Zagrosek V, Schaufelberger M, Tavazzi L, RoosHesselink JW, Seferovic P, van Spaendonck-Zwarts K, Mbakwem A, Bohm M,
Mouquet F, Pieske B, Johnson MR, Hamdan R, Ponikowski P, Van Veldhuisen
DJ, McMurray JJV, Bauersachs J. Clinical presentation, management, and 6month outcomes in women with peripartum cardiomyopathy: an ESC EORP
registry. Eur Heart J 2020;41:37873797.
887. Davis MB, Arany Z, McNamara DM, Goland S, Elkayam U. Peripartum cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 2020;75:207221.
888. Moulig V, Pfeffer TJ, Ricke-Hoch M, Schlothauer S, Koenig T, Schwab J, Berliner
D, Pfister R, Michels G, Haghikia A, Falk CS, Duncker D, Veltmann C, HilfikerKleiner D, Bauersachs J. Long-term follow-up in peripartum cardiomyopathy patients with contemporary treatment: low mortality, high cardiac recovery,
but significant cardiovascular co-morbidities.
Eur
J
Heart
Fail
2019;21:15341542.
889. Stapel B, Kohlhaas M, Ricke-Hoch M, Haghikia A, Erschow S, Knuuti J, Silvola
JM, Roivainen A, Saraste A, Nickel AG, Saar JA, Sieve I, Pietzsch S, Muller M,
Bogeski I, Kappl R, Jauhiainen M, Thackeray JT, Scherr M, Bengel FM, Hagl C,
Tudorache I, Bauersachs J, Maack C, Hilfiker-Kleiner D. Low STAT3 expression sensitizes to toxic effects of beta-adrenergic receptor stimulation in peripartum cardiomyopathy. Eur Heart J 2017;38:349361.
890. Hilfiker-Kleiner D, Haghikia A, Berliner D, Vogel-Claussen J, Schwab J, Franke
A, Schwarzkopf M, Ehlermann P, Pfister R, Michels G, Westenfeld R, Stangl V,
Kindermann I, Kuhl U, Angermann CE, Schlitt A, Fischer D, Podewski E, Bohm
M, Sliwa K, Bauersachs J. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J 2017;38:26712679.


<!-- PAGE 125 -->

### Page 125

.............................................................................................................................................................................
891. Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema JP, Becker A, McMurray
J, Yamac H, Labidi S, Struman I, Hilfiker-Kleiner D. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-ofconcept pilot study. Circulation 2010;121:14651473.
892. Arbustini E, Narula N, Dec GW, Reddy KS, Greenberg B, Kushwaha S, Marwick
T, Pinney S, Bellazzi R, Favalli V, Kramer C, Roberts R, Zoghbi WA, Bonow R,
Tavazzi L, Fuster V, Narula J. The MOGE(S) classification for a phenotypegenotype nomenclature of cardiomyopathy: endorsed by the World Heart
Federation. J Am Coll Cardiol 2013;62:20462072.
893. Hazebroek MR, Kemna MJ, Schalla S, Sanders-van Wijk S, Gerretsen SC,
Dennert R, Merken J, Kuznetsova T, Staessen JA, Brunner-La Rocca HP, van
Paassen P, Cohen Tervaert JW, Heymans S. Prevalence and prognostic relevance of cardiac involvement in ANCA-associated vasculitis: eosinophilic granulomatosis with polyangiitis and granulomatosis with polyangiitis. Int J Cardiol
2015;199:170179.
894. Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Bohm M, Duboc D,
Gimeno J, de Groote P, Imazio M, Heymans S, Klingel K, Komajda M, Limongelli
G, Linhart A, Mogensen J, Moon J, Pieper PG, Seferovic PM, Schueler S,
Zamorano JL, Caforio AL, Charron P. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J 2016;37:18501858.
895. Seferovic PM, Polovina M, Bauersachs J, Arad M, Gal TB, Lund LH, Felix SB,
Arbustini E, Caforio ALP, Farmakis D, Filippatos GS, Gialafos E, Kanjuh V,
Krljanac G, Limongelli G, Linhart A, Lyon AR, Maksimovic R, Milicic D,
Milinkovic I, Noutsias M, Oto A, Oto O, Pavlovic SU, Piepoli MF, Ristic AD,
Rosano GMC, Seggewiss H, Asanin M, Seferovic JP, Ruschitzka F, Celutkiene J,
Jaarsma T, Mueller C, Moura B, Hill L, Volterrani M, Lopatin Y, Metra M, Backs
J, Mullens W, Chioncel O, de Boer RA, Anker S, Rapezzi C, Coats AJS,
Tschope C. Heart failure in cardiomyopathies: a position paper from the Heart
Failure Association of the European Society of Cardiology. Eur J Heart Fail
2019;21:553576.
896. members Authors/Task Force, Elliott PM, Anastasakis A, Borger MA, Borggrefe
M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H,
McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B,
Rapezzi C, Rutten FH, Tillmanns C, Watkins H. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the
European Society of Cardiology (ESC). Eur Heart J 2014;35:27332779.
897. Bondue A, Arbustini E, Bianco A, Ciccarelli M, Dawson D, De Rosa M,
Hamdani N, Hilfiker-Kleiner D, Meder B, Leite-Moreira AF, Thum T, Tocchetti
CG, Varricchi G, Van der Velden J, Walsh R, Heymans S. Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the
Working Group of Myocardial Function of the European Society of Cardiology.
Cardiovasc Res 2018;114:12871303.
898. Hershberger RE, Givertz MM, Ho CY, Judge DP, Kantor PF, McBride KL,
Morales A, Taylor MRG, Vatta M, Ware SM. Genetic evaluation of cardiomyopathy–a Heart Failure Society of America practice guideline. J Card Fail
2018;24:281302.
899. Merlo M, Cannata A, Gobbo M, Stolfo D, Elliott PM, Sinagra G. Evolving concepts in dilated cardiomyopathy. Eur J Heart Fail 2018;20:228239.
900. Linschoten M, Teske AJ, Baas AF, Vink A, Dooijes D, Baars HF, Asselbergs FW.
Truncating titin (TTN) variants in chemotherapy-induced cardiomyopathy. J
Card Fail 2017;23:476479.
901. Wasielewski M, van Spaendonck-Zwarts KY, Westerink ND, Jongbloed JD,
Postma A, Gietema JA, van Tintelen JP, van den Berg MP. Potential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy. Open Heart 2014;1:e000116.
902. Ware JS, Amor-Salamanca A, Tayal U, Govind R, Serrano I, Salazar-Mendiguchia
J, Garcia-Pinilla JM, Pascual-Figal DA, Nunez J, Guzzo-Merello G, GonzalezVioque E, Bardaji A, Manito N, Lopez-Garrido MA, Padron-Barthe L, Edwards
E, Whiffin N, Walsh R, Buchan RJ, Midwinter W, Wilk A, Prasad S, Pantazis A,
Baski J, O’Regan DP, Alonso-Pulpon L, Cook SA, Lara-Pezzi E, Barton PJ,
Garcia-Pavia P. Genetic etiology for alcohol-induced cardiac toxicity. J Am Coll
Cardiol 2018;71:22932302.
903. Ware JS, Li J, Mazaika E, Yasso CM, DeSouza T, Cappola TP, Tsai EJ, HilfikerKleiner D, Kamiya CA, Mazzarotto F, Cook SA, Halder I, Prasad SK, Pisarcik J,
Hanley-Yanez K, Alharethi R, Damp J, Hsich E, Elkayam U, Sheppard R, Kealey
A, Alexis J, Ramani G, Safirstein J, Boehmer J, Pauly DF, Wittstein IS, Thohan V,
Zucker MJ, Liu P, Gorcsan J, 3rd, McNamara DM, Seidman CE, Seidman JG,
Arany Z, IPAC Investigators, Imac. Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med 2016;374:233241.
904. van Spaendonck-Zwarts KY, Posafalvi A, van den Berg MP, Hilfiker-Kleiner D,
Bollen IA, Sliwa K, Alders M, Almomani R, van Langen IM, van der Meer P,
Sinke RJ, van der Velden J, Van Veldhuisen DJ, van Tintelen JP, Jongbloed JD.
Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. Eur Heart J 2014;35:21652173.
905. Choi SH, Weng LC, Roselli C, Lin H, Haggerty CM, Shoemaker MB, Barnard J,
Arking DE, Chasman DI, Albert CM, Chaffin M, Tucker NR, Smith JD, Gupta N,
Gabriel S, Margolin L, Shea MA, Shaffer CM, Yoneda ZT, Boerwinkle E, Smith
NL, Silverman EK, Redline S, Vasan RS, Burchard EG, Gogarten SM, Laurie C,
Blackwell TW, Abecasis G, Carey DJ, Fornwalt BK, Smelser DT, Baras A,
Dewey FE, Jaquish CE, Papanicolaou GJ, Sotoodehnia N, Van Wagoner DR,
Psaty BM, Kathiresan S, Darbar D, Alonso A, Heckbert SR, Chung MK, Roden
DM, Benjamin EJ, Murray MF, Lunetta KL, Lubitz SA, Ellinor PT, DiscovEHR
study and the
NHLBI
Trans-Omics for
Precision
Medicine
(TOPMed)
Consortium. Association between titin loss-of-function variants and early-onset atrial fibrillation. JAMA 2018;320:23542364.
906. Hazebroek MR, Krapels I, Verdonschot J, van den Wijngaard A, Vanhoutte E,
Hoos M, Snijders L, van Montfort L, Witjens M, Dennert R, Crijns H, BrunnerLa Rocca HP, Brunner HG, Heymans S. Prevalence of pathogenic gene mutations and prognosis do not differ in isolated left ventricular dysfunction compared with dilated cardiomyopathy. Circ Heart Fail 2018;11:e004682.
907. Leone O, Veinot JP, Angelini A, Baandrup UT, Basso C, Berry G, Bruneval P,
Burke M, Butany J, Calabrese F, d’Amati G, Edwards WD, Fallon JT, Fishbein
MC, Gallagher PJ, Halushka MK, McManus B, Pucci A, Rodriguez ER, Saffitz JE,
Sheppard MN, Steenbergen C, Stone JR, Tan C, Thiene G, van der Wal AC,
Winters GL. 2011 consensus statement on endomyocardial biopsy from the
Association for European Cardiovascular Pathology and the Society for
Cardiovascular Pathology. Cardiovasc Pathol 2012;21:245274.
908. Halliday BP, Owen R, Gregson J, Vassiliou VS, Chen X, Wage R, Lota AS,
Khalique Z, Tayal U, Hammersley DJ, Jones RE, Baksi AJ, Cowie MR, Cleland
JGF, Pennell DJ, Prasad SK. Myocardial remodelling after withdrawing therapy for heart failure in patients with recovered dilated cardiomyopathy: insights from TRED-HF. Eur J Heart Fail 2021;23:293301.
909. Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P,
Saberi S, Lakdawala NK, Wheeler MT, Owens A, Kubanek M, Wojakowski W,
Jensen MK, Gimeno-Blanes J, Afshar K, Myers J, Hegde SM, Solomon SD,
Sehnert AJ, Zhang D, Li W, Bhattacharya M, Edelberg JM, Waldman CB, Lester
SJ, Wang A, Ho CY, Jacoby D, EXPLORER-HCM Study Investigators.
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled,
phase 3 trial. Lancet 2020;396:759769.
910. Cadrin-Tourigny J, Bosman LP, Nozza A, Wang W, Tadros R, Bhonsale A, Bourfiss
M, Fortier A, Lie OH, Saguner AM, Svensson A, Andorin A, Tichnell C, Murray B,
Zeppenfeld K, van den Berg MP, Asselbergs FW, Wilde AAM, Krahn AD, Talajic
M, Rivard L, Chelko S, Zimmerman SL, Kamel IR, Crosson JE, Judge DP, Yap SC,
van der Heijden JF, Tandri H, Jongbloed JDH, Guertin MC, van Tintelen JP,
Platonov PG, Duru F, Haugaa KH, Khairy P, Hauer RNW, Calkins H, Te Riele A,
James CA. A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 2019;40:18501858.
911. Leren IS, Saberniak J, Haland TF, Edvardsen T, Haugaa KH. Combination of
ECG and echocardiography for identification of arrhythmic events in early
ARVC. JACC Cardiovasc Imaging 2017;10:503513.
912. Towbin JA, McKenna WJ, Abrams DJ, Ackerman MJ, Calkins H, Darrieux FCC,
Daubert JP, de Chillou C, DePasquale EC, Desai MY, Estes NAM, 3rd, Hua W,
Indik JH, Ingles J, James CA, John RM, Judge DP, Keegan R, Krahn AD, Link MS,
Marcus FI, McLeod CJ, Mestroni L, Priori SG, Saffitz JE, Sanatani S, Shimizu W,
van Tintelen JP, Wilde AAM, Zareba W. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm 2019;16:e301e372.
913. Kristensen SL, Levy WC, Shadman R, Nielsen JC, Haarbo J, Videbaek L, Bruun
NE, Eiskjaer H, Wiggers H, Brandes A, Thogersen AM, Hassager C, Svendsen
JH, Hofsten DE, Torp-Pedersen C, Pehrson S, Signorovitch J, Kober L, Thune JJ.
Risk models for prediction of implantable cardioverter-defibrillator benefit:
insights from the DANISH trial. JACC Heart Fail 2019;7:717724.
914. Corrado D, Wichter T, Link MS, Hauer R, Marchlinski F, Anastasakis A, Bauce
B, Basso C, Brunckhorst C, Tsatsopoulou A, Tandri H, Paul M, Schmied C,
Pelliccia A, Duru F, Protonotarios N, Estes NA, 3rd, McKenna WJ, Thiene G,
Marcus FI, Calkins H. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement. Eur Heart J
2015;36:32273237.
915. Elliott PM, Anastasakis A, Asimaki A, Basso C, Bauce B, Brooke MA, Calkins H,
Corrado D, Duru F, Green KJ, Judge DP, Kelsell D, Lambiase PD, McKenna WJ,
Pilichou K, Protonotarios A, Saffitz JE, Syrris P, Tandri H, Te Riele A, Thiene G,
Tsatsopoulou A, Tintelen JP. Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report. Eur J Heart Fail 2019;21:955964.
916. Mazzarotto F, Tayal U, Buchan RJ, Midwinter W, Wilk A, Whiffin N, Govind R,
Mazaika E, de Marvao A, Dawes TJW, Felkin LE, Ahmad M, Theotokis PI,
Edwards E, Ing AY, Thomson KL, Chan LLH, Sim D, Baksi AJ, Pantazis A,
Roberts AM, Watkins H, Funke B, O’Regan DP, Olivotto I, Barton PJR, Prasad
ESC Guidelines
3723


<!-- PAGE 126 -->

### Page 126

.............................................................................................................................................................................
SK, Cook SA, Ware JS, Walsh R. Reevaluating the genetic contribution of monogenic dilated cardiomyopathy. Circulation 2020;141:387398.
917. Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M,
Helio T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W,
Mogensen J, Pinto YM, Ristic A, Schultheiss HP, Seggewiss H, Tavazzi L, Thiene
G, Yilmaz A, Charron P, Elliott PM, European Society of Cardiology Working
Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013;34:2636-2648, 2648a-2648d.
918. Heymans S, Eriksson U, Lehtonen J, Cooper LT, Jr. The quest for new approaches in myocarditis and inflammatory cardiomyopathy. J Am Coll Cardiol
2016;68:23482364.
919. Tschope C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB, Hare JM,
Heidecker B, Heymans S, Hubner N, Kelle S, Klingel K, Maatz H, Parwani AS,
Spillmann F, Starling RC, Tsutsui H, Seferovic P, Van Linthout S. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat
Rev Cardiol 2021;18:169193.
920. Wahbi K, Ben Yaou R, Gandjbakhch E, Anselme F, Gossios T, Lakdawala NK,
Stalens C, Sacher F, Babuty D, Trochu JN, Moubarak G, Savvatis K, Porcher R,
Laforet P, Fayssoil A, Marijon E, Stojkovic T, Behin A, Leonard-Louis S, Sole G,
Labombarda F, Richard P, Metay C, Quijano-Roy S, Dabaj I, Klug D, Vantyghem
MC, Chevalier P, Ambrosi P, Salort E, Sadoul N, Waintraub X, Chikhaoui K,
Mabo P, Combes N, Maury P, Sellal JM, Tedrow UB, Kalman JM, Vohra J,
Androulakis AFA, Zeppenfeld K, Thompson T, Barnerias C, Becane HM, Bieth
E, Boccara F, Bonnet D, Bouhour F, Boule S, Brehin AC, Chapon F, Cintas P,
Cuisset JM, Davy JM, De Sandre-Giovannoli A, Demurger F, Desguerre I,
Dieterich K, Durigneux J, Echaniz-Laguna A, Eschalier R, Ferreiro A, Ferrer X,
Francannet C, Fradin M, Gaborit B, Gay A, Hagege A, Isapof A, Jeru I, Juntas
Morales R, Lagrue E, Lamblin N, Lascols O, Laugel V, Lazarus A, Leturcq F,
Levy N, Magot A, Manel V, Martins R, Mayer M, Mercier S, Meune C, Michaud
M, Minot-Myhie MC, Muchir A, Nadaj-Pakleza A, Pereon Y, Petiot P, Petit F,
Praline J, Rollin A, Sabouraud P, Sarret C, Schaeffer S, Taithe F, Tard C, Tiffreau
V, Toutain A, Vatier C, Walther-Louvier U, Eymard B, Charron P, Vigouroux C,
Bonne G, Kumar S, Elliott P, Duboc D. Development and validation of a new risk prediction score for life-threatening ventricular tachyarrhythmias in laminopathies. Circulation 2019;140:293302.
921. Echeverria LE, Marcus R, Novick G, Sosa-Estani S, Ralston K, Zaidel EJ, Forsyth
C, ALP RI, Mendoza I, Falconi ML, Mitelman J, Morillo CA, Pereiro AC, Pinazo
MJ, Salvatella R, Martinez F, Perel P, Liprandi AS, Pineiro DJ, Molina GR. WHF
IASC roadmap on Chagas disease. Glob Heart 2020;15:26.
922. Martinez F, Perna E, Perrone SV, Liprandi AS. Chagas disease and heart failure:
an expanding issue worldwide. Eur Cardiol 2019;14:8288.
923. Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL,
Hung J, Joglar JA, Kantor P, Kimmelstiel C, Kittleson M, Link MS, Maron MS,
Martinez MW, Miyake CY, Schaff HV, Semsarian C, Sorajja P. 2020 AHA/ACC
Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy:
executive summary:
a report of the
American
College of
Cardiology/American Heart Association Joint Committee on Clinical Practice
Guidelines. Circulation 2020;142:e533e557.
924. Walsh R, Mazzarotto F, Whiffin N, Buchan R, Midwinter W, Wilk A, Li N,
Felkin L, Ingold N, Govind R, Ahmad M, Mazaika E, Allouba M, Zhang X, de
Marvao A, Day SM, Ashley E, Colan SD, Michels M, Pereira AC, Jacoby D, Ho
CY, Thomson KL, Watkins H, Barton PJR, Olivotto I, Cook SA, Ware JS.
Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: the case of hypertrophic cardiomyopathy. Genome Med 2019;11:5.
925. Ingles J, Goldstein J, Thaxton C, Caleshu C, Corty EW, Crowley SB, Dougherty
K, Harrison SM, McGlaughon J, Milko LV, Morales A, Seifert BA, Strande N,
Thomson K, Peter van Tintelen J, Wallace K, Walsh R, Wells Q, Whiffin N,
Witkowski L, Semsarian C, Ware JS, Hershberger RE, Funke B. Evaluating the clinical validity of hypertrophic cardiomyopathy genes. Circ Genom Precis Med
2019;12:e002460.
926. Thomson KL, Ormondroyd E, Harper AR, Dent T, McGuire K, Baksi J, Blair E,
Brennan P, Buchan R, Bueser T, Campbell C, Carr-White G, Cook S, Daniels
M, Deevi SVV, Goodship J, Hayesmoore JBG, Henderson A, Lamb T, Prasad S,
Rayner-Matthews P, Robert L, Sneddon L, Stark H, Walsh R, Ware JS, Farrall
M, Watkins HC, NIHR BioResource - Rare Diseases Consortium. Analysis of
51 proposed hypertrophic cardiomyopathy genes from genome sequencing data in sarcomere negative cases has negligible diagnostic yield. Genet Med
2019;21:15761584.
927. Tuohy CV, Kaul S, Song HK, Nazer B, Heitner SB. Hypertrophic cardiomyopathy: the future of treatment. Eur J Heart Fail 2020;22:228240.
928. O’Mahony C, Akhtar MM, Anastasiou Z, Guttmann OP, Vriesendorp PA,
Michels M, Magri D, Autore C, Fernandez A, Ochoa JP, Leong KMW, Varnava
AM, Monserrat L, Anastasakis A, Garcia-Pavia P, Rapezzi C, Biagini E, Gimeno
JR, Limongelli G, Omar RZ, Elliott PM. Effectiveness of the 2014 European
Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysis. Heart 2019;105:623631.
929. O’Mahony C, Jichi F, Ommen SR, Christiaans I, Arbustini E, Garcia-Pavia P,
Cecchi F, Olivotto I, Kitaoka H, Gotsman I, Carr-White G, Mogensen J,
Antoniades L, Mohiddin SA, Maurer MS, Tang HC, Geske JB, Siontis KC,
Mahmoud KD, Vermeer A, Wilde A, Favalli V, Guttmann OP, Gallego-Delgado
M, Dominguez F, Tanini I, Kubo T, Keren A, Bueser T, Waters S, Issa IF,
Malcolmson J, Burns T, Sekhri N, Hoeger CW, Omar RZ, Elliott PM.
International external validation study of the 2014 European Society of
Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic
Cardiomyopathy (EVIDENCE-HCM). Circulation 2018;137:10151023.
930. O’Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, Biagini E,
Gimeno JR, Limongelli G, McKenna WJ, Omar RZ, Elliott PM, Hypertrophic
Cardiomyopathy Outcomes Investigators. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur
Heart J 2014;35:20102020.
931. Brignole M, Moya A, de Lange FJ, Deharo JC, Elliott PM, Fanciulli A, Fedorowski
A, Furlan R, Kenny RA, Martin A, Probst V, Reed MJ, Rice CP, Sutton R, Ungar
A, van Dijk JG, ESC Scientific Document Group. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J 2018;39:18831948.
932. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, Calkins H,
Corrado D, Cox MG, Daubert JP, Fontaine G, Gear K, Hauer R, Nava A, Picard
MH, Protonotarios N, Saffitz JE, Sanborn DM, Steinberg JS, Tandri H, Thiene G,
Towbin JA, Tsatsopoulou A, Wichter T, Zareba W. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation 2010;121:15331541.
933. Corrado D, van Tintelen PJ, McKenna WJ, Hauer RNW, Anastastakis A,
Asimaki A, Basso C, Bauce B, Brunckhorst C, Bucciarelli-Ducci C, Duru F,
Elliott P, Hamilton RM, Haugaa KH, James CA, Judge D, Link MS, Marchlinski FE,
Mazzanti A, Mestroni L, Pantazis A, Pelliccia A, Marra MP, Pilichou K, Platonov
PGA, Protonotarios A, Rampazzo A, Saffitz JE, Saguner AM, Schmied C, Sharma
S, Tandri H, Te Riele A, Thiene G, Tsatsopoulou A, Zareba W, Zorzi A,
Wichter T, Marcus FI, Calkins H, International Experts. Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis. Eur Heart J 2020;41:14141429.
934. Reichl K, Kreykes SE, Martin CM, Shenoy C. Desmoplakin variant-associated arrhythmogenic cardiomyopathy presenting as acute myocarditis. Circ Genom
Precis Med 2018;11:e002373.
935. Lopez-Ayala JM, Pastor-Quirante F, Gonzalez-Carrillo J, Lopez-Cuenca D,
Sanchez-Munoz JJ, Oliva-Sandoval MJ, Gimeno JR. Genetics of myocarditis in arrhythmogenic right ventricular dysplasia. Heart Rhythm 2015;12:766773.
936. Pelliccia A, Solberg EE, Papadakis M, Adami PE, Biffi A, Caselli S, La Gerche A,
Niebauer J, Pressler A, Schmied CM, Serratosa L, Halle M, Van Buuren F,
Borjesson M, Carre F, Panhuyzen-Goedkoop NM, Heidbuchel H, Olivotto I,
Corrado D, Sinagra G, Sharma S. Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis,
and pericarditis: position statement of the Sport Cardiology Section of the
European
Association of
Preventive
Cardiology
(EAPC).
Eur
Heart
J
2019;40:1933.
937. Sedaghat-Hamedani F, Haas J, Zhu F, Geier C, Kayvanpour E, Liss M, Lai A,
Frese K, Pribe-Wolferts R, Amr A, Li DT, Samani OS, Carstensen A, Bordalo
DM, Muller M, Fischer C, Shao J, Wang J, Nie M, Yuan L, Hassfeld S, Schwartz
C, Zhou M, Zhou Z, Shu Y, Wang M, Huang K, Zeng Q, Cheng L, Fehlmann T,
Ehlermann P, Keller A, Dieterich C, Streckfuss-Bomeke K, Liao Y, Gotthardt M,
Katus HA, Meder B. Clinical genetics and outcome of left ventricular noncompaction cardiomyopathy. Eur Heart J 2017;38:34493460.
938. Towbin JA, Lorts A, Jefferies JL. Left ventricular non-compaction cardiomyopathy. Lancet 2015;386:813825.
939. Towbin JA, Jefferies JL. Cardiomyopathies due to left ventricular noncompaction, mitochondrial and storage diseases, and inborn errors of metabolism. Circ
Res 2017;121:838854.
940. Shen
MJ,
Arora
R,
Jalife
J.
Atrial myopathy.
JACC
Basic
Transl
Sci
2019;4:640654.
941. Reddy YNV, Borlaug BA. Left atrial myopathy in heart failure with preserved ejection fraction. Eur J Heart Fail 2020;22:486488.
942. Reddy YNV, Obokata M, Gersh BJ, Borlaug BA. High prevalence of occult heart failure with preserved ejection fraction among patients with atrial fibrillation and dyspnea. Circulation 2018;137:534535.
943. Packer M, Lam CSP, Lund LH, Redfield MM. Interdependence of atrial fibrillation and heart failure with a preserved ejection fraction reflects a common underlying atrial and ventricular myopathy. Circulation 2020;141:46.
944. To AC, Flamm SD, Marwick TH, Klein AL. Clinical utility of multimodality LA
imaging: assessment of size, function, and structure. JACC Cardiovasc Imaging
2011;4:788798.


<!-- PAGE 127 -->

### Page 127

.............................................................................................................................................................................
945. Farmakis D, Mueller C, Apple FS. High-sensitivity cardiac troponin assays for cardiovascular risk stratification in the general population. Eur Heart J
2020;41:40504056.
946. Westermann D, Neumann JT, Sorensen NA, Blankenberg S. High-sensitivity assays for troponin in patients with cardiac disease.
Nat
Rev
Cardiol
2017;14:472483.
947. Santema BT, Kloosterman M, Van Gelder IC, Mordi I, Lang CC, Lam CSP,
Anker SD, Cleland JG, Dickstein K, Filippatos G, Van der Harst P, Hillege HL,
Ter Maaten JM, Metra M, Ng LL, Ponikowski P, Samani NJ, Van Veldhuisen DJ,
Zwinderman AH, Zannad F, Damman K, Van der Meer P, Rienstra M, Voors
AA. Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. Eur Heart J
2018;39:38673875.
948. Richards M, Di Somma S, Mueller C, Nowak R, Peacock WF, Ponikowski P,
Mockel M, Hogan C, Wu AH, Clopton P, Filippatos GS, Anand I, Ng L, Daniels
LB, Neath SX, Shah K, Christenson R, Hartmann O, Anker SD, Maisel A. Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: results from the BACH Study (Biomarkers in ACute Heart
Failure). JACC Heart Fail 2013;1:192199.
949. Kamel H, Longstreth WT, Jr., Tirschwell DL, Kronmal RA, Broderick JP, Palesch
YY, Meinzer C, Dillon C, Ewing I, Spilker JA, Di Tullio MR, Hod EA, Soliman EZ,
Chaturvedi S, Moy CS, Janis S, Elkind MS. The AtRial Cardiopathy and
Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial:
rationale and methods. Int J Stroke 2019;14:207214.
950. Zelniker TA, Bonaca MP, Furtado RHM, Mosenzon O, Kuder JF, Murphy SA,
Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Budaj A, Kiss RG, Padilla F,
Gause-Nilsson I, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial. Circulation 2020;141:12271234.
951. Global Burden of Disease Study Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the
Global Burden of Disease Study 2013. Lancet 2015;386:743800.
952. Cooper LT Jr, Keren A, Sliwa K, Matsumori A, Mensah GA. The global burden of myocarditis: part 1: a systematic literature review for the Global Burden of
Diseases, Injuries, and Risk Factors 2010 study. Glob Heart 2014;9:121129.
953. Merken J, Hazebroek M, Van Paassen P, Verdonschot J, Van Empel V,
Knackstedt C, Abdul Hamid M, Seiler M, Kolb J, Hoermann P, Ensinger C,
Brunner-La Rocca HP, Poelzl G, Heymans S. Immunosuppressive therapy improves both short- and long-term prognosis in patients with virus-negative nonfulminant inflammatory cardiomyopathy. Circ Heart Fail 2018;11:e004228.
954. Ammirati E, Frigerio M, Adler ED, Basso C, Birnie DH, Brambatti M, Friedrich
MG, Klingel K, Lehtonen J, Moslehi JJ, Pedrotti P, Rimoldi OE, Schultheiss HP,
Tschope C, Cooper LT, Jr., Camici PG. Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document. Circ
Heart Fail 2020;13:e007405.
955. Grigoratos C, Di Bella G, Aquaro GD. Diagnostic and prognostic role of cardiac magnetic resonance in acute myocarditis. Heart Fail Rev 2019;24:8190.
956. Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem
U, Kindermann I, Gutberlet M, Cooper LT, Liu P, Friedrich MG. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol 2018;72:31583176.
957. Birnie DH, Nery PB, Ha AC, Beanlands RS. Cardiac sarcoidosis. J Am Coll Cardiol
2016;68:411421.
958. Bang V, Ganatra S, Shah SP, Dani SS, Neilan TG, Thavendiranathan P, Resnic FS,
Piemonte TC, Barac A, Patel R, Sharma A, Parikh R, Chaudhry GM, Vesely M,
Hayek SS, Leja M, Venesy D, Patten R, Lenihan D, Nohria A, Cooper LT.
Management of patients with giant cell myocarditis: JACC review topic of the week. J Am Coll Cardiol 2021;77:11221134.
959. Sinagra G, Porcari A, Gentile P, Artico J, Fabris E, Bussani R, Merlo M. Viral presence-guided immunomodulation in lymphocytic myocarditis: an update. Eur
J Heart Fail 2021;23:211216.
960. Gannon MP, Schaub E, Grines CL, Saba SG. State of the art: evaluation and prognostication of myocarditis using cardiac MRI. J Magn Reson Imaging
2019;49:e122e131.
961. Maisch B, Hufnagel G, Kolsch S, Funck R, Richter A, Rupp H, Herzum M,
Pankuweit S. Treatment of inflammatory dilated cardiomyopathy and (peri)myocarditis with immunosuppression and i.v. immunoglobulins. Herz 2004;29:624636.
962. Kociol RD, Cooper LT, Fang JC, Moslehi JJ, Pang PS, Sabe MA, Shah RV, Sims
DB, Thiene G, Vardeny O, American Heart Association Heart Failure
Transplantation Committee of the Council on Clinical Cardiology. Recognition and initial management of fulminant myocarditis: a scientific statement from the
American Heart Association. Circulation 2020;141:e69e92.
963. Felix SB, Staudt A, Dorffel WV, Stangl V, Merkel K, Pohl M, Docke WD,
Morgera S, Neumayer HH, Wernecke KD, Wallukat G, Stangl K, Baumann G.
Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J Am Coll Cardiol 2000;35:15901598.
964. Bajaj NS, Gupta K, Gharpure N, Pate M, Chopra L, Kalra R, Prabhu SD. Effect of immunomodulation on cardiac remodelling and outcomes in heart failure: a quantitative synthesis of the literature. ESC Heart Fail 2020;7:13191330.
965. Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med
(Lond) 2018;18:s30s35.
966. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy:
JACC
state-of-the-art review.
J
Am
Coll
Cardiol
2019;73:28722891.
967. Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral
FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, AlonsoPulpon L, Garcia-Pavia P. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015;36:25852594.
968. Helder MR, Schaff HV, Nishimura RA, Gersh BJ, Dearani JA, Ommen SR,
Mereuta OM, Theis JD, Dogan A, Edwards WD. Impact of incidental amyloidosis on the prognosis of patients with hypertrophic cardiomyopathy undergoing septal myectomy for left ventricular outflow tract obstruction. Am J Cardiol
2014;114:13961399.
969. Treibel TA, Fontana M, Gilbertson JA, Castelletti S, White SK, Scully PR,
Roberts N, Hutt DF, Rowczenio DM, Whelan CJ, Ashworth MA, Gillmore JD,
Hawkins PN, Moon JC. Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement. Circ Cardiovasc Imaging 2016;9.
970. Cavalcante JL, Rijal S, Abdelkarim I, Althouse AD, Sharbaugh MS, Fridman Y,
Soman P, Forman DE, Schindler JT, Gleason TG, Lee JS, Schelbert EB. Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis. J Cardiovasc Magn Reson 2017;19:98.
971. Castano A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A,
Rubin J, Chiuzan C, Nazif T, Vahl T, George I, Kodali S, Leon MB, Hahn R,
Bokhari S, Maurer MS. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 2017;38:28792887.
972. Nitsche C, Aschauer S, Kammerlander AA, Schneider M, Poschner T, Duca F,
Binder C, Koschutnik M, Stiftinger J, Goliasch G, Siller-Matula J, Winter MP,
Anvari-Pirsch A, Andreas M, Geppert A, Beitzke D, Loewe C, Hacker M, Agis
H, Kain R, Lang I, Bonderman D, Hengstenberg C, Mascherbauer J. Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence,
screening possibilities, and outcome. Eur J Heart Fail 2020;22:18521862.
973. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I,
Caforio ALP, Damy T, Eriksson U, Fontana M, Gillmore JD, Gonzalez-Lopez E,
Grogan M, Heymans S, Imazio M, Kindermann I, Kristen AV, Maurer MS, Merlini
G, Pantazis A, Pankuweit S, Rigopoulos AG, Linhart A. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of
Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart
Fail 2021;23:512526.
974. Boldrini M, Cappelli F, Chacko L, Restrepo-Cordoba MA, Lopez-Sainz A,
Giannoni A, Aimo A, Baggiano A, Martinez-Naharro A, Whelan C, Quarta C,
Passino C, Castiglione V, Chubuchnyi V, Spini V, Taddei C, Vergaro G, Petrie A,
Ruiz-Guerrero L, Monivas V, Mingo-Santos S, Mirelis JG, Dominguez F,
Gonzalez-Lopez E, Perlini S, Pontone G, Gillmore J, Hawkins PN, Garcia-Pavia
P, Emdin M, Fontana M. Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 2020;13:909920.
975. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A,
Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S,
Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M,
Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ,
Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN.
Nonbiopsy diagnosis of cardiac transthyretin amyloidosis.
Circulation
2016;133:24042412.
976. Zhao L, Tian Z, Fang Q. Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis. BMC Cardiovasc Disord 2016;16:129.
977. Bhuiyan T, Helmke S, Patel AR, Ruberg FL, Packman J, Cheung K, Grogan D,
Maurer MS. Pressure-volume relationships in patients with transthyretin (ATTR)
cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin:
Transthyretin Cardiac Amyloid Study (TRACS). Circ Heart Fail 2011;4:121128.
978. Cheung CC, Roston TM, Andrade JG, Bennett MT, Davis MK. Arrhythmias in cardiac amyloidosis: challenges in risk stratification and treatment. Can J Cardiol
2020;36:416423.
979. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, WaddingtonCruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ,
Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J,
Stewart M, Sultan MB, Rapezzi C, ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med
2018;379:10071016.
ESC Guidelines
3725


<!-- PAGE 128 -->

### Page 128

....................................................................................................
980. Damy T, Garcia-Pavia P, Hanna M, Judge DP, Merlini G, Gundapaneni B,
Patterson TA, Riley S, Schwartz JH, Sultan MB, Witteles R. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical
Trial
(ATTR-ACT)
and long-term extension study.
Eur
J
Heart
Fail
2021;23:277285.
981. Solomon SD, Adams D, Kristen A, Grogan M, Gonzalez-Duarte A, Maurer MS,
Merlini G, Damy T, Slama MS, Brannagan TH, 3rd, Dispenzieri A, Berk JL, Shah
AM, Garg P, Vaishnaw A, Karsten V, Chen J, Gollob J, Vest J, Suhr O. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 2019;139:431443.
982. Suhr OB, Coelho T, Buades J, Pouget J, Conceicao I, Berk J, Schmidt H,
Waddington-Cruz M, Campistol JM, Bettencourt BR, Vaishnaw A, Gollob J,
Adams D. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J Rare Dis 2015;10:109.
983. Rosenblum H, Castano A, Alvarez J, Goldsmith J, Helmke S, Maurer MS. TTR
(transthyretin) stabilizers are associated with improved survival in patients with
TTR cardiac amyloidosis. Circ Heart Fail 2018;11:e004769.
984. Kremastinos DT, Farmakis D. Iron overload cardiomyopathy in clinical practice.
Circulation 2011;124:22532263.
985. Farmakis D, Triposkiadis F, Lekakis J, Parissis J. Heart failure in haemoglobinopathies: pathophysiology, clinical phenotypes, and management. Eur J Heart Fail
2017;19:479489.
986. Aessopos A, Farmakis D, Deftereos S, Tsironi M, Tassiopoulos S, Moyssakis I,
Karagiorga M. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest 2005;127:15231530.
987. Farmakis D, Aessopos A. Pulmonary hypertension associated with hemoglobinopathies: prevalent but overlooked. Circulation 2011;123:12271232.
988. Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller GP,
Lung B, Kluin J, Lang IM, Meijboom F, Moons P, Mulder BJM, Oechslin E, RoosHesselink JW, Schwerzmann M, Sondergaard L, Zeppenfeld K, ESC Scientific
Document Group. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J 2021;42:563645.
989. Diller GP, Kempny A, Alonso-Gonzalez R, Swan L, Uebing A, Li W, BabuNarayan S, Wort SJ, Dimopoulos K, Gatzoulis MA. Survival prospects and circumstances of death in contemporary adult congenital heart disease patients under follow-up at a large tertiary centre. Circulation 2015;132:21182125.
990. Budts W, Roos-Hesselink J, Radle-Hurst T, Eicken A, McDonagh TA,
Lambrinou E, Crespo-Leiro MG, Walker F, Frogoudaki AA. Treatment of heart failure in adult congenital heart disease: a position paper of the Working Group of Grown-Up Congenital Heart Disease and the Heart Failure Association of the European Society of Cardiology. Eur Heart J 2016;37:14191427.
991. Lluri G, Lin J, Reardon L, Miner P, Whalen K, Aboulhosn J. Early experience with sacubitril/valsartan in adult patients with congenital heart disease. World J
Pediatr Congenit Heart Surg 2019;10:292295.
992. Appadurai V, Thoreau J, Malpas T, Nicolae M. Sacubitril/valsartan in adult congenital heart disease patients with chronic heart failure – a single centre case series and call for an international registry. Heart Lung Circ 2020;29:137141.
993. Maurer SJ, Pujol Salvador C, Schiele S, Hager A, Ewert P, Tutarel O. Sacubitril/
valsartan for heart failure in adults with complex congenital heart disease. Int J
Cardiol 2020;300:137140.
994. Van De Bruaene A, Meier L, Droogne W, De Meester P, Troost E, Gewillig M,
Budts W. Management of acute heart failure in adult patients with congenital heart disease. Heart Fail Rev 2018;23:114.
995. Minchin M, Roland M, Richardson J, Rowark S, Guthrie B. Quality of care in the United Kingdom after removal of financial incentives. N Engl J Med
2018;379:948957.
996. Song Z, Ji Y, Safran DG, Chernew ME. Health care spending, utilization, and quality 8 years into global payment. N Engl J Med 2019;381:252263.
997. Aktaa S, Batra G, Wallentin L, Baigent C, Erlinge D, James S, Ludman P,
Maggioni AP, Price S, Weston C, Casadei B, Gale CP. European Society of
Cardiology methodology for the development of quality indicators for the quantification of cardiovascular care and outcomes. Eur Heart J Qual Care Clin
Outcomes 2020. doi: 10.1093/ehjqcco/qcaa069.
998. Arbelo E, Aktaa S, Bollmann A, D’Avila A, Drossart I, Dwight J, Hills MT,
Hindricks G, Kusumoto FM, Lane DA, Lau DH, Lettino M, Lip GYH, Lobban
T, Pak HN, Potpara T, Saenz LC, Van Gelder IC, Varosy P, Gale CP, Dagres
N, Reviewers, Boveda S, Deneke T, Defaye P, Conte G, Lenarczyk R,
Providencia R, Guerra JM, Takahashi Y, Pisani C, Nava S, Sarkozy A, Glotzer
TV, Martins Oliveira M. Quality indicators for the care and outcomes of adults with atrial fibrillation. Europace 2021;23:494495.
999. Schiele F, Aktaa S, Rossello X, Ahrens I, Claeys MJ, Collet JP, Fox KAA, Gale
CP, Huber K, Iakobishvili Z, Keys A, Lambrinou E, Leonardi S, Lettino M,
Masoudi FA, Price S, Quinn T, Swahn E, Thiele H, Timmis A, Tubaro M, Vrints
CJM, Walker D, Bueno H, Scientific Document Group ESC, Halvorsen S,
Jernberg T, Jortveit J, Blondal M, Ibanez B, Hassager C. 2020 Update of the quality indicators for acute myocardial infarction: a position paper of the
Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTE-ACS guideline group. Eur Heart J Acute
Cardiovasc Care 2021;10:224233.
1000. Collet JP, Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt DL, Dendale P,
Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Juni P,
Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten
FH, Sibbing D, Siontis GCM, ESC Scientific Document Group. 2020 ESC
Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021;42:12891367.
1001. Wallentin L, Gale CP, Maggioni A, Bardinet I, Casadei B. EuroHeart: European
Unified Registries On Heart Care Evaluation and Randomized Trials. Eur Heart
J 2019;40:27452749.

<!-- 2021_Valvular_Heart_Disease.md -->

# ESC Guidelines: Valvular Heart Disease (2021)

**Source**: `2021_Valvular_Heart_Disease.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 72

---

## Table of Contents

- [ehab395-S1](#ehab395-s1) *(p. 4)*
- [ehab395-S2](#ehab395-s2) *(p. 6)*
- [ehab395-S2.1](#ehab395-s21) *(p. 6)*
- [ehab395-S2.2](#ehab395-s22) *(p. 7)*
- [ehab395-S2.3](#ehab395-s23) *(p. 12)*
- [ehab395-S2.4](#ehab395-s24) *(p. 12)*
- [tblfn1](#tblfn1) *(p. 12)*
- [ehab395-S3](#ehab395-s3) *(p. 13)*
- [ehab395-S3.1](#ehab395-s31) *(p. 13)*
- [ehab395-S3.2](#ehab395-s32) *(p. 13)*
- [tblfn3](#tblfn3) *(p. 13)*
- [ehab395-S3.2.1](#ehab395-s321) *(p. 14)*
- [ehab395-S3.2.2](#ehab395-s322) *(p. 14)*
- [ehab395-S3.2.3](#ehab395-s323) *(p. 15)*
- [ehab395-S3.2.3.1](#ehab395-s3231) *(p. 15)*
- [ehab395-S3.2.3.2](#ehab395-s3232) *(p. 15)*
- [ehab395-S3.2.3.3](#ehab395-s3233) *(p. 15)*
- [ehab395-S3.2.3.4](#ehab395-s3234) *(p. 15)*
- [ehab395-S3.2.3.5](#ehab395-s3235) *(p. 15)*
- [ehab395-S3.2.3.6](#ehab395-s3236) *(p. 15)*
- [ehab395-S3.2.4](#ehab395-s324) *(p. 15)*
- [ehab395-S3.2.4.1](#ehab395-s3241) *(p. 15)*
- [ehab395-S3.2.4.2](#ehab395-s3242) *(p. 15)*
- [ehab395-S3.2.5](#ehab395-s325) *(p. 15)*
- [ehab395-S3.3](#ehab395-s33) *(p. 15)*
- [ehab395-S3.3.1](#ehab395-s331) *(p. 16)*
- [ehab395-S3.3.2](#ehab395-s332) *(p. 16)*
- [ehab395-S3.4](#ehab395-s34) *(p. 16)*
- [ehab395-S3.5](#ehab395-s35) *(p. 16)*
- [ehab395-S3.6](#ehab395-s36) *(p. 16)*
- [ehab395-S3.6.1](#ehab395-s361) *(p. 16)*
- [ehab395-S3.6.2](#ehab395-s362) *(p. 17)*
- [ehab395-S3.7](#ehab395-s37) *(p. 17)*
- [tblfn5](#tblfn5) *(p. 17)*
- [tblfn6](#tblfn6) *(p. 17)*
- [tblfn7](#tblfn7) *(p. 17)*
- [tblfn8](#tblfn8) *(p. 17)*
- [tblfn9](#tblfn9) *(p. 17)*
- [tblfn10](#tblfn10) *(p. 17)*
- [tblfn11](#tblfn11) *(p. 17)*
- [tblfn13](#tblfn13) *(p. 17)*
- [tblfn14](#tblfn14) *(p. 17)*
- [tblfn15](#tblfn15) *(p. 17)*
- [ehab395-S3.8](#ehab395-s38) *(p. 18)*
- [ehab395-S4](#ehab395-s4) *(p. 18)*
- [ehab395-S4.1](#ehab395-s41) *(p. 18)*
- [ehab395-S4.1.1](#ehab395-s411) *(p. 18)*
- [ehab395-S4.1.2](#ehab395-s412) *(p. 18)*
- [ehab395-S4.2](#ehab395-s42) *(p. 18)*
- [tblfn17](#tblfn17) *(p. 18)*
- [tblfn18](#tblfn18) *(p. 18)*
- [tblfn19](#tblfn19) *(p. 18)*
- [tblfn20](#tblfn20) *(p. 18)*
- [ehab395-S4.3](#ehab395-s43) *(p. 20)*
- [ehab395-S4.4](#ehab395-s44) *(p. 20)*
- [tblfn22](#tblfn22) *(p. 20)*
- [tblfn23](#tblfn23) *(p. 20)*
- [tblfn24](#tblfn24) *(p. 20)*
- [tblfn25](#tblfn25) *(p. 20)*
- [tblfn26](#tblfn26) *(p. 20)*
- [tblfn27](#tblfn27) *(p. 20)*
- [tblfn28](#tblfn28) *(p. 20)*
- [ehab395-S4.5](#ehab395-s45) *(p. 21)*
- [ehab395-S5](#ehab395-s5) *(p. 21)*
- [ehab395-S5.1](#ehab395-s51) *(p. 21)*
- [ehab395-S5.1.1](#ehab395-s511) *(p. 21)*
- [ehab395-S5.1.2](#ehab395-s512) *(p. 21)*
- [ehab395-S5.1.3](#ehab395-s513) *(p. 23)*
- [tblfn30](#tblfn30) *(p. 23)*
- [tblfn31](#tblfn31) *(p. 23)*
- [tblfn32](#tblfn32) *(p. 23)*
- [tblfn33](#tblfn33) *(p. 23)*
- [tblfn34](#tblfn34) *(p. 23)*
- [tblfn35](#tblfn35) *(p. 23)*
- [ehab395-S5.2](#ehab395-s52) *(p. 24)*
- [ehab395-S5.2.1](#ehab395-s521) *(p. 24)*
- [ehab395-S5.2.2](#ehab395-s522) *(p. 25)*
- [ehab395-S5.2.3](#ehab395-s523) *(p. 25)*
- [ehab395-S5.3](#ehab395-s53) *(p. 27)*
- [ehab395-S5.4](#ehab395-s54) *(p. 27)*
- [ehab395-S5.5](#ehab395-s55) *(p. 27)*
- [tblfn37](#tblfn37) *(p. 27)*
- [tblfn38](#tblfn38) *(p. 27)*
- [tblfn39](#tblfn39) *(p. 27)*
- [tblfn40](#tblfn40) *(p. 27)*
- [tblfn41](#tblfn41) *(p. 27)*
- [tblfn42](#tblfn42) *(p. 27)*
- [tblfn43](#tblfn43) *(p. 27)*
- [tblfn44](#tblfn44) *(p. 27)*
- [tblfn45](#tblfn45) *(p. 27)*
- [ehab395-S6](#ehab395-s6) *(p. 28)*
- [ehab395-S6.1](#ehab395-s61) *(p. 28)*
- [ehab395-S6.1.1](#ehab395-s611) *(p. 28)*
- [ehab395-S6.1.2](#ehab395-s612) *(p. 28)*
- [tblfn47](#tblfn47) *(p. 29)*
- [tblfn48](#tblfn48) *(p. 29)*
- [tblfn49](#tblfn49) *(p. 29)*
- [ehab395-S6.1.3](#ehab395-s613) *(p. 30)*
- [ehab395-S6.1.4](#ehab395-s614) *(p. 30)*
- [ehab395-S6.1.5](#ehab395-s615) *(p. 30)*
- [ehab395-S6.2](#ehab395-s62) *(p. 30)*
- [ehab395-S6.2.1](#ehab395-s621) *(p. 30)*
- [tblfn51](#tblfn51) *(p. 30)*
- [tblfn52](#tblfn52) *(p. 30)*
- [tblfn53](#tblfn53) *(p. 30)*
- [tblfn54](#tblfn54) *(p. 30)*
- [tblfn55](#tblfn55) *(p. 30)*
- [ehab395-S6.2.2](#ehab395-s622) *(p. 31)*
- [ehab395-S6.2.3](#ehab395-s623) *(p. 31)*
- [tblfn57](#tblfn57) *(p. 32)*
- [tblfn58](#tblfn58) *(p. 32)*
- [tblfn59](#tblfn59) *(p. 32)*
- [tblfn60](#tblfn60) *(p. 32)*
- [tblfn61](#tblfn61) *(p. 32)*
- [tblfn62](#tblfn62) *(p. 32)*
- [ehab395-S7](#ehab395-s7) *(p. 34)*
- [ehab395-S7.1](#ehab395-s71) *(p. 34)*
- [ehab395-S7.1.1](#ehab395-s711) *(p. 34)*
- [ehab395-S7.1.2](#ehab395-s712) *(p. 34)*
- [tblfn64](#tblfn64) *(p. 34)*
- [tblfn65](#tblfn65) *(p. 34)*
- [tblfn66](#tblfn66) *(p. 34)*
- [tblfn67](#tblfn67) *(p. 34)*
- [tblfn69](#tblfn69) *(p. 34)*
- [tblfn70](#tblfn70) *(p. 34)*
- [ehab395-S7.1.3](#ehab395-s713) *(p. 35)*
- [ehab395-S7.1.4](#ehab395-s714) *(p. 36)*
- [ehab395-S7.1.5](#ehab395-s715) *(p. 36)*
- [ehab395-S7.2](#ehab395-s72) *(p. 36)*
- [ehab395-S7.2.1](#ehab395-s721) *(p. 36)*
- [ehab395-S7.2.2](#ehab395-s722) *(p. 36)*
- [ehab395-S8](#ehab395-s8) *(p. 36)*
- [ehab395-S8.1](#ehab395-s81) *(p. 36)*
- [ehab395-S8.2](#ehab395-s82) *(p. 37)*
- [tblfn72](#tblfn72) *(p. 37)*
- [tblfn73](#tblfn73) *(p. 37)*
- [tblfn74](#tblfn74) *(p. 37)*
- [tblfn75](#tblfn75) *(p. 37)*
- [tblfn76](#tblfn76) *(p. 37)*
- [ehab395-S8.3](#ehab395-s83) *(p. 38)*
- [ehab395-S9](#ehab395-s9) *(p. 38)*
- [ehab395-S9.1](#ehab395-s91) *(p. 39)*
- [ehab395-S9.2](#ehab395-s92) *(p. 39)*
- [ehab395-S9.3](#ehab395-s93) *(p. 39)*
- [ehab395-S10](#ehab395-s10) *(p. 39)*
- [tblfn78](#tblfn78) *(p. 39)*
- [tblfn79](#tblfn79) *(p. 39)*
- [tblfn80](#tblfn80) *(p. 39)*
- [tblfn81](#tblfn81) *(p. 39)*
- [tblfn82](#tblfn82) *(p. 39)*
- [tblfn83](#tblfn83) *(p. 39)*
- [tblfn84](#tblfn84) *(p. 39)*
- [ehab395-S11](#ehab395-s11) *(p. 40)*
- [ehab395-S11.1](#ehab395-s111) *(p. 40)*
- [tblfn86](#tblfn86) *(p. 40)*
- [tblfn87](#tblfn87) *(p. 40)*
- [tblfn88](#tblfn88) *(p. 40)*
- [tblfn89](#tblfn89) *(p. 40)*
- [tblfn90](#tblfn90) *(p. 40)*
- [tblfn91](#tblfn91) *(p. 40)*
- [tblfn92](#tblfn92) *(p. 40)*
- [tblfn93](#tblfn93) *(p. 40)*
- [ehab395-S11.2](#ehab395-s112) *(p. 41)*
- [ehab395-S11.3](#ehab395-s113) *(p. 41)*
- [ehab395-S11.3.1](#ehab395-s1131) *(p. 41)*
- [ehab395-S11.3.1.1](#ehab395-s11311) *(p. 41)*
- [ehab395-S11.3.1.2](#ehab395-s11312) *(p. 41)*
- [ehab395-S11.3.1.3](#ehab395-s11313) *(p. 41)*
- [tblfn95](#tblfn95) *(p. 41)*
- [tblfn96](#tblfn96) *(p. 41)*
- [tblfn97](#tblfn97) *(p. 41)*
- [tblfn98](#tblfn98) *(p. 41)*
- [tblfn99](#tblfn99) *(p. 41)*
- [ehab395-S11.3.1.4](#ehab395-s11314) *(p. 42)*
- [ehab395-S11.3.1.5](#ehab395-s11315) *(p. 42)*
- [ehab395-S11.3.2](#ehab395-s1132) *(p. 42)*
- [ehab395-S11.3.2.1](#ehab395-s11321) *(p. 42)*
- [ehab395-S11.3.2.2](#ehab395-s11322) *(p. 42)*
- [tblfn101](#tblfn101) *(p. 43)*
- [tblfn102](#tblfn102) *(p. 43)*
- [tblfn103](#tblfn103) *(p. 43)*
- [tblfn104](#tblfn104) *(p. 43)*
- [tblfn105](#tblfn105) *(p. 43)*
- [tblfn106](#tblfn106) *(p. 43)*
- [tblfn107](#tblfn107) *(p. 43)*
- [ehab395-S11.3.3](#ehab395-s1133) *(p. 44)*
- [ehab395-S11.4](#ehab395-s114) *(p. 44)*
- [ehab395-S11.4.1](#ehab395-s1141) *(p. 44)*
- [ehab395-S11.4.2](#ehab395-s1142) *(p. 46)*
- [ehab395-S11.4.2.1](#ehab395-s11421) *(p. 46)*
- [ehab395-S11.4.2.2](#ehab395-s11422) *(p. 46)*
- [ehab395-S11.4.3](#ehab395-s1143) *(p. 46)*
- [ehab395-S11.4.4](#ehab395-s1144) *(p. 46)*
- [ehab395-S11.4.4.1](#ehab395-s11441) *(p. 46)*
- [ehab395-S11.4.4.2](#ehab395-s11442) *(p. 46)*
- [ehab395-S11.4.4.3](#ehab395-s11443) *(p. 46)*
- [ehab395-S11.4.5](#ehab395-s1145) *(p. 46)*
- [ehab395-S12](#ehab395-s12) *(p. 47)*
- [ehab395-S12.1](#ehab395-s121) *(p. 47)*
- [ehab395-S12.2](#ehab395-s122) *(p. 47)*
- [ehab395-S12.2.1](#ehab395-s1221) *(p. 47)*
- [ehab395-S12.2.2](#ehab395-s1222) *(p. 47)*
- [ehab395-S12.2.3](#ehab395-s1223) *(p. 47)*
- [ehab395-S12.3](#ehab395-s123) *(p. 47)*
- [ehab395-S13](#ehab395-s13) *(p. 47)*
- [tblfn108](#tblfn108) *(p. 47)*
- [tblfn109](#tblfn109) *(p. 47)*
- [tblfn110](#tblfn110) *(p. 47)*
- [ehab395-S13.1](#ehab395-s131) *(p. 48)*
- [ehab395-S13.2](#ehab395-s132) *(p. 48)*
- [ehab395-S13.2.1](#ehab395-s1321) *(p. 48)*
- [ehab395-S13.2.2](#ehab395-s1322) *(p. 49)*
- [ehab395-S14](#ehab395-s14) *(p. 49)*
- [ehab395-S15](#ehab395-s15) *(p. 50)*
- [ehab395-S16](#ehab395-s16) *(p. 51)*
- [tblfn111](#tblfn111) *(p. 53)*
- [ehab395-S17](#ehab395-s17) *(p. 54)*
- [ehab395-S18](#ehab395-s18) *(p. 54)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2021 ESC/EACTS Guidelines for the management of valvular heart disease
Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the
European Association for Cardio-Thoracic Surgery (EACTS)
Authors/Task Force Members: Alec Vahanian
* (ESC Chairperson) (France),
Friedhelm Beyersdorf*1 (EACTS Chairperson) (Germany), Fabien Praz
(ESC Task Force Coordinator) (Switzerland), Milan Milojevic1 (EACTS Task Force
Coordinator) (Serbia), Stephan Baldus (Germany), Johann Bauersachs (Germany),
Davide Capodanno (Italy), Lenard Conradi1 (Germany), Michele De Bonis1 (Italy),
Ruggero De Paulis1 (Italy), Victoria Delgado (Netherlands), Nick Freemantle1
(United Kingdom), Martine Gilard (France), Kristina H. Haugaa (Norway),
Anders Jeppsson1 (Sweden), Peter Ju¨ni (Canada), Luc Pierard (Belgium),
Bernard D. Prendergast (United Kingdom), J. Rafael Sadaba1 (Spain),
Christophe Tribouilloy (France), Wojtek Wojakowski (Poland), ESC/EACTS
Scientific Document Group
* Corresponding authors: Alec Vahanian, UFR Medecine, Universite´ de Paris, site Bichat, 16 rue Huchard, 75018 Paris, France; and LVTS INSERM U1148, GH Bichat, 46, rue
Henri Huchard, 75018 Paris, France. Tel: þ 33 6 63 15 56 68, E-mail: alec.vahanian@gmail.com; Friedhelm Beyersdorf, Department of Cardiovascular Surgery, University Heart
Center, University Hospital Freiburg, Germany; and Medical Faculty of the Albert-Ludwigs-University, Freiburg, Germany, Hugstetterstr. 55, D-79106 Freiburg, Germany. Tel:
þ49 761 270 28180. E-mail: friedhelm.beyersdorf@uniklinik-freiburg.de
Author/Task Force Member afﬁliations: listed in Author information.
ESC Clinical Practice Guidelines Committee (CPG): listed in the Appendix.
EACTS Council: listed in the Appendix.
1Representing the European Association for Cardio-Thoracic Surgery (EACTS)
ESC subspecialty communities having participated in the development of this document:
Associations: Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging (EACVI), European Association of Percutaneous
Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA).
Councils: Council on Valvular Heart Disease.
Working Groups: Cardiovascular Surgery, Thrombosis.
Patient Forum
The content of these European Society of Cardiology (ESC) / European Association for Cardio-Thoracic Surgery (EACTS) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC/EACTS Guidelines may be translated or reproduced in any form without written permission from the ESC
and the EACTS. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
Disclaimer: The ESC/EACTS Guidelines represent the views of the ESC and the EACTS and were produced after careful consideration of the scientiﬁc and medical knowledge and the evidence available at the time of their publication. The ESC and the EACTS are not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC/EACTS Guidelines and any other ofﬁcial recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC/EACTS Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC/EACTS Guidelines do not override, in any way whatsoever,
the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC/EACTS Guidelines exempt health professionals from taking into full and careful consideration the relevant ofﬁcial updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientiﬁcally accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
This article has been co-published with permission in the European Heart Journal and European Journal of Cardio-Thoracic Surgery. V
C the European Society of Cardiology and the
European Association for Cardio-Thoracic Surgery 2021. All rights reserved. The articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Either citation can be used when citing this article. For permissions, please email journals.permissions@oup.com.
ESC/EACTS GUIDELINES
https://doi.org/10.1093/eurheartj/ehab395


<!-- PAGE 2 -->

### Page 2

....................................................................................
Document Reviewers: Franz-Josef Neumann (ESC Review Coordinator) (Germany), Patrick Myers1
(EACTS Review Coordinator) (Switzerland), Magdy Abdelhamid (Egypt), Stephan Achenbach (Germany),
Riccardo Asteggiano (Italy), Fabio Barili1 (Italy), Michael A. Borger (Germany), Thierry Carrel1
(Switzerland), Jean-Philippe Collet (France), Dan Foldager (Denmark), Gilbert Habib (France),
Christian Hassager (Denmark), Alar Irs1 (Estonia), Bernard Iung (France), Marjan Jahangiri1 (United
Kingdom), Hugo A. Katus (Germany), Konstantinos C. Koskinas (Switzerland), Steffen Massberg
(Germany), Christian E. Mueller (Switzerland), Jens Cosedis Nielsen (Denmark), Philippe Pibarot (Canada),
Amina Rakisheva (Kazakhstan), Marco Rofﬁ(Switzerland), Andrea Rubboli (Italy), Evgeny Shlyakhto
(Russia), Matthias Siepe1 (Germany), Marta Sitges (Spain), Lars Sondergaard (Denmark),
Miguel Sousa-Uva1 (Portugal), Guiseppe Tarantini (Italy), Jose Luis Zamorano (Spain)
All experts involved in the development of these guidelines have submitted declarations of interest.
These have been compiled in a report and published in a supplementary document simultaneously to the guidelines. The report is also available on the ESC website www.escardio.org/guidelines.
For the Supplementary Data which include background information and detailed discussion of the data that have provided the basis for the guidelines see European Heart Journal online.
...................................................................................................................................................................................................
Keywords
Guidelines • valvular heart disease • valve disease • valve surgery • percutaneous valve intervention •
aortic regurgitation • aortic stenosis • mitral regurgitation • mitral stenosis • tricuspid regurgitation •
tricuspid stenosis • prosthetic heart valves
Table of Contents
1 Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2.1 Why do we need new guidelines on valvular heart disease? . . . . . 6
2.2 Methodology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
2.3 Content of these guidelines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
2.4 New format of the guidelines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
2.5 How to use these guidelines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
3 General comments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
3.1 Concepts of Heart Team and Heart Valve Centre . . . . . . . . . . . . . 13
3.2 Patient evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
3.2.1 Clinical evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
3.2.2 Echocardiography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
3.2.3 Other non-invasive investigations . . . . . . . . . . . . . . . . . . . . . . . . 15
3.2.4 Invasive investigations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
3.2.5 Assessment of comorbidity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
3.3 Risk stratification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
3.3.1 Risk scores . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
3.3.2 Other factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
3.4 Patient-related aspects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
3.5 Local resources . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
3.6 Management of associated conditions . . . . . . . . . . . . . . . . . . . . . . . . 16
3.6.1 Coronary artery disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
3.6.2 Atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
3.7 Endocarditis prophylaxis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
3.8 Prophylaxis for rheumatic fever . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
4 Aortic regurgitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
4.1 Evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
4.1.1 Echocardiography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
4.1.2 Computed tomography and cardiac magnetic resonance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
4.2 Indications for intervention . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
4.3 Medical therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
4.4 Serial testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
4.5 Special patient populations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
5 Aortic stenosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
5.1 Evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
5.1.1 Echocardiography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
5.1.2 Additional diagnostic and prognostic parameters . . . . . . . . . 21
5.1.3 TAVI diagnostic workup . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
5.2 Indications for intervention (SAVR or TAVI) . . . . . . . . . . . . . . . . . . 24
5.2.1 Symptomatic aortic stenosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
5.2.2 Asymptomatic aortic stenosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
5.2.3 The mode of intervention . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
5.3 Medical therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
5.4 Serial testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
5.5 Special patient populations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
6 Mitral regurgitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
6.1 Primary mitral regurgitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
6.1.1 Evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
6.1.2 Indications for intervention . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
6.1.3 Medical therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
6.1.4 Serial testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
ESC/EACTS Guidelines
562
Online publish-ahead-of-print 28 August 2021


<!-- PAGE 3 -->

### Page 3

.............................................................................................................................................................................
6.1.5 Special populations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
6.2 Secondary mitral regurgitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
6.2.1 Evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
6.2.2 Medical therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
6.2.3 Indications for intervention . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
7 Mitral stenosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
7.1 Rheumatic mitral stenosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
7.1.1 Evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
7.1.2 Indications for intervention . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
7.1.3 Medical therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
7.1.4 Serial testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
7.1.5 Special patient populations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
7.2 Degenerative mitral stenosis with mitral annular calcification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
7.2.1 Evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
7.2.2 Indications for intervention . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
8 Tricuspid regurgitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
8.1 Evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
8.2 Indications for intervention . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
8.3 Medical therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
9 Tricuspid stenosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
9.1 Evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
9.2 Indications for intervention . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
9.3 Medical therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
10 Combined and multiple-valve diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
11 Prosthetic valves . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
11.1 Choice of prosthetic valve . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
11.2 Baseline assessment and follow-up . . . . . . . . . . . . . . . . . . . . . . . . . . 41
11.3 Antithrombotic management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
11.3.1 Mechanical prostheses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
11.3.2 Bioprostheses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
11.3.3 Valve repair . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
11.4 Management of prosthetic valve dysfunction and complications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
11.4.1 Structural valve deterioration . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
11.4.2 Non-structural valve dysfunction . . . . . . . . . . . . . . . . . . . . . . . 46
11.4.3 Endocarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
11.4.4 Thrombosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
11.4.5 Heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
12 Management during non-cardiac surgery . . . . . . . . . . . . . . . . . . . . . . . . 47
12.1 Preoperative evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
12.2 Specific valve lesions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
12.2.1 Aortic stenosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
12.2.2 Mitral stenosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
12.2.3 Aortic andmitral regurgitation . . . . . . . . . . . . . . . . . . . . . . . . . . 47
12.3 Perioperativemonitoring . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
13 Management during pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
13.1 Management before pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
13.2 Management during pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
13.2.1 Patients with native valve disease . . . . . . . . . . . . . . . . . . . . . . . 48
13.2.2 Mechanical prosthesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
14 Key messages . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
15 Gaps in evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
16 To Do and Not To Do . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
17 Supplementary data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
18 Author information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
19 Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
20 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
List of Tables
Table 1 Classes of recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
Table 2 Levels of evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
Table 3 What is new . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
Table 4 Requirements for a Heart Valve Centre . . . . . . . . . . . . . . . . . . . . 13
Table 5 Echocardiographic criteria for the definition of severe aortic valve regurgitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Table 6 Clinical, anatomical and procedural factors that influence the choice of treatment modality for an individual patient . . . . . . . . . . . . 23
Table 7 Severe mitral regurgitation criteria based on 2D
echocardiography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Table 8 Contraindications for percutaneous mitral commissurotomy in rheumatic mitral stenosisa . . . . . . . . . . . . . . . . . . . . . 34
Table 9 Echocardiographic criteria for grading severity of tricuspid regurgitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
Table 10 Target international normalized ratio for mechanical prostheses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
List of Figures
Figure 1 Central illustration: Patient-centred evaluation for intervention . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Figure 2 Management of patients with aortic regurgitation . . . . . . . . . . . 20
Figure 3 Integrated imaging assessment of aortic stenosis . . . . . . . . . . . . 22
Figure 4 Management of patients with severe aortic stenosis . . . . . . . . . 24
Figure 5 Management of patients with severe chronic primary mitral regurgitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
Figure 6 Management of patients with chronic severe secondary mitral regurgitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
Figure 7 Management of clinically significant rheumatic mitral stenosis (MVA <_1.5 cm2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
Figure 8 Management of tricuspid regurgitation (TR) . . . . . . . . . . . . . . . . 38
Figure 9 Antithrombotic therapy for valve prostheses . . . . . . . . . . . . . . . 44
Figure 10 Management of left-sided obstructive and non-obstructive mechanical prosthetic thrombosis . . . . . . . . . . . . . . . . . 45
Figure 11 Management of non-cardiac surgery (NCS) in patients with severe aortic stenosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
Tables of Recommendations
Recommendations for management of CAD in patients with VHD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
Recommendations on management of atrial fibrillation in patients with native VHD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Recommendations on indications for surgery in (A) severe aortic regurgitation and (B) aortic root or tubular ascending aortic aneurysm (irrespective of the severity of aortic regurgitation) . . . . . . . 19
Recommendations on indications for interventiona in symptomatic
(A) and asymptomatic (B) aortic stenosis and recommended mode of intervention (C) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
Recommendations on indications for intervention in severe primary mitral regurgitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
ESC/EACTS Guidelines
563


<!-- PAGE 4 -->

### Page 4

............................................................................................................................................................................
Recommendations on indications for mitral valve intervention in chronic severe secondary mitral regurgitation . . . . . . . . . . . . . . . . . . . . . . 32
Recommendations on indications for percutaneous mitral commissurotomy and mitral valve surgery in clinically significant
(moderate or severe) mitral stenosis (valve area <_1.5 cm2) . . . . . . . . . . 34
Recommendations on indications for intervention in tricuspid valve disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
Recommendations for prosthetic valve selection . . . . . . . . . . . . . . . . . . . . 40
Recommendations for management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
Recommendations on management of prosthetic valve dysfunction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
Abbreviations and acronyms
2D
Two-dimensional
3D
Three-dimensional
ACEI
Angiotensin-converting enzyme inhibitor
ACS
Acute coronary syndrome
AF
Atrial ﬁbrillation
ARB
Angiotensin receptor blocker
ARC-HBR
Academic Research Consortium  High Bleeding
Risk
ASA
Acetylsalicylic acid
AVA
Aortic valve area
BAV
Balloon aortic valvuloplasty
BHV
Biological heart valve
BVF
Bioprosthetic valve failure
BNP
B-type natriuretic peptide
BP
Blood pressure
BSA
Body surface area
CABG
Coronary artery bypass grafting
CAD
Coronary artery disease
CCT
Cardiac computed tomography
CI
Conﬁdence interval
CMR
Cardiac magnetic resonance
CRT
Cardiac resynchronization therapy
CT
Computed tomography
DAPT
Dual antiplatelet therapy
DPm
Mean pressure gradient
DSE
Dobutamine stress echocardiography
DVI
Doppler velocity index/dimensionless index
EACTS
European Association for Cardio-Thoracic Surgery
ECG
Electrocardiogram
EDV
End-diastolic velocity
EROA
Effective regurgitant oriﬁce area
ESC
European Society of Cardiology
EuroSCORE
European System for Cardiac Operative Risk
Evaluation
FFP
Fresh frozen plasma
GDMT
Guideline-directed medical treatment therapy
HALT
Hypo-attenuated leaﬂet thickening
HTx
Heart transplantation
INR
International normalized ratio i.v.
Intravenous
LA
Left atrium/left atrial
LAA
Left atrial appendage
LMWH
Low-molecular-weight heparin
LV
Left ventricle/left ventricular
LVAD
Left ventricular assist devices
LVEDD
Left ventricular end-diastolic diameter
LVEF
Left ventricular ejection fraction
LVESD
Left ventricular end-systolic diameter
LVOT
Left ventricular outﬂow tract
MAC
Mitral annular calciﬁcation
MHV
Mechanical heart valve
MIDA
Mitral Regurgitation International Database
MVA
Mitral valve area
NCS
Non-cardiac surgery
NOAC
Non-vitamin K antagonist oral anticoagulant
NYHA
New York Heart Association
OAC
Oral anticoagulation
PCC
Prothrombin complex concentration
PCI
Percutaneous coronary intervention
PET
Positron emission tomography
PISA
Proximal isovelocity surface area
PMC
Percutaneous mitral commissurotomy
PMR
Primary mitral regurgitation
PPM
Patient-prosthesis mismatch
PROM
Predicted risk of mortality
RCT
Randomized controlled trial
RV
Right ventricle/right ventricular
SAPT
Single antiplatelet therapy
SAVR
Surgical aortic valve replacement
SMR
Secondary mitral regurgitation
SVD
Structural valve deterioration
SPAP
Systolic pulmonary arterial pressure
STS
Society of Thoracic Surgeons
SVi
Stroke volume index
TAPSE
Tricuspid annular pulmonary systolic excursion
TAVI
Transcatheter aortic valve implantation
TE
Thromboembolism
TEER
Transcatheter edge-to-edge repair
TTVI
Transcatheter tricuspid valve intervention
TOE
Transoesophageal echocardiography
TTE
Transthoracic echocardiography
TVI
Time-velocity integral
TVR
Tricuspid valve replacement or repair
UFH
Unfractionated heparin
VHD
Valvular heart disease
VKA
Vitamin K antagonist
Vmax
Peak transvalvular velocity
1 Preamble
Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the
ESC/EACTS Guidelines
564


<!-- PAGE 5 -->

### Page 5

.....................................................................................................
responsible health professional(s) in consultation with the patient and caregiver as appropriate.
A great number of guidelines have been issued in recent years by the European Society of Cardiology (ESC) and its partners such as the European Association for Cardio-Thoracic Surgery (EACTS), as well as by other societies and organizations. Because of their impact on clinical practice, quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC
Guidelines can be found on the ESC website (https://www.escardio.
org/Guidelines). The ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated.
In addition to the publication of Clinical Practice Guidelines, the
ESC carries out the EURObservational Research Programme of international registries of cardiovascular diseases and interventions which are essential to assess diagnostic/therapeutic processes, use of resources and adherence to guidelines. These registries aim at providing a better understanding of medical practice in Europe and around the world, based on high-quality data collected during routine clinical practice.
The Members of this Task Force were selected by the ESC and
EACTS, including representation from relevant ESC and EACTS subspecialty groups, in order to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a comprehensive review of the published evidence for management of a given condition according to ESC Clinical Practice
Guidelines Committee (CPG). A critical evaluation of diagnostic and therapeutic procedures was performed, including assessment of the riskbenefit ratio. The level of evidence and the strength of the recommendation of particular management options were weighed and graded according to predefined scales, as outlined below.
The experts of the writing and reviewing panels provided declaration of interest forms for all relationships that might be perceived as real or potential sources of conflicts of interest. Their declarations of interest were reviewed according to the ESC declaration of interest rules and can be found on the ESC website (http://www.escardio.org/
guidelines) and have been compiled in a report and published in a supplementary document simultaneously to the guidelines.
This process ensures transparency and prevents potential biases in the development and review processes. Any changes in declarations of interest that arise during the writing period were notified to the ESC and updated. The Task Force received its entire financial support from the
ESC and EACTS without any involvement fromthe healthcare industry.
The ESC CPG supervises and coordinates the preparation of new guidelines. The Committee is also responsible for the endorsement process of these guidelines. The ESC Guidelines undergo extensive review by the CPG and external experts. After appropriate revisions the guidelines are signed-off by all the experts involved in the Task
Force. The finalized document is signed-off by the CPG for publication in the European Heart Journal and the European Journal of
Cardio-Thoracic Surgery. The guidelines were developed after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating.
The task of developing ESC/EACTS Guidelines also includes the creation of educational tools and implementation programmes for the recommendations including condensed pocket guideline versions, summary slides, summary cards for non-specialists and an electronic version for digital applications (smartphones, etc.). These versions are abridged and thus, for more detailed information, the user should always access to the full text version of the guidelines,
which is freely available via the ESC and EACTS website and hosted on the EHJ and EJCTS website. The National Cardiac Societies of the
ESC are encouraged to endorse, adopt, translate and implement all
ESC Guidelines. Implementation programmes are needed because it has been shown that the outcome of disease may be favourably influenced by the thorough application of clinical recommendations.
Table 1
Classes of recommendations
©ESC/EACTS 2021
Classes of recommendations
Class I 
Evidence and/or general agreement 
that a given treatment or procedure is 
Is recommended or is indicated
Wording to use
Class III 
Evidence or general agreement that the 
given treatment or procedure is not 
useful/effective, and in some cases 
may be harmful.
Is not recommended
   Class IIb established by evidence/opinion.
May be considered
   Class IIa
Weight of evidence/opinion is in 
Should be considered
Class II 
ESC/EACTS Guidelines
565


<!-- PAGE 6 -->

### Page 6

...............................................................................................................
Health professionals are encouraged to take the ESC/EACTS
Guidelines fully into account when exercising their clinical judgment,
as well as in the determination and the implementation of preventive,
diagnostic or therapeutic medical strategies. However, the ESC/
EACTS Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient or the patient’s caregiver where appropriate and/or necessary. It is also the healthcare professional’s responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription.
2 Introduction
2.1 Why do we need new guidelines on valvular heart disease?
Since the publication of the previous version of the guidelines on the management of valvular heart disease (VHD) in 2017, new evidence has accumulated, particularly on the following topics:
• Epidemiology: the incidence of the degenerative aetiology has increased in industrialized countries while, unfortunately, rheumatic heart disease is still too frequently observed in many parts of the world.13
• Current practices regarding interventions and medical management have been analysed in new surveys at the national and
European level.
• Non-invasive evaluation using three-dimensional (3D) echocardiography, cardiac computed tomography (CCT), cardiac magnetic resonance (CMR), and biomarkers plays a more and more central role.
• New definitions of severity of secondary mitral regurgitation
(SMR) based on the outcomes of studies on intervention.
• New evidence on anti-thrombotic therapies leading to new recommendations in patients with surgical or transcatheter bioprostheses for bridging during perioperative periods and over the long term. The recommendation for non- vitamin K antagonist oral anticoagulants (NOACs) was reinforced in patients with native valvular disease, except for significant mitral stenosis, and in those with bioprostheses.
• Risk stratification for the timing of intervention. This applies mostly to (i) the evaluation of progression in asymptomatic patients based on recent longitudinal studies mostly in aortic stenosis, and (ii)
interventions in high-risk patients in whom futility should be avoided. Regarding this last aspect, the role of frailty is outlined.
• Results and indication of intervention:
 The choice of the mode of intervention: current evidence reinforces the critical role of the Heart Team, which should integrate clinical, anatomical, and procedural characteristics beyond conventional scores,
and informed patient’s treatment choice.
 Surgery: increasing experience and procedural safety led to expansion of indications toward earlier intervention in asymptomatic patients with aortic stenosis,
aortic regurgitation or mitral regurgitation and stress the preference for valve repair when it is expected to be durable. A particular emphasis is put on the need for more comprehensive evaluation and earlier surgery in tricuspid regurgitation.
 Transcatheter techniques: (i) Concerning transcatheter aortic valve implantation (TAVI), new information from randomized studies comparing TAVI
vs. surgery in low-risk patients with a follow-up of
2 years has led to a need to clarify which types of patients should be considered for each mode of intervention.
(ii)
Transcatheter edge-to-edge repair (TEER) is increasingly used in SMR and has been evaluated against optimal medical therapy resulting in an upgrade of the recommendation.
(iii) The larger number of studies on transcatheter valve-in-valve implantation after failure of surgical bioprostheses served as a basis to upgrade its
Table 2
Levels of evidence
Level of 
evidence A
Data derived from multiple randomized clinical trials 
or meta-analyses. 
Level of 
evidence B
Data derived from a single randomized clinical trial or large non-randomized studies. 
Level of 
evidence C
Consensus of opinion of the experts and/or small studies, 
retrospective studies, registries.
©ESC/EACTS 2021
ESC/EACTS Guidelines
566


<!-- PAGE 7 -->

### Page 7

.......................
indication. (iv) Finally, the encouraging preliminary experience with transcatheter tricuspid valve interventions (TTVI) suggests a potential role of this treatment in inoperable patients, although this needs to be confirmed by further evaluation.
The new evidence described above made a revision of the recommendations necessary.
2.2 Methodology
In preparation of the 2021 VHD Guidelines, a methodology group has been created for the first time, to assist the Task Force for the collection and interpretation of the evidence supporting specific recommendations. The group was constituted of two European Society of Cardiology (ESC) and two European Association for CardioThoracic Surgery (EACTS) delegates who were also members of the
Table 3
What is new
New or Revised
Recommendations in 2017 version
Class
Recommendations in 2021 version
Class
Section 3: Management of atrial ﬁbrillation in patients with native VHD
Revised
Surgical excision or external clipping of the LAA
may be considered in patients undergoing valve surgery.
IIb
LAA occlusion should be considered to reduce the thromboembolic risk in patients with AF and a CHA2DS2VASc score >_2 undergoing valve surgery.
IIa
Revised
NOACs should be considered as an alternative to
VKAs in patients with aortic stenosis, aortic regurgitation and mitral regurgitation presenting with
AF.
IIa
For stroke prevention in AF patients who are eligible for OAC, NOACs are recommended in preference to VKAs in patients with aortic stenosis,
aortic and mitral regurgitation.
I
Section 4. Recommendations on indications for surgery in severe aortic regurgitation
Revised
Surgery is indicated in asymptomatic patients with resting ejection fraction <_50%.
I
Surgery is recommended in asymptomatic patients with LVESD >50 mm or LVESD >25 mm/m2 BSA
(in patients with small body size) or resting LVEF
<_50%.
I
Surgery should be considered in asymptomatic patients with resting ejection fraction >50% with severe LV dilatation: LVEDD >70 mm or LVESD
>50 mm (or LVESD >25 mm/m2 BSA in patients with small body size).
IIa
New
Surgery may be considered in asymptomatic patients with LVESD >20 mm/m2 BSA (especially in patients with small body size) or resting LVEF
<_55%, if surgery at low-risk.
IIb
Revised
Heart Team discussion is recommended in selected patients in whom aortic valve repair may be a feasible alternative to valve replacement.
I
Aortic valve repair may be considered in selected patients at experienced centres when durable results are expected.
IIb
Section 4. Recommendations on indications for surgery in aortic root or tubular ascending aortic aneurysm (irrespective of the severity of aortic regurgitation)
Revised
Aortic valve repair, using the reimplantation or remodelling with aortic annuloplasty technique, is recommended in young patients with aortic root dilation and tricuspid aortic valves, when performed by experienced surgeons.
I
Valve-sparing aortic root replacement is recommended in young patients with aortic root dilation,
if performed in experienced centres and durable results are expected.
I
Section 5. Recommendations on indications for intervention in symptomatic and asymptomatic aortic stenosis
Symptomatic aortic stenosis
Revised
Intervention is indicated in symptomatic patients with severe, high-gradient aortic stenosis (mean gradient >_40 mmHg or peak velocity >_4.0 m/s).
I
Intervention is recommended in symptomatic patients with severe, high-gradient aortic stenosis
[mean gradient >_40 mmHg, peak velocity >_4.0 m/s and valve area <_1.0 cm2 (or <_0.6 cm2/m2)].
I
Asymptomatic patients with severe aortic stenosis
New
Intervention should be considered in asymptomatic patients with severe aortic stenosis and systolic LV dysfunction (LVEF <55%) without another cause.
IIa
Continued
ESC/EACTS Guidelines
567


<!-- PAGE 8 -->

### Page 8

Table 3
Continued
New or Revised
Recommendations in 2017 version
Class
Recommendations in 2021 version
Class
Revised
SAVR should be considered in asymptomatic patients with normal ejection fraction and none of the above-mentioned exercise test abnormalities if the surgical risk is low and one of the following
ﬁndings is present:
• Very severe aortic stenosis deﬁned by a Vmax
>5.5 m/s.
• Severe valve calciﬁcation and a rate of Vmax progression >_0.3 m/s/year.
• Markedly elevated BNP levels (>3x age- and sex-corrected normal range) conﬁrmed by repeated measurements without other explanations.
• Severe pulmonary hypertension (systolic pulmonary artery pressure at rest >60 mmHg conﬁrmed by invasive measurement) without other explanation.
IIa
Intervention should be considered in asymptomatic patients with LVEF >55% and a normal exercise test if the procedural risk is low and one of the following parameters is present:
• Very severe aortic stenosis (mean gradient
>_60 mmHg or Vmax >_5 m/s).
• Severe valve calciﬁcation (ideally assessed by
CCT) and Vmax progression >_0.3 m/s/year.
• Markedly elevated BNP levels (>3 age- and sex-corrected normal range) conﬁrmed by repeated measurements and without other explanation.
IIa
Section 5. Recommended mode of intervention In patients with aortic stenosis
Revised
The choice for intervention must be based on careful individual evaluation of technical suitability and weighing of risks and beneﬁts of each modality.
In addition, the local expertise and outcomes data for the given intervention must be taken into account.
I
The choice between surgical and transcatheter intervention must be based upon careful evaluation of clinical, anatomical and procedural factors by the Heart Team, weighing the risks and beneﬁts of each approach for an individual patient. The Heart
Team recommendation should be discussed with the patient who can then make an informed treatment choice.
I
Revised
SAVR is recommended in patients at low surgical risk (STS or EuroSCORE II <4% or logistic
EuroSCORE I <10%, and no other risk factors not included in these scores, such as frailty, porcelain aorta, sequelae of chest radiation).
I
SAVR is recommended in younger patients who are low risk for surgery (<75 years and STSPROM/ EuroSCORE II <4%) or in patients who are operable and unsuitable for transfemoral TAVI.
I
Revised
TAVI is recommended in patients who are not suitable for SAVR as assessed by the Heart Team.
I
TAVI is recommended in older patients (>_75
years), or in those who are high-risk (STS-PROM/
EuroSCORE II >8%) or unsuitable for surgery.
I
Revised
In patients who are at increased surgical risk (STS
or EuroSCORE II >_4% or logistic EuroSCORE I
>_10%, or other risk factors not included in these scores such as frailty, porcelain aorta, sequelae of chest radiation), the decision between SAVR and
TAVI should be made by the Heart Team according to the individual patient characteristics, with
TAVI being favoured in elderly patients suitable for transfemoral access.
I
SAVR or TAVI are recommended for remaining patients according to individual clinical, anatomical and procedural characteristics.
I
New
Non-transfemoral TAVI may be considered in patients who are inoperable for SAVR and unsuitable for transfemoral TAVI.
IIb
Section 6. Indications for intervention in severe primary mitral regurgitation
Revised
Surgery is indicated in asymptomatic patients with
LV dysfunction (LVESD>_45 mm and/or
LVEF<_60%).
I
Surgery is recommended in asymptomatic patients with LV dysfunction (LVESD >_40 mm and/or LVEF
<_60%).
I
Continued
ESC/EACTS Guidelines
568


<!-- PAGE 9 -->

### Page 9

Table 3
Continued
New or Revised
Recommendations in 2017 version
Class
Recommendations in 2021 version
Class
Revised
Surgery should be considered in asymptomatic patients with preserved LV function (LVESD
<45 mm and LVEF >60%) and AF secondary to mitral regurgitation or pulmonary hypertension
(SPAP at rest >50 mmHg).
IIa
Surgery should be considered in asymptomatic patients with preserved LV function (LVESD
<40 mm and LVEF >60%) and AF secondary to mitral regurgitation or pulmonary hypertension
(SPAP at rest >50 mmHg).
IIa
Revised
Surgery should be considered in asymptomatic patients with preserved LVEF (>60%) and LVESD
4044 mm when a durable repair is likely, surgical risk is low, the repair is performed in a Heart Valve
Centre and at least one of the following ﬁndings is present:
• ﬂail leaﬂet or;
• presence of signiﬁcant LA dilatation (volume index >_60 mL/m2 BSA) in sinus rhythm.
IIa
Surgical mitral valve repair should be considered in low-risk asymptomatic patients with LVEF >60%,
LVESD <40 mm and signiﬁcant LA dilatation (volume index >_60 mL/m2 or diameter >_55 mm)
when performed in a Heart Valve Centre and a durable repair is likely.
IIa
Section 6. Indications for mitral valve intervention in chronic severe secondary mitral regurgitation
New
Valve surgery/intervention is recommended only in patients with severe SMR who remain symptomatic despite GDMT (including CRT if indicated)
and has to be decided by a structured collaborative
Heart Team.
I
Patients with concomitant coronary artery or other cardiac disease requiring treatment
New
In symptomatic patients, who are judged not appropriate for surgery by the Heart Team on the basis of their individual characteristics, PCI (and/or
TAVI) possibly followed by TEER (in case of persisting severe SMR) should be considered.
IIa
Revised
Surgery is indicated in patients with severe SMR
undergoing CABG and LVEF >30%.
I
Valve surgery is recommended in patients undergoing CABG or other cardiac surgery.
I
Patients without concomitant coronary artery or other cardiac disease requiring treatment
Revised
When revascularization is not indicated and surgical risk is not low, a percutaneous edge-to-edge procedure may be considered in patients with severe secondary mitral regurgitation and LVEF
>30% who remain symptomatic despite optimal medical management (including CRT if indicated)
and who have a suitable valve morphology by echocardiography, avoiding futility.
IIb
TEER should be considered in selected symptomatic patients, not eligible for surgery and fulﬁlling criteria suggesting an increased chance of responding to the therapy.
IIa
Revised
In patients with severe SMR and LVEF <30% who remain symptomatic despite optimal medical management (including CRT if indicated) and who have no option for revascularization, the Heart Team may consider a percutaneous edge-to-edge procedure or valve surgery after careful evaluation for a ventricular assist device or heart transplant according to individual patient characteristics.
IIb
In high-risk symptomatic patients not eligible for surgery and not fulﬁlling the criteria suggesting an increased chance of responding to TEER, the
Heart Team may consider in selected cases a TEER
procedure or other trans-catheter valve therapy if applicable, after careful evaluation for ventricular assist device or heart transplant.
IIb
Section 8: Indications for intervention in primary tricuspid regurgitation
Revised
Surgery should be considered in asymptomatic or mildly symptomatic patients with severe isolated primary tricuspid regurgitation and progressive RV
dilatation or deterioration of RV function.
IIa
Surgery should be considered in asymptomatic or mildly symptomatic patients with isolated severe primary tricuspid regurgitation and RV dilatation who are appropriate for surgery.
IIa
Continued
ESC/EACTS Guidelines
569


<!-- PAGE 10 -->

### Page 10

Table 3
Continued
New or Revised
Recommendations in 2017 version
Class
Recommendations in 2021 version
Class
Section 8: Indications for intervention in secondary tricuspid regurgitation
Revised
After previous left-sided surgery and in absence of recurrent left-sided valve dysfunction, surgery should be considered in patients with severe tricuspid regurgitation who are symptomatic or have progressive RV dilatation/dysfunction, in the absence of severe RV or LV dysfunction and severe pulmonary vascular disease/hypertension.
IIa
Surgery should be considered in patients with severe secondary tricuspid regurgitation (with or without previous left-sided surgery) who are symptomatic or have RV dilatation, in the absence of severe RV or LV dysfunction and severe pulmonary vascular disease/hypertension.
IIa
New
Transcatheter treatment of symptomatic secondary severe tricuspid regurgitation may be considered in inoperable patients at a Heart Valve
Centre with expertise in the treatment of tricuspid valve disease.
IIb
Section 11. Recommendations for prosthetic valve selection
New
A bioprosthesis may be considered in patients already on long-term NOACs due to the high risk for thromboembolism.
IIb
Revised
A bioprosthesis should be considered in those
(patients) whose life expectancy is lower than the presumed durability of the bioprosthesis.
IIa
A bioprosthesis is recommended when good-quality anticoagulation is unlikely (adherence problems,
not readily available), contraindicated because of high bleeding risk (previous major bleed, comorbidities, unwillingness, adherence problems, lifestyle, occupation) and in those patients whose life expectancy is lower than the presumed durability of the bioprosthesis.
I
Section 11. Recommendations for perioperative and postoperative antithrombotic management of valve replacement or repair
Management of antithrombotic therapy in the perioperative period
New
Bridging of OAC, when interruption is needed, is recommended in patients with any of the following indication:
• Mechanical prosthetic heart valve.
• AF with signiﬁcant mitral stenosis.
• AF with a CHA2DS2-VASc score >_3 for women or 2 for men.
• Acute thrombotic event within the previous 4
weeks.
• High acute thromboembolic risk.
I
New
It is recommended that VKAs are timely discontinued prior to elective surgery to aim for an INR
<1.5.
I
New
In patients undergoing surgery, it is recommended that aspirin therapy, if indicated, is maintained during the periprocedural period.
I
New
In patients who have undergone valve surgery with an indication for postoperative therapeutic bridging, it is recommended to start either UFH or
LMWH 1224 hours after surgery.
I
New
In patients with MHVs, it is recommended to (re)-
initiate VKAs on the ﬁrst postoperative day.
I
Continued
ESC/EACTS Guidelines
570


<!-- PAGE 11 -->

### Page 11

Table 3
Continued
New or Revised
Recommendations in 2017 version
Class
Recommendations in 2021 version
Class
New
In patients treated with DAPT after recent PCI
(within 1 month) who need to undergo heart valve surgery, in the absence of an indication for OAC, it is recommended to resume the P2Y12 inhibitor postoperatively, as soon as there is no concern over bleeding.
I
New
In patients treated with DAPT after recent PCI
(within 1 month) who need to undergo heart valve surgery, in the absence of an indication for OAC,
bridging P2Y12 inhibitors with glycoprotein IIb/IIIa inhibitors or cangrelor may be considered.
IIb
Patients with an indication to concomitant antiplatelet therapy
Revised
In patients undergoing an uncomplicated PCI dual therapy comprising VKA and clopidogrel (75 mg/
day) should be considered as an alternative to 1month triple antithrombotic therapy in patients in whom the bleeding risk outweighs the ischaemic risk.
IIa
After uncomplicated PCI or ACS in patients requiring long -term OAC, early cessation (<_1
week) of aspirin and continuation of dual therapy with OAC and a P2Y12 inhibitor (preferably clopidogrel) for up to 6 months (or up to 12 months in
ACS) is recommended if the risk of stent thrombosis is low or if concerns about bleeding risk prevail over concerns about risk of stent thrombosis,
irrespective of the type of stent used.
I
New
Discontinuation of antiplatelet treatment in patients treated with an OAC is recommended after 12 months.
I
New
In patients treated with a VKA (e.g. MHVs), clopidogrel alone should be considered in selected patients (e.g. HAS-BLED >_3 or ARC-HBR met and low risk of stent thrombosis) for up to 12 months.
IIa
New
In patients requiring aspirin and/or clopidogrel in addition to VKA, the dose intensity of VKA should be considered and carefully regulated with a target
INR in the lower part of the recommended target range and a time in the therapeutic range >6570%.
IIa
New
After uncomplicated PCI or ACS in patients requiring both OAC and antiplatelet therapy, triple therapy with aspirin, clopidogrel and OAC for longer than 1 week should be considered when the risk of stent thrombosis outweighs the risk of bleeding, with a total duration (<_1 month) decided according to assessment of these risks and clearly speciﬁed at hospital discharge.
IIa
Surgical valve replacement
New
NOACs should be considered over VKA after 3
months following surgical implantation of a BHV, in patients with AF.
IIa
New
In patients with no baseline indications for OAC,
low-dose aspirin (75-100 mg/day) or OAC using a
VKA should be considered for the ﬁrst 3 months after surgical implantation of an aortic BHV.
IIa
New
NOACs may be considered over VKA within 3
months following surgical implantation of a BHV in mitral position in patients with AF.
IIb
Continued
ESC/EACTS Guidelines
571


<!-- PAGE 12 -->

### Page 12

.............................................................
Task Force. Although the principle activities of the group concerned the chapter on aortic stenosis and SMR, it was not limited to these two domains. The methodology group was at disposal, upon request of the Task Force members, to resolve specific methodological issues.
2.3 Content of these guidelines
Decision making in VHD involves accurate diagnosis, timing of intervention, risk assessment and, based on these, selection of the most suitable type of intervention. These guidelines focus on acquired
VHD, are oriented towards management, and do not deal with endocarditis,4 congenital valve disease5 (including pulmonary valve disease), or recommendations concerning sports cardiology and exercise in patients with cardiovascular disease,6 as separate guidelines have been published by the ESC on these topics.
2.4 New format of the guidelines
The new guidelines have been adapted to facilitate their use in clinical practice and to meet readers’ demands by focusing on condensed,
clearly represented recommendations. At the end of the document,
key points summarize the essentials. Gaps in evidence are listed to propose topics for future research. The guideline document will be harmonized with the chapter on VHD included in the ESC Textbook of
Cardiovascular Medicine (ISBN: 9780198784906). The guidelines and the textbook are complementary. Background information and detailed discussion of the data that have provided the basis for the recommendations will be found in the relevant book chapter.
2.5 How to use these guidelines
The Committee emphasizes that many factors ultimately determine the most appropriate treatment in individual patients within a given community. These factors include the availability of diagnostic equipment, the expertise of cardiologists and surgeons, especially in the field of valve repair and percutaneous intervention, and, notably, the wishes of well-informed patients. Furthermore, owing to the lack of evidence-based data in the field of VHD, most recommendations are largely the result of expert consensus opinion. Therefore, deviations from these guidelines may be appropriate in certain clinical circumstances.
Table 3
Continued
New or Revised
Recommendations in 2017 version
Class
Recommendations in 2021 version
Class
Transcatheter Aortic Valve Implantation
New
OAC is recommended lifelong for TAVI patients who have other indications for OAC.
I
Revised
SAPT may be considered after TAVI in the case of high bleeding risk.
IIb
Lifelong SAPT is recommended after TAVI in patients with no baseline indication for OAC.
I
New
Routine use of OAC is not recommended after
TAVI in patients with no baseline indication for
OAC.
III
Section 11. Recommendations on management of prosthetic valve dysfunction
Haemolysis and paravalvular leak
New
Decision on transcatheter or surgical closure of clinically signiﬁcant paravalvular leaks should be considered based on patient risk status, leak morphology, and local expertise.
IIa
Bioprosthetic thrombosis
New
Anticoagulation should be considered in patients with leaﬂet thickening and reduced leaﬂet motion leading to elevated gradients, at least until resolution.
IIa
Bioprosthetic failure
New
Transcatheter valve-in-valve implantation in the mitral and tricuspid position may be considered in selected patients at high-risk for surgical reintervention.
IIb
ACS = acute coronary syndrome; AF = atrial ﬁbrillation; ARC-HBR = Academic Research Consortium - high bleeding risk; BHV = biological heart valve; BNP = B-type natriuretic peptide; BSA = body surface area; CABG = Coronary artery bypass grafting; CCT = cardiac computed tomography; CRT = cardiac resynchronization therapy; DAPT = dual antiplatelet therapy; EuroSCORE = European System for Cardiac Operative Risk Evaluation; GDMT = guideline-directed medical therapy; INR = international normalized ratio;
LA = left atrium/left atrial; LAA = left atrial appendage; LMWH = low-molecular-weight heparin; LV = left ventricle/left ventricular; LVEDD = left ventricular end-diastolic diameter; LVEF = left ventricular ejection fraction; LVESD = Left ventricular end-systolic diameter; MHV = mechanical heart valve; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation; PCI = percutaneous coronary intervention; RV = right ventricle/right ventricular; SAPT = single antiplatelet therapy; SAVR = surgical aortic valve replacement; SMR = secondary mitral regurgitation; SPAP = systolic pulmonary arterial pressure; STS-PROM = Society of Thoracic Surgeons - predicted risk of mortality;
TAVI = transcatheter aortic valve implantation; TEER = transcatheter edge-to-edge repair; UFH = unfractionated heparin; VHD = valvular heart disease; VKA = vitamin K antagonist; Vmax = peak transvalvular velocity.
ESC/EACTS 2021
ESC/EACTS Guidelines
572


<!-- PAGE 13 -->

### Page 13

..................................................................
3 General comments
This section defines and discusses concepts common to all the types of VHD including the Heart Team and Heart Valve Centres, the main evaluation steps of patients presenting with VHD, as well as the most commonly associated cardiac diseases.
3.1 Concepts of Heart Team and Heart
Valve Centre
The main purpose of Heart Valve Centres as centres of excellence in the treatment of VHD is to deliver optimal quality of care with a patient-centred approach. The main requirements of a Heart Valve
Centre are presented in Table 4.
This is achieved through high procedural volume in conjunction with specialized training, continuous education, and focused clinical interest. Heart Valve Centres should promote timely referral of patients with VHD for comprehensive evaluation before irreversible damage occurs.
Decisions concerning treatment and intervention should be made by an active and collaborative Heart Team with expertise in
VHD, comprising clinical and interventional cardiologists, cardiac surgeons, imaging specialists with expertise in interventional imaging,7,8 cardiovascular anaesthesiologists, and other specialists if necessary (e.g. heart failure specialists or electrophysiologists).
Dedicated nursing personnel with expertise in the care of patients with VHD are also an important asset to the Heart Team. The
Heart Team approach is particularly advisable for the management of high-risk and asymptomatic patients, as well as in case of uncertainty or lack of strong evidence.
Heart Valve Clinics are an important component of the Heart
Valve Centres, aiming to provide standardized organization of care based on guidelines. Access to Heart Valve Clinics improves outcomes.9
Physicians experienced in the management of VHD and dedicated nurses organize outpatient visits, and referral to the Heart Team, if needed. Earlier referral should be encouraged if patient’s symptoms develop or worsen before the next planned visit.10,11
Beside the whole spectrum of valvular interventions, expertise in interventional and surgical management of coronary artery disease (CAD), vascular diseases, and complications must be available.
Techniques with a steep learning curve may be performed with better results at hospitals with high procedural volume and experience. The relationship between case volume and outcomes for surgery and transcatheter interventions is complex but should not be denied.1214 However, the precise numbers of procedures per individual operator or hospital required to provide high-quality care remain controversial as inequalities exist between high- and middleincome countries.15 High-volume TAVI programmes are associated with lower mortality at 30 days, particularly at hospitals with a high surgical aortic valve replacement (SAVR) volume.16,17 The data available on transcatheter mitral valve repair14,18 and, even more so,
transcatheter tricuspid procedures are more limited.
Since performance does not exclusively relate to intervention volume, internal quality assessment consisting of systematic recording of procedural data and patient outcomes at the level of a given Heart
Valve Centre is essential, as well as participation in national or ESC/
EACTS registries.
A Heart Valve Centre should have structured and possibly combined training programmes for interventionalists, cardiac surgeons,
and imaging specialists13,19,20 (https://ebcts.org/syllabus/). New techniques should be taught by competent mentors to minimize the effects of the learning curve.
Finally, Heart Valve Centres should contribute to optimizing the management of patients with VHD, provide corresponding services at the community level, and promote networks that include other medical departments, referring cardiologists and primary care physicians.
3.2 Patient evaluation
The aims of the evaluation of patients with VHD are to diagnose,
quantify, and assess the mechanism of VHD, as well as its consequences.
Table 4
Requirements for a Heart Valve Centre
Requirements
Centre performing heart valve procedures with institutional cardiology and cardiac surgery departments with 24 h/7-day services.
Heart Team: clinical cardiologist, interventional cardiologist, cardiac surgeon, imaging specialist with expertise in interventional imaging, cardiovascular anaesthesiologist.
Additional specialists if required: heart failure specialist, electrophysiologist, geriatrician and other specialists (intensive care, vascular surgery, infectious disease, neurology). Dedicated nursing personnel is an important asset to the Heart Team.
The Heart Team must meet on a frequent basis and work with standard operating procedures and clinical governance arrangements deﬁned locally.
A hybrid catheterization laboratory is desirable.
The entire spectrum of surgical and transcatheter valve procedures should be available.
High volume for hospital and individual operators.
Multimodality imaging including echocardiography, CCT, CMR, and nuclear medicine, as well as expertise on guidance of surgical and interventional procedures.
Heart Valve Clinic for outpatient and follow-up management.
Data review: continuous evaluation of outcomes with quality review and/or local/external audit.
Education programmes targeting patient primary care, operator,
diagnostic and interventional imager training and referring cardiologist.
CCT = cardiac computed tomography; CMR = cardiac magnetic resonance.
ESC/EACTS 2021
..................................................................................................................................................................
ESC/EACTS Guidelines
573


<!-- PAGE 14 -->

### Page 14

......................
3.2.1
Clinical evaluation
Precise evaluation of the patient’s history and symptomatic status,
and proper physical examination, in particular auscultation21 and search for heart failure signs, are crucial. In addition, assessment of their comorbidities and general condition require particular attention. The essential questions in the evaluation of a patient for valvular intervention are summarized in Figure 1 (Central illustration).
3.2.2
Echocardiography
Following adequate clinical evaluation, echocardiography is the key technique used to confirm the diagnosis of VHD, as well as to assess its aetiology, mechanisms, function, severity, and prognosis. It should be performed and interpreted by properly trained imagers.22,23
Echocardiographic criteria for the definition of severe valve stenosis and regurgitation are addressed in specific documents24,25 and
Heart Valve Centre
Centre of excellence in the treatment of VHD
Heart Valve Clinic
Standardized organisation of care providing guidelinedirected treatment of VHD
Network
Medical departments, referring cardiologists and primary care physicians
Aetiology, lesion and mechanisms of VHD
Severity of VHD
Symptoms related to VHD
Life expectancy and quality of life
Optimal local resources
Benefits outweigh the risks
Treatment options
Patient’s goals
Individual anatomical and procedural factors
Echocardiography (TTE and TOE), CCT
Patient-centred evaluation for intervention
Integrative echocardiography, CCT
CMR, stress testing
Clinical evaluation, biomarkers, stress testing in asymptomatic patients
Age/estimated life expectancy, sex,
country, comorbidities
Operative risk, comorbidities, markers of progression in asymptomatic patients
Values and expectations of the informed patient
Heart Team decision
Availability and expected outcomes of a given intervention at a given centre
Clinical and imaging assessment
Heart
Team evaluation
Figure 1 Central illustration: Patient-centred evaluation for intervention. VHD= valvular heart disease; CCT = cardiac computed tomography;
CMR = cardiac magnetic resonance; TOE= transoesophageal echocardiography; TTE = transthoracic echocardiography.
ESC/EACTS Guidelines
574


<!-- PAGE 15 -->

### Page 15

.............................................................................................................................................................................
summarized in the specific sections of these guidelines.
Echocardiography is also key to evaluating the feasibility of a specific intervention.
Indices of left ventricular (LV) enlargement and function are strong prognostic factors. Recent studies suggest that global longitudinal strain has greater prognostic value than LV ejection fraction (LVEF),
although cut-off values are not uniform.26,27 Transoesophageal echocardiography (TOE) should be considered when transthoracic echocardiography (TTE) is of suboptimal quality or when thrombosis, prosthetic valve dysfunction, or endocarditis is suspected.
TOE is useful when detailed functional valve anatomy is required to assess repairability. Intraprocedural TOE, preferably 3D, is used to guide transcatheter mitral and tricuspid valve procedures and to assess the immediate result of surgical valve operations.
Multimodality imaging may be required in specific conditions for evaluation and/or procedural guidance in TAVI and transcatheter mitral interventions.28,29
3.2.3
Other non-invasive investigations
3.2.3.1 Stress testing
The primary purpose of exercise testing is to unmask the objective occurrence of symptoms in patients who claim to be asymptomatic.
It is especially useful for risk stratification in aortic stenosis.30 Exercise testing will also determine the level of recommended physical activity, including participation in sports. It should be emphasized that stress testing is safe and useful in asymptomatic patients with VHD.
Unfortunately, the VHD II survey indicates that it is rarely performed in asymptomatic patients.1
Exercise echocardiography may identify the cardiac origin of dyspnoea. Prognostic impact has been shown mainly for aortic stenosis and mitral regurgitation.31,32
The use of stress tests to detect CAD associated with severe valvular disease is discouraged because of their low diagnostic value and potential risks in symptomatic patients with aortic stenosis.
3.2.3.2 Cardiac magnetic resonance
In patients with inadequate echocardiographic quality or discrepant results, CMR should be used to assess the severity of valvular lesions,
particularly regurgitant lesions, and to assess ventricular volumes, systolic function, abnormalities of the ascending aorta, and myocardial fibrosis.33 CMR is the reference method for the evaluation of right ventricular (RV) volumes and function and is therefore particularly useful to evaluate the consequences of tricuspid regurgitation.34 It also has an incremental value for assessing the severity of aortic and mitral regurgitation.
3.2.3.3 Computed tomography
CCT may contribute to the evaluation of valve disease severity,
particularly in aortic stenosis35,36 and possibly associated disease of the thoracic aorta (dilatation, calcification), as well as to evaluate the extent of MAC. CCT should be performed whenever the echocardiographic data indicate an aortic enlargement >40 mm,
to clarify aortic diameter and to assess aortic morphology and configuration. CCT is essential in the pre-procedural planning of
TAVI and can also be useful to assess patient-prosthesis mismatch
(PPM).37 It is also a prerequisite for pre-procedural planning of mitral and tricuspid valve interventions.38 Positron emission tomography (PET)/CCT is useful in patients with a suspicion of endocarditis of a prosthetic valve.39,40
3.2.3.4 Cinefluoroscopy
Cinefluoroscopy is particularly useful for assessing the kinetics of the leaflet occluders of a mechanical prosthesis.
3.2.3.5 Biomarkers
B-type natriuretic peptide (BNP) serum levels, corrected for age and sex, are useful in asymptomatic patients and may assist selection of the appropriate time point for a given intervention,41 particularly if the level rises during follow-up. Other biomarkers have been tested,
with evidence for fibrosis, inflammation, and adverse ventricular remodelling, which could improve decision making.42
3.2.3.6 Multimarkers and staging
In patients with at least moderate aortic stenosis and LVEF >50%,
staging according to damage associated with aortic stenosis on LV/
RV, left atrium (LA), mitral /tricuspid valve, and pulmonary circulation was predictive of excess mortality after TAVI and SAVR, and may help to identify patients who will benefit from an intervention.43,44
3.2.4
Invasive investigations
3.2.4.1 Coronary angiography
Coronary angiography is recommended for the assessment of CAD
when surgery or an intervention is planned, to determine if concomitant coronary revascularization is recommended (see recommendations for management of CAD in patients with VHD).45,46
Alternatively, owing to its high negative predictive value, CCT may be used to rule out CAD in patients who are at low risk of atherosclerosis. The usefulness of fractional flow reserve or instantaneous wavefree ratio in patients with VHD is not well established, and caution is warranted in the interpretation of these measurements when VHD,
and in particular aortic stenosis, is present.47,48
3.2.4.2 Cardiac catheterization
The measurement of pressures and cardiac output or the assessment of ventricular performance and valvular regurgitation by ventricular angiography or aortography is restricted to situations where noninvasive evaluation by multimodality imaging is inconclusive or discordant with clinical findings. When elevated, pulmonary pressure is the only criterion to support the indication for surgery, and confirmation of echo data by invasive measurement is recommended. Right heart catheterization is also indicated in patients with severe tricuspid regurgitation as Doppler gradient may be impossible or underestimate the severity of pulmonary hypertension.
3.2.5
Assessment of comorbidity
The choice of specific examinations to assess comorbidity is guided by the clinical evaluation.
3.3 Risk stratification
Risk stratification applies to any sort of intervention and is required for weighing the risk of intervention against the expected natural history of VHD and for choosing the type of intervention. Most experience relates to surgery and TAVI.
ESC/EACTS Guidelines
575


<!-- PAGE 16 -->

### Page 16

.....................................................................................................................
3.3.1
Risk scores
The Society of Thoracic Surgeons (STS) predicted risk of mortality
(PROM) score (http://riskcalc.sts.org/stswebriskcalc/calculate) and the European System for Cardiac Operative Risk Evaluation II
(EuroSCORE II; http://www.euroscore.org/calc.html) accurately discriminate high- and low-risk surgical patients and show good calibration to predict postoperative outcome after valvular surgery in the majority of the patients,49,50 while risk estimation may be less accurate in high-risk patients.51 The STS-PROM score is dynamic and changes over time. Of note, the risk scores have not been validated for isolated tricuspid surgical interventions.
In isolation, surgical scores have major limitations for practical use in patients undergoing transcatheter intervention because they do not include major risk factors such as frailty, as well as anatomical factors with impact on the procedure, either surgical or transcatheter
[porcelain aorta, previous chest radiation, mitral annular calcification
(MAC)].
New scores have been developed to estimate the risk in patients undergoing TAVI, with better accuracy and discrimination than the surgical risk scores,
despite numerous limitations5254
(Supplementary Table 1).
Experience with risk stratification is currently limited for other interventional procedures, such as mitral or tricuspid interventions.
3.3.2
Other factors
Other factors should be taken into account:
• Frailty, defined as a decrease of physiologic reserve and ability to maintain homeostasis leading to an increased vulnerability to stresses and conferring an increased risk of morbidity and mortality after both surgery and TAVI.55 The assessment of frailty should not rely on a subjective approach, such as the ‘eyeball test’, but rather on a combination of different objective estimates.5559 Several tools are available for assessing frailty
(Supplementary Table 2,59 and Supplementary Table 3).60
• Malnutrition61 and cognitive dysfunction62 both predict poor prognosis.
• Other major organ failures (Supplementary Table 4), in particular the combination of severe lung disease,63,64 postoperative pain from sternotomy or thoracotomy and prolonged time under anaesthesia in patients undergoing SAVR via full sternotomy, may contribute to pulmonary complications. There is a positive association between the impairment of renal function and increased mortality after valvular surgery and transcatheter procedures,65
especially when the glomerular filtration rate is <30 mL/min.
Liver disease, is also an important prognostic factor.66
• Anatomical aspects affecting procedural performance such as porcelain aorta or severe MAC67 (see Table 6 in section 5.1.3,
and Supplementary Figure 1).
At the extreme of the risk spectrum, futility should be avoided.
Therapeutic futility has been defined as a lack of medical efficacy, particularly when the physician judges that the therapy is unlikely to produce its intended clinical results, or lack of meaningful survival according to the personal values of the patient. Assessment of futility goes beyond survival and includes functional recovery. The futility of interventions has to be taken into consideration, particularly for transcatheter interventions.63
The high prevalence of comorbidity in the elderly makes assessment of the risk/benefit ratios of interventions more difficult, therefore the role of the Heart Team is essential in this specific population of patients (Supplementary Table 5).
3.4 Patient-related aspects
Patient-related life expectancy and expected quality of life should be considered. The patient and their family should be thoroughly informed and assisted in their decision on the best treatment option.13 A patient-centred approach would take patient-reported outcome measures and patient-reported experience measures into consideration and make these parameters part of the informed choice offered to patients.68,69
When benefit in symptom relief aligns with a patient’s goals, care is not futile. However, care is futile when no life prolongation or symptom relief is anticipated.70
3.5 Local resources
Even if it is desirable that Heart Valve Centres are able to perform a large spectrum of procedures, either surgical or catheter-based,
specialization and thereby expertise in specific domains will vary and should be taken into account when deciding on the orientation of the patient in specific cases, such as complex surgical valve repair or transcatheter intervention.
In addition, penetration of transcatheter interventions is heterogeneous worldwide and highly dependent on socioeconomic inequalities.15,71 Appropriate stewardship of economic resources is a fundamental responsibility of the Heart Team.
3.6 Management of associated conditions
3.6.1
Coronary artery disease
Recommendations for the management of CAD associated with
VHD are provided below and are detailed in specific sections (section 5 and section 6.2) of this guideline document, as well as in other dedicated guideline documents.45,46,72,73
Recommendations for management of CAD in patients with VHD.
Recommendations
Classa
Levelb
Diagnosis of CAD
Coronary angiography is recommended before valve surgery in patients with severe VHD and any of the following:
• History of cardiovascular disease.
• Suspected myocardial ischaemia.c
• LV systolic dysfunction.
• In men >40 years of age and postmenopausal women.
• One or more cardiovascular risk factors.
I
C
Continued
....................................................
ESC/EACTS Guidelines
576


<!-- PAGE 17 -->

### Page 17

..........................................
3.6.2
Atrial fibrillation
Detailed recommendations on the management of patients with atrial fibrillation (AF) including management of anticoagulation are provided in specific guidelines.74 NOACs are recommended in patients with aortic stenosis, aortic regurgitation or mitral regurgitation presenting with AF7578 as subgroup analyses of randomized controlled trials (RCTs) support the use of apixaban, dabigatran,
edoxaban, and rivaroxaban. The use of NOACs is not recommended in patients who have AF associated with clinically significant mitral stenosis or those with mechanical prostheses.
Surgical ablation of AF combined with mitral valve surgery effectively reduces the incidence of AF but has no impact on adjusted short-term survival. An increased rate of pacemaker implantation has been observed after surgical ablation (9.5%, vs. 7.6% in the group with AF and no surgical ablation).79 Concomitant AF ablation should be considered in patients undergoing cardiac surgery, balancing the benefits of freedom from atrial arrhythmias with the risk factors for recurrence, such as age, LA dilatation, years in AF, renal dysfunction,
and other cardiovascular risk factors. In addition, left atrial appendage
(LAA) occlusion should be considered in combination with valve surgery in patients with AF and a CHA2DS2VASc score >_2 to reduce the thromboembolic risk.8082 The selected surgical technique should ensure complete occlusion of the LAA. For patients with AF
and risk factors for stroke, long-term oral anticoagulation (OAC) is currently recommended, irrespective of the use of surgical ablation of AF and/or surgical LAA occlusion.
Recommendations for the management of AF in native VHD are summarized in the following table. The recommendations concerning patients with valve prostheses, and the combination of anticoagulants and antiplatelet agents in patients undergoing PCI, are described in section 11 (section 11.3.2.2 and related table of recommendations for perioperative and postoperative antithrombotic management of valve replacement or repair).
3.7 Endocarditis prophylaxis
Antibiotic prophylaxis should be considered for high-risk procedures in patients with prosthetic valves, including transcatheter valves, or with repairs using prosthetic material, and in patients with previous episode(s) of infective endocarditis.4 Particular attention to dental and cutaneous hygiene and strict aseptic measures during any invasive procedure are advised in this population. Antibiotic prophylaxis should be considered in dental procedures involving manipulation of the gingival or periapical region of the teeth or manipulation of the oral mucosa.4
Coronary angiography is recommended in the evaluation of severe SMR.
I
C
Coronary CT angiography should be considered as an alternative to coronary angiography before valve surgery in patients with severe VHD and low probability of CAD.d
IIa
C
Indications for myocardial revascularization
CABG is recommended in patients with a primary indication for aortic/mitral/tricuspid valve surgery and coronary artery diameter stenosis
>_70%.e,f
I
C
CABG should be considered in patients with a primary indication for aortic/mitral/tricuspid valve surgery and coronary artery diameter stenosis >_5070%.
IIa
C
PCI should be considered in patients with a primary indication to undergo TAVI and coronary artery diameter stenosis >70% in proximal segments.
IIa
C
PCI should be considered in patients with a primary indication to undergo transcatheter mitral valve intervention and coronary artery diameter stenosis >70% in proximal segments.
IIa
C
CABG = coronary artery bypass grafting;
CAD = coronary artery disease;
CT = computed tomography;
LV = left ventricle/left ventricular;
PCI = percutaneous coronary intervention; SMR = secondary mitral regurgitation;
TAVI = transcatheter aortic valve implantation; VHD = valvular heart disease.
aClass of recommendation.
bLevel of evidence.
cChest pain, abnormal non-invasive testing.
dCoronary CT angiography may also be used in patients requiring emergency surgery with acute infective endocarditis with large vegetations protruding in front of a coronary ostium.
eStenosis >_50% can be considered for left main stenosis.
fFFR <_0.8 is a useful cut-off indicating the need for an intervention in patients with mitral or tricuspid diseases, but has not been validated in patients with aortic stenosis.
Adapted from45,72
Recommendations on management of atrial ﬁbrillation in patients with native VHD
Recommendations
Classa
Levelb
Anticoagulation
For stroke prevention in AF patients who are eligible for OAC, NOACs are recommended in preference to VKAs in patients with aortic stenosis, aortic and mitral regurgitation.7578,83,84
I
A
The use of NOACs is not recommended in patients with AF and moderate to severe mitral stenosis.
III
C
Surgical interventions
Concomitant AF ablation should be considered in patients undergoing valve surgery, balancing the beneﬁts of freedom from atrial arrhythmias and the risk factors for recurrence (LA dilatation, years in AF, age, renal dysfunction, and other cardiovascular risk factors).79,8590
IIa
A
LAA occlusion should be considered to reduce the thromboembolic risk in patients, with
AF and a CHA2DS2VASc score >_2 undergoing valve surgery.82
IIa
B
AF = atrial ﬁbrillation; LA = left atrium/left atrial; LAA = left atrial appendage;
NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation; VKA = vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.
ESC/EACTS 2021
ESC/EACTS 2021
...................................................................................................................................
ESC/EACTS Guidelines
577


<!-- PAGE 18 -->

### Page 18

...............................................................................
3.8 Prophylaxis for rheumatic fever
Prevention of rheumatic heart disease should preferably target the first attack of acute rheumatic fever. Antibiotic treatment of group A Streptococcus infection throat is key in primary prevention. Echocardiographic screening in combination with secondary antibiotic prophylaxis in children with evidence of latent rheumatic heart disease is currently investigated to reduce its prevalence in endemic regions.91 In patients with established rheumatic heart disease, secondary long-term prophylaxis against rheumatic fever is recommended: benzathine benzyl penicillin 1.2 MUI every 3 to 4 weeks over 10 years. Lifelong prophylaxis should be considered in high-risk patients according to the severity of
VHD and exposure to group A Streptococcus.9295
4 Aortic regurgitation
Aortic regurgitation can be caused by primary disease of the aortic valve cusps and/or abnormalities of the aortic root and ascending aortic geometry. Degenerative tricuspid and bicuspid aortic regurgitation are the most common aetiologies in high-income countries, accounting for approximately two-thirds of the underlying aetiology of aortic regurgitation in the EURObservational Registry Programme Valvular Heart
Disease II registry.1 Other causes include infective and rheumatic endocarditis. Acute severe aortic regurgitation is mostly caused by infective endocarditis, and less frequently by aortic dissection.
4.1 Evaluation
4.1.1
Echocardiography
Echocardiography is the key examination used to describe valve anatomy, quantify aortic regurgitation, evaluate its mechanisms, define the morphology of the aorta, and determine the feasibility of valvesparing aortic surgery or valve repair.96,97 Identification of the mechanism follows the same principle such as for mitral regurgitation:
normal cusps but insufficient coaptation due to dilatation of the aortic root with central jet (type 1), cusp prolapse with eccentric jet (type
2), or retraction with poor cusp tissue quality and large central or eccentric jet (type 3).96 Quantification of aortic regurgitation follows an integrated approach considering qualitative, semi-quantitative, and quantitative parameters24,98 (Table 5). New parameters obtained by
3D echocardiography and two-dimensional (2D) strain imaging as LV
global longitudinal strain may be useful, particularly in patients with borderline LVEF where they may help in the decision for surgery.99
Measurement of the aortic root and ascending aorta in 2D is performed at four levels: annulus, sinuses of Valsalva, sinotubular junction, and tubular ascending aorta.100,101 Measurements are performed in the parasternal long-axis view from leading edge to leading edge at end diastole, except for the aortic annulus, which is measured in mid systole. As it will have surgical consequences, it is important to differentiate three phenotypes of the ascending aorta: aortic root aneurysms (sinuses of Valsalva >45 mm), tubular ascending aneurysm
(sinuses of Valsalva <4045 mm), and isolated aortic regurgitation
(all aortic diameters <40 mm). The calculation of indexed values to account for body size has been suggested,102 in particular in patients with small stature. Anatomy of the aortic valve cusps and its suitability for valve repair should be provided by preoperative TOE if aortic valve repair or a valve-sparing surgery of the aortic root is considered. Intraoperative evaluation of the surgical result by TOE is mandatory in patients undergoing aortic valve preservation or repair.
4.1.2
Computed tomography and cardiac magnetic resonance
CMR should be used to quantify the regurgitant fraction when echocardiographic measurements are equivocal or discordant with clinical findings. In patients with aortic dilatation, CCT is recommended to assess the maximum diameter at four levels, as in echocardiography.
CMR can be used for follow-up, but indication for surgery should preferably be based on CCT measurements. Different methods of aortic measurements have been reported. To improve reproducibility, it is recommended to measure diameters using the inner-inneredge technique at end diastole on the strictly transverse plane by double oblique reconstruction perpendicular to the axis of blood flow of the corresponding segment. Maximum root diameter should be taken from sinus-to-sinus diameter rather than sinus-tocommissure diameter, as it correlates more closely to long-axis leading-edge-to-leading-edge echo maximum diameters.103,104
4.2 Indications for intervention
Acute aortic regurgitation may require urgent surgery. It is mainly caused by infective endocarditis and aortic dissection but may also occur after blunt chest trauma and iatrogenic complications during catheter-based cardiac interventions. Specific guidelines deal with
Table 5
Echocardiographic criteria for the deﬁnition of severe aortic valve regurgitation
Qualitative
Valve morphology
Abnormal/ﬂail/large coaptation defect
Colour ﬂow regurgitant jet areaa
Large in central jets, variable in eccentric jets
CW signal of regurgitant jet
Dense
Other
Holodiastolic ﬂow reversal in descending aorta (EDV >20 cm/s)
Semiquantitative
Vena contracta width (mm)
>6
Pressure half-timeb (ms)
<200
Quantitative
EROA (mm2)
>_30
Regurgitant volume (mL/beat)
>_60
Enlargement of cardiac chambers
LV dilatation
CW = continuous wave; EDV = end-diastolic velocity; EROA = effective regurgitant oriﬁce area; LV = left ventricle/left ventricular.
aAt a Nyquist limit of 5060 cm/s.
bPressure half-time is shortened with increasing LV diastolic pressure, vasodilator therapy, and in patients with a dilated compliant aorta, or lengthened in chronic aortic regurgitation.
Adapted from Lancellotti P et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the
European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging
2013;14:611644. Copyright (2013) by permission of Oxford University Press on behalf of the European Society of Cardiology.
ESC/EACTS 2021
............................................................................................
ESC/EACTS Guidelines
578


<!-- PAGE 19 -->

### Page 19

...................................................................
these entities.4,101 The recommendations on indications for surgery in severe aortic regurgitation and aortic root disease may be related to symptoms, status of the LV, or dilatation of the aorta [see table of recommendations on indications for surgery in severe aortic regurgitation and aortic root or tubular ascending aortic aneurysm (irrespective of the severity of aortic regurgitation), and Figure 2].
In symptomatic patients, surgery is recommended irrespective of the LVEF as long as aortic regurgitation is severe and the operative risk is not prohibitive.105109 Surgery is recommended in symptomatic and asymptomatic patients with severe aortic regurgitation undergoing coronary artery bypass grafting (CABG), or surgery of the ascending aorta or another valve.110,111 In asymptomatic patients with severe aortic regurgitation, impairment of LV function [LVEF
<_50% or left ventricular end-systolic diameter (LVESD) >50 mm] are associated with worse outcomes and surgery should therefore be pursued when these cut-offs are reached.107,108,112114 LVESD should be related to body surface area (BSA) and a cut-off of 25 mm/m2 BSA
appeared to be more appropriate, especially in patients with small body size (BSA <1.68 m2) or with large BSA who are not overweight.108,115 Some recent retrospective, non-randomized studies emphasized the role of indexed LVESD and proposed a lower cut-off value of 20 or 22 mm/m2 BSA for the indexed LVESD.116118 One of these studies also suggests a higher cut-off value of 55% for LVEF.118
Based on these data, low-risk surgery may be discussed in some selected asymptomatic patients with LVESD >20 mm/m2 or resting
LVEF between 50% and 55%. In patients not reaching the thresholds for surgery, close follow-up is needed, and exercise testing should be liberally performed to identify borderline symptomatic patients.
Progressive enlargement of the LV, or a progressive decrease in its function in asymptomatic patients not reaching the thresholds for surgery but with significant LV dilatation [left ventricular end-diastolic diameter (LVEDD) >65 mm], may also be an appropriate indicator for timing operations in asymptomatic patients.
TAVI may be considered in experienced centres for selected patients with aortic regurgitation and ineligible for SAVR.119,120
In patients with a dilated aorta, the rationale for surgery has been best defined in patients with Marfan syndrome and root dilation.121,122 Root aneurysms require root replacement, with or without preservation of the native aortic valve. In contrast, tubular ascending aortic aneurysms in the presence of normal aortic valves require only a supracommissural tube graft replacement. In patients with aortic diameters borderline indicated for aortic surgery, the family history, age, and anticipated risk of the procedure should be taken into consideration. Irrespective of the degree of aortic regurgitation and type of valve pathology, in patients with an aortic diameter
>_55 mm with tricuspid or bicuspid aortic valves, ascending aortic surgery is recommended (see recommendations on indications for surgery in severe aortic regurgitation and aortic root disease) when the operative risk is not prohibitive.123125 In individuals with bicuspid aortic valve, when additional risk factors or coarctation126 are present, surgery should be considered when aortic diameter is
>_50 mm.127129 In all patients with Marfan syndrome, aortic surgery is recommended for a maximal aortic diameter >_50 mm.5,121,122
When additional risk factors are present in patients with Marfan syndrome and in patients with a TGFBR1 or TGFBR2 mutation (including
LoeysDietz syndrome), surgery should be considered at a maximal aortic diameter >_45 mm121,130 and even earlier (aortic diameter of
The choice of the surgical procedure should be adapted according to the experience of the team, the presence of an aortic root aneurysm, characteristics of the cusps, life expectancy, and desired anticoagulation status.
Valve replacement is the standard procedure in the majority of patients with aortic regurgitation. Aortic valve-sparing root replacement and valve repair yield good long-term results in selected patients, with low rates of valve-related events as well as good quality of life131140
when performed in experienced centres. Aortic valve-sparing root replacement is recommended in younger patients who have an enlargement of the aortic root with normal cusp motion, when performed by experienced surgeons.133136,140 In selected patients, aortic valve repair132,132,137 or the Ross procedure138,139 may be an alternative to valve replacement, when performed by experienced surgeons.
Recommendations on indications for surgery in (A)
severe aortic regurgitation and (B) aortic root or tubular ascending aortic aneurysm (irrespective of the severity of aortic regurgitation)
Indications for surgery
Classa
Levelb
A) Severe aortic regurgitation
Surgery is recommended in symptomatic patients regardless of LV function.105109
I
B
Surgery is recommended in asymptomatic patients with LVESD >50 mm or LVESD
>25 mm/m2 BSA (in patients with small body size) or resting LVEF <_50%.107,108,112,114,115
I
B
Surgery may be considered in asymptomatic patients with LVESD >20 mm/m2 BSA (especially in patients with small body size) or resting LVEF
<_55%, if surgery is at low risk.
IIb
C
Surgery is recommended in symptomatic and asymptomatic patients with severe aortic regurgitation undergoing CABG or surgery of the ascending aorta or of another valve.
I
C
Aortic valve repair may be considered in selected patients at experienced centres when durable results are expected.
IIb
C
B) Aortic root or tubular ascending aortic aneurysmc (irrespective of the severity of aortic regurgitation)
Valve-sparing aortic root replacement is recommended in young patients with aortic root dilation, if performed in experienced centres and durable results are expected.133136,140
I
B
Ascending aortic surgery is recommended in patients with Marfan syndrome who have aortic root disease with a maximal ascending aortic diameter >_50 mm.
I
C
Continued
..........................................................................................................
ESC/EACTS Guidelines
579
40 mm or more) in women with low BSA, TGFBR2 mutation, and severe extra-aortic features.130 For patients who have an indication for aortic valve surgery, an aortic diameter ≥45 mm is considered to indicate concomitant surgery of the aortic root or tubular ascending aorta. The patient’s stature, the aetiology of the valvular disease (bicuspid valve), and the intraoperative shape and wall thickness of the ascending aorta should be considered for individual decisions.


<!-- PAGE 20 -->

### Page 20

......................................................................................
4.3 Medical therapy
Medical therapy, especially angiotensin-converting enzyme inhibitors
(ACEI) or dihydropiridines, may provide symptomatic improvement in individuals with chronic severe aortic regurgitation in whom surgery is not feasible. The value of ACEI or dihydropiridine in delaying surgery in the presence of moderate or severe aortic regurgitation in asymptomatic patients has not been established and their use is not recommended for this indication.
In patients who undergo surgery but continue to suffer from heart failure or hypertension, ACEI, angiotensin receptor blockers (ARBs),
and beta-blockers are useful.141,142
In patients with Marfan syndrome, beta-blockers remain the mainstay for medical treatment and reducing shear stress and aortic growth rate and should be considered before and after surgery.143145 While ARBs did not prove to have a superior effect when compared to beta-blockers, they may be considered as an alternative in patients intolerant to beta-blockers.146148 By analogy,
while there are no studies that provide supporting evidence, it is common clinical practice to advise beta-blocker or ARBs in patients with bicuspid aortic valve if the aortic root and/or ascending aorta is dilated. Management of aortic regurgitation during pregnancy is discussed in section 13.
4.4 Serial testing
All asymptomatic patients with severe aortic regurgitation and normal LV function should be followed up at least every year. In patients with either a first diagnosis or with LV diameter and/or ejection fraction showing significant changes or approaching thresholds for
Ascending aortic surgery should be considered in patients who have aortic root disease with maximal ascending aortic diameter:
• >_55 mm in all patients.
• >_45 mm in the presence of Marfan syndrome and additional risk factorsd or patients with a
TGFBR1 or TGFBR2 mutation (including
LoeysDietz syndrome).e
• >_50 mm in the presence of a bicuspid valve with additional risk factorsd or coarctation.
IIa
C
When surgery is primarily indicated for the aortic valve, replacement of the aortic root or tubular ascending aorta should be considered when >_45 mm.f
IIa
C
BSA= body surface area; CABG = coronary artery bypass grafting; CCT= cardiac computed tomography; CMR= cardiac magnetic resonance; ECG= electrocardiogram; LV= left ventricle/left ventricular; LVEF = left ventricular ejection fraction;
LVESD= left ventricular end-systolic diameter.
aClass of recommendation.
bLevel of evidence.
cFor clinical decision making, dimensions of the aorta should be conﬁrmed by
ECG-gated CCT.
dFamily history of aortic dissection (or personal history of spontaneous vascular dissection), severe aortic or mitral regurgitation, desire for pregnancy, uncontrolled systemic arterial hypertension and/or aortic size increase >3 mm/year
(using serial echocardiography or CMR measurements at the same level of the aorta conﬁrmed by ECG-gated CCT).
fConsidering age, BSA, aetiology of the valvular disease, presence of a bicuspid aortic valve, and intraoperative shape and thickness of the ascending aorta.
Management of patients with aortic regurgitation
Significant enlargement of ascending aortaa
Follow-up
Surgeryb
LVEF ≤ 50% or
LVESD > 50 mm
(or > 25 mm/m2 BSA)
N
N
Y
Y
Severe aortic regurgitation
N
N
Y
Symptoms
Y
Figure 2 Management of patients with aortic regurgitation. BSA = body surface area; LV = left ventricle/left ventricular; LVESD = left ventricle end-systolic diameter; LVEF = left ventricular ejection fraction. aSee recommendations on indications for surgery in severe aortic regurgitation and aortic root disease for definition. bSurgery should also be considered if significant changes in LV or aortic size occur during follow-up.
ESC/EACTS 2021
ESC/EACTS Guidelines
580
eA lower threshold of 40 mm may be considered in women with low BSA, TGFBR2
mutation and severe extra-aortic features.130


<!-- PAGE 21 -->

### Page 21

.............................................................................................................................................................................
surgery, follow-up should be continued at 36-month intervals.
Surgery may be considered in asymptomatic patients with significant
LV dilatation (LVEDD >65 mm), and with progressive enlargement in the size of LV or progressive decrease of LVEF during follow-up.
Patient’s BNP levels could be of potential interest as a predictor of outcomes (particularly symptom onset and deterioration of LV function) and may be helpful in the follow-up of asymptomatic patients.149
Patients with mild-to-moderate aortic regurgitation can be seen on a yearly basis and echocardiography performed every 2 years.
If the ascending aorta is dilated (>40 mm), it is recommended to systematically perform CCT or CMR. Follow-up assessment of the aortic dimension should be performed using echocardiography and/
or CMR. Any increase >3 mm should be validated by CCT angiography/CMR and compared with baseline data. After repair of the ascending aorta, Marfan patients remain at risk for dissection of the residual aorta and lifelong regular multidisciplinary follow-up at an expert centre is required.
4.5 Special patient populations
If aortic regurgitation requiring surgery is associated with severe primary and secondary mitral regurgitation, both should be treated during the same operation.
In patients with moderate aortic regurgitation who undergo
CABG or mitral valve surgery, the decision to treat the aortic valve is controversial, as data show that progression of moderate aortic regurgitation is very slow in patients without aortic dilation.150 The
Heart Team should decide based on the aetiology of aortic regurgitation, other clinical factors, the life expectancy of the patient, and the patient’s operative risk.
The level of physical and sports activity in the presence of a dilated aorta remains a matter of clinical judgment in the absence of evidence. Current guidelines are very restrictive, particularly regarding isometric exercise, to avoid a catastrophic event.151 This approach is justified in the presence of connective tissue disease, but a more liberal approach is likely to be appropriate in other patients.
Given the familial risk of thoracic aortic aneurysms, screening and referral for genetic testing of the patient’s first-degree relatives with appropriate imaging studies is indicated in patients with connective tissue disease. For patients with bicuspid valves, it is appropriate to have an echocardiographic screening of first-degree relatives.
5 Aortic stenosis
Aortic stenosis is the most common primary valve lesion requiring surgery or transcatheter intervention in Europe1 and North America.
Its prevalence is rising rapidly as a consequence of the ageing population.2,152
5.1 Evaluation
5.1.1
Echocardiography
Echocardiography is key to confirming the diagnosis and severity of aortic stenosis, assessing valve calcification, LV function and wall thickness, detecting other valve disease or aortic pathology, and providing prognostic information.43,153,154 Assessment should be undertaken when blood pressure (BP) is well controlled to avoid the confounding flow effects of increased afterload.
New echocardiographic parameters,
stress imaging and
CCT
provide important adjunctive information when severity is uncertain
(Figure 3).
Current international recommendations for the echocardiographic evaluation of patients with aortic stenosis25 depend upon measurement of mean pressure gradient (the most robust parameter), peak transvalvular velocity (Vmax), and valve area. Although valve area is the theoretically ideal measurement for assessing severity,
there are numerous technical limitations. Clinical decision making in discordant cases should therefore take account of additional parameters: functional status, stroke volume, Doppler velocity index,156
degree of valve calcification, LV function, the presence or absence of
LV hypertrophy, flow conditions, and the adequacy of BP control.25
Low flow is arbitrarily defined by a stroke volume index (SVi) <_35
mL/m2—a threshold that is under current debate.155,157,158 The use of sex -specific thresholds has been recently proposed.159 Four broad categories can be defined:
• High-gradient aortic stenosis [mean gradient >_40 mmHg, peak velocity >_4.0 m/s, valve area <_1 cm2 (or <_0.6 cm2/m2)]. Severe aortic stenosis can be assumed irrespective of LV function and flow conditions.
• Low-flow, low-gradient aortic stenosis with reduced ejection fraction (mean gradient <40 mmHg, valve area <_1 cm2, LVEF
<50%, SVi <_35 mL/m2). Low-dose dobutamine stress echocardiography (DSE) is recommended to distinguish between true severe and pseudo-severe aortic stenosis (increase in valve area to >1.0 cm2 with increased flow) and identify patients with no flow (or contractile) reserve.160 However, utility in elderly patients has only been evaluated in small registries.161
• Low-flow, low-gradient aortic stenosis with preserved ejection fraction (mean gradient <40 mmHg, valve area <_1 cm2, LVEF
>_50%, SVi <_35 mL/m2). Typically encountered in hypertensive elderly subjects with small LV size and marked hypertrophy.157,162 This scenario may also result from conditions associated with low stroke volume (e.g. moderate/severe mitral regurgitation, severe tricuspid regurgitation, severe mitral stenosis, and large ventricular septal defect and severe RV dysfunction).
Diagnosis of severe aortic stenosis is challenging and requires careful exclusion of measurement errors and other explanations for the echocardiographic findings,25 as well as the presence or absence of typical symptoms (with no other explanation), LV
hypertrophy (in the absence of coexistent hypertension) or reduced LV longitudinal strain (with no other cause). CCT
assessment of the degree of valve calcification provides important additional information [thresholds (Agatston units) for severe aortic stenosis: men >3000, women >1600= highly likely;
men >2000, women >1200 = likely; men <1600, women
<800 = unlikely].35,36,163,164
• Normal-flow, low-gradient aortic stenosis with preserved ejection fraction (mean gradient <40 mmHg, valve area <_1 cm2,
LVEF>_50%, SVi >35 mL/m2). These patients usually have only moderate aortic stenosis.36,165167
5.1.2
Additional diagnostic and prognostic parameters
The resting Doppler velocity index (DVI, also termed ‘dimensionless index’)—the ratio of the left ventricular outflow tract (LVOT) timeESC/EACTS Guidelines
581


<!-- PAGE 22 -->

### Page 22

Valve morphology by echocardiography suspicious of AS
AVA ≤ 1.0 cm2
Reassess under normal flow conditions
N
N
Y
CCT to assess
AV calcificatione
Pseudo-severe ASd
Severe AS
Severe AS
Assess velocity/gradient
Low-gradient AS
Vmax < 4 m/s,
ΔPm < 40 mmHg
High-gradient AS
Vmax ≥ 4 m/s,
ΔPm ≥ 40 mmHg
High flow statusa
Moderate AS
N
Y
High flow status reversible
Check blood pressure and exclude measurement errors that may cause underestimation of gradient, flow or AVA
Y
Define flow statusa
Low flow
SVi ≤ 35 mL/m2
Normal flow
SVi > 35 mL/m2
Severe AS unlikely
LVEF ≥ 50%
Y
DSE flow reservec
N
AVA ≤ 1.0 cm2
Y
Y
Integrated approachb
N
N
Figure 3 Integrated imaging assessment of aortic stenosis. AS= aortic stenosis; AV= aortic valve; AVA = aortic valve area; CT= computed tomography;
DPm= mean pressure gradient; DSE= dobutamine stress echocardiography; LV= left ventricle/left ventricular; LVEF = left ventricular ejection fraction;
SVi= stroke volume index; Vmax = peak transvalvular velocity. aHigh flow may be reversible in patients with anaemia, hyperthyroidism or arterio-venous fistulae, and may also be present in patients with hypertrophic obstructive cardiomyopathy. Upper limit of normal flow using pulsed Doppler echocardiography: cardiac index 4.1 L/min/m2 in men and women, SVi 54 mL/m2 in men, 51 mL/m2 in women).155 bConsider also: typical symptoms (with no other explanation), LV hypertrophy (in the absence of coexistent hypertension) or reduced LV longitudinal function (with no other cause). cDSE flow reserve= >20% increase in stroke volume in response to low-dose dobutamine. dPseudo-severe aortic stenosis= AVA >1.0 cm2 with increased flow.
eThresholds for severe aortic stenosis assessed by means of CT measurement of aortic valve calcification (Agatston units): men >3000, women
>1600= highly likely; men >2000, women >1200= likely; men <1600, women <800 = unlikely.
ESC/EACTS Guidelines
582


<!-- PAGE 23 -->

### Page 23

velocity integral (TVI) to that of the aortic valve jet—does not require calculation of LVOT area and may assist evaluation when other parameters are equivocal (a value <0.25 suggests that severe aortic stenosis is highly likely).156 Assessment of global longitudinal strain provides additional information concerning LV function and a threshold of 15% may help to identify patients with severe asymptomatic aortic stenosis who are at higher risk of clinical deterioration or premature mortality.26,168 TOE allows evaluation of concomitant mitral valve disease and may be of value for periprocedural imaging during TAVI and SAVR.169
Natriuretic peptides predict symptom-free survival and outcome in normal and low-flow severe aortic stenosis.170,171 They can be used to arbitrate the source of symptoms in patients with multiple potential causes and identify those with high-risk asymptomatic aortic stenosis who may benefit from early intervention (section 5.2.2, Table
6 and Figure 3).
Exercise testing may unmask symptoms and is recommended for risk stratification of asymptomatic patients with severe aortic stenosis.172 Exercise echocardiography provides additional prognostic information by assessing the increase in mean pressure gradient and change in LV function.173
CCT provides information concerning the anatomy of the aortic root and ascending aorta, and the extent and distribution of valve and vascular calcification,
and feasibility of vascular access.174
Quantification of valve calcification predicts disease progression and clinical events164 and may be useful when combined with geometric assessment of valve area in assessing the severity of aortic stenosis in patients with low valve gradient.35,36,163,164
Myocardial fibrosis is a major driver of LV decompensation in aortic stenosis (regardless of the presence or absence of CAD),
which can be detected and quantified using CMR. Amyloidosis is also frequently associated with aortic stenosis in elderly patients (incidence 915%).175 When cardiac amyloidosis is clinically suspected,
based on symptoms (neuropathy and hematologic data), diphosphonate scintigraphy and/or CMR should be considered. Both entities persist following valve intervention and are associated with poor long-term prognosis.176179
Coronary angiography is essential prior to TAVI and SAVR to determine the potential need for concomitant revascularization (see section 3.2.4.1 and section 5.5). Retrograde LV catheterization is not recommended unless there are symptoms and signs of severe aortic stenosis and non-invasive investigations are inconclusive.
5.1.3
TAVI diagnostic workup
Prior to TAVI, CCT is the preferred imaging tool to assess: (i) aortic valve anatomy, (ii) annular size and shape, (iii) extent and distribution of valve and vascular calcification, (iv) risk of coronary ostial obstruction, (v) aortic root dimensions, (vi) optimal fluoroscopic projections for valve deployment, and (vii) feasibility of vascular access (femoral,
subclavian, axillary, carotid, transcaval or transapical). Adverse anatomical findings may suggest that SAVR is a better treatment option
(Table 6). TOE is more operator-dependent but may be considered when CCT is difficult to interpret or relatively contraindicated (e.g.
chronic renal failure).
Table 6
Clinical, anatomical and procedural factors that inﬂuence the choice of treatment modality for an individual patient
Favours
Favours
TAVI
SAVR
Clinical characteristics
Lower surgical risk
2
1
Higher surgical risk
1
2
Younger agea
2
1
Older agea
1
2
Previous cardiac surgery (particularly intact coronary artery bypass grafts at risk of injury during repeat sternotomy)
1
2
Severe frailtyb
1
2
Active or suspected endocarditis
2
1
Anatomical and procedural factors
TAVI feasible via transfemoral approach
1
2
Transfemoral access challenging or impossible and SAVR feasible
Transfemoral access challenging or impossible and SAVR inadvisable
2
1c
1
2
Sequelae of chest radiation
1
2
Porcelain aorta
1
2
High likelihood of severe patientprosthesis mismatch (AVA <0.65 cm2/m2 BSA)
1
2
Severe chest deformation or scoliosis
1
2
Aortic annular dimensions unsuitable for available TAVI devices
2
1
Bicuspid aortic valve
2
1
Valve morphology unfavourable for TAVI (e.g.
high risk of coronary obstruction due to low coronary ostia or heavy leaﬂet/LVOT
calciﬁcation)
2
1
Thrombus in aorta or LV
2
1
Concomitant cardiac conditions requiring intervention
Signiﬁcant multi-vessel CAD requiring surgical revascularizationd
2
1
Severe primary mitral valve disease
2
1
Severe tricuspid valve disease
2
1
Signiﬁcant dilatation/aneurysm of the aortic root and/or ascending aorta
2
1
Septal hypertrophy requiring myectomy
2
1
AVA = aortic valve area, BSA = body surface area, CAD = coronary artery disease; ESC = European Society of Cardiology; LV = left ventricle/left ventricular;
LVOT = left ventricular outﬂow tract; SAVR = surgical aortic valve replacement;
TAVI = transcatheter aortic valve implantation.
Integration of these factors provides guidance for the Heart Team decision (indications for intervention are provided in the table of recommendations on indications for intervention in symptomatic and asymptomatic aortic stenosis and recommended mode of intervention).
aLife expectancy is highly dependent on absolute age and frailty, differs between men and women, and may be a better guide than age alone. There is wide variation across Europe and elsewhere in the world (http://ghdx.healthdata.org/
record/ihme-data/gbd-2017-life-tables-1950-2017).
bSevere frailty = >2 factors according to Katz index59 (see section 3.3 for further discussion).
cVia non-transfemoral approach.
dAccording to the 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes.
ESC/EACTS 2021
............................................................................................................................................................................
ESC/EACTS Guidelines
583


<!-- PAGE 24 -->

### Page 24

................................
5.2 Indications for intervention (SAVR or
TAVI)
Indications for aortic valve intervention are summarized in the table of recommendations on indications for intervention in symptomatic and asymptomatic aortic stenosis and recommended mode of intervention and in Figure 4.
5.2.1
Symptomatic aortic stenosis
Symptomatic severe aortic stenosis has dismal prognosis and early intervention is strongly recommended in all patients. The only exceptions are for those in whom intervention is unlikely to improve quality of life or survival (due to severe comorbidities) or for those with concomitant conditions associated with survival <1 year (e.g.
malignancy) (section 3).
Intervention is recommended in symptomatic patients with highgradient aortic stenosis, regardless of LVEF. However, management of patients with low-gradient aortic stenosis is more challenging:
• LV function usually improves after intervention in patients with low-flow, low-gradient aortic stenosis, when reduced ejection fraction is predominantly caused by excessive afterload.32,180
Management of patients with severe aortic stenosisa 
Symptoms
Y
N
LVEF < 50%
Intervention likely to be of benefitb (after assessment of comorbidity and frailty)
Physically active
Exercise test
Symptoms or sustained fall in BP below baseline
Indicators of adverse prognosisd and low procedural risk
Heart Team evaluationc
Educate patient and reassess in 6 months
(or as soon as possible if symptoms occur)
Medical therapy
N
Y
Y
N
N
N
N
Y
Y
Y
Patients < 75 years at low-risk for SAVR
(STS-PROM/
EuroSCORE II < 4%)e
OR
Unsuitable for TF TAVI
and operable
All other patients
Patients ≥ 75 years
OR
Unsuitable/High risk 
for SAVR (STS-PROM/
EuroSCORE II > 8%)e
AND
Suitable for TF TAVI
SAVRf
SAVRf or 
TAVIf
TAVIf
Figure 4 Management of patients with severe aortic stenosis. BP= blood pressure; EuroSCORE = European System for Cardiac Operative Risk
Evaluation; LVEF= left ventricular ejection fraction; SAVR= surgical aortic valve replacement; STS-PROM= Society of Thoracic Surgeons  predicted risk of mortality; TAVI = transcatheter aortic valve implantation; TF= transfemoral. aSee Figure 3: Integrated imaging assessment of aortic stenosis. bProhibitive risk is defined in Supplementary Table 5. cHeart Team assessment based upon careful evaluation of clinical, anatomical, and procedural factors (see Table 6
and table on Recommendations on indications for intervention in symptomatic and asymptomatic aortic stenosis and recommended mode of intervention). The Heart Team recommendation should be discussed with the patient who can then make an informed treatment choice. dAdverse features according to clinical, imaging (echocardiography/CT), and/or biomarker assessment.
eSTS-PROM: http://riskcalc.sts.org/stswebriskcalc/#/calculate,
EuroSCORE II: http://www.euroscore.org/calc.html. fIf suitable for procedure according to clinical, anatomical, and procedural factors (Table 6).
ESC/EACTS Guidelines
584


<!-- PAGE 25 -->

### Page 25

..........................................................................................................................................................................
Conversely, improvement is uncertain if the primary cause of reduced ejection fraction is scarring due to myocardial infarction or cardiomyopathy. Intervention is recommended when severe aortic stenosis is confirmed by stress echocardiography (true severe aortic stenosis; Figure 3),32 while patients with pseudosevere aortic stenosis should receive conventional heart failure treatment.142,181 The presence or absence of flow reserve
(increase in stroke volume >_20%) does not appear to influence prognosis in contemporary series of patients undergoing TAVI or
SAVR,182184 and although those with no flow reserve show increased procedural mortality, both modes of intervention improve ejection fraction and clinical outcomes.32,180,182
Decision making for such patients should take account of comorbidities, degree of valve calcification, extent of CAD, and feasibility of revascularization.
• Data concerning the natural history of low-flow, low-gradient aortic stenosis and preserved ejection fraction, and outcomes after SAVR and TAVI remain controversial.162,165,167 Intervention should only be considered in those with symptoms and significant valve obstruction (see table of recommendations on indications for intervention in symptomatic and asymptomatic aortic stenosis and recommended mode of intervention and Figure 4).
• The prognosis of patients with normal-flow, low-gradient aortic stenosis and preserved ejection fraction is similar to that of moderate aortic stenosis—regular clinical and echocardiographic surveillance is recommended.165,166,185
5.2.2
Asymptomatic aortic stenosis
Intervention is recommended in asymptomatic patients with severe aortic stenosis and impaired LV function of no other cause,9 and those who are asymptomatic during normal activities but develop symptoms during exercise testing.172,186 Management of asymptomatic severe aortic stenosis is otherwise controversial and the decision to intervene requires careful assessment of the benefits and risks in an individual patient.
In the absence of adverse prognostic features, watchful waiting has generally been recommended with prompt intervention at symptom onset.187 Data from a single RCT have shown significant reduction in the primary endpoint (death during or within 30 days of surgery or cardiovascular death during the entire follow-up period) following early SAVR compared with conservative management [1% vs. 15%;
hazard ratio 0.09; 95% confidence interval (CI), 0.010.67;
P = 0.003].188 However, subjects were selected per inclusion criteria
(median age 64 years, minimal comorbidities, low operative risk) and follow-up in the conservative group was limited. Further randomized trials [EARLY TAVR (NCT03042104), AVATAR (NCT02436655),
EASY-AS (NCT04204915), EVOLVED (NCT03094143)] will help determine future recommendations.
Predictors of symptom development and adverse outcomes in asymptomatic patients include clinical characteristics (older age, atherosclerotic risk factors), echocardiographic parameters (valve calcification, peak jet velocity189,190), LVEF, rate of haemodynamic progression,189 increase in mean gradient >20 mmHg with exercise,172 severe LV hypertrophy,191 indexed stroke volume,158 LA
volume,192 LV global longitudinal strain,26,168,193 and abnormal biomarker levels
(natriuretic peptides,
troponin,
and fetuinA).170,171,194,195 Early intervention may be considered in asymptomatic patients with severe aortic stenosis and one or more of these predictors if procedural risk is low (although application of TAVI in this setting has yet to be formally evaluated) (Table 6 and Figure 4).
Otherwise, watchful waiting is a safer and more appropriate strategy.
5.2.3
The mode of intervention
Use of SAVR and TAVI as complementary treatment options has allowed a substantial increase in the overall number of patients with aortic stenosis undergoing surgical or transcatheter intervention in the past decade.196 RCTs have assessed the two modes of intervention across the spectrum of surgical risk in predominantly elderly patients and a detailed appraisal of the evidence base is provided in
Supplementary Section 5. In brief, these trials used surgical risk scores to govern patient selection and demonstrate that TAVI is superior to medical therapy in extreme-risk patients,197 and non-inferior to
SAVR in high-198201 and intermediate-risk patients at follow-up extending to 5 years.202208 The more recent PARTNER 3 and
Evolut Low Risk trials demonstrate that TAVI is non-inferior to
SAVR in low-risk patients at 2-year follow-up.209212 Importantly,
patients in the low-risk trials were predominantly male and relatively elderly (e.g. PARTNER 3: mean age 73.4 years, <70 years 24%,
7075 years 36%, >75 years 40%, >80 years 13%) whilst those with low-flow aortic stenosis or adverse anatomical characteristics for either procedure (including bicuspid aortic valves or complex coronary disease) were excluded.
Rates of vascular complications, pacemaker implantation, and paravalvular regurgitation are consistently higher after TAVI, whereas severe bleeding, acute kidney injury, and new-onset AF are more frequent after SAVR. Although the likelihood of paravalvular regurgitation has been reduced with newer transcatheter heart valve designs,
pacemaker implantation (and new-onset left bundle branch block)
may have long-term consequences213215 and further refinements are required. Most patients undergoing TAVI have a swift recovery,
short hospital stay, and rapidly return to normal activities.216,217
Despite these benefits, there is wide variation in worldwide access to the procedure as a result of high device costs and differing levels of healthcare resources.71,218,219
The Task Force has attempted to address the gaps in evidence and provide recommendations concerning the indications for intervention and mode of treatment (Recommendations on indications for intervention in symptomatic and asymptomatic aortic stenosis and recommended mode of intervention, Figure 4) that are guided by the RCT findings and compatible with real-world
Heart Team decision making for individual patients (many of whom fall outside the RCT inclusion criteria). Aortic stenosis is a heterogeneous condition and selection of the most appropriate mode of intervention should be carefully considered by the Heart
Team for all patients, accounting for individual age and estimated life expectancy, comorbidities (including frailty and overall quality of life, section 3), anatomical and procedural characteristics (Table
6), the relative risks of SAVR and TAVI and their long-term outcomes, prosthetic heart valve durability, feasibility of transfemoral
TAVI, and local experience and outcome data. These factors should be discussed with the patient and their family to allow informed treatment choice.
ESC/EACTS Guidelines
585


<!-- PAGE 26 -->

### Page 26

The interplay between estimated life expectancy and prosthetic heart valve durability is a key consideration in these discussions. Age is a surrogate for life expectancy but had no impact on the outcomes of the low-risk RCTs at 12 year follow-up. Life expectancy varies widely across the world and is highly dependent on absolute age, sex,
frailty, and the presence of comorbidities (http://ghdx.healthdata.org/
record/ihme-data/gbd-2017-life-tables-1950-2017); it may be a better guide than age alone but is difficult to determine in individual patients.
Recommendations on indications for interventiona in symptomatic (A) and asymptomatic (B) aortic stenosis and recommended mode of intervention (C)
A) Symptomatic aortic stenosis
Classb
Levelc
Intervention is recommended in symptomatic patients with severe, high-gradient aortic stenosis [mean gradient >_40 mmHg, peak velocity
>_4.0 m/s, and valve area <_1.0 cm2 (or <_0.6 cm2/
m2)].235,236
I
B
Intervention is recommended in symptomatic patients with severe low-ﬂow (SVi <_35 mL/m2),
low-gradient (<40 mmHg) aortic stenosis with reduced ejection fraction (<50%), and evidence of ﬂow (contractile) reserve.32,237
I
B
Intervention should be considered in symptomatic patients with low-ﬂow, low-gradient
(<40 mmHg) aortic stenosis with normal ejection fraction after careful conﬁrmation that the aortic stenosis is severed (Figure 3).
IIa
C
Intervention should be considered in symptomatic patients with low-ﬂow, low-gradient severe aortic stenosis and reduced ejection fraction without ﬂow (contractile) reserve, particularly when CCT calcium scoring conﬁrms severe aortic stenosis.
IIa
C
Intervention is not recommended in patients with severe comorbidities when the intervention is unlikely to improve quality of life or prolong survival >1 year.
III
C
B) Asymptomatic patients with severe aortic stenosis
Intervention is recommended in asymptomatic patients with severe aortic stenosis and systolic
LV dysfunction (LVEF <50%) without another cause.9,238,239
I
B
Intervention is recommended in asymptomatic patients with severe aortic stenosis and demonstrable symptoms on exercise testing.
I
C
Intervention should be considered in asymptomatic patients with severe aortic stenosis and systolic LV dysfunction (LVEF <55%) without another cause.9,240,241
IIa
B
Intervention should be considered in asymptomatic patients with severe aortic stenosis and a sustained fall in BP (>20 mmHg) during exercise testing.
IIa
C
Continued
............................................................................................................................................................................
Intervention should be considered in asymptomatic patients with LVEF >55% and a normal exercise test if the procedural risk is low and one of the following parameters is present:
• Very severe aortic stenosis (mean gradient
>_60 mmHg or Vmax >5 m/s).9,242
• Severe valve calciﬁcation (ideally assessed by
CCT) and Vmax progression >_0.3 m/s/
year.164,189,243
• Markedly elevated BNP levels (>3 age- and sex-corrected normal range) conﬁrmed by repeated measurements and without other explanation.163,171
IIa
B
C) Mode of intervention
Aortic valve interventions must be performed in
Heart Valve Centres that declare their local expertise and outcomes data, have active interventional cardiology and cardiac surgical programmes on site, and a structured collaborative
Heart Team approach.
I
C
The choice between surgical and transcatheter intervention must be based upon careful evaluation of clinical, anatomical, and procedural factors by the Heart Team, weighing the risks and beneﬁts of each approach for an individual patient. The Heart Team recommendation should be discussed with the patient who can then make an informed treatment choice.
I
C
SAVR is recommended in younger patients who are low risk for surgery (<75 yearse and STSPROM/EuroSCORE II <4%)e,f, or in patients who are operable and unsuitable for transfemoral TAVI.244
I
B
TAVI is recommended in older patients (>_75
years), or in those who are high risk (STSPROM/EuroSCORE IIf >8%) or unsuitable for surgery.197206,245
I
A
SAVR or TAVI are recommended for remaining patients according to individual clinical,
anatomical, and procedural characteristics.202205,207,209,210,212 f,g
I
B
Non-transfemoral TAVI may be considered in patients who are inoperable and unsuitable for transfemoral TAVI.
IIb
C
Balloon aortic valvotomy may be considered as a bridge to SAVR or TAVI in haemodynamically unstable patients and (if feasible) in those with severe aortic stenosis who require urgent highrisk NCS (Figure 11).
IIb
C
D) Concomitant aortic valve surgery at the time of other cardiac/ascending aorta surgery
SAVR is recommended in patients with severe aortic stenosis undergoing CABG or surgical intervention on the ascending aorta or another valve.
I
C
Continued
ESC/EACTS Guidelines
586


<!-- PAGE 27 -->

### Page 27

.............................................................................................................................................................................
Although some (now abandoned) surgical bioprosthetic designs have failed early, the durability of contemporary surgical bioprosthetic valves beyond 10 years is well established.220 Conversely,
registry data provide some reassurance concerning the long-term durability of TAVI devices up to 8 years but largely relate to older high-/intermediate-risk patients,221224 whereas information concerning durability in low-risk patients is currently limited to 2-year follow-up. Data comparing the durability of transcatheter heart valves and surgical bioprostheses directly remain limited. Rates of aortic valve re-intervention were higher after TAVI using a balloon-expandable valve compared to SAVR at 5-year follow-up in the PARTNER 2A trial (3.2% vs. 0.8%; hazard ratio, 3.3; 95% CI,
1.38.1),206 whereas rates of structural valve deterioration
(SVD) were not statistically different following SAVR and TAVI
using the third generation SAPIEN 3 device in a parallel observational registry over the same time frame.225
Valve-in-valve TAVI is an established treatment option for surgical bioprosthetic valve deterioration but may not be appropriate or feasible in all patients due to the increased likelihood of PPM in patients with a small aortic root (or undersized original prosthesis), incompatible surgical valve designs associated with increased risk of coronary occlusion, or difficult vascular access; re-do SAVR
should also be considered in these settings.226228 Favourable short-term outcomes of redo-TAVI have been demonstrated in selected older patients with transcatheter heart valve deterioration,229 despite theoretical concerns relating to maintained coronary access.230
A bicuspid aortic valve is more frequent in younger patients with aortic stenosis. While several registries have reported excellent outcomes of TAVI in patients with a bicuspid valve who were unsuitable for surgery,231233 SAVR remains more appropriate in patients with aortic stenosis affecting a bicuspid valve and in those with associated disease (e.g. aortic root dilatation, complex coronary disease, or severe mitral regurgitation) requiring a surgical approach.
In summary, prosthetic heart valve durability is a key consideration in younger patients (<75 years) at low surgical risk and SAVR (if feasible) is therefore the preferred treatment option. Conversely, durability is a lower priority in older patients (>_75 years), or those who are inoperable or high risk for surgery, and TAVI is preferred in these groups (particularly if feasible via transfemoral approach). The Heart
Team should make tailored recommendations for remaining patients based upon their individual characteristics (Table 6). This guidance should be re-addressed when further data concerning the long-term durability of TAVI become available.
Balloon aortic valvuloplasty (BAV) may be considered as a bridge to TAVI or SAVR in patients with decompensated aortic stenosis and
(when feasible) in those with severe aortic stenosis who require urgent high-risk non-cardiac surgery (NCS) (section 12). The procedure carries significant risk of complications234 and should only be undertaken after Heart Team discussion.
5.3 Medical therapy
No medical therapies influence the natural history of aortic stenosis. Statins (which demonstrated favourable effects in pre-clinical studies) do not affect disease progression246 and clinical trials targeting calcium metabolic pathways are ongoing. Patients with heart failure who are unsuitable (or waiting) for SAVR or TAVI should be medically treated according to ESC heart failure Guidelines.247 ACEI
are safe in aortic stenosis (provided that BP is monitored carefully)
and may have beneficial myocardial effects before the onset of symptoms, and after TAVI and SAVR.248250 Coexisting hypertension should be treated to avoid additional afterload, although medication
(particularly vasodilators) should be titrated to avoid symptomatic hypotension.
Antithrombotic therapy after TAVI is discussed in section 11.
5.4 Serial testing
Rate of progression of aortic stenosis varies widely. Asymptomatic patients, their family and medical carers need careful education, with emphasis on the importance of regular follow-up (ideally in a Heart
Valve Clinic9) and prompt reporting of symptoms. Those with severe aortic stenosis should be followed up every 6 months (at least) to allow earliest symptom detection (using exercise testing if symptoms are doubtful) and any change in echocardiographic parameters (particularly LVEF). Measurement of natriuretic peptides may be considered.
Several studies suggest that the prognosis of moderate degenerative aortic stenosis is worse than previously considered251254 (particularly if there is significant valve calcification) and these patients should be reevaluated at least annually. Younger patients with mild aortic stenosis and no significant calcification may be followed up every 23 years.
5.5 Special patient populations
Women with aortic stenosis have higher mortality than men, resulting from late diagnosis and initial specialist assessment followed by less frequent and delayed referral for intervention.255257 Measures are needed to improve this situation and ensure that both sexes receive equivalent care.
CAD and aortic stenosis frequently coexist and the combination confers higher risk of clinical events, therefore the need to consider revascularization in conjunction with aortic valve intervention is
SAVR should be considered in patients with moderate aortic stenosish undergoing CABG or surgical intervention on the ascending aorta or another valve after Heart Team discussion.
IIa
C
BNP = B-type natriuretic peptide; BP = blood pressure; CABG = coronary artery bypass grafting; CCT = cardiac computed tomography; EuroSCORE = European
System for Cardiac Operative Risk Evaluation; LV = left ventricle/left ventricular;
LVEF = left ventricular ejection fraction;
NCS = non-cardiac surgery;
SAVR = surgical aortic valve replacement; STS-PROM = Society of Thoracic
Surgeons

predicted risk of mortality;
SVi = stroke volume index;
TAVI = transcatheter aortic valve implantation; Vmax = peak transvalvular velocity.
aSAVR or TAVI.
bClass of recommendation.
cLevel of evidence.
dExplanations other than severe aortic stenosis for a small valve area but low gradient despite preserved LVEF are frequent and must be carefully excluded
(Figure 3).
eSTS-PROM:
http://riskcalc.sts.org/stswebriskcalc/#/calculate,
EuroSCORE
II:
http://www.euroscore.org/calc.html.
fIf suitable for surgery (see Table 6).
gIf suitable for transfemoral TAVI (see Table 6).
hModerate aortic stenosis is deﬁned as a valve area of 1.01.5 cm2 (or mean aortic gradient of 2540 mmHg) in normal ﬂow conditions—clinical assessment is essential to determine whether SAVR is appropriate for an individual patient.
ESC/EACTS 2021
...................................................................
ESC/EACTS Guidelines
587


<!-- PAGE 28 -->

### Page 28

.............................................................................................................................................................................
common. The impact of coronary revascularization in patients with silent CAD accompanying aortic stenosis is unclear and further studies are warranted in this context (section 3). Both simultaneous
SAVR and CABG, and SAVR late after CABG, carry a higher procedural risk than isolated SAVR. Nevertheless, retrospective data indicate that patients with moderate aortic stenosis, in whom CABG is indicated, benefit from concomitant SAVR. Patients aged <70
years with mean gradient progression >_5 mmHg/year benefit from
SAVR at the time of CABG once baseline peak gradient exceeds
30 mmHg.258 Decisions for individual patients should take into account haemodynamic data, rate of progression, extent of leaflet calcification, life expectancy, and associated comorbidities, as well as the individual risk of concomitant SAVR or deferred TAVI.244
Percutaneous coronary intervention (PCI) and TAVI may be undertaken as combined or staged procedures according to the clinical situation, pattern of CAD, and extent of myocardium at risk.259 In the SURTAVI trial, there was no significant difference in the primary endpoint (all-cause mortality or stroke at 2-year follow-up) in intermediate-risk patients with severe aortic stenosis and noncomplex CAD (SYNTAX score <22) undergoing either TAVI and
PCI or SAVR and CABG [16.0% (95% CI, 11.122.9) vs. 14% (95%
CI, 9.221.1); P = 0.62].260 Assessing the clinical value of systematic
PCI in TAVI patients with significant associated CAD is the objective of ongoing RCTs. Patients with severe symptomatic aortic stenosis and diffuse CAD unsuitable for revascularization should receive optimal medical therapy and undergo SAVR or TAVI according to individual characteristics.
Severity of mitral regurgitation accompanying severe aortic stenosis may be overestimated as a result of elevated LV pressures and careful quantification is required. In patients with severe primary mitral regurgitation (PMR), mitral valve surgery is required at the time of SAVR. In patients with severe SMR, surgery may also be considered in the presence of significant annular dilatation and marked
LV enlargement. In high-risk or inoperable patients with severe aortic stenosis and severe mitral regurgitation, combined (or more often sequential) TAVI and TEER may be feasible, but there is insufficient experience to allow robust recommendations.261263 In patients with severe PMR, TEER should be considered early if the patient remains symptomatic and mitral regurgitation is still severe after
TAVI. In patients with severe SMR, TAVI should be followed by careful clinical and echocardiographic reassessment to determine whether further mitral intervention is required.264
Section 4 provides recommendations for the management of aneurysm/dilatation of the ascending aorta accompanying aortic stenosis. Assessment and management of congenital aortic stenosis is addressed in ESC Guidelines on adult congenital heart disease.265
6 Mitral regurgitation
Mitral regurgitation is the second-most frequent VHD in Europe.1,3
The underlying mechanism (primary or secondary) determines the therapeutic approach.
6.1 Primary mitral regurgitation
Primary lesion of one or more components of the mitral valve apparatus characterizes
PMR.
Degenerative aetiology
(fibroelastic deficiency and Barlow disease) is most frequent in Western countries.1,2,266 In low-income countries, rheumatic aetiology is the most frequent cause of mitral regurgitation.267 Endocarditis can cause PMR
and is addressed in the corresponding ESC Guidelines.4
6.1.1
Evaluation
Echocardiography is the first choice of imaging technique to grade
PMR (Table 7). An integrative approach including qualitative, semiquantitative, and quantitative measures of mitral regurgitation (besides quantification of LV and LA dimensions) is recommended.24,268
Routinely measured effective regurgitant orifice area (EROA) is strongly associated with all-cause mortality, and compared with the general population an excess mortality appears for an EROA
>_20 mm2 and steadily increases beyond 40 mm2.269 Evaluation of the specific lesion leading to mitral regurgitation has prognostic implications266,270 and is fundamental to determine the feasibility of surgical and transcatheter valve repair271273 (Supplementary Figure 1). Threedimensional TOE provides an ‘en face’ view of the mitral leaflets resembling the surgical inspection of the valve, thereby facilitating
Heart Team discussion.24,268 In addition, 3D echocardiography has shown better agreement with CMR in quantifying the regurgitant volume than 2D echocardiography, particularly in eccentric, multiple and late-systolic regurgitant jets.274277 When various echocardiographic parameters used to grade mitral regurgitation are inconsistent, CMR
is a valid alternative to quantify the regurgitant volume and is the reference standard to quantify LV and LA volumes.278 In addition,
quantification of mitral regurgitation with CMR has shown prognostic implications.277 Finally, preliminary data show that myocardial fibrosis assessed with CMR is frequent in PMR and has been associated with sudden cardiac death and ventricular arrhythmias.279
Exercise echocardiography permits evaluation of changes in mitral regurgitant volume and pulmonary pressures during peak exercise and is particularly helpful in patients with discordant symptoms and regurgitation grade at rest.280,281 In asymptomatic patients with severe PMR and non-dilated LV and LA, low BNP values are associated with low mortality and can be useful during follow-up.41,282
LV dimensions and ejection fraction are considered to guide the management of patients with severe PMR. However, there is cumulative evidence showing that LV global longitudinal strain has incremental prognostic value in patients treated with surgical repair.283,284
Recently, the Mitral Regurgitation International Database (MIDA)
score has been proposed to estimate the risk of all-cause mortality in patients with severe PMR due to flail leaflet, who are under medical treatment or surgically treated.285 Among the variables included in the score, LA diameter >_55 mm and LVESD >_40 mm are new thresholds that have been included in the current recommendations.
Right heart catheterization is systematically used to confirm pulmonary hypertension diagnosed by echocardiography when this is the only criterion to refer the patient for surgery.
6.1.2
Indications for intervention
Urgent surgery is indicated in patients with acute severe mitral regurgitation. In the case of papillary muscle rupture as the underlying disease, valve replacement is generally required.
Indications for surgery in severe chronic PMR are shown in the following table of recommendations and in Figure 5. Surgery is
ESC/EACTS Guidelines
588


<!-- PAGE 29 -->

### Page 29

..............
recommended in patients with symptomatic severe PMR and acceptable surgical risk according to the Heart Team decision. The presence of LVEF <_60%, LVESD >_40 mm,285,286 LA volume >_60 mL/m2 or diameter >_55 mm,287,288 systolic pulmonary arterial pressure (SPAP)
>50 mmHg,289 and AF290,291 have been associated with worse outcomes and are considered triggers for intervention regardless of symptomatic status.292 In the absence of these criteria, watchful waiting is a safe strategy in asymptomatic patients with severe PMR and ideally should be performed in a Heart Valve Clinic.
When surgery is considered, mitral valve repair is the surgical intervention of first choice when the results are expected to be durable according to the Heart Team evaluation since it is associated with better survival compared to mitral valve replacement.293,294 PMR
due to segmental valve prolapse can be repaired with a low risk of recurrence and reoperation.294296 The reparability of rheumatic lesions, extensive valve prolapse and to a greater extent leaflet calcification or extensive annular calcification is more challenging.297,298
Patients requiring a predictably complex repair should undergo surgery in experienced repair centres with high repair rates, low operative mortality, and a record of durable results. When repair is not feasible, mitral valve replacement with preservation of the subvalvular apparatus is favoured.
Transcatheter mitral valve implantation for severe PMR is a safe alternative in patients with contraindications for surgery or high operative risk.299302 TEER is the most evidenced, while the safety and efficacy of other techniques have been demonstrated in smaller series.303306 The efficacy of more recent TEER system iterations307
will be investigated in high-risk (MITRA-HR study NCT03271762)308
and intermediate-risk patients (REPAIR-MR study NCT04198870).
Table 7
Severe mitral regurgitation criteria based on 2D echocardiography
Primary mitral regurgitation
Secondary mitral regurgitation
Qualitative
Mitral valve morphology
Flail leaﬂet, ruptured papillary muscle, severe retraction, large perforation
Normal leaﬂets but with severe tenting, poor leaﬂet coaptation
Colour ﬂow jet area
Large central jet (>50% of LA) or eccentric wall impinging jet of variable size
Large central jet (>50% of LA) or eccentric wall impinging jet of variable size
Flow convergence
Large throughout systole
Large throughout systole
Continuous wave Doppler jet
Holosystolic/dense/triangular
Holosystolic/dense/triangular
Semiquantitative
Vena contracta width (mm)
>_7 (>_8 mm for biplane)
>_7 (>_8 mm for biplane)
Pulmonary vein ﬂow
Systolic ﬂow reversal
Systolic ﬂow reversal
Mitral inﬂow
E-wave dominant (>1.2 m/s)
E-wave dominant (>1.2 m/s)
TVI mitral/TVI aortic
>1.4
>1.4
Quantitative
EROA (2D PISA, mm2)
>_40 mm2
>_40 mm2 (may be >_30 mm2 if elliptical regurgitant oriﬁce area)
Regurgitant volume (mL/beat)
>_60 mL
>_60 mL (may be >_45 mL if low ﬂow conditions)
Regurgitant fraction (%)
>_50%
>_50%
Structural
Left ventricle
Dilated (ESD >_40 mm)
Dilated
Left atrium
Dilated (diameter >_55 mm or volume >_60 mL/m2)
Dilated
2D = two-dimensional; ESD = endsystolic diameter; EROA = effective regurgitant oriﬁce area; LA = left atrium; PMR = primary mitral regurgitation; SMR = secondary mitral regurgitation; PISA = proximal isovelocity surface area; TVI = time-velocity integral.
Adapted from Lancellotti P et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European
Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2013;14:611644. Copyright (2013) by permission of Oxford University Press on behalf of the European
Society of Cardiology.
Reproduced from Zoghbi WA et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 2017;30:303371. Copyright (2017), with permission from the
American Society of Echocardiography.
ESC/EACTS 2021
Recommendations on indications for intervention in severe primary mitral regurgitation
Recommendations
Classa
Levelb
Mitral valve repair is the recommended surgical technique when the results are expected to be durable.293296
I
B
Surgery is recommended in symptomatic patients who are operable and not high risk.293296
I
B
Surgery is recommended in asymptomatic patients with LV dysfunction (LVESD >_40 mm and/or LVEF <_60%).277,286,292
I
B
Surgery should be considered in asymptomatic patients with preserved LV function (LVESD
<40 mm and LVEF >60%) and AF secondary to mitral regurgitation or pulmonary hypertensionc
(SPAP at rest >50 mmHg).285,289
IIa
B
Continued
.............................................................
ESC/EACTS Guidelines
589


<!-- PAGE 30 -->

### Page 30

.............................................................................................................................................................................
6.1.3
Medical therapy
In acute mitral regurgitation, nitrates and diuretics are used to reduce filling pressures. Sodium nitroprusside reduces afterload and regurgitant fraction. Inotropic agents and an intra-aortic balloon pump are of use in hypotension and haemodynamic instability.
In chronic PMR with preserved LVEF, there is no evidence to support the prophylactic use of vasodilators. In patients with overt heart failure,
medical treatment as per current heart failure guidelines applies.247
6.1.4
Serial testing
Asymptomatic patients with severe mitral regurgitation and LVEF
>60% should be followed clinically and by echocardiography every 6
months, ideally in the setting of a Heart Valve Centre.309 Measurement of BNP levels, exercise echocardiography, electrocardiogram-Holter monitoring and CMR are useful complementary diagnostic and risk stratification tools.268 The association between PMR, sudden cardiac death and ventricular arrhythmias remains controversial.310312 The presence of mitral annulus disjunction (abnormal atrial displacement of the hinge point of the mitral valve away from the ventricular myocardium) has been also associated with increased risk of ventricular arrhythmias.310,311,313 Interestingly, the majority of these patients did not have severe mitral regurgitation. In asymptomatic patients with severe PMR and progressive increase of LV size (LVESD approaching
40 mm) or decrease of LVEF on serial studies, surgical mitral valve repair should be discussed. Asymptomatic patients with moderate mitral regurgitation and preserved LV function can be followed on a yearly basis and echocardiography should be performed every
12 years. After intervention, serial follow-up focuses on evaluation of symptomatic status, presence of arrhythmic events, assessment of valve function,314 and recurrence of mitral regurgitation. After surgical mitral valve repair, high-volume centres have reported good durability with a recurrence rate of moderate or severe mitral regurgitation of
12.5% at 20 years of follow-up.296 After transcatheter mitral valve repair, the currently reported rates of residual moderate and severe mitral regurgitation (2330%) would suggest that yearly echocardiogram is appropriate.14,300,301
6.1.5
Special populations
Sex differences in terms of prevalence of underlying aetiology of PMR
and management have been reported.298,315,316 Despite the reduction in the prevalence of rheumatic disease in Western countries,
women still have higher rates of rheumatic mitral regurgitation than men and emerging aetiologies such as radiation heart disease are also more frequent in women.297 These aetiologies are often characterized by severe calcification of the mitral valve apparatus and associated with mitral stenosis precluding durable repair. Women with
PMR referred for surgical treatment received mitral valve repair at a similar rate to men.316 However, women more frequently present with post-operative heart failure, probably related to a later referral and more advanced disease as compared to men.
6.2 Secondary mitral regurgitation
In SMR, the valve leaflets and chordae are structurally normal and mitral regurgitation results from an imbalance between closing and tethering forces secondary to alterations in LV and LA geometry.317,318 It is most commonly seen in dilated or ischaemic cardiomyopathies, both in severely dilated LV with markedly depressed LV
function or after an isolated infero-basal myocardial infarction leading to posterior leaflet tethering, despite almost normal LV size and ejection fraction. SMR may also arise as a consequence of LA enlargement and mitral annular dilatation in patients with longstanding AF, in whom LVEF is usually normal and LV dilatation less pronounced (so called ‘atrial functional mitral regurgitation’).319
6.2.1
Evaluation
The echocardiographic criteria to define severe SMR do not differ from those used in PMR and an integrative approach should be used
(Table 7).24,268 However, it should be acknowledged that when quantifying EROA and regurgitant volume in SMR, lower thresholds may be applied to define severe SMR. In heart failure patients, the total forward LV stroke volume is lower and that may lead to lower estimated regurgitant volume (<60 mL/beat). Calculation of regurgitant fraction in those circumstances could account for lower flows and has shown prognostic implications.320 In addition, the crescent shape of the regurgitant orifice, characteristic of SMR, may lead to underestimation of the vena contracta width and of the EROA. An EROA
>_30 mm2 by 2D proximal isovelocity surface area (PISA) likely corresponds to severe SMR. In contrast, whether an EROA >_20 mm2
defines severe SMR remains controversial. In heart failure patients,
even mild mitral regurgitation is associated with poor prognosis321
and evidence that surgical or transcatheter treatment of moderate
SMR does not seem to improve patient outcomes322,323 supports the change in definition of severe SMR. Caution is required, therefore, when labelling severe SMR based solely on prognostic implications. Other factors such as the extent of myocardial scar, as assessed with CMR, have been associated with poor prognosis.324 In addition, LVEF has been shown to be misleading in patients with severe SMR, while LV global longitudinal strain has been shown to have incremental prognostic value.325,326 The use of 3D echocardiography, CMR and exercise echocardiography may help to identify patients with severe mitral regurgitation when 2D echocardiography at rest is inconclusive.24,268
Surgical mitral valve repair should be considered in low-risk asymptomatic patients with LVEF
>60%, LVESD <40 mmd and signiﬁcant LA dilatation (volume index >_60 mL/m2 or diameter
>_55 mm) when performed in a Heart Valve
Centre and a durable repair is likely.285,288
IIa
B
TEER may be considered in symptomatic patients who fulﬁl the echocardiographic criteria of eligibility, are judged inoperable or at high surgical risk by the Heart Team and for whom the procedure is not considered futile.299302
IIb
B
AF = atrial ﬁbrillation; LA = left atrium/left atrial; LV = left ventricle/left ventricular;
LVEF = left ventricular ejection fraction; LVESD = left ventricular end-systolic to-edge repair.
aClass of recommendations.
bLevel of evidence.
cIf an elevated SPAP is the only indication for surgery, the value should be conﬁrmed by invasive measurement.
dCut-offs refer to average-size adults and may require adaptations in patients with unusually small or large stature.
ESC/EACTS 2021
ESC/EACTS Guidelines
590
diameter; SPAP = systolic pulmonary arterial pressure; TEER = transcatheter edgeDownloaded from https://academic.oup.com/eurheartj/article/43/7/561/6358470 by guest on 28 April 2025


<!-- PAGE 31 -->

### Page 31

......................................................
6.2.2
Medical therapy
Optimal medical therapy in line with the guidelines for the management of heart failure247 should be the first and essential step in the management of all patients with SMR and should include replacement of ACEI or ARB with sacubitril/valsartan, sodium-glucose co-transporter 2 inhibitors and/or ivabradine, whenever indicated.247,327
Indications for cardiac resynchronization therapy (CRT) should be evaluated in accordance with related guidelines.247 If symptoms persist after optimization of conventional heart failure therapy, options for mitral valve intervention should be promptly evaluated before further deterioration of LV systolic function or cardiac remodelling occur.
6.2.3
Indications for intervention
Chronic SMR is associated with impaired prognosis321,328 and its interventional management is complex (see recommendations on indications for mitral valve intervention in chronic severe SMR, and
Figure 6). The detailed analysis of the available level of evidence made by the methodology group of the task force is available in
Supplementary Section 5. The importance of decision making by a multidisciplinary Heart Team needs to be emphasized in this setting.
The Heart Team, including a heart failure specialist, should optimize guideline-directed medical therapy (GDMT) and consider the indications of electrophysiological, transcatheter and surgical interventions,
their priority and order of implementation.
The evidence supporting surgical intervention remains limited.
Mitral valve surgery is recommended in patients with severe SMR
undergoing CABG or other cardiac surgery.329,330 The surgical approach has to be tailored to the individual patient.247,331 In selected patients without advanced LV remodelling, mitral valve repair with an undersized complete rigid ring restores valve competence, improves symptoms, and results in reverse LV remodelling.331 Additional valvular/subvalvular techniques or chordal sparing valve replacement may be considered in patients with echocardiographic predictors of repair failure.332 Valve replacement avoids recurrence of mitral regurgitation, although this does not translate into better LV reverse
Symptoms
Management of patients with severe chronic primary mitral regurgitation
LVEF ≤ 60% or
LVESD ≥ 40 mm
Operative risk judged by the
Heart Team
N
Y
Follow-up
Surgical mitral valve repair
Surgery
(repair whenever possible)
TEER if anatomically suitable/extended
HF treatmentb
Palliative care
New onset of AF or
SPAP > 50 mmHg
High likelihood of durable repair, low surgical risk,
and LA dilatationa
N
Y
N
Y
Y
Inoperable or at high surgical risk
High risk of futility
Y
N
N
Figure 5 Management of patients with severe chronic primary mitral regurgitation. AF= atrial fibrillation; HF= heart failure; LA= left atrium/left atrial;
LVEF= left ventricular ejection fraction; LVESD= left ventricular end-systolic diameter; SPAP= systolic pulmonary arterial pressure; TEER: transcatheter edge-to-edge repair. aLA dilatation: volume index >_60 mL/m2 or diameter >_55 mm at sinus rhythm. bExtended heart failure treatment includes the following: CRT; ventricular assist devices; heart transplantation.247
ESC/EACTS Guidelines
591


<!-- PAGE 32 -->

### Page 32

.................
remodelling or survival.333 Indications for isolated mitral valve surgery in SMR are particularly restrictive, owing to significant procedural risk, high rates of recurrent mitral regurgitation, and the absence of proven survival benefit.333335 In patients with atrial functional mitral regurgitation, LVEF is usually normal, LV dilatation less pronounced and mitral annular dilatation represents the main mechanism of mitral regurgitation. This subgroup may be more effectively treated by ring annuloplasty often associated with ablation of AF but evidence is still limited.319
TEER with the MitraClip system is a minimal-invasive treatment option for SMR. Two RCTs (COAPT and MITRA-FR)323,336,337 have evaluated its safety and efficacy in patients with symptomatic heart failure and severe SMR persisting despite medical therapy, who were considered either ineligible or not appropriate for surgery by the
Heart Team (Supplementary Table 7). The results indicate that the procedure is safe and effectively reduces SMR up to 3 years.338
However, in the MITRA-FR trial,323,336 MitraClip implantation had no impact on the primary endpoint of all-cause mortality or heart failure hospitalization at 12 months and 2 years compared to GDMT alone.
In the COAPT trial,337 MitraClip implantation substantially reduced the primary endpoint of cumulative hospitalizations for heart failure,
as well as several pre-specified secondary endpoints, including allcause mortality at 2 years.
Subanalyses of the COAPT trial confirm the positive response to
TEER in several patient subgroups;339343 conversely, the effect of the interventional treatment was neutral throughout all subgroups in an echocardiographic subanalyses of the MITRA-FR trial.344
The conflicting results of these two trials have generated considerable discussion. These diverging results might be partially explained by effect size of the trials, differences in trial design, patient selection,
echocardiographic assessment of SMR severity, use of medical therapy, and technical factors. Patients in COAPT demonstrated greater severity of SMR (EROA 41±15 mm2 vs. 31±10 mm2) and less LV dilatation (mean indexed LV end-diastolic volume 101±34 mL/m2 vs.
135±35 mL/m2) than those enrolled in MITRA-FR. Perhaps reflecting greater severity of SMR in relation to LV dimensions (‘disproportionate’ mitral regurgitation), patients in COAPT were overall more likely to benefit from TEER in terms of reduced mortality and heart failure hospitalization.345
Additional studies are needed to identify patients who will benefit the most from TEER.
Therefore, TEER should be considered in selected patients with severe SMR fulfilling the COAPT inclusion criteria,346348 who receive optimal medical therapy supervised by a heart failure specialist and are as close as possible to the patients actually enrolled in the study.
Optimization of the procedural result should also be pursued. In addition, TEER may be considered only in selected cases when the
COAPT criteria are not fulfilled with the aim of improving symptoms and quality of life.349353 In patients with less severe SMR (EROA
<30 mm2) and advanced LV dilatation/dysfunction, the prognostic benefit of MitraClip remains unproven.323,354,355 Patients with end-stage
LV and/or RV failure and no option for revascularization may be better served by cardiac transplantation or LV assist device implantation.
Valve intervention is generally not an option when LVEF is <15%.247
The management of moderate ischaemic SMR in patients undergoing CABG remains an object of debate.322,330 Surgery is more likely to be considered if myocardial viability is present and if comorbidity is low. Exercise-induced dyspnoea and a large increase in mitral regurgitation severity and SPAP favour combined surgery.
Transcatheter mitral valve repair systems other than TEER, as well as transcatheter mitral valve replacement devices, are currently the subject of intense investigation but clinical data are still limited.
Recommendations on indications for mitral valve intervention in chronic severe secondary mitral regurgitationa
Recommendations
Classb
Levelc
Valve surgery/intervention is recommended only in patients with severe SMR who remain symptomatic despite GDMT (including CRT if indicated) and has to be decided by a structured collaborative Heart Team.247,323,336,337
I
B
Patients with concomitant coronary artery or other cardiac disease requiring treatment
Valve surgery is recommended in patients undergoing CABG or other cardiac surgery.329,330,333
I
B
In symptomatic patients, who are judged not appropriate for surgery by the Heart Team on the basis of their individual characteristics,d PCI
(and/or TAVI) possibly followed by TEER (in case of persisting severe SMR) should be considered.
IIa
C
Patients without concomitant coronary artery or other cardiac disease requiring treatment
TEER should be considered in selected symptomatic patients, not eligible for surgery and fulﬁlling criteria suggesting an increased chance of responding to the treatment.337,338,356,357 e
IIa
B
Valve surgery may be considered in symptomatic patients judged appropriate for surgery by the Heart Team.
IIb
C
In high-risk symptomatic patients not eligible for surgery and not fulﬁlling the criteria suggesting an increased chance of responding to TEER, the
Heart Team may consider in selected cases a
TEER procedure or other transcatheter valve therapy if applicable, after careful evaluation for ventricular assist device or heart transplant.e
IIb
C
2D = two-dimensional; CABG = coronary artery bypass grafting; CRT = cardiac resynchronization therapy; EROA = effective regurgitation oriﬁce area; GDMT
= guideline-directed medical therapy; LVEF = left ventricular ejection fraction;
SMR = secondary mitral regurgitation; PCI = percutaneous coronary intervention;
SMR = secondary mitral regurgitation; TAVI = transcatheter aortic valve implantation; TEER: transcatheter edge-to-edge repair.
aSee Table 7 for SMR quantiﬁcation (an EROA >_30 mm2 by 2D proximal isovelocity surface area corresponds likely to severe SMR). Quantiﬁcation of SMR
must always be performed under optimal guidelines-directed medical treatment.
bClass of recommendation.
cLevel of evidence.
dLVEF, predicted surgical risk, amount of myocardial viability, coronary anatomy/
target vessels, type of concomitant procedure needed, TEER eligibility, likelihood of durable surgical repair, need of surgical mitral replacement, local expertise.
eCOAPT criteria (Cardiovascular Outcomes Assessment of the MitraClip
Percutaneous Therapy for Heart Failure Patients With Functional Mitral
Regurgitation): see Supplementary Table 7.
ESC/EACTS 2021
...........................................................................................................................................................
ESC/EACTS Guidelines
592


<!-- PAGE 33 -->

### Page 33

Symptoms despite GDMT
Management of patients with chronic severe secondary mitral regurgitation
Appropriate for surgery on the base of individual patient characteristicsa
Persisting severe
SMR and 
symptoms
N
Y
Y
Severe comorbidities or life expectancy < 1 year
N
CAD or other cardiac disease requiring treatment
PCI/TAVI
Appropriate for valve surgery
Fulfilling criteria suggesting an increased chance of responding to TEERc
HTx/LVAD
Palliative care
TEER
Close follow-up
TEER in selected cases or other transcatheter valve therapy if applicable (for symptoms improvement),
after careful evaluation for HTx/LVAD
MV
surgeryb
N
Referral to Heart Team
GDMT optimization
CRT when indicated (ESC HF Guidelines)
CABG or other cardiac surgery
AND
MV
surgery
End stage
LV/RV
failure
N
Palliative care
Y
N
Y
N
Y
Y
N
Y
Figure 6 Management of patients with chronic severe secondary mitral regurgitation. CAD = coronary artery disease; CABG= coronary artery bypass grafting; CRT = cardiac resynchronization therapy; ESC = European Society of Cardiology; GDMT = guideline-directed medical therapy; HF= heart failure;
HTx = heart transplantation; LVAD= left ventricular assist devices; LV= left ventricle/left ventricular; LVEF= left ventricular ejection fraction; MV = mitral valve; PCI = percutaneous coronary intervention; RV = right ventricle/right ventricular; SMR = secondary mitral regurgitation; TAVI= transcatheter aortic valve implantation; TEER: transcatheter edge-to-edge repair. aLVEF, predicted surgical risk, amount of myocardial viability, coronary anatomy/target vessels, type of concomitant procedure needed, TEER eligibility, likelihood of durable surgical repair, need of surgical mitral replacement, local expertise.
bParticularly when concomitant tricuspid valve surgery is needed. cCOAPT criteria (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous
Therapy for Heart Failure Patients With Functional Mitral Regurgitation): see Supplementary Table 7.
ESC/EACTS Guidelines
593


<!-- PAGE 34 -->

### Page 34

7 Mitral stenosis
Aetiology of mitral stenosis is mostly rheumatic or degenerative.
Rheumatic fever is the most common cause of mitral stenosis worldwide. Its prevalence has greatly decreased in industrialized countries,
but it remains a significant healthcare problem in developing countries and affects young patients.2,267,358 Degenerative mitral stenosis related to MAC is a distinct pathology and its prevalence significantly increases with age.359,360 Both types of mitral stenosis are more frequent in females.361 In rare cases, mitral stenosis due to valve rigidity but without commissural fusion, may be related to chest radiation,
carcinoid heart disease, or inherited metabolic diseases.
7.1 Rheumatic mitral stenosis
7.1.1
Evaluation
Clinically significant mitral stenosis is defined by a mitral valve area (MVA) <_1.5 cm2. Commissural fusion with thickening of the posterior leaflet is the most important mechanism of stenosis.
Echocardiography is the preferred method for diagnosis, assessment of severity, and haemodynamic consequences of mitral stenosis. Valve area using 2D planimetry is the reference measurement of mitral stenosis severity, whereas mean transvalvular gradient and pulmonary pressures reflect its consequences and have a prognostic role.362 3D-TTE
planimetry may have an additional diagnostic value. TTE usually provides sufficient information for routine management. Scoring systems have been developed to help assess suitability for percutaneous mitral commissurotomy (PMC; Supplementary Table 8),363365 TOE should be performed to exclude LA thrombus before PMC or after an embolic episode, and to obtain detailed information on mitral anatomy (commissural zones and subvalvular apparatus) before intervention when
TTE is suboptimal. Stress testing is indicated in patients with no symptoms or symptoms equivocal or discordant with the severity of mitral stenosis. Exercise echocardiography may provide objective information by assessing changes in mitral gradient and pulmonary artery pressure and is superior to DSE. Echocardiography plays an important role in the periprocedural monitoring of PMC and follow-up.
7.1.2
Indications for intervention
The type of treatment (PMC or surgery), as well as its timing, should be decided based on clinical characteristics, anatomy of valve and subvalvular apparatus, and local expertise.366369 In general, indication for intervention should be limited to patients with clinically significant (moderate-to-severe) rheumatic mitral stenosis (valve area
<_1.5 cm2) in whom PMC has had a significant impact on its management. In Western countries where incidence of rheumatic fever and number of PMC is low, this treatment should be restricted to expert operators in specialized centres to improve safety and procedural success rate.366 Efforts should be made to increase availability of
PMC in developing countries where access to treatment is limited due to economic reasons.267 PMC should be considered as an initial treatment for selected patients with mild to moderate calcification or impaired subvalvular apparatus, but who have otherwise favourable clinical characteristics.360
The management of clinically significant rheumatic mitral stenosis is summarized in Figure 7 and the indications and contraindications for
PMC are provided in the table of recommendations below, and Table 8.
Recommendations on indications for percutaneous mitral commissurotomy and mitral valve surgery in clinically signiﬁcant (moderate or severe) mitral stenosis (valve area 1.5 cm2)
Recommendations
Classa
Levelb
PMC is recommended in symptomatic patients without unfavourable characteristicsc for
PMC.360,363365,367
I
B
PMC is recommended in any symptomatic patients with a contraindication or a high risk for surgery.
I
C
Mitral valve surgery is recommended in symptomatic patients who are not suitable for PMC in the absence of futility.
I
C
PMC should be considered as initial treatment in symptomatic patients with suboptimal anatomy but no unfavourable clinical characteristics for PMC.c
IIa
C
PMC should be considered in asymptomatic patients without unfavourable clinical and anatomical characteristicsc for PMC and:
• High thromboembolic risk (history of systemic embolism, dense spontaneous contrast in the
LA, new-onset or paroxysmal AF), and/or
• High risk of haemodynamic decompensation
(systolic pulmonary pressure >50mmHg at rest,
need for major NCS, desire for pregnancy).
IIa
C
AF = atrial ﬁbrillation; LA = left atrium/left atrial; MVA = mitral valve area;
NCS = non-cardiac surgery; PMC = percutaneous mitral commissurotomy.
aClass of recommendation.
bLevel of evidence.
cUnfavourable characteristics for PMC can be deﬁned by the presence of several of the following characteristics. Clinical characteristics: old age, history of commissurotomy, New York Heart Association class IV, permanent AF, severe pulmonary hypertension. Anatomical characteristics: echocardiographic score >8,
Cormier score 3 (calciﬁcation of mitral valve of any extent as assessed by ﬂuoroscopy), very small MVA, severe tricuspid regurgitation. For the deﬁnition of scores, see Supplementary Table 8.
ESC/EACTS 2021
Table 8
Contraindications for percutaneous mitral commissurotomy in rheumatic mitral stenosisa
Contraindications
MVA >1.5 cm2a
LA thrombus
More than mild mitral regurgitation
Severe or bi-commissural calciﬁcation
Absence of commissural fusion
Severe concomitant aortic valve disease, or severe combined tricuspid stenosis and regurgitation requiring surgery
Concomitant CAD requiring bypass surgery
CAD = coronary artery disease; LA = left atrium/left atrial; MVA = mitral valve area; PMC = percutaneous mitral commissurotomy.
aPMC may be considered in patients with valve area >1.5 cm2 with symptoms that cannot be explained by another cause and if the anatomy is favourable.
............................................................................................................................................................................
ESC/EACTS 2021
ESC/EACTS Guidelines
594


<!-- PAGE 35 -->

### Page 35

.................................
7.1.3
Medical therapy
Diuretics, beta-blockers, digoxin, non-dihydropyridine calcium channel blockers and ivabradine can improve symptoms. Anticoagulation with vitamin K antagonist (VKA) with a target international normalized ratio (INR) between 2 and 3 is indicated in patients with AF.
Patients with moderate-to-severe mitral stenosis and AF should be kept on VKA and not receive NOACs. Currently there is no solid evidence to support the use of NOACs in this setting370 and a randomized clinical trial is underway (INVICTUS VKA NCT
02832544). Neither cardioversion nor catheter pulmonary vein isolation are indicated before intervention in patients with significant mitral stenosis, as they do not durably restore sinus rhythm. If AF is of recent onset and the LA is only moderately enlarged, cardioversion should be performed soon after successful intervention, it should also be considered in patients with less than severe mitral stenosis. Amiodarone is most effective in maintaining the sinus rhythm after cardioversion. In patients in sinus rhythm, OAC is recommended when there has been a history of systemic embolism or a thrombus is present in the LA and should also be considered when
TOE shows dense spontaneous echocardiographic contrast or an enlarged LA (M-mode diameter >50 mm or LA volume >60 mL/m2).
Symptoms
High risk of embolism or haemodynamic decompensationa
Contraindication to PMC
Management of clinically significant rheumatic mitral stenosis (MVA ≤ 1.5 cm2)
Y
Favourable anatomical characteristicsc
Contraindication to or unfavourable characteristics for PMC
Symptoms
Exercise testing
N
N
N
Y
Contraindication or high risk for surgery
Y
N
Y
Y
Follow up
PMC
Surgeryd
PMCb
Surgery
Surgery
N
Favourable clinical characteristicsc
N
Y
N
Y
Y
N
Figure 7 Management of clinically significant rheumatic mitral stenosis (MVA <_1.5 cm2). AF= atrial fibrillation; LA= left atrium/left atrial; MVA = mitral valve area; NCS= non-cardiac surgery; PMC = percutaneous mitral commissurotomy. aHigh thromboembolic risk: history of systemic embolism, dense spontaneous contrast in the LA, new-onset AF. High-risk of haemodynamic decompensation: systolic pulmonary pressure >50 mmHg at rest, need for major NCS, desire for pregnancy. bSurgical commissurotomy may be considered by experienced surgical teams in patients with contraindications to PMC.
cSee recommendations on indications for PMC and mitral valve surgery in clinically significant mitral stenosis in section 7.2. dSurgery if symptoms occur for a low level of exercise and operative risk is low.
ESC/EACTS Guidelines
595


<!-- PAGE 36 -->

### Page 36

.............................................................................................................................................................................
7.1.4
Serial testing
Asymptomatic patients with clinically significant mitral stenosis should be followed up yearly by clinical and echocardiographic examinations; and at longer intervals (23 years) in case of moderate stenosis. Follow-up of patients after successful PMC is similar to that of asymptomatic patients and should be more frequent if asymptomatic restenosis occurs.
7.1.5
Special patient populations
When symptomatic restenosis occurs after surgical commissurotomy or PMC, re-intervention in most cases requires valve replacement, but PMC can be proposed in selected candidates with favourable characteristics if the predominant mechanism is commissural refusion.369
In patients with severe rheumatic mitral stenosis combined with severe aortic valve disease, surgery is preferable when it is not contraindicated. The management of patients in whom surgery is contraindicated is difficult and requires a comprehensive and individualized evaluation by the Heart Team. In cases with severe mitral stenosis associated with moderate aortic valve disease, PMC can be performed to postpone the surgical treatment of both valves. In patients with severe tricuspid regurgitation, PMC may be considered in selected patients with sinus rhythm, moderate atrial enlargement,
and severe functional tricuspid regurgitation secondary to pulmonary hypertension. In other cases, surgery on both valves is preferred.371
In the elderly population with rheumatic mitral stenosis when surgery is high risk, PMC is a useful option, even if as palliative care.364,367,368 Treatment of patients with low-gradient severe mitral stenosis (MVA <_1.5 cm2, mean gradient <10 mmHg) is difficult, as these patients are older and have less optimal anatomy.372
7.2 Degenerative mitral stenosis with mitral annular calcification
MAC is a distinct entity that differs from rheumatic mitral stenosis.
Usually, these patients are elderly and may have significant comorbidities including disease of other valves. Overall, the prognosis is poor due to high-risk profile and technical anatomic challenges resulting from the presence of annular calcification.373 Between 9% and 15%
of the general population may have MAC, with higher frequency in elderly patients (40%).67,374376 Furthermore, almost half of patients with aortic stenosis undergoing TAVI have MAC, and the disease is severe in 9.5% of cases.359,377 Severe MAC may result in mitral stenosis (more frequently) or mitral regurgitation, or both.
7.2.1
Evaluation
In patients with degenerative mitral stenosis and MAC, the echocardiographic evaluation of the disease severity is difficult and the usual parameters lack validation. Planimetry is less reliable due to diffuse calcium and irregular orifice. The mean transmitral gradient has been shown to have prognostic value.378 For the evaluation of severity, it is necessary to take into account the abnormalities of LA and LV compliance before indicating an intervention. If an intervention is planned,
echocardiography is used for initial evaluation and CCT is necessary to assess the degree and location of calcification and to evaluate the feasibility of an intervention.379
7.2.2
Indications for intervention
Treatment options, including transcatheter and surgical approaches,
are high-risk procedures and evidence from randomized trials is lacking. Even if the procedure is done successfully and the transvalvular gradient is reduced, due to low compliance of the LA and LV the mean atrial pressure may remain elevated.
In elderly patients with degenerative mitral stenosis and MAC, surgery is technically challenging and high risk.380 As there is no commissural fusion, degenerative mitral stenosis is not amenable to PMC.359
In symptomatic inoperable patients with suitable anatomy, preliminary experience showed that transcatheter mitral valve implantation
(in mitral position, using an inverted balloon-expandable TAVI prosthesis), is feasible in selected patients with severe mitral stenosis,
when performed by experienced operators after careful preplanning using multimodality imaging.379 The largest case series reported to date included only 116 patients.381 However, operative mortality is high, in particular due to the risk of LVOT obstruction and mid-term results are less favourable compared to mitral valve-invalve procedures.382,383 The most recent case series show that results are improving owing to better patient selection and the use of different accesses, as well as concomitant or preventive measures such as alcohol septal ablation384 or laceration/resection of the anterior leaflet.385387
Recently, a preliminary case series suggested that transcatheter mitral valve replacement using a dedicated prosthesis is feasible and can result in symptom improvement.388
8 Tricuspid regurgitation
Moderate or severe tricuspid regurgitation is observed in 0.55% of the general population and its prevalence increases with age, affecting about 4% of the patients aged 75 years or more.389 Aetiology is secondary in >_90% of cases, due to pressure and/or volume overload mediated RV dilatation or enlarged right atrium and tricuspid annulus due to chronic AF. Secondary tricuspid regurgitation is associated with left-sided valvular or myocardial dysfunction in most cases,
whereas it is isolated in 8.1% of subjects and independently related to mortality.389 Secondary tricuspid regurgitation may also develop late after left-sided valve surgery.390,391
Causes of primary tricuspid regurgitation include infective endocarditis [especially in intravenous (i.v.) drug addicts], rheumatic heart disease, carcinoid syndrome, myxomatous disease, endomyocardial fibrosis, congenital valve dysplasia (e.g. Ebstein’s anomaly), thoracic trauma, and iatrogenic valve damage.
Atrial fibrillation induces annular remodelling even in the absence of left-heart disease.392 Cardiac implantable electronic device-lead implantation leads to progressive tricuspid regurgitation in 2030%
of the patients393395 and predicts its progression over time.396
In patients with heart failure and reduced LVEF, secondary tricuspid regurgitation is a very frequent finding and is an independent predictor of clinical outcomes.397
8.1 Evaluation
Tricuspid regurgitation should be evaluated first by echocardiography. In primary tricuspid regurgitation, specific abnormalities of the valve can be identified. In secondary tricuspid regurgitation, annular
ESC/EACTS Guidelines
596


<!-- PAGE 37 -->

### Page 37

.............................................................................................................................................................................
dilatation, along with RV and right atrium dimensions, as well as RV
function should be measured, owing to their prognostic relevance.398
In experienced laboratories, RV strain27 and/or 3D measurements of
RV volumes399,400 may be considered to overcome the existing limitations of conventional RV function indices.102 When available, CMR
is the preferred method to assess the RV400 due to its high accuracy and reproducibility.401
Echocardiographic evaluation of tricuspid regurgitation severity is based on an integrative approach considering multiple qualitative and quantitative parameters (Table 9). Due to the non-circular and nonplanar shape of the regurgitant orifice, biplane vena contracta width should be considered in addition to the conventional 2D measurement.402 Similarly, underestimation of tricuspid regurgitation severity by the PISA method may occur.403 In case of inconsistent findings, the
3D vena contracta area may be evaluated, although diverging cut-offs have been reported.402,404406 Recently, a new grading scheme including two additional grades (‘massive’ and ‘torrential’) has been proposed407 and used in clinical studies on transcatheter interventions.408,409 Studies showed an incremental prognostic value of the two additional grades (massive and torrential) in terms of mortality and rehospitalization for heart failure in patients with advanced disease.410412
Alternatively, calculation of the tricuspid regurgitant volume by
CMR using RV volumetry may be helpful.
Importantly, estimation of pulmonary pressures using Doppler gradient may be impossible or might underestimate the severity of pulmonary hypertension in the presence of severe tricuspid regurgitation, justifying cardiac catheterization to evaluate pulmonary vascular resistances.413
8.2 Indications for intervention
Severe tricuspid regurgitation is associated with impaired survival389,414416 and worsening heart failure.397,417 In clinical practice, tricuspid valve interventions are underused and often initiated too late.418420 Appropriate timing of intervention is crucial to avoid irreversible RV damage and organ failure with subsequent increased surgical risk421,422 (see table of recommendations on indications for intervention in tricuspid valve disease in section 9 and Figure 8).
Surgery is recommended in symptomatic patients with severe primary tricuspid regurgitation. In selected asymptomatic or mildly symptomatic patients who are appropriate for surgery, an intervention should also be considered when RV dilatation or declining RV function is observed. However, exact thresholds have not yet been defined.
According to observational data, tricuspid valve repair should be performed liberally during left-sided surgery in patients with secondary tricuspid regurgitation. Indeed, it does not increase operative risk, but promotes reverse remodelling of the RV and improves functional status when annular dilatation is present, even in the absence of severe tricuspid regurgitation.423427
The benefit of surgical correction of isolated secondary tricuspid regurgitation compared to medical treatment is not well established428
and the procedure has a non-negligible risk of periprocedural mortality and morbidity when patients present late.429432 However, in carefully selected candidates, surgery can be performed safely with good longterm survival.418,433 It should therefore be considered early in selected symptomatic patients appropriate for surgery, as well as in those with no or mild symptoms, RV dilatation and severe tricuspid regurgitation.
Although a tricuspid annular pulmonary systolic excursion (TAPSE)
<17 mm has been associated with worse prognosis in patients with secondary tricuspid regurgitation,398,434 thresholds for severe RV dysfunction making intervention futile have not yet been defined.
Reoperation on the tricuspid valve in new-onset or worsening secondary tricuspid regurgitation after left-sided surgery carries a high procedural risk, possibly due to late referral and subsequent poor clinical condition.435 To improve prognosis, treatment of severe tricuspid regurgitation in this challenging scenario should be considered even in asymptomatic patients if there are signs of RV dilatation or decline in RV function (after exclusion of left-sided valve dysfunction,
severe RV or LV dysfunction and severe pulmonary vascular disease/
hypertension).
Whenever possible, annuloplasty with prosthetic rings is preferable to valve replacement,423,430,436 which should only be considered when the tricuspid valve leaflets are tethered and the annulus severely dilated. In presence of a cardiac implantable electronic device lead, the technique used should be adapted to the patient’s condition and the surgeon’s experience.437
TTVI are under clinical development. Early registry and study data demonstrated the feasibility to reduce tricuspid regurgitation using various systems, enabling either leaflet approximation,408,438440
direct annuloplasty,409,441 or valve replacement,442444 with subsequent symptomatic and haemodynamic improvement.445,446 In a propensity-score-matched study comparing medical treatment to
TTVI, all-cause mortality and rehospitalizations at 1 year were lower among the patients who received the interventional treatment.447
Several RCTs will investigate the efficacy of TTVI against medical treatment.
Table 9
Echocardiographic criteria for grading severity of tricuspid regurgitation
Qualitative
Tricuspid valve morphology
Abnormal/ﬂail
Colour ﬂow regurgitant jet
Very large central jet or eccentric wall impinging jeta
CW signal of regurgitant jet
Dense/triangular with early peaking
Semiquantitative
Vena contracta width (mm)
>7a,b
PISA radius (mm)
>9c
Hepatic vein ﬂowc
Systolic ﬂow reversal
Tricuspid inﬂow
E-wave dominant >_1m/sd
Quantitative
EROA (mm2)
>_40
Regurgitant volume (mL/beat)
>_45
Enlargement of cardiac chambers/vessels
RV, RA, inferior vena cava
CW = continuous wave; EROA= effective regurgitant oriﬁce area; PISA = proximal isovelocity surface area; RA= right atrium/right atrial; RV= right ventricle/right ventricular; TR = tricuspid regurgitation.
aAt a Nyquist limit of 5060 cm/s.
bPreferably biplane.
cBaseline Nyquist limit shift of 28 cm/s.
dIn the absence of other causes of elevated RA pressure.
ESC/EACTS 2021
ESC/EACTS Guidelines
597


<!-- PAGE 38 -->

### Page 38

......................................
Therefore, TTVI may be considered by the Heart Team at experienced Heart Valve Centres in symptomatic, inoperable, anatomically eligible patients in whom symptomatic or prognostic improvement can be expected. For detailed anatomical evaluation, TOE and CCT
may be preferred owing to higher spatial resolution.448,449
8.3 Medical therapy
Diuretics are useful in the presence of right heart failure. To counterbalance the activation of the renin-angiotensin-aldosterone system associated with hepatic congestion, the addition of an aldosterone antagonist may be considered.247 Dedicated treatment of pulmonary hypertension is indicated in specific cases. Although data are limited,
rhythm control may help to decrease tricuspid regurgitation and contain annular dilatation in patients with chronic AF.450 Importantly,
in the absence of advanced RV dysfunction or severe pulmonary hypertension, none of the above-mentioned therapies should delay referral for surgery or transcatheter therapy.
9 Tricuspid stenosis
Tricuspid stenosis is often combined with tricuspid regurgitation and most frequently of rheumatic origin. It is therefore usually associated with left-sided valve lesions, particularly mitral stenosis. Other causes are rare, including congenital, carcinoid and drug-induced valve diseases, Whipple’s disease, endocarditis, and large right atrial tumour.
Management of tricuspid regurgitation
Need for left-sided valve surgery
Severe secondary TR
N
Y
N
Severity/aetiology of TR
Severity/aetiology of TR
Severe primary TR
Mild-moderate TR
Severe primary or secondary TR
Medical therapy
TV repair or replacementb
Evaluation of transcatheter therapya
TV repair or replacementb
Severe RV/LV
dysfunction or severe pulmonary hypertension
Symptomatic
RV dilatation
Symptomatic
RV dilatation
TA dilatation
No concomitant
TV surgery
Y
N
N
N
Y
N
N
Medical therapy
Appropriate for surgery according to the Heart Team
N
Y
Y
Y
Y
Y
Figure 8 Management of tricuspid regurgitation. LV= left ventricle/left ventricular; RV= right ventricle/right ventricular; TA= tricuspid annulus;
TR= tricuspid regurgitation; TV= tricuspid valve. aThe Heart Team with expertise in the treatment of tricuspid valve disease evaluates anatomical eligibility for transcatheter therapy including jet location, coaptation gap, leaflet tethering, potential interference with pacing lead. bReplacement when repair is not feasible.
ESC/EACTS Guidelines
598


<!-- PAGE 39 -->

### Page 39

#### 9.1 Evaluation

Echocardiography provides the most useful information. Tricuspid stenosis is often overlooked and requires careful evaluation.
Echocardiographic evaluation of valve anatomy and subvalvular apparatus is important to assess valve reparability. No generally accepted grading of tricuspid stenosis severity exists, but a mean echocardiographic transvalvular gradient >_5 mmHg at normal heart rate is considered indicative of significant tricuspid stenosis.362
9.2 Indications for intervention
Intervention on the tricuspid valve is usually performed concomitantly during procedures for left-sided valve disease in patients who are symptomatic despite medical therapy. Although the lack of pliable leaflet tissue is a main limitation for valve repair, the choice between repair and replacement depends on anatomy and surgical expertise.
Owing to satisfactory long-term durability, biological prostheses are usually preferred over mechanical valves, which have a high risk of thrombosis.451
Percutaneous tricuspid balloon valvuloplasty has been performed in a limited number of cases, either alone or in combination with
PMC. It frequently induces significant regurgitation and long-term results are lacking.452 It can be considered in rare cases with anatomically suitable valves, when tricuspid stenosis is isolated or additional mitral stenosis can also be treated interventionally (see recommendations on indications for PMC and mitral valve surgery in clinically significant mitral stenosis in section 7).
9.3 Medical therapy
Diuretics are useful in the presence of heart failure symptoms but are of limited long-term efficacy.
10 Combined and multiple-valve diseases
Significant stenosis and regurgitation can be found on the same valve. Disease of multiple valves may be encountered in several conditions, particularly in rheumatic and congenital heart disease,
but also less frequently in degenerative valve disease. There is a lack of data on combined or multiple-valve disease.453460 This does not allow for evidence-based recommendations. The general principles for the management of combined or multiple-valve disease are as follows:
• When either stenosis or regurgitation is predominant, management follows the recommendations concerning the predominant VHD. When the severity of both stenosis and regurgitation is balanced, indications for interventions should be based on symptoms and objective consequences rather than on the indices of severity of stenosis or regurgitation.453456 In this setting, Doppler pressure gradient reflects the global haemodynamic burden (stenosis and regurgitation) of the valve lesion.453
• Besides the separate assessment of each valve lesion, it is necessary to consider the interaction between the different valve lesions. As an illustration, associated mitral regurgitation may
Recommendations on indications for intervention in tricuspid valve disease
Recommendations
Classa
Levelb
Recommendations on tricuspid stenosis
Surgery is recommended in symptomatic patients with severe tricuspid stenosis.c
I
C
Surgery is recommended in patients with severe tricuspid stenosis undergoing left-sided valve intervention.d
I
C
Recommendations on primary tricuspid regurgitation
Surgery is recommended in patients with severe primary tricuspid regurgitation undergoing leftsided valve surgery.
I
C
Surgery is recommended in symptomatic patients with isolated severe primary tricuspid regurgitation without severe RV dysfunction.
I
C
Surgery should be considered in patients with moderate primary tricuspid regurgitation undergoing left-sided valve surgery.
IIa
C
Surgery should be considered in asymptomatic or mildly symptomatic patients with isolated severe primary tricuspid regurgitation and RV
dilatation who are appropriate for surgery.
IIa
C
Recommendations on secondary tricuspid regurgitation
Surgery is recommended in patients with severe secondary tricuspid regurgitation undergoing left-sided valve surgery.423427
I
B
Surgery should be considered in patients with mild or moderate secondary tricuspid regurgitation with a dilated annulus (>_40 mm or >21
mm/m2 by 2D echocardiography) undergoing left-sided valve surgery.423,425427
IIa
B
Surgery should be considered in patients with severe secondary tricuspid regurgitation (with or without previous left-sided surgery) who are symptomatic or have RV dilatation, in the absence of severe RV or LV dysfunction and severe pulmonary vascular disease/hypertension.418,433 e
IIa
B
Transcatheter treatment of symptomatic secondary severe tricuspid regurgitation may be considered in inoperable patients at a Heart Valve
Centre with expertise in the treatment of tricuspid valve disease.f
IIb
C
2D = two-dimensional; LV = left ventricle/left ventricular; PMC = percutaneous mitral commissurotomy; RV = right ventricle/right ventricular.
aClass of recommendation.
bLevel of evidence.
cPercutaneous balloon valvuloplasty can be attempted as a ﬁrst approach if tricuspid stenosis is isolated.
dPercutaneous balloon valvuloplasty can be attempted if PMC can be performed on the mitral valve.
eIn patients with previous surgery recurrent left-sided valve dysfunction needs to be excluded.
fTranscatheter treatment can be performed according to Heart Team at experienced valve centres in anatomically eligible patients in whom improvement of quality of life or survival can be expected.
ESC/EACTS 2021
............................................................................................................................................................................
ESC/EACTS Guidelines
599


<!-- PAGE 40 -->

### Page 40

................
lead to underestimation of the severity of aortic stenosis, as decreased stroke volume due to mitral regurgitation lowers the flow across the aortic valve and hence the aortic gradient.453 This underlines the need to combine different measurements, including assessment of valve areas, if possible using methods that are less dependent on loading conditions, such as planimetry.457
• Indications for intervention are based on global assessment of the consequences of the different valve lesions (i.e. symptoms or presence of LV dilatation or dysfunction). Intervention can be considered for non-severe multiple lesions associated with symptoms or leading to LV impairment.453
• The decision to intervene on multiple valves should take into account the age, comorbidities, and risk of combined procedures,
and should be made by the Heart Team after precise and comprehensive evaluation of valve lesions and their interactions with each other.453,461 The risk of combined intervention should be weighed against the evolution of untreated valve disease and the inherent risk of subsequent intervention.
• The choice of surgical technique/interventional procedure should take into account the presence of the other
VHD.453,458,459,461
• When interventional procedures are considered, staged procedures may be preferable in cases with aortic stenosis and mitral regurgitation (see section 5.5). Improved 1-year survival after combined transcatheter treatment of mitral and tricuspid regurgitation has been reported compared to mitral regurgitation alone.263 PMC may delay surgery, in situations such as severe mitral stenosis associated with moderate aortic regurgitation.
The management of specific associations of VHD is detailed in the individual sections of this document.
11 Prosthetic valves
11.1 Choice of prosthetic valve
Factors for valve selection are the patient’s life expectancy, lifestyle,
and environmental factors, bleeding and thromboembolic risks related to anticoagulation, potential for surgical or transcatheter reintervention,
and,
importantly,
informed patient preference.
Generally, biological heart valves (BHVs) should be preferred in patients with shorter anticipated survival or comorbidities that may lead to further surgical procedures, and those who are at increased risk for bleeding complications. Thromboembolic complications are less frequent in pregnant women with BHVs.
Recommendations for prosthetic valve selection
Recommendations
Classa
Levelb
Mechanical prostheses
A mechanical prosthesis is recommended according to the desire of the informed patient and if there are no contraindications to longterm anticoagulation.c
I
C
A mechanical prosthesis is recommended in patients at risk of accelerated SVD.d
I
C
A mechanical prosthesis should be considered in patients already on anticoagulation because of a mechanical prosthesis in another valve position.
IIa
C
Continued
A mechanical prosthesis should be considered in patients aged <60 years for prostheses in the aortic position and aged <65 years for prostheses in the mitral position.462, 464 e
IIa
B
A mechanical prosthesis should be considered in patients with a reasonable life expectancy for whom future redo valve surgery or TAVI (if appropriate) would be at high risk.f
IIa
C
A mechanical prosthesis may be considered in patients already on long-term anticoagulation due to the high risk for thromboembolism.f
IIb
C
Biological prostheses
A bioprosthesis is recommended according to the desire of the informed patient.
I
C
A bioprosthesis is recommended when goodquality anticoagulation is unlikely (adherence problems, not readily available), contraindicated because of high bleeding risk (previous major bleed, comorbidities, unwillingness, adherence problems, lifestyle, occupation) and in those patients whose life expectancy is lower than the presumed durability of the bioprosthesis.g
I
C
A bioprosthesis is recommended in case of reoperation for mechanical valve thrombosis despite good long-term anticoagulant control.
I
C
A bioprosthesis should be considered in patients for whom there is a low likelihood and/or a low operative risk of future redo valve surgery.
IIa
C
A bioprosthesis should be considered in young women contemplating pregnancy.
IIa
C
A bioprosthesis should be considered in patients aged >65 years for a prosthesis in the aortic position or aged >70 years in a mitral position.
IIa
C
A bioprosthesis may be considered in patients already on long-term NOACs due to the high risk for thromboembolism.466469 f
IIb
B
AF = atrial ﬁbrillation; NOAC = non-vitamin K antagonist oral anticoagulant;
SVD = structural valve deterioration;
TAVI = transcatheter aortic valve implantation.
aClass of recommendation.
bLevel of evidence.
cIncreased bleeding risk because of comorbidities, adherence concerns or geographic, lifestyle or occupational conditions.
dYoung age (<40 years), hyperparathyroidism, haemodialysis.
eIn patients 6065 years of age who should receive an aortic prosthesis and those between 65 and 70 years of age in the case of mitral prosthesis, both valves are acceptable and the choice requires careful analysis of factors other than age.
fRisk factors for thromboembolism are AF, previous unprovoked proximal deep venous thromboembolism and/or symptomatic pulmonary embolism, hypercoagulable state, antiphospholipid antibody.
gLife expectancy should be estimated at >10 years according to age, sex, comorbidities, and country-speciﬁc life expectancy.
ESC/EACTS 2021
............................................................................................................................................................................
ESC/EACTS Guidelines
600


<!-- PAGE 41 -->

### Page 41

...............................................................................
In a nationwide observational study, patients aged 45 to 54 with surgical aortic BHV implantation and those aged 40 to 70 years with surgical mitral BHV implantation had a significantly higher 15-year mortality than those with a mechanical heart valve (MHV). An analysis of patients 55 to 64 years of age showed no difference in mortality between aortic BHV and MHV prosthesis.462 However, an earlier systematic review463 and a recent meta-analysis464 of studies comparing aortic MHVs and BHVs showed a significant mortality reduction with MHVs in patients <_60 and in those 5070 years of age,
respectively. All these studies are limited by their predominantly observational nature and missing information on the type of prostheses implanted. There is no new high-quality evidence supporting a decrease in the established age cut-off for prosthesis selection.
The best aortic valve substitute for younger adults remains unclear. In appropriately selected patients, replacement of the aortic valve using an autograft may be performed, with long-term survival rates and valve-related reoperation that are comparable to those achieved with a MHV, but high expertise in aortic root surgery is required.465 Strategies for patients with small aortic annulus include root enlargement and use of stentless valves. Although the use of sutureless and rapid-deployment aortic valves may reduce invasiveness, cross-clamp and cardiopulmonary bypass times, and potentially lower perioperative complications of SAVR, there is a lack of a largescale randomized comparison on both short- and long-term safety,
efficacy, and haemodynamic performance of this approach against conventional aortic valve replacement, which remains the gold standard of procedure.
11.2 Baseline assessment and follow-up
All patients with prosthetic valves require lifelong follow-up to detect early deterioration in prosthetic function or ventricular function, or progressive disease of another heart valve.314 Clinical assessment should be performed yearly or as soon as possible if new cardiac symptoms occur. TTE should be performed if any new symptoms occur or if complications are suspected. After transcatheter, as well as surgical implantation of a BHV, echocardiography, including measurement of transprosthetic gradients, should be performed within
30 days after valve implantation (i.e. baseline), at 1 year, and annually thereafter.470 TOE should be considered if TTE is of poor quality and in all cases of suspected prosthetic dysfunction (especially if the prosthesis is in the mitral position) or endocarditis.314,471 Cinefluoroscopy for MHVs and CCT scanning provide useful additional information if valve thrombus or pannus are suspected to impair valve function.314
11.3 Antithrombotic management
11.3.1
Mechanical prostheses
11.3.1.1 Postoperative anticoagulation management
MHVs require lifelong treatment with VKA guided by the INR.472,473
NOACs currently have no role in patients with MHVs.474 Treatment with VKA should be started on the first postoperative day in combination with bridging therapy [with therapeutic doses of either unfractionated heparin (UFH) or off-label use of low-molecular-weight heparin (LMWH)] until therapeutic INR is achieved.475 Similar safety and efficacy outcomes have been reported following bridging with either UFH or LMWH.476 Once a stable therapeutic INR is reached for >_24 h, bridging can be discontinued. The postoperative risk of thromboembolism peaks about 1 month after implantation, but risks are substantially increased up to 6 months.477,478 Long-term prevention of valve thrombosis and thromboembolism after MHV implantation involves effective antithrombotic medication and risk factor modification for thromboembolism.479
11.3.1.2 Target international normalized ratio
Target INR should be based upon prosthesis thrombogenicity and patient-related risk factors (Table 10).479 It is recommended to target a median INR value rather than a range to avoid considering extreme values in the target range as a valid target INR. High INR variability is a strong independent predictor of adverse events after valve replacement. Although some studies have supported lowering a target INR
for aortic MHVs,480,481 further evaluation in larger cohorts is warranted before updating current recommendations. The use of selfmonitoring INR is associated with a lower rate of VKA-related complications in all ages.482 In a trial of lower intensity warfarin plus aspirin (INR 1.52.0) or standard warfarin plus aspirin (INR
2.03.0) after implantation of the On-X MHV in the aortic position,
the similar safety of the two approaches was partly attributed to use of home INR monitoring and high degree of adherence among patients.481 Patient’s education plays an important role for achieving stable anticoagulation in the therapeutic range. Effective management of patients with unstable INR requires frequent in-clinic testing and dose titration. Because of the lack of good-quality evidence, pharmacogenetic testing cannot be recommended to guide the dosing of
VKAs.
11.3.1.3 Management of vitamin K antagonist (VKA) overdose and bleeding
Bleeding increases exponentially with INR >4.5.483 In case of major and/or life-threatening bleeding and in patients who need to undergo urgent surgery, the VKA should be discontinued and 10 mg vitamin K
should be administrated by slow i.v. infusion and repeated every 12 h if needed. Until the anticoagulation effect is reversed, administration of prothrombin complex concentration (PCC) and/or fresh frozen plasma (FFP) therapy should be initiated according to body weight and pre-treatment INR. The efficacy should be monitored by recheck of INR at 30 min and every 46 h until normalization. The optimal time to restart anticoagulation should be discussed in relation to location of the bleeding event and interventions performed to stop bleeding and/or to treat an underlying cause.484
Table 10
Target international normalized ratio for mechanical prostheses
Prosthesis thrombogenicity
Patient-related risk factorsa
None
1 risk factor
Lowb
2.5
3.0
Mediumc
3.0
3.5
Highd
3.5
4.0
AF = atrial ﬁbrillation; LVEF = left ventricular ejection fraction.
aMitral or tricuspid valve replacement; previous thromboembolism; AF; mitral stenosis of any degree; LVEF <35%.
bCarbomedics, Medtronic Hall, ATS, Medtronic Open-Pivot, St Jude Medical,
Sorin Bicarbon.
cOther bileaﬂet valves with insufﬁcient data.
dLillehei-Kaster, Omniscience, Starr-Edwards (ball-cage), Bjork-Shiley and other tilting-disc valves.
ESC/EACTS 2021
..............................................................................................
ESC/EACTS Guidelines
601


<!-- PAGE 42 -->

### Page 42

................................................................................................
In the absence of bleeding, the use of PCC and/or FFP therapy is not recommended and the decision to start vitamin K should be individualized. In asymptomatic patients with INR >10, the VKA must be stopped and oral vitamin K (2.55 mg) prescribed, while the INR
must be monitored on a daily base for 2 weeks. Multiple RCTs in patients with INR between 4.5 and 10 suggest no difference in bleeding events with vitamin K vs. placebo.483,485 Therefore, in such patients, warfarin should be stopped temporarily, and a small dose of oral vitamin K (12 mg) can be considered on an individual basis balancing between the risks. Finally, asymptomatic patients with INR
<4.5 require careful down-titration and/or skipping one or more doses. In all patients with MHVs, VKAs must be resumed once the
INR achieves the therapeutic range or is slightly elevated.
11.3.1.4 Combination of oral anticoagulation (OAC) with antiplatelet drugs
The addition of low-dose (75100 mg) acetylsalicylic acid (ASA)
to VKA may reduce the incidence of thromboembolism at the cost of bleeding.477 Therefore, addition of antiplatelets to VKAs should be reserved for patients at very high risk of thromboembolism where advantages clearly outweigh the risks.486,487 In patients with thromboembolism despite adequate
INR,
low dose
(75100 mg) ASA should be added to VKAs. Management of oral antithrombotic therapy in patients with CAD is summarized in
Supplementary Figure 2.
11.3.1.5 Interruption of anticoagulant therapy for planned invasive procedures
In patients with MHVs, preoperative bridging with UFH or LMWH
before surgery imposes a risk of perioperative bleeding while interrupting anticoagulation results in an increased risk of thromboembolism.488 Therefore, anticoagulation in patients with MHVs undergoing elective NCS requires careful management by multidisciplinary consensus.478,489 For minor surgical procedures (e.g. dental, cataract,
skin incision) in which blood loss is usually small and easily controlled,
it is recommended that OAC is not interrupted. Major surgeries require temporary interruption and therapeutic bridging with either
UFH or LMWH, aiming for an INR <1.5 (Supplementary Figure 3).
Fondaparinux should not be routinely used for bridging, but may have a role in patients with history of heparin-induced thrombocytopenia.490
11.3.2
Bioprostheses
11.3.2.1 Patients with no baseline indication to oral anticoagulation
(OAC)
Surgical bioprostheses: The optimal antithrombotic strategy early after surgical implantation of an aortic BHV remains controversial due to lack of high-quality evidence. Multiple observational studies support the use of
VKAs to reduce the risk of thromboembolism.491493 A small randomized trial found that VKA
for 3 months significantly increased major bleeding compared with
ASA, without reducing the rate of deaths or thromboembolic events,
but the statistical power was low for demonstrating a thrombotic benefit.494 VKA for 3 months should be considered in all patients with a mitral or tricuspid BHV and ASA or VKA should be considered for 3 months after surgical implantation of an aortic bioprosthesis.
Transcatheter bioprostheses: A meta-analysis of three small RCTs showed a significant increase in major or life-threatening bleeding with dual antiplatelet therapy (DAPT) over ASA at 30 days, with no difference in ischaemic outcomes.495 Consistently, the more recent
POPular TAVI trial (cohort A) found reduced bleeding and the composite of bleeding or thromboembolic events with ASA compared with DAPT.496 A randomized trial was halted prematurely due to safety concerns with a rivaroxaban-based regimen as compared with
DAPT, including a higher risk of death or thromboembolic complications and a higher risk of bleeding.497 There is a lack of data on the management of antithrombotic therapy after implantation of transcatheter mitral BHVs (e.g. valve-in-valve or valve-in-ring) for which 3
months of VKA is commonly prescribed.498
11.3.2.2 Patients with baseline indication to oral anticoagulation (OAC)
Surgical bioprostheses: OAC is recommended lifelong for patients with surgical BHVs who have other indications for anticoagulation.
The evidence supporting the use of NOACs in preference to VKA
has increased since the publication of the 2017 VHD Guidelines. In the RIVER trial, including patients with AF and a BHV in the mitral position, the NOAC rivaroxaban was non-inferior to warfarin with respect to a net benefit endpoint at 12 months.499 The benefit of
NOAC was consistent among subgroups. However, only 20% of patients were enrolled in the trial before the third postoperative month, which raises a note of caution and calls for additional data in this particular subgroup. In the small ENAVLE trial (N = 220), including patients with and without AF, edoxaban was non-inferior to warfarin for preventing thromboembolism and the occurrence of major bleeding in the first 3 months after aortic or mitral surgical bioprosthetic valve implantation or repair, which warrants confirmation in larger investigations.500
Recommendations for management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods
Recommendations
Classa
Levelb
Management of antithrombotic therapy in the perioperative period
It is recommended that VKAs are timely discontinued prior to elective surgery to aim for an
INR <1.5.c
I
C
Bridging of OAC, when interruption is needed, is recommended in patients with any of the following indications:
• Mechanical prosthetic heart valve.
• AF with signiﬁcant mitral stenosis.
• AF with a CHA2DS2-VASc score >_3 for women or 2 for men.d
• Acute thrombotic event within the previous 4
weeks.
• High acute thromboembolic risk.e
I
C
Therapeutic doses of either UFH or subcutaneous
LMWH are recommended for bridging.476,504
I
B
In patients with MHVs, it is recommended to (re)-
initiate the VKA on the ﬁrst postoperative day.
I
C
Continued
.............................................................................
ESC/EACTS Guidelines
602


<!-- PAGE 43 -->

### Page 43

In patients who have undergone valve surgery with an indication for postoperative therapeutic bridging, it is recommended to start either UFH
or LMWH 1224 h after surgery.
I
C
In patients undergoing surgery, it is recommended that aspirin therapy, if indicated, is maintained during the periprocedural period.
I
C
In patients treated with DAPT after recent PCI
(within 1 month) who need to undergo heart valve surgery in the absence of an indication for
OAC, it is recommended to resume the P2Y12
inhibitor postoperatively, as soon as there is no concern over bleeding.
I
C
In patients treated with DAPT after recent PCI
(within 1 month) who need to undergo heart valve surgery in the absence of an indication for
OAC, bridging P2Y12 inhibitors with short-acting glycoprotein IIb/IIIa inhibitors or cangrelor may be considered.
IIb
C
Patients with an indication to concomitant antiplatelet therapy
After uncomplicated PCI or ACS in patients requiring long-term OAC, early cessation
(<_1 week) of aspirin and continuation of dual therapy with OAC and a P2Y12 inhibitor (preferably clopidogrel) for up to 6 months (or up to
12 months in ACS) is recommended if the risk of stent thrombosis is low or if concerns about bleeding risk prevail over concerns about risk of stent thrombosis, irrespective of the type of stent used.505509
I
B
Discontinuation of antiplatelet treatment in patients treated with an OAC is recommended after 12 months.74,510512
I
B
After uncomplicated PCI or ACS in patients requiring both OAC and antiplatelet therapy, triple therapy with aspirin, clopidogrel and OAC
for longer than 1 week should be considered when the risk of stent thrombosis outweighs the risk of bleeding, with the total duration
(<_1 month) decided according to assessment of these risks and clearly speciﬁed at hospital discharge.
IIa
C
In patients treated with a VKA (e.g. MHVs), clopidogrel alone should be considered in selected patients (e.g. HAS-BLED >_3 or ARC-HBR met and low risk of stent thrombosis) for up to 12
months.512,513
IIa
B
In patients requiring aspirin and/or clopidogrel in addition to VKA, the dose intensity of VKA
should be considered and carefully regulated with a target INR in the lower part of the recommended target range and a time in the therapeutic range >6570%.505,514
IIa
B
Surgical valve replacement
OAC using a VKA is recommended lifelong for all patients with an MHV prosthesis.472,473
I
B
Continued
For patients with a VKA, INR self-management is recommended provided appropriate training and quality control are performed.482
I
B
OAC is recommended for patients undergoing implantation of a surgical BHV who have other indications for anticoagulation.f
I
C
NOACs should be considered over VKA after 3
months following surgical implantation of a BHV
in patients with AF.74,499,500,515518
IIa
B
In patients with no baseline indications for OAC,
low-dose aspirin (75100 mg/day) or OAC using a VKA should be considered for the ﬁrst 3 months after surgical implantation of an aortic BHV.491,494
IIa
B
In patients with no baseline indications for OAC,
OAC using a VKA should be considered for the
ﬁrst 3 months after surgical implantation of a bioprosthesis in the mitral or tricuspid position.519,520
IIa
B
The addition of low-dose aspirin (75100 mg/
day) to VKA may be considered in selected patients with MHVs in case of concomitant atherosclerotic disease and low risk of bleeding.
IIb
C
The addition of low-dose aspirin (75100 mg/
day) to VKA should be considered after thromboembolism despite an adequate INR.
IIa
C
NOACs may be considered over VKA within 3
months following surgical implantation of a BHV
in mitral position in patients with AF.499
IIb
C
NOACs are not recommended in patients with a mechanical valve prosthesis.474
III
B
Surgical valve repair
OAC with VKA should be considered during the
ﬁrst 3 months after mitral and tricuspid repair.
IIa
C
SAPT with low-dose ASA (75100 mg/day)
should be considered for the ﬁrst 3 months after valve-sparing aortic surgery when there are no other baseline indications to OAC.
IIa
C
Transcatheter aortic valve implantation
OAC is recommended lifelong for TAVI patients who have other indications for OAC.501 f
I
B
Lifelong SAPT is recommended after TAVI in patients with no baseline indication for
OAC.495,496,521
I
A
Routine use OAC is not recommended after TAVI
in patients with no baseline indication for OAC.497
III
B
ACS = acute coronary syndrome; AF = atrial ﬁbrillation; ARC-HBR = Academic
Research
Consortium

high bleeding risk;
ASA = acetylsalicylic acid;
BHV = biological heart valve;
DAPT = dual antiplatelet therapy;
INR = international normalized ratio; LMWH = low-molecular-weight heparin;
LV = left ventricle/left ventricular; PCI = percutaneous coronary intervention;
MHV = mechanical heart valve; NOAC = non-vitamin K antagonist oral anticoagulant;
OAC = oral anticoagulation;
SAPT = single antiplatelet therapy;
TAVI = transcatheter aortic valve implantation; UFH = unfractionated heparin;
VKA = vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.
c<_5 days for warfarin and <_3 days for acenocoumarol.
dCHA2DS2-VASc, congestive heart failure, hypertension, age >_75 (2 points), diabetes,
prior stroke (2 points)  vascular disease, age 6574, sex category (female).
eLV apex thrombus, antithrombin 3 deﬁcit and proteins C and/or S deﬁcit.
fAF, venous thromboembolism, hypercoagulable state or, with a lesser degree of evidence, severely impaired LV dysfunction (ejection fraction <35%).
ESC/EACTS 2021
................................................................................................................................................................................
ESC/EACTS Guidelines
603


<!-- PAGE 44 -->

### Page 44

...........................................................
Transcatheter bioprostheses: In the POPular TAVI trial (cohort B),
the incidence of bleeding over a period of 1 month or 1 year was lower with OAC than with OAC plus clopidogrel.501 OAC alone was non-inferior to OAC plus clopidogrel with respect to ischaemic events, but the non-inferiority margin was large. An observational study suggested that there is a higher risk of ischaemic events at
1 year with NOACs compared with VKAs, after adjustment for potential confounders.502 Randomized trials comparing NOACs vs.
VKAs are ongoing (NCT02943785, NCT02664649). Data on the management of antithrombotic therapy after transcatheter mitral or tricuspid valve implantation are scant.498
11.3.3
Valve repair
Observational data suggest comparable risk of thromboembolism with ASA or VKAs following mitral valve repair,503 but randomized data are lacking. The high incidence of new-onset AF and its recurrence, the thrombogenic tendency of the non-endothelialized repair components, and a relatively high rate of patients who are resistant to ASA establish VKAs as a preferable option for the initial period
(e.g. 3 months). However, the potential for bleeding complications in the postoperative phase dictates careful patient selection.
The management of antithrombotic treatment after prosthetic valve implantation or valve repair is summarized in the table of recommendations for management of antithrombotic therapy after prosthetic valve implantation or valve repair and in Figure 9.
11.4 Management of prosthetic valve dysfunction and complications
11.4.1
Structural valve deterioration
Definitions of SVD and bioprosthetic valve failure (BVF) were standardized by recent consensus.470,522 The comparative durability of
TAVI and SAVR BHVs must be ascertained at longer term.
Reversible causes of BVF (e.g. endocarditis, thrombosis) should be excluded, and considerations on timing of dysfunction (e.g. for BHV
obstruction, mismatch in early phases, thrombosis in later phases)
and location of malfunction (e.g. endocarditis or SVD in case of central regurgitation, endocarditis or anatomical/technical factors in case
Antithrombotic therapy for valve prostheses
Mechanical heart valve
Bioprosthetic heart valve
Bridging anticoagulation with UFH or
LMWH (not required for minor surgeries)
(Class I)
IfVKA therapy interrupted for major planned invasive procedure, minimize time with subtherapeutic INR
Add low-dose ASA in selected patients at low risk of bleeding
(Class IIb)
CAD
VKA lifelong (Class I)
MVR/TVR
SAVR
TAVI
Other indications for oral anticoagulation
OAC 
long-term
(Class I)
SAPT
long-term
(Class I)
OAC 
long-term
(Class I)
OAC 
long-term
(Class I)
SAPT or OAC 
for 3 months
(Class IIa)
OAC 
for 3 months
(Class IIa)
Y
N
Y
N
Y
N
Figure 9 Antithrombotic therapy for valve prostheses. AF= atrial fibrillation; ASA = acetylsalicylic acid; CAD = coronary artery disease; DAPT= dual antiplatelet therapy; INR = international normalized ratio; LMWH = low-molecular-weight heparin; LV= left ventricle/left ventricular; MHV= mechanical heart valve; MVR= mitral valve replacement or repair; OAC = oral anticoagulation; SAPT= single antiplatelet therapy; SAVR = surgical aortic valve replacement; TAVI= transcatheter aortic valve implantation; TVR= tricuspid valve replacement or repair; UFH = unfractionated heparin; VKA = vitamin K
antagonist. Colour coding corresponds to class of recommendation.
ESC/EACTS Guidelines
604


<!-- PAGE 45 -->

### Page 45

Suspicion of thrombosis
Management of left-sided obstructive and non-obstructive mechanical prosthetic thrombosis
Y
Echo (TTE + TOE/fluoroscopy)
Obstructive thrombosisa
Disappearance or decrease of thrombus
Recent inadequate anticoagulation
Surgery immediately available
High-risk for surgery
Surgery
Fibrinolysis
Follow-up i.v. UFH ± ASA
Surgery
Fibrinolysis
Success/failure
Non-obstructive thrombosis
Large thrombus
(≥ 10 mm)
Large thrombus
(≥ 10 mm)
Persistence of thrombus or TE
Surgery
(or fibrinolysis if surgery is high risk)
Optimize anticoagulation (follow-up)
Signs of TE
Critically ill
Thromboembolism
(clinical/cerebral imaging)
FAILURE
N
N
Y
SUCCESS
Y
N
Y
N
Y
N
Optimize anticoagulation
Y
N
Follow-up
N
Y
Optimize anticoagulation (follow-up)
Y
N
Persistence of thrombus
Figure 10 Management of left-sided obstructive and non-obstructive mechanical prosthetic thrombosis. ASA = acetylsalicylic acid; CCT = cardiac computed tomography; i.v.= intravenous; TOE= transoesophageal echocardiography; TE = thromboembolism; TTE = transthoracic echocardiography;
UFH= unfractionated heparin. Risk and benefits of both treatments should be individualized. The presence of a first-generation prosthesis is an incentive to surgery. aRefer to recommendations for the imaging assessment of prosthetic heart valves. Evaluation generally includes TTE plus TOE or CCT and occasionally fluoroscopy.
ESC/EACTS Guidelines
605


<!-- PAGE 46 -->

### Page 46

................................................................................................................................
of paravalvular regurgitation) may reveal the most plausible underlying cause and guide clinical decision making.
Percutaneous balloon interventions should be avoided in the treatment of stenotic left-sided bioprostheses. Transcatheter valve-in-valve implantation is an option for treating degenerated BHVs in patients with increased surgical risk.227,523525 Redo-TAVI is a safe and feasible option in selected patients, but the risk of PPM in small valves and that of coronary occlusion, as well the possibility for future access to the coronary arteries need to be considered.229,526528 Experience is mostly in aortic BHVs and remains limited for BHVs in the mitral position and even more so in the tricuspid position529532 for which valvein-valve procedures may be reasonable in patients at increased surgical risk.531,533 Valve-in-ring mitral procedures are also acceptable in selected candidates, while the role of valve-in-ring tricuspid procedures remains uncertain. It is necessary for the Heart Team to discuss every patient and choose the best individualized approach. Careful preprocedural planning is needed to minimize the risk of coronary artery obstruction and enable future coronary re-access in aortic BHV reinterventions if necessary. For mitral re-interventions the risk of LVOT
obstruction should be carefully evaluated.534
11.4.2
Non-structural valve dysfunction
11.4.2.1 Patient-prosthesis mismatch
Patient-prosthesis mismatch (PPM) significantly decreases long-term survival, correlates with SVD and increases readmission rates for both heart failure and reoperation.535537 Efforts to prevent PPM
should receive more emphasis to improve long-term survival after either SAVR or TAVI.538
11.4.2.2 Paravalvular leak and haemolysis
Blood tests for haemolysis should be part of routine follow-up after valve replacement. Diagnosis of haemolytic anaemia requires TOE to detect paravalvular leaks for prostheses in the mitral position if TTE
is not contributory. Reoperation is recommended if the paravalvular leak is related to endocarditis or causes haemolysis requiring repeated blood transfusions or leading to severe symptoms.
Transcatheter closure of a paravalvular leak is feasible, but experience is limited and there is presently no conclusive evidence to show consistent efficacy.539 Transcatheter closure of paravalvular leaks should be considered for anatomically suitable paravalvular leaks in candidates selected by the Heart Team.540 Medical therapy (including iron supplementation, beta-blockers, and erythropoietin) is indicated in patients with severe haemolytic anaemia when contraindications to surgical or transcatheter closure are present.540
11.4.3
Endocarditis
The management of patients with endocarditis should follow the relevant guidelines.4
11.4.4
Thrombosis
11.4.4.1 General comments
Obstructive valve thrombosis should be suspected promptly in any patient with any type of prosthetic valve who presents with recent dyspnoea or an embolic event. The diagnosis should be confirmed by TTE
and TOE, cinefluoroscopy, or CCT if promptly available.268,314 Valve thrombosis occurs mainly in MHVs. However, cases of thrombosis of
BHVs have also been reported after surgery or transcatheter valve implantation.541 Thrombus on BHVs can present as hypo-attenuated leaflet thickening (HALT) with relatively normal leaflet motion, HALT
with reduced leaflet motion but normal gradients, and clinical valve thrombosis with elevated gradients. Distinguishing between thrombus and pannus by means of CCT is important to guide decision making.
11.4.4.2 Valve thrombosis
The management of MHVs thrombosis is high risk, whatever the option taken. Fibrinolysis carries risks of bleeding, systemic embolism, and recurrent thrombosis.542 Emergency valve replacement is recommended for obstructive prosthetic valve thrombosis in critically ill patients without a contraindication to surgery. Management of nonobstructive thrombosis of an MHV depends mainly on the occurrence of a thromboembolic event and the size of the thrombus. Surgery should be considered for a large (>10 mm) non-obstructive prosthetic valve thrombus that is complicated by embolism or persists despite optimal anticoagulation.543 Fibrinolysis may be considered if surgery is not an option or is very high risk for the treatment of thrombosis of right-sided prostheses, but carries a risk of bleeding and thromboembolism. Anticoagulation using a VKA and/or UFH is the first-line treatment of BHV thrombosis. Because BHV thrombosis is associated with recurrence and early prosthetic degeneration, indefinite anticoagulation should be considered after a confirmed episode, but this strategy must be balanced against an increased risk of bleeding544,545 (Figure 10).
11.4.4.3 Subclinical leaflet thrombosis
HALT is detected by CCT in 12.4% and 32.4% of TAVI patients on
OAC or DAPT at 3 months, respectively.546 The clinical significance of these findings is uncertain. Selective use of oral anticoagulants in patients with confirmed HALT and restricted leaflet motion with elevated gradients should be considered.
11.4.5
Heart failure
Heart failure after valve surgery should lead to a quick search for
SVD or PPM, deterioration of repair, LV dysfunction, or progression of another valve disease. Non-valvular-related causes such as CAD,
hypertension, or sustained arrhythmias should also be considered.
The management of patients with heart failure should follow the relevant guidelines and consensus documents.142,247
Recommendations on management of prosthetic valve dysfunction
Recommendations
Classa
Levelb
Mechanical prosthetic thrombosis
Urgent or emergency valve replacement is recommended for obstructive thrombosis in critically ill patients without serious comorbidity.542
I
B
Fibrinolysis (using recombinant tissue plasminogen activator 10 mg bolus þ 90 mg in 90 min with UFH or streptokinase 1 500 000 U in 60 min without UFH) should be considered when surgery is not available or is very high risk, or for thrombosis of right-sided prostheses.542
IIa
B
Continued
.............................................
ESC/EACTS Guidelines
606


<!-- PAGE 47 -->

### Page 47

.............................................................................................................................................................................
12 Management during noncardiac surgery
Cardiovascular morbidity and mortality are increased in patients with
VHD who undergo NCS. Symptomatic severe aortic stenosis or mitral stenosis may require valve replacement or percutaneous intervention before NCS. A detailed description of recommendations in the setting is available in specific ESC Guidelines.489
12.1 Preoperative evaluation
Patient and surgical specific factors dictate the strategy.489,548,549 The cardiologist provides recommendations on pre- and perioperative management, surveillance, and continuation of chronic cardiovascular medical treatment. Echocardiography should be performed in any patient with VHD requiring NCS. Determination of functional capacity is a pivotal step in preoperative risk assessment, measured either by ability to perform activities in daily life or by exercise test.
The decision for management should be taken after multidisciplinary discussion involving cardiologists, surgeons, and cardiac anaesthesiologists, as well as the team who will be in charge of NCS.
Patients receiving anticoagulation treatment should be managed as discussed in section 11.
12.2 Specific valve lesions
12.2.1
Aortic stenosis
In patients with severe aortic stenosis, urgent NCS should be performed under careful haemodynamic monitoring. In case of high risk of NCS, balloon valvuloplasty may be considered before NCS.549
Management related to elective NCS depends on the presence of symptoms and the type of surgery.489,549553 In symptomatic patients, aortic valve procedure should be considered before NCS.
The type of procedure, TAVI or SAVR, is decided by the Heart
Team. In asymptomatic patients, elective NCS, if at low to moderate risk, can be performed safely, albeit with a risk of worsening heart failure.489,552,553 If NCS implies large volume shifts, aortic valve procedure (TAVI or SAVR) should be considered first according to the
Heart Team’s decision (Figure 11).
12.2.2
Mitral stenosis
NCS can be performed safely in patients with non-significant mitral stenosis (valve area >1.5 cm2) and in asymptomatic patients with significant mitral stenosis and an SPAP <50 mmHg. In symptomatic patients or in patients with SPAP >50 mmHg, correction of mitral stenosis, by means of PMC whenever possible, should be attempted before NCS if it is high risk.
12.2.3
Aortic and mitral regurgitation
NCS can be performed safely in asymptomatic patients with severe mitral regurgitation or aortic regurgitation and preserved LV function. The presence of symptoms or LV dysfunction should lead to consideration of valvular surgery, but this is seldom needed before
NCS. If LV dysfunction is severe (ejection fraction <30%) and/or
SPAP is >50/60 mmHg, NCS should be performed only if strictly necessary and after optimization of medical therapy for heart failure.
12.3 Perioperative monitoring
Heart rate control (particularly in mitral stenosis) and careful fluid management (particularly in aortic stenosis) are needed. TOE monitoring may be considered.
13 Management during pregnancy
Detailed guidelines on the management of cardiovascular disease during pregnancy are available in another document.554 The decision for
Surgery should be considered for large
(>10 mm) non-obstructive prosthetic thrombus complicated by embolism.
IIa
C
Bioprosthetic thrombosis
Anticoagulation using a VKA and/or UFH is recommended in bioprosthetic valve thrombosis before considering re-intervention.
I
C
Anticoagulation should be considered in patients with leaﬂet thickening and reduced leaﬂet motion leading to elevated gradients, at least until resolution.541,546
IIa
B
Haemolysis and paravalvular leak
Reoperation is recommended if a paravalvular leak is related to endocarditis or causes haemolysis requiring repeated blood transfusions or leading to severe heart failure symptoms.
I
C
Transcatheter closure should be considered for suitable paravalvular leaks with clinically signiﬁcant regurgitation and/or haemolysis in patients at high or prohibitive surgical risk.547
IIa
B
Decision on transcatheter or surgical closure of clinically signiﬁcant paravalvular leaks should be considered based on patient risk status, leak morphology, and local expertise.
IIa
C
Bioprosthetic failure
Reoperation is recommended in symptomatic patients with a signiﬁcant increase in transprosthetic gradient (after exclusion of valve thrombosis) or severe regurgitation.
I
C
Transcatheter, transfemoral valve-in-valve implantation in the aortic position should be considered by the Heart Team depending on anatomic considerations, features of the prosthesis, and in patients who are at high operative risk or inoperable.529
IIa
B
Transcatheter valve-in-valve implantation in the mitral and tricuspid position may be considered in selected patients at high risk for surgical reintervention.382,531,532
IIb
B
Reoperation should be considered in asymptomatic patients with signiﬁcant prosthetic dysfunction if reoperation is low risk.
IIa
C
UFH = unfractionated heparin; VKA = vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.
ESC/EACTS 2021
ESC/EACTS Guidelines
607


<!-- PAGE 48 -->

### Page 48

.........................................................................
management before and during pregnancy should be taken after multidisciplinary discussion in the pregnancy Heart Team involving cardiologists,
cardiac surgeons,
obstetricians,
neonatologists,
and anaesthesiologists.
13.1 Management before pregnancy
Valve disease should be evaluated before pregnancy and treated if necessary.554,555
Pregnancy should be discouraged, and intervention should be recommended before pregnancy in the following cases:
• Patients with mitral stenosis and a valve area <1.5 cm2 (especially if <1.0 cm2).554,556
• All symptomatic patients with severe AS or asymptomatic patients with impaired LV function (LVEF <50%) or an abnormal exercise test should be counselled against pregnancy, and surgery should be performed pre-pregnancy.554,557
• Women with Marfan syndrome and an aortic diameter >45 mm should be strongly discouraged from becoming pregnant without prior aortic repair because of the high risk of aortic dissection.
Although an aortic diameter <40 mm is rarely associated with aortic dissection, a completely safe diameter does not exist. With an aortic diameter between 40 and 45 mm, previous aortic growth and family history are important for advising pregnancy with or without aortic repair.558 Although the actual risk of dissection is not well documented in the setting of bicuspid valves, counselling against pregnancy is recommended in the setting of aortic diameters >50 mm (>27 mm2 BSA).559 Finally, an aortic diameter
>25 mm/m2 BSA in Turner syndrome and all patients with vascular
Ehlers-Danlos syndrome are also contraindications for pregnancy.
In women considering pregnancy and requiring heart valve replacement, it is recommended to choose the prosthesis in consultation with a pregnancy Heart Team.554,560
Pregnancy in women with a mechanical valve, especially in the mitral position, is associated with a high risk of maternal and foetal complications,554,561 which should be carefully discussed with the patient and family.
13.2 Management during pregnancy
13.2.1
Patients with native valve disease
Moderate or severe mitral stenosis with a valve area <1.5 cm2 in pregnant women is usually poorly tolerated. PMC should be considered in severely symptomatic patients [New York Heart Association
(NYHA) class IIIIV] and/or those with SPAP >50 mmHg despite optimal therapy. PMC should preferably be performed after the 20th week of pregnancy in experienced centres.554
Urgent or elective NCS
Management of non-cardiac surgery (NCS) in patients with severe aortic stenosis
Patient risk for
AV procedure
(TAVI/SAVR)
Risk of NCS
Heart Team decision:
SAVR or TAVI
NCS under strict monitoring
NCS
Consider BAV before
NCS if doable, or NCS
under strict monitoring
HIGH
LOW
Risk of NCS
Symptoms
HIGH
Y
HIGH
LOW-MODERATE
ELECTIVE
URGENT
N
Figure 11 Management of non-cardiac surgery (NCS) in patients with severe aortic stenosis. AV= aortic valve; BAV = balloon aortic valvuloplasty;
NCS= non cardiac surgery; SAVR= surgical aortic valve replacement; TAVI = transcatheter aortic valve implantation.
ESC/EACTS Guidelines
608


<!-- PAGE 49 -->

### Page 49

.............................................................................................................................................................................
In patients who are severely symptomatic despite medical therapy,
BAV for severe aortic stenosis can be undertaken by an experienced operator.557 TAVI is a promising alternative, but experience during pregnancy is very limited.554
Surgery under cardiopulmonary bypass is associated with a foetal mortality rate of 1556%562 and should be restricted to the rare conditions that threaten the mother’s life if transcatheter intervention is not possible or has failed. Valve replacement should be considered after early delivery by caesarean section.
Caesarean section is recommended for patients with severe mitral or aortic stenosis, ascending aortic diameter >45 mm, severe pulmonary hypertension, or if delivery starts while treated with a VKA or
<2 weeks after discontinuation of a VKA.
13.2.2
Mechanical prosthesis
It is recommended to manage pregnancy in patients with MHV in a centre with a pregnancy Heart Team.554
Therapeutic anticoagulation during pregnancy is of utmost importance to avoid complications in these patients, keeping in mind that no anticoagulation regimen is ideal and management will require a careful balance between maternal and foetal risks.
In patients requiring <5 mg/day warfarin, oral anticoagulants throughout pregnancy and a change to UFH before delivery is favoured. In patients requiring higher doses, switching to LMWH during the first trimester with strict anti-Xa monitoring (therapeutic range
0.81.2 IU/mL, aortic valve prosthesis; and 1.01.2 IU/mL, mitral and right sided valve prosthesis) and the use of oral anticoagulants afterwards is favoured with a change to UFH before delivery.554
14 Key messages
General comments
1. Precise evaluation of the patient’s history and symptomatic status, as well as proper physical examination, are crucial for the diagnosis and management of VHD.
2. Echocardiography is the key technique to diagnose VHD and assess its severity and prognosis. Other non-invasive investigations such as CMR, CCT, fluoroscopy, and biomarkers provide important additional information in selected patients. Stress testing should be widely used in asymptomatic patients. Invasive investigation, beyond preoperative coronary angiography, is restricted to situations where non-invasive evaluation is inconclusive.
3. Decision making in elderly patients requires the integration of multiple parameters, including estimation of life expectancy and anticipated quality of life, evaluation of comorbidities, and general condition (including frailty).
4. Decision making in asymptomatic patients weighs the risk of intervention against the expected natural history of VHD. Stress testing should be liberally performed.
5. Informed patient’s expectations and values are an important part of the decision-making process.
6. Interventions (surgery or transcatheter) are indicated in symptomatic patients (spontaneous or exercise induced) in the absence of futility. In selected asymptomatic patients, presence of predictors of rapid symptom progression justifies early intervention when procedural risk is low.
7. Heart Valve Centres with multidisciplinary Heart Teams, Heart
Valve Clinics, comprehensive equipment, and sufficient volumes of procedures are required to deliver high-quality care and provide adequate training.
8. Careful follow-up of symptomatic status, LV/RV size, and function is mandatory in asymptomatic patients with severe VHD if an intervention is not yet indicated.
9. In patients with AF, NOACs are contraindicated in patients with clinically significant mitral stenosis or mechanical valves. For stroke prevention in patients who are eligible for OAC, NOACs are recommended in preference to VKAs in patients with aortic stenosis, aortic and mitral regurgitation, or aortic bioprostheses >3 months after implantation.
Aortic regurgitation
10. The evaluation of aortic regurgitation requires careful assessment of potentially associated aortic dilatation to guide the timing and type of surgery.
Aortic stenosis
11. Diagnosis of severe aortic stenosis requires integrative evaluation of pressure gradients (the most robust measurements), AVA,
extent of valve calcification, flow conditions, and LV function.
12. Selection of the most appropriate mode of intervention by the
Heart Team should take into account clinical characteristics (age and estimated life expectancy, general condition), anatomical characteristics, the relative risks of SAVR and TAVI, the feasibility of transfemoral TAVI, local experience and outcome data, as well as informed patient preference.
Mitral regurgitation
13. Regarding imaging, routine quantification of EROA is an important part of the integrative evaluation for quantification and risk stratification in patients with PMR. 3D transoesophageal echocardiography is more accurate than 2D echocardiography for defining the underlying mechanism of PMR. CMR is useful when echocardiographic evaluation of severe PMR grade is inconclusive.
14. Surgical mitral valve repair is the preferred method of treatment in PMR if a durable repair can be achieved. TEER is a safe but less efficacious alternative that may be considered in patients with contraindications for surgery or high operative risk.
15. In patients with severe SMR, GDMT (including CRT if indicated)
should be the first step. If the patient remains symptomatic: mitral surgery is recommended concomitantly in patients with an indication for
CABG or other cardiac surgery. Isolated valve surgery may be considered in selected patients. TEER should be considered in patients not eligible for surgery and fulfilling criteria indicating an increased chance of responding to the treatment. Circulatory support devices, cardiac transplantation, or palliative care should be considered as an alternative in patients with end-stage LV and/or RV failure.
Mitral stenosis
16. PMC is currently the standard of care in patients with severe rheumatic mitral stenosis and favourable valve anatomy.
17. Decision making as to the type of intervention used in patients with unfavourable anatomy is still a matter of debate and must take into account the multifactorial nature of predicting the results of PMC.
ESC/EACTS Guidelines
609


<!-- PAGE 50 -->

### Page 50

......................................................................................................................................................................
Tricuspid regurgitation
18. Relevant tricuspid regurgitation requires early intervention to avoid secondary damage of the RV.
19. Tricuspid regurgitation should be liberally treated at the time of left-sided valve surgery. Isolated surgery of severe secondary tricuspid regurgitation (with or without previous left-sided valve surgery) requires comprehensive assessment of the underlying disease,
pulmonary haemodynamics, and RV function.
Prosthetic valves
20. The choice between a mechanical prosthesis and a bioprosthesis should be patient-centred and multifactorial based on patient characteristics, the indication for lifelong anticoagulation, the potential and risks of a re-intervention, and the informed patient preference.
21. Clinical assessment of prosthetic valves should be performed yearly and as soon as possible if new cardiac symptoms occur.
15 Gaps in evidence
Important gaps in evidence exist in the following aspects of VHD:
General comments
1. Prognostic value of CMR-derived indices in patients with aortic regurgitation, aortic stenosis, and mitral regurgitation.
2. Tools for risk stratification for the decision for intervention
(including the avoidance of futile interventions) and the choice of the type of intervention (TAVI vs. SAVR for aortic stenosis, repair vs.
replacement for mitral and aortic regurgitation).
3. In asymptomatic patients with aortic regurgitation, aortic stenosis, and mitral regurgitation, identification and evaluation of earlier markers of LV dysfunction (biomarkers, imaging, multimodality) as well as longitudinal and translational studies on progression.
4. Gender issues regarding pathophysiology, indications, and timing of treatment.
5. Minimum volumes of procedures that are required to achieve optimal results of intervention.
6. Safety and efficacy of NOACs in patients with surgical or transcatheter bioprostheses in the first 3 months after implantation.
7. Patient education for shared decision making and timely evaluation.
8. Systematic epidemiological data addressing the burden of rheumatic heart disease.
9. Advocacy of VHD.
Aortic regurgitation
10. Potential differences in the risk of aortic complications depending on subtypes of aortic aneurysms (site and morphology), as well as in patients with bicuspid aortic valves.
11. Further evaluation of surgical aortic valve repair.
Aortic stenosis
12. Pathophysiology of progression and novel therapeutic targets for medical treatment.
13. Further research to evaluate the role of intervention:
a. Long-term durability of transcatheter heart valves in comparison with surgical bioprostheses.
b. Role of intervention (SAVR or TAVI) in asymptomatic patients.
c. Role of TAVI in younger low-risk patients, patients with aortic stenosis affecting bicuspid valves, and patients with moderate aortic stenosis and LV impairment.
d. Results of re-intervention (valve or coronary) after TAVI or SAVR.
e. The role of revascularization in patients with severe aortic stenosis and asymptomatic concomitant CAD.
Mitral regurgitation
14. Association between PMR and sudden cardiac death and ventricular arrhythmias.
15. Role of genetic testing to mitral valve prolapse.
16. Further evaluation of the role of intervention:
a. Long-term results of transcatheter intervention.
b. Indications of transcatheter intervention in patients with severe PMR
at lower surgical risk.
c. Potential impact of mitral valve intervention (surgery and catheter intervention) on survival in patients with SMR.
d. Selection of criteria to identify responders to TEER for SMR (severity criteria, concept of ‘disproportionate mitral regurgitation’).
e. The role of newer transcatheter treatment options (annuloplasty,
combined repair techniques, valve replacement).
Mitral stenosis
17. Scores predicting the results and complications of PMC, particularly that of severe mitral regurgitation.
18. Role of transcatheter mitral valve implantation in high-risk patients, particularly in patients with severe degenerative mitral stenosis and MAC.
Tricuspid regurgitation
19. Quantification of tricuspid regurgitation severity and evaluation of RV function.
20. Further research to evaluate the role of intervention:
a. Criteria for optimal timing of surgery in primary tricuspid regurgitation.
b. Evidence on the clinical impact, timing, and treatment modality of isolated severe secondary tricuspid regurgitation.
c. Criteria for concomitant tricuspid valve surgery at the time of leftsided surgery in patients without severe tricuspid regurgitation.
d. Results and indications of transcatheter tricuspid valve treatment.
Combined and multi-valve diseases
21. Further evaluation of the impact on outcomes and modalities of transcatheter intervention to better define the indications for intervention.
Pregnancy
22. Optimal management of pregnant women with MHVs regarding antithrombotic regimens.
Non-cardiac surgery
23. Evaluation of the role of ‘urgent TAVI’ in the management of patients with severe aortic stenosis undergoing NCS.
ESC/EACTS Guidelines
610


<!-- PAGE 51 -->

### Page 51

16 To Do and Not To Do
Recommendations
Classa
Levelb
Recommendations for management of CAD in patients with VHD
Diagnosis of CAD
Coronary angiography is recommended before valve surgery in patients with severe VHD and any of the following:
• History of cardiovascular disease.
• Suspected myocardial ischaemia.
• LV systolic dysfunction.
• In men >40 years of age and postmenopausal women.
• One or more cardiovascular risk factors.
I
C
Coronary angiography is recommended in the evaluation of severe SMR.
I
C
Indications for myocardial revascularization
CABG is recommended in patients with a primary indication for aortic/mitral/tricuspid valve surgery and coronary artery diameter stenosis >_70%.
I
C
Recommendations on management of atrial ﬁbrillation in patients with native VHD
Anticoagulation
For stroke prevention in AF patients who are eligible for OAC, NOACs are recommended in preference to VKAs in patients with aortic stenosis, aortic and mitral regurgitation.
I
A
The use of NOACs is not recommended in patients with AF and moderate to severe mitral stenosis.
III
C
Recommendations on indications for surgery in (A) severe aortic regurgitation and (B) aortic root or tubular ascending aortic aneurysm (irrespective of the severity of aortic regurgitation)
A) Severe aortic regurgitation
Surgery is recommended in symptomatic patients regardless of LV function.
I
B
Surgery is recommended in asymptomatic patients with LVESD >50 mm or LVESD >25 mm/m2 BSA (in patients with small body size) or resting LVEF <_50%.
I
B
Surgery is recommended in symptomatic and asymptomatic patients with severe aortic regurgitation undergoing
CABG or surgery of the ascending aorta or of another valve.
I
C
B) Aortic root or tubular ascending aortic aneurysm (irrespective of the severity of aortic regurgitation)
Valve-sparing aortic root replacement is recommended in young patients with aortic root dilation, if performed in experienced centres and durable results are expected.
I
B
Ascending aortic surgery is indicated in patients with Marfan syndrome who have aortic root disease with a maximal ascending aortic diameter >_50 mm.
I
C
Recommendations on indications for intervention in symptomatic (A) and asymptomatic (B) aortic stenosis and recommended mode of intervention (C)
A) Symptomatic aortic stenosis
Intervention is recommended in symptomatic patients with severe, high-gradient aortic stenosis [mean gradient
>_40 mmHg, peak velocity >_4.0 m/s and valve area <_1.0 cm2 (or <_0.6 cm2/m2)].
I
B
Intervention is recommended in symptomatic patients with severe low-ﬂow (SVi <_35 mL/m2), low-gradient
(<40 mmHg) aortic stenosis with reduced ejection fraction (<50%) and evidence of ﬂow (contractile) reserve.
I
B
Intervention is not recommended in patients with severe comorbidities when the intervention is unlikely to improve quality of life or prolong survival >1 year.
III
C
B) Asymptomatic patients with severe aortic stenosis
Intervention is recommended in asymptomatic patients with severe aortic stenosis and systolic LV dysfunction (LVEF
<50%) without another cause.
I
B
Intervention is recommended in asymptomatic patients with severe aortic stenosis and demonstrable symptoms on exercise testing.
I
C
C) Mode of intervention
Aortic valve interventions must be performed in Heart Valve Centres that declare their local expertise and outcomes data, have active interventional cardiology and cardiac surgical programmes on site, and a structured collaborative
Heart Team approach.
I
C
Continued
ESC/EACTS Guidelines
611


<!-- PAGE 52 -->

### Page 52

The choice between surgical and transcatheter intervention must be based upon careful evaluation of clinical, anatomical, and procedural factors by the Heart Team, weighing the risks and beneﬁts of each approach for an individual patient. The Heart Team recommendation should be discussed with the patient who can then make an informed treatment choice.
I
C
SAVR is recommended in younger patients who are low risk for surgery (<75 years and STS-PROM/ EuroSCORE II
<4%), or in patients who are operable and unsuitable for transfemoral TAVI.
I
B
TAVI is recommended in older patients (>_75 years), or in those who are high risk (STS-PROM/EuroSCORE II >8%)
or unsuitable for surgery.
I
A
SAVR or TAVI are recommended for remaining patients according to individual clinical, anatomical, and procedural characteristics.
I
B
D) Concomitant aortic valve surgery at the time of other cardiac/ascending aorta surgery
SAVR is recommended in patients with severe aortic stenosis undergoing CABG or surgical intervention on the ascending aorta or another valve.
I
C
Recommendations on indications for intervention in severe primary mitral regurgitation
Mitral valve repair is the recommended surgical technique when the results are expected to be durable.
I
B
Surgery is recommended in symptomatic patients who are operable and not high risk.
I
B
Surgery is recommended in asymptomatic patients with LV dysfunction (LVESD >_40 mm and/or LVEF <_60%).
I
B
Recommendations on indications for mitral valve intervention in chronic severe secondary mitral regurgitation
Valve surgery/intervention is recommended only in patients with severe SMR who remain symptomatic despite
GDMT (including CRT if indicated) and has to be decided by a structured collaborative Heart Team.
I
B
Patients with concomitant coronary artery or other cardiac disease requiring treatment
Valve surgery is recommended in patients undergoing CABG or other cardiac surgery.
I
B
Recommendations on indications for percutaneous mitral commissurotomy and mitral valve surgery in clinically signiﬁcant (moderate or severe) mitral stenosis (valve area 1.5 cm2)
PMC is recommended in symptomatic patients without unfavourable characteristics for PMC.
I
B
PMC is recommended in any symptomatic patients with a contraindication or a high risk for surgery.
I
C
Mitral valve surgery is recommended in symptomatic patients who are not suitable for PMC in the absence of futility.
I
C
Recommendations on indications for intervention in tricuspid valve disease
Recommendations on tricuspid stenosis
Surgery is recommended in symptomatic patients with severe tricuspid stenosis.
I
C
Surgery is recommended in patients with severe tricuspid stenosis undergoing left-sided valve intervention.
I
C
Recommendations on primary tricuspid regurgitation
Surgery is recommended in patients with severe primary tricuspid regurgitation undergoing left-sided valve surgery.
I
C
Surgery is recommended in symptomatic patients with isolated severe primary tricuspid regurgitation without severe
RV dysfunction.
I
C
Recommendations on secondary tricuspid regurgitation
Surgery is recommended in patients with severe secondary tricuspid regurgitation undergoing left-sided valve surgery.
I
B
Recommendations for prosthetic valve selection
Mechanical prostheses
A mechanical prosthesis is recommended according to the desire of the informed patient and if there are no contraindications to long-term anticoagulation.
I
C
A mechanical prosthesis is recommended in patients at risk of accelerated SVD.
I
C
Biological prostheses
A bioprosthesis is recommended according to the desire of the informed patient.
I
C
A bioprosthesis is recommended when good-quality anticoagulation is unlikely (adherence problems, not readily available), contraindicated because of high bleeding risk (previous major bleed, comorbidities, unwillingness, adherence problems, lifestyle, occupation), and in those patients whose life expectancy is lower than the presumed durability of the bioprosthesis.
I
C
A bioprosthesis is recommended in case of reoperation for mechanical valve thrombosis despite good long-term anticoagulant control.
I
C
Continued
ESC/EACTS Guidelines
612


<!-- PAGE 53 -->

### Page 53

Recommendations for perioperative and postoperative antithrombotic management of valve replacement or repair
Management of antithrombotic therapy in the perioperative period
It is recommended that VKAs are timely discontinued prior to elective surgery to aim for an INR <1.5.
I
C
Bridging of OAC, when interruption is needed, is recommended in patients with any of the following indications:
• Mechanical prosthetic heart valve.
• AF with signiﬁcant mitral stenosis.
• AF with a CHA2DS2-VASc score >_3 for women or 2 for men.
• Acute thrombotic event within the previous 4 weeks.
• High acute thromboembolic risk.
I
C
Therapeutic doses of either UFH or subcutaneous LMWH are recommended for bridging.
I
B
In patients with MHVs, it is recommended to (re)-initiate the VKA on the ﬁrst postoperative day.
I
C
In patients who have undergone valve surgery with an indication for postoperative therapeutic bridging, it is recommended to start either UFH or LMWH 1224 h after surgery.
I
C
In patients undergoing surgery, it is recommended that aspirin therapy, if indicated, is maintained during the periprocedural period.
I
C
In patients treated with DAPT after recent PCI (within 1 month) who need to undergo heart valve surgery in the absence of an indication for OAC, it is recommended to resume the P2Y12 inhibitor postoperatively as soon as there is no concern over bleeding.
I
C
Patients with an indication to concomitant antiplatelet therapy
After uncomplicated PCI or ACS in patients requiring long-term OAC, early cessation (<_1 week) of aspirin and continuation of dual therapy with OAC and a P2Y12 inhibitor (preferably clopidogrel) for up to 6 months (or up to
12 months in ACS) is recommended if the risk of stent thrombosis is low or if concerns about bleeding risk prevail over concerns about risk of stent thrombosis, irrespective of the type of stent used.
I
B
Discontinuation of antiplatelet treatment in patients treated with an OAC is recommended after 12 months.
I
B
Surgical valve replacement
OAC using a VKA is recommended lifelong for all patients with a MHV prosthesis.
I
B
For patients with a VKA, INR self-management is recommended provided appropriate training and quality control are performed.
I
B
OAC is recommended for patients undergoing implantation of a surgical BHV who have other indications for anticoagulation.
I
C
NOACs are not recommended in patients with an MHV.
III
B
Transcatheter aortic valve implantation
OAC is recommended lifelong for TAVI patients who have other indications for anticoagulation.
I
B
Lifelong SAPT is recommended after TAVI in patients with no baseline indication for OAC.
I
A
Routine use of OAC is not recommended after TAVI in patients who have no baseline indication for OAC.
III
B
Recommendations on management of prosthetic valve dysfunction
Mechanical prosthetic thrombosis
Urgent or emergency valve replacement is recommended for obstructive thrombosis in critically ill patients without serious comorbidity.
I
B
Bioprosthetic thrombosis
Anticoagulation using a VKA and/or UFH is recommended in bioprosthetic valve thrombosis before considering reintervention.
I
C
Haemolysis and paravalvular leak
Reoperation is recommended if a paravalvular leak is related to endocarditis or causes haemolysis requiring repeated blood transfusions or leading to severe heart failure symptoms.
I
C
Bioprosthetic failure
Reoperation is recommended in symptomatic patients with a signiﬁcant increase in transprosthetic gradient (after exclusion of valve thrombosis) or severe regurgitation.
I
C
ACS = acute coronary syndrome; AF = atrial ﬁbrillation; BHV = biological heart valve; BSA = body surface area; CABG = coronary artery bypass grafting; CAD = coronary artery disease; CRT = cardiac resynchronization therapy; DAPT = dual antiplatelet therapy; EuroSCORE = European System for Cardiac Operative Risk Evaluation; GDMT = guidelinedirected medical therapy; h = hours; INR = international normalized ratio; LMWH = low-molecular-weight heparin; LV = left ventricle/left ventricular; LVEF = left ventricular ejection fraction; LVESD = left ventricular end-systolic diameter; MHV = mechanical heart valve; MR = mitral regurgitation; NOAC = non-vitamin K antagonist oral anticoagulant;
OAC = oral anticoagulation; PCI = percutaneous coronary intervention; PMC = percutaneous mitral commissurotomy; RV = right ventricle/right ventricular; SAPT = single antiplatelet therapy; SAVR = surgical aortic valve replacement; SMR = secondary mitral regurgitation; STS-PROM = Society of Thoracic Surgeons  predicted risk of mortality;
SVD = structural valve deterioration; SVi = stroke volume index; TAVI = transcatheter aortic valve implantation; UFH = unfractionated heparin; VHD = valvular heart disease;
VKA = vitamin K antagonist.
ESC/EACTS 2021
ESC/EACTS Guidelines
613


<!-- PAGE 54 -->

### Page 54

.............................................................................................................................................................................
17 Supplementary data
Supplementary Data with additional Supplementary figures, tables, and text complementing the full text are available on the European Heart
Journal website and via the ESC website at https://www.escardio.org/
guidelines.
18 Author information
Author/Task Force Member Affiliations: Fabien Praz,
Department of Cardiology, Bern University Hospital, University of
Bern, Bern, Switzerland; Milan Milojevic1, Department of Cardiac
Surgery and Cardiovascular Research, Dedinje Cardiovascular
Institute, Belgrade, Serbia and Department of Cardiothoracic Surgery,
Erasmus
University
Medical
Center,
Rotterdam,
Netherlands;
Stephan Baldus, Heart Centre, Department of Cardiology,
University
Hospital
Cologne,
Cologne,
Germany;
Johann
Bauersachs, Department of Cardiology and Angiology, Hannover
Medical School, Hannover, Germany; Davide Capodanno, Division of Cardiology, Azienda Ospedaliero Universitaria Policlinico ‘Gaspare
Rodolico

San
Marco’,
Catania,
Italy;
Lenard
Conradi1,
Department of Cardiovascular Surgery, University Heart and Vascular
Centre Hamburg, Hamburg, Germany; Michele De Bonis1,
Department of Cardiac Surgery, IRCCS San Raffaele Hospital, ‘VitaSalute’ San Raffaele University, Milan, Italy; Ruggero De Paulis1,
Cardiac
Surgery
Department,
European
Hospital,
Unicamillus
International Medical University, Rome, Italy; Victoria Delgado,
Cardiology, Leiden University Medical Centre, Leiden, Netherlands;
Nick Freemantle1, Institute of Clinical Trials and Methodology,
University College London, London, United Kingdom; Martine
Gilard, Cardiology, Brest University Hospital, Brest, France; Kristina
H. Haugaa, Department of Cardiology, Oslo University Hospital and
University of Oslo, Oslo, Norway; Anders Jeppsson1, Department of
Cardiothoracic
Surgery,
Sahlgrenska
University
Hospital,
Gothenburg, Sweden; Peter Ju¨ni, Applied Health Research Centre
(AHRC), Li Ka Shing Knowledge Institute of St. Michael’s Hospital,
Department of
Medicine and
Institute of
Health
Policy,
Management and Evaluation, University of Toronto, Canada; Luc
Pierard,
Cardiology,
University of
Lie`ge,
Lie`ge,
Belgium;
Bernard D. Prendergast, Department of Cardiology, St
Thomas’ Hospital and Cleveland Clinic London, London, United
Kingdom; J. Rafael Sadaba1, Department of Cardiac Surgery,
Complejo
Hospitalario de
Navarra,
Pamplona,
Spain;
Christophe Tribouilloy, Department of Cardiology, Amiens
University Hospital, Amiens, France; Wojtek Wojakowski,
Cardiology and Structural Heart Diseases, Medical University of
Silesia, Katowice, Poland.
19 Appendix
ESC/EACTS Scientific Document Group
Includes Document Reviewers and ESC National Cardiac Societies.
Document Reviewers: Franz-Josef Neumann (ESC Review
Coordinator)
(Germany),
Patrick
Myers1
(EACTS
Review
Coordinator) (Switzerland), Magdy Abdelhamid (Egypt), Stephan
Achenbach (Germany), Riccardo Asteggiano (Italy), Fabio Barili1
(Italy), Michael A. Borger (Germany), Thierry Carrel1 (Switzerland),
Jean-Philippe Collet (France), Dan Foldager (Denmark), Gilbert
Habib (France), Christian Hassager (Denmark), Alar Irs1 (Estonia),
Bernard Iung (France), Marjan Jahangiri1 (United Kingdom), Hugo A.
Katus (Germany), Konstantinos C. Koskinas (Switzerland), Steffen
Massberg (Germany), Christian E. Mueller (Switzerland), Jens
Cosedis Nielsen (Denmark), Philippe Pibarot (Canada), Amina
Rakisheva (Kazakhstan), Marco Roffi (Switzerland), Andrea Rubboli
(Italy), Evgeny Shlyakhto (Russia), Matthias Siepe1 (Germany), Marta
Sitges (Spain), Lars Sondergaard (Denmark), Miguel Sousa-Uva1
(Portugal), Guiseppe Tarantini (Italy), Jose Luis Zamorano (Spain).
ESC National Cardiac Societies actively involved in the review process of the 2021 ESC/EACTS Guidelines for the management of valvular heart disease.
Algeria:
Algerian Society of Cardiology, Yasmina
Benchabi;
Armenia: Armenian Cardiologists Association, Aram Chilingaryan;
Austria:
Austrian Society of
Cardiology, Bernhard Metzler;
Azerbaijan: Azerbaijan Society of Cardiology, Yasmin Rustamova;
Belarus: Belorussian Scientific Society of Cardiologists, Vadim
Shumavets; Belgium: Belgian Society of Cardiology, Patrizio
Lancellotti; Bosnia and Herzegovina: Association of Cardiologists of Bosnia and Herzegovina, Elnur Smajic; Bulgaria: Bulgarian Society of Cardiology, Diana Trendafilova-Lazarova; Croatia: Croatian
Cardiac Society, Jure Samardzic; Cyprus: Cyprus Society of
Cardiology, Maria Karakyriou; Czech Republic: Czech Society of
Cardiology,
Tomas
Palecek;
Denmark:
Danish
Society of
Cardiology, Jordi Sanchez Dahl; Egypt: Egyptian Society of
Cardiology, Marwa Sayed Meshaal; Estonia: Estonian Society of
Cardiology, Kairit Palm; Finland: Finnish Cardiac Society, Marko
Virtanen; France: French Society of Cardiology, Claire Bouleti;
Georgia: Georgian Society of Cardiology, Zviad Bakhutashvili;
Germany: German Cardiac Society, Stephan Achenbach; Greece:
Hellenic Society of Cardiology,
Maria
Boutsikou; Hungary:
Hungarian Society of Cardiology, Attila Be´la Kerte´sz; Iceland:
Icelandic Society of Cardiology, Ragnar Danielsen; Israel: Israel
Heart Society, Yan Topilsky; Italy: Italian Federation of Cardiology,
Paolo Golino;
Kazakhstan:
Association of
Cardiologists of
Kazakhstan, Rustem Tuleutayev; Kosovo (Republic of): Kosovo
Society of Cardiology, Shpend Elezi; Kyrgyzstan: Kyrgyz Society of
Cardiology,
Alina
Kerimkulova;
Latvia:
Latvian
Society of
Cardiology, Ainars Rudzitis; Lithuania: Lithuanian Society of
Cardiology, Sigita Glaveckaite; Luxembourg: Luxembourg Society of Cardiology, Rouguiatou Sow; Malta: Maltese Cardiac Society,
Daniela Cassar Demarco; Montenegro: Montenegro Society of
Cardiology, Nebojsa Bulatovic; Morocco: Moroccan Society of
Cardiology, Aicha Aouad; Netherlands: Netherlands Society of
Cardiology, Rene´e van den Brink; North Macedonia: North
Macedonian Society of Cardiology, Emilija Antova; Norway:
Norwegian Society of Cardiology, Jan Otto Beitnes; Poland: Polish
Cardiac Society, Andrzej Ochala; Portugal: Portuguese Society of
Cardiology, Regina Ribeiras; Romania: Romanian Society of
Cardiology, Dragos Vinereanu; Russian Federation: Russian
Society of Cardiology, Olga Irtyuga; Serbia: Cardiology Society of
Serbia, Branislava Ivanovic; Slovakia: Slovak Society of Cardiology,
ESC/EACTS Guidelines
614


<!-- PAGE 55 -->

### Page 55

.............................................................................................................................................................................
Iveta Simkova; Spain: Spanish Society of Cardiology, Ariana
Gonzalez Gomez; Sweden: Swedish Society of Cardiology,
Giovanna Sarno; Switzerland: Swiss Society of Cardiology,
Giovanni
B.
Pedrazzini;
Syrian
Arab
Republic:
Syrian
Cardiovascular Association, Walid Bsata; Tunisia: Tunisian Society of Cardiology and Cardio-Vascular Surgery, Lilia Zakhama; Turkey:
Turkish Society of Cardiology, Levent Korkmaz; Ukraine: Ukrainian
Association of Cardiology, Sergii Cherniuk; United Kingdom of
Great Britain and Northern Ireland: British Cardiovascular
Society,
Mohammed
Y.
Khanji;
Uzbekistan:
Association of
Cardiologists of Uzbekistan, Islamjan Sharipov.
ESC Clinical Practice Guidelines Committee (CPG): Colin
Baigent (Chairperson) (United Kingdom), Magdy Abdelhamid (Egypt),
Victor Aboyans (France), Sotiris Antoniou (United Kingdom), Elena
Arbelo (Spain), Riccardo Asteggiano (Italy), Andreas Baumbach
(United Kingdom), Michael A. Borger (Germany), Jelena Celutkien_e
(Lithuania), Maja Cikes (Croatia), Jean-Philippe Collet (France),
Volkmar Falk (Germany), Laurent Fauchier (France), Chris P. Gale
(United Kingdom), Sigrun Halvorsen (Norway), Bernard Iung (France),
Tiny Jaarsma (Sweden), Aleksandra Konradi (Russia), Konstantinos C.
Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Ulf
Landmesser (Germany), Basil S. Lewis (Israel), Ales Linhart (Czech
Republic),
Maja-Lisa
Løchen
(Norway),
Lis
Neubeck
(United
Kingdom), Jens Cosedis Nielsen (Denmark), Steffen E. Petersen
(United Kingdom), Eva Prescott (Denmark), Amina Rakisheva
(Kazakhstan), Marta Sitges (Spain), Rhian M. Touyz (United Kingdom).
EACTS Council: Friedhelm Beyersdorf (Germany), Lorenzo
Galletti
(Italy),
Mark
Hazekamp
(Netherlands),
Peter
Licht
(Denmark), Patrick Myers (Switzerland), Patrick Perier (Germany),
Richard Prager (United States of America), Eric Roessner (Germany),
J. Rafael Sadaba (Spain), Matthias Siepe (Germany), Konstantinos
Tsagakis (Germany), Alicja Zientara (United Kingdom).
References
1. Iung B, Delgado V, Rosenhek R, Price S, Prendergast B, Wendler O, De Bonis M,
Tribouilloy C, Evangelista A, Bogachev-Prokophiev A, Apor A, Ince H, Laroche C,
Popescu BA, Pierard L, Haude M, Hindricks G, Ruschitzka F, Windecker S, Bax JJ,
Maggioni A, Vahanian A, EORP VHD II Investigators. Contemporary presentation and management of valvular heart disease: The EURObservational Research
Programme Valvular Heart Disease II Survey. Circulation 2019;140:11561169.
2. Yadgir S, Johnson CO, Aboyans V, Adebayo OM, Adedoyin RA, Afarideh M,
Alahdab F, Alashi A, Alipour V, Arabloo J, Azari S, Barthelemy CM, Benziger CP,
Berman AE, Bijani A, Carrero JJ, Carvalho F, Daryani A, Duraes AR, Esteghamati
A, Farid TA, Farzadfar F, Fernandes E, Filip I, Gad MM, Hamidi S, Hay SI, Ilesanmi
OS, Naghibi Irvani SS, Jurisson M, Kasaeian A, Kengne AP, Khan AR, Kisa A, Kisa S,
Kolte D, Manafi N, Manafi A, Mensah GA, Mirrakhimov EM, Mohammad Y,
Mokdad AH, Negoi RI, Thi Nguyen HL, Nguyen TH, Nixon MR, Otto CM, Patel
S, Pilgrim T, Radfar A, Rawaf DL, Rawaf S, Rawasia WF, Rezapour A, Roever L,
Saad AM, Saadatagah S, Senthilkumaran S, Sliwa K, Tesfay BE, Tran BX, Ullah I,
Vaduganathan M, Vasankari TJ, Wolfe CDA, Yonemoto N, Roth GA, Global
Burden of Disease Study Nonrheumatic Valve Disease Collaborators. Global,
regional, and national burden of calcific aortic valve and degenerative mitral valve diseases, 1990-2017. Circulation 2020;141:16701680.
3. Cahill TJ, Prothero A, Wilson J, Kennedy A, Brubert J, Masters M, Newton JD,
Dawkins S, Enriquez-Sarano M, Prendergast BD, Myerson SG. Community prevalence, mechanisms and outcome of mitral or tricuspid regurgitation. Heart 2021
doi: 10.1136/heartjnl-2020-318482.
4. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F,
Dulgheru R, El Khoury G, Erba PA, Iung B, Miro JM, Mulder BJ, Plonska-Gosciniak
E, Price S, Roos-Hesselink J, Snygg-Martin U, Thuny F, Tornos Mas P, Vilacosta I,
Zamorano JL, ESC Scientific Document Group. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of
Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by:
European Association for Cardio-Thoracic Surgery (EACTS), the European
Association of Nuclear Medicine (EANM). Eur Heart J 2015;36:30753128.
5. Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller GP,
Lung B, Kluin J, Lang IM, Meijboom F, Moons P, Mulder BJM, Oechslin E, RoosHesselink JW, Schwerzmann M, Sondergaard L, Zeppenfeld K, ESC Scientific
Document Group. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J 2021;42:563645.
6. Pelliccia A, Sharma S, Gati S, Back M, Borjesson M, Caselli S, Collet JP, Corrado
D, Drezner JA, Halle M, Hansen D, Heidbuchel H, Myers J, Niebauer J, Papadakis
M, Piepoli MF, Prescott E, Roos-Hesselink JW, Graham Stuart A, Taylor RS,
Thompson PD, Tiberi M, Vanhees L, Wilhelm M, ESC Scientific Document Group.
7. Agricola E, Ancona F, Brochet E, Donal E, Dweck M, Faletra F, Lancellotti P,
Mahmoud-Elsayed H, Marsan NA, Maurovich-Hovart P, Monaghan M, Ribeiro J,
Sade LE, Swaans M, Von Bardeleben RS, Wunderlich N, Zamorano JL, Popescu
BA, Cosyns B, Edvardsen T. The structural heart disease interventional imager rationale, skills and training: a position paper of the European Association of
Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2021;22:471479.
8. Hahn RT, Mahmood F, Kodali S, Lang R, Monaghan M, Gillam LD, Swaminathan M,
Bonow RO, von Bardeleben RS, Bax JJ, Grayburn P, Zoghbi WA, Sengupta PP,
Chandrashekhar Y, Little SH. Core competencies in echocardiography for imaging structural heart disease interventions: an expert consensus statement. JACC
Cardiovasc Imaging 2019;12:25602570.
09. Lancellotti P, Magne J, Dulgheru R, Clavel MA, Donal E, Vannan MA, Chambers J,
Rosenhek R, Habib G, Lloyd G, Nistri S, Garbi M, Marchetta S, Fattouch K,
Coisne A, Montaigne D, Modine T, Davin L, Gach O, Radermecker M, Liu S,
Gillam L, Rossi A, Galli E, Ilardi F, Tastet L, Capoulade R, Zilberszac R, Vollema
EM, Delgado V, Cosyns B, Lafitte S, Bernard A, Pierard LA, Bax JJ, Pibarot POury
C. Outcomes of patients with asymptomatic aortic stenosis followed up in heart valve clinics. JAMA Cardiol 2018;3:10601068.
10. Lancellotti P, Rosenhek R, Pibarot P, Iung B, Otto CM, Tornos P, Donal E,
Prendergast B, Magne J, La Canna G, Pierard LA, Maurer G. ESC Working Group on Valvular Heart Disease position paperheart valve clinics: organization, structure, and experiences. Eur Heart J 2013;34:15971606.
11. Chambers JB, Prendergast B, Iung B, Rosenhek R, Zamorano JL, Pierard LA,
Modine T, Falk V, Kappetein AP, Pibarot P, Sundt T, Baumgartner H, Bax JJ,
Lancellotti P. Standards defining a ‘Heart Valve Centre’: ESC Working Group on
Valvular Heart Disease and European Association for Cardiothoracic Surgery
Viewpoint. Eur Heart J 2017;38:21772183.
12. Badheka AO, Patel NJ, Panaich SS, Patel SV, Jhamnani S, Singh V, Pant S, Patel N,
Patel N, Arora S, Thakkar B, Manvar S, Dhoble A, Patel A, Savani C, Patel J,
Chothani A, Savani GT, Deshmukh A, Grines CL, Curtis J, Mangi AA, Cleman M,
Forrest JK. Effect of hospital volume on outcomes of transcatheter aortic valve implantation. Am J Cardiol 2015;116:587594.
13. Nishimura RA, O’Gara PT, Bavaria JE, Brindis RG, Carroll JD, Kavinsky CJ,
Lindman BR, Linderbaum JA, Little SH, Mack MJ, Mauri L, Miranda WR, Shahian
DM, Sundt TM, 3rd. 2019 AATS/ACC/ASE/SCAI/STS Expert Consensus Systems of Care Document: a proposal to optimize care for patients with valvular heart disease: a joint report of the American Association for Thoracic Surgery,
American College of Cardiology, American Society of Echocardiography, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic
Surgeons. J Am Coll Cardiol 2019;73:26092635.
14. Chhatriwalla AK, Vemulapalli S, Szerlip M, Kodali S, Hahn RT, Saxon JT, Mack MJ,
Ailawadi G, Rymer J, Manandhar P, Kosinski AS, Sorajja P. Operator experience and outcomes of transcatheter mitral valve repair in the United States. J Am Coll
Cardiol 2019;74:29552965.
15. Timmis A, Townsend N, Gale CP, Torbica A, Lettino M, Petersen SE, Mossialos
EA, Maggioni AP, Kazakiewicz D, May HT, De Smedt D, Flather M, Zuhlke L,
Beltrame JF, Huculeci R, Tavazzi L, Hindricks G, Bax J, Casadei B, Achenbach S,
Wright L, Vardas P, European Society of Cardiology. European Society of
Cardiology: cardiovascular disease statistics 2019. Eur Heart J 2020;41:1285.
16. Vemulapalli S, Carroll JD, Mack MJ, Li Z, Dai D, Kosinski AS, Kumbhani DJ, Ruiz
CE, Thourani VH, Hanzel G, Gleason TG, Herrmann HC, Brindis RG, Bavaria JE.
Procedural volume and outcomes for transcatheter aortic-valve replacement. N
Engl J Med 2019;380:25412550.
17. Mao J, Redberg RF, Carroll JD, Marinac-Dabic D, Laschinger J, Thourani V, Mack
M, Sedrakyan A. Association between hospital surgical aortic valve replacement volume and transcatheter aortic valve replacement outcomes. JAMA Cardiol
2018;3:10701078.
18. Bonow RO, O’Gara PT, Adams DH, Badhwar V, Bavaria JE, Elmariah S, Hung
JW, Lindenfeld J, Morris A, Satpathy R, Whisenant B, Woo YJ. 2019 AATS/ACC/
SCAI/STS Expert Consensus Systems of Care Document: operator and
ESC/EACTS Guidelines
615


<!-- PAGE 56 -->

### Page 56

.............................................................................................................................................................................
institutional recommendations and requirements for transcatheter mitral valve intervention: a joint report of the American Association for Thoracic Surgery,
the American College of Cardiology, the Society for Cardiovascular Angiography and Interventions, and The Society of Thoracic Surgeons. J Am Coll Cardiol
2020;76:96117.
19. Garbi M, Chambers J, Pierard L, Maisano F, Lancellotti P. Heart Valve Specialist
Core Syllabus: a learning framework for continuous medical education on valvular heart disease. European Society of Cardiology, 1 June 2021. https://www.
escardio.org/Councils/Council-on-Valvular-Heart-Disease/heart-valve-specialistcore-syllabus. Accessed on 20 July 2021.
20. Dreyfus G, Windecker S. How to shape the future of cardiology and cardiac surgery? Eur Heart J 2020;41:36933701.
21. Iung B, Delgado V, Lazure P, Murray S, Sirnes PA, Rosenhek R, Price S, Metra M,
Carrera C, De Bonis M, Haude M, Hindricks G, Bax J, Vahanian A. Educational needs and application of guidelines in the management of patients with mitral regurgitation.
A
European mixed-methods study.
Eur
Heart
J
2018;39:12951303.
22. Popescu BA, Andrade MJ, Badano LP, Fox KF, Flachskampf FA, Lancellotti P, Varga
A, Sicari R, Evangelista A, Nihoyannopoulos P, Zamorano JL, European Association of E, Document RDerumeaux G, Kasprzak JD, Roelandt JR. European Association of Echocardiography recommendations for training, competence, and quality improvement in echocardiography. Eur J Echocardiogr 2009;10:893905.
23. Chambers JB, Garbi M, Nieman K, Myerson S, Pierard LA, Habib G, Zamorano
JL, Edvardsen T, Lancellotti P, This document was reviewed by members of the
ESDC, Delgado V, Cosyns B, Donal E, Dulgheru R, Galderisi M, Lombardi M,
Muraru D, Kauffmann P, Cardim N, Haugaa K, Rosenhek R. Appropriateness criteria for the use of cardiovascular imaging in heart valve disease in adults: a
European Association of Cardiovascular Imaging report of literature review and current practice. Eur Heart J Cardiovasc Imaging 2017;18:489498.
24. Lancellotti P, Tribouilloy C, Hagendorff A, Popescu BA, Edvardsen T, Pierard LA,
Badano L, Zamorano JL, Scientific Document Committee of the European
Association of Cardiovascular Imaging. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc
Imaging 2013;14:611644.
25. Baumgartner HC, Hung JC-C, Bermejo J, Chambers JB, Edvardsen T, Goldstein S,
Lancellotti P, LeFevre M, Miller F, Jr., Otto CM. Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the
European Association of Cardiovascular Imaging and the American Society of
Echocardiography. Eur Heart J Cardiovasc Imaging 2017;18:254275.
26. Magne J, Cosyns B, Popescu BA, Carstensen HG, Dahl J, Desai MY, Kearney L,
Lancellotti P, Marwick TH, Sato K, Takeuchi M, Zito C, Casalta AC, Mohty D,
Pierard L, Habib G, Donal E. Distribution and prognostic significance of left ventricular global longitudinal strain in asymptomatic significant aortic stenosis: an individual participant data meta-analysis. JACC Cardiovasc Imaging 2019;12:8492.
27. Prihadi EA, van der Bijl P, Dietz M, Abou R, Vollema EM, Marsan NA, Delgado V,
Bax JJ. Prognostic implications of right ventricular free wall longitudinal strain in patients with significant functional tricuspid regurgitation. Circ Cardiovasc Imaging
2019;12:e008666.
28. van Rosendael PJ, van Wijngaarden SE, Kamperidis V, Kong WKF, Leung M, Ajmone
Marsan N, Delgado V, Bax JJ. Integrated imaging of echocardiography and computed tomography to grade mitral regurgitation severity in patients undergoing transcatheter aortic valve implantation. Eur Heart J 2017;38:22212226.
29. Schulz E, Tamm A, Kasper-Konig W, Beiras-Fernandez A, Vahl CF, Munzel T,
von Bardeleben RS. Transapical implantation of a transcatheter aortic valve prosthesis into a mitral annuloplasty ring guided by real-time three-dimensional cardiac computed tomography-fluoroscopy fusion imaging.
Eur
Heart
J
2018;39:327328.
30. Henri C, Pierard LA, Lancellotti P, Mongeon FP, Pibarot P, Basmadjian AJ.
Exercise testing and stress imaging in valvular heart disease. Can J Cardiol
2014;30:10121026.
31. Picano E, Pibarot P, Lancellotti P, Monin JL, Bonow RO. The emerging role of exercise testing and stress echocardiography in valvular heart disease. J Am Coll
Cardiol 2009;54:22512260.
32. Monin JL, Quere JP, Monchi M, Petit H, Baleynaud S, Chauvel C, Pop C,
Ohlmann P, Lelguen C, Dehant P, Tribouilloy C, Gueret P. Low-gradient aortic stenosis: operative risk stratification and predictors for long-term outcome: a multicenter study using dobutamine stress hemodynamics.
Circulation
2003;108:319324.
33. Bing R, Cavalcante JL, Everett RJ, Clavel MA, Newby DE, Dweck MR. Imaging and impact of myocardial fibrosis in aortic stenosis. JACC Cardiovasc Imaging
2019;12:283296.
34. American College of Cardiology Foundation Task Force on Expert Consensus
D, Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, Friedrich MG, Ho
VB, Jerosch-Herold M, Kramer CM, Manning WJ, Patel M, Pohost GM, Stillman
AE, White RD, Woodard PK., ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American
College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am
Coll Cardiol 2010;55:26142662.
35. Cueff C , Serfaty JM, Cimadevilla C, Laissy JP, Himbert D, Tubach F, Duval X,
Iung B, Enriquez-Sarano M, Vahanian A, Messika-Zeitoun D. Measurement of aortic valve calcification using multislice computed tomography: correlation with haemodynamic severity of aortic stenosis and clinical implication for patients with low ejection fraction. Heart 2011;97:721726.
36. Clavel MA, Messika-Zeitoun D, Pibarot P, Aggarwal SR, Malouf J, Araoz PA,
Michelena HI, Cueff C, Larose E, Capoulade R, Vahanian A, Enriquez-Sarano M.
The complex nature of discordant severe calcified aortic valve disease grading:
new insights from combined Doppler echocardiographic and computed tomographic study. J Am Coll Cardiol 2013;62:23292338.
37. Pibarot P, Magne J, Leipsic J, Cote N, Blanke P, Thourani VH, Hahn R. Imaging for predicting and assessing prosthesis-patient mismatch after aortic valve replacement. JACC Cardiovasc Imaging 2019;12:149162.
38. Pulerwitz TC, Khalique OK, Leb J, Hahn RT, Nazif TM, Leon MB, George I, Vahl
TP, D’Souza B, Bapat VN, Dumeer S, Kodali SK, Einstein AJ. Optimizing cardiac
CT protocols for comprehensive acquisition prior to percutaneous MV and TV
repair/replacement. JACC Cardiovasc Imaging 2020;13:836850.
39. San S, Ravis E, Tessonier L, Philip M, Cammilleri S, Lavagna F, Norscini G,
Arregle F, Martel H, Oliver L, Torras O, Renard S, Ambrosi P, Camoin L, Casalta
AC, Hubert S, Casalta JP, Gouriet F, Riberi A, Avierinos JF, Lepidi H, Collart F,
Raoult D, Drancourt M, Habib G. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in infective endocarditis. J
Am Coll Cardiol 2019;74:10311040.
40. Habib G, Erba PA, Iung B, Donal E, Cosyns B, Laroche C, Popescu BA,
Prendergast B, Tornos P, Sadeghpour A, Oliver L, Vaskelyte JJ, Sow R, Axler O,
Maggioni AP, Lancellotti P, EURO-ENDO Investigators. Clinical presentation,
aetiology and outcome of infective endocarditis. Results of the ESC-EORP
EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. Eur Heart J 2019;40:32223232.
41. Clavel MA, Tribouilloy C, Vanoverschelde JL, Pizarro R, Suri RM, Szymanski C,
Lazam S, Oberti P, Michelena HI, Jaffe A, Enriquez-Sarano M. Association of Btype natriuretic peptide with survival in patients with degenerative mitral regurgitation. J Am Coll Cardiol 2016;68:12971307.
42. Lindman BR, Clavel MA, Abu-Alhayja’a R, Cote N, Dagenais F, Novak E, Voisine
P, Poulin A, Arsenault BJ, Desmeules P, Dahou A, Taster L, Aldahoun K, Bosse Y,
Mathieu P, Pibarot P. Multimarker approach to identify patients with higher mortality and rehospitalization rate after surgical aortic valve replacement for aortic stenosis. JACC Cardiovasc Interv 2018;11:21722181.
43. Tastet L, Tribouilloy C, Marechaux S, Vollema EM, Delgado V, Salaun E, Shen M,
Capoulade R, Clavel MA, Arsenault M, Bedard E, Bernier M, Beaudoin J, Narula J,
Lancellotti P, Bax JJ, Genereux P, Pibarot P. Staging cardiac damage in patients with asymptomatic aortic valve stenosis. J Am Coll Cardiol 2019;74:550563.
44. Genereux P, Pibarot P, Redfors B, Mack MJ, Makkar RR, Jaber WA, Svensson LG,
Kapadia S, Tuzcu EM, Thourani VH, Babaliaros V, Herrmann HC, Szeto WY,
Cohen DJ, Lindman BR, McAndrew T, Alu MC, Douglas PS, Hahn RT, Kodali SK,
Smith CR, Miller DC, Webb JG, Leon MB. Staging classification of aortic stenosis based on the extent of cardiac damage. Eur Heart J 2017;38:33513358.
45. Authors/Task Force m, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk
V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J,
Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M,
Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A.
2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC)
and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous
Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:25412619.
46. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C,
Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T,
Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J,
Muneretto C, Valgimigli M, Achenbach S, Bax JJ, ESC Scientific Document Group.
47. Scarsini R, Pesarini G, Zivelonghi C, Piccoli A, Ferrero V, Lunardi M, Gottin L,
Zanetti C, Faggian G, Ribichini F. Physiologic evaluation of coronary lesions using instantaneous wave-free ratio (iFR) in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation.
EuroIntervention
2018;13:15121519.
48. Scarsini R, Pesarini G, Zivelonghi C, Piccoli A, Ferrero V, Lunardi M, Barbierato
M, Caprioglio F, Vassanelli C, Ribichini F. Coronary physiology in patients with severe aortic stenosis: comparison between fractional flow reserve and instantaneous wave-free ratio. Int J Cardiol 2017;243:4046.
49. Osnabrugge RL, Speir AM, Head SJ, Fonner CE, Fonner E, Kappetein AP, Rich JB.
Performance of EuroSCORE II in a large US database: implications for
ESC/EACTS Guidelines
616


<!-- PAGE 57 -->

### Page 57

.............................................................................................................................................................................
transcatheter aortic valve implantation. Eur J Cardiothorac Surg 2014;46:400408;
discussion 408.
50. Barili F, Pacini D, Capo A, Rasovic O, Grossi C, Alamanni F, Di Bartolomeo R
Parolari A. Does EuroSCORE II perform better than its original versions? A multicentre validation study. Eur Heart J 2013;34:2229.
51. Provenchere S, Chevalier A, Ghodbane W, Bouleti C, Montravers P, Longrois D,
Iung B. Is the EuroSCORE II reliable to estimate operative mortality among octogenarians? PLoS One 2017;12:e0187056.
52. Iung B, Laouenan C, Himbert D, Eltchaninoff H, Chevreul K, Donzeau-Gouge P,
Fajadet J, Leprince P, Leguerrier A, Lievre M, Prat A, Teiger E, Laskar M,
Vahanian A, Gilard M, FRANCE 2 Investigators. Predictive factors of early mortality after transcatheter aortic valve implantation: individual risk assessment using a simple score. Heart 2014;100:10161023.
53. Edwards FH, Cohen DJ, O’Brien SM, Peterson ED, Mack MJ, Shahian DM,
Grover FL, Tuzcu EM, Thourani VH, Carroll J, Brennan JM, Brindis RG, Rumsfeld
J, Holmes DR, Jr., Steering Committee of the Society of Thoracic Surgeons/
American College of Cardiology Transcatheter Valve Therapy R. Development and validation of a risk prediction model for in-hospital mortality after transcatheter aortic valve replacement. JAMA Cardiol 2016;1:4652.
54. Arnold SV, Reynolds MR, Lei Y, Magnuson EA, Kirtane AJ, Kodali SK, Zajarias A,
Thourani VH, Green P, Rodes-Cabau J, Beohar N, Mack MJ, Leon MB, Cohen DJ,
PARTNER Investigators. Predictors of poor outcomes after transcatheter aortic valve replacement:
results from the
PARTNER
(Placement of
Aortic
Transcatheter Valve) trial. Circulation 2014;129:26822690.
55. Afilalo J. The Clinical Frailty Scale: Upgrade your eyeball test. Circulation
2017;135:20252027.
56. Kundi H, Popma JJ, Reynolds MR, Strom JB, Pinto DS, Valsdottir LR, Shen C,
Choi E, Yeh RW. Frailty and related outcomes in patients undergoing transcatheter valve therapies in a nationwide cohort. Eur Heart J 2019;40:22312239.
57. Hosler QP, Maltagliati AJ, Shi SM, Afilalo J, Popma JJ, Khabbaz KR, Laham RJ,
Guibone K, Kim DH. A practical two-stage frailty assessment for older adults undergoing aortic valve replacement. J Am Geriatr Soc 2019;67:20312037.
58. Dent E, Martin FC, Bergman H, Woo J, Romero-Ortuno R, Walston JD.
Management of frailty: opportunities, challenges, and future directions. Lancet
2019;394:13761386.
59. Katz S. Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living. J Am Geriatr Soc 1983;31:721727.
60. Afilalo J, Lauck S, Kim DH, Lefevre T, Piazza N, Lachapelle K, Martucci G, Lamy
A, Labinaz M, Peterson MD, Arora RC, Noiseux N, Rassi A, Palacios IF,
Genereux P, Lindman BR, Asgar AW, Kim CA, Trnkus A, Morais JA, Langlois Y,
Rudski LG, Morin JF, Popma JJ, Webb JG, Perrault LP. Frailty in older adults undergoing aortic valve replacement: the FRAILTY-AVR study. J Am Coll Cardiol
2017;70:689700.
61. Goldfarb M, Lauck S, Webb JG, Asgar AW, Perrault LP, Piazza N, Martucci G,
Lachapelle K, Noiseux N, Kim DH, Popma JJ, Lefevre T, Labinaz M, Lamy A,
Peterson MD, Arora RC, Morais JA, Morin JF, Rudski LG, Afilalo J. Malnutrition and mortality in frail and non-frail older adults undergoing aortic valve replacement. Circulation 2018;138:22022211.
62. Yanagisawa R, Tanaka M, Yashima F, Arai T, Kohno T, Shimizu H, Fukuda K,
Naganuma T, Mizutani K, Araki M, Tada N, Yamanaka F, Shirai S, Tabata M,
Ueno H, Takagi K, Higashimori A, Watanabe Y, Yamamoto M, Hayashida K.
Frequency and consequences of cognitive impairment in patients underwent transcatheter aortic valve implantation. Am J Cardiol 2018;122:844850.
63. Puri R, Iung B, Cohen DJ, Rodes-Cabau J. TAVI or no TAVI: identifying patients unlikely to benefit from transcatheter aortic valve implantation. Eur Heart J
2016;37:22172225.
64. Gunter RL, Kilgo P, Guyton RA, Chen EP, Puskas JD, Cooper WA, Halkos ME,
Lattouf OM, Babaliaros V, Myung R, Leshnower B, Thourani VH. Impact of preoperative chronic lung disease on survival after surgical aortic valve replacement.
Ann Thorac Surg 2013;96:13221328.
65. Allende R, Webb JG, Munoz-Garcia AJ, de Jaegere P, Tamburino C, Dager AE,
Cheema A, Serra V, Amat-Santos I, Velianou JL, Barbanti M, Dvir D, AlonsoBriales JH, Nuis RJ, Faqiri E, Imme S, Benitez LM, Cucalon AM, Al Lawati H,
Garcia del Blanco B, Lopez J, Natarajan MK, DeLarochelliere R, Urena M, Ribeiro
HB, Dumont E, Nombela-Franco L, Rodes-Cabau J. Advanced chronic kidney disease in patients undergoing transcatheter aortic valve implantation: insights on clinical outcomes and prognostic markers from a large cohort of patients. Eur
Heart J 2014;35:26852696.
66. Tirado-Conte G, Rodes-Cabau J, Rodriguez-Olivares R, Barbanti M, Lhermusier
T, Amat-Santos I, Toggweiler S, Cheema AN, Munoz-Garcia AJ, Serra V,
Giordana F, Veiga G, Jimenez-Quevedo P, Campelo-Parada F, Loretz L, Todaro
D, Del Trigo M, Hernandez-Garcia JM, Garcia Del Blanco B, Bruno F, de la
Torre Hernandez JM, Stella P, Tamburino C, Macaya C, Nombela-Franco L.
Clinical outcomes and prognosis markers of patients with liver disease undergoing transcatheter aortic valve replacement: a propensity score-matched analysis. Circ Cardiovasc Interv 2018;11:e005727.
67. Abramowitz Y, Kazuno Y, Chakravarty T, Kawamori H, Maeno Y, Anderson D,
Allison Z, Mangat G, Cheng W, Gopal A, Jilaihawi H, Mack MJ, Makkar RR.
Concomitant mitral annular calcification and severe aortic stenosis: prevalence,
characteristics and outcome following transcatheter aortic valve replacement.
Eur Heart J 2017;38:11941203.
68. Lindman BR, Arnold SV, Bagur R, Clarke L, Coylewright M, Evans F, Hung J,
Lauck SB, Peschin S, Sachdev V, Tate LM, Wasfy JH, Otto CM. Priorities for patient-centered research in valvular heart disease: a report from the National
Heart,
Lung,
and
Blood
Institute
Working
Group.
J
Am
Heart
Assoc
2020;9:e015975.
69. Hejjaji V, Cohen DJ, Carroll JD, Li Z, Manandhar P, Vemulapalli S, Nelson AJ,
Malik AO, Mack MJ, Spertus JA, Arnold SV. Practical application of patientreported health status measures for transcatheter valve therapies: insights from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter
Valve Therapies Registry. Circ Cardiovasc Qual Outcomes 2021;14:e007187.
70. Steiner JM, Cooper S, Kirkpatrick JN. Palliative care in end-stage valvular heart disease. Heart 2017;103:12331237.
71. Timmis A, Gale CP, Flather M, Maniadakis N, Vardas P. Cardiovascular disease statistics from the European atlas: inequalities between high- and middle-income member countries of the ESC. Eur Heart J Qual Care Clin Outcomes 2018;4:13.
72. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U,
Byrne RA, Collet JP, Falk V, Head SJ, Juni P, Kastrati A, Koller A, Kristensen SD,
Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S,
Yadav R, Zembala MO, ESC Scientific Document Group. 2018 ESC/EACTS
Guidelines on myocardial revascularization. Eur Heart J 2019;40:87165.
73. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman
MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser
U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR,
Tokgozoglu L, Wiklund O, ESC Scientific Document Group. 2019 ESC/EAS
Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111188.
74. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C,
Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM,
La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN,
Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL, ESC Scientific
Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for
Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC).
Developed with the special contribution of the European Heart Rhythm
Association (EHRA) of the ESC. Eur Heart J 2021;42:373498.
75. Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens SR,
Lokhnygina Y, Patel MR, Halperin JL, Singer DE, Hankey GJ, Hacke W, Becker RC,
Nessel CC, Mahaffey KW, Fox KA, Califf RM, Committee RAS, Investigators.
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J 2014;35:33773385.
76. Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, Pais P, Erol C,
Diaz R, Bahit MC, Bartunek J, De Caterina R, Goto S, Ruzyllo W, Zhu J, Granger
CB, Alexander JH. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)
trial. Circulation 2015;132:624632.
77. Ezekowitz MD, Nagarakanti R, Noack H, Brueckmann M, Litherland C, Jacobs M,
Clemens A, Reilly PA, Connolly SJ, Yusuf S, Wallentin L. Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: the
RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy).
Circulation 2016;134:589598.
78. De Caterina R, Renda G, Carnicelli AP, Nordio F, Trevisan M, Mercuri MF, Ruff
CT, Antman EM, Braunwald E, Giugliano RP. Valvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. J Am Coll Cardiol
2017;69:13721382.
79. Rankin JS, Grau-Sepulveda MV, Ad N, Damiano RJ, Jr., Gillinov AM, Brennan JM,
McCarthy PM, Thourani VH, Jacobs JP, Shahian DM, Badhwar V. Associations between surgical ablation and operative mortality after mitral valve procedures.
Ann Thorac Surg 2018;105:17901796.
80. Tsai YC, Phan K, Munkholm-Larsen S, Tian DH, La Meir M, Yan TD. Surgical left atrial appendage occlusion during cardiac surgery for patients with atrial fibrillation: a meta-analysis. Eur J Cardiothorac Surg 2015;47:847854.
81. Martin Gutierrez E, Castano M, Gualis J, Martinez-Comendador JM, Maiorano P,
Castillo L, Laguna G. Beneficial effect of left atrial appendage closure during cardiac surgery: a meta-analysis of 280 585 patients. Eur J Cardiothorac Surg
2020;57:252262.
82. Whitlock RP, Belley-Cote EP, Paparella D, Healey JS, Brady K, Sharma M, Reents
W, Budera P, Baddour AJ, Fila P, Devereaux PJ, Bogachev-Prokophiev A, Boening
A, Teoh KHT, Tagarakis GI, Slaughter MS, Royse AG, McGuinness S, Alings M,
ESC/EACTS Guidelines
617


<!-- PAGE 58 -->

### Page 58

.............................................................................................................................................................................
Punjabi PP, Mazer CD, Folkeringa RJ, Colli A, Avezum A, Nakamya J,
Balasubramanian K, Vincent J, Voisine P, Lamy A, Yusuf S, Connolly SJ, LAAOS III
Investigators. Left atrial appendage occlusion during cardiac surgery to prevent stroke. N Engl J Med 2021;384:20812091.
83. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz
MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM.
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet
2014;383:955962.
84. Wang KL, Lip GY, Lin SJ, Chiang CE. Non-vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation:
meta-analysis. Stroke 2015;46:25552561.
85. Badhwar V, Rankin JS, Ad N, Grau-Sepulveda M, Damiano RJ, Gillinov AM,
McCarthy PM, Thourani VH, Suri RM, Jacobs JP, Cox JL. Surgical ablation of atrial fibrillation in the United States: trends and propensity matched outcomes. Ann
Thorac Surg 2017;104:493500.
86. Gillinov AM, Gelijns AC, Parides MK, DeRose JJ, Jr., Moskowitz AJ, Voisine P,
Ailawadi G, Bouchard D, Smith PK, Mack MJ, Acker MA, Mullen JC, Rose EA,
Chang HL, Puskas JD, Couderc JP, Gardner TJ, Varghese R, Horvath KA, Bolling
SF, Michler RE, Geller NL, Ascheim DD, Miller MA, Bagiella E, Moquete EG,
Williams P, Taddei-Peters WC, O’Gara PT, Blackstone EH, Argenziano M,
Investigators C. Surgical ablation of atrial fibrillation during mitral-valve surgery.
N Engl J Med 2015;372:13991409.
87. Huffman MD, Karmali KN, Berendsen MA, Andrei AC, Kruse J, McCarthy PM,
Malaisrie SC. Concomitant atrial fibrillation surgery for people undergoing cardiac surgery. Cochrane Database Syst Rev 2016:CD011814.
88. Wang H, Han J, Wang Z, Yin Z, Liu Z, Jin Y, Han H. A prospective randomized trial of the cut-and-sew Maze procedure in patients undergoing surgery for rheumatic mitral valve disease. J Thorac Cardiovasc Surg 2018;155:608617.
89. Lawrance CP, Henn MC, Miller JR, Sinn LA, Schuessler RB, Maniar HS, Damiano
RJ, Jr. A minimally invasive Cox maze IV procedure is as effective as sternotomy while decreasing major morbidity and hospital stay. J Thorac Cardiovasc Surg
2014;148:955961.
90. Weimar T, Schena S, Bailey MS, Maniar HS, Schuessler RB, Cox JL, Damiano RJ,
Jr. The Cox-Maze procedure for lone atrial fibrillation: a single-center experience over 2 decades. Circ Arrhythm Electrophysiol 2012;5:814.
91. Karki P, Uranw S, Bastola S, Mahato R, Shrestha NR, Sherpa K, Dhungana S,
Odutayo A, Gurung K, Pandey N, Agrawal K, Shah P, Rothenbuhler M, Juni P,
Pilgrim T. Effectiveness of systematic echocardiographic screening for rheumatic heart disease in Nepalese schoolchildren: a cluster randomized clinical trial.
JAMA Cardiol 2021;6:420426.
92. Gerber MA, Baltimore RS, Eaton CB, Gewitz M, Rowley AH, Shulman ST,
Taubert KA. Prevention of rheumatic fever and diagnosis and treatment of acute
Streptococcal pharyngitis: a scientific statement from the American Heart
Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary
Council on
Functional
Genomics and
Translational
Biology,
and the
Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2009;119:15411551.
93. Remenyi B, Carapetis J, Wyber R, Taubert K, Mayosi BM, World Heart
Federation. Position statement of the World Heart Federation on the prevention and control of rheumatic heart disease. Nat Rev Cardiol 2013;10:284292.
94. Watkins DA, Beaton AZ, Carapetis JR, Karthikeyan G, Mayosi BM, Wyber R,
Yacoub MH, Zuhlke LJ. Rheumatic heart disease worldwide: JACC Scientific
Expert Panel. J Am Coll Cardiol 2018;72:13971416.
95. Kumar RK, Antunes MJ, Beaton A, Mirabel M, Nkomo VT, Okello E, Regmi PR,
Remenyi B, Sliwa-Hahnle K, Zuhlke LJ, Sable C, American Heart Association
Council on Lifelong Congenital Heart Disease and Heart Health in the Young;
Council on Cardiovascular and Stroke Nursing; and Council on Clinical
Cardiology. Contemporary diagnosis and management of rheumatic heart disease: implications for closing the gap: a scientific statement from the American
Heart Association. Circulation 2020;142:e337e357.
96. le Polain de Waroux JB, Pouleur AC, Goffinet C, Vancraeynest D, Van Dyck M,
Robert A, Gerber BL, Pasquet A, El Khoury G, Vanoverschelde JL. Functional anatomy of aortic regurgitation: accuracy, prediction of surgical repairability, and outcome implications of transesophageal echocardiography. Circulation 2007;116:I264269.
97. Lansac E, Di Centa I, Raoux F, Al Attar N, Acar C, Joudinaud T, Raffoul R. A
lesional classification to standardize surgical management of aortic insufficiency towards valve repair. Eur J Cardiothorac Surg 2008;33:872878; discussion 878-880.
98. Lancellotti P, Tribouilloy C, Hagendorff A, Moura L, Popescu BA, Agricola E,
Monin JL, Pierard LA, Badano L, Zamorano JL, European Association of
Echocardiography. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 1: aortic and pulmonary regurgitation (native valve disease). Eur J Echocardiogr 2010;11:223244.
99. Alashi A, Khullar T, Mentias A, Gillinov AM, Roselli EE, Svensson LG, Popovic
ZB, Griffin BP, Desai MY. Long-term outcomes after aortic valve surgery in patients with asymptomatic chronic aortic regurgitation and preserved LVEF:
impact of baseline and follow-up global longitudinal strain. JACC Cardiovasc
Imaging 2020;13:1221.
100. Goldstein SA, Evangelista A, Abbara S, Arai A, Asch FM, Badano LP, Bolen MA,
Connolly HM, Cuellar-Calabria H, Czerny M, Devereux RB, Erbel RA, Fattori
R, Isselbacher EM, Lindsay JM, McCulloch M, Michelena HI, Nienaber CA, Oh
JK, Pepi M, Taylor AJ, Weinsaft JW, Zamorano JL, Dietz H, Eagle K, Elefteriades
J, Jondeau G, Rousseau H, Schepens M. Multimodality imaging of diseases of the thoracic aorta in adults: from the American Society of Echocardiography and the European Association of Cardiovascular Imaging: endorsed by the Society of Cardiovascular Computed Tomography and Society for Cardiovascular
Magnetic Resonance. J Am Soc Echocardiogr 2015;28:119182.
101. Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H,
Evangelista A, Falk V, Frank H, Gaemperli O, Grabenwoger M, Haverich A, Iung
B, Manolis AJ, Meijboom F, Nienaber CA, Roffi M, Rousseau H, Sechtem U,
Sirnes PA, Allmen RS, Vrints CJ, ESC Committee for Practice Guidelines. 2014
ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic
Diseases of the
European
Society of
Cardiology
(ESC).
Eur
Heart
J
2014;35:28732926.
102. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf
FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH,
Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of
Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16:233270.
103. Freeman LA, Young PM, Foley TA, Williamson EE, Bruce CJ, Greason KL. CT
and MRI assessment of the aortic root and ascending aorta. AJR Am J Roentgenol
2013;200:W581592.
104. Amsallem M, Ou P, Milleron O, Henry-Feugeas MC, Detaint D, Arnoult F,
Vahanian A, Jondeau G. Comparative assessment of ascending aortic aneurysms in Marfan patients using ECG-gated computerized tomographic angiography versus trans-thoracic echocardiography. Int J Cardiol 2015;184:2227.
105. Chaliki HP, Mohty D, Avierinos JF, Scott CG, Schaff HV, Tajik AJ, EnriquezSarano M. Outcomes after aortic valve replacement in patients with severe aortic regurgitation and markedly reduced left ventricular function. Circulation
2002;106:26872693.
106. Kaneko T, Ejiofor JI, Neely RC, McGurk S, Ivkovic V, Stevenson LW, Leacche
M, Cohn LH. Aortic regurgitation with markedly reduced left ventricular function is not a contraindication for aortic valve replacement. Ann Thorac Surg
2016;102:4147.
107. Tornos P, Sambola A, Permanyer-Miralda G, Evangelista A, Gomez Z, SolerSoler J. Long-term outcome of surgically treated aortic regurgitation: influence of guideline adherence toward early surgery.
J
Am
Coll
Cardiol
2006;47:10121017.
108. Dujardin KS, Enriquez-Sarano M, Schaff HV, Bailey KR, Seward JB, Tajik AJ.
Mortality and morbidity of aortic regurgitation in clinical practice. A long-term follow-up study. Circulation 1999;99:18511857.
109. Klodas E, Enriquez-Sarano M, Tajik AJ, Mullany CJ, Bailey KR, Seward JB.
Optimizing timing of surgical correction in patients with severe aortic regurgitation: role of symptoms. J Am Coll Cardiol 1997;30:746752.
110. Tribouilloy CM, Enriquez-Sarano M, Schaff HV, Orszulak TA, Fett SL, Bailey KR,
Tajik AJ, Frye RL. Excess mortality due to coronary artery disease after valve surgery. Secular trends in valvular regurgitation and effect of internal mammary artery bypass. Circulation 1998;98:II108115.
111. Fiedler AG, Bhambhani V, Laikhter E, Picard MH, Wasfy MM, Tolis G,
Melnitchouk S, Sundt TM, Wasfy JH. Aortic valve replacement associated with survival in severe regurgitation and low ejection fraction. Heart 2018;104:835840.
112. Forman R, Firth BG, Barnard MS. Prognostic significance of preoperative left ventricular ejection fraction and valve lesion in patients with aortic valve replacement. Am J Cardiol 1980;45:11201125.
113. Bonow RO, Lakatos E, Maron BJ, Epstein SE. Serial long-term assessment of the natural history of asymptomatic patients with chronic aortic regurgitation and normal left ventricular systolic function. Circulation 1991;84:16251635.
114. Bhudia SK, McCarthy PM, Kumpati GS, Helou J, Hoercher KJ, Rajeswaran J,
Blackstone EH. Improved outcomes after aortic valve surgery for chronic aortic regurgitation with severe left ventricular dysfunction. J Am Coll Cardiol
2007;49:14651471.
115. Sambola A, Tornos P, Ferreira-Gonzalez I, Evangelista A. Prognostic value of preoperative indexed end-systolic left ventricle diameter in the outcome after surgery in patients with chronic aortic regurgitation.
Am
Heart
J
2008;155:11141120.
116. Yang LT, Michelena HI, Scott CG, Enriquez-Sarano M, Pislaru SV, Schaff HV,
Pellikka PA. Outcomes in chronic hemodynamically significant aortic regurgitation and limitations of current guidelines. J Am Coll Cardiol 2019;73:17411752.
ESC/EACTS Guidelines
618


<!-- PAGE 59 -->

### Page 59

.............................................................................................................................................................................
117. Mentias A, Feng K, Alashi A, Rodriguez LL, Gillinov AM, Johnston DR, Sabik JF,
Svensson LG, Grimm RA, Griffin BP, Desai MY. Long-term outcomes in patients with aortic regurgitation and preserved left ventricular ejection fraction. J Am
Coll Cardiol 2016;68:21442153.
118. de Meester C, Gerber BL, Vancraeynest D, Pouleur AC, Noirhomme P,
Pasquet A, de Kerchove L, El Khoury G, Vanoverschelde JL. Do guideline-based indications result in an outcome penalty for patients with severe aortic regurgitation? JACC Cardiovasc Imaging 2019;12:21262138.
119. Sawaya FJ, Deutsch MA, Seiffert M, Yoon SH, Codner P, Wickramarachchi U,
Latib A, Petronio AS, Rodes-Cabau J, Taramasso M, Spaziano M, Bosmans J,
Biasco L, Mylotte D, Savontaus M, Gheeraert P, Chan J, Jorgensen TH, Sievert
H, Mocetti M, Lefevre T, Maisano F, Mangieri A, Hildick-Smith D, Kornowski R,
Makkar R, Bleiziffer S, Sondergaard L, De Backer O. Safety and efficacy of transcatheter aortic valve replacement in the treatment of pure aortic regurgitation in native valves and failing surgical bioprostheses: results from an International
Registry Study. JACC Cardiovasc Interv 2017;10:10481056.
120. Yoon SH, Schmidt T, Bleiziffer S, Schofer N, Fiorina C, Munoz-Garcia AJ,
Yzeiraj E, Amat-Santos IJ, Tchetche D, Jung C, Fujita B, Mangieri A, Deutsch
MA, Ubben T, Deuschl F, Kuwata S, De Biase C, Williams T, Dhoble A, Kim
WK, Ferrari E, Barbanti M, Vollema EM, Miceli A, Giannini C, Attizzani GF,
Kong WKF, Gutierrez-Ibanes E, Jimenez Diaz VA, Wijeysundera HC, Kaneko H,
Chakravarty T, Makar M, Sievert H, Hengstenberg C, Prendergast BD, Vincent
F, Abdel-Wahab M, Nombela-Franco L, Silaschi M, Tarantini G, Butter C,
Ensminger SM, Hildick-Smith D, Petronio AS, Yin WH, De Marco F, Testa L,
Van Mieghem NM, Whisenant BK, Kuck KH, Colombo A, Kar S, Moris C,
Delgado V, Maisano F, Nietlispach F, Mack MJ, Schofer J, Schaefer U, Bax JJ,
Frerker C, Latib A, Makkar RR. Transcatheter aortic valve replacement in pure native aortic valve regurgitation. J Am Coll Cardiol 2017;70:27522763.
121. Jondeau G, Detaint D, Tubach F, Arnoult F, Milleron O, Raoux F, Delorme G,
Mimoun L, Krapf L, Hamroun D, Beroud C, Roy C, Vahanian A, Boileau C.
Aortic event rate in the Marfan population: a cohort study. Circulation
2012;125:226232.
122. Desai MY, Kalahasti V, Hutt Centeno E, Chen K, Alashi A, Rivas CG, Roselli EE,
Johnston DR, Griffin BP, Svensson LG. Adult patients with Marfan syndrome and ascending aortic surgery. J Am Coll Cardiol 2019;73:733734.
123. Borger MA, Preston M, Ivanov J, Fedak PW, Davierwala P, Armstrong S, David TE.
Should the ascending aorta be replaced more frequently in patients with bicuspid aortic valve disease? J Thorac Cardiovasc Surg 2004;128:677683.
124. Coady MA, Rizzo JA, Hammond GL, Mandapati D, Darr U, Kopf GS, Elefteriades
JA. What is the appropriate size criterion for resection of thoracic aortic aneurysms? J Thorac Cardiovasc Surg 1997;113:476491.
125. Davies RR, Goldstein LJ, Coady MA, Tittle SL, Rizzo JA, Kopf GS, Elefteriades
JA. Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg 2002;73:1727.
126. Oliver JM, Alonso-Gonzalez R, Gonzalez AE, Gallego P, Sanchez-Recalde A,
Cuesta E, Aroca A, Lopez-Sendon JL. Risk of aortic root or ascending aorta complications in patients with bicuspid aortic valve with and without coarctation of the aorta. Am J Cardiol 2009;104:10011006.
127. Michelena HI, Khanna AD, Mahoney D, Margaryan E, Topilsky Y, Suri RM, Eidem
B, Edwards WD, Sundt TM, 3rd, Enriquez-Sarano M. Incidence of aortic complications in patients with bicuspid aortic valves. JAMA 2011;306:11041112.
128. Tzemos N, Therrien J, Yip J, Thanassoulis G, Tremblay S, Jamorski MT, Webb
GD,
Siu
SC.
Outcomes in adults with bicuspid aortic valves.
JAMA
2008;300:13171325.
129. Elefteriades JA. Natural history of thoracic aortic aneurysms: indications for surgery,
and surgical versus nonsurgical risks.
Ann
Thorac
Surg
2002;74:S18771880.
130. Jondeau G, Ropers J, Regalado E, Braverman A, Evangelista A, Teixedo G, De
Backer J, Muino-Mosquera L, Naudion S, Zordan C, Morisaki T, Morisaki H,
Von Kodolitsch Y, Dupuis-Girod S, Morris SA, Jeremy R, Odent S, Ades LC,
Bakshi M, Holman K, LeMaire S, Milleron O, Langeois M, Spentchian M, Aubart
M, Boileau C, Pyeritz R, Milewicz DM, Montalcino Aortic Consortium.
International Registry of patients carrying TGFBR1 or TGFBR2 mutations:
results of the MAC (Montalcino Aortic Consortium). Circ Cardiovasc Genet
2016;9:548558.
131. Aicher D, Fries R, Rodionycheva S, Schmidt K, Langer F, Schafers HJ. Aortic valve repair leads to a low incidence of valve-related complications. Eur J
Cardiothorac Surg 2010;37:127132.
132. de Meester C, Pasquet A, Gerber BL, Vancraeynest D, Noirhomme P, El
Khoury G, Vanoverschelde JL. Valve repair improves the outcome of surgery for chronic severe aortic regurgitation: a propensity score analysis. J Thorac
Cardiovasc Surg 2014;148:19131920.
133. Klotz S, Stock S, Sievers HH, Diwoky M, Petersen M, Stierle U, Richardt D.
Survival and reoperation pattern after 20 years of experience with aortic valvesparing root replacement in patients with tricuspid and bicuspid valves. J Thorac
Cardiovasc Surg 2018;155:14031411 e1401.
134. Elbatarny M, Tam DY, Edelman JJ, Rocha RV, Chu MWA, Peterson MD, ElHamamsy I, Appoo JJ, Friedrich JO, Boodhwani M, Yanagawa B, Ouzounian M,
Canadian Thoracic Aortic Collaborative Investigators. Valve-sparing root replacement versus composite valve grafting in aortic root dilation: a meta-analysis. Ann Thorac Surg 2020;110:296306.
135. Leontyev S, Schamberger L, Davierwala PM, Von Aspern K, Etz C, Lehmann S,
Misfeld M, Borger MA. Early and late results after David vs Bentall procedure: a propensity matched analysis. Ann Thorac Surg 2020;110:120126.
136. Mastrobuoni S, de Kerchove L, Navarra E, Watremez C, Vancraeynest D,
Rubay J, Noirhomme P, El Khoury G. Long-term experience with valve-sparing reimplantation technique for the treatment of aortic aneurysm and aortic regurgitation. J Thorac Cardiovasc Surg 2019;158:1423.
137. Lansac E, Di Centa I, Sleilaty G, Lejeune S, Khelil N, Berrebi A, Diakov C,
Mankoubi L, Malergue MC, Noghin M, Zannis K, Salvi S, Dervanian P,
Debauchez M. Long-term results of external aortic ring annuloplasty for aortic valve repair. Eur J Cardiothorac Surg 2016;50:350360.
138. Mazine A, Rocha RV, El-Hamamsy I, Ouzounian M, Yanagawa B, Bhatt DL,
Verma S, Friedrich JO. Ross procedure vs mechanical aortic valve replacement in adults: a systematic review and meta-analysis. JAMA Cardiol 2018;3:978987.
139. Takkenberg JJ, Klieverik LM, Schoof PH, van Suylen RJ, van Herwerden LA,
Zondervan PE, Roos-Hesselink JW, Eijkemans MJ, Yacoub MH, Bogers AJ. The
Ross procedure:
a systematic review and meta-analysis.
Circulation
2009;119:222228.
140. Lee H, Cho YH, Sung K, Kim WS, Park KH, Jeong DS, Park PW, Lee YT.
Clinical outcomes of root reimplantation and Bentall procedure: propensity score matching analysis. Ann Thorac Surg 2018;106:539547.
141. Elder DH, Wei L, Szwejkowski BR, Libianto R, Nadir A, Pauriah M, Rekhraj S,
Lim TK, George J, Doney A, Pringle SD, Choy AM, Struthers AD, Lang CC.
The impact of renin-angiotensin-aldosterone system blockade on heart failure outcomes and mortality in patients identified to have aortic regurgitation: a large population cohort study. J Am Coll Cardiol 2011;58:20842091.
142. Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF,
de Boer RA, Drexel H, Ben Gal T, Hill L, Jaarsma T, Jankowska EA, Anker MS,
Lainscak M, Lewis BS, McDonagh T, Metra M, Milicic D, Mullens W, Piepoli MF,
Rosano G, Ruschitzka F, Volterrani M, Voors AA, Filippatos G, Coats AJS.
Clinical practice update on heart failure 2019: pharmacotherapy, procedures,
devices and patient management. An expert consensus meeting report of the
Heart Failure Association of the European Society of Cardiology. Eur J Heart
Fail 2019;21:11691186.
143. Lacro RV, Dietz HC, Sleeper LA, Yetman AT, Bradley TJ, Colan SD, Pearson
GD, Selamet Tierney ES, Levine JC, Atz AM, Benson DW, Braverman AC,
Chen S, De Backer J, Gelb BD, Grossfeld PD, Klein GL, Lai WW, Liou A, Loeys
BL, Markham LW, Olson AK, Paridon SM, Pemberton VL, Pierpont ME, Pyeritz
RE, Radojewski E, Roman MJ, Sharkey AM, Stylianou MP, Wechsler SB, Young
LT, Mahony L, Pediatric Heart Network Investigators. Atenolol versus losartan in children and young adults with Marfan’s syndrome. N Engl J Med
2014;371:20612071.
144. Forteza A, Evangelista A, Sanchez V, Teixido-Tura G, Sanz P, Gutierrez L,
Gracia T, Centeno J, Rodriguez-Palomares J, Rufilanchas JJ, Cortina J, FerreiraGonzalez I, Garcia-Dorado D. Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial. Eur Heart
J 2016;37:978985.
145. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC, 3rd. Angiotensin
II blockade and aortic-root dilation in Marfan’s syndrome. N Engl J Med
2008;358:27872795.
146. Milleron O, Arnoult F, Ropers J, Aegerter P, Detaint D, Delorme G, Attias D,
Tubach F, Dupuis-Girod S, Plauchu H, Barthelet M, Sassolas F, Pangaud N,
Naudion S, Thomas-Chabaneix J, Dulac Y, Edouard T, Wolf JE, Faivre L, Odent S,
Basquin A, Habib G, Collignon P, Boileau C, Jondeau G Marfan Sartan: a randomized, double-blind, placebo-controlled trial. Eur Heart J 2015;36:21602166.
147. Groenink M, den Hartog AW, Franken R, Radonic T, de Waard V,
Timmermans J, Scholte AJ, van den Berg MP, Spijkerboer AM, Marquering HA,
Zwinderman AH, Mulder BJ. Losartan reduces aortic dilatation rate in adults with
Marfan syndrome:
a randomized controlled trial.
Eur
Heart
J
2013;34:34913500.
148. Mullen M, Jin XY, Child A, Stuart AG, Dodd M, Aragon-Martin JA, Gaze D,
Kiotsekoglou A, Yuan L, Hu J, Foley C, Van Dyck L, Knight R, Clayton T, Swan
L, Thomson JDR, Erdem G, Crossman D, Flather M, AIMS Investigators.
Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial. Lancet 2020;394:22632270.
149. Pizarro R, Bazzino OO, Oberti PF, Falconi ML, Arias AM, Krauss JG, Cagide
AM. Prospective validation of the prognostic usefulness of B-type natriuretic peptide in asymptomatic patients with chronic severe aortic regurgitation. J Am
Coll Cardiol 2011;58:17051714.
150. Weisenberg D, Omelchenko A, Shapira Y, Vaturi M, Monakier D, Bental T,
Sagie A. Mid-term echocardiographic progression of patients with moderate
ESC/EACTS Guidelines
619


<!-- PAGE 60 -->

### Page 60

.............................................................................................................................................................................
aortic regurgitation: implications for aortic valve surgery. J Heart Valve Dis
2013;22:192194.
151. Budts W, Pieles GE, Roos-Hesselink JW, Sanz de la Garza M, D’Ascenzi F,
Giannakoulas G, Muller J, Oberhoffer R, Ehringer-Schetitska D, Herceg-Cavrak
V, Gabriel H, Corrado D, van Buuren F, Niebauer J, Borjesson M, Caselli S,
Fritsch P, Pelliccia A, Heidbuchel H, Sharma S, Stuart AG, Papadakis M.
Recommendations for participation in competitive sport in adolescent and adult athletes with Congenital Heart Disease (CHD): position statement of the
Sports Cardiology & Exercise Section of the European Association of
Preventive Cardiology (EAPC), the European Society of Cardiology (ESC)
Working Group on Adult Congenital Heart Disease and the Sports Cardiology,
Physical Activity and Prevention Working Group of the Association for
European
Paediatric and
Congenital
Cardiology
(AEPC).
Eur
Heart
J
2020;41:41914199.
152. d’Arcy JL, Coffey S, Loudon MA, Kennedy A, Pearson-Stuttard J, Birks J,
Frangou E, Farmer AJ, Mant D, Wilson J, Myerson SG, Prendergast BD. Largescale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort
Study. Eur Heart J 2016;37:35153522.
153. Prihadi EA, Vollema EM, Ng ACT, Ajmone Marsan N, Bax JJ, Delgado V.
Determinants and prognostic implications of left ventricular mechanical dispersion in aortic stenosis. Eur Heart J Cardiovasc Imaging 2019;20:740748.
154. Ilardi F, Marchetta S, Martinez C, Sprynger M, Ancion A, Manganaro R,
Sugimoto T, Tsugu T, Postolache A, Piette C, Cicenia M, Esposito G, Galderisi
M, Oury C, Dulgheru R, Lancellotti P. Impact of aortic stenosis on layer-specific longitudinal strain: relationship with symptoms and outcome. Eur Heart J
Cardiovasc Imaging 2020;21:408416.
155. Rusinaru D, Bohbot Y, Djelaili F, Delpierre Q, Altes A, Serbout S, Kubala M,
Marechaux S, Tribouilloy C. Normative reference values of cardiac output by pulsed-wave
Doppler echocardiography in adults.
Am
J
Cardiol
2021;140:128133.
156. Rusinaru D, Malaquin D, Marechaux S, Debry N, Tribouilloy C. Relation of dimensionless index to long-term outcome in aortic stenosis with preserved
LVEF. JACC Cardiovasc Imaging 2015;8:766775.
157. Hachicha Z, Dumesnil JG, Bogaty P, Pibarot P. Paradoxical low-flow, low-gradient severe aortic stenosis despite preserved ejection fraction is associated with higher afterload and reduced survival. Circulation 2007;115:28562864.
158. Rusinaru D, Bohbot Y, Ringle A, Marechaux S, Diouf M, Tribouilloy C. Impact of low stroke volume on mortality in patients with severe aortic stenosis and preserved left ventricular ejection fraction. Eur Heart J 2018;39:19921999.
159. Guzzetti E, Poulin A, Annabi MS, Zhang B, Kalavrouziotis D, Couture C,
Dagenais F, Pibarot P, Clavel MA. Transvalvular flow, sex, and survival after valve replacement surgery in patients with severe aortic stenosis. J Am Coll
Cardiol 2020;75:18971909.
160. Annabi MS, Touboul E, Dahou A, Burwash IG, Bergler-Klein J, Enriquez-Sarano
M, Orwat S, Baumgartner H, Mascherbauer J, Mundigler G, Cavalcante JL,
Larose E, Pibarot P, Clavel MA. Dobutamine stress echocardiography for management of low-flow,
low-gradient aortic stenosis.
J
Am
Coll
Cardiol
2018;71:475485.
161. Ribeiro HB, Lerakis S, Gilard M, Cavalcante JL, Makkar R, Herrmann HC,
Windecker S, Enriquez-Sarano M, Cheema AN, Nombela-Franco L, AmatSantos I, Munoz-Garcia AJ, Garcia Del Blanco B, Zajarias A, Lisko JC, Hayek S,
Babaliaros V, Le Ven F, Gleason TG, Chakravarty T, Szeto WY, Clavel MA, de
Agustin A, Serra V, Schindler JT, Dahou A, Puri R, Pelletier-Beaumont E, Cote
M, Pibarot P, Rodes-Cabau J. Transcatheter aortic valve replacement in patients with low-flow, low-gradient aortic stenosis: the TOPAS-TAVI Registry. J Am
Coll Cardiol 2018;71:12971308.
162. Clavel MA, Dumesnil JG, Capoulade R, Mathieu P, Senechal M, Pibarot P.
Outcome of patients with aortic stenosis, small valve area, and low-flow, lowgradient despite preserved left ventricular ejection fraction. J Am Coll Cardiol
2012;60:12591267.
163. Clavel MA, Pibarot P, Messika-Zeitoun D, Capoulade R, Malouf J, Aggarval S,
Araoz PA, Michelena HI, Cueff C, Larose E, Miller JD, Vahanian A, EnriquezSarano M. Impact of aortic valve calcification, as measured by MDCT, on survival in patients with aortic stenosis: results of an international registry study. J
Am Coll Cardiol 2014;64:12021213.
164. Pawade T, Clavel MA, Tribouilloy C, Dreyfus J, Mathieu T, Tastet L, Renard C,
Gun M, Jenkins WSA, Macron L, Sechrist JW, Lacomis JM, Nguyen V, Galian
Gay L, Cuellar Calabria H, Ntalas I, Cartlidge TRG, Prendergast B, Rajani R,
Evangelista A, Cavalcante JL, Newby DE, Pibarot P, Messika Zeitoun D, Dweck
MR. Computed tomography aortic valve calcium scoring in patients with aortic stenosis. Circ Cardiovasc Imaging 2018;11:e007146.
165. Mehrotra P, Jansen K, Flynn AW, Tan TC, Elmariah S, Picard MH, Hung J.
Differential left ventricular remodelling and longitudinal function distinguishes low flow from normal-flow preserved ejection fraction low-gradient severe aortic stenosis. Eur Heart J 2013;34:19061914.
166. Tribouilloy C, Rusinaru D, Marechaux S, Castel AL, Debry N, Maizel J,
Mentaverri R, Kamel S, Slama M, Levy F. Low-gradient, low-flow severe aortic stenosis with preserved left ventricular ejection fraction: characteristics, outcome, and implications for surgery. J Am Coll Cardiol 2015;65:5566.
167. Jander N, Minners J, Holme I, Gerdts E, Boman K, Brudi P, Chambers JB,
Egstrup K, Kesaniemi YA, Malbecq W, Nienaber CA, Ray S, Rossebo A,
Pedersen TR, Skjaerpe T, Willenheimer R, Wachtell K, Neumann FJ, GohlkeBarwolf C. Outcome of patients with low-gradient “severe” aortic stenosis and preserved ejection fraction. Circulation 2011;123:887895.
168. Vollema EM, Sugimoto T, Shen M, Tastet L, Ng ACT, Abou R, Marsan NA,
Mertens B, Dulgheru R, Lancellotti P, Clavel MA, Pibarot P, Genereux P, Leon
MB, Delgado V, Bax JJ. Association of left ventricular global longitudinal strain with asymptomatic severe aortic stenosis: natural course and prognostic value.
JAMA Cardiol 2018;3:839847.
169. Zamorano JL, Badano LP, Bruce C, Chan KL, Goncalves A, Hahn RT, Keane
MG,
La
Canna
G,
Monaghan
MJ,
Nihoyannopoulos
P,
Silvestry
FE,
Vanoverschelde JL, Gillam LD. EAE/ASE recommendations for the use of echocardiography in new transcatheter interventions for valvular heart disease. Eur
Heart J 2011;32:21892214.
170. Bergler-Klein J, Klaar U, Heger M, Rosenhek R, Mundigler G, Gabriel H, Binder
T, Pacher R, Maurer G, Baumgartner H. Natriuretic peptides predict symptomfree survival and postoperative outcome in severe aortic stenosis. Circulation
2004;109:23022308.
171. Clavel MA, Malouf J, Michelena HI, Suri RM, Jaffe AS, Mahoney DW, EnriquezSarano M. B-type natriuretic peptide clinical activation in aortic stenosis: impact on long-term survival. J Am Coll Cardiol 2014;63:20162025.
172. Rafique AM, Biner S, Ray I, Forrester JS, Tolstrup K, Siegel RJ. Meta-analysis of prognostic value of stress testing in patients with asymptomatic severe aortic stenosis. Am J Cardiol 2009;104:972977.
173. Marechaux S, Hachicha Z, Bellouin A, Dumesnil JG, Meimoun P, Pasquet A,
Bergeron S, Arsenault M, Le Tourneau T, Ennezat PV, Pibarot P. Usefulness of exercise-stress echocardiography for risk stratification of true asymptomatic patients with aortic valve stenosis. Eur Heart J 2010;31:13901397.
174. Pawade T, Sheth T, Guzzetti E, Dweck MR, Clavel MA. Why and how to measure aortic valve calcification in patients with aortic stenosis. JACC Cardiovasc
Imaging 2019;12:18351848.
175. Nitsche C, Scully PR, Patel KP, Kammerlander AA, Koschutnik M, Dona C,
Wollenweber T, Ahmed N, Thornton GD, Kelion AD, Sabharwal N, Newton
JD, Ozkor M, Kennon S, Mullen M, Lloyd G, Fontana M, Hawkins PN, Pugliese
F, Menezes LJ, Moon JC, Mascherbauer J, Treibel TA. Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J Am Coll Cardiol
2021;77:128139.
176. Treibel TA, Lopez B, Gonzalez A, Menacho K, Schofield RS, Ravassa S, Fontana
M, White SK, DiSalvo C, Roberts N, Ashworth MT, Diez J, Moon JC.
Reappraising myocardial fibrosis in severe aortic stenosis: an invasive and noninvasive study in 133 patients. Eur Heart J 2018;39:699709.
177. Everett RJ, Tastet L, Clavel MA, Chin CWL, Capoulade R, Vassiliou VS,
Kwiecinski J, Gomez M, van Beek EJR, White AC, Prasad SK, Larose E, Tuck C,
Semple S, Newby DE, Pibarot P, Dweck MR. Progression of hypertrophy and myocardial fibrosis in aortic stenosis: a multicenter cardiac magnetic resonance study. Circ Cardiovasc Imaging 2018;11:e007451.
178. Musa TA, Treibel TA, Vassiliou VS, Captur G, Singh A, Chin C, Dobson LE, Pica
S, Loudon M, Malley T, Rigolli M, Foley JRJ, Bijsterveld P, Law GR, Dweck MR,
Myerson SG, McCann GP, Prasad SK, Moon JC, Greenwood JP. Myocardial scar and mortality in severe aortic stenosis. Circulation 2018;138:19351947.
179. Ternacle J, Krapf L, Mohty D, Magne J, Nguyen A, Galat A, Gallet R, Teiger E,
Cote N, Clavel MA, Tournoux F, Pibarot P, Damy T. Aortic stenosis and cardiac amyloidosis: JACC Review Topic of the Week. J Am Coll Cardiol
2019;74:26382651.
180. Tribouilloy C, Levy F, Rusinaru D, Gueret P, Petit-Eisenmann H, Baleynaud S,
Jobic Y, Adams C, Lelong B, Pasquet A, Chauvel C, Metz D, Quere JP, Monin JL.
Outcome after aortic valve replacement for low-flow/low-gradient aortic stenosis without contractile reserve on dobutamine stress echocardiography. J
Am Coll Cardiol 2009;53:18651873.
181. Fougeres E, Tribouilloy C, Monchi M, Petit-Eisenmann H, Baleynaud S, Pasquet
A, Chauvel C, Metz D, Adams C, Rusinaru D, Gueret P, Monin JL. Outcomes of pseudo-severe aortic stenosis under conservative treatment. Eur Heart J
2012;33:24262433.
182. Levy F, Laurent M, Monin JL, Maillet JM, Pasquet A, Le Tourneau T, PetitEisenmann H, Gori M, Jobic Y, Bauer F, Chauvel C, Leguerrier A, Tribouilloy C.
Aortic valve replacement for low-flow/low-gradient aortic stenosis operative risk stratification and long-term outcome: a European multicenter study. J Am
Coll Cardiol 2008;51:14661472.
183. Sato K, Sankaramangalam K, Kandregula K, Bullen JA, Kapadia SR, Krishnaswamy
A, Mick S, Rodriguez LL, Grimm RA, Menon V, Desai MY, Svensson LG, Griffin
BP, Popovic ZB. Contemporary outcomes in low-gradient aortic stenosis
ESC/EACTS Guidelines
620


<!-- PAGE 61 -->

### Page 61

.............................................................................................................................................................................
patients who underwent dobutamine stress echocardiography. J Am Heart Assoc
2019;8:e011168.
184. Maes F, Lerakis S, Barbosa Ribeiro H, Gilard M, Cavalcante JL, Makkar R,
Herrmann HC, Windecker S, Enriquez-Sarano M, Cheema AN, NombelaFranco L, Amat-Santos I, Munoz-Garcia AJ, Garcia Del Blanco B, Zajarias A,
Lisko JC, Hayek S, Babaliaros V, Le Ven F, Gleason TG, Chakravarty T, Szeto
W, Clavel MA, de Agustin A, Serra V, Schindler JT, Dahou A, Salah-Annabi M,
Pelletier-Beaumont E, Cote M, Puri R, Pibarot P, Rodes-Cabau J. Outcomes from transcatheter aortic valve replacement in patients with low-flow, low-gradient aortic stenosis and left ventricular ejection fraction less than 30%: a substudy from the TOPAS-TAVI Registry. JAMA Cardiol 2019;4:6470.
185. Chadha G, Bohbot Y, Rusinaru D, Marechaux S, Tribouilloy C. Outcome of normal-flow low-gradient severe aortic stenosis with preserved left ventricular ejection fraction: a propensity-matched study. J Am Heart Assoc 2019;8:e012301.
186. Das P, Rimington H, Chambers J. Exercise testing to stratify risk in aortic stenosis. Eur Heart J 2005;26:13091313.
187. Genereux P, Stone GW, O’Gara PT, Marquis-Gravel G, Redfors B, Giustino G,
Pibarot P, Bax JJ, Bonow RO, Leon MB. Natural history, diagnostic approaches,
and therapeutic strategies for patients with asymptomatic severe aortic stenosis. J Am Coll Cardiol 2016;67:22632288.
188. Kang DH, Park SJ, Lee SA, Lee S, Kim DH, Kim HK, Yun SC, Hong GR, Song
JM, Chung CH, Song JK, Lee JW, Park SW. Early surgery or conservative care for asymptomatic aortic stenosis. N Engl J Med 2020;382:111119.
189. Rosenhek R, Binder T, Porenta G, Lang I, Christ G, Schemper M, Maurer G,
Baumgartner H. Predictors of outcome in severe, asymptomatic aortic stenosis.
N Engl J Med 2000;343:611617.
190. Rosenhek R, Zilberszac R, Schemper M, Czerny M, Mundigler G, Graf S,
Bergler-Klein J, Grimm M, Gabriel H, Maurer G. Natural history of very severe aortic stenosis. Circulation 2010;121:151156.
191. Cioffi G, Faggiano P, Vizzardi E, Tarantini L, Cramariuc D, Gerdts E, de Simone
G. Prognostic effect of inappropriately high left ventricular mass in asymptomatic severe aortic stenosis. Heart 2011;97:301307.
192. Rusinaru D, Bohbot Y, Kowalski C, Ringle A, Marechaux S, Tribouilloy C. Left atrial volume and mortality in patients with aortic stenosis. J Am Heart Assoc
2017;6: e006615.
193. Dahl JS, Videbaek L, Poulsen MK, Rudbaek TR, Pellikka PA, Moller JE. Global strain in severe aortic valve stenosis: relation to clinical outcome after aortic valve replacement. Circ Cardiovasc Imaging 2012;5:613620.
194. Chin CW, Shah AS, McAllister DA, Joanna Cowell S, Alam S, Langrish JP,
Strachan FE, Hunter AL, Maria Choy A, Lang CC, Walker S, Boon NA, Newby
DE, Mills NL, Dweck MR. High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis. Eur Heart J 2014;35:23122321.
195. Koos R, Brandenburg V, Mahnken AH, Muhlenbruch G, Stanzel S, Gunther RW,
Floege J, Jahnen-Dechent W, Kelm M, Kuhl HP. Association of fetuin-A levels with the progression of aortic valve calcification in non-dialyzed patients. Eur
Heart J 2009;30:20542061.
196. Carroll JD, Mack MJ, Vemulapalli S, Herrmann HC, Gleason TG, Hanzel G,
Deeb GM, Thourani VH, Cohen DJ, Desai N, Kirtane AJ, Fitzgerald S,
Michaels J, Krohn C, Masoudi FA, Brindis RG, Bavaria JE. STS-ACC TVT
Registry of transcatheter aortic valve replacement.
J Am Coll Cardiol
2020;76:24922516.
197. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM,
Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard
AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN,
Wang D, Pocock S, PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl
J Med 2010;363:15971607.
198. Deeb GM, Reardon MJ, Chetcuti S, Patel HJ, Grossman PM, Yakubov SJ,
Kleiman NS, Coselli JS, Gleason TG, Lee JS, Hermiller JB, Jr., Heiser J, Merhi W,
Zorn GL, 3rd, Tadros P, Robinson N, Petrossian G, Hughes GC, Harrison JK,
Maini B, Mumtaz M, Conte J, Resar J, Aharonian V, Pfeffer T, Oh JK, Qiao H,
Adams DH, Popma JJ, CoreValve USCI. 3-Year outcomes in high-risk patients who underwent surgical or transcatheter aortic valve replacement. J Am Coll
Cardiol 2016;67:25652574.
199. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM,
Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babaliaros
V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ,
Anderson
WN,
Wang
D,
Pocock
SJ,
PARTNER
Trial
Investigators.
Transcatheter versus surgical aortic-valve replacement in high-risk patients. N
Engl J Med 2011;364:21872198.
200. Mack MJ, Leon MB, Smith CR, Miller DC, Moses JW, Tuzcu EM, Webb JG,
Douglas PS, Anderson WN, Blackstone EH, Kodali SK, Makkar RR, Fontana GP,
Kapadia S, Bavaria J, Hahn RT, Thourani VH, Babaliaros V, Pichard A, Herrmann
HC, Brown DL, Williams M, Akin J, Davidson MJ, Svensson LG, PARTNER 1 trial
Investigators. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis
(PARTNER 1): a randomised controlled trial. Lancet 2015;385:24772484.
201. Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, Gleason
TG, Buchbinder M, Hermiller J, Jr., Kleiman NS, Chetcuti S, Heiser J, Merhi W,
Zorn G, Tadros P, Robinson N, Petrossian G, Hughes GC, Harrison JK, Conte
J, Maini B, Mumtaz M, Chenoweth S, Oh JK, Investigators USCC. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med
2014;370:17901798.
202. Thyregod HG, Steinbruchel DA, Ihlemann N, Nissen H, Kjeldsen BJ, Petursson
P, Chang Y, Franzen OW, Engstrom T, Clemmensen P, Hansen PB, Andersen
LW, Olsen PS, Sondergaard L. Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the
All-Comers
NOTION
randomized clinical trial.
J
Am
Coll
Cardiol
2015;65:21842194.
203. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani
VH, Tuzcu EM, Miller DC, Herrmann HC, Doshi D, Cohen DJ, Pichard AD,
Kapadia S, Dewey T, Babaliaros V, Szeto WY, Williams MR, Kereiakes D,
Zajarias A, Greason KL, Whisenant BK, Hodson RW, Moses JW, Trento A,
Brown DL, Fearon WF, Pibarot P, Hahn RT, Jaber WA, Anderson WN, Alu
MC, Webb JG, PARTNER 2 Investigators. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016;374:16091620.
204. Thourani VH, Kodali S, Makkar RR, Herrmann HC, Williams M, Babaliaros V,
Smalling R, Lim S, Malaisrie SC, Kapadia S, Szeto WY, Greason KL, Kereiakes D,
Ailawadi G, Whisenant BK, Devireddy C, Leipsic J, Hahn RT, Pibarot P,
Weissman NJ, Jaber WA, Cohen DJ, Suri R, Tuzcu EM, Svensson LG, Webb JG,
Moses JW, Mack MJ, Miller DC, Smith CR, Alu MC, Parvataneni R, D’Agostino
RB, Jr., Leon MB. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet
2016;387:22182225.
205. Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Sondergaard L, Mumtaz
M, Adams DH, Deeb GM, Maini B, Gada H, Chetcuti S, Gleason T, Heiser J,
Lange R, Merhi W, Oh JK, Olsen PS, Piazza N, Williams M, Windecker S,
Yakubov SJ, Grube E, Makkar R, Lee JS, Conte J, Vang E, Nguyen H, Chang Y,
Mugglin AS, Serruys PW, Kappetein AP, SURTAVI Investigators. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J
Med 2017;376:13211331.
206. Makkar RR, Thourani VH, Mack MJ, Kodali SK, Kapadia S, Webb JG, Yoon SH,
Trento A, Svensson LG, Herrmann HC, Szeto WY, Miller DC, Satler L, Cohen
DJ, Dewey TM, Babaliaros V, Williams MR, Kereiakes DJ, Zajarias A, Greason
KL, Whisenant BK, Hodson RW, Brown DL, Fearon WF, Russo MJ, Pibarot P,
Hahn RT, Jaber WA, Rogers E, Xu K, Wheeler J, Alu MC, Smith CR, Leon MB,
Investigators P. Five-year outcomes of transcatheter or surgical aortic-valve replacement. N Engl J Med 2020;382:799809.
207. Thyregod HGH, Ihlemann N, Jorgensen TH, Nissen H, Kjeldsen BJ, Petursson P,
Chang Y, Franzen OW, Engstrom T, Clemmensen P, Hansen PB, Andersen LW,
Steinbruchel DA, Olsen PS, Sondergaard L. Five-year clinical and echocardiographic outcomes from the Nordic Aortic Valve Intervention (NOTION)
randomized clinical trial in lower surgical risk patients.
Circulation
2019;139:27142723.
208. Siontis GC, Praz F, Pilgrim T, Mavridis D, Verma S, Salanti G, Sondergaard L,
Juni P, Windecker S. Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of severe aortic stenosis: a meta-analysis of randomized trials. Eur Heart J 2016;37:35033512.
209. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, Kapadia SR,
Malaisrie SC, Cohen DJ, Pibarot P, Leipsic J, Hahn RT, Blanke P, Williams MR,
McCabe JM, Brown DL, Babaliaros V, Goldman S, Szeto WY, Genereux P,
Pershad A, Pocock SJ, Alu MC, Webb JG, Smith CR, PARTNER 3 Investigators.
Transcatheter aortic-valve replacement with a balloon-expandable valve in lowrisk patients. N Engl J Med 2019;380:16951705.
210. Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O’Hair D, Bajwa T,
Heiser JC, Merhi W, Kleiman NS, Askew J, Sorajja P, Rovin J, Chetcuti SJ,
Adams DH, Teirstein PS, Zorn GL, 3rd, Forrest JK, Tchetche D, Resar J,
Walton A, Piazza N, Ramlawi B, Robinson N, Petrossian G, Gleason TG, Oh JK,
Boulware MJ, Qiao H, Mugglin AS, Reardon MJ, Evolut Low Risk Trial
Investigators. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 2019;380:17061715.
211. Siontis GCM, Overtchouk P, Cahill TJ, Modine T, Prendergast B, Praz F, Pilgrim
T, Petrinic T, Nikolakopoulou A, Salanti G, Sondergaard L, Verma S, Juni P,
Windecker S. Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis. Eur Heart J 2019;40:31433153.
212. Leon MB, Mack MJ, Hahn RT, Thourani VH, Makkar R, Kodali SK, Alu MC,
Madhavan MV, Chau KH, Russo M, Kapadia SR, Malaisrie SC, Cohen DJ, Blanke
P, Leipsic JA, Williams MR, McCabe JM, Brown DL, Babaliaros V, Goldman S,
Herrmann HC, Szeto WY, Genereux P, Pershad A, Lu M, Webb JG, Smith CR,
Pibarot P, PARTNER 3 Investigators. Outcomes 2 years after transcatheter
ESC/EACTS Guidelines
621


<!-- PAGE 62 -->

### Page 62

.............................................................................................................................................................................
aortic valve replacement in patients at low surgical risk. J Am Coll Cardiol
2021;77:11491161.
213. Greason KL, Lahr BD, Stulak JM, Cha YM, Rea RF, Schaff HV, Dearani JA. Longterm mortality effect of early pacemaker implantation after surgical aortic valve replacement. Ann Thorac Surg 2017;104:12591264.
214. Auffret V, Puri R, Urena M, Chamandi C, Rodriguez-Gabella T, Philippon F,
Rodes-Cabau J. Conduction disturbances after transcatheter aortic valve replacement: current status and future perspectives. Circulation 2017;136:10491069.
215. Nazif TM, Chen S, George I, Dizon JM, Hahn RT, Crowley A, Alu MC,
Babaliaros V, Thourani VH, Herrmann HC, Smalling RW, Brown DL, Mack MJ,
Kapadia S, Makkar R, Webb JG, Leon MB, Kodali SK. New-onset left bundle branch block after transcatheter aortic valve replacement is associated with adverse long-term clinical outcomes in intermediate-risk patients: an analysis from the PARTNER II trial. Eur Heart J 2019;40:22182227.
216. Tam DY, Hughes A, Wijeysundera HC, Fremes SE. Cost-effectiveness of selfexpandable transcatheter aortic valves in intermediate-risk patients. Ann Thorac
Surg 2018;106:676683.
217. Baron SJ, Wang K, House JA, Magnuson EA, Reynolds MR, Makkar R, Herrmann
HC, Kodali S, Thourani VH, Kapadia S, Svensson L, Mack MJ, Brown DL, Russo
MJ, Smith CR, Webb J, Miller C, Leon MB, Cohen DJ. Cost-effectiveness of transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis at intermediate risk. Circulation 2019;139:877888.
218. Pilgrim T, Windecker S. Expansion of transcatheter aortic valve implantation:
new indications and socio-economic considerations.
Eur
Heart
J
2018;39:26432645.
219. Barbato E, Noc M, Baumbach A, Dudek D, Bunc M, Skalidis E, Banning A,
Legutko J, Witt N, Pan M, Tilsted HH, Nef H, Tarantini G, Kazakiewicz D,
Huculeci R, Cook S, Magdy A, Desmet W, Cayla G, Vinereanu D, Voskuil M,
Goktekin O, Vardas P, Timmis A, Haude M. Mapping interventional cardiology in
Europe:
the
European
Association of
Percutaneous
Cardiovascular
Interventions (EAPCI) Atlas Project. Eur Heart J 2020;41:25792588.
220. Johnston DR, Soltesz EG, Vakil N, Rajeswaran J, Roselli EE, Sabik JF, 3rd,
Smedira NG, Svensson LG, Lytle BW, Blackstone EH. Long-term durability of bioprosthetic aortic valves: implications from 12,569 implants. Ann Thorac Surg
2015;99:12391247.
221. Blackman DJ, Saraf S, MacCarthy PA, Myat A, Anderson SG, Malkin CJ,
Cunnington MS, Somers K, Brennan P, Manoharan G, Parker J, Aldalati O,
Brecker SJ, Dowling C, Hoole SP, Dorman S, Mullen M, Kennon S, Jerrum M,
Chandrala P, Roberts DH, Tay J, Doshi SN, Ludman PF, Fairbairn TA, Crowe J,
Levy RD, Banning AP, Ruparelia N, Spence MS, Hildick-Smith D. Long-term durability of transcatheter aortic valve prostheses.
J
Am
Coll
Cardiol
2019;73:537545.
222. Barbanti M, Costa G, Zappulla P, Todaro D, Picci A, Rapisarda G, Di Simone E,
Sicuso R, Buccheri S, Gulino S, Pilato G, La Spina K, D’Arrigo P, Valvo R,
Indelicato A, Giannazzo D, Imme S, Tamburino C, Patane M, Sgroi C, Giuffrida
A, Trovato D, Monte IP, Deste W, Capranzano P, Capodanno D, Tamburino
C. Incidence of long-term structural valve dysfunction and bioprosthetic valve failure after transcatheter aortic valve replacement.
J
Am
Heart
Assoc
2018;7:e008440.
223. Didier R, Eltchaninoff H, Donzeau-Gouge P, Chevreul K, Fajadet J, Leprince P,
Leguerrier A, Lievre M, Prat A, Teiger E, Lefevre T, Tchetche D, Carrie D,
Himbert D, Albat B, Cribier A, Sudre A, Blanchard D, Rioufol G, Collet F,
Houel R, Dos Santos P, Meneveau N, Ghostine S, Manigold T, Guyon P,
Cuisset T, Le Breton H, Delepine S, Favereau X, Souteyrand G, Ohlmann P,
Doisy V, Lognone T, Gommeaux A, Claudel JP, Bourlon F, Bertrand B, Iung B,
Gilard M. Five-year clinical outcome and valve durability after transcatheter aortic valve replacement in high-risk patients. Circulation 2018;138:25972607.
224. Deutsch MA, Erlebach M, Burri M, Hapfelmeier A, Witt OG, Ziegelmueller JA,
Wottke M, Ruge H, Krane M, Piazza N, Bleiziffer S, Lange R. Beyond the fiveyear horizon: long-term outcome of high-risk and inoperable patients undergoing TAVR with first-generation devices. EuroIntervention 2018;14:4149.
225. Pibarot P, Ternacle J, Jaber WA, Salaun E, Dahou A, Asch FM, Weissman NJ,
Rodriguez L, Xu K, Annabi MS, Guzzetti E, Beaudoin J, Bernier M, Leipsic J,
Blanke P, Clavel MA, Rogers E, Alu MC, Douglas PS, Makkar R, Miller DC,
Kapadia SR, Mack MJ, Webb JG, Kodali SK, Smith CR, Herrmann HC, Thourani
VH, Leon MB, Hahn RT, PARTNER 2 Investigators. Structural deterioration of transcatheter versus surgical aortic valve bioprostheses in the PARTNER-2
Trial. J Am Coll Cardiol 2020;76:18301843.
226. Tam DY, Vo TX, Wijeysundera HC, Dvir D, Friedrich JO, Fremes SE.
Transcatheter valve-in-valve versus redo surgical aortic valve replacement for the treatment of degenerated bioprosthetic aortic valve: a systematic review and meta-analysis. Catheter Cardiovasc Interv 2018;92:14041411.
227. Deharo P, Bisson A, Herbert J, Lacour T, Etienne CS, Porto A, Theron A,
Collart F, Bourguignon T, Cuisset T, Fauchier L. Transcatheter valve-in-valve aortic valve replacement as an alternative to surgical re-replacement. J Am Coll
Cardiol 2020;76:489499.
228. Gozdek M, Raffa GM, Suwalski P, Kolodziejczak M, Anisimowicz L, Kubica J,
Navarese EP, Kowalewski M, SIRIO-TAVI group. Comparative performance of transcatheter aortic valve-in-valve implantation versus conventional surgical redo aortic valve replacement in patients with degenerated aortic valve bioprostheses: systematic review and meta-analysis. Eur J Cardiothorac Surg
2018;53:495504.
229. Landes U, Webb JG, De Backer O, Sondergaard L, Abdel-Wahab M, Crusius L,
Kim WK, Hamm C, Buzzatti N, Montorfano M, Ludwig S, Schofer N,
Voigtlaender L, Guerrero M, El Sabbagh A, Rodes-Cabau J, Guimaraes L,
Kornowski R, Codner P, Okuno T, Pilgrim T, Fiorina C, Colombo A, Mangieri
A, Eltchaninoff H, Nombela-Franco L, Van Wiechen MPH, Van Mieghem NM,
Tchetche D, Schoels WH, Kullmer M, Tamburino C, Sinning JM, Al-Kassou B,
Perlman GY, Danenberg H, Ielasi A, Fraccaro C, Tarantini G, De Marco F,
Witberg G, Redwood SR, Lisko JC, Babaliaros VC, Laine M, Nerla R, Castriota
F, Finkelstein A, Loewenstein I, Eitan A, Jaffe R, Ruile P, Neumann FJ, Piazza N,
Alosaimi H, Sievert H, Sievert K, Russo M, Andreas M, Bunc M, Latib A,
Govdfrey R, Hildick-Smith D, Sathananthan J, Hensey M, Alkhodair A, Blanke P,
Leipsic J, Wood DA, Nazif TM, Kodali S, Leon MB, Barbanti M, Repeat transcatheter aortic valve replacement for transcatheter prosthesis dysfunction. J Am
Coll Cardiol 2020;75:18821893.
230. Buzzatti N, Romano V, De Backer O, Soendergaard L, Rosseel L, MaurovichHorvat P, Karady J, Merkely B, Ruggeri S, Prendergast B, De Bonis M, Colombo
A, Montorfano M, Latib A. Coronary access after repeated transcatheter aortic valve implantation:
a glimpse into the future.
JACC
Cardiovasc
Imaging
2020;13:508515.
231. Yoon SH, Bleiziffer S, De Backer O, Delgado V, Arai T, Ziegelmueller J, Barbanti
M, Sharma R, Perlman GY, Khalique OK, Holy EW, Saraf S, Deuschl F, Fujita B,
Ruile P, Neumann FJ, Pache G, Takahashi M, Kaneko H, Schmidt T, Ohno Y,
Schofer N, Kong WKF, Tay E, Sugiyama D, Kawamori H, Maeno Y, Abramowitz
Y, Chakravarty T, Nakamura M, Kuwata S, Yong G, Kao HL, Lee M, Kim HS,
Modine T, Wong SC, Bedgoni F, Testa L, Teiger E, Butter C, Ensminger SM,
Schaefer U, Dvir D, Blanke P, Leipsic J, Nietlispach F, Abdel-Wahab M, Chevalier
B, Tamburino C, Hildick-Smith D, Whisenant BK, Park SJ, Colombo A, Latib A,
Kodali SK, Bax JJ, Sondergaard L, Webb JG, Lefevre T, Leon MB, Makkar R.
Outcomes in transcatheter aortic valve replacement for bicuspid versus tricuspid aortic valve stenosis. J Am Coll Cardiol 2017;69:25792589.
232. Halim SA, Edwards FH, Dai D, Li Z, Mack MJ, Holmes DR, Tuzcu EM, Thourani
VH, Harrison JK, Brennan JM. Outcomes of transcatheter aortic valve replacement in patients with bicuspid aortic valve disease: a report from the Society of
Thoracic Surgeons/American College of Cardiology Transcatheter Valve
Therapy Registry. Circulation 2020;141:10711079.
233. Forrest JK, Kaple RK, Ramlawi B, Gleason TG, Meduri CU, Yakubov SJ, Jilaihawi
H, Liu F, Reardon MJ. Transcatheter aortic valve replacement in bicuspid versus tricuspid aortic valves from the STS/ACC TVT Registry. JACC Cardiovasc Interv
2020;13:17491759.
234. Alkhouli M, Zack CJ, Sarraf M, Bashir R, Nishimura RA, Eleid MF, Nkomo VT,
Sandhu GS, Gulati R, Greason KL, Holmes DR, Rihal CS. Morbidity and mortality associated with balloon aortic valvuloplasty: a national perspective. Circ
Cardiovasc Interv 2017;10.
235. Horstkotte D, Loogen F. The natural history of aortic valve stenosis. Eur Heart J
1988;9 Suppl E:5764.
236. Lund O. Preoperative risk evaluation and stratification of long-term survival after valve replacement for aortic stenosis. Reasons for earlier operative intervention. Circulation 1990;82:124139.
237. Mangner N, Stachel G, Woitek F, Haussig S, Schlotter F, Hollriegel R, Adam J,
Lindner A, Mohr FW, Schuler G, Kiefer P, Leontyev S, Borger MA, Thiele H,
Holzhey D, Linke A. Predictors of mortality and symptomatic outcome of patients with low-flow severe aortic stenosis undergoing transcatheter aortic valve replacement. J Am Heart Assoc 2018;7:e007977.
238. Dahl JS, Eleid MF, Michelena HI, Scott CG, Suri RM, Schaff HV, Pellikka PA.
Effect of left ventricular ejection fraction on postoperative outcome in patients with severe aortic stenosis undergoing aortic valve replacement. Circ Cardiovasc
Imaging 2015;8:e002917.
239. Taniguchi T, Morimoto T, Shiomi H, Ando K, Kanamori N, Murata K, Kitai T,
Kadota K, Izumi C, Nakatsuma K, Sasa T, Watanabe H, Kuwabara Y, Makiyama
T, Ono K, Shizuta S, Kato T, Saito N, Minatoya K, Kimura T, CURRENT
AS Registry Investigators. Prognostic impact of left ventricular ejection fraction in patients with severe aortic stenosis.
JACC
Cardiovasc
Interv
2018;11:145157.
240. Bohbot Y, de Meester de Ravenstein C, Chadha G, Rusinaru D, Belkhir K,
Trouillet C, Pasquet A, Marechaux S, Vanoverschelde JL, Tribouilloy C.
Relationship between left ventricular ejection fraction and mortality in asymptomatic and minimally symptomatic patients with severe aortic stenosis. JACC
Cardiovasc Imaging 2019;12:3848.
241. Capoulade R, Le Ven F, Clavel MA, Dumesnil JG, Dahou A, Thebault C,
Arsenault M, O’Connor K, Bedard E, Beaudoin J, Senechal M, Bernier MPibarot
ESC/EACTS Guidelines
622


<!-- PAGE 63 -->

### Page 63

.............................................................................................................................................................................
P. Echocardiographic predictors of outcomes in adults with aortic stenosis.
Heart 2016;102:934942.
242. Bohbot Y, Kowalski C, Rusinaru D, Ringle A, Marechaux S, Tribouilloy C.
Impact of mean transaortic pressure gradient on long-term outcome in patients with severe aortic stenosis and preserved left ventricular ejection fraction. J Am
Heart Assoc 2017;6.
243. Otto CM, Burwash IG, Legget ME, Munt BI, Fujioka M, Healy NL, Kraft CD,
Miyake-Hull CY, Schwaegler RG. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome.
Circulation 1997;95:22622270.
244. Thourani VH, Suri RM, Gunter RL, Sheng S, O’Brien SM, Ailawadi G, Szeto
WY, Dewey TM, Guyton RA, Bavaria JE, Babaliaros V, Gammie JS, Svensson L,
Williams M, Badhwar V, Mack MJ. Contemporary real-world outcomes of surgical aortic valve replacement in 141,905 low-risk, intermediate-risk, and high-risk patients. Ann Thorac Surg 2015;99:5561.
245. Gleason TG, Reardon MJ, Popma JJ, Deeb GM, Yakubov SJ, Lee JS, Kleiman NS,
Chetcuti S, Hermiller JB, Jr., Heiser J, Merhi W, Zorn GL, 3rd, Tadros P,
Robinson N, Petrossian G, Hughes GC, Harrison JK, Conte JV, Mumtaz M, Oh
JK, Huang J, Adams DH, CoreValve US Pivotal High Risk Trial Clinical
Investigators. 5-Year outcomes of self-expanding transcatheter versus surgical aortic valve replacement in high-risk patients.
J
Am
Coll
Cardiol
2018;72:26872696.
246. Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts
E, Gohlke-Barwolf C, Holme I, Kesaniemi YA, Malbecq W, Nienaber CA, Ray S,
Skjaerpe T, Wachtell K, Willenheimer R, SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med
2008;359:13431356.
247. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V,
Gonzalez-Juanatey
JR,
Harjola
VP,
Jankowska
EA,
Jessup
M,
Linde
C,
Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM,
Ruschitzka F, Rutten FH, van der Meer P, ESC Scientific Document Group.
ESC. Eur Heart J 2016;37:21292200.
248. Bull S, Loudon M, Francis JM, Joseph J, Gerry S, Karamitsos TD, Prendergast
BD, Banning AP, Neubauer S, Myerson SG. A prospective, double-blind,
randomized controlled trial of the angiotensin-converting enzyme inhibitor
Ramipril In Aortic Stenosis (RIAS trial). Eur Heart J Cardiovasc Imaging
2015;16:834841.
249. Ochiai T, Saito S, Yamanaka F, Shishido K, Tanaka Y, Yamabe T, Shirai S, Tada
N, Araki M, Naganuma T, Watanabe Y, Yamamoto M, Hayashida K. Reninangiotensin system blockade therapy after transcatheter aortic valve implantation. Heart 2018;104:644651.
250. Dahl JS, Videbaek L, Poulsen MK, Pellikka PA, Veien K, Andersen LI, Haghfelt T,
Moller JE. Effect of candesartan treatment on left ventricular remodeling after aortic valve replacement for aortic stenosis.
Am
J
Cardiol
2010;106:713719.
251. Strange G, Stewart S, Celermajer D, Prior D, Scalia GM, Marwick T, Ilton M,
Joseph M, Codde J, Playford D, National Echocardiography Database of
Australia contributing sites. Poor long-term survival in patients with moderate aortic stenosis. J Am Coll Cardiol 2019;74:18511863.
252. van Gils L, Clavel MA, Vollema EM, Hahn RT, Spitzer E, Delgado V, Nazif T, De
Jaegere PP, Geleijnse ML, Ben-Yehuda O, Bax JJ, Leon MB, Pibarot P, Van
Mieghem NM. Prognostic implications of moderate aortic stenosis in patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2017;69:23832392.
253. Delesalle G, Bohbot Y, Rusinaru D, Delpierre Q, Marechaux S, Tribouilloy C.
Characteristics and prognosis of patients with moderate aortic stenosis and preserved left ventricular ejection fraction. J Am Heart Assoc 2019;8:e011036.
254. Samad Z, Vora AN, Dunning A, Schulte PJ, Shaw LK, Al-Enezi F, Ersboll M,
McGarrah RW, 3rd, Vavalle JP, Shah SH, Kisslo J, Glower D, Harrison JK,
Velazquez EJ. Aortic valve surgery and survival in patients with moderate or severe aortic stenosis and left ventricular dysfunction.
Eur
Heart
J
2016;37:22762286.
255. Chaker Z, Badhwar V, Alqahtani F, Aljohani S, Zack CJ, Holmes DR, Rihal CS,
Alkhouli M. Sex differences in the utilization and outcomes of surgical aortic valve replacement for severe aortic stenosis. J Am Heart Assoc 2017;6.
256. Cote N, Clavel MA. Sex differences in the pathophysiology, diagnosis, and management of aortic stenosis. Cardiol Clin 2020;38:129138.
257. Tribouilloy C, Bohbot Y, Rusinaru D, Belkhir K, Diouf M, Altes A, Delpierre Q,
Serbout S, Kubala M, Levy F, Marechaux S, Enriquez Sarano M. Excess mortality and undertreatment of women with severe aortic stenosis. J Am Heart Assoc
2021;10:e018816.
258. Smith WTt, Ferguson TB, Jr., Ryan T, Landolfo CK, Peterson ED. Should coronary artery bypass graft surgery patients with mild or moderate aortic stenosis undergo concomitant aortic valve replacement? A decision analysis approach to the surgical dilemma. J Am Coll Cardiol 2004;44:12411247.
259. Faroux L, Campelo-Parada F, Munoz-Garcia E, Nombela-Franco L, Fischer Q,
Donaint P, Serra V, Veiga G, Gutierrez E, Vilalta V, Alperi A, Regueiro A,
Asmarats L, Ribeiro HB, Matta A, Munoz-Garcia A, Armijo G, Urena M, Metz
D, Rodenas-Alesina E, la de Torre Hernandez JM, Fernandez-Nofrerias E, Pascual
I, Perez-Fuentes P, Arzamendi D, Campanha-Borges DC, Del Val D, Couture T, RodesCabau J. Procedural characteristics and late outcomes of percutaneous coronary intervention in the workup pre-TAVR. JACC Cardiovasc Interv 2020;13:26012613.
260. Sondergaard L, Popma JJ, Reardon MJ, Van Mieghem NM, Deeb GM, Kodali S,
George I, Williams MR, Yakubov SJ, Kappetein AP, Serruys PW, Grube E,
Schiltgen MB, Chang Y, Engstrom T, SURTAVI Trial Investigators. Comparison of a complete percutaneous versus surgical approach to aortic valve replacement and revascularization in patients at intermediate surgical risk: results from the randomized SURTAVI Trial. Circulation 2019;140:12961305.
261. Nombela-Franco L, Eltchaninoff H, Zahn R, Testa L, Leon MB, Trillo-Nouche R,
D’Onofrio A, Smith CR, Webb J, Bleiziffer S, De Chiara B, Gilard M, Tamburino
C, Bedogni F, Barbanti M, Salizzoni S, Garcia del Blanco B, Sabate M, Moreo A,
Fernandez C, Ribeiro HB, Amat-Santos I, Urena M, Allende R, Garcia E, Macaya
C, Dumont E, Pibarot P, Rodes-Cabau J. Clinical impact and evolution of mitral regurgitation following transcatheter aortic valve replacement: a meta-analysis.
Heart 2015;101:13951405.
262. D’Ancona G, Kische S, Senges J, Ouarrak T, Puls M, Bekeredjian R, Sievert H,
Safak E, Ortak J, Oner A, Schillinger W, Ince H. Combined mitro-aortic pathology: impact of previous aortic valve replacement upon outcomes of MitraClip therapy (from the German transcatheter mitral valve interventions registry).
EuroIntervention 2017;13:475482.
263. Witberg G, Codner P, Landes U, Barbanti M, Valvo R, De Backer O, Ooms JF,
Sievert K, El Sabbagh A, Jimenez-Quevedo P, Brennan PF, Sedaghat A, Masiero
G, Werner P, Overtchouk P, Watanabe Y, Montorfano M, Bijjam VR, Hein M,
Fiorina C, Arzamendi D, Rodriguez-Gabella T, Fernandez-Vazquez F, Baz JA,
Laperche C, Grasso C, Branca L, Estevez-Loureiro R, Benito-Gonzalez T, Amat
Santos IJ, Ruile P, Mylotte D, Buzzatti N, Piazza N, Andreas M, Tarantini G,
Sinning
JM,
Spence
MS,
Nombela-Franco
L,
Guerrero
M,
Sievert
H,
Sondergaard L, Van Mieghem NM, Tchetche D, Webb JG, Kornowski R.
Transcatheter treatment of residual significant mitral regurgitation following
TAVR: a multicenter registry. JACC Cardiovasc Interv 2020;13:27822791.
264. Khan F, Okuno T, Malebranche D, Lanz J, Praz F, Stortecky S, Windecker S,
Pilgrim T. Transcatheter aortic valve replacement in patients with multivalvular heart disease. JACC Cardiovasc Interv 2020;13:15031514.
265. Baumgartner H, Bonhoeffer P, De Groot NM, de Haan F, Deanfield JE, Galie N,
Gatzoulis MA, Gohlke-Baerwolf C, Kaemmerer H, Kilner P, Meijboom F,
Mulder BJ, Oechslin E, Oliver JM, Serraf A, Szatmari A, Thaulow E, Vouhe PR,
Walma E, Task Force on the Management of Grown-up Congenital Heart
Disease of the European Society of Cardiology, Association for European
Paediatric Cardiology, ESC Committee for Practice Guidelines. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010).
Eur Heart J 2010;31:29152957.
266. Dziadzko V, Dziadzko M, Medina-Inojosa JR, Benfari G, Michelena HI,
Crestanello JA, Maalouf J, Thapa P, Enriquez-Sarano M. Causes and mechanisms of isolated mitral regurgitation in the community: clinical context and outcome.
Eur Heart J 2019;40:21942202.
267. Kingue S, Ba SA, Balde D, Diarra MB, Anzouan-Kacou JB, Anisubia B, Damorou
JM, Ndobo P, Menanga A, Kane A, Kakou-Guikahue M, Kenfack M, Metogo B,
Chelo D, Yangnigni E, Tantchou C, Bertrand E, Monsuez JJ, Working Group on
Tropical Cardiology of the Socie´te´ franc¸aise de cardiologie. The VALVAFRIC
study: a registry of rheumatic heart disease in Western and Central Africa. Arch
Cardiovasc Dis 2016;109:321329.
268. Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA,
Hahn RT, Han Y, Hung J, Lang RM, Little SH, Shah DJ, Shernan S,
Thavendiranathan P, Thomas JD, Weissman NJ. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American
Society of Echocardiography developed in collaboration with the Society for
Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 2017;30:303371.
269. Antoine C, Benfari G, Michelena HI, Maalouf JF, Nkomo VT, Thapa P, EnriquezSarano M. Clinical outcome of degenerative mitral regurgitation. Circulation
2018;138:13171326.
270. Samad Z, Shaw LK, Phelan M, Glower DD, Ersboll M, Toptine JH, Alexander
JH, Kisslo JA, Wang A, Mark DB, Velazquez EJ. Long-term outcomes of mitral regurgitation by type and severity. Am Heart J 2018;203:3948.
271. Carpentier A. Cardiac valve surgerythe “French correction”. J Thorac
Cardiovasc Surg 1983;86:323337.
272. Boekstegers P, Hausleiter J, Baldus S, von Bardeleben RS, Beucher H, Butter C,
Franzen O, Hoffmann R, Ince H, Kuck KH, Rudolph V, Schafer U, Schillinger W,
Wunderlich
N,
Germany
Society of
Cardiology
Working
Group on
Interventional Cardiology Focus Group on Interventional Mitral Valve Therapy.
ESC/EACTS Guidelines
623


<!-- PAGE 64 -->

### Page 64

.............................................................................................................................................................................
Percutaneous interventional mitral regurgitation treatment using the Mitra-Clip system. Clin Res Cardiol 2014;103:8596.
273. Gavazzoni M, Taramasso M, Zuber M, Russo G, Pozzoli A, Miura M, Maisano F.
Conceiving MitraClip as a tool: percutaneous edge-to-edge repair in complex mitral valve anatomies. Eur Heart J Cardiovasc Imaging 2020;21:10591067.
274. Cawley PJ, Hamilton-Craig C, Owens DS, Krieger EV, Strugnell WE, Mitsumori
L, D’Jang CL, Schwaegler RG, Nguyen KQ, Nguyen B, Maki JH, Otto CM.
Prospective comparison of valve regurgitation quantitation by cardiac magnetic resonance imaging and transthoracic echocardiography. Circ Cardiovasc Imaging
2013;6:4857.
275. Shanks M, Siebelink HM, Delgado V, van de Veire NR, Ng AC, Sieders A,
Schuijf JD, Lamb HJ, Ajmone Marsan N, Westenberg JJ, Kroft LJ, de Roos A, Bax
JJ. Quantitative assessment of mitral regurgitation: comparison between threedimensional transesophageal echocardiography and magnetic resonance imaging. Circ Cardiovasc Imaging 2010;3:694700.
276. Uretsky S, Gillam L, Lang R, Chaudhry FA, Argulian E, Supariwala A, Gurram S,
Jain K, Subero M, Jang JJ, Cohen R, Wolff SD. Discordance between echocardiography and MRI in the assessment of mitral regurgitation severity: a prospective multicenter trial. J Am Coll Cardiol 2015;65:10781088.
277. Penicka M, Vecera J, Mirica DC, Kotrc M, Kockova R, Van Camp G. Prognostic implications of magnetic resonance-derived quantification in asymptomatic patients with organic mitral regurgitation:
comparison with
Doppler echocardiography-derived integrative approach.
Circulation
2018;137:13491360.
278. Garg P, Swift AJ, Zhong L, Carlhall CJ, Ebbers T, Westenberg J, Hope MD,
Bucciarelli-Ducci C, Bax JJ, Myerson SG. Assessment of mitral valve regurgitation by cardiovascular magnetic resonance imaging.
Nat
Rev
Cardiol
2020;17:298312.
279. Kitkungvan D, Nabi F, Kim RJ, Bonow RO, Khan MA, Xu J, Little SH, Quinones
MA, Lawrie GM, Zoghbi WA, Shah DJ. Myocardial fibrosis in patients with primary mitral regurgitation with and without prolapse. J Am Coll Cardiol
2018;72:823834.
280. Bakkestrom R, Banke A, Christensen NL, Pecini R, Irmukhamedov A, Andersen
M, Borlaug BA, Moller JE. Hemodynamic characteristics in significant symptomatic and asymptomatic primary mitral valve regurgitation at rest and during exercise. Circ Cardiovasc Imaging 2018;11:e007171.
281. Utsunomiya H, Hidaka T, Susawa H, Izumi K, Harada Y, Kinoshita M, Itakura K,
Masada K, Kihara Y. Exercise-stress echocardiography and effort intolerance in asymptomatic/minimally symptomatic patients with degenerative mitral regurgitation combined invasive-noninvasive hemodynamic monitoring. Circ Cardiovasc
Imaging 2018;11:e007282.
282. Pizarro R, Bazzino OO, Oberti PF, Falconi M, Achilli F, Arias A, Krauss JG,
Cagide AM. Prospective validation of the prognostic usefulness of brain natriuretic peptide in asymptomatic patients with chronic severe mitral regurgitation.
J Am Coll Cardiol 2009;54:10991106.
283. Hiemstra YL, Tomsic A, van Wijngaarden SE, Palmen M, Klautz RJM, Bax JJ,
Delgado V, Ajmone Marsan N. Prognostic value of global longitudinal strain and etiology after surgery for primary mitral regurgitation. JACC Cardiovasc Imaging
2020;13:577585.
284. Kim HM, Cho GY, Hwang IC, Choi HM, Park JB, Yoon YE, Kim HK. Myocardial strain in prediction of outcomes after surgery for severe mitral regurgitation.
JACC Cardiovasc Imaging 2018;11:12351244.
285. Grigioni F, Clavel MA, Vanoverschelde JL, Tribouilloy C, Pizarro R, Huebner M,
Avierinos JF, Barbieri A, Suri R, Pasquet A, Rusinaru D, Gargiulo GD, Oberti P,
Theron A, Bursi F, Michelena H, Lazam S, Szymanski C, Nkomo VT,
Schumacher M, Bacchi-Reggiani L, Enriquez-Sarano M, MIDA Investigators. The
MIDA Mortality Risk Score: development and external validation of a prognostic model for early and late death in degenerative mitral regurgitation. Eur Heart
J 2018;39:12811291.
286. Tribouilloy C, Grigioni F, Avierinos JF, Barbieri A, Rusinaru D, Szymanski C,
Ferlito M, Tafanelli L, Bursi F, Trojette F, Branzi A, Habib G, Modena MG,
Enriquez-Sarano M, MIDA Investigators. Survival implication of left ventricular end-systolic diameter in mitral regurgitation due to flail leaflets a long-term follow-up multicenter study. J Am Coll Cardiol 2009;54:19611968.
287. Essayagh B, Antoine C, Benfari G, Messika-Zeitoun D, Michelena H, Le
Tourneau T, Mankad S, Tribouilloy CM, Thapa P, Enriquez-Sarano M.
Prognostic implications of left atrial enlargement in degenerative mitral regurgitation. J Am Coll Cardiol 2019;74:858870.
288. Rusinaru D, Tribouilloy C, Grigioni F, Avierinos JF, Suri RM, Barbieri A,
Szymanski C, Ferlito M, Michelena H, Tafanelli L, Bursi F, Mezghani S, Branzi A,
Habib G, Modena MG, Enriquez-Sarano M, Mitral Regurgitation International
DAtabase (MIDA) Investigators. Left atrial size is a potent predictor of mortality in mitral regurgitation due to flail leaflets: results from a large international multicenter study. Circ Cardiovasc Imaging 2011;4:473481.
289. Barbieri A, Bursi F, Grigioni F, Tribouilloy C, Avierinos JF, Michelena HI,
Rusinaru D, Szymansky C, Russo A, Suri R, Bacchi Reggiani ML, Branzi A,
Modena MG, Enriquez-Sarano M, Mitral Regurgitation International DAtabase
(MIDA) Investigators. Prognostic and therapeutic implications of pulmonary hypertension complicating degenerative mitral regurgitation due to flail leaflet: a multicenter long-term international study. Eur Heart J 2011;32:751759.
290. Grigioni F, Benfari G, Vanoverschelde JL, Tribouilloy C, Avierinos JF, Bursi F, Suri
RM, Guerra F, Pasquet A, Rusinaru D, Marcelli E, Theron A, Barbieri A, Michelena
H, Lazam S, Szymanski C, Nkomo VT, Capucci A, Thapa P, Enriquez-Sarano M,
MIDA Investigators. Long-term implications of atrial fibrillation in patients with degenerative mitral regurgitation. J Am Coll Cardiol 2019;73:264274.
291. Szymanski C, Magne J, Fournier A, Rusinaru D, Touati G, Tribouilloy C.
Usefulness of preoperative atrial fibrillation to predict outcome and left ventricular dysfunction after valve repair for mitral valve prolapse. Am J Cardiol
2015;115:14481453.
292. Suri RM, Vanoverschelde JL, Grigioni F, Schaff HV, Tribouilloy C, Avierinos JF,
Barbieri A, Pasquet A, Huebner M, Rusinaru D, Russo A, Michelena HI,
Enriquez-Sarano M. Association between early surgical intervention vs watchful waiting and outcomes for mitral regurgitation due to flail mitral valve leaflets.
JAMA 2013;310:609616.
293. Jung JC, Jang MJ, Hwang HY. Meta-analysis comparing mitral valve repair versus replacement for degenerative mitral regurgitation across all ages. Am J Cardiol
2019;123:446453.
294. Lazam S, Vanoverschelde JL, Tribouilloy C, Grigioni F, Suri RM, Avierinos JF, de
Meester C, Barbieri A, Rusinaru D, Russo A, Pasquet A, Michelena HI, Huebner
M, Maalouf J, Clavel MA, Szymanski C, Enriquez-Sarano M, MIDA Investigators.
Twenty-year outcome after mitral repair versus replacement for severe degenerative mitral regurgitation: analysis of a large, prospective, multicenter, international registry. Circulation 2017;135:410422.
295. Chikwe J, Toyoda N, Anyanwu AC, Itagaki S, Egorova NN, Boateng P, ElEshmawi A, Adams DH. Relation of mitral valve surgery volume to repair rate,
durability, and survival. J Am Coll Cardiol 2017;doi: 10.1016/j.jacc.2017.02.026.
296. David TE, David CM, Tsang W, Lafreniere-Roula M, Manlhiot C. Long-term results of mitral valve repair for regurgitation due to leaflet prolapse. J Am Coll
Cardiol 2019;74:10441053.
297. Donnellan E, Alashi A, Johnston DR, Gillinov AM, Pettersson GB, Svensson LG,
Griffin BP, Desai MY. Outcomes of patients with mediastinal radiation-associated mitral valve disease undergoing cardiac surgery. Circulation 2019;140:12881290.
298. Vakamudi S, Jellis C, Mick S, Wu Y, Gillinov AM, Mihaljevic T, Cosgrove DM,
Svensson L, Cho L. Sex differences in the etiology of surgical mitral valve disease. Circulation 2018;138:17491751.
299. Feldman T, Foster E, Glower DD, Kar S, Rinaldi MJ, Fail PS, Smalling RW, Siegel
R, Rose GA, Engeron E, Loghin C, Trento A, Skipper ER, Fudge T, Letsou GV,
Massaro JM, Mauri L, EVEREST II Investigators. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 2011;364:13951406.
300. Feldman T, Kar S, Elmariah S, Smart SC, Trento A, Siegel RJ, Apruzzese P, Fail
P, Rinaldi MJ, Smalling RW, Hermiller JB, Heimansohn D, Gray WA, Grayburn
PA, Mack MJ, Lim DS, Ailawadi G, Herrmann HC, Acker MA, Silvestry FE,
Foster E, Wang A, Glower DD, Mauri L, EVEREST II Investigators. Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II. J Am Coll Cardiol 2015;66:28442854.
301. Buzzatti N, Van Hemelrijck M, Denti P, Ruggeri S, Schiavi D, Scarfo IS, Reser D,
Taramasso M, Weber A, La Canna G, De Bonis M, Maisano F, Alfieri O.
Transcatheter or surgical repair for degenerative mitral regurgitation in elderly patients: a propensity-weighted analysis. J Thorac Cardiovasc Surg 2019;158:8694
e81.
302. Sorajja P, Vemulapalli S, Feldman T, Mack M, Holmes DR, Jr., Stebbins A, Kar S,
Thourani V, Ailawadi G. Outcomes with transcatheter mitral valve repair in the
United
States:
an
STS/ACC
TVT
Registry
Report.
J
Am
Coll
Cardiol
2017;70:23152327.
303. Gammie JS, Bartus K, Gackowski A, D’Ambra MN, Szymanski P, Bilewska A,
Kusmierczyk M, Kapelak B, Rzucidlo-Resil J, Moat N, Duncan A, Yadev R,
Livesey S, Diprose P, Gerosa G, D’Onofrio A, Pitterello D, Denti P, La Canna
G, De Bonis M, Alfieri O, Hung J, Kolsut P. Beating-heart mitral valve repair using a novel ePTFE cordal implantation device: a prospective trial. J Am Coll
Cardiol 2018;71:2536.
304. Lim DS, Kar S, Spargias K, Kipperman RM, O’Neill WW, Ng MKC, Fam NP,
Walters DL, Webb JG, Smith RL, Rinaldi MJ, Latib A, Cohen GN, Schafer U,
Marcoff L, Vandrangi P, Verta P, Feldman TE. Transcatheter valve repair for patients with mitral regurgitation: 30-day results of the CLASP Study. JACC
Cardiovasc Interv 2019;12:13691378.
305. Praz F, Braun D, Unterhuber M, Spirito A, Orban M, Brugger N, Brinkmann I,
Spring K, Moschovitis A, Nabauer M, Blazek S, Pilgrim T, Thiele H, Lurz P,
Hausleiter J, Windecker S. Edge-to-edge mitral valve repair with extended clip arms: early experience from a multicenter observational study. JACC Cardiovasc
Interv 2019;12:13561365.
306. Praz F, Spargias K, Chrissoheris M, Bullesfeld L, Nickenig G, Deuschl F, Schueler
R, Fam NP, Moss R, Makar M, Boone R, Edwards J, Moschovitis A, Kar S, Webb
ESC/EACTS Guidelines
624


<!-- PAGE 65 -->

### Page 65

.............................................................................................................................................................................
J, Schafer U, Feldman T, Windecker S. Compassionate use of the PASCAL
transcatheter mitral valve repair system for patients with severe mitral regurgitation: a multicentre, prospective, observational, first-in-man study. Lancet
2017;390:773780.
307. Chakravarty T, Makar M, Patel D, Oakley L, Yoon SH, Stegic J, Singh S, Skaf S,
Nakamura M, Makkar RR. Transcatheter edge-to-edge mitral valve repair with the MitraClip G4 system. JACC Cardiovasc Interv 2020;13:24022414.
308. Piriou N, Al Habash O, Donal
E, Senage T, Le Tourneau T, Pattier S,
Guyomarch B, Roussel JC, Trochu JN, Vahanian A, Obadia JF, Iung BGuerin P.
The MITRA-HR study: design and rationale of a randomised study of MitraClip transcatheter mitral valve repair in patients with severe primary mitral regurgitation eligible for high-risk surgery. EuroIntervention 2019;15:e329e335.
309. Zilberszac R, Heinze G, Binder T, Laufer G, Gabriel H, Rosenhek R. Long-term outcome of active surveillance in severe but asymptomatic primary mitral regurgitation. JACC Cardiovasc Imaging 2018;11:12131221.
310. Dejgaard LA, Skjolsvik ET, Lie OH, Ribe M, Stokke MK, Hegbom F, Scheirlynck
ES, Gjertsen E, Andresen K, Helle-Valle TM, Hopp E, Edvardsen T, Haugaa KH.
The mitral annulus disjunction arrhythmic syndrome. J Am Coll Cardiol
2018;72:16001609.
311. Han HC, Ha FJ, Teh AW, Calafiore P, Jones EF, Johns J, Koshy AN, O’Donnell
D, Hare DL, Farouque O, Lim HS. Mitral valve prolapse and sudden cardiac death: a systematic review. J Am Heart Assoc 2018;7:e010584.
312. Nalliah CJ, Mahajan R, Elliott AD, Haqqani H, Lau DH, Vohra JK, Morton JB,
Semsarian C, Marwick T, Kalman JM, Sanders P. Mitral valve prolapse and sudden cardiac death: a systematic review and meta-analysis. Heart 2019;105:144151.
313. Essayagh B, Sabbag A, Antoine C, Benfari G, Yang LT, Maalouf J, Asirvatham S,
Michelena H, Enriquez-Sarano M. Presentation and outcome of arrhythmic mitral valve prolapse. J Am Coll Cardiol 2020;76:637649.
314. Lancellotti P, Pibarot P, Chambers J, Edvardsen T, Delgado V, Dulgheru R, Pepi
M, Cosyns B, Dweck MR, Garbi M, Magne J, Nieman K, Rosenhek R, Bernard A,
Lowenstein J, Vieira ML, Rabischoffsky A, Vyhmeister RH, Zhou X, Zhang Y,
Zamorano JL, Habib G. Recommendations for the imaging assessment of prosthetic heart valves: a report from the European Association of Cardiovascular
Imaging endorsed by the Chinese Society of Echocardiography, the InterAmerican Society of Echocardiography, and the Brazilian Department of
Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2016;17:589590.
315. Yu M, Georges A, Tucker NR, Kyryachenko S, Toomer K, Schott JJ, Delling FN,
Fernandez-Friera L, Solis J, Ellinor PT, Levine RA, Slaugenhaupt SA, Hagege AA,
Dina C, Jeunemaitre X, Milan DJ, Norris RA, Bouatia-Naji N. Genome-wide association study-driven gene-set analyses, genetic, and functional follow-up suggest GLIS1 as a susceptibility gene for mitral valve prolapse. Circ Genom
Precis Med 2019;12:e002497.
316. Mantovani F, Clavel MA, Michelena HI, Suri RM, Schaff HV, Enriquez-Sarano M.
Comprehensive imaging in women with organic mitral regurgitation: implications for clinical outcome. JACC Cardiovasc Imaging 2016;9:388396.
317. Asgar AW, Mack MJ, Stone GW. Secondary mitral regurgitation in heart failure:
pathophysiology, prognosis, and therapeutic considerations. J Am Coll Cardiol
2015;65:12311248.
318. Bertrand PB, Schwammenthal E, Levine RA, Vandervoort PM. Exercise dynamics in secondary mitral regurgitation: pathophysiology and therapeutic implications. Circulation 2017;135:297314.
319. Deferm S, Bertrand PB, Verbrugge FH, Verhaert D, Rega F, Thomas JD,
Vandervoort PM. Atrial functional mitral regurgitation: JACC Review Topic of the Week. J Am Coll Cardiol 2019;73:24652476.
320. Bartko PE, Arfsten H, Heitzinger G, Pavo N, Toma A, Strunk G, Hengstenberg
C, Hulsmann M, Goliasch G. A unifying concept for the quantitative assessment of secondary mitral regurgitation. J Am Coll Cardiol 2019;73:25062517.
321. Goliasch G, Bartko PE, Pavo N, Neuhold S, Wurm R, Mascherbauer J, Lang IM,
Strunk G, Hulsmann M. Refining the prognostic impact of functional mitral regurgitation in chronic heart failure. Eur Heart J 2018;39:3946.
322. Michler RE, Smith PK, Parides MK, Ailawadi G, Thourani V, Moskowitz AJ,
Acker MA, Hung JW, Chang HL, Perrault LP, Gillinov AM, Argenziano M,
Bagiella E, Overbey JR, Moquete EG, Gupta LN, Miller MA, Taddei-Peters WC,
Jeffries N, Weisel RD, Rose EA, Gammie JS, DeRose JJ, Jr., Puskas JD, Dagenais
F, Burks SG, El-Hamamsy I, Milano CA, Atluri P, Voisine P, O’Gara PT, Gelijns
AC, CTSN. Two-year outcomes of surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med 2016;374:19321941.
323. Obadia JF, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, Lefevre
T, Piot C, Rouleau F, Carrie D, Nejjari M, Ohlmann P, Leclercq F, Saint Etienne
C, Teiger E, Leroux L, Karam N, Michel N, Gilard M, Donal E, Trochu JN,
Cormier B, Armoiry X, Boutitie F, Maucort-Boulch D, Barnel C, Samson G,
Guerin P, Vahanian A, Mewton N, MITRA-FR Investigators. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med
2018;379:22972306.
324. Cavalcante JL, Kusunose K, Obuchowski NA, Jellis C, Griffin BP, Flamm SD,
Kwon DH. Prognostic impact of ischemic mitral regurgitation severity and myocardial infarct quantification by cardiovascular magnetic resonance. JACC
Cardiovasc Imaging 2020;13:14891501.
325. Kamperidis V, Marsan NA, Delgado V, Bax JJ. Left ventricular systolic function assessment in secondary mitral regurgitation: left ventricular ejection fraction vs. speckle tracking global longitudinal strain. Eur Heart J 2016;37:
811816.
326. Namazi F, van der Bijl P, Hirasawa K, Kamperidis V, van Wijngaarden SE,
Mertens B, Leon MB, Hahn RT, Stone GW, Narula J, Ajmone Marsan N,
Delgado V, Bax JJ. Prognostic value of left ventricular global longitudinal strain in patients with secondary mitral regurgitation.
J
Am
Coll
Cardiol
2020;75:750758.
327. Kang DH, Park SJ, Shin SH, Hong GR, Lee S, Kim MS, Yun SC, Song JM, Park
SW, Kim JJ. Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation. Circulation 2019;139:13541365.
328. Grigioni F, Enriquez-Sarano M, Zehr KJ, Bailey KR, Tajik AJ. Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative
Doppler assessment. Circulation 2001;103:17591764.
329. Acker MA, Jessup M, Bolling SF, Oh J, Starling RC, Mann DL, Sabbah HN,
Shemin R, Kirklin J, Kubo SH. Mitral valve repair in heart failure: five-year follow-up from the mitral valve replacement stratum of the Acorn randomized trial. J Thorac Cardiovasc Surg 2011;142:569574, 574 e561.
330. Deja MA, Grayburn PA, Sun B, Rao V, She L, Krejca M, Jain AR, Leng Chua Y,
Daly R, Senni M, Mokrzycki K, Menicanti L, Oh JK, Michler R, Wrobel K, Lamy
A, Velazquez EJ, Lee KL, Jones RH. Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial. Circulation
2012;125:26392648.
331. Petrus AHJ, Dekkers OM, Tops LF, Timmer E, Klautz RJM, Braun J. Impact of recurrent mitral regurgitation after mitral valve repair for functional mitral regurgitation:
long-term analysis of competing outcomes.
Eur
Heart
J
2019;40:22062214.
332. Harmel EK, Reichenspurner H, Girdauskas E. Subannular reconstruction in secondary mitral regurgitation: a meta-analysis. Heart 2018;104:17831790.
333. Acker MA, Parides MK, Perrault LP, Moskowitz AJ, Gelijns AC, Voisine P, Smith
PK, Hung JW, Blackstone EH, Puskas JD, Argenziano M, Gammie JS, Mack M,
Ascheim DD, Bagiella E, Moquete EG, Ferguson TB, Horvath KA, Geller NL,
Miller MA, Woo YJ, D’Alessandro DA, Ailawadi G, Dagenais F, Gardner TJ,
O’Gara PT, Michler RE, Kron IL, CTSN. Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N Engl J Med 2014;370:2332.
334. Mihaljevic T, Lam BK, Rajeswaran J, Takagaki M, Lauer MS, Gillinov AM,
Blackstone EH, Lytle BW. Impact of mitral valve annuloplasty combined with revascularization in patients with functional ischemic mitral regurgitation. J Am
Coll Cardiol 2007;49:21912201.
335. Wu AH, Aaronson KD, Bolling SF, Pagani FD, Welch K, Koelling TM. Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol 2005;45:381387.
336. Iung B, Armoiry X, Vahanian A, Boutitie F, Mewton N, Trochu JN, Lefevre T,
Messika-Zeitoun D, Guerin P, Cormier B, Brochet E, Thibault H, Himbert D,
Thivolet S, Leurent G, Bonnet G, Donal E, Piriou N, Piot C, Habib G, Rouleau
F, Carrie D, Nejjari M, Ohlmann P, Saint Etienne C, Leroux L, Gilard M,
Samson G, Rioufol G, Maucort-Boulch D, Obadia JF, MITRA-FR Investigators.
Percutaneous repair or medical treatment for secondary mitral regurgitation:
outcomes at 2 years. Eur J Heart Fail 2019;21:16191627.
337. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, Whisenant B,
Grayburn PA, Rinaldi M, Kapadia SR, Rajagopal V, Sarembock IJ, Brieke A, Marx
SO, Cohen DJ, Weissman NJ, Mack MJ, COAPT Investigators. Transcatheter mitral-valve repair in patients with heart failure.
N
Engl
J
Med
2018;379:23072318.
338. Mack MJ, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, Whisenant BK,
Grayburn PA, Rinaldi MJ, Kapadia SR, Rajagopal V, Sarembock IJ, Brieke A,
Rogers JH, Marx SO, Cohen DJ, Weissman NJ, Stone GW, COAPT
Investigators. 3-Year outcomes of transcatheter mitral valve repair in patients with heart failure. J Am Coll Cardiol 2021;77:10291040.
339. Giustino G, Lindenfeld J, Abraham WT, Kar S, Lim DS, Grayburn PA, Kapadia
SR, Cohen DJ, Kotinkaduwa LN, Weissman NJ, Mack MJ, Stone GW. NYHA
functional classification and outcomes after transcatheter mitral valve repair in heart failure: the COAPT Trial. JACC Cardiovasc Interv 2020;13:23172328.
340. Malik UI, Ambrosy AP, Ku IA, Mishell JM, Kar S, Lim DS, Whisenant BK, Cohen
DJ, Arnold SV, Kotinkaduwa LN, Lindenfeld J, Abraham WT, Mack MJ, Stone
GW. Baseline functional capacity and transcatheter mitral valve repair in heart failure with secondary mitral regurgitation.
JACC
Cardiovasc
Interv
2020;13:23312341.
341. Kosmidou I, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, Whisenant
BK, Kipperman RM, Boudoulas KD, Redfors B, Shahim B, Zhang Z, Mack MJ,
Stone GW. Transcatheter mitral valve repair in patients with and without cardiac resynchronization therapy:
the
COAPT
Trial.
Circ
Heart
Fail
2020;13:e007293.
ESC/EACTS Guidelines
625


<!-- PAGE 66 -->

### Page 66

.............................................................................................................................................................................
342. Lerakis S, Kini AS, Asch FM, Kar S, Lim DS, Mishell JM, Whisenant B, Grayburn
PA, Weissman NJ, Rinaldi MJ, Sharma SK, Kapadia SR, Rajagopal V, Sarembock
IJ, Brieke A, Tang GHL, Li D, Crowley A, Lindenfeld J, Abraham WT, Mack MJ,
Stone GW. Outcomes of transcatheter mitral valve repair for secondary mitral regurgitation by severity of left ventricular dysfunction.
EuroIntervention
2021;17:e335e342.
343. Gertz ZM, Herrmann HC, Lim DS, Kar S, Kapadia SR, Reed GW, Puri R,
Krishnaswamy A, Gersh BJ, Weissman NJ, Asch FM, Grayburn PA, Kosmidou I,
Redfors B, Zhang Z, Abraham WT, Lindenfeld J, Stone GW, Mack MJ.
Implications of atrial fibrillation on the mechanisms of mitral regurgitation and response to
MitraClip in the
COAPT
Trial.
Circ
Cardiovasc
Interv
2021;14:e010300.
344. Messika-Zeitoun D, Iung B, Armoiry X, Trochu JN, Donal E, Habib G, Brochet
E, Thibault H, Piriou N, Cormier B, Tribouilloy C, Guerin P, Lefevre T,
Maucort-Boulch D, Vahanian A, Boutitie F, Obadia JF. Impact of mitral regurgitation severity and left ventricular remodeling on outcome after MitraClip implantation:
results from the
Mitra-FR
Trial.
JACC
Cardiovasc
Imaging
2021;14:742752.
345. Grayburn PA, Sannino A, Packer M. Proportionate and disproportionate functional mitral regurgitation: a new conceptual framework that reconciles the results of the
MITRA-FR
and
COAPT
trials.
JACC
Cardiovasc
Imaging
2019;12:353362.
346. Mack MJ, Abraham WT, Lindenfeld J, Bolling SF, Feldman TE, Grayburn PA,
Kapadia SR, McCarthy PM, Lim DS, Udelson JE, Zile MR, Gammie JS, Gillinov
AM, Glower DD, Heimansohn DA, Suri RM, Ellis JT, Shu Y, Kar S, Weissman
NJ, Stone GW. Cardiovascular outcomes assessment of the MitraClip in patients with heart failure and secondary mitral regurgitation: design and rationale of the COAPT trial. Am Heart J 2018;205:111.
347. Asch FM, Grayburn PA, Siegel RJ, Kar S, Lim DS, Zaroff JG, Mishell JM,
Whisenant B, Mack MJ, Lindenfeld J, Abraham WT, Stone GW, Weissman NJ,
COAPT Investigators. Echocardiographic outcomes after transcatheter leaflet approximation in patients with secondary mitral regurgitation: the COAPT
Trial. J Am Coll Cardiol 2019;74:29692979.
348. Coats AJS, Anker SD, Baumbach A, Alfieri O, von Bardeleben RS, Bauersachs J,
Bax JJ, Boveda S, Celutkiene J, Cleland JG, Dagres N, Deneke T, Farmakis D,
Filippatos G, Hausleiter J, Hindricks G, Jankowska EA, Lainscak M, Leclercq C,
Lund LH, McDonagh T, Mehra MR, Metra M, Mewton N, Mueller C, Mullens
W, Muneretto C, Obadia JF, Ponikowski P, Praz F, Rudolph V, Ruschitzka F,
Vahanian A, Windecker S, Zamorano JL, Edvardsen T, Heidbuchel H, Seferovic
PM, Prendergast B. The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure
Association (HFA), European Association of Cardiovascular Imaging (EACVI),
European Heart Rhythm Association (EHRA), and European Association of
Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. Eur Heart J
2021;42:12541269.
349. Pibarot P, Delgado V, Bax JJ. MITRA-FR vs. COAPT: lessons from two trials with diametrically opposed results.
Eur
Heart
J
Cardiovasc
Imaging
2019;20:620624.
350. Praz F, Grasso C, Taramasso M, Baumbach A, Piazza N, Tamburino C,
Windecker S, Maisano F, Prendergast B. Mitral regurgitation in heart failure:
time for a rethink. Eur Heart J 2019;40:21892193.
351. Adamo M, Grasso C, Capodanno D, Rubbio AP, Scandura S, Giannini C, Fiorelli
F, Fiorina C, Branca L, Brambilla N, Bedogni F, Petronio AS, Curello S,
Tamburino C. Five-year clinical outcomes after percutaneous edge-to-edge mitral valve repair: insights from the multicenter GRASP-IT registry. Am Heart J
2019;217:3241.
352. Ailawadi G, Lim DS, Mack MJ, Trento A, Kar S, Grayburn PA, Glower DD,
Wang A, Foster E, Qasim A, Weissman NJ, Ellis J, Crosson L, Fan F, Kron IL,
Pearson PJ, Feldman T, EVEREST II Investigators. One-year outcomes after
MitraClip for functional mitral regurgitation. Circulation 2019;139:3747.
353. Iliadis C, Metze C, Korber MI, Baldus S, Pfister R. Impact of COAPT trial exclusion criteria in real-world patients undergoing transcatheter mitral valve repair.
Int J Cardiol 2020;316:189194.
354. Lindenfeld J, Abraham WT, Grayburn PA, Kar S, Asch FM, Lim DS, Nie H,
Singhal
P,
Sundareswaran
KS,
Weissman
NJ,
Mack
MJ,
Stone
GW,
Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation Investigators.
Association of effective regurgitation orifice area to left ventricular end-diastolic volume ratio with transcatheter mitral valve repair outcomes: a secondary analysis of the COAPT Trial. JAMA Cardiol 2021;6:427436.
355. Jung RG, Simard T, Kovach C, Flint K, Don C, Di Santo P, Adamo M, Branca L,
Valentini F, Benito-Gonzalez T, Fernandez-Vazquez F, Estevez-Loureiro R,
Berardini A, Conti N, Rapezzi C, Biagini E, Parlow S, Shorr R, Levi A, Manovel
A, Cardenal-Piris R, Diaz Fernandez J, Shuvy M, Haberman D, Sala A, Alkhouli
MA, Marini C, Bargagna M, Schiavi D, Denti P, Markovic S, Buzzatti N, Chan V,
Hynes M, Mesana T, Labinaz M, Pappalardo F, Taramasso M, Hibbert B.
Transcatheter mitral valve repair in cardiogenic shock and mitral regurgitation:
a patient-level, multicenter analysis. JACC Cardiovasc Interv 2021;14:111.
356. Adamo M, Fiorelli F, Melica B, D’Ortona R, Lupi L, Giannini C, Silva G, Fiorina
C, Branca L, Chiari E, Chizzola G, Spontoni P, Espada Guerreiro C, Curello S,
Petronio AS, Metra M COAPT-like profile predicts long-term outcomes in patients with secondary mitral regurgitation undergoing MitraClip implantation.
JACC Cardiovasc Interv 2021;14:1525.
357. Iung B, Messika-Zeitoun D, Boutitie F, Trochu JN, Armoiry X, Maucort-Boulch
D, Obadia JF, Vahanian A. Characteristics and outcome of COAPT-eligible patients in the MITRA-FR Trial. Circulation 2020;142:24822484.
358. Iung B, Vahanian A. Epidemiology of acquired valvular heart disease. Can J
Cardiol 2014;30:962970.
359. Abramowitz Y, Jilaihawi H, Chakravarty T, Mack MJ, Makkar RR. Mitral annulus calcification. J Am Coll Cardiol 2015;66:19341941.
360. Desnos C, Iung B, Himbert D, Ducrocq G, Urena M, Cormier B, Brochet E, Ou
P, Vahanian A, Bouleti C. Temporal trends on percutaneous mitral commissurotomy: 30 years of experience. J Am Heart Assoc 2019;8:e012031.
361. Andell P, Li X, Martinsson A, Andersson C, Stagmo M, Zoller B, Sundquist K,
Smith JG. Epidemiology of valvular heart disease in a Swedish nationwide hospital-based register study. Heart 2017;103:16961703.
362. Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, Iung
B, Otto CM, Pellikka PA, Quinones M, EAE/ASE. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. Eur J
Echocardiogr 2009;10:125.
363. Bouleti C, Iung B, Laouenan C, Himbert D, Brochet E, Messika-Zeitoun D,
Detaint D, Garbarz E, Cormier B, Michel PL, Mentre F, Vahanian A. Late results of percutaneous mitral commissurotomy up to 20 years: development and validation of a risk score predicting late functional results from a series of 912
patients. Circulation 2012;125:21192127.
364. Nunes MC, Tan TC, Elmariah S, do Lago R, Margey R, Cruz-Gonzalez I, Zheng
H, Handschumacher MD, Inglessis I, Palacios IF, Weyman AE, Hung J. The echo score revisited: impact of incorporating commissural morphology and leaflet displacement to the prediction of outcome for patients undergoing percutaneous mitral valvuloplasty. Circulation 2014;129:886895.
365. Wilkins GT, Weyman AE, Abascal VM, Block PC, Palacios IF. Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation.
Br
Heart
J
1988;60:299308.
366. Badheka AO, Shah N, Ghatak A, Patel NJ, Chothani A, Mehta K, Singh V, Patel
N, Grover P, Deshmukh A, Panaich SS, Savani GT, Bhalara V, Arora S, Rathod
A, Desai H, Kar S, Alfonso C, Palacios IF, Grines C, Schreiber T, Rihal CS,
Makkar R, Cohen MG, O’Neill W, de Marchena E. Balloon mitral valvuloplasty in the
United
States:
a
13-year perspective.
Am
J
Med
2014;127:1126.e11126.e12.
367. Tomai F, Gaspardone A, Versaci F, Ghini AS, Altamura L, De Luca L, Gioffre G,
Gioffre PA. Twenty year follow-up after successful percutaneous balloon mitral valvuloplasty in a large contemporary series of patients with mitral stenosis. Int J
Cardiol 2014;177:881885.
368. Bouleti C, Iung B, Himbert D, Messika-Zeitoun D, Brochet E, Garbarz E,
Cormier B, Vahanian A. Relationship between valve calcification and long-term results of percutaneous mitral commissurotomy for rheumatic mitral stenosis.
Circ Cardiovasc Interv 2014;7:381389.
369. Bouleti C, Iung B, Himbert D, Brochet E, Messika-Zeitoun D, Detaint D,
Garbarz E, Cormier B, Vahanian A. Reinterventions after percutaneous mitral commissurotomy during long-term follow-up, up to 20 years: the role of repeat percutaneous mitral commissurotomy. Eur Heart J 2013;34:19231930.
370. Kim JY, Kim SH, Myong JP, Kim YR, Kim TS, Kim JH, Jang SW, Oh YS, Lee MY,
Rho TH. Outcomes of direct oral anticoagulants in patients with mitral stenosis.
J Am Coll Cardiol 2019;73:11231131.
371. Song H, Kang DH, Kim JH, Park KM, Song JM, Choi KJ, Hong MK, Chung CH,
Song JK, Lee JW, Park SW, Park SJ. Percutaneous mitral valvuloplasty versus surgical treatment in mitral stenosis with severe tricuspid regurgitation.
Circulation 2007;116:I246250.
372. El Sabbagh A, Reddy YNV, Barros-Gomes S, Borlaug BA, Miranda WR, Pislaru SV,
Nishimura RA, Pellikka PA. Low-gradient severe mitral stenosis: hemodynamic profiles, clinical characteristics, and outcomes. J Am Heart Assoc 2019;8:e010736.
373. Kato N, Padang R, Scott CG, Guerrero M, Pislaru SV, Pellikka PA. The natural history of severe calcific mitral stenosis. J Am Coll Cardiol 2020;75:30483057.
374. Nishimura RA, Vahanian A, Eleid MF, Mack MJ. Mitral valve diseasecurrent management and future challenges. Lancet 2016;387:13241334.
375. Barasch E, Gottdiener JS, Larsen EK, Chaves PH, Newman AB, Manolio TA.
Clinical significance of calcification of the fibrous skeleton of the heart and aortosclerosis in community dwelling elderly. The Cardiovascular Health Study
(CHS). Am Heart J 2006;151:3947.
376. Alexis SL, Malik AH, El-Eshmawi A, George I, Sengupta A, Kodali SK, Hahn RT,
Khalique OK, Zaid S, Guerrero M, Bapat VN, Leon MB, Adams DH, Tang GHL.
ESC/EACTS Guidelines
626


<!-- PAGE 67 -->

### Page 67

.............................................................................................................................................................................
Surgical and transcatheter mitral valve replacement in mitral annular calcification: a systematic review. J Am Heart Assoc 2021;10:e018514.
377. Okuno T, Brugger N, Asami M, Heg D, Siontis GCM, Winkel MG, Lanz J, Grani C,
Huber A, Stortecky S, George I, Kodali S, Pilgrim T, Windecker S, Khalique OK,
Praz F. Clinical impact of mitral calcium volume in patients undergoing transcatheter aortic valve implantation. J Cardiovasc Comput Tomogr 2021;15:356365.
378. Bertrand PB, Churchill TW, Yucel E, Namasivayam M, Bernard S, Nagata Y, He
W, Andrews CT, Picard MH, Weyman AE, Levine RA, Hung J. Prognostic importance of the transmitral pressure gradient in mitral annular calcification with associated mitral valve dysfunction. Eur Heart J 2020;41:43214328.
379. Urena M, Himbert D, Brochet E, Carrasco JL, Iung B, Nataf P, Vahanian A.
Transseptal transcatheter mitral valve replacement using balloon-expandable transcatheter heart valves: a step-by-step approach. JACC Cardiovasc Interv
2017;10:19051919.
380. Sud K, Agarwal S, Parashar A, Raza MQ, Patel K, Min D, Rodriguez LL,
Krishnaswamy A, Mick SL, Gillinov AM, Tuzcu EM, Kapadia SR. Degenerative mitral stenosis:
unmet need for percutaneous interventions.
Circulation
2016;133:15941604.
381. Guerrero M, Urena M, Himbert D, Wang DD, Eleid M, Kodali S, George I,
Chakravarty T, Mathur M, Holzhey D, Pershad A, Fang HK, O’Hair D, Jones N,
Mahadevan VS, Dumonteil N, Rodes-Cabau J, Piazza N, Ferrari E, Ciaburri D, Nejjari
M, DeLago A, Sorajja P, Zahr F, Rajagopal V, Whisenant B, Shah PB, Sinning JM,
Witkowski A, Eltchaninoff H, Dvir D, Martin B, Attizzani GF, Gaia D, Nunes NSV,
Fassa AA, Kerendi F, Pavlides G, Iyer V, Kaddissi G, Witzke C, Wudel J, Mishkel G,
Raybuck B, Wang C, Waksman R, Palacios I, Cribier A, Webb J, Bapat V, Reisman
M, Makkar R, Leon M, Rihal C, Vahanian A, O’Neill W, Feldman T. 1-Year outcomes of transcatheter mitral valve replacement in patients with severe mitral annular calcification. J Am Coll Cardiol 2018;71:18411853.
382. Yoon SH, Whisenant BK, Bleiziffer S, Delgado V, Dhoble A, Schofer N,
Eschenbach L, Bansal E, Murdoch DJ, Ancona M, Schmidt T, Yzeiraj E, Vincent
F, Niikura H, Kim WK, Asami M, Unbehaun A, Hirji S, Fujita B, Silaschi M, Tang
GHL, Kuwata S, Wong SC, Frangieh AH, Barker CM, Davies JE, Lauten A,
Deuschl F, Nombela-Franco L, Rampat R, Nicz PFG, Masson JB, Wijeysundera
HC, Sievert H, Blackman DJ, Gutierrez-Ibanes E, Sugiyama D, Chakravarty T,
Hildick-Smith D, de Brito FS, Jr., Jensen C, Jung C, Smalling RW, Arnold M,
Redwood S, Kasel AM, Maisano F, Treede H, Ensminger SM, Kar S, Kaneko T,
Pilgrim T, Sorajja P, Van Belle E, Prendergast BD, Bapat V, Modine T, Schofer J,
Frerker C, Kempfert J, Attizzani GF, Latib A, Schaefer U, Webb JG, Bax JJ,
Makkar RR. Outcomes of transcatheter mitral valve replacement for degenerated bioprostheses, failed annuloplasty rings, and mitral annular calcification. Eur
Heart J 2019;40:441451.
383. Guerrero M, Vemulapalli S, Xiang Q, Wang DD, Eleid M, Cabalka AK, Sandhu
G, Salinger M, Russell H, Greenbaum A, Kodali S, George I, Dvir D, Whisenant
B, Russo MJ, Pershad A, Fang K, Coylewright M, Shah P, Babaliaros V, Khan JM,
Tommaso C, Saucedo J, Kar S, Makkar R, Mack M, Holmes D, Leon M, Bapat V,
Thourani VH, Rihal C, O’Neill W, Feldman T. Thirty-day outcomes of transcatheter mitral valve replacement for degenerated mitral bioprostheses (valvein-valve), failed surgical rings (valve-in-ring), and native valve with severe mitral annular calcification (valve-in-mitral annular calcification) in the United States:
data from the Society of Thoracic Surgeons/American College of Cardiology/
Transcatheter Valve Therapy Registry. Circ Cardiovasc Interv 2020;13:e008425.
384. Wang DD, Guerrero M, Eng MH, Eleid MF, Meduri CU, Rajagopal V, Yadav PK,
Fifer MA, Palacios IF, Rihal CS, Feldman TE, O’Neill WW. Alcohol septal ablation to prevent left ventricular outflow tract obstruction during transcatheter mitral valve replacement: first-in-man study. JACC Cardiovasc Interv 2019;12:12681279.
385. Khan JM, Babaliaros VC, Greenbaum AB, Foerst JR, Yazdani S, McCabe JM,
Paone G, Eng MH, Leshnower BG, Gleason PT, Chen MY, Wang DD, Tian X,
Stine AM, Rogers T, Lederman RJ. Anterior leaflet laceration to prevent ventricular outflow tract obstruction during transcatheter mitral valve replacement. J
Am Coll Cardiol 2019;73:25212534.
386. El Sabbagh A, Eleid MF, Foley TA, Al-Hijji MA, Daly RC, Rihal CS, Said SM.
Direct transatrial implantation of balloon-expandable valve for mitral stenosis with severe annular calcifications: early experience and lessons learned. Eur J
Cardiothorac Surg 2018;53:162169.
387. Praz F, Khalique OK, Lee R, Veeragandham R, Russell H, Guerrero M, Islam
AM, Deaton DW, Kaneko T, Kodali SK, Leon MB, Bapat V, Takayama H, Borger
MA, George I. Transatrial implantation of a transcatheter heart valve for severe mitral annular calcification. J Thorac Cardiovasc Surg 2018;156:132142.
388. Sorajja P, Gossl M, Babaliaros V, Rizik D, Conradi L, Bae R, Burke RF, Schafer
U, Lisko JC, Riley RD, Guyton R, Dumonteil N, Berthoumieu P, Tchetche D,
Blanke P, Cavalcante JL, Sun B. Novel transcatheter mitral valve prosthesis for patients with severe mitral annular calcification.
J
Am
Coll
Cardiol
2019;74:14311440.
389. Topilsky Y, Maltais S, Medina Inojosa J, Oguz D, Michelena H, Maalouf J,
Mahoney DW, Enriquez-Sarano M. Burden of tricuspid regurgitation in patients diagnosed in the community setting. JACC Cardiovasc Imaging 2019;12:433442.
390. Song H, Kim MJ, Chung CH, Choo SJ, Song MG, Song JM, Kang DH, Lee JW,
Song JK. Factors associated with development of late significant tricuspid regurgitation after successful left-sided valve surgery. Heart 2009;95:931936.
391. Kwak JJ, Kim YJ, Kim MK, Kim HK, Park JS, Kim KH, Kim KB, Ahn H, Sohn DW,
Oh BH, Park YB. Development of tricuspid regurgitation late after left-sided valve surgery: a single-center experience with long-term echocardiographic examinations. Am Heart J 2008;155:732737.
392. Ortiz-Leon XA, Posada-Martinez EL, Trejo-Paredes MC, Ivey-Miranda JB,
Pereira J, Crandall I, DaSilva P, Bouman E, Brooks A, Gerardi C, Ugonabo I,
Chen W, Houle H, Akar JG, Lin BA, McNamara RL, Lombo-Lievano B, AriasGodinez JA, Sugeng L. Understanding tricuspid valve remodelling in atrial fibrillation using three-dimensional echocardiography. Eur Heart J Cardiovasc Imaging
2020;21:747755.
393. Kim JB, Spevack DM, Tunick PA, Bullinga JR, Kronzon I, Chinitz LA, Reynolds
HR. The effect of transvenous pacemaker and implantable cardioverter defibrillator lead placement on tricuspid valve function: an observational study. J Am
Soc Echocardiogr 2008;21:284287.
394. Hoke U, Auger D, Thijssen J, Wolterbeek R, van der Velde ET, Holman ER,
Schalij MJ, Bax JJ, Delgado V, Marsan NA. Significant lead-induced tricuspid regurgitation is associated with poor prognosis at long-term follow-up. Heart
2014;100:960968.
395. Anvardeen K, Rao R, Hazra S, Hay K, Dai H, Stoyanov N, Birnie D, Dwivedi G,
Chan KL. Prevalence and significance of tricuspid regurgitation post-endocardial lead placement. JACC Cardiovasc Imaging 2019;12:562564.
396. Prihadi EA, van der Bijl P, Gursoy E, Abou R, Mara Vollema E, Hahn RT, Stone
GW, Leon MB, Ajmone Marsan N, Delgado V, Bax JJ. Development of significant tricuspid regurgitation over time and prognostic implications: new insights into natural history. Eur Heart J 2018;39:35743581.
397. Benfari G, Antoine C, Miller WL, Thapa P, Topilsky Y, Rossi A, Michelena HI,
Pislaru S, Enriquez-Sarano M. Excess mortality associated with functional tricuspid regurgitation complicating heart failure with reduced ejection fraction.
Circulation 2019;140:196206.
398. Dietz MF, Prihadi EA, van der Bijl P, Goedemans L, Mertens BJA, Gursoy E, van
Genderen OS, Ajmone Marsan N, Delgado V, Bax JJ. Prognostic implications of right ventricular remodeling and function in patients with significant secondary tricuspid regurgitation. Circulation 2019;140:836845.
399. Muraru D, Badano LP, Nagata Y, Surkova E, Nabeshima Y, Genovese D, Otsuji
Y, Guida V, Azzolina D, Palermo C, Takeuchi M. Development and prognostic validation of partition values to grade right ventricular dysfunction severity using
3D echocardiography. Eur Heart J Cardiovasc Imaging 2020;21:1021.
400. Park JB, Lee SP, Lee JH, Yoon YE, Park EA, Kim HK, Lee W, Kim YJ, Cho GY,
Sohn DW. Quantification of right ventricular volume and function using singlebeat three-dimensional echocardiography: a validation study with cardiac magnetic resonance. J Am Soc Echocardiogr 2016;29:392401.
401. Grothues F, Moon JC, Bellenger NG, Smith GS, Klein HU, Pennell DJ.
Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J 2004;147:218223.
402. Song JM, Jang MK, Choi YS, Kim YJ, Min SY, Kim DH, Kang DH, Song JK. The vena contracta in functional tricuspid regurgitation: a real-time three-dimensional color
Doppler echocardiography study.
J
Am
Soc
Echocardiogr
2011;24:663670.
403. de Agustin JA, Viliani D, Vieira C, Islas F, Marcos-Alberca P, Gomez de Diego JJ,
Nunez-Gil IJ, Almeria C, Rodrigo JL, Luaces M, Garcia-Fernandez MA, Macaya
C, Perez de Isla L. Proximal isovelocity surface area by single-beat three-dimensional color Doppler echocardiography applied for tricuspid regurgitation quantification. J Am Soc Echocardiogr 2013;26:10631072.
404. Chen TE, Kwon SH, Enriquez-Sarano M, Wong BF, Mankad SV. Three-dimensional color Doppler echocardiographic quantification of tricuspid regurgitation orifice area: comparison with conventional two-dimensional measures. J Am Soc
Echocardiogr 2013;26:11431152.
405. Dahou A, Ong G, Hamid N, Avenatti E, Yao J, Hahn RT. Quantifying tricuspid regurgitation severity: a comparison of proximal isovelocity surface area and novel quantitative
Doppler methods.
JACC
Cardiovasc
Imaging
2019;12:560562.
406. Utsunomiya H, Harada Y, Susawa H, Takahari K, Ueda Y, Izumi K, Itakura K,
Ikenaga H, Hidaka T, Fukuda Y, Shiota T, Kihara Y. Comprehensive evaluation of tricuspid regurgitation location and severity using vena contracta analysis: a color Doppler three-dimensional transesophageal echocardiographic study. J
Am Soc Echocardiogr 2019;32:15261537.e2.
407. Hahn RT, Zamorano JL. The need for a new tricuspid regurgitation grading scheme. Eur Heart J Cardiovasc Imaging 2017;18:13421343.
408. Nickenig G, Weber M, Lurz P, von Bardeleben RS, Sitges M, Sorajja P,
Hausleiter
J,
Denti
P,
Trochu
JN,
Nabauer
M,
Dahou
A,
Hahn
RT.
Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6month outcomes of the
TRILUMINATE
single-arm study.
Lancet
2019;394:20022011.
ESC/EACTS Guidelines
627


<!-- PAGE 68 -->

### Page 68

.............................................................................................................................................................................
409. Nickenig G, Weber M, Schueler R, Hausleiter J, Nabauer M, von Bardeleben
RS, Sotiriou E, Schafer U, Deuschl F, Kuck KH, Kreidel F, Juliard JM, Brochet E,
Latib A, Agricola E, Baldus S, Friedrichs K, Vandrangi P, Verta P, Hahn RT,
Maisano F. 6-Month outcomes of tricuspid valve reconstruction for patients with severe tricuspid regurgitation. J Am Coll Cardiol 2019;73:19051915.
410. Santoro C, Marco Del Castillo A, Gonzalez-Gomez A, Monteagudo JM, Hinojar
R, Lorente A, Abellas M, Vieitez JM, Garcia Martin A, Casas Rojo E, Ruiz S,
Barrios V, Luis Moya J, Jimenez-Nacher JJ, Zamorano Gomez JL, FernandezGolfin C. Mid-term outcome of severe tricuspid regurgitation: are there any differences according to mechanism and severity? Eur Heart J Cardiovasc Imaging
2019;20:10351042.
411. Miura M, Alessandrini H, Alkhodair A, Attinger-Toller A, Biasco L, Lurz P,
Braun D, Brochet E, Connelly KA, de Bruijn S, Denti P, Deuschl F, EstevezLoureiro R, Fam N, Frerker C, Gavazzoni M, Hausleiter J, Himbert D, Ho E,
Juliard JM, Kaple R, Besler C, Kodali S, Kreidel F, Kuck KH, Latib A, Lauten A,
Monivas V, Mehr M, Muntane-Carol G, Nazif T, Nickenig G, Pedrazzini G,
Philippon F, Pozzoli A, Praz F, Puri R, Rodes-Cabau J, Schafer U, Schofer J,
Sievert H, Tang GHL, Thiele H, Rommel KP, Vahanian A, Von Bardeleben RS,
Webb JG, Weber M, Windecker S, Winkel M, Zuber M, Leon MB, Maisano F,
Hahn RT, Taramasso M, TriValve Investigators. Impact of massive or torrential tricuspid regurgitation in patients undergoing transcatheter tricuspid valve intervention. JACC Cardiovasc Interv 2020;13:19992009.
412. Peri Y, Sadeh B, Sherez C, Hochstadt A, Biner S, Aviram G, Ingbir M, Nachmany I,
Topaz G, Flint N, Keren G, Topilsky Y. Quantitative assessment of effective regurgitant orifice: impact on risk stratification, and cut-off for severe and torrential tricuspid regurgitation grade. Eur Heart J Cardiovasc Imaging 2020;21:768776.
413. Stocker TJ, Hertell H, Orban M, Braun D, Rommel KP, Ruf T, Ong G, Nabauer
M, Deseive S, Fam N, von Bardeleben RS, Thiele H, Massberg S, Lurz P,
Hausleiter J. Cardiopulmonary hemodynamic profile predicts mortality after transcatheter tricuspid valve repair in chronic heart failure. JACC Cardiovasc
Interv 2021;14:2938.
414. Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on longterm survival. J Am Coll Cardiol 2004;43:405409.
415. Topilsky Y, Nkomo VT, Vatury O, Michelena HI, Letourneau T, Suri RM, Pislaru
S, Park S, Mahoney DW, Biner S, Enriquez-Sarano M. Clinical outcome of isolated tricuspid regurgitation. JACC Cardiovasc Imaging 2014;7:11851194.
416. Chorin E, Rozenbaum Z, Topilsky Y, Konigstein M, Ziv-Baran T, Richert E,
Keren G, Banai S. Tricuspid regurgitation and long-term clinical outcomes. Eur
Heart J Cardiovasc Imaging 2020;21:157165.
417. Topilsky Y, Inojosa JM, Benfari G, Vaturi O, Maltais S, Michelena H, Mankad S,
Enriquez-Sarano M. Clinical presentation and outcome of tricuspid regurgitation in patients with systolic dysfunction. Eur Heart J 2018;39:35843592.
418. Kadri AN, Menon V, Sammour YM, Gajulapalli RD, Meenakshisundaram C,
Nusairat L, Mohananey D, Hernandez AV, Navia J, Krishnaswamy A, Griffin B,
Rodriguez L, Harb SC, Kapadia S. Outcomes of patients with severe tricuspid regurgitation and congestive heart failure. Heart 2019;105:18131817.
419. Stuge O, Liddicoat J. Emerging opportunities for cardiac surgeons within structural heart disease. J Thorac Cardiovasc Surg 2006;132:12581261.
420. Kilic A, Saha-Chaudhuri P, Rankin JS, Conte JV. Trends and outcomes of tricuspid valve surgery in North America: an analysis of more than 50,000 patients from the
Society of
Thoracic
Surgeons database.
Ann
Thorac
Surg
2013;96:15461552.
421. Dreyfus J, Ghalem N, Garbarz E, Cimadevilla C, Nataf P, Vahanian A, Caranhac
G, Messika-Zeitoun D. Timing of referral of patients with severe isolated tricuspid valve regurgitation to surgeons (from a French nationwide database). Am J
Cardiol 2018;122:323326.
422. Antunes MJ, Rodriguez-Palomares J, Prendergast B, De Bonis M, Rosenhek R,
Al-Attar N, Barili F, Casselman F, Folliguet T, Iung B, Lancellotti P, Muneretto
C, Obadia JF, Pierard L, Suwalski P, Zamorano P, ESC Working Groups of
Cardiovascular Surgery and Valvular Heart Disease. Management of tricuspid valve regurgitation: position statement of the European Society of Cardiology
Working Groups of Cardiovascular Surgery and Valvular Heart Disease. Eur J
Cardiothorac Surg 2017;52:10221030.
423. Dreyfus GD, Corbi PJ, Chan KM, Bahrami T. Secondary tricuspid regurgitation or dilatation: which should be the criteria for surgical repair? Ann Thorac Surg
2005;79:127132.
424. Van de Veire NR, Braun J, Delgado V, Versteegh MI, Dion RA, Klautz RJ, Bax JJ.
Tricuspid annuloplasty prevents right ventricular dilatation and progression of tricuspid regurgitation in patients with tricuspid annular dilatation undergoing mitral valve repair. J Thorac Cardiovasc Surg 2011;141:14311439.
425. Chikwe J, Itagaki S, Anyanwu A, Adams DH. Impact of concomitant tricuspid annuloplasty on tricuspid regurgitation, right ventricular function, and pulmonary artery hypertension after repair of mitral valve prolapse. J Am Coll Cardiol
2015;65:19311938.
426. Badhwar V, Rankin JS, He M, Jacobs JP, Furnary AP, Fazzalari FL, O’Brien S,
Gammie JS, Shahian DM. Performing concomitant tricuspid valve repair at the time of mitral valve operations is not associated with increased operative mortality. Ann Thorac Surg 2017;103:587593.
427. Brescia AA, Ward ST, Watt TMF, Rosenbloom LM, Baker M, Khan S, Ziese E,
Romano MA, Bolling SF, Michigan Mitral Research Group. Outcomes of guideline-directed concomitant annuloplasty for functional tricuspid regurgitation. Ann Thorac Surg 2020;109:12271232.
428. Axtell AL, Bhambhani V, Moonsamy P, Healy EW, Picard MH, Sundt TM, 3rd,
Wasfy JH. Surgery does not improve survival in patients with isolated severe tricuspid regurgitation. J Am Coll Cardiol 2019;74:715725.
429. Zack CJ, Fender EA, Chandrashekar P, Reddy YNV, Bennett CE, Stulak JM,
Miller VM, Nishimura RA. National trends and outcomes in isolated tricuspid valve surgery. J Am Coll Cardiol 2017;70:29532960.
430. Dhoble A, Zhao Y, Vejpongsa P, Loghin C, Smalling RW, Estrera A, Nguyen
TC. National 10-year trends and outcomes of isolated and concomitant tricuspid valve surgery. J Cardiovasc Surg (Torino) 2019;60:119127.
431. Alqahtani F, Berzingi CO, Aljohani S, Hijazi M, Al-Hallak A, Alkhouli M.
Contemporary trends in the use and outcomes of surgical treatment of tricuspid regurgitation. J Am Heart Assoc 2017;6.
432. Dreyfus J, Flagiello M, Bazire B, Eggenspieler F, Viau F, Riant E, Mbaki Y, Bohbot
Y, Eyharts D, Senage T, Dubrulle H, Nicol M, Doguet F, Nguyen V, Coisne A,
Le Tourneau T, Lavie-Badie Y, Tribouilloy C, Donal E, Tomasi J, Habib G,
Selton-Suty C, Raffoul R, Iung B, Obadia JF, Messika-Zeitoun D. Isolated tricuspid valve surgery: impact of aetiology and clinical presentation on outcomes.
Eur Heart J 2020;41:43044317.
433. Hamandi M, Smith RL, Ryan WH, Grayburn PA, Vasudevan A, George TJ,
DiMaio JM, Hutcheson KA, Brinkman W, Szerlip M, Moore DO, Mack MJ.
Outcomes of isolated tricuspid valve surgery have improved in the modern era.
Ann Thorac Surg 2019;108:1115.
434. Dietz MF, Prihadi EA, van der Bijl P, Ajmone Marsan N, Delgado V, Bax JJ.
Prognostic implications of staging right heart failure in patients with significant secondary tricuspid regurgitation. JACC Heart Fail 2020;8:627636.
435. McCarthy PM, Bhudia SK, Rajeswaran J, Hoercher KJ, Lytle BW, Cosgrove DM,
Blackstone EH. Tricuspid valve repair: durability and risk factors for failure. J
Thorac Cardiovasc Surg 2004;127:674685.
436. Chang BC, Lim SH, Yi G, Hong YS, Lee S, Yoo KJ, Kang MS, Cho BK. Long-term clinical results of tricuspid valve replacement. Ann Thorac Surg 2006;81:13171323.
437. Glikson M, Nielsen JC, Michowitz Y, Kronborg MB, Auricchio A, Barbash IM,
Barrabe´s JA, Boriani G, Braunschweig F, Brignole M, Burri H, Coats AJS,
Deharo JC, Delgado V, Diller GP, Israel CW, Keren A, Knops RE, Kotecha D,
Leclercq C, Merkely B, Starck C, Thyle´n I, Tolosana JM, ESC Scientific
Document Group. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J 2021;doi:10.1093/eurheartj/ehab364.
438. Fam NP, Braun D, von Bardeleben RS, Nabauer M, Ruf T, Connelly KA, Ho E,
Thiele H, Lurz P, Weber M, Nickenig G, Narang A, Davidson CJ, Hausleiter J.
Compassionate use of the PASCAL transcatheter valve repair system for severe tricuspid regurgitation: a multicenter, observational, first-in-human experience.
JACC Cardiovasc Interv 2019;12:24882495.
439. Lurz P, Stephan von Bardeleben R, Weber M, Sitges M, Sorajja P, Hausleiter J,
Denti P, Trochu JN, Nabauer M, Tang GHL, Biaggi P, Ying SW, Trusty PM,
Dahou A, Hahn RT, Nickenig G, TRILUMINATE Investigators. Transcatheter edge-to-edge repair for treatment of tricuspid regurgitation. J Am Coll Cardiol
2021;77:229239.
440. Kodali S, Hahn RT, Eleid MF, Kipperman R, Smith R, Lim DS, Gray WA, Narang
A, Pislaru SV, Koulogiannis K, Grayburn P, Fowler D, Hawthorne K, Dahou A,
Deo SH, Vandrangi P, Deuschl F, Mack MJ, Leon MB, Feldman T, Davidson CJ,
CLASP TR EFS Investigators. Feasibility study of the transcatheter valve repair system for severe tricuspid regurgitation. J Am Coll Cardiol 2021;77:345356.
441. Nickenig G, Weber M, Schuler R, Hausleiter J, Nabauer M, von Bardeleben RS,
Sotiriou E, Schafer U, Deuschl F, Alessandrini H, Kreidel F, Juliard JM, Brochet
E, Latib A, Montorfano M, Agricola E, Baldus S, Friedrichs KP, Deo SH, Gilmore
SY, Feldman T, Hahn RT, Maisano F. Tricuspid valve repair with the Cardioband system: two-year outcomes of the multicentre, prospective TRI-REPAIR study.
EuroIntervention 2021;16:e1264e1271.
442. Hahn RT, Kodali S, Fam N, Bapat V, Bartus K, Rodes-Cabau J, Dagenais F,
Estevez-Loureiro R, Forteza A, Kapadia S, Latib A, Maisano F, McCarthy P,
Navia J, Ong G, Peterson M, Petrossian G, Pozzoli A, Reinartz M, Ricciardi MJ,
Robinson N, Sievert H, Taramasso M, Agarwal V, Bedard E, Tarantini G, Colli
A. Early multinational experience of transcatheter tricuspid valve replacement for treating severe tricuspid regurgitation.
JACC
Cardiovasc
Interv
2020;13:24822493.
443. Fam NP, von Bardeleben RS, Hensey M, Kodali SK, Smith RL, Hausleiter J, Ong
G, Boone R, Ruf T, George I, Szerlip M, Nabauer M, Ali FM, Moss R, Bapat V,
Schnitzler K, Kreidel F, Ye J, Deva DP, Mack MJ, Grayburn PA, Peterson MD,
Leon MB, Hahn RT, Webb JG. Transfemoral transcatheter tricuspid valve replacement with the EVOQUE system: a multicenter, observational, first-inhuman experience. JACC Cardiovasc Interv 2021;14:501511.
ESC/EACTS Guidelines
628


<!-- PAGE 69 -->

### Page 69

.............................................................................................................................................................................
444. Lu FL, Ma Y, An Z, Cai CL, Li BL, Song ZG, Han L, Wang J, Qiao F, Xu ZY.
First-in-man experience of transcatheter tricuspid valve replacement with luxvalve in high-risk tricuspid regurgitation patients. JACC Cardiovasc Interv
2020;13:16141616.
445. Rommel KP, Besler C, Noack T, Blazek S, von Roeder M, Fengler K, Ender J,
Gutberlet M, Desch S, Borger MA, Thiele H, Lurz P. Physiological and clinical consequences of right ventricular volume overload reduction after transcatheter treatment for tricuspid regurgitation. JACC Cardiovasc Interv 2019;12:14231434.
446. Montalto C, Sticchi A, Crimi G, Laricchia A, Khokhar A, Giannini F, Ferlini M,
Colombo A, Latib A, Mangieri A. Functional and echocardiographic improvement after transcatheter repair for tricuspid regurgitation: a systematic review and pooled analysis. JACC Cardiovasc Interv 2020;13:27192729.
447. Taramasso M, Benfari G, van der Bijl P, Alessandrini H, Attinger-Toller A,
Biasco L, Lurz P, Braun D, Brochet E, Connelly KA, de Bruijn S, Denti P,
Deuschl F, Estevez-Loureiro R, Fam N, Frerker C, Gavazzoni M, Hausleiter J,
Ho E, Juliard JM, Kaple R, Besler C, Kodali S, Kreidel F, Kuck KH, Latib A,
Lauten A, Monivas V, Mehr M, Muntane-Carol G, Nazif T, Nickening G,
Pedrazzini G, Philippon F, Pozzoli A, Praz F, Puri R, Rodes-Cabau J, Schafer U,
Schofer J, Sievert H, Tang GHL, Thiele H, Topilsky Y, Rommel KP, Delgado V,
Vahanian A, Von Bardeleben RS, Webb JG, Weber M, Windecker S, Winkel M,
Zuber M, Leon MB, Hahn RT, Bax JJ, Enriquez-Sarano M, Maisano F.
Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation. J Am Coll Cardiol 2019;74:29983008.
448. Prihadi EA, Delgado V, Hahn RT, Leipsic J, Min JK, Bax JJ. Imaging needs in novel transcatheter tricuspid valve interventions.
JACC
Cardiovasc
Imaging
2018;11:736754.
449. Hahn RT. State-of-the-art review of echocardiographic imaging in the evaluation and treatment of functional tricuspid regurgitation. Circ Cardiovasc Imaging
2016;9.
450. Utsunomiya H, Itabashi Y, Mihara H, Berdejo J, Kobayashi S, Siegel RJ, Shiota T.
Functional tricuspid regurgitation caused by chronic atrial fibrillation: a real-time
3-dimensional transesophageal echocardiography study. Circ Cardiovasc Imaging
2017;10.
451. Filsoufi F, Anyanwu AC, Salzberg SP, Frankel T, Cohn LH, Adams DH. Longterm outcomes of tricuspid valve replacement in the current era. Ann Thorac
Surg 2005;80:845850.
452. Yeter E, Ozlem K, Kilic H, Ramazan A, Acikel S. Tricuspid balloon valvuloplasty to treat tricuspid stenosis. J Heart Valve Dis 2010;19:159160.
453. Unger P, Pibarot P, Tribouilloy C, Lancellotti P, Maisano F, Iung B, Pierard L,
European
Society of
Cardiology
Council on
Valvular
Heart
Disease.
Multiple and mixed valvular heart diseases.
Circ
Cardiovasc
Imaging
2018;11:e007862.
454. Egbe AC, Luis SA, Padang R, Warnes CA. Outcomes in moderate mixed aortic valve disease:
is it time for a
paradigm shift?
J
Am
Coll
Cardiol
2016;67:23212329.
455. Egbe AC, Poterucha JT, Warnes CA. Mixed aortic valve disease: midterm outcome and predictors of adverse events. Eur Heart J 2016;37:26712678.
456. Zilberszac R, Gabriel H, Schemper M, Zahler D, Czerny M, Maurer G,
Rosenhek R. Outcome of combined stenotic and regurgitant aortic valve disease. J Am Coll Cardiol 2013;61:14891495.
457. Unger P, Tribouilloy C. Aortic stenosis with other concomitant valvular disease:
aortic regurgitation, mitral regurgitation, mitral stenosis, or tricuspid regurgitation. Cardiol Clin 2020;38:3346.
458. Philip JL, Zens T, Lozonschi L, De Oliveira NC, Osaki S, Kohmoto T, Akhter
SA, Tang PC. Outcomes of surgical aortic valve replacement for mixed aortic valve disease. J Thorac Dis 2018;10:40424051.
459. Chahine J, Kadri AN, Gajulapalli RD, Krishnaswamy A, Mick S, Perez O, Lak H,
Nair RM, Montane B, Tak J, Tuzcu EM, Griffin B, Svensson LG, Harb SC,
Kapadia SR. Outcomes of transcatheter aortic valve replacement in mixed aortic valve disease. JACC Cardiovasc Interv 2019;12:22992306.
460. Yang LT, Enriquez-Sarano M, Scott CG, Padang R, Maalouf JF, Pellikka PA,
Michelena HI. Concomitant mitral regurgitation in patients with chronic aortic regurgitation. J Am Coll Cardiol 2020;76:233246.
461. Mehr M, Karam N, Taramasso M, Ouarrak T, Schneider S, Lurz P, von
Bardeleben RS, Fam N, Pozzoli A, Lubos E, Boekstegers P, Schillinger W, Plicht
B, Eggebrecht H, Baldus S, Senges J, Maisano F, Hausleiter J, TriValve, TRAMI
Investigators. Combined tricuspid and mitral versus isolated mitral valve repair for severe MR and TR: an analysis from the TriValve and TRAMI registries. JACC
Cardiovasc Interv 2020;13:543550.
462. Goldstone AB, Chiu P, Baiocchi M, Lingala B, Patrick WL, Fischbein MP, Woo
YJ. Mechanical or biologic prostheses for aortic-valve and mitral-valve replacement. N Engl J Med 2017;377:18471857.
463. Head SJ, Celik M, Kappetein AP. Mechanical versus bioprosthetic aortic valve replacement. Eur Heart J 2017;38:21832191.
464. Diaz R, Hernandez-Vaquero D, Alvarez-Cabo R, Avanzas P, Silva J, Moris C,
Pascual I. Long-term outcomes of mechanical versus biological aortic valve prosthesis: systematic review and meta-analysis. J Thorac Cardiovasc Surg
2019;158:706714.e18.
465. David TE, Ouzounian M, David CM, Lafreniere-Roula M, Manlhiot C. Late results of the Ross procedure. J Thorac Cardiovasc Surg 2019;157:201208.
466. Malik AH, Yandrapalli S, Aronow WS, Panza JA, Cooper HA. Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves. Heart 2019;105:14321436.
467. Duan L, Doctor JN, Adams JL, Romley JA, Nguyen LA, An J, Lee MS.
Comparison of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and bioprosthetic heart valves. Am J Cardiol 2021;146:2228.
468. Pasciolla S, Zizza LF, Le T, Wright K. Comparison of the efficacy and safety of direct oral anticoagulants and warfarin after bioprosthetic valve replacements.
Clin Drug Investig 2020;40:839845.
469. Russo V, Carbone A, Attena E, Rago A, Mazzone C, Proietti R, Parisi V, Scotti
A, Nigro G, Golino P, D’Onofrio A. Clinical benefit of direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and bioprosthetic heart valves. Clin Ther 2019;41:25492557.
470. Capodanno D, Petronio AS, Prendergast B, Eltchaninoff H, Vahanian A, Modine
T, Lancellotti P, Sondergaard L, Ludman PF, Tamburino C, Piazza N, Hancock J,
Mehilli J, Byrne RA, Baumbach A, Kappetein AP, Windecker S, Bax J, Haude M.
Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the
European
Association of
Percutaneous
Cardiovascular Interventions (EAPCI) endorsed by the European Society of
Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery
(EACTS). Eur Heart J 2017;38:33823390.
471. Zoghbi WA, Chambers JB, Dumesnil JG, Foster E, Gottdiener JS, Grayburn PA,
Khandheria BK, Levine RA, Marx GR, Miller FA, Jr., Nakatani S, Quinones MA,
Rakowski H, Rodriguez LL, Swaminathan M, Waggoner AD, Weissman NJ,
Zabalgoitia M, American Society of Echocardiography’s G, Standards C, Task
Force on Prosthetic V, American College of Cardiology Cardiovascular Imaging
C, Cardiac Imaging Committee of the American Heart A, European Association of E, European Society of C, Japanese Society of E, Canadian Society of E,
American College of Cardiology F, American Heart A, European Association of
E, European Society of C, Japanese Society of E, Canadian Society of E.
Recommendations for evaluation of prosthetic valves with echocardiography and
Doppler ultrasound:
a report from the
American
Society of
Echocardiography’s Guidelines and Standards Committee and the Task Force on Prosthetic Valves, developed in conjunction with the American College of
Cardiology Cardiovascular Imaging Committee, Cardiac Imaging Committee of the
American
Heart
Association,
the
European
Association of
Echocardiography, a registered branch of the European Society of Cardiology,
the Japanese Society of Echocardiography and the Canadian Society of
Echocardiography,
endorsed by the
American
College of
Cardiology
Foundation,
American
Heart
Association,
European
Association of
Echocardiography, a registered branch of the European Society of Cardiology,
the
Japanese
Society of
Echocardiography,
and
Canadian
Society of
Echocardiography. J Am Soc Echocardiogr 2009;22:9751014.
472. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses.
Circulation
1994;89:635641.
473. Mok CK, Boey J, Wang R, Chan TK, Cheung KL, Lee PK, Chow J, Ng RP, Tse
TF. Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial. Circulation 1985;72:10591063.
474. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack
MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y,
Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van de Werf F, RE-ALIGN
Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369:12061214.
475. Iung B, Rodes-Cabau J. The optimal management of anti-thrombotic therapy after valve replacement: certainties and uncertainties. Eur Heart J 2014;35:29422949.
476. Caldeira D, David C, Santos AT, Costa J, Pinto FJ, Ferreira JJ. Efficacy and safety of low molecular weight heparin in patients with mechanical heart valves: systematic review and meta-analysis. J Thromb Haemost 2014;12:650659.
477. Laffort P, Roudaut R, Roques X, Lafitte S, Deville C, Bonnet J, Baudet E. Early and long-term (one-year) effects of the association of aspirin and oral anticoagulant on thrombi and morbidity after replacement of the mitral valve with the
St. Jude medical prosthesis: a clinical and transesophageal echocardiographic study. J Am Coll Cardiol 2000;35:739746.
478. Sousa-Uva M, Head SJ, Milojevic M, Collet JP, Landoni G, Castella M, Dunning J,
Gudbjartsson T, Linker NJ, Sandoval E, Thielmann M, Jeppsson A, Landmesser
U. 2017 EACTS Guidelines on perioperative medication in adult cardiac surgery. Eur J Cardiothorac Surg 2018;53:533.
479. Butchart EG, Gohlke-Barwolf C, Antunes MJ, Tornos P, De Caterina R,
Cormier B, Prendergast B, Iung B, Bjornstad H, Leport C, Hall RJ, Vahanian A,
ESC/EACTS Guidelines
629


<!-- PAGE 70 -->

### Page 70

.............................................................................................................................................................................
Working Groups on Valvular Heart Disease; Thrombosis and Cardiac
Rehabilitation and Exercise Physiology, European Society of Cardiology.
Recommendations for the management of patients after heart valve surgery.
Eur Heart J 2005;26:24632471.
480. Torella M, Torella D, Chiodini P, Franciulli M, Romano G, De Santo L, De Feo
M, Amarelli C, Sasso FC, Salvatore T, Ellison GM, Indolfi C, Cotrufo M, Nappi
G. LOWERing the INtensity of oral anticoaGulant Therapy in patients with bileaflet mechanical aortic valve replacement: results from the “LOWERINGIT” Trial. Am Heart J 2010;160:171178.
481. Puskas J, Gerdisch M, Nichols D, Quinn R, Anderson C, Rhenman B, Fermin L,
McGrath M, Kong B, Hughes C, Sethi G, Wait M, Martin T, Graeve A,
PROACT Investigators. Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial. J Thorac Cardiovasc Surg 2014;147:12021210;
discussion 1210-1201.
482. Heneghan C, Ward A, Perera R, Self-Monitoring Trialist C, Bankhead C, Fuller
A, Stevens R, Bradford K, Tyndel S, Alonso-Coello P, Ansell J, Beyth R,
Bernardo A, Christensen TD, Cromheecke ME, Edson RG, Fitzmaurice D,
Gadisseur AP, Garcia-Alamino JM, Gardiner C, Hasenkam JM, Jacobson A,
Kaatz S, Kamali F, Khan TI, Knight E, Kortke H, Levi M, Matchar D, MenendezJandula B, Rakovac I, Schaefer C, Siebenhofer A, Souto JC, Sunderji R, Gin K,
Shalansky K, Voller H, Wagner O, Zittermann A. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet
2012;379:322334.
483. Crowther MA, Ageno W, Garcia D, Wang L, Witt DM, Clark NP, Blostein MD,
Kahn SR, Vesely SK, Schulman S, Kovacs MJ, Rodger MA, Wells P, Anderson D,
Ginsberg J, Selby R, Siragusa S, Silingardi M, Dowd MB, Kearon C. Oral vitamin
K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med 2009;150:293300.
484. Halvorsen S, Storey RF, Rocca B, Sibbing D, Ten Berg J, Grove EL, Weiss TW,
Collet JP, Andreotti F, Gulba DC, Lip GYH, Husted S, Vilahur G, Morais J,
Verheugt FWA, Lanas A, Al-Shahi Salman R, Steg PG, Huber K, ESC Working
Group on Thrombosis. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis.
Eur Heart J 2017;38:14551462.
485. Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D.
Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch
Intern Med 2003;163:24692473.
486. Massel DR, Little SH. Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database Syst Rev 2013:CD003464.
487. Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N,
Gislason GH, Folke F, Andersen SS, Schramm TK, Abildstrom SZ, Poulsen HE,
Kober L, Torp-Pedersen C. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch
Intern Med 2010;170:14331441.
488. Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS,
Garcia DA, Jacobson A, Jaffer AK, Kong DF, Schulman S, Turpie AG, Hasselblad
V, Ortel TL, BRIDGE Investigators. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 2015;373:823833.
489. Kristensen SD, Knuuti J, Saraste A, Anker S, Botker HE, Hert SD, Ford I,
Gonzalez-Juanatey JR, Gorenek B, Heyndrickx GR, Hoeft A, Huber K, Iung B,
Kjeldsen KP, Longrois D, Luscher TF, Pierard L, Pocock S, Price S, Roffi M,
Sirnes PA, Sousa-Uva M, Voudris V, Funck-Brentano C, Authors/Task Force
Members. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology
(ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J
2014;35:23832431.
490. Gellatly RM, Leet A, Brown KE. Fondaparinux: an effective bridging strategy in heparin-induced thrombocytopenia and mechanical circulatory support. J Heart
Lung Transplant 2014;33:118.
491. Brennan JM, Edwards FH, Zhao Y, O’Brien S, Booth ME, Dokholyan RS,
Douglas PS, Peterson ED, DEcIDE AVR Research Team. Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of
Thoracic Surgeons Adult Cardiac Surgery National Database. J Am Coll Cardiol
2012;60:971977.
492. Merie C, Kober L, Skov Olsen P, Andersson C, Gislason G, Skov Jensen J,
Torp-Pedersen C. Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications,
and bleeding. JAMA 2012;308:21182125.
493. Christersson C, James SK, Lindhagen L, Ahlsson A, Friberg O, Jeppsson A,
Stahle E. Comparison of warfarin versus antiplatelet therapy after surgical bioprosthetic aortic valve replacement. Heart 2020;106:838844.
494. Rafiq S, Steinbruchel DA, Lilleor NB, Moller CH, Lund JT, Thiis JJ, Kober L,
Olsen PS. Antithrombotic therapy after bioprosthetic aortic valve implantation:
warfarin versus aspirin,
a randomized controlled trial.
Thromb
Res
2017;150:104110.
495. Maes F, Stabile E, Ussia GP, Tamburino C, Pucciarelli A, Masson JB, Marsal JR,
Barbanti M, Cote M, Rodes-Cabau J. Meta-analysis comparing single versus dual antiplatelet therapy following transcatheter aortic valve implantation. Am J
Cardiol 2018;122:310315.
496. Brouwer J, Nijenhuis VJ, Delewi R, Hermanides RS, Holvoet W, Dubois CLF,
Frambach P, De Bruyne B, van Houwelingen GK, Van Der Heyden JAS, Tousek
P, van der Kley F, Buysschaert I, Schotborgh CE, Ferdinande B, van der Harst P,
Roosen J, Peper J, Thielen FWF, Veenstra L, Chan Pin Yin D, Swaans MJ,
Rensing B, van ‘t Hof AWJ, Timmers L, Kelder JC, Stella PR, Baan J, Ten Berg
JM. Aspirin with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med 2020;383:14471457.
497. Dangas GD, Tijssen JGP, Wohrle J, Sondergaard L, Gilard M, Mollmann H,
Makkar RR, Herrmann HC, Giustino G, Baldus S, De Backer O, Guimaraes
AHC, Gullestad L, Kini A, von Lewinski D, Mack M, Moreno R, Schafer U,
Seeger J, Tchetche D, Thomitzek K, Valgimigli M, Vranckx P, Welsh RC,
Wildgoose P, Volkl AA, Zazula A, van Amsterdam RGM, Mehran R, Windecker
S, GALILEO Investigators. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med 2020;382:120129.
498. Pagnesi M, Moroni F, Beneduce A, Giannini F, Colombo A, Weisz G, Latib A.
Thrombotic risk and antithrombotic strategies after transcatheter mitral valve replacement. JACC Cardiovasc Interv 2019;12:23882401.
499. Guimaraes HP, Lopes RD, de Barros ESPGM, Liporace IL, Sampaio RO,
Tarasoutchi F, Hoffmann-Filho CR, de Lemos Soares Patriota R, Leiria TLL,
Lamprea D, Precoma DB, Atik FA, Silveira FS, Farias FR, Barreto DO, Almeida
AP, Zilli AC, de Souza Neto JD, Cavalcante MA, Figueira F, Kojima FCS,
Damiani L, Santos RHN, Valeis N, Campos VB, Saraiva JFK, Fonseca FH, Pinto
IM, Magalhaes CC, Ferreira JFM, Alexander JH, Pavanello R, Cavalcanti AB,
Berwanger O, RIVER Trial Investigators. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med 2020;383:21172126.
500. Shim CY, Seo J, Kim YJ, Lee SH, De Caterina R, Lee S, Hong GR; Explore the
Efficacy and Safety of Edoxaban in Patients after Heart Valve Repair or
Bioprosthetic Valve Replacement (ENAVLE) study group. Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: a randomized clinical trial. J Thorac Cardiovasc Surg 2021;doi:
10.1016/j.jtcvs.2021.01.127.
501. Nijenhuis VJ, Brouwer J, Delewi R, Hermanides RS, Holvoet W, Dubois CLF,
Frambach P, De Bruyne B, van Houwelingen GK, Van Der Heyden JAS, Tousek
P, van der Kley F, Buysschaert I, Schotborgh CE, Ferdinande B, van der Harst P,
Roosen J, Peper J, Thielen FWF, Veenstra L, Chan Pin Yin D, Swaans MJ,
Rensing B, van ‘t Hof AWJ, Timmers L, Kelder JC, Stella PR, Baan J, Ten Berg
JM. Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med 2020;382:16961707.
502. Jochheim D, Barbanti M, Capretti G, Stefanini GG, Hapfelmeier A, Zadrozny M,
Baquet M, Fischer J, Theiss H, Todaro D, Chieffo A, Presbitero P, Colombo A,
Massberg S, Tamburino C, Mehilli J. Oral anticoagulant type and outcomes after transcatheter aortic valve replacement. JACC Cardiovasc Interv 2019;12:15661576.
503. van der Wall SJ, Olsthoorn JR, Heuts S, Klautz RJM, Tomsic A, Jansen EK, Vonk
ABA, Sardari Nia P, Klok FA, Huisman MV. Antithrombotic therapy after mitral valve repair: VKA or aspirin? J Thromb Thrombolysis 2018;46:473481.
504. Spyropoulos AC, Turpie AG, Dunn AS, Kaatz S, Douketis J, Jacobson A,
Petersen H, REGIMEN Investigators. Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN
Registry). Am J Cardiol 2008;102:883889.
505. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP,
Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijsen JG, van ‘t Hof AW,
ten Berg JM, WOEST Study Investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet
2013;381:11071115.
506. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P,
Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GY,
Cohen M, Husted S, Peterson ED, Fox KA. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016;375:24232434.
507. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, Goodman
SG, Windecker S, Darius H, Li J, Averkov O, Bahit MC, Berwanger O, Budaj A,
Hijazi Z, Parkhomenko A, Sinnaeve P, Storey RF, Thiele H, Vinereanu D,
Granger CB, Alexander JH, AUGUSTUS Investigators. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med
2019;380:15091524.
508. Fiedler KA, Maeng M, Mehilli J, Schulz-Schupke S, Byrne RA, Sibbing D,
Hoppmann P, Schneider S, Fusaro M, Ott I, Kristensen SD, Ibrahim T, Massberg
ESC/EACTS Guidelines
630


<!-- PAGE 71 -->

### Page 71

.............................................................................................................................................................................
S, Schunkert H, Laugwitz KL, Kastrati A, Sarafoff N. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation:
the ISAR-TRIPLE Trial. J Am Coll Cardiol 2015;65:16191629.
509. Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, Batushkin
V, Campo G, Lysak Z, Vakaliuk I, Milewski K, Laeis P, Reimitz PE, Smolnik R,
Zierhut W, Goette A. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet
2019;394:13351343.
510. Lamberts M, Gislason GH, Lip GY, Lassen JF, Olesen JB, Mikkelsen AP,
Sorensen R, Kober L, Torp-Pedersen C, Hansen ML. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation 2014;129:15771585.
511. Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Miyauchi K,
Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H, AFIRE Investigators.
Antithrombotic therapy for atrial fibrillation with stable coronary disease. N
Engl J Med 2019;381:11031113.
512. Collet JP, Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt DL, Dendale
P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Juni P,
Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M,
Rutten FH, Sibbing D, Siontis GCM, ESC Scientific Document Group. 2020 ESC
Guidelines for the management of acute coronary syndromes in patients presenting without persistent
ST-segment elevation.
Eur
Heart
J
2021;42:12891367.
513. Dewilde WJ, Janssen PW, Kelder JC, Verheugt FW, De Smet BJ, Adriaenssens
T, Vrolix M, Brueren GB, Van Mieghem C, Cornelis K, Vos J, Breet NJ, ten Berg
JM. Uninterrupted oral anticoagulation versus bridging in patients with longterm oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial. EuroIntervention 2015;11:381390.
514. Lip GYH, Collet JP, Haude M, Byrne R, Chung EH, Fauchier L, Halvorsen S, Lau
D, Lopez-Cabanillas N, Lettino M, Marin F, Obel I, Rubboli A, Storey RF,
Valgimigli M, Huber K, ESC Scientific Document Group. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of
Cardiology
Working
Group on
Thrombosis,
European
Association of
Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS),
Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm
Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA).
Europace 2019;21:192193.
515. Carnicelli AP, De Caterina R, Halperin JL, Renda G, Ruff CT, Trevisan M,
Nordio F, Mercuri MF, Antman E, Giugliano RP, ENGAGE AF-TIMI 48
Investigators.
Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves. Circulation 2017;135:
12731275.
516. Philippart R, Brunet-Bernard A, Clementy N, Bourguignon T, Mirza A, Babuty
D, Angoulvant D, Lip GY, Fauchier L. Prognostic value of CHA2DS2-VASc score in patients with ‘non-valvular atrial fibrillation’ and valvular heart disease:
the Loire Valley Atrial Fibrillation Project. Eur Heart J 2015;36:18221830.
517. Philippart R, Brunet-Bernard A, Clementy N, Bourguignon T, Mirza A,
Angoulvant D, Babuty D, Lip GY, Fauchier L. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The
Loire Valley Atrial Fibrillation Project. Thromb Haemost 2016;115:10561063.
518. Siontis KC, Yao X, Gersh BJ, Noseworthy PA. Direct oral anticoagulants in patients with atrial fibrillation and valvular heart disease other than significant mitral stenosis and mechanical valves:
a meta-analysis.
Circulation
2017;135:714716.
519. Russo A, Grigioni F, Avierinos JF, Freeman WK, Suri R, Michelena H, Brown R,
Sundt TM, Enriquez-Sarano M. Thromboembolic complications after surgical correction of mitral regurgitation incidence, predictors, and clinical implications.
J Am Coll Cardiol 2008;51:12031211.
520. Butnaru A, Shaheen J, Tzivoni D, Tauber R, Bitran D, Silberman S. Diagnosis and treatment of early bioprosthetic malfunction in the mitral valve position due to thrombus formation. Am J Cardiol 2013;112:14391444.
521. Rodes-Cabau J, Masson JB, Welsh RC, Garcia Del Blanco B, Pelletier M, Webb
JG, Al-Qoofi F, Genereux P, Maluenda G, Thoenes M, Paradis JM, Chamandi C,
Serra V, Dumont E, Cote M. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (Aspirin Versus Aspirin þ Clopidogrel
Following Transcatheter Aortic Valve Implantation) randomized clinical trial.
JACC Cardiovasc Interv 2017;10:13571365.
522. Dvir D, Bourguignon T, Otto CM, Hahn RT, Rosenhek R, Webb JG, Treede H,
Sarano ME, Feldman T, Wijeysundera HC, Topilsky Y, Aupart M, Reardon MJ,
Mackensen GB, Szeto WY, Kornowski R, Gammie JS, Yoganathan AP, Arbel Y,
Borger MA, Simonato M, Reisman M, Makkar RR, Abizaid A, McCabe JM, Dahle
G, Aldea GS, Leipsic J, Pibarot P, Moat NE, Mack MJ, Kappetein AP, Leon MB,
VIVID Investigators. Standardized definition of structural valve degeneration for surgical and transcatheter bioprosthetic aortic valves.
Circulation
2018;137:388399.
523. Tam DY, Dharma C, Rocha RV, Ouzounian M, Wijeysundera HC, Austin PC,
Chikwe J, Gaudino M, Fremes SE. Transcatheter ViV versus redo surgical AVR
for the management of failed biological prosthesis: early and late outcomes in a propensity-matched cohort. JACC Cardiovasc Interv 2020;13:765774.
524. Bleiziffer S, Simonato M, Webb JG, Rodes-Cabau J, Pibarot P, Kornowski R,
Windecker S, Erlebach M, Duncan A, Seiffert M, Unbehaun A, Frerker C,
Conzelmann L, Wijeysundera H, Kim WK, Montorfano M, Latib A, Tchetche D,
Allali A, Abdel-Wahab M, Orvin K, Stortecky S, Nissen H, Holzamer A, Urena
M, Testa L, Agrifoglio M, Whisenant B, Sathananthan J, Napodano M, Landi A,
Fiorina C, Zittermann A, Veulemans V, Sinning JM, Saia F, Brecker S, Presbitero
P, De Backer O, Sondergaard L, Bruschi G, Franco LN, Petronio AS, Barbanti
M, Cerillo A, Spargias K, Schofer J, Cohen M, Munoz-Garcia A, Finkelstein A,
Adam M, Serra V, Teles RC, Champagnac D, Iadanza A, Chodor P, Eggebrecht
H, Welsh R, Caixeta A, Salizzoni S, Dager A, Auffret V, Cheema A, Ubben T,
Ancona M, Rudolph T, Gummert J, Tseng E, Noble S, Bunc M, Roberts D, Kass
M, Gupta A, Leon MB, Dvir D. Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves.
Eur
Heart
J
2020;41:27312742.
525. Hirji SA, Percy ED, Zogg CK, Malarczyk A, Harloff MT, Yazdchi F, Kaneko T.
Comparison of in-hospital outcomes and readmissions for valve-in-valve transcatheter aortic valve replacement vs. reoperative surgical aortic valve replacement: a contemporary assessment of real-world outcomes. Eur Heart J
2020;41:27472755.
526. Barbanti M, Costa G, Picci A, Criscione E, Reddavid C, Valvo R, Todaro D, Deste
W, Condorelli A, Scalia M, Licciardello A, Politi G, De Luca G, Strazzieri O, Motta S,
Garretto V, Veroux P, Giaquinta A, Giuffrida A, Sgroi C, Leon MB, Webb JG,
Tamburino C. Coronary cannulation after transcatheter aortic valve replacement:
the RE-ACCESS Study. JACC Cardiovasc Interv 2020;13:25422555.
527. De Backer O, Landes U, Fuchs A, Yoon SH, Mathiassen ON, Sedaghat A, Kim
WK, Pilgrim T, Buzzatti N, Ruile P, El Sabbagh A, Barbanti M, Fiorina C,
Nombela-Franco L, Steinvil A, Finkelstein A, Montorfano M, Maurovich-Horvat
P, Kofoed KF, Blanke P, Bunc M, Neumann FJ, Latib A, Windecker S, Sinning JM,
Norgaard BL, Makkar R, Webb JG, Sondergaard L. Coronary access after
TAVR-in-TAVR as evaluated by multidetector computed tomography. JACC
Cardiovasc Interv 2020;13:25282538.
528. Jawitz OK, Gulack BC, Grau-Sepulveda MV, Matsouaka RA, Mack MJ, Holmes
DR, Jr., Carroll JD, Thourani VH, Brennan JM. Reoperation after transcatheter aortic valve replacement: an analysis of the Society of Thoracic Surgeons
Database. JACC Cardiovasc Interv 2020;13:15151525.
529. Dvir D, Webb JG, Bleiziffer S, Pasic M, Waksman R, Kodali S, Barbanti M, Latib
A, Schaefer U, Rodes-Cabau J, Treede H, Piazza N, Hildick-Smith D, Himbert
D, Walther T, Hengstenberg C, Nissen H, Bekeredjian R, Presbitero P, Ferrari
E, Segev A, de Weger A, Windecker S, Moat NE, Napodano M, Wilbring M,
Cerillo AG, Brecker S, Tchetche D, Lefevre T, De Marco F, Fiorina C, Petronio
AS, Teles RC, Testa L, Laborde JC, Leon MB, Kornowski R, Valve-in-Valve
International Data Registry Investigators. Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. JAMA 2014;312:162170.
530. Ye J, Cheung A, Yamashita M, Wood D, Peng D, Gao M, Thompson CR, Munt
B, Moss RR, Blanke P, Leipsic J, Dvir D, Webb JG. Transcatheter aortic and mitral valve-in-valve implantation for failed surgical bioprosthetic valves: an 8year single-center experience. JACC Cardiovasc Interv 2015;8:17351744.
531. Simonato M, Whisenant B, Ribeiro HB, Webb JG, Kornowski R, Guerrero M,
Wijeysundera H, Sondergaard L, De Backer O, Villablanca P, Rihal C, Eleid M,
Kempfert J, Unbehaun A, Erlebach M, Casselman F, Adam M, Montorfano M,
Ancona M, Saia F, Ubben T, Meincke F, Napodano M, Codner P, Schofer J,
Pelletier M, Cheung A, Shuvy M, Palma JH, Gaia DF, Duncan A, Hildick-Smith
D, Veulemans V, Sinning JM, Arbel Y, Testa L, de Weger A, Eltchaninoff H,
Hemery T, Landes U, Tchetche D, Dumonteil N, Rodes-Cabau J, Kim WK,
Spargias K, Kourkoveli P, Ben-Yehuda O, Teles RC, Barbanti M, Fiorina C,
Thukkani A, Mackensen GB, Jones N, Presbitero P, Petronio AS, Allali A,
Champagnac D, Bleiziffer S, Rudolph T, Iadanza A, Salizzoni S, Agrifoglio M,
Nombela-Franco L, Bonaros N, Kass M, Bruschi G, Amabile N, Chhatriwalla A,
Messina A, Hirji SA, Andreas M, Welsh R, Schoels W, Hellig F, Windecker S,
Stortecky S, Maisano F, Stone GW, Dvir D. Transcatheter mitral valve replacement after surgical repair or replacement: comprehensive midterm evaluation of valve-in-valve and valve-in-ring implantation from the VIVID Registry.
Circulation 2021;143:104116.
532. Sengupta A, Yazdchi F, Alexis SL, Percy E, Premkumar A, Hirji S, Bapat VN,
Bhatt DL, Kaneko T, Tang GHL. Reoperative mitral surgery versus transcatheter mitral valve replacement: a systematic review. J Am Heart Assoc
2021;10:e019854.
ESC/EACTS Guidelines
631


<!-- PAGE 72 -->

### Page 72

....................................................................................................................................................
533. Urena M, Vahanian A, Brochet E, Ducrocq G, Iung B, Himbert D. Current indications for transcatheter mitral valve replacement using transcatheter aortic valves: valve-in-valve, valve-in-ring, and valve-in-mitral annulus calcification.
Circulation 2021;143:178196.
534. Little SH, Bapat V, Blanke P, Guerrero M, Rajagopal V, Siegel R. Imaging guidance for transcatheter mitral valve intervention on prosthetic valves, rings, and annular calcification. JACC Cardiovasc Imaging 2021;14:2240.
535. Fallon JM, DeSimone JP, Brennan JM, O’Brien S, Thibault DP, DiScipio AW,
Pibarot P, Jacobs JP, Malenka DJ. The incidence and consequence of prosthesispatient mismatch after surgical aortic valve replacement. Ann Thorac Surg
2018;106:1422.
536. Flameng W, Herregods MC, Vercalsteren M, Herijgers P, Bogaerts K, Meuris B.
Prosthesis-patient mismatch predicts structural valve degeneration in bioprosthetic heart valves. Circulation 2010;121:21232129.
537. Zorn GL, 3rd, Little SH, Tadros P, Deeb GM, Gleason TG, Heiser J, Kleiman
NS, Oh JK, Popma JJ, Adams D, Huang J, Reardon MJ. Prosthesis-patient mismatch in high-risk patients with severe aortic stenosis: a randomized trial of a self-expanding prosthesis. J Thorac Cardiovasc Surg 2016;151:10141022, 1023.
e13.
538. Head SJ, Mokhles MM, Osnabrugge RL, Pibarot P, Mack MJ, Takkenberg JJ,
Bogers AJ, Kappetein AP. The impact of prosthesis-patient mismatch on long-term survival after aortic valve replacement: a systematic review and meta-analysis of 34 observational studies comprising 27 186 patients with 133
141 patient-years. Eur Heart J 2012;33:15181529.
539. Sorajja P, Bae R, Lesser JA, Pedersen WA. Percutaneous repair of paravalvular prosthetic regurgitation: patient selection, techniques and outcomes. Heart
2015;101:665673.
540. Ruiz CE, Hahn RT, Berrebi A, Borer JS, Cutlip DE, Fontana G, Gerosa G,
Ibrahim R, Jelnin V, Jilaihawi H, Jolicoeur EM, Kliger C, Kronzon I, Leipsic J,
Maisano F, Millan X, Nataf P, O’Gara PT, Pibarot P, Ramee SR, Rihal CS, RodesCabau J, Sorajja P, Suri R, Swain JA, Turi ZG, Tuzcu EM, Weissman NJ,
Zamorano JL, Serruys PW, Leon MB, Paravalvular Leak Academic Research
Consortium. Clinical trial principles and endpoint definitions for paravalvular leaks in surgical prosthesis. Eur Heart J 2018;39:12241245.
541. Chakravarty T, Sondergaard L, Friedman J, De Backer O, Berman D, Kofoed
KF, Jilaihawi H, Shiota T, Abramowitz Y, Jorgensen TH, Rami T, Israr S, Fontana
G, de Knegt M, Fuchs A, Lyden P, Trento A, Bhatt DL, Leon MB, Makkar RR,
Resolve, SAVORY Investigators. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet
2017;389:23832392.
542. Karthikeyan G, Senguttuvan NB, Joseph J, Devasenapathy N, Bahl VK, Airan B.
Urgent surgery compared with fibrinolytic therapy for the treatment of leftsided prosthetic heart valve thrombosis: a systematic review and meta-analysis of observational studies. Eur Heart J 2013;34:15571566.
543. Laplace G, Lafitte S, Labeque JN, Perron JM, Baudet E, Deville C, Roques X,
Roudaut R. Clinical significance of early thrombosis after prosthetic mitral valve replacement: a postoperative monocentric study of 680 patients. J Am Coll
Cardiol 2004;43:12831290.
544. Petrescu I, Egbe AC, Ionescu F, Nkomo VT, Greason KL, Pislaru C, Pellikka PA,
Connolly HM, Pislaru SV. Long-term outcomes of anticoagulation for bioprosthetic valve thrombosis. J Am Coll Cardiol 2020;75:857866.
545. Sellers SL, Turner CT, Sathananthan J, Cartlidge TRG, Sin F, Bouchareb R,
Mooney J, Norgaard BL, Bax JJ, Bernatchez PN, Dweck MR, Granville DJ,
Newby DE, Lauck S, Webb JG, Payne GW, Pibarot P, Blanke P, Seidman MA,
Leipsic JA. Transcatheter aortic heart valves: histological analysis providing insight to leaflet thickening and structural valve degeneration. JACC Cardiovasc
Imaging 2019;12:135145.
546. De Backer O, Dangas GD, Jilaihawi H, Leipsic JA, Terkelsen CJ, Makkar R, Kini
AS, Veien KT, Abdel-Wahab M, Kim WK, Balan P, Van Mieghem N, Mathiassen
ON, Jeger RV, Arnold M, Mehran R, Guimaraes AHC, Norgaard BL, Kofoed KF,
Blanke P, Windecker S, Sondergaard L, GALILEO-4D Investigators. Reduced leaflet motion after transcatheter aortic-valve replacement. N Engl J Med
2020;382:130139.
547. Alkhouli M, Rihal CS, Zack CJ, Eleid MF, Maor E, Sarraf M, Cabalka AK, Reeder
GS, Hagler DJ, Maalouf JF, Nkomo VT, Schaff HV, Said SM. Transcatheter and surgical management of mitral paravalvular leak: long-term outcomes. JACC
Cardiovasc Interv 2017;10:19461956.
548. Dakik HA, Chehab O, Eldirani M, Sbeity E, Karam C, Abou Hassan O, Msheik
M, Hassan H, Msheik A, Kaspar C, Makki M, Tamim H. A new index for preoperative cardiovascular evaluation. J Am Coll Cardiol 2019;73:30673078.
549. Tashiro T, Pislaru SV, Blustin JM, Nkomo VT, Abel MD, Scott CG, Pellikka PA.
Perioperative risk of major non-cardiac surgery in patients with severe aortic stenosis:
a reappraisal in contemporary practice.
Eur
Heart
J
2014;35:23722381.
550. Eugene M, Urena M, Abtan J, Carrasco JL, Ghodbane W, Nataf P, Vahanian A,
Himbert D. Effectiveness of rescue percutaneous balloon aortic valvuloplasty in patients with severe aortic stenosis and acute heart failure. Am J Cardiol
2018;121:746750.
551. Kolte D, Khera S, Vemulapalli S, Dai D, Heo S, Goldsweig AM, Aronow HD,
Elmariah S, Inglessis I, Palacios IF, Thourani VH, Sharaf BL, Gordon PC, Abbott
JD. Outcomes following urgent/emergent transcatheter aortic valve replacement: insights from the STS/ACC TVT Registry. JACC Cardiovasc Interv
2018;11:11751185.
552. Calleja AM, Dommaraju S, Gaddam R, Cha S, Khandheria BK, Chaliki HP.
Cardiac risk in patients aged >75 years with asymptomatic, severe aortic stenosis undergoing noncardiac surgery. Am J Cardiol 2010;105:11591163.
553. Tarantini G, Nai Fovino L, Tellaroli P, Fabris T, Iliceto S. Asymptomatic severe aortic stenosis and noncardiac surgery. Am J Cardiol 2016;117:486488.
554. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomstrom-Lundqvist C,
Cifkova R, De Bonis M, Iung B, Johnson MR, Kintscher U, Kranke P, Lang IM,
Morais J, Pieper PG, Presbitero P, Price S, Rosano GMC, Seeland U, Simoncini
T, Swan L, Warnes CA, ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J
2018;39:31653241.
555. Roos-Hesselink J, Baris L, Johnson M, De Backer J, Otto C, Marelli A, Jondeau
G, Budts W, Grewal J, Sliwa K, Parsonage W, Maggioni AP, van Hagen I,
Vahanian A, Tavazzi L, Elkayam U, Boersma E, Hall R. Pregnancy outcomes in women with cardiovascular disease: evolving trends over 10 years in the ESC
Registry
Of
Pregnancy
And
Cardiac disease
(ROPAC).
Eur
Heart
J
2019;40:38483855.
556. van Hagen IM, Thorne SA, Taha N, Youssef G, Elnagar A, Gabriel H, ElRakshy
Y, Iung B, Johnson MR, Hall R, Roos-Hesselink JW, ROPAC Investigators and
EORP Team. Pregnancy outcomes in women with rheumatic mitral valve disease: results from the registry of pregnancy and cardiac disease. Circulation
2018;137:806816.
557. Orwat S, Diller GP, van Hagen IM, Schmidt R, Tobler D, Greutmann M,
Jonkaitiene R, Elnagar A, Johnson MR, Hall R, Roos-Hesselink JW, Baumgartner
H, ROPAC Investigators. Risk of pregnancy in moderate and severe aortic stenosis:
from the
Multinational
ROPAC
Registry.
J
Am
Coll
Cardiol
2016;68:17271737.
558. Meijboom LJ, Vos FE, Timmermans J, Boers GH, Zwinderman AH, Mulder BJ.
Pregnancy and aortic root growth in the Marfan syndrome: a prospective study.
Eur Heart J 2005;26:914920.
559. McKellar SH, MacDonald RJ, Michelena HI, Connolly HM, Sundt TM, 3rd.
Frequency of cardiovascular events in women with a congenitally bicuspid aortic valve in a single community and effect of pregnancy on events. Am J
Cardiol 2011;107:9699.
560. Fuchs A, Urena M, Chong-Nguyen C, Kikoine J, Brochet E, Abtan J, Fischer Q,
Ducrocq G, Vahanian A, Iung B, Himbert D. Valve-in-valve and valve-in-ring transcatheter mitral valve implantation in young women contemplating pregnancy. Circ Cardiovasc Interv 2020;13:e009579.
561. van Hagen IM, Roos-Hesselink JW, Ruys TP, Merz WM, Goland S, Gabriel H,
Lelonek
M,
Trojnarska
O,
Al
Mahmeed
WA,
Balint
HO,
Ashour
Z,
Baumgartner H, Boersma E, Johnson MR, Hall R; ROPAC Investigators and the
EURObservational Research Programme (EORP) Team. Pregnancy in women with a mechanical heart valve: data of the European Society of Cardiology
Registry of
Pregnancy and
Cardiac
Disease
(ROPAC).
Circulation
2015;132:132142.
562. Elassy SM, Elmidany AA, Elbawab HY. Urgent cardiac surgery during pregnancy:
a continuous challenge. Ann Thorac Surg 2014;97:16241629.
ESC/EACTS Guidelines
632
